Rofecoxib None None O
as None None O
adjunctive None None O
therapy None None O
for None None O
haemophilic None None O
arthropathy None None O
. None None O

Joint None None O
haemorrhage None None O
and None None O
subsequent None None O
haemophilic None None O
arthropathy None None O
are None None O
significant None None O
complications None None O
in None None O
haemophilia None None O
. None None O

The None None O
pathophysiology None None O
involves None None O
inflammation None None O
and None None O
angiogenesis None None O
. None None O

Cyclooxygenase None None O
- None None O
2 None None O
( None None O
COX None None O
- None None O
2 None None O
) None None O
inhibitors None None O
are None None O
anti None None O
- None None O
inflammatory None None O
agents None None O
, None None O
which None None O
have None None O
potent None None O
anti None None O
- None None O
inflammatory None None O
, None None O
anti None None O
- None None O
angiogenic None None O
and None None O
analgesic None None O
properties None None O
yet None None O
do None None O
not None None O
affect None None O
platelet None None O
function None None O
in None None O
the None None O
manner None None O
of None None O
traditional None None O
non None None O
- None None O
steroidal None None O
anti None None O
- None None O
inflammatory None None O
drugs None None O
. None None O

These None None O
properties None None O
make None None O
such None None O
agents None None O
potentially None None O
useful None None O
as None None O
adjunctive None None O
therapy None None O
in None None O
haemophilia None None O
. None None O

There None None O
is None None O
only None None O
one None None O
prior None None O
report None None O
describing None None O
rofecoxib None None O
treatment None None O
in None None O
a None None O
single None None O
haemophilia None None O
patient None None O
. None None O

Our None None O
objectives None None O
were None None O
to None None O
determine None None O
the None None O
safety None None O
and None None O
efficacy None None O
of None None O
rofecoxib None None O
in None None O
treating None None O
acute None None O
haemarthrosis None None O
, None None O
chronic None None O
synovitis None None O
, None None O
target None None O
joints None None O
and None None O
pain None None O
. None None O

We None None O
conducted None None O
a None None O
retrospective None None O
medical None None O
record None None O
review None None O
of None None O
patients None None O
treated None None O
with None None O
rofecoxib None None O
for None None O
acute None None O
haemarthrosis None None O
, None None O
chronic None None O
synovitis None None O
, None None O
target None None O
joint None None O
or None None O
pain None None O
. None None O

The None None O
safety None None O
and None None O
efficacy None None O
of None None O
rofecoxib None None O
treatment None None O
were None None O
determined None None O
based None None O
on None None O
subjective None None O
patient None None O
reports None None O
and None None O
physical None None O
examinations None None O
during None None O
follow None None O
- None None O
up None None O
clinic None None O
visits None None O
. None None O

A None None O
total None None O
of None None O
28 None None O
patients None None O
between None None O
3 None None O
and None None O
37 None None O
years None None O
of None None O
age None None O
were None None O
treated None None O
for None None O
a None None O
total None None O
of None None O
42 None None O
courses None None O
of None None O
rofecoxib None None O
treatment None None O
. None None O

All None None O
courses None None O
were None None O
evaluated None None O
for None None O
safety None None O
and None None O
31 None None O
for None None O
efficacy None None O
. None None O

Rofecoxib None None O
was None None O
used None None O
for None None O
eight None None O
acute None None O
haemarthrosis None None O
, None None O
four None None O
target None None O
joints None None O
, None None O
seven None None O
cases None None O
of None None O
synovitis None None O
and None None O
12 None None O
episodes None None O
of None None O
pain None None O
. None None O

Efficacy None None O
was None None O
demonstrated None None O
particularly None None O
for None None O
chronic None None O
synovitis None None O
and None None O
pain None None O
and None None O
no None None O
serious None None O
adverse None None O
events None None O
occurred None None O
. None None O

This None None O
is None None O
the None None O
largest None None O
study None None O
to None None O
date None None O
evaluating None None O
COX None None O
- None None O
2 None None O
inhibitors None None O
as None None O
adjunctive None None O
therapy None None O
in None None O
haemophilia None None O
and None None O
suggests None None O
that None None O
these None None O
agents None None O
may None None O
be None None O
an None None O
important None None O
adjunctive None None O
therapy None None O
in None None O
the None None O
management None None O
of None None O
haemophilia None None O
. None None O

Water None None O
emerging None None O
from None None O
the None None O
yoke None None O
adapter None None O
of None None O
the None None O
nitrous None None O
oxide None None O
hose None None O

Wnt None None O
signaling None None O
, None None O
stem None None O
cells None None O
, None None O
and None None O
the None None O
cellular None None O
origin None None O
of None None O
breast None None O
cancer None None O
. None None O

The None None O
breast None None O
epithelium None None O
comprises None None O
cells None None O
at None None O
different None None O
stages None None O
of None None O
differentiation None None O
, None None O
including None None O
stem None None O
cells None None O
, None None O
progenitor None None O
cells None None O
, None None O
and None None O
more None None O
differentiated None None O
epithelial None None O
and None None O
myoepithelial None None O
cells None None O
. None None O

Wnt None None O
signaling None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
regulating None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
in None None O
the None None O
mammary None None O
gland None None O
as None None O
well None None O
as None None O
other None None O
tissue None None O
compartments None None O
. None None O

Furthermore None None O
, None None O
there None None O
is None None O
strong None None O
evidence None None O
suggesting None None O
that None None O
aberrant None None O
activation None None O
of None None O
Wnt None None O
signaling None None O
induces None None O
mammary None None O
tumors None None O
from None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
, None None O
and None None O
that None None O
Wnt None None O
exerts None None O
its None None O
oncogenic None None O
effects None None O
through None None O
LRP5 None None O
/ None None O
6 None None O
- None None O
mediated None None O
activation None None O
of None None O
beta None None O
- None None O
catenin None None O
and None None O
mTOR None None O
pathways None None O
. None None O

Recent None None O
studies None None O
using None None O
avian None None O
retrovirus None None O
- None None O
mediated None None O
introduction None None O
of None None O
oncogenes None None O
into None None O
a None None O
small None None O
subset None None O
of None None O
somatic None None O
mammary None None O
cells None None O
suggest None None O
that None None O
polyoma None None O
middle None None O
T None None O
antigen None None O
( None None O
PyMT None None O
) None None O
may None None O
also None None O
preferentially None None O
transform None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
. None None O

These None None O
observations None None O
suggest None None O
that None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
in None None O
the None None O
mammary None None O
gland None None O
may None None O
be None None O
especially None None O
susceptible None None O
to None None O
oncogenic None None O
transformation None None O
. None None O

Whether None None O
more None None O
differentiated None None O
cells None None O
may None None O
also None None O
be None None O
transformed None None O
by None None O
particular None None O
oncogenes None None O
is None None O
actively None None O
debated None None O
; None None O
it None None O
is None None O
presently None None O
unclear None None O
whether None None O
stem None None O
cells None None O
or None None O
differentiated None None O
mammary None None O
cells None None O
are None None O
more None None O
susceptible None None O
to None None O
transformation None None O
by None None O
individual None None O
oncogenes None None O
. None None O

Better None None O
stem None None O
cell None None O
and None None O
progenitor None None O
cell None None O
markers None None O
as None None O
well None None O
as None None O
the None None O
ability None None O
to None None O
specifically None None O
target None None O
oncogenes None None O
into None None O
different None None O
mammary None None O
cell None None O
types None None O
will None None O
be None None O
needed None None O
to None None O
determine None None O
the None None O
spectrum None None O
of None None O
oncogene None None O
transformation None None O
for None None O
stem None None O
cells None None O
versus None None O
more None None O
differentiated None None O
cells None None O
. None None O

Chicken None None O
CCN3 None None O
expression None None O
in None None O
embryonic None None O
and None None O
extraembryonic None None O
tissues None None O

Expression None None O
of None None O
CCN3 None None O
in None None O
axial None None O
structure None None O
becomes None None O
visible None None O
in None None O
the None None O
presegmentation None None O
stage None None O
and None None O
reaches None None O
to None None O
the None None O
highest None None O
level None None O
at None None O
the None None O
beginning None None O
of None None O
somitogenesis None None O
( None None O
HH None None O
stage None None O
7 None None O
, None None O
Fig None None O
. None None O
1a None None O
) None None O
. None None O

Strong None None O
similarity None None O
between None None O
CCN3 None None O
and None None O
Sonic None None O
Hedgehog None None O
was None None O
observed None None O
for None None O
the None None O
expression None None O
pattern None None O
in None None O
axial None None O
structure None None O
( None None O
notochord None None O
and None None O
floor None None O
plate None None O
) None None O
, None None O
in None None O
which None None O
the None None O
left None None O
- None None O
right None None O
asymmetrical None None O
pattern None None O
in None None O
the None None O
node None None O
area None None O
is None None O
also None None O
conserved None None O
( None None O
Fig None None O
. None None O
1b None None O
) None None O
. None None O

However None None O
, None None O
Sonic None None O
Hedgehog None None O
expression None None O
is None None O
slightly None None O
broader None None O
than None None O
that None None O
of None None O
CCN3 None None O
. None None O

Since None None O
CCN3 None None O
stimulates None None O
Notch None None O
signaling None None O
( None None O
Sakamoto None None O
et None None O
al None None O
. None None O
2002 None None O
) None None O
, None None O
we None None O
investigated None None O
the None None O
expression None None O
of None None O
Notch None None O
signal None None O
genes None None O
. None None O

Among None None O
them None None O
, None None O
Serrate1 None None O
, None None O
a None None O
ligand None None O
of None None O
Notch None None O
is None None O
unique None None O
because None None O
its None None O
expression None None O
is None None O
apparently None None O
a None None O
right None None O
deviated None None O
pattern None None O
in None None O
the None None O
node None None O
area None None O
( None None O
Fig None None O
. None None O
1c None None O
) None None O
. None None O

Another None None O
Notch None None O
ligand None None O
, None None O
Delta1 None None O
shows None None O
a None None O
right None None O
deviated None None O
pattern None None O
, None None O
but None None O
is None None O
more None None O
caudal None None O
area None None O
of None None O
the None None O
node None None O
extending None None O
to None None O
the None None O
primitive None None O
streak None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
CCN3 None None O
in None None O
axial None None O
structure None None O
was None None O
followed None None O
by None None O
the None None O
presomitic None None O
mesoderm None None O
although None None O
it None None O
is None None O
diminished None None O
( None None O
Sakamoto None None O
et None None O
al None None O
. None None O
2002 None None O
) None None O
. None None O

Fig None None O
. None None O

1 None None O

Expression None None O
of None None O
mRNA None None O
in None None O
early None None O
stage None None O
chicken None None O
embryo None None O
; None None O
CCN3 None None O
( None None O
a None None O
) None None O
, None None O
Sonic None None O
Hedgehog None None O
( None None O
b None None O
) None None O
and None None O
Serrate1 None None O
( None None O
c None None O
) None None O
at None None O
the None None O
beginning None None O
stage None None O
of None None O
somitogenesis None None O
( None None O
Hamburger None None O
and None None O
Hamilton None None O
( None None O
HH None None O
) None None O
Stage None None O
7 None None O
) None None O
. None None O

Arrowheads None None O
indicate None None O
Hensen None None O
' None None O
s None None O
node None None O
. None None O

Demonstrates None None O
the None None O
schematic None None O
view None None O
of None None O
tissue None None O
organization None None O
at None None O
this None None O
stage None None O
( None None O
d None None O
) None None O
. None None O

Expression None None O
of None None O
CCN3 None None O
mRNA None None O
in None None O
blood None None O
islands None None O
of None None O
chicken None None O
extraembryonic None None O
tissue None None O
( None None O
HH None None O
stage None None O
10 None None O
) None None O
( None None O
e None None O
) None None O
. None None O

Ventral None None O
part None None O
of None None O
the None None O
endothelial None None O
precursor None None O
cells None None O
in None None O
blood None None O
islands None None O
is None None O
positive None None O
for None None O
CCN3 None None O
expression None None O
. None None O

Coloration None None O
was None None O
stopped None None O
before None None O
the None None O
background None None O
staining None None O
started None None O
in None None O
sense None None O
probes None None O
( None None O
negative None None O
control None None O
) None None O

There None None O
is None None O
accumulating None None O
evidence None None O
of None None O
CCN3 None None O
commitment None None O
to None None O
hematopoiesis None None O
and None None O
therefore None None O
we None None O
investigated None None O
the None None O
CCN3 None None O
expression None None O
in None None O
extraembryonic None None O
tissues None None O
. None None O

Blood None None O
islands None None O
are None None O
formed None None O
in None None O
the None None O
yolk None None O
sac None None O
mesodermal None None O
area None None O
just None None O
between None None O
the None None O
visceral None None O
endodermal None None O
and None None O
ectodermal None None O
layers None None O
, None None O
which None None O
supply None None O
the None None O
red None None O
blood None None O
cells None None O
at None None O
the None None O
primary None None O
stage None None O
. None None O

The None None O
cells None None O
in None None O
blood None None O
islands None None O
are None None O
called None None O
hemangioblasts None None O
since None None O
they None None O
also None None O
differentiate None None O
into None None O
the None None O
endothelial None None O
cells None None O
of None None O
extraembryonic None None O
blood None None O
vessel None None O
structure None None O
. None None O

In None None O
chicken None None O
embryo None None O
, None None O
differentiating None None O
endothelial None None O
cells None None O
in None None O
the None None O
ventral None None O
part None None O
of None None O
blood None None O
islands None None O
express None None O
CCN3 None None O
from None None O
the None None O
initial None None O
stage None None O
( None None O
Fig None None O
. None None O
1e None None O
) None None O
. None None O

Erythroblasts None None O
in None None O
the None None O
center None None O
of None None O
blood None None O
islands None None O
( None None O
spherical None None O
cells None None O
in None None O
Fig None None O
. None None O
1e None None O
) None None O
weakly None None O
express None None O
CCN3 None None O
and None None O
their None None O
expression None None O
is None None O
mildly None None O
enhanced None None O
in None None O
later None None O
stage None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Erbb2 None None O
suppresses None None O
DNA None None O
damage None None O
- None None O
induced None None O
checkpoint None None O
activation None None O
and None None O
UV None None O
- None None O
induced None None O
mouse None None O
skin None None O
tumorigenesis None None O
. None None O

The None None O
Erbb2 None None O
receptor None None O
is None None O
activated None None O
by None None O
UV None None O
irradiation None None O
, None None O
the None None O
primary None None O
cause None None O
of None None O
non None None O
- None None O
melanoma None None O
skin None None O
cancer None None O
. None None O

We None None O
hypothesized None None O
that None None O
Erbb2 None None O
activation None None O
contributes None None O
to None None O
UV None None O
- None None O
induced None None O
skin None None O
tumorigenesis None None O
by None None O
suppressing None None O
cell None None O
cycle None None O
arrest None None O
. None None O

Consistent None None O
with None None O
this None None O
hypothesis None None O
, None None O
inhibition None None O
of None None O
Erbb2 None None O
in None None O
v None None O
- None None O
ras None None O
( None None O
Ha None None O
) None None O
transgenic None None O
mice None None O
before None None O
UV None None O
exposure None None O
resulted None None O
in None None O
both None None O
56 None None O
% None None O
fewer None None O
skin None None O
tumors None None O
and None None O
tumors None None O
that None None O
were None None O
70 None None O
% None None O
smaller None None O
. None None O

Inhibition None None O
of None None O
the None None O
UV None None O
- None None O
induced None None O
activation None None O
of None None O
Erbb2 None None O
also None None O
resulted None None O
in None None O
milder None None O
epidermal None None O
hyperplasia None None O
, None None O
S None None O
- None None O
phase None None O
accumulation None None O
, None None O
and None None O
decreased None None O
levels None None O
of None None O
the None None O
cell None None O
cycle None None O
regulator None None O
Cdc25a None None O
, None None O
suggesting None None O
altered None None O
cell None None O
cycle None None O
regulation None None O
on None None O
inhibition None None O
of None None O
Erbb2 None None O
. None None O

Further None None O
investigation None None O
using None None O
inhibition None None O
or None None O
genetic None None O
deletion None None O
of None None O
Erbb2 None None O
in None None O
vitro None None O
revealed None None O
reduced None None O
Cdc25a None None O
levels None None O
and None None O
increased None None O
S None None O
- None None O
phase None None O
arrest None None O
in None None O
UV None None O
- None None O
irradiated None None O
cells None None O
lacking None None O
Erbb2 None None O
activity None None O
. None None O

Ectopic None None O
expression None None O
of None None O
Cdc25a None None O
prevented None None O
UV None None O
- None None O
induced None None O
S None None O
- None None O
phase None None O
arrest None None O
in None None O
keratinocytes None None O
lacking None None O
Erbb2 None None O
activity None None O
, None None O
demonstrating None None O
that None None O
maintenance None None O
of None None O
Cdc25a None None O
by None None O
Erbb2 None None O
suppresses None None O
cell None None O
cycle None None O
arrest None None O
. None None O

Examination None None O
of None None O
checkpoint None None O
pathway None None O
activation None None O
upstream None None O
of None None O
Cdc25a None None O
revealed None None O
Erbb2 None None O
activation None None O
did None None O
not None None O
alter None None O
Ataxia None None O
Telangiectasia None None O
and None None O
Rad3 None None O
- None None O
related None None O
/ None None O
Ataxia None None O
Telangiectasia None None O
Mutated None None O
activity None None O
but None None O
increased None None O
inhibitory None None O
phosphorylation None None O
of None None O
Chk1 None None O
- None None O
Ser None None O
( None None O
280 None None O
) None None O
. None None O

Since None None O
Akt None None O
phosphorylates None None O
Chk1 None None O
- None None O
Ser None None O
( None None O
280 None None O
) None None O
, None None O
the None None O
effect None None O
of None None O
Erbb2 None None O
on None None O
phosphatidyl None None O
inositol None None O
- None None O
3 None None O
- None None O
kinase None None O
( None None O
PI3K None None O
) None None O
/ None None O
Akt None None O
signaling None None O
during None None O
UV None None O
- None None O
induced None None O
cell None None O
cycle None None O
arrest None None O
was None None O
determined None None O
. None None O

Erbb2 None None O
ablation None None O
reduced None None O
the None None O
UV None None O
- None None O
induced None None O
activation None None O
of None None O
PI3K None None O
while None None O
inhibition None None O
of None None O
PI3K None None O
/ None None O
Akt None None O
increased None None O
UV None None O
- None None O
induced None None O
S None None O
- None None O
phase None None O
arrest None None O
. None None O

Thus None None O
, None None O
UV None None O
- None None O
induced None None O
Erbb2 None None O
activation None None O
increases None None O
skin None None O
tumorigenesis None None O
through None None O
inhibitory None None O
phosphorylation None None O
of None None O
Chk1 None None O
, None None O
Cdc25a None None O
maintenance None None O
, None None O
and None None O
suppression None None O
of None None O
S None None O
- None None O
phase None None O
arrest None None O
via None None O
a None None O
PI3K None None O
/ None None O
Akt None None O
- None None O
dependent None None O
mechanism None None O
. None None O

Effect None None O
of None None O
a None None O
mutation None None O
in None None O
the None None O
anticodon None None O
of None None O
human None None O
mitochondrial None None O
tRNAPro None None O
on None None O
its None None O
post None None O
- None None O
transcriptional None None O
modification None None O
pattern None None O
. None None O

Although None None O
the None None O
gene None None O
sequences None None O
of None None O
all None None O
22 None None O
tRNAs None None O
encoded None None O
in None None O
the None None O
human None None O
mitochondrial None None O
genome None None O
are None None O
known None None O
, None None O
little None None O
information None None O
exists None None O
about None None O
their None None O
sequences None None O
at None None O
the None None O
RNA None None O
level None None O
. None None O

This None None O
becomes None None O
a None None O
crucial None None O
limitation None None O
when None None O
searching None None O
for None None O
a None None O
molecular None None O
understanding None None O
of None None O
the None None O
growing None None O
number None None O
of None None O
maternally None None O
inherited None None O
human None None O
diseases None None O
correlated None None O
with None None O
point None None O
mutations None None O
in None None O
tRNA None None O
genes None None O
. None None O

Here None None O
we None None O
describe None None O
the None None O
sequence None None O
of None None O
human None None O
mt None None O
- None None O
tRNAPropurified None None O
from None None O
placenta None None O
. None None O

It None None O
shows None None O
absence None None O
of None None O
editing None None O
events None None O
in None None O
this None None O
tRNA None None O
and None None O
highlights None None O
the None None O
presence None None O
of None None O
eight None None O
post None None O
- None None O
transcriptional None None O
modifications None None O
. None None O

These None None O
include None None O
T54 None None O
, None None O
never None None O
found None None O
so None None O
far None None O
in None None O
an None None O
animal None None O
mt None None O
- None None O
tRNA None None O
, None None O
and None None O
m1G37 None None O
, None None O
a None None O
modification None None O
known None None O
to None None O
have None None O
fundamental None None O
functional None None O
properties None None O
in None None O
a None None O
number None None O
of None None O
canonical None None O
tRNAs None None O
. None None O

Occurrence None None O
of None None O
m1G37 None None O
was None None O
further None None O
investigated None None O
in None None O
an None None O
analysis None None O
of None None O
the None None O
substrate None None O
properties None None O
of None None O
in None None O
vitro None None O
transcripts None None O
of None None O
human None None O
mt None None O
- None None O
tRNAProtowards None None O
pure None None O
Escherichia None None O
coli None None O
methylguanosine None None O
transferase None None O
. None None O

This None None O
enzyme None None O
properly None None O
methylates None None O
G37 None None O
in None None O
mt None None O
- None None O
tRNA None None O
and None None O
is None None O
sensitive None None O
to None None O
the None None O
presence None None O
of None None O
a None None O
second None None O
G None None O
at None None O
position None None O
36 None None O
, None None O
neighboring None None O
the None None O
target None None O
nucleotide None None O
for None None O
methylation None None O
. None None O

Since None None O
mutation None None O
of None None O
nt None None O
36 None None O
was None None O
shown None None O
to None None O
be None None O
correlated None None O
with None None O
myopathy None None O
, None None O
the None None O
potential None None O
consequences None None O
of None None O
non None None O
- None None O
modification None None O
or None None O
under None None O
- None None O
modification None None O
of None None O
mt None None O
- None None O
tRNA None None O
nucleotides None None O
in None None O
expression None None O
of None None O
the None None O
particular None None O
myopathy None None O
and None None O
of None None O
mitochondrial None None O
diseases None None O
in None None O
general None None O
are None None O
discussed None None O
. None None O

Hypoxia None None O
- None None O
responsive None None O
element None None O
- None None O
mediated None None O
soluble None None O
Tie2 None None O
vector None None O
exhibits None None O
an None None O
anti None None O
- None None O
angiogenic None None O
activity None None O
in None None O
vitro None None O
under None None O
hypoxic None None O
condition None None O
. None None O

Hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1 None None O
( None None O
HIF None None O
- None None O
1 None None O
) None None O
is None None O
one None None O
of None None O
the None None O
key None None O
mammalian None None O
transcription None None O
factors None None O
and None None O
shows None None O
increased None None O
levels None None O
in None None O
both None None O
protein None None O
stability None None O
and None None O
intrinsic None None O
transcriptional None None O
activity None None O
during None None O
low None None O
oxygen None None O
tension None None O
. None None O

Hypoxia None None O
- None None O
activated None None O
functional None None O
HIF None None O
- None None O
1 None None O
protein None None O
binds None None O
to None None O
hypoxia None None O
- None None O
responsive None None O
elements None None O
( None None O
HRE None None O
) None None O
in None None O
the None None O
enhancers None None O
of None None O
several None None O
genes None None O
including None None O
VEGF None None O
, None None O
the None None O
major None None O
player None None O
in None None O
angiogenesis None None O
, None None O
and None None O
initiates None None O
their None None O
mRNA None None O
expression None None O
. None None O

The None None O
molecular None None O
mechanisms None None O
regulating None None O
the None None O
gene None None O
expression None None O
under None None O
hypoxic None None O
conditions None None O
could None None O
increase None None O
the None None O
therapeutic None None O
window None None O
of None None O
tumor None None O
- None None O
specific None None O
delivery None None O
systems None None O
. None None O

In None None O
this None None O
study None None O
, None None O
to None None O
examine None None O
hypoxia None None O
- None None O
specific None None O
production None None O
of None None O
anti None None O
- None None O
angiogenic None None O
therapeutic None None O
gene None None O
, None None O
we None None O
constructed None None O
5 None None O
copies None None O
of None None O
HRE None None O
( None None O
5xHRE None None O
) None None O
of None None O
human None None O
VEGF None None O
linked None None O
to None None O
soluble None None O
Tie2 None None O
( None None O
sTie2 None None O
) None None O
driven None None O
by None None O
minimal None None O
SV40 None None O
promoter None None O
( None None O
5xHRE None None O
/ None None O
SV40 None None O
/ None None O
sTie2 None None O
) None None O
. None None O

Our None None O
data None None O
showed None None O
that None None O
under None None O
hypoxia None None O
the None None O
secreted None None O
sTie2 None None O
selectively None None O
inhibited None None O
tube None None O
formation None None O
and None None O
migration None None O
capacities None None O
of None None O
endothelial None None O
cells None None O
in None None O
vitro None None O
. None None O

Hence None None O
, None None O
we None None O
propose None None O
that None None O
the None None O
vector None None O
system None None O
, None None O
5xHRE None None O
/ None None O
SV40 None None O
/ None None O
sTie2 None None O
, None None O
might None None O
be None None O
a None None O
useful None None O
tool None None O
for None None O
down None None O
- None None O
regulating None None O
tumor None None O
angiogenesis None None O
under None None O
hypoxic None None O
condition None None O
. None None O

FOXO3a None None O
elicits None None O
a None None O
pro None None O
- None None O
apoptotic None None O
transcription None None O
program None None O
and None None O
cellular None None O
response None None O
to None None O
human None None O
lung None None O
carcinogen None None O
nicotine None None O
- None None O
derived None None O
nitrosaminoketone None None O
( None None O
NNK None None O
) None None O
. None None O

Long None None O
- None None O
term None None O
carcinogen None None O
exposure None None O
exerts None None O
continuous None None O
pressure None None O
on None None O
key None None O
mechanisms None None O
that None None O
repair None None O
or None None O
eliminate None None O
carcinogen None None O
- None None O
damaged None None O
cells None None O
giving None None O
rise None None O
to None None O
selective None None O
failures None None O
that None None O
contribute None None O
to None None O
lung None None O
cancer None None O
. None None O

FOXO3a None None O
is None None O
a None None O
transcription None None O
factor None None O
that None None O
elicits None None O
a None None O
protective None None O
response None None O
to None None O
diverse None None O
cellular None None O
stresses None None O
. None None O

Although None None O
implicated None None O
as None None O
a None None O
tumor None None O
suppressor None None O
, None None O
its None None O
role None None O
in None None O
sporadic None None O
cancer None None O
is None None O
uncertain None None O
. None None O

We None None O
recently None None O
observed None None O
that None None O
FOXO3a None None O
gene None None O
inactivation None None O
occurs None None O
frequently None None O
in None None O
carcinogen None None O
- None None O
induced None None O
lung None None O
adenocarcinoma None None O
( None None O
LAC None None O
) None None O
. None None O

This None None O
suggests None None O
that None None O
FOXO3a None None O
may None None O
play None None O
a None None O
role None None O
in None None O
LAC None None O
suppression None None O
by None None O
eliciting None None O
a None None O
protective None None O
response None None O
to None None O
carcinogenic None None O
stress None None O
. None None O

Here None None O
we None None O
investigated None None O
this None None O
possibility None None O
by None None O
examining None None O
the None None O
role None None O
of None None O
FOXO3a None None O
in None None O
the None None O
cellular None None O
response None None O
to None None O
nicotine None None O
- None None O
derived None None O
nitrosaminoketone None None O
( None None O
NNK None None O
) None None O
, None None O
a None None O
lung None None O
carcinogen None None O
implicated None None O
as None None O
a None None O
cause None None O
of None None O
human None None O
LAC None None O
. None None O

We None None O
show None None O
that None None O
restoration None None O
of None None O
FOXO3a None None O
in None None O
FOXO3a None None O
- None None O
deficient None None O
LAC None None O
cells None None O
increases None None O
sensitivity None None O
to None None O
apoptosis None None O
caused None None O
by None None O
a None None O
DNA None None O
- None None O
damaging None None O
intermediate None None O
of None None O
NNK None None O
. None None O

Prior None None O
to None None O
this None None O
cellular None None O
outcome None None O
, None None O
FOXO3a None None O
is None None O
functionally None None O
activated None None O
and None None O
mediates None None O
a None None O
large None None O
- None None O
scale None None O
transcription None None O
program None None O
in None None O
response None None O
to None None O
this None None O
damage None None O
involving None None O
a None None O
significant None None O
modulation None None O
of None None O
440 None None O
genes None None O
. None None O

Genes None None O
most None None O
significantly None None O
represented None None O
in None None O
this None None O
program None None O
are None None O
those None None O
with None None O
roles None None O
in None None O
cell None None O
growth None None O
and None None O
proliferation None None O
> None None O
protein None None O
synthesis None None O
> None None O
gene None None O
expression None None O
> None None O
cell None None O
death None None O
> None None O
cell None None O
cycle None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
show None None O
that None None O
FOXO3a None None O
directs None None O
an None None O
anti None None O
- None None O
carcinogenic None None O
transcription None None O
program None None O
that None None O
culminates None None O
in None None O
the None None O
elimination None None O
of None None O
carcinogen None None O
- None None O
damaged None None O
cells None None O
. None None O

This None None O
suggests None None O
that None None O
FOXO3a None None O
is None None O
a None None O
potential None None O
suppressor None None O
of None None O
carcinogenic None None O
damage None None O
in None None O
LAC None None O
. None None O

Selective None None O
SMA None None O
angiography None None O
was None None O
performed None None O
5 None None O
h None None O
from None None O
onset None None O
. None None O

Before None None O
therapy None None O
, None None O
the None None O
SMA None None O
was None None O
completely None None O
occluded None None O
by None None O
an None None O
embolus None None O
at None None O
the None None O
proximal None None O
portion None None O
( None None O
a None None O
) None None O
, None None O
and None None O
after None None O
the None None O
bolus None None O
infusion None None O
of None None O
urokinase None None O
( None None O
600 None None O
, None None O
000 None None O
IU None None O
) None None O
into None None O
the None None O
SMA None None O
, None None O
peripheral None None O
blood None None O
flow None None O
was None None O
improved None None O
. None None O

However None None O
, None None O
the None None O
thrombus None None O
decreased None None O
in None None O
size None None O
, None None O
but None None O
remained None None O
( None None O
b None None O
) None None O
. None None O

Asterisks None None O
indicate None None O
thrombus None None O
. None None O

Store None None O
- None None O
operated None None O
calcium None None O
entry None None O
promotes None None O
shape None None O
change None None O
in None None O
pulmonary None None O
endothelial None None O
cells None None O
expressing None None O
Trp1 None None O
. None None O

Activation None None O
of None None O
Ca2 None None O
+ None None O
entry None None O
is None None O
known None None O
to None None O
produce None None O
endothelial None None O
cell None None O
shape None None O
change None None O
, None None O
leading None None O
to None None O
increased None None O
permeability None None O
, None None O
leukocyte None None O
migration None None O
, None None O
and None None O
initiation None None O
of None None O
angiogenesis None None O
in None None O
conduit None None O
- None None O
vessel None None O
endothelial None None O
cells None None O
. None None O

The None None O
mode None None O
of None None O
Ca2 None None O
+ None None O
entry None None O
regulating None None O
cell None None O
shape None None O
is None None O
unknown None None O
. None None O

We None None O
hypothesized None None O
that None None O
activation None None O
of None None O
store None None O
- None None O
operated None None O
Ca2 None None O
+ None None O
channels None None O
( None None O
SOCs None None O
) None None O
is None None O
sufficient None None O
to None None O
promote None None O
cell None None O
shape None None O
change None None O
necessary None None O
for None None O
these None None O
processes None None O
. None None O

SOC None None O
activation None None O
in None None O
rat None None O
pulmonary None None O
arterial None None O
endothelial None None O
cells None None O
increased None None O
free None None O
cytosolic None None O
Ca2 None None O
+ None None O
that None None O
was None None O
dependent None None O
on None None O
a None None O
membrane None None O
current None None O
having None None O
a None None O
net None None O
inward None None O
component None None O
of None None O
5 None None O
. None None O
45 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
90 None None O
pA None None O
/ None None O
pF None None O
at None None O
- None None O
80 None None O
mV None None O
. None None O

Changes None None O
in None None O
endothelial None None O
cell None None O
shape None None O
accompanied None None O
SOC None None O
activation None None O
and None None O
were None None O
dependent None None O
on None None O
Ca2 None None O
+ None None O
entry None None O
- None None O
induced None None O
reconfiguration None None O
of None None O
peripheral None None O
( None None O
cortical None None O
) None None O
filamentous None None O
actin None None O
( None None O
F None None O
- None None O
actin None None O
) None None O
. None None O

Because None None O
the None None O
identity None None O
of None None O
pulmonary None None O
endothelial None None O
SOCs None None O
is None None O
unknown None None O
, None None O
but None None O
mammalian None None O
homologues None None O
of None None O
the None None O
Drosophila None None O
melanogaster None None O
transient None None O
receptor None None O
potential None None O
( None None O
trp None None O
) None None O
gene None None O
have None None O
been None None O
proposed None None O
to None None O
form None None O
Ca2 None None O
+ None None O
entry None None O
channels None None O
in None None O
nonexcitable None None O
cells None None O
, None None O
we None None O
performed None None O
RT None None O
- None None O
PCR None None O
using None None O
Trp None None O
oligonucleotide None None O
primers None None O
in None None O
both None None O
rat None None O
and None None O
human None None O
pulmonary None None O
arterial None None O
endothelial None None O
cells None None O
. None None O

Both None None O
cell None None O
types None None O
were None None O
found None None O
to None None O
express None None O
Trp1 None None O
, None None O
but None None O
neither None None O
expressed None None O
Trp3 None None O
nor None None O
Trp6 None None O
. None None O

Our None None O
study None None O
indicates None None O
that None None O
1 None None O
) None None O
Ca2 None None O
+ None None O
entry None None O
in None None O
pulmonary None None O
endothelial None None O
cells None None O
through None None O
SOCs None None O
produces None None O
cell None None O
shape None None O
change None None O
that None None O
is None None O
dependent None None O
on None None O
site None None O
- None None O
specific None None O
rearrangement None None O
of None None O
the None None O
microfilamentous None None O
cytoskeleton None None O
and None None O
2 None None O
) None None O
Trp1 None None O
may None None O
be None None O
a None None O
component None None O
of None None O
pulmonary None None O
endothelial None None O
SOCs None None O
. None None O

Angiogenesis None None O
in None None O
platelet None None O
endothelial None None O
cell None None O
adhesion None None O
molecule None None O
- None None O
1 None None O
- None None O
null None None O
mice None None O
. None None O

Platelet None None O
endothelial None None O
cell None None O
adhesion None None O
molecule None None O
( None None O
PECAM None None O
) None None O
- None None O
1 None None O
has None None O
been None None O
previously None None O
implicated None None O
in None None O
endothelial None None O
cell None None O
migration None None O
; None None O
additionally None None O
, None None O
anti None None O
- None None O
PECAM None None O
- None None O
1 None None O
antibodies None None O
have None None O
been None None O
shown None None O
to None None O
inhibit None None O
in None None O
vivo None None O
angiogenesis None None O
. None None O

Studies None None O
were None None O
therefore None None O
performed None None O
with None None O
PECAM None None O
- None None O
1 None None O
- None None O
null None None O
mice None None O
to None None O
further None None O
define None None O
the None None O
involvement None None O
of None None O
PECAM None None O
- None None O
1 None None O
in None None O
blood None None O
vessel None None O
formation None None O
. None None O

Vascularization None None O
of None None O
subcutaneous None None O
Matrigel None None O
implants None None O
as None None O
well None None O
as None None O
tumor None None O
angiogenesis None None O
were None None O
both None None O
inhibited None None O
in None None O
PECAM None None O
- None None O
1 None None O
- None None O
null None None O
mice None None O
. None None O

Reciprocal None None O
bone None None O
marrow None None O
transplants None None O
that None None O
involved None None O
both None None O
wild None None O
- None None O
type None None O
and None None O
PECAM None None O
- None None O
1 None None O
- None None O
deficient None None O
mice None None O
revealed None None O
that None None O
the None None O
impaired None None O
angiogenic None None O
response None None O
resulted None None O
from None None O
a None None O
loss None None O
of None None O
endothelial None None O
, None None O
but None None O
not None None O
leukocyte None None O
, None None O
PECAM None None O
- None None O
1 None None O
. None None O

In None None O
vitro None None O
wound None None O
migration None None O
and None None O
single None None O
- None None O
cell None None O
motility None None O
by None None O
PECAM None None O
- None None O
1 None None O
- None None O
null None None O
endothelial None None O
cells None None O
were None None O
also None None O
compromised None None O
. None None O

In None None O
addition None None O
, None None O
filopodia None None O
formation None None O
, None None O
a None None O
feature None None O
of None None O
motile None None O
cells None None O
, None None O
was None None O
inhibited None None O
in None None O
PECAM None None O
- None None O
1 None None O
- None None O
null None None O
endothelial None None O
cells None None O
as None None O
well None None O
as None None O
in None None O
human None None O
endothelial None None O
cells None None O
treated None None O
with None None O
either None None O
anti None None O
- None None O
PECAM None None O
- None None O
1 None None O
antibody None None O
or None None O
PECAM None None O
- None None O
1 None None O
siRNA None None O
. None None O

Furthermore None None O
, None None O
the None None O
expression None None O
of None None O
PECAM None None O
- None None O
1 None None O
promoted None None O
filopodia None None O
formation None None O
and None None O
increased None None O
the None None O
protein None None O
expression None None O
levels None None O
of None None O
Cdc42 None None O
, None None O
a None None O
Rho None None O
GTPase None None O
that None None O
is None None O
known None None O
to None None O
promote None None O
the None None O
formation None None O
of None None O
filopodia None None O
. None None O

In None None O
the None None O
developing None None O
retinal None None O
vasculature None None O
, None None O
numerous None None O
, None None O
long None None O
filamentous None None O
filopodia None None O
, None None O
emanating None None O
from None None O
endothelial None None O
cells None None O
at None None O
the None None O
tips None None O
of None None O
angiogenic None None O
sprouts None None O
, None None O
were None None O
observed None None O
in None None O
wild None None O
- None None O
type None None O
animals None None O
, None None O
but None None O
to None None O
a None None O
lesser None None O
extent None None O
in None None O
the None None O
PECAM None None O
- None None O
1 None None O
- None None O
null None None O
mice None None O
. None None O

Together None None O
, None None O
these None None O
data None None O
further None None O
establish None None O
the None None O
involvement None None O
of None None O
endothelial None None O
PECAM None None O
- None None O
1 None None O
in None None O
angiogenesis None None O
and None None O
suggest None None O
that None None O
, None None O
in None None O
vivo None None O
, None None O
PECAM None None O
- None None O
1 None None O
may None None O
stimulate None None O
endothelial None None O
cell None None O
motility None None O
by None None O
promoting None None O
the None None O
formation None None O
of None None O
filopodia None None O
. None None O

Rapid None None O
enzyme None None O
analysis None None O
of None None O
amniotic None None O
fluid None None O
phospholipids None None O
containing None None O
choline None None O
: None None O
a None None O
comparison None None O
with None None O
the None None O
lecithin None None O
to None None O
sphingomyelin None None O
ratio None None O
in None None O
prenatal None None O
assessment None None O
of None None O
fetal None None O
lung None None O
maturity None None O
. None None O

The None None O
relation None None O
between None None O
the None None O
choline None None O
containing None None O
surfactant None None O
phospholipids None None O
lecithin None None O
and None None O
sphingomyelin None None O
in None None O
amniotic None None O
fluid None None O
and None None O
fetal None None O
lung None None O
maturity None None O
is None None O
well None None O
established None None O
. None None O

An None None O
enzymatic None None O
method None None O
that None None O
had None None O
been None None O
automated None None O
and None None O
optimised None None O
for None None O
use None None O
on None None O
a None None O
centrifugal None None O
analyser None None O
was None None O
used None None O
to None None O
measure None None O
the None None O
total None None O
choline None None O
containing None None O
phospholipids None None O
in None None O
amniotic None None O
fluid None None O
. None None O

The None None O
total None None O
time None None O
taken None None O
for None None O
this None None O
assay None None O
was None None O
10 None None O
minutes None None O
. None None O

The None None O
results None None O
obtained None None O
from None None O
100 None None O
patient None None O
samples None None O
, None None O
using None None O
this None None O
procedure None None O
, None None O
compared None None O
favourably None None O
with None None O
the None None O
results None None O
obtained None None O
by None None O
the None None O
thin None None O
layer None None O
chromatography None None O
procedure None None O
used None None O
to None None O
determine None None O
the None None O
lecithin None None O
to None None O
sphingomyelin None None O
ratio None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
93 None None O
) None None O
. None None O

A None None O
clinical None None O
study None None O
of None None O
60 None None O
patients None None O
showed None None O
that None None O
this None None O
assay None None O
predicted None None O
prenatal None None O
respiratory None None O
distress None None O
syndrome None None O
as None None O
well None None O
as None None O
the None None O
lecithin None None O
to None None O
sphingomyelin None None O
ratios None None O
. None None O

The None None O
advantage None None O
of None None O
this None None O
assay None None O
over None None O
existing None None O
procedures None None O
is None None O
that None None O
it None None O
requires None None O
minimum None None O
preparation None None O
of None None O
the None None O
specimen None None O
and None None O
no None None O
extraction None None O
, None None O
is None None O
quick None None O
, None None O
and None None O
shows None None O
a None None O
high None None O
degree None None O
of None None O
precision None None O
. None None O

Granulocyte None None O
- None None O
macrophage None None O
colony None None O
- None None O
stimulating None None O
factor None None O
and None None O
interleukin None None O
- None None O
3 None None O
enhance None None O
the None None O
incorporation None None O
of None None O
cytosine None None O
arabinoside None None O
into None None O
the None None O
DNA None None O
of None None O
leukemic None None O
blasts None None O
and None None O
the None None O
cytotoxic None None O
effect None None O
on None None O
clonogenic None None O
cells None None O
from None None O
patients None None O
with None None O
acute None None O
myeloid None None O
leukemia None None O
. None None O

In None None O
the None None O
present None None O
study None None O
the None None O
effects None None O
of None None O
the None None O
48 None None O
- None None O
hour None None O
administration None None O
of None None O
granulocyte None None O
- None None O
macrophage None None O
colony None None O
- None None O
stimulating None None O
factor None None O
( None None O
GM None None O
- None None O
CSF None None O
) None None O
( None None O
100 None None O
U None None O
/ None None O
mL None None O
) None None O
or None None O
interleukin None None O
- None None O
3 None None O
( None None O
IL None None O
- None None O
3 None None O
) None None O
( None None O
100 None None O
U None None O
/ None None O
mL None None O
) None None O
on None None O
the None None O
proliferative None None O
activity None None O
of None None O
leukemic None None O
cells None None O
and None None O
on None None O
the None None O
intracellular None None O
metabolism None None O
and None None O
cytotoxic None None O
efficacy None None O
of None None O
a None None O
subsequent None None O
12 None None O
- None None O
hour None None O
application None None O
of None None O
cytosine None None O
arabinoside None None O
( None None O
ara None None O
- None None O
C None None O
) None None O
at None None O
doses None None O
of None None O
0 None None O
. None None O
1 None None O
, None None O
1 None None O
. None None O
0 None None O
, None None O
10 None None O
. None None O
0 None None O
, None None O
and None None O
100 None None O
. None None O
0 None None O
mumol None None O
/ None None O
L None None O
were None None O
evaluated None None O
on None None O
bone None None O
marrow None None O
cells None None O
from None None O
17 None None O
patients None None O
with None None O
acute None None O
myeloid None None O
leukemia None None O
. None None O

After None None O
GM None None O
- None None O
CSF None None O
or None None O
IL None None O
- None None O
3 None None O
, None None O
a None None O
1 None None O
. None None O
2 None None O
- None None O
to None None O
2 None None O
. None None O
4 None None O
- None None O
fold None None O
increase None None O
in None None O
S None None O
- None None O
phase None None O
cells None None O
was None None O
observed None None O
in None None O
nine None None O
of None None O
14 None None O
GM None None O
- None None O
CSF None None O
and None None O
seven None None O
of None None O
11 None None O
IL None None O
- None None O
3 None None O
cases None None O
. None None O

3H None None O
- None None O
Cytosine None None O
arabinoside None None O
incorporation None None O
into None None O
the None None O
DNA None None O
was None None O
enhanced None None O
1 None None O
. None None O
33 None None O
- None None O
to None None O
18 None None O
. None None O
3 None None O
- None None O
fold None None O
over None None O
respective None None O
controls None None O
in None None O
14 None None O
of None None O
17 None None O
patients None None O
. None None O

While None None O
in None None O
control None None O
specimens None None O
are None None O
ara None None O
- None None O
C None None O
dose None None O
- None None O
dependent None None O
increase None None O
in None None O
3H None None O
- None None O
ara None None O
- None None O
C None None O
uptake None None O
was None None O
accompanied None None O
by None None O
a None None O
corresponding None None O
rise None None O
in None None O
intracellular None None O
ara None None O
- None None O
C None None O
- None None O
5 None None O
' None None O
triphosphate None None O
( None None O
ara None None O
- None None O
CTP None None O
) None None O
levels None None O
, None None O
ara None None O
- None None O
CTP None None O
concentrations None None O
were None None O
not None None O
increased None None O
after None None O
GM None None O
- None None O
CSF None None O
or None None O
IL None None O
- None None O
3 None None O
exposure None None O
, None None O
resulting None None O
in None None O
a None None O
higher None None O
ara None None O
- None None O
C None None O
to None None O
ara None None O
- None None O
CTP None None O
ratio None None O
over None None O
controls None None O
. None None O

This None None O
finding None None O
may None None O
be None None O
explained None None O
by None None O
a None None O
stimulatory None None O
effect None None O
of None None O
GM None None O
- None None O
CSF None None O
and None None O
IL None None O
- None None O
3 None None O
on None None O
ara None None O
- None None O
C None None O
phosphorylating None None O
enzymes None None O
and None None O
a None None O
more None None O
rapid None None O
incorporation None None O
of None None O
ara None None O
- None None O
CTP None None O
into None None O
the None None O
DNA None None O
of None None O
leukemic None None O
blasts None None O
. None None O

These None None O
effects None None O
translated None None O
into None None O
a None None O
2 None None O
. None None O
2 None None O
- None None O
to None None O
229 None None O
. None None O
0 None None O
- None None O
fold None None O
increase None None O
in None None O
the None None O
cytotoxic None None O
activity None None O
of None None O
ara None None O
- None None O
C None None O
against None None O
clonogenic None None O
leukemic None None O
cells None None O
after None None O
GM None None O
- None None O
CSF None None O
or None None O
IL None None O
- None None O
3 None None O
pretreatment None None O
. None None O

Hence None None O
, None None O
GM None None O
- None None O
CSF None None O
and None None O
IL None None O
- None None O
3 None None O
enhance None None O
the None None O
intracellular None None O
metabolism None None O
of None None O
ara None None O
- None None O
C None None O
and None None O
its None None O
incorporation None None O
into None None O
the None None O
DNA None None O
of None None O
leukemic None None O
cells None None O
leading None None O
to None None O
a None None O
higher None None O
antileukemic None None O
activity None None O
of None None O
ara None None O
- None None O
C None None O
on None None O
clonogenic None None O
leukemic None None O
cells None None O
( None None O
CFU None None O
- None None O
L None None O
) None None O
. None None O

ACKNOWLEDGEMENTS None None O

The None None O
authors None None O
thank None None O
Mr None None O
. None None O
C None None O
. None None O

Roberto None None O
for None None O
providing None None O
animal None None O
care None None O
. None None O

This None None O
research None None O
was None None O
supported None None O
by None None O
the None None O
State None None O
of None None O
Rio None None O
de None None O
Janeiro None None O
Carlos None None O
Chagas None None O
Filho None None O
Research None None O
Foundation None None O
( None None O
FAPERJ None None O
) None None O
and None None O
the None None O
Coordination None None O
for None None O
the None None O
Enhancement None None O
of None None O
Higher None None O
Education None None O
Personnel None None O
( None None O
CAPES None None O
) None None O
. None None O

Statistics None None O

The None None O
survival None None O
of None None O
mice None None O
was None None O
analyzed None None O
using None None O
Kaplan None None O
- None None O
Meier None None O
survival None None O
analysis None None O
. None None O

All None None O
other None None O
data None None O
were None None O
analyzed None None O
by None None O
one None None O
- None None O
way None None O
ANOVA None None O
, None None O
followed None None O
by None None O
the None None O
Student None None O
- None None O
Newman None None O
- None None O
Keuls None None O
test None None O
for None None O
all None None O
pairwise None None O
comparisons None None O
. None None O

Prior None None O
to None None O
ANOVA None None O
, None None O
Levene None None O
' None None O
s None None O
Test None None O
for None None O
Equality None None O
of None None O
Variances None None O
was None None O
performed None None O
. None None O

All None None O
statistical None None O
analyses None None O
were None None O
performed None None O
using None None O
MedCalc None None O
software None None O
, None None O
version None None O
11 None None O
. None None O
2 None None O
. None None O
1 None None O
. None None O
0 None None O
. None None O

2 None None O
. None None O

Methods None None O

Vitamins None None O
regulate None None O
gene None None O
expression None None O
and None None O
induce None None O
differentiation None None O
and None None O
growth None None O
inhibition None None O
in None None O
cancer None None O
cells None None O
. None None O

Their None None O
relevance None None O
in None None O
cancer None None O
prevention None None O
. None None O

Although None None O
several None None O
hypotheses None None O
for None None O
human None None O
carcinogenesis None None O
have None None O
been None None O
proposed None None O
, None None O
the None None O
specific None None O
genetic None None O
changes None None O
that None None O
cause None None O
normal None None O
cells None None O
to None None O
become None None O
cancer None None O
cells None None O
have None None O
not None None O
been None None O
identified None None O
. None None O

In None None O
spite None None O
of None None O
uncertainties None None O
regarding None None O
the None None O
mechanisms None None O
of None None O
carcinogenesis None None O
, None None O
several None None O
vitamins None None O
such None None O
as None None O
beta None None O
- None None O
carotene None None O
and None None O
vitamins None None O
A None None O
, None None O
C None None O
, None None O
and None None O
E None None O
, None None O
which None None O
can None None O
reduce None None O
the None None O
risk None None O
of None None O
cancer None None O
, None None O
have None None O
been None None O
identified None None O
, None None O
using None None O
animal None None O
and None None O
in None None O
vitro None None O
models None None O
of None None O
carcinogenesis None None O
. None None O

These None None O
studies None None O
have None None O
led None None O
to None None O
a None None O
hypothesis None None O
that None None O
the None None O
supplemental None None O
intake None None O
of None None O
these None None O
vitamins None None O
may None None O
reduce None None O
the None None O
risk None None O
of None None O
cancer None None O
. None None O

This None None O
hypothesis None None O
in None None O
humans None None O
can None None O
be None None O
tested None None O
only None None O
by None None O
intervention None None O
trials None None O
that None None O
are None None O
in None None O
progress None None O
. None None O

Prospective None None O
and None None O
retrospective None None O
case None None O
- None None O
controlled None None O
experimental None None O
designs None None O
are None None O
not None None O
suitable None None O
for None None O
testing None None O
the None None O
above None None O
hypothesis None None O
. None None O

The None None O
fact None None O
that None None O
some None None O
vitamins None None O
induce None None O
cell None None O
differentiation None None O
and None None O
/ None None O
or None None O
growth None None O
inhibition None None O
in None None O
tumor None None O
cells None None O
in None None O
culture None None O
suggests None None O
that None None O
the None None O
use None None O
of None None O
these None None O
vitamins None None O
in None None O
cancer None None O
prevention None None O
has None None O
a None None O
cellular None None O
basis None None O
. None None O

In None None O
addition None None O
to None None O
having None None O
a None None O
direct None None O
effect None None O
on None None O
tumor None None O
cells None None O
, None None O
vitamins None None O
such None None O
as None None O
alpha None None O
- None None O
tocopheryl None None O
succinate None None O
and None None O
beta None None O
- None None O
carotene None None O
enhance None None O
the None None O
effect None None O
of None None O
other None None O
agents None None O
that None None O
induce None None O
differentiation None None O
in None None O
tumor None None O
cells None None O
. None None O

Some None None O
vitamins None None O
like None None O
beta None None O
- None None O
carotene None None O
, None None O
retinoic None None O
acid None None O
, None None O
alpha None None O
- None None O
tocopheryl None None O
succinate None None O
, None None O
and None None O
vitamin None None O
D None None O
also None None O
regulate None None O
the None None O
expressions None None O
of None None O
certain None None O
oncogenes None None O
and None None O
cellular None None O
genes None None O
. None None O

These None None O
are None None O
exciting None None O
new None None O
functions None None O
of None None O
vitamins None None O
that None None O
nobody None None O
could None None O
have None None O
predicted None None O
only None None O
a None None O
few None None O
years None None O
ago None None O
. None None O

[ None None O
Incidence None None O
of None None O
fungal None None O
infection None None O
in None None O
surgical None None O
diseases None None O
of None None O
the None None O
pancreas None None O
] None None O
. None None O

Recently None None O
the None None O
number None None O
of None None O
mycotic None None O
infections None None O
has None None O
increased None None O
significantly None None O
. None None O

Authors None None O
have None None O
observed None None O
13 None None O
mycotic None None O
infections None None O
on None None O
operated None None O
patients None None O
suffering None None O
pancreatic None None O
diseases None None O
between None None O
1984 None None O
and None None O
1990 None None O
. None None O

9 None None O
of None None O
13 None None O
patients None None O
had None None O
pancreatic None None O
abscesses None None O
as None None O
well None None O
. None None O

The None None O
risk None None O
factors None None O
of None None O
fungal None None O
infections None None O
are None None O
analysed None None O
. None None O

It None None O
is None None O
important None None O
to None None O
take None None O
differentiation None None O
between None None O
fungal None None O
colonisation None None O
and None None O
septicaemia None None O
caused None None O
by None None O
yeasts None None O
. None None O

Repeated None None O
microbiological None None O
examinations None None O
can None None O
promote None None O
recognising None None O
of None None O
the None None O
fungal None None O
invasion None None O
. None None O

The None None O
base None None O
of None None O
the None None O
therapy None None O
is None None O
to None None O
avoid None None O
risk None None O
factors None None O
of None None O
infections None None O
and None None O
to None None O
use None None O
antifungal None None O
medication None None O
in None None O
time None None O
. None None O

Distribution None None O
and None None O
predictors None None O
of None None O
depressive None None O
symptoms None None O
in None None O
osteoarthritis None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
determine None None O
the None None O
prevalence None None O
and None None O
correlates None None O
of None None O
depressive None None O
symptoms None None O
in None None O
a None None O
sample None None O
of None None O
elderly None None O
persons None None O
with None None O
osteoarthritis None None O
( None None O
OA None None O
) None None O
. None None O

METHODS None None O
: None None O

Secondary None None O
analysis None None O
of None None O
cross None None O
sectional None None O
interview None None O
data None None O
from None None O
108 None None O
community None None O
living None None O
persons None None O
age None None O
50 None None O
or None None O
over None None O
who None None O
met None None O
American None None O
College None None O
of None None O
Rheumatology None None O
clinical None None O
criteria None None O
for None None O
OA None None O
of None None O
the None None O
hip None None O
and None None O
/ None None O
or None None O
knee None None O
. None None O

RESULTS None None O
: None None O

The None None O
prevalence None None O
of None None O
substantial None None O
depressive None None O
symptomatology None None O
appeared None None O
to None None O
be None None O
no None None O
greater None None O
than None None O
would None None O
be None None O
expected None None O
in None None O
the None None O
general None None O
population None None O
for None None O
this None None O
age None None O
group None None O
. None None O

However None None O
, None None O
persons None None O
currently None None O
under None None O
a None None O
physician None None O
' None None O
s None None O
care None None O
for None None O
OA None None O
were None None O
significantly None None O
more None None O
depressed None None O
than None None O
those None None O
not None None O
under None None O
care None None O
, None None O
and None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
those None None O
who None None O
had None None O
post None None O
- None None O
high None None O
school None None O
education None None O
, None None O
depression None None O
was None None O
a None None O
better None None O
predictor None None O
of None None O
being None None O
under None None O
care None None O
than None None O
OA None None O
symptoms None None O
. None None O

The None None O
direct None None O
and None None O
interactive None None O
effects None None O
of None None O
3 None None O
variables None None O
- None None O
- None None O
education None None O
, None None O
age None None O
and None None O
self None None O
- None None O
perceived None None O
impact None None O
of None None O
the None None O
OA None None O
problem None None O
- None None O
- None None O
were None None O
found None None O
to None None O
explain None None O
40 None None O
% None None O
of None None O
variance None None O
in None None O
depression None None O
scores None None O
in None None O
the None None O
total None None O
sample None None O
and None None O
50 None None O
% None None O
among None None O
those None None O
currently None None O
receiving None None O
care None None O
. None None O

Younger None None O
and None None O
less None None O
educated None None O
subjects None None O
had None None O
relatively None None O
more None None O
depressive None None O
symptoms None None O
and None None O
, None None O
furthermore None None O
, None None O
in None None O
this None None O
subgroup None None O
the None None O
correlation None None O
between None None O
OA None None O
impact None None O
and None None O
depression None None O
was None None O
high None None O
. None None O

CONCLUSIONS None None O
: None None O

The None None O
importance None None O
of None None O
assessing None None O
depression None None O
in None None O
persons None None O
who None None O
seek None None O
care None None O
for None None O
OA None None O
is None None O
supported None None O
. None None O

Furthermore None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
the None None O
observed None None O
relationship None None O
between None None O
education None None O
and None None O
arthritis None None O
outcomes None None O
could None None O
be None None O
mediated None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
by None None O
depression None None O
. None None O

Unsatisfactory None None O
forehead None None O
scar None None O
following None None O
face None None O
lift None None O
. None None O

The None None O
W None None O
- None None O
plasty None None O
scar None None O
revision None None O
technique None None O
has None None O
been None None O
found None None O
to None None O
be None None O
effective None None O
in None None O
the None None O
repair None None O
of None None O
the None None O
difficult None None O
and None None O
cosmetically None None O
unsatisfactory None None O
hairline None None O
scar None None O
following None None O
the None None O
ill None None O
- None None O
advised None None O
face None None O
lift None None O
technique None None O
that None None O
excises None None O
forehead None None O
skin None None O
. None None O

Metronomic None None O
5 None None O
- None None O
fluorouracil None None O
, None None O
oxaliplatin None None O
and None None O
irinotecan None None O
in None None O
colorectal None None O
cancer None None O
. None None O

Metronomic None None O
chemotherapy None None O
( None None O
the None None O
frequent None None O
, None None O
long None None O
term None None O
, None None O
low None None O
dose None None O
administration None None O
of None None O
chemotherapeutic None None O
drugs None None O
) None None O
is None None O
a None None O
promising None None O
therapy None None O
because None None O
it None None O
enhances None None O
the None None O
anti None None O
- None None O
endothelial None None O
activity None None O
of None None O
conventional None None O
chemotherapeutics None None O
, None None O
but None None O
with None None O
lower None None O
or None None O
no None None O
toxic None None O
effects None None O
compared None None O
to None None O
maximum None None O
tolerated None None O
dose None None O
administration None None O
. None None O

The None None O
aims None None O
of None None O
the None None O
present None None O
study None None O
were None None O
to None None O
compare None None O
, None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
, None None O
the None None O
antiangiogenic None None O
and None None O
antitumor None None O
activities None None O
of None None O
metronomic None None O
irinotecan None None O
( None None O
CPT None None O
- None None O
11 None None O
) None None O
, None None O
oxaliplatin None None O
( None None O
L None None O
- None None O
OHP None None O
) None None O
and None None O
5 None None O
- None None O
fluorouracil None None O
( None None O
5 None None O
- None None O
FU None None O
) None None O
in None None O
colorectal None None O
cancer None None O
and None None O
to None None O
investigate None None O
the None None O
metronomic None None O
combination None None O
of None None O
these None None O
drugs None None O
. None None O

In None None O
vitro None None O
cell None None O
proliferation None None O
, None None O
combination None None O
studies None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
secretion None None O
analyses None None O
were None None O
performed None None O
on None None O
endothelial None None O
( None None O
HMVEC None None I-Cell-line-name
- None None I-Cell-line-name
d None None I-Cell-line-name
) None None O
and None None O
colorectal None None O
cancer None None O
( None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
) None None O
cells None None O
exposed None None O
for None None O
144 None None O
h None None O
to None None O
metronomic None None O
concentrations None None O
of None None O
SN None None O
- None None O
38 None None O
, None None O
the None None O
active None None O
metabolite None None O
of None None O
CPT None None O
- None None O
11 None None O
, None None O
L None None O
- None None O
OHP None None O
and None None O
5 None None O
- None None O
FU None None O
. None None O

HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
human None None O
colorectal None None O
cancer None None O
xenograft None None O
model None None O
was None None O
used None None O
and None None O
tumour None None O
growth None None O
, None None O
microvessel None None O
density None None O
and None None O
VEGF None None O
quantification None None O
were None None O
performed None None O
in None None O
tumours None None O
after None None O
the None None O
administration None None O
of None None O
metronomic None None O
CPT None None O
- None None O
11 None None O
, None None O
L None None O
- None None O
OHP None None O
, None None O
5 None None O
- None None O
FU None None O
and None None O
their None None O
simultaneous None None O
combination None None O
. None None O

Low None None O
concentrations None None O
of None None O
SN None None O
- None None O
38 None None O
, None None O
but None None O
not None None O
5 None None O
- None None O
FU None None O
and None None O
L None None O
- None None O
OHP None None O
, None None O
preferentially None None O
inhibited None None O
endothelial None None O
cell None None O
proliferation None None O
. None None O

Simultaneous None None O
and None None O
continuous None None O
exposure None None O
of None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
and None None O
HMVEC None None I-Cell-line-name
- None None I-Cell-line-name
d None None I-Cell-line-name
cells None None O
to None None O
low None None O
concentrations None None O
SN None None O
- None None O
38 None None O
+ None None O
L None None O
- None None O
OHP None None O
+ None None O
5 None None O
- None None O
FU None None O
for None None O
144 None None O
h None None O
showed None None O
a None None O
strong None None O
antagonism None None O
and None None O
an None None O
unfavorable None None O
dose None None O
- None None O
reduction None None O
index None None O
. None None O

Moreover None None O
, None None O
the None None O
ternary None None O
combination None None O
resulted None None O
in None None O
a None None O
significant None None O
increase None None O
of None None O
VEGF None None O
secretion None None O
in None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
cancer None None O
cells None None O
. None None O

In None None O
a None None O
xenograft None None O
model None None O
metronomic None None O
CPT None None O
- None None O
11 None None O
, None None O
but None None O
not None None O
5 None None O
- None None O
FU None None O
and None None O
L None None O
- None None O
OHP None None O
, None None O
significantly None None O
inhibits None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
29 None None I-Cell-line-name
tumor None None O
growth None None O
and None None O
microvessel None None O
density None None O
in None None O
the None None O
absence None None O
of None None O
toxicity None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
metronomic None None O
5 None None O
- None None O
FU None None O
+ None None O
L None None O
- None None O
OHP None None O
+ None None O
CPT None None O
- None None O
11 None None O
therapy None None O
did None None O
not None None O
affect None None O
the None None O
microvascular None None O
count None None O
. None None O

The None None O
metronomic None None O
concept None None O
might None None O
not None None O
universally None None O
apply None None O
to None None O
every None None O
cytotoxic None None O
drug None None O
in None None O
colorectal None None O
cancer None None O
and None None O
metronomic None None O
combination None None O
regimens None None O
should None None O
be None None O
used None None O
with None None O
caution None None O
. None None O

Role None None O
of None None O
telomeres None None O
in None None O
vascular None None O
senescence None None O
. None None O

Telomeres None None O
are None None O
DNA None None O
regions None None O
composed None None O
of None None O
TTAGGG None None O
repeats None None O
that None None O
are None None O
located None None O
at None None O
the None None O
ends None None O
of None None O
chromosomes None None O
. None None O

Specific None None O
proteins None None O
associate None None O
with None None O
the None None O
telomeres None None O
and None None O
form None None O
non None None O
- None None O
nucleosomal None None O
DNA None None O
- None None O
protein None None O
complexes None None O
that None None O
serve None None O
as None None O
protective None None O
caps None None O
for None None O
the None None O
chromosome None None O
ends None None O
. None None O

There None None O
is None None O
accumulating None None O
evidence None None O
that None None O
progressive None None O
telomere None None O
shortening None None O
is None None O
closely None None O
related None None O
to None None O
cardiovascular None None O
disease None None O
. None None O

For None None O
example None None O
, None None O
vascular None None O
cell None None O
senescence None None O
has None None O
been None None O
reported None None O
to None None O
occur None None O
in None None O
human None None O
atherosclerotic None None O
lesions None None O
and None None O
this None None O
change None None O
is None None O
associated None None O
with None None O
telomere None None O
shortening None None O
. None None O

Impairment None None O
of None None O
telomere None None O
integrity None None O
causes None None O
vascular None None O
dysfunction None None O
, None None O
which None None O
is None None O
prevented None None O
by None None O
the None None O
activation None None O
of None None O
telomerase None None O
. None None O

Mice None None O
with None None O
short None None O
telomeres None None O
develop None None O
hypertension None None O
and None None O
exhibit None None O
impaired None None O
neovascularization None None O
. None None O

Short None None O
telomeres None None O
have None None O
also None None O
been None None O
reported None None O
in None None O
the None None O
leukocytes None None O
of None None O
patients None None O
with None None O
cardiovascular None None O
disease None None O
or None None O
various None None O
cardiovascular None None O
risk None None O
factors None None O
. None None O

Although None None O
it None None O
remains None None O
unclear None None O
whether None None O
short None None O
telomeres None None O
directly None None O
cause None None O
cardiovascular None None O
disease None None O
, None None O
manipulation None None O
of None None O
telomere None None O
function None None O
is None None O
potentially None None O
an None None O
attractive None None O
strategy None None O
for None None O
the None None O
treatment None None O
of None None O
vascular None None O
senescence None None O
. None None O

Posterior None None O
stabilization None None O
of None None O
the None None O
cervical None None O
spine None None O
with None None O
hook None None O
plates None None O
. None None O

Hook None None O
- None None O
plate None None O
fixation None None O
is None None O
designed None None O
for None None O
posterior None None O
cervical None None O
stabilization None None O
from None None O
C2 None None O
to None None O
C7 None None O
. None None O

Indications None None O
remain None None O
the None None O
same None None O
as None None O
for None None O
standard None None O
posterior None None O
fixations None None O
. None None O

The None None O
prime None None O
indications None None O
are None None O
discoligamentous None None O
injuries None None O
. None None O

The None None O
plates None None O
are None None O
hooked None None O
under None None O
the None None O
lower None None O
laminas None None O
and None None O
attached None None O
to None None O
the None None O
articular None None O
masses None None O
of None None O
the None None O
upper None None O
vertebra None None O
by None None O
oblique None None O
screws None None O
. None None O

An None None O
H None None O
- None None O
graft None None O
is None None O
placed None None O
between None None O
the None None O
spinous None None O
processes None None O
. None None O

The None None O
vertebrae None None O
are None None O
compressed None None O
together None None O
by None None O
the None None O
plates None None O
at None None O
three None None O
points None None O
, None None O
the None None O
facet None None O
joints None None O
, None None O
and None None O
graft None None O
. None None O

The None None O
resulting None None O
pre None None O
- None None O
stressed None None O
system None None O
is None None O
stable None None O
in None None O
all None None O
directions None None O
. None None O

A None None O
protocol None None O
for None None O
safe None None O
reduction None None O
of None None O
cervical None None O
dislocations None None O
is None None O
observed None None O
. None None O

Of None None O
70 None None O
patients None None O
treated None None O
from None None O
1979 None None O
to None None O
1986 None None O
, None None O
51 None None O
were None None O
examined None None O
12 None None O
- None None O
54 None None O
months None None O
after None None O
surgery None None O
. None None O

All None None O
fusions None None O
consolidated None None O
. None None O

Two None None O
neurologic None None O
complications None None O
not None None O
attributable None None O
to None None O
the None None O
fixation None None O
occurred None None O
. None None O

Other None None O
major None None O
complications None None O
were None None O
not None None O
seen None None O
. None None O

Expression None None O
of None None O
two None None O
type None None O
II None None O
- None None O
like None None O
tumor None None O
hexokinase None None O
RNA None None O
transcripts None None O
in None None O
cancer None None O
cell None None O
lines None None O
. None None O

To None None O
maintain None None O
an None None O
elevated None None O
glycolytic None None O
rate None None O
, None None O
cancerous None None O
or None None O
proliferating None None O
cells None None O
alter None None O
the None None O
expression None None O
pattern None None O
of None None O
rate None None O
limiting None None O
glycolytic None None O
enzymes None None O
. None None O

Since None None O
glucose None None O
phosphorylation None None O
is None None O
the None None O
first None None O
step None None O
in None None O
glycolysis None None O
, None None O
hexokinase None None O
( None None O
HK None None O
) None None O
, None None O
the None None O
first None None O
rate None None O
limiting None None O
glycolytic None None O
enzyme None None O
, None None O
can None None O
play None None O
a None None O
key None None O
regulatory None None O
role None None O
in None None O
this None None O
process None None O
. None None O

A None None O
low None None O
- None None O
Km None None O
, None None O
mitochondrial None None O
type None None O
II None None O
- None None O
like None None O
tumor None None O
HK None None O
is None None O
described None None O
as None None O
the None None O
predominant None None O
form None None O
in None None O
hepatomas None None O
. None None O

However None None O
, None None O
recent None None O
identification None None O
of None None O
a None None O
high None None O
- None None O
Km None None O
glucose None None O
phosphorylating None None O
activity None None O
in None None O
a None None O
range None None O
of None None O
cancer None None O
cells None None O
prompted None None O
us None None O
to None None O
characterize None None O
glucose None None O
phosphorylating None None O
enzymes None None O
of None None O
cancer None None O
cells None None O
at None None O
the None None O
molecular None None O
level None None O
. None None O

Highly None None O
sensitive None None O
reverse None None O
- None None O
transcription None None O
polymerase None None O
chain None None O
reaction None None O
identifies None None O
an None None O
induction None None O
and None None O
overexpression None None O
of None None O
a None None O
type None None O
II None None O
- None None O
like None None O
tumor None None O
HK None None O
RNA None None O
in None None O
a None None O
range None None O
of None None O
cancer None None O
cell None None O
lines None None O
irrespective None None O
of None None O
tissue None None O
origin None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
report None None O
here None None O
the None None O
identification None None O
of None None O
two None None O
RNA None None O
transcripts None None O
of None None O
type None None O
II None None O
- None None O
like None None O
tumor None None O
HK None None O
of None None O
approximately None None O
5 None None O
. None None O
5 None None O
and None None O
approximately None None O
4 None None O
. None None O
0 None None O
kb None None O
in None None O
these None None O
cancer None None O
cells None None O
lines None None O
, None None O
including None None O
muscle None None O
- None None O
derived None None O
L6 None None I-Cell-line-name
myoblast None None O
cells None None O
. None None O

Interestingly None None O
, None None O
under None None O
normal None None O
conditions None None O
muscle None None O
cells None None O
express None None O
only None None O
a None None O
approximately None None O
5 None None O
. None None O
5 None None O
- None None O
kb None None O
type None None O
II None None O
HK None None O
RNA None None O
transcript None None O
. None None O

A None None O
significant None None O
amount None None O
of None None O
type None None O
I None None O
HK None None O
RNA None None O
was None None O
also None None O
found None None O
expressed None None O
in None None O
cancer None None O
cell None None O
lines None None O
. None None O

RNA None None O
encoding None None O
glucokinase None None O
( None None O
GK None None O
) None None O
, None None O
the None None O
high None None O
- None None O
Km None None O
HK None None O
isozyme None None O
, None None O
was None None O
found None None O
only None None O
in None None O
cancer None None O
cells None None O
originating None None O
from None None O
liver None None O
and None None O
pancreas None None O
, None None O
which None None O
express None None O
GK None None O
under None None O
normal None None O
conditions None None O
. None None O

beta None None O
- None None O
catenin None None O
signaling None None O
controls None None O
metastasis None None O
in None None O
Braf None None O
- None None O
activated None None O
Pten None None O
- None None O
deficient None None O
melanomas None None O
. None None O

Malignant None None O
melanoma None None O
is None None O
characterized None None O
by None None O
frequent None None O
metastasis None None O
, None None O
however None None O
, None None O
specific None None O
changes None None O
that None None O
regulate None None O
this None None O
process None None O
have None None O
not None None O
been None None O
clearly None None O
delineated None None O
. None None O

Although None None O
it None None O
is None None O
well None None O
known None None O
that None None O
Wnt None None O
signaling None None O
is None None O
frequently None None O
dysregulated None None O
in None None O
melanoma None None O
, None None O
the None None O
functional None None O
implications None None O
of None None O
this None None O
observation None None O
are None None O
unclear None None O
. None None O

By None None O
modulating None None O
beta None None O
- None None O
catenin None None O
levels None None O
in None None O
a None None O
mouse None None O
model None None O
of None None O
melanoma None None O
that None None O
is None None O
based None None O
on None None O
melanocyte None None O
- None None O
specific None None O
Pten None None O
loss None None O
and None None O
Braf None None O
( None None O
V600E None None O
) None None O
mutation None None O
, None None O
we None None O
demonstrate None None O
that None None O
beta None None O
- None None O
catenin None None O
is None None O
a None None O
central None None O
mediator None None O
of None None O
melanoma None None O
metastasis None None O
to None None O
the None None O
lymph None None O
nodes None None O
and None None O
lungs None None O
. None None O

In None None O
addition None None O
to None None O
altering None None O
metastasis None None O
, None None O
beta None None O
- None None O
catenin None None O
levels None None O
control None None O
tumor None None O
differentiation None None O
and None None O
regulate None None O
both None None O
MAPK None None O
/ None None O
Erk None None O
and None None O
PI3K None None O
/ None None O
Akt None None O
signaling None None O
. None None O

Highly None None O
metastatic None None O
tumors None None O
with None None O
beta None None O
- None None O
catenin None None O
stabilization None None O
are None None O
very None None O
similar None None O
to None None O
a None None O
subset None None O
of None None O
human None None O
melanomas None None O
. None None O

Together None None O
these None None O
findings None None O
establish None None O
Wnt None None O
signaling None None O
as None None O
a None None O
metastasis None None O
regulator None None O
in None None O
melanoma None None O
. None None O

Reversal None None O
of None None O
the None None O
malignant None None O
phenotype None None O
of None None O
ovarian None None O
cancer None None O
A2780 None None I-Cell-line-name
cells None None O
through None None O
transfection None None O
with None None O
wild None None O
- None None O
type None None O
PTEN None None O
gene None None O
. None None O

OBJECTIVE None None O
: None None O
PTEN None None O
( None None O
phosphatase None None O
and None None O
tensin None None O
homologue None None O
deleted None None O
on None None O
chromosome None None O
10 None None O
) None None O
is None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
identified None None O
on None None O
human None None O
chromosome None None O
10q23 None None O
. None None O

Substantial None None O
studies None None O
have None None O
demonstrated None None O
that None None O
PTEN None None O
can None None O
inhibit None None O
cell None None O
proliferation None None O
, None None O
migration None None O
and None None O
invasion None None O
of None None O
many None None O
cancer None None O
cells None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
whether None None O
upregulation None None O
of None None O
PTEN None None O
gene None None O
by None None O
transfection None None O
wild None None O
- None None O
type None None O
PTEN None None O
gene None None O
to None None O
ovarian None None O
cancer None None O
cells None None O
can None None O
inhibit None None O
growth None None O
and None None O
migration None None O
and None None O
to None None O
explore None None O
the None None O
potential None None O
for None None O
PTEN None None O
gene None None O
therapy None None O
of None None O
ovarian None None O
cancers None None O
. None None O

METHOD None None O
: None None O
Wild None None O
- None None O
type None None O
and None None O
phosphatase None None O
- None None O
inactive None None O
( None None O
C124A None None O
) None None O
PTEN None None O
plasmids None None O
were None None O
transfected None None O
into None None O
ovarian None None O
epithelial None None O
cancer None None O
A2780 None None I-Cell-line-name
cells None None O
, None None O
and None None O
their None None O
effects None None O
on None None O
cell None None O
apoptosis None None O
, None None O
cell None None O
proliferation None None O
, None None O
cell None None O
migration None None O
and None None O
cell None None O
invasion None None O
were None None O
analyzed None None O
by None None O
flow None None O
cytometry None None O
analysis None None O
, None None O
TUNEL None None O
assay None None O
, None None O
MTT None None O
assay None None O
, None None O
wound None None O
- None None O
healing None None O
assay None None O
and None None O
transwell None None O
assay None None O
. None None O

RESULTS None None O
: None None O
Both None None O
wild None None O
- None None O
type None None O
and None None O
mutant None None O
PTEN None None O
can None None O
upregulate None None O
the None None O
expression None None O
of None None O
PTEN None None O
gene None None O
dramatically None None O
; None None O
however None None O
, None None O
it None None O
is None None O
wild None None O
- None None O
type None None O
PTEN None None O
not None None O
phosphatase None None O
- None None O
inactive None None O
PTEN None None O
that None None O
can None None O
induce None None O
apoptosis None None O
and None None O
decrease None None O
cell None None O
migration None None O
, None None O
invasion None None O
and None None O
proliferation None None O
in None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
demonstrated None None O
that None None O
PTEN None None O
had None None O
played None None O
an None None O
important None None O
role None None O
in None None O
the None None O
cell None None O
proliferation None None O
, None None O
cell None None O
migration None None O
and None None O
invasion None None O
dependent None None O
on None None O
its None None O
phosphatase None None O
activity None None O
. None None O

Enhanced None None O
expression None None O
of None None O
PTEN None None O
by None None O
gene None None O
transfer None None O
is None None O
sufficient None None O
to None None O
reverse None None O
the None None O
malignant None None O
phenotype None None O
of None None O
ovarian None None O
cancer None None O
cells None None O
and None None O
transfection None None O
of None None O
ovarian None None O
cancer None None O
cells None None O
with None None O
wild None None O
- None None O
type None None O
PTEN None None O
gene None None O
might None None O
be None None O
another None None O
novel None None O
approach None None O
for None None O
therapeutic None None O
intervention None None O
in None None O
ovarian None None O
cancer None None O
. None None O

In None None O
vivo None None O
p53 None None O
response None None O
and None None O
immune None None O
reaction None None O
underlie None None O
highly None None O
effective None None O
low None None O
- None None O
dose None None O
radiotherapy None None O
in None None O
follicular None None O
lymphoma None None O
. None None O

Very None None O
low None None O
- None None O
dose None None O
irradiation None None O
( None None O
2 None None O
x None None O
2 None None O
Gy None None O
) None None O
is None None O
a None None O
new None None O
, None None O
effective None None O
, None None O
and None None O
safe None None O
local None None O
treatment None None O
for None None O
follicular None None O
lymphoma None None O
. None None O

To None None O
understand None None O
the None None O
biologic None None O
mechanisms None None O
of None None O
this None None O
extremely None None O
effective None None O
response None None O
, None None O
we None None O
compared None None O
by None None O
microarray None None O
the None None O
gene None None O
- None None O
expression None None O
profile None None O
of None None O
patients None None O
' None None O
biopsies None None O
taken None None O
before None None O
and None None O
after None None O
radiation None None O
. None None O

In None None O
all None None O
patients None None O
, None None O
a None None O
major None None O
and None None O
consistent None None O
induction None None O
of None None O
p53 None None O
target None None O
genes None None O
was None None O
seen None None O
. None None O

p53 None None O
targets None None O
involved None None O
in None None O
cell None None O
- None None O
cycle None None O
arrest None None O
and None None O
apoptosis None None O
showed None None O
the None None O
same None None O
mode None None O
of None None O
regulation None None O
, None None O
indicating None None O
that None None O
, None None O
in None None O
vivo None None O
, None None O
both None None O
are None None O
activated None None O
simultaneously None None O
. None None O

p53 None None O
up None None O
- None None O
regulation None None O
and None None O
p53 None None O
- None None O
mediated None None O
proliferation None None O
arrest None None O
and None None O
apoptosis None None O
were None None O
substantiated None None O
using None None O
immunohistochemistry None None O
, None None O
with None None O
activation None None O
of None None O
both None None O
the None None O
intrinsic None None O
and None None O
the None None O
extrinsic None None O
apoptotic None None O
pathways None None O
. None None O

The None None O
other None None O
induced None None O
genes None None O
revealed None None O
a None None O
whole None None O
set None None O
of None None O
biologically None None O
meaningful None None O
genes None None O
related None None O
to None None O
macrophage None None O
activation None None O
and None None O
TH1 None None O
immune None None O
response None None O
. None None O

Immunohistochemical None None O
analysis None None O
suggested None None O
a None None O
specific None None O
activation None None O
or None None O
differentiation None None O
of None None O
resident None None O
macrophages None None O
by None None O
apoptotic None None O
cells None None O
. None None O

These None None O
biologic None None O
insights None None O
are None None O
important None None O
arguments None None O
to None None O
advocate None None O
the None None O
use None None O
of None None O
low None None O
- None None O
dose None None O
radiotherapy None None O
as None None O
an None None O
effective None None O
palliative None None O
treatment None None O
for None None O
follicular None None O
lymphoma None None O
. None None O

Moreover None None O
, None None O
this None None O
study None None O
is None None O
the None None O
first None None O
in None None O
vivo None None O
report None None O
of None None O
the None None O
radiation None None O
- None None O
induced None None O
p53 None None O
apoptotic None None O
response None None O
in None None O
patients None None O
and None None O
suggests None None O
that None None O
this None None O
apoptotic None None O
response None None O
is None None O
not None None O
immunologically None None O
silent None None O
. None None O

Islet None None O
endothelial None None O
activation None None O
and None None O
oxidative None None O
stress None None O
gene None None O
expression None None O
is None None O
reduced None None O
by None None O
IL None None O
- None None O
1Ra None None O
treatment None None O
in None None O
the None None O
type None None O
2 None None O
diabetic None None O
GK None None O
rat None None O
. None None O

BACKGROUND None None O
: None None O
Inflammation None None O
followed None None O
by None None O
fibrosis None None O
is None None O
a None None O
component None None O
of None None O
islet None None O
dysfunction None None O
in None None O
both None None O
rodent None None O
and None None O
human None None O
type None None O
2 None None O
diabetes None None O
. None None O

Because None None O
islet None None O
inflammation None None O
may None None O
originate None None O
from None None O
endothelial None None O
cells None None O
, None None O
we None None O
assessed None None O
the None None O
expression None None O
of None None O
selected None None O
genes None None O
involved None None O
in None None O
endothelial None None O
cell None None O
activation None None O
in None None O
islets None None O
from None None O
a None None O
spontaneous None None O
model None None O
of None None O
type None None O
2 None None O
diabetes None None O
, None None O
the None None O
Goto None None O
- None None O
Kakizaki None None O
( None None O
GK None None O
) None None O
rat None None O
. None None O

We None None O
also None None O
examined None None O
islet None None O
endotheliuml None None O
/ None None O
oxidative None None O
stress None None O
( None None O
OS None None O
) None None O
/ None None O
inflammation None None O
- None None O
related None None O
gene None None O
expression None None O
, None None O
islet None None O
vascularization None None O
and None None O
fibrosis None None O
after None None O
treatment None None O
with None None O
the None None O
interleukin None None O
- None None O
1 None None O
( None None O
IL None None O
- None None O
1 None None O
) None None O
receptor None None O
antagonist None None O
( None None O
IL None None O
- None None O
1Ra None None O
) None None O
. None None O

METHODOLOGY None None O
/ None None O
PRINCIPAL None None O
FINDINGS None None O
: None None O
Gene None None O
expression None None O
was None None O
analyzed None None O
by None None O
quantitative None None O
RT None None O
- None None O
PCR None None O
on None None O
islets None None O
isolated None None O
from None None O
10 None None O
- None None O
week None None O
- None None O
old None None O
diabetic None None O
GK None None O
and None None O
control None None O
Wistar None None O
rats None None O
. None None O

Furthermore None None O
, None None O
GK None None O
rats None None O
were None None O
treated None None O
s None None O
. None None O
c None None O
twice None None O
daily None None O
with None None O
IL None None O
- None None O
1Ra None None O
( None None O
Kineret None None O
, None None O
Amgen None None O
, None None O
100 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
or None None O
saline None None O
, None None O
from None None O
4 None None O
weeks None None O
of None None O
age None None O
onwards None None O
( None None O
onset None None O
of None None O
diabetes None None O
) None None O
. None None O

Four None None O
weeks None None O
later None None O
, None None O
islet None None O
gene None None O
analysis None None O
and None None O
pancreas None None O
immunochemistry None None O
were None None O
performed None None O
. None None O

Thirty None None O
- None None O
two None None O
genes None None O
were None None O
selected None None O
encoding None None O
molecules None None O
involved None None O
in None None O
endothelial None None O
cell None None O
activation None None O
, None None O
particularly None None O
fibrinolysis None None O
, None None O
vascular None None O
tone None None O
, None None O
OS None None O
, None None O
angiogenesis None None O
and None None O
also None None O
inflammation None None O
. None None O

All None None O
genes None None O
except None None O
those None None O
encoding None None O
angiotensinogen None None O
and None None O
epoxide None None O
hydrolase None None O
( None None O
that None None O
were None None O
decreased None None O
) None None O
, None None O
and None None O
12 None None O
- None None O
lipoxygenase None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
that None None O
showed None None O
no None None O
change None None O
) None None O
, None None O
were None None O
significantly None None O
up None None O
- None None O
regulated None None O
in None None O
GK None None O
islets None None O
. None None O

After None None O
IL None None O
- None None O
1Ra None None O
treatment None None O
of None None O
GK None None O
rats None None O
in None None O
vivo None None O
, None None O
most None None O
selected None None O
genes None None O
implied None None O
in None None O
endothelium None None O
/ None None O
OS None None O
/ None None O
immune None None O
cells None None O
/ None None O
fibrosis None None O
were None None O
significantly None None O
down None None O
- None None O
regulated None None O
. None None O

IL None None O
- None None O
1Ra None None O
also None None O
improved None None O
islet None None O
vascularization None None O
, None None O
reduced None None O
fibrosis None None O
and None None O
ameliorated None None O
glycemia None None O
. None None O

CONCLUSIONS None None O
/ None None O
SIGNIFICANCE None None O
: None None O
GK None None O
rat None None O
islets None None O
have None None O
increased None None O
mRNA None None O
expression None None O
of None None O
markers None None O
of None None O
early None None O
islet None None O
endothelial None None O
cell None None O
activation None None O
, None None O
possibly None None O
triggered None None O
by None None O
several None None O
metabolic None None O
factors None None O
, None None O
and None None O
also None None O
some None None O
defense None None O
mechanisms None None O
. None None O

The None None O
beneficial None None O
effect None None O
of None None O
IL None None O
- None None O
1Ra None None O
on None None O
most None None O
islet None None O
endothelial None None O
/ None None O
OS None None O
/ None None O
immune None None O
cells None None O
/ None None O
fibrosis None None O
parameters None None O
analyzed None None O
highlights None None O
a None None O
major None None O
endothelial None None O
- None None O
related None None O
role None None O
for None None O
IL None None O
- None None O
1 None None O
in None None O
GK None None O
islet None None O
alterations None None O
. None None O

Thus None None O
, None None O
metabolically None None O
- None None O
altered None None O
islet None None O
endothelium None None O
might None None O
affect None None O
the None None O
beta None None O
- None None O
cell None None O
microenvironment None None O
and None None O
contribute None None O
to None None O
progressive None None O
type None None O
2 None None O
diabetic None None O
beta None None O
- None None O
cell None None O
dysfunction None None O
in None None O
GK None None O
rats None None O
. None None O

Counteracting None None O
islet None None O
endothelial None None O
cell None None O
inflammation None None O
might None None O
be None None O
one None None O
way None None O
to None None O
ameliorate None None O
/ None None O
prevent None None O
beta None None O
- None None O
cell None None O
dysfunction None None O
in None None O
type None None O
2 None None O
diabetes None None O
. None None O

p18Ink4c None None O
, None None O
but None None O
not None None O
p27Kip1 None None O
, None None O
collaborates None None O
with None None O
Men1 None None O
to None None O
suppress None None O
neuroendocrine None None O
organ None None O
tumors None None O
. None None O

Mutant None None O
mice None None O
lacking None None O
both None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
( None None O
CDK None None O
) None None O
inhibitors None None O
p18 None None O
( None None O
Ink4c None None O
) None None O
and None None O
p27 None None O
( None None O
Kip1 None None O
) None None O
develop None None O
a None None O
tumor None None O
spectrum None None O
reminiscent None None O
of None None O
human None None O
multiple None None O
endocrine None None O
neoplasia None None O
( None None O
MEN None None O
) None None O
syndromes None None O
. None None O

To None None O
determine None None O
how None None O
p18 None None O
and None None O
p27 None None O
genetically None None O
interact None None O
with None None O
Men1 None None O
, None None O
the None None O
tumor None None O
suppressor None None O
gene None None O
mutated None None O
in None None O
familial None None O
MEN1 None None O
, None None O
we None None O
characterized None None O
p18 None None O
- None None O
Men1 None None O
and None None O
p27 None None O
- None None O
Men1 None None O
double None None O
mutant None None O
mice None None O
. None None O

Compared None None O
with None None O
their None None O
corresponding None None O
single None None O
mutant None None O
littermates None None O
, None None O
the None None O
p18 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
; None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
mice None None O
develop None None O
tumors None None O
at None None O
an None None O
accelerated None None O
rate None None O
and None None O
with None None O
an None None O
increased None None O
incidence None None O
in None None O
the None None O
pituitary None None O
, None None O
thyroid None None O
, None None O
parathyroid None None O
, None None O
and None None O
pancreas None None O
. None None O

In None None O
the None None O
pituitary None None O
and None None O
pancreatic None None O
islets None None O
, None None O
phosphorylation None None O
of None None O
the None None O
retinoblastoma None None O
( None None O
Rb None None O
) None None O
protein None None O
at None None O
both None None O
CDK2 None None O
and None None O
CDK4 None None O
/ None None O
6 None None O
sites None None O
was None None O
increased None None O
in None None O
p18 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
and None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
cells None None O
and None None O
was None None O
further None None O
increased None None O
in None None O
p18 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
; None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
cells None None O
. None None O

The None None O
remaining None None O
wild None None O
- None None O
type None None O
Men1 None None O
allele None None O
was None None O
lost None None O
in None None O
most None None O
tumors None None O
from None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
mice None None O
but None None O
was None None O
retained None None O
in None None O
most None None O
tumors None None O
from None None O
p18 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
; None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
mice None None O
. None None O

Combined None None O
mutations None None O
of None None O
p27 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
and None None O
Men1 None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
, None None O
in None None O
contrast None None O
, None None O
did None None O
not None None O
exhibit None None O
noticeable None None O
synergistic None None O
stimulation None None O
of None None O
Rb None None O
kinase None None O
activity None None O
, None None O
cell None None O
proliferation None None O
, None None O
and None None O
tumor None None O
growth None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
functional None None O
collaboration None None O
exists None None O
between None None O
p18 None None O
and None None O
Men1 None None O
and None None O
suggest None None O
that None None O
Men1 None None O
may None None O
regulate None None O
additional None None O
factor None None O
( None None O
s None None O
) None None O
that None None O
interact None None O
with None None O
p18 None None O
and None None O
p27 None None O
differently None None O
. None None O

Background None None O

Eucalyptus None None O
globulus None None O
is None None O
the None None O
most None None O
widely None None O
planted None None O
species None None O
for None None O
pulpwood None None O
production None None O
in None None O
temperate None None O
regions None None O
of None None O
the None None O
world None None O
and None None O
there None None O
are None None O
breeding None None O
programs None None O
in None None O
numerous None None O
countries None None O
. None None O

There None None O
is None None O
interest None None O
in None None O
molecular None None O
approaches None None O
to None None O
breeding None None O
, None None O
particularly None None O
marker None None O
assisted None None O
selection None None O
of None None O
wood None None O
properties None None O
. None None O

QTL None None O
analysis None None O
has None None O
an None None O
important None None O
role None None O
in None None O
identifying None None O
positional None None O
candidate None None O
genes None None O
responsible None None O
for None None O
variation None None O
in None None O
wood None None O
properties None None O
. None None O

This None None O
is None None O
one None None O
approach None None O
to None None O
targeting None None O
genes None None O
which None None O
may None None O
harbour None None O
functional None None O
allelic None None O
variants None None O
( None None O
SNPs None None O
) None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
detect None None O
and None None O
validate None None O
QTL None None O
across None None O
multiple None None O
sites None None O
and None None O
pedigrees None None O
, None None O
in None None O
order None None O
to None None O
identify None None O
genomic None None O
regions None None O
and None None O
genes None None O
affecting None None O
growth None None O
and None None O
wood None None O
properties None None O
with None None O
wide None None O
applicability None None O
in None None O
the None None O
species None None O
. None None O

We None None O
also None None O
aimed None None O
to None None O
determine None None O
the None None O
proportion None None O
of None None O
QTL None None O
which None None O
were None None O
stable None None O
in None None O
their None None O
expression None None O
across None None O
sites None None O
of None None O
contrasting None None O
productivity None None O
. None None O

Such None None O
information None None O
will None None O
be None None O
important None None O
to None None O
exploit None None O
the None None O
full None None O
potential None None O
of None None O
the None None O
impending None None O
Eucalyptus None None O
genome None None O
sequences None None O
. None None O

Therapeutic None None O
angiogenesis None None O
: None None O
a None None O
complex None None O
problem None None O
requiring None None O
a None None O
sophisticated None None O
approach None None O
. None None O

Blood None None O
and None None O
vascular None None O
disorders None None O
underlie None None O
a None None O
plethora None None O
of None None O
pathologic None None O
conditions None None O
and None None O
are None None O
the None None O
single None None O
most None None O
frequent None None O
cause None None O
of None None O
human None None O
disease None None O
. None None O

Ischemia None None O
, None None O
involving None None O
restricted None None O
blood None None O
flow None None O
to None None O
tissues None None O
is None None O
the None None O
most None None O
common None None O
consequence None None O
of None None O
vessel None None O
dysfunction None None O
resulting None None O
in None None O
the None None O
disruption None None O
of None None O
oxygen None None O
and None None O
nutrient None None O
delivery None None O
and None None O
the None None O
accumulation None None O
of None None O
waste None None O
metabolites None None O
. None None O

Cells None None O
cannot None None O
survive None None O
extended None None O
severe None None O
ischemia None None O
but None None O
may None None O
be None None O
able None None O
to None None O
adapt None None O
to None None O
a None None O
moderate None None O
condition None None O
where None None O
diffusion None None O
to None None O
and None None O
from None None O
bordering None None O
nonischemic None None O
regions None None O
sustains None None O
vital None None O
functions None None O
. None None O

Under None None O
this None None O
condition None None O
, None None O
the None None O
secondary None None O
functions None None O
of None None O
effected None None O
cells None None O
are None None O
likely None None O
to None None O
be None None O
impaired None None O
, None None O
and None None O
a None None O
new None None O
metabolic None None O
equilibrium None None O
is None None O
established None None O
, None None O
determined None None O
by None None O
the None None O
level None None O
of None None O
cross None None O
- None None O
diffusion None None O
and None None O
degree None None O
of None None O
hypoxia None None O
. None None O

In None None O
tissues None None O
with None None O
a None None O
normally None None O
high None None O
metabolic None None O
turnover None None O
such None None O
as None None O
skeletal None None O
and None None O
cardiac None None O
muscle None None O
, None None O
even None None O
mild None None O
ischemia None None O
causes None None O
hypoxia None None O
, None None O
acidosis None None O
, None None O
and None None O
depressed None None O
function None None O
( None None O
contractility None None O
) None None O
and None None O
eventually None None O
threatens None None O
myocyte None None O
viability None None O
and None None O
organ None None O
function None None O
. None None O

Ischemic None None O
cardiac None None O
muscle None None O
is None None O
additionally None None O
vulnerable None None O
because None None O
reperfusion None None O
is None None O
essential None None O
for None None O
survival None None O
but None None O
reperfusion None None O
itself None None O
poses None None O
additional None None O
stress None None O
principally None None O
from None None O
increased None None O
production None None O
of None None O
free None None O
radicals None None O
during None None O
reoxygenation None None O
. None None O

The None None O
latter None None O
effect None None O
is None None O
called None None O
reperfusion None None O
injury None None O
and None None O
can None None O
cause None None O
as None None O
much None None O
damage None None O
as None None O
the None None O
ischemia None None O
. None None O

The None None O
treatment None None O
possibilities None None O
for None None O
ischemia None None O
- None None O
related None None O
vascular None None O
disease None None O
are None None O
limited None None O
. None None O

Lipid None None O
/ None None O
cholesterol None None O
- None None O
lowering None None O
agents None None O
, None None O
diet None None O
and None None O
antiplatelet None None O
adherence None None O
( None None O
aspirin None None O
) None None O
therapy None None O
may None None O
help None None O
slow None None O
the None None O
progression None None O
of None None O
vessel None None O
disease None None O
in None None O
some None None O
instances None None O
; None None O
but None None O
surgical None None O
reconstruction None None O
may None None O
be None None O
the None None O
only None None O
option None None O
in None None O
advanced None None O
stages None None O
, None None O
and None None O
even None None O
this None None O
is None None O
not None None O
always None None O
an None None O
option None None O
. None None O

An None None O
alternative None None O
and None None O
rather None None O
obvious None None O
strategy None None O
to None None O
treat None None O
ischemia None None O
is None None O
to None None O
activate None None O
endogenous None None O
angiogenic None None O
or None None O
arteriogenic None None O
pathways None None O
to None None O
stimulate None None O
revascularization None None O
of None None O
the None None O
tissue None None O
. None None O

The None None O
feasibility None None O
of None None O
such None None O
a None None O
strategy None None O
has None None O
now None None O
been None None O
established None None O
through None None O
the None None O
results None None O
of None None O
studies None None O
over None None O
the None None O
past None None O
decade None None O
, None None O
and None None O
a None None O
new None None O
discipline None None O
called None None O
therapeutic None None O
angiogenesis None None O
has None None O
emerged None None O
. None None O

This None None O
review None None O
focuses None None O
on None None O
the None None O
application None None O
of None None O
therapeutic None None O
angiogenesis None None O
for None None O
treating None None O
ischemic None None O
muscle None None O
disease None None O
and None None O
includes None None O
a None None O
critical None None O
evaluation None None O
of None None O
the None None O
parameters None None O
and None None O
limitations None None O
of None None O
current None None O
procedures None None O
. None None O

The None None O
development None None O
of None None O
this None None O
technology None None O
has None None O
benefited None None O
from None None O
its None None O
application None None O
to None None O
both None None O
peripheral None None O
and None None O
coronary None None O
artery None None O
disease None None O
and None None O
results None None O
from None None O
both None None O
are None None O
reviewed None None O
here None None O
. None None O

Burns None None O
from None None O
hot None None O
wheat None None O
bags None None O
: None None O
a None None O
public None None O
safety None None O
issue None None O
. None None O

Introduction None None O
: None None O
Wheat None None O
bags None None O
are None None O
therapeutic None None O
devices None None O
that None None O
are None None O
heated None None O
in None None O
microwaves None None O
and None None O
commonly None None O
used None None O
to None None O
provide None None O
relief None None O
from None None O
muscle None None O
and None None O
joint None None O
pain None None O
. None None O

The None None O
Royal None None O
Adelaide None None O
Hospital None None O
Burns None None O
Unit None None O
has None None O
observed None None O
a None None O
number None None O
of None None O
patients None None O
with None None O
significant None None O
burn None None O
injuries None None O
resulting None None O
from None None O
their None None O
use None None O
. None None O

Despite None None O
their None None O
dangers None None O
, None None O
the None None O
products None None O
come None None O
with None None O
limited None None O
safety None None O
information None None O
. None None O

Methods None None O
: None None O
Data None None O
were None None O
collected None None O
from None None O
the None None O
Burns None None O
Unit None None O
database None None O
for None None O
all None None O
patients None None O
admitted None None O
with None None O
burns None None O
due None None O
to None None O
hot None None O
wheat None None O
bags None None O
from None None O
2004 None None O
to None None O
2009 None None O
. None None O

This None None O
was None None O
analyzed None None O
to None None O
determine None None O
the None None O
severity None None O
of None None O
the None None O
burn None None O
injury None None O
and None None O
identify None None O
any None None O
predisposing None None O
factors None None O
. None None O

An None None O
experimental None None O
study None None O
was None None O
performed None None O
to None None O
measure None None O
the None None O
temperature None None O
of None None O
wheat None None O
bags None None O
when None None O
heated None None O
to None None O
determine None None O
their None None O
potential None None O
for None None O
causing None None O
thermal None None O
injury None None O
. None None O

Results None None O
: None None O
11 None None O
patients None None O
were None None O
admitted None None O
with None None O
burns None None O
due None None O
to None None O
hot None None O
wheat None None O
bags None None O
. None None O

The None None O
median None None O
age None None O
was None None O
52 None None O
years None None O
and None None O
the None None O
mean None None O
total None None O
body None None O
surface None None O
area None None O
was None None O
1 None None O
. None None O
1 None None O
% None None O
. None None O

All None None O
burns None None O
were None None O
either None None O
deep None None O
dermal None None O
( None None O
45 None None O
. None None O
5 None None O
% None None O
) None None O
or None None O
full None None O
thickness None None O
( None None O
54 None None O
. None None O
5 None None O
% None None O
) None None O
. None None O

Ten None None O
patients None None O
required None None O
operative None None O
management None None O
. None None O

Predisposing None None O
factors None None O
( None None O
eg None None O
, None None O
neuropathy None None O
) None None O
to None None O
thermal None None O
injury None None O
were None None O
identified None None O
in None None O
7 None None O
patients None None O
. None None O

The None None O
experimental None None O
study None None O
showed None None O
that None None O
hot None None O
wheat None None O
bags None None O
reached None None O
temperatures None None O
of None None O
57 None None O
. None None O
3degreesC None None O
( None None O
135 None None O
. None None O
1degreesF None None O
) None None O
when None None O
heated None None O
according None None O
to None None O
instructions None None O
, None None O
63 None None O
. None None O
3degreesC None None O
( None None O
145 None None O
. None None O
9degreesF None None O
) None None O
in None None O
a None None O
1000 None None O
W None None O
microwave None None O
and None None O
69 None None O
. None None O
6degreesC None None O
( None None O
157 None None O
. None None O
3degreesF None None O
) None None O
on None None O
reheating None None O
. None None O

Conclusions None None O
: None None O
Hot None None O
wheat None None O
bags None None O
cause None None O
serious None None O
burn None None O
injury None None O
. None None O

When None None O
heated None None O
improperly None None O
, None None O
they None None O
can None None O
reach None None O
temperatures None None O
high None None O
enough None None O
to None None O
cause None None O
epidermal None None O
necrosis None None O
in None None O
a None None O
short None None O
period None None O
of None None O
time None None O
. None None O

Patients None None O
with None None O
impaired None None O
temperature None None O
sensation None None O
are None None O
particularly None None O
at None None O
risk None None O
. None None O

There None None O
should None None O
be None None O
greater None None O
public None None O
awareness None None O
of None None O
the None None O
dangers None None O
of None None O
wheat None None O
bag None None O
use None None O
and None None O
more None None O
specific None None O
safety None None O
warnings None None O
on None None O
the None None O
products None None O
. None None O

IL None None O
- None None O
17F None None O
deficiency None None O
inhibits None None O
small None None O
intestinal None None O
tumorigenesis None None O
in None None O
ApcMin None None O
/ None None O
+ None None O
mice None None O
. None None O

IL None None O
- None None O
17 None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
gut None None O
homeostasis None None O
. None None O

However None None O
, None None O
the None None O
role None None O
of None None O
IL None None O
- None None O
17F None None O
in None None O
intestinal None None O
tumorigenesis None None O
has None None O
not None None O
been None None O
addressed None None O
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
ablation None None O
of None None O
IL None None O
- None None O
17F None None O
significantly None None O
inhibits None None O
spontaneous None None O
intestinal None None O
tumorigenesis None None O
in None None O
the None None O
small None None O
intestine None None O
of None None O
Apc None None O
( None None O
Min None None O
/ None None O
+ None None O
) None None O
mice None None O
. None None O

IL None None O
- None None O
17F None None O
ablation None None O
decreased None None O
IL None None O
- None None O
1beta None None O
and None None O
Cox None None O
- None None O
2 None None O
expression None None O
as None None O
well None None O
as None None O
IL None None O
- None None O
17 None None O
receptor None None O
C None None O
( None None O
IL None None O
- None None O
17RC None None O
) None None O
expression None None O
, None None O
which None None O
were None None O
increased None None O
in None None O
tumors None None O
from None None O
Apc None None O
( None None O
Min None None O
/ None None O
+ None None O
) None None O
mice None None O
. None None O

Lack None None O
of None None O
IL None None O
- None None O
17F None None O
did None None O
not None None O
reverse None None O
the None None O
splenomegaly None None O
but None None O
partially None None O
restored None None O
thymic None None O
atrophy None None O
, None None O
suggesting None None O
a None None O
local None None O
effect None None O
of None None O
IL None None O
- None None O
17F None None O
in None None O
the None None O
intestine None None O
. None None O

IL None None O
- None None O
17F None None O
deficient None None O
Apc None None O
( None None O
Min None None O
/ None None O
+ None None O
) None None O
mice None None O
showed None None O
a None None O
significant None None O
decrease None None O
in None None O
immune None None O
cell None None O
infiltration None None O
in None None O
the None None O
lamina None None O
propria None None O
. None None O

Interestingly None None O
, None None O
the None None O
expression None None O
of None None O
IL None None O
- None None O
17A None None O
from None None O
CD4 None None O
T None None O
cells None None O
in None None O
the None None O
lamina None None O
propria None None O
remains None None O
unchanged None None O
in None None O
the None None O
absence None None O
of None None O
IL None None O
- None None O
17F None None O
. None None O

Collectively None None O
, None None O
our None None O
results None None O
suggest None None O
the None None O
proinflammatory None None O
and None None O
essential None None O
role None None O
of None None O
IL None None O
- None None O
17F None None O
to None None O
develop None None O
spontaneous None None O
intestinal None None O
tumorigenesis None None O
in None None O
Apc None None O
( None None O
Min None None O
/ None None O
+ None None O
) None None O
mice None None O
in None None O
the None None O
presence None None O
of None None O
IL None None O
- None None O
17A None None O
. None None O

Overexpression None None O
confers None None O
an None None O
oncogenic None None O
potential None None O
upon None None O
the None None O
eph None None O
gene None None O
. None None O

The None None O
eph None None O
gene None None O
encodes None None O
a None None O
putative None None O
receptor None None O
tyrosine None None O
kinase None None O
for None None O
an None None O
as None None O
yet None None O
unknown None None O
ligand None None O
. None None O

Some None None O
human None None O
cancer None None O
cells None None O
have None None O
been None None O
found None None O
to None None O
overexpress None None O
eph None None O
mRNAs None None O
without None None O
gene None None O
amplification None None O
. None None O

We None None O
show None None O
here None None O
that None None O
NIH3T3 None None I-Cell-line-name
cells None None O
acquire None None O
tumorigenic None None O
ability None None O
in None None O
nude None None O
mice None None O
and None None O
make None None O
colonies None None O
in None None O
soft None None O
agar None None O
with None None O
a None None O
viral None None O
LTR None None O
( None None O
Long None None O
Terminal None None O
Repeat None None O
) None None O
- None None O
driven None None O
artificial None None O
expression None None O
of None None O
the None None O
eph None None O
gene None None O
to None None O
a None None O
high None None O
level None None O
. None None O

This None None O
result None None O
supports None None O
the None None O
alleged None None O
contribution None None O
of None None O
overexpressed None None O
receptor None None O
tyrosine None None O
kinases None None O
to None None O
cell None None O
transformation None None O
. None None O

4 None None O
. None None O

The None None O
kinetochore None None O

The None None O
arguments None None O
built None None O
in None None O
the None None O
previous None None O
section None None O
lead None None O
to None None O
the None None O
conclusion None None O
that None None O
it None None O
is None None O
essential None None O
to None None O
understand None None O
error None None O
correction None None O
and None None O
spindle None None O
checkpoint None None O
signalling None None O
in None None O
the None None O
context None None O
of None None O
the None None O
complex None None O
structural None None O
organization None None O
of None None O
the None None O
kinetochore None None O
. None None O

A None None O
complete None None O
account None None O
of None None O
kinetochore None None O
organization None None O
is None None O
beyond None None O
the None None O
scope None None O
of None None O
this None None O
review None None O
and None None O
several None None O
reviews None None O
on None None O
this None None O
topic None None O
have None None O
been None None O
made None None O
available None None O
recently None None O
[ None None O
21 None None O
, None None O
22 None None O
] None None O
. None None O

Suffice None None O
to None None O
say None None O
that None None O
kinetochores None None O
are None None O
thought None None O
to None None O
consist None None O
of None None O
an None None O
inner None None O
plate None None O
hosting None None O
an None None O
interface None None O
between None None O
the None None O
15 None None O
- None None O
subunit None None O
constitutive None None O
centromere None None O
- None None O
associated None None O
network None None O
( None None O
CCAN None None O
) None None O
and None None O
specialized None None O
centromeric None None O
chromatin None None O
; None None O
and None None O
an None None O
outer None None O
plate None None O
containing None None O
the None None O
10 None None O
- None None O
subunit None None O
KMN None None O
network None None O
( None None O
from None None O
the None None O
initials None None O
of None None O
its None None O
Knl1 None None O
, None None O
Mis12 None None O
and None None O
Ndc80 None None O
subcomplexes None None O
) None None O
implicated None None O
in None None O
microtubule None None O
binding None None O
. None None O

The None None O
CCAN None None O
and None None O
KMN None None O
networks None None O
are None None O
tightly None None O
connected None None O
. None None O

An None None O
interaction None None O
between None None O
CENP None None O
- None None O
C None None O
( None None O
CCAN None None O
) None None O
and None None O
the None None O
Mis12 None None O
complex None None O
( None None O
KMN None None O
network None None O
) None None O
provides None None O
an None None O
important None None O
point None None O
of None None O
contact None None O
[ None None O
81 None None O
- None None O
83 None None O
] None None O
. None None O

The None None O
existence None None O
of None None O
additional None None O
points None None O
of None None O
contact None None O
, None None O
including None None O
one None None O
between None None O
CENP None None O
- None None O
T None None O
( None None O
CCAN None None O
) None None O
and None None O
the None None O
Ndc80 None None O
subcomplex None None O
( None None O
KMN None None O
network None None O
) None None O
[ None None O
83 None None O
, None None O
84 None None O
] None None O
, None None O
is None None O
supported None None O
by None None O
extensive None None O
analyses None None O
of None None O
localization None None O
dependencies None None O
of None None O
kinetochore None None O
proteins None None O
and None None O
from None None O
initial None None O
experiments None None O
of None None O
biochemical None None O
reconstitution None None O
. None None O

Biochemical None None O
and None None O
structural None None O
studies None None O
, None None O
including None None O
super None None O
- None None O
resolution None None O
investigations None None O
of None None O
kinetochore None None O
organization None None O
by None None O
fluorescence None None O
microscopy None None O
, None None O
have None None O
finally None None O
resulted None None O
in None None O
rather None None O
precise None None O
maps None None O
of None None O
the None None O
relative None None O
position None None O
of None None O
many None None O
structural None None O
kinetochore None None O
proteins None None O
and None None O
of None None O
several None None O
checkpoint None None O
components None None O
[ None None O
85 None None O
- None None O
88 None None O
] None None O
. None None O

For None None O
instance None None O
, None None O
these None None O
studies None None O
clarified None None O
that None None O
the None None O
highly None None O
elongated None None O
4 None None O
- None None O
subunit None None O
Ndc80 None None O
complex None None O
, None None O
conserved None None O
in None None O
all None None O
eukaryotes None None O
, None None O
orients None None O
its None None O
approximately None None O
60 None None O
nm None None O
long None None O
axis None None O
at None None O
a None None O
relatively None None O
small None None O
angle None None O
with None None O
the None None O
inter None None O
- None None O
kinetochore None None O
axis None None O
[ None None O
85 None None O
- None None O
87 None None O
] None None O
. None None O

The None None O
kinetochore None None O
- None None O
binding None None O
end None None O
of None None O
the None None O
Ndc80 None None O
complex None None O
was None None O
predicted None None O
to None None O
be None None O
positioned None None O
near None None O
the None None O
Mis12 None None O
and None None O
Knl1 None None O
complexes None None O
[ None None O
87 None None O
, None None O
88 None None O
] None None O
, None None O
and None None O
this None None O
prediction None None O
was None None O
fully None None O
confirmed None None O
in None None O
experiments None None O
of None None O
biochemical None None O
reconstitution None None O
[ None None O
89 None None O
] None None O
. None None O

In None None O
prophase None None O
Drosophila None None O
melanogaster None None O
S2 None None I-Cell-line-name
cells None None O
, None None O
the None None O
C None None O
- None None O
terminal None None O
region None None O
of None None O
the None None O
Ndc80 None None O
subunit None None O
is None None O
located None None O
approximately None None O
65 None None O
nm None None O
outward None None O
( None None O
i None None O
. None None O
e None None O
. None None O
towards None None O
the None None O
microtubule None None O
) None None O
relative None None O
to None None O
CENP None None O
- None None O
A None None O
, None None O
the None None O
histone None None O
H3 None None O
variant None None O
that None None O
marks None None O
centromeres None None O
from None None O
yeast None None O
to None None O
humans None None O
[ None None O
40 None None O
] None None O
. None None O

Remarkably None None O
, None None O
it None None O
was None None O
shown None None O
that None None O
this None None O
distance None None O
increases None None O
to None None O
approximately None None O
100 None None O
nm None None O
when None None O
kinetochores None None O
experience None None O
microtubule None None O
- None None O
dependent None None O
tension None None O
at None None O
metaphase None None O
[ None None O
40 None None O
] None None O
. None None O

This None None O
phenomenon None None O
is None None O
now None None O
known None None O
as None None O
intra None None O
- None None O
kinetochore None None O
stretch None None O
or None None O
tension None None O
[ None None O
40 None None O
, None None O
90 None None O
] None None O
. None None O

A None None O
major None None O
task None None O
for None None O
the None None O
future None None O
is None None O
to None None O
understand None None O
how None None O
intra None None O
- None None O
kinetochore None None O
stretch None None O
is None None O
generated None None O
when None None O
microtubules None None O
bind None None O
the None None O
kinetochore None None O
. None None O

At None None O
one None None O
extreme None None O
, None None O
intra None None O
- None None O
kinetochore None None O
stretching None None O
might None None O
be None None O
the None None O
result None None O
of None None O
a None None O
discreet None None O
conformational None None O
change None None O
in None None O
the None None O
kinetochore None None O
caused None None O
by None None O
microtubule None None O
binding None None O
[ None None O
22 None None O
, None None O
91 None None O
] None None O
. None None O

While None None O
this None None O
is None None O
possible None None O
, None None O
it None None O
seems None None O
unlikely None None O
when None None O
considering None None O
the None None O
great None None O
structural None None O
complexity None None O
of None None O
kinetochores None None O
. None None O

Each None None O
microtubule None None O
- None None O
binding None None O
site None None O
contains None None O
six None None O
to None None O
eight None None O
copies None None O
of None None O
the None None O
approximately None None O
30 None None O
structural None None O
kinetochore None None O
components None None O
[ None None O
85 None None O
] None None O
. None None O

Furthermore None None O
, None None O
in None None O
most None None O
species None None O
, None None O
kinetochores None None O
are None None O
designed None None O
to None None O
bind None None O
multiple None None O
microtubules None None O
. None None O

Plausibly None None O
, None None O
each None None O
microtubule None None O
- None None O
binding None None O
site None None O
becomes None None O
engaged None None O
at None None O
a None None O
different None None O
time None None O
. None None O

Thus None None O
, None None O
it None None O
may None None O
be None None O
more None None O
sensible None None O
to None None O
interpret None None O
intra None None O
- None None O
kinetochore None None O
stretching None None O
as None None O
a None None O
progressive None None O
, None None O
continuous None None O
distortion None None O
of None None O
the None None O
kinetochore None None O
when None None O
microtubules None None O
are None None O
added None None O
. None None O

In None None O
agreement None None O
with None None O
this None None O
idea None None O
, None None O
intermediate None None O
levels None None O
of None None O
stretching None None O
are None None O
observed None None O
when None None O
microtubule None None O
end None None O
dynamics None None O
are None None O
inhibited None None O
through None None O
addition None None O
of None None O
taxol None None O
[ None None O
40 None None O
] None None O
. None None O

Importantly None None O
, None None O
intra None None O
- None None O
kinetochore None None O
stretch None None O
was None None O
shown None None O
to None None O
correlate None None O
with None None O
the None None O
status None None O
of None None O
checkpoint None None O
activation None None O
, None None O
with None None O
high None None O
stretch None None O
being None None O
correlated None None O
with None None O
checkpoint None None O
satisfaction None None O
. None None O

This None None O
idea None None O
of None None O
checkpoint None None O
control None None O
is None None O
alternative None None O
to None None O
a None None O
previous None None O
idea None None O
that None None O
tension None None O
might None None O
be None None O
monitored None None O
at None None O
the None None O
centromere None None O
, None None O
i None None O
. None None O
e None None O
. None None O
between None None O
sister None None O
kinetochores None None O
( None None O
inter None None O
- None None O
kinetochore None None O
tension None None O
) None None O
[ None None O
46 None None O
] None None O
. None None O

A None None O
significant None None O
theoretical None None O
limitation None None O
of None None O
the None None O
idea None None O
that None None O
the None None O
checkpoint None None O
sensor None None O
monitors None None O
tension None None O
between None None O
sister None None O
kinetochores None None O
is None None O
that None None O
it None None O
is None None O
not None None O
applicable None None O
to None None O
meiosis None None O
I None None O
, None None O
when None None O
the None None O
sisters None None O
co None None O
- None None O
orient None None O
and None None O
the None None O
homologues None None O
pair None None O
through None None O
the None None O
chiasmata None None O
. None None O

Conversely None None O
, None None O
the None None O
intra None None O
- None None O
kinetochore None None O
tension None None O
idea None None O
is None None O
also None None O
applicable None None O
to None None O
checkpoint None None O
control None None O
in None None O
meiosis None None O
I None None O
. None None O

The None None O
effect None None O
of None None O
perfluorocarbon None None O
- None None O
based None None O
artificial None None O
oxygen None None O
carriers None None O
on None None O
tissue None None O
- None None O
engineered None None O
trachea None None O
. None None O

The None None O
biological None None O
effect None None O
of None None O
the None None O
perfluorocarbon None None O
- None None O
based None None O
artificial None None O
oxygen None None O
carrier None None O
( None None O
Oxygent None None O
) None None O
was None None O
investigated None None O
in None None O
tissue None None O
- None None O
engineered None None O
trachea None None O
( None None O
TET None None O
) None None O
construction None None O
. None None O

Media None None O
supplemented None None O
with None None O
and None None O
without None None O
10 None None O
% None None O
Oxygent None None O
were None None O
compared None None O
in None None O
all None None O
assessments None None O
. None None O

Partial None None O
tissue None None O
oxygen None None O
tension None None O
( None None O
PtO None None O
( None None O
2 None None O
) None None O
) None None O
was None None O
measured None None O
with None None O
polarographic None None O
microprobes None None O
; None None O
epithelial None None O
metabolism None None O
was None None O
monitored None None O
by None None O
microdialysis None None O
inside None None O
the None None O
TET None None O
epithelium None None O
perfused None None O
with None None O
the None None O
medium None None O
underneath None None O
. None None O

Chondrocyte None None O
- None None O
DegraPol None None O
constructs None None O
were None None O
cultured None None O
for None None O
1 None None O
month None None O
with None None O
the None None O
medium None None O
before None None O
glycosaminoglycan None None O
assessment None None O
and None None O
histology None None O
. None None O

Tissue None None O
reaction None None O
of None None O
TET None None O
epithelial None None O
scaffolds None None O
immersed None None O
with None None O
the None None O
medium None None O
was None None O
evaluated None None O
on None None O
the None None O
chick None None O
embryo None None O
chorioallantoic None None O
membrane None None O
. None None O

Oxygent None None O
perfusion None None O
medium None None O
increased None None O
the None None O
TET None None O
epithelial None None O
PtO None None O
( None None O
2 None None O
) None None O
( None None O
51 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
3 None None O
mm None None O
Hg None None O
vs None None O
. None None O
33 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
3 None None O
mm None None O
Hg None None O
at None None O
200 None None O
microm None None O
thickness None None O
; None None O
12 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
1 None None O
mm None None O
Hg None None O
vs None None O
. None None O
3 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
1 None None O
mm None None O
Hg None None O
at None None O
400 None None O
microm None None O
thickness None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
decreased None None O
the None None O
lactate None None O
concentration None None O
( None None O
0 None None O
. None None O
63 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
08 None None O
vs None None O
. None None O
0 None None O
. None None O
80 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
06 None None O
mmol None None O
/ None None O
L None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
lactate None None O
/ None None O
pyruvate None None O
( None None O
1 None None O
. None None O
87 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
26 None None O
vs None None O
. None None O
3 None None O
. None None O
36 None None O
+ None None O
/ None None O
- None None O
10 None None O
. None None O
13 None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
and None None O
lactate None None O
/ None None O
glucose None None O
ratios None None O
( None None O
0 None None O
. None None O
10 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
00 None None O
vs None None O
. None None O
0 None None O
. None None O
29 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
14 None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Chondrocyte None None O
- None None O
DegraPol None None O
in None None O
Oxygent None None O
group None None O
presented None None O
lower None None O
glycosaminoglycan None None O
value None None O
( None None O
0 None None O
. None None O
03 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
00 None None O
vs None None O
. None None O
0 None None O
. None None O
13 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
00 None None O
, None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
; None None O
histology None None O
slides None None O
showed None None O
poor None None O
acid None None O
mucopolysaccharides None None O
formation None None O
. None None O

Orthogonal None None O
polarization None None O
spectral None None O
imaging None None O
showed None None O
no None None O
difference None None O
in None None O
functional None None O
capillary None None O
density None None O
between None None O
the None None O
scaffolds None None O
cultured None None O
on None None O
chorioallantoic None None O
membranes None None O
. None None O

The None None O
foreign None None O
body None None O
reaction None None O
was None None O
similar None None O
in None None O
both None None O
groups None None O
. None None O

We None None O
conclude None None O
that None None O
Oxygent None None O
increases None None O
TET None None O
epithelial None None O
PtO None None O
( None None O
2 None None O
) None None O
, None None O
improves None None O
epithelial None None O
metabolism None None O
, None None O
does None None O
not None None O
impair None None O
angiogenesis None None O
, None None O
and None None O
tends None None O
to None None O
slow None None O
cartilage None None O
tissue None None O
formation None None O
. None None O

Prenatal None None O
aspects None None O
of None None O
ascorbic None None O
acid None None O
metabolism None None O
in None None O
the None None O
albino None None O
rat None None O
. None None O

Transfer None None O
of None None O
ascorbic None None O
acid None None O
and None None O
/ None None O
or None None O
its None None O
derivatives None None O
from None None O
maternal None None O
blood None None O
into None None O
the None None O
fetus None None O
was None None O
studied None None O
during None None O
the None None O
last None None O
week None None O
of None None O
gestation None None O
in None None O
the None None O
rat None None O
. None None O

Rats None None O
were None None O
injected None None O
intravenously None None O
with None None O
[ None None O
1 None None O
- None None O
14C None None O
] None None O
- None None O
ascorbic None None O
acid None None O
and None None O
the None None O
rate None None O
of None None O
transfer None None O
estimated None None O
by None None O
the None None O
concentration None None O
and None None O
content None None O
of None None O
label None None O
present None None O
in None None O
placentas None None O
and None None O
fetuses None None O
. None None O

At None None O
all None None O
times None None O
studied None None O
the None None O
concentration None None O
of None None O
label None None O
in None None O
the None None O
placenta None None O
was None None O
greater None None O
than None None O
in None None O
the None None O
fetus None None O
. None None O

The None None O
highest None None O
capacity None None O
of None None O
the None None O
placenta None None O
to None None O
concentrate None None O
label None None O
was None None O
found None None O
on None None O
day None None O
15 None None O
decreasing None None O
to None None O
a None None O
low None None O
at None None O
day None None O
19 None None O
and None None O
again None None O
increasing None None O
up None None O
to None None O
day None None O
21 None None O
. None None O

While None None O
in None None O
the None None O
fetuses None None O
, None None O
the None None O
concentration None None O
of None None O
label None None O
per None None O
gram None None O
of None None O
tissue None None O
remained None None O
remarkably None None O
constant None None O
throughout None None O
the None None O
study None None O
. None None O

The None None O
quantity None None O
of None None O
labeled None None O
compounds None None O
transferred None None O
into None None O
the None None O
fetus None None O
per None None O
gram None None O
of None None O
placental None None O
tissue None None O
increased None None O
between None None O
day None None O
15 None None O
and None None O
day None None O
21 None None O
of None None O
gestation None None O
. None None O

Skin None None O
deep None None O
and None None O
deeper None None O
: None None O
multiple None None O
pathways None None O
in None None O
basal None None O
cell None None O
carcinogenesis None None O
. None None O

This None None O
perspective None None O
places None None O
the None None O
report None None O
by None None O
Villani None None O
et None None O
al None None O
. None None O
that None None O
appears None None O
in None None O
this None None O
issue None None O
of None None O
the None None O
journal None None O
( None None O
beginning None None O
on None None O
page None None O
1222 None None O
) None None O
in None None O
the None None O
context None None O
of None None O
recent None None O
work None None O
showing None None O
an None None O
intersection None None O
between None None O
two None None O
important None None O
developmental None None O
pathways None None O
implicated None None O
in None None O
oncogenesis None None O
: None None O
the None None O
hedgehog None None O
and None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
( None None O
IGF None None O
) None None O
pathways None None O
. None None O

Villani None None O
et None None O
al None None O
. None None O
define None None O
a None None O
key None None O
role None None O
for None None O
the None None O
IGF None None O
regulatory None None O
protein None None O
Igfbp2 None None O
in None None O
a None None O
genetic None None O
model None None O
of None None O
basal None None O
cell None None O
carcinogenesis None None O
driven None None O
by None None O
targeted None None O
constitutive None None O
activation None None O
of None None O
hedgehog None None O
signaling None None O
. None None O

Placed None None O
in None None O
the None None O
framework None None O
of None None O
other None None O
recently None None O
published None None O
work None None O
, None None O
the None None O
observations None None O
of None None O
Villani None None O
et None None O
al None None O
. None None O
both None None O
raise None None O
questions None None O
about None None O
the None None O
cell None None O
of None None O
origin None None O
for None None O
basal None None O
cell None None O
cancers None None O
and None None O
define None None O
additional None None O
putative None None O
therapeutic None None O
and None None O
preventive None None O
targets None None O
for None None O
this None None O
disease None None O
. None None O

Angiogenin None None O
is None None O
up None None O
- None None O
regulated None None O
in None None O
the None None O
nucleus None None O
and None None O
cytoplasm None None O
in None None O
human None None O
primary None None O
breast None None O
carcinoma None None O
and None None O
is None None O
associated None None O
with None None O
markers None None O
of None None O
hypoxia None None O
but None None O
not None None O
survival None None O
. None None O

Angiogenin None None O
, None None O
a None None O
14 None None O
. None None O
2 None None O
kD None None O
polypeptide None None O
that None None O
was None None O
originally None None O
noted None None O
for None None O
its None None O
angiogenic None None O
activity None None O
, None None O
is None None O
now None None O
increasingly None None O
recognized None None O
to None None O
have None None O
a None None O
multiplicity None None O
of None None O
biological None None O
roles None None O
in None None O
both None None O
physiological None None O
and None None O
pathological None None O
conditions None None O
. None None O

In None None O
breast None None O
cancer None None O
, None None O
there None None O
are None None O
conflicting None None O
studies None None O
questioning None None O
the None None O
role None None O
of None None O
angiogenin None None O
. None None O

Here None None O
, None None O
the None None O
pattern None None O
of None None O
expression None None O
of None None O
angiogenin None None O
during None None O
the None None O
transition None None O
from None None O
normal None None O
breast None None O
tissue None None O
to None None O
ductal None None O
carcinoma None None O
in None None O
situ None None O
and None None O
invasive None None O
carcinoma None None O
is None None O
reported None None O
together None None O
with None None O
the None None O
correlates None None O
between None None O
the None None O
level None None O
of None None O
angiogenin None None O
in None None O
239 None None O
invasive None None O
carcinomas None None O
and None None O
standard None None O
clinicopathological None None O
parameters None None O
, None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
( None None O
HIF None None O
) None None O
- None None O
1 None None O
alpha None None O
and None None O
the None None O
HIF None None O
- None None O
1 None None O
alpha None None O
target None None O
gene None None O
DEC None None O
- None None O
1 None None O
. None None O

This None None O
study None None O
shows None None O
that None None O
angiogenin None None O
expression None None O
is None None O
up None None O
- None None O
regulated None None O
in None None O
the None None O
cytoplasmic None None O
and None None O
nuclear None None O
compartments None None O
in None None O
in None None O
situ None None O
carcinoma None None O
and None None O
invasive None None O
carcinoma None None O
compared None None O
with None None O
normal None None O
breast None None O
tissue None None O
and None None O
that None None O
angiogenin None None O
expression None None O
in None None O
invasive None None O
carcinomas None None O
is None None O
significantly None None O
positively None None O
associated None None O
with None None O
high None None O
tumour None None O
grade None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
, None None O
positive None None O
oestrogen None None O
receptor None None O
( None None O
ER None None O
) None None O
status None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
, None None O
HIF None None O
- None None O
1 None None O
alpha None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
DEC None None O
1 None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
but None None O
not None None O
with None None O
patient None None O
age None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
8 None None O
) None None O
, None None O
tumour None None O
size None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
25 None None O
) None None O
, None None O
lymph None None O
node None None O
status None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
69 None None O
) None None O
, None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
56 None None O
) None None O
or None None O
microvessel None None O
density None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
32 None None O
) None None O
. None None O

No None None O
difference None None O
in None None O
relapse None None O
- None None O
free None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
26 None None O
) None None O
or None None O
overall None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
63 None None O
) None None O
survival None None O
was None None O
observed None None O
in None None O
patients None None O
stratified None None O
by None None O
angiogenin None None O
expression None None O
. None None O

This None None O
study None None O
suggests None None O
that None None O
angiogenin None None O
may None None O
be None None O
important None None O
in None None O
breast None None O
cancer None None O
progression None None O
and None None O
that None None O
, None None O
through None None O
its None None O
relationship None None O
with None None O
ER None None O
, None None O
it None None O
may None None O
be None None O
a None None O
target None None O
for None None O
tamoxifen None None O
. None None O

[ None None O
In None None O
vitro None None O
studies None None O
of None None O
the None None O
thyroid None None O
gland None None O
regulation None None O
principles None None O
and None None O
their None None O
evaluation None None O
] None None O
. None None O

The None None O
free None None O
fractions None None O
of None None O
the None None O
thyroid None None O
hormone None None O
further None None O
the None None O
metabolism None None O
of None None O
the None None O
body None None O
cells None None O
and None None O
regulate None None O
the None None O
synthesis None None O
of None None O
the None None O
thyroid None None O
hormone None None O
. None None O

Once None None O
the None None O
level None None O
of None None O
FT3 None None O
and None None O
FT4 None None O
decreases None None O
. None None O

With None None O
the None None O
help None None O
of None None O
a None None O
liberation None None O
of None None O
the None None O
hormone None None O
stimulating None None O
the None None O
thyroid None None O
gland None None O
from None None O
the None None O
anterior None None O
lobe None None O
of None None O
the None None O
pituitary None None O
gland None None O
the None None O
lack None None O
of None None O
thyroid None None O
hormone None None O
is None None O
corrected None None O
. None None O

The None None O
synthesis None None O
and None None O
secretion None None O
of None None O
the None None O
thyroid None None O
gland None None O
stimulating None None O
hormone None None O
is None None O
induced None None O
by None None O
the None None O
thyreotropin None None O
releasing None None O
hormone None None O
which None None O
is None None O
given None None O
by None None O
the None None O
hypothalamus None None O
. None None O

Moreover None None O
, None None O
the None None O
organism None None O
is None None O
able None None O
as None None O
needed None None O
to None None O
carry None None O
out None None O
the None None O
monodiodation None None O
of None None O
LT4 None None O
to None None O
biologically None None O
active None None O
LT3 None None O
or None None O
biologically None None O
inactive None None O
so None None O
- None None O
called None None O
revers None None O
T3 None None O
( None None O
RT3 None None O
) None None O
. None None O

The None None O
estimation None None O
of None None O
thyroid None None O
gland None None O
stimulating None None O
hormone None None O
before None None O
and None None O
30 None None O
minutes None None O
after None None O
intravenous None None O
application None None O
of None None O
thyreotropin None None O
releasing None None O
hormone None None O
has None None O
its None None O
main None None O
importance None None O
for None None O
the None None O
early None None O
recognition None None O
of None None O
a None None O
disturbance None None O
of None None O
the None None O
regulating None None O
circle None None O
hypophysis None None O
- None None O
thyroid None None O
gland None None O
, None None O
above None None O
all None None O
in None None O
the None None O
diagnosis None None O
of None None O
clinically None None O
not None None O
yet None None O
manifest None None O
clinical None None O
pictures None None O
, None None O
such None None O
as None None O
the None None O
latent None None O
hypothyreosis None None O
and None None O
the None None O
latent None None O
hyperthyreosis None None O
, None None O
respectively None None O
( None None O
Basedow None None O
hyperthyreosis None None O
and None None O
thyroidal None None O
autonomy None None O
) None None O
. None None O

According None None O
to None None O
the None None O
questioning None None O
the None None O
estimations None None O
of None None O
the None None O
levels None None O
of None None O
the None None O
thyroid None None O
hormones None None O
and None None O
of None None O
the None None O
thyroid None None O
gland None None O
stimulating None None O
hormone None None O
should None None O
be None None O
used None None O
stepwise None None O
. None None O

Metabolic None None O
alterations None None O
in None None O
a None None O
noncachectic None None O
animal None None O
tumor None None O
system None None O
. None None O

The None None O
increased None None O
energy None None O
expended None None O
by None None O
the None None O
host None None O
to None None O
synthesize None None O
substrate None None O
, None None O
which None None O
is None None O
utilized None None O
by None None O
the None None O
tumor None None O
, None None O
is None None O
a None None O
potential None None O
cause None None O
of None None O
cancer None None O
cachexia None None O
. None None O

In None None O
vivo None None O
glucose None None O
and None None O
alanine None None O
kinetics None None O
were None None O
examined None None O
by None None O
tracer None None O
methodology None None O
in None None O
a None None O
sarcoma None None O
- None None O
bearing None None O
rat None None O
model None None O
. None None O

The None None O
effects None None O
of None None O
3 None None O
- None None O
mercaptopicolinic None None O
acid None None O
, None None O
a None None O
potent None None O
inhibitor None None O
of None None O
gluconeogenesis None None O
, None None O
was None None O
also None None O
examined None None O
on None None O
this None None O
model None None O
. None None O

Both None None O
tumor None None O
- None None O
bearing None None O
( None None O
TB None None O
) None None O
and None None O
nontumor None None O
bearing None None O
( None None O
NTB None None O
) None None O
animals None None O
were None None O
gaining None None O
weight None None O
prior None None O
to None None O
study None None O
and None None O
the None None O
tumors None None O
were None None O
relatively None None O
small None None O
. None None O

The None None O
TB None None O
animals None None O
had None None O
significantly None None O
lower None None O
plasma None None O
glucose None None O
and None None O
higher None None O
blood None None O
lactic None None O
acid None None O
levels None None O
compared None None O
with None None O
NTB None None O
animals None None O
. None None O

After None None O
inhibition None None O
of None None O
gluconeogenesis None None O
, None None O
the None None O
plasma None None O
glucose None None O
decreased None None O
and None None O
the None None O
blood None None O
lactate None None O
increased None None O
significantly None None O
more None None O
in None None O
TB None None O
than None None O
NTB None None O
animals None None O
. None None O

The None None O
glucose None None O
turnover None None O
rate None None O
was None None O
significantly None None O
greater None None O
in None None O
TB None None O
compared None None O
with None None O
NTB None None O
animals None None O
, None None O
as None None O
was None None O
the None None O
rate None None O
of None None O
glucose None None O
recycling None None O
and None None O
the None None O
rate None None O
of None None O
gluconeogenesis None None O
( None None O
alanine None None O
leads None None O
to None None O
glucose None None O
) None None O
, None None O
both None None O
energy None None O
demanding None None O
processes None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
tumor None None O
- None None O
bearing None None O
animal None None O
, None None O
even None None O
prior None None O
to None None O
significant None None O
cachexia None None O
, None None O
has None None O
an None None O
excess None None O
demand None None O
for None None O
energy None None O
, None None O
the None None O
provision None None O
of None None O
which None None O
may None None O
be None None O
a None None O
significant None None O
factor None None O
in None None O
malignant None None O
cachexia None None O
. None None O

Glutamine None None O
and None None O
glucose None None O
as None None O
energy None None O
substrates None None O
for None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
. None None O

Energy None None O
metabolism None None O
of None None O
freshly None None O
harvested None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
in None None O
the None None O
presence None None O
of None None O
5 None None O
mM None None O
glucose None None O
and None None O
/ None None O
or None None O
0 None None O
. None None O
5 None None O
mM None None O
glutamine None None O
was None None O
studied None None O
. None None O

The None None O
rate None None O
of None None O
oxygen None None O
utilization None None O
was None None O
not None None O
altered None None O
by None None O
the None None O
addition None None O
of None None O
0 None None O
. None None O
5 None None O
mM None None O
glutamine None None O
; None None O
5 None None O
mM None None O
glucose None None O
induced None None O
an None None O
inhibition None None O
of None None O
respiration None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
both None None O
glucose None None O
and None None O
glutamine None None O
, None None O
the None None O
Crabtree None None O
effect None None O
decreased None None O
. None None O

In None None O
these None None O
conditions None None O
, None None O
the None None O
rates None None O
of None None O
oxygen None None O
uptake None None O
, None None O
the None None O
CO2 None None O
evolution None None O
and None None O
the None None O
changes None None O
in None None O
the None None O
redox None None O
states None None O
of None None O
cytochromes None None O
indicate None None O
that None None O
glucose None None O
is None None O
preferred None None O
by None None O
Ehrlich None None O
ascites None None O
tumour None None O
cells None None O
as None None O
energy None None O
substrate None None O
. None None O

Glucose None None O
decreased None None O
the None None O
rate None None O
of None None O
glutamine None None O
utilization None None O
by None None O
34 None None O
% None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
glutaminolysis None None O
did None None O
not None None O
inhibit None None O
glycolysis None None O
. None None O

Effect None None O
of None None O
1 None None O
- None None O
alkylpyrrolidine None None O
N None None O
- None None O
oxides None None O
on None None O
energy None None O
metabolism None None O
of None None O
cancer None None O
cells None None O
. None None O

The None None O
main None None O
purpose None None O
of None None O
the None None O
present None None O
investigation None None O
was None None O
to None None O
study None None O
the None None O
effect None None O
of None None O
a None None O
homologous None None O
series None None O
of None None O
1 None None O
- None None O
alkylpyrrolidine None None O
N None None O
- None None O
oxides None None O
on None None O
ATP None None O
- None None O
producing None None O
processes None None O
in None None O
Ehrlich None None O
ascites None None O
and None None O
L1210 None None I-Cell-line-name
murine None None O
leukemia None None O
cells None None O
. None None O

The None None O
effect None None O
on None None O
aerobic None None O
glucose None None O
consumption None None O
, None None O
lactic None None O
acid None None O
formation None None O
, None None O
content None None O
of None None O
total None None O
( None None O
T None None O
- None None O
SH None None O
) None None O
and None None O
non None None O
- None None O
protein None None O
thiol None None O
groups None None O
( None None O
NP None None O
- None None O
SH None None O
) None None O
, None None O
endogenous None None O
respiration None None O
and None None O
the None None O
level None None O
of None None O
ATP None None O
in None None O
tumor None None O
cells None None O
incubated None None O
in None None O
vitro None None O
was None None O
investigated None None O
. None None O

1 None None O
- None None O
Tetradecylpyrrolidine None None O
N None None O
- None None O
oxide None None O
( None None O
TPNO None None O
) None None O
, None None O
one None None O
of None None O
the None None O
most None None O
active None None O
compounds None None O
, None None O
immediately None None O
after None None O
addition None None O
to None None O
the None None O
suspension None None O
of None None O
Ehrlich None None O
cells None None O
in None None O
an None None O
ice None None O
bath None None O
, None None O
decreased None None O
the None None O
level None None O
of None None O
ATP None None O
to None None O
the None None O
same None None O
extent None None O
over None None O
the None None O
whole None None O
concentration None None O
range None None O
. None None O

After None None O
2 None None O
h None None O
incubation None None O
at None None O
37 None None O
degrees None None O
C None None O
the None None O
drop None None O
in None None O
the None None O
ATP None None O
level None None O
was None None O
lower None None O
. None None O

The None None O
decrease None None O
in None None O
ATP None None O
level None None O
might None None O
be None None O
explained None None O
through None None O
the None None O
interaction None None O
of None None O
the None None O
amine None None O
oxide None None O
with None None O
the None None O
cell None None O
membrane None None O
integrity None None O
. None None O

MTSS1 None None O
: None None O
a None None O
multifunctional None None O
protein None None O
and None None O
its None None O
role None None O
in None None O
cancer None None O
invasion None None O
and None None O
metastasis None None O
. None None O

MTSS1 None None O
( None None O
metastasis None None O
suppressor None None O
- None None O
1 None None O
) None None O
was None None O
first None None O
identified None None O
as None None O
a None None O
metastasis None None O
suppressor None None O
missing None None O
in None None O
metastatic None None O
bladder None None O
carcinoma None None O
cell None None O
lines None None O
. None None O

The None None O
down None None O
- None None O
regulation None None O
of None None O
MTSS1 None None O
that None None O
may None None O
be None None O
caused None None O
by None None O
DNA None None O
methylation None None O
was None None O
also None None O
observed None None O
in None None O
many None None O
other None None O
types None None O
of None None O
cancer None None O
. None None O

While None None O
accumlating None None O
evidence None None O
for None None O
the None None O
function None None O
of None None O
MTSS1 None None O
support None None O
the None None O
concept None None O
that None None O
it None None O
is None None O
unlikely None None O
to None None O
be None None O
a None None O
metastasis None None O
suppressor None None O
, None None O
but None None O
actually None None O
acts None None O
as None None O
a None None O
scaffold None None O
protein None None O
that None None O
interacts None None O
with None None O
multiple None None O
partners None None O
to None None O
regulate None None O
actin None None O
dynamics None None O
. None None O

It None None O
has None None O
also None None O
been None None O
demonstrated None None O
that None None O
MTSS1 None None O
is None None O
involved None None O
in None None O
the None None O
Shh None None O
signaling None None O
pathway None None O
in None None O
the None None O
developing None None O
hair None None O
follicle None None O
and None None O
in None None O
basal None None O
cell None None O
carcinomas None None O
of None None O
the None None O
skin None None O
. None None O

Such None None O
evidence None None O
indicates None None O
that None None O
MTSS1 None None O
as None None O
a None None O
multiple None None O
functional None None O
molecular None None O
player None None O
and None None O
has None None O
an None None O
important None None O
role None None O
in None None O
development None None O
, None None O
carcinogenesis None None O
and None None O
metastasis None None O
. None None O

However None None O
, None None O
the None None O
biochemical None None O
mechanisms None None O
by None None O
which None None O
MTSS1 None None O
functions None None O
in None None O
cells None None O
and None None O
the None None O
physiological None None O
role None None O
of None None O
this None None O
protein None None O
in None None O
animals None None O
remain None None O
largely None None O
unknown None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
will None None O
discuss None None O
the None None O
current None None O
knowledge None None O
of None None O
MTSS1 None None O
' None None O
s None None O
role None None O
in None None O
cancer None None O
metastasis None None O
, None None O
carcinogenesis None None O
, None None O
and None None O
development None None O
. None None O

The None None O
clinical None None O
significance None None O
of None None O
MTSS1 None None O
will None None O
also None None O
be None None O
discussed None None O
. None None O

N None None O
- None None O
glycosylation None None O
of None None O
glucose None None O
transporter None None O
- None None O
1 None None O
( None None O
Glut None None O
- None None O
1 None None O
) None None O
is None None O
associated None None O
with None None O
increased None None O
transporter None None O
affinity None None O
for None None O
glucose None None O
in None None O
human None None O
leukemic None None O
cells None None O
. None None O

To None None O
elucidate None None O
the None None O
role None None O
of None None O
N None None O
- None None O
glycosylation None None O
in None None O
the None None O
functional None None O
activity None None O
of None None O
the None None O
universal None None O
glucose None None O
transporter None None O
, None None O
Glut None None O
- None None O
1 None None O
, None None O
we None None O
investigated None None O
effects None None O
of None None O
the None None O
N None None O
- None None O
glycosylation None None O
inhibitor None None O
, None None O
tunicamycin None None O
, None None O
on None None O
glucose None None O
transport None None O
by None None O
human None None O
leukemic None None O
cell None None O
lines None None O
K562 None None I-Cell-line-name
, None None O
U937 None None I-Cell-line-name
and None None O
HL60 None None I-Cell-line-name
. None None O

Treatment None None O
with None None O
tunicamycin None None O
produced None None O
a None None O
40 None None O
- None None O
50 None None O
% None None O
inhibition None None O
of None None O
2 None None O
- None None O
deoxyglucose None None O
uptake None None O
and None None O
this None None O
was None None O
associated None None O
with None None O
a None None O
2 None None O
- None None O
2 None None O
. None None O
5 None None O
- None None O
fold None None O
decrease None None O
in None None O
transporter None None O
affinity None None O
for None None O
glucose None None O
( None None O
Km None None O
) None None O
without None None O
a None None O
change None None O
in None None O
Vmax None None O
. None None O

Leukemic None None O
K562 None None I-Cell-line-name
, None None O
U937 None None I-Cell-line-name
and None None O
HL60 None None I-Cell-line-name
cells None None O
expressed None None O
Glut None None O
- None None O
1 None None O
transporter None None O
protein None None O
. None None O

With None None O
K562 None None I-Cell-line-name
cells None None O
Glut None None O
- None None O
1 None None O
appeared None None O
as None None O
a None None O
broad None None O
band None None O
of None None O
50 None None O
- None None O
60 None None O
kDa None None O
, None None O
whereas None None O
with None None O
U937 None None I-Cell-line-name
and None None O
HL60 None None I-Cell-line-name
cells None None O
a None None O
diffuse None None O
band None None O
was None None O
observed None None O
at None None O
approximately None None O
55 None None O
kDa None None O
. None None O

Treatment None None O
of None None O
K562 None None I-Cell-line-name
cells None None O
with None None O
tunicamycin None None O
for None None O
18 None None O
h None None O
, None None O
resulted None None O
in None None O
extensive None None O
loss None None O
of None None O
the None None O
50 None None O
- None None O
60 None None O
kDa None None O
glycoprotein None None O
, None None O
appearance None None O
of None None O
a None None O
30 None None O
- None None O
40 None None O
kDa None None O
band None None O
and None None O
increased None None O
staining None None O
of None None O
a None None O
45 None None O
kDa None None O
band None None O
. None None O

With None None O
U937 None None I-Cell-line-name
cells None None O
, None None O
tunicamycin None None O
treatment None None O
resulted None None O
in None None O
the None None O
appearance None None O
of None None O
a None None O
30 None None O
- None None O
40 None None O
kDa None None O
band None None O
and None None O
increased None None O
staining None None O
of None None O
a None None O
45 None None O
kDa None None O
band None None O
. None None O

With None None O
HL60 None None I-Cell-line-name
cells None None O
loss None None O
of None None O
the None None O
55 None None O
kDa None None O
Glut None None O
- None None O
1 None None O
band None None O
was None None O
observed None None O
and None None O
a None None O
band None None O
of None None O
45 None None O
kDa None None O
appeared None None O
. None None O

Tunicamycin None None O
- None None O
treatment None None O
resulted None None O
in None None O
75 None None O
- None None O
90 None None O
% None None O
inhibition None None O
in None None O
[ None None O
3H None None O
] None None O
mannose None None O
incorporation None None O
but None None O
only None None O
20 None None O
- None None O
25 None None O
% None None O
inhibition None None O
in None None O
[ None None O
3H None None O
] None None O
thymidine None None O
and None None O
[ None None O
3H None None O
] None None O
leucine None None O
incorporation None None O
. None None O

In None None O
contrast None None O
, None None O
tunicamycin None None O
had None None O
little None None O
effect None None O
on None None O
the None None O
viability None None O
and None None O
MTT None None O
responses None None O
of None None O
the None None O
cells None None O
used None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
in None None O
leukemic None None O
cells None None O
N None None O
- None None O
glycosylation None None O
of None None O
Glut None None O
- None None O
1 None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
maintaining None None O
its None None O
structure None None O
and None None O
functional None None O
integration None None O
. None None O

[ None None O
Anesthetic None None O
management None None O
of None None O
a None None O
patient None None O
with None None O
Dyggve None None O
- None None O
Melchior None None O
- None None O
Clausen None None O
syndrome None None O
] None None O
. None None O

The None None O
Dyggve None None O
- None None O
Melchior None None O
- None None O
Clausen None None O
syndrome None None O
( None None O
DMCS None None O
) None None O
is None None O
a None None O
rare None None O
autosomal None None O
recessive None None O
skeletal None None O
dysplasia None None O
characterized None None O
by None None O
short None None O
- None None O
trunk None None O
dwarfism None None O
and None None O
mental None None O
retardation None None O
. None None O

A None None O
49 None None O
- None None O
year None None O
- None None O
old None None O
male None None O
with None None O
DMCS None None O
underwent None None O
resection None None O
arthroplasty None None O
for None None O
contracture None None O
of None None O
the None None O
right None None O
hip None None O
joint None None O
under None None O
general None None O
anesthesia None None O
using None None O
thiamylal None None O
, None None O
nitrous None None O
oxide None None O
, None None O
sevoflurane None None O
, None None O
and None None O
vecuronium None None O
. None None O

Although None None O
he None None O
was None None O
assumed None None O
to None None O
have None None O
difficult None None O
airway None None O
due None None O
to None None O
short None None O
neck None None O
, None None O
macroglossia None None O
, None None O
and None None O
disturbance None None O
of None None O
neck None None O
flexion None None O
, None None O
tracheal None None O
intubation None None O
was None None O
not None None O
difficult None None O
. None None O

No None None O
complications None None O
including None None O
malignant None None O
hyperthermia None None O
were None None O
observed None None O
during None None O
the None None O
95 None None O
min None None O
of None None O
the None None O
operation None None O
. None None O

Invagination None None O
of None None O
the None None O
otic None None O
placode None None O
: None None O
normal None None O
development None None O
and None None O
experimental None None O
manipulation None None O
. None None O

The None None O
inner None None O
ear None None O
forms None None O
from None None O
paired None None O
ectodermal None None O
primordia None None O
that None None O
lie None None O
to None None O
either None None O
side None None O
of None None O
the None None O
developing None None O
hindbrain None None O
. None None O

Initially None None O
each None None O
primordium None None O
forms None None O
a None None O
shallow None None O
depression None None O
in None None O
the None None O
ectodermal None None O
surface None None O
. None None O

Invagination None None O
to None None O
form None None O
an None None O
otic None None O
pit None None O
coincides None None O
with None None O
the None None O
formation None None O
of None None O
several None None O
deep None None O
folds None None O
in None None O
the None None O
epithelial None None O
surface None None O
. None None O

An None None O
initial None None O
fold None None O
appears None None O
parallel None None O
to None None O
the None None O
embryonic None None O
axis None None O
and None None O
at None None O
the None None O
junction None None O
of None None O
the None None O
rhombencephalon None None O
with None None O
somitomeric None None O
mesoderm None None O
. None None O

This None None O
is None None O
followed None None O
by None None O
formation None None O
of None None O
cranial None None O
and None None O
caudal None None O
folds None None O
perpendicular None None O
to None None O
the None None O
axis None None O
and None None O
minor None None O
folds None None O
that None None O
are None None O
within None None O
the None None O
pit None None O
formed None None O
by None None O
earlier None None O
folding None None O
. None None O

The None None O
central None None O
region None None O
of None None O
the None None O
otic None None O
primordium None None O
remains None None O
in None None O
close None None O
apposition None None O
to None None O
the None None O
lateral None None O
surface None None O
of None None O
the None None O
neural None None O
tube None None O
during None None O
the None None O
process None None O
of None None O
fold None None O
formation None None O
, None None O
until None None O
the None None O
otic None None O
pit None None O
becomes None None O
quite None None O
deep None None O
. None None O

At None None O
that None None O
time None None O
, None None O
mesenchymal None None O
cells None None O
penetrate None None O
between None None O
the None None O
two None None O
layers None None O
. None None O

Experimental None None O
analysis None None O
of None None O
invagination None None O
supports None None O
the None None O
conclusion None None O
that None None O
otic None None O
invagination None None O
is None None O
controlled None None O
differently None None O
from None None O
that None None O
of None None O
similar None None O
organ None None O
primordia None None O
, None None O
such None None O
as None None O
the None None O
eye None None O
and None None O
thyroid None None O
. None None O

Whereas None None O
these None None O
other None None O
primordia None None O
can None None O
be None None O
stimulated None None O
to None None O
undergo None None O
normal None None O
morphogenetic None None O
shape None None O
changes None None O
precociously None None O
by None None O
treatments None None O
that None None O
presumably None None O
activate None None O
motile None None O
processes None None O
in None None O
the None None O
cytoskeleton None None O
, None None O
the None None O
same None None O
conditions None None O
have None None O
little None None O
effect None None O
on None None O
the None None O
otic None None O
placode None None O
. None None O

Similarly None None O
, None None O
neither None None O
inhibitors None None O
of None None O
calcium None None O
transport None None O
nor None None O
inactivators None None O
of None None O
calmodulin None None O
activity None None O
prevent None None O
otic None None O
pit None None O
formation None None O
, None None O
while None None O
these None None O
drugs None None O
block None None O
invagination None None O
of None None O
other None None O
primordia None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
otic None None O
invagination None None O
may None None O
be None None O
caused None None O
by None None O
changes None None O
in None None O
the None None O
surrounding None None O
tissues None None O
rather None None O
than None None O
by None None O
an None None O
activation None None O
of None None O
motility None None O
within None None O
the None None O
primordium None None O
. None None O

Gene None None O
transfer None None O
of None None O
naked None None O
DNA None None O
encoding None None O
for None None O
three None None O
isoforms None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
stimulates None None O
collateral None None O
development None None O
in None None O
vivo None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
a None None O
naturally None None O
secreted None None O
endothelial None None O
cell None None O
- None None O
specific None None O
mitogen None None O
. None None O

We None None O
investigated None None O
the None None O
hypothesis None None O
that None None O
naked None None O
DNA None None O
encoding None None O
for None None O
VEGF None None O
could None None O
be None None O
used None None O
in None None O
a None None O
strategy None None O
of None None O
arterial None None O
gene None None O
therapy None None O
to None None O
stimulate None None O
collateral None None O
artery None None O
development None None O
. None None O

Plasmid None None O
DNA None None O
encoding None None O
each None None O
of None None O
the None None O
three None None O
principal None None O
human None None O
VEGF None None O
isoforms None None O
( None None O
phVEGF121 None None O
, None None O
phVEGF165 None None O
, None None O
or None None O
phVEGF189 None None O
) None None O
was None None O
applied None None O
to None None O
the None None O
hydrogel None None O
polymer None None O
coating None None O
of None None O
an None None O
angioplasty None None O
balloon None None O
and None None O
delivered None None O
percutaneously None None O
to None None O
one None None O
iliac None None O
artery None None O
of None None O
rabbits None None O
with None None O
operatively None None O
induced None None O
hindlimb None None O
ischemia None None O
. None None O

Compared None None O
with None None O
control None None O
animals None None O
transfected None None O
with None None O
LacZ None None O
, None None O
site None None O
- None None O
specific None None O
transfection None None O
of None None O
phVEGF None None O
resulted None None O
in None None O
augmented None None O
collateral None None O
vessel None None O
development None None O
documented None None O
by None None O
serial None None O
angiography None None O
, None None O
and None None O
improvement None None O
in None None O
calf None None O
blood None None O
pressure None None O
ratio None None O
( None None O
ischemic None None O
to None None O
normal None None O
limb None None O
) None None O
, None None O
resting None None O
and None None O
maximum None None O
blood None None O
flow None None O
, None None O
and None None O
capillary None None O
to None None O
myocyte None None O
ratio None None O
. None None O

Similar None None O
results None None O
were None None O
obtained None None O
with None None O
phVEGF121 None None O
, None None O
phVEGF165 None None O
, None None O
and None None O
phVEGF189 None None O
, None None O
which None None O
suggests None None O
that None None O
these None None O
isoforms None None O
are None None O
biologically None None O
equivalent None None O
with None None O
respect None None O
to None None O
in None None O
vivo None None O
angiogenesis None None O
. None None O

The None None O
fact None None O
that None None O
viral None None O
or None None O
other None None O
adjunctive None None O
vectors None None O
were None None O
not None None O
required None None O
further None None O
suggests None None O
that None None O
secreted None None O
gene None None O
products None None O
may None None O
have None None O
potential None None O
therapeutic None None O
utility None None O
even None None O
when None None O
the None None O
number None None O
of None None O
successfully None None O
transfected None None O
cells None None O
remains None None O
low None None O
. None None O

Arterial None None O
gene None None O
transfer None None O
of None None O
naked None None O
DNA None None O
encoding None None O
for None None O
a None None O
secreted None None O
angiogenic None None O
cytokine None None O
, None None O
thus None None O
, None None O
represents None None O
a None None O
potential None None O
alternative None None O
to None None O
recombinant None None O
protein None None O
administration None None O
for None None O
stimulating None None O
collateral None None O
vessel None None O
development None None O
. None None O

Tsg101 None None O
is None None O
upregulated None None O
in None None O
a None None O
subset None None O
of None None O
invasive None None O
human None None O
breast None None O
cancers None None O
and None None O
its None None O
targeted None None O
overexpression None None O
in None None O
transgenic None None O
mice None None O
reveals None None O
weak None None O
oncogenic None None O
properties None None O
for None None O
mammary None None O
cancer None None O
initiation None None O
. None None O

Previous None None O
studies None None O
reported None None O
that None None O
the None None O
Tumor None None O
Susceptibility None None O
Gene None None O
101 None None O
( None None O
TSG101 None None O
) None None O
is None None O
upregulated None None O
in None None O
selected None None O
human None None O
malignancies None None O
, None None O
and None None O
the None None O
expression None None O
of None None O
exogenous None None O
Tsg101 None None O
was None None O
suggested None None O
to None None O
transform None None O
immortalized None None O
fibroblasts None None O
in None None O
culture None None O
. None None O

To None None O
date None None O
, None None O
the None None O
potential None None O
oncogenic None None O
properties None None O
of None None O
Tsg101 None None O
have None None O
not None None O
been None None O
examined None None O
in None None O
vivo None None O
owing None None O
to None None O
the None None O
lack None None O
of None None O
appropriate None None O
model None None O
systems None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
show None None O
that None None O
Tsg101 None None O
is None None O
highly None None O
expressed None None O
in None None O
a None None O
subset None None O
of None None O
invasive None None O
human None None O
breast None None O
cancers None None O
. None None O

Based None None O
on None None O
this None None O
observation None None O
, None None O
we None None O
generated None None O
the None None O
first None None O
transgenic None None O
mouse None None O
model None None O
with None None O
a None None O
targeted None None O
overexpression None None O
of None None O
Tsg101 None None O
in None None O
the None None O
developing None None O
mammary None None O
gland None None O
to None None O
test None None O
whether None None O
exogenous None None O
Tsg101 None None O
is None None O
capable None None O
of None None O
initiating None None O
tumorigenesis None None O
. None None O

Normal None None O
functionality None None O
of None None O
exogenous None None O
Tsg101 None None O
was None None O
tested None None O
by None None O
rescuing None None O
the None None O
survival None None O
of None None O
Tsg101 None None O
- None None O
deficient None None O
mammary None None O
epithelial None None O
cells None None O
in None None O
conditional None None O
knockout None None O
mice None None O
. None None O

The None None O
overexpression None None O
of None None O
Tsg101 None None O
resulted None None O
in None None O
increased None None O
phosphorylation None None O
of None None O
the None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
and None None O
downstream None None O
activation None None O
of None None O
MAP None None O
kinases None None O
. None None O

Despite None None O
an None None O
increase None None O
in None None O
the None None O
activation None None O
of None None O
these None None O
signal None None O
transducers None None O
, None None O
the None None O
mammary None None O
gland None None O
of None None O
females None None O
expressing None None O
exogenous None None O
Tsg101 None None O
developed None None O
normally None None O
throughout None None O
the None None O
reproductive None None O
cycle None None O
. None None O

In None None O
aging None None O
females None None O
, None None O
the None None O
overexpression None None O
of None None O
Tsg101 None None O
seemed None None O
to None None O
increase None None O
the None None O
susceptibility None None O
of None None O
mammary None None O
epithelia None None O
toward None None O
malignant None None O
transformation None None O
. None None O

However None None O
, None None O
owing None None O
to None None O
the None None O
long None None O
latency None None O
of None None O
tumor None None O
formation None None O
and None None O
the None None O
sporadic None None O
occurrence None None O
of None None O
bona None None O
fide None None O
mammary None None O
cancers None None O
, None None O
we None None O
conclude None None O
that None None O
the None None O
Tsg101 None None O
protein None None O
has None None O
only None None O
weak None None O
oncogenic None None O
properties None None O
. None None O

Instead None None O
of None None O
cancer None None O
initiation None None O
, None None O
it None None O
is None None O
therefore None None O
likely None None O
that None None O
Tsg101 None None O
plays None None O
a None None O
more None None O
predominant None None O
role None None O
in None None O
the None None O
progression None None O
of None None O
a None None O
subset None None O
of None None O
spontaneously None None O
arising None None O
breast None None O
cancers None None O
. None None O

Dose None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
effects None None O
of None None O
doxorubicin None None O
on None None O
cytotoxicity None None O
, None None O
cell None None O
cycle None None O
and None None O
apoptotic None None O
cell None None O
death None None O
in None None O
human None None O
colon None None O
cancer None None O
cells None None O
. None None O

The None None O
cytostatic None None O
drug None None O
doxorubicin None None O
is None None O
a None None O
well None None O
- None None O
known None None O
chemotherapeutic None None O
agent None None O
which None None O
is None None O
used None None O
in None None O
treatment None None O
of None None O
a None None O
wide None None O
variety None None O
of None None O
cancers None None O
. None None O

A None None O
key None None O
factor None None O
in None None O
the None None O
response None None O
of None None O
cancer None None O
cells None None O
to None None O
chemotherapeutic None None O
drugs None None O
is None None O
the None None O
activation None None O
of None None O
the None None O
apoptotic None None O
pathway None None O
, None None O
a None None O
pathway None None O
that None None O
is None None O
often None None O
impaired None None O
in None None O
chemoresistant None None O
colon None None O
cancer None None O
cells None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
effects None None O
of None None O
doxorubicin None None O
in None None O
Hct None None I-Cell-line-name
- None None I-Cell-line-name
116 None None I-Cell-line-name
human None None O
colon None None O
carcinoma None None O
cells None None O
in None None O
order None None O
to None None O
clarify None None O
if None None O
a None None O
time None None O
/ None None O
concentration None None O
range None None O
for None None O
optimal None None O
doxorubicin None None O
- None None O
induced None None O
apoptosis None None O
exists None None O
. None None O

We None None O
compared None None O
a None None O
treatment None None O
schedule None None O
were None None O
cells None None O
were None None O
bolus None None O
incubated None None O
for None None O
3h None None O
with None None O
doxorubicin None None O
followed None None O
by None None O
24h None None O
in None None O
drug None None O
- None None O
free None None O
medium None None O
, None None O
with None None O
a None None O
continuous None None O
doxorubicin None None O
treatment None None O
schedule None None O
for None None O
24h None None O
. None None O

Bolus None None O
incubation None None O
was None None O
carried None None O
out None None O
to None None O
determine None None O
effects None None O
of None None O
doxorubicin None None O
accumulated None None O
during None None O
the None None O
first None None O
3h None None O
, None None O
whereas None None O
continuous None None O
incubation None None O
allowed None None O
further None None O
( None None O
continuous None None O
) None None O
exposure None None O
to None None O
doxorubicin None None O
. None None O

We None None O
found None None O
that None None O
bolus None None O
( None None O
3h None None O
) None None O
treatment None None O
with None None O
doxorubicin None None O
resulted None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
decrease None None O
of None None O
viable None None O
cells None None O
and None None O
concomitant None None O
increase None None O
of None None O
apoptosis None None O
. None None O

Additionally None None O
, None None O
bolus None None O
( None None O
3h None None O
) None None O
doxorubicin None None O
incubation None None O
led None None O
to None None O
phosphorylation None None O
of None None O
p53 None None O
at None None O
serine None None O
392 None None O
, None None O
induction None None O
of None None O
p21 None None O
, None None O
G2 None None O
arrest None None O
and None None O
increase None None O
of None None O
proapoptotic None None O
protein None None O
Bax None None O
. None None O

In None None O
contrast None None O
, None None O
continuous None None O
( None None O
24h None None O
) None None O
treatment None None O
with None None O
doxorubicin None None O
reduced None None O
the None None O
number None None O
of None None O
living None None O
cells None None O
with None None O
no None None O
parallel None None O
raise None None O
in None None O
the None None O
amount None None O
of None None O
dead None None O
cells None None O
. None None O

Continuous None None O
( None None O
24h None None O
) None None O
treatment None None O
with None None O
5 None None O
microM None None O
doxorubicin None None O
resulted None None O
in None None O
cell None None O
cycle None None O
arrest None None O
in None None O
G0 None None O
/ None None O
G1 None None O
phase None None O
that None None O
was None None O
neither None None O
accompanied None None O
by None None O
phosphorylation None None O
and None None O
activation None None O
of None None O
p53 None None O
nor None None O
enhanced None None O
expression None None O
of None None O
p21 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
doxorubicin None None O
is None None O
able None None O
to None None O
induce None None O
cell None None O
death None None O
by None None O
apoptosis None None O
only None None O
at None None O
particular None None O
dose None None O
and None None O
treatment None None O
conditions None None O
and None None O
imply None None O
a None None O
completely None None O
different None None O
cellular None None O
response None None O
following None None O
bolus None None O
or None None O
continuous None None O
exposure None None O
to None None O
doxorubicin None None O
. None None O

Effect None None O
of None None O
U None None O
- None None O
995 None None O
, None None O
a None None O
potent None None O
shark None None O
cartilage None None O
- None None O
derived None None O
angiogenesis None None O
inhibitor None None O
, None None O
on None None O
anti None None O
- None None O
angiogenesis None None O
and None None O
anti None None O
- None None O
tumor None None O
activities None None O
. None None O

BACKGROUND None None O
: None None O
A None None O
potent None None O
angiogenesis None None O
inhibitor None None O
, None None O
U None None O
- None None O
995 None None O
, None None O
has None None O
been None None O
purified None None O
from None None O
the None None O
cartilage None None O
of None None O
the None None O
blue None None O
shark None None O
( None None O
Prionace None None O
glauca None None O
) None None O
. None None O

U None None O
- None None O
995 None None O
is None None O
composed None None O
of None None O
two None None O
single None None O
peptides None None O
with None None O
molecular None None O
mass None None O
of None None O
10 None None O
and None None O
14 None None O
kDa None None O
, None None O
respectively None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
U None None O
- None None O
995 None None O
was None None O
designed None None O
to None None O
study None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
( None None O
HUVEC None None O
) None None O
migration None None O
and None None O
proliferation None None O
in None None O
vitro None None O
and None None O
angiogenesis None None O
induced None None O
by None None O
TNF None None O
alpha None None O
in None None O
chicken None None O
chorioallantoic None None O
membrane None None O
( None None O
CAM None None O
) None None O
. None None O

Furthermore None None O
, None None O
we None None O
determined None None O
the None None O
ability None None O
of None None O
U None None O
- None None O
995 None None O
to None None O
inhibiting None None O
tumor None None O
cell None None O
growth None None O
and None None O
metastasis None None O
. None None O

RESULTS None None O
: None None O
U None None O
- None None O
995 None None O
( None None O
15 None None O
and None None O
30 None None O
micrograms None None O
/ None None O
ml None None O
) None None O
markedly None None O
inhibited None None O
HUVEC None None O
migration None None O
and None None O
, None None O
at None None O
15 None None O
- None None O
50 None None O
micrograms None None O
/ None None O
ml None None O
produced None None O
a None None O
dose None None O
- None None O
dependent None None O
decline None None O
in None None O
[ None None O
3H None None O
] None None O
- None None O
thymidine None None O
incorporation None None O
. None None O

30 None None O
and None None O
50 None None O
micrograms None None O
/ None None O
ml None None O
of None None O
U None None O
- None None O
995 None None O
, None None O
when None None O
added None None O
to None None O
TNF None None O
alpha None None O
- None None O
induced None None O
angiogenesis None None O
caused None None O
discontinuous None None O
and None None O
disrupted None None O
blood None None O
vessels None None O
. None None O

Moreover None None O
, None None O
U None None O
- None None O
995 None None O
( None None O
30 None None O
micrograms None None O
/ None None O
ml None None O
) None None O
markedly None None O
prevented None None O
collagenase None None O
- None None O
induced None None O
collagenolysis None None O
. None None O

In None None O
addition None None O
, None None O
when None None O
200 None None O
micrograms None None O
U None None O
- None None O
995 None None O
was None None O
injected None None O
i None None O
. None None O
p None None O
. None None O
into None None O
mice None None O
it None None O
suppressed None None O
sarcoma None None I-Cell-line-name
- None None I-Cell-line-name
180 None None I-Cell-line-name
cell None None O
growth None None O
and None None O
B16 None None I-Cell-line-name
- None None I-Cell-line-name
F10 None None I-Cell-line-name
mouse None None O
melanoma None None O
cell None None O
metastasis None None O
in None None O
vivo None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
the None None O
anti None None O
- None None O
angiogenic None None O
effects None None O
of None None O
U None None O
- None None O
995 None None O
may None None O
be None None O
be None None O
due None None O
to None None O
interference None None O
with None None O
the None None O
proliferation None None O
and None None O
migration None None O
of None None O
HUVECs None None O
as None None O
well None None O
as None None O
inhibition None None O
of None None O
collagenolysis None None O
, None None O
thereby None None O
leading None None O
to None None O
inhibition None None O
of None None O
both None None O
angiogenesis None None O
and None None O
tumor None None O
cell None None O
growth None None O
. None None O

[ None None O
The None None O
value None None O
of None None O
intermittent None None O
ultrasound None None O
treatment None None O
in None None O
subacromial None None O
impingement None None O
syndrome None None O
] None None O
. None None O

OBJECTIVES None None O
: None None O

The None None O
role None None O
of None None O
intermittent None None O
ultrasound None None O
in None None O
the None None O
conservative None None O
treatment None None O
of None None O
subacromial None None O
impingement None None O
syndrome None None O
( None None O
SIS None None O
) None None O
has None None O
not None None O
been None None O
clarified None None O
. None None O

We None None O
aimed None None O
to None None O
evaluate None None O
the None None O
efficacy None None O
of None None O
ultrasound None None O
treatment None None O
in None None O
SIS None None O
. None None O

METHODS None None O
: None None O

Thirty None None O
- None None O
six None None O
patients None None O
( None None O
29 None None O
females None None O
, None None O
7 None None O
males None None O
; None None O
mean None None O
age None None O
51 None None O
years None None O
; None None O
range None None O
40 None None O
to None None O
69 None None O
years None None O
) None None O
with None None O
type None None O
II None None O
SIS None None O
were None None O
randomized None None O
to None None O
two None None O
groups None None O
to None None O
receive None None O
intermittent None None O
ultrasound None None O
( None None O
group None None O
1 None None O
, None None O
n None None O
= None None O
20 None None O
) None None O
and None None O
placebo None None O
ultrasound None None O
( None None O
group None None O
2 None None O
, None None O
n None None O
= None None O
16 None None O
) None None O
for None None O
three None None O
weeks None None O
( None None O
15 None None O
sessions None None O
) None None O
. None None O

All None None O
the None None O
patients None None O
received None None O
the None None O
same None None O
standard None None O
physical None None O
therapy None None O
and None None O
rehabilitation None None O
modalities None None O
besides None None O
ultrasound None None O
treatment None None O
. None None O

Evaluations None None O
were None None O
made None None O
before None None O
and None None O
three None None O
and None None O
six None None O
weeks None None O
after None None O
treatment None None O
. None None O

Functional None None O
results None None O
were None None O
assessed None None O
by None None O
the None None O
Constant None None O
score None None O
, None None O
pain None None O
was None None O
assessed None None O
by None None O
a None None O
visual None None O
analog None None O
scale None None O
, None None O
and None None O
range None None O
of None None O
motion None None O
was None None O
measured None None O
. None None O

RESULTS None None O
: None None O

Within None None O
- None None O
group None None O
comparisons None None O
showed None None O
significant None None O
improvements None None O
in None None O
both None None O
groups None None O
three None None O
and None None O
six None None O
weeks None None O
after None None O
treatment None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Comparison None None O
between None None O
pretreatment None None O
and None None O
6 None None O
- None None O
week None None O
values None None O
were None None O
as None None O
follows None None O
: None None O
the None None O
mean None None O
flexion None None O
increased None None O
from None None O
148 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
20 None None O
. None None O
4 None None O
degrees None None O
to None None O
175 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
6 None None O
. None None O
0 None None O
degrees None None O
in None None O
group None None O
1 None None O
, None None O
and None None O
from None None O
165 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
14 None None O
. None None O
1 None None O
degrees None None O
to None None O
177 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
4 None None O
degrees None None O
in None None O
group None None O
2 None None O
; None None O
internal None None O
and None None O
external None None O
rotation None None O
increased None None O
from None None O
66 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
20 None None O
. None None O
7 None None O
degrees None None O
and None None O
61 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
22 None None O
. None None O
9 None None O
degrees None None O
to None None O
83 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
10 None None O
. None None O
9 None None O
degrees None None O
and None None O
84 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
9 None None O
. None None O
6 None None O
degrees None None O
in None None O
group None None O
1 None None O
, None None O
and None None O
from None None O
75 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
17 None None O
. None None O
3 None None O
degrees None None O
and None None O
70 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
19 None None O
. None None O
8 None None O
degrees None None O
to None None O
87 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
6 None None O
. None None O
8 None None O
degrees None None O
and None None O
84 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
8 None None O
. None None O
4 None None O
degrees None None O
in None None O
group None None O
2 None None O
, None None O
respectively None None O
. None None O

There None None O
were None None O
no None None O
significant None None O
differences None None O
between None None O
the None None O
two None None O
groups None None O
with None None O
respect None None O
to None None O
the None None O
range None None O
of None None O
motion None None O
at None None O
the None None O
end None None O
of None None O
six None None O
weeks None None O
( None None O
p None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
Constant None None O
score None None O
improved None None O
from None None O
43 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
12 None None O
. None None O
9 None None O
to None None O
65 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
7 None None O
. None None O
7 None None O
in None None O
group None None O
1 None None O
, None None O
and None None O
from None None O
43 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
16 None None O
. None None O
4 None None O
to None None O
65 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
7 None None O
. None None O
6 None None O
in None None O
group None None O
2 None None O
. None None O

Pain None None O
scores None None O
decreased None None O
from None None O
5 None None O
. None None O
5 None None O
to None None O
2 None None O
and None None O
from None None O
5 None None O
to None None O
1 None None O
in None None O
group None None O
1 None None O
and None None O
2 None None O
, None None O
respectively None None O
. None None O

Improvements None None O
in None None O
Constant None None O
scores None None O
and None None O
pain None None O
scores None None O
were None None O
similar None None O
in None None O
both None None O
groups None None O
( None None O
p None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O

Our None None O
findings None None O
suggest None None O
that None None O
intermittent None None O
ultrasound None None O
added None None O
to None None O
conservative None None O
treatment None None O
of None None O
SIS None None O
do None None O
not None None O
provide None None O
an None None O
additional None None O
benefit None None O
to None None O
the None None O
patients None None O
. None None O

Identification None None O
of None None O
latency None None O
- None None O
associated None None O
transcripts None None O
that None None O
map None None O
antisense None None O
to None None O
the None None O
ICP4 None None O
homolog None None O
gene None None O
of None None O
Marek None None O
' None None O
s None None O
disease None None O
virus None None O
. None None O

Two None None O
small None None O
RNAs None None O
( None None O
0 None None O
. None None O
9 None None O
and None None O
0 None None O
. None None O
75 None None O
kb None None O
) None None O
, None None O
named None None O
Marek None None O
' None None O
s None None O
disease None None O
virus None None O
( None None O
MDV None None O
) None None O
small None None O
RNAs None None O
( None None O
MSRs None None O
) None None O
and None None O
a None None O
10 None None O
- None None O
kb None None O
RNA None None O
, None None O
all None None O
of None None O
which None None O
map None None O
antisense None None O
to None None O
the None None O
MDV None None O
ICP4 None None O
homolog None None O
gene None None O
, None None O
have None None O
been None None O
readily None None O
detected None None O
in None None O
MDCC None None I-Cell-line-name
- None None I-Cell-line-name
MSB1 None None I-Cell-line-name
MDV None None O
- None None O
transformed None None O
T None None O
- None None O
lymphoblastoid None None O
cells None None O
. None None O

These None None O
RNAs None None O
were None None O
not None None O
detectable None None O
in None None O
reticuloendotheliosis None None O
virus None None O
- None None O
transformed None None O
T None None O
cells None None O
. None None O

When None None O
MDV None None O
was None None O
reactivated None None O
by None None O
treatment None None O
of None None O
lymphoblastoid None None O
cells None None O
with None None O
25 None None O
micrograms None None O
of None None O
iododeoxyuridine None None O
per None None O
ml None None O
, None None O
the None None O
relative None None O
levels None None O
of None None O
the None None O
transcripts None None O
decreased None None O
. None None O

These None None O
RNAs None None O
were None None O
not None None O
detected None None O
by None None O
Northern None None O
( None None O
RNA None None O
) None None O
hybridization None None O
in None None O
productively None None O
infected None None O
chicken None None O
embryo None None O
fibroblasts None None O
48 None None O
h None None O
postinfection None None O
; None None O
however None None O
, None None O
they None None O
were None None O
apparent None None O
140 None None O
h None None O
postinfection None None O
. None None O

By None None O
using None None O
Northern None None O
hybridization None None O
, None None O
RNase None None O
protection None None O
assays None None O
, None None O
and None None O
primer None None O
extension None None O
analysis None None O
, None None O
the None None O
MSRs None None O
were None None O
determined None None O
to None None O
map None None O
antisense None None O
to None None O
the None None O
predicted None None O
translational None None O
start None None O
site None None O
of None None O
the None None O
ICP4 None None O
homolog None None O
gene None None O
. None None O

The None None O
conclusion None None O
most None None O
consistent None None O
with None None O
the None None O
data None None O
is None None O
that None None O
the None None O
two None None O
MSRs None None O
are None None O
overlapping None None O
, None None O
spliced None None O
RNAs None None O
. None None O

Both None None O
small None None O
RNAs None None O
contain None None O
a None None O
latency None None O
promoter None None O
binding None None O
factor None None O
consensus None None O
recognition None None O
sequence None None O
located None None O
toward None None O
their None None O
5 None None O
' None None O
ends None None O
as None None O
well None None O
as None None O
two None None O
potential None None O
ICP4 None None O
recognition None None O
consensus None None O
sequences None None O
, None None O
one None None O
in None None O
each None None O
orientation None None O
. None None O

The None None O
region None None O
contains None None O
a None None O
number None None O
of None None O
small None None O
open None None O
reading None None O
frames None None O
on None None O
each None None O
side None None O
and None None O
within None None O
the None None O
MSRs None None O
. None None O

Although None None O
the None None O
exact None None O
endpoints None None O
are None None O
unknown None None O
, None None O
the None None O
large None None O
10 None None O
- None None O
kb None None O
species None None O
spans None None O
the None None O
entire None None O
ICP4 None None O
homolog None None O
region None None O
. None None O

We None None O
believe None None O
that None None O
this None None O
group None None O
of None None O
RNAs None None O
, None None O
which None None O
map None None O
antisense None None O
to None None O
the None None O
ICP4 None None O
homolog None None O
gene None None O
, None None O
are None None O
latency None None O
- None None O
associated None None O
transcripts None None O
of None None O
MDV None None O
. None None O

Comparison None None O
of None None O
transformation None None O
by None None O
manganese None None O
sulfate None None O
and None None O
5 None None O
- None None O
azacytidine None None O
in None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
cells None None O
overexpressing None None O
the None None O
c None None O
- None None O
myc None None O
oncogene None None O
. None None O

Rat None None I-Cell-line-name
6 None None I-Cell-line-name
cells None None O
are None None O
not None None O
transformed None None O
by None None O
treatment None None O
with None None O
the None None O
well None None O
- None None O
known None None O
carcinogens None None O
benzo None None O
[ None None O
a None None O
] None None O
pyrene None None O
( None None O
BP None None O
) None None O
or None None O
N None None O
- None None O
methyl None None O
- None None O
N None None O
- None None O
nitro None None O
- None None O
N None None O
' None None O
- None None O
nitrosoguanidine None None O
( None None O
MNNG None None O
) None None O
. None None O

Upon None None O
retroviral None None O
transduction None None O
of None None O
the None None O
mouse None None O
c None None O
- None None O
myc None None O
gene None None O
, None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
cells None None O
showed None None O
mildly None None O
altered None None O
morphology None None O
and None None O
formed None None O
microcolonies None None O
in None None O
soft None None O
agar None None O
; None None O
furthermore None None O
, None None O
they None None O
could None None O
be None None O
transformed None None O
by None None O
BP None None O
and None None O
MNNG None None O
to None None O
form None None O
large None None O
colonies None None O
in None None O
agar None None O
( None None O
Hsiao None None O
et None None O
al None None O
. None None O
( None None O
1992 None None O
) None None O
Mol None None O
. None None O
Carcinogenesis None None O
, None None O
5 None None O
, None None O
140 None None O
- None None O
154 None None O
) None None O
. None None O

In None None O
the None None O
current None None O
report None None O
, None None O
we None None O
tested None None O
the None None O
sensitivity None None O
of None None O
the None None O
c None None O
- None None O
myc None None O
- None None O
overexpressing None None O
cells None None O
( None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
/ None None O
c None None O
- None None O
myc None None O
) None None O
to None None O
two None None O
additional None None O
chemicals None None O
: None None O
5 None None O
- None None O
azacytidine None None O
and None None O
MnSO4 None None O
. None None O

These None None O
chemicals None None O
differ None None O
from None None O
the None None O
direct None None O
- None None O
acting None None O
mutagens None None O
tested None None O
previously None None O
. None None O

5 None None O
- None None O
Azacytidine None None O
, None None O
a None None O
potent None None O
DNA None None O
methylation None None O
inhibitor None None O
, None None O
induced None None O
growth None None O
of None None O
large None None O
colonies None None O
in None None O
soft None None O
agar None None O
cultures None None O
of None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
or None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
/ None None O
c None None O
- None None O
myc None None O
cells None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
MnSO4 None None O
only None None O
induced None None O
transformation None None O
in None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
/ None None O
c None None O
- None None O
myc None None O
cells None None O
, None None O
but None None O
not None None O
the None None O
parental None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
cells None None O
. None None O

Transformants None None O
induced None None O
by None None O
5 None None O
- None None O
azacytidine None None O
lost None None O
c None None O
- None None O
myc None None O
- None None O
induced None None O
apoptotic None None O
cell None None O
death None None O
, None None O
whereas None None O
MnSO4 None None O
- None None O
induced None None O
transformants None None O
showed None None O
a None None O
higher None None O
degree None None O
of None None O
apoptosis None None O
than None None O
the None None O
parental None None O
Rat None None I-Cell-line-name
6 None None I-Cell-line-name
/ None None O
c None None O
- None None O
myc None None O
cells None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
MnSO4 None None O
co None None O
- None None O
operates None None O
with None None O
overexpressed None None O
c None None O
- None None O
myc None None O
in None None O
inducing None None O
transformation None None O
, None None O
while None None O
5 None None O
- None None O
azacytidine None None O
transformation None None O
is None None O
independent None None O
of None None O
c None None O
- None None O
myc None None O
overexpression None None O
and None None O
may None None O
involve None None O
alterations None None O
in None None O
the None None O
regulation None None O
of None None O
apoptosis None None O
. None None O

Loss None None O
of None None O
both None None O
apical None None O
pathways None None O
( None None O
bottom None None O
) None None O
allows None None O
astral None None O
microtubules None None O
( None None O
arrows None None O
) None None O
to None None O
form None None O
apically None None O
and None None O
basally None None O
in None None O
neuroblasts None None O
. None None O

Regulation None None O
of None None O
transforming None None O
growth None None O
factor None None O
- None None O
beta None None O
signaling None None O
and None None O
vascular None None O
diseases None None O
. None None O

PURPOSE None None O
: None None O
Members None None O
of None None O
the None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
- None None O
beta None None O
superfamily None None O
play None None O
critical None None O
roles None None O
in None None O
regulation None None O
of None None O
various None None O
cellular None None O
functions None None O
. None None O

Dysregulation None None O
of None None O
the None None O
signaling None None O
mechanisms None None O
of None None O
the None None O
TGF None None O
- None None O
beta None None O
superfamily None None O
proteins None None O
is None None O
associated None None O
with None None O
clinical None None O
diseases None None O
such None None O
as None None O
cancer None None O
, None None O
fibrotic None None O
diseases None None O
, None None O
and None None O
vascular None None O
disorders None None O
. None None O

Therefore None None O
, None None O
understanding None None O
these None None O
signaling None None O
mechanisms None None O
may None None O
provide None None O
us None None O
with None None O
novel None None O
ways None None O
to None None O
develop None None O
strategies None None O
for None None O
treating None None O
clinical None None O
diseases None None O
induced None None O
by None None O
these None None O
cytokines None None O
. None None O

METHODS None None O
: None None O
This None None O
review None None O
discusses None None O
our None None O
current None None O
understanding None None O
of None None O
the None None O
mechanisms None None O
of None None O
TGF None None O
- None None O
beta None None O
signaling None None O
, None None O
focusing None None O
on None None O
the None None O
roles None None O
of None None O
TGF None None O
- None None O
beta None None O
in None None O
regulation None None O
of None None O
vascular None None O
wall None None O
cells None None O
and None None O
on None None O
the None None O
regulation None None O
of None None O
TGF None None O
- None None O
beta None None O
superfamily None None O
signals None None O
by None None O
inhibitory None None O
Smads None None O
. None None O

The None None O
role None None O
of None None O
organ None None O
vascularization None None O
and None None O
lipoplex None None O
- None None O
serum None None O
initial None None O
contact None None O
in None None O
intravenous None None O
murine None None O
lipofection None None O
. None None O

Following None None O
intravenous None None O
administration None None O
of None None O
cationic None None O
lipid None None O
- None None O
DNA None None O
complexes None None O
( None None O
lipoplexes None None O
) None None O
into None None O
mice None None O
, None None O
transfection None None O
( None None O
lipofection None None O
) None None O
occurs None None O
predominantly None None O
in None None O
the None None O
lungs None None O
. None None O

This None None O
was None None O
attributed None None O
to None None O
high None None O
entrapment None None O
of None None O
lipoplexes None None O
in None None O
the None None O
extended None None O
lung None None O
vascular None None O
tree None None O
. None None O

To None None O
determine None None O
whether None None O
lipofection None None O
in None None O
other None None O
organs None None O
could None None O
be None None O
enhanced None None O
by None None O
increasing None None O
the None None O
degree None None O
of None None O
vascularization None None O
, None None O
we None None O
used None None O
a None None O
transgenic None None O
mouse None None O
model None None O
with None None O
tissue None None O
- None None O
specific None None O
angiogenesis None None O
in None None O
liver None None O
. None None O

Tail None None O
vein None None O
injection None None O
of None None O
N None None O
- None None O
( None None O
1 None None O
- None None O
( None None O
2 None None O
, None None O
3 None None O
- None None O
dioleoyloxy None None O
) None None O
propyl None None O
) None None O
- None None O
N None None O
, None None O
N None None O
, None None O
N None None O
- None None O
trimethylammonium None None O
chloride None None O
( None None O
DOTAP None None O
) None None O
/ None None O
cholesterol None None O
lipoplexes None None O
resulted None None O
in None None O
increased None None O
lipoplex None None O
entrapment None None O
in None None O
hypervascularized None None O
liver None None O
but None None O
did None None O
not None None O
boost None None O
luciferase None None O
expression None None O
, None None O
suggesting None None O
that None None O
lipoplex None None O
delivery None None O
is None None O
not None None O
a None None O
sufficient None None O
condition None None O
for None None O
efficient None None O
organ None None O
lipofection None None O
. None None O

Because None None O
the None None O
intravenously None None O
injected None None O
lipoplexes None None O
migrated None None O
within None None O
seconds None None O
to None None O
lungs None None O
, None None O
we None None O
checked None None O
whether None None O
the None None O
effects None None O
of None None O
immediate None None O
contact None None O
with None None O
serum None None O
correlate None None O
with None None O
lung None None O
lipofection None None O
efficiency None None O
of None None O
different None None O
DOTAP None None O
- None None O
based None None O
formulations None None O
. None None O

Under None None O
conditions None None O
mimicking None None O
the None None O
injection None None O
environment None None O
, None None O
the None None O
lipoplex None None O
- None None O
serum None None O
interaction None None O
was None None O
strongly None None O
dependent None None O
on None None O
helper None None O
lipid None None O
and None None O
ionic None None O
strength None None O
: None None O
lipoplexes None None O
prepared None None O
in None None O
150 None None O
mM None None O
NaCl None None O
or None None O
lipoplexes None None O
with None None O
high None None O
( None None O
greater None None O
than None None O
33 None None O
mol None None O
% None None O
) None None O
cholesterol None None O
were None None O
found None None O
to None None O
aggregate None None O
immediately None None O
. None None O

This None None O
aggregation None None O
process None None O
was None None O
irreversible None None O
and None None O
was None None O
inversely None None O
correlated None None O
with None None O
the None None O
percentage None None O
of None None O
lung None None O
cells None None O
that None None O
took None None O
up None None O
lipoplexes None None O
and None None O
with None None O
the None None O
efficiency None None O
of None None O
lipofection None None O
. None None O

No None None O
other None None O
structural None None O
changes None None O
in None None O
serum None None O
were None None O
observed None None O
for None None O
cholesterol None None O
- None None O
based None None O
lipoplexes None None O
. None None O

Dioleoyl None None O
phosphatidylethanolamine None None O
- None None O
based None None O
lipoplexes None None O
were None None O
found None None O
to None None O
give None None O
low None None O
expression None None O
, None None O
apparently None None O
because None None O
of None None O
an None None O
immediate None None O
loss None None O
of None None O
integrity None None O
in None None O
serum None None O
, None None O
without None None O
lipid None None O
- None None O
DNA None None O
dissociation None None O
. None None O

Our None None O
study None None O
suggests None None O
that None None O
efficient None None O
in None None O
vivo None None O
lipofection None None O
is None None O
the None None O
result None None O
of None None O
cross None None O
- None None O
talk None None O
between None None O
lipoplex None None O
composition None None O
, None None O
interaction None None O
with None None O
serum None None O
, None None O
hemodynamics None None O
, None None O
and None None O
target None None O
tissue None None O
" None None O
susceptibility None None O
" None None O
to None None O
transfection None None O
. None None O

Active None None O
respiratory None None O
syncytial None None O
virus None None O
purified None None O
by None None O
ion None None O
- None None O
exchange None None O
chromatography None None O
: None None O
characterization None None O
of None None O
binding None None O
and None None O
elution None None O
requirements None None O
. None None O

Two None None O
viruses None None O
, None None O
respiratory None None O
syncytial None None O
virus None None O
( None None O
RSV None None O
) None None O
and None None O
vesicular None None O
stomatitis None None O
virus None None O
( None None O
VSV None None O
) None None O
were None None O
used None None O
to None None O
evaluate None None O
viral None None O
purification None None O
by None None O
an None None O
affinity None None O
resin None None O
column None None O
( None None O
Matrex None None O
Cellufine None None O
Sulfate None None O
( None None O
MCS None None O
) None None O
; None None O
Amicon None None O
Division None None O
, None None O
WR None None O
Grace None None O
& None None O
Co None None O
. None None O
) None None O
. None None O

Viable None None O
RSV None None O
was None None O
purified None None O
significantly None None O
from None None O
crude None None O
cell None None O
lysate None None O
by None None O
a None None O
single None None O
pass None None O
through None None O
a None None O
column None None O
containing None None O
the None None O
anionic None None O
MCS None None O
resin None None O
. None None O

Most None None O
cell None None O
protein None None O
and None None O
albumin None None O
eluted None None O
from None None O
the None None O
MCS None None O
resin None None O
with None None O
phosphate None None O
buffered None None O
saline None None O
( None None O
PBS None None O
) None None O
but None None O
RSV None None O
eluted None None O
at None None O
high None None O
ionic None None O
strength None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
0 None None O
. None None O
6 None None O
M None None O
NaCl None None O
. None None O

Further None None O
purification None None O
was None None O
possible None None O
by None None O
sucrose None None O
step None None O
gradient None None O
centrifugation None None O
. None None O

The None None O
RSV None None O
prepared None None O
by None None O
column None None O
purification None None O
or None None O
by None None O
column None None O
plus None None O
sucrose None None O
gradient None None O
separation None None O
was None None O
both None None O
intact None None O
and None None O
infective None None O
. None None O

RSV None None O
and None None O
pure None None O
samples None None O
of None None O
VSV None None O
were None None O
used None None O
to None None O
optimize None None O
ionic None None O
strength None None O
and None None O
salts None None O
for None None O
elution None None O
from None None O
the None None O
MCS None None O
column None None O
: None None O
0 None None O
. None None O
8 None None O
M None None O
NaCl None None O
removed None None O
most None None O
of None None O
the None None O
viral None None O
protein None None O
. None None O

The None None O
capacity None None O
of None None O
the None None O
MCS None None O
gel None None O
for None None O
RSV None None O
or None None O
VSV None None O
was None None O
found None None O
to None None O
be None None O
about None None O
0 None None O
. None None O
6 None None O
- None None O
0 None None O
. None None O
8 None None O
mg None None O
viral None None O
protein None None O
per None None O
ml None None O
of None None O
hydrated None None O
resin None None O
. None None O

Detergent None None O
- None None O
solubilized None None O
viral None None O
membrane None None O
proteins None None O
bound None None O
to None None O
the None None O
MCS None None O
resin None None O
in None None O
0 None None O
. None None O
145 None None O
M None None O
NaCl None None O
and None None O
eluted None None O
with None None O
higher None None O
salt None None O
concentrations None None O
. None None O

Thus None None O
, None None O
this None None O
resin None None O
also None None O
may None None O
be None None O
a None None O
useful None None O
aid None None O
for None None O
relatively None None O
gentle None None O
purification None None O
of None None O
these None None O
proteins None None O
. None None O

Vimentin None None O
is None None O
preferentially None None O
expressed None None O
in None None O
human None None O
breast None None O
carcinomas None None O
with None None O
low None None O
estrogen None None O
receptor None None O
and None None O
high None None O
Ki None None O
- None None O
67 None None O
growth None None O
fraction None None O
. None None O

Vimentin None None O
expression None None O
, None None O
growth None None O
fractions None None O
( None None O
GF None None O
) None None O
, None None O
and None None O
estrogen None None O
receptor None None O
( None None O
ER None None O
) None None O
levels None None O
were None None O
determined None None O
for None None O
90 None None O
untreated None None O
primary None None O
breast None None O
carcinomas None None O
. None None O

Coexpression None None O
of None None O
keratin None None O
and None None O
vimentin None None O
was None None O
found None None O
in None None O
approximately None None O
20 None None O
% None None O
of None None O
the None None O
tumors None None O
regardless None None O
of None None O
menopausal None None O
status None None O
. None None O

Vimentin None None O
was None None O
expressed None None O
preferentially None None O
in None None O
tumor None None O
cells None None O
of None None O
high None None O
- None None O
grade None None O
ductal None None O
breast None None O
carcinomas None None O
( None None O
15 None None O
of None None O
28 None None O
histologic None None O
grade None None O
3 None None O
vs None None O
. None None O
0 None None O
of None None O
40 None None O
grades None None O
1 None None O
and None None O
2 None None O
) None None O
. None None O

Vimentin None None O
expression None None O
was None None O
found None None O
preferentially None None O
in None None O
tumors None None O
with None None O
high None None O
GF None None O
( None None O
greater None None O
than None None O
15 None None O
% None None O
Ki None None O
- None None O
67 None None O
positive None None O
by None None O
immunoperoxidase None None O
staining None None O
) None None O
and None None O
low None None O
ER None None O
levels None None O
( None None O
less None None O
than None None O
60 None None O
fmols None None O
/ None None O
mg None None O
protein None None O
by None None O
a None None O
monoclonal None None O
enzyme None None O
immunoassay None None O
) None None O
. None None O

Sixty None None O
- None None O
eight None None O
percent None None O
of None None O
tumors None None O
in None None O
this None None O
group None None O
were None None O
vimentin None None O
positive None None O
and None None O
88 None None O
% None None O
of None None O
all None None O
vimentin None None O
- None None O
positive None None O
tumors None None O
fell None None O
into None None O
this None None O
category None None O
. None None O

More None None O
than None None O
50 None None O
% None None O
of None None O
the None None O
tumor None None O
cells None None O
coexpressed None None O
vimentin None None O
and None None O
keratin None None O
. None None O

Thus None None O
, None None O
vimentin None None O
expression None None O
may None None O
be None None O
helpful None None O
in None None O
identifying None None O
a None None O
substantial None None O
subset None None O
of None None O
ER None None O
- None None O
independent None None O
breast None None O
carcinomas None None O
with None None O
poor None None O
prognostic None None O
indicators None None O
. None None O

2 None None O
- None None O
methoxyestradiol None None O
inhibits None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
1alpha None None O
, None None O
tumor None None O
growth None None O
, None None O
and None None O
angiogenesis None None O
and None None O
augments None None O
paclitaxel None None O
efficacy None None O
in None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

PURPOSE None None O
: None None O
Head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinomas None None O
have None None O
been None None O
reported None None O
to None None O
overexpress None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
( None None O
HIF None None O
) None None O
- None None O
1alpha None None O
, None None O
a None None O
transcription None None O
factor None None O
that None None O
promotes None None O
expression None None O
of None None O
angiogenesis None None O
factors None None O
and None None O
resistance None None O
to None None O
programmed None None O
and None None O
therapy None None O
- None None O
induced None None O
cell None None O
death None None O
. None None O

2 None None O
- None None O
Methoxyestradiol None None O
( None None O
2ME2 None None O
) None None O
is None None O
a None None O
natural None None O
compound None None O
with None None O
HIF None None O
- None None O
1alpha None None O
inhibitory None None O
activity None None O
that None None O
is None None O
currently None None O
being None None O
evaluated None None O
in None None O
phase None None O
1 None None O
and None None O
2 None None O
clinical None None O
trials None None O
for None None O
advanced None None O
solid None None O
tumors None None O
and None None O
multiple None None O
myeloma None None O
. None None O

To None None O
our None None O
knowledge None None O
, None None O
this None None O
is None None O
the None None O
first None None O
study None None O
to None None O
evaluate None None O
the None None O
effects None None O
of None None O
2ME2 None None O
in None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
effects None None O
of None None O
2ME2 None None O
alone None None O
and None None O
in None None O
combination None None O
with None None O
paclitaxel None None O
, None None O
an None None O
active None None O
agent None None O
in None None O
recurrent None None O
or None None O
advanced None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

RESULTS None None O
: None None O
2ME2 None None O
exhibited None None O
antiproliferative None None O
and None None O
cytotoxic None None O
effects None None O
in None None O
a None None O
panel None None O
of None None O
five None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
cell None None O
lines None None O
in None None O
the None None O
0 None None O
. None None O
5 None None O
to None None O
10 None None O
micromol None None O
/ None None O
L None None O
range None None O
, None None O
including None None O
induction None None O
of None None O
G2 None None O
- None None O
M None None O
blockade None None O
, None None O
caspase None None O
- None None O
3 None None O
/ None None O
7 None None O
activation None None O
, None None O
and None None O
apoptosis None None O
at None None O
48 None None O
hours None None O
. None None O

2ME2 None None O
resulted None None O
in None None O
decreased None None O
nuclear None None O
HIF None None O
- None None O
1alpha None None O
- None None O
binding None None O
activity None None O
and None None O
affected None None O
the None None O
expression None None O
of None None O
downstream None None O
genes None None O
, None None O
such None None O
as None None O
bid None None O
, None None O
a None None O
proapoptotic None None O
bcl None None O
- None None O
2 None None O
family None None O
member None None O
, None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
a None None O
proangiogenic None None O
cytokine None None O
. None None O

The None None O
up None None O
- None None O
regulation None None O
of None None O
Bid None None O
( None None O
57 None None O
. None None O
5 None None O
% None None O
at None None O
12 None None O
hours None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0006 None None O
) None None O
and None None O
inhibition None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
secretion None None O
( None None O
57 None None O
. None None O
7 None None O
% None None O
at None None O
24 None None O
hours None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
015 None None O
; None None O
and None None O
50 None None O
. None None O
3 None None O
% None None O
at None None O
48 None None O
hours None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0006 None None O
) None None O
could None None O
be None None O
partially None None O
attributed None None O
to None None O
the None None O
effects None None O
on None None O
HIF None None O
- None None O
1alpha None None O
, None None O
because None None O
HIF None None O
- None None O
1alpha None None O
small None None O
interfering None None O
RNAs None None O
produced None None O
similar None None O
effects None None O
. None None O

Finally None None O
, None None O
in None None O
vivo None None O
, None None O
in None None O
a None None O
xenograft None None O
model None None O
of None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
using None None O
UM None None I-Cell-line-name
- None None I-Cell-line-name
SCC None None I-Cell-line-name
- None None I-Cell-line-name
11A None None I-Cell-line-name
cells None None O
, None None O
2ME2 None None O
exhibited None None O
antitumor None None O
and None None O
antiangiogenic None None O
activity None None O
, None None O
as None None O
measured None None O
by None None O
CD31 None None O
immunostaining None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
results None None O
provide None None O
support None None O
for None None O
the None None O
use None None O
of None None O
2ME2 None None O
in None None O
combination None None O
with None None O
paclitaxel None None O
for None None O
the None None O
treatment None None O
of None None O
recurrent None None O
or None None O
advanced None None O
head None None O
and None None O
neck None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Characteristics None None O
of None None O
fistula None None O
lesions None None O

HIF None None O
- None None O
2alpha None None O
expression None None O
in None None O
human None None O
fetal None None O
paraganglia None None O
and None None O
neuroblastoma None None O
: None None O
relation None None O
to None None O
sympathetic None None O
differentiation None None O
, None None O
glucose None None O
deficiency None None O
, None None O
and None None O
hypoxia None None O
. None None O

Solid None None O
tumors None None O
are None None O
frequently None None O
necrotic None None O
and None None O
hypoxic None None O
due None None O
to None None O
poor None None O
vascularization None None O
. None None O

Tumor None None O
cells None None O
adapt None None O
to None None O
hypoxia None None O
by None None O
modulating None None O
their None None O
phenotype None None O
. None None O

Key None None O
players None None O
in None None O
this None None O
process None None O
are None None O
the None None O
hypoxia None None O
- None None O
inducible None None O
factors None None O
( None None O
HIF None None O
- None None O
1alpha None None O
to None None O
3alpha None None O
) None None O
. None None O

HIFs None None O
are None None O
also None None O
expressed None None O
during None None O
normal None None O
development None None O
; None None O
for None None O
example None None O
, None None O
HIF None None O
- None None O
2alpha None None O
is None None O
specifically None None O
expressed None None O
and None None O
appears None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
development None None O
of None None O
the None None O
murine None None O
sympathetic None None O
nervous None None O
system None None O
( None None O
SNS None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
HIF None None O
- None None O
2alpha None None O
protein None None O
is None None O
selectively None None O
present None None O
in None None O
human None None O
fetal None None O
week None None O
8 None None O
. None None O
5 None None O
SNS None None O
paraganglia None None O
. None None O

Neuroblastoma None None O
is None None O
derived None None O
from None None O
SNS None None O
precursors None None O
. None None O

In None None O
a None None O
subset None None O
of None None O
neuroblastomas None None O
, None None O
a None None O
spontaneous None None O
neuronal None None O
to None None O
neuroendocrine None None O
differentiation None None O
occurs None None O
in None None O
areas None None O
adjacent None None O
to None None O
necrotic None None O
zones None None O
. None None O

As None None O
HIF None None O
- None None O
2alpha None None O
activity None None O
has None None O
been None None O
associated None None O
not None None O
only None None O
with None None O
hypoxic None None O
but None None O
also None None O
with None None O
hypoglycemic None None O
conditions None None O
, None None O
we None None O
have None None O
investigated None None O
putative None None O
effects None None O
of None None O
hypoxia None None O
, None None O
glucose None None O
depletion None None O
, None None O
and None None O
HIF None None O
- None None O
2alpha None None O
on None None O
the None None O
neuroblastoma None None O
phenotype None None O
. None None O

HIF None None O
- None None O
2alpha None None O
was None None O
detected None None O
in None None O
hypoxic None None O
and None None O
in None None O
well None None O
- None None O
oxygenized None None O
neuroblastoma None None O
cells None None O
and None None O
tissue None None O
, None None O
presumably None None O
reflecting None None O
their None None O
embryonic None None O
features None None O
. None None O

With None None O
regard None None O
to None None O
differentiation None None O
, None None O
hypoxic None None O
cells None None O
lost None None O
their None None O
neuronal None None O
/ None None O
neuroendocrine None None O
features None None O
and None None O
gained None None O
marker None None O
gene None None O
expression None None O
associated None None O
with None None O
an None None O
immature None None O
, None None O
neural None None O
crest None None O
- None None O
like None None O
phenotype None None O
. None None O

Low None None O
glucose None None O
potentiated None None O
the None None O
effect None None O
of None None O
hypoxia None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
poorly None None O
vascularized None None O
neuroblastomas None None O
become None None O
immature None None O
and None None O
maintain None None O
a None None O
more None None O
aggressive None None O
phenotype None None O
, None None O
which None None O
possibly None None O
could None None O
involve None None O
a None None O
sustained None None O
stabilization None None O
and None None O
activation None None O
of None None O
HIF None None O
- None None O
2alpha None None O
. None None O

Induction None None O
of None None O
p18INK4c None None O
and None None O
its None None O
predominant None None O
association None None O
with None None O
CDK4 None None O
and None None O
CDK6 None None O
during None None O
myogenic None None O
differentiation None None O
. None None O

Terminal None None O
cell None None O
differentiation None None O
involves None None O
permanent None None O
withdrawal None None O
from None None O
the None None O
cell None None O
division None None O
cycle None None O
. None None O

The None None O
inhibitors None None O
of None None O
cyclin None None O
- None None O
dependent None None O
kinases None None O
( None None O
CDKs None None O
) None None O
are None None O
potential None None O
molecules None None O
functioning None None O
to None None O
couple None None O
cell None None O
cycle None None O
arrest None None O
and None None O
cell None None O
differentiation None None O
. None None O

In None None O
murine None None O
C2C12 None None I-Cell-line-name
myoblast None None O
cells None None O
, None None O
G1 None None O
CDK None None O
enzymes None None O
( None None O
CDK2 None None O
, None None O
CDK4 None None O
, None None O
and None None O
CDK6 None None O
) None None O
associate None None O
with None None O
four None None O
CDK None None O
inhibitors None None O
: None None O
p18INK4c None None O
, None None O
p19INK4d None None O
, None None O
p21 None None O
, None None O
and None None O
p27Kip1 None None O
. None None O

During None None O
induced None None O
myogenesis None None O
, None None O
p21 None None O
and None None O
its None None O
associated None None O
CDK None None O
proteins None None O
underwent None None O
an None None O
initial None None O
increase None None O
followed None None O
by None None O
a None None O
decrease None None O
as None None O
cells None None O
became None None O
terminally None None O
differentiated None None O
. None None O

The None None O
level None None O
of None None O
p27 None None O
protein None None O
gradually None None O
increased None None O
, None None O
but None None O
the None None O
amount None None O
of None None O
total None None O
associated None None O
CDK None None O
proteins None None O
remained None None O
unchanged None None O
. None None O

p19 None None O
protein None None O
decreased None None O
gradually None None O
during None None O
differentiation None None O
, None None O
as None None O
did None None O
its None None O
associated None None O
CDK4 None None O
protein None None O
. None None O

In None None O
contrast None None O
, None None O
p18 None None O
protein None None O
increased None None O
50 None None O
- None None O
fold None None O
, None None O
from None None O
negligible None None O
levels None None O
in None None O
proliferating None None O
myoblasts None None O
to None None O
clearly None None O
detectable None None O
levels None None O
within None None O
8 None None O
- None None O
12 None None O
h None None O
of None None O
myogenic None None O
induction None None O
. None None O

This None None O
initial None None O
rise None None O
was None None O
followed None None O
by None None O
a None None O
precipitous None None O
increase None None O
between None None O
12 None None O
and None None O
24 None None O
h None None O
postinduction None None O
, None None O
with None None O
p18 None None O
protein None None O
finally None None O
accumulating None None O
to None None O
its None None O
highest None None O
level None None O
in None None O
terminally None None O
differentiated None None O
cells None None O
. None None O

Induction None None O
of None None O
p18 None None O
correlated None None O
with None None O
increased None None O
and None None O
sequential None None O
complex None None O
formation None None O
- None None O
- None None O
first None None O
increasing None None O
association None None O
with None None O
CDK6 None None O
and None None O
then None None O
with None None O
CDK4 None None O
over None None O
the None None O
course None None O
of None None O
myogenic None None O
differentiation None None O
. None None O

All None None O
of None None O
the None None O
CDK6 None None O
and None None O
half None None O
of None None O
the None None O
CDK4 None None O
were None None O
complexed None None O
with None None O
p18 None None O
in None None O
terminally None None O
differentiated None None O
C2C12 None None I-Cell-line-name
cells None None O
as None None O
well None None O
as None None O
in None None O
adult None None O
mouse None None O
muscle None None O
tissue None None O
. None None O

Finally None None O
, None None O
kinase None None O
activity None None O
of None None O
CDK2 None None O
and None None O
CDK4 None None O
decreases None None O
as None None O
C2C12 None None I-Cell-line-name
cells None None O
differentiate None None O
, None None O
whereas None None O
the None None O
CDK6 None None O
kinase None None O
activity None None O
is None None O
low None None O
in None None O
both None None O
proliferating None None O
myoblasts None None O
and None None O
differentiated None None O
myotubes None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
p18 None None O
may None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
causing None None O
and None None O
/ None None O
or None None O
maintaining None None O
permanent None None O
cell None None O
cycle None None O
arrest None None O
associated None None O
with None None O
mature None None O
muscle None None O
formation None None O
. None None O

Elevated None None O
levels None None O
of None None O
diacylglycerol None None O
and None None O
decreased None None O
phorbol None None O
ester None None O
sensitivity None None O
in None None O
ras None None O
- None None O
transformed None None O
fibroblasts None None O
. None None O

Diacylglycerol None None O
( None None O
DG None None O
) None None O
plays None None O
a None None O
central None None O
role None None O
in None None O
phospholipid None None O
metabolism None None O
and None None O
is None None O
an None None O
endogenous None None O
activator None None O
of None None O
protein None None O
kinase None None O
C None None O
. None None O

We None None O
have None None O
suggested None None O
that None None O
constitutive None None O
activation None None O
of None None O
this None None O
kinase None None O
is None None O
one None None O
mechanism None None O
by None None O
which None None O
oncogenes None None O
transform None None O
cells None None O
. None None O

The None None O
ras None None O
- None None O
encoded None None O
proteins None None O
are None None O
similar None None O
to None None O
regulatory None None O
G None None O
- None None O
proteins None None O
and None None O
are None None O
candidates None None O
for None None O
the None None O
unknown None None O
G None None O
- None None O
protein None None O
that None None O
modulates None None O
phosphatidylinositol None None O
( None None O
PI None None O
) None None O
turnover None None O
. None None O

Differences None None O
in None None O
polyphosphoinositide None None O
metabolism None None O
have None None O
been None None O
reported None None O
for None None O
ras None None O
- None None O
transformed None None O
cells None None O
. None None O

But None None O
because None None O
these None None O
experiments None None O
were None None O
performed None None O
on None None O
confluent None None O
cultures None None O
of None None O
established None None O
cell None None O
lines None None O
, None None O
the None None O
differences None None O
are None None O
difficult None None O
to None None O
attribute None None O
to None None O
ras None None O
transformation None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
exponentially None None O
growing None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
fibroblasts None None O
recently None None O
transformed None None O
by None None O
Ha None None O
- None None O
ras None None O
or None None O
Ki None None O
- None None O
ras None None O
possess None None O
elevated None None O
DG None None O
concentrations None None O
without None None O
significant None None O
alterations None None O
in None None O
the None None O
levels None None O
of None None O
other None None O
polyphosphoinositide None None O
metabolites None None O
. None None O

The None None O
basal None None O
phosphorylation None None O
of None None O
protein None None O
kinase None None O
C None None O
substrate None None O
of None None O
relative None None O
molecular None None O
mass None None O
( None None O
Mr None None O
) None None O
80 None None O
, None None O
000 None None O
( None None O
80K None None O
) None None O
is None None O
significantly None None O
increased None None O
in None None O
all None None O
the None None O
ras None None O
- None None O
transformed None None O
cell None None O
lines None None O
. None None O

Surprisingly None None O
, None None O
however None None O
, None None O
further None None O
phosphorylation None None O
of None None O
this None None O
protein None None O
on None None O
addition None None O
of None None O
phorbol None None O
ester None None O
was None None O
greatly None None O
reduced None None O
. None None O

Ha None None O
- None None O
ras None None O
cells None None O
also None None O
show None None O
less None None O
binding None None O
of None None O
phorbol None None O
ester None None O
than None None O
control None None O
cells None None O
, None None O
suggesting None None O
that None None O
elevation None None O
of None None O
DG None None O
causes None None O
partial None None O
down None None O
- None None O
regulation None None O
in None None O
addition None None O
to None None O
activation None None O
of None None O
protein None None O
kinase None None O
C None None O
. None None O

Intact None None O
mass None None O
analysis None None O
of None None O
a None None O
mixed None None O
population None None O
of None None O
proteins None None O
. None None O

A None None O
mixture None None O
of None None O
the None None O
membrane None None O
protein None None O
KCNJ12 None None O
, None None O
the None None O
soluble None None O
TEV None None O
protease None None O
used None None O
to None None O
cleave None None O
the None None O
fusion None None O
tag None None O
, None None O
and None None O
the None None O
membrane None None O
protein None None O
HVCN1 None None O
, None None O
which None None O
occurred None None O
as None None O
a None None O
contaminant None None O
from None None O
an None None O
earlier None None O
analysis None None O
on None None O
the None None O
same None None O
LC None None O
column None None O
. None None O

The None None O
effect None None O
of None None O
aflatoxin None None O
B1 None None O
on None None O
the None None O
utilization None None O
of None None O
serum None None O
calcium None None O
. None None O

The None None O
mathematical None None O
analysis None None O
for None None O
plasma None None O
disappearance None None O
curve None None O
of None None O
aflatoxicosed None None O
animals None None O
, None None O
subsequently None None O
injected None None O
with None None O
45Ca None None O
was None None O
determined None None O
. None None O

The None None O
analysis None None O
showed None None O
that None None O
the None None O
three None None O
main None None O
compartments None None O
of None None O
the None None O
calcium None None O
pool None None O
( None None O
plasma None None O
, None None O
bone None None O
and None None O
the None None O
labile None None O
calcium None None O
pool None None O
on None None O
the None None O
surface None None O
of None None O
bone None None O
and None None O
soft None None O
tissues None None O
) None None O
had None None O
been None None O
affected None None O
. None None O

Specifically None None O
, None None O
the None None O
fractional None None O
rate None None O
constant None None O
for None None O
migration None None O
of None None O
45Ca None None O
from None None O
plasma None None O
pool None None O
to None None O
the None None O
labile None None O
pool None None O
had None None O
been None None O
diminished None None O
to None None O
its None None O
third None None O
value None None O
. None None O

This None None O
led None None O
to None None O
a None None O
corresponding None None O
reduction None None O
in None None O
the None None O
calcium None None O
content None None O
of None None O
the None None O
bone None None O
ash None None O
. None None O

The None None O
probable None None O
mechanism None None O
by None None O
which None None O
aflatoxin None None O
B1 None None O
affects None None O
calcium None None O
dynamics None None O
may None None O
be None None O
interpreted None None O
by None None O
the None None O
inhibitory None None O
effect None None O
of None None O
aflatoxin None None O
in None None O
the None None O
hydroxylation None None O
mechanism None None O
of None None O
vitamin None None O
D3 None None O
into None None O
an None None O
active None None O
intermediate None None O
. None None O

During None None O
aflatoxicosis None None O
( None None O
induction None None O
of None None O
15 None None O
days None None O
) None None O
the None None O
animals None None O
entered None None O
a None None O
state None None O
of None None O
calcium None None O
deficiency None None O
, None None O
secondary None None O
to None None O
intestinal None None O
absorption None None O
inhibition None None O
. None None O

This None None O
was None None O
followed None None O
by None None O
bone None None O
resorption None None O
and None None O
disturbance None None O
of None None O
the None None O
fractional None None O
removal None None O
rate None None O
constant None None O
among None None O
different None None O
calcium None None O
compartments None None O
. None None O

[ None None O
Effects None None O
of None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
latent None None O
membrane None None O
protein None None O
1 None None O
( None None O
EBV None None O
- None None O
LMP1 None None O
) None None O
on None None O
related None None O
factors None None O
of None None O
metastasis None None O
of None None O
nasopharyngeal None None O
carcinoma None None O
cell None None O
line None None O
CNE1 None None I-Cell-line-name
] None None O
. None None O

BACKGROUND None None O
& None None O
# None None O
38 None None O
; None None O
OBJECTIVE None None O
: None None O
It None None O
has None None O
been None None O
proved None None O
that None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
latent None None O
membrane None None O
protein None None O
1 None None O
( None None O
EBV None None O
- None None O
LMP1 None None O
) None None O
can None None O
induce None None O
the None None O
expression None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
( None None O
MMP None None O
- None None O
9 None None O
) None None O
. None None O

This None None O
study None None O
was None None O
designed None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
EBV None None O
- None None O
LMP1 None None O
on None None O
related None None O
factors None None O
of None None O
metastasis None None O
of None None O
nasopharyngeal None None O
carcinoma None None O
cell None None O
line None None O
CNE1 None None I-Cell-line-name
. None None O

METHODS None None O
: None None O
Expression None None O
of None None O
MMP None None O
- None None O
9 None None O
was None None O
studied None None O
in None None O
human None None O
NPC None None O
cell None None O
lines None None O
cultured None None O
in None None O
vitro None None O
: None None O
CNE1 None None I-Cell-line-name
( None None O
well None None O
differentiated None None O
cell None None O
line None None O
of None None O
NPC None None O
) None None O
and None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
( None None O
CNE1 None None I-Cell-line-name
cell None None O
line None None O
transfected None None O
with None None O
an None None O
eukaryotic None None O
LMP1 None None O
- None None O
expression None None O
plasmid None None O
) None None O
by None None O
SP None None O
immunohistochemistry None None O
and None None O
Western None None O
blot None None O
analysis None None O
. None None O

Cell None None O
- None None O
matrix None None O
adhesion None None O
assay None None O
was None None O
used None None O
to None None O
study None None O
the None None O
adhesive None None O
ability None None O
of None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
cells None None O
. None None O

The None None O
effects None None O
of None None O
LMP1 None None O
on None None O
the None None O
invasion None None O
and None None O
migration None None O
of None None O
CNE1 None None I-Cell-line-name
cells None None O
were None None O
investigated None None O
by None None O
transwell None None O
methods None None O
. None None O

RESULTS None None O
: None None O
MMP None None O
- None None O
9 None None O
was None None O
expressed None None O
in None None O
both None None O
cell None None O
lines None None O
but None None O
the None None O
intensity None None O
of None None O
the None None O
staining None None O
was None None O
different None None O
. None None O

The None None O
positive None None O
rates None None O
of None None O
expression None None O
of None None O
MMP None None O
- None None O
9 None None O
in None None O
CNE1 None None I-Cell-line-name
and None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
cells None None O
were None None O
30 None None O
. None None O
2 None None O
% None None O
and None None O
98 None None O
. None None O
2 None None O
% None None O
, None None O
respectively None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
increased None None O
expression None None O
of None None O
MMP None None O
- None None O
9 None None O
was None None O
also None None O
shown None None O
in None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
cells None None O
by None None O
Western None None O
blot None None O
analysis None None O
. None None O

Cell None None O
- None None O
matrix None None O
adhesion None None O
assay None None O
showed None None O
that None None O
the None None O
adhesive None None O
ability None None O
of None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
with None None O
the None None O
matrix None None O
( None None O
mean None None O
A None None O
value None None O
: None None O
1 None None O
. None None O
2508 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
0711 None None O
) None None O
was None None O
higher None None O
than None None O
that None None O
of None None O
CNE1 None None I-Cell-line-name
cell None None O
( None None O
mean None None O
A None None O
value None None O
: None None O
0 None None O
. None None O
9519 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
068 None None O
) None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Invasion None None O
assay None None O
and None None O
migration None None O
assay None None O
showed None None O
that None None O
the None None O
invasion None None O
and None None O
migration None None O
of None None O
CNE1 None None I-Cell-line-name
- None None O
GL None None O
cell None None O
were None None O
higher None None O
than None None O
those None None O
of None None O
CNE1 None None I-Cell-line-name
cells None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
transfection None None O
of None None O
LMP1 None None O
can None None O
increase None None O
the None None O
expression None None O
of None None O
MMP None None O
- None None O
9 None None O
in None None O
CNE1 None None I-Cell-line-name
cells None None O
. None None O

Abilities None None O
of None None O
adhesion None None O
, None None O
migration None None O
, None None O
and None None O
invasion None None O
of None None O
CNE1 None None I-Cell-line-name
cell None None O
were None None O
induced None None O
by None None O
LMP1 None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
MMP None None O
- None None O
9 None None O
may None None O
have None None O
a None None O
role None None O
in None None O
the None None O
LMP1 None None O
- None None O
induced None None O
acceleration None None O
of None None O
invasion None None O
and None None O
metastasis None None O
of None None O
NPC None None O
cells None None O
. None None O

Images None None O

Fig None None O
. None None O

1 None None O

Fig None None O
. None None O

2 None None O

Fig None None O
. None None O

3 None None O

Bicistronic None None O
retroviral None None O
vector None None O
reveals None None O
capacity None None O
of None None O
v None None O
- None None O
erbA None None O
to None None O
induce None None O
erythroleukemia None None O
and None None O
to None None O
co None None O
- None None O
operate None None O
with None None O
v None None O
- None None O
myb None None O
. None None O

Previous None None O
studies None None O
have None None O
shown None None O
that None None O
v None None O
- None None O
erbA None None O
and None None O
v None None O
- None None O
myb None None O
can None None O
induce None None O
the None None O
proliferation None None O
of None None O
avian None None O
erythroid None None O
cells None None O
in None None O
culture None None O
. None None O

To None None O
study None None O
the None None O
combined None None O
effects None None O
of None None O
v None None O
- None None O
erbA None None O
and None None O
v None None O
- None None O
myb None None O
, None None O
the None None O
two None None O
oncogenes None None O
were None None O
engineered None None O
into None None O
a None None O
retrovirus None None O
bicistronic None None O
vector None None O
with None None O
an None None O
internal None None O
ribosomal None None O
entry None None O
site None None O
( None None O
IRES None None O
) None None O
or None None O
into None None O
a None None O
vector None None O
with None None O
a None None O
splice None None O
acceptor None None O
( None None O
SPL None None O
) None None O
. None None O

This None None O
allowed None None O
coexpression None None O
of None None O
the None None O
two None None O
proteins None None O
and None None O
a None None O
comparison None None O
with None None O
the None None O
same None None O
vector None None O
containing None None O
either None None O
v None None O
- None None O
erbA None None O
or None None O
v None None O
- None None O
myb None None O
only None None O
. None None O

Both None None O
the None None O
erbA None None O
IRES None None O
and None None O
the None None O
erbA None None O
/ None None O
myb None None O
IRES None None O
virus None None O
constructs None None O
transformed None None O
erythroid None None O
cells None None O
after None None O
infection None None O
of None None O
bone None None O
marrow None None O
or None None O
blastoderm None None O
cultures None None O
. None None O

The None None O
erbA None None O
/ None None O
myb None None O
IRES None None O
virus None None O
exhibited None None O
a None None O
5 None None O
- None None O
10 None None O
- None None O
fold None None O
higher None None O
transformed None None O
colony None None O
forming None None O
efficiency None None O
than None None O
the None None O
erbA None None O
IRES None None O
virus None None O
in None None O
the None None O
blastoderm None None O
assay None None O
. None None O

Surprisingly None None O
, None None O
when None None O
injected None None O
into None None O
chicken None None O
embryos None None O
in None None O
the None None O
presence None None O
of None None O
helper None None O
virus None None O
, None None O
both None None O
viruses None None O
induced None None O
an None None O
erythroleukemia None None O
in None None O
about None None O
half None None O
of None None O
the None None O
animals None None O
. None None O

In None None O
contrast None None O
, None None O
no None None O
leukemia None None O
was None None O
observed None None O
with None None O
a None None O
myb None None O
IRES None None O
virus None None O
, None None O
with None None O
spliced None None O
vectors None None O
containing None None O
v None None O
- None None O
erbA None None O
alone None None O
or None None O
v None None O
- None None O
erbA None None O
in None None O
combination None None O
with None None O
v None None O
- None None O
myb None None O
, None None O
nor None None O
with None None O
erbA None None O
IRES None None O
and None None O
erbA None None O
/ None None O
myb None None O
IRES None None O
viruses None None O
produced None None O
in None None O
the None None O
absence None None O
of None None O
helper None None O
virus None None O
. None None O

The None None O
average None None O
latency None None O
of None None O
leukemia None None O
induction None None O
was None None O
shorter None None O
for None None O
the None None O
erbA None None O
/ None None O
myb None None O
IRES None None O
virus None None O
( None None O
3 None None O
. None None O
5 None None O
weeks None None O
) None None O
than None None O
for None None O
the None None O
erbA None None O
IRES None None O
virus None None O
( None None O
5 None None O
weeks None None O
) None None O
. None None O

Nevertheless None None O
, None None O
for None None O
both None None O
viruses None None O
the None None O
leukemic None None O
blasts None None O
retained None None O
full None None O
factor None None O
dependence None None O
for None None O
growth None None O
. None None O

These None None O
results None None O
show None None O
that None None O
v None None O
- None None O
erbA None None O
is None None O
capable None None O
of None None O
inducing None None O
an None None O
erythroleukemia None None O
when None None O
expressed None None O
by None None O
a None None O
high None None O
titer None None O
bicistronic None None O
retrovirus None None O
under None None O
conditions None None O
of None None O
virus None None O
spreading None None O
and None None O
that None None O
its None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
transforming None None O
potential None None O
can None None O
be None None O
enhanced None None O
by None None O
v None None O
- None None O
myb None None O
. None None O

Induction None None O
of None None O
Ets None None O
- None None O
1 None None O
in None None O
endothelial None None O
cells None None O
during None None O
reendothelialization None None O
after None None O
denuding None None O
injury None None O
. None None O

Ets None None O
- None None O
1 None None O
, None None O
a None None O
transcription None None O
factor None None O
, None None O
is None None O
induced None None O
in None None O
endothelial None None O
cells None None O
( None None O
ECs None None O
) None None O
during None None O
angiogenesis None None O
. None None O

Here None None O
, None None O
we None None O
investigated None None O
the None None O
expression None None O
of None None O
Ets None None O
- None None O
1 None None O
during None None O
reendothelialization None None O
. None None O

When None None O
a None None O
confluent None None O
monolayer None None O
of None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
line None None O
, None None O
ECV304 None None I-Cell-line-name
, None None O
was None None O
denuded None None O
, None None O
ECV304 None None I-Cell-line-name
at None None O
the None None O
wound None None O
edge None None O
expressed None None O
Ets None None O
- None None O
1 None None O
. None None O

An None None O
immunohistochemical None None O
analysis None None O
revealed None None O
that None None O
Ets None None O
- None None O
1 None None O
accumulated None None O
in None None O
migrating None None O
cells None None O
at None None O
the None None O
wound None None O
edge None None O
and None None O
returned None None O
to None None O
basal None None O
level None None O
when None None O
reendothelialization None None O
was None None O
accomplished None None O
. None None O

This None None O
induction None None O
of None None O
Ets None None O
- None None O
1 None None O
could None None O
be None None O
reproduced None None O
in None None O
in None None O
vivo None None O
denudation None None O
of None None O
rat None None O
aortic None None O
endothelium None None O
by None None O
a None None O
balloon None None O
catheter None None O
. None None O

The None None O
induction None None O
of None None O
Ets None None O
- None None O
1 None None O
in None None O
ECs None None O
after None None O
denudation None None O
was None None O
regulated None None O
transcriptionally None None O
, None None O
and None None O
humeral None None O
factors None None O
released None None O
from None None O
injured None None O
ECs None None O
might None None O
not None None O
be None None O
responsible None None O
. None None O

Mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
activities None None O
were None None O
investigated None None O
to None None O
explore None None O
the None None O
mechanism None None O
of None None O
this None None O
induction None None O
. None None O

Although None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
protein None None O
kinase None None O
1 None None O
/ None None O
2 None None O
( None None O
ERK1 None None O
/ None None O
2 None None O
) None None O
, None None O
c None None O
- None None O
Jun None None O
N None None O
- None None O
terminal None None O
kinase None None O
1 None None O
( None None O
JNK1 None None O
) None None O
, None None O
and None None O
p38 None None O
were None None O
activated None None O
after None None O
denudation None None O
, None None O
the None None O
activation None None O
of None None O
ERK1 None None O
and None None O
p38 None None O
was None None O
more None None O
rapid None None O
and None None O
prominent None None O
. None None O

PD98059 None None O
, None None O
a None None O
specific None None O
MAPK None None O
/ None None O
ERK None None O
kinase None None O
( None None O
MEK None None O
) None None O
1 None None O
inhibitor None None O
, None None O
did None None O
not None None O
affect None None O
the None None O
induction None None O
of None None O
ets None None O
- None None O
1 None None O
mRNA None None O
, None None O
whereas None None O
SB203580 None None O
, None None O
a None None O
specific None None O
p38 None None O
inhibitor None None O
, None None O
almost None None O
completely None None O
abrogated None None O
its None None O
induction None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
Ets None None O
- None None O
1 None None O
is None None O
induced None None O
in None None O
ECs None None O
after None None O
denudation None None O
through None None O
activation None None O
of None None O
p38 None None O
. None None O

This None None O
induction None None O
of None None O
Ets None None O
- None None O
1 None None O
may None None O
be None None O
relevant None None O
for None None O
reendothelialization None None O
by None None O
regulating None None O
the None None O
expression None None O
of None None O
certain None None O
genes None None O
. None None O

Inhibition None None O
of None None O
the None None O
mammalian None None O
target None None O
of None None O
rapamycin None None O
( None None O
mTOR None None O
) None None O
by None None O
rapamycin None None O
increases None None O
chemosensitivity None None O
of None None O
CaSki None None I-Cell-line-name
cells None None O
to None None O
paclitaxel None None O
. None None O

Paclitaxel None None O
, None None O
a None None O
potent None None O
anti None None O
- None None O
neoplastic None None O
agent None None O
, None None O
has None None O
been None None O
found None None O
to None None O
be None None O
effective None None O
against None None O
several None None O
tumours None None O
, None None O
including None None O
cervical None None O
cancer None None O
. None None O

However None None O
, None None O
the None None O
exact None None O
mechanism None None O
underlying None None O
the None None O
cytotoxic None None O
effects None None O
of None None O
pacitaxel None None O
, None None O
especially None None O
in None None O
the None None O
survival None None O
- None None O
signalling None None O
pathway None None O
, None None O
is None None O
poorly None None O
understood None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
molecular None None O
pathway None None O
of None None O
the None None O
cytotoxic None None O
effect None None O
of None None O
paclitaxel None None O
in None None O
human None None O
cervical None None O
cancer None None O
cell None None O
lines None None O
. None None O

Four None None O
human None None O
cervical None None O
cancer None None O
cell None None O
lines None None O
were None None O
treated None None O
for None None O
24 None None O
h None None O
with None None O
various None None O
concentration None None O
of None None O
paclitaxel None None O
, None None O
and None None O
the None None O
sensitivity None None O
was None None O
analysed None None O
by None None O
an None None O
MTT None None O
assay None None O
. None None O

The None None O
cell None None O
cycle None None O
progression None None O
and None None O
sub None None O
- None None O
G1 None None O
population None None O
were None None O
analysed None None O
by None None O
flow None None O
cytometry None None O
. None None O

Apoptosis None None O
was None None O
further None None O
measured None None O
by None None O
DNA None None O
fragmentation None None O
and None None O
microscope None None O
examination None None O
. None None O

The None None O
protein None None O
expression None None O
was None None O
determined None None O
by None None O
Western None None O
blot None None O
analysis None None O
. None None O

Our None None O
results None None O
showed None None O
that None None O
HeLa None None I-Cell-line-name
cells None None O
demonstrated None None O
the None None O
highest None None O
sensitivity None None O
to None None O
paclitaxel None None O
, None None O
whereas None None O
CaSki None None I-Cell-line-name
cells None None O
showed None None O
the None None O
lowest None None O
. None None O

In None None O
cervical None None O
cancer None None O
cells None None O
, None None O
paclitaxel None None O
induced None None O
apoptosis None None O
through None None O
an None None O
intrinsic None None O
pathway None None O
with None None O
prior None None O
G2 None None O
/ None None O
M None None O
arrest None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
showed None None O
that None None O
paclitaxel None None O
downregulated None None O
the None None O
phosphorylation None None O
of None None O
Akt None None O
in None None O
both None None O
HeLa None None I-Cell-line-name
and None None O
CaSki None None I-Cell-line-name
cells None None O
. None None O

Interestingly None None O
, None None O
in None None O
CaSki None None I-Cell-line-name
cells None None O
, None None O
which None None O
were None None O
more None None O
suggestive None None O
of None None O
a None None O
resistant None None O
phenotype None None O
, None None O
paclitaxel None None O
induced None None O
the None None O
activation None None O
of None None O
mTOR None None O
as None None O
a None None O
downstream None None O
target None None O
of None None O
Akt None None O
. None None O

Pre None None O
- None None O
treatment None None O
with None None O
rapamycin None None O
inhibited None None O
activation None None O
of None None O
mTOR None None O
signalling None None O
and None None O
significantly None None O
enhanced None None O
the None None O
sensitivity None None O
of None None O
CaSki None None I-Cell-line-name
cells None None O
to None None O
paclitaxel None None O
by None None O
increasing None None O
apoptotic None None O
cell None None O
death None None O
. None None O

This None None O
effect None None O
was None None O
mediated None None O
, None None O
at None None O
least None None O
partly None None O
, None None O
through None None O
caspase None None O
activation None None O
. None None O

Overall None None O
, None None O
paclitaxel None None O
exerts None None O
its None None O
anti None None O
- None None O
tumour None None O
effects None None O
on None None O
cervical None None O
cancer None None O
cells None None O
by None None O
inducing None None O
apoptosis None None O
through None None O
intrinsic None None O
pathway None None O
, None None O
and None None O
rapamycin None None O
targeted None None O
to None None O
mTOR None None O
can None None O
sensitise None None O
paclitaxel None None O
- None None O
resistant None None O
cervical None None O
cancer None None O
cells None None O
. None None O

Pericytes None None O
limit None None O
tumor None None O
cell None None O
metastasis None None O
. None None O

Previously None None O
we None None O
observed None None O
that None None O
neural None None O
cell None None O
adhesion None None O
molecule None None O
( None None O
NCAM None None O
) None None O
deficiency None None O
in None None O
beta None None O
tumor None None O
cells None None O
facilitates None None O
metastasis None None O
into None None O
distant None None O
organs None None O
and None None O
local None None O
lymph None None O
nodes None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
NCAM None None O
- None None O
deficient None None O
beta None None O
cell None None O
tumors None None O
grew None None O
leaky None None O
blood None None O
vessels None None O
with None None O
perturbed None None O
pericyte None None O
- None None O
endothelial None None O
cell None None O
- None None O
cell None None O
interactions None None O
and None None O
deficient None None O
perivascular None None O
deposition None None O
of None None O
ECM None None O
components None None O
. None None O

Conversely None None O
, None None O
tumor None None O
cell None None O
expression None None O
of None None O
NCAM None None O
in None None O
a None None O
fibrosarcoma None None O
model None None O
( None None O
T241 None None O
) None None O
improved None None O
pericyte None None O
recruitment None None O
and None None O
increased None None O
perivascular None None O
deposition None None O
of None None O
ECM None None O
molecules None None O
. None None O

Together None None O
, None None O
these None None O
findings None None O
suggest None None O
that None None O
NCAM None None O
may None None O
limit None None O
tumor None None O
cell None None O
metastasis None None O
by None None O
stabilizing None None O
the None None O
microvessel None None O
wall None None O
. None None O

To None None O
directly None None O
address None None O
whether None None O
pericyte None None O
dysfunction None None O
increases None None O
the None None O
metastatic None None O
potential None None O
of None None O
solid None None O
tumors None None O
, None None O
we None None O
studied None None O
beta None None O
cell None None O
tumorigenesis None None O
in None None O
primary None None O
pericyte None None O
- None None O
deficient None None O
Pdgfb None None O
( None None O
ret None None O
/ None None O
ret None None O
) None None O
mice None None O
. None None O

This None None O
resulted None None O
in None None O
beta None None O
tumor None None O
cell None None O
metastases None None O
in None None O
distant None None O
organs None None O
and None None O
local None None O
lymph None None O
nodes None None O
, None None O
demonstrating None None O
a None None O
role None None O
for None None O
pericytes None None O
in None None O
limiting None None O
tumor None None O
cell None None O
metastasis None None O
. None None O

These None None O
data None None O
support None None O
a None None O
new None None O
model None None O
for None None O
how None None O
tumor None None O
cells None None O
trigger None None O
metastasis None None O
by None None O
perturbing None None O
pericyte None None O
- None None O
endothelial None None O
cell None None O
- None None O
cell None None O
interactions None None O
. None None O

Molecular None None O
analysis None None O
of None None O
genetic None None O
instability None None O
caused None None O
by None None O
chronic None None O
inflammation None None O
. None None O

Genetic None None O
instability None None O
is None None O
a None None O
hallmark None None O
of None None O
human None None O
cancers None None O
. None None O

It None None O
is None None O
the None None O
driving None None O
force None None O
for None None O
tumor None None O
development None None O
as None None O
it None None O
facilitates None None O
the None None O
accumulation None None O
of None None O
mutations None None O
in None None O
genes None None O
that None None O
regulate None None O
cell None None O
death None None O
and None None O
proliferation None None O
and None None O
therefore None None O
promotes None None O
malignant None None O
transformation None None O
. None None O

Chronic None None O
inflammation None None O
is None None O
a None None O
common None None O
underlying None None O
condition None None O
for None None O
human None None O
tumor None None O
development None None O
, None None O
accounting None None O
for None None O
approximately None None O
20 None None O
% None None O
of None None O
human None None O
cancers None None O
. None None O

TNFalpha None None O
is None None O
an None None O
important None None O
inflammation None None O
cytokine None None O
and None None O
is None None O
crucial None None O
to None None O
the None None O
development None None O
of None None O
inflammation None None O
- None None O
associated None None O
cancers None None O
. None None O

We None None O
have None None O
shown None None O
that None None O
TNFalpha None None O
can None None O
cause None None O
DNA None None O
damages None None O
through None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
. None None O

TNFalpha None None O
treatment None None O
in None None O
cultured None None O
cells None None O
resulted None None O
in None None O
increased None None O
gene None None O
mutations None None O
, None None O
gene None None O
amplification None None O
, None None O
micronuclei None None O
formation None None O
and None None O
chromosomal None None O
instability None None O
. None None O

Antioxidants None None O
significantly None None O
reduced None None O
TNFalpha None None O
- None None O
induced None None O
genetic None None O
damage None None O
. None None O

In None None O
addition None None O
, None None O
TNFalpha None None O
treatment None None O
alone None None O
led None None O
to None None O
increased None None O
malignant None None O
transformation None None O
of None None O
mouse None None O
embryo None None O
fibroblasts None None O
, None None O
which None None O
could None None O
be None None O
partially None None O
suppressed None None O
by None None O
antioxidants None None O
. None None O

Therefore None None O
, None None O
genetic None None O
instability None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
inflammation None None O
- None None O
associated None None O
cancers None None O
. None None O

Epidermal None None O
growth None None O
factor None None O
and None None O
its None None O
receptor None None O
. None None O

Epidermal None None O
growth None None O
factor None None O
( None None O
EGF None None O
) None None O
binds None None O
with None None O
high None None O
affinity None None O
and None None O
specificity None None O
to None None O
a None None O
single None None O
site None None O
on None None O
the None None O
external None None O
domain None None O
of None None O
its None None O
transmembrane None None O
receptor None None O
to None None O
activate None None O
the None None O
tyrosine None None O
protein None None O
kinase None None O
activity None None O
of None None O
its None None O
cytoplasmic None None O
portion None None O
. None None O

The None None O
EGF None None O
receptor None None O
gene None None O
is None None O
amplified None None O
and None None O
over None None O
- None None O
expressed None None O
in None None O
several None None O
human None None O
tumors None None O
, None None O
suggesting None None O
that None None O
increased None None O
concentrations None None O
of None None O
the None None O
proto None None O
- None None O
oncogene None None O
leads None None O
to None None O
constitutive None None O
activity None None O
similar None None O
to None None O
that None None O
seen None None O
with None None O
oncogene None None O
erb None None O
B None None O
. None None O

Synthesis None None O
and None None O
degradation None None O
of None None O
the None None O
EGF None None O
receptor None None O
are None None O
regulated None None O
, None None O
in None None O
addition None None O
, None None O
covalent None None O
modification None None O
by None None O
phosphorylation None None O
regulates None None O
activity None None O
of None None O
the None None O
receptor None None O
protein None None O
. None None O

Intramolecular None None O
self None None O
- None None O
phosphorylation None None O
of None None O
Tyr1173 None None O
removes None None O
a None None O
competitive None None O
inhibitory None None O
constraint None None O
to None None O
enhance None None O
phosphorylation None None O
of None None O
substrates None None O
. None None O

Phosphorylation None None O
of None None O
Thr654 None None O
by None None O
protein None None O
kinase None None O
C None None O
decreases None None O
high None None O
affinity None None O
EGF None None O
binding None None O
and None None O
EGF None None O
- None None O
stimulated None None O
tyrosine None None O
protein None None O
kinase None None O
activity None None O
, None None O
providing None None O
a None None O
mechanism None None O
for None None O
heterologous None None O
regulation None None O
of None None O
the None None O
EGF None None O
receptor None None O
by None None O
tumor None None O
promoters None None O
and None None O
other None None O
ligand None None O
X None None O
receptor None None O
complexes None None O
. None None O

Extensive None None O
regulation None None O
contributes None None O
to None None O
normal None None O
growth None None O
control None None O
, None None O
abrogation None None O
of None None O
regulatory None None O
controls None None O
contributes None None O
to None None O
uncontrolled None None O
growth None None O
as None None O
seen None None O
with None None O
erb None None O
B None None O
transformation None None O
and None None O
EGF None None O
receptor None None O
gene None None O
amplification None None O
in None None O
human None None O
tumors None None O
. None None O

Suppression None None O
and None None O
re None None O
- None None O
expression None None O
of None None O
transformed None None O
phenotype None None O
in None None O
hybrids None None O
of None None O
HA None None O
- None None O
ras None None O
- None None O
1 None None O
- None None O
transformed None None O
rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
and None None O
early None None O
- None None O
passage None None O
rat None None O
embryonic None None O
fibroblasts None None O
. None None O

Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
which None None O
had None None O
been None None O
transformed None None O
with None None O
the None None O
activated None None O
Ha None None O
- None None O
ras None None O
- None None O
1 None None O
gene None None O
from None None O
human None None O
EJ None None I-Cell-line-name
bladder None None O
carcinoma None None O
cells None None O
were None None O
fused None None O
with None None O
diploid None None O
embryonic None None O
rat None None O
fibroblasts None None O
. None None O

Four None None O
selected None None O
cell None None O
hybrids None None O
expressed None None O
the None None O
human None None O
transforming None None O
gene None None O
product None None O
p21 None None O
at None None O
levels None None O
of None None O
10 None None O
to None None O
30 None None O
% None None O
compared None None O
to None None O
100 None None O
% None None O
in None None O
the None None O
transformed None None O
parental None None O
cells None None O
. None None O

The None None O
hybrid None None O
cells None None O
, None None O
however None None O
, None None O
exhibited None None O
normal None None O
morphology None None O
, None None O
anchorage None None O
requirement None None O
for None None O
proliferation None None O
, None None O
and None None O
largely None None O
extended None None O
latency None None O
periods None None O
of None None O
tumorigenicity None None O
in None None O
newborn None None O
rats None None O
. None None O

Tumorigenic None None O
hybrid None None O
derivatives None None O
contained None None O
lower None None O
numbers None None O
of None None O
chromosomes None None O
than None None O
the None None O
tetraploid None None O
parental None None O
hybrids None None O
. None None O

DNA None None O
of None None O
the None None O
non None None O
- None None O
tumorigenic None None O
cell None None O
hybrids None None O
transformed None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
to None None O
anchorage None None O
- None None O
independent None None O
proliferation None None O
as None None O
expected None None O
for None None O
the None None O
transforming None None O
human None None O
Ha None None O
- None None O
ras None None O
gene None None O
present None None O
in None None O
the None None O
donor None None O
DNA None None O
. None None O

We None None O
conclude None None O
that None None O
the None None O
transforming None None O
properties None None O
of None None O
the None None O
activated None None O
Ha None None O
- None None O
ras None None O
gene None None O
in None None O
Rat None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
can None None O
be None None O
suppressed None None O
at None None O
the None None O
post None None O
- None None O
translational None None O
level None None O
by None None O
the None None O
presence None None O
of None None O
the None None O
genome None None O
from None None O
diploid None None O
embryonic None None O
rat None None O
fibroblasts None None O
but None None O
additional None None O
controls None None O
of None None O
expression None None O
of None None O
the None None O
transforming None None O
gene None None O
are None None O
likely None None O
to None None O
exist None None O
. None None O

Normal None None O
cells None None O
contain None None O
suppressor None None O
gene None None O
( None None O
s None None O
) None None O
which None None O
safeguard None None O
these None None O
cells None None O
against None None O
transformation None None O
by None None O
the None None O
product None None O
of None None O
the None None O
transforming None None O
Ha None None O
- None None O
ras None None O
- None None O
1 None None O
oncogene None None O
. None None O

Expression None None O
of None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
in None None O
normal None None O
human None None O
tissues None None O
. None None O

The None None O
distribution None None O
of None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
bFGF None None O
) None None O
was None None O
studied None None O
immunohistochemically None None O
in None None O
fresh None None O
frozen None None O
sections None None O
of None None O
normal None None O
human None None O
tissues None None O
. None None O

Immunodetection None None O
was None None O
performed None None O
with None None O
a None None O
specific None None O
anti None None O
- None None O
bFGF None None O
mouse None None O
monoclonal None None O
antibody None None O
that None None O
was None None O
found None None O
to None None O
react None None O
with None None O
recombinant None None O
human None None O
bFGF None None O
in None None O
Western None None O
blot None None O
analysis None None O
, None None O
and None None O
to None None O
specifically None None O
neutralize None None O
the None None O
mitogenic None None O
activity None None O
of None None O
bFGF None None O
on None None O
bovine None None O
vascular None None O
endothelial None None O
cells None None O
. None None O

Expression None None O
of None None O
bFGF None None O
on None None O
normal None None O
human None None O
tissues None None O
was None None O
ubiquitously None None O
detected None None O
in None None O
the None None O
basement None None O
membranes None None O
of None None O
all None None O
size None None O
blood None None O
vessels None None O
, None None O
but None None O
was None None O
not None None O
found None None O
in None None O
epidermal None None O
or None None O
epithelial None None O
basement None None O
membranes None None O
of None None O
a None None O
variety None None O
of None None O
tissues None None O
tested None None O
. None None O

Intensity None None O
and None None O
patterns None None O
of None None O
localization None None O
in None None O
blood None None O
vessels None None O
was None None O
consistent None None O
in None None O
various None None O
tissues None None O
, None None O
but None None O
varied None None O
among None None O
different None None O
regions None None O
of None None O
the None None O
vascular None None O
bed None None O
. None None O

Whereas None None O
homogeneous None None O
and None None O
intense None None O
immunoreactivity None None O
were None None O
observed None None O
in None None O
large None None O
and None None O
intermediate None None O
size None None O
blood None None O
vessels None None O
, None None O
heterogeneity None None O
of None None O
expression None None O
was None None O
found None None O
in None None O
capillaries None None O
. None None O

The None None O
most None None O
intense None None O
immunoreactivity None None O
was None None O
observed None None O
in None None O
branching None None O
capillaries None None O
. None None O

Endothelial None None O
cell None None O
staining None None O
was None None O
heterogeneous None None O
and None None O
varied None None O
in None None O
different None None O
regions None None O
. None None O

Strong None None O
staining None None O
for None None O
bFGF None None O
was None None O
also None None O
found None None O
in None None O
cardiac None None O
muscle None None O
fibers None None O
, None None O
smooth None None O
muscle None None O
cells None None O
of None None O
mid None None O
- None None O
size None None O
blood None None O
vessels None None O
, None None O
the None None O
gut None None O
and None None O
the None None O
myometrium None None O
, None None O
in None None O
central None None O
nervous None None O
system None None O
neurons None None O
and None None O
cerebellar None None O
Purkinje None None O
cells None None O
, None None O
and None None O
on None None O
epithelial None None O
cells None None O
of None None O
the None None O
bronchi None None O
, None None O
colon None None O
, None None O
endometrium None None O
, None None O
and None None O
sweat None None O
gland None None O
ducts None None O
of None None O
the None None O
skin None None O
. None None O

The None None O
presence None None O
of None None O
bFGF None None O
in None None O
the None None O
extracellular None None O
compartment None None O
of None None O
a None None O
diverse None None O
variety None None O
of None None O
organs None None O
may None None O
play None None O
a None None O
role None None O
in None None O
angiogenesis None None O
. None None O

However None None O
, None None O
the None None O
function None None O
of None None O
bFGF None None O
in None None O
parenchymal None None O
cells None None O
remains None None O
to None None O
be None None O
determined None None O
. None None O

Caspase None None O
- None None O
3 None None O
is None None O
essential None None O
for None None O
procaspase None None O
- None None O
9 None None O
processing None None O
and None None O
cisplatin None None O
- None None O
induced None None O
apoptosis None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
sought None None O
to None None O
investigate None None O
in None None O
more None None O
detail None None O
the None None O
role None None O
of None None O
caspase None None O
- None None O
3 None None O
in None None O
apoptotic None None O
processes None None O
in None None O
cultured None None O
cells None None O
and None None O
in None None O
cell None None O
- None None O
free None None O
extracts None None O
of None None O
breast None None O
cancer None None O
cells None None O
. None None O

We None None O
present None None O
evidence None None O
that None None O
apoptosis None None O
of None None O
caspase None None O
- None None O
3 None None O
- None None O
deficient None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
is None None O
defective None None O
in None None O
response None None O
to None None O
cisplatin None None O
treatment None None O
, None None O
as None None O
determined None None O
by None None O
chromatin None None O
condensation None None O
, None None O
nuclear None None O
fragmentation None None O
, None None O
DNA None None O
fragmentation None None O
, None None O
and None None O
release None None O
of None None O
cytochrome None None O
c None None O
from None None O
the None None O
mitochondria None None O
. None None O

Reconstitution None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
by None None O
stable None None O
transfection None None O
of None None O
CASP None None O
- None None O
3 None None O
cDNA None None O
restores None None O
all None None O
these None None O
defects None None O
and None None O
results None None O
in None None O
an None None O
extensive None None O
apoptosis None None O
after None None O
cisplatin None None O
treatment None None O
. None None O

We None None O
further None None O
show None None O
that None None O
in None None O
extracts None None O
from None None O
caspase None None O
- None None O
3 None None O
- None None O
deficient None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
, None None O
procaspase None None O
- None None O
9 None None O
processing None None O
is None None O
strongly None None O
impaired None None O
after None None O
stimulation None None O
with None None O
either None None O
cytochrome None None O
c None None O
or None None O
recombinant None None O
caspase None None O
- None None O
8 None None O
. None None O

Reconstitution None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cell None None O
extracts None None O
with None None O
procaspase None None O
- None None O
3 None None O
corrects None None O
this None None O
defect None None O
, None None O
resulting None None O
in None None O
an None None O
efficient None None O
and None None O
complete None None O
processing None None O
of None None O
procaspase None None O
- None None O
9 None None O
. None None O

Together None None O
, None None O
our None None O
data None None O
define None None O
caspase None None O
- None None O
3 None None O
as None None O
an None None O
important None None O
integrator None None O
of None None O
the None None O
apoptotic None None O
process None None O
in None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
breast None None O
cancer None None O
cells None None O
and None None O
reveal None None O
an None None O
essential None None O
function None None O
of None None O
caspase None None O
- None None O
3 None None O
for None None O
procaspase None None O
- None None O
9 None None O
processing None None O
. None None O

Endothelial None None O
cell None None O
migration None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
expression None None O
are None None O
the None None O
result None None O
of None None O
loss None None O
of None None O
breast None None O
tissue None None O
polarity None None O
. None None O

Recruiting None None O
a None None O
new None None O
blood None None O
supply None None O
is None None O
a None None O
rate None None O
- None None O
limiting None None O
step None None O
in None None O
tumor None None O
progression None None O
. None None O

In None None O
a None None O
three None None O
- None None O
dimensional None None O
model None None O
of None None O
breast None None O
carcinogenesis None None O
, None None O
disorganized None None O
, None None O
proliferative None None O
transformed None None O
breast None None O
epithelial None None O
cells None None O
express None None O
significantly None None O
higher None None O
expression None None O
of None None O
angiogenic None None O
genes None None O
compared None None O
with None None O
their None None O
polarized None None O
, None None O
growth None None O
- None None O
arrested None None O
nonmalignant None None O
counterparts None None O
. None None O

Elevated None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
secretion None None O
by None None O
malignant None None O
cells None None O
enhanced None None O
recruitment None None O
of None None O
endothelial None None O
cells None None O
( None None O
EC None None O
) None None O
in None None O
heterotypic None None O
cocultures None None O
. None None O

Significantly None None O
, None None O
phenotypic None None O
reversion None None O
of None None O
malignant None None O
cells None None O
via None None O
reexpression None None O
of None None O
HoxD10 None None O
, None None O
which None None O
is None None O
lost None None O
in None None O
malignant None None O
progression None None O
, None None O
significantly None None O
attenuated None None O
VEGF None None O
expression None None O
in None None O
a None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
1alpha None None O
- None None O
independent None None O
fashion None None O
and None None O
reduced None None O
EC None None O
migration None None O
. None None O

This None None O
was None None O
due None None O
primarily None None O
to None None O
restoring None None O
polarity None None O
: None None O
forced None None O
proliferation None None O
of None None O
polarized None None O
, None None O
nonmalignant None None O
cells None None O
did None None O
not None None O
induce None None O
VEGF None None O
expression None None O
and None None O
EC None None O
recruitment None None O
, None None O
whereas None None O
disrupting None None O
the None None O
architecture None None O
of None None O
growth None None O
- None None O
arrested None None O
, None None O
reverted None None O
cells None None O
did None None O
. None None O

These None None O
data None None O
show None None O
that None None O
disrupting None None O
cytostructure None None O
activates None None O
the None None O
angiogenic None None O
switch None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
proliferation None None O
and None None O
/ None None O
or None None O
hypoxia None None O
and None None O
restoring None None O
organization None None O
of None None O
malignant None None O
clusters None None O
reduces None None O
VEGF None None O
expression None None O
and None None O
EC None None O
activation None None O
to None None O
levels None None O
found None None O
in None None O
quiescent None None O
nonmalignant None None O
epithelium None None O
. None None O

These None None O
data None None O
confirm None None O
the None None O
importance None None O
of None None O
tissue None None O
architecture None None O
and None None O
polarity None None O
in None None O
malignant None None O
progression None None O
. None None O

Hemispheric None None O
control None None O
of None None O
motor None None O
function None None O
: None None O
a None None O
whole None None O
brain None None O
echo None None O
planar None None O
fMRI None None O
study None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
explore None None O
whether None None O
recruitment None None O
of None None O
the None None O
ipsilateral None None O
motor None None O
cortex None None O
during None None O
non None None O
- None None O
dominant None None O
motor None None O
movement None None O
reflects None None O
left None None O
hemispheric None None O
control None None O
of None None O
motor None None O
function None None O
or None None O
simply None None O
the None None O
greater None None O
complexity None None O
or None None O
unfamiliarity None None O
of None None O
the None None O
motor None None O
task None None O
. None None O

BOLD None None O
fMRI None None O
was None None O
performed None None O
in None None O
normal None None O
right None None O
- None None O
handers None None O
during None None O
two None None O
motor None None O
tasks None None O
: None None O
( None None O
1 None None O
) None None O
sequential None None O
finger None None O
movements None None O
( None None O
SM None None O
task None None O
) None None O
with None None O
the None None O
right None None O
or None None O
left None None O
hand None None O
; None None O
and None None O
( None None O
2 None None O
) None None O
random None None O
finger None None O
movements None None O
( None None O
RM None None O
task None None O
) None None O
with None None O
the None None O
right None None O
hand None None O
. None None O

In None None O
all None None O
subjects None None O
, None None O
activation None None O
was None None O
predominantly None None O
in None None O
the None None O
contralateral None None O
motor None None O
areas None None O
( None None O
primary None None O
sensorimotor None None O
, None None O
lateral None None O
premotor None None O
, None None O
parietal None None O
and None None O
supplementary None None O
motor None None O
regions None None O
) None None O
and None None O
ipsilateral None None O
cerebellum None None O
. None None O

While None None O
the None None O
ipsilateral None None O
motor None None O
areas None None O
were None None O
also None None O
activated None None O
, None None O
single None None O
subject None None O
analysis None None O
revealed None None O
these None None O
areas None None O
to None None O
be None None O
more None None O
extensive None None O
and None None O
to None None O
be None None O
seen None None O
in None None O
more None None O
subjects None None O
during None None O
the None None O
non None None O
- None None O
dominant None None O
hand None None O
SM None None O
task None None O
and None None O
dominant None None O
hand None None O
RM None None O
task None None O
than None None O
during None None O
the None None O
more None None O
familiar None None O
dominant None None O
hand None None O
SM None None O
task None None O
. None None O

Similarly None None O
, None None O
group None None O
analysis None None O
also None None O
revealed None None O
ipsilateral None None O
activation None None O
in None None O
the None None O
primary None None O
sensorimotor None None O
and None None O
lateral None None O
premotor None None O
areas None None O
, None None O
but None None O
only None None O
during None None O
the None None O
non None None O
- None None O
dominant None None O
SM None None O
task None None O
and None None O
the None None O
dominant None None O
hand None None O
RM None None O
task None None O
. None None O

Non None None O
- None None O
dominant None None O
hand None None O
movements None None O
, None None O
perhaps None None O
because None None O
they None None O
are None None O
less None None O
' None None O
automatic None None O
' None None O
, None None O
appear None None O
to None None O
require None None O
more None None O
cortical None None O
activity None None O
similar None None O
to None None O
complex None None O
tasks None None O
with None None O
the None None O
dominant None None O
hand None None O
, None None O
and None None O
result None None O
in None None O
greater None None O
recruitment None None O
of None None O
ipsilateral None None O
cortical None None O
motor None None O
areas None None O
and None None O
striatum None None O
. None None O

The None None O
study None None O
also None None O
illustrates None None O
how None None O
potentially None None O
meaningful None None O
subtleties None None O
seen None None O
on None None O
individual None None O
maps None None O
may None None O
be None None O
obscured None None O
with None None O
group None None O
averaging None None O
approaches None None O
. None None O

Electrostatic None None O
interaction None None O
energies None None O
between None None O
the None None O
SNARE None None O
complex None None O
and None None O
fusing None None O
membranes None None O
. None None O

( None None O
A None None O
) None None O
Schematic None None O
diagram None None O
and None None O
definitions None None O
of None None O
intermolecular None None O
interaction None None O
energies None None O
presented None None O
in None None O
( None None O
B None None O
) None None O
and None None O
( None None O
C None None O
) None None O
. None None O

In None None O
( None None O
A None None O
) None None O
through None None O
( None None O
C None None O
) None None O
, None None O
only None None O
the None None O
SNARE None None O
core None None O
complex None None O
is None None O
considered None None O
. None None O

Interaction None None O
free None None O
energies None None O
are None None O
calculated None None O
for None None O
( None None O
B None None O
) None None O
a None None O
series None None O
of None None O
SNARE None None O
/ None None O
membrane None None O
distances None None O
and None None O
( None None O
C None None O
) None None O
different None None O
membrane None None O
lipid None None O
compositions None None O
. None None O

Arrow None None O
in None None O
( None None O
B None None O
) None None O
indicates None None O
the None None O
most None None O
physiologically None None O
relevant None None O
distance None None O
when None None O
the None None O
closest None None O
points None None O
between None None O
SNARE None None O
and None None O
membranes None None O
are None None O
3 None None O
A None None O
, None None O
the None None O
thickness None None O
of None None O
a None None O
layer None None O
of None None O
water None None O
. None None O
[ None None O
19 None None O
] None None O
In None None O
( None None O
D None None O
) None None O
through None None O
( None None O
F None None O
) None None O
, None None O
TMDs None None O
of None None O
VAMP None None O
and None None O
syntaxin None None O
are None None O
present None None O
and None None O
embedded None None O
in None None O
membranes None None O
. None None O

Furthermore None None O
, None None O
the None None O
C None None O
- None None O
terminus None None O
of None None O
the None None O
SNARE None None O
motif None None O
is None None O
partially None None O
unraveled None None O
into None None O
individual None None O
alpha None None O
- None None O
helices None None O
by None None O
molecular None None O
dynamics None None O
simulations None None O
to None None O
represent None None O
trans None None O
- None None O
SNARE None None O
complex None None O
. None None O

Interaction None None O
free None None O
energies None None O
are None None O
then None None O
calculated None None O
for None None O
( None None O
E None None O
) None None O
a None None O
series None None O
of None None O
SNARE None None O
motif None None O
C None None O
- None None O
terminus None None O
separation None None O
distances None None O
and None None O
( None None O
F None None O
) None None O
different None None O
lipid None None O
compositions None None O
of None None O
the None None O
membranes None None O
. None None O

Conclusions None None O
drawn None None O
from None None O
both None None O
groups None None O
of None None O
studies None None O
are None None O
essentially None None O
the None None O
same None None O
. None None O

V None None O
( None None O
circles None None O
) None None O
: None None O
Interaction None None O
energies None None O
between None None O
the None None O
SNARE None None O
complex None None O
and None None O
the None None O
v None None O
- None None O
membrane None None O
. None None O

T None None O
( None None O
squares None None O
) None None O
: None None O
Interaction None None O
energies None None O
between None None O
SNARE None None O
and None None O
the None None O
t None None O
- None None O
membrane None None O
. None None O

VT None None O
( None None O
triangles None None O
) None None O
: None None O
Interaction None None O
energies None None O
between None None O
the None None O
v None None O
- None None O
and None None O
the None None O
t None None O
- None None O
membranes None None O
if None None O
the None None O
SNARE None None O
complex None None O
were None None O
extracted None None O
. None None O

Effect None None O
of None None O
transplanted None None O
mesenchymal None None O
stem None None O
cells None None O
from None None O
rats None None O
of None None O
different None None O
ages None None O
on None None O
the None None O
improvement None None O
of None None O
heart None None O
function None None O
after None None O
acute None None O
myocardial None None O
infarction None None O
. None None O

BACKGROUND None None O
: None None O
Mesenchymal None None O
stem None None O
cells None None O
( None None O
MSCs None None O
) None None O
transplantation None None O
is None None O
of None None O
therapeutic None None O
potential None None O
after None None O
ischemic None None O
injury None None O
in None None O
both None None O
experimental None None O
and None None O
clinical None None O
studies None None O
. None None O

Clinically None None O
, None None O
elderly None None O
patients None None O
are None None O
more None None O
vulnerable None None O
to None None O
acute None None O
myocardial None None O
infarction None None O
( None None O
AMI None None O
) None None O
. None None O

But None None O
little None None O
is None None O
known None None O
about None None O
the None None O
characteristics None None O
of None None O
young None None O
donor None None O
- None None O
derived None None O
MSCs None None O
transplanted None None O
to None None O
old None None O
patients None None O
with None None O
AMI None None O
. None None O

The None None O
present None None O
study None None O
was None None O
designed None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
transplanted None None O
MSCs None None O
from None None O
rats None None O
of None None O
different None None O
ages None None O
on None None O
the None None O
improvement None None O
of None None O
heart None None O
function None None O
after None None O
AMI None None O
. None None O

METHODS None None O
: None None O
MSCs None None O
from None None O
Sprague None None O
- None None O
Dawley None None O
( None None O
SD None None O
) None None O
rats None None O
were None None O
isolated None None O
and None None O
cultured None None O
in None None O
vitro None None O
. None None O

The None None O
apoptosis None None O
characteristics None None O
of None None O
MSCs None None O
were None None O
observed None None O
under None None O
conditions None None O
of None None O
ischemia None None O
and None None O
anoxia None None O
. None None O

SD None None O
rats None None O
underwent None None O
MI None None O
received None None O
intramyocardial None None O
injection None None O
of None None O
MSCs None None O
from None None O
young None None O
donor None None O
rats None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
, None None O
old None None O
donor None None O
rats None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
, None None O
respectively None None O
. None None O

AMI None None O
control None None O
group None None O
received None None O
equal None None O
volume None None O
physiological None None O
saline None None O
. None None O

Immunofluorescence None None O
was None None O
used None None O
to None None O
observe None None O
the None None O
differentiation None None O
of None None O
the None None O
grafted None None O
cells None None O
into None None O
cardiomyocytes None None O
. None None O

Four None None O
weeks None None O
after None None O
cell None None O
transplantation None None O
, None None O
reverse None None O
transcriptase None None O
- None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT None None O
- None None O
PCR None None O
) None None O
and None None O
immunohistochemistry None None O
for None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
VIII None None O
- None None O
factor None None O
immunohistochemistry None None O
for None None O
vessel None None O
density None None O
, None None O
TUNEL None None O
, None None O
caspase None None O
- None None O
3 None None O
for None None O
cardiomyocyte None None O
apoptosis None None O
, None None O
echocardiography None None O
and None None O
hemodynamic None None O
detection None None O
for None None O
heart None None O
function None None O
were None None O
performed None None O
. None None O

RESULTS None None O
: None None O
The None None O
apoptosis None None O
rate None None O
of None None O
the None None O
old None None O
donor None None O
- None None O
derived None None O
MSCs None None O
group None None O
was None None O
significantly None None O
higher None None O
than None None O
that None None O
of None None O
the None None O
young None None O
donor None None O
- None None O
derived None None O
MSCs None None O
group None None O
under None None O
conditions None None O
of None None O
ischemia None None O
and None None O
anoxia None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Engrafted None None O
MSCs None None O
survived None None O
, None None O
proliferated None None O
and None None O
differentiated None None O
into None None O
myocardium None None O
- None None O
like None None O
cells None None O
. None None O

VEGF None None O
gene None None O
expression None None O
and None None O
capillary None None O
density None None O
in None None O
the None None O
old None None O
donor None None O
- None None O
derived None None O
group None None O
were None None O
lower None None O
than None None O
those None None O
in None None O
the None None O
young None None O
donor None None O
- None None O
derived None None O
group None None O
but None None O
higher None None O
than None None O
those None None O
in None None O
the None None O
control None None O
group None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
transplantation None None O
of None None O
old None None O
donor None None O
- None None O
derived None None O
MSCs None None O
attenuated None None O
apoptosis None None O
of None None O
cardiomyocytes None None O
in None None O
the None None O
peri None None O
- None None O
infarct None None O
region None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
and None None O
the None None O
effect None None O
was None None O
elevated None None O
in None None O
young None None O
donor None None O
- None None O
derived None None O
MSCs None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
heart None None O
functions None None O
( None None O
left None None O
ventricle None None O
ejection None None O
fraction None None O
( None None O
LVEF None None O
) None None O
, None None O
left None None O
ventricle None None O
fractional None None O
shortening None None O
( None None O
LVFS None None O
) None None O
) None None O
were None None O
improved None None O
more None None O
significantly None None O
in None None O
the None None O
old None None O
donor None None O
- None None O
derived None None O
MSCs None None O
group None None O
than None None O
in None None O
the None None O
control None None O
group None None O
and None None O
the None None O
heart None None O
function None None O
in None None O
the None None O
young None None O
donor None None O
- None None O
derived None None O
MSCs None None O
group None None O
further None None O
improved None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
Young None None O
donor None None O
- None None O
derived None None O
MSCs None None O
can None None O
improve None None O
heart None None O
function None None O
significantly None None O
through None None O
angiogenesis None None O
and None None O
decreasing None None O
cardiomyocyte None None O
apoptosis None None O
when None None O
transplanted None None O
to None None O
the None None O
infarcted None None O
area None None O
. None None O

Prognostic None None O
significance None None O
and None None O
correlation None None O
with None None O
survival None None O
of None None O
bcl None None O
- None None O
2 None None O
and None None O
TGF None None O
- None None O
beta None None O
RII None None O
in None None O
colon None None O
cancer None None O
. None None O

Bcl None None O
- None None O
2 None None O
and None None O
TGF None None O
- None None O
beta None None O
receptors None None O
type None None O
II None None O
( None None O
RII None None O
) None None O
in None None O
colon None None O
carcinomas None None O
were None None O
studied None None O
in None None O
a None None O
series None None O
of None None O
113 None None O
patients None None O
, None None O
to None None O
determine None None O
their None None O
prognostic None None O
significance None None O
and None None O
to None None O
correlate None None O
their None None O
expression None None O
with None None O
other None None O
prognostic None None O
indicators None None O
. None None O

Bcl None None O
- None None O
2 None None O
expression None None O
in None None O
the None None O
tumor None None O
cells None None O
showed None None O
a None None O
reverse None None O
relation None None O
with None None O
tumor None None O
size None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
018 None None O
) None None O
, None None O
histological None None O
grade None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
, None None O
and None None O
stage None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
013 None None O
) None None O
. None None O

Univariate None None O
survival None None O
analysis None None O
using None None O
the None None O
log None None O
rank None None O
test None None O
showed None None O
that None None O
the None None O
survival None None O
of None None O
patients None None O
with None None O
bcl None None O
- None None O
2 None None O
- None None O
positive None None O
tumors None None O
was None None O
significantly None None O
better None None O
than None None O
the None None O
survival None None O
of None None O
patients None None O
with None None O
bcl None None O
- None None O
2 None None O
- None None O
negative None None O
tumors None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
02 None None O
) None None O
. None None O

However None None O
, None None O
when None None O
entered None None O
into None None O
a None None O
multivariate None None O
analysis None None O
model None None O
, None None O
it None None O
was None None O
not None None O
found None None O
to None None O
be None None O
of None None O
independent None None O
prognostic None None O
significance None None O
. None None O

TGF None None O
- None None O
beta None None O
RII None None O
expression None None O
was None None O
correlated None None O
with None None O
stage None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
03 None None O
) None None O
, None None O
while None None O
no None None O
statistically None None O
significant None None O
correlation None None O
was None None O
found None None O
between None None O
TGF None None O
- None None O
beta None None O
RII None None O
expression None None O
and None None O
histological None None O
grade None None O
or None None O
survival None None O
. None None O

In None None O
conclusion None None O
, None None O
these None None O
results None None O
provide None None O
additional None None O
evidence None None O
for None None O
the None None O
role None None O
of None None O
bcl None None O
- None None O
2 None None O
and None None O
TGF None None O
- None None O
beta None None O
RII None None O
in None None O
carcinogenesis None None O
of None None O
the None None O
colon None None O
, None None O
while None None O
they None None O
do None None O
not None None O
support None None O
the None None O
use None None O
of None None O
these None None O
factors None None O
as None None O
prognostic None None O
markers None None O
in None None O
patients None None O
with None None O
colon None None O
cancer None None O
. None None O

Rapid None None O
micromeasurement None None O
of None None O
lactate None None O
in None None O
whole None None O
blood None None O
. None None O

A None None O
new None None O
lactate None None O
sensor None None O
makes None None O
it None None O
possible None None O
to None None O
measure None None O
the None None O
lactate None None O
content None None O
of None None O
whole None None O
blood None None O
directly None None O
in None None O
less None None O
than None None O
1 None None O
min None None O
, None None O
using None None O
only None None O
a None None O
10 None None O
- None None O
microL None None O
blood None None O
sample None None O
. None None O

The None None O
procedure None None O
works None None O
equally None None O
well None None O
with None None O
plasma None None O
, None None O
serum None None O
, None None O
spinal None None O
fluid None None O
, None None O
other None None O
body None None O
fluids None None O
, None None O
or None None O
tissue None None O
homogenates None None O
. None None O

The None None O
instrument None None O
is None None O
calibrated None None O
with None None O
lactate None None O
standards None None O
between None None O
0 None None O
and None None O
15 None None O
mMol None None O
/ None None O
L None None O
. None None O

The None None O
sensor None None O
, None None O
a None None O
polarographic None None O
enzyme None None O
electrode None None O
, None None O
gives None None O
a None None O
current None None O
which None None O
is None None O
a None None O
linear None None O
function None None O
of None None O
the None None O
lactate None None O
concentration None None O
. None None O

There None None O
is None None O
no None None O
interference None None O
from None None O
glucose None None O
, None None O
pyruvate None None O
, None None O
alcohol None None O
, None None O
ascorbate None None O
, None None O
anticoagulants None None O
, None None O
lidocaine None None O
, None None O
acetaminophen None None O
, None None O
or None None O
other None None O
drugs None None O
and None None O
metabolites None None O
commonly None None O
encountered None None O
in None None O
critically None None O
ill None None O
patients None None O
. None None O

The None None O
lactate None None O
sensor None None O
is None None O
composed None None O
of None None O
a None None O
peroxide None None O
sensor None None O
and None None O
an None None O
enzyme None None O
transducer None None O
membrane None None O
. None None O

The None None O
lactate None None O
is None None O
stoichiometrically None None O
converted None None O
to None None O
pyruvate None None O
and None None O
hydrogen None None O
peroxide None None O
by None None O
lactate None None O
oxygen None None O
oxidoreductase None None O
derived None None O
from None None O
Pediococcus None None O
species None None O
. None None O

The None None O
oxygen None None O
required None None O
for None None O
the None None O
enzymatic None None O
oxidation None None O
is None None O
supplied None None O
via None None O
an None None O
air None None O
- None None O
permeable None None O
silicone None None O
elastomeric None None O
membrane None None O
used None None O
for None None O
stirring None None O
. None None O

Comparison None None O
of None None O
our None None O
new None None O
electroenzymatic None None O
method None None O
with None None O
the None None O
Boehringer None None O
- None None O
Mannheim None None O
photoenzymatic None None O
method None None O
gives None None O
correlations None None O
of None None O
0 None None O
. None None O
997 None None O
for None None O
both None None O
whole None None O
blood None None O
and None None O
plasma None None O
. None None O

Ventricular None None O
fibrillation None None O
due None None O
to None None O
long None None O
QT None None O
syndrome None None O
probably None None O
caused None None O
by None None O
clindamycin None None O
. None None O

Prolongation None None O
of None None O
QT None None O
time None None O
interval None None O
may None None O
be None None O
provoked None None O
by None None O
a None None O
limited None None O
number None None O
of None None O
drugs None None O
, None None O
especially None None O
macrolide None None O
antibiotics None None O
. None None O

We None None O
describe None None O
a None None O
case None None O
of None None O
QT None None O
time None None O
interval None None O
prolongation None None O
induced None None O
by None None O
clindamycin None None O
with None None O
subsequent None None O
repeated None None O
ventricular None None O
fibrillation None None O
and None None O
resuscitation None None O
; None None O
there None None O
is None None O
no None None O
previous None None O
report None None O
in None None O
the None None O
literature None None O
of None None O
QT None None O
time None None O
prolongation None None O
caused None None O
by None None O
lincosamides None None O
. None None O

Bcl None None O
- None None O
2 None None O
decreases None None O
cell None None O
proliferation None None O
and None None O
promotes None None O
accumulation None None O
of None None O
cells None None O
in None None O
S None None O
phase None None O
without None None O
affecting None None O
the None None O
rate None None O
of None None O
apoptosis None None O
in None None O
human None None O
ovarian None None O
carcinoma None None O
cells None None O
. None None O

OBJECTIVES None None O
: None None O

The None None O
Bcl None None O
- None None O
2 None None O
protein None None O
is None None O
an None None O
important None None O
regulator None None O
of None None O
the None None O
apoptotic None None O
cascade None None O
and None None O
promotes None None O
cell None None O
survival None None O
. None None O

Bcl None None O
- None None O
2 None None O
can None None O
also None None O
delay None None O
entry None None O
into None None O
the None None O
cell None None O
cycle None None O
from None None O
quiescence None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
used None None O
two None None O
isogenic None None O
human None None O
ovarian None None O
carcinoma None None O
cell None None O
lines None None O
, None None O
which None None O
expressed None None O
differential None None O
levels None None O
of None None O
Bcl None None O
- None None O
2 None None O
proteins None None O
, None None O
to None None O
demonstrate None None O
that None None O
Bcl None None O
- None None O
2 None None O
may None None O
regulate None None O
the None None O
growth None None O
rates None None O
of None None O
adenocarcinoma None None O
cells None None O
. None None O

METHODS None None O
: None None O

The None None O
growth None None O
rates None None O
of None None O
two None None O
isogenic None None O
ovarian None None O
cancer None None O
cell None None O
lines None None O
were None None O
determined None None O
by None None O
XTT None None O
assays None None O
and None None O
flow None None O
cytometry None None O
combined None None O
with None None O
PI None None O
staining None None O
. None None O

Bcl None None O
- None None O
2 None None O
- None None O
overexpressing None None O
SKOV3 None None I-Cell-line-name
cells None None O
were None None O
modified None None O
to None None O
express None None O
a None None O
doxycycline None None O
- None None O
inducible None None O
anti None None O
- None None O
Bcl None None O
- None None O
2 None None O
single None None O
- None None O
chain None None O
antibody None None O
and None None O
the None None O
effects None None O
of None None O
Bcl None None O
- None None O
2 None None O
protein None None O
inhibition None None O
on None None O
cell None None O
proliferation None None O
and None None O
apoptosis None None O
were None None O
assessed None None O
. None None O

RESULTS None None O
: None None O

We None None O
demonstrate None None O
that None None O
Bcl None None O
- None None O
2 None None O
promotes None None O
the None None O
accumulation None None O
of None None O
proliferating None None O
carcinoma None None O
cells None None O
in None None O
S None None O
phase None None O
. None None O

The None None O
Bcl None None O
- None None O
2 None None O
- None None O
overexpressing None None O
SKOV3 None None I-Cell-line-name
cell None None O
line None None O
proliferates None None O
markedly None None O
faster None None O
and None None O
shows None None O
delayed None None O
progression None None O
to None None O
G2M None None O
phase None None O
compared None None O
to None None O
its None None O
low None None O
Bcl None None O
- None None O
2 None None O
- None None O
expressing None None O
counterpart None None O
SKOV3 None None I-Cell-line-name
. None None I-Cell-line-name
ip1 None None I-Cell-line-name
cell None None O
line None None O
. None None O

Single None None O
- None None O
chain None None O
antibody None None O
- None None O
mediated None None O
inhibition None None O
of None None O
Bcl None None O
- None None O
2 None None O
in None None O
SKOV3 None None I-Cell-line-name
cells None None O
was None None O
associated None None O
with None None O
increased None None O
growth None None O
rates None None O
and None None O
more None None O
rapid None None O
cell None None O
cycle None None O
progression None None O
. None None O

Treatment None None O
with None None O
cisplatin None None O
resulted None None O
in None None O
more None None O
cells None None O
accumulating None None O
in None None O
S None None O
phase None None O
in None None O
Bcl None None O
- None None O
2 None None O
- None None O
overexpressing None None O
SKOV3 None None I-Cell-line-name
cells None None O
, None None O
while None None O
the None None O
inhibition None None O
of None None O
Bcl None None O
- None None O
2 None None O
abolished None None O
delayed None None O
entry None None O
into None None O
G2M None None O
phase None None O
without None None O
affecting None None O
cisplatin None None O
- None None O
induced None None O
apoptosis None None O
. None None O

CONCLUSIONS None None O
: None None O

Our None None O
results None None O
suggest None None O
that None None O
, None None O
in None None O
ovarian None None O
cancer None None O
cells None None O
, None None O
Bcl None None O
- None None O
2 None None O
delays None None O
cell None None O
cycle None None O
progression None None O
by None None O
promoting None None O
accumulation None None O
of None None O
cells None None O
in None None O
S None None O
phase None None O
without None None O
affecting None None O
the None None O
rate None None O
of None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
in None None O
addition None None O
to None None O
its None None O
known None None O
role None None O
at None None O
the None None O
G0 None None O
/ None None O
G1 None None O
checkpoint None None O
, None None O
we None None O
demonstrate None None O
for None None O
the None None O
first None None O
time None None O
that None None O
Bcl None None O
- None None O
2 None None O
also None None O
regulates None None O
the None None O
S None None O
phase None None O
. None None O

Background None None O

Inflammation None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
plaque None None O
initiation None None O
, None None O
progression None None O
, None None O
and None None O
disruption None None O
. None None O

As None None O
such None None O
, None None O
inflammation None None O
represents None None O
an None None O
emerging None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
atherosclerosis None None O
. None None O

c None None O
- None None O
erb None None O
B2 None None O
overexpression None None O
decreases None None O
the None None O
benefit None None O
of None None O
adjuvant None None O
tamoxifen None None O
in None None O
early None None O
- None None O
stage None None O
breast None None O
cancer None None O
without None None O
axillary None None O
lymph None None O
node None None O
metastases None None O
. None None O

PURPOSE None None O
: None None O
We None None O
studied None None O
retrospectively None None O
the None None O
interaction None None O
between None None O
c None None O
- None None O
erbB2 None None O
overexpression None None O
and None None O
adjuvant None None O
tomoxifen None None O
in None None O
node None None O
- None None O
negative None None O
breast None None O
cancer None None O
patients None None O
enrolled None None O
in None None O
the None None O
Gruppo None None O
Universitario None None O
Napoletano None None O
1 None None O
( None None O
GUN None None O
- None None O
1 None None O
) None None O
trial None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
c None None O
- None None O
erbB2 None None O
, None None O
evaluated None None O
by None None O
immunohistochemistry None None O
in None None O
145 None None O
of None None O
173 None None O
patients None None O
randomly None None O
assigned None None O
to None None O
2 None None O
- None None O
year None None O
adjuvant None None O
tamoxifen None None O
or None None O
no None None O
further None None O
therapy None None O
, None None O
was None None O
considered None None O
overexpressed None None O
if None None O
greater None None O
than None None O
10 None None O
% None None O
of None None O
the None None O
cells None None O
showed None None O
specific None None O
membrane None None O
staining None None O
. None None O

The None None O
role None None O
of None None O
each None None O
prognostic None None O
variable None None O
and None None O
their None None O
independent None None O
effect None None O
were None None O
studied None None O
using None None O
the None None O
Cox None None O
model None None O
. None None O

Disease None None O
- None None O
free None None O
( None None O
DFS None None O
) None None O
and None None O
overall None None O
( None None O
OAS None None O
) None None O
survival None None O
curves None None O
were None None O
estimated None None O
by None None O
the None None O
Kaplan None None O
- None None O
Meier None None O
method None None O
. None None O

RESULTS None None O
: None None O
As None None O
of None None O
November None None O
30 None None O
, None None O
1994 None None O
, None None O
the None None O
median None None O
follow None None O
- None None O
up None None O
period None None O
was None None O
12 None None O
years None None O
. None None O

c None None O
- None None O
erbB2 None None O
was None None O
overexpressed None None O
in None None O
43 None None O
of None None O
145 None None O
patients None None O
( None None O
29 None None O
. None None O
7 None None O
% None None O
) None None O
, None None O
which None None O
directly None None O
correlated None None O
with None None O
tumor None None O
size None None O
and None None O
inversely None None O
with None None O
estrogen None None O
receptor None None O
( None None O
ER None None O
) None None O
level None None O
. None None O

At None None O
univariate None None O
analysis None None O
, None None O
overexpression None None O
of None None O
c None None O
- None None O
erbB2 None None O
did None None O
not None None O
affect None None O
either None None O
DFS None None O
or None None O
OAS None None O
; None None O
tamoxifen None None O
had None None O
a None None O
greater None None O
effect None None O
on None None O
reducing None None O
the None None O
risk None None O
of None None O
recurrence None None O
than None None O
of None None O
death None None O
. None None O

Addition None None O
of None None O
c None None O
- None None O
erbB2 None None O
to None None O
a None None O
multivariate None None O
Cox None None O
model None None O
that None None O
contained None None O
menopausal None None O
status None None O
, None None O
tumor None None O
size None None O
, None None O
nuclear None None O
grade None None O
, None None O
and None None O
treatment None None O
as None None O
covariates None None O
did None None O
not None None O
affect None None O
the None None O
significance None None O
of None None O
the None None O
model None None O
for None None O
DSF None None O
or None None O
OAS None None O
, None None O
whereas None None O
addition None None O
of None None O
the None None O
first None None O
- None None O
order None None O
interaction None None O
between None None O
c None None O
- None None O
erbB2 None None O
and None None O
tamoxifen None None O
was None None O
statistically None None O
significant None None O
both None None O
for None None O
DFS None None O
and None None O
OAS None None O
. None None O

The None None O
same None None O
result None None O
was None None O
obtained None None O
when None None O
the None None O
model None None O
contained None None O
ER None None O
status None None O
and None None O
ER None None O
- None None O
tamoxifen None None O
interaction None None O
. None None O

Indeed None None O
, None None O
adjuvant None None O
tamoxifen None None O
significantly None None O
prolonged None None O
DFS None None O
and None None O
OAS None None O
in None None O
c None None O
- None None O
erbB2 None None O
- None None O
negative None None O
cases None None O
, None None O
whereas None None O
it None None O
had None None O
no None None O
effect None None O
on None None O
DFS None None O
and None None O
OAS None None O
in None None O
c None None O
- None None O
erbB2 None None O
- None None O
positive None None O
patients None None O
. None None O

CONCLUSION None None O
: None None O
In None None O
early None None O
- None None O
stage None None O
breast None None O
cancer None None O
patients None None O
, None None O
overexpression None None O
of None None O
c None None O
- None None O
erbB2 None None O
is None None O
a None None O
marker None None O
of None None O
lack None None O
of None None O
efficacy None None O
of None None O
adjuvant None None O
tamoxifen None None O
. None None O

Coagulation None None O
function None None O
in None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
coagulation None None O
function None None O
in None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
is None None O
abnormal None None O
and None None O
the None None O
reason None None O
is None None O
not None None O
very None None O
clear None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
retrospectively None None O
analyzed None None O
the None None O
coagulation None None O
function None None O
in None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
. None None O

METHODS None None O
: None None O
From None None O
June None None O
2004 None None O
to None None O
December None None O
2007 None None O
, None None O
132 None None O
patients None None O
received None None O
diagnosis None None O
and None None O
treatment None None O
in None None O
our None None O
hospital None None O
. None None O

The None None O
coagulative None None O
parameters None None O
including None None O
the None None O
prothrombin None None O
time None None O
, None None O
activated None None O
partial None None O
thromboplastin None None O
time None None O
, None None O
and None None O
fibrinogen None None O
levels None None O
were None None O
collected None None O
and None None O
studied None None O
retrospectively None None O
. None None O

RESULTS None None O
: None None O
The None None O
average None None O
fibrinogen None None O
levels None None O
in None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
, None None O
( None None O
476 None None O
. None None O
21 None None O
+ None None O
/ None None O
- None None O
142 None None O
. None None O
05 None None O
) None None O
mg None None O
/ None None O
dl None None O
, None None O
were None None O
significantly None None O
higher None None O
than None None O
in None None O
patients None None O
with None None O
cholangiolithiasis None None O
, None None O
( None None O
403 None None O
. None None O
28 None None O
+ None None O
/ None None O
- None None O
126 None None O
. None None O
41 None None O
) None None O
mg None None O
/ None None O
dl None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

In None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
, None None O
the None None O
levels None None O
of None None O
fibrinogen None None O
in None None O
the None None O
group None None O
with None None O
jaundice None None O
were None None O
significantly None None O
higher None None O
than None None O
in None None O
patients None None O
without None None O
jaundice None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

In None None O
patients None None O
who None None O
received None None O
Pancreaticoduodenectomy None None O
, None None O
Whipple None None O
' None None O
s None None O
operation None None O
, None None O
the None None O
level None None O
of None None O
fibrinogen None None O
in None None O
the None None O
group None None O
with None None O
local None None O
invasiveness None None O
was None None O
significantly None None O
higher None None O
than None None O
in None None O
the None None O
group None None O
without None None O
invasiveness None None O
. None None O

The None None O
group None None O
with None None O
lymphatic None None O
metastasis None None O
had None None O
higher None None O
levels None None O
than None None O
the None None O
group None None O
without None None O
lymphatic None None O
metastasis None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
difference None None O
of None None O
intraoperative None None O
blood None None O
loss None None O
between None None O
patients None None O
with None None O
vitamin None None O
K None None O
, None None O
( None None O
748 None None O
. None None O
27 None None O
+ None None O
/ None None O
- None None O
448 None None O
. None None O
51 None None O
) None None O
ml None None O
, None None O
and None None O
those None None O
without None None O
vitamin None None O
K None None O
, None None O
( None None O
767 None None O
. None None O
31 None None O
+ None None O
/ None None O
- None None O
547 None None O
. None None O
89 None None O
) None None O
ml None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
level None None O
of None None O
fibrinogen None None O
in None None O
patients None None O
with None None O
pancreatic None None O
carcinoma None None O
was None None O
elevated None None O
. None None O

The None None O
elevated None None O
fibrinogen None None O
level None None O
may None None O
be None None O
associated None None O
with None None O
invasiveness None None O
and None None O
lymphatic None None O
metastasis None None O
. None None O

Using None None O
vitamin None None O
K None None O
in None None O
perioperation None None O
management None None O
did None None O
not None None O
reduce None None O
intraoperative None None O
blood None None O
loss None None O
. None None O

Differential None None O
secretion None None O
of None None O
proteins None None O
and None None O
glycoproteins None None O
by None None O
livers None None O
of None None O
immature None None O
and None None O
adult None None O
rats None None O
. None None O

Effect None None O
of None None O
antimicrotubule None None O
drugs None None O
. None None O

This None None O
study None None O
was None None O
initiated None None O
to None None O
re None None O
- None None O
examine None None O
reported None None O
differences None None O
in None None O
the None None O
action None None O
of None None O
antimicrotubule None None O
agents None None O
on None None O
plasma None None O
protein None None O
secretion None None O
from None None O
livers None None O
of None None O
immature None None O
versus None None O
adult None None O
rats None None O
. None None O

The None None O
aim None None O
was None None O
( None None O
1 None None O
) None None O
to None None O
determine None None O
the None None O
composition None None O
and None None O
to None None O
monitor None None O
the None None O
secretion None None O
of None None O
various None None O
plasma None None O
proteins None None O
and None None O
glycoproteins None None O
from None None O
liver None None O
slices None None O
labeled None None O
in None None O
vitro None None O
with None None O
specific None None O
amino None None O
acids None None O
and None None O
sugar None None O
residues None None O
, None None O
and None None O
( None None O
2 None None O
) None None O
to None None O
correlate None None O
observed None None O
differences None None O
in None None O
secretion None None O
of None None O
these None None O
proteins None None O
with None None O
structural None None O
changes None None O
in None None O
the None None O
hepatocytes None None O
of None None O
the None None O
different None None O
aged None None O
animals None None O
. None None O

For None None O
the None None O
most None None O
part None None O
, None None O
slices None None O
of None None O
liver None None O
from None None O
fetal None None O
( None None O
term None None O
) None None O
, None None O
neonatal None None O
( None None O
4 None None O
- None None O
to None None O
5 None None O
days None None O
old None None O
) None None O
, None None O
and None None O
adult None None O
rats None None O
( None None O
70 None None O
days None None O
old None None O
) None None O
were None None O
incubated None None O
with None None O
radioactive None None O
amino None None O
acids None None O
or None None O
various None None O
tritiated None None O
sugars None None O
specific None None O
for None None O
N None None O
- None None O
linked None None O
core None None O
oligosaccharide None None O
and None None O
/ None None O
or None None O
N None None O
- None None O
linked None None O
terminal None None O
oligosaccharide None None O
chains None None O
. None None O

Our None None O
findings None None O
indicate None None O
that None None O
liver None None O
slices None None O
of None None O
fetal None None O
and None None O
neonatal None None O
rats None None O
are None None O
efficient None None O
in None None O
synthesizing None None O
plasma None None O
proteins None None O
including None None O
fully None None O
glycosylated None None O
glycoproteins None None O
. None None O

The None None O
secretion None None O
of None None O
glycosylated None None O
and None None O
nonglycosylated None None O
proteins None None O
believed None None O
to None None O
be None None O
processed None None O
through None None O
Golgi None None O
complexes None None O
was None None O
inhibited None None O
to None None O
the None None O
same None None O
extent None None O
( None None O
approximately None None O
70 None None O
- None None O
80 None None O
% None None O
) None None O
by None None O
antimicrotubule None None O
agents None None O
, None None O
regardless None None O
of None None O
the None None O
age None None O
of None None O
the None None O
host None None O
animal None None O
. None None O

However None None O
, None None O
other None None O
proteins None None O
and None None O
glycoproteins None None O
secreted None None O
by None None O
livers None None O
of None None O
immature None None O
rats None None O
were None None O
found None None O
to None None O
be None None O
relatively None None O
insensitive None None O
( None None O
i None None O
. None None O
e None None O
. None None O
inhibited None None O
to None None O
only None None O
30 None None O
- None None O
40 None None O
% None None O
) None None O
to None None O
the None None O
action None None O
of None None O
various None None O
antimicrotubule None None O
drugs None None O
. None None O

The None None O
glycoproteins None None O
were None None O
found None None O
to None None O
lack None None O
N None None O
- None None O
linked None None O
terminal None None O
sugars None None O
( None None O
although None None O
the None None O
glycoproteins None None O
did None None O
contain None None O
N None None O
- None None O
linked None None O
core None None O
sugars None None O
) None None O
, None None O
and None None O
it None None O
is None None O
likely None None O
that None None O
the None None O
drug None None O
- None None O
insensitive None None O
proteins None None O
bypassed None None O
critical None None O
glycosylating None None O
sites None None O
in None None O
the None None O
Golgi None None O
compartment None None O
prior None None O
to None None O
release None None O
. None None O

Overall None None O
, None None O
these None None O
findings None None O
support None None O
earlier None None O
data None None O
showing None None O
that None None O
antimicrotubule None None O
drugs None None O
have None None O
a None None O
special None None O
impact None None O
on None None O
Golgi None None O
- None None O
associated None None O
events None None O
in None None O
liver None None O
cells None None O
. None None O

To None None O
what None None O
extent None None O
these None None O
findings None None O
are None None O
related None None O
to None None O
the None None O
action None None O
of None None O
microtubules None None O
remains None None O
to None None O
be None None O
seen None None O
. None None O

Roles None None O
of None None O
cell None None O
adhesion None None O
molecules None None O
in None None O
tumor None None O
angiogenesis None None O
induced None None O
by None None O
cotransplantation None None O
of None None O
cancer None None O
and None None O
endothelial None None O
cells None None O
to None None O
nude None None O
rats None None O
. None None O

Roles None None O
of None None O
cell None None O
adhesion None None O
molecules None None O
mediating None None O
the None None O
interaction None None O
of None None O
cancer None None O
and None None O
endothelial None None O
cells None None O
in None None O
tumor None None O
angiogenesis None None O
were None None O
investigated None None O
using None None O
new None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
model None None O
systems None None O
with None None O
a None None O
cultured None None O
murine None None O
endothelial None None O
cell None None O
line None None O
( None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
) None None O
and None None O
human None None O
cultured None None O
epidermoid None None O
cancer None None O
cells None None O
( None None O
A431 None None I-Cell-line-name
) None None O
. None None O

The None None O
A431 None None I-Cell-line-name
cells None None O
exhibited None None O
typical None None O
in None None O
vitro None None O
cell None None O
adhesion None None O
to None None O
the None None O
endothelial None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

The None None O
initial None None O
step None None O
of None None O
adhesion None None O
was None None O
mediated None None O
by None None O
sialyl None None O
Lewis None None O
( None None O
x None None O
) None None O
( None None O
Le None None O
( None None O
x None None O
) None None O
) None None O
and None None O
sialyl None None O
Le None None O
( None None O
a None None O
) None None O
, None None O
the None None O
carbohydrate None None O
determinants None None O
expressed None None O
on None None O
the None None O
cancer None None O
cells None None O
, None None O
and None None O
E None None O
- None None O
selectin None None O
expressed None None O
constitutively None None O
on None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

Prolonged None None O
culture None None O
led None None O
to None None O
the None None O
implantation None None O
of None None O
cancer None None O
cells None None O
into None None O
the None None O
monolayer None None O
of None None O
the None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
, None None O
which None None O
was None None O
mediated None None O
mainly None None O
by None None O
alpha None None O
( None None O
3 None None O
) None None O
beta None None O
( None None O
1 None None O
) None None O
- None None O
integrin None None O
. None None O

F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
cultured None None O
on None None O
Matrigel None None O
showed None None O
evident None None O
tube None None O
formation None None O
, None None O
and None None O
coculture None None O
of None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
with None None O
A431 None None I-Cell-line-name
cells None None O
led None None O
to None None O
the None None O
formation None None O
of None None O
A431 None None I-Cell-line-name
cell None None O
nests None None O
constantly None None O
surrounded None None O
by None None O
tube None None O
- None None O
like None None O
networks None None O
consisting None None O
of None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

This None None O
in None None O
vitro None None O
morphogenesis None None O
was None None O
inhibited None None O
by None None O
the None None O
addition None None O
of None None O
anti None None O
- None None O
sialyl None None O
Le None None O
( None None O
x None None O
) None None O
/ None None O
Le None None O
( None None O
a None None O
) None None O
or None None O
anti None None O
- None None O
beta None None O
( None None O
1 None None O
) None None O
- None None O
integrin None None O
antibodies None None O
, None None O
which None None O
led None None O
to None None O
the None None O
formation None None O
of None None O
cancer None None O
cell None None O
aggregates None None O
that None None O
were None None O
independent None None O
from None None O
the None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cell None None O
networks None None O
. None None O

This None None O
in None None O
vitro None None O
morphological None None O
appearance None None O
was None None O
exactly None None O
reproduced None None O
in None None O
the None None O
in None None O
vivo None None O
tumors None None O
, None None O
which None None O
were None None O
formed None None O
when None None O
the None None O
mixture None None O
of None None O
A431 None None I-Cell-line-name
and None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
at None None O
the None None O
ratio None None O
of None None O
10 None None O
: None None O
1 None None O
were None None O
cotransplanted None None O
s None None O
. None None O
c None None O
. None None O
into None None O
the None None O
back None None O
of None None O
nude None None O
rats None None O
. None None O

The None None O
tumors None None O
of None None O
A431 None None I-Cell-line-name
supplemented None None O
with None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
were None None O
profoundly None None O
vascularized None None O
throughout None None O
by None None O
the None None O
tubular None None O
structures None None O
formed None None O
by None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
, None None O
the None None O
lumen None None O
of None None O
which None None O
contained None None O
the None None O
host None None O
rat None None O
blood None None O
cells None None O
. None None O

The None None O
tumor None None O
mass None None O
thus None None O
formed None None O
was None None O
an None None O
average None None O
5 None None O
. None None O
8 None None O
- None None O
fold None None O
as None None O
large None None O
as None None O
control None None O
A431 None None I-Cell-line-name
tumors None None O
that None None O
were None None O
grown None None O
without None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

The None None O
co None None O
- None None O
injection None None O
of None None O
anti None None O
- None None O
Le None None O
( None None O
x None None O
) None None O
/ None None O
Le None None O
( None None O
a None None O
) None None O
or None None O
anti None None O
- None None O
beta None None O
( None None O
1 None None O
) None None O
- None None O
integrin None None O
antibodies None None O
produced None None O
a None None O
marked None None O
reduction None None O
in None None O
the None None O
size None None O
of None None O
A431 None None I-Cell-line-name
tumors None None O
, None None O
which None None O
were None None O
not None None O
vascularized None None O
and None None O
accompanied None None O
an None None O
independent None None O
tiny None None O
remnant None None O
clump None None O
of None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

The None None O
size None None O
of None None O
these None None O
A431 None None I-Cell-line-name
tumors None None O
did None None O
not None None O
differ None None O
significantly None None O
from None None O
those None None O
of None None O
control None None O
A431 None None I-Cell-line-name
tumors None None O
raised None None O
without None None O
F None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
cells None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
the None None O
interaction None None O
of None None O
tumor None None O
cells None None O
and None None O
endothelial None None O
cells None None O
in None None O
orderly None None O
tumor None None O
angiomorphogenesis None None O
is None None O
highly None None O
dependent None None O
on None None O
the None None O
action None None O
of None None O
cell None None O
adhesion None None O
molecules None None O
mediating None None O
the None None O
adhesion None None O
of None None O
cancer None None O
cells None None O
to None None O
endothelial None None O
cells None None O
, None None O
inhibition None None O
of None None O
which None None O
remarkably None None O
retards None None O
tumor None None O
growth None None O
and None None O
angiogenesis None None O
. None None O

Use None None O
of None None O
monoclonal None None O
antibodies None None O
to None None O
investigate None None O
a None None O
possible None None O
role None None O
of None None O
thyroglobulin None None O
in None None O
the None None O
pathogenesis None None O
of None None O
Graves None None O
' None None O
ophthalmopathy None None O
. None None O

One None None O
possible None None O
mechanism None None O
for None None O
Graves None None O
' None None O
ophthalmopathy None None O
is None None O
that None None O
the None None O
progressive None None O
orbital None None O
inflammation None None O
is None None O
initiated None None O
by None None O
formation None None O
of None None O
thyroglobulin None None O
( None None O
Tg None None O
) None None O
- None None O
anti None None O
- None None O
Tg None None O
immune None None O
complexes None None O
at None None O
sites None None O
of None None O
Tg None None O
binding None None O
to None None O
extraocular None None O
muscle None None O
membranes None None O
. None None O

In None None O
this None None O
study None None O
monoclonal None None O
antibodies None None O
( None None O
MCAB None None O
) None None O
against None None O
human None None O
Tg None None O
were None None O
used None None O
as None None O
probes None None O
( None None O
1 None None O
) None None O
to None None O
identify None None O
Tg None None O
in None None O
eye None None O
muscle None None O
membranes None None O
prepared None None O
from None None O
normal None None O
subjects None None O
and None None O
( None None O
2 None None O
) None None O
to None None O
measure None None O
binding None None O
of None None O
human None None O
Tg None None O
and None None O
Tg None None O
- None None O
anti None None O
- None None O
Tg None None O
immune None None O
complexes None None O
to None None O
eye None None O
muscle None None O
membranes None None O
. None None O

Reactivity None None O
of None None O
anti None None O
- None None O
Tg None None O
MCAB None None O
with None None O
Tg None None O
, None None O
thyroid None None O
, None None O
and None None O
eye None None O
muscle None None O
membranes None None O
was None None O
determined None None O
by None None O
binding None None O
of None None O
[ None None O
125I None None O
] None None O
anti None None O
- None None O
Tg None None O
monoclonal None None O
antibody None None O
, None None O
an None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
, None None O
and None None O
the None None O
indirect None None O
immunofluorescence None None O
technique None None O
. None None O

Seven None None O
membrane None None O
fractions None None O
, None None O
prepared None None O
by None None O
differential None None O
sucrose None None O
gradient None None O
centrifugation None None O
, None None O
were None None O
used None None O
. None None O

Whereas None None O
[ None None O
125I None None O
] None None O
anti None None O
- None None O
Tg None None O
MCAB None None O
bound None None O
to None None O
all None None O
thyroid None None O
membrane None None O
fractions None None O
tested None None O
, None None O
no None None O
[ None None O
125I None None O
] None None O
anti None None O
- None None O
Tg None None O
bound None None O
to None None O
eye None None O
muscle None None O
membranes None None O
. None None O

Similarly None None O
, None None O
reactivity None None O
of None None O
anti None None O
- None None O
Tg None None O
MCAB None None O
with None None O
eye None None O
muscle None None O
membranes None None O
was None None O
not None None O
demonstrated None None O
in None None O
ELISA None None O
or None None O
immunofluorescence None None O
tests None None O
. None None O

Although None None O
Tg None None O
- None None O
anti None None O
- None None O
Tg None None O
immune None None O
complexes None None O
bound None None O
to None None O
thyroid None None O
membranes None None O
, None None O
such None None O
complexes None None O
did None None O
not None None O
bind None None O
to None None O
eye None None O
muscle None None O
membranes None None O
. None None O

Significant None None O
binding None None O
of None None O
[ None None O
125I None None O
] None None O
human None None O
Tg None None O
to None None O
eye None None O
muscle None None O
or None None O
thyroid None None O
membranes None None O
was None None O
not None None O
demonstrated None None O
for None None O
any None None O
membrane None None O
preparation None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
moderate None None O
, None None O
but None None O
significant None None O
, None None O
binding None None O
to None None O
skeletal None None O
muscle None None O
was None None O
shown None None O
. None None O

Similar None None O
results None None O
were None None O
found None None O
using None None O
an None None O
ELISA None None O
. None None O

Binding None None O
of None None O
[ None None O
125I None None O
] None None O
anti None None O
- None None O
Tg None None O
- None None O
Tg None None O
complexes None None O
of None None O
[ None None O
125I None None O
] None None O
Tg None None O
to None None O
thyroid None None O
and None None O
eye None None O
muscle None None O
membranes None None O
was None None O
not None None O
affected None None O
by None None O
the None None O
presence None None O
of None None O
normal None None O
human None None O
serum None None O
, None None O
phosphate None None O
ions None None O
, None None O
pH None None O
, None None O
or None None O
incubation None None O
temperature None None O
, None None O
conditions None None O
claimed None None O
by None None O
others None None O
to None None O
be None None O
critical None None O
for None None O
Tg None None O
and None None O
Tg None None O
- None None O
anti None None O
- None None O
Tg None None O
immune None None O
complex None None O
binding None None O
. None None O

Since None None O
Tg None None O
is None None O
not None None O
present None None O
in None None O
normal None None O
human None None O
eye None None O
muscle None None O
a None None O
major None None O
role None None O
of None None O
Tg None None O
, None None O
or None None O
Tg None None O
- None None O
anti None None O
- None None O
Tg None None O
immune None None O
complexes None None O
, None None O
in None None O
the None None O
pathogenesis None None O
of None None O
Graves None None O
' None None O
ophthalmopathy None None O
appears None None O
to None None O
have None None O
been None None O
excluded None None O
by None None O
these None None O
findings None None O
. None None O

[ None None O
Effect None None O
of None None O
osteopontin None None O
silencing None None O
by None None O
lentivirus None None O
- None None O
mediated None None O
delivery None None O
of None None O
siRNA None None O
on None None O
glioma None None O
cell None None O
invasion None None O
and None None O
apoptosis None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
effect None None O
of None None O
osteopontin None None O
silencing None None O
on None None O
the None None O
invasion None None O
and None None O
apoptosis None None O
of None None O
U251 None None I-Cell-line-name
cells None None O
. None None O

METHODS None None O
: None None O
The None None O
invasion None None O
, None None O
apoptosis None None O
and None None O
levels None None O
of None None O
uPA None None O
, None None O
MMP None None O
- None None O
2 None None O
and None None O
MMP None None O
- None None O
9 None None O
were None None O
determined None None O
by None None O
invasion None None O
assay None None O
, None None O
flow None None O
cytometry None None O
, None None O
Western None None O
blot None None O
and None None O
real None None O
- None None O
time None None O
fluorescence None None O
quantitative None None O
PCR None None O
respectively None None O
. None None O

RESULTS None None O
: None None O
Osteopontin None None O
small None None O
interference None None O
RNA None None O
( None None O
siRNA None None O
) None None O
inhibited None None O
osteopontin None None O
expression None None O
and None None O
cell None None O
invasion None None O
, None None O
promoted None None O
apoptosis None None O
in None None O
U251 None None I-Cell-line-name
cells None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
expression None None O
of None None O
Bcl None None O
- None None O
2 None None O
, None None O
uPA None None O
, None None O
MMP None None O
- None None O
2 None None O
and None None O
MMP None None O
- None None O
9 None None O
was None None O
decreased None None O
, None None O
while None None O
Bax None None O
level None None O
was None None O
elevated None None O
. None None O

CONCLUSION None None O
: None None O
Osteopontin None None O
siRNA None None O
can None None O
inhibit None None O
U251 None None I-Cell-line-name
cells None None O
invasion None None O
via None None O
the None None O
down None None O
- None None O
regulation None None O
of None None O
uPA None None O
, None None O
MMP None None O
- None None O
2 None None O
and None None O
MMP None None O
- None None O
9 None None O
levels None None O
, None None O
and None None O
promote None None O
apoptosis None None O
through None None O
induction None None O
of None None O
Bax None None O
expression None None O
and None None O
inhibition None None O
of None None O
Bcl None None O
2 None None O
level None None O
. None None O

It None None O
suggests None None O
that None None O
osteopontin None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
human None None O
glioma None None O
progression None None O
. None None O

Defective None None O
expression None None O
of None None O
HRK None None O
is None None O
associated None None O
with None None O
promoter None None O
methylation None None O
in None None O
primary None None O
central None None O
nervous None None O
system None None O
lymphomas None None O
. None None O

OBJECTIVES None None O
: None None O
Recently None None O
, None None O
it None None O
has None None O
been None None O
reported None None O
that None None O
expression None None O
of None None O
the None None O
HRK None None O
gene None None O
was None None O
significantly None None O
reduced None None O
by None None O
hypermethylation None None O
in None None O
astrocytic None None O
tumors None None O
. None None O

Our None None O
aim None None O
is None None O
to None None O
verify None None O
the None None O
alterations None None O
in None None O
the None None O
HRK None None O
gene None None O
in None None O
primary None None O
central None None O
nervous None None O
system None None O
lymphomas None None O
( None None O
PCNSLs None None O
) None None O
. None None O

METHODS None None O
: None None O
We None None O
analyzed None None O
the None None O
hypermethylation None None O
status None None O
and None None O
expression None None O
of None None O
the None None O
gene None None O
and None None O
12q13 None None O
. None None O
1 None None O
loss None None O
of None None O
heterozygosity None None O
in None None O
31 None None O
PCNSLs None None O
. None None O

RESULTS None None O
: None None O
A None None O
total None None O
of None None O
13 None None O
PCNSLs None None O
( None None O
31 None None O
% None None O
) None None O
demonstrated None None O
hypermethylation None None O
in None None O
either None None O
the None None O
promoter None None O
or None None O
exon None None O
1 None None O
; None None O
loss None None O
of None None O
HRK None None O
expression None None O
was None None O
immunohistochemically None None O
observed None None O
in None None O
9 None None O
tumors None None O
and None None O
was None None O
significantly None None O
associated None None O
with None None O
promoter None None O
methylation None None O
. None None O

In None None O
addition None None O
, None None O
higher None None O
apoptotic None None O
counts None None O
were None None O
associated None None O
with None None O
HRK None None O
positivity None None O
. None None O

PCNSLs None None O
with None None O
HRK None None O
methylation None None O
also None None O
showed None None O
methylation None None O
of None None O
multiple None None O
genes None None O
, None None O
such None None O
as None None O
p14ARF None None O
, None None O
p16INK4a None None O
, None None O
RB1 None None O
, None None O
p27Kip1 None None O
and None None O
O6 None None O
- None None O
MGMT None None O
. None None O

Patients None None O
with None None O
tumors None None O
demonstrating None None O
concurrent None None O
methylation None None O
of None None O
more None None O
than None None O
half None None O
of None None O
their None None O
genes None None O
demonstrated None None O
significantly None None O
poorer None None O
survival None None O
and None None O
earlier None None O
recurrence None None O
. None None O

Hypermethylation None None O
of None None O
the None None O
HRK None None O
promoter None None O
alone None None O
was None None O
not None None O
associated None None O
with None None O
overall None None O
outcome None None O
, None None O
but None None O
relapse None None O
- None None O
free None None O
survival None None O
was None None O
significantly None None O
shorter None None O
. None None O

CONCLUSIONS None None O
: None None O
Our None None O
findings None None O
suggest None None O
that None None O
transcriptional None None O
repression None None O
of None None O
HRK None None O
is None None O
caused None None O
by None None O
promoter None None O
hypermethylation None None O
in None None O
PCNSL None None O
, None None O
and None None O
that None None O
the None None O
loss None None O
of None None O
HRK None None O
associated None None O
with None None O
the None None O
methylation None None O
profile None None O
of None None O
other None None O
genes None None O
is None None O
a None None O
potential None None O
step None None O
in None None O
the None None O
modulation None None O
of None None O
cellular None None O
death None None O
by None None O
apoptosis None None O
during None None O
PCNSL None None O
tumorigenesis None None O
. None None O

Growth None None O
state None None O
- None None O
dependent None None O
regulation None None O
of None None O
protein None None O
kinase None None O
C None None O
in None None O
normal None None O
and None None O
transformed None None O
murine None None O
cells None None O
. None None O

We None None O
determined None None O
whether None None O
growth None None O
state None None O
can None None O
influence None None O
the None None O
action None None O
of None None O
protein None None O
kinase None None O
C None None O
by None None O
measuring None None O
protein None None O
kinase None None O
C None None O
activity None None O
in None None O
growing None None O
and None None O
stationary None None O
cultures None None O
of None None O
normal None None O
and None None O
transformed None None O
cells None None O
. None None O

Two None None O
approaches None None O
were None None O
used None None O
to None None O
measure None None O
protein None None O
kinase None None O
C None None O
: None None O
assay None None O
of None None O
intact None None O
cells None None O
for None None O
inhibition None None O
of None None O
epidermal None None O
growth None None O
factor None None O
( None None O
EGF None None O
) None None O
binding None None O
in None None O
response None None O
to None None O
phorbol None None O
dibutyrate None None O
( None None O
PDBu None None O
) None None O
; None None O
and None None O
assay None None O
of None None O
detergent None None O
extracts None None O
for None None O
total None None O
calcium None None O
, None None O
phospholipid None None O
- None None O
dependent None None O
kinase None None O
activity None None O
. None None O

In None None O
extracts None None O
of None None O
growing None None O
and None None O
stationary None None O
Swiss None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
, None None O
the None None O
total None None O
amount None None O
of None None O
protein None None O
kinase None None O
C None None O
activity None None O
was None None O
similar None None O
, None None O
indicating None None O
that None None O
growth None None O
state None None O
does None None O
not None None O
alter None None O
the None None O
level None None O
of None None O
enzyme None None O
in None None O
the None None O
cell None None O
. None None O

The None None O
short None None O
- None None O
term None None O
response None None O
of None None O
Swiss None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
to None None O
an None None O
activator None None O
of None None O
protein None None O
kinase None None O
C None None O
also None None O
appeared None None O
to None None O
be None None O
independent None None O
of None None O
growth None None O
state None None O
, None None O
since None None O
the None None O
50 None None O
% None None O
effective None None O
dose None None O
for None None O
PDBu None None O
inhibition None None O
of None None O
EGF None None O
binding None None O
to None None O
its None None O
receptor None None O
was None None O
approximately None None O
7 None None O
nM None None O
for None None O
both None None O
growth None None O
conditions None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
response None None O
of None None O
cells None None O
to None None O
long None None O
- None None O
term None None O
treatment None None O
with None None O
PDBu None None O
was None None O
significantly None None O
different None None O
depending None None O
upon None None O
the None None O
initial None None O
growth None None O
state None None O
of None None O
the None None O
cells None None O
. None None O

In None None O
both None None O
growth None None O
states None None O
, None None O
PDBu None None O
caused None None O
loss None None O
of None None O
protein None None O
kinase None None O
C None None O
activity None None O
, None None O
which None None O
reflected None None O
a None None O
loss None None O
in None None O
protein None None O
mass None None O
as None None O
determined None None O
by None None O
immunoblotting None None O
with None None O
antiserum None None O
to None None O
protein None None O
kinase None None O
C None None O
. None None O

However None None O
, None None O
the None None O
maximum None None O
decrease None None O
approached None None O
100 None None O
% None None O
in None None O
stationary None None O
cultures None None O
versus None None O
approximately None None O
75 None None O
% None None O
in None None O
growing None None O
cells None None O
. None None O

Protein None None O
kinase None None O
C None None O
levels None None O
in None None O
several None None O
transformed None None O
cell None None O
lines None None O
were None None O
subject None None O
to None None O
down None None O
modulation None None O
in None None O
a None None O
similar None None O
growth None None O
state None None O
- None None O
dependent None None O
manner None None O
. None None O

Further None None O
, None None O
the None None O
inhibition None None O
of None None O
EGF None None O
binding None None O
by None None O
tumor None None O
promoters None None O
following None None O
long None None O
- None None O
term None None O
treatment None None O
of None None O
Swiss None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
with None None O
PDBu None None O
also None None O
varied None None O
with None None O
growth None None O
state None None O
. None None O

In None None O
down None None O
modulated None None O
growing None None O
cells None None O
, None None O
PDBu None None O
caused None None O
almost None None O
complete None None O
inhibition None None O
of None None O
EGF None None O
binding None None O
, None None O
whereas None None O
in None None O
down None None O
modulated None None O
stationary None None O
cells None None O
, None None O
minimal None None O
inhibition None None O
of None None O
EGF None None O
binding None None O
by None None O
PDBu None None O
was None None O
observed None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
prolonged None None O
treatment None None O
with None None O
tumor None None O
promoters None None O
alters None None O
the None None O
sensitivity None None O
of None None O
cells None None O
to None None O
activators None None O
of None None O
protein None None O
kinase None None O
C None None O
in None None O
a None None O
growth None None O
state None None O
- None None O
dependent None None O
manner None None O
. None None O

Supplementary None None O
Material None None O

Crystal None None O
structure None None O
: None None O
contains None None O
datablock None None O
( None None O
s None None O
) None None O
global None None O
, None None O
I None None O
. None None O

DOI None None O
: None None O
10 None None O
. None None O
1107 None None O
/ None None O
S1600536812002796 None None O
/ None None O
hg5166sup1 None None O
. None None O
cif None None O

Structure None None O
factors None None O
: None None O
contains None None O
datablock None None O
( None None O
s None None O
) None None O
I None None O
. None None O

DOI None None O
: None None O
10 None None O
. None None O
1107 None None O
/ None None O
S1600536812002796 None None O
/ None None O
hg5166Isup2 None None O
. None None O
hkl None None O

Additional None None O
supplementary None None O
materials None None O
: None None O
crystallographic None None O
information None None O
; None None O
3D None None O
view None None O
; None None O
checkCIF None None O
report None None O

Additional None None O
file None None O
2 None None O

Video None None O
S2 None None O
TTE None None O
apical None None O
4 None None O
- None None O
chamber None None O
view None None O
. None None O

The None None O
vegetation None None O
seems None None O
located None None O
just None None O
above None None O
the None None O
tricuspid None None O
septal None None O
valve None None O
without None None O
causing None None O
obstruction None None O
on None None O
it None None O
. None None O

Hyperforin None None O
blocks None None O
neutrophil None None O
activation None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
, None None O
motility None None O
and None None O
recruitment None None O
, None None O
and None None O
restrains None None O
inflammation None None O
- None None O
triggered None None O
angiogenesis None None O
and None None O
lung None None O
fibrosis None None O
. None None O

Hyperforin None None O
( None None O
Hyp None None O
) None None O
, None None O
a None None O
polyphenol None None O
- None None O
derivative None None O
of None None O
St None None O
. None None O

John None None O
' None None O
s None None O
wort None None O
( None None O
Hypericum None None O
perforatum None None O
) None None O
, None None O
has None None O
emerged None None O
as None None O
key None None O
player None None O
not None None O
only None None O
in None None O
the None None O
antidepressant None None O
activity None None O
of None None O
the None None O
plant None None O
but None None O
also None None O
as None None O
an None None O
inhibitor None None O
of None None O
bacteria None None O
lymphocyte None None O
and None None O
tumor None None O
cell None None O
proliferation None None O
, None None O
and None None O
matrix None None O
proteinases None None O
. None None O

We None None O
tested None None O
whether None None O
as None None O
well None None O
as None None O
inhibiting None None O
leukocyte None None O
elastase None None O
( None None O
LE None None O
) None None O
activity None None O
, None None O
Hyp None None O
might None None O
be None None O
effective None None O
in None None O
containing None None O
both None None O
polymorphonuclear None None O
neutrophil None None O
( None None O
PMN None None O
) None None O
leukocyte None None O
recruitment None None O
and None None O
unfavorable None None O
eventual None None O
tissue None None O
responses None None O
. None None O

The None None O
results None None O
show None None O
that None None O
, None None O
without None None O
affecting None None O
in None None O
vitro None None O
human None None O
PMN None None O
viability None None O
and None None O
chemokine None None O
- None None O
receptor None None O
expression None None O
, None None O
Hyp None None O
( None None O
as None None O
stable None None O
dicyclohexylammonium None None O
salt None None O
) None None O
was None None O
able None None O
to None None O
inhibit None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
their None None O
chemotaxis None None O
and None None O
chemoinvasion None None O
( None None O
IC50 None None O
= None None O
1 None None O
microM None None O
for None None O
both None None O
) None None O
; None None O
this None None O
effect None None O
was None None O
associated None None O
with None None O
a None None O
reduced None None O
expression None None O
of None None O
the None None O
adhesion None None O
molecule None None O
CD11b None None O
by None None O
formyl None None O
- None None O
Met None None O
- None None O
Leu None None O
- None None O
Phe None None O
- None None O
stimulated None None O
neutrophils None None O
and None None O
block None None O
of None None O
LE None None O
- None None O
triggered None None O
activation None None O
of None None O
the None None O
gelatinase None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
. None None O

PMN None None O
- None None O
triggered None None O
angiogenesis None None O
is None None O
also None None O
blocked None None O
by None None O
both None None O
local None None O
injection None None O
and None None O
daily None None O
i None None O
. None None O
p None None O
. None None O
administration None None O
of None None O
the None None O
Hyp None None O
salt None None O
in None None O
an None None O
interleukin None None O
- None None O
8 None None O
- None None O
induced None None O
murine None None O
model None None O
. None None O

Furthermore None None O
, None None O
i None None O
. None None O
p None None O
. None None O
treatment None None O
with None None O
Hyp None None O
reduces None None O
acute None None O
PMN None None O
recruitment None None O
and None None O
enhances None None O
resolution None None O
in None None O
a None None O
pulmonary None None O
bleomycin None None O
- None None O
induced None None O
inflammation None None O
model None None O
, None None O
significantly None None O
reducing None None O
consequent None None O
fibrosis None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
Hyp None None O
is None None O
a None None O
powerful None None O
anti None None O
- None None O
inflammatory None None O
compound None None O
with None None O
therapeutic None None O
potential None None O
, None None O
and None None O
they None None O
elucidate None None O
mechanistic None None O
keys None None O
. None None O

Screening None None O
method None None O
for None None O
insecticidal None None O
activity None None O
using None None O
first None None O
instars None None O
of None None O
black None None O
blow None None O
fly None None O
( None None O
Diptera None None O
: None None O
Calliphoridae None None O
) None None O
. None None O

A None None O
bioassay None None O
method None None O
suitable None None O
for None None O
rapid None None O
mass None None O
screening None None O
of None None O
fermentation None None O
and None None O
synthetic None None O
organic None None O
compounds None None O
for None None O
insecticidal None None O
activity None None O
is None None O
described None None O
. None None O

The None None O
test None None O
, None None O
which None None O
uses None None O
first None None O
instars None None O
of None None O
susceptible None None O
black None None O
blow None None O
fly None None O
, None None O
Phormia None None O
regina None None O
( None None O
Meigen None None O
) None None O
, None None O
in None None O
a None None O
bovine None None O
serum None None O
medium None None O
, None None O
detects None None O
insecticidal None None O
activity None None O
with None None O
reproducible None None O
results None None O
. None None O

It None None O
is None None O
capable None None O
of None None O
selecting None None O
the None None O
most None None O
active None None O
compound None None O
in None None O
structure None None O
- None None O
activity None None O
relationships None None O
by None None O
minimum None None O
effective None None O
dose None None O
concentration None None O
studies None None O
. None None O

The None None O
bioassay None None O
system None None O
is None None O
easy None None O
to None None O
operate None None O
and None None O
requires None None O
only None None O
a None None O
minute None None O
quantity None None O
of None None O
chemical None None O
compound None None O
. None None O

Chelation None None O
treatment None None O
of None None O
neurological None None O
Wilson None None O
' None None O
s None None O
disease None None O
. None None O

The None None O
results None None O
of None None O
chelation None None O
treatment None None O
of None None O
137 None None O
patients None None O
presenting None None O
with None None O
neurological None None O
Wilson None None O
' None None O
s None None O
disease None None O
are None None O
described None None O
, None None O
together None None O
with None None O
the None None O
more None None O
commonly None None O
observed None None O
toxic None None O
reactions None None O
to None None O
the None None O
various None None O
drugs None None O
employed None None O
. None None O

Fifty None None O
- None None O
seven None None O
patients None None O
made None None O
an None None O
excellent None None O
response None None O
to None None O
treatment None None O
and None None O
became None None O
symptom None None O
free None None O
. None None O

Thirty None None O
- None None O
six None None O
patients None None O
made None None O
a None None O
good None None O
recovery None None O
, None None O
but None None O
were None None O
left None None O
with None None O
some None None O
minor None None O
neurological None None O
deficit None None O
. None None O

Twenty None None O
- None None O
four None None O
patients None None O
had None None O
a None None O
poor None None O
response None None O
: None None O
although None None O
the None None O
disease None None O
process None None O
was None None O
arrested None None O
they None None O
were None None O
left None None O
more None None O
or None None O
less None None O
disabled None None O
. None None O

Twenty None None O
patients None None O
died None None O
: None None O
nine None None O
had None None O
little None None O
or None None O
no None None O
treatment None None O
, None None O
but None None O
11 None None O
died None None O
despite None None O
apparently None None O
adequate None None O
chelation None None O
therapy None None O
. None None O

There None None O
was None None O
no None None O
obvious None None O
reason None None O
for None None O
this None None O
failure None None O
. None None O

The None None O
liver None None O
copper None None O
level None None O
was None None O
estimated None None O
in None None O
six None None O
of None None O
these None None O
patients None None O
: None None O
it None None O
was None None O
still None None O
significantly None None O
elevated None None O
in None None O
only None None O
one None None O
, None None O
but None None O
in None None O
all None None O
four None None O
in None None O
whom None None O
it None None O
was None None O
possible None None O
to None None O
make None None O
the None None O
determination None None O
, None None O
the None None O
concentration None None O
of None None O
copper None None O
in None None O
the None None O
basal None None O
ganglia None None O
was None None O
in None None O
excess None None O
of None None O
45 None None O
micrograms None None O
/ None None O
g None None O
wet None None O
weight None None O
. None None O

It None None O
was None None O
not None None O
apparent None None O
why None None O
adequate None None O
therapy None None O
failed None None O
to None None O
remove None None O
copper None None O
from None None O
the None None O
brains None None O
of None None O
these None None O
patients None None O
. None None O

There None None O
was None None O
no None None O
obvious None None O
clinical None None O
, None None O
histological None None O
or None None O
biochemical None None O
indicator None None O
of None None O
failure None None O
to None None O
respond None None O
to None None O
treatment None None O
. None None O

Initial None None O
deterioration None None O
before None None O
improvement None None O
was None None O
seen None None O
in None None O
30 None None O
patients None None O
: None None O
the None None O
prognosis None None O
for None None O
a None None O
useful None None O
recovery None None O
was None None O
not None None O
necessarily None None O
worse None None O
than None None O
that None None O
in None None O
patients None None O
who None None O
did None None O
not None None O
show None None O
this None None O
phenomenon None None O
. None None O

Subretinal None None O
neovascularization None None O
following None None O
rubella None None O
retinopathy None None O
. None None O

A None None O
17 None None O
- None None O
year None None O
- None None O
old None None O
girl None None O
and None None O
an None None O
11 None None O
- None None O
year None None O
- None None O
old None None O
girl None None O
with None None O
rubella None None O
retinopathy None None O
had None None O
decreased None None O
vision None None O
in None None O
one None None O
eye None None O
secondary None None O
to None None O
subretinal None None O
neovascularization None None O
and None None O
hemorrhage None None O
. None None O

In None None O
both None None O
cases None None O
a None None O
disciform None None O
scar None None O
with None None O
permanent None None O
decrease None None O
in None None O
central None None O
vision None None O
resulted None None O
. None None O

Inhibition None None O
of None None O
angiogenesis None None O
by None None O
the None None O
cancer None None O
chemopreventive None None O
agent None None O
conjugated None None O
linoleic None None O
acid None None O
. None None O

Dietary None None O
conjugated None None O
linoleic None None O
acid None None O
( None None O
CLA None None O
) None None O
has None None O
been None None O
shown None None O
previously None None O
to None None O
inhibit None None O
rat None None O
mammary None None O
carcinogenesis None None O
. None None O

In None None O
addition None None O
to None None O
direct None None O
effects None None O
on None None O
mammary None None O
epithelial None None O
cells None None O
, None None O
including None None O
decreased None None O
proliferation None None O
and None None O
induction None None O
of None None O
apoptosis None None O
, None None O
CLA None None O
may None None O
exert None None O
its None None O
effects None None O
indirectly None None O
by None None O
inhibiting None None O
the None None O
differentiation None None O
of None None O
mammary None None O
stromal None None O
cells None None O
to None None O
an None None O
endothelial None None O
cell None None O
type None None O
. None None O

Specifically None None O
, None None O
CLA None None O
was None None O
found None None O
to None None O
decrease None None O
the None None O
ability None None O
of None None O
mammary None None O
stromal None None O
cells None None O
to None None O
form None None O
complex None None O
anastomosing None None O
microcapillary None None O
networks None None O
in None None O
vitro None None O
on None None O
Engelbreth None None O
- None None O
Holm None None O
- None None O
Swarm None None O
- None None O
derived None None O
reconstituted None None O
basement None None O
membrane None None O
. None None O

This None None O
suggested None None O
that None None O
CLA None None O
might None None O
inhibit None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

To None None O
test None None O
this None None O
possibility None None O
, None None O
CD2 None None O
/ None None O
F None None O
( None None O
1 None None O
) None None O
mice None None O
were None None O
placed None None O
on None None O
synthetic None None O
diets None None O
containing None None O
0 None None O
, None None O
1 None None O
, None None O
or None None O
2 None None O
% None None O
CLA None None O
for None None O
6 None None O
weeks None None O
, None None O
before None None O
angiogenic None None O
challenge None None O
by None None O
s None None O
. None None O
c None None O
. None None O
injection None None O
with None None O
an None None O
angiogenic None None O
gel None None O
substrate None None O
( None None O
Matrigel None None O
pellet None None O
assay None None O
) None None O
. None None O

After None None O
7 None None O
days None None O
, None None O
the None None O
pellets None None O
from None None O
animals None None O
fed None None O
the None None O
control None None O
diet None None O
were None None O
infiltrated None None O
by None None O
abundant None None O
branching None None O
networks None None O
of None None O
blood None None O
vessels None None O
with None None O
patent None None O
lumen None None O
- None None O
containing None None O
RBCs None None O
. None None O

In None None O
contrast None None O
, None None O
pellets None None O
from None None O
the None None O
CLA None None O
- None None O
fed None None O
animals None None O
contained None None O
fewer None None O
infiltrating None None O
cells None None O
, None None O
which None None O
formed None None O
limited None None O
branching None None O
cellular None None O
networks None None O
, None None O
the None None O
majority None None O
of None None O
which None None O
had None None O
collapsed None None O
lumen None None O
and None None O
no None None O
RBCs None None O
. None None O

Both None None O
levels None None O
of None None O
dietary None None O
CLA None None O
showed None None O
similar None None O
effects None None O
, None None O
with None None O
the None None O
number None None O
of None None O
RBC None None O
- None None O
containing None None O
vessels None None O
per None None O
20x None None O
field None None O
decreased None None O
to None None O
a None None O
third None None O
of None None O
that None None O
seen None None O
in None None O
control None None O
. None None O

Dietary None None O
CLA None None O
decreased None None O
serum None None O
levels None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
whole None None O
mammary None None O
gland None None O
levels None None O
of None None O
VEGF None None O
and None None O
its None None O
receptor None None O
Flk None None O
- None None O
1 None None O
. None None O

Both None None O
cis None None O
- None None O
9 None None O
, None None O
trans None None O
- None None O
11 None None O
and None None O
trans None None O
- None None O
10 None None O
, None None O
cis None None O
- None None O
12 None None O
CLA None None O
isomers None None O
were None None O
effective None None O
in None None O
inhibiting None None O
angiogenesis None None O
in None None O
vitro None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
fashion None None O
. None None O

The None None O
ability None None O
of None None O
CLA None None O
to None None O
inhibit None None O
angiogenesis None None O
may None None O
contribute None None O
to None None O
its None None O
efficacy None None O
as None None O
a None None O
chemopreventive None None O
agent None None O
. None None O

Phonology None None O
: None None O
a None None O
review None None O
and None None O
proposals None None O
from None None O
a None None O
connectionist None None O
perspective None None O
. None None O

A None None O
parallel None None O
distributed None None O
processing None None O
( None None O
PDP None None O
) None None O
model None None O
of None None O
phonological None None O
processing None None O
is None None O
developed None None O
, None None O
including None None O
components None None O
to None None O
support None None O
repetition None None O
, None None O
auditory None None O
processing None None O
, None None O
comprehension None None O
, None None O
and None None O
language None None O
production None None O
. None None O

From None None O
the None None O
performance None None O
of None None O
the None None O
PDP None None O
reading None None O
model None None O
of None None O
Plaut None None O
, None None O
McClelland None None O
, None None O
Seidenberg None None O
, None None O
and None None O
Patterson None None O
( None None O
1996 None None O
) None None O
, None None O
it None None O
is None None O
inferred None None O
that None None O
the None None O
acoustic None None O
- None None O
articulatory None None O
motor None None O
pattern None None O
associator None None O
that None None O
supports None None O
repetition None None O
provides None None O
the None None O
basis None None O
for None None O
phonological None None O
sequence None None O
knowledge None None O
. None None O

From None None O
the None None O
observation None None O
that None None O
many None None O
patients None None O
make None None O
phonemic None None O
paraphasic None None O
errors None None O
in None None O
language None None O
production None None O
, None None O
as None None O
in None None O
repetition None None O
, None None O
it None None O
is None None O
argued None None O
that None None O
there None None O
must None None O
be None None O
a None None O
direct None None O
link None None O
between None None O
distributed None None O
concept None None O
representations None None O
( None None O
lexical None None O
semantic None None O
knowledge None None O
) None None O
and None None O
this None None O
network None None O
representation None None O
of None None O
sequence None None O
knowledge None None O
. None None O

In None None O
this None None O
way None None O
, None None O
both None None O
lexical None None O
semantic None None O
and None None O
phonotactic None None O
constraints None None O
are None None O
brought None None O
to None None O
bear None None O
on None None O
language None None O
production None None O
. None None O

The None None O
literature None None O
on None None O
phonological None None O
function None None O
in None None O
normal None None O
subjects None None O
( None None O
slip None None O
- None None O
of None None O
- None None O
the None None O
- None None O
tongue None None O
corpora None None O
) None None O
and None None O
in None None O
patients None None O
with None None O
aphasia None None O
is None None O
critically None None O
reviewed None None O
from None None O
this None None O
perspective None None O
. None None O

The None None O
relationship None None O
between None None O
acoustic None None O
and None None O
articulatory None None O
motor None None O
representations None None O
in None None O
the None None O
process None None O
of None None O
phonetic None None O
perception None None O
is None None O
considered None None O
. None None O

Repetition None None O
and None None O
reproduction None None O
conduction None None O
aphasia None None O
are None None O
reviewed None None O
in None None O
detail None None O
and None None O
extended None None O
consideration None None O
is None None O
given None None O
to None None O
the None None O
representation None None O
of None None O
auditory None None O
verbal None None O
short None None O
- None None O
term None None O
memory None None O
in None None O
the None None O
model None None O
. None None O

Finally None None O
, None None O
the None None O
PDP None None O
model None None O
is None None O
reconciled None None O
with None None O
information None None O
processing None None O
models None None O
of None None O
phonological None None O
processing None None O
, None None O
including None None O
that None None O
of None None O
Lichtheim None None O
, None None O
and None None O
with None None O
current None None O
knowledge None None O
of None None O
the None None O
anatomic None None O
localization None None O
of None None O
phonological None None O
processing None None O
. None None O

Although None None O
no None None O
simulations None None O
of None None O
the None None O
model None None O
were None None O
run None None O
, None None O
a None None O
number None None O
of None None O
simulation None None O
studies None None O
are None None O
proposed None None O
. None None O

Effects None None O
of None None O
morphological None None O
patterning None None O
on None None O
endothelial None None O
cell None None O
migration None None O
. None None O

The None None O
migration None None O
of None None O
vascular None None O
endothelial None None O
cells None None O
( None None O
ECs None None O
) None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
vascular None None O
remodeling None None O
. None None O

Here None None O
we None None O
studied None None O
the None None O
effects None None O
of None None O
cell None None O
morphology None None O
on None None O
the None None O
migration None None O
of None None O
bovine None None O
aortic None None O
ECs None None O
by None None O
culturing None None O
cells None None O
on None None O
micropatterned None None O
strips None None O
of None None O
collagen None None O
matrix None None O
( None None O
60 None None O
- None None O
, None None O
30 None None O
- None None O
, None None O
and None None O
15 None None O
- None None O
microm None None O
wide None None O
) None None O
. None None O

The None None O
spreading None None O
areas None None O
of None None O
the None None O
cells None None O
on None None O
15 None None O
- None None O
and None None O
30 None None O
- None None O
microm None None O
wide None None O
strips None None O
were None None O
30 None None O
% None None O
lower None None O
than None None O
those None None O
on None None O
60 None None O
- None None O
microm None None O
wide None None O
strips None None O
and None None O
unpatterned None None O
collagen None None O
. None None O

The None None O
cells None None O
on None None O
15 None None O
- None None O
microm None None O
wide None None O
strips None None O
completely None None O
aligned None None O
in None None O
the None None O
direction None None O
of None None O
the None None O
strip None None O
, None None O
and None None O
had None None O
significantly None None O
lower None None O
shape None None O
index None None O
than None None O
those None None O
in None None O
all None None O
other None None O
groups None None O
. None None O

On None None O
strips None None O
of None None O
all None None O
widths None None O
, None None O
ECs None None O
tended None None O
to None None O
migrate None None O
in None None O
the None None O
direction None None O
of None None O
strips None None O
. None None O

ECs None None O
on None None O
15 None None O
- None None O
microm None None O
wide None None O
strips None None O
had None None O
highest None None O
speed None None O
, None None O
particularly None None O
in None None O
the None None O
direction None None O
of None None O
the None None O
strip None None O
. None None O

Vinculin None None O
staining None None O
showed None None O
that None None O
the None None O
leading None None O
edge None None O
of None None O
ECs None None O
on None None O
15 None None O
- None None O
microm None None O
wide None None O
strips None None O
had None None O
focal None None O
adhesions None None O
that None None O
were None None O
oriented None None O
with None None O
their None None O
lamellipodial None None O
protrusion None None O
and None None O
the None None O
direction None None O
of None None O
cell None None O
migration None None O
; None None O
this None None O
arrangement None None O
of None None O
the None None O
focal None None O
adhesions None None O
may None None O
promote None None O
EC None None O
migration None None O
. None None O

The None None O
present None None O
study None None O
provides None None O
direct None None O
evidence None None O
on None None O
the None None O
role None None O
of None None O
cell None None O
morphology None None O
in None None O
EC None None O
migration None None O
, None None O
and None None O
will None None O
help None None O
us None None O
to None None O
understand None None O
the None None O
mechanisms None None O
of None None O
EC None None O
migration None None O
during None None O
angiogenesis None None O
and None None O
wound None None O
healing None None O
. None None O

RUNX1 None None O
DNA None None O
- None None O
binding None None O
mutations None None O
and None None O
RUNX1 None None O
- None None O
PRDM16 None None O
cryptic None None O
fusions None None O
in None None O
BCR None None O
- None None O
ABL None None O
+ None None O
leukemias None None O
are None None O
frequently None None O
associated None None O
with None None O
secondary None None O
trisomy None None O
21 None None O
and None None O
may None None O
contribute None None O
to None None O
clonal None None O
evolution None None O
and None None O
imatinib None None O
resistance None None O
. None None O

Acquired None None O
molecular None None O
abnormalities None None O
( None None O
mutations None None O
or None None O
chromosomal None None O
translocations None None O
) None None O
of None None O
the None None O
RUNX1 None None O
transcription None None O
factor None None O
gene None None O
are None None O
frequent None None O
in None None O
acute None None O
myeloblastic None None O
leukemias None None O
( None None O
AMLs None None O
) None None O
and None None O
in None None O
therapy None None O
- None None O
related None None O
myelodysplastic None None O
syndromes None None O
, None None O
but None None O
rarely None None O
in None None O
acute None None O
lymphoblastic None None O
leukemias None None O
( None None O
ALLs None None O
) None None O
and None None O
chronic None None O
myelogenous None None O
leukemias None None O
( None None O
CMLs None None O
) None None O
. None None O

Among None None O
18 None None O
BCR None None O
- None None O
ABL None None O
+ None None O
leukemias None None O
presenting None None O
acquired None None O
trisomy None None O
of None None O
chromosome None None O
21 None None O
, None None O
we None None O
report None None O
a None None O
high None None O
frequency None None O
( None None O
33 None None O
% None None O
) None None O
of None None O
recurrent None None O
point None None O
mutations None None O
( None None O
4 None None O
in None None O
myeloid None None O
blast None None O
crisis None None O
[ None None O
BC None None O
] None None O
CML None None O
and None None O
one None None O
in None None O
chronic None None O
phase None None O
CML None None O
) None None O
within None None O
the None None O
DNA None None O
- None None O
binding None None O
region None None O
of None None O
RUNX1 None None O
. None None O

We None None O
did None None O
not None None O
found None None O
any None None O
mutation None None O
in None None O
de None None O
novo None None O
BCR None None O
- None None O
ABL None None O
+ None None O
ALLs None None O
or None None O
lymphoid None None O
BC None None O
CML None None O
. None None O

Emergence None None O
of None None O
the None None O
RUNX1 None None O
mutations None None O
was None None O
detected None None O
at None None O
diagnosis None None O
or None None O
before None None O
the None None O
acquisition None None O
of None None O
trisomy None None O
21 None None O
during None None O
disease None None O
progression None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
also None None O
report None None O
a None None O
high None None O
frequency None None O
of None None O
cryptic None None O
chromosomal None None O
RUNX1 None None O
translocation None None O
to None None O
a None None O
novel None None O
recently None None O
described None None O
gene None None O
partner None None O
, None None O
PRDM16 None None O
on None None O
chromosome None None O
1p36 None None O
, None None O
for None None O
3 None None O
( None None O
21 None None O
. None None O
4 None None O
% None None O
) None None O
of None None O
14 None None O
investigated None None O
patients None None O
: None None O
2 None None O
myeloid None None O
BC None None O
CMLs None None O
and None None O
, None None O
for None None O
the None None O
first None None O
time None None O
, None None O
1 None None O
therapy None None O
- None None O
related None None O
BCR None None O
- None None O
ABL None None O
+ None None O
ALL None None O
. None None O

Two None None O
patients None None O
presented None None O
both None None O
RUNX1 None None O
mutations None None O
and None None O
RUNX1 None None O
- None None O
PRDM16 None None O
fusion None None O
. None None O

These None None O
events None None O
are None None O
associated None None O
with None None O
a None None O
short None None O
survival None None O
and None None O
support None None O
the None None O
concept None None O
of None None O
a None None O
cooperative None None O
effect None None O
of None None O
BCR None None O
- None None O
ABL None None O
with None None O
molecular None None O
RUNX1 None None O
abnormalities None None O
on None None O
the None None O
differentiation None None O
arrest None None O
phenotype None None O
observed None None O
during None None O
progression None None O
of None None O
CML None None O
and None None O
in None None O
BCR None None O
- None None O
ABL None None O
+ None None O
ALL None None O
. None None O

Telomere None None O
/ None None O
telomerase None None O
interplay None None O
in None None O
virus None None O
- None None O
driven None None O
and None None O
virus None None O
- None None O
independent None None O
lymphomagenesis None None O
: None None O
pathogenic None None O
and None None O
clinical None None O
implications None None O
. None None O

Telomerase None None O
is None None O
a None None O
ribonucleoprotein None None O
complex None None O
critically None None O
involved None None O
in None None O
extending None None O
and None None O
maintaining None None O
telomeres None None O
. None None O

Unlike None None O
the None None O
majority None None O
of None None O
somatic None None O
cells None None O
, None None O
in None None O
which None None O
hTERT None None O
and None None O
telomerase None None O
activity None None O
are None None O
generally None None O
silent None None O
, None None O
normal None None O
lymphocytes None None O
show None None O
transient None None O
physiological None None O
hTERT None None O
expression None None O
and None None O
telomerase None None O
activity None None O
according None None O
to None None O
their None None O
differentiation None None O
/ None None O
activation None None O
status None None O
. None None O

During None None O
lymphomagenesis None None O
, None None O
induction None None O
of None None O
persistent None None O
telomerase None None O
expression None None O
and None None O
activity None None O
may None None O
occur None None O
before None None O
or None None O
after None None O
telomere None None O
shortening None None O
, None None O
as None None O
a None None O
consequence None None O
of None None O
the None None O
different None None O
mechanisms None None O
through None None O
which None None O
transforming None None O
factors None None O
/ None None O
agents None None O
may None None O
activate None None O
telomerase None None O
. None None O

Available None None O
data None None O
indicate None None O
that None None O
the None None O
timing None None O
of None None O
telomerase None None O
activation None None O
may None None O
allow None None O
the None None O
distinction None None O
of None None O
two None None O
different None None O
lymphomagenetic None None O
models None None O
: None None O
( None None O
i None None O
) None None O
an None None O
early None None O
activation None None O
of None None O
telomerase None None O
via None None O
exogenous None None O
regulators None None O
of None None O
hTERT None None O
, None None O
along None None O
with None None O
an None None O
increased None None O
lymphocyte None None O
growth None None O
and None None O
a None None O
subsequent None None O
selection None None O
of None None O
cells None None O
with None None O
increased None None O
transforming None None O
potential None None O
may None None O
characterize None None O
several None None O
virus None None O
- None None O
related None None O
lymphoid None None O
malignancies None None O
; None None O
( None None O
ii None None O
) None None O
a None None O
progressive None None O
shortening None None O
of None None O
telomeres None None O
, None None O
leading None None O
to None None O
genetic None None O
instability None None O
which None None O
favors None None O
a None None O
subsequent None None O
activation None None O
of None None O
telomerase None None O
via None None O
endogenous None None O
regulators None None O
may None None O
occur None None O
in None None O
most None None O
virus None None O
- None None O
unrelated None None O
lymphoid None None O
tumors None None O
. None None O

These None None O
models None None O
may None None O
have None None O
clinically None None O
relevant None None O
implications None None O
, None None O
particularly None None O
for None None O
the None None O
tailoring None None O
of None None O
therapeutic None None O
strategies None None O
targeting None None O
telomerase None None O
. None None O

The None None O
growth None None O
in None None O
the None None O
number None None O
of None None O
database None None O
publications None None O
per None None O
year None None O
. None None O

Each None None O
bar None None O
shows None None O
the None None O
number None None O
of None None O
research None None O
articles None None O
with None None O
the None None O
keyword None None O
' None None O
database None None O
' None None O
appearing None None O
in None None O
the None None O
article None None O
title None None O
in None None O
the None None O
given None None O
year None None O
. None None O

The None None O
count None None O
only None None O
covers None None O
articles None None O
indexed None None O
in None None O
PubMed None None O
. None None O

The None None O
increase None None O
shows None None O
an None None O
exponential None None O
trend None None O
that None None O
will None None O
produce None None O
nearly None None O
2000 None None O
database None None O
publications None None O
per None None O
year None None O
by None None O
2015 None None O
. None None O

[ None None O
TESE None None O
and None None O
mTESE None None O
. None None O
Therapeutic None None O
options None None O
in None None O
male None None O
infertility None None O
due None None O
to None None O
testicular None None O
azoospermia None None O
] None None O
. None None O

Modern None None O
techniques None None O
of None None O
testicular None None O
sperm None None O
extraction None None O
( None None O
TESE None None O
) None None O
make None None O
it None None O
possible None None O
for None None O
an None None O
infertile None None O
man None None O
to None None O
father None None O
a None None O
child None None O
. None None O

The None None O
operations None None O
are None None O
standardized None None O
to None None O
a None None O
large None None O
extent None None O
and None None O
the None None O
underlying None None O
morphological None None O
alterations None None O
of None None O
spermatogenesis None None O
also None None O
appear None None O
to None None O
be None None O
sufficiently None None O
known None None O
. None None O

Current None None O
research None None O
is None None O
focused None None O
on None None O
prognostic None None O
factors None None O
for None None O
the None None O
testicular None None O
material None None O
that None None O
determine None None O
the None None O
sperm None None O
retrieval None None O
rate None None O
and None None O
success None None O
rates None None O
after None None O
in None None O
vitro None None O
fertilization None None O
/ None None O
intracytoplasmic None None O
sperm None None O
injection None None O
( None None O
IVF None None O
- None None O
ICSI None None O
) None None O
. None None O
TESE None None O
and None None O
microTESE None None O
are None None O
accepted None None O
standard None None O
operations None None O
for None None O
testicular None None O
sperm None None O
retrieval None None O
for None None O
IVF None None O
/ None None O
ICSI None None O
. None None O

Predictions None None O
for None None O
effective None None O
sperm None None O
recovery None None O
are None None O
addressed None None O
. None None O

Patients None None O
and None None O
Study None None O
Design None None O

A None None O
prospective None None O
evaluation None None O
of None None O
the None None O
different None None O
CMR None None O
parameters None None O
for None None O
predicting None None O
LV None None O
segmental None None O
and None None O
global None None O
functional None None O
recovery None None O
was None None O
performed None None O
in None None O
46 None None O
patients None None O
( None None O
63 None None O
+ None None O
/ None None O
- None None O
10 None None O
years None None O
old None None O
, None None O
3 None None O
with None None O
previous None None O
CABG None None O
, None None O
35 None None O
with None None O
three None None O
- None None O
vessel None None O
disease None None O
, None None O
3 None None O
with None None O
one None None O
- None None O
vessel None None O
disease None None O
) None None O
with None None O
LV None None O
systolic None None O
dysfunction None None O
( None None O
LVEF None None O
35 None None O
+ None None O
/ None None O
- None None O
8 None None O
% None None O
) None None O
before None None O
they None None O
underwent None None O
surgical None None O
( None None O
n None None O
= None None O
34 None None O
) None None O
or None None O
percutaneous None None O
( None None O
n None None O
= None None O
12 None None O
) None None O
revascularisation None None O
. None None O

Sixty None None O
patients None None O
without None None O
contraindications None None O
for None None O
CMR None None O
were None None O
screened None None O
for None None O
the None None O
following None None O
inclusion None None O
criteria None None O
: None None O
( None None O
1 None None O
) None None O
CAD None None O
( None None O
> None None O
70 None None O
% None None O
stenosis None None O
in None None O
one None None O
or None None O
more None None O
major None None O
epicardial None None O
vessels None None O
) None None O
, None None O
scheduled None None O
for None None O
a None None O
revascularisation None None O
procedure None None O
; None None O
( None None O
2 None None O
) None None O
LVEF None None O
< None None O
= None None O
45 None None O
% None None O
; None None O
( None None O
3 None None O
) None None O
at None None O
least None None O
two None None O
adjacent None None O
segments None None O
with None None O
wall None None O
motion None None O
abnormalities None None O
at None None O
rest None None O
; None None O
and None None O
( None None O
4 None None O
) None None O
no None None O
infarction None None O
or None None O
revascularisation None None O
within None None O
the None None O
last None None O
two None None O
months None None O
. None None O

Patients None None O
were None None O
included None None O
in None None O
the None None O
study None None O
only None None O
after None None O
a None None O
successful None None O
and None None O
complete None None O
coronary None None O
revascularisation None None O
. None None O

Of None None O
the None None O
14 None None O
patients None None O
who None None O
did None None O
not None None O
complete None None O
the None None O
study None None O
, None None O
3 None None O
decided None None O
not None None O
to None None O
undergo None None O
the None None O
repeated None None O
CMR None None O
scan None None O
or None None O
were None None O
lost None None O
during None None O
follow None None O
- None None O
up None None O
; None None O
7 None None O
had None None O
significant None None O
periprocedural None None O
injury None None O
( None None O
new None None O
LGE None None O
zones None None O
on None None O
repeated None None O
CMR None None O
scans None None O
and None None O
clinically None None O
proven None None O
periprocedural None None O
myocardial None None O
infarction None None O
( None None O
MI None None O
) None None O
or None None O
MI None None O
between None None O
both None None O
scans None None O
) None None O
; None None O
3 None None O
had None None O
pacemakers None None O
or None None O
defibrillators None None O
implanted None None O
in None None O
the None None O
period None None O
between None None O
the None None O
MR None None O
scans None None O
; None None O
and None None O
1 None None O
was None None O
excluded None None O
because None None O
of None None O
dilated None None O
cardiomyopathy None None O
with None None O
secondary None None O
CAD None None O
. None None O

None None None O
of None None O
the None None O
patients None None O
were None None O
excluded None None O
from None None O
the None None O
study None None O
for None None O
technical None None O
reasons None None O
or None None O
image None None O
quality None None O
. None None O

The None None O
mean None None O
interval None None O
between None None O
CMR None None O
and None None O
revascularisation None None O
was None None O
12 None None O
+ None None O
/ None None O
- None None O
13 None None O
days None None O
, None None O
and None None O
none None None O
of None None O
the None None O
patients None None O
presented None None O
clinical None None O
evidence None None O
of None None O
infarction None None O
during None None O
this None None O
period None None O
. None None O

The None None O
mean None None O
interval None None O
between None None O
MI None None O
and None None O
the None None O
first None None O
CMR None None O
was None None O
3 None None O
. None None O
6 None None O
years None None O
. None None O

In None None O
46 None None O
patients None None O
, None None O
the None None O
extent None None O
of None None O
regional None None O
contractility None None O
and None None O
LGE None None O
were None None O
determined None None O
repeatedly None None O
by None None O
CMR None None O
28 None None O
+ None None O
/ None None O
- None None O
4 None None O
weeks None None O
( None None O
6 None None O
months None None O
) None None O
after None None O
revascularisation None None O
. None None O

The None None O
study None None O
was None None O
approved None None O
by None None O
the None None O
Lithuanian None None O
Bioethics None None O
Committee None None O
( None None O
Nr None None O
. None None O
17 None None O
) None None O
, None None O
and None None O
informed None None O
written None None O
consent None None O
was None None O
obtained None None O
from None None O
each None None O
patient None None O
prior None None O
to None None O
inclusion None None O
in None None O
the None None O
study None None O
. None None O

Clinical None None O
significance None None O
of None None O
chicken None None O
ovalbumin None None O
upstream None None O
promoter None None O
- None None O
transcription None None O
factor None None O
II None None O
expression None None O
in None None O
human None None O
colorectal None None O
cancer None None O
. None None O

Chicken None None O
ovalbumin None None O
upstream None None O
promoter None None O
- None None O
transcription None None O
factor None None O
II None None O
( None None O
COUP None None O
- None None O
TFII None None O
) None None O
plays None None O
an None None O
essential None None O
role None None O
in None None O
angiogenesis None None O
and None None O
development None None O
. None None O

A None None O
previous None None O
study None None O
showed None None O
that None None O
the None None O
expression None None O
of None None O
COUP None None O
- None None O
TFII None None O
enhanced None None O
invasiveness None None O
of None None O
human None None O
lung None None O
carcinoma None None O
cells None None O
. None None O

However None None O
, None None O
no None None O
published None None O
data None None O
are None None O
available None None O
concerning None None O
the None None O
biological None None O
and None None O
clinical None None O
significance None None O
of None None O
COUP None None O
- None None O
TFII None None O
expression None None O
in None None O
colorectal None None O
cancer None None O
. None None O

Thus None None O
, None None O
our None None O
objective None None O
was None None O
to None None O
explore None None O
the None None O
expression None None O
of None None O
COUP None None O
- None None O
TFII None None O
in None None O
colorectal None None O
cancer None None O
as None None O
well None None O
as None None O
its None None O
association None None O
with None None O
clinicopathological None None O
features None None O
, None None O
and None None O
to None None O
evaluate None None O
the None None O
role None None O
of None None O
COUP None None O
- None None O
TFII None None O
as None None O
a None None O
prognostic None None O
indicator None None O
in None None O
colorectal None None O
cancer None None O
. None None O

We None None O
investigated None None O
the None None O
presence None None O
of None None O
COUP None None O
- None None O
TFII None None O
in None None O
human None None O
colorectal None None O
cancer None None O
tissues None None O
and None None O
adjacent None None O
normal None None O
tissues None None O
from None None O
95 None None O
primary None None O
colorectal None None O
cancer None None O
patients None None O
by None None O
immunohistochemistry None None O
. None None O

The None None O
correlation None None O
between None None O
the None None O
expression None None O
of None None O
COUP None None O
- None None O
TFII None None O
and None None O
clinicopathologic None None O
features None None O
was None None O
investigated None None O
. None None O

The None None O
3 None None O
- None None O
year None None O
disease None None O
- None None O
free None None O
survival None None O
( None None O
DFS None None O
) None None O
and None None O
overall None None O
survival None None O
( None None O
OS None None O
) None None O
of None None O
patients None None O
with None None O
tumors None None O
expressing None None O
different None None O
levels None None O
of None None O
COUP None None O
- None None O
TFII None None O
were None None O
evaluated None None O
by None None O
the None None O
Kaplan None None O
- None None O
Meier None None O
method None None O
. None None O

No None None O
significant None None O
correlation None None O
was None None O
found None None O
between None None O
COUP None None O
- None None O
TFII None None O
expression None None O
and None None O
age None None O
at None None O
surgery None None O
, None None O
gender None None O
, None None O
histopathologic None None O
differentiation None None O
, None None O
vessel None None O
invasion None None O
, None None O
carcinoembryonic None None O
antigen None None O
( None None O
CEA None None O
) None None O
, None None O
or None None O
nodal None None O
involvement None None O
. None None O

However None None O
, None None O
survival None None O
analysis None None O
showed None None O
that None None O
the None None O
COUP None None O
- None None O
TFII None None O
- None None O
positive None None O
group None None O
had None None O
a None None O
significantly None None O
better None None O
OS None None O
compared None None O
to None None O
COUP None None O
- None None O
TFII None None O
- None None O
negative None None O
group None None O
( None None O
80 None None O
. None None O
4 None None O
% None None O
vs None None O
. None None O
57 None None O
. None None O
7 None None O
% None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
0491 None None O
) None None O
. None None O

Based None None O
on None None O
our None None O
results None None O
, None None O
COUP None None O
- None None O
TFII None None O
may None None O
represent None None O
a None None O
biomarker None None O
for None None O
good None None O
prognosis None None O
in None None O
colorectal None None O
cancer None None O
. None None O

Applying None None O
A1C None None O
cut None None O
offs None None O
to None None O
the None None O
AusDiab None None O
population None None O
( None None O
4 None None O
. None None O
6 None None O
% None None O
undiagnosed None None O
diabetes None None O
) None None O

Applying None None O
the None None O
same None None O
cut None None O
offs None None O
, None None O
a None None O
total None None O
75 None None O
. None None O
9 None None O
% None None O
of None None O
the None None O
AusDiab None None O
population None None O
had None None O
diabetes None None O
ruled None None O
in None None O
or None None O
ruled None None O
out None None O
( None None O
Fig None None O
. None None O
1B None None O
) None None O
, None None O
while None None O
the None None O
remaining None None O
24 None None O
. None None O
1 None None O
% None None O
had None None O
impaired None None O
A1C None None O
. None None O

From None None O
those None None O
with None None O
impaired None None O
A1C None None O
, None None O
69 None None O
. None None O
3 None None O
% None None O
had None None O
abnormal None None O
glucose None None O
status None None O
. None None O

For None None O
diabetes None None O
, None None O
A1C None None O
at None None O
5 None None O
. None None O
5 None None O
% None None O
provided None None O
moderate None None O
sensitivity None None O
( None None O
83 None None O
. None None O
5 None None O
% None None O
) None None O
but None None O
high None None O
NPV None None O
( None None O
99 None None O
. None None O
0 None None O
% None None O
) None None O
, None None O
since None None O
diabetes None None O
prevalence None None O
was None None O
lower None None O
in None None O
the None None O
AusDiab None None O
than None None O
in None None O
the None None O
MP None None O
population None None O
. None None O

A1C None None O
at None None O
7 None None O
. None None O
0 None None O
% None None O
gave None None O
100 None None O
% None None O
specificity None None O
and None None O
100 None None O
% None None O
PPV None None O
. None None O

By None None O
dropping None None O
the None None O
cut None None O
off None None O
to None None O
6 None None O
. None None O
5 None None O
% None None O
, None None O
specificity None None O
remained None None O
99 None None O
. None None O
9 None None O
% None None O
, None None O
with None None O
PPV None None O
near None None O
100 None None O
% None None O
. None None O

Decontamination None None O
of None None O
medical None None O
equipment None None O
- None None O
- None None O
manufacturer None None O
' None None O
s None None O
problems None None O
. None None O

1 None None O
. None None O

Small None None O
items None None O
sent None None O
via None None O
the None None O
post None None O
present None None O
a None None O
much None None O
greater None None O
hidden None None O
hazard None None O
and None None O
a None None O
higher None None O
potential None None O
for None None O
catching None None O
people None None O
unawares None None O
. None None O

2 None None O
. None None O

Large None None O
items None None O
accompanied None None O
by None None O
a None None O
Decontamination None None O
Certificate None None O
need None None O
to None None O
be None None O
treated None None O
with None None O
caution None None O
because None None O
only None None O
those None None O
surfaces None None O
which None None O
are None None O
accessible None None O
will None None O
have None None O
been None None O
cleaned None None O
; None None O
as None None O
soon None None O
as None None O
engineers None None O
start None None O
dismantling None None O
equipment None None O
, None None O
areas None None O
which None None O
are None None O
still None None O
soiled None None O
become None None O
exposed None None O
. None None O

3 None None O
. None None O

Total None None O
co None None O
- None None O
operation None None O
between None None O
hospital None None O
staff None None O
and None None O
service None None O
engineers None None O
is None None O
necessary None None O
to None None O
resolve None None O
these None None O
problems None None O
- None None O
neither None None O
can None None O
work None None O
safely None None O
without None None O
the None None O
assistance None None O
of None None O
the None None O
other None None O
. None None O

4 None None O
. None None O

Many None None O
products None None O
in None None O
use None None O
in None None O
hospitals None None O
may None None O
be None None O
up None None O
to None None O
20 None None O
years None None O
old None None O
and None None O
clearly None None O
were None None O
not None None O
designed None None O
to None None O
facilitate None None O
decontamination None None O
and None None O
therefore None None O
present None None O
far None None O
greater None None O
risk None None O
to None None O
all None None O
concerned None None O
. None None O

5 None None O
. None None O

For None None O
the None None O
future None None O
there None None O
a None None O
clearly None None O
a None None O
responsibility None None O
with None None O
manufacturers None None O
to None None O
give None None O
more None None O
thought None None O
to None None O
the None None O
design None None O
of None None O
their None None O
equipment None None O
so None None O
that None None O
decontamination None None O
can None None O
be None None O
achieved None None O
more None None O
effectively None None O
. None None O

[ None None O
Rubella None None O
in None None O
Poland None None O
in None None O
2009 None None O
] None None O
. None None O

In None None O
Poland None None O
, None None O
7 None None O
, None None O
587 None None O
cases None None O
of None None O
rubella None None O
were None None O
registered None None O
in None None O
2009 None None O
( None None O
incidence None None O
19 None None O
. None None O
9 None None O
per None None O
100 None None O
, None None O
000 None None O
population None None O
) None None O
. None None O

According None None O
to None None O
a None None O
new None None O
rubella None None O
case None None O
definition None None O
, None None O
introduced None None O
in None None O
2009 None None O
, None None O
7 None None O
( None None O
0 None None O
. None None O
1 None None O
% None None O
) None None O
cases None None O
were None None O
classified None None O
as None None O
confirmed None None O
cases None None O
, None None O
30 None None O
( None None O
0 None None O
. None None O
4 None None O
% None None O
) None None O
as None None O
probable None None O
. None None O

One None None O
case None None O
of None None O
congenital None None O
rubella None None O
syndrome None None O
was None None O
reported None None O
. None None O

The None None O
incidence None None O
in None None O
men None None O
( None None O
26 None None O
. None None O
6 None None O
) None None O
was None None O
1 None None O
. None None O
9 None None O
- None None O
times None None O
higher None None O
than None None O
in None None O
women None None O
( None None O
13 None None O
. None None O
6 None None O
) None None O
. None None O

The None None O
highest None None O
incidence None None O
was None None O
observed None None O
in None None O
children None None O
aged None None O
7 None None O
and None None O
8 None None O
years None None O
( None None O
180 None None O
. None None O
3 None None O
and None None O
175 None None O
. None None O
6 None None O
, None None O
respectively None None O
) None None O
. None None O

No None None O
rubella None None O
deaths None None O
were None None O
registered None None O
. None None O

An None None O
improvement None None O
of None None O
laboratory None None O
diagnosis None None O
of None None O
reported None None O
cases None None O
is None None O
necessary None None O
to None None O
assess None None O
the None None O
impact None None O
of None None O
2 None None O
- None None O
dose None None O
immunization None None O
implemented None None O
in None None O
2003 None None O
on None None O
rubella None None O
epidemiology None None O
in None None O
Poland None None O
. None None O

Effect None None O
of None None O
thalidomide None None O
affecting None None O
VEGF None None O
secretion None None O
, None None O
cell None None O
migration None None O
, None None O
adhesion None None O
and None None O
capillary None None O
tube None None O
formation None None O
of None None O
human None None O
endothelial None None O
EA None None I-Cell-line-name
. None None I-Cell-line-name
hy None None I-Cell-line-name
926 None None I-Cell-line-name
cells None None O
. None None O

Angiogenesis None None O
, None None O
new None None O
blood None None O
vessel None None O
formation None None O
, None None O
is None None O
a None None O
multistep None None O
process None None O
, None None O
precisely None None O
regulated None None O
by None None O
pro None None O
- None None O
angiogenic None None O
cytokines None None O
, None None O
which None None O
stimulate None None O
endothelial None None O
cells None None O
to None None O
migrate None None O
, None None O
proliferate None None O
and None None O
differentiate None None O
to None None O
form None None O
new None None O
capillary None None O
microvessels None None O
. None None O

Excessive None None O
vascular None None O
development None None O
and None None O
blood None None O
vessel None None O
remodeling None None O
appears None None O
in None None O
psoriasis None None O
, None None O
rheumatoid None None O
arthritis None None O
, None None O
diabetic None None O
retinopathy None None O
and None None O
solid None None O
tumors None None O
formation None None O
. None None O

Thalidomide None None O
[ None None O
alpha None None O
- None None O
( None None O
N None None O
- None None O
phthalimido None None O
) None None O
- None None O
glutarimide None None O
] None None O
is None None O
known None None O
to None None O
be None None O
a None None O
potent None None O
inhibitor None None O
of None None O
angiogenesis None None O
, None None O
but None None O
the None None O
mechanism None None O
of None None O
its None None O
inhibitory None None O
action None None O
remains None None O
unclear None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
potential None None O
influence None None O
of None None O
thalidomide None None O
on None None O
the None None O
several None None O
steps None None O
of None None O
angiogenesis None None O
, None None O
using None None O
in None None O
vitro None None O
models None None O
. None None O

We None None O
have None None O
evaluated None None O
the None None O
effect None None O
of None None O
thalidomide None None O
on None None O
VEGF None None O
secretion None None O
, None None O
cell None None O
migration None None O
, None None O
adhesion None None O
as None None O
well None None O
as None None O
in None None O
capillary None None O
formation None None O
of None None O
human None None O
endothelial None None O
cell None None O
line None None O
EA None None I-Cell-line-name
. None None I-Cell-line-name
hy None None I-Cell-line-name
926 None None I-Cell-line-name
. None None O

Thalidomide None None O
at None None O
the None None O
concentrations None None O
of None None O
0 None None O
. None None O
01 None None O
microM None None O
and None None O
10 None None O
microM None None O
inhibited None None O
VEGF None None O
secretion None None O
into None None O
supernatants None None O
, None None O
decreased None None O
the None None O
number None None O
of None None O
formed None None O
capillary None None O
tubes None None O
and None None O
increased None None O
cell None None O
adhesion None None O
to None None O
collagen None None O
. None None O

Administration None None O
of None None O
thalidomide None None O
at None None O
the None None O
concentration None None O
of None None O
0 None None O
. None None O
01 None None O
microM None None O
increased None None O
cell None None O
migration None None O
, None None O
while None None O
at None None O
10 None None O
microM None None O
, None None O
it None None O
decreased None None O
cell None None O
migration None None O
. None None O

Thalidomide None None O
in None None O
concentrations None None O
from None None O
0 None None O
. None None O
1 None None O
microM None None O
to None None O
10 None None O
microM None None O
did None None O
not None None O
change None None O
cell None None O
proliferation None None O
of None None O
72 None None O
- None None O
h None None O
cell None None O
cultures None None O
. None None O

We None None O
conclude None None O
that None None O
anti None None O
- None None O
angiogenic None None O
action None None O
of None None O
thalidomide None None O
is None None O
due None None O
to None None O
direct None None O
inhibitory None None O
action None None O
on None None O
VEGF None None O
secretion None None O
and None None O
capillary None None O
microvessel None None O
formation None None O
as None None O
well None None O
as None None O
immunomodulatory None None O
influence None None O
on None None O
EA None None O
. None None O
hy None None O
926 None None O
cells None None O
migration None None O
and None None O
adhesion None None O
. None None O

Transformation None None O
- None None O
associated None None O
cytokine None None O
9E3 None None O
/ None None O
CEF4 None None O
is None None O
chemotactic None None O
for None None O
chicken None None O
peripheral None None O
blood None None O
mononuclear None None O
cells None None O
. None None O

9E3 None None O
/ None None O
CEF4 None None O
, None None O
which None None O
is None None O
released None None O
from None None O
transformed None None O
chicken None None O
embryo None None O
fibroblasts None None O
( None None O
CEF None None O
) None None O
, None None O
is None None O
a None None O
member None None O
of None None O
the None None O
platelet None None O
factor None None O
4 None None O
family None None O
of None None O
inflammatory None None O
proteins None None O
and None None O
may None None O
be None None O
the None None O
avian None None O
homolog None None O
of None None O
interleukin None None O
- None None O
8 None None O
. None None O

Since None None O
the None None O
function None None O
of None None O
9E3 None None O
/ None None O
CEF4 None None O
is None None O
unknown None None O
, None None O
we None None O
examined None None O
the None None O
effect None None O
of None None O
the None None O
protein None None O
on None None O
mitogenicity None None O
and None None O
chemotaxis None None O
, None None O
as None None O
well None None O
as None None O
its None None O
expression None None O
, None None O
in None None O
fibroblasts None None O
and None None O
peripheral None None O
blood None None O
cells None None O
. None None O

9E3 None None O
/ None None O
CEF4 None None O
mRNA None None O
was None None O
expressed None None O
in None None O
chicken None None O
peripheral None None O
blood None None O
monocytes None None O
, None None O
and None None O
its None None O
expression None None O
was None None O
stimulated None None O
by None None O
incubation None None O
of None None O
the None None O
monocytes None None O
with None None O
lipopolysaccharide None None O
or None None O
phorbol None None O
myristic None None O
acetate None None O
. None None O

Boyden None None O
double None None O
- None None O
membrane None None O
analysis None None O
of None None O
chemotaxis None None O
showed None None O
that None None O
9E3 None None O
/ None None O
CEF4 None None O
was None None O
chemotactic None None O
for None None O
chicken None None O
peripheral None None O
blood None None O
mononuclear None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
for None None O
heterophils None None O
. None None O

Untransformed None None O
CEF None None O
and None None O
CEF None None O
transformed None None O
with None None O
Rous None None O
sarcoma None None O
virus None None O
also None None O
migrated None None O
to None None O
9E3 None None O
/ None None O
CEF4 None None O
protein None None O
, None None O
as None None O
measured None None O
by None None O
Boyden None None O
single None None O
- None None O
membrane None None O
analysis None None O
. None None O

9E3 None None O
/ None None O
CEF4 None None O
was None None O
slightly None None O
mitogenic None None O
for None None O
CEF None None O
, None None O
causing None None O
a None None O
doubling None None O
of None None O
[ None None O
3H None None O
] None None O
thymidine None None O
uptake None None O
when None None O
added None None O
to None None O
serum None None O
- None None O
starved None None O
CEF None None O
. None None O
9E3 None None O
/ None None O
CEF4 None None O
was None None O
found None None O
associated None None O
not None None O
only None None O
with None None O
the None None O
cell None None O
and None None O
in None None O
the None None O
culture None None O
medium None None O
of None None O
Rous None None O
sarcoma None None O
virus None None O
- None None O
transformed None None O
CEF None None O
but None None O
also None None O
with None None O
the None None O
extracellular None None O
matrix None None O
. None None O

The None None O
in None None O
vivo None None O
role None None O
of None None O
9E3 None None O
/ None None O
CEF4 None None O
may None None O
be None None O
involved None None O
with None None O
chemotaxis None None O
and None None O
metastasis None None O
, None None O
rather None None O
than None None O
with None None O
direct None None O
stimulation None None O
of None None O
mitogenicity None None O
. None None O

A None None O
novel None None O
integrin None None O
alpha5beta1 None None O
antagonistic None None O
peptide None None O
, None None O
A5 None None O
- None None O
1 None None O
, None None O
screened None None O
by None None O
Protein None None O
Chip None None O
system None None O
as None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
. None None O

Integrin None None O
alpha5beta1 None None O
immobilized None None O
on None None O
a None None O
ProteoChip None None O
was None None O
used None None O
to None None O
screen None None O
new None None O
antagonistic None None O
peptides None None O
from None None O
multiple None None O
hexapeptide None None O
sub None None O
- None None O
libraries None None O
of None None O
the None None O
positional None None O
scanning None None O
synthetic None None O
peptide None None O
combinatorial None None O
library None None O
( None None O
PS None None O
- None None O
SPCL None None O
) None None O
. None None O

The None None O
integrin None None O
alpha5beta1 None None O
- None None O
Fibronectin None None O
interaction None None O
was None None O
demonstrated None None O
on None None O
the None None O
chip None None O
. None None O

A None None O
novel None None O
peptide None None O
ligand None None O
, None None O
A5 None None O
- None None O
1 None None O
( None None O
VILVLF None None O
) None None O
, None None O
with None None O
high None None O
affinity None None O
to None None O
integrin None None O
alpha5beta1 None None O
was None None O
identified None None O
from None None O
the None None O
hexapeptide None None O
libraries None None O
with None None O
this None None O
chip None None O
- None None O
based None None O
screening None None O
method None None O
on None None O
the None None O
basis None None O
of None None O
a None None O
competitive None None O
inhibition None None O
assay None None O
. None None O

A5 None None O
- None None O
1 None None O
inhibits None None O
the None None O
integrin None None O
- None None O
fibronectin None None O
interaction None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
; None None O
1 None None O
. None None O
56 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
28 None None O
microM None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
inhibits None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
migration None None O
, None None O
adhesion None None O
, None None O
tubular None None O
network None None O
formation None None O
, None None O
and None None O
bFGF None None O
- None None O
induced None None O
neovascularization None None O
in None None O
a None None O
chick None None O
chorioallantoic None None O
membrane None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
A5 None None O
- None None O
1 None None O
will None None O
be None None O
a None None O
potent None None O
inhibitor None None O
of None None O
neovascularization None None O
. None None O

Demographic None None O
data None None O
of None None O
subjects None None O

Images None None O

Figure None None O
1 None None O

LMP1 None None O
of None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
induces None None O
proliferation None None O
of None None O
primary None None O
mouse None None O
embryonic None None O
fibroblasts None None O
and None None O
cooperatively None None O
transforms None None O
the None None O
cells None None O
with None None O
a None None O
p16 None None O
- None None O
insensitive None None O
CDK4 None None O
oncogene None None O
. None None O

The None None O
latent None None O
membrane None None O
protein None None O
LMP1 None None O
of None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
is None None O
often None None O
present None None O
in None None O
EBV None None O
- None None O
associated None None O
malignancies None None O
including None None O
nasopharyngeal None None O
carcinoma None None O
and None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
. None None O

Previous None None O
work None None O
demonstrates None None O
that None None O
the None None O
LMP1 None None O
gene None None O
of None None O
EBV None None O
is None None O
sufficient None None O
to None None O
transform None None O
certain None None O
established None None O
rodent None None O
fibroblast None None O
cell None None O
lines None None O
and None None O
to None None O
induce None None O
the None None O
tumorigenicity None None O
of None None O
some None None O
human None None O
epithelial None None O
cell None None O
lines None None O
. None None O

In None None O
addition None None O
, None None O
LMP1 None None O
plays None None O
pleiotropic None None O
roles None None O
in None None O
cell None None O
growth None None O
arrest None None O
, None None O
differentiation None None O
, None None O
and None None O
apoptosis None None O
, None None O
depending None None O
on None None O
the None None O
background None None O
of None None O
the None None O
target None None O
cells None None O
. None None O

To None None O
examine None None O
the None None O
roles None None O
of None None O
LMP1 None None O
in None None O
cell None None O
proliferation None None O
and None None O
growth None None O
regulation None None O
in None None O
primary None None O
culture None None O
cells None None O
, None None O
we None None O
constructed None None O
a None None O
recombinant None None O
retrovirus None None O
containing None None O
an None None O
LMP1 None None O
gene None None O
. None None O

With None None O
this None None O
retrovirus None None O
, None None O
LMP1 None None O
was None None O
shown None None O
to None None O
stimulate None None O
the None None O
proliferation None None O
of None None O
primary None None O
mouse None None O
embryonic None None O
fibroblasts None None O
( None None O
MEF None None O
cells None None O
) None None O
. None None O

It None None O
has None None O
a None None O
mitogenic None None O
activity None None O
for None None O
MEF None None O
cells None None O
, None None O
as None None O
demonstrated None None O
by None None O
an None None O
immediate None None O
induction None None O
of None None O
cell None None O
doubling None None O
time None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
significantly None None O
extends None None O
the None None O
passage None None O
number None None O
of None None O
MEF None None O
cells None None O
to None None O
more None None O
than None None O
30 None None O
after None None O
retroviral None None O
infection None None O
, None None O
compared None None O
with None None O
less None None O
than None None O
5 None None O
for None None O
uninfected None None O
MEF None None O
cells None None O
. None None O

Furthermore None None O
, None None O
LMP1 None None O
cooperates None None O
with None None O
a None None O
p16 None None O
- None None O
insensitive None None O
CDK4 None None O
( None None O
R24C None None O
) None None O
oncogene None None O
in None None O
transforming None None O
MEF None None O
cells None None O
. None None O

Our None None O
results None None O
provide None None O
the None None O
first None None O
evidence None None O
of None None O
the None None O
abilities None None O
of None None O
the None None O
LMP1 None None O
gene None None O
, None None O
acting None None O
alone None None O
, None None O
to None None O
effectively None None O
induce None None O
the None None O
proliferation None None O
of None None O
primary None None O
MEF None None O
cells None None O
and None None O
of None None O
its None None O
cooperativity None None O
with None None O
another None None O
cellular None None O
oncogene None None O
in None None O
transforming None None O
primary None None O
cells None None O
. None None O

Research None None O
and None None O
discovery None None O
of None None O
the None None O
first None None O
human None None O
cancer None None O
virus None None O
, None None O
HTLV None None O
- None None O
1 None None O
. None None O

Human None None O
T None None O
- None None O
cell None None O
lymphoma None None O
virus None None O
( None None O
HTLV None None O
) None None O
- None None O
1 None None O
was None None O
the None None O
first None None O
human None None O
retrovirus None None O
to None None O
be None None O
discovered None None O
. None None O

It None None O
has None None O
been None None O
recognized None None O
as None None O
the None None O
cause None None O
of None None O
adult None None O
T None None O
- None None O
cell None None O
leukemia None None O
( None None O
ATL None None O
) None None O
. None None O

In None None O
addition None None O
to None None O
giving None None O
a None None O
historical None None O
perspective None None O
on None None O
HTLV None None O
- None None O
1 None None O
and None None O
other None None O
retrovirus None None O
research None None O
, None None O
this None None O
paper None None O
discusses None None O
the None None O
origin None None O
of None None O
HTLV None None O
- None None O
1 None None O
; None None O
the None None O
modes None None O
of None None O
transmission None None O
and None None O
global None None O
epidemiology None None O
of None None O
HTLV None None O
- None None O
1 None None O
infection None None O
; None None O
the None None O
genome None None O
of None None O
HTLV None None O
- None None O
1 None None O
and None None O
the None None O
mechanism None None O
of None None O
HTLV None None O
- None None O
1 None None O
- None None O
induced None None O
leukemogenesis None None O
; None None O
the None None O
role None None O
of None None O
HTLV None None O
- None None O
1 None None O
in None None O
other None None O
diseases None None O
, None None O
and None None O
recent None None O
breakthroughs None None O
in None None O
ATL None None O
therapy None None O
. None None O

Possible None None O
role None None O
of None None O
cyclooxygenase None None O
II None None O
in None None O
the None None O
acquisition None None O
of None None O
ovarian None None O
luteal None None O
function None None O
in None None O
rodents None None O
. None None O

The None None O
development None None O
of None None O
the None None O
corpus None None O
luteum None None O
( None None O
CL None None O
) None None O
, None None O
which None None O
involves None None O
angiogenesis None None O
, None None O
is None None O
essential None None O
for None None O
the None None O
establishment None None O
of None None O
early None None O
pregnancy None None O
. None None O

We None None O
investigated None None O
the None None O
roles None None O
of None None O
the None None O
prostaglandin None None O
synthases None None O
cyclooxygenase None None O
( None None O
COX None None O
) None None O
I None None O
and None None O
COX None None O
- None None O
II None None O
in None None O
angiogenesis None None O
and None None O
progesterone None None O
production None None O
in None None O
the None None O
newly None None O
formed None None O
CL None None O
, None None O
using None None O
inhibitors None None O
of None None O
the None None O
COX None None O
enzymes None None O
and None None O
the None None O
gonadotropin None None O
- None None O
induced None None O
pseudopregnant None None O
rat None None O
as None None O
a None None O
model None None O
. None None O

Injection None None O
of None None O
indomethacin None None O
, None None O
a None None O
nonselective None None O
COX None None O
inhibitor None None O
, None None O
on None None O
the None None O
day None None O
of None None O
ovulation None None O
and None None O
the None None O
following None None O
day None None O
decreased None None O
serum None None O
levels None None O
of None None O
progesterone None None O
, None None O
as None None O
did None None O
injection None None O
of None None O
the None None O
selective None None O
COX None None O
- None None O
II None None O
inhibitor None None O
NS None None O
- None None O
398 None None O
. None None O

In None None O
contrast None None O
, None None O
a None None O
selective None None O
COX None None O
- None None O
I None None O
inhibitor None None O
, None None O
SC None None O
- None None O
560 None None O
, None None O
had None None O
no None None O
effect None None O
on None None O
serum None None O
progesterone None None O
concentrations None None O
. None None O

None None None O
of None None O
the None None O
inhibitors None None O
had None None O
any None None O
effect None None O
on None None O
the None None O
weight None None O
of None None O
the None None O
superovulated None None O
ovaries None None O
or None None O
on None None O
the None None O
synthesis None None O
of None None O
progesterone None None O
by None None O
cultured None None O
luteal None None O
cells None None O
. None None O

To None None O
determine None None O
whether None None O
changes None None O
in None None O
angiogenesis None None O
are None None O
responsible None None O
for None None O
the None None O
decrease None None O
in None None O
progesterone None None O
synthesis None None O
, None None O
we None None O
measured None None O
hemoglobin None None O
and None None O
CD34 None None O
levels None None O
in None None O
luteinized None None O
ovaries None None O
following None None O
injection None None O
of None None O
COX None None O
inhibitors None None O
and None None O
measured None None O
the None None O
relative None None O
frequency None None O
of None None O
cells None None O
positive None None O
for None None O
platelet None None O
- None None O
endothelial None None O
cell None None O
adhesion None None O
molecule None None O
as None None O
a None None O
specific None None O
marker None None O
for None None O
endothelial None None O
cells None None O
. None None O

All None None O
of None None O
these None None O
parameters None None O
were None None O
reduced None None O
by None None O
the None None O
COX None None O
- None None O
II None None O
inhibitors None None O
, None None O
suggesting None None O
that None None O
changes None None O
in None None O
the None None O
vasculature None None O
are None None O
responsible None None O
for None None O
the None None O
decrease None None O
in None None O
serum None None O
progesterone None None O
. None None O

Histological None None O
examination None None O
of None None O
ovarian None None O
corrosion None None O
casts None None O
indicated None None O
that None None O
NS None None O
- None None O
398 None None O
inhibited None None O
the None None O
establishment None None O
of None None O
luteal None None O
capillary None None O
vessels None None O
following None None O
the None None O
injection None None O
of None None O
hCG None None O
. None None O

The None None O
results None None O
are None None O
consistent None None O
with None None O
the None None O
hypothesis None None O
that None None O
the None None O
activity None None O
of None None O
COX None None O
- None None O
II None None O
is None None O
associated None None O
with None None O
the None None O
formation None None O
of None None O
functional None None O
CL None None O
via None None O
its None None O
stimulation None None O
of None None O
angiogenesis None None O
. None None O

Targeting None None O
TNF None None O
for None None O
Treatment None None O
of None None O
Cancer None None O
and None None O
Autoimmunity None None O
. None None O

Tumor None None O
necrosis None None O
factor None None O
- None None O
alpha None None O
( None None O
TNF None None O
- None None O
alpha None None O
) None None O
was None None O
first None None O
isolated None None O
two None None O
decades None None O
ago None None O
as None None O
a None None O
macrophageproduced None None O
protein None None O
that None None O
can None None O
effectively None None O
kill None None O
tumor None None O
cells None None O
. None None O

TNF None None O
- None None O
alpha None None O
is None None O
also None None O
an None None O
essential None None O
component None None O
of None None O
the None None O
immune None None O
system None None O
and None None O
is None None O
required None None O
for None None O
hematopoiesis None None O
, None None O
for None None O
protection None None O
from None None O
bacterial None None O
infection None None O
and None None O
for None None O
immune None None O
cell None None O
- None None O
mediated None None O
cytotoxicity None None O
. None None O

Extensive None None O
research None None O
, None None O
however None None O
, None None O
has None None O
revealed None None O
that None None O
TNF None None O
- None None O
alpha None None O
is None None O
one None None O
of None None O
the None None O
major None None O
players None None O
in None None O
tumor None None O
initiation None None O
, None None O
proliferation None None O
, None None O
invasion None None O
, None None O
angiogenesis None None O
and None None O
metastasis None None O
. None None O

The None None O
proinflammatory None None O
activities None None O
link None None O
TNF None None O
- None None O
alpha None None O
with None None O
a None None O
wide None None O
variety None None O
of None None O
autoimmune None None O
diseases None None O
, None None O
including None None O
psoriasis None None O
, None None O
inflammatory None None O
bowel None None O
disease None None O
, None None O
rheumatoid None None O
arthritis None None O
, None None O
systemic None None O
sclerosis None None O
, None None O
systemic None None O
lupus None None O
erythematosus None None O
, None None O
multiple None None O
sclerosis None None O
, None None O
diabetes None None O
and None None O
ankylosing None None O
spondylitis None None O
. None None O

Systemic None None O
inhibitors None None O
of None None O
TNF None None O
such None None O
as None None O
etanercept None None O
( None None O
Enbrel None None O
) None None O
( None None O
a None None O
soluble None None O
TNF None None O
receptor None None O
) None None O
and None None O
infliximab None None O
( None None O
Remicade None None O
) None None O
and None None O
adalimumab None None O
( None None O
Humira None None O
) None None O
( None None O
anti None None O
- None None O
TNF None None O
antibodies None None O
) None None O
have None None O
been None None O
approved None None O
for None None O
the None None O
treatment None None O
inflammatory None None O
bowel None None O
disease None None O
, None None O
psoriasis None None O
and None None O
rheumatoid None None O
arthritis None None O
. None None O

These None None O
drugs None None O
, None None O
however None None O
, None None O
exhibit None None O
severe None None O
side None None O
effects None None O
and None None O
are None None O
expensive None None O
. None None O

Hence None None O
orally None None O
active None None O
blockers None None O
of None None O
TNF None None O
- None None O
alpha None None O
that None None O
are None None O
safe None None O
, None None O
efficacious None None O
and None None O
inexpensive None None O
are None None O
urgently None None O
needed None None O
. None None O

Numerous None None O
products None None O
from None None O
fruits None None O
, None None O
vegetable None None O
and None None O
traditional None None O
medicinal None None O
plants None None O
have None None O
been None None O
described None None O
which None None O
can None None O
suppress None None O
TNF None None O
expression None None O
and None None O
TNF None None O
signaling None None O
but None None O
their None None O
clinical None None O
potential None None O
is None None O
yet None None O
uncertain None None O
. None None O

Medical None None O
therapy None None O
for None None O
intermittent None None O
claudication None None O
. None None O

Medical None None O
therapy None None O
to None None O
improve None None O
symptoms None None O
, None None O
stabilise None None O
the None None O
underlying None None O
vascular None None O
disease None None O
and None None O
improve None None O
lower None None O
limb None None O
outcomes None None O
is None None O
an None None O
important None None O
and None None O
effective None None O
adjunct None None O
to None None O
lifestyle None None O
modification None None O
and None None O
surgical None None O
or None None O
endovascular None None O
interventions None None O
in None None O
patients None None O
with None None O
IC None None O
. None None O

Randomised None None O
placebo None None O
controlled None None O
trials None None O
have None None O
shown None None O
that None None O
the None None O
phosphodiesterase None None O
III None None O
inhibitor None None O
cilostazol None None O
100mg None None O
bid None None O
improves None None O
pain None None O
- None None O
free None None O
and None None O
maximum None None O
walking None None O
distance None None O
, None None O
as None None O
well None None O
as None None O
quality None None O
of None None O
life None None O
, None None O
in None None O
a None None O
range None None O
of None None O
patients None None O
with None None O
intermittent None None O
claudication None None O
in None None O
whom None None O
there None None O
is None None O
no None None O
evidence None None O
of None None O
tissue None None O
necrosis None None O
or None None O
rest None None O
pain None None O
. None None O

This None None O
review None None O
summarises None None O
the None None O
evidence None None O
from None None O
8 None None O
pivotal None None O
trials None None O
of None None O
cilostazol None None O
involving None None O
over None None O
2000 None None O
patients None None O
with None None O
intermittent None None O
claudication None None O
treated None None O
for None None O
up None None O
to None None O
6 None None O
months None None O
. None None O

There None None O
is None None O
comparatively None None O
less None None O
evidence None None O
to None None O
support None None O
the None None O
use None None O
of None None O
other None None O
treatment None None O
modalities None None O
for None None O
relief None None O
of None None O
symptoms None None O
in None None O
intermittent None None O
claudication None None O
, None None O
but None None O
there None None O
is None None O
considerable None None O
interest None None O
in None None O
therapeutic None None O
angiogenesis None None O
to None None O
promote None None O
new None None O
vessel None None O
formation None None O
and None None O
enhance None None O
collateralisation None None O
of None None O
the None None O
lower None None O
limb None None O
using None None O
recombinant None None O
growth None None O
factor None None O
proteins None None O
or None None O
gene None None O
transfer None None O
strategies None None O
. None None O

The None None O
rationale None None O
for None None O
therapeutic None None O
angiogenesis None None O
is None None O
discussed None None O
, None None O
together None None O
with None None O
the None None O
most None None O
recent None None O
results None None O
from None None O
randomised None None O
trials None None O
in None None O
patients None None O
with None None O
peripheral None None O
arterial None None O
disease None None O
. None None O

The None None O
importance None None O
in None None O
identifying None None O
genes None None O
involved None None O
in None None O
spinal None None O
curvature None None O

Spinal None None O
curvature None None O
is None None O
a None None O
prevalent None None O
and None None O
costly None None O
deformity None None O
among None None O
humans None None O
and None None O
teleosts None None O
. None None O

The None None O
estimated None None O
annual None None O
cost None None O
of None None O
treating None None O
children None None O
hospitalized None None O
with None None O
idiopathic None None O
scoliosis None None O
( None None O
IS None None O
) None None O
in None None O
the None None O
United None None O
States None None O
alone None None O
is None None O
over None None O
$ None None O
3 None None O
billion None None O
. None None O

This None None O
cost None None O
estimate None None O
does None None O
not None None O
consider None None O
Scheuermann None None O
kyphosis None None O
, None None O
or None None O
adults None None O
with None None O
idiopathic None None O
- None None O
type None None O
spinal None None O
curvature None None O
who None None O
suffer None None O
from None None O
chronic None None O
back None None O
pain None None O
, None None O
contributing None None O
to None None O
the None None O
estimated None None O
$ None None O
849 None None O
billion None None O
cost None None O
of None None O
treatment None None O
and None None O
lost None None O
wages None None O
associated None None O
with None None O
musculoskeletal None None O
disease None None O
[ None None O
24 None None O
] None None O
. None None O

Among None None O
teleosts None None O
, None None O
spinal None None O
column None None O
deformities None None O
reduce None None O
total None None O
production None None O
in None None O
the None None O
aquaculture None None O
industry None None O
substantially None None O
[ None None O
12 None None O
] None None O
. None None O

In None None O
contrast None None O
to None None O
humans None None O
, None None O
teleost None None O
curve None None O
phenotypes None None O
are None None O
less None None O
well None None O
characterized None None O
; None None O
although None None O
heritable None None O
curves None None O
are None None O
acknowledged None None O
to None None O
account None None O
for None None O
many None None O
cases None None O
among None None O
cultured None None O
stocks None None O
, None None O
whether None None O
these None None O
cases None None O
are None None O
from None None O
congenital None None O
defects None None O
or None None O
are None None O
idiopathic None None O
- None None O
type None None O
is None None O
often None None O
not None None O
known None None O
. None None O

Despite None None O
the None None O
prevalence None None O
and None None O
impact None None O
of None None O
this None None O
type None None O
of None None O
deformity None None O
, None None O
the None None O
genetic None None O
architecture None None O
and None None O
specific None None O
genes None None O
involved None None O
are None None O
unknown None None O
. None None O

The None None O
current None None O
view None None O
is None None O
that None None O
human None None O
idiopathic None None O
- None None O
type None None O
scoliosis None None O
is None None O
a None None O
complex None None O
genetic None None O
disorder None None O
with None None O
multiple None None O
genes None None O
segregating None None O
in None None O
the None None O
population None None O
exhibiting None None O
complex None None O
genotype None None O
by None None O
environment None None O
interactions None None O
[ None None O
25 None None O
- None None O
30 None None O
] None None O
. None None O

In None None O
aquaculture None None O
stocks None None O
, None None O
inheritance None None O
for None None O
spinal None None O
curvature None None O
has None None O
been None None O
described None None O
as None None O
Mendelian None None O
recessive None None O
or None None O
dominant None None O
, None None O
as None None O
well None None O
as None None O
polygenic None None O
, None None O
depending None None O
on None None O
how None None O
well None None O
the None None O
phenotype None None O
is None None O
characterized None None O
and None None O
what None None O
stock None None O
is None None O
considered None None O
( None None O
reviewed None None O
in None None O
[ None None O
13 None None O
] None None O
, None None O
[ None None O
16 None None O
] None None O
) None None O
. None None O

The None None O
guppy None None O
curveback None None O
phenotype None None O
has None None O
been None None O
extensively None None O
characterized None None O
so None None O
that None None O
the None None O
lineage None None O
can None None O
be None None O
applied None None O
as None None O
a None None O
model None None O
for None None O
understanding None None O
the None None O
biological None None O
context None None O
of None None O
heritable None None O
spinal None None O
curvature None None O
[ None None O
1 None None O
, None None O
7 None None O
- None None O
9 None None O
] None None O
. None None O

Future None None O
studies None None O
can None None O
use None None O
approaches None None O
to None None O
map None None O
QTL None None O
affecting None None O
shape None None O
based None None O
on None None O
digital None None O
photos None None O
[ None None O
31 None None O
, None None O
32 None None O
] None None O
, None None O
rather None None O
than None None O
the None None O
qualitative None None O
scale None None O
used None None O
in None None O
the None None O
present None None O
study None None O
. None None O

The None None O
identification None None O
of None None O
QTL None None O
in None None O
this None None O
study None None O
is None None O
a None None O
first None None O
step None None O
in None None O
understanding None None O
the None None O
genetics None None O
of None None O
this None None O
type None None O
of None None O
deformity None None O
and None None O
will None None O
lead None None O
to None None O
the None None O
identification None None O
of None None O
biological None None O
pathways None None O
associated None None O
with None None O
spinal None None O
integrity None None O
. None None O

The None None O
role None None O
of None None O
platelet None None O
- None None O
derived None None O
endothelial None None O
cell None None O
growth None None O
factor None None O
/ None None O
thymidine None None O
phosphorylase None None O
in None None O
tumor None None O
behavior None None O
. None None O

Platelet None None O
- None None O
derived None None O
endothelial None None O
cell None None O
growth None None O
- None None O
factor None None O
( None None O
PD None None O
- None None O
ECGF None None O
) None None O
is None None O
similar None None O
to None None O
the None None O
pyrimidine None None O
enzyme None None O
thymidine None None O
phosphorylase None None O
( None None O
TP None None O
) None None O
. None None O

A None None O
high None None O
TP None None O
expression None None O
at None None O
tumor None None O
sites None None O
is None None O
correlated None None O
with None None O
tumor None None O
growth None None O
, None None O
induction None None O
of None None O
angiogenesis None None O
, None None O
and None None O
metastasis None None O
. None None O

Therefore None None O
, None None O
high None None O
TP None None O
is None None O
most None None O
likely None None O
associated None None O
with None None O
a None None O
poor None None O
prognosis None None O
. None None O

TP None None O
is None None O
not None None O
only None None O
expressed None None O
in None None O
tumor None None O
cells None None O
but None None O
also None None O
in None None O
tumor None None O
surrounding None None O
tissues None None O
, None None O
such None None O
as None None O
tumor None None O
infiltrating None None O
macrophages None None O
. None None O

TP None None O
catalyzes None None O
the None None O
conversion None None O
of None None O
thymidine None None O
to None None O
thymine None None O
and None None O
doxyribose None None O
- None None O
1 None None O
- None None O
phosphate None None O
( None None O
dR None None O
- None None O
1 None None O
- None None O
P None None O
) None None O
. None None O

The None None O
latter None None O
in None None O
its None None O
parent None None O
form None None O
or None None O
in None None O
its None None O
sugar None None O
form None None O
, None None O
deoxyribose None None O
( None None O
dR None None O
) None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
induction None None O
of None None O
angiogenesis None None O
. None None O

It None None O
may None None O
modulate None None O
cellular None None O
energy None None O
metabolism None None O
or None None O
be None None O
a None None O
substrate None None O
in None None O
a None None O
chemical None None O
reaction None None O
generating None None O
reactive None None O
oxygen None None O
species None None O
. None None O

L None None O
- None None O
deoxyribose None None O
( None None O
L None None O
- None None O
dR None None O
) None None O
and None None O
thymidine None None O
phosphorylase None None O
inhibitor None None O
( None None O
TPI None None O
) None None O
can None None O
reverse None None O
these None None O
effects None None O
. None None O

The None None O
mechanism None None O
of None None O
TP None None O
induction None None O
is None None O
not None None O
yet None None O
completely None None O
clear None None O
, None None O
but None None O
TNF None None O
, None None O
IL10 None None O
and None None O
other None None O
cytokines None None O
have None None O
been None None O
clearly None None O
shown None None O
to None None O
induce None None O
its None None O
expression None None O
. None None O

The None None O
various None None O
complex None None O
interactions None None O
of None None O
TP None None O
give None None O
it None None O
an None None O
essential None None O
role None None O
in None None O
cellular None None O
functioning None None O
and None None O
, None None O
hence None None O
, None None O
it None None O
is None None O
an None None O
ideal None None O
target None None O
in None None O
cancer None None O
therapy None None O
. None None O

Aging None None O
affects None None O
the None None O
cardiovascular None None O
responses None None O
to None None O
cold None None O
stress None None O
in None None O
humans None None O
. None None O

Cardiovascular None None O
- None None O
related None None O
mortality None None O
peaks None None O
during None None O
cold None None O
winter None None O
months None None O
, None None O
particularly None None O
in None None O
older None None O
adults None None O
. None None O

Acute None None O
physiological None None O
responses None None O
, None None O
such None None O
as None None O
increases None None O
in None None O
blood None None O
pressure None None O
, None None O
in None None O
response None None O
to None None O
cold None None O
exposure None None O
may None None O
contribute None None O
to None None O
these None None O
associations None None O
. None None O

To None None O
determine None None O
whether None None O
the None None O
blood None None O
pressure None None O
- None None O
raising None None O
effect None None O
( None None O
pressor None None O
response None None O
) None None O
of None None O
non None None O
- None None O
internal None None O
body None None O
temperature None None O
- None None O
reducing None None O
cold None None O
stress None None O
is None None O
greater None None O
with None None O
age None None O
, None None O
we None None O
measured None None O
physiological None None O
responses None None O
to None None O
20 None None O
min None None O
of None None O
superficial None None O
skin None None O
cooling None None O
, None None O
via None None O
water None None O
- None None O
perfused None None O
suit None None O
, None None O
in None None O
12 None None O
younger None None O
[ None None O
25 None None O
+ None None O
/ None None O
- None None O
1 None None O
( None None O
SE None None O
) None None O
yr None None O
old None None O
] None None O
and None None O
12 None None O
older None None O
( None None O
65 None None O
+ None None O
/ None None O
- None None O
2 None None O
yr None None O
old None None O
) None None O
adults None None O
. None None O

We None None O
found None None O
that None None O
superficial None None O
skin None None O
cooling None None O
elicited None None O
an None None O
increase None None O
in None None O
blood None None O
pressure None None O
from None None O
resting None None O
levels None None O
( None None O
pressor None None O
response None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
in None None O
younger None None O
and None None O
older None None O
adults None None O
. None None O

However None None O
, None None O
the None None O
magnitude None None O
of None None O
this None None O
pressor None None O
response None None O
( None None O
systolic None None O
and None None O
mean None None O
blood None None O
pressure None None O
) None None O
was None None O
more None None O
than None None O
twofold None None O
higher None None O
in None None O
older None None O
adults None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
vs None None O
. None None O
younger None None O
adults None None O
) None None O
. None None O

The None None O
magnitude None None O
of None None O
the None None O
pressor None None O
response None None O
was None None O
similar None None O
at None None O
peripheral None None O
( None None O
brachial None None O
) None None O
and None None O
central None None O
( None None O
estimated None None O
in None None O
the None None O
aorta None None O
) None None O
measurement None None O
sites None None O
. None None O

Regression None None O
analysis None None O
revealed None None O
that None None O
aortic None None O
pulse None None O
wave None None O
velocity None None O
, None None O
a None None O
measure None None O
of None None O
central None None O
arterial None None O
stiffness None None O
obtained None None O
before None None O
cooling None None O
, None None O
was None None O
the None None O
best None None O
predictor None None O
of None None O
the None None O
increased None None O
pressor None None O
response None None O
to None None O
superficial None None O
skin None None O
cooling None None O
in None None O
older None None O
adults None None O
, None None O
explaining None None O
approximately None None O
63 None None O
% None None O
of None None O
its None None O
variability None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
there None None O
is None None O
a None None O
greater None None O
pressor None None O
response None None O
to None None O
non None None O
- None None O
internal None None O
body None None O
temperature None None O
- None None O
reducing None None O
cold None None O
stress None None O
with None None O
age None None O
in None None O
humans None None O
that None None O
may None None O
be None None O
mediated None None O
by None None O
increased None None O
levels None None O
of None None O
central None None O
arterial None None O
stiffness None None O
. None None O

Data None None O
collection None None O
: None None O
CrystalClear None None O
( None None O
Rigaku None None O
/ None None O
MSC None None O
, None None O
2005 None None O
> None None O
) None None O
; None None O
cell None None O
refinement None None O
: None None O
CrystalClear None None O
; None None O
data None None O
reduction None None O
: None None O
CrystalClear None None O
; None None O
program None None O
( None None O
s None None O
) None None O
used None None O
to None None O
solve None None O
structure None None O
: None None O
SHELXS97 None None O
( None None O
Sheldrick None None O
, None None O
2008 None None O
> None None O
) None None O
; None None O
program None None O
( None None O
s None None O
) None None O
used None None O
to None None O
refine None None O
structure None None O
: None None O
SHELXL97 None None O
( None None O
Sheldrick None None O
, None None O
2008 None None O
> None None O
) None None O
; None None O
molecular None None O
graphics None None O
: None None O
ORTEPII None None O
( None None O
Johnson None None O
, None None O
1976 None None O
> None None O
) None None O
; None None O
software None None O
used None None O
to None None O
prepare None None O
material None None O
for None None O
publication None None O
: None None O
SHELXL97 None None O
. None None O

Allogeneic None None O
injection None None O
of None None O
fetal None None O
membrane None None O
- None None O
derived None None O
mesenchymal None None O
stem None None O
cells None None O
induces None None O
therapeutic None None O
angiogenesis None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
hind None None O
limb None None O
ischemia None None O
. None None O

Bone None None O
marrow None None O
- None None O
derived None None O
mesenchymal None None O
stem None None O
cells None None O
( None None O
BM None None O
- None None O
MSC None None O
) None None O
have None None O
been None None O
demonstrated None None O
to None None O
be None None O
an None None O
attractive None None O
therapeutic None None O
cell None None O
source None None O
for None None O
tissue None None O
regeneration None None O
and None None O
repair None None O
. None None O

However None None O
, None None O
it None None O
remains None None O
unknown None None O
whether None None O
or None None O
not None None O
allogeneic None None O
transplantation None None O
of None None O
mesenchymal None None O
stem None None O
cells None None O
( None None O
MSC None None O
) None None O
derived None None O
from None None O
fetal None None O
membranes None None O
( None None O
FM None None O
) None None O
, None None O
which None None O
are None None O
generally None None O
discarded None None O
as None None O
medical None None O
waste None None O
after None None O
delivery None None O
, None None O
has None None O
therapeutic None None O
potential None None O
. None None O

FM None None O
- None None O
MSC None None O
were None None O
obtained None None O
from None None O
Lewis None None O
rats None None O
and None None O
had None None O
surface None None O
antigen None None O
expression None None O
and None None O
multipotent None None O
potential None None O
partly None None O
similar None None O
to None None O
those None None O
of None None O
BM None None O
- None None O
MSC None None O
. None None O

Compared None None O
with None None O
BM None None O
- None None O
MSC None None O
, None None O
FM None None O
- None None O
MSC None None O
secreted None None O
a None None O
comparable None None O
amount None None O
of None None O
hepatocyte None None O
growth None None O
factor None None O
despite None None O
a None None O
small None None O
amount None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
. None None O

FM None None O
- None None O
MSC None None O
and None None O
BM None None O
- None None O
MSC None None O
both None None O
expressed None None O
major None None O
histocompatibility None None O
complex None None O
( None None O
MHC None None O
) None None O
class None None O
I None None O
but None None O
not None None O
MHC None None O
class None None O
II None None O
antigens None None O
and None None O
did None None O
not None None O
elicit None None O
allogeneic None None O
lymphocyte None None O
proliferation None None O
in None None O
mixed None None O
lymphocyte None None O
culture None None O
. None None O

FM None None O
- None None O
MSC None None O
or None None O
BM None None O
- None None O
MSC None None O
obtained None None O
from None None O
Lewis None None O
rats None None O
were None None O
injected None None O
into None None O
a None None O
MHC None None O
- None None O
mismatched None None O
August None None O
- None None O
Copenhagen None None O
- None None O
Irish None None O
rat None None O
model None None O
of None None O
hind None None O
limb None None O
ischemia None None O
. None None O

Three None None O
weeks None None O
after None None O
injection None None O
, None None O
blood None None O
perfusion None None O
and None None O
capillary None None O
density None None O
were None None O
significantly None None O
higher None None O
in None None O
the None None O
FM None None O
- None None O
MSC None None O
and None None O
BM None None O
- None None O
MSC None None O
groups None None O
than None None O
in None None O
the None None O
phosphate None None O
- None None O
buffered None None O
saline None None O
group None None O
, None None O
and None None O
allogeneic None None O
FM None None O
- None None O
MSC None None O
and None None O
BM None None O
- None None O
MSC None None O
were None None O
still None None O
observed None None O
. None None O

In None None O
nonischemic None None O
hind None None O
limb None None O
tissues None None O
, None None O
allogeneic None None O
FM None None O
- None None O
MSC None None O
and None None O
BM None None O
- None None O
MSC None None O
injection None None O
were None None O
associated None None O
with None None O
a None None O
comparatively None None O
small None None O
amount None None O
of None None O
T None None O
lymphocyte None None O
infiltration None None O
, None None O
compared None None O
with None None O
the None None O
injection None None O
of None None O
allogeneic None None O
splenic None None O
lymphocytes None None O
. None None O

In None None O
conclusion None None O
, None None O
allogeneic None None O
FM None None O
- None None O
MSC None None O
injection None None O
did None None O
not None None O
elicit None None O
a None None O
lymphocyte None None O
proliferative None None O
response None None O
and None None O
provided None None O
significant None None O
improvement None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
hind None None O
limb None None O
ischemia None None O
, None None O
comparable None None O
to None None O
the None None O
response None None O
to None None O
BM None None O
- None None O
MSC None None O
. None None O

Thus None None O
, None None O
allogeneic None None O
injection None None O
of None None O
FM None None O
- None None O
MSC None None O
may None None O
be None None O
a None None O
new None None O
therapeutic None None O
strategy None None O
for None None O
the None None O
treatment None None O
of None None O
severe None None O
peripheral None None O
vascular None None O
disease None None O
. None None O

Disclosure None None O
of None None O
potential None None O
conflicts None None O
of None None O
interest None None O
is None None O
found None None O
at None None O
the None None O
end None None O
of None None O
this None None O
article None None O
. None None O

Covariance None None O
structure None None O
analysis None None O
: None None O
statistical None None O
practice None None O
, None None O
theory None None O
, None None O
and None None O
directions None None O
. None None O

Although None None O
covariance None None O
structure None None O
analysis None None O
is None None O
used None None O
increasingly None None O
to None None O
analyze None None O
nonexperimental None None O
data None None O
, None None O
important None None O
statistical None None O
requirements None None O
for None None O
its None None O
proper None None O
use None None O
are None None O
frequently None None O
ignored None None O
. None None O

Valid None None O
conclusions None None O
about None None O
the None None O
adequacy None None O
of None None O
a None None O
model None None O
as None None O
an None None O
acceptable None None O
representation None None O
of None None O
data None None O
, None None O
which None None O
are None None O
based None None O
on None None O
goodness None None O
- None None O
of None None O
- None None O
fit None None O
test None None O
statistics None None O
and None None O
standard None None O
errors None None O
of None None O
parameter None None O
estimates None None O
, None None O
rely None None O
on None None O
the None None O
model None None O
estimation None None O
procedure None None O
being None None O
appropriate None None O
for None None O
the None None O
data None None O
. None None O

Using None None O
analogies None None O
to None None O
linear None None O
regression None None O
and None None O
anova None None O
, None None O
this None None O
review None None O
examines None None O
conditions None None O
under None None O
which None None O
conclusions None None O
drawn None None O
from None None O
various None None O
estimation None None O
methods None None O
will None None O
be None None O
correct None None O
and None None O
the None None O
consequences None None O
of None None O
ignoring None None O
these None None O
conditions None None O
. None None O

A None None O
distinction None None O
is None None O
made None None O
between None None O
estimation None None O
methods None None O
that None None O
are None None O
either None None O
correctly None None O
or None None O
incorrectly None None O
specified None None O
for None None O
the None None O
distribution None None O
of None None O
data None None O
being None None O
analyzed None None O
, None None O
and None None O
it None None O
is None None O
shown None None O
that None None O
valid None None O
conclusions None None O
are None None O
possible None None O
even None None O
under None None O
misspecification None None O
. None None O

A None None O
brief None None O
example None None O
illustrates None None O
the None None O
ideas None None O
. None None O

Internet None None O
access None None O
is None None O
given None None O
to None None O
a None None O
computer None None O
code None None O
for None None O
several None None O
methods None None O
that None None O
are None None O
not None None O
available None None O
in None None O
programs None None O
such None None O
as None None O
EQS None None O
or None None O
LISREL None None O
. None None O

Phosphatidyl None None O
serine None None O
exposure None None O
during None None O
apoptosis None None O
precedes None None O
release None None O
of None None O
cytochrome None None O
c None None O
and None None O
decrease None None O
in None None O
mitochondrial None None O
transmembrane None None O
potential None None O
. None None O

Time None None O
kinetics None None O
of None None O
phosphatidyl None None O
serine None None O
( None None O
PS None None O
) None None O
exposure None None O
were None None O
compared None None O
to None None O
other None None O
apoptotic None None O
parameters None None O
following None None O
different None None O
apoptotic None None O
stimuli None None O
. None None O

Our None None O
data None None O
indicate None None O
that None None O
anti None None O
- None None O
Fas None None O
treatment None None O
of None None O
L929sAhFas None None I-Cell-line-name
cells None None O
results None None O
in None None O
rapid None None O
exposure None None O
of None None O
PS None None O
, None None O
which None None O
precedes None None O
decrease None None O
in None None O
mitochondrial None None O
transmembrane None None O
potential None None O
( None None O
DeltaPsi None None O
( None None O
m None None O
) None None O
) None None O
and None None O
release None None O
of None None O
cytochrome None None O
c None None O
, None None O
indicating None None O
that None None O
PS None None O
exposure None None O
occurs None None O
independently None None O
of None None O
these None None O
mitochondrial None None O
events None None O
. None None O

Also None None O
during None None O
TNF None None O
- None None O
, None None O
etoposide None None O
- None None O
or None None O
staurosporine None None O
- None None O
mediated None None O
apoptosis None None O
in None None O
PC60 None None I-Cell-line-name
RI None None O
/ None None O
RII None None O
cells None None O
, None None O
PS None None O
- None None O
positive None None O
cells None None O
were None None O
observed None None O
before None None O
they None None O
had None None O
a None None O
decreased None None O
DeltaPsi None None O
( None None O
m None None O
) None None O
. None None O

However None None O
, None None O
during None None O
growth None None O
factor None None O
depletion None None O
- None None O
induced None None O
death None None O
of None None O
32D None None I-Cell-line-name
cells None None O
, None None O
both None None O
phenomena None None O
seemed None None O
to None None O
occur None None O
at None None O
the None None O
same None None O
time None None O
. None None O

The None None O
asymmetric None None O
unit None None O
of None None O
the None None O
title None None O
compound None None O
with None None O
the None None O
atomic None None O
labelling None None O
scheme None None O
. None None O
Displacement None None O
are None None O
drawn None None O
at None None O
the None None O
50 None None O
% None None O
probability None None O
level None None O
. None None O

H None None O
atoms None None O
are None None O
represented None None O
as None None O
small None None O
spheres None None O
of None None O
arbitrary None None O
radii None None O
. None None O

Hydrogen None None O
bonds None None O
are None None O
shown None None O
as None None O
dashed None None O
lines None None O
. None None O

Role None None O
of None None O
stromal None None O
myofibroblasts None None O
in None None O
invasive None None O
breast None None O
cancer None None O
: None None O
stromal None None O
expression None None O
of None None O
alpha None None O
- None None O
smooth None None O
muscle None None O
actin None None O
correlates None None O
with None None O
worse None None O
clinical None None O
outcome None None O
. None None O

BACKGROUND None None O
: None None O
Recently None None O
, None None O
the None None O
desmoplastic None None O
reaction None None O
has None None O
been None None O
implicated None None O
as None None O
having None None O
an None None O
important None None O
function None None O
in None None O
epithelial None None O
solid None None O
tumor None None O
biology None None O
. None None O

There None None O
have None None O
been None None O
no None None O
reports None None O
showing None None O
the None None O
relativity None None O
of None None O
invasive None None O
breast None None O
cancer None None O
and None None O
the None None O
desmoplastic None None O
reaction None None O
by None None O
a None None O
quantitative None None O
analysis None None O
of None None O
the None None O
myofibroblasts None None O
that None None O
were None None O
an None None O
important None None O
player None None O
in None None O
the None None O
desmoplastic None None O
reaction None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
immunohistochemically None None O
investigate None None O
the None None O
correlation None None O
between None None O
the None None O
desmoplastic None None O
reaction None None O
and None None O
the None None O
clinicopathology None None O
of None None O
invasive None None O
breast None None O
cancer None None O
. None None O

METHODS None None O
: None None O
The None None O
study None None O
included None None O
60 None None O
patients None None O
with None None O
a None None O
known None None O
prognosis None None O
of None None O
invasive None None O
breast None None O
cancer None None O
. None None O

We None None O
quantified None None O
the None None O
expression None None O
of None None O
alpha None None O
- None None O
SMA None None O
as None None O
a None None O
marker None None O
of None None O
myofibroblasts None None O
in None None O
the None None O
invasive None None O
breast None None O
cancer None None O
. None None O

After None None O
staining None None O
samples None None O
for None None O
alpha None None O
- None None O
SMA None None O
, None None O
their None None O
expression None None O
was None None O
extracted None None O
and None None O
quantified None None O
as None None O
a None None O
relative None None O
percentage None None O
by None None O
computer None None O
- None None O
assisted None None O
image None None O
analysis None None O
. None None O

RESULTS None None O
: None None O
There None None O
was None None O
relatively None None O
wide None None O
variation None None O
in None None O
the None None O
expression None None O
of None None O
alpha None None O
- None None O
SMA None None O
with None None O
the None None O
percentage None None O
of None None O
the None None O
area None None O
from None None O
0 None None O
. None None O
68 None None O
to None None O
28 None None O
. None None O
15 None None O
% None None O
( None None O
mean None None O
8 None None O
. None None O
48 None None O
+ None None O
/ None None O
- None None O
5 None None O
. None None O
40 None None O
% None None O
) None None O
. None None O

The None None O
metastasis None None O
group None None O
showed None None O
significantly None None O
higher None None O
alpha None None O
- None None O
SMA None None O
expression None None O
compared None None O
with None None O
the None None O
no None None O
metastasis None None O
group None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

When None None O
the None None O
patients None None O
were None None O
divided None None O
into None None O
two None None O
groups None None O
according None None O
to None None O
their None None O
alpha None None O
- None None O
SMA None None O
expression None None O
using None None O
a None None O
cutoff None None O
point None None O
at None None O
the None None O
mean None None O
value None None O
of None None O
8 None None O
. None None O
48 None None O
% None None O
, None None O
the None None O
high None None O
alpha None None O
- None None O
SMA None None O
group None None O
had None None O
a None None O
significantly None None O
poorer None None O
overall None None O
survival None None O
rate None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Multivariate None None O
analysis None None O
demonstrated None None O
that None None O
alpha None None O
- None None O
SMA None None O
and None None O
lymph None None O
node None None O
metastasis None None O
were None None O
identified None None O
as None None O
independent None None O
predictive None None O
factors None None O
of None None O
metastasis None None O
. None None O

CONCLUSION None None O
: None None O
Myofibroblasts None None O
represent None None O
an None None O
important None None O
prognostic None None O
factor None None O
for None None O
invasive None None O
growth None None O
that None None O
is None None O
translated None None O
into None None O
a None None O
poor None None O
clinical None None O
prognosis None None O
for None None O
patients None None O
with None None O
invasive None None O
breast None None O
cancer None None O
. None None O

Lactate None None O
- None None O
dehydrogenase None None O
5 None None O
is None None O
overexpressed None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
and None None O
correlates None None O
with None None O
the None None O
expression None None O
of None None O
the None None O
transketolase None None O
- None None O
like None None O
protein None None O
1 None None O
. None None O

AIMS None None O
: None None O
As None None O
one None None O
of None None O
the None None O
five None None O
lactate None None O
dehydrogenase None None O
( None None O
LDH None None O
) None None O
isoenzymes None None O
, None None O
LDH5 None None O
has None None O
the None None O
highest None None O
efficiency None None O
to None None O
catalyze None None O
pyruvate None None O
transformation None None O
to None None O
lactate None None O
. None None O

LDH5 None None O
overexpression None None O
in None None O
cancer None None O
cells None None O
induces None None O
an None None O
upregulated None None O
glycolytic None None O
metabolism None None O
and None None O
reduced None None O
dependence None None O
on None None O
the None None O
presence None None O
of None None O
oxygen None None O
. None None O

Here None None O
we None None O
analyzed None None O
LDH5 None None O
protein None None O
expression None None O
in None None O
a None None O
well None None O
characterized None None O
large None None O
cohort None None O
of None None O
primary None None O
lung None None O
cancers None None O
in None None O
correlation None None O
to None None O
clinico None None O
- None None O
pathological None None O
data None None O
and None None O
its None None O
possible None None O
impact None None O
on None None O
patient None None O
survival None None O
. None None O

METHODS None None O
: None None O
Primary None None O
lung None None O
cancers None None O
( None None O
n None None O
= None None O
269 None None O
) None None O
and None None O
non None None O
neoplastic None None O
lung None None O
tissue None None O
( None None O
n None None O
= None None O
35 None None O
) None None O
were None None O
tested None None O
for None None O
LDH5 None None O
expression None None O
by None None O
immunohistochemistry None None O
using None None O
a None None O
polyclonal None None O
LDH5 None None O
antibody None None O
( None None O
ab53010 None None O
) None None O
. None None O

The None None O
results None None O
of None None O
LDH5 None None O
expression None None O
were None None O
correlated None None O
to None None O
clinico None None O
- None None O
pathological None None O
data None None O
as None None O
well None None O
as None None O
to None None O
patient None None O
' None None O
s None None O
survival None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
results None None O
of None None O
the None None O
previously None None O
tested None None O
transketolase None None O
like None None O
1 None None O
protein None None O
( None None O
TKTL1 None None O
) None None O
expression None None O
were None None O
correlated None None O
to None None O
LDH5 None None O
expression None None O
. None None O

RESULTS None None O
: None None O
89 None None O
. None None O
5 None None O
% None None O
( None None O
n None None O
= None None O
238 None None O
) None None O
of None None O
NSCLC None None O
revealed None None O
LDH5 None None O
expression None None O
whereas None None O
LDH5 None None O
expression None None O
was None None O
not None None O
detected None None O
in None None O
non None None O
neoplastic None None O
lung None None O
tissues None None O
( None None O
n None None O
= None None O
34 None None O
) None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

LDH5 None None O
overexpression None None O
was None None O
associated None None O
with None None O
histological None None O
type None None O
( None None O
adenocarcinoma None None O
= None None O
57 None None O
% None None O
, None None O
squamous None None O
cell None None O
carcinoma None None O
= None None O
45 None None O
% None None O
, None None O
large None None O
cell None None O
carcinoma None None O
= None None O
46 None None O
% None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
006 None None O
) None None O
. None None O

No None None O
significant None None O
correlation None None O
could None None O
be None None O
detected None None O
with None None O
regard None None O
to None None O
TNM None None O
- None None O
stage None None O
, None None O
grading None None O
or None None O
survival None None O
. None None O

A None None O
two None None O
sided None None O
correlation None None O
between None None O
the None None O
expression None None O
of None None O
TKTL1 None None O
and None None O
LDH5 None None O
could None None O
be None None O
shown None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
within None None O
the None None O
overall None None O
cohort None None O
as None None O
well None None O
as None None O
for None None O
each None None O
grading None None O
and None None O
pN None None O
group None None O
. None None O

A None None O
significant None None O
correlation None None O
between None None O
LDH5 None None O
and None None O
TKTL1 None None O
within None None O
each None None O
histologic None None O
tumortype None None O
could None None O
not None None O
be None None O
revealed None None O
. None None O

CONCLUSIONS None None O
: None None O
LDH5 None None O
is None None O
overexpressed None None O
in None None O
NSCLC None None O
and None None O
could None None O
hence None None O
serve None None O
as None None O
an None None O
additional None None O
marker None None O
for None None O
malignancy None None O
. None None O

Furthermore None None O
, None None O
LDH5 None None O
correlates None None O
positively None None O
with None None O
the None None O
prognostic None None O
marker None None O
TKTL1 None None O
. None None O

Our None None O
results None None O
confirm None None O
a None None O
close None None O
link None None O
between None None O
the None None O
two None None O
metabolic None None O
enzymes None None O
and None None O
indicate None None O
an None None O
alteration None None O
in None None O
the None None O
glucose None None O
metabolism None None O
in None None O
the None None O
process None None O
of None None O
malignant None None O
transformation None None O
. None None O

Tumorigenic None None O
activity None None O
of None None O
rho None None O
genes None None O
from None None O
Aplysia None None O
californica None None O
. None None O

rho None None O
genes None None O
have None None O
been None None O
found None None O
in None None O
both None None O
lower None None O
and None None O
higher None None O
eucaryotes None None O
. None None O

They None None O
code None None O
for None None O
proteins None None O
of None None O
21 None None O
kDa None None O
, None None O
highly None None O
conserved None None O
in None None O
evolution None None O
, None None O
which None None O
belong None None O
to None None O
the None None O
superfamily None None O
of None None O
ras None None O
GTPases None None O
. None None O

Among None None O
the None None O
members None None O
of None None O
this None None O
superfamily None None O
there None None O
are None None O
proteins None None O
with None None O
a None None O
regulatory None None O
function None None O
, None None O
such None None O
as None None O
ras None None O
, None None O
and None None O
proteins None None O
involved None None O
in None None O
vesicular None None O
trafficking None None O
, None None O
such None None O
as None None O
the None None O
family None None O
of None None O
rab None None O
proteins None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
putative None None O
role None None O
of None None O
rho None None O
proteins None None O
from None None O
Aplysia None None O
californica None None O
as None None O
transforming None None O
GTPases None None O
utilizing None None O
the None None O
wild None None O
- None None O
type None None O
and None None O
a None None O
Val None None O
- None None O
14 None None O
mutant None None O
, None None O
equivalent None None O
to None None O
the None None O
oncogenic None None O
Val None None O
- None None O
12 None None O
mutation None None O
of None None O
ras None None O
genes None None O
found None None O
in None None O
animal None None O
and None None O
human None None O
tumors None None O
. None None O

Over None None O
- None None O
expression None None O
of None None O
either None None O
rho None None O
gene None None O
was None None O
sufficient None None O
to None None O
confer None None O
anchorage None None O
- None None O
and None None O
serum None None O
- None None O
independent None None O
growth None None O
. None None O

Moreover None None O
, None None O
when None None O
introduced None None O
into None None O
nude None None O
mice None None O
, None None O
selected None None O
clones None None O
generated None None O
from None None O
either None None O
gene None None O
were None None O
able None None O
to None None O
induce None None O
tumors None None O
, None None O
although None None O
those None None O
carrying None None O
the None None O
mutated None None O
version None None O
were None None O
more None None O
efficient None None O
. None None O

Pathological None None O
analysis None None O
indicated None None O
that None None O
generated None None O
tumors None None O
corresponded None None O
to None None O
well None None O
- None None O
differentiated None None O
fibrosarcomas None None O
with None None O
distinct None None O
and None None O
intersecting None None O
bundles None None O
and None None O
spindle None None O
cells None None O
. None None O

By None None O
contrast None None O
, None None O
ras None None O
- None None O
induced None None O
tumors None None O
were None None O
poorly None None O
differentiated None None O
fibrosarcomas None None O
. None None O

Thus None None O
, None None O
our None None O
results None None O
indicate None None O
that None None O
under None None O
appropriate None None O
conditions None None O
rho None None O
genes None None O
function None None O
as None None O
oncogenes None None O
and None None O
may None None O
have None None O
a None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
proliferation None None O
in None None O
fibroblast None None O
cells None None O
. None None O

Aflibercept None None O
( None None O
AVE0005 None None O
) None None O
: None None O
an None None O
alternative None None O
strategy None None O
for None None O
inhibiting None None O
tumour None None O
angiogenesis None None O
by None None O
vascular None None O
endothelial None None O
growth None None O
factors None None O
. None None O

BACKGROUND None None O
: None None O
Aberrant None None O
angiogenesis None None O
is None None O
a None None O
landmark None None O
feature None None O
in None None O
cancer None None O
, None None O
which None None O
is None None O
important None None O
for None None O
proliferation None None O
, None None O
growth None None O
and None None O
metastasis None None O
, None None O
and None None O
is None None O
mediated None None O
by None None O
various None None O
pro None None O
- None None O
angiogenic None None O
factors None None O
. None None O

The None None O
VEGF None None O
pathway None None O
is None None O
one None None O
of None None O
the None None O
most None None O
important None None O
and None None O
best None None O
- None None O
studied None None O
angiogenic None None O
pathways None None O
. None None O

Inhibition None None O
of None None O
this None None O
pathway None None O
may None None O
provide None None O
clinical None None O
benefits None None O
to None None O
cancer None None O
patients None None O
. None None O

OBJECTIVES None None O
: None None O
Strategies None None O
to None None O
inhibit None None O
the None None O
VEGF None None O
pathway None None O
, None None O
including None None O
antibodies None None O
to None None O
VEGF None None O
, None None O
antibodies None None O
to None None O
the None None O
extracellular None None O
domain None None O
of None None O
VEGFR None None O
- None None O
1 None None O
or None None O
VEGFR None None O
- None None O
2 None None O
, None None O
decoy None None O
receptors None None O
for None None O
VEGF None None O
and None None O
tyrosine None None O
kinase None None O
inhibitors None None O
of None None O
VEGFRs None None O
, None None O
are None None O
summarized None None O
. None None O

METHODS None None O
: None None O
This None None O
review None None O
outlines None None O
and None None O
compares None None O
the None None O
latest None None O
development None None O
of None None O
these None None O
strategies None None O
, None None O
with None None O
emphasis None None O
on None None O
aflibercept None None O
, None None O
a None None O
novel None None O
decoy None None O
fusion None None O
protein None None O
of None None O
domain None None O
2 None None O
of None None O
VEGFR None None O
- None None O
1 None None O
and None None O
domain None None O
3 None None O
of None None O
VEGFR None None O
- None None O
2 None None O
with None None O
the None None O
Fc None None O
fragment None None O
of None None O
IgG1 None None O
. None None O

RESULTS None None O
: None None O
Aflibercept None None O
was None None O
shown None None O
to None None O
have None None O
early None None O
clinical None None O
activity None None O
. None None O

Multiple None None O
studies None None O
are None None O
ongoing None None O
to None None O
determine None None O
the None None O
clinical None None O
benefits None None O
of None None O
aflibercept None None O
in None None O
cancer None None O
patients None None O
. None None O

Absolute None None O
responder None None O
rates None None O
for None None O
medical None None O
management None None O
recommendations None None O
. None None O

Figures None None O
and None None O
Tables None None O

Figure None None O
1 None None O

Modular None None O
crosstalking None None O
in None None O
synthetic None None O
gene None None O
networks None None O
. None None O

A None None O
promoter None None O
with None None O
binding None None O
sites None None O
for None None O
lambda None None O
cI None None O
dimers None None O
( None None O
OR1 None None O
and None None O
OR2 None None O
) None None O
and None None O
for None None O
the None None O
lac None None O
repressor None None O
( None None O
Olac None None O
) None None O
controls None None O
the None None O
production None None O
of None None O
the None None O
lac None None O
repressor None None O
( None None O
encoded None None O
by None None O
lacI None None O
) None None O
in None None O
module None None O
1 None None O
and None None O
lambda None None O
cI None None O
( None None O
encoded None None O
by None None O
cI None None O
) None None O
in None None O
module None None O
2 None None O
. None None O

The None None O
lac None None O
repressor None None O
and None None O
lambda None None O
cI None None O
dimers None None O
are None None O
represented None None O
by None None O
blue None None O
ellipsoids None None O
and None None O
red None None O
circles None None O
, None None O
respectively None None O
. None None O

When None None O
the None None O
two None None O
modules None None O
are None None O
put None None O
together None None O
, None None O
two None None O
pairs None None O
of None None O
lambda None None O
cI None None O
dimers None None O
bound None None O
at None None O
different None None O
operators None None O
can None None O
loop None None O
DNA None None O
and None None O
octamerize None None O
, None None O
forming None None O
a None None O
tetramer None None O
of None None O
dimers None None O
. None None O

Anti None None O
- None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
- None None O
beta None None O
antibodies None None O
inhibit None None O
breast None None O
cancer None None O
cell None None O
tumorigenicity None None O
and None None O
increase None None O
mouse None None O
spleen None None O
natural None None O
killer None None O
cell None None O
activity None None O
. None None O

Implications None None O
for None None O
a None None O
possible None None O
role None None O
of None None O
tumor None None O
cell None None O
/ None None O
host None None O
TGF None None O
- None None O
beta None None O
interactions None None O
in None None O
human None None O
breast None None O
cancer None None O
progression None None O
. None None O

TGF None None O
- None None O
beta None None O
effects None None O
on None None O
angiogenesis None None O
, None None O
stroma None None O
formation None None O
, None None O
and None None O
immune None None O
function None None O
suggest None None O
its None None O
possible None None O
involvement None None O
in None None O
tumor None None O
progression None None O
. None None O

This None None O
hypothesis None None O
was None None O
tested None None O
using None None O
the None None O
2G7 None None O
IgG2b None None O
, None None O
which None None O
neutralizes None None O
TGF None None O
- None None O
beta None None O
1 None None O
, None None O
- None None O
beta None None O
2 None None O
, None None O
and None None O
- None None O
beta None None O
3 None None O
, None None O
and None None O
the None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
human None None O
breast None None O
cancer None None O
cell None None O
line None None O
. None None O

Inoculation None None O
of None None O
these None None O
cells None None O
in None None O
athymic None None O
mice None None O
decreases None None O
mouse None None O
spleen None None O
natural None None O
killer None None O
( None None O
NK None None O
) None None O
cell None None O
activity None None O
. None None O

Intraperitoneal None None O
injections None None O
of None None O
2G7 None None O
starting None None O
1 None None O
d None None O
after None None O
intraperitoneal None None O
inoculation None None O
of None None O
tumor None None O
cells None None O
suppressed None None O
intraabdominal None None O
tumor None None O
and None None O
lung None None O
metastases None None O
, None None O
whereas None None O
the None None O
nonneutralizing None None O
anti None None O
- None None O
TGF None None O
- None None O
beta None None O
12H5 None None O
IgG2a None None O
had None None O
no None None O
effect None None O
. None None O

2G7 None None O
transiently None None O
inhibited None None O
growth None None O
of None None O
established None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
subcutaneous None None O
tumors None None O
. None None O

Histologically None None O
, None None O
both None None O
2G7 None None O
- None None O
treated None None O
and None None O
control None None O
tumors None None O
were None None O
identical None None O
. None None O

Intraperitoneal None None O
administration None None O
of None None O
2G7 None None O
resulted None None O
in None None O
a None None O
marked None None O
increase None None O
in None None O
mouse None None O
spleen None None O
NK None None O
cell None None O
activity None None O
. None None O

2G7 None None O
did None None O
not None None O
inhibit None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
primary None None O
tumor None None O
or None None O
metastases None None O
formation None None O
, None None O
nor None None O
did None None O
it None None O
stimulate None None O
NK None None O
cell None None O
- None None O
mediated None None O
cytotoxicity None None O
in None None O
beige None None O
NK None None O
- None None O
deficient None None O
nude None None O
mice None None O
. None None O

Finally None None O
, None None O
serum None None O
- None None O
free None None O
conditioned None None O
medium None None O
from None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
cells None None O
inhibited None None O
the None None O
NK None None O
cell None None O
activity None None O
of None None O
human None None O
blood None None O
lymphocytes None None O
. None None O

This None None O
inhibition None None O
was None None O
blocked None None O
by None None O
the None None O
neutralizing None None O
anti None None O
- None None O
TGF None None O
- None None O
beta None None O
2G7 None None O
antibody None None O
but None None O
not None None O
by None None O
a None None O
nonspecific None None O
IgG2 None None O
. None None O

These None None O
data None None O
support None None O
a None None O
possible None None O
role None None O
for None None O
tumor None None O
cell None None O
TGF None None O
- None None O
beta None None O
in None None O
the None None O
progression None None O
of None None O
mammary None None O
carcinomas None None O
by None None O
suppressing None None O
host None None O
immune None None O
surveillance None None O
. None None O

Representative None None O
time None None O
histories None None O
of None None O
the None None O
estimated None None O
SatO2 None None O
levels None None O
of None None O
normal None None O
cortex None None O
( None None O
black None None O
) None None O
and None None O
tumor None None O
( None None O
grey None None O
) None None O
from None None O
all None None O
six None None O
patients None None O
. None None O

Energy None None O
supply None None O
of None None O
the None None O
mitotic None None O
cell None None O
cycle None None O
and None None O
the None None O
Na None None O
+ None None O
/ None None O
H None None O
+ None None O
- None None O
antiport None None O
in None None O
ascites None None O
tumors None None O
. None None O

The None None O
activation None None O
of None None O
Na None None O
+ None None O
transport None None O
is None None O
due None None O
to None None O
the None None O
exchange None None O
of None None O
protons None None O
formed None None O
via None None O
glucose None None O
conversion None None O
into None None O
lactate None None O
for None None O
Na None None O
+ None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
to None None O
the None None O
stimulation None None O
of None None O
the None None O
Na None None O
+ None None O
/ None None O
H None None O
+ None None O
- None None O
antiport None None O
. None None O

Experimental None None O
results None None O
and None None O
theoretical None None O
calculations None None O
suggest None None O
that None None O
in None None O
glucose None None O
- None None O
containing None None O
medium None None O
the None None O
Na None None O
+ None None O
transport None None O
increases None None O
from None None O
0 None None O
. None None O
75 None None O
to None None O
1 None None O
. None None O
78 None None O
pmol None None O
/ None None O
hour None None O
per None None O
cell None None O
. None None O

The None None O
permeability None None O
of None None O
plasma None None O
membranes None None O
for None None O
K None None O
+ None None O
increases None None O
2 None None O
. None None O
75 None None O
fold None None O
, None None O
while None None O
the None None O
passive None None O
flux None None O
of None None O
Na None None O
+ None None O
diminishes None None O
. None None O

The None None O
intensity None None O
of None None O
O2 None None O
adsorption None None O
by None None O
ascites None None O
tumor None None O
cells None None O
does None None O
not None None O
practically None None O
depend None None O
on None None O
the None None O
monovalent None None O
cation None None O
concentration None None O
gradient None None O
between None None O
the None None O
cells None None O
and None None O
the None None O
culture None None O
medium None None O
, None None O
whereas None None O
the None None O
rate None None O
of None None O
glycolysis None None O
decreases None None O
simultaneously None None O
with None None O
the None None O
diminution None None O
of None None O
the None None O
concentration None None O
gradient None None O
. None None O

In None None O
synchronized None None O
cultures None None O
at None None O
the None None O
beginning None None O
of None None O
the None None O
mitotic None None O
cycle None None O
, None None O
the None None O
bulk None None O
of None None O
ATP None None O
resynthesized None None O
via None None O
glycolysis None None O
is None None O
utilized None None O
for None None O
the None None O
synthesis None None O
of None None O
biopolymers None None O
, None None O
whereas None None O
that None None O
at None None O
the None None O
end None None O
of None None O
the None None O
S None None O
- None None O
phase None None O
and None None O
in None None O
the None None O
G2 None None O
- None None O
phase None None O
is None None O
utilized None None O
for None None O
cation None None O
transport None None O
across None None O
plasma None None O
membranes None None O
. None None O

From None None O
35 None None O
to None None O
100 None None O
% None None O
of None None O
the None None O
whole None None O
amount None None O
of None None O
ATP None None O
resynthesized None None O
via None None O
glycolysis None None O
is None None O
utilized None None O
for None None O
transport None None O
purposes None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
the None None O
observed None None O
increase None None O
in None None O
the None None O
Na None None O
+ None None O
/ None None O
K None None O
+ None None O
ratio None None O
in None None O
ascites None None O
tumor None None O
cells None None O
is None None O
connected None None O
with None None O
their None None O
enhanced None None O
ability None None O
to None None O
synthesize None None O
lactic None None O
acid None None O
. None None O

Presumably None None O
, None None O
glycolysis None None O
is None None O
one None None O
of None None O
the None None O
regulatory None None O
mechanisms None None O
of None None O
intracellular None None O
ratios None None O
of None None O
monovalent None None O
cations None None O
. None None O

Acute None None O
ethanol None None O
exposure None None O
disrupts None None O
VEGF None None O
receptor None None O
cell None None O
signaling None None O
in None None O
endothelial None None O
cells None None O
. None None O

Physiological None None O
angiogenesis None None O
is None None O
regulated None None O
by None None O
various None None O
factors None None O
, None None O
including None None O
signaling None None O
through None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
receptors None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
a None None O
single None None O
dose None None O
of None None O
ethanol None None O
( None None O
1 None None O
. None None O
4 None None O
g None None O
/ None None O
kg None None O
) None None O
, None None O
yielding None None O
a None None O
blood None None O
alcohol None None O
concentration None None O
of None None O
100 None None O
mg None None O
/ None None O
dl None None O
, None None O
significantly None None O
impairs None None O
angiogenesis None None O
in None None O
murine None None O
wounds None None O
, None None O
despite None None O
adequate None None O
levels None None O
of None None O
VEGF None None O
, None None O
suggesting None None O
direct None None O
effects None None O
of None None O
ethanol None None O
on None None O
endothelial None None O
cell None None O
signaling None None O
( None None O
40 None None O
) None None O
. None None O

To None None O
examine None None O
the None None O
mechanism None None O
by None None O
which None None O
ethanol None None O
influences None None O
angiogenesis None None O
in None None O
wounds None None O
, None None O
we None None O
employed None None O
two None None O
different None None O
in None None O
vitro None None O
angiogenesis None None O
assays None None O
to None None O
determine None None O
whether None None O
acute None None O
ethanol None None O
exposure None None O
( None None O
100 None None O
mg None None O
/ None None O
dl None None O
) None None O
would None None O
have None None O
long None None O
- None None O
lasting None None O
effects None None O
on None None O
VEGF None None O
- None None O
induced None None O
capillary None None O
network None None O
formation None None O
. None None O

Ethanol None None O
exposure None None O
resulted None None O
in None None O
reduced None None O
VEGF None None O
- None None O
induced None None O
cord None None O
formation None None O
on None None O
collagen None None O
and None None O
reduced None None O
capillary None None O
network None None O
structure None None O
on None None O
Matrigel None None O
in None None O
vitro None None O
. None None O

In None None O
addition None None O
, None None O
ethanol None None O
exposure None None O
decreased None None O
expression None None O
of None None O
endothelial None None O
VEGF None None O
receptor None None O
- None None O
2 None None O
, None None O
as None None O
well None None O
as None None O
VEGF None None O
receptor None None O
- None None O
2 None None O
phosphorylation None None O
in None None O
vitro None None O
. None None O

Inhibition None None O
of None None O
ethanol None None O
metabolism None None O
by None None O
4 None None O
- None None O
methylpyrazole None None O
partially None None O
abrogated None None O
the None None O
effect None None O
of None None O
ethanol None None O
on None None O
endothelial None None O
cell None None O
cord None None O
formation None None O
. None None O

However None None O
, None None O
mice None None O
treated None None O
with None None O
t None None O
- None None O
butanol None None O
, None None O
an None None O
alcohol None None O
not None None O
metabolized None None O
by None None O
alcohol None None O
dehydrogenase None None O
, None None O
exhibited None None O
no None None O
change None None O
in None None O
wound None None O
vascularity None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
products None None O
of None None O
ethanol None None O
metabolism None None O
are None None O
important None None O
factors None None O
in None None O
the None None O
development None None O
of None None O
ethanol None None O
- None None O
induced None None O
changes None None O
in None None O
endothelial None None O
cell None None O
responsiveness None None O
to None None O
VEGF None None O
. None None O

In None None O
vivo None None O
, None None O
ethanol None None O
exposure None None O
caused None None O
both None None O
decreased None None O
angiogenesis None None O
and None None O
increased None None O
hypoxia None None O
in None None O
wounds None None O
. None None O

Moreover None None O
, None None O
in None None O
vitro None None O
experiments None None O
demonstrated None None O
a None None O
direct None None O
effect None None O
of None None O
ethanol None None O
on None None O
the None None O
response None None O
to None None O
hypoxia None None O
in None None O
endothelial None None O
cells None None O
, None None O
as None None O
ethanol None None O
diminished None None O
nuclear None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1alpha None None O
protein None None O
levels None None O
. None None O

Together None None O
, None None O
the None None O
data None None O
establish None None O
that None None O
acute None None O
ethanol None None O
exposure None None O
significantly None None O
impairs None None O
angiogenesis None None O
and None None O
suggest None None O
that None None O
this None None O
effect None None O
is None None O
mediated None None O
by None None O
changes None None O
in None None O
endothelial None None O
cell None None O
responsiveness None None O
to None None O
both None None O
VEGF None None O
and None None O
hypoxia None None O
. None None O

Results None None O

VEGF165 None None O
expressed None None O
by None None O
a None None O
replication None None O
- None None O
deficient None None O
recombinant None None O
adenovirus None None O
vector None None O
induces None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

To None None O
evaluate None None O
the None None O
concept None None O
that None None O
localized None None O
delivery None None O
of None None O
angiogenic None None O
factors None None O
via None None O
virus None None O
- None None O
mediated None None O
gene None None O
transfer None None O
may None None O
be None None O
useful None None O
in None None O
the None None O
treatment None None O
of None None O
ischemic None None O
disorders None None O
, None None O
the None None O
replication None None O
- None None O
deficient None None O
adenovirus None None O
( None None O
Ad None None O
) None None O
vector None None O
AdCMV None None O
. None None O
VEGF165 None None O
( None None O
where None None O
CMV None None O
is None None O
cytomegalovirus None None O
and None None O
VEGF None None O
is None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
) None None O
containing None None O
the None None O
cDNA None None O
for None None O
human None None O
VEGF165 None None O
, None None O
a None None O
secreted None None O
endothelial None None O
cell None None O
- None None O
specific None None O
angiogenic None None O
growth None None O
factor None None O
, None None O
was None None O
constructed None None O
. None None O

Human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVECs None None O
) None None O
and None None O
rat None None O
aorta None None O
smooth None None O
muscle None None O
cells None None O
( None None O
RASMCs None None O
) None None O
infected None None O
with None None O
AdCMV None None O
. None None O
VEGF165 None None O
( None None O
5 None None O
and None None O
20 None None O
plaque None None O
- None None O
forming None None O
units None None O
[ None None O
pfu None None O
] None None O
per None None O
cell None None O
) None None O
demonstrated None None O
VEGF None None O
mRNA None None O
expression None None O
and None None O
protein None None O
secretion None None O
into None None O
the None None O
supernatant None None O
. None None O

Furthermore None None O
, None None O
the None None O
conditioned None None O
medium None None O
from None None O
these None None O
cells None None O
enhanced None None O
vascular None None O
permeability None None O
in None None O
vivo None None O
. None None O

In None None O
contrast None None O
, None None O
neither None None O
VEGF None None O
mRNA None None O
nor None None O
secreted None None O
protein None None O
was None None O
found None None O
in None None O
uninfected None None O
HUVECs None None O
or None None O
RASMCs None None O
or None None O
in None None O
cells None None O
infected None None O
with None None O
the None None O
control None None O
vector None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
( None None O
where None None O
beta None None O
gal None None O
is None None O
beta None None O
- None None O
galactosidase None None O
) None None O
. None None O

Assessment None None O
of None None O
starved None None O
HUVECs None None O
at None None O
14 None None O
days None None O
demonstrated None None O
sixfold None None O
more None None O
cells None None O
for None None O
AdCMV None None O
. None None O
VEGF165 None None O
- None None O
infected None None O
HUVECs None None O
( None None O
20 None None O
pfu None None O
per None None O
cell None None O
) None None O
than None None O
for None None O
either None None O
infected None None O
or None None O
uninfected None None O
control None None O
cells None None O
. None None O

RASMC None None O
proliferation None None O
was None None O
unaffected None None O
by None None O
infection None None O
with None None O
AdCMV None None O
. None None O
VEGF165 None None O
. None None O

When None None O
plated None None O
in None None O
2 None None O
% None None O
serum None None O
on None None O
dishes None None O
precoated None None O
with None None O
reconstituted None None O
basement None None O
membrane None None O
( None None O
Matrigel None None O
) None None O
, None None O
HUVECs None None O
infected None None O
with None None O
AdCMV None None O
. None None O
VEGF165 None None O
( None None O
20 None None O
pfu None None O
per None None O
cell None None O
) None None O
differentiated None None O
into None None O
capillary None None O
- None None O
like None None O
structures None None O
. None None O

Under None None O
similar None None O
conditions None None O
, None None O
both None None O
uninfected None None O
HUVECs None None O
and None None O
HUVECs None None O
infected None None O
with None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
did None None O
not None None O
differentiate None None O
. None None O

To None None O
evaluate None None O
the None None O
ability None None O
of None None O
AdCMV None None O
. None None O
VEGF165 None None O
to None None O
function None None O
in None None O
vivo None None O
, None None O
either None None O
AdCMV None None O
. None None O

VEGF165 None None O
or None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
( None None O
2 None None O
x None None O
10 None None O
( None None O
10 None None O
) None None O
pfu None None O
) None None O
was None None O
resuspended None None O
in None None O
0 None None O
. None None O
5 None None O
mL None None O
Matrigel None None O
and None None O
injected None None O
subcutaneously None None O
into None None O
mice None None O
. None None O

Immunohistochemical None None O
staining None None O
demonstrated None None O
VEGF None None O
in None None O
the None None O
tissues None None O
surrounding None None O
the None None O
Matrigel None None O
plugs None None O
containing None None O
AdCMV None None O
. None None O
VEGF165 None None O
up None None O
to None None O
3 None None O
weeks None None O
after None None O
injection None None O
, None None O
whereas None None O
no None None O
VEGF None None O
was None None O
found None None O
in None None O
the None None O
control None None O
plugs None None O
with None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
. None None O

Two None None O
weeks None None O
after None None O
injection None None O
, None None O
there None None O
was None None O
histological None None O
evidence None None O
of None None O
neovascularization None None O
in None None O
the None None O
tissues None None O
surrounding None None O
the None None O
Matrigel None None O
containing None None O
AdCMV None None O
. None None O
VEGF165 None None O
, None None O
whereas None None O
no None None O
significant None None O
angiogenesis None None O
was None None O
observed None None O
in None None O
response None None O
to None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
. None None O

Furthermore None None O
, None None O
the None None O
Matrigel None None O
plugs None None O
with None None O
AdCMV None None O
. None None O
VEGF165 None None O
demonstrated None None O
hemoglobin None None O
content None None O
fourfold None None O
higher None None O
than None None O
the None None O
plugs None None O
with None None O
AdCMV None None O
. None None O
beta None None O
gal None None O
. None None O

Together None None O
, None None O
these None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
studies None None O
are None None O
consistent None None O
with None None O
the None None O
concept None None O
that None None O
Ad None None O
vectors None None O
may None None O
provide None None O
a None None O
useful None None O
strategy None None O
for None None O
efficient None None O
local None None O
delivery None None O
of None None O
VEGF165 None None O
in None None O
the None None O
treatment None None O
of None None O
ischemic None None O
diseases None None O
. None None O

Suppression None None O
of None None O
lung None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
in None None O
mice None None O
by None None O
adeno None None O
- None None O
associated None None O
virus None None O
- None None O
mediated None None O
expression None None O
of None None O
vasostatin None None O
. None None O

PURPOSE None None O
: None None O
Angiogenesis None None O
inhibitors None None O
have None None O
strong None None O
therapeutic None None O
potential None None O
as None None O
antitumor None None O
agents None None O
in None None O
suppressing None None O
tumor None None O
growth None None O
and None None O
metastatic None None O
progression None None O
. None None O

Vasostatin None None O
, None None O
the None None O
N None None O
- None None O
terminal None None O
domain None None O
of None None O
calreticulin None None O
, None None O
is None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
determined None None O
the None None O
effectiveness None None O
of None None O
vasostatin None None O
delivered None None O
by None None O
recombinant None None O
pseudotype None None O
adeno None None O
- None None O
associated None None O
virus None None O
2 None None O
/ None None O
5 None None O
( None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
) None None O
as None None O
a None None O
gene None None O
therapy None None O
approach None None O
for None None O
lung None None O
cancer None None O
treatment None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
We None None O
used None None O
rAAV2 None None O
/ None None O
5 None None O
to None None O
deliver None None O
vasostatin None None O
intratumorally None None O
or None None O
systemically None None O
in None None O
different None None O
mouse None None O
lung None None O
tumor None None O
models None None O
- None None O
- None None O
subcutaneous None None O
, None None O
orthotopic None None O
xenograft None None O
, None None O
and None None O
spontaneous None None O
metastasis None None O
lung None None O
tumor None None O
models None None O
. None None O

The None None O
therapeutic None None O
efficacy None None O
of None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
was None None O
determined None None O
by None None O
monitoring None None O
tumor None None O
volume None None O
, None None O
survival None None O
rate None None O
, None None O
and None None O
degree None None O
of None None O
neovascularization None None O
after None None O
treatment None None O
in None None O
these None None O
models None None O
. None None O

RESULTS None None O
: None None O
Mice None None O
bearing None None O
subcutaneous None None O
tumor None None O
of None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
pretreated None None O
Lewis None None O
lung None None O
carcinoma None None O
cells None None O
showed None None O
> None None O
50 None None O
% None None O
reduction None None O
in None None O
primary None None O
tumor None None O
volume None None O
and None None O
reduced None None O
spontaneous None None O
pulmonary None None O
metastases None None O
. None None O

The None None O
tumor None None O
- None None O
suppressive None None O
action None None O
of None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
in None None O
subcutaneous None None O
human None None O
lung None None O
tumor None None O
A549 None None I-Cell-line-name
xenograft None None O
correlated None None O
with None None O
a None None O
reduced None None O
number None None O
of None None O
capillary None None O
vessels None None O
in None None O
tumors None None O
. None None O

In None None O
the None None O
orthotopic None None O
xenograft None None O
model None None O
, None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
suppressed None None O
metastasis None None O
of None None O
A549 None None I-Cell-line-name
tumors None None O
to None None O
mediastinal None None O
lymph None None O
nodes None None O
and None None O
contralateral None None O
lung None None O
. None None O

Furthermore None None O
, None None O
treatment None None O
of None None O
immunocompetent None None O
mice None None O
in None None O
the None None O
spontaneous None None O
lung None None O
metastases None None O
model None None O
with None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
after None None O
primary None None O
tumor None None O
excision None None O
prolonged None None O
their None None O
median None None O
survival None None O
from None None O
21 None None O
to None None O
51 None None O
. None None O
5 None None O
days None None O
. None None O

CONCLUSION None None O
: None None O
Our None None O
results None None O
show None None O
the None None O
effectiveness None None O
of None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
as None None O
an None None O
angiogenesis None None O
inhibitor None None O
in None None O
suppressing None None O
tumor None None O
growth None None O
during None None O
different None None O
stages None None O
of None None O
tumor None None O
progression None None O
, None None O
validating None None O
the None None O
application None None O
of None None O
rAAV2 None None O
/ None None O
5 None None O
- None None O
VAS None None O
gene None None O
therapy None None O
in None None O
treatment None None O
against None None O
lung None None O
cancer None None O
. None None O

The None None O
value None None O
of None None O
serum None None O
S None None O
- None None O
100beta None None O
and None None O
interleukins None None O
as None None O
tumour None None O
markers None None O
in None None O
advanced None None O
melanoma None None O
. None None O

Recently None None O
serum None None O
S None None O
- None None O
100beta None None O
has None None O
shown None None O
promise None None O
as None None O
a None None O
tumour None None O
marker None None O
in None None O
melanoma None None O
; None None O
however None None O
, None None O
its None None O
use None None O
as None None O
a None None O
prognostic None None O
marker None None O
in None None O
the None None O
advanced None None O
stage None None O
needs None None O
to None None O
be None None O
confirmed None None O
. None None O

Interleukins None None O
( None None O
ILs None None O
) None None O
may None None O
mediate None None O
regression None None O
or None None O
progression None None O
of None None O
cancer None None O
. None None O

In None None O
order None None O
to None None O
study None None O
their None None O
relation None None O
to None None O
the None None O
metastatic None None O
profile None None O
and None None O
survival None None O
, None None O
we None None O
evaluated None None O
the None None O
association None None O
between None None O
pretreatment None None O
serum None None O
levels None None O
of None None O
S None None O
- None None O
100beta None None O
, None None O
IL None None O
- None None O
6 None None O
, None None O
IL None None O
- None None O
10 None None O
and None None O
IL None None O
- None None O
12 None None O
and None None O
metastatic None None O
site None None O
and None None O
survival None None O
in None None O
50 None None O
patients None None O
with None None O
advanced None None O
melanoma None None O
who None None O
were None None O
to None None O
receive None None O
chemoimmunotherapy None None O
. None None O

Patients None None O
with None None O
liver None None O
and None None O
/ None None O
or None None O
bone None None O
metastases None None O
had None None O
significantly None None O
higher None None O
median None None O
concentrations None None O
of None None O
S None None O
- None None O
100beta None None O
, None None O
IL None None O
- None None O
6 None None O
and None None O
IL None None O
- None None O
10 None None O
than None None O
those None None O
with None None O
only None None O
skin None None O
, None None O
nodal None None O
and None None O
/ None None O
or None None O
lung None None O
involvement None None O
. None None O

The None None O
differences None None O
in None None O
IL None None O
- None None O
12 None None O
levels None None O
were None None O
unremarkable None None O
. None None O

Using None None O
univariate None None O
analysis None None O
, None None O
the None None O
S None None O
- None None O
100beta None None O
level None None O
and None None O
metastatic None None O
profile None None O
were None None O
found None None O
to None None O
be None None O
statistically None None O
significant None None O
prognostic None None O
factors None None O
for None None O
survival None None O
. None None O

Using None None O
multivariate None None O
analysis None None O
the None None O
S None None O
- None None O
100beta None None O
level None None O
was None None O
the None None O
most None None O
powerful None None O
prognostic None None O
indicator None None O
, None None O
while None None O
the None None O
metastatic None None O
profile None None O
was None None O
found None None O
to None None O
be None None O
significant None None O
after None None O
exclusion None None O
of None None O
S None None O
- None None O
100beta None None O
. None None O

The None None O
findings None None O
suggest None None O
that None None O
elevated None None O
serum None None O
levels None None O
of None None O
S None None O
- None None O
100beta None None O
, None None O
IL None None O
- None None O
6 None None O
and None None O
IL None None O
- None None O
10 None None O
reflect None None O
concurrent None None O
liver None None O
or None None O
bone None None O
metastases None None O
in None None O
melanoma None None O
. None None O

S None None O
- None None O
100beta None None O
is None None O
also None None O
an None None O
independent None None O
prognostic None None O
marker None None O
. None None O

Pretreatment None None O
IL None None O
levels None None O
were None None O
not None None O
associated None None O
with None None O
outcome None None O
. None None O

External None None O
beam None None O
radiotherapy None None O
for None None O
subretinal None None O
neovascularization None None O
in None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
: None None O
is None None O
this None None O
treatment None None O
efficient None None O
? None None O

PURPOSE None None O
: None None O
Control None None O
of None None O
the None None O
natural None None O
course None None O
of None None O
subretinal None None O
neovascularization None None O
( None None O
SRNV None None O
) None None O
in None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
( None None O
AMD None None O
) None None O
is None None O
difficult None None O
. None None O

Only None None O
a None None O
subset None None O
of None None O
patients None None O
is None None O
suitable None None O
for None None O
laser None None O
coagulation None None O
. None None O

This None None O
prospective None None O
study None None O
aimed None None O
to None None O
determine None None O
the None None O
efficacy None None O
and None None O
individual None None O
benefit None None O
of None None O
external None None O
beam None None O
radiotherapy None None O
( None None O
EBRT None None O
) None None O
. None None O

METHODS None None O
AND None None O
MATERIALS None None O
: None None O
The None None O
prospective None None O
trial None None O
included None None O
287 None None O
patients None None O
with None None O
subfoveal None None O
neovascularization None None O
due None None O
to None None O
AMD None None O
which None None O
was None None O
verified None None O
by None None O
fluorescein None None O
angiography None None O
. None None O

Patients None None O
have None None O
been None None O
treated None None O
between None None O
January None None O
1996 None None O
and None None O
October None None O
1997 None None O
. None None O

All None None O
patients None None O
received None None O
a None None O
total None None O
dose None None O
of None None O
16 None None O
Gy None None O
in None None O
2 None None O
- None None O
Gy None None O
daily None None O
fractions None None O
with None None O
5 None None O
- None None O
6 None None O
MeV None None O
photons None None O
based None None O
on None None O
computerized None None O
treatment None None O
planning None None O
in None None O
individual None None O
head None None O
mask None None O
fixation None None O
. None None O

This None None O
first None None O
analysis None None O
is None None O
based None None O
on None None O
73 None None O
patients None None O
( None None O
50 None None O
women None None O
, None None O
23 None None O
men None None O
, None None O
median None None O
age None None O
74 None None O
. None None O
3 None None O
years None None O
) None None O
, None None O
with None None O
a None None O
median None None O
follow None None O
- None None O
up None None O
of None None O
13 None None O
. None None O
3 None None O
months None None O
and None None O
a None None O
minimum None None O
follow None None O
- None None O
up None None O
of None None O
11 None None O
months None None O
. None None O

RESULTS None None O
: None None O
All None None O
patients None None O
completed None None O
therapy None None O
and None None O
tolerability None None O
was None None O
good None None O
. None None O

First None None O
clinical None None O
control None None O
with None None O
second None None O
angiography None None O
was None None O
performed None None O
6 None None O
weeks None None O
after None None O
irradiation None None O
, None None O
then None None O
in None None O
3 None None O
- None None O
month None None O
intervals None None O
. None None O

Eighteen None None O
patients None None O
with None None O
SRNV None None O
refusing None None O
radiotherapy None None O
served None None O
as None None O
a None None O
control None None O
group None None O
and None None O
were None None O
matched None None O
with None None O
18 None None O
irradiated None None O
patients None None O
. None None O

After None None O
7 None None O
months None None O
median None None O
visual None None O
acuity None None O
( None None O
VA None None O
) None None O
was None None O
20 None None O
/ None None O
160 None None O
for None None O
the None None O
irradiated None None O
and None None O
20 None None O
/ None None O
400 None None O
for None None O
the None None O
untreated None None O
patients None None O
. None None O

One None None O
year None None O
after None None O
radiotherapy None None O
final None None O
median None None O
VA None None O
was None None O
20 None None O
/ None None O
400 None None O
in None None O
both None None O
groups None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
16 None None O
Gy None None O
of None None O
conventionally None None O
fractionated None None O
external None None O
beam None None O
irradiation None None O
slows None None O
down None None O
the None None O
visual None None O
loss None None O
in None None O
exudative None None O
AMD None None O
for None None O
only None None O
a None None O
few None None O
months None None O
. None None O

Patients None None O
' None None O
reading None None O
vision None None O
could None None O
not None None O
be None None O
saved None None O
for None None O
a None None O
long None None O
- None None O
term None None O
run None None O
. None None O

Appendix None None O
Table None None O

Detection None None O
of None None O
Nipah None None O
virus None None O
antibody None None O
among None None O
bat None None O
serum None None O
samples None None O
collected None None O
from None None O
10 None None O
provinces None None O
in None None O
China None None O
, None None O
2004 None None O
- None None O
2007 None None O
* None None O

Enforced None None O
expression None None O
of None None O
tissue None None O
inhibitor None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
3 None None O
affects None None O
functional None None O
capillary None None O
morphogenesis None None O
and None None O
inhibits None None O
tumor None None O
growth None None O
in None None O
a None None O
murine None None O
tumor None None O
model None None O
. None None O

Homeostasis None None O
of None None O
the None None O
extracellular None None O
matrix None None O
is None None O
a None None O
delicate None None O
balance None None O
between None None O
degradation None None O
and None None O
remodeling None None O
, None None O
the None None O
balance None None O
being None None O
maintained None None O
by None None O
the None None O
interaction None None O
of None None O
activated None None O
matrix None None O
metalloproteinases None None O
( None None O
MMPs None None O
) None None O
and None None O
specific None None O
tissue None None O
inhibitors None None O
of None None O
matrix None None O
metalloproteinases None None O
( None None O
TIMPs None None O
) None None O
. None None O

Up None None O
- None None O
regulation None None O
of None None O
MMP None None O
activity None None O
, None None O
favoring None None O
proteolytic None None O
degradation None None O
of None None O
the None None O
basement None None O
membrane None None O
and None None O
extracellular None None O
matrix None None O
, None None O
has None None O
been None None O
linked None None O
to None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
, None None O
as None None O
well None None O
as None None O
tumor None None O
- None None O
associated None None O
angiogenesis None None O
, None None O
whereas None None O
inhibition None None O
of None None O
MMP None None O
activity None None O
appears None None O
to None None O
restrict None None O
these None None O
processes None None O
. None None O

We None None O
have None None O
used None None O
retroviral None None O
- None None O
mediated None None O
gene None None O
delivery None None O
to None None O
effect None None O
sustained None None O
autocrine None None O
expression None None O
of None None O
TIMP None None O
- None None O
3 None None O
in None None O
murine None None O
neuroblastoma None None O
and None None O
melanoma None None O
tumor None None O
cells None None O
in None None O
order None None O
to None None O
further None None O
examine None None O
the None None O
ability None None O
of None None O
TIMPs None None O
to None None O
inhibit None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

Growth None None O
of None None O
both None None O
histologic None None O
types None None O
of None None O
gene None None O
- None None O
modified None None O
tumor None None O
cells None None O
in None None O
severe None None O
combined None None O
immunodeficiency None None O
( None None O
SCID None None O
) None None O
mice None None O
was None None O
significantly None None O
restricted None None O
when None None O
compared None None O
with None None O
controls None None O
. None None O

Grossly None None O
, None None O
these None None O
tumors None None O
were None None O
small None None O
and None None O
had None None O
few None None O
feeding None None O
vessels None None O
. None None O

Histologic None None O
evaluation None None O
revealed None None O
that None None O
although None None O
tumors None None O
overexpressing None None O
TIMP None None O
- None None O
3 None None O
had None None O
an None None O
increased None None O
number None None O
of None None O
CD31 None None O
( None None O
+ None None O
) None None O
endothelial None None O
cells None None O
, None None O
these None None O
endothelial None None O
cells None None O
had None None O
not None None O
formed None None O
functional None None O
tubules None None O
, None None O
as None None O
evidenced None None O
by None None O
decreased None None O
vessel None None O
continuity None None O
and None None O
minimal None None O
pericyte None None O
recruitment None None O
. None None O

This None None O
effect None None O
appears None None O
to None None O
be None None O
mediated None None O
, None None O
in None None O
part None None O
, None None O
by None None O
decreased None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
( None None O
VE None None O
) None None O
- None None O
cadherin None None O
by None None O
endothelial None None O
cells None None O
in None None O
the None None O
presence None None O
of None None O
TIMP None None O
- None None O
3 None None O
as None None O
seen None None O
both None None O
in None None O
an None None O
in None None O
vitro None None O
assay None None O
and None None O
in None None O
TIMP None None O
- None None O
3 None None O
- None None O
overexpressing None None O
tumors None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
demonstrate None None O
that None None O
overexpression None None O
of None None O
TIMP None None O
- None None O
3 None None O
can None None O
inhibit None None O
angiogenesis None None O
and None None O
associated None None O
tumor None None O
growth None None O
, None None O
and None None O
that None None O
the None None O
antiangiogenic None None O
effects None None O
of None None O
TIMP None None O
- None None O
3 None None O
appear None None O
to None None O
be None None O
mediated None None O
through None None O
the None None O
inhibition None None O
of None None O
functional None None O
capillary None None O
morphogenesis None None O
. None None O

Thrombospondin None None O
- None None O
2 None None O
plays None None O
a None None O
protective None None O
role None None O
in None None O
multistep None None O
carcinogenesis None None O
: None None O
a None None O
novel None None O
host None None O
anti None None O
- None None O
tumor None None O
defense None None O
mechanism None None O
. None None O

The None None O
angiogenic None None O
switch None None O
during None None O
tumorigenesis None None O
is None None O
thought None None O
to None None O
be None None O
induced None None O
by None None O
a None None O
change None None O
in None None O
the None None O
balance None None O
of None None O
pro None None O
- None None O
angiogenic None None O
and None None O
anti None None O
- None None O
angiogenic None None O
factors None None O
. None None O

To None None O
elucidate None None O
the None None O
biological None None O
role None None O
of None None O
the None None O
endogenous None None O
angiogenesis None None O
inhibitor None None O
thrombospondin None None O
- None None O
2 None None O
( None None O
TSP None None O
- None None O
2 None None O
) None None O
during None None O
multistep None None O
carcinogenesis None None O
, None None O
we None None O
subjected None None O
TSP None None O
- None None O
2 None None O
- None None O
deficient None None O
and None None O
wild None None O
- None None O
type None None O
mice None None O
to None None O
a None None O
chemical None None O
skin None None O
carcinogenesis None None O
regimen None None O
. None None O

Surprisingly None None O
, None None O
TSP None None O
- None None O
2 None None O
expression None None O
was None None O
strongly None None O
upregulated None None O
in None None O
the None None O
mesenchymal None None O
stroma None None O
of None None O
wild None None O
- None None O
type None None O
mice None None O
throughout None None O
the None None O
consecutive None None O
stages None None O
of None None O
tumorigenesis None None O
whereas None None O
the None None O
angiogenesis None None O
factor None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
was None None O
induced None None O
predominantly None None O
in None None O
tumor None None O
cells None None O
. None None O

TSP None None O
- None None O
2 None None O
deficiency None None O
dramatically None None O
enhanced None None O
susceptibility None None O
to None None O
skin None None O
carcinogenesis None None O
and None None O
resulted None None O
in None None O
accelerated None None O
and None None O
increased None None O
tumor None None O
formation None None O
. None None O

The None None O
angiogenic None None O
switch None None O
occurred None None O
in None None O
early None None O
stages None None O
of None None O
pre None None O
- None None O
malignant None None O
tumor None None O
formation None None O
, None None O
and None None O
tumor None None O
angiogenesis None None O
was None None O
significantly None None O
enhanced None None O
in None None O
TSP None None O
- None None O
2 None None O
- None None O
deficient None None O
mice None None O
. None None O

While None None O
TSP None None O
- None None O
2 None None O
deficiency None None O
did None None O
not None None O
affect None None O
tumor None None O
differentiation None None O
or None None O
proliferation None None O
, None None O
tumor None None O
cell None None O
apoptosis None None O
was None None O
significantly None None O
reduced None None O
. None None O

These None None O
results None None O
reveal None None O
upregulation None None O
of None None O
an None None O
endogenous None None O
angiogenesis None None O
inhibitor None None O
during None None O
multi None None O
step None None O
tumorigenesis None None O
and None None O
identify None None O
enhanced None None O
stromal None None O
TSP None None O
- None None O
2 None None O
expression None None O
as None None O
a None None O
novel None None O
host None None O
anti None None O
- None None O
tumor None None O
defense None None O
mechanism None None O
. None None O

Novel None None O
biological None None O
agents None None O
for None None O
the None None O
treatment None None O
of None None O
hormone None None O
- None None O
refractory None None O
prostate None None O
cancer None None O
( None None O
HRPC None None O
) None None O
. None None O

Hormone None None O
- None None O
refractory None None O
prostate None None O
cancer None None O
( None None O
HRPC None None O
) None None O
is None None O
an None None O
inevitable None None O
evolution None None O
of None None O
prostate None None O
carcinogenesis None None O
, None None O
through None None O
which None None O
the None None O
normal None None O
dependence None None O
on None None O
hormones None None O
for None None O
growth None None O
and None None O
survival None None O
is None None O
bypassed None None O
. None None O

Although None None O
advances None None O
in None None O
terms None None O
of None None O
symptoms None None O
palliation None None O
and None None O
quality None None O
of None None O
life None None O
improvement None None O
have None None O
been None None O
addressed None None O
with None None O
current None None O
treatment None None O
options None None O
, None None O
innovative None None O
approaches None None O
are None None O
needed None None O
to None None O
improve None None O
survival None None O
rates None None O
. None None O

A None None O
thorough None None O
understanding None None O
of None None O
HRPC None None O
- None None O
associated None None O
molecular None None O
pathways None None O
and None None O
mechanisms None None O
of None None O
resistance None None O
are None None O
a None None O
prerequisite None None O
for None None O
novel None None O
potential None None O
therapeutic None None O
interventions None None O
. None None O

Preclinical None None O
and None None O
early None None O
clinical None None O
studies None None O
are None None O
ongoing None None O
to None None O
evaluate None None O
new None None O
therapies None None O
that None None O
target None None O
specific None None O
molecular None None O
entities None None O
. None None O

Agents None None O
under None None O
development None None O
include None None O
growth None None O
factor None None O
receptor None None O
inhibitors None None O
, None None O
small None None O
molecules None None O
targeting None None O
signal None None O
transduction None None O
pathways None None O
, None None O
apoptosis None None O
and None None O
cell None None O
- None None O
cycle None None O
regulators None None O
, None None O
angiogenesis None None O
and None None O
metastasis None None O
inhibitors None None O
, None None O
differentiation None None O
agents None None O
, None None O
telomerase None None O
inactivators None None O
, None None O
and None None O
epigenetic None None O
therapeutics None None O
. None None O

Incorporation None None O
of None None O
these None None O
agents None None O
into None None O
existing None None O
treatment None None O
regimens None None O
will None None O
guide None None O
us None None O
in None None O
the None None O
development None None O
of None None O
a None None O
multidisciplinary None None O
treatment None None O
strategy None None O
of None None O
HRPC None None O
. None None O

This None None O
article None None O
critically None None O
reviews None None O
published None None O
data None None O
on None None O
new None None O
biological None None O
agents None None O
that None None O
are None None O
being None None O
tested None None O
in None None O
HRPC None None O
clinical None None O
trials None None O
, None None O
highlights None None O
ongoing None None O
research None None O
and None None O
considers None None O
the None None O
future None None O
perspectives None None O
of None None O
this None None O
new None None O
class None None O
of None None O
agents None None O
. None None O

Parameters None None O
derived None None O
from None None O
normalized None None O
averaged None None O
data None None O
across None None O
participants None None O

Promotion None None O
of None None O
tumorigenesis None None O
by None None O
heterozygous None None O
disruption None None O
of None None O
the None None O
beclin None None O
1 None None O
autophagy None None O
gene None None O
. None None O

Malignant None None O
cells None None O
often None None O
display None None O
defects None None O
in None None O
autophagy None None O
, None None O
an None None O
evolutionarily None None O
conserved None None O
pathway None None O
for None None O
degrading None None O
long None None O
- None None O
lived None None O
proteins None None O
and None None O
cytoplasmic None None O
organelles None None O
. None None O

However None None O
, None None O
as None None O
yet None None O
, None None O
there None None O
is None None O
no None None O
genetic None None O
evidence None None O
for None None O
a None None O
role None None O
of None None O
autophagy None None O
genes None None O
in None None O
tumor None None O
suppression None None O
. None None O

The None None O
beclin None None O
1 None None O
autophagy None None O
gene None None O
is None None O
monoallelically None None O
deleted None None O
in None None O
40 None None O
- None None O
75 None None O
% None None O
of None None O
cases None None O
of None None O
human None None O
sporadic None None O
breast None None O
, None None O
ovarian None None O
, None None O
and None None O
prostate None None O
cancer None None O
. None None O

Therefore None None O
, None None O
we None None O
used None None O
a None None O
targeted None None O
mutant None None O
mouse None None O
model None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
monoallelic None None O
deletion None None O
of None None O
beclin None None O
1 None None O
promotes None None O
tumorigenesis None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
heterozygous None None O
disruption None None O
of None None O
beclin None None O
1 None None O
increases None None O
the None None O
frequency None None O
of None None O
spontaneous None None O
malignancies None None O
and None None O
accelerates None None O
the None None O
development None None O
of None None O
hepatitis None None O
B None None O
virus None None O
- None None O
induced None None O
premalignant None None O
lesions None None O
. None None O

Molecular None None O
analyses None None O
of None None O
tumors None None O
in None None O
beclin None None O
1 None None O
heterozygous None None O
mice None None O
show None None O
that None None O
the None None O
remaining None None O
wild None None O
- None None O
type None None O
allele None None O
is None None O
neither None None O
mutated None None O
nor None None O
silenced None None O
. None None O

Furthermore None None O
, None None O
beclin None None O
1 None None O
heterozygous None None O
disruption None None O
results None None O
in None None O
increased None None O
cellular None None O
proliferation None None O
and None None O
reduced None None O
autophagy None None O
in None None O
vivo None None O
. None None O

These None None O
findings None None O
demonstrate None None O
that None None O
beclin None None O
1 None None O
is None None O
a None None O
haplo None None O
- None None O
insufficient None None O
tumor None None O
- None None O
suppressor None None O
gene None None O
and None None O
provide None None O
genetic None None O
evidence None None O
that None None O
autophagy None None O
is None None O
a None None O
novel None None O
mechanism None None O
of None None O
cell None None O
- None None O
growth None None O
control None None O
and None None O
tumor None None O
suppression None None O
. None None O

Thus None None O
, None None O
mutation None None O
of None None O
beclin None None O
1 None None O
or None None O
other None None O
autophagy None None O
genes None None O
may None None O
contribute None None O
to None None O
the None None O
pathogenesis None None O
of None None O
human None None O
cancers None None O
. None None O

Surgery None None O

Trabeculectomy None None O
should None None O
be None None O
considered None None O
in None None O
all None None O
patients None None O
, None None O
when None None O
the None None O
' None None O
target None None O
IOP None None O
' None None O
is None None O
not None None O
achieved None None O
with None None O
glaucoma None None O
medications None None O
and None None O
if None None O
the None None O
expected None None O
rate None None O
of None None O
visual None None O
loss None None O
could None None O
affect None None O
the None None O
patient None None O
during None None O
their None None O
lifetime None None O
. None None O

In None None O
this None None O
procedure None None O
, None None O
an None None O
opening None None O
is None None O
made None None O
in None None O
the None None O
trabecular None None O
meshwork None None O
, None None O
so None None O
that None None O
aqueous None None O
humor None None O
can None None O
drain None None O
into None None O
the None None O
sclera None None O
. None None O

Many None None O
patients None None O
can None None O
discontinue None None O
glaucoma None None O
medications None None O
after None None O
surgery None None O
. None None O

Approximately None None O
one None None O
- None None O
third None None O
of None None O
the None None O
trabeculectomy None None O
patients None None O
develop None None O
cataract None None O
within None None O
five None None O
years None None O
. None None O

If None None O
trabeculectomy None None O
fails None None O
, None None O
another None None O
type None None O
of None None O
surgery None None O
places None None O
a None None O
drainage None None O
tube None None O
( None None O
Molteno None None O
tube None None O
) None None O
in None None O
the None None O
eye None None O
, None None O
between None None O
the None None O
cornea None None O
and None None O
iris None None O
, None None O
which None None O
exits None None O
at None None O
the None None O
junction None None O
of None None O
the None None O
cornea None None O
and None None O
sclera None None O
. None None O

Cyclodestructive None None O
procedures None None O
, None None O
which None None O
lower None None O
IOP None None O
by None None O
destroying None None O
the None None O
ciliary None None O
body None None O
, None None O
are None None O
typically None None O
reserved None None O
for None None O
eyes None None O
, None None O
which None None O
are None None O
refractory None None O
to None None O
all None None O
other None None O
forms None None O
of None None O
therapy None None O
. None None O

These None None O
procedures None None O
include None None O
cyclocryotherapy None None O
, None None O
cylcodiathermy None None O
and None None O
laser None None O
cyclophotocoagulation None None O
. None None O
[ None None O
91 None None O
- None None O
93 None None O
] None None O

Type None None O
- None None O
A None None O
cholecystokinin None None O
receptors None None O
in None None O
CHP212 None None I-Cell-line-name
neuroblastoma None None O
cells None None O
: None None O
evidence None None O
for None None O
association None None O
with None None O
G None None O
protein None None O
and None None O
activation None None O
of None None O
phosphoinositide None None O
hydrolysis None None O
. None None O

125I None None O
- None None O
Bolton None None O
Hunter None None O
- None None O
cholecystokinin None None O
octapeptide None None O
( None None O
BH None None O
- None None O
CCK8 None None O
) None None O
and None None O
( None None O
- None None O
) None None O
- None None O
[ None None O
3H None None O
] None None O
L None None O
- None None O
364718 None None O
membrane None None O
binding None None O
assays None None O
were None None O
used None None O
to None None O
identify None None O
and None None O
characterize None None O
cholecystokinin None None O
( None None O
CCK None None O
) None None O
receptors None None O
in None None O
CHP212 None None I-Cell-line-name
human None None O
neuroblastoma None None O
cells None None O
. None None O

The None None O
ligand None None O
binding None None O
properties None None O
of None None O
CCK None None O
receptors None None O
in None None O
these None None O
cells None None O
are None None O
similar None None O
to None None O
those None None O
found None None O
in None None O
pancreas None None O
( None None O
CCK None None O
- None None O
A None None O
sites None None O
) None None O
and None None O
differ None None O
from None None O
the None None O
predominant None None O
type None None O
of None None O
CCK None None O
binding None None O
site None None O
found None None O
in None None O
brain None None O
( None None O
CCK None None O
- None None O
B None None O
sites None None O
) None None O
. None None O

The None None O
specific None None O
binding None None O
of None None O
125I None None O
- None None O
BH None None O
- None None O
CCK8 None None O
but None None O
not None None O
( None None O
- None None O
) None None O
- None None O
[ None None O
3H None None O
] None None O
L None None O
- None None O
364718 None None O
was None None O
reduced None None O
by None None O
the None None O
metabolically None None O
stable None None O
GTP None None O
analog None None O
guanosine None None O
5 None None O
' None None O
- None None O
( None None O
beta None None O
- None None O
delta None None O
- None None O
imido None None O
) None None O
trisphosphate None None O
. None None O

A None None O
substantial None None O
difference None None O
in None None O
the None None O
Bmax None None O
for None None O
the None None O
radiolabeled None None O
agonist None None O
( None None O
125I None None O
- None None O
BH None None O
- None None O
CCK8 None None O
) None None O
and None None O
antagonist None None O
[ None None O
( None None O
- None None O
) None None O
- None None O
[ None None O
3H None None O
] None None O
L None None O
- None None O
364718 None None O
] None None O
was None None O
noted None None O
. None None O

These None None O
observations None None O
are None None O
consistent None None O
with None None O
CCK None None O
receptors None None O
existing None None O
in None None O
guanine None None O
nucleotide None None O
- None None O
binding None None O
protein None None O
- None None O
coupled None None O
and None None O
- None None O
uncoupled None None O
states None None O
. None None O

Similar None None O
to None None O
its None None O
action None None O
in None None O
pancreatic None None O
acinar None None O
cells None None O
, None None O
CCK8 None None O
( None None O
S None None O
) None None O
stimulated None None O
the None None O
accumulation None None O
of None None O
[ None None O
3H None None O
] None None O
inositol None None O
phosphates None None O
in None None O
cells None None O
prelabeled None None O
with None None O
[ None None O
3H None None O
] None None O
myo None None O
- None None O
inositol None None O
( None None O
EC50 None None O
= None None O
3 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
4 None None O
nM None None O
; None None O
maximum None None O
response None None O
= None None O
4 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
4 None None O
x None None O
basal None None O
) None None O
. None None O

The None None O
intrinsic None None O
activity None None O
of None None O
CCK None None O
analogues None None O
in None None O
stimulating None None O
phosphoinositide None None O
hydrolysis None None O
was None None O
substantially None None O
less None None O
than None None O
their None None O
reported None None O
intrinsic None None O
activity None None O
in None None O
stimulating None None O
phosphoinositide None None O
hydrolysis None None O
in None None O
pancreatic None None O
acinar None None O
cells None None O
. None None O

The None None O
CHP212 None None I-Cell-line-name
neuroblastoma None None O
cell None None O
may None None O
serve None None O
as None None O
a None None O
useful None None O
model None None O
for None None O
the None None O
recently None None O
reported None None O
CCK None None O
- None None O
A None None O
binding None None O
site None None O
found None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
. None None O

Full None None O
sequencing None None O
analysis None None O
of None None O
estrogen None None O
receptor None None O
- None None O
alpha None None O
gene None None O
polymorphism None None O
and None None O
its None None O
association None None O
with None None O
breast None None O
cancer None None O
risk None None O
. None None O

BACKGROUND None None O
: None None O

The None None O
estrogen None None O
receptor None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
breast None None O
cancer None None O
development None None O
and None None O
progression None None O
. None None O

So None None O
the None None O
genetic None None O
polymorphism None None O
of None None O
ER None None O
- None None O
alpha None None O
gene None None O
could None None O
affect None None O
cancer None None O
risk None None O
and None None O
phenotype None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O

We None None O
fully None None O
sequenced None None O
the None None O
ER None None O
- None None O
alpha None None O
gene None None O
to None None O
investigate None None O
its None None O
single None None O
nucleotide None None O
polymorphisms None None O
( None None O
SNPs None None O
) None None O
in None None O
100 None None O
breast None None O
cancer None None O
patients None None O
and None None O
100 None None O
controls None None O
. None None O

RESULTS None None O
: None None O

Six None None O
novel None None O
polymorphism None None O
in None None O
the None None O
control None None O
and None None O
11 None None O
in None None O
cancer None None O
patients None None O
were None None O
found None None O
. None None O

The None None O
G None None O
/ None None O
G None None O
genotype None None O
at None None O
C975 None None O
G None None O
and None None O
A None None O
/ None None O
A None None O
genotype None None O
at None None O
G1782 None None O
A None None O
had None None O
a None None O
protective None None O
effect None None O
against None None O
breast None None O
cancer None None O
when None None O
compared None None O
to None None O
other None None O
genotypes None None O
( None None O
OR None None O
= None None O
0 None None O
. None None O
3 None None O
and None None O
0 None None O
. None None O
3 None None O
, None None O
respectively None None O
) None None O
. None None O

975G None None O
allele None None O
was None None O
associated None None O
inversely None None O
with None None O
the None None O
p53 None None O
expression None None O
and None None O
positively None None O
with None None O
the None None O
bcl None None O
- None None O
2 None None O
expression None None O
in None None O
cancer None None O
with None None O
borderline None None O
significance None None O
. None None O

Combining None None O
this None None O
result None None O
with None None O
our None None O
previous None None O
study None None O
, None None O
these None None O
associations None None O
became None None O
more None None O
significant None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
005 None None O
and None None O
0 None None O
. None None O
019 None None O
, None None O
respectively None None O
) None None O
. None None O

CONCLUSION None None O
: None None O

Polymorphisms None None O
in None None O
ER None None O
- None None O
alpha None None O
gene None None O
can None None O
affect None None O
the None None O
breast None None O
cancer None None O
susceptibility None None O
and None None O
may None None O
be None None O
related None None O
to None None O
other None None O
protein None None O
expression None None O
, None None O
such None None O
as None None O
p53 None None O
and None None O
bcl None None O
- None None O
2 None None O
. None None O

Identification None None O
of None None O
the None None O
putative None None O
transforming None None O
protein None None O
of None None O
the None None O
human None None O
T None None O
- None None O
cell None None O
leukemia None None O
viruses None None O
HTLV None None O
- None None O
I None None O
and None None O
HTLV None None O
- None None O
II None None O
. None None O

The None None O
human None None O
T None None O
- None None O
cell None None O
leukemia None None O
viruses None None O
HTLV None None O
- None None O
I None None O
and None None O
HTLV None None O
- None None O
II None None O
are None None O
unique None None O
among None None O
the None None O
transforming None None O
retroviruses None None O
of None None O
vertebrates None None O
in None None O
their None None O
ability None None O
to None None O
transform None None O
human None None O
T None None O
cells None None O
in None None O
vitro None None O
and None None O
in None None O
their None None O
close None None O
association None None O
with None None O
human None None O
malignancies None None O
( None None O
T None None O
- None None O
cell None None O
lymphomas None None O
and None None O
leukemia None None O
) None None O
. None None O

Their None None O
genomes None None O
are None None O
relatively None None O
simple None None O
, None None O
containing None None O
the None None O
genes None None O
gag None None O
, None None O
pol None None O
, None None O
env None None O
, None None O
and None None O
a None None O
3 None None O
' None None O
region None None O
termed None None O
" None None O
X None None O
. None None O
" None None O
This None None O
3 None None O
' None None O
region None None O
may None None O
be None None O
responsible None None O
for None None O
the None None O
transforming None None O
potential None None O
of None None O
the None None O
viruses None None O
. None None O

The None None O
existence None None O
of None None O
proteins None None O
encoded None None O
by None None O
the None None O
3 None None O
' None None O
region None None O
has None None O
been None None O
postulated None None O
on None None O
the None None O
basis None None O
of None None O
multiple None None O
open None None O
reading None None O
frames None None O
. None None O

In None None O
the None None O
present None None O
study None None O
this None None O
region None None O
is None None O
shown None None O
to None None O
contain None None O
a None None O
gene None None O
encoding None None O
a None None O
protein None None O
of None None O
40 None None O
kilodaltons None None O
in None None O
HTLV None None O
- None None O
I None None O
and None None O
37 None None O
kilodaltons None None O
in None None O
HTLV None None O
- None None O
II None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
these None None O
proteins None None O
be None None O
called None None O
, None None O
respectively None None O
, None None O
p40xI None None O
and None None O
p37xII None None O
. None None O

Sensitivity None None O
of None None O
intervention None None O
cost None None O
- None None O
effectiveness None None O
to None None O
rates None None O
of None None O
decay None None O
in None None O
intervention None None O
effectiveness None None O
between None None O
0 None None O
% None None O
( None None O
life None None O
- None None O
long None None O
health None None O
benefits None None O
from None None O
one None None O
- None None O
off None None O
intervention None None O
) None None O
and None None O
100 None None O
% None None O
( None None O
no None None O
health None None O
benefits None None O
beyond None None O
the None None O
end None None O
of None None O
intervention None None O
) None None O
. None None O

Pancreatic None None O
somatostatin None None O
- None None O
secreting None None O
gangliocytic None None O
paraganglioma None None O
with None None O
lymph None None O
node None None O
metastases None None O
. None None O

Gangliocytic None None O
paraganglioma None None O
( None None O
GPG None None O
) None None O
with None None O
local None None O
lymph None None O
node None None O
metastasis None None O
was None None O
found None None O
in None None O
the None None O
pancreas None None O
of None None O
a None None O
74 None None O
- None None O
yr None None O
- None None O
old None None O
female None None O
who None None O
presented None None O
with None None O
diarrhea None None O
, None None O
steatorrhea None None O
, None None O
vomiting None None O
, None None O
nausea None None O
, None None O
and None None O
abdominal None None O
pain None None O
. None None O

A None None O
Whipple None None O
procedure None None O
led None None O
to None None O
a None None O
complete None None O
resolution None None O
of None None O
these None None O
symptoms None None O
and None None O
a None None O
return None None O
of None None O
an None None O
elevated None None O
stomatostatin None None O
level None None O
to None None O
normal None None O
. None None O

This None None O
is None None O
the None None O
first None None O
description None None O
of None None O
GPG None None O
in None None O
this None None O
location None None O
and None None O
the None None O
first None None O
endocrinologically None None O
active None None O
GPG None None O
. None None O

Oncogenic None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
mutants None None O
with None None O
tandem None None O
duplication None None O
: None None O
gene None None O
structure None None O
and None None O
effects None None O
on None None O
receptor None None O
function None None O
. None None O

A None None O
number None None O
of None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
deletion None None O
mutants None None O
have None None O
been None None O
identified None None O
in None None O
gliomas None None O
, None None O
in None None O
which None None O
the None None O
EGFR None None O
gene None None O
is None None O
frequently None None O
amplified None None O
and None None O
rearranged None None O
. None None O

We None None O
have None None O
previously None None O
characterized None None O
the None None O
structure None None O
of None None O
a None None O
gene None None O
in None None O
A None None I-Cell-line-name
- None None I-Cell-line-name
172 None None I-Cell-line-name
human None None O
glioma None None O
cells None None O
that None None O
encodes None None O
a None None O
190 None None O
- None None O
kDa None None O
EGFR None None O
mutant None None O
with None None O
tandem None None O
duplication None None O
of None None O
the None None O
tyrosine None None O
kinase None None O
( None None O
TK None None O
) None None O
and None None O
calcium None None O
- None None O
mediated None None O
internalization None None O
( None None O
CAIN None None O
) None None O
domains None None O
. None None O

Here None None O
we None None O
describe None None O
a None None O
185 None None O
- None None O
kDa None None O
tandem None None O
duplication None None O
mutant None None O
( None None O
TDM None None O
) None None O
that None None O
is None None O
expressed None None O
in None None O
KE None None O
and None None O
A None None I-Cell-line-name
- None None I-Cell-line-name
1235 None None I-Cell-line-name
glioma None None O
cells None None O
, None None O
along None None O
with None None O
certain None None O
functional None None O
characteristics None None O
of None None O
the None None O
mutants None None O
. None None O

The None None O
corresponding None None O
transcripts None None O
in None None O
KE None None O
and None None O
A None None I-Cell-line-name
- None None I-Cell-line-name
1235 None None I-Cell-line-name
cells None None O
contain None None O
1053 None None O
additional None None O
nucleotides None None O
representing None None O
an None None O
in None None O
- None None O
frame None None O
duplication None None O
of None None O
exons None None O
18 None None O
through None None O
25 None None O
which None None O
encode None None O
the None None O
entire None None O
TK None None O
region None None O
and None None O
a None None O
portion None None O
of None None O
the None None O
CAIN None None O
domain None None O
. None None O

As None None O
with None None O
duplication None None O
of None None O
the None None O
entire None None O
TK None None O
/ None None O
CAIN None None O
region None None O
( None None O
exons None None O
18 None None O
- None None O
26 None None O
) None None O
in None None O
A None None I-Cell-line-name
- None None I-Cell-line-name
172 None None I-Cell-line-name
cells None None O
, None None O
duplication None None O
of None None O
exons None None O
18 None None O
- None None O
25 None None O
is None None O
associated None None O
with None None O
a None None O
specific None None O
genomic None None O
rearrangement None None O
between None None O
flanking None None O
introns None None O
. None None O

Involved None None O
introns None None O
contain None None O
homology None None O
to None None O
recombination None None O
signal None None O
sequence None None O
( None None O
RSS None None O
) None None O
heptamers None None O
present None None O
in None None O
the None None O
V None None O
( None None O
D None None O
) None None O
J None None O
region None None O
of None None O
the None None O
T None None O
lymphocyte None None O
receptor None None O
gene None None O
. None None O

In None None O
defined None None O
medium None None O
, None None O
both None None O
oncogenic None None O
TDM None None O
are None None O
constitutively None None O
autophosphorylated None None O
and None None O
inefficiently None None O
downregulated None None O
. None None O

High None None O
- None None O
affinity None None O
binding None None O
is None None O
reduced None None O
in None None O
EGFR None None O
. None None O
TDM None None O
/ None None O
18 None None O
- None None O
26 None None O
, None None O
although None None O
the None None O
t1 None None O
/ None None O
2 None None O
of None None O
receptor None None O
internalization None None O
is None None O
not None None O
prolonged None None O
. None None O

A None None O
practical None None O
interface None None O
for None None O
microfluidics None None O
and None None O
nanoelectrospray None None O
mass None None O
spectrometry None None O
. None None O

We None None O
report None None O
a None None O
new None None O
method None None O
for None None O
fabricating None None O
nanospray None None O
ionization None None O
tips None None O
for None None O
MS None None O
, None None O
formed None None O
from None None O
glass None None O
substrates None None O
and None None O
the None None O
inert None None O
polymer None None O
, None None O
parylene None None O
- None None O
C None None O
. None None O

Using None None O
a None None O
single None None O
photolithography None None O
step None None O
, None None O
the None None O
emitters None None O
are None None O
formed None None O
contiguously None None O
with None None O
microchannels None None O
, None None O
such None None O
that None None O
no None None O
dead None None O
volumes None None O
are None None O
observed None None O
. None None O

In None None O
addition None None O
, None None O
because None None O
the None None O
devices None None O
are None None O
very None None O
thin None None O
( None None O
approximately None None O
0 None None O
. None None O
3 None None O
mm None None O
) None None O
and None None O
the None None O
tips None None O
are None None O
formed None None O
at None None O
rectangular None None O
corners None None O
, None None O
the None None O
Taylor None None O
cone None None O
volumes None None O
are None None O
small None None O
, None None O
which None None O
makes None None O
the None None O
method None None O
attractive None None O
for None None O
future None None O
integration None None O
with None None O
microfluidic None None O
separations None None O
. None None O

Device None None O
performance None None O
was None None O
demonstrated None None O
by None None O
evaluating None None O
diverse None None O
analytes None None O
, None None O
ranging None None O
from None None O
synthetic None None O
polymers None None O
, None None O
to None None O
peptides None None O
, None None O
to None None O
nucleic None None O
acids None None O
. None None O

For None None O
all None None O
analytes None None O
, None None O
performance None None O
was None None O
similar None None O
to None None O
that None None O
of None None O
conventional None None O
emitters None None O
( None None O
pulled None None O
- None None O
glass None None O
capillaries None None O
and None None O
the None None O
Agilent None None O
HPLC None None O
Chip None None O
) None None O
with None None O
the None None O
advantage None None O
of None None O
rapid None None O
, None None O
batch None None O
fabrication None None O
of None None O
identical None None O
devices None None O
. None None O

3 None None O
. None None O
1 None None O
. None None O

Glucose None None O
Tolerance None None O
Test None None O
at None None O
Various None None O
Times None None O
following None None O
Dosing None None O

DIO None None O
mice None None O
were None None O
treated None None O
with None None O
a None None O
single None None O
IV None None O
dose None None O
of None None O
CNTO None None O
530 None None O
( None None O
0 None None O
. None None O
3 None None O
mg None None O
/ None None O
kg None None O
) None None O
, None None O
and None None O
glucose None None O
metabolism None None O
was None None O
monitored None None O
using None None O
an None None O
intraperitoneal None None O
glucose None None O
tolerance None None O
test None None O
( None None O
IPGTT None None O
) None None O
at None None O
various None None O
times None None O
following None None O
dosing None None O
( None None O
day None None O
1 None None O
to None None O
35 None None O
) None None O
. None None O

CNTO None None O
530 None None O
did None None O
not None None O
influence None None O
glucose None None O
tolerance None None O
24 None None O
hours None None O
after None None O
dosing None None O
. None None O

However None None O
, None None O
a None None O
significant None None O
improvement None None O
was None None O
observed None None O
in None None O
both None None O
fasting None None O
glucose None None O
( None None O
179 None None O
+ None None O
/ None None O
- None None O
29 None None O
versus None None O
133 None None O
+ None None O
/ None None O
- None None O
19 None None O
mg None None O
/ None None O
dL None None O
for None None O
untreated None None O
versus None None O
treated None None O
) None None O
and None None O
overall None None O
glucose None None O
tolerance None None O
seven None None O
days None None O
after None None O
a None None O
single None None O
dose None None O
of None None O
CNTO None None O
530 None None O
( None None O
Figure None None O
2 None None O
( None None O
b None None O
) None None O
) None None O
. None None O

In None None O
a None None O
separate None None O
study None None O
, None None O
the None None O
activity None None O
of None None O
CNTO None None O
530 None None O
was None None O
compared None None O
to None None O
a None None O
control None None O
protein None None O
that None None O
lacked None None O
the None None O
EMP None None O
- None None O
1 None None O
peptides None None O
to None None O
ensure None None O
that None None O
the None None O
observed None None O
effects None None O
were None None O
due None None O
to None None O
the None None O
peptide None None O
and None None O
not None None O
the None None O
Fc None None O
. None None O

The None None O
glucose None None O
lowering None None O
effect None None O
was None None O
not None None O
observed None None O
in None None O
the None None O
mice None None O
treated None None O
with None None O
the None None O
protein None None O
lacking None None O
the None None O
EMP None None O
- None None O
1 None None O
peptides None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Fasting None None O
blood None None O
glucose None None O
remained None None O
improved None None O
in None None O
the None None O
treated None None O
animals None None O
14 None None O
and None None O
21 None None O
days None None O
after None None O
CNTO530 None None O
treatment None None O
, None None O
but None None O
was None None O
similar None None O
to None None O
the None None O
untreated None None O
group None None O
after None None O
35 None None O
days None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

The None None O
area None None O
under None None O
the None None O
curve None None O
( None None O
AUC None None O
) None None O
for None None O
the None None O
glucose None None O
tolerance None None O
tests None None O
showed None None O
a None None O
significant None None O
improvement None None O
with None None O
CNTO None None O
530 None None O
treatment None None O
on None None O
days None None O
7 None None O
, None None O
14 None None O
, None None O
20 None None O
, None None O
and None None O
28 None None O
( None None O
Figure None None O
2 None None O
( None None O
b None None O
) None None O
) None None O
. None None O

The None None O
most None None O
dramatic None None O
effect None None O
on None None O
glucose None None O
tolerance None None O
following None None O
CNTO None None O
530 None None O
- None None O
treatment None None O
was None None O
observed None None O
on None None O
day None None O
14 None None O
where None None O
glucose None None O
was None None O
cleared None None O
from None None O
circulation None None O
by None None O
the None None O
15 None None O
- None None O
minute None None O
time None None O
point None None O
( None None O
Figure None None O
2 None None O
( None None O
a None None O
) None None O
) None None O
. None None O

CNTO None None O
530 None None O
- None None O
mediated None None O
acceleration None None O
of None None O
glucose None None O
utilization None None O
was None None O
diminished None None O
but None None O
still None None O
significant None None O
by None None O
day None None O
28 None None O
and None None O
not None None O
seen None None O
by None None O
day None None O
35 None None O
( None None O
Figure None None O
2 None None O
( None None O
b None None O
) None None O
) None None O
. None None O

Hemoglobin None None O
levels None None O
followed None None O
a None None O
similar None None O
time None None O
- None None O
dependent None None O
change None None O
, None None O
showing None None O
an None None O
increase None None O
that None None O
peaked None None O
on None None O
day None None O
22 None None O
and None None O
returned None None O
to None None O
normal None None O
levels None None O
by None None O
day None None O
29 None None O
( None None O
Figure None None O
2 None None O
( None None O
c None None O
) None None O
) None None O
. None None O

Similar None None O
studies None None O
were None None O
completed None None O
in None None O
lean None None O
littermate None None O
mice None None O
fed None None O
a None None O
normal None None O
chow None None O
diet None None O
. None None O

Mice None None O
( None None O
n None None O
= None None O
7 None None O
) None None O
were None None O
given None None O
a None None O
single None None O
administration None None O
of None None O
CNTO None None O
530 None None O
( None None O
0 None None O
. None None O
01 None None O
- None None O
0 None None O
. None None O
3 None None O
mg None None O
/ None None O
kg None None O
) None None O
, None None O
and None None O
glucose None None O
tolerance None None O
tests None None O
were None None O
completed None None O
after None None O
1 None None O
and None None O
14 None None O
days None None O
. None None O

As None None O
we None None O
observed None None O
in None None O
the None None O
diabetic None None O
rodents None None O
, None None O
no None None O
significant None None O
changes None None O
were None None O
seen None None O
in None None O
glucose None None O
clearance None None O
24 None None O
hours None None O
after None None O
dosing None None O
. None None O

However None None O
, None None O
there None None O
were None None O
significant None None O
improvements None None O
in None None O
the None None O
area None None O
under None None O
the None None O
curve None None O
in None None O
the None None O
glucose None None O
tolerance None None O
test None None O
in None None O
animals None None O
dosed None None O
with None None O
0 None None O
. None None O
3 None None O
and None None O
0 None None O
. None None O
1 None None O
mg None None O
/ None None O
kg None None O
CNTO None None O
530 None None O
as None None O
compared None None O
to None None O
PBS None None O
( None None O
22865 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
1900 None None O
. None None O
2 None None O
, None None O
24478 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
1093 None None O
. None None O
4 None None O
, None None O
and None None O
28773 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
1368 None None O
. None None O
3 None None O
, None None O
resp None None O
. None None O
, None None O
mean None None O
+ None None O
/ None None O
- None None O
SEM None None O
) None None O
. None None O

There None None O
were None None O
no None None O
dose None None O
- None None O
dependent None None O
changes None None O
in None None O
the None None O
fasting None None O
blood None None O
glucose None None O
. None None O

Atomic None None O
displacement None None O
parameters None None O
( None None O
A2 None None O
) None None O

U11 None None O
U22 None None O
U33 None None O
U12 None None O
U13 None None O
U23 None None O

Br None None O
0 None None O
. None None O
03555 None None O
( None None O
15 None None O
) None None O
0 None None O
. None None O
05091 None None O
( None None O
17 None None O
) None None O
0 None None O
. None None O
03161 None None O
( None None O
14 None None O
) None None O
- None None O
0 None None O
. None None O
01198 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
01077 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
00502 None None O
( None None O
11 None None O
) None None O

S None None O
0 None None O
. None None O
0273 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
0176 None None O
( None None O
2 None None O
) None None O
0 None None O
. None None O
0338 None None O
( None None O
3 None None O
) None None O
0 None None O
. None None O
0016 None None O
( None None O
2 None None O
) None None O
- None None O
0 None None O
. None None O
0020 None None O
( None None O
2 None None O
) None None O
0 None None O
. None None O
0026 None None O
( None None O
2 None None O
) None None O

F None None O
0 None None O
. None None O
0514 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0486 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0464 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0068 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0279 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0001 None None O
( None None O
7 None None O
) None None O

O1 None None O
0 None None O
. None None O
0293 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0186 None None O
( None None O
7 None None O
) None None O
0 None None O
. None None O
0251 None None O
( None None O
7 None None O
) None None O
- None None O
0 None None O
. None None O
0030 None None O
( None None O
6 None None O
) None None O
0 None None O
. None None O
0028 None None O
( None None O
6 None None O
) None None O
0 None None O
. None None O
0004 None None O
( None None O
6 None None O
) None None O

O2A None None O
0 None None O
. None None O
0417 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0238 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0326 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0001 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0051 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0102 None None O
( None None O
7 None None O
) None None O

O2B None None O
0 None None O
. None None O
036 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
010 None None O
( None None O
7 None None O
) None None O
0 None None O
. None None O
025 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
003 None None O
( None None O
7 None None O
) None None O
0 None None O
. None None O
003 None None O
( None None O
7 None None O
) None None O
0 None None O
. None None O
007 None None O
( None None O
6 None None O
) None None O

C1 None None O
0 None None O
. None None O
0228 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0192 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0233 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0001 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0023 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0019 None None O
( None None O
8 None None O
) None None O

C2 None None O
0 None None O
. None None O
0258 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0199 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0193 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0000 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0033 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0016 None None O
( None None O
7 None None O
) None None O

C3 None None O
0 None None O
. None None O
0263 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0229 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0177 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0020 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0031 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0008 None None O
( None None O
8 None None O
) None None O

C4 None None O
0 None None O
. None None O
0294 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0228 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0277 None None O
( None None O
11 None None O
) None None O
- None None O
0 None None O
. None None O
0014 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0008 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0027 None None O
( None None O
8 None None O
) None None O

C5 None None O
0 None None O
. None None O
0323 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0297 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0285 None None O
( None None O
11 None None O
) None None O
- None None O
0 None None O
. None None O
0081 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0003 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0042 None None O
( None None O
9 None None O
) None None O

C6 None None O
0 None None O
. None None O
0257 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0389 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0207 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0049 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0013 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0001 None None O
( None None O
9 None None O
) None None O

C7 None None O
0 None None O
. None None O
0320 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0304 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0218 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0015 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0009 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0005 None None O
( None None O
9 None None O
) None None O

C8 None None O
0 None None O
. None None O
0298 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0257 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0178 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0006 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0012 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0001 None None O
( None None O
8 None None O
) None None O

C9 None None O
0 None None O
. None None O
0392 None None O
( None None O
14 None None O
) None None O
0 None None O
. None None O
0205 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0219 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0034 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0031 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0010 None None O
( None None O
8 None None O
) None None O

C10 None None O
0 None None O
. None None O
0378 None None O
( None None O
13 None None O
) None None O
0 None None O
. None None O
0184 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0234 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0017 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0014 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0006 None None O
( None None O
8 None None O
) None None O

C11 None None O
0 None None O
. None None O
0254 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0227 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0198 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0024 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0004 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0006 None None O
( None None O
8 None None O
) None None O

C12 None None O
0 None None O
. None None O
0254 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0187 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0222 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0003 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0032 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0007 None None O
( None None O
7 None None O
) None None O

C13 None None O
0 None None O
. None None O
0237 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0220 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0222 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0012 None None O
( None None O
8 None None O
) None None O
- None None O
0 None None O
. None None O
0008 None None O
( None None O
8 None None O
) None None O
0 None None O
. None None O
0030 None None O
( None None O
8 None None O
) None None O

C14 None None O
0 None None O
. None None O
0298 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0241 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0286 None None O
( None None O
11 None None O
) None None O
- None None O
0 None None O
. None None O
0009 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0007 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0006 None None O
( None None O
9 None None O
) None None O

C15 None None O
0 None None O
. None None O
0408 None None O
( None None O
14 None None O
) None None O
0 None None O
. None None O
0267 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0269 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0049 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0028 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0031 None None O
( None None O
9 None None O
) None None O

C16 None None O
0 None None O
. None None O
0353 None None O
( None None O
14 None None O
) None None O
0 None None O
. None None O
0326 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0294 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0094 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0094 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0058 None None O
( None None O
9 None None O
) None None O

C17 None None O
0 None None O
. None None O
0255 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0281 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0349 None None O
( None None O
12 None None O
) None None O
- None None O
0 None None O
. None None O
0001 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0015 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0082 None None O
( None None O
9 None None O
) None None O

C18 None None O
0 None None O
. None None O
0271 None None O
( None None O
12 None None O
) None None O
0 None None O
. None None O
0231 None None O
( None None O
10 None None O
) None None O
0 None None O
. None None O
0250 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0002 None None O
( None None O
9 None None O
) None None O
- None None O
0 None None O
. None None O
0032 None None O
( None None O
9 None None O
) None None O
0 None None O
. None None O
0011 None None O
( None None O
8 None None O
) None None O

C19 None None O
0 None None O
. None None O
0353 None None O
( None None O
14 None None O
) None None O
0 None None O
. None None O
0251 None None O
( None None O
11 None None O
) None None O
0 None None O
. None None O
0375 None None O
( None None O
13 None None O
) None None O
- None None O
0 None None O
. None None O
0045 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0070 None None O
( None None O
10 None None O
) None None O
- None None O
0 None None O
. None None O
0012 None None O
( None None O
9 None None O
) None None O

Ras None None O
- None None O
association None None O
domain None None O
family None None O
1C None None O
protein None None O
promotes None None O
breast None None O
cancer None None O
cell None None O
migration None None O
and None None O
attenuates None None O
apoptosis None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
Ras None None O
association None None O
domain None None O
family None None O
1 None None O
( None None O
RASSF1 None None O
) None None O
gene None None O
is None None O
a None None O
Ras None None O
effector None None O
encoding None None O
two None None O
major None None O
mRNA None None O
forms None None O
, None None O
RASSF1A None None O
and None None O
RASSF1C None None O
, None None O
derived None None O
by None None O
alternative None None O
promoter None None O
selection None None O
and None None O
alternative None None O
mRNA None None O
splicing None None O
. None None O

RASSF1A None None O
is None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
. None None O

However None None O
, None None O
very None None O
little None None O
is None None O
known None None O
about None None O
the None None O
function None None O
of None None O
RASSF1C None None O
both None None O
in None None O
normal None None O
and None None O
transformed None None O
cells None None O
. None None O

METHODS None None O
: None None O
Gene None None O
silencing None None O
and None None O
over None None O
- None None O
expression None None O
techniques None None O
were None None O
used None None O
to None None O
modulate None None O
RASSF1C None None O
expression None None O
in None None O
human None None O
breast None None O
cancer None None O
cells None None O
. None None O

Affymetrix None None O
- None None O
microarray None None O
analysis None None O
was None None O
performed None None O
using None None O
T47D None None I-Cell-line-name
cells None None O
over None None O
- None None O
expressing None None O
RASSF1C None None O
to None None O
identify None None O
RASSF1C None None O
target None None O
genes None None O
. None None O

RT None None O
- None None O
PCR None None O
and None None O
western None None O
blot None None O
techniques None None O
were None None O
used None None O
to None None O
validate None None O
target None None O
gene None None O
expression None None O
. None None O

Cell None None O
invasion None None O
and None None O
apoptosis None None O
assays None None O
were None None O
also None None O
performed None None O
. None None O

RESULTS None None O
: None None O
In None None O
this None None O
article None None O
, None None O
we None None O
report None None O
the None None O
effects None None O
of None None O
altering None None O
RASSF1C None None O
expression None None O
in None None O
human None None O
breast None None O
cancer None None O
cells None None O
. None None O

We None None O
found None None O
that None None O
silencing None None O
RASSF1C None None O
mRNA None None O
in None None O
breast None None O
cancer None None O
cell None None O
lines None None O
( None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB231 None None I-Cell-line-name
and None None O
T47D None None I-Cell-line-name
) None None O
caused None None O
a None None O
small None None O
but None None O
significant None None O
decrease None None O
in None None O
cell None None O
proliferation None None O
. None None O

Conversely None None O
, None None O
inducible None None O
over None None O
- None None O
expression None None O
of None None O
RASSF1C None None O
in None None O
breast None None O
cancer None None O
cells None None O
( None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB231 None None I-Cell-line-name
and None None O
T47D None None I-Cell-line-name
) None None O
resulted None None O
in None None O
a None None O
small None None O
increase None None O
in None None O
cell None None O
proliferation None None O
. None None O

We None None O
also None None O
report None None O
on None None O
the None None O
identification None None O
of None None O
novel None None O
RASSF1C None None O
target None None O
genes None None O
. None None O

RASSF1C None None O
down None None O
- None None O
regulates None None O
several None None O
pro None None O
- None None O
apoptotic None None O
and None None O
tumor None None O
suppressor None None O
genes None None O
and None None O
up None None O
- None None O
regulates None None O
several None None O
growth None None O
promoting None None O
genes None None O
in None None O
breast None None O
cancer None None O
cells None None O
. None None O

We None None O
further None None O
show None None O
that None None O
down None None O
- None None O
regulation None None O
of None None O
caspase None None O
3 None None O
via None None O
overexpression None None O
of None None O
RASSF1C None None O
reduces None None O
breast None None O
cancer None None O
cells None None O
' None None O
sensitivity None None O
to None None O
the None None O
apoptosis None None O
inducing None None O
agent None None O
, None None O
etoposide None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
RASSF1C None None O
over None None O
- None None O
expression None None O
enhances None None O
T47D None None I-Cell-line-name
cell None None O
invasion None None O
/ None None O
migration None None O
in None None O
vitro None None O
. None None O

CONCLUSION None None O
: None None O
Together None None O
, None None O
our None None O
findings None None O
suggest None None O
that None None O
RASSF1C None None O
, None None O
unlike None None O
RASSF1A None None O
, None None O
is None None O
not None None O
a None None O
tumor None None O
suppressor None None O
, None None O
but None None O
instead None None O
may None None O
play None None O
a None None O
role None None O
in None None O
stimulating None None O
metastasis None None O
and None None O
survival None None O
in None None O
breast None None O
cancer None None O
cells None None O
. None None O

Flow None None O
dynamics None None O
of None None O
the None None O
internal None None O
thoracic None None O
and None None O
radial None None O
artery None None O
T None None O
- None None O
graft None None O
. None None O

BACKGROUND None None O
: None None O

Complex None None O
use None None O
of None None O
arterial None None O
conduits None None O
has None None O
resurrected None None O
concerns None None O
about None None O
the None None O
adequacy None None O
of None None O
conduit None None O
flow None None O
. None None O

The None None O
T None None O
- None None O
graft None None O
is None None O
the None None O
extreme None None O
example None None O
of None None O
this None None O
trend None None O
. None None O

Our None None O
purpose None None O
was None None O
to None None O
identify None None O
the None None O
limitation None None O
of None None O
single None None O
source None None O
inflow None None O
and None None O
to None None O
compare None None O
flow None None O
capacity None None O
with None None O
completion None None O
coronary None None O
flow None None O
. None None O

METHODS None None O
: None None O

Between None None O
February None None O
1999 None None O
and None None O
November None None O
2001 None None O
, None None O
372 None None O
patients None None O
underwent None None O
total None None O
arterial None None O
revascularization None None O
with None None O
the None None O
T None None O
- None None O
graft None None O
alone None None O
. None None O

Intraoperative None None O
flows None None O
were None None O
recorded None None O
for None None O
each None None O
limb None None O
of None None O
the None None O
T None None O
- None None O
graft None None O
before None None O
and None None O
after None None O
distal None None O
anastomoses None None O
in None None O
204 None None O
patients None None O
. None None O

Independent None None O
predictors None None O
of None None O
T None None O
- None None O
graft None None O
flow None None O
were None None O
identified None None O
by None None O
multivariate None None O
analysis None None O
. None None O

RESULTS None None O
: None None O

Free None None O
flow None None O
for None None O
the None None O
radial None None O
arterial None None O
( None None O
RA None None O
) None None O
limb None None O
was None None O
161 None None O
+ None None O
/ None None O
- None None O
81 None None O
mL None None O
/ None None O
min None None O
, None None O
the None None O
internal None None O
thoracic None None O
artery None None O
( None None O
ITA None None O
) None None O
limb None None O
137 None None O
+ None None O
/ None None O
- None None O
57 None None O
mL None None O
/ None None O
min None None O
( None None O
combined None None O
298 None None O
+ None None O
/ None None O
- None None O
101 None None O
mL None None O
/ None None O
min None None O
) None None O
versus None None O
simultaneous None None O
limb None None O
flow None None O
of None None O
226 None None O
+ None None O
/ None None O
- None None O
84 None None O
mL None None O
/ None None O
min None None O
giving None None O
a None None O
flow None None O
restriction None None O
of None None O
24 None None O
% None None O
+ None None O
/ None None O
- None None O
14 None None O
% None None O
. None None O

Completion None None O
coronary None None O
flow None None O
was None None O
88 None None O
+ None None O
/ None None O
- None None O
49 None None O
mL None None O
/ None None O
min None None O
for None None O
the None None O
RA None None O
, None None O
60 None None O
+ None None O
/ None None O
- None None O
45 None None O
mL None None O
/ None None O
min None None O
for None None O
the None None O
ITA None None O
, None None O
and None None O
140 None None O
+ None None O
/ None None O
- None None O
70 None None O
mL None None O
/ None None O
min None None O
for None None O
both None None O
limbs None None O
simultaneously None None O
to None None O
give None None O
a None None O
flow None None O
reserve None None O
( None None O
vs None None O
simultaneous None None O
free None None O
flow None None O
) None None O
of None None O
160 None None O
% None None O
or None None O
1 None None O
. None None O
6 None None O
. None None O

Independent None None O
predictors None None O
of None None O
completion None None O
RA None None O
limb None None O
flow None None O
are None None O
RA None None O
proximal None None O
diameter None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
005 None None O
) None None O
, None None O
number None None O
of None None O
anastomoses None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
018 None None O
) None None O
, None None O
and None None O
target None None O
stenosis None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
005 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

A None None O
flow None None O
reserve None None O
of None None O
1 None None O
. None None O
6 None None O
compares None None O
favorably None None O
with None None O
an None None O
ITA None None O
flow None None O
reserve None None O
of None None O
1 None None O
. None None O
8 None None O
at None None O
1 None None O
- None None O
month None None O
postoperatively None None O
and None None O
1 None None O
. None None O
8 None None O
for None None O
both None None O
the None None O
ITA None None O
T None None O
- None None O
graft None None O
and None None O
the None None O
ITA None None O
/ None None O
RA None None O
T None None O
- None None O
graft None None O
at None None O
1 None None O
- None None O
week None None O
postoperatively None None O
as None None O
reported None None O
by None None O
others None None O
. None None O

Proximal None None O
RA None None O
diameter None None O
and None None O
competitive None None O
coronary None None O
flow None None O
influence None None O
completion None None O
T None None O
- None None O
graft None None O
flow None None O
. None None O

These None None O
data None None O
quantitate None None O
the None None O
limitation None None O
of None None O
single None None O
source None None O
inflow None None O
of None None O
the None None O
T None None O
- None None O
graft None None O
configuration None None O
and None None O
support None None O
its None None O
continued None None O
use None None O
. None None O

Collagen None None O
- None None O
poly None None O
glycolic None None O
acid None None O
hybrid None None O
matrix None None O
with None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
accelerated None None O
angiogenesis None None O
and None None O
granulation None None O
tissue None None O
formation None None O
in None None O
diabetic None None O
mice None None O
. None None O

Because None None O
poor None None O
skin None None O
wound None None O
healing None None O
associated None None O
with None None O
diabetes None None O
is None None O
thought None None O
to None None O
be None None O
partly None None O
a None None O
result None None O
from None None O
impaired None None O
angiogenesis None None O
, None None O
treatments None None O
that None None O
improve None None O
angiogenesis None None O
could None None O
have None None O
important None None O
clinical None None O
applications None None O
. None None O

We None None O
herein None None O
report None None O
the None None O
effects None None O
of None None O
novel None None O
developed None None O
material None None O
, None None O
collagen None None O
- None None O
poly None None O
glycolic None None O
acid None None O
fiber None None O
hybrid None None O
matrix None None O
, None None O
being None None O
used None None O
together None None O
with None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
to None None O
promote None None O
wound None None O
healing None None O
of None None O
full None None O
- None None O
thickness None None O
skin None None O
defects None None O
on None None O
the None None O
back None None O
of None None O
type None None O
2 None None O
diabetic None None O
Lepr None None O
( None None O
db None None O
) None None O
mice None None O
. None None O

Our None None O
data None None O
indicates None None O
that None None O
this None None O
therapeutic None None O
approach None None O
markedly None None O
promotes None None O
angiogenesis None None O
and None None O
granulation None None O
tissue None None O
formation None None O
in None None O
comparison None None O
with None None O
other None None O
conditions None None O
14 None None O
days None None O
after None None O
wounding None None O
. None None O

Differences None None O
between None None O
the None None O
arterial None None O
and None None O
the None None O
venous None None O
pathomorphology None None O
in None None O
Buerger None None O
' None None O
s None None O
disease None None O
. None None O

Morphological None None O
lesions None None O
were None None O
found None None O
to None None O
be None None O
different None None O
in None None O
arteries None None O
and None None O
in None None O
veins None None O
, None None O
in None None O
9 None None O
cases None None O
of None None O
Buerger None None O
' None None O
s None None O
disease None None O
. None None O

The None None O
arterial None None O
lesions None None O
were None None O
not None None O
characteristic None None O
and None None O
consisted None None O
of None None O
non None None O
- None None O
specific None None O
inflammation None None O
, None None O
thrombosis None None O
and None None O
obliteration None None O
which None None O
also None None O
occur None None O
in None None O
many None None O
other None None O
disease None None O
. None None O

In None None O
contrast None None O
, None None O
in None None O
addition None None O
to None None O
wall None None O
infiltration None None O
and None None O
thrombosis None None O
, None None O
the None None O
veins None None O
showed None None O
microabscesses None None O
and None None O
giant None None O
cell None None O
granulomas None None O
, None None O
which None None O
we None None O
believe None None O
to None None O
be None None O
absent None None O
in None None O
all None None O
other None None O
known None None O
diseases None None O
. None None O

The None None O
affected None None O
venous None None O
segment None None O
exhibited None None O
a None None O
variety None None O
of None None O
lesions None None O
. None None O

In None None O
the None None O
earliest None None O
period None None O
, None None O
the None None O
morphological None None O
aspect None None O
of None None O
inflammation None None O
in None None O
arteries None None O
and None None O
veins None None O
was None None O
fairly None None O
similar None None O
. None None O

In None None O
a None None O
late None None O
periods None None O
, None None O
that None None O
is None None O
those None None O
of None None O
vascular None None O
obliteration None None O
, None None O
the None None O
arteries None None O
and None None O
veins None None O
did None None O
not None None O
show None None O
any None None O
distinguishing None None O
morphological None None O
differences None None O
. None None O

PI3K None None O
/ None None O
Akt None None O
- None None O
dependent None None O
transcriptional None None O
regulation None None O
and None None O
activation None None O
of None None O
BMP None None O
- None None O
2 None None O
- None None O
Smad None None O
signaling None None O
by None None O
NF None None O
- None None O
kappaB None None O
in None None O
metastatic None None O
prostate None None O
cancer None None O
cells None None O
. None None O

BACKGROUND None None O
: None None O
Bone None None O
morphogenetic None None O
proteins None None O
( None None O
BMPs None None O
) None None O
exert None None O
osteoinductive None None O
effects None None O
in None None O
prostate None None O
cancer None None O
( None None O
PC None None O
) None None O
via None None O
uncharacterized None None O
mechanisms None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
whether None None O
the None None O
nuclear None None O
transcription None None O
factor None None O
NF None None O
- None None O
kappaB None None O
, None None O
implicated None None O
in None None O
PC None None O
metastasis None None O
, None None O
is None None O
involved None None O
in None None O
transcriptional None None O
regulation None None O
and None None O
activation None None O
of None None O
BMP None None O
- None None O
2 None None O
or None None O
BMP None None O
- None None O
4 None None O
/ None None O
Smad None None O
signaling None None O
in None None O
PC None None O
cells None None O
. None None O

METHODS None None O
: None None O
NF None None O
- None None O
kappaB None None O
inhibition None None O
was None None O
achieved None None O
by None None O
IkappaBalpha None None O
super None None O
- None None O
repressor None None O
adenoviral None None O
vector None None O
and None None O
activation None None O
was None None O
monitored None None O
by None None O
EMSA None None O
and None None O
reporter None None O
assays None None O
. None None O

BMP None None O
expression None None O
and None None O
activation None None O
was None None O
measured None None O
by None None O
PCR None None O
and None None O
reporter None None O
assays None None O
. None None O

Promoter None None O
binding None None O
assay None None O
was None None O
performed None None O
by None None O
chromatin None None O
immunoprecipitation None None O
( None None O
ChIP None None O
) None None O
assay None None O
. None None O

Smad1 None None O
/ None None O
5 None None O
/ None None O
8 None None O
phosphorylation None None O
was None None O
measured None None O
by None None O
Western None None O
blot None None O
analysis None None O
. None None O

RESULTS None None O
: None None O
PCR None None O
and None None O
chimeric None None O
BMP None None O
- None None O
2 None None O
and None None O
BMP None None O
- None None O
4 None None O
luciferase None None O
assays None None O
demonstrate None None O
that None None O
NF None None O
- None None O
kappaB None None O
confers None None O
robust None None O
and None None O
selective None None O
activation None None O
of None None O
BMP None None O
- None None O
2 None None O
in None None O
p65 None None O
overexpressing None None O
or None None O
rhTNF None None O
- None None O
alpha None None O
- None None O
stimulated None None O
PC None None O
cells None None O
. None None O

Inhibition None None O
of None None O
NF None None O
- None None O
kappaB None None O
significantly None None O
reduced None None O
transcript None None O
levels None None O
and None None O
autocrine None None O
production None None O
of None None O
BMP None None O
- None None O
2 None None O
by None None O
rhTNF None None O
- None None O
alpha None None O
stimulated None None O
C4 None None I-Cell-line-name
- None None I-Cell-line-name
2B None None I-Cell-line-name
cells None None O
and None None O
to None None O
a None None O
lesser None None O
extent None None O
by None None O
the None None O
parental None None O
LNCaP None None I-Cell-line-name
cells None None O
. None None O

Selective None None O
inhibition None None O
of None None O
PI3K None None O
/ None None O
Akt None None O
suppressed None None O
the None None O
NF None None O
- None None O
kappaB None None O
- None None O
induced None None O
BMP None None O
- None None O
2 None None O
promoter None None O
activity None None O
. None None O

Furthermore None None O
, None None O
suppression None None O
of None None O
NF None None O
- None None O
kappaB None None O
activation None None O
decreased None None O
the None None O
transcript None None O
levels None None O
and None None O
BMP None None O
- None None O
2 None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
Smad1 None None O
/ None None O
5 None None O
/ None None O
8 None None O
, None None O
critical None None O
downstream None None O
targets None None O
of None None O
BMP None None O
- None None O
2 None None O
signaling None None O
in None None O
PC None None O
cells None None O
. None None O

Notably None None O
, None None O
the None None O
activation None None O
of None None O
BMPRII None None O
by None None O
BMP None None O
- None None O
2 None None O
is None None O
required None None O
for None None O
modulation None None O
of None None O
Smad None None O
activation None None O
by None None O
NF None None O
- None None O
kappaB None None O
in None None O
PC None None O
cells None None O
. None None O

Based None None O
on None None O
ChIP None None O
analysis None None O
, None None O
the None None O
transcriptional None None O
regulation None None O
of None None O
BMP None None O
- None None O
2 None None O
gene None None O
by None None O
NF None None O
- None None O
kappaB None None O
may None None O
be None None O
partially None None O
attributed None None O
to None None O
binding None None O
to None None O
kappab None None O
site None None O
on None None O
the None None O
BMP None None O
- None None O
2 None None O
promoter None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
data None None O
suggest None None O
that None None O
PI3K None None O
/ None None O
Akt None None O
- None None O
NF None None O
- None None O
kappaB None None O
axis None None O
may None None O
promote None None O
PC None None O
bone None None O
metastasis None None O
in None None O
part None None O
by None None O
regulating None None O
transcription None None O
and None None O
activation None None O
of None None O
the None None O
BMP None None O
- None None O
2 None None O
- None None O
Smad None None O
signaling None None O
cascade None None O
in None None O
osteotropic None None O
PC None None O
cells None None O
. None None O

A None None O
key None None O
role None None O
for None None O
the None None O
integrin None None O
alpha2beta1 None None O
in None None O
experimental None None O
and None None O
developmental None None O
angiogenesis None None O
. None None O

The None None O
alpha2beta1 None None O
integrin None None O
receptor None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
angiogenesis None None O
. None None O

Here None None O
we None None O
investigated None None O
the None None O
effects None None O
of None None O
small None None O
molecule None None O
inhibitors None None O
( None None O
SMIs None None O
) None None O
designed None None O
to None None O
disrupt None None O
integrin None None O
alpha2 None None O
I None None O
or None None O
beta1 None None O
I None None O
- None None O
like None None O
domain None None O
function None None O
on None None O
angiogenesis None None O
. None None O

In None None O
unchallenged None None O
endothelial None None O
cells None None O
, None None O
fibrillar None None O
collagen None None O
induced None None O
robust None None O
capillary None None O
morphogenesis None None O
. None None O

In None None O
contrast None None O
, None None O
tube None None O
formation None None O
was None None O
significantly None None O
reduced None None O
by None None O
SMI496 None None O
, None None O
a None None O
beta1 None None O
I None None O
- None None O
like None None O
domain None None O
inhibitor None None O
and None None O
by None None O
function None None O
- None None O
blocking None None O
anti None None O
- None None O
alpha2beta1 None None O
but None None O
not None None O
- None None O
alpha1beta1 None None O
antibodies None None O
. None None O

Endothelial None None O
cells None None O
bound None None O
fluorescein None None O
- None None O
labeled None None O
collagen None None O
I None None O
fibrils None None O
, None None O
an None None O
interaction None None O
specifically None None O
inhibited None None O
by None None O
SMI496 None None O
. None None O

Moreover None None O
, None None O
SMI496 None None O
caused None None O
cell None None O
retraction None None O
and None None O
cytoskeletal None None O
collapse None None O
of None None O
endothelial None None O
cells None None O
as None None O
well None None O
as None None O
delayed None None O
endothelial None None O
cell None None O
wound None None O
healing None None O
. None None O

SMI None None O
activities None None O
were None None O
examined None None O
in None None O
vivo None None O
by None None O
supplementing None None O
the None None O
growth None None O
medium None None O
of None None O
zebrafish None None O
embryos None None O
expressing None None O
green None None O
fluorescent None None O
protein None None O
under None None O
the None None O
control None None O
of None None O
the None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
- None None O
2 None None O
promoter None None O
. None None O

SMI496 None None O
, None None O
but None None O
not None None O
a None None O
control None None O
compound None None O
, None None O
interfered None None O
with None None O
angiogenesis None None O
in None None O
vivo None None O
by None None O
reversibly None None O
inhibiting None None O
sprouting None None O
from None None O
the None None O
axial None None O
vessels None None O
. None None O

We None None O
further None None O
characterized None None O
zebrafish None None O
alpha2 None None O
integrin None None O
and None None O
discovered None None O
that None None O
this None None O
integrin None None O
is None None O
highly None None O
conserved None None O
, None None O
especially None None O
the None None O
I None None O
domain None None O
. None None O

Notably None None O
, None None O
a None None O
similar None None O
vascular None None O
phenotype None None O
was None None O
induced None None O
by None None O
morpholino None None O
- None None O
mediated None None O
knockdown None None O
of None None O
the None None O
integrin None None O
alpha2 None None O
subunit None None O
. None None O

By None None O
live None None O
videomicroscopy None None O
, None None O
we None None O
confirmed None None O
that None None O
the None None O
vessels None None O
were None None O
largely None None O
nonfunctional None None O
in None None O
the None None O
absence None None O
of None None O
alpha2beta1 None None O
integrin None None O
. None None O

Collectively None None O
, None None O
our None None O
results None None O
provide None None O
strong None None O
biochemical None None O
and None None O
genetic None None O
evidence None None O
of None None O
a None None O
central None None O
role None None O
for None None O
alpha2beta1 None None O
integrin None None O
in None None O
experimental None None O
and None None O
developmental None None O
angiogenesis None None O
. None None O

Epilepsy None None O
in None None O
Down None None O
syndrome None None O
: None None O
clinical None None O
aspects None None O
and None None O
possible None None O
mechanisms None None O
. None None O

Although None None O
epilepsy None None O
is None None O
more None None O
common None None O
in None None O
persons None None O
with None None O
trisomy None None O
21 None None O
( None None O
Down None None O
syndrome None None O
) None None O
than None None O
in None None O
the None None O
general None None O
population None None O
, None None O
the None None O
mechanisms None None O
by None None O
which None None O
seizures None None O
are None None O
generated None None O
in None None O
this None None O
population None None O
have None None O
received None None O
little None None O
attention None None O
. None None O

It None None O
is None None O
likely None None O
that None None O
this None None O
increased None None O
seizure None None O
susceptibility None None O
is None None O
due None None O
to None None O
a None None O
combination None None O
of None None O
medical None None O
risk None None O
factors None None O
and None None O
inherent None None O
neurologic None None O
abnormalities None None O
characteristic None None O
of None None O
Down None None O
syndrome None None O
. None None O

In None None O
this None None O
review None None O
clinical None None O
aspects None None O
of None None O
seizures None None O
among None None O
individuals None None O
with None None O
Down None None O
syndrome None None O
were None None O
described None None O
and None None O
possible None None O
mechanisms None None O
by None None O
which None None O
the None None O
trisomy None None O
21 None None O
brain None None O
may None None O
generate None None O
seizures None None O
were None None O
explored None None O
. None None O

Combined None None O
tracheal None None O
and None None O
esophageal None None O
stenting None None O
for None None O
palliation None None O
of None None O
tracheoesophageal None None O
symptoms None None O
from None None O
mediastinal None None O
lymphoma None None O
. None None O

Mediastinal None None O
lymphoma None None O
as None None O
a None None O
cause None None O
of None None O
tracheobronchial None None O
obstruction None None O
is None None O
uncommon None None O
, None None O
and None None O
a None None O
malignant None None O
tracheoesophageal None None O
fistula None None O
in None None O
the None None O
setting None None O
of None None O
mediastinal None None O
lymphoma None None O
is None None O
rare None None O
. None None O

Malignant None None O
tracheoesophageal None None O
fistulas None None O
are None None O
associated None None O
with None None O
pronounced None None O
morbidity None None O
and None None O
mortality None None O
. None None O

We None None O
describe None None O
a None None O
patient None None O
with None None O
mediastinal None None O
lymphomatous None None O
infiltration None None O
resulting None None O
in None None O
tracheal None None O
obstruction None None O
, None None O
esophageal None None O
obstruction None None O
, None None O
and None None O
tracheoesophageal None None O
fistula None None O
that None None O
were None None O
successfully None None O
palliated None None O
with None None O
combined None None O
airway None None O
and None None O
esophageal None None O
stent None None O
placement None None O
. None None O

A None None O
novel None None O
conotoxin None None O
from None None O
Conus None None O
delessertii None None O
with None None O
posttranslationally None None O
modified None None O
lysine None None O
residues None None O
. None None O

A None None O
major None None O
peptide None None O
, None None O
de13a None None O
from None None O
the None None O
crude None None O
venom None None O
of None None O
Conus None None O
delessertii None None O
collected None None O
in None None O
the None None O
Yucatan None None O
Channel None None O
, None None O
Mexico None None O
, None None O
was None None O
purified None None O
. None None O

The None None O
peptide None None O
had None None O
a None None O
high None None O
content None None O
of None None O
posttranslationally None None O
modified None None O
amino None None O
acids None None O
, None None O
including None None O
6 None None O
- None None O
bromotryptophan None None O
and None None O
a None None O
nonstandard None None O
amino None None O
acid None None O
that None None O
proved None None O
to None None O
be None None O
5 None None O
- None None O
hydroxylysine None None O
. None None O

This None None O
is None None O
the None None O
first None None O
report None None O
of None None O
5 None None O
- None None O
hydroxylysine None None O
residues None None O
in None None O
conotoxins None None O
. None None O

The None None O
sequence None None O
analysis None None O
, None None O
together None None O
with None None O
cDNA None None O
cloning None None O
and None None O
a None None O
mass None None O
determination None None O
( None None O
monoisotopic None None O
mass None None O
of None None O
3486 None None O
. None None O
76 None None O
Da None None O
) None None O
, None None O
established None None O
that None None O
the None None O
mature None None O
toxin None None O
has None None O
the None None O
sequence None None O
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH None None O
, None None O
where None None O
O None None O
is None None O
4 None None O
- None None O
hydroxyproline None None O
, None None O
W None None O
6 None None O
- None None O
bromotryptophan None None O
, None None O
and None None O
K None None O
5 None None O
- None None O
hydroxylysine None None O
, None None O
the None None O
asterisk None None O
represents None None O
the None None O
amidated None None O
C None None O
- None None O
terminus None None O
, None None O
and None None O
the None None O
calculated None None O
monoisotopic None None O
mass None None O
is None None O
3487 None None O
. None None O
09 None None O
Da None None O
. None None O

The None None O
eight None None O
Cys None None O
residues None None O
are None None O
arranged None None O
in None None O
a None None O
pattern None None O
( None None O
C None None O
- None None O
C None None O
- None None O
C None None O
- None None O
CC None None O
- None None O
C None None O
- None None O
C None None O
- None None O
C None None O
) None None O
not None None O
described None None O
previously None None O
in None None O
conotoxins None None O
. None None O

This None None O
arrangement None None O
, None None O
for None None O
which None None O
we None None O
propose None None O
the None None O
designation None None O
of None None O
framework None None O
# None None O
13 None None O
or None None O
XIII None None O
, None None O
differs None None O
from None None O
the None None O
ones None None O
( None None O
C None None O
- None None O
C None None O
- None None O
CC None None O
- None None O
CC None None O
- None None O
C None None O
- None None O
C None None O
and None None O
C None None O
- None None O
C None None O
- None None O
C None None O
- None None O
C None None O
- None None O
CC None None O
- None None O
C None None O
- None None O
C None None O
) None None O
present None None O
in None None O
other None None O
conotoxins None None O
which None None O
also None None O
contain None None O
eight None None O
Cys None None O
residues None None O
. None None O

This None None O
peptide None None O
thus None None O
defines None None O
a None None O
novel None None O
class None None O
of None None O
conotoxins None None O
, None None O
with None None O
a None None O
new None None O
posttranslational None None O
modification None None O
not None None O
previously None None O
found None None O
in None None O
other None None O
Conus None None O
peptide None None O
families None None O
. None None O

Glucose None None O
and None None O
lactate None None O
metabolism None None O
in None None O
C6 None None I-Cell-line-name
glioma None None O
cells None None O
: None None O
evidence None None O
for None None O
the None None O
preferential None None O
utilization None None O
of None None O
lactate None None O
for None None O
cell None None O
oxidative None None O
metabolism None None O
. None None O

13C None None O
and None None O
1H None None O
nuclear None None O
magnetic None None O
resonance None None O
spectroscopy None None O
( None None O
NMR None None O
) None None O
was None None O
used None None O
to None None O
investigate None None O
the None None O
metabolism None None O
of None None O
L None None O
- None None O
lactate None None O
and None None O
D None None O
- None None O
glucose None None O
in None None O
C6 None None I-Cell-line-name
glioma None None O
cells None None O
. None None O

The None None O
13C None None O
enrichment None None O
of None None O
cell None None O
metabolites None None O
was None None O
examined None None O
after None None O
a None None O
4 None None O
- None None O
h None None O
incubation None None O
in None None O
media None None O
containing None None O
5 None None O
. None None O
5 None None O
mM None None O
glucose None None O
and None None O
11 None None O
mM None None O
lactate None None O
, None None O
each None None O
metabolite None None O
being None None O
alternatively None None O
labelled None None O
with None None O
either None None O
[ None None O
1 None None O
- None None O
13C None None O
] None None O
D None None O
- None None O
glucose None None O
or None None O
[ None None O
3 None None O
- None None O
13C None None O
] None None O
L None None O
- None None O
lactate None None O
. None None O

The None None O
results None None O
indicated None None O
that None None O
exogenous None None O
lactate None None O
was None None O
the None None O
major None None O
substrate None None O
for None None O
oxidative None None O
metabolism None None O
. None None O

They None None O
were None None O
consistent None None O
with None None O
the None None O
concept None None O
of None None O
the None None O
existence None None O
of None None O
2 None None O
pools None None O
of None None O
both None None O
lactate None None O
and None None O
pyruvate None None O
, None None O
of None None O
which None None O
1 None None O
pool None None O
was None None O
closely None None O
connected None None O
with None None O
exogenous None None O
lactate None None O
and None None O
oxidative None None O
metabolism None None O
, None None O
and None None O
the None None O
other None None O
pool None None O
was None None O
closely None None O
related None None O
to None None O
glycolysis None None O
and None None O
disconnected None None O
from None None O
oxidative None None O
metabolism None None O
. None None O

The None None O
molecular None None O
basis None None O
of None None O
this None None O
behaviour None None O
could None None O
be None None O
related None None O
to None None O
different None None O
locations None None O
for None None O
the None None O
lactate None None O
dehydrogenase None None O
isoenzymes None None O
, None None O
as None None O
suggested None None O
by None None O
their None None O
immunohistochemical None None O
labelling None None O
. None None O

Convergence None None O
of None None O
p53 None None O
and None None O
TGF None None O
- None None O
beta None None O
signaling None None O
networks None None O
. None None O

p53 None None O
is None None O
a None None O
protein None None O
with None None O
many None None O
talents None None O
. None None O

One None None O
of None None O
the None None O
most None None O
fundamental None None O
is None None O
the None None O
ability None None O
to None None O
act None None O
as None None O
essential None None O
growth None None O
checkpoint None None O
that None None O
protects None None O
cells None None O
against None None O
cellular None None O
transformation None None O
. None None O

p53 None None O
does None None O
so None None O
through None None O
the None None O
induction None None O
of None None O
genes None None O
leading None None O
to None None O
growth None None O
arrest None None O
or None None O
apoptosis None None O
. None None O

Most None None O
of None None O
the None None O
studies None None O
focusing None None O
on None None O
the None None O
mechanisms None None O
of None None O
p53 None None O
activity None None O
have None None O
been None None O
performed None None O
in None None O
cultured None None O
cells None None O
upon None None O
treatment None None O
with None None O
well None None O
- None None O
established None None O
p53 None None O
- None None O
activating None None O
inputs None None O
, None None O
such None None O
as None None O
high None None O
doses None None O
of None None O
radiations None None O
, None None O
DNA None None O
- None None O
damaging None None O
drugs None None O
and None None O
activated None None O
oncogenes None None O
. None None O

However None None O
, None None O
how None None O
the None None O
tumor None None O
suppressive None None O
functions None None O
of None None O
p53 None None O
become None None O
concerted None None O
with None None O
the None None O
extracellular None None O
cues None None O
arriving None None O
at None None O
the None None O
cell None None O
surface None None O
during None None O
tissue None None O
homeostasis None None O
, None None O
remains None None O
largely None None O
unknown None None O
. None None O

Intriguingly None None O
, None None O
two None None O
recent None None O
papers None None O
have None None O
shed None None O
new None None O
light None None O
into None None O
this None None O
unexplored None None O
field None None O
, None None O
indicating None None O
that None None O
p53 None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
TGF None None O
- None None O
beta None None O
- None None O
induced None None O
growth None None O
arrest None None O
and None None O
, None None O
unexpectedly None None O
, None None O
in None None O
the None None O
developmental None None O
effects None None O
of None None O
TGF None None O
- None None O
beta None None O
in None None O
early None None O
embryos None None O
. None None O

Here None None O
we None None O
review None None O
and None None O
comment None None O
on None None O
these None None O
findings None None O
and None None O
on None None O
their None None O
implications None None O
for None None O
cancer None None O
biology None None O
. None None O

Polybrominated None None O
diphenyl None None O
ethers None None O
in None None O
indoor None None O
dust None None O
in None None O
Ottawa None None O
, None None O
Canada None None O
: None None O
implications None None O
for None None O
sources None None O
and None None O
exposure None None O
. None None O

Polybrominated None None O
diphenyl None None O
ethers None None O
( None None O
PBDEs None None O
) None None O
are None None O
widely None None O
used None None O
as None None O
additive None None O
flame None None O
retardants None None O
in None None O
plastics None None O
, None None O
soft None None O
furnishings None None O
, None None O
electrical None None O
and None None O
electronic None None O
equipment None None O
, None None O
and None None O
insulation None None O
in None None O
the None None O
indoor None None O
environment None None O
, None None O
and None None O
may None None O
be None None O
released None None O
indoors None None O
via None None O
volatilization None None O
or None None O
as None None O
dusts None None O
. None None O

The None None O
penta None None O
- None None O
and None None O
octa None None O
- None None O
brominated None None O
mixes None None O
are None None O
now None None O
banned None None O
in None None O
most None None O
parts None None O
of None None O
Europe None None O
, None None O
and None None O
phasing None None O
out None None O
of None None O
their None None O
use None None O
has None None O
recently None None O
begun None None O
in None None O
North None None O
America None None O
. None None O

This None None O
study None None O
follows None None O
a None None O
previous None None O
investigation None None O
into None None O
indoor None None O
air None None O
levels None None O
of None None O
PBDEs None None O
. None None O

House None None O
dust None None O
was None None O
analyzed None None O
from None None O
the None None O
family None None O
vacuum None None O
cleaners None None O
of None None O
68 None None O
of None None O
the None None O
same None None O
74 None None O
randomly None None O
selected None None O
homes None None O
, None None O
in None None O
Ottawa None None O
, None None O
Canada None None O
during None None O
the None None O
winter None None O
of None None O
2002 None None O
- None None O
2003 None None O
. None None O

PBDEs None None O
, None None O
comprising None None O
on None None O
average None None O
42 None None O
% None None O
BDE None None O
- None None O
209 None None O
, None None O
were None None O
found None None O
in None None O
all None None O
samples None None O
. None None O

The None None O
levels None None O
were None None O
log None None O
- None None O
normally None None O
distributed None None O
with None None O
a None None O
geometric None None O
mean None None O
sigmaPBDE None None O
of None None O
2000 None None O
ng None None O
g None None O
( None None O
- None None O
1 None None O
) None None O
, None None O
and None None O
a None None O
median None None O
of None None O
1800 None None O
ng None None O
g None None O
( None None O
- None None O
1 None None O
) None None O
dust None None O
. None None O

The None None O
levels None None O
in None None O
dust None None O
did None None O
not None None O
correlate None None O
with None None O
questionnaire None None O
information None None O
on None None O
house None None O
characteristics None None O
. None None O

Correlations None None O
were None None O
found None None O
between None None O
pentamix None None O
congener None None O
levels None None O
in None None O
dust None None O
and None None O
in None None O
air None None O
from None None O
the None None O
same None None O
homes None None O
, None None O
but None None O
not None None O
for None None O
congeners None None O
of None None O
the None None O
more None None O
highly None None O
brominated None None O
mixes None None O
. None None O

Exposure None None O
scenarios None None O
are None None O
presented None None O
for None None O
mean None None O
and None None O
high None None O
dust None None O
ingestion None None O
rates None None O
, None None O
and None None O
compared None None O
against None None O
exposures None None O
from None None O
other None None O
pathways None None O
, None None O
for None None O
both None None O
adults None None O
and None None O
toddlers None None O
( None None O
6 None None O
months None None O
- None None O
2 None None O
years None None O
) None None O
. None None O

Assuming None None O
a None None O
mean None None O
dust None None O
ingestion None None O
rate None None O
and None None O
median None None O
dust None None O
and None None O
air None None O
concentrations None None O
, None None O
adults None None O
would None None O
be None None O
exposed None None O
to None None O
ca None None O
. None None O

7 None None O
. None None O
5 None None O
ng None None O
sigmaPBDE None None O
d None None O
( None None O
- None None O
1 None None O
) None None O
via None None O
the None None O
dust None None O
ingestion None None O
pathway None None O
, None None O
which None None O
represents None None O
approximately None None O
14 None None O
% None None O
of None None O
total None None O
daily None None O
exposure None None O
when None None O
compared None None O
to None None O
diet None None O
( None None O
82 None None O
% None None O
) None None O
and None None O
inhalation None None O
( None None O
4 None None O
% None None O
) None None O
. None None O

However None None O
, None None O
for None None O
toddlers None None O
the None None O
equivalent None None O
intakes None None O
would None None O
be None None O
99 None None O
ng None None O
d None None O
( None None O
- None None O
1 None None O
) None None O
, None None O
representing None None O
80 None None O
% None None O
of None None O
their None None O
daily None None O
PBDE None None O
exposure None None O
. None None O

At None None O
high None None O
dust None None O
ingestion None None O
rates None None O
these None None O
values None None O
increase None None O
to None None O
180 None None O
ng None None O
d None None O
( None None O
- None None O
1 None None O
) None None O
( None None O
80 None None O
% None None O
daily None None O
intake None None O
) None None O
for None None O
adults None None O
and None None O
360 None None O
ng None None O
d None None O
( None None O
- None None O
1 None None O
) None None O
( None None O
89 None None O
% None None O
daily None None O
intake None None O
) None None O
for None None O
toddlers None None O
. None None O

The None None O
data None None O
give None None O
a None None O
clearer None None O
picture None None O
of None None O
sources None None O
of None None O
PBDE None None O
exposure None None O
in None None O
the None None O
home None None O
environment None None O
and None None O
suggest None None O
that None None O
dust None None O
could None None O
be None None O
a None None O
significant None None O
exposure None None O
pathway None None O
for None None O
some None None O
individuals None None O
, None None O
particularly None None O
children None None O
. None None O

Lactoferrin None None O
enhances None None O
Fas None None O
expression None None O
and None None O
apoptosis None None O
in None None O
the None None O
colon None None O
mucosa None None O
of None None O
azoxymethane None None O
- None None O
treated None None O
rats None None O
. None None O

Bovine None None O
lactoferrin None None O
, None None O
a None None O
multifunctional None None O
glycoprotein None None O
, None None O
has None None O
been None None O
shown None None O
to None None O
strongly None None O
inhibit None None O
development None None O
of None None O
azoxymethane None None O
( None None O
AOM None None O
) None None O
- None None O
induced None None O
rat None None O
colon None None O
tumors None None O
. None None O

Little None None O
, None None O
however None None O
, None None O
is None None O
known None None O
about None None O
the None None O
inhibitory None None O
mechanisms None None O
. None None O

We None None O
have None None O
demonstrated None None O
recently None None O
that None None O
lactoferrin None None O
enhances None None O
the None None O
expression None None O
of None None O
a None None O
member None None O
of None None O
the None None O
tumor None None O
necrosis None None O
factor None None O
receptor None None O
family None None O
, None None O
Fas None None O
, None None O
in None None O
the None None O
colon None None O
mucosa None None O
during None None O
both None None O
early None None O
and None None O
late None None O
stages None None O
of None None O
carcinogenesis None None O
. None None O

Thus None None O
, None None O
Fas None None O
could None None O
be None None O
involved None None O
in None None O
bovine None None O
lactoferrin None None O
- None None O
mediated None None O
inhibition None None O
of None None O
tumor None None O
development None None O
. None None O

To None None O
investigate None None O
this None None O
possibility None None O
, None None O
we None None O
studied None None O
the None None O
influence None None O
of None None O
bovine None None O
lactoferrin None None O
on None None O
Fas None None O
- None None O
mediated None None O
apoptosis None None O
with None None O
regard None None O
to None None O
expression None None O
of None None O
Fas None None O
, None None O
activation None None O
of None None O
caspase None None O
- None None O
8 None None O
and None None O
caspase None None O
- None None O
3 None None O
, None None O
and None None O
DNA None None O
fragmentation None None O
in None None O
the None None O
colon None None O
mucosa None None O
of None None O
AOM None None O
- None None O
treated None None O
rats None None O
. None None O

Western None None O
blot None None O
analysis None None O
demonstrated None None O
a None None O
> None None O
2 None None O
. None None O
5 None None O
- None None O
fold None None O
increase None None O
in None None O
Fas None None O
protein None None O
expression None None O
, None None O
as None None O
well None None O
as None None O
elevation None None O
of None None O
the None None O
active None None O
forms None None O
of None None O
both None None O
caspase None None O
- None None O
8 None None O
and None None O
caspase None None O
- None None O
3 None None O
. None None O

Immunohistochemical None None O
analysis None None O
revealed None None O
Fas None None O
- None None O
positive None None O
cells None None O
and None None O
apoptotic None None O
cells None None O
preferentially None None O
within None None O
the None None O
proximal None None O
colon None None O
region None None O
, None None O
clearly None None O
at None None O
the None None O
site None None O
of None None O
bovine None None O
lactoferrin None None O
- None None O
mediated None None O
tumor None None O
inhibition None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
apoptosis None None O
caused None None O
by None None O
elevated None None O
expression None None O
of None None O
Fas None None O
is None None O
involved None None O
in None None O
chemoprevention None None O
by None None O
lactoferrin None None O
of None None O
colon None None O
carcinogenesis None None O
. None None O

Expression None None O
of None None O
HER2 None None O
and None None O
bradykinin None None O
B1 None None O
receptors None None O
in None None O
precursor None None O
lesions None None O
of None None O
gallbladder None None O
carcinoma None None O
. None None O

AIM None None O
: None None O
To None None O
determine None None O
the None None O
expression None None O
of None None O
HER2 None None O
and None None O
bradykinin None None O
B None None O
( None None O
1 None None O
) None None O
receptors None None O
( None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
) None None O
in None None O
the None None O
two None None O
pathogenic None None O
models None None O
of None None O
gallbladder None None O
cancer None None O
: None None O
the None None O
metaplasia None None O
- None None O
dysplasia None None O
- None None O
carcinoma None None O
and None None O
the None None O
adenoma None None O
- None None O
carcinoma None None O
pathways None None O
. None None O

METHODS None None O
: None None O
Receptor None None O
proteins None None O
were None None O
visualized None None O
by None None O
immunohistochemistry None None O
on None None O
5 None None O
- None None O
mum None None O
sections None None O
of None None O
paraffin None None O
- None None O
embedded None None O
tissue None None O
. None None O

Expression None None O
of None None O
both None None O
receptors None None O
was None None O
studied None None O
in None None O
biopsy None None O
samples None None O
from None None O
92 None None O
patients None None O
( None None O
6 None None O
males None None O
and None None O
86 None None O
females None None O
; None None O
age None None O
ranging None None O
from None None O
28 None None O
to None None O
86 None None O
years None None O
, None None O
mean None None O
56 None None O
years None None O
) None None O
. None None O

High None None O
HER2 None None O
expression None None O
in None None O
specimens None None O
was None None O
additionally None None O
investigated None None O
by None None O
fluorescence None None O
in None None O
situ None None O
hybridization None None O
. None None O

Cell None None O
proliferation None None O
in None None O
each None None O
sample None None O
was None None O
assessed None None O
by None None O
using None None O
the None None O
Ki None None O
- None None O
67 None None O
proliferation None None O
marker None None O
. None None O

RESULTS None None O
: None None O
HER2 None None O
receptor None None O
protein None None O
was None None O
absent None None O
in None None O
adenomas None None O
and None None O
in None None O
normal None None O
gallbladder None None O
epithelium None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
there None None O
was None None O
intense None None O
staining None None O
for None None O
HER2 None None O
on None None O
the None None O
basolateral None None O
membrane None None O
of None None O
epithelial None None O
cells None None O
of None None O
intestinal None None O
metaplasia None None O
( None None O
22 None None O
/ None None O
24 None None O
; None None O
91 None None O
. None None O
7 None None O
% None None O
) None None O
and None None O
carcinoma None None O
in None None O
situ None None O
( None None O
9 None None O
/ None None O
10 None None O
; None None O
90 None None O
% None None O
) None None O
, None None O
the None None O
lesions None None O
that None None O
displayed None None O
a None None O
significantly None None O
high None None O
proliferation None None O
index None None O
. None None O

Protein None None O
up None None O
- None None O
regulation None None O
of None None O
HER2 None None O
in None None O
the None None O
epithelium None None O
with None None O
metaplasia None None O
or None None O
carcinoma None None O
in None None O
situ None None O
was None None O
not None None O
accompanied None None O
by None None O
HER2 None None O
gene None None O
amplification None None O
. None None O

A None None O
similar None None O
result None None O
was None None O
observed None None O
in None None O
invasive None None O
carcinomas None None O
( None None O
0 None None O
/ None None O
12 None None O
) None None O
. None None O

The None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
distribution None None O
pattern None None O
mirrored None None O
that None None O
of None None O
HER2 None None O
except None None O
that None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
was None None O
additionally None None O
observed None None O
in None None O
the None None O
adenomas None None O
. None None O

The None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
appeared None None O
either None None O
as None None O
cytoplasmic None None O
dots None None O
or None None O
labeling None None O
on None None O
the None None O
apical None None O
cell None None O
membrane None None O
of None None O
the None None O
cells None None O
composing None None O
the None None O
epithelia None None O
with None None O
intestinal None None O
metaplasia None None O
( None None O
24 None None O
/ None None O
24 None None O
; None None O
100 None None O
% None None O
) None None O
and None None O
carcinoma None None O
in None None O
situ None None O
( None None O
10 None None O
/ None None O
10 None None O
; None None O
100 None None O
% None None O
) None None O
and None None O
in None None O
the None None O
epithelial None None O
cells None None O
of None None O
adenomas None None O
. None None O

In None None O
contrast None None O
, None None O
both None None O
HER2 None None O
( None None O
4 None None O
/ None None O
12 None None O
; None None O
33 None None O
% None None O
) None None O
and None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
( None None O
1 None None O
/ None None O
12 None None O
; None None O
8 None None O
. None None O
3 None None O
% None None O
) None None O
showed None None O
a None None O
low None None O
expression None None O
in None None O
invasive None None O
gallbladder None None O
carcinomas None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
up None None O
- None None O
regulation None None O
of None None O
HER2 None None O
and None None O
B None None O
( None None O
1 None None O
) None None O
R None None O
in None None O
precursor None None O
lesions None None O
of None None O
gallbladder None None O
carcinoma None None O
suggests None None O
cross None None O
- None None O
talk None None O
between None None O
these None None O
two None None O
receptors None None O
that None None O
may None None O
be None None O
of None None O
importance None None O
in None None O
the None None O
modulation None None O
of None None O
cell None None O
proliferation None None O
in None None O
gallbladder None None O
carcinogenesis None None O
. None None O

Conclusions None None O

Only None None O
after None None O
careful None None O
consideration None None O
of None None O
the None None O
biological None None O
underpinnings None None O
of None None O
a None None O
truly None None O
beneficial None None O
response None None O
can None None O
an None None O
exposure None None O
be None None O
considered None None O
for None None O
the None None O
general None None O
population None None O
, None None O
such None None O
as None None O
the None None O
addition None None O
of None None O
folic None None O
acid None None O
to None None O
cereals None None O
. None None O

If None None O
a None None O
toxic None None O
or None None O
hazardous None None O
pollutant None None O
were None None O
found None None O
to None None O
have None None O
truly None None O
beneficial None None O
effects None None O
at None None O
low None None O
dose None None O
, None None O
then None None O
that None None O
agent None None O
should None None O
be None None O
tested None None O
clinically None None O
, None None O
go None None O
through None None O
the None None O
U None None O
. None None O
S None None O
. None None O

Food None None O
and None None O
Drug None None O
Administration None None O
( None None O
FDA None None O
) None None O
approval None None O
process None None O
, None None O
and None None O
be None None O
regulated None None O
as None None O
a None None O
pharmaceutical None None O
for None None O
those None None O
who None None O
might None None O
benefit None None O
from None None O
its None None O
use None None O
. None None O

Certainly None None O
, None None O
the None None O
general None None O
population None None O
should None None O
not None None O
be None None O
exposed None None O
to None None O
chemotherapeutic None None O
agents None None O
that None None O
benefit None None O
cancer None None O
patients None None O
. None None O

For None None O
pharmaceuticals None None O
, None None O
it None None O
is None None O
understood None None O
that None None O
there None None O
are None None O
trade None None O
offs None None O
between None None O
benefits None None O
and None None O
risks None None O
. None None O

For None None O
example None None O
, None None O
although None None O
aspirin None None O
is None None O
a None None O
generally None None O
well None None O
- None None O
tolerated None None O
pain None None O
reliever None None O
and None None O
is None None O
increasingly None None O
advocated None None O
as None None O
a None None O
preventative None None O
tool None None O
for None None O
heart None None O
attacks None None O
and None None O
colorectal None None O
cancer None None O
( None None O
Vainio None None O
and None None O
Miller None None O
2003 None None O
; None None O
Werner None None O
et None None O
al None None O
. None None O
2004 None None O
) None None O
, None None O
it None None O
is None None O
also None None O
linked None None O
to None None O
increased None None O
risk None None O
of None None O
gastrointestinal None None O
bleeding None None O
, None None O
cerebral None None O
hemorrhage None None O
( None None O
Werner None None O
et None None O
al None None O
. None None O
2004 None None O
) None None O
, None None O
and None None O
asthma None None O
attacks None None O
( None None O
Jenkins None None O
et None None O
al None None O
. None None O
2004 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
aspirin None None O
is None None O
not None None O
recommended None None O
for None None O
children None None O
or None None O
teenagers None None O
who None None O
have None None O
or None None O
are None None O
recovering None None O
from None None O
chicken None None O
pox None None O
or None None O
flulike None None O
symptoms None None O
because None None O
it None None O
can None None O
cause None None O
debilitating None None O
and None None O
sometimes None None O
lethal None None O
Reyes None None O
syndrome None None O
( None None O
U None None O
. None None O
S None None O
. None None O
FDA None None O
2003 None None O
) None None O
. None None O

Individual None None O
risks None None O
to None None O
pharmaceutical None None O
agents None None O
can None None O
be None None O
controlled None None O
with None None O
proper None None O
usage None None O
; None None O
however None None O
, None None O
increased None None O
exposure None None O
to None None O
environmental None None O
toxins None None O
presents None None O
additional None None O
involuntary None None O
risks None None O
for None None O
the None None O
general None None O
population None None O
. None None O

Under None None O
the None None O
latter None None O
condition None None O
, None None O
exposure None None O
is None None O
inadequately None None O
controlled None None O
, None None O
and None None O
there None None O
is None None O
no None None O
mechanism None None O
to None None O
correct None None O
for None None O
individual None None O
circumstances None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
medical None None O
condition None None O
or None None O
age None None O
) None None O
that None None O
may None None O
result None None O
in None None O
harm None None O
. None None O

Although None None O
hormetic None None O
effects None None O
may None None O
occur None None O
in None None O
some None None O
instances None None O
, None None O
it None None O
is None None O
indeed None None O
rare None None O
that None None O
exposures None None O
to None None O
toxic None None O
, None None O
mutagenic None None O
, None None O
teratogenic None None O
, None None O
and None None O
carcinogenic None None O
chemicals None None O
, None None O
even None None O
at None None O
low None None O
exposure None None O
levels None None O
, None None O
would None None O
be None None O
risk None None O
free None None O
and None None O
provide None None O
health None None O
benefits None None O
for None None O
the None None O
general None None O
public None None O
. None None O

Portraying None None O
chemicals None None O
with None None O
numerous None None O
adverse None None O
effects None None O
as None None O
having None None O
benefits None None O
while None None O
ignoring None None O
their None None O
hazards None None O
is None None O
irresponsible None None O
and None None O
does None None O
not None None O
provide None None O
full None None O
and None None O
objective None None O
disclosure None None O
. None None O

In None None O
the None None O
1950s None None O
doctors None None O
prescribed None None O
DES None None O
to None None O
pregnant None None O
women None None O
to None None O
prevent None None O
miscarriage None None O
and None None O
premature None None O
births None None O
and None None O
to None None O
produce None None O
" None None O
bigger None None O
and None None O
stronger None None O
babies None None O
" None None O
even None None O
though None None O
DES None None O
had None None O
been None None O
shown None None O
to None None O
cause None None O
damage None None O
to None None O
reproductive None None O
tissues None None O
in None None O
animals None None O
( None None O
Dinusson None None O
et None None O
al None None O
. None None O
1948 None None O
; None None O
Dunn None None O
and None None O
Green None None O
1963 None None O
; None None O
Takasugi None None O
and None None O
Bern None None O
1964 None None O
) None None O
. None None O

Human None None O
use None None O
of None None O
DES None None O
was None None O
banned None None O
in None None O
the None None O
United None None O
States None None O
in None None O
1971 None None O
after None None O
the None None O
discovery None None O
of None None O
high None None O
rates None None O
of None None O
rare None None O
, None None O
clear None None O
- None None O
cell None None O
adenocarcinomas None None O
of None None O
the None None O
vagina None None O
and None None O
cervix None None O
in None None O
DES None None O
- None None O
exposed None None O
daughters None None O
( None None O
Herbst None None O
1981 None None O
) None None O
, None None O
and None None O
later None None O
studies None None O
showed None None O
elevated None None O
breast None None O
cancer None None O
risk None None O
in None None O
women None None O
who None None O
took None None O
DES None None O
during None None O
pregnancy None None O
( None None O
Titus None None O
- None None O
Ernstoff None None O
et None None O
al None None O
. None None O
2001 None None O
) None None O
. None None O

Certainly None None O
, None None O
health None None O
policy None None O
decisions None None O
should None None O
be None None O
based None None O
on None None O
scientific None None O
evidence None None O
and None None O
not None None O
on None None O
speculation None None O
of None None O
health None None O
benefits None None O
in None None O
order None None O
for None None O
the None None O
general None None O
population None None O
to None None O
avoid None None O
repeating None None O
the None None O
mistakes None None O
of None None O
the None None O
past None None O
similar None None O
to None None O
that None None O
of None None O
the None None O
DES None None O
tragedy None None O
. None None O

The None None O
claims None None O
and None None O
projections None None O
of None None O
health None None O
benefits None None O
from None None O
exposures None None O
to None None O
environmental None None O
toxicants None None O
and None None O
carcinogens None None O
are None None O
based None None O
on None None O
untested None None O
assumptions None None O
and None None O
disregard None None O
numerous None None O
well None None O
- None None O
established None None O
scientific None None O
principles None None O
that None None O
underpin None None O
a None None O
public None None O
health None None O
- None None O
protective None None O
approach None None O
to None None O
regulating None None O
exposure None None O
to None None O
toxic None None O
substances None None O
. None None O

If None None O
hormesis None None O
were None None O
used None None O
in None None O
the None None O
decision None None O
- None None O
making None None O
process None None O
to None None O
allow None None O
higher None None O
exposures None None O
to None None O
toxic None None O
and None None O
carcinogenic None None O
agents None None O
, None None O
this None None O
would None None O
substantially None None O
increase None None O
health None None O
risks None None O
for None None O
many None None O
, None None O
if None None O
not None None O
most None None O
, None None O
segments None None O
of None None O
the None None O
general None None O
population None None O
. None None O

Punica None None O
granatum None None O
( None None O
pomegranate None None O
) None None O
and None None O
its None None O
potential None None O
for None None O
prevention None None O
and None None O
treatment None None O
of None None O
inflammation None None O
and None None O
cancer None None O
. None None O

The None None O
last None None O
7 None None O
years None None O
have None None O
seen None None O
over None None O
seven None None O
times None None O
as None None O
many None None O
publications None None O
indexed None None O
by None None O
Medline None None O
dealing None None O
with None None O
pomegranate None None O
and None None O
Punica None None O
granatum None None O
than None None O
in None None O
all None None O
the None None O
years None None O
preceding None None O
them None None O
. None None O

Because None None O
of None None O
this None None O
, None None O
and None None O
the None None O
virtual None None O
explosion None None O
of None None O
interest None None O
in None None O
pomegranate None None O
as None None O
a None None O
medicinal None None O
and None None O
nutritional None None O
product None None O
that None None O
has None None O
followed None None O
, None None O
this None None O
review None None O
is None None O
accordingly None None O
launched None None O
. None None O

The None None O
pomegranate None None O
tree None None O
, None None O
Punica None None O
granatum None None O
, None None O
especially None None O
its None None O
fruit None None O
, None None O
possesses None None O
a None None O
vast None None O
ethnomedical None None O
history None None O
and None None O
represents None None O
a None None O
phytochemical None None O
reservoir None None O
of None None O
heuristic None None O
medicinal None None O
value None None O
. None None O

The None None O
tree None None O
/ None None O
fruit None None O
can None None O
be None None O
divided None None O
into None None O
several None None O
anatomical None None O
compartments None None O
: None None O
( None None O
1 None None O
) None None O
seed None None O
, None None O
( None None O
2 None None O
) None None O
juice None None O
, None None O
( None None O
3 None None O
) None None O
peel None None O
, None None O
( None None O
4 None None O
) None None O
leaf None None O
, None None O
( None None O
5 None None O
) None None O
flower None None O
, None None O
( None None O
6 None None O
) None None O
bark None None O
, None None O
and None None O
( None None O
7 None None O
) None None O
roots None None O
, None None O
each None None O
of None None O
which None None O
has None None O
interesting None None O
pharmacologic None None O
activity None None O
. None None O

Juice None None O
and None None O
peels None None O
, None None O
for None None O
example None None O
, None None O
possess None None O
potent None None O
antioxidant None None O
properties None None O
, None None O
while None None O
juice None None O
, None None O
peel None None O
and None None O
oil None None O
are None None O
all None None O
weakly None None O
estrogenic None None O
and None None O
heuristically None None O
of None None O
interest None None O
for None None O
the None None O
treatment None None O
of None None O
menopausal None None O
symptoms None None O
and None None O
sequellae None None O
. None None O

The None None O
use None None O
of None None O
juice None None O
, None None O
peel None None O
and None None O
oil None None O
have None None O
also None None O
been None None O
shown None None O
to None None O
possess None None O
anticancer None None O
activities None None O
, None None O
including None None O
interference None None O
with None None O
tumor None None O
cell None None O
proliferation None None O
, None None O
cell None None O
cycle None None O
, None None O
invasion None None O
and None None O
angiogenesis None None O
. None None O

These None None O
may None None O
be None None O
associated None None O
with None None O
plant None None O
based None None O
anti None None O
- None None O
inflammatory None None O
effects None None O
, None None O
The None None O
phytochemistry None None O
and None None O
pharmacological None None O
actions None None O
of None None O
all None None O
Punica None None O
granatum None None O
components None None O
suggest None None O
a None None O
wide None None O
range None None O
of None None O
clinical None None O
applications None None O
for None None O
the None None O
treatment None None O
and None None O
prevention None None O
of None None O
cancer None None O
, None None O
as None None O
well None None O
as None None O
other None None O
diseases None None O
where None None O
chronic None None O
inflammation None None O
is None None O
believed None None O
to None None O
play None None O
an None None O
essential None None O
etiologic None None O
role None None O
. None None O

Predicted None None O
methylation None None O
level None None O
of None None O
C None None O
. None None O
gigas None None O
genes None None O
categorized None None O
by None None O
biological None None O
processes None None O
compared None None O
to None None O
measured None None O
level None None O
of None None O
DNA None None O
methylation None None O
. None None O

Mean None None O
CpG None None O
O None None O
/ None None O
E None None O
for None None O
10 None None O
, None None O
699 None None O
C None None O
. None None O
gigas None None O
genes None None O
categorized None None O
according None None O
to None None O
Biological None None O
Process None None O
Gene None None O
Ontology None None O
( None None O
GO None None O
) None None O
Slim None None O
terms None None O
are None None O
plotted None None O
on None None O
the None None O
x None None O
- None None O
axis None None O
( None None O
modified None None O
from None None O
Gavery None None O
and None None O
Roberts None None O
, None None O
2010 None None O
) None None O
. None None O

DNA None None O
methylation None None O
was None None O
empirically None None O
measured None None O
by None None O
performing None None O
MBD None None O
- None None O
seq None None O
on None None O
the None None O
SOLiD None None O
4 None None O
platform None None O
( None None O
Applied None None O
Biosystems None None O
) None None O
. None None O

Genes None None O
identified None None O
in None None O
the None None O
MBD None None O
- None None O
library None None O
were None None O
associated None None O
with None None O
respective None None O
GO None None O
terms None None O
and None None O
enrichment None None O
analysis None None O
was None None O
performed None None O
based None None O
on None None O
the None None O
entire None None O
transcriptome None None O
( None None O
Fleury None None O
et None None O
al None None O
. None None O
, None None O
2009 None None O
) None None O
using None None O
DAVID None None O
( None None O
Huang None None O
et None None O
al None None O
. None None O
, None None O
2009a None None O
, None None O
b None None O
) None None O
. None None O

Results None None O
indicate None None O
the None None O
most None None O
underrepresented None None O
genes None None O
in None None O
the None None O
library None None O
are None None O
involved None None O
in None None O
cell None None O
adhesion None None O
and None None O
genes None None O
involved None None O
in None None O
DNA None None O
and None None O
protein None None O
metabolism None None O
were None None O
most None None O
prevalent None None O
in None None O
the None None O
MBD None None O
- None None O
library None None O
. None None O

Cytology None None O
and None None O
Histology None None O

For None None O
semithin None None O
sections None None O
, None None O
embryoid None None O
bodies None None O
were None None O
washed None None O
twice None None O
in None None O
PBS None None O
, None None O
fixed None None O
in None None O
4 None None O
% None None O
paraformaldehyde None None O
at None None O
4degreesC None None O
overnight None None O
, None None O
and None None O
after None None O
dehydration None None O
in None None O
ethanol None None O
were None None O
embedded None None O
in None None O
JB None None O
- None None O
4 None None O
resin None None O
( None None O
Polysciences None None O
, None None O
Inc None None O
. None None O
) None None O
. None None O

1 None None O
- None None O
4 None None O
- None None O
mum None None O
sections None None O
were None None O
cut None None O
with None None O
a None None O
glass None None O
knife None None O
. None None O

For None None O
cytology None None O
, None None O
the None None O
sections None None O
were None None O
stained None None O
with None None O
toluidine None None O
blue None None O
. None None O

In None None O
cell None None O
mixing None None O
experiments None None O
, None None O
the None None O
embryoid None None O
bodies None None O
were None None O
prefixed None None O
and None None O
stained None None O
for None None O
beta None None O
- None None O
galactosidase None None O
and None None O
the None None O
sections None None O
were None None O
counterstained None None O
with None None O
neutral None None O
red None None O
. None None O

Teratocarcinomas None None O
were None None O
fixed None None O
in None None O
Bouin None None O
fixative None None O
, None None O
embedded None None O
in None None O
Paraplast None None O
, None None O
and None None O
the None None O
sections None None O
were None None O
stained None None O
with None None O
hematoxylin None None O
and None None O
eosin None None O
. None None O

Microphotography None None O
was None None O
with None None O
a None None O
ZEISS None None O
Axiomat None None O
microscope None None O
. None None O

Films None None O
were None None O
scanned None None O
and None None O
figures None None O
were None None O
prepared None None O
with None None O
Photoshop None None O
5 None None O
. None None O
5 None None O
software None None O
. None None O

Application None None O
of None None O
microsatellite None None O
PCR None None O
techniques None None O
in None None O
the None None O
identification None None O
of None None O
mixed None None O
up None None O
tissue None None O
specimens None None O
in None None O
surgical None None O
pathology None None O
. None None O

A None None O
fragment None None O
of None None O
tumour None None O
was None None O
erroneously None None O
mixed None None O
up None None O
with None None O
an None None O
endometrial None None O
biopsy None None O
. None None O

Micro None None O
- None None O
satellite None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
PCR None None O
) None None O
clearly None None O
demonstrated None None O
the None None O
extraneous None None O
nature None None O
of None None O
the None None O
fragment None None O
. None None O

Micro None None O
- None None O
satellite None None O
PCR None None O
may None None O
be None None O
useful None None O
for None None O
the None None O
identification None None O
of None None O
mis None None O
- None None O
labelled None None O
or None None O
mismatched None None O
tissue None None O
fragments None None O
in None None O
surgical None None O
pathology None None O
specimens None None O
. None None O

Homeostatic None None O
functions None None O
of None None O
the None None O
p53 None None O
tumor None None O
suppressor None None O
: None None O
regulation None None O
of None None O
energy None None O
metabolism None None O
and None None O
antioxidant None None O
defense None None O
. None None O

The None None O
p53 None None O
tumor None None O
suppressor None None O
plays None None O
pivotal None None O
role None None O
in None None O
the None None O
organism None None O
by None None O
supervising None None O
strict None None O
compliance None None O
of None None O
individual None None O
cells None None O
to None None O
needs None None O
of None None O
the None None O
whole None None O
organisms None None O
. None None O

It None None O
has None None O
been None None O
widely None None O
accepted None None O
that None None O
p53 None None O
acts None None O
in None None O
response None None O
to None None O
stresses None None O
and None None O
abnormalities None None O
in None None O
cell None None O
physiology None None O
by None None O
mobilizing None None O
the None None O
repair None None O
processes None None O
or None None O
by None None O
removing None None O
the None None O
diseased None None O
cells None None O
through None None O
initiating None None O
the None None O
cell None None O
death None None O
programs None None O
. None None O

Recent None None O
studies None None O
, None None O
however None None O
, None None O
indicate None None O
that None None O
even None None O
under None None O
normal None None O
physiological None None O
conditions None None O
certain None None O
activities None None O
of None None O
p53 None None O
participate None None O
in None None O
homeostatic None None O
regulation None None O
of None None O
metabolic None None O
processes None None O
and None None O
that None None O
these None None O
activities None None O
are None None O
important None None O
for None None O
prevention None None O
of None None O
cancer None None O
. None None O

These None None O
novel None None O
functions None None O
of None None O
p53 None None O
help None None O
to None None O
align None None O
metabolic None None O
processes None None O
with None None O
the None None O
proliferation None None O
and None None O
energy None None O
status None None O
, None None O
to None None O
maintain None None O
optimal None None O
mode None None O
of None None O
glucose None None O
metabolism None None O
and None None O
to None None O
boost None None O
the None None O
energy None None O
efficient None None O
mitochondrial None None O
respiration None None O
in None None O
response None None O
to None None O
ATP None None O
deficiency None None O
. None None O

Additional None None O
activities None None O
of None None O
p53 None None O
in None None O
non None None O
- None None O
stressed None None O
cells None None O
tune None None O
up None None O
the None None O
antioxidant None None O
defense None None O
mechanisms None None O
reducing None None O
the None None O
probability None None O
of None None O
mutations None None O
caused None None O
by None None O
DNA None None O
oxidation None None O
under None None O
conditions None None O
of None None O
daily None None O
stresses None None O
. None None O

The None None O
deficiency None None O
in None None O
the None None O
p53 None None O
- None None O
mediated None None O
regulation None None O
of None None O
glycolysis None None O
and None None O
mitochondrial None None O
respiration None None O
greatly None None O
accounts None None O
for None None O
the None None O
deficient None None O
respiration None None O
of None None O
the None None O
predominance None None O
of None None O
aerobic None None O
glycolysis None None O
in None None O
cancer None None O
cells None None O
( None None O
the None None O
Warburg None None O
effect None None O
) None None O
, None None O
while None None O
the None None O
deficiency None None O
in None None O
the None None O
p53 None None O
- None None O
modulated None None O
antioxidant None None O
defense None None O
mechanisms None None O
contributes None None O
to None None O
mutagenesis None None O
and None None O
additionally None None O
boosts None None O
the None None O
carcinogenesis None None O
process None None O
. None None O

Anaplastic None None O
and None None O
sarcomatoid None None O
carcinoma None None O
of None None O
the None None O
small None None O
intestine None None O
: None None O
a None None O
clinicopathologic None None O
study None None O
. None None O

Carcinomas None None O
involving None None O
the None None O
jejunum None None O
and None None O
ileum None None O
are None None O
rare None None O
tumors None None O
. None None O

During None None O
a None None O
review None None O
of None None O
small None None O
intestinal None None O
neoplasms None None O
, None None O
six None None O
primary None None O
carcinomas None None O
of None None O
jejunum None None O
or None None O
ileum None None O
with None None O
an None None O
anaplastic None None O
and None None O
sarcomatoid None None O
histology None None O
were None None O
identified None None O
. None None O

At None None O
presentation None None O
, None None O
three None None O
of None None O
the None None O
patients None None O
had None None O
symptoms None None O
related None None O
to None None O
metastatic None None O
disease None None O
and None None O
three None None O
had None None O
symptoms None None O
referable None None O
to None None O
the None None O
local None None O
tumor None None O
. None None O

The None None O
tumors None None O
were None None O
large None None O
( None None O
greater None None O
than None None O
4 None None O
. None None O
5 None None O
cm None None O
in None None O
diameter None None O
) None None O
, None None O
usually None None O
endophytic None None O
masses None None O
composed None None O
of None None O
large None None O
cells None None O
with None None O
eosinophilic None None O
cytoplasm None None O
, None None O
anaplastic None None O
nuclei None None O
, None None O
and None None O
prominent None None O
nucleoli None None O
. None None O

In None None O
many None None O
areas None None O
, None None O
the None None O
cells None None O
had None None O
a None None O
spindled None None O
configuration None None O
. None None O

Mucin None None O
positivity None None O
was None None O
identified None None O
in None None O
all None None O
six None None O
cases None None O
. None None O

Electron None None O
microscopic None None O
findings None None O
in None None O
two None None O
cases None None O
were None None O
indicative None None O
of None None O
epithelial None None O
differentiation None None O
. None None O

The None None O
tumors None None O
behaved None None O
aggressively None None O
; None None O
all None None O
five None None O
patients None None O
for None None O
whom None None O
there None None O
was None None O
clinical None None O
follow None None O
- None None O
up None None O
died None None O
of None None O
metastases None None O
within None None O
40 None None O
months None None O
. None None O

The None None O
six None None O
anaplastic None None O
and None None O
sarcomatoid None None O
carcinomas None None O
were None None O
compared None None O
with None None O
29 None None O
typical None None O
adenocarcinomas None None O
arising None None O
in None None O
the None None O
jejunum None None O
or None None O
ileum None None O
. None None O

Only None None O
two None None O
of None None O
the None None O
latter None None O
group None None O
had None None O
symptoms None None O
referable None None O
to None None O
distant None None O
metastases None None O
at None None O
presentation None None O
. None None O

These None None O
tumors None None O
also None None O
tended None None O
to None None O
be None None O
smaller None None O
at None None O
presentation None None O
( None None O
11 None None O
tumors None None O
were None None O
less None None O
than None None O
4 None None O
cm None None O
in None None O
greatest None None O
dimension None None O
) None None O
. None None O

Of None None O
25 None None O
patients None None O
with None None O
typical None None O
adenocarcinomas None None O
who None None O
had None None O
acceptable None None O
follow None None O
- None None O
up None None O
, None None O
18 None None O
( None None O
72 None None O
% None None O
) None None O
died None None O
of None None O
disease None None O
and None None O
five None None O
( None None O
20 None None O
% None None O
) None None O
were None None O
alive None None O
with None None O
no None None O
evidence None None O
of None None O
disease None None O
after None None O
5 None None O
years None None O
. None None O

We None None O
conclude None None O
that None None O
anaplastic None None O
and None None O
sarcomatoid None None O
carcinoma None None O
is None None O
a None None O
rare None None O
variant None None O
of None None O
small None None O
intestinal None None O
carcinoma None None O
with None None O
an None None O
aggressive None None O
clinical None None O
course None None O
. None None O

Immunostaining None None O
and None None O
confocal None None O
analysis None None O

DNA None None O
labelling None None O
and None None O
staining None None O
with None None O
5 None None O
- None None O
bromo None None O
- None None O
2 None None O
' None None O
- None None O
deoxyuridine None None O
( None None O
BrdU None None O
labelling None None O
and None None O
detection None None O
kit None None O
I None None O
; None None O
Boehringer None None O
Mannheim None None O
, None None O
Germany None None O
) None None O
was None None O
performed None None O
according None None O
to None None O
the None None O
manufacturer None None O
' None None O
s None None O
instructions None None O
. None None O

The None None O
nucleoli None None O
were None None O
detected None None O
with None None O
an None None O
anti None None O
- None None O
nucleolin None None O
antibody None None O
( None None O
clone None None O
3G4B2 None None O
; None None O
Upstate None None O
biotechnology None None O
, None None O
Lake None None O
Placid None None O
, None None O
NY None None O
) None None O
on None None O
cells None None O
fixed None None O
in None None O
2 None None O
% None None O
formalin None None O
for None None O
10 None None O
min None None O
followed None None O
by None None O
permeabilization None None O
with None None O
ice None None O
- None None O
cold None None O
methanol None None O
for None None O
30 None None O
min None None O
. None None O

The None None O
secondary None None O
antibody None None O
used None None O
for None None O
both None None O
BrdU None None O
and None None O
nucleoli None None O
staining None None O
was None None O
a None None O
rhodamine None None O
( None None O
tetra None None O
- None None O
methyl None None O
) None None O
- None None O
conjugated None None O
goat None None O
anti None None O
- None None O
mouse None None O
antibody None None O
( None None O
T None None O
- None None O
2762 None None O
) None None O
from None None O
Molecular None None O
Probe None None O
( None None O
Eugene None None O
, None None O
OR None None O
) None None O
. None None O

The None None O
cells None None O
were None None O
examined None None O
in None None O
a None None O
Zeiss None None O
LSM None None O
510 None None O
laser None None O
scanning None None O
microscope None None O
equipped None None O
with None None O
a None None O
Plan None None O
- None None O
Apochromate None None O
63x None None O
/ None None O
1 None None O
. None None O
4 None None O
oil None None O
immersion None None O
objective None None O
. None None O

We None None O
used None None O
the None None O
488 None None O
nm None None O
laser None None O
line None None O
for None None O
excitation None None O
of None None O
EGFP None None O
( None None O
detected None None O
at None None O
505 None None O
nm None None O
< None None O
lambdaEGFP None None O
< None None O
530 None None O
nm None None O
) None None O
and None None O
the None None O
543 None None O
nm None None O
laser None None O
line None None O
for None None O
rhodamine None None O
( None None O
tetra None None O
- None None O
methyl None None O
) None None O
( None None O
detected None None O
at None None O
lambdaRhodamine None None O
> None None O
560 None None O
nm None None O
) None None O
. None None O

ECFP None None O
fusion None None O
protein None None O
was None None O
excited None None O
with None None O
a None None O
458 None None O
nm None None O
laser None None O
line None None O
( None None O
detected None None O
at None None O
480 None None O
nm None None O
< None None O
lambdaECFP None None O
< None None O
520 None None O
nm None None O
) None None O
, None None O
EYFP None None O
fusion None None O
protein None None O
was None None O
excited None None O
with None None O
a None None O
514 None None O
nm None None O
laser None None O
line None None O
( None None O
lambdaEGFP None None O
> None None O
560 None None O
nm None None O
) None None O
and None None O
HcRed None None O
fusion None None O
protein None None O
was None None O
excited None None O
with None None O
a None None O
543 None None O
nm None None O
laser None None O
line None None O
and None None O
detected None None O
at None None O
> None None O
585 None None O
or None None O
650 None None O
nm None None O
. None None O

The None None O
images None None O
were None None O
from None None O
1 None None O
mum None None O
thick None None O
slices None None O
of None None O
the None None O
cells None None O
. None None O

The None None O
images None None O
were None None O
exported None None O
into None None O
Adobe None None O
Photoshop None None O
( None None O
Adobe None None O
Systems None None O
Inc None None O
. None None O
, None None O
San None None O
Jose None None O
, None None O
CA None None O
) None None O
. None None O

CASE None None O
: None None O

Here None None O
for None None O
the None None O
first None None O
time None None O
a None None O
case None None O
of None None O
CDLS None None O
from None None O
Iran None None O
, None None O
a None None O
15 None None O
- None None O
week None None O
- None None O
old None None O
male None None O
infant None None O
who None None O
was None None O
refereed None None O
as None None O
a None None O
case None None O
of None None O
multiple None None O
congenital None None O
anomalies None None O
. None None O

Clinical None None O
investigation None None O
showed None None O
that None None O
the None None O
child None None O
was None None O
a None None O
case None None O
of None None O
CDLS None None O
. None None O

[ None None O
Autologous None None O
bone None None O
marrow None None O
stem None None O
cell None None O
or None None O
peripheral None None O
blood None None O
endothelial None None O
progenitor None None O
cell None None O
therapy None None O
in None None O
patients None None O
with None None O
peripheral None None O
limb None None O
ischaemia None None O
] None None O

No None None O
effective None None O
medical None None O
therapies None None O
have None None O
been None None O
developed None None O
sofar None None O
to None None O
enhance None None O
blood None None O
flow None None O
in None None O
the None None O
legs None None O
of None None O
patients None None O
with None None O
peripheral None None O
arterial None None O
disease None None O
( None None O
PAD None None O
) None None O
. None None O

For None None O
patients None None O
with None None O
limb None None O
threatening None None O
ischaemia None None O
the None None O
only None None O
option None None O
for None None O
relief None None O
of None None O
rest None None O
pain None None O
or None None O
gangraena None None O
is None None O
amputation None None O
. None None O

There None None O
is None None O
evidence None None O
in None None O
experimental None None O
and None None O
clinical None None O
studies None None O
that None None O
adult None None O
bone None None O
marrow None None O
- None None O
derived None None O
stem None None O
cells None None O
and None None O
endothelial None None O
progenitor None None O
cells None None O
participate None None O
in None None O
the None None O
development None None O
of None None O
new None None O
blood None None O
vessels None None O
, None None O
called None None O
neoangiogenesis None None O
or None None O
neovascularization None None O
. None None O

Clinical None None O
results None None O
induced None None O
by None None O
autologous None None O
bone None None O
marrow None None O
stem None None O
cells None None O
or None None O
angiogenic None None O
growth None None O
/ None None O
differentiation None None O
factors None None O
in None None O
end None None O
- None None O
stage None None O
patients None None O
with None None O
PAD None None O
are None None O
summarized None None O
. None None O

Considering None None O
the None None O
relatively None None O
few None None O
number None None O
of None None O
patients None None O
treated None None O
by None None O
angiogenic None None O
therapy None None O
, None None O
the None None O
interpretation None None O
of None None O
clinical None None O
results None None O
needs None None O
cautiousness None None O
. None None O

[ None None O
Community None None O
intervention None None O
on None None O
hypertension None None O
and None None O
stroke None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
evaluate None None O
the None None O
community None None O
- None None O
based None None O
intervention None None O
on None None O
reduction None None O
of None None O
hypertension None None O
and None None O
stroke None None O
in None None O
different None None O
age None None O
groups None None O
and None None O
subtypes None None O
hypertension None None O
. None None O

METHODS None None O
: None None O

In None None O
6 None None O
cities None None O
, None None O
2 None None O
geographically None None O
separated None None O
communities None None O
with None None O
a None None O
registered None None O
population None None O
about None None O
10 None None O
000 None None O
of None None O
each None None O
were None None O
selected None None O
as None None O
either None None O
intervention None None O
or None None O
control None None O
communities None None O
. None None O

A None None O
cohort None None O
containing None None O
2 None None O
700 None None O
subjects None None O
, None None O
35 None None O
years None None O
or None None O
older None None O
, None None O
and None None O
free None None O
of None None O
stroke None None O
were None None O
sampled None None O
from None None O
each None None O
community None None O
. None None O

The None None O
baseline None None O
survey None None O
was None None O
conducted None None O
to None None O
screen None None O
the None None O
subjects None None O
for None None O
intervention None None O
. None None O

In None None O
each None None O
city None None O
, None None O
a None None O
program None None O
for None None O
control None None O
of None None O
hypertension None None O
, None None O
heart None None O
diseases None None O
and None None O
diabetes None None O
was None None O
initiated None None O
in None None O
the None None O
intervention None None O
cohort None None O
and None None O
health None None O
education None None O
was None None O
provided None None O
to None None O
the None None O
whole None None O
intervention None None O
community None None O
. None None O

A None None O
follow None None O
- None None O
up None None O
survey None None O
was None None O
conducted None None O
3 None None O
years None None O
later None None O
. None None O

RESULTS None None O
: None None O

Within None None O
3 None None O
years None None O
, None None O
the None None O
prevalence None None O
of None None O
hypertension None None O
increased None None O
in None None O
both None None O
intervention None None O
and None None O
control None None O
cohorts None None O
, None None O
as None None O
well None None O
as None None O
in None None O
the None None O
middle None None O
and None None O
elderly None None O
cohorts None None O
, None None O
especially None None O
in None None O
the None None O
middle None None O
aged None None O
in None None O
control None None O
group None None O
. None None O

Among None None O
hypertensives None None O
in None None O
the None None O
intervention None None O
cohort None None O
, None None O
the None None O
rates None None O
of None None O
awareness None None O
, None None O
treatment None None O
and None None O
control None None O
of None None O
hypertension None None O
got None None O
improved None None O
. None None O

The None None O
incidence None None O
of None None O
stroke None None O
was None None O
29 None None O
% None None O
lower None None O
( None None O
HR None None O
= None None O
0 None None O
. None None O
71 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0 None None O
. None None O
58 None None O
- None None O
0 None None O
. None None O
87 None None O
) None None O
and None None O
mortality None None O
of None None O
stroke None None O
was None None O
40 None None O
% None None O
lower None None O
( None None O
HR None None O
= None None O
0 None None O
. None None O
60 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0 None None O
. None None O
42 None None O
- None None O
0 None None O
. None None O
86 None None O
) None None O
in None None O
the None None O
intervention None None O
cohort None None O
than None None O
the None None O
control None None O
cohort None None O
. None None O

The None None O
intervention None None O
was None None O
most None None O
effective None None O
in None None O
reduction None None O
of None None O
stroke None None O
for None None O
those None None O
with None None O
isolated None None O
systolic None None O
hypertension None None O
and None None O
combined None None O
systolic None None O
and None None O
diastolic None None O
hypertension None None O
( None None O
All None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Meanwhile None None O
, None None O
all None None O
- None None O
cause None None O
mortality None None O
was None None O
11 None None O
% None None O
lower None None O
( None None O
HR None None O
= None None O
0 None None O
. None None O
89 None None O
, None None O
95 None None O
% None None O
CI None None O
: None None O
0 None None O
. None None O
78 None None O
- None None O
0 None None O
. None None O
99 None None O
) None None O
in None None O
the None None O
intervention None None O
cohort None None O
than None None O
in None None O
the None None O
control None None O
cohort None None O
. None None O

CONCLUSION None None O
: None None O

The None None O
community None None O
- None None O
based None None O
intervention None None O
was None None O
effective None None O
in None None O
controlling None None O
the None None O
development None None O
of None None O
hypertension None None O
and None None O
stroke None None O
, None None O
while None None O
the None None O
elderly None None O
people None None O
benefit None None O
more None None O
than None None O
the None None O
middle None None O
aged None None O
people None None O
from None None O
the None None O
intervention None None O
. None None O

Modulating None None O
metastasis None None O
by None None O
a None None O
lymphangiogenic None None O
switch None None O
in None None O
prostate None None O
cancer None None O
. None None O

Prostate None None O
cancer None None O
dissemination None None O
is None None O
difficult None None O
to None None O
detect None None O
in None None O
the None None O
clinic None None O
, None None O
and None None O
few None None O
treatment None None O
options None None O
exist None None O
for None None O
patients None None O
with None None O
advanced None None O
- None None O
stage None None O
disease None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
tumor None None O
lymphangiogenesis None None O
during None None O
metastasis None None O
. None None O

Further None None O
, None None O
we None None O
implemented None None O
a None None O
noninvasive None None O
molecular None None O
imaging None None O
technique None None O
to None None O
facilitate None None O
the None None O
assessment None None O
of None None O
the None None O
metastatic None None O
process None None O
. None None O

The None None O
metastatic None None O
potentials None None O
of None None O
several None None O
human None None O
prostate None None O
cancer None None O
xenograft None None O
models None None O
, None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
, None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
, None None O
PC3 None None I-Cell-line-name
and None None O
CWR22Rv None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
were None None O
compared None None O
. None None O

The None None O
cells None None O
were None None O
labeled None None O
with None None O
luciferase None None O
, None None O
a None None O
bioluminescence None None O
imaging None None O
reporter None None O
gene None None O
, None None O
to None None O
enable None None O
optical None None O
imaging None None O
. None None O

After None None O
tumor None None O
implantation None None O
the None None O
animals None None O
were None None O
examined None None O
weekly None None O
during None None O
several None None O
months None None O
for None None O
the None None O
appearance None None O
of None None O
metastases None None O
. None None O

Metastatic None None O
lesions None None O
were None None O
confirmed None None O
by None None O
immunohistochemistry None None O
. None None O

Additionally None None O
, None None O
the None None O
angiogenic None None O
and None None O
lymphangiogenic None None O
profiles None None O
of None None O
the None None O
tumors None None O
were None None O
characterized None None O
. None None O

To None None O
confirm None None O
the None None O
role None None O
of None None O
lymphangiogenesis None None O
in None None O
mediating None None O
metastasis None None O
, None None O
the None None O
low None None O
- None None O
metastatic None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
tumor None None O
cells None None O
were None None O
engineered None None O
to None None O
overexpress None None O
VEGF None None O
- None None O
C None None O
, None None O
and None None O
the None None O
development None None O
of None None O
metastases None None O
was None None O
evaluated None None O
. None None O

Our None None O
results None None O
show None None O
CWR22Rv None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
and None None O
PC3 None None I-Cell-line-name
tumor None None O
cell None None O
lines None None O
to None None O
be None None O
more None None O
metastatic None None O
than None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
4 None None I-Cell-line-name
, None None O
which None None O
in None None O
turn None None O
disseminates None None O
more None None O
readily None None O
than None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
. None None O

The None None O
difference None None O
in None None O
metastatic None None O
potential None None O
correlated None None O
with None None O
the None None O
endogenous None None O
production None None O
levels None None O
of None None O
lymphangiogenic None None O
growth None None O
factor None None O
VEGF None None O
- None None O
C None None O
and None None O
the None None O
presence None None O
of None None O
tumor None None O
lymphatics None None O
. None None O

In None None O
agreement None None O
, None None O
induced None None O
overexpression None None O
of None None O
VEGF None None O
- None None O
C None None O
in None None O
LAPC None None I-Cell-line-name
- None None I-Cell-line-name
9 None None I-Cell-line-name
enhanced None None O
tumor None None O
lymphangiogenesis None None O
leading None None O
to None None O
the None None O
development None None O
of None None O
metastatic None None O
lesions None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
studies None None O
, None None O
based None None O
on None None O
a None None O
molecular None None O
imaging None None O
approach None None O
for None None O
semiquantitative None None O
detection None None O
of None None O
micrometastases None None O
, None None O
point None None O
to None None O
an None None O
important None None O
role None None O
of None None O
tumor None None O
lymphatics None None O
in None None O
the None None O
metastatic None None O
process None None O
of None None O
human None None O
prostate None None O
cancer None None O
. None None O

In None None O
particular None None O
, None None O
VEGF None None O
- None None O
C None None O
seems None None O
to None None O
play None None O
a None None O
key None None O
role None None O
in None None O
prostate None None O
cancer None None O
metastasis None None O
. None None O

Regulation None None O
of None None O
skin None None O
microvasculature None None O
angiogenesis None None O
, None None O
cell None None O
migration None None O
, None None O
and None None O
permeability None None O
by None None O
a None None O
specific None None O
inhibitor None None O
of None None O
PKCalpha None None O
. None None O

Activation None None O
of None None O
protein None None O
kinase None None O
C None None O
( None None O
PKC None None O
) None None O
induces None None O
phenotypic None None O
changes None None O
in None None O
the None None O
morphology None None O
of None None O
microvascular None None O
endothelial None None O
cells None None O
that None None O
affect None None O
major None None O
functions None None O
of None None O
the None None O
microvasculature None None O
. None None O

These None None O
functions None None O
include None None O
the None None O
first None None O
stages None None O
of None None O
sprouting None None O
in None None O
angiogenesis None None O
, None None O
cell None None O
migration None None O
following None None O
wounding None None O
, None None O
and None None O
vascular None None O
permeability None None O
. None None O

The None None O
specific None None O
isoform None None O
( None None O
s None None O
) None None O
of None None O
PKC None None O
responsible None None O
for None None O
each None None O
of None None O
these None None O
changes None None O
has None None O
not None None O
been None None O
previously None None O
identified None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
used None None O
two None None O
inflammatory None None O
agents None None O
, None None O
IL None None O
- None None O
1beta None None O
and None None O
phorbol None None O
myristic None None O
acetate None None O
, None None O
to None None O
activate None None O
PKC None None O
isozymes None None O
and None None O
specific None None O
inhibitors None None O
of None None O
PKCalpha None None O
( None None O
Go6976 None None O
) None None O
and None None O
PKCbeta None None O
( None None O
hispidin None None O
) None None O
to None None O
distinguish None None O
how None None O
each None None O
of None None O
these None None O
isoform None None O
( None None O
s None None O
) None None O
controls None None O
angiogenesis None None O
, None None O
wound None None O
healing None None O
, None None O
and None None O
permeability None None O
. None None O

In None None O
all None None O
cases None None O
, None None O
only None None O
inhibition None None O
of None None O
PKCalpha None None O
inhibited None None O
each None None O
of None None O
these None None O
functions None None O
when None None O
compared None None O
to None None O
the None None O
inhibition None None O
of None None O
PKCbeta None None O
. None None O

Additional None None O
analysis None None O
of None None O
the None None O
mechanism None None O
of None None O
action None None O
of None None O
Go6976 None None O
( None None O
RT None None O
- None None O
PCR None None O
, None None O
Western None None O
blots None None O
, None None O
and None None O
immunohistochemistry None None O
) None None O
of None None O
the None None O
changes None None O
in None None O
the None None O
phosphorylated None None O
and None None O
nonphosphorylated None None O
forms None None O
of None None O
PKCalpha None None O
in None None O
the None None O
cell None None O
membrane None None O
and None None O
cytoplasm None None O
confirmed None None O
the None None O
specificity None None O
of None None O
PKCalpha None None O
inhibition None None O
by None None O
Go6976 None None O
. None None O

These None None O
studies None None O
therefore None None O
indicate None None O
a None None O
specific None None O
and None None O
a None None O
regulatory None None O
role None None O
of None None O
the None None O
PKCalpha None None O
isoform None None O
in None None O
three None None O
major None None O
endothelial None None O
cell None None O
functions None None O
that None None O
are None None O
important None None O
in None None O
the None None O
maintenance None None O
of None None O
microvascular None None O
homeostasis None None O
. None None O

[ None None O
Treatment None None O
of None None O
acute None None O
liver None None O
failure None None O
in None None O
children None None O
] None None O
. None None O

Among None None O
the None None O
main None None O
causes None None O
of None None O
acute None None O
liver None None O
failure None None O
( None None O
ALF None None O
) None None O
in None None O
children None None O
, None None O
metabolic None None O
diseases None None O
( None None O
especially None None O
in None None O
infants None None O
) None None O
, None None O
viral None None O
and None None O
toxin None None O
or None None O
drug None None O
induced None None O
hepatitis None None O
are None None O
the None None O
most None None O
frequent None None O
. None None O

The None None O
cause None None O
remains None None O
, None None O
however None None O
, None None O
undetermined None None O
in None None O
about None None O
30 None None O
% None None O
of None None O
the None None O
cases None None O
. None None O

Management None None O
must None None O
be None None O
conducted None None O
in None None O
a None None O
pediatric None None O
hepatology None None O
unit None None O
or None None O
intensive None None O
care None None O
unit None None O
in None None O
relation None None O
with None None O
a None None O
pediatric None None O
transplant None None O
team None None O
in None None O
order None None O
: None None O
1 None None O
) None None O
to None None O
perform None None O
urgent None None O
etiological None None O
diagnosis None None O
; None None O
2 None None O
) None None O
to None None O
initiate None None O
specific None None O
therapy None None O
and None None O
symptomatic None None O
treatment None None O
; None None O
3 None None O
) None None O
to None None O
evaluate None None O
the None None O
severity None None O
and None None O
prognosis None None O
of None None O
liver None None O
disease None None O
for None None O
selection None None O
of None None O
children None None O
for None None O
emergency None None O
liver None None O
transplantation None None O
; None None O
4 None None O
) None None O
to None None O
evaluate None None O
contraindications None None O
to None None O
liver None None O
transplantation None None O
. None None O

The None None O
overall None None O
survival None None O
of None None O
post None None O
- None None O
emergency None None O
liver None None O
transplantation None None O
for None None O
ALF None None O
in None None O
children None None O
averages None None O
65 None None O
% None None O
. None None O

[ None None O
The None None O
prevalence None None O
of None None O
ADHD None None O
and None None O
attention None None O
problems None None O
in None None O
preschool None None O
- None None O
aged None None O
children None None O
. None None O
A None None O
comparison None None O
of None None O
two None None O
diagnostic None None O
instruments None None O
] None None O
. None None O

OBJECTIVES None None O
: None None O

In None None O
order None None O
to None None O
analyse None None O
the None None O
prevalence None None O
of None None O
ADHD None None O
and None None O
attention None None O
problems None None O
in None None O
preschool None None O
- None None O
aged None None O
children None None O
, None None O
mothers None None O
were None None O
asked None None O
to None None O
rate None None O
their None None O
children None None O
using None None O
two None None O
measuring None None O
instruments None None O
. None None O

METHODS None None O
: None None O

The None None O
analysis None None O
is None None O
part None None O
of None None O
a None None O
prospective None None O
, None None O
randomised None None O
control None None O
study None None O
of None None O
N None None O
= None None O
280 None None O
children None None O
aged None None O
three None None O
to None None O
six None None O
years None None O
, None None O
whose None None O
mothers None None O
rated None None O
them None None O
using None None O
the None None O
Child None None O
Behaviour None None O
Checklist None None O
/ None None O
CBCL None None O
1 None None O
1 None None O
/ None None O
2 None None O
- None None O
5 None None O
and None None O
the None None O
Parent None None O
Rating None None O
Scale None None O
for None None O
Attention None None O
- None None O
Deficit None None O
Hyperactivity None None O
Disorder None None O
( None None O
ADHD None None O
) None None O
. None None O

RESULTS None None O
: None None O

The None None O
prevalence None None O
rates None None O
ranged None None O
from None None O
2 None None O
. None None O
7 None None O
% None None O
to None None O
9 None None O
. None None O
9 None None O
% None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
gender None None O
effect None None O
in None None O
this None None O
age None None O
group None None O
. None None O

CONCLUSIONS None None O
: None None O

The None None O
study None None O
delivers None None O
initial None None O
findings None None O
and None None O
provides None None O
support None None O
for None None O
decisions None None O
to None None O
implement None None O
in None None O
Germany None None O
new None None O
assessment None None O
methods None None O
for None None O
preschool None None O
- None None O
aged None None O
children None None O
with None None O
ADHD None None O
or None None O
hyperkinetic None None O
syndrome None None O
. None None O

Finally None None O
, None None O
the None None O
different None None O
rates None None O
of None None O
prevalence None None O
and None None O
the None None O
implications None None O
of None None O
the None None O
findings None None O
for None None O
epidemiology None None O
and None None O
the None None O
prevention None None O
of None None O
ADHD None None O
and None None O
attention None None O
problems None None O
among None None O
preschool None None O
- None None O
aged None None O
children None None O
are None None O
discussed None None O
. None None O

Reduced None None O
prognostic None None O
power None None O
of None None O
ventricular None None O
late None None O
potentials None None O
in None None O
post None None O
- None None O
infarction None None O
patients None None O
of None None O
the None None O
reperfusion None None O
era None None O
. None None O

AIMS None None O
: None None O

To None None O
test None None O
the None None O
prognostic None None O
value None None O
of None None O
ventricular None None O
late None None O
potentials None None O
( None None O
LPs None None O
) None None O
in None None O
a None None O
large None None O
cohort None None O
of None None O
post None None O
- None None O
infarction None None O
patients None None O
in None None O
the None None O
modern None None O
reperfusion None None O
era None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O

1800 None None O
consecutive None None O
survivors None None O
of None None O
acute None None O
myocardial None None O
infarction None None O
in None None O
sinus None None O
rhythm None None O
and None None O
under None None O
76 None None O
years None None O
of None None O
age None None O
were None None O
enrolled None None O
. None None O

Many None None O
( None None O
99 None None O
% None None O
) None None O
of None None O
the None None O
patients None None O
received None None O
reperfusion None None O
/ None None O
revascularization None None O
therapy None None O
( None None O
91 None None O
% None None O
percutaneous None None O
coronary None None O
intervention None None O
) None None O
and None None O
up None None O
- None None O
to None None O
- None None O
date None None O
pharmacological None None O
treatment None None O
( None None O
99 None None O
% None None O
aspirin None None O
, None None O
93 None None O
% None None O
beta None None O
- None None O
blockers None None O
, None None O
90 None None O
% None None O
ACE None None O
- None None O
inhibitors None None O
, None None O
and None None O
85 None None O
% None None O
statins None None O
) None None O
. None None O

LPs None None O
were None None O
calculated None None O
in None None O
968 None None O
patients None None O
and None None O
found None None O
to None None O
be None None O
present None None O
in None None O
90 None None O
( None None O
9 None None O
. None None O
3 None None O
% None None O
) None None O
. None None O

The None None O
primary None None O
endpoint None None O
was None None O
the None None O
composite None None O
of None None O
cardiac None None O
death None None O
and None None O
serious None None O
arrhythmic None None O
events None None O
. None None O

The None None O
secondary None None O
endpoint None None O
was None None O
the None None O
composite None None O
of None None O
sudden None None O
cardiac None None O
death None None O
and None None O
serious None None O
arrhythmic None None O
events None None O
. None None O

During None None O
follow None None O
- None None O
up None None O
( None None O
median None None O
34 None None O
months None None O
) None None O
, None None O
26 None None O
patients None None O
reached None None O
the None None O
primary None None O
endpoint None None O
. None None O

The None None O
presence None None O
of None None O
LPs None None O
was None None O
not None None O
significantly None None O
associated None None O
with None None O
the None None O
primary None None O
endpoint None None O
in None None O
univariable None None O
or None None O
multivariable None None O
analysis None None O
. None None O

In None None O
contrast None None O
, None None O
low None None O
( None None O
< None None O
or None None O
= None None O
30 None None O
% None None O
) None None O
left None None O
ventricular None None O
ejection None None O
fraction None None O
( None None O
hazard None None O
ratio None None O
9 None None O
. None None O
6 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
4 None None O
. None None O
1 None None O
- None None O
22 None None O
. None None O
4 None None O
) None None O
, None None O
heart None None O
rate None None O
turbulence None None O
category None None O
2 None None O
( None None O
7 None None O
. None None O
5 None None O
, None None O
2 None None O
. None None O
4 None None O
- None None O
23 None None O
. None None O
9 None None O
) None None O
and None None O
category None None O
1 None None O
( None None O
5 None None O
. None None O
3 None None O
, None None O
1 None None O
. None None O
9 None None O
- None None O
14 None None O
. None None O
9 None None O
) None None O
were None None O
significant None None O
predictors None None O
in None None O
both None None O
univariable None None O
and None None O
multivariable None None O
analysis None None O
. None None O

CONCLUSION None None O
: None None O

Ventricular None None O
LPs None None O
are None None O
of None None O
limited None None O
use None None O
for None None O
risk None None O
stratification None None O
in None None O
unselected None None O
post None None O
- None None O
infarction None None O
patients None None O
in None None O
the None None O
modern None None O
reperfusion None None O
era None None O
. None None O

Caffeine None None O
inhibits None None O
adenosine None None O
- None None O
induced None None O
accumulation None None O
of None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1alpha None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
and None None O
interleukin None None O
- None None O
8 None None O
expression None None O
in None None O
hypoxic None None O
human None None O
colon None None O
cancer None None O
cells None None O
. None None O

Frequent None None O
coffee None None O
consumption None None O
has None None O
been None None O
associated None None O
with None None O
a None None O
reduced None None O
risk None None O
of None None O
colorectal None None O
cancer None None O
in None None O
a None None O
number None None O
of None None O
case None None O
- None None O
control None None O
studies None None O
. None None O

Coffee None None O
is None None O
a None None O
leading None None O
source None None O
of None None O
methylxanthines None None O
, None None O
such None None O
as None None O
caffeine None None O
. None None O

The None None O
induction None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
interleukin None None O
- None None O
8 None None O
( None None O
IL None None O
- None None O
8 None None O
) None None O
is None None O
an None None O
essential None None O
feature None None O
of None None O
tumor None None O
angiogenesis None None O
, None None O
and None None O
the None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
- None None O
1 None None O
( None None O
HIF None None O
- None None O
1 None None O
) None None O
transcription None None O
factor None None O
is None None O
known None None O
to None None O
be None None O
a None None O
key None None O
regulator None None O
of None None O
this None None O
process None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
effects None None O
of None None O
caffeine None None O
on None None O
HIF None None O
- None None O
1 None None O
protein None None O
accumulation None None O
and None None O
on None None O
VEGF None None O
and None None O
IL None None O
- None None O
8 None None O
expression None None O
in None None O
the None None O
human None None O
colon None None O
cancer None None O
cell None None O
line None None O
HT29 None None I-Cell-line-name
under None None O
hypoxic None None O
conditions None None O
. None None O

Our None None O
results None None O
show None None O
that None None O
caffeine None None O
significantly None None O
inhibits None None O
adenosine None None O
- None None O
induced None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
accumulation None None O
in None None O
cancer None None O
cells None None O
. None None O

We None None O
show None None O
that None None O
HIF None None O
- None None O
1alpha None None O
and None None O
VEGF None None O
are None None O
increased None None O
through None None O
A3 None None O
adenosine None None O
receptor None None O
stimulation None None O
, None None O
whereas None None O
the None None O
effects None None O
on None None O
IL None None O
- None None O
8 None None O
are None None O
mediated None None O
via None None O
the None None O
A2B None None O
subtype None None O
. None None O

Pretreatment None None O
of None None O
cells None None O
with None None O
caffeine None None O
significantly None None O
reduces None None O
adenosine None None O
- None None O
induced None None O
VEGF None None O
promoter None None O
activity None None O
and None None O
VEGF None None O
and None None O
IL None None O
- None None O
8 None None O
expression None None O
. None None O

The None None O
mechanism None None O
of None None O
caffeine None None O
seems None None O
to None None O
involve None None O
the None None O
inhibition None None O
of None None O
the None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
1 None None O
/ None None O
2 None None O
( None None O
ERK1 None None O
/ None None O
2 None None O
) None None O
, None None O
p38 None None O
, None None O
and None None O
Akt None None O
, None None O
leading None None O
to None None O
a None None O
marked None None O
decrease None None O
in None None O
adenosine None None O
- None None O
induced None None O
HIF None None O
- None None O
1alpha None None O
accumulation None None O
, None None O
VEGF None None O
transcriptional None None O
activation None None O
, None None O
and None None O
VEGF None None O
and None None O
IL None None O
- None None O
8 None None O
protein None None O
accumulation None None O
. None None O

From None None O
a None None O
functional None None O
perspective None None O
, None None O
we None None O
observe None None O
that None None O
caffeine None None O
also None None O
significantly None None O
inhibits None None O
the None None O
A3 None None O
receptor None None O
- None None O
stimulated None None O
cell None None O
migration None None O
of None None O
colon None None O
cancer None None O
cells None None O
. None None O

Conditioned None None O
media None None O
prepared None None O
from None None O
colon None None O
cells None None O
treated None None O
with None None O
an None None O
adenosine None None O
analog None None O
increased None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
migration None None O
. None None O

These None None O
data None None O
provide None None O
evidence None None O
that None None O
adenosine None None O
could None None O
modulate None None O
the None None O
migration None None O
of None None O
colon None None O
cancer None None O
cells None None O
by None None O
an None None O
HIF None None O
- None None O
1alpha None None O
/ None None O
VEGF None None O
/ None None O
IL None None O
- None None O
8 None None O
- None None O
dependent None None O
mechanism None None O
and None None O
that None None O
caffeine None None O
has None None O
the None None O
potential None None O
to None None O
inhibit None None O
colon None None O
cancer None None O
cell None None O
growth None None O
. None None O

Recent None None O
advances None None O
in None None O
minisatellite None None O
biology None None O
. None None O

Highly None None O
polymorphic None None O
tandemly None None O
repeated None None O
' None None O
minisatellite None None O
' None None O
loci None None O
are None None O
very None None O
abundant None None O
in None None O
the None None O
human None None O
genome None None O
, None None O
and None None O
of None None O
considerable None None O
utility None None O
in None None O
human None None O
genetic None None O
analysis None None O
. None None O

This None None O
review None None O
describes None None O
the None None O
use None None O
of None None O
an None None O
ordered None None O
- None None O
array None None O
Charomid None None O
library None None O
in None None O
the None None O
systematic None None O
and None None O
efficient None None O
cloning None None O
of None None O
these None None O
regions None None O
, None None O
and None None O
in None None O
the None None O
analysis None None O
of None None O
the None None O
relative None None O
overlap None None O
between None None O
the None None O
different None None O
probes None None O
used None None O
to None None O
screen None None O
for None None O
hypervariable None None O
loci None None O
. None None O

Recent None None O
work None None O
on None None O
the None None O
process None None O
of None None O
mutation None None O
leading None None O
to None None O
the None None O
generation None None O
of None None O
new None None O
- None None O
length None None O
alleles None None O
is None None O
also None None O
discussed None None O
, None None O
including None None O
the None None O
observation None None O
that None None O
at None None O
least None None O
some None None O
mutations None None O
may None None O
be None None O
due None None O
to None None O
unequal None None O
exchanges None None O
. None None O

Transcriptional None None O
and None None O
post None None O
- None None O
translation None None O
regulation None None O
of None None O
the None None O
Tie1 None None O
receptor None None O
by None None O
fluid None None O
shear None None O
stress None None O
changes None None O
in None None O
vascular None None O
endothelial None None O
cells None None O
. None None O

The None None O
interaction None None O
between None None O
the None None O
vascular None None O
endothelium None None O
and None None O
hemodynamic None None O
forces None None O
( None None O
and None None O
more None None O
specifically None None O
, None None O
fluid None None O
shear None None O
stress None None O
) None None O
, None None O
induced None None O
by None None O
the None None O
flow None None O
of None None O
blood None None O
, None None O
plays None None O
a None None O
major None None O
role None None O
in None None O
vascular None None O
remodeling None None O
and None None O
in None None O
new None None O
blood None None O
vessels None None O
formation None None O
via None None O
a None None O
process None None O
termed None None O
arteriogenesis None None O
. None None O

Tie1 None None O
is None None O
an None None O
orphan None None O
tyrosine None None O
kinase None None O
receptor None None O
expressed None None O
almost None None O
exclusively None None O
in None None O
endothelial None None O
cells None None O
and None None O
is None None O
required None None O
for None None O
normal None None O
vascular None None O
development None None O
and None None O
maintenance None None O
. None None O

The None None O
present None None O
study None None O
demonstrates None None O
that None None O
Tie1 None None O
expression None None O
is None None O
rapidly None None O
down None None O
- None None O
regulated None None O
in None None O
endothelial None None O
cells None None O
exposed None None O
to None None O
shear None None O
stress None None O
, None None O
and None None O
more None None O
so None None O
to None None O
shear None None O
stress None None O
changes None None O
. None None O

This None None O
down None None O
- None None O
regulation None None O
is None None O
accompanied None None O
by None None O
a None None O
rapid None None O
cleavage None None O
of None None O
Tie1 None None O
and None None O
binding None None O
of None None O
the None None O
cleaved None None O
Tie1 None None O
45 None None O
kDa None None O
endodomain None None O
to None None O
Tie2 None None O
. None None O

The None None O
rapid None None O
cleavage None None O
of None None O
Tie1 None None O
is None None O
followed None None O
by None None O
a None None O
transcriptional None None O
down None None O
- None None O
regulation None None O
in None None O
response None None O
to None None O
shear None None O
stress None None O
. None None O

The None None O
activity None None O
of None None O
the None None O
Tie1 None None O
promoter None None O
is None None O
suppressed None None O
by None None O
shear None None O
stress None None O
and None None O
by None None O
tumor None None O
necrosis None None O
factor None None O
alpha None None O
. None None O

Shear None None O
stress None None O
- None None O
induced None None O
transcriptional None None O
suppression None None O
of None None O
Tie1 None None O
is None None O
mediated None None O
by None None O
a None None O
negative None None O
shear None None O
stress None None O
response None None O
element None None O
, None None O
localized None None O
in None None O
a None None O
region None None O
of None None O
250 None None O
bp None None O
within None None O
the None None O
promoter None None O
. None None O

The None None O
rapid None None O
down None None O
- None None O
regulation None None O
of None None O
Tie1 None None O
by None None O
shear None None O
stress None None O
changes None None O
and None None O
its None None O
rapid None None O
binding None None O
to None None O
Tie2 None None O
may None None O
be None None O
required None None O
for None None O
destabilization None None O
of None None O
endothelial None None O
cells None None O
in None None O
order None None O
to None None O
initiate None None O
the None None O
process None None O
of None None O
vascular None None O
restructuring None None O
. None None O

Referral None None O
bias None None O
among None None O
health None None O
workers None None O
in None None O
studies None None O
using None None O
hospitalization None None O
as None None O
a None None O
proxy None None O
measure None None O
of None None O
the None None O
underlying None None O
incidence None None O
rate None None O
. None None O

Contacts None None O
with None None O
health None None O
services None None O
like None None O
hospitals None None O
or None None O
general None None O
practitioners None None O
are None None O
usually None None O
the None None O
only None None O
available None None O
proxy None None O
measure None None O
of None None O
incidence None None O
of None None O
disease None None O
in None None O
studies None None O
based None None O
on None None O
secondary None None O
data None None O
and None None O
differential None None O
referrals None None O
or None None O
care None None O
- None None O
seeking None None O
behavior None None O
often None None O
bias None None O
such None None O
proxy None None O
measures None None O
. None None O

In None None O
former None None O
analyses None None O
based None None O
on None None O
the None None O
Occupational None None O
Hospitalization None None O
Register None None O
in None None O
Denmark None None O
assisting None None O
nurses None None O
had None None O
high None None O
Standardized None None O
Hospitalization None None O
Ratios None None O
for None None O
many None None O
diseases None None O
. None None O

It None None O
was None None O
, None None O
however None None O
, None None O
suspected None None O
that None None O
it None None O
fully None None O
or None None O
partly None None O
was None None O
due None None O
to None None O
a None None O
referral None None O
bias None None O
or None None O
self None None O
- None None O
selection None None O
to None None O
hospital None None O
treatment None None O
rather None None O
than None None O
exposures None None O
to None None O
occupational None None O
hazards None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
is None None O
to None None O
evaluate None None O
the None None O
referral None None O
bias None None O
hypothesis None None O
by None None O
comparing None None O
hospitalization None None O
and None None O
mortality None None O
data None None O
for None None O
health None None O
workers None None O
for None None O
a None None O
disease None None O
category None None O
with None None O
a None None O
high None None O
mortality None None O
. None None O

Cohorts None None O
of None None O
all None None O
gainfully None None O
employed None None O
20 None None O
- None None O
to None None O
59 None None O
- None None O
year None None O
- None None O
old None None O
Danes None None O
were None None O
formed None None O
in None None O
order None None O
to None None O
compare None None O
Standardized None None O
Mortality None None O
Ratios None None O
and None None O
Standardized None None O
Hospitalization None None O
Ratios None None O
of None None O
ischemic None None O
heart None None O
disease None None O
( None None O
IHD None None O
) None None O
in None None O
occupational None None O
groups None None O
. None None O

The None None O
follow None None O
- None None O
up None None O
period None None O
was None None O
10 None None O
years None None O
. None None O

For None None O
most None None O
of None None O
the None None O
investigated None None O
occupational None None O
groups None None O
a None None O
similar None None O
disease None None O
pattern None None O
was None None O
found None None O
whether None None O
hospitalization None None O
or None None O
death None None O
was None None O
used None None O
as None None O
the None None O
outcome None None O
measure None None O
. None None O

In None None O
" None None O
nurse None None O
assistants None None O
" None None O
a None None O
statistically None None O
significant None None O
higher None None O
risk None None O
was None None O
, None None O
however None None O
, None None O
found None None O
using None None O
hospitalization None None O
due None None O
to None None O
IHD None None O
as None None O
the None None O
end None None O
point None None O
rather None None O
than None None O
mortality None None O
. None None O

Additional None None O
analysis None None O
did None None O
not None None O
support None None O
the None None O
hypothesis None None O
that None None O
the None None O
finding None None O
could None None O
be None None O
explained None None O
by None None O
differentiated None None O
hospitalization None None O
due None None O
to None None O
social None None O
factors None None O
. None None O

The None None O
true None None O
incidence None None O
rates None None O
of None None O
the None None O
disease None None O
need None None O
not None None O
be None None O
equally None None O
well None None O
described None None O
by None None O
proxy None None O
measures None None O
such None None O
as None None O
hospitalization None None O
diagnosis None None O
or None None O
death None None O
diagnosis None None O
in None None O
all None None O
occupational None None O
groups None None O
. None None O

Differential None None O
access None None O
to None None O
medical None None O
treatment None None O
in None None O
some None None O
groups None None O
may None None O
lead None None O
to None None O
bias None None O
when None None O
hospital None None O
data None None O
are None None O
used None None O
as None None O
proxy None None O
measures None None O
for None None O
the None None O
underlying None None O
incidence None None O
rates None None O
. None None O

Proliferative None None O
diabetic None None O
retinopathy None None O
is None None O
associated None None O
with None None O
a None None O
low None None O
level None None O
of None None O
the None None O
natural None None O
ocular None None O
anti None None O
- None None O
angiogenic None None O
agent None None O
pigment None None O
epithelium None None O
- None None O
derived None None O
factor None None O
( None None O
PEDF None None O
) None None O
in None None O
aqueous None None O
humor None None O
. None None O

a None None O
pilot None None O
study None None O
. None None O

Retinopathy None None O
is None None O
the None None O
most None None O
common None None O
microvascular None None O
diabetes None None O
complication None None O
and None None O
represents None None O
a None None O
major None None O
threat None None O
to None None O
the None None O
eyesight None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
address None None O
the None None O
role None None O
of None None O
pro None None O
- None None O
and None None O
anti None None O
- None None O
angiogenic None None O
molecules None None O
in None None O
diabetic None None O
retinopathy None None O
in None None O
the None None O
aqueous None None O
humor None None O
of None None O
the None None O
eye None None O
. None None O

Aqueous None None O
humor None None O
was None None O
collected None None O
at None None O
cataract None None O
surgery None None O
from None None O
19 None None O
diabetic None None O
patients None None O
and None None O
from None None O
13 None None O
age None None O
- None None O
and None None O
sex None None O
- None None O
matched None None O
normoglycemic None None O
controls None None O
. None None O

Levels None None O
of None None O
pro None None O
- None None O
angiogenic None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
angiogenic None None O
inhibitor None None O
pigment None None O
epithelium None None O
- None None O
derived None None O
factor None None O
( None None O
PEDF None None O
) None None O
were None None O
determined None None O
. None None O

Angiogenic None None O
activity None None O
of None None O
the None None O
aqueous None None O
humor None None O
was None None O
quantified None None O
by None None O
measuring None None O
its None None O
effect None None O
on None None O
the None None O
migration None None O
of None None O
capillary None None O
endothelial None None O
cells None None O
. None None O

In None None O
the None None O
aqueous None None O
fluid None None O
, None None O
VEGF None None O
levels None None O
were None None O
increased None None O
in None None O
diabetics None None O
( None None O
mean None None O
values None None O
: None None O
501 None None O
vs None None O
. None None O
367 None None O
pg None None O
/ None None O
ml None None O
; None None O
p None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
compared None None O
to None None O
controls None None O
. None None O

PEDF None None O
was None None O
found None None O
to None None O
be None None O
decreased None None O
in None None O
diabetics None None O
( None None O
mean None None O
values None None O
: None None O
2080 None None O
vs None None O
. None None O
5780 None None O
ng None None O
/ None None O
ml None None O
; None None O
p None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
compared None None O
to None None O
controls None None O
. None None O

In None None O
seven None None O
diabetic None None O
patients None None O
with None None O
proliferative None None O
retinopathy None None O
, None None O
the None None O
most None None O
profound None None O
finding None None O
was None None O
a None None O
significant None None O
decrease None None O
of None None O
the None None O
PEDF None None O
level None None O
( None None O
mean None None O
value None None O
: None None O
237 None None O
ng None None O
/ None None O
ml None None O
) None None O
, None None O
whereas None None O
VEGF None None O
levels None None O
were None None O
comparable None None O
to None None O
diabetic None None O
patients None None O
without None None O
proliferation None None O
( None None O
mean None None O
value None None O
: None None O
3153 None None O
; None None O
p None None O
= None None O
0 None None O
. None None O
003 None None O
) None None O
. None None O

Angiogenic None None O
activity None None O
in None None O
samples None None O
of None None O
patients None None O
from None None O
the None None O
control None None O
group None None O
was None None O
generally None None O
inhibitory None None O
due None None O
to None None O
PEDF None None O
, None None O
and None None O
inhibition None None O
was None None O
blocked None None O
by None None O
neutralizing None None O
antibodies None None O
to None None O
PEDF None None O
. None None O

Likewise None None O
, None None O
in None None O
diabetics None None O
without None None O
proliferation None None O
, None None O
angiogenic None None O
activity None None O
was None None O
also None None O
blocked None None O
by None None O
antibodies None None O
to None None O
PEDF None None O
. None None O

We None None O
will None None O
demonstrate None None O
here None None O
that None None O
the None None O
level None None O
of None None O
the None None O
natural None None O
ocular None None O
anti None None O
- None None O
angiogenic None None O
agent None None O
PEDF None None O
is None None O
inversely None None O
associated None None O
with None None O
proliferative None None O
retinopathy None None O
. None None O

PEDF None None O
is None None O
an None None O
important None None O
negative None None O
regulator None None O
of None None O
angiogenic None None O
activity None None O
of None None O
aqueous None None O
humor None None O
. None None O

Our None None O
data None None O
may None None O
have None None O
implications None None O
for None None O
the None None O
development None None O
of None None O
novel None None O
regimens None None O
for None None O
diabetic None None O
retinopathy None None O
. None None O

The None None O
genetics None None O
of None None O
transformation None None O
by None None O
SV None None O
40 None None O
. None None O

Experiments None None O
using None None O
the None None O
tsA None None O
58 None None O
allele None None O
of None None O
the None None O
SV None None O
40 None None O
- None None O
A None None O
gene None None O
have None None O
demonstrated None None O
that None None O
the None None O
SV None None O
40 None None O
large None None O
T None None O
- None None O
antigen None None O
is None None O
strictly None None O
required None None O
both None None O
for None None O
immortalization None None O
and None None O
induction None None O
anchorage None None O
independence None None O
of None None O
cells None None O
. None None O

It None None O
has None None O
been None None O
suggested None None O
that None None O
the None None O
immortalized None None O
phenotype None None O
is None None O
mediated None None O
by None None O
an None None O
extra None None O
cellular None None O
factor None None O
. None None O

The None None O
synthesis None None O
and None None O
/ None None O
or None None O
the None None O
excretion None None O
of None None O
this None None O
factor None None O
in None None O
a None None O
medium None None O
is None None O
controlled None None O
by None None O
the None None O
A None None O
gene None None O
. None None O

Relationship None None O
of None None O
p53 None None O
and None None O
Helicobacter None None O
pylori None None O
to None None O
clinicopathological None None O
features None None O
of None None O
human None None O
remnant None None O
stomach None None O
cancer None None O
after None None O
gastric None None O
surgery None None O
for None None O
primary None None O
gastric None None O
cancer None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
biological None None O
features None None O
of None None O
gastric None None O
cancer None None O
of None None O
the None None O
remnant None None O
stomach None None O
( None None O
RSC None None O
) None None O
. None None O

Twenty None None O
- None None O
one None None O
patients None None O
underwent None None O
resection None None O
of None None O
the None None O
remnant None None O
stomach None None O
for None None O
RSC None None O
and None None O
were None None O
divided None None O
into None None O
two None None O
groups None None O
: None None O
the None None O
RSCB None None O
group None None O
consisted None None O
of None None O
11 None None O
patients None None O
who None None O
underwent None None O
distal None None O
gastrectomy None None O
for None None O
benign None None O
disease None None O
and None None O
the None None O
RSCM None None O
group None None O
consisted None None O
of None None O
10 None None O
patients None None O
who None None O
underwent None None O
gastrectomy None None O
for None None O
primary None None O
gastric None None O
cancer None None O
. None None O

The None None O
interval None None O
between None None O
primary None None O
surgery None None O
and None None O
the None None O
appearance None None O
of None None O
gastric None None O
cancer None None O
in None None O
the None None O
remnant None None O
stomach None None O
was None None O
significantly None None O
shorter None None O
in None None O
the None None O
RSCM None None O
group None None O
than None None O
in None None O
the None None O
RSCB None None O
group None None O
. None None O

Invasion None None O
of None None O
adjacent None None O
organs None None O
was None None O
more None None O
frequent None None O
in None None O
the None None O
RSCM None None O
group None None O
than None None O
in None None O
the None None O
RSCB None None O
group None None O
and None None O
the None None O
Ki None None O
- None None O
67 None None O
labeling None None O
index None None O
of None None O
the None None O
tumors None None O
was None None O
significantly None None O
higher None None O
in None None O
the None None O
former None None O
group None None O
. None None O

Furthermore None None O
, None None O
p53 None None O
overexpression None None O
by None None O
tumors None None O
was None None O
almost None None O
twice None None O
as None None O
common None None O
in None None O
the None None O
RSCM None None O
group None None O
as None None O
in None None O
the None None O
RSCB None None O
group None None O
. None None O

Although None None O
there None None O
was None None O
no None None O
significant None None O
difference None None O
of None None O
the None None O
H None None O
. None None O
pylori None None O
positivity None None O
between None None O
the None None O
two None None O
groups None None O
, None None O
the None None O
rate None None O
for None None O
both None None O
groups None None O
was None None O
higher None None O
than None None O
reported None None O
in None None O
previous None None O
studies None None O
. None None O

Mutation None None O
of None None O
p53 None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
high None None O
proliferative None None O
activity None None O
of None None O
tumors None None O
in None None O
the None None O
RSCM None None O
group None None O
and None None O
H None None O
. None None O
pylori None None O
infection None None O
may None None O
be None None O
closely None None O
related None None O
to None None O
carcinogenesis None None O
in None None O
patients None None O
with None None O
RSC None None O
. None None O

Vascular None None O
proliferation None None O
and None None O
enhanced None None O
expression None None O
of None None O
endothelial None None O
nitric None None O
oxide None None O
synthase None None O
in None None O
human None None O
peritoneum None None O
exposed None None O
to None None O
long None None O
- None None O
term None None O
peritoneal None None O
dialysis None None O
. None None O

Long None None O
- None None O
term None None O
peritoneal None None O
dialysis None None O
( None None O
PD None None O
) None None O
is None None O
associated None None O
with None None O
alterations None None O
in None None O
peritoneal None None O
permeability None None O
and None None O
loss None None O
of None None O
ultrafiltration None None O
. None None O

These None None O
changes None None O
originate None None O
from None None O
increased None None O
peritoneal None None O
surface None None O
area None None O
, None None O
but None None O
the None None O
morphologic None None O
and None None O
molecular None None O
mechanisms None None O
involved None None O
remain None None O
unknown None None O
. None None O

The None None O
hypothesis None None O
that None None O
modifications None None O
of None None O
activity None None O
and None None O
/ None None O
or None None O
expression None None O
of None None O
nitric None None O
oxide None None O
synthase None None O
( None None O
NOS None None O
) None None O
isozymes None None O
might None None O
play None None O
a None None O
role None None O
in None None O
these None None O
modifications None None O
, None None O
via None None O
enhanced None None O
local None None O
production None None O
of None None O
nitric None None O
oxide None None O
, None None O
was None None O
tested None None O
in None None O
this None None O
study None None O
. None None O

NOS None None O
activities None None O
were None None O
measured None None O
by None None O
the None None O
L None None O
- None None O
citrulline None None O
assay None None O
in None None O
peritoneal None None O
biopsies None None O
from None None O
seven None None O
control None None O
subjects None None O
, None None O
eight None None O
uremic None None O
patients None None O
immediately None None O
before None None O
the None None O
onset None None O
of None None O
PD None None O
, None None O
and None None O
13 None None O
uremic None None O
patients None None O
on None None O
short None None O
- None None O
term None None O
( None None O
less None None O
than None None O
18 None None O
mo None None O
, None None O
n None None O
= None None O
6 None None O
) None None O
or None None O
long None None O
- None None O
term None None O
( None None O
greater None None O
than None None O
18 None None O
mo None None O
, None None O
n None None O
= None None O
7 None None O
) None None O
PD None None O
. None None O

Peritoneal None None O
NOS None None O
activity None None O
is None None O
increased None None O
fivefold None None O
in None None O
long None None O
- None None O
term None None O
PD None None O
patients None None O
compared None None O
with None None O
control None None O
subjects None None O
. None None O

In None None O
uremic None None O
patients None None O
, None None O
NOS None None O
activity None None O
is None None O
positively None None O
correlated None None O
with None None O
the None None O
duration None None O
of None None O
PD None None O
. None None O

Increased None None O
NOS None None O
activity None None O
is None None O
mediated None None O
solely None None O
by None None O
Ca None None O
( None None O
2 None None O
+ None None O
) None None O
- None None O
dependent None None O
NOS None None O
and None None O
, None None O
as None None O
shown None None O
by None None O
immunoblotting None None O
, None None O
an None None O
upregulation None None O
of None None O
endothelial None None O
NOS None None O
. None None O

The None None O
biologic None None O
relevance None None O
of None None O
increased None None O
NOS None None O
in None None O
long None None O
- None None O
term None None O
PD None None O
was None None O
demonstrated None None O
by None None O
enhanced None None O
nitrotyrosine None None O
immunoreactivity None None O
and None None O
a None None O
significant None None O
increase None None O
in None None O
vascular None None O
density None None O
and None None O
endothelial None None O
area None None O
in None None O
the None None O
peritoneum None None O
. None None O

Immunoblotting None None O
and None None O
immunostaining None None O
studies None None O
demonstrated None None O
an None None O
upregulation None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
mostly None None O
along None None O
the None None O
endothelium None None O
lining None None O
peritoneal None None O
blood None None O
vessels None None O
in None None O
long None None O
- None None O
term None None O
PD None None O
patients None None O
. None None O

In None None O
the None None O
latter None None O
, None None O
VEGF None None O
colocalized None None O
with None None O
the None None O
advanced None None O
glycation None None O
end None None O
product None None O
pentosidine None None O
deposits None None O
. None None O

These None None O
data None None O
provide None None O
a None None O
morphologic None None O
( None None O
angiogenesis None None O
and None None O
increased None None O
endothelial None None O
area None None O
) None None O
and None None O
molecular None None O
( None None O
enhanced None None O
NOS None None O
activity None None O
and None None O
endothelial None None O
NOS None None O
upregulation None None O
) None None O
basis None None O
for None None O
explaining None None O
the None None O
permeability None None O
changes None None O
observed None None O
in None None O
long None None O
- None None O
term None None O
PD None None O
. None None O

They None None O
also None None O
support None None O
the None None O
implication None None O
of None None O
local None None O
advanced None None O
glycation None None O
end None None O
product None None O
deposits None None O
and None None O
liberation None None O
of None None O
VEGF None None O
in None None O
that None None O
process None None O
. None None O

Oncogenic None None O
mechanisms None None O
of None None O
Evi None None O
- None None O
1 None None O
protein None None O
. None None O

Although None None O
Evi None None O
- None None O
1 None None O
is None None O
thought None None O
to None None O
promote None None O
growth None None O
or None None O
block None None O
differentiation None None O
in None None O
some None None O
cell None None O
types None None O
, None None O
its None None O
biological None None O
functions None None O
have None None O
not None None O
been None None O
elucidated None None O
. None None O

To None None O
explore None None O
the None None O
mechanisms None None O
underlying None None O
Evi None None O
- None None O
1 None None O
- None None O
induced None None O
oncogenesis None None O
, None None O
we None None O
investigated None None O
whether None None O
Evi None None O
- None None O
1 None None O
affects None None O
the None None O
signaling None None O
of None None O
transforming None None O
growth None None O
factor None None O
beta None None O
( None None O
TGF None None O
- None None O
beta None None O
) None None O
, None None O
which None None O
inhibits None None O
proliferation None None O
of None None O
a None None O
wide None None O
range None None O
of None None O
cell None None O
types None None O
and None None O
is None None O
one None None O
of None None O
the None None O
most None None O
studied None None O
growth None None O
regulatory None None O
factors None None O
. None None O

We None None O
demonstrated None None O
that None None O
Evi None None O
- None None O
1 None None O
represses None None O
TGF None None O
- None None O
beta None None O
signaling None None O
and None None O
antagonizes None None O
its None None O
growth None None O
- None None O
inhibitory None None O
effects None None O
. None None O

Two None None O
separate None None O
regions None None O
of None None O
Evi None None O
- None None O
1 None None O
are None None O
responsible None None O
for None None O
this None None O
repression None None O
, None None O
one None None O
of None None O
which None None O
is None None O
the None None O
first None None O
zinc None None O
- None None O
finger None None O
domain None None O
. None None O

Through None None O
this None None O
domain None None O
, None None O
Evi None None O
- None None O
1 None None O
physically None None O
interacts None None O
with None None O
Smad3 None None O
, None None O
an None None O
intracellular None None O
mediator None None O
of None None O
TGF None None O
- None None O
beta None None O
signaling None None O
, None None O
thereby None None O
suppressing None None O
the None None O
transcriptional None None O
activity None None O
of None None O
Smad3 None None O
. None None O

These None None O
results None None O
define None None O
a None None O
novel None None O
function None None O
of None None O
Evi None None O
- None None O
1 None None O
as None None O
a None None O
repressor None None O
of None None O
signaling None None O
components None None O
of None None O
TGF None None O
- None None O
beta None None O
. None None O

We None None O
also None None O
demonstrated None None O
that None None O
Evi None None O
- None None O
1 None None O
represses None None O
Smad None None O
- None None O
induced None None O
transcriptional None None O
activation None None O
by None None O
recruiting None None O
CtBP None None O
as None None O
a None None O
corepressor None None O
. None None O

Evi None None O
- None None O
1 None None O
associates None None O
with None None O
CtBP1 None None O
through None None O
one None None O
of None None O
the None None O
CtBP None None O
- None None O
binding None None O
consensus None None O
motifs None None O
within None None O
the None None O
region None None O
from None None O
amino None None O
acid None None O
544 None None O
to None None O
607 None None O
, None None O
and None None O
this None None O
association None None O
is None None O
required None None O
for None None O
the None None O
efficient None None O
inhibition None None O
of None None O
TGF None None O
- None None O
beta None None O
signaling None None O
. None None O

A None None O
specific None None O
histone None None O
deacetylase None None O
( None None O
HDAc None None O
) None None O
inhibitor None None O
, None None O
trichostatin None None O
A None None O
( None None O
TSA None None O
) None None O
, None None O
alleviates None None O
Evi None None O
- None None O
1 None None O
- None None O
mediated None None O
repression None None O
of None None O
TGF None None O
- None None O
beta None None O
signaling None None O
, None None O
suggesting None None O
that None None O
HDAc None None O
is None None O
involved None None O
in None None O
transcriptional None None O
repression None None O
by None None O
Evi None None O
- None None O
1 None None O
. None None O

This None None O
identifies None None O
a None None O
novel None None O
function None None O
of None None O
Evi None None O
- None None O
1 None None O
as None None O
a None None O
member None None O
of None None O
corepressor None None O
complexes None None O
and None None O
suggests None None O
that None None O
aberrant None None O
recruitment None None O
of None None O
corepressors None None O
is None None O
one None None O
of None None O
the None None O
mechanisms None None O
involved None None O
in None None O
Evi None None O
- None None O
1 None None O
- None None O
induced None None O
leukemogenesis None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
specific None None O
HDAc None None O
inhibitors None None O
may None None O
be None None O
useful None None O
in None None O
the None None O
treatment None None O
of None None O
Evi None None O
- None None O
1 None None O
- None None O
induced None None O
neoplastic None None O
tumors None None O
, None None O
including None None O
myeloid None None O
leukemias None None O
. None None O

Saliva None None O
proteins None None O
of None None O
vector None None O
Culicoides None None O
modify None None O
structure None None O
and None None O
infectivity None None O
of None None O
bluetongue None None O
virus None None O
particles None None O
. None None O

Bluetongue None None O
virus None None O
( None None O
BTV None None O
) None None O
and None None O
epizootic None None O
haemorrhagic None None O
disease None None O
virus None None O
( None None O
EHDV None None O
) None None O
are None None O
related None None O
orbiviruses None None O
, None None O
transmitted None None O
between None None O
their None None O
ruminant None None O
hosts None None O
primarily None None O
by None None O
certain None None O
haematophagous None None O
midge None None O
vectors None None O
( None None O
Culicoides None None O
spp None None O
. None None O
) None None O
. None None O

The None None O
larger None None O
of None None O
the None None O
BTV None None O
outer None None O
- None None O
capsid None None O
proteins None None O
, None None O
' None None O
VP2 None None O
' None None O
, None None O
can None None O
be None None O
cleaved None None O
by None None O
proteases None None O
( None None O
including None None O
trypsin None None O
or None None O
chymotrypsin None None O
) None None O
, None None O
forming None None O
infectious None None O
subviral None None O
particles None None O
( None None O
ISVP None None O
) None None O
which None None O
have None None O
enhanced None None O
infectivity None None O
for None None O
adult None None O
Culicoides None None O
, None None O
or None None O
KC None None O
cells None None O
( None None O
a None None O
cell None None O
- None None O
line None None O
derived None None O
from None None O
C None None O
. None None O
sonorensis None None O
) None None O
. None None O

We None None O
demonstrate None None O
that None None O
VP2 None None O
present None None O
on None None O
purified None None O
virus None None O
particles None None O
from None None O
3 None None O
different None None O
BTV None None O
strains None None O
can None None O
also None None O
be None None O
cleaved None None O
by None None O
treatment None None O
with None None O
saliva None None O
from None None O
adult None None O
Culicoides None None O
. None None O

The None None O
saliva None None O
proteins None None O
from None None O
C None None O
. None None O
sonorensis None None O
( None None O
a None None O
competent None None O
BTV None None O
vector None None O
) None None O
, None None O
cleaved None None O
BTV None None O
- None None O
VP2 None None O
more None None O
efficiently None None O
than None None O
those None None O
from None None O
C None None O
. None None O
nubeculosus None None O
( None None O
a None None O
less None None O
competent None None O
/ None None O
non None None O
- None None O
vector None None O
species None None O
) None None O
. None None O

Electrophoresis None None O
and None None O
mass None None O
spectrometry None None O
identified None None O
a None None O
trypsin None None O
- None None O
like None None O
protease None None O
in None None O
C None None O
. None None O
sonorensis None None O
saliva None None O
, None None O
which None None O
was None None O
significantly None None O
reduced None None O
or None None O
absent None None O
from None None O
C None None O
. None None O
nubeculosus None None O
saliva None None O
. None None O

Incubating None None O
purified None None O
BTV None None O
- None None O
1 None None O
with None None O
C None None O
. None None O
sonorensis None None O
saliva None None O
proteins None None O
also None None O
increased None None O
their None None O
infectivity None None O
for None None O
KC None None O
cells None None O
~ None None O
10 None None O
fold None None O
, None None O
while None None O
infectivity None None O
for None None O
BHK None None I-Cell-line-name
cells None None O
was None None O
reduced None None O
by None None O
2 None None O
- None None O
6 None None O
fold None None O
. None None O

Treatment None None O
of None None O
an None None O
' None None O
eastern None None O
' None None O
strain None None O
of None None O
EHDV None None O
- None None O
2 None None O
with None None O
saliva None None O
proteins None None O
of None None O
either None None O
C None None O
. None None O
sonorensis None None O
or None None O
C None None O
. None None O
nubeculosus None None O
cleaved None None O
VP2 None None O
, None None O
but None None O
a None None O
' None None O
western None None O
' None None O
strain None None O
of None None O
EHDV None None O
- None None O
2 None None O
remained None None O
unmodified None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
temperature None None O
, None None O
strain None None O
of None None O
virus None None O
and None None O
protein None None O
composition None None O
of None None O
Culicoides None None O
saliva None None O
( None None O
particularly None None O
its None None O
protease None None O
content None None O
which None None O
is None None O
dependent None None O
upon None None O
vector None None O
species None None O
) None None O
, None None O
can None None O
all None None O
play None None O
a None None O
significant None None O
role None None O
in None None O
the None None O
efficiency None None O
of None None O
VP2 None None O
cleavage None None O
, None None O
influencing None None O
virus None None O
infectivity None None O
. None None O

Saliva None None O
of None None O
several None None O
other None None O
arthropod None None O
species None None O
has None None O
previously None None O
been None None O
shown None None O
to None None O
increase None None O
transmission None None O
, None None O
infectivity None None O
and None None O
virulence None None O
of None None O
certain None None O
arboviruses None None O
, None None O
by None None O
modulating None None O
and None None O
/ None None O
or None None O
suppressing None None O
the None None O
mammalian None None O
immune None None O
response None None O
. None None O

The None None O
findings None None O
presented None None O
here None None O
, None None O
however None None O
, None None O
demonstrate None None O
a None None O
novel None None O
mechanism None None O
by None None O
which None None O
proteases None None O
in None None O
Culicoides None None O
saliva None None O
can None None O
also None None O
directly None None O
modify None None O
the None None O
orbivirus None None O
particle None None O
structure None None O
, None None O
leading None None O
to None None O
increased None None O
infectivity None None O
specifically None None O
for None None O
Culicoides None None O
cells None None O
and None None O
, None None O
in None None O
turn None None O
, None None O
efficiency None None O
of None None O
transmission None None O
to None None O
the None None O
insect None None O
vector None None O
. None None O

The None None O
antiangiogenic None None O
agent None None O
linomide None None O
inhibits None None O
the None None O
growth None None O
rate None None O
of None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
paraganglioma None None O
xenografts None None O
to None None O
mice None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
ascertain None None O
the None None O
potential None None O
usefulness None None O
of None None O
the None None O
antiangiogenic None None O
compound None None O
linomide None None O
for None None O
treatment None None O
of None None O
von None None O
Hippel None None O
- None None O
Lindau None None O
( None None O
VHL None None O
) None None O
- None None O
related None None O
tumors None None O
. None None O

Paraganglioma None None O
tissue None None O
fragments None None O
obtained None None O
at None None O
surgery None None O
from None None O
a None None O
VHL None None O
type None None O
2a None None O
patient None None O
were None None O
transplanted None None O
s None None O
. None None O
c None None O
. None None O
to None None O
male None None O
BALB None None O
/ None None O
c None None O
nu None None O
/ None None O
nu None None O
( None None O
nude None None O
) None None O
mice None None O
: None None O
( None None O
a None None O
) None None O
2 None None O
- None None O
3 None None O
- None None O
mm None None O
fragments None None O
for None None O
" None None O
prevention None None O
" None None O
experiments None None O
; None None O
and None None O
( None None O
b None None O
) None None O
2 None None O
- None None O
3 None None O
- None None O
mm None None O
fragments None None O
allowed None None O
to None None O
grow None None O
to None None O
1 None None O
cm None None O
for None None O
" None None O
intervention None None O
" None None O
studies None None O
. None None O

Both None None O
groups None None O
received None None O
either None None O
0 None None O
. None None O
5 None None O
mg None None O
/ None None O
ml None None O
linomide None None O
in None None O
drinking None None O
water None None O
or None None O
acidified None None O
water None None O
and None None O
were None None O
followed None None O
until None None O
tumor None None O
diameter None None O
reached None None O
3 None None O
cm None None O
or None None O
for None None O
4 None None O
weeks None None O
. None None O

In None None O
both None None O
the None None O
prevention None None O
and None None O
intervention None None O
experiments None None O
, None None O
a None None O
significant None None O
diminution None None O
of None None O
tumor None None O
size None None O
and None None O
weight None None O
was None None O
observed None None O
in None None O
the None None O
drug None None O
- None None O
treated None None O
animals None None O
. None None O

In None None O
vivo None None O
nuclear None None O
magnetic None None O
resonance None None O
analysis None None O
of None None O
tumor None None O
blood None None O
flow None None O
in None None O
linomide None None O
- None None O
treated None None O
animals None None O
showed None None O
localization None None O
of None None O
blood None None O
vessels None None O
almost None None O
exclusively None None O
to None None O
the None None O
periphery None None O
of None None O
the None None O
poorly None None O
vascularized None None O
tumors None None O
with None None O
a None None O
significant None None O
reduction None None O
of None None O
both None None O
vascular None None O
functionality None None O
and None None O
vasodilation None None O
. None None O

Histological None None O
examination None None O
of None None O
tumors None None O
from None None O
linomide None None O
- None None O
treated None None O
animals None None O
revealed None None O
marked None None O
avascularity None None O
. None None O

Treated None None O
animals None None O
also None None O
displayed None None O
a None None O
2 None None O
. None None O
4 None None O
- None None O
fold None None O
reduction None None O
of None None O
tumor None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
mRNA None None O
levels None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
data None None O
indicate None None O
that None None O
in None None O
VHL None None O
disease None None O
, None None O
therapy None None O
directed None None O
at None None O
inhibition None None O
of None None O
constitutively None None O
expressed None None O
VEGF None None O
induction None None O
of None None O
angiogenesis None None O
by None None O
VHL None None O
tumors None None O
may None None O
constitute None None O
an None None O
effective None None O
medical None None O
treatment None None O
. None None O

Cation None None O
binding None None O
to None None O
yolk None None O
platelet None None O
phosvitin None None O

In None None O
addition None None O
to None None O
non None None O
- None None O
heme None None O
iron None None O
[ None None O
23 None None O
] None None O
, None None O
yolk None None O
phosvitin None None O
also None None O
contains None None O
Ca2 None None O
+ None None O
, None None O
Mg2 None None O
+ None None O
, None None O
Na None None O
+ None None O
and None None O
K None None O
+ None None O
[ None None O
11 None None O
] None None O
. None None O

Partially None None O
relaxed None None O
23Na None None O
Fourier None None O
transform None None O
NMR None None O
spectra None None O
revealed None None O
the None None O
existence None None O
of None None O
at None None O
least None None O
two None None O
major None None O
intracellular None None O
compartments None None O
of None None O
NMR None None O
- None None O
visible None None O
Na None None O
+ None None O
[ None None O
35 None None O
] None None O
. None None O

A None None O
large None None O
fraction None None O
of None None O
the None None O
Rana None None O
oocyte None None O
Na None None O
+ None None O
was None None O
NMR None None O
- None None O
invisible None None O
and None None O
could None None O
be None None O
recovered None None O
in None None O
the None None O
yolk None None O
platelets None None O
[ None None O
35 None None O
] None None O
. None None O

During None None O
the None None O
first None None O
meiotic None None O
division None None O
there None None O
is None None O
a None None O
net None None O
increase None None O
in None None O
NMR None None O
- None None O
visible None None O
Na None None O
+ None None O
; None None O
by None None O
completion None None O
of None None O
the None None O
second None None O
meiotic None None O
division None None O
( None None O
following None None O
fertilization None None O
) None None O
, None None O
about None None O
70 None None O
% None None O
of None None O
the None None O
total None None O
Na None None O
+ None None O
becomes None None O
NMR None None O
- None None O
visible None None O
. None None O

Thus None None O
, None None O
phosvitin None None O
not None None O
only None None O
serves None None O
as None None O
a None None O
site None None O
for None None O
energy None None O
storage None None O
, None None O
but None None O
also None None O
as None None O
a None None O
storage None None O
site None None O
for None None O
iron None None O
and None None O
other None None O
ions None None O
essential None None O
for None None O
embryonic None None O
development None None O
in None None O
ponds None None O
and None None O
streams None None O
that None None O
contain None None O
little None None O
dissolved None None O
salts None None O
and None None O
minerals None None O
. None None O

Stimulation None None O
of None None O
endothelial None None O
cell None None O
migration None None O
by None None O
vascular None None O
permeability None None O
factor None None O
/ None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
through None None O
cooperative None None O
mechanisms None None O
involving None None O
the None None O
alphavbeta3 None None O
integrin None None O
, None None O
osteopontin None None O
, None None O
and None None O
thrombin None None O
. None None O

We None None O
have None None O
identified None None O
several None None O
mechanisms None None O
by None None O
which None None O
the None None O
angiogenic None None O
cytokine None None O
vascular None None O
permeability None None O
factor None None O
/ None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VPF None None O
/ None None O
VEGF None None O
) None None O
likely None None O
regulates None None O
endothelial None None O
cells None None O
( None None O
EC None None O
) None None O
migration None None O
. None None O

VPF None None O
/ None None O
VEGF None None O
induced None None O
dermal None None O
microvascular None None O
EC None None O
expression None None O
of None None O
mRNAs None None O
encoding None None O
the None None O
alphav None None O
and None None O
beta3 None None O
integrin None None O
subunits None None O
resulting None None O
in None None O
increased None None O
levels None None O
of None None O
the None None O
alphavbeta3 None None O
heterodimer None None O
at None None O
the None None O
cell None None O
surface None None O
, None None O
and None None O
VPF None None O
/ None None O
VEGF None None O
also None None O
induced None None O
mRNA None None O
encoding None None O
osteopontin None None O
( None None O
OPN None None O
) None None O
, None None O
an None None O
alphavbeta3 None None O
ligand None None O
. None None O

OPN None None O
promoted None None O
EC None None O
migration None None O
in None None O
vitro None None O
; None None O
and None None O
VPF None None O
/ None None O
VEGF None None O
induction None None O
of None None O
alphavbeta3 None None O
was None None O
accompanied None None O
by None None O
increased None None O
EC None None O
migration None None O
toward None None O
OPN None None O
. None None O

Because None None O
thrombin None None O
cleavage None None O
of None None O
OPN None None O
results None None O
in None None O
substantial None None O
enhancement None None O
of None None O
OPN None None O
' None None O
s None None O
adhesive None None O
properties None None O
, None None O
and None None O
because None None O
VPF None None O
/ None None O
VEGF None None O
promotes None None O
increased None None O
microvascular None None O
permeability None None O
leading None None O
to None None O
activation None None O
of None None O
the None None O
extrinsic None None O
coagulation None None O
pathway None None O
, None None O
we None None O
also None None O
investigated None None O
whether None None O
VPF None None O
/ None None O
VEGF None None O
facilitates None None O
thrombin None None O
cleavage None None O
of None None O
OPN None None O
in None None O
vivo None None O
. None None O

Consistent None None O
with None None O
this None None O
hypothesis None None O
, None None O
co None None O
- None None O
injection None None O
of None None O
VPF None None O
/ None None O
VEGF None None O
together None None O
with None None O
OPN None None O
resulted None None O
in None None O
rapid None None O
cleavage None None O
of None None O
OPN None None O
by None None O
endogenous None None O
thrombin None None O
. None None O

Furthermore None None O
, None None O
in None None O
comparison None None O
with None None O
native None None O
OPN None None O
, None None O
thrombin None None O
- None None O
cleaved None None O
OPN None None O
stimulated None None O
a None None O
greater None None O
rate None None O
of None None O
EC None None O
migration None None O
in None None O
vitro None None O
, None None O
which None None O
was None None O
additive None None O
to None None O
the None None O
increased None None O
migration None None O
associated None None O
with None None O
induction None None O
of None None O
alpha None None O
v None None O
beta None None O
3 None None O
. None None O

Thus None None O
, None None O
these None None O
data None None O
demonstrate None None O
cooperative None None O
mechanisms None None O
for None None O
VPF None None O
/ None None O
VEGF None None O
regulation None None O
of None None O
EC None None O
migration None None O
involving None None O
the None None O
alphavbeta3 None None O
integrin None None O
, None None O
the None None O
alphavbeta3 None None O
ligand None None O
OPN None None O
, None None O
and None None O
thrombin None None O
cleavage None None O
of None None O
OPN None None O
. None None O

These None None O
findings None None O
also None None O
illustrate None None O
an None None O
operational None None O
link None None O
between None None O
VPF None None O
/ None None O
VEGF None None O
induction None None O
of None None O
EC None None O
gene None None O
expression None None O
and None None O
VPF None None O
/ None None O
VEGF None None O
enhancement None None O
of None None O
microvascular None None O
permeability None None O
, None None O
suggesting None None O
that None None O
these None None O
distinct None None O
biological None None O
activities None None O
may None None O
act None None O
accordingly None None O
to None None O
stimulate None None O
EC None None O
migration None None O
during None None O
angiogenesis None None O
. None None O

M None None O
- None None O
CSF None None O
signals None None O
through None None O
the None None O
MAPK None None O
/ None None O
ERK None None O
pathway None None O
via None None O
Sp1 None None O
to None None O
induce None None O
VEGF None None O
production None None O
and None None O
induces None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

BACKGROUND None None O
: None None O
M None None O
- None None O
CSF None None O
recruits None None O
mononuclear None None O
phagocytes None None O
which None None O
regulate None None O
processes None None O
such None None O
as None None O
angiogenesis None None O
and None None O
metastases None None O
in None None O
tumors None None O
. None None O

VEGF None None O
is None None O
a None None O
potent None None O
activator None None O
of None None O
angiogenesis None None O
as None None O
it None None O
promotes None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
new None None O
blood None None O
vessel None None O
formation None None O
. None None O

Previously None None O
, None None O
we None None O
reported None None O
that None None O
in None None O
vitro None None O
M None None O
- None None O
CSF None None O
induces None None O
the None None O
expression None None O
of None None O
biologically None None O
- None None O
active None None O
VEGF None None O
from None None O
human None None O
monocytes None None O
. None None O

METHODOLOGY None None O
AND None None O
RESULTS None None O
: None None O
In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
the None None O
molecular None None O
mechanism None None O
of None None O
M None None O
- None None O
CSF None None O
- None None O
induced None None O
VEGF None None O
production None None O
. None None O

Using None None O
a None None O
construct None None O
containing None None O
the None None O
VEGF None None O
promoter None None O
linked None None O
to None None O
a None None O
luciferase None None O
reporter None None O
, None None O
we None None O
found None None O
that None None O
a None None O
mutation None None O
reducing None None O
HIF None None O
binding None None O
to None None O
the None None O
VEGF None None O
promoter None None O
had None None O
no None None O
significant None None O
effect None None O
on None None O
luciferase None None O
production None None O
induced None None O
by None None O
M None None O
- None None O
CSF None None O
stimulation None None O
. None None O

Further None None O
analysis None None O
revealed None None O
that None None O
M None None O
- None None O
CSF None None O
induced None None O
VEGF None None O
through None None O
the None None O
MAPK None None O
/ None None O
ERK None None O
signaling None None O
pathway None None O
via None None O
the None None O
transcription None None O
factor None None O
, None None O
Sp1 None None O
. None None O

Thus None None O
, None None O
inhibition None None O
of None None O
either None None O
ERK None None O
or None None O
Sp1 None None O
suppressed None None O
M None None O
- None None O
CSF None None O
- None None O
induced None None O
VEGF None None O
at None None O
the None None O
mRNA None None O
and None None O
protein None None O
level None None O
. None None O

M None None O
- None None O
CSF None None O
also None None O
induced None None O
the None None O
nuclear None None O
localization None None O
of None None O
Sp1 None None O
, None None O
which None None O
was None None O
blocked None None O
by None None O
ERK None None O
inhibition None None O
. None None O

Finally None None O
, None None O
mutating None None O
the None None O
Sp1 None None O
binding None None O
sites None None O
within None None O
the None None O
VEGF None None O
promoter None None O
or None None O
inhibiting None None O
ERK None None O
decreased None None O
VEGF None None O
promoter None None O
activity None None O
in None None O
M None None O
- None None O
CSF None None O
- None None O
treated None None O
human None None O
monocytes None None O
. None None O

To None None O
evaluate None None O
the None None O
biological None None O
significance None None O
of None None O
M None None O
- None None O
CSF None None O
induced None None O
VEGF None None O
production None None O
, None None O
we None None O
used None None O
an None None O
in None None O
vivo None None O
angiogenesis None None O
model None None O
to None None O
illustrate None None O
the None None O
ability None None O
of None None O
M None None O
- None None O
CSF None None O
to None None O
recruit None None O
mononuclear None None O
phagocytes None None O
, None None O
increase None None O
VEGF None None O
levels None None O
, None None O
and None None O
enhance None None O
angiogenesis None None O
. None None O

Importantly None None O
, None None O
the None None O
addition None None O
of None None O
a None None O
neutralizing None None O
VEGF None None O
antibody None None O
abolished None None O
M None None O
- None None O
CSF None None O
- None None O
induced None None O
blood None None O
vessel None None O
formation None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
data None None O
delineate None None O
an None None O
ERK None None O
- None None O
and None None O
Sp1 None None O
- None None O
dependent None None O
mechanism None None O
of None None O
M None None O
- None None O
CSF None None O
induced None None O
VEGF None None O
production None None O
and None None O
demonstrate None None O
for None None O
the None None O
first None None O
time None None O
the None None O
ability None None O
of None None O
M None None O
- None None O
CSF None None O
to None None O
induce None None O
angiogenesis None None O
via None None O
VEGF None None O
in None None O
vivo None None O
. None None O

Normal None None O
and None None O
transforming None None O
functions None None O
of None None O
RUNX1 None None O
: None None O
a None None O
perspective None None O
. None None O

Converging None None O
studies None None O
from None None O
many None None O
investigators None None O
indicate None None O
that None None O
RUNX1 None None O
has None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
correct None None O
maintenance None None O
of None None O
essential None None O
cellular None None O
functions None None O
during None None O
embryonic None None O
development None None O
and None None O
after None None O
birth None None O
. None None O

The None None O
discovery None None O
that None None O
this None None O
gene None None O
is None None O
also None None O
frequently None None O
mutated None None O
in None None O
human None None O
leukemia None None O
has None None O
increased None None O
the None None O
interest None None O
in None None O
the None None O
role None None O
that None None O
RUNX1 None None O
plays None None O
in None None O
both None None O
normal None None O
and None None O
transforming None None O
pathways None None O
. None None O

Here None None O
, None None O
we None None O
provide None None O
an None None O
overview None None O
of None None O
the None None O
many None None O
roles None None O
of None None O
RUNX1 None None O
in None None O
hematopoietic None None O
self None None O
- None None O
renewal None None O
and None None O
differentiation None None O
and None None O
summarize None None O
the None None O
information None None O
that None None O
is None None O
currently None None O
available None None O
on None None O
the None None O
many None None O
mechanisms None None O
of None None O
RUNX1 None None O
deregulation None None O
in None None O
human None None O
leukemia None None O
. None None O

The None None O
impact None None O
of None None O
multiskilling None None O
on None None O
quality None None O
of None None O
care None None O
. None None O

Hospital None None O
finances None None O
in None None O
the None None O
USA None None O
are None None O
in None None O
a None None O
crisis None None O
. None None O

While None None O
profits None None O
earned None None O
from None None O
the None None O
healthcare None None O
industry None None O
appear None None O
to None None O
be None None O
at None None O
an None None O
all None None O
- None None O
time None None O
high None None O
, None None O
individual None None O
hospitals None None O
are None None O
going None None O
bankrupt None None O
. None None O

Hospitals None None O
are None None O
not None None O
generating None None O
sufficient None None O
income None None O
to None None O
pay None None O
their None None O
expenses None None O
given None None O
how None None O
they None None O
have None None O
traditionally None None O
operated None None O
. None None O

Hence None None O
, None None O
we None None O
are None None O
witnessing None None O
the None None O
merger None None O
and None None O
consolidation None None O
of None None O
competitors None None O
, None None O
resulting None None O
in None None O
significantly None None O
fewer None None O
hospital None None O
beds None None O
in None None O
certain None None O
geographical None None O
areas None None O
. None None O

In None None O
addition None None O
to None None O
the None None O
strategy None None O
of None None O
closing None None O
hospital None None O
beds None None O
, None None O
severe None None O
budget None None O
restrictions None None O
are None None O
impacting None None O
upon None None O
all None None O
remaining None None O
services None None O
within None None O
the None None O
hospitals None None O
. None None O

Mast None None O
cells None None O
and None None O
tumors None None O
. None None O

The None None O
specific None None O
enhancement None None O
of None None O
tumor None None O
proliferation None None O
in None None O
vitro None None O
. None None O

Mast None None O
cells None None O
were None None O
found None None O
to None None O
be None None O
unique None None O
among None None O
the None None O
peritoneal None None O
leukocytes None None O
by None None O
virtue None None O
of None None O
their None None O
capacity None None O
to None None O
enhance None None O
profoundly None None O
the None None O
proliferation None None O
of None None O
a None None O
variety None None O
of None None O
tumors None None O
in None None O
vitro None None O
. None None O

This None None O
phenomenon None None O
occurs None None O
at None None O
mast None None O
cell None None O
/ None None O
tumor None None O
ratios None None O
which None None O
reflect None None O
the None None O
stoichiometry None None O
of None None O
host None None O
cell None None O
/ None None O
tumor None None O
relationships None None O
in None None O
vivo None None O
. None None O

The None None O
growth None None O
factor None None O
was None None O
found None None O
to None None O
reside None None O
in None None O
mast None None O
cell None None O
granules None None O
and None None O
was None None O
identified None None O
as None None O
heparin None None O
by None None O
sequential None None O
purification None None O
and None None O
enzymatic None None O
degradation None None O
. None None O

This None None O
cellular None None O
interaction None None O
was None None O
tumor None None O
- None None O
specific None None O
, None None O
although None None O
isolated None None O
granules None None O
could None None O
enhance None None O
fibroblast None None O
proliferation None None O
. None None O

The None None O
findings None None O
are None None O
discussed None None O
in None None O
relation None None O
to None None O
previous None None O
morphologic None None O
studies None None O
, None None O
reports None None O
of None None O
in None None O
vitro None None O
mast None None O
- None None O
cell None None O
- None None O
mediated None None O
tumor None None O
cytotoxicity None None O
, None None O
and None None O
the None None O
role None None O
of None None O
mast None None O
cells None None O
in None None O
angiogenesis None None O
and None None O
connective None None O
tissue None None O
proliferation None None O
. None None O

[ None None O
Extra None None O
- None None O
anatomic None None O
bypass None None O
from None None O
the None None O
ascending None None O
aorta None None O
to None None O
the None None O
supraceliac None None O
abdominal None None O
aorta None None O
- None None O
- None None O
surgical None None O
option None None O
applied None None O
to None None O
reoperation None None O
for None None O
aortic None None O
coarctation None None O
or None None O
interruption None None O
] None None O
. None None O

The None None O
optimal None None O
approach None None O
for None None O
reoperation None None O
following None None O
repair None None O
of None None O
aortic None None O
coarctation None None O
( None None O
CoA None None O
) None None O
or None None O
interruption None None O
( None None O
IAA None None O
) None None O
remains None None O
controversial None None O
. None None O

Four None None O
patients None None O
underwent None None O
extra None None O
- None None O
anatomic None None O
bypass None None O
for None None O
restenosis None None O
after None None O
repair None None O
of None None O
CoA None None O
or None None O
IAA None None O
. None None O

The None None O
age None None O
ranged None None O
from None None O
4 None None O
to None None O
12 None None O
years None None O
. None None O

The None None O
initial None None O
repairs None None O
for None None O
two None None O
CoA None None O
, None None O
one None None O
type None None O
A None None O
- None None O
IAA None None O
, None None O
and None None O
one None None O
type None None O
B None None O
- None None O
IAA None None O
consisted None None O
of None None O
two None None O
grafting None None O
, None None O
one None None O
subclavian None None O
arterial None None O
turning None None O
- None None O
down None None O
aortoplasty None None O
, None None O
and None None O
one None None O
subclavian None None O
flap None None O
aortoplasty None None O
. None None O

All None None O
of None None O
them None None O
underwent None None O
during None None O
infancy None None O
. None None O

Preoperative None None O
right None None O
arm None None O
systolic None None O
pressure None None O
ranged None None O
from None None O
140 None None O
to None None O
190 None None O
mmHg None None O
ar None None O
rest None None O
. None None O

Through None None O
a None None O
midline None None O
sternotomy None None O
and None None O
an None None O
upper None None O
laparotmy None None O
incision None None O
, None None O
an None None O
extra None None O
- None None O
anatomic None None O
bypass None None O
from None None O
the None None O
ascending None None O
aorta None None O
to None None O
the None None O
supraceliac None None O
abdominal None None O
aorta None None O
was None None O
employed None None O
using None None O
a None None O
12 None None O
to None None O
18 None None O
mm None None O
tube None None O
graft None None O
. None None O

All None None O
patients None None O
survived None None O
surgeries None None O
, None None O
and None None O
their None None O
hypertension None None O
markedly None None O
improved None None O
. None None O

Our None None O
experience None None O
confirms None None O
safety None None O
and None None O
effectiveness None None O
of None None O
this None None O
option None None O
in None None O
selected None None O
young None None O
patients None None O
with None None O
re None None O
- None None O
stenosis None None O
of None None O
following None None O
repair None None O
of None None O
CoA None None O
or None None O
IAA None None O
. None None O

Mitochondria None None O
in None None O
Cardiac None None O
Myocyte None None O
Apoptosis None None O

It None None O
has None None O
been None None O
suggested None None O
that None None O
activation None None O
of None None O
the None None O
mitochondrial None None O
apoptotic None None O
pathway None None O
leading None None O
to None None O
executioner None None O
casp None None O
activation None None O
is None None O
relevant None None O
in None None O
heart None None O
injury None None O
. None None O
1 None None O
The None None O
notion None None O
of None None O
participation None None O
of None None O
casp None None O
activation None None O
in None None O
adult None None O
cardiac None None O
myocyte None None O
apoptosis None None O
emerged None None O
from None None O
studies None None O
using None None O
immunofluorescence None None O
microscopy16 None None O
and None None O
casp None None O
inhibitors None None O
. None None O
37 None None O
Bahi None None O
et None None O
al None None O
. None None O
38 None None O
demonstrated None None O
that None None O
cardiomyocyte None None O
levels None None O
of None None O
all None None O
casps None None O
decrease None None O
with None None O
age None None O
, None None O
and None None O
they None None O
are None None O
very None None O
low None None O
in None None O
adult None None O
cardiac None None O
cells None None O
. None None O

Recently None None O
, None None O
Bae None None O
et None None O
al None None O
. None None O
39 None None O
reported None None O
that None None O
apoptosis None None O
can None None O
be None None O
induced None None O
in None None O
the None None O
heart None None O
lacking None None O
casp None None O
activation None None O
via None None O
casp None None O
- None None O
independent None None O
pathways None None O
, None None O
probably None None O
through None None O
apoptosis None None O
- None None O
inducing None None O
factor None None O
( None None O
AIF None None O
) None None O
. None None O

Both None None O
the None None O
intrinsic None None O
and None None O
extrinsic None None O
pathways None None O
can None None O
be None None O
inhibited None None O
by None None O
the None None O
cytoprotective None None O
protein None None O
apoptosis None None O
repressor None None O
with None None O
caspase None None O
recruitment None None O
domain None None O
( None None O
ARC None None O
) None None O
. None None O

ARC None None O
inhibits None None O
the None None O
extrinsic None None O
pathway None None O
by None None O
interacting None None O
with None None O
casp None None O
8 None None O
and None None O
components None None O
of None None O
the None None O
death None None O
- None None O
inducing None None O
signaling None None O
complex None None O
, None None O
such None None O
as None None O
FADD None None O
, None None O
whereas None None O
inhibition None None O
of None None O
the None None O
intrinsic None None O
pathway None None O
is None None O
mediated None None O
by None None O
blocking None None O
BAX None None O
activation None None O
and None None O
mitochondria None None O
translocation None None O
. None None O
40 None None O

AIF None None O
is None None O
anchored None None O
by None None O
its None None O
N None None O
terminus None None O
to None None O
the None None O
mitochondrial None None O
inner None None O
membrane None None O
, None None O
with None None O
its None None O
C None None O
terminus None None O
oriented None None O
toward None None O
the None None O
intermembrane None None O
space None None O
. None None O

AIF None None O
is None None O
required None None O
for None None O
oxidative None None O
phosphorylation None None O
and None None O
for None None O
the None None O
assembly None None O
and None None O
/ None None O
or None None O
stabilization None None O
of None None O
respiratory None None O
complex None None O
I None None O
. None None O
41 None None O
Upon None None O
induction None None O
of None None O
apoptosis None None O
, None None O
AIF None None O
is None None O
cleaved None None O
and None None O
released None None O
into None None O
the None None O
cytosol None None O
, None None O
where None None O
it None None O
translocates None None O
to None None O
the None None O
nucleus None None O
and None None O
mediates None None O
chromatin None None O
condensation None None O
and None None O
large None None O
- None None O
scale None None O
DNA None None O
fragmentation None None O
. None None O
41 None None O
However None None O
, None None O
this None None O
well None None O
- None None O
known None None O
pro None None O
- None None O
apoptotic None None O
action None None O
of None None O
AIF None None O
is None None O
in None None O
conflict None None O
with None None O
the None None O
observation None None O
that None None O
AIF None None O
is None None O
essential None None O
for None None O
the None None O
maintenance None None O
of None None O
normal None None O
heart None None O
function None None O
and None None O
its None None O
inactivation None None O
results None None O
in None None O
dilated None None O
C None None O
. None None O
42 None None O
Moreover None None O
, None None O
cardiac None None O
myocytes None None O
isolated None None O
from None None O
a None None O
mouse None None O
model None None O
with None None O
80 None None O
% None None O
reduction None None O
in None None O
AIF None None O
levels None None O
manifested None None O
increased None None O
cell None None O
death None None O
induced None None O
by None None O
oxidative None None O
stress None None O
, None None O
and None None O
the None None O
hearts None None O
of None None O
these None None O
mice None None O
displayed None None O
enhanced None None O
ischemic None None O
damage None None O
after None None O
in None None O
vivo None None O
I None None O
/ None None O
R None None O
. None None O
43 None None O
Although None None O
it None None O
has None None O
been None None O
described None None O
that None None O
AIF None None O
is None None O
released None None O
from None None O
cardiac None None O
myocyte None None O
mitochondria None None O
during None None O
I None None O
/ None None O
R None None O
, None None O
its None None O
contribution None None O
to None None O
I None None O
/ None None O
R None None O
- None None O
induced None None O
apoptosis None None O
was None None O
discounted None None O
. None None O
38 None None O
However None None O
, None None O
AIF None None O
has None None O
been None None O
implicated None None O
in None None O
cardiac None None O
myocyte None None O
death None None O
induced None None O
by None None O
oxidative None None O
stress None None O
and None None O
HF None None O
. None None O
44 None None O

Endonuclease None None O
G None None O
( None None O
Endo None None O
G None None O
) None None O
is None None O
a None None O
nuclear None None O
- None None O
encoded None None O
endonuclease None None O
localized None None O
to None None O
the None None O
intermembrane None None O
space None None O
of None None O
mitochondria None None O
. None None O

In None None O
cardiac None None O
myocyte None None O
apoptosis None None O
, None None O
Endo None None O
G None None O
translocates None None O
to None None O
the None None O
nucleus None None O
, None None O
where None None O
it None None O
cleaves None None O
DNA None None O
. None None O

In None None O
heart None None O
and None None O
cultured None None O
cardiac None None O
myocytes None None O
, None None O
Endo None None O
G None None O
has None None O
a None None O
role None None O
in None None O
I None None O
/ None None O
R None None O
- None None O
mediated None None O
cell None None O
death None None O
. None None O
38 None None O
Activation None None O
of None None O
the None None O
intrinsic None None O
pathway None None O
by None None O
the None None O
extrinsic None None O
apoptotic None None O
pathway None None O
can None None O
take None None O
place None None O
through None None O
casp None None O
- None None O
8 None None O
- None None O
dependent None None O
cleavage None None O
of None None O
BCL2 None None O
- None None O
interacting None None O
protein None None O
( None None O
BID None None O
) None None O
to None None O
truncated None None O
BID None None O
( None None O
t None None O
- None None O
BID None None O
) None None O
. None None O

The None None O
C None None O
- None None O
terminal None None O
fragment None None O
of None None O
t None None O
- None None O
BID None None O
subsequently None None O
translocates None None O
to None None O
the None None O
mitochondrial None None O
outer None None O
membrane None None O
, None None O
where None None O
it None None O
presumably None None O
activates None None O
the None None O
intrinsic None None O
pathway None None O
. None None O

This None None O
pathway None None O
is None None O
operative None None O
in None None O
the None None O
heart None None O
. None None O
1 None None O

Thiazole None None O
orange None None O
positive None None O
platelets None None O
in None None O
a None None O
dog None None O
with None None O
Evans None None O
' None None O
syndrome None None O
. None None O

We None None O
examined None None O
transition None None O
for None None O
the None None O
percentage None None O
of None None O
reticulated None None O
platelets None None O
( None None O
RP None None O
% None None O
) None None O
and None None O
platelet None None O
count None None O
in None None O
a None None O
canine None None O
case None None O
of None None O
Evans None None O
' None None O
syndrome None None O
. None None O

The None None O
result None None O
demonstrated None None O
that None None O
measurement None None O
of None None O
the None None O
RP None None O
% None None O
can None None O
be None None O
useful None None O
in None None O
evaluating None None O
platelet None None O
production None None O
in None None O
the None None O
bone None None O
marrow None None O
and None None O
response None None O
to None None O
treatment None None O
. None None O

[ None None O
Prehospital None None O
service None None O
in None None O
Denmark None None O
] None None O
. None None O

In None None O
Denmark None None O
, None None O
emergency None None O
ambulances None None O
are None None O
dispatched None None O
by None None O
41 None None O
centres None None O
manned None None O
either None None O
by None None O
trained None None O
firemen None None O
( None None O
in None None O
Copenhagen None None O
) None None O
or None None O
policemen None None O
( None None O
outside None None O
Copenhagen None None O
) None None O
. None None O

In None None O
1990 None None O
, None None O
emergency None None O
ambulance None None O
calls None None O
totalled None None O
284 None None O
, None None O
000 None None O
. None None O

Utilisation None None O
of None None O
emergency None None O
ambulance None None O
services None None O
increases None None O
with None None O
urbanisation None None O
. None None O

A None None O
doctor None None O
- None None O
manned None None O
ambulance None None O
is None None O
in None None O
operation None None O
in None None O
Copenhagen None None O
, None None O
and None None O
in None None O
some None None O
other None None O
large None None O
towns None None O
anaesthesiology None None O
and None None O
intensive None None O
care None None O
teams None None O
can None None O
be None None O
dispatched None None O
from None None O
hospital None None O
to None None O
give None None O
on None None O
- None None O
the None None O
- None None O
spot None None O
care None None O
. None None O

In None None O
less None None O
populated None None O
areas None None O
, None None O
some None None O
general None None O
practitioners None None O
give None None O
advanced None None O
life None None O
- None None O
support None None O
. None None O

Although None None O
many None None O
areas None None O
are None None O
serviced None None O
by None None O
ambulances None None O
equipped None None O
with None None O
defibrillators None None O
, None None O
the None None O
majority None None O
of None None O
patients None None O
receive None None O
only None None O
basic None None O
life None None O
- None None O
support None None O
from None None O
ambulance None None O
personnel None None O
. None None O

New None None O
initiatives None None O
resulting None None O
from None None O
a None None O
recent None None O
report None None O
by None None O
a None None O
commission None None O
appointed None None O
by None None O
central None None O
authorities None None O
, None None O
and None None O
focused None None O
on None None O
prehospital None None O
treatment None None O
, None None O
are None None O
expected None None O
to None None O
improve None None O
the None None O
service None None O
by None None O
raising None None O
the None None O
level None None O
of None None O
training None None O
given None None O
to None None O
ambulance None None O
personnel None None O
. None None O

Development None None O
of None None O
a None None O
mouse None None O
model None None O
for None None O
lymph None None O
node None None O
metastasis None None O
with None None O
endometrial None None O
cancer None None O
. None None O

Controlling None None O
lymph None None O
node None None O
metastasis None None O
is None None O
currently None None O
a None None O
key None None O
issue None None O
in None None O
cancer None None O
therapy None None O
. None None O

Lymph None None O
node None None O
metastasis None None O
is None None O
one None None O
of None None O
the None None O
most None None O
important None None O
prognostic None None O
factors None None O
in None None O
various None None O
types None None O
of None None O
cancers None None O
, None None O
including None None O
endometrial None None O
cancer None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
C None None O
( None None O
VEGF None None O
- None None O
C None None O
) None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
lymphangiogenesis None None O
, None None O
and None None O
is None None O
implicated None None O
to None None O
play None None O
an None None O
important None None O
role None None O
in None None O
lymph None None O
node None None O
metastasis None None O
. None None O

To None None O
evaluate None None O
the None None O
role None None O
of None None O
VEGF None None O
- None None O
C None None O
in None None O
lymph None None O
node None None O
metastasis None None O
, None None O
we None None O
developed None None O
an None None O
animal None None O
model None None O
by None None O
using None None O
an None None O
endometrial None None O
cancer None None O
cell None None O
line None None O
, None None O
HEC1A None None I-Cell-line-name
. None None O

This None None O
cell None None O
line None None O
is None None O
not None None O
invasive None None O
by None None O
nature None None O
and None None O
secretes None None O
moderate None None O
amounts None None O
of None None O
VEGF None None O
- None None O
C None None O
; None None O
intrauterine None None O
injection None None O
of None None O
HEC1A None None I-Cell-line-name
cells None None O
into None None O
Balb None None O
/ None None O
c None None O
nude None None O
mice None None O
resulted None None O
in None None O
uterine None None O
cancer None None O
with None None O
lymph None None O
node None None O
metastasis None None O
after None None O
8 None None O
weeks None None O
. None None O

To None None O
analyze None None O
the None None O
contribution None None O
of None None O
VEGF None None O
- None None O
C None None O
to None None O
lymph None None O
node None None O
metastasis None None O
, None None O
its None None O
corresponding None None O
gene None None O
was None None O
stably None None O
introduced None None O
into None None O
HEC1A None None I-Cell-line-name
cells None None O
( None None O
HEC1A None None I-Cell-line-name
/ None None O
VEGF None None O
- None None O
C None None O
) None None O
, None None O
which None None O
then None None O
produced None None O
more None None O
than None None O
10 None None O
times None None O
the None None O
amount None None O
of None None O
VEGF None None O
- None None O
C None None O
. None None O

The None None O
number None None O
of None None O
lymph None None O
node None None O
metastases None None O
was None None O
significantly None None O
higher None None O
in None None O
HEC1A None None I-Cell-line-name
/ None None I-Cell-line-name
VEGF None None I-Cell-line-name
- None None I-Cell-line-name
C None None I-Cell-line-name
cells None None O
than None None O
in None None O
HEC1A None None I-Cell-line-name
cells None None O
( None None O
3 None None O
. None None O
2 None None O
vs None None O
1 None None O
. None None O
1 None None O
nodes None None O
/ None None O
animal None None O
, None None O
respectively None None O
) None None O
. None None O

Augmented None None O
lymphangiogenesis None None O
was None None O
observed None None O
within None None O
tumors None None O
when None None O
HEC1A None None I-Cell-line-name
/ None None I-Cell-line-name
VEGF None None I-Cell-line-name
- None None I-Cell-line-name
C None None I-Cell-line-name
cells None None O
were None None O
inoculated None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
VEGF None None O
- None None O
C None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
lymph None None O
node None None O
metastasis None None O
, None None O
in None None O
addition None None O
to None None O
serving None None O
as None None O
a None None O
platform None None O
to None None O
test None None O
the None None O
efficacy None None O
of None None O
various None None O
therapeutic None None O
modalities None None O
against None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Expression None None O
of None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
in None None O
primary None None O
tumors None None O
and None None O
lymph None None O
node None None O
metastases None None O
in None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Disturbances None None O
in None None O
expression None None O
of None None O
apoptosis None None O
- None None O
associated None None O
proteins None None O
take None None O
part None None O
in None None O
the None None O
development None None O
and None None O
progression None None O
of None None O
many None None O
human None None O
malignancies None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
the None None O
assessment None None O
of None None O
correlations None None O
among None None O
proteins None None O
involved None None O
in None None O
apoptosis None None O
- None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
- None None O
as None None O
well None None O
as None None O
relationships None None O
of None None O
these None None O
proteins None None O
with None None O
selected None None O
clinicopathological None None O
features None None O
in None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Consequently None None O
, None None O
we None None O
examined None None O
by None None O
immunohistochemistry None None O
, None None O
using None None O
the None None O
avidin None None O
- None None O
biotin None None O
- None None O
peroxidase None None O
method None None O
, None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
expression None None O
in None None O
56 None None O
samples None None O
of None None O
primary None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
and None None O
in None None O
22 None None O
matched None None O
pairs None None O
of None None O
primary None None O
and None None O
metastatic None None O
tumors None None O
. None None O

The None None O
evaluation None None O
of None None O
immunostaining None None O
of None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
was None None O
analyzed None None O
in None None O
10 None None O
different None None O
tumor None None O
fields None None O
, None None O
and None None O
the None None O
mean None None O
percentage None None O
of None None O
tumor None None O
cells None None O
with None None O
positive None None O
staining None None O
was None None O
evaluated None None O
. None None O

The None None O
significance None None O
of None None O
the None None O
associations None None O
was None None O
determined None None O
using None None O
Spearman None None O
correlation None None O
analysis None None O
and None None O
the None None O
chi None None O
- None None O
square None None O
test None None O
. None None O

We None None O
found None None O
positive None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
immunostaining None None O
in None None O
44 None None O
. None None O
6 None None O
% None None O
, None None O
28 None None O
. None None O
6 None None O
% None None O
, None None O
and None None O
58 None None O
. None None O
9 None None O
% None None O
of None None O
the None None O
studied None None O
primary None None O
tumors None None O
and None None O
in None None O
63 None None O
. None None O
6 None None O
% None None O
, None None O
45 None None O
. None None O
5 None None O
% None None O
, None None O
and None None O
72 None None O
. None None O
7 None None O
% None None O
of None None O
lymph None None O
node None None O
metastases None None O
, None None O
respectively None None O
. None None O

Analysis None None O
of None None O
associations None None O
among None None O
studied None None O
proteins None None O
revealed None None O
positive None None O
correlation None None O
between None None O
Bcl None None O
- None None O
xL None None O
and None None O
Bax None None O
in None None O
primary None None O
tumors None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
03 None None O
, None None O
r None None O
= None None O
0 None None O
. None None O
307 None None O
) None None O
. None None O

Statistically None None O
significant None None O
relationship None None O
between None None O
p53 None None O
expression None None O
in None None O
primary None None O
oral None None O
cancers None None O
and None None O
its None None O
expression None None O
in None None O
lymph None None O
node None None O
metastases None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
02 None None O
) None None O
as None None O
well None None O
as None None O
increased None None O
expression None None O
of None None O
Bcl None None O
- None None O
xL None None O
, None None O
Bax None None O
, None None O
and None None O
p53 None None O
in None None O
metastatic None None O
sites None None O
compared None None O
with None None O
primary None None O
tumors None None O
could None None O
indicate None None O
an None None O
association None None O
of None None O
these None None O
proteins None None O
with None None O
oral None None O
cancer None None O
progression None None O
and None None O
development None None O
of None None O
metastases None None O
. None None O

Moreover None None O
, None None O
we None None O
suppose None None O
that None None O
knowledge None None O
about None None O
heterogeneity None None O
between None None O
primary None None O
and None None O
metastatic None None O
tumor None None O
might None None O
help None None O
to None None O
understand None None O
mechanisms None None O
of None None O
oral None None O
cancer None None O
progression None None O
. None None O

Hormonal None None O
regulation None None O
and None None O
distinct None None O
functions None None O
of None None O
semaphorin None None O
- None None O
3B None None O
and None None O
semaphorin None None O
- None None O
3F None None O
in None None O
ovarian None None O
cancer None None O
. None None O

Semaphorins None None O
comprise None None O
a None None O
family None None O
of None None O
molecules None None O
that None None O
influence None None O
neuronal None None O
growth None None O
and None None O
guidance None None O
. None None O

Class None None O
- None None O
3 None None O
semaphorins None None O
, None None O
semaphorin None None O
- None None O
3B None None O
( None None O
SEMA3B None None O
) None None O
and None None O
semaphorin None None O
- None None O
3F None None O
( None None O
SEMA3F None None O
) None None O
, None None O
illustrate None None O
their None None O
effects None None O
by None None O
forming None None O
a None None O
complex None None O
with None None O
neuropilins None None O
( None None O
NP None None O
- None None O
1 None None O
or None None O
NP None None O
- None None O
2 None None O
) None None O
and None None O
plexins None None O
. None None O

We None None O
examined None None O
the None None O
status None None O
and None None O
regulation None None O
of None None O
semaphorins None None O
and None None O
their None None O
receptors None None O
in None None O
human None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

A None None O
significantly None None O
reduced None None O
expression None None O
of None None O
SEMA3B None None O
( None None O
83 None None O
kDa None None O
) None None O
, None None O
SEMA3F None None O
( None None O
90 None None O
kDa None None O
) None None O
, None None O
and None None O
plexin None None O
- None None O
A3 None None O
was None None O
observed None None O
in None None O
ovarian None None O
cancer None None O
cell None None O
lines None None O
when None None O
compared None None O
with None None O
normal None None O
human None None O
ovarian None None O
surface None None O
epithelial None None O
cells None None O
. None None O

The None None O
expression None None O
of None None O
NP None None O
- None None O
1 None None O
, None None O
NP None None O
- None None O
2 None None O
, None None O
and None None O
plexin None None O
- None None O
A1 None None O
was None None O
not None None O
altered None None O
in None None O
human None None O
ovarian None None O
surface None None O
epithelial None None O
and None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

The None None O
decreased None None O
expression None None O
of None None O
SEMA3B None None O
, None None O
SEMA3F None None O
, None None O
and None None O
plexin None None O
- None None O
A3 None None O
was None None O
confirmed None None O
in None None O
stage None None O
3 None None O
ovarian None None O
tumors None None O
. None None O

The None None O
treatment None None O
of None None O
ovarian None None O
cancer None None O
cells None None O
with None None O
luteinizing None None O
hormone None None O
, None None O
follicle None None O
- None None O
stimulating None None O
hormone None None O
, None None O
and None None O
estrogen None None O
induced None None O
a None None O
significant None None O
upregulation None None O
of None None O
SEMA3B None None O
, None None O
whereas None None O
SEMA3F None None O
was None None O
upregulated None None O
only None None O
by None None O
estrogen None None O
. None None O

Cotreatment None None O
of None None O
cell None None O
lines None None O
with None None O
a None None O
hormone None None O
and None None O
its None None O
specific None None O
antagonist None None O
blocked None None O
the None None O
effect None None O
of None None O
the None None O
hormone None None O
. None None O

Ectopic None None O
expression None None O
of None None O
SEMA3B None None O
or None None O
SEMA3F None None O
reduced None None O
soft None None O
- None None O
agar None None O
colony None None O
formation None None O
, None None O
adhesion None None O
, None None O
and None None O
cell None None O
invasion None None O
of None None O
ovarian None None O
cancer None None O
cell None None O
cultures None None O
. None None O

Forced None None O
expression None None O
of None None O
SEMA3B None None O
, None None O
but None None O
not None None O
SEMA3F None None O
, None None O
inhibited None None O
viability None None O
of None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

Overexpression None None O
of None None O
SEMA3B None None O
and None None O
SEMA3F None None O
reduced None None O
focal None None O
adhesion None None O
kinase None None O
phosphorylation None None O
and None None O
matrix None None O
metalloproteinase None None O
- None None O
2 None None O
and None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
expression None None O
in None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

Forced None None O
expression None None O
of None None O
SEMA3F None None O
, None None O
but None None O
not None None O
SEMA3B None None O
in None None O
ovarian None None O
cancer None None O
cells None None O
, None None O
significantly None None O
inhibited None None O
endothelial None None O
cell None None O
tube None None O
formation None None O
. None None O

Collectively None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
the None None O
loss None None O
of None None O
SEMA3 None None O
expression None None O
could None None O
be None None O
a None None O
hallmark None None O
of None None O
cancer None None O
progression None None O
. None None O

Furthermore None None O
, None None O
gonadotropin None None O
- None None O
and None None O
/ None None O
or None None O
estrogen None None O
- None None O
mediated None None O
maintenance None None O
of None None O
SEMA3 None None O
expression None None O
could None None O
control None None O
ovarian None None O
cancer None None O
angiogenesis None None O
and None None O
metastasis None None O
. None None O

Ciprofloxacin None None O
mediated None None O
cell None None O
growth None None O
inhibition None None O
, None None O
S None None O
/ None None O
G2 None None O
- None None O
M None None O
cell None None O
cycle None None O
arrest None None O
, None None O
and None None O
apoptosis None None O
in None None O
a None None O
human None None O
transitional None None O
cell None None O
carcinoma None None O
of None None O
the None None O
bladder None None O
cell None None O
line None None O
. None None O

The None None O
second None None O
most None None O
prevalent None None O
urological None None O
malignancy None None O
in None None O
middle None None O
aged None None O
and None None O
elderly None None O
men None None O
is None None O
bladder None None O
cancer None None O
, None None O
with None None O
90 None None O
% None None O
of None None O
the None None O
cases None None O
being None None O
transitional None None O
cell None None O
carcinomas None None O
. None None O

The None None O
success None None O
of None None O
current None None O
systemic None None O
and None None O
intravesical None None O
therapeutic None None O
agents None None O
, None None O
such None None O
as None None O
cisplatin None None O
, None None O
thiotepa None None O
, None None O
Adriamycin None None O
, None None O
mitomycin None None O
C None None O
, None None O
and None None O
bacillus None None O
Calmette None None O
- None None O
Guerin None None O
, None None O
is None None O
limited None None O
with None None O
recurrence None None O
rates None None O
reduced None None O
to None None O
17 None None O
- None None O
44 None None O
% None None O
. None None O

In None None O
addition None None O
, None None O
most None None O
of None None O
these None None O
agents None None O
require None None O
instrumentation None None O
of None None O
the None None O
urinary None None O
tract None None O
and None None O
are None None O
delivered None None O
at None None O
a None None O
significant None None O
cost None None O
and None None O
potential None None O
morbidity None None O
to None None O
the None None O
patient None None O
. None None O

Fluroquinolone None None O
antibiotics None None O
such None None O
as None None O
ciprofloxacin None None O
, None None O
which None None O
can None None O
be None None O
administered None None O
p None None O
. None None O
o None None O
. None None O
, None None O
may None None O
have None None O
a None None O
profound None None O
effect None None O
in None None O
bladder None None O
cancer None None O
management None None O
. None None O

This None None O
is None None O
primarily None None O
based None None O
on None None O
limited None None O
in None None O
vitro None None O
studies None None O
on None None O
tumor None None O
cells None None O
derived None None O
from None None O
transitional None None O
cell None None O
carcinoma None None O
of None None O
the None None O
bladder None None O
that None None O
revealed None None O
a None None O
dose None None O
- None None O
and None None O
time None None O
- None None O
dependent None None O
inhibition None None O
of None None O
cell None None O
growth None None O
by None None O
ciprofloxacin None None O
at None None O
concentrations None None O
that None None O
are None None O
easily None None O
attainable None None O
in None None O
the None None O
urine None None O
of None None O
patients None None O
. None None O

However None None O
, None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
by None None O
which None None O
ciprofloxacin None None O
elicits None None O
its None None O
biological None None O
effects None None O
on None None O
bladder None None O
cancer None None O
cells None None O
is None None O
not None None O
well None None O
documented None None O
. None None O

Our None None O
experimental None None O
data None None O
confirm None None O
previous None None O
studies None None O
showing None None O
the None None O
in None None O
vitro None None O
cell None None O
growth None None O
inhibition None None O
of None None O
the None None O
transitional None None O
cell None None O
carcinoma None None O
of None None O
the None None O
bladder None None O
cell None None O
line None None O
HTB9 None None I-Cell-line-name
and None None O
further None None O
showed None None O
the None None O
induction None None O
of None None O
cell None None O
cycle None None O
arrest None None O
at None None O
the None None O
S None None O
/ None None O
G2 None None O
- None None O
M None None O
checkpoints None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
found None None O
down None None O
- None None O
regulation None None O
of None None O
cyclin None None O
B None None O
, None None O
cyclin None None O
E None None O
, None None O
and None None O
dephosphorylation None None O
of None None O
cdk2 None None O
in None None O
ciprofloxacin None None O
- None None O
treated None None O
bladder None None O
tumor None None O
cells None None O
. None None O

There None None O
was None None O
also None None O
an None None O
up None None O
- None None O
regulation None None O
of None None O
Bax None None O
, None None O
which None None O
altered None None O
the None None O
Bax None None O
: None None O
Bcl None None O
- None None O
2 None None O
ratio None None O
, None None O
which None None O
may None None O
be None None O
responsible None None O
for None None O
mitochondrial None None O
depolarization None None O
reported None None O
to None None O
be None None O
involved None None O
prior None None O
to None None O
the None None O
induction None None O
of None None O
apoptosis None None O
. None None O

The None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
inhibitor None None O
p21WAF1 None None O
level None None O
was None None O
found None None O
to None None O
be None None O
decreased None None O
within None None O
12 None None O
h None None O
of None None O
ciprofloxacin None None O
treatment None None O
and None None O
disappeared None None O
completely None None O
when None None O
HTB9 None None I-Cell-line-name
cells None None O
were None None O
treated None None O
with None None O
200 None None O
microg None None O
/ None None O
ml None None O
ciprofloxacin None None O
for None None O
24 None None O
h None None O
. None None O

The None None O
down None None O
- None None O
regulation None None O
of None None O
p21WAF1 None None O
closely None None O
correlated None None O
with None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
cleavage None None O
and None None O
CPP32 None None O
activation None None O
. None None O

Recent None None O
studies None None O
revealed None None O
that None None O
p21WAF1 None None O
protects None None O
cells None None O
from None None O
apoptosis None None O
by None None O
arresting None None O
them None None O
in None None O
G1 None None O
and None None O
further None None O
binds None None O
to None None O
pro None None O
- None None O
caspase None None O
- None None O
3 None None O
, None None O
preventing None None O
its None None O
activation None None O
and None None O
thus None None O
, None None O
inhibiting None None O
the None None O
apoptotic None None O
cascade None None O
. None None O

Hence None None O
, None None O
the None None O
down None None O
- None None O
regulation None None O
of None None O
p21WAF1 None None O
, None None O
together None None O
with None None O
the None None O
alterations None None O
in None None O
Bax None None O
and None None O
cdk2 None None O
as None None O
observed None None O
in None None O
our None None O
studies None None O
, None None O
may None None O
define None None O
a None None O
novel None None O
mechanism None None O
by None None O
which None None O
ciprofloxacin None None O
inhibits None None O
tumor None None O
cell None None O
growth None None O
and None None O
induces None None O
apoptotic None None O
cell None None O
death None None O
. None None O

The None None O
results None None O
of None None O
our None None O
current None None O
studies None None O
provide None None O
strong None None O
experimental None None O
evidence None None O
for None None O
the None None O
use None None O
of None None O
ciprofloxacin None None O
as None None O
a None None O
potential None None O
preventive None None O
and None None O
/ None None O
or None None O
therapeutic None None O
agent None None O
for None None O
the None None O
management None None O
of None None O
transitional None None O
cell None None O
carcinoma None None O
of None None O
the None None O
bladder None None O
. None None O

Concurrent None None O
disease None None O
in None None O
33 None None O
cows None None O
with None None O
LDA None None O
. None None O

Mass None None O
casualty None None O
estimation None None O
on None None O
a None None O
geographic None None O
basis None None O

The None None O
Defense None None O
Threat None None O
Reduction None None O
Agency None None O
( None None O
DTRA None None O
) None None O
has None None O
expended None None O
considerable None None O
effort None None O
to None None O
develop None None O
models None None O
for None None O
calculating None None O
mass None None O
casualties None None O
from None None O
a None None O
nuclear None None O
detonation None None O
. None None O

In None None O
order None None O
to None None O
specifically None None O
evaluate None None O
urban None None O
medical None None O
systems None None O
vulnerability None None O
we None None O
are None None O
employing None None O
the None None O
PC None None O
based None None O
Consequence None None O
Assessment None None O
Tool None None O
Set None None O
( None None O
CATS None None O
) None None O
v6 None None O
, None None O
with None None O
ESRI None None O
' None None O
s None None O
ArcGIS9 None None O
[ None None O
14 None None O
] None None O
, None None O
CATS None None O
/ None None O
JACE None None O
( None None O
Joint None None O
Assessment None None O
of None None O
Catastrophic None None O
Events None None O
) None None O
v5 None None O
with None None O
ESRI None None O
' None None O
s None None O
ArcView None None O
3 None None O
. None None O
3 None None O
, None None O
Hazard None None O
Prediction None None O
and None None O
Assessment None None O
Capability None None O
( None None O
HPAC None None O
) None None O
V4 None None O
. None None O
04SP3 None None O
[ None None O
15 None None O
] None None O
, None None O
as None None O
well None None O
as None None O
custom None None O
GIS None None O
and None None O
database None None O
software None None O
applications None None O
. None None O

HPAC None None O
does None None O
excellent None None O
Chemical None None O
Biological None None O
and None None O
Nuclear None None O
( None None O
CBN None None O
) None None O
modeling None None O
, None None O
although None None O
output None None O
could None None O
provide None None O
more None None O
flexibility None None O
. None None O

Additionally None None O
, None None O
results None None O
can None None O
be None None O
exported None None O
to None None O
CATS None None O
for None None O
further None None O
analysis None None O
and None None O
display None None O
. None None O

All None None O
three None None O
programs None None O
can None None O
access None None O
the None None O
current None None O
weather None None O
data None None O
from None None O
both None None O
classified None None O
and None None O
unclassified None None O
weather None None O
servers None None O
. None None O

Examples None None O
of None None O
uses None None O
of None None O
CATS None None O
/ None None O
HPAC None None O
are None None O
hurricane None None O
, None None O
tidal None None O
surge None None O
and None None O
earthquake None None O
damage None None O
, None None O
prediction None None O
of None None O
the None None O
results None None O
from None None O
nuclear None None O
, None None O
biological None None O
and None None O
chemical None None O
releases None None O
, None None O
assessment None None O
of None None O
persons None None O
and None None O
infrastructure None None O
affected None None O
and None None O
at None None O
risk None None O
( None None O
e None None O
. None None O
g None None O
. None None O
which None None O
hospitals None None O
and None None O
pharmacies None None O
are None None O
under None None O
a None None O
CBN None None O
plume None None O
and None None O
are None None O
thus None None O
out None None O
of None None O
commission None None O
) None None O
, None None O
and None None O
mobilization None None O
of None None O
surviving None None O
and None None O
nearby None None O
infrastructure None None O
outside None None O
the None None O
plume None None O
that None None O
would None None O
be None None O
needed None None O
to None None O
address None None O
healthcare None None O
and None None O
other None None O
emergency None None O
response None None O
needs None None O
of None None O
the None None O
community None None O
. None None O

These None None O
models None None O
have None None O
been None None O
, None None O
and None None O
continue None None O
to None None O
be None None O
, None None O
developed None None O
with None None O
a None None O
view None None O
to None None O
better None None O
estimating None None O
the None None O
impact None None O
of None None O
WMD None None O
weapons None None O
in None None O
an None None O
offensive None None O
setting None None O
. None None O

However None None O
, None None O
recent None None O
DTRA None None O
enhancements None None O
and None None O
our None None O
modifications None None O
have None None O
facilitated None None O
their None None O
use None None O
in None None O
helping None None O
estimate None None O
potential None None O
casualties None None O
from None None O
a None None O
WMD None None O
terrorist None None O
incident None None O
. None None O

One None None O
area None None O
of None None O
intense None None O
interest None None O
, None None O
and None None O
somewhat None None O
of None None O
a None None O
vacuum None None O
in None None O
public None None O
health None None O
planning None None O
, None None O
has None None O
been None None O
the None None O
utility None None O
of None None O
this None None O
approach None None O
in None None O
estimating None None O
medical None None O
care None None O
vulnerabilities None None O
in None None O
such None None O
an None None O
attack None None O
, None None O
and None None O
for None None O
the None None O
calculation None None O
of None None O
the None None O
distribution None None O
of None None O
surviving None None O
medical None None O
care None None O
resources None None O
. None None O

While None None O
much None None O
work None None O
has None None O
already None None O
occurred None None O
in None None O
estimating None None O
the None None O
impact None None O
of None None O
chemical None None O
weapons None None O
( None None O
due None None O
to None None O
the None None O
dual None None O
use None None O
in None None O
chemical None None O
spill None None O
management None None O
from None None O
transportation None None O
and None None O
industrial None None O
accidents None None O
) None None O
, None None O
or None None O
in None None O
nuclear None None O
power None None O
plant None None O
accident None None O
management None None O
, None None O
much None None O
less None None O
research None None O
and None None O
development None None O
has None None O
gone None None O
into None None O
estimating None None O
the None None O
impact None None O
on None None O
our None None O
civilian None None O
population None None O
of None None O
a None None O
nuclear None None O
weapon None None O
detonation None None O
from None None O
a None None O
terrorist None None O
incident None None O
in None None O
a None None O
large None None O
urban None None O
area None None O
. None None O

The None None O
models None None O
already None None O
calculate None None O
such None None O
factors None None O
as None None O
the None None O
impact None None O
of None None O
blast None None O
, None None O
thermal None None O
effects None None O
and None None O
fallout None None O
, None None O
but None None O
results None None O
are None None O
often None None O
not None None O
available None None O
at None None O
the None None O
detail None None O
level None None O
needed None None O
for None None O
civil None None O
defense None None O
purposes None None O
, None None O
casualty None None O
management None None O
, None None O
and None None O
planning None None O
the None None O
use None None O
of None None O
scarce None None O
health None None O
resources None None O
in None None O
response None None O
to None None O
a None None O
nuclear None None O
weapon None None O
detonation None None O
. None None O

Furthermore None None O
, None None O
the None None O
models None None O
do None None O
not None None O
readily None None O
facilitate None None O
the None None O
calculation None None O
of None None O
injuries None None O
from None None O
multiple None None O
effects None None O
such None None O
as None None O
burns None None O
and None None O
blast None None O
with None None O
fallout None None O
or None None O
prompt None None O
radiation None None O
. None None O

The None None O
complexity None None O
of None None O
the None None O
urban None None O
three None None O
- None None O
dimensional None None O
landscape None None O
and None None O
its None None O
local None None O
impact None None O
on None None O
thermal None None O
, None None O
blast None None O
and None None O
radiation None None O
is None None O
also None None O
poorly None None O
understood None None O
. None None O

Additionally None None O
, None None O
given None None O
their None None O
traditional None None O
world None None O
- None None O
wide None None O
focus None None O
, None None O
and None None O
the None None O
increased None None O
sensitivity None None O
to None None O
providing None None O
information None None O
on None None O
the None None O
U None None O
. None None O
S None None O
. None None O
A None None O
. None None O
of None None O
use None None O
to None None O
terrorists None None O
, None None O
the None None O
models None None O
do None None O
not None None O
provide None None O
detailed None None O
or None None O
current None None O
data None None O
that None None O
exists None None O
for None None O
the None None O
United None None O
States None None O
that None None O
would None None O
help None None O
provide None None O
better None None O
casualty None None O
estimates None None O
and None None O
response None None O
. None None O

The None None O
models None None O
can None None O
be None None O
customized None None O
locally None None O
and None None O
data None None O
updated None None O
if None None O
the None None O
user None None O
has None None O
sufficient None None O
expertise None None O
. None None O

However None None O
, None None O
there None None O
is None None O
often None None O
a None None O
significant None None O
duplication None None O
of None None O
effort None None O
due None None O
to None None O
overlapping None None O
jurisdictions None None O
and None None O
the None None O
lack None None O
of None None O
data None None O
sharing None None O
due None None O
to None None O
security None None O
and None None O
other None None O
considerations None None O
. None None O

CATS None None O
and None None O
HPAC None None O
are None None O
also None None O
useful None None O
for None None O
creating None None O
realistic None None O
scenarios None None O
for None None O
training None None O
and None None O
planning None None O
before None None O
a None None O
disaster None None O
strikes None None O
, None None O
thus None None O
enabling None None O
responders None None O
to None None O
drill None None O
and None None O
exercise None None O
so None None O
they None None O
know None None O
roughly None None O
what None None O
to None None O
expect None None O
and None None O
how None None O
to None None O
react None None O
. None None O

Contingency None None O
plans None None O
can None None O
be None None O
created None None O
using None None O
comprehensive None None O
national None None O
and None None O
more None None O
detailed None None O
population None None O
and None None O
infrastructure None None O
data None None O
. None None O

Should None None O
disaster None None O
strike None None O
, None None O
the None None O
affected None None O
population None None O
and None None O
the None None O
impact None None O
on None None O
critical None None O
facilities None None O
can None None O
be None None O
quickly None None O
assessed None None O
, None None O
although None None O
efforts None None O
frequently None None O
need None None O
to None None O
be None None O
expended None None O
to None None O
ensure None None O
regional None None O
and None None O
local None None O
databases None None O
are None None O
current None None O
and None None O
useful None None O
. None None O

AngiomiRs None None O
- None None O
- None None O
key None None O
regulators None None O
of None None O
angiogenesis None None O
. None None O

The None None O
formation None None O
of None None O
new None None O
blood None None O
vessels None None O
through None None O
the None None O
process None None O
of None None O
angiogenesis None None O
is None None O
critical None None O
in None None O
vascular None None O
development None None O
and None None O
homeostasis None None O
. None None O

Aberrant None None O
angiogenesis None None O
leads None None O
to None None O
a None None O
variety None None O
of None None O
diseases None None O
, None None O
such None None O
as None None O
ischemia None None O
and None None O
cancer None None O
. None None O

Recent None None O
studies None None O
have None None O
revealed None None O
important None None O
roles None None O
for None None O
miRNAs None None O
in None None O
regulating None None O
endothelial None None O
cell None None O
( None None O
EC None None O
) None None O
function None None O
, None None O
especially None None O
angiogenesis None None O
. None None O

Mice None None O
with None None O
EC None None O
- None None O
specific None None O
deletion None None O
of None None O
Dicer None None O
, None None O
a None None O
key None None O
enzyme None None O
for None None O
generating None None O
miRNAs None None O
, None None O
display None None O
defective None None O
postnatal None None O
angiogenesis None None O
. None None O

Specific None None O
miRNAs None None O
( None None O
angiomiRs None None O
) None None O
have None None O
recently None None O
been None None O
shown None None O
to None None O
regulate None None O
angiogenesis None None O
in None None O
vivo None None O
. None None O

miRNA None None O
- None None O
126 None None O
, None None O
an None None O
EC None None O
- None None O
restricted None None O
miRNA None None O
, None None O
regulates None None O
vascular None None O
integrity None None O
and None None O
developmental None None O
angiogenesis None None O
. None None O

miR None None O
- None None O
378 None None O
, None None O
miR None None O
- None None O
296 None None O
, None None O
and None None O
the None None O
miR None None O
- None None O
17 None None O
- None None O
92 None None O
cluster None None O
contribute None None O
to None None O
tumor None None O
angiogenesis None None O
. None None O

Manipulating None None O
angiomiRs None None O
in None None O
the None None O
settings None None O
of None None O
pathological None None O
vascularization None None O
represents None None O
a None None O
new None None O
therapeutic None None O
approach None None O
. None None O

Acknowledgements None None O

We None None O
would None None O
like None None O
to None None O
thank None None O
our None None O
colleague None None O
Dr None None O
. None None O
Nikolaos None None O
Papathanasiou None None O
for None None O
his None None O
assistance None None O
in None None O
performing None None O
the None None O
statistical None None O
analysis None None O
. None None O

Discussion None None O

We None None O
estimated None None O
the None None O
future None None O
acceptability None None O
of None None O
PrEP None None O
, None None O
examining None None O
the None None O
attitudes None None O
and None None O
preferences None None O
of None None O
potential None None O
user None None O
groups None None O
from None None O
different None None O
countries None None O
towards None None O
hypothetical None None O
and None None O
known None None O
PrEP None None O
attributes None None O
. None None O

Our None None O
results None None O
show None None O
that None None O
participants None None O
were None None O
generally None None O
willing None None O
to None None O
accept None None O
PrEP None None O
and None None O
adopt None None O
it None None O
as None None O
soon None None O
as None None O
it None None O
becomes None None O
available None None O
. None None O

Surprisingly None None O
, None None O
participants None None O
were None None O
also None None O
willing None None O
to None None O
take None None O
PrEP None None O
even None None O
when None None O
reminded None None O
of None None O
potential None None O
side None None O
effects None None O
, None None O
cost None None O
, None None O
condom None None O
use None None O
, None None O
and None None O
frequent None None O
HIV None None O
testing None None O
. None None O

These None None O
findings None None O
indicate None None O
participants None None O
' None None O
motivation None None O
to None None O
overcome None None O
barriers None None O
which None None O
can None None O
have None None O
a None None O
considerable None None O
impact None None O
on None None O
uptake None None O
. None None O

In None None O
contrast None None O
, None None O
participants None None O
mentioned None None O
that None None O
the None None O
thought None None O
of None None O
taking None None O
PrEP None None O
made None None O
them None None O
feel None None O
anxious None None O
, None None O
although None None O
they None None O
also None None O
indicated None None O
that None None O
taking None None O
PrEP None None O
would None None O
not None None O
be None None O
embarrassing None None O
and None None O
they None None O
would None None O
want None None O
their None None O
partner None None O
or None None O
partners None None O
to None None O
know None None O
. None None O

Participants None None O
' None None O
anxiety None None O
may None None O
be None None O
explained None None O
by None None O
the None None O
hypothetical None None O
nature None None O
of None None O
most None None O
of None None O
the None None O
presented None None O
PrEP None None O
characteristics None None O
, None None O
the None None O
stigma None None O
associated None None O
with None None O
HIV None None O
[ None None O
34 None None O
] None None O
, None None O
and None None O
in None None O
some None None O
settings None None O
, None None O
the None None O
criminalization None None O
of None None O
sex None None O
work None None O
, None None O
injected None None O
drug None None O
use None None O
and None None O
homosexuality None None O
[ None None O
35 None None O
] None None O
. None None O

Most None None O
participants None None O
, None None O
nonetheless None None O
, None None O
subsequently None None O
indicated None None O
that None None O
PrEP None None O
would None None O
give None None O
them None None O
hope None None O
, None None O
which None None O
suggests None None O
that None None O
their None None O
initial None None O
willingness None None O
to None None O
take None None O
it None None O
remained None None O
largely None None O
unscathed None None O
. None None O

Female None None O
participants None None O
indicated None None O
a None None O
higher None None O
level None None O
of None None O
willingness None None O
to None None O
take None None O
PrEP None None O
than None None O
male None None O
participants None None O
, None None O
which None None O
may None None O
be None None O
explained None None O
by None None O
women None None O
' None None O
s None None O
difficulty None None O
negotiating None None O
the None None O
use None None O
of None None O
condoms None None O
and None None O
awareness None None O
of None None O
their None None O
and None None O
/ None None O
or None None O
their None None O
partners None None O
' None None O
risk None None O
of None None O
becoming None None O
infected None None O
with None None O
HIV None None O
[ None None O
36 None None O
] None None O
. None None O

We None None O
also None None O
found None None O
that None None O
younger None None O
participants None None O
and None None O
those None None O
with None None O
fewer None None O
children None None O
, None None O
those None None O
who None None O
reported None None O
adherence None None O
to None None O
past None None O
medication None None O
, None None O
more None None O
frequent None None O
condom None None O
usage None None O
, None None O
having None None O
been None None O
tested None None O
for None None O
HIV None None O
in None None O
the None None O
past None None O
and None None O
never None None O
injecting None None O
drugs None None O
, None None O
reported None None O
greater None None O
willingness None None O
to None None O
take None None O
PrEP None None O
. None None O

These None None O
promising None None O
findings None None O
suggest None None O
that None None O
those None None O
who None None O
are None None O
currently None None O
bearing None None O
the None None O
brunt None None O
of None None O
HIV None None O
[ None None O
1 None None O
] None None O
, None None O
have None None O
higher None None O
perceived None None O
risk None None O
, None None O
and None None O
are None None O
most None None O
likely None None O
to None None O
adhere None None O
to None None O
a None None O
comprehensive None None O
PrEP None None O
program None None O
, None None O
are None None O
also None None O
the None None O
most None None O
motivated None None O
to None None O
enroll None None O
. None None O

Yet None None O
, None None O
while None None O
participants None None O
stated None None O
not None None O
being None None O
interested None None O
in None None O
selling None None O
PrEP None None O
, None None O
the None None O
majority None None O
reported None None O
intentions None None O
to None None O
share None None O
it None None O
. None None O

Therefore None None O
, None None O
information None None O
and None None O
counseling None None O
about None None O
the None None O
risks None None O
of None None O
sharing None None O
PrEP None None O
should None None O
be None None O
readily None None O
available None None O
as None None O
part None None O
of None None O
any None None O
implementation None None O
program None None O
. None None O

Results None None O
from None None O
the None None O
conjoint None None O
analysis None None O
reveal None None O
trends None None O
in None None O
participants None None O
' None None O
preferences None None O
which None None O
deserve None None O
consideration None None O
. None None O

PrEP None None O
route None None O
of None None O
administration None None O
was None None O
the None None O
most None None O
important None None O
attribute None None O
, None None O
and None None O
bi None None O
- None None O
monthly None None O
and None None O
monthly None None O
injections None None O
were None None O
the None None O
preferred None None O
alternatives None None O
. None None O

This None None O
finding None None O
is None None O
encouraging None None O
from None None O
a None None O
policy None None O
perspective None None O
if None None O
such None None O
modalities None None O
become None None O
available None None O
; None None O
since None None O
it None None O
may None None O
reduce None None O
users None None O
' None None O
likelihood None None O
of None None O
sharing None None O
, None None O
selling None None O
or None None O
forgetting None None O
to None None O
take None None O
PrEP None None O
, None None O
but None None O
it None None O
also None None O
raises None None O
questions None None O
regarding None None O
participants None None O
' None None O
willingness None None O
to None None O
take None None O
oral None None O
PrEP None None O
. None None O

HIV None None O
testing None None O
was None None O
the None None O
second None None O
most None None O
important None None O
attribute None None O
, None None O
and None None O
a None None O
test None None O
every None None O
six None None O
months None None O
was None None O
, None None O
as None None O
expected None None O
, None None O
the None None O
preferred None None O
alternative None None O
. None None O

Interestingly None None O
, None None O
dispensing None None O
sites None None O
were None None O
more None None O
important None None O
than None None O
any None None O
other None None O
attribute None None O
for None None O
some None None O
groups None None O
, None None O
particularly None None O
in None None O
Africa None None O
. None None O

This None None O
may None None O
indicate None None O
concerns None None O
about None None O
social None None O
stigma None None O
and None None O
access None None O
[ None None O
37 None None O
] None None O
. None None O

However None None O
, None None O
it None None O
is None None O
encouraging None None O
that None None O
most None None O
participants None None O
were None None O
willing None None O
to None None O
receive None None O
PrEP None None O
at None None O
a None None O
healthcare None None O
facility None None O
, None None O
which None None O
can None None O
facilitate None None O
synergies None None O
between None None O
PrEP None None O
and None None O
other None None O
existing None None O
prevention None None O
services None None O
. None None O

Time None None O
spent None None O
obtaining None None O
PrEP None None O
and None None O
frequency None None O
of None None O
pick None None O
up None None O
, None None O
which None None O
we None None O
used None None O
as None None O
a None None O
proxy None None O
measure None None O
for None None O
cost None None O
- None None O
opportunity None None O
, None None O
were None None O
generally None None O
less None None O
important None None O
, None None O
consistent None None O
with None None O
participants None None O
' None None O
willingness None None O
to None None O
pay None None O
for None None O
PrEP None None O
. None None O

Our None None O
findings None None O
are None None O
broadly None None O
consistent None None O
with None None O
the None None O
work None None O
of None None O
Guest None None O
et None None O
al None None O
. None None O
and None None O
Galea None None O
et None None O
al None None O
[ None None O
18 None None O
] None None O
, None None O
[ None None O
19 None None O
] None None O
. None None O

However None None O
, None None O
specific None None O
comparisons None None O
are None None O
not None None O
advisable None None O
as None None O
the None None O
composition None None O
and None None O
size None None O
of None None O
the None None O
samples None None O
, None None O
recruitment None None O
methods None None O
, None None O
measures None None O
and None None O
statistical None None O
analyses None None O
differ None None O
greatly None None O
. None None O

Previous None None O
work None None O
on None None O
PrEP None None O
implementation None None O
suggests None None O
that None None O
delivery None None O
programs None None O
will None None O
need None None O
to None None O
meet None None O
a None None O
number None None O
of None None O
requirements None None O
in None None O
order None None O
to None None O
be None None O
effective None None O
, None None O
including None None O
: None None O
prioritization None None O
of None None O
groups None None O
at None None O
higher None None O
risk None None O
of None None O
infection None None O
; None None O
delivery None None O
of None None O
PrEP None None O
in None None O
combination None None O
with None None O
other None None O
prevention None None O
services None None O
, None None O
including None None O
risk None None O
reduction None None O
and None None O
medication None None O
adherence None None O
counseling None None O
, None None O
condoms None None O
provision None None O
, None None O
diagnosis None None O
and None None O
treatment None None O
of None None O
other None None O
sexually None None O
transmitted None None O
infections None None O
, None None O
and None None O
frequent None None O
HIV None None O
testing None None O
; None None O
and None None O
monitoring None None O
of None None O
side None None O
effects None None O
, None None O
adherence None None O
and None None O
risk None None O
behaviors None None O
[ None None O
8 None None O
] None None O
, None None O
[ None None O
38 None None O
] None None O
, None None O
[ None None O
39 None None O
] None None O
, None None O
[ None None O
40 None None O
] None None O
, None None O
[ None None O
41 None None O
] None None O
, None None O
[ None None O
42 None None O
] None None O
. None None O

Our None None O
results None None O
provide None None O
valuable None None O
clues None None O
that None None O
can None None O
help None None O
countries None None O
to None None O
deliver None None O
PrEP None None O
more None None O
effectively None None O
, None None O
should None None O
they None None O
decide None None O
to None None O
implement None None O
it None None O
, None None O
by None None O
focusing None None O
their None None O
efforts None None O
on None None O
the None None O
aspects None None O
that None None O
need None None O
more None None O
attention None None O
. None None O

This None None O
is None None O
the None None O
first None None O
multinational None None O
study None None O
, None None O
to None None O
our None None O
knowledge None None O
, None None O
that None None O
integrates None None O
different None None O
disciplines None None O
to None None O
shed None None O
light None None O
on None None O
a None None O
question None None O
that None None O
we None None O
believe None None O
is None None O
of None None O
global None None O
importance None None O
. None None O

Our None None O
study None None O
complements None None O
previous None None O
work None None O
on None None O
PrEP None None O
by None None O
examining None None O
potential None None O
users None None O
' None None O
perspective None None O
and None None O
offering None None O
insights None None O
into None None O
their None None O
attitudes None None O
and None None O
preferences None None O
. None None O

We None None O
note None None O
that None None O
it None None O
may None None O
not None None O
be None None O
possible None None O
to None None O
generalize None None O
the None None O
observed None None O
PrEP None None O
acceptability None None O
to None None O
other None None O
settings None None O
and None None O
our None None O
results None None O
should None None O
be None None O
considered None None O
within None None O
the None None O
context None None O
of None None O
this None None O
study None None O
' None None O
s None None O
limitations None None O
. None None O

Given None None O
the None None O
sensitive None None O
nature None None O
of None None O
the None None O
addressed None None O
questions None None O
, None None O
and None None O
despite None None O
all None None O
our None None O
efforts None None O
to None None O
reduce None None O
social None None O
desirability None None O
bias None None O
, None None O
there None None O
is None None O
an None None O
unavoidable None None O
risk None None O
that None None O
participants None None O
may None None O
have None None O
felt None None O
at None None O
times None None O
compelled None None O
to None None O
provide None None O
what None None O
they None None O
felt None None O
was None None O
the None None O
" None None O
right None None O
" None None O
answer None None O
. None None O

Additionally None None O
, None None O
our None None O
data None None O
collection None None O
took None None O
place None None O
in None None O
urban None None O
areas None None O
, None None O
where None None O
HIV None None O
incidence None None O
is None None O
normally None None O
higher None None O
, None None O
thus None None O
current None None O
findings None None O
may None None O
not None None O
be None None O
generalizable None None O
to None None O
rural None None O
settings None None O
. None None O

Finally None None O
, None None O
examining None None O
acceptability None None O
among None None O
users None None O
enrolled None None O
in None None O
pilot None None O
programs None None O
is None None O
much None None O
deserving None None O
, None None O
as None None O
actual None None O
acceptability None None O
may None None O
differ None None O
from None None O
potential None None O
willingness None None O
to None None O
take None None O
PrEP None None O
, None None O
especially None None O
if None None O
relevant None None O
attributes None None O
of None None O
a None None O
product None None O
or None None O
program None None O
are None None O
modified None None O
, None None O
as None None O
observed None None O
in None None O
other None None O
comparable None None O
interventions None None O
[ None None O
43 None None O
] None None O
. None None O

Results None None O

c None None O
- None None O
MYC None None O
functions None None O
as None None O
a None None O
molecular None None O
switch None None O
to None None O
alter None None O
the None None O
response None None O
of None None O
human None None O
mammary None None O
epithelial None None O
cells None None O
to None None O
oncostatin None None O
M None None O
. None None O

Cytokines None None O
play None None O
an None None O
important None None O
role None None O
in None None O
creating None None O
an None None O
inflammatory None None O
microenvironment None None O
, None None O
which None None O
is None None O
now None None O
considered None None O
a None None O
hallmark None None O
of None None O
cancer None None O
. None None O

Although None None O
tumor None None O
cells None None O
can None None O
exploit None None O
cytokine None None O
signaling None None O
to None None O
promote None None O
growth None None O
, None None O
invasion None None O
, None None O
and None None O
metastasis None None O
, None None O
the None None O
response None None O
of None None O
normal None None O
and None None O
premalignant None None O
epithelial None None O
cells None None O
to None None O
cytokines None None O
present None None O
in None None O
a None None O
developing None None O
tumor None None O
microenvironment None None O
remains None None O
unclear None None O
. None None O

Oncostatin None None O
M None None O
( None None O
OSM None None O
) None None O
, None None O
an None None O
IL None None O
- None None O
6 None None O
family None None O
cytokine None None O
responsible None None O
for None None O
STAT3 None None O
activation None None O
, None None O
has None None O
been None None O
implicated None None O
in None None O
cancer None None O
development None None O
, None None O
progression None None O
, None None O
invasion None None O
, None None O
and None None O
metastasis None None O
. None None O

Paradoxically None None O
, None None O
OSM None None O
can None None O
also None None O
suppress None None O
the None None O
growth None None O
of None None O
normal None None O
cells None None O
and None None O
certain None None O
tumor None None O
- None None O
derived None None O
cell None None O
lines None None O
. None None O

Using None None O
isogenic None None O
human None None O
mammary None None O
epithelial None None O
cells None None O
( None None O
HMEC None None O
) None None O
at None None O
different None None O
stages None None O
of None None O
neoplastic None None O
transformation None None O
, None None O
we None None O
found None None O
that None None O
OSM None None O
signaling None None O
suppressed None None O
c None None O
- None None O
MYC None None O
expression None None O
and None None O
engaged None None O
a None None O
p16 None None O
- None None O
and None None O
p53 None None O
- None None O
independent None None O
growth None None O
arrest None None O
that None None O
required None None O
STAT3 None None O
activity None None O
. None None O

Inhibition None None O
of None None O
STAT3 None None O
activation None None O
by None None O
expressing None None O
a None None O
dominant None None O
- None None O
negative None None O
STAT3 None None O
protein None None O
or None None O
a None None O
STAT3 None None O
- None None O
shRNA None None O
prevented None None O
the None None O
OSM None None O
- None None O
mediated None None O
arrest None None O
. None None O

In None None O
addition None None O
, None None O
expression None None O
of None None O
c None None O
- None None O
MYC None None O
from None None O
a None None O
constitutive None None O
promoter None None O
also None None O
abrogated None None O
the None None O
STAT3 None None O
- None None O
mediated None None O
arrest None None O
, None None O
and None None O
strikingly None None O
, None None O
cooperated None None O
with None None O
OSM None None O
to None None O
promote None None O
anchorage None None O
- None None O
independent None None O
growth None None O
( None None O
AIG None None O
) None None O
, None None O
a None None O
property None None O
associated None None O
with None None O
malignant None None O
transformation None None O
. None None O

Cooperative None None O
transformation None None O
by None None O
c None None O
- None None O
MYC None None O
and None None O
OSM None None O
required None None O
PI3K None None O
and None None O
AKT None None O
signaling None None O
, None None O
showing None None O
the None None O
importance None None O
of None None O
multiple None None O
signaling None None O
pathways None None O
downstream None None O
of None None O
the None None O
OSM None None O
receptor None None O
in None None O
defining None None O
the None None O
cellular None None O
response None None O
to None None O
cytokines None None O
. None None O

These None None O
findings None None O
identify None None O
c None None O
- None None O
MYC None None O
as None None O
an None None O
important None None O
molecular None None O
switch None None O
that None None O
alters None None O
the None None O
cellular None None O
response None None O
to None None O
OSM None None O
- None None O
mediated None None O
signaling None None O
from None None O
tumor None None O
suppressive None None O
to None None O
tumor None None O
promoting None None O
. None None O

Curcumin None None O
inhibits None None O
metastatic None None O
progression None None O
of None None O
breast None None O
cancer None None O
cell None None O
through None None O
suppression None None O
of None None O
urokinase None None O
- None None O
type None None O
plasminogen None None O
activator None None O
by None None O
NF None None O
- None None O
kappa None None O
B None None O
signaling None None O
pathways None None O
. None None O

Curcumin None None O
( None None O
1 None None O
, None None O
7 None None O
- None None O
bis None None O
( None None O
4 None None O
- None None O
hydroxy None None O
- None None O
3 None None O
- None None O
methoxyphenyl None None O
) None None O
- None None O
1 None None O
, None None O
6 None None O
- None None O
heptadiene None None O
- None None O
3 None None O
, None None O
5 None None O
- None None O
dione None None O
) None None O
, None None O
is None None O
extracted None None O
from None None O
the None None O
plant None None O
Curcuma None None O
longa None None O
. None None O

It None None O
was None None O
recently None None O
reported None None O
for None None O
its None None O
anticancer None None O
effect None None O
on None None O
several None None O
types None None O
of None None O
cancer None None O
cells None None O
in None None O
vitro None None O
however None None O
, None None O
the None None O
molecular None None O
mechanisms None None O
of None None O
this None None O
anticancer None None O
effect None None O
are None None O
not None None O
fully None None O
understood None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
evaluated None None O
the None None O
effects None None O
of None None O
curcumin None None O
on None None O
human None None O
mammary None None O
epithelial None None O
carcinoma None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
. None None O

Cells None None O
were None None O
treated None None O
with None None O
curcumin None None O
and None None O
examined None None O
for None None O
cell None None O
viability None None O
by None None O
MTT None None O
assay None None O
. None None O

The None None O
cells None None O
invasion None None O
was None None O
demonstrated None None O
by None None O
transwell None None O
assay None None O
. None None O

The None None O
binding None None O
activity None None O
of None None O
NF None None O
- None None O
kappaB None None O
to None None O
DNA None None O
was None None O
examined None None O
in None None O
nuclear None None O
extracts None None O
using None None O
Trans None None O
- None None O
AM None None O
NF None None O
- None None O
kappaB None None O
ELISA None None O
kit None None O
. None None O

Western None None O
blot None None O
was None None O
performed None None O
to None None O
detect None None O
the None None O
effect None None O
of None None O
curcumin None None O
on None None O
the None None O
expression None None O
of None None O
uPA None None O
. None None O

Our None None O
results None None O
showed None None O
that None None O
curcumin None None O
dose None None O
- None None O
dependently None None O
inhibited None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
the None None O
proliferation None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
. None None O

Meanwhile None None O
, None None O
the None None O
adhesion None None O
and None None O
invasion None None O
ability None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
were None None O
sharply None None O
inhibited None None O
when None None O
treated None None O
with None None O
different None None O
concentrations None None O
of None None O
curcumin None None O
. None None O

Curcumin None None O
also None None O
significantly None None O
decreased None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
the None None O
expression None None O
of None None O
uPA None None O
and None None O
NF None None O
- None None O
kappaB None None O
DNA None None O
binding None None O
activity None None O
, None None O
respectively None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
curcumin None None O
inhibits None None O
the None None O
adhesion None None O
and None None O
invasion None None O
of None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
through None None O
down None None O
- None None O
regulating None None O
the None None O
protein None None O
expression None None O
of None None O
uPA None None O
via None None O
of None None O
NF None None O
- None None O
kappaB None None O
activation None None O
. None None O

Accordingly None None O
, None None O
the None None O
therapeutic None None O
potential None None O
of None None O
curcumin None None O
for None None O
breast None None O
cancer None None O
deserves None None O
further None None O
study None None O
. None None O

Efficacy None None O
of None None O
MMF None None O
in None None O
current None None O
immunosuppressive None None O
regimens None None O
after None None O
kidney None None O
transplantation None None O

Current None None O
established None None O
immunosuppressive None None O
strategies None None O
in None None O
kidney None None O
transplantation None None O
often None None O
include None None O
an None None O
induction None None O
agent None None O
( None None O
monoclonal None None O
or None None O
polyclonal None None O
anti None None O
- None None O
T None None O
- None None O
cell None None O
antibodies None None O
) None None O
based None None O
on None None O
the None None O
immunologic None None O
risk None None O
of None None O
the None None O
recipient None None O
, None None O
followed None None O
by None None O
a None None O
maintenance None None O
regimen None None O
combining None None O
a None None O
CNI None None O
and None None O
an None None O
anti None None O
- None None O
proliferative None None O
agent None None O
, None None O
with None None O
or None None O
without None None O
corticosteroids None None O
. None None O
2 None None O
- None None O
4 None None O
As None None O
MMF None None O
was None None O
the None None O
first None None O
MPA None None O
formulation None None O
approved None None O
in None None O
clinical None None O
kidney None None O
transplantation None None O
, None None O
more None None O
extensive None None O
clinical None None O
data None None O
are None None O
available None None O
with None None O
this None None O
drug None None O
in None None O
comparison None None O
to None None O
EC None None O
- None None O
MPS None None O
. None None O

Quantitative None None O
retention None None O
- None None O
biological None None O
activity None None O
relationship None None O
study None None O
by None None O
micellar None None O
liquid None None O
chromatography None None O
. None None O

In None None O
a None None O
previous None None O
paper None None O
, None None O
the None None O
usefulness None None O
of None None O
micellar None None O
liquid None None O
chromatography None None O
( None None O
MLC None None O
) None None O
in None None O
predicting None None O
octanol None None O
- None None O
water None None O
partition None None O
coefficients None None O
of None None O
organic None None O
compounds None None O
was None None O
reported None None O
. None None O

This None None O
paper None None O
is None None O
the None None O
first None None O
successful None None O
report None None O
of None None O
a None None O
quantitative None None O
retention None None O
- None None O
activity None None O
relationship None None O
study None None O
using None None O
the None None O
retention None None O
factor None None O
in None None O
MLC None None O
for None None O
predicting None None O
the None None O
biological None None O
activity None None O
of None None O
a None None O
group None None O
of None None O
phenolic None None O
compounds None None O
. None None O

Excellent None None O
correlation None None O
was None None O
obtained None None O
between None None O
the None None O
capacity None None O
factor None None O
in None None O
MLC None None O
and None None O
the None None O
bioactivity None None O
( None None O
measured None None O
as None None O
log None None O
1 None None O
/ None None O
C None None O
, None None O
where None None O
C None None O
is None None O
the None None O
50 None None O
% None None O
inhibitory None None O
growth None None O
concentration None None O
) None None O
of None None O
26 None None O
para None None O
- None None O
substituted None None O
phenols None None O
. None None O

A None None O
single None None O
MLC None None O
retention None None O
parameter None None O
is None None O
capable None None O
of None None O
describing None None O
the None None O
bioactivity None None O
of None None O
phenols None None O
, None None O
while None None O
three None None O
conventional None None O
molecular None None O
descriptors None None O
( None None O
log None None O
P None None O
( None None O
ow None None O
) None None O
, None None O
pKa None None O
, None None O
and None None O
R None None O
) None None O
are None None O
needed None None O
to None None O
achieve None None O
a None None O
similar None None O
correlation None None O
. None None O

This None None O
indicates None None O
that None None O
both None None O
hydrophobic None None O
and None None O
electronic None None O
interactions None None O
are None None O
incorporated None None O
in None None O
a None None O
single None None O
MLC None None O
retention None None O
parameter None None O
, None None O
which None None O
is None None O
due None None O
to None None O
the None None O
amphiphilic None None O
nature None None O
of None None O
surfactants None None O
in None None O
the None None O
system None None O
. None None O

In None None O
situations None None O
like None None O
this None None O
, None None O
QRAR None None O
is None None O
a None None O
suitable None None O
alternative None None O
to None None O
QSAR None None O
since None None O
measuring None None O
MLC None None O
retention None None O
is None None O
much None None O
easier None None O
than None None O
measuring None None O
different None None O
molecular None None O
descriptors None None O
needed None None O
to None None O
build None None O
the None None O
QSAR None None O
model None None O
. None None O

Addition None None O
of None None O
10 None None O
% None None O
2 None None O
- None None O
propanol None None O
to None None O
a None None O
micellar None None O
system None None O
( None None O
hybrid None None O
system None None O
) None None O
proved None None O
to None None O
be None None O
the None None O
best None None O
chromatographic None None O
system None None O
for None None O
the None None O
best None None O
estimation None None O
of None None O
the None None O
phenols None None O
bioactivity None None O
. None None O

Other None None O
chromatographic None None O
factors None None O
such None None O
as None None O
pH None None O
and None None O
stationary None None O
phase None None O
also None None O
showed None None O
significant None None O
effect None None O
on None None O
the None None O
correlation None None O
between None None O
capacity None None O
factor None None O
k None None O
' None None O
and None None O
log None None O
1 None None O
/ None None O
C None None O
. None None O

[ None None O
Laboratory None None O
diagnostics None None O
of None None O
Crimean None None O
hemorrhagic None None O
fever None None O
by None None O
polymerase None None O
chain None None O
reaction None None O
] None None O
. None None O

Our None None O
group None None O
developed None None O
, None None O
within None None O
the None None O
present None None O
case None None O
study None None O
, None None O
two None None O
techniques None None O
' None None O
variations None None O
, None None O
i None None O
. None None O
e None None O
. None None O
a None None O
single None None O
- None None O
step None None O
RT None None O
- None None O
PCR None None O
and None None O
nested None None O
RT None None O
- None None O
PCR None None O
assays None None O
, None None O
for None None O
the None None O
purpose None None O
of None None O
detecting None None O
the None None O
Crimean None None O
- None None O
Congo None None O
hemorrhagic None None O
fever None None O
RNA None None O
virus None None O
in None None O
human None None O
samples None None O
. None None O

The None None O
above None None O
assays None None O
as None None O
well None None O
as None None O
those None None O
previously None None O
recommended None None O
by None None O
the None None O
Ministry None None O
of None None O
Health None None O
of None None O
the None None O
Russian None None O
Federation None None O
were None None O
simultaneously None None O
used None None O
in None None O
14 None None O
clinical None None O
samples None None O
obtained None None O
from None None O
patients None None O
with None None O
Crimean None None O
hemorrhagic None None O
fever None None O
. None None O

After None None O
assessing None None O
the None None O
detection None None O
accuracy None None O
, None None O
it None None O
was None None O
found None None O
that None None O
the None None O
developed None None O
- None None O
by None None O
- None None O
us None None O
test None None O
system None None O
displayed None None O
the None None O
same None None O
or None None O
even None None O
better None None O
diagnostic None None O
values None None O
versus None None O
the None None O
previously None None O
recommended None None O
nested None None O
RT None None O
- None None O
PCR None None O
and None None O
a None None O
1000 None None O
- None None O
fold None None O
advantage None None O
over None None O
the None None O
previously None None O
recommended None None O
single None None O
- None None O
step None None O
RT None None O
- None None O
PCA None None O
. None None O

The None None O
single None None O
- None None O
step None None O
RT None None O
- None None O
PCR None None O
assay None None O
variation None None O
is None None O
always None None O
more None None O
preferable None None O
in None None O
sense None None O
of None None O
technical None None O
and None None O
economic None None O
motivations None None O
. None None O

Finally None None O
, None None O
the None None O
test None None O
system None None O
developed None None O
by None None O
us None None O
has None None O
every None None O
reason None None O
to None None O
become None None O
the None None O
method None None O
of None None O
choice None None O
in None None O
routine None None O
PCR None None O
diagnosis None None O
of None None O
Crimean None None O
hemorrhagic None None O
fever None None O
after None None O
all None None O
official None None O
trials None None O
and None None O
approvals None None O
are None None O
duly None None O
complied None None O
with None None O
. None None O

Rab None None O
GTPase None None O
regulation None None O
of None None O
VEGFR2 None None O
trafficking None None O
and None None O
signaling None None O
in None None O
endothelial None None O
cells None None O
. None None O

OBJECTIVE None None O
: None None O
Vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
( None None O
VEGFR2 None None O
) None None O
is None None O
a None None O
receptor None None O
tyrosine None None O
kinase None None O
that None None O
regulates None None O
vascular None None O
physiology None None O
. None None O

However None None O
, None None O
mechanism None None O
( None None O
s None None O
) None None O
by None None O
which None None O
VEGFR2 None None O
signaling None None O
and None None O
trafficking None None O
is None None O
coordinated None None O
are None None O
not None None O
clear None None O
. None None O

Here None None O
, None None O
we None None O
have None None O
tested None None O
endocytic None None O
Rab None None O
GTPases None None O
for None None O
regulation None None O
of None None O
VEGFR2 None None O
trafficking None None O
and None None O
signaling None None O
linked None None O
to None None O
endothelial None None O
cell None None O
migration None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O
Quiescent None None O
VEGFR2 None None O
displays None None O
endosomal None None O
localization None None O
and None None O
colocalization None None O
with None None O
the None None O
Rab5a None None O
GTPase None None O
, None None O
an None None O
early None None O
endosome None None O
fusion None None O
regulator None None O
. None None O

Expression None None O
of None None O
GTP None None O
or None None O
GDP None None O
- None None O
bound None None O
Rab5a None None O
mutants None None O
block None None O
activated None None O
VEGFR2 None None O
trafficking None None O
and None None O
degradation None None O
. None None O

Manipulation None None O
of None None O
Rab7a None None O
GTPase None None O
activity None None O
associated None None O
with None None O
late None None O
endosomes None None O
using None None O
overexpression None None O
of None None O
wild None None O
- None None O
type None None O
or None None O
mutant None None O
proteins None None O
blocks None None O
activated None None O
VEGFR2 None None O
trafficking None None O
and None None O
degradation None None O
. None None O

Depletion None None O
of None None O
Rab7a None None O
decreased None None O
VEGFR2 None None O
Y1175 None None O
phosphorylation None None O
but None None O
increased None None O
p42 None None O
/ None None O
44 None None O
( None None O
pERK1 None None O
/ None None O
2 None None O
) None None O
MAPK None None O
phosphorylation None None O
. None None O

Endothelial None None O
cell None None O
migration None None O
was None None O
increased None None O
by None None O
Rab5a None None O
depletion None None O
but None None O
decreased None None O
by None None O
Rab7a None None O
depletion None None O
. None None O

CONCLUSIONS None None O
: None None O
Rab5a None None O
and None None O
Rab7a None None O
regulate None None O
VEGFR2 None None O
trafficking None None O
toward None None O
early None None O
and None None O
late None None O
endosomes None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
VEGFR2 None None O
- None None O
mediated None None O
regulation None None O
of None None O
endothelial None None O
function None None O
is None None O
dependent None None O
on None None O
different None None O
but None None O
specific None None O
Rab None None O
- None None O
mediated None None O
GTP None None O
hydrolysis None None O
activity None None O
required None None O
for None None O
endosomal None None O
trafficking None None O
. None None O

Increased None None O
expression None None O
of None None O
specific None None O
protein None None O
tyrosine None None O
phosphatases None None O
in None None O
human None None O
breast None None O
epithelial None None O
cells None None O
neoplastically None None O
transformed None None O
by None None O
the None None O
neu None None O
oncogene None None O
. None None O

Protein None None O
tyrosine None None O
phosphorylation None None O
/ None None O
dephosphorylation None None O
is None None O
a None None O
fundamental None None O
mechanism None None O
in None None O
the None None O
regulation None None O
of None None O
cell None None O
proliferation None None O
and None None O
neoplastic None None O
transformation None None O
; None None O
this None None O
metabolic None None O
process None None O
is None None O
modulated None None O
by None None O
the None None O
opposing None None O
activities None None O
of None None O
protein None None O
tyrosine None None O
kinases None None O
and None None O
protein None None O
tyrosine None None O
phosphatases None None O
( None None O
PTPases None None O
) None None O
. None None O

While None None O
the None None O
role None None O
of None None O
protein None None O
tyrosine None None O
kinases None None O
has None None O
been None None O
examined None None O
extensively None None O
in None None O
human None None O
breast None None O
tumorigenesis None None O
, None None O
the None None O
role None None O
of None None O
PTPases None None O
in None None O
this None None O
process None None O
is None None O
virtually None None O
unknown None None O
. None None O

To None None O
address None None O
this None None O
issue None None O
, None None O
an None None O
activated None None O
neu None None O
oncogene None None O
was None None O
introduced None None O
into None None O
an None None O
immortalized None None O
nontumorigenic None None O
human None None O
breast None None O
epithelial None None O
cell None None O
line None None O
( None None O
184B5 None None I-Cell-line-name
) None None O
. None None O

This None None O
resulted None None O
in None None O
a None None O
substantial None None O
increase None None O
in None None O
P185neu None None O
expression None None O
, None None O
which None None O
led None None O
to None None O
the None None O
formation None None O
of None None O
progressively None None O
growing None None O
carcinomas None None O
after None None O
such None None O
cells None None O
were None None O
inoculated None None O
into None None O
athymic None None O
nude None None O
mice None None O
. None None O

Importantly None None O
, None None O
a None None O
striking None None O
increase None None O
in None None O
the None None O
expression None None O
of None None O
specific None None O
PTPases None None O
, None None O
LAR None None O
and None None O
PTP1B None None O
, None None O
was None None O
observed None None O
in None None O
3 None None O
independently None None O
neu None None O
transformed None None O
cell None None O
lines None None O
and None None O
their None None O
derived None None O
tumors None None O
. None None O

This None None O
elevation None None O
was None None O
verified None None O
at None None O
both None None O
the None None O
mRNA None None O
and None None O
protein None None O
levels None None O
. None None O

TC None None O
- None None O
PTP None None O
PTPase None None O
expression None None O
was None None O
only None None O
slightly None None O
increased None None O
in None None O
these None None O
neu None None O
transformed None None O
cells None None O
, None None O
and None None O
no None None O
expression None None O
of None None O
CD45 None None O
PTPase None None O
was None None O
observed None None O
. None None O

The None None O
level None None O
of None None O
neu None None O
expression None None O
, None None O
as None None O
well None None O
as None None O
the None None O
differential None None O
expression None None O
between None None O
P185neu None None O
and None None O
LAR None None O
/ None None O
PTP1B None None O
, None None O
directly None None O
correlated None None O
with None None O
tumorigenicity None None O
. None None O

Furthermore None None O
, None None O
rat None None O
mammary None None O
carcinomas None None O
with None None O
elevated None None O
neu None None O
expression None None O
( None None O
neu None None O
- None None O
induced None None O
) None None O
also None None O
had None None O
sharply None None O
elevated None None O
LAR None None O
- None None O
PTPase None None O
expression None None O
when None None O
compared None None O
to None None O
rat None None O
mammary None None O
carcinomas None None O
with None None O
little None None O
or None None O
no None None O
neu None None O
expression None None O
( None None O
7 None None O
, None None O
12 None None O
- None None O
dimethylbenzanthracene None None O
induced None None O
) None None O
; None None O
the None None O
level None None O
of None None O
expression None None O
of None None O
LAR None None O
PTPase None None O
was None None O
directly None None O
correlated None None O
with None None O
the None None O
level None None O
of None None O
neu None None O
expression None None O
. None None O

Thus None None O
, None None O
our None None O
results None None O
provide None None O
the None None O
first None None O
evidence None None O
that None None O
, None None O
in None None O
human None None O
breast None None O
carcinoma None None O
cells None None O
and None None O
in None None O
rat None None O
mammary None None O
carcinomas None None O
that None None O
have None None O
an None None O
induced None None O
increase None None O
in None None O
neu None None O
expression None None O
, None None O
a None None O
consistent None None O
and None None O
substantial None None O
increase None None O
in None None O
the None None O
expression None None O
of None None O
specific None None O
PTPases None None O
occurs None None O
. None None O

The None None O
relationship None None O
between None None O
P185neu None None O
- None None O
protein None None O
tyrosine None None O
kinase None None O
expression None None O
and None None O
specific None None O
PTPase None None O
expression None None O
may None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
human None None O
breast None None O
tumorigenesis None None O
. None None O

Results None None O

OFTT None None O
was None None O
given None None O
to None None O
33 None None O
men None None O
with None None O
MetS None None O
( None None O
defined None None O
by None None O
the None None O
Adult None None O
Treatment None None O
Panel None None O
III None None O
) None None O
, None None O
17 None None O
HTN None None O
and None None O
14 None None O
healthy None None O
men None None O
. None None O

The None None O
MetS None None O
group None None O
was None None O
further None None O
divided None None O
according None None O
to None None O
fasting None None O
triglycerides None None O
( None None O
TG None None O
) None None O
into None None O
TG None None O
> None None O
= None None O
150 None None O
[ None None O
MetS None None O
+ None None O
TG None None O
, None None O
( None None O
n None None O
= None None O
22 None None O
) None None O
] None None O
or None None O
< None None O
150 None None O
mg None None O
/ None None O
dl None None O
[ None None O
MetS None None O
- None None O
TG None None O
( None None O
n None None O
= None None O
11 None None O
) None None O
] None None O
, None None O
and None None O
into None None O
those None None O
with None None O
or None None O
without None None O
hypertension None None O
[ None None O
MetS None None O
+ None None O
HTN None None O
( None None O
n None None O
= None None O
24 None None O
) None None O
, None None O
MetS None None O
- None None O
HTN None None O
( None None O
n None None O
= None None O
9 None None O
) None None O
, None None O
respectively None None O
] None None O
. None None O

TG None None O
concentrations None None O
were None None O
measured None None O
before None None O
and None None O
at None None O
4 None None O
, None None O
6 None None O
and None None O
8 None None O
h None None O
after None None O
OFTT None None O
and None None O
the None None O
postprandial None None O
response None None O
was None None O
quantified None None O
using None None O
the None None O
area None None O
under None None O
the None None O
curve None None O
( None None O
AUC None None O
) None None O
for None None O
TG None None O
. None None O

The None None O
postprandial None None O
response None None O
was None None O
significantly None None O
higher None None O
in None None O
MetS None None O
compared None None O
to None None O
HTN None None O
and None None O
healthy None None O
men None None O
[ None None O
AUC None None O
( None None O
SD None None O
) None None O
in None None O
mg None None O
/ None None O
dl None None O
/ None None O
h None None O
; None None O
2534 None None O
+ None None O
/ None None O
- None None O
1016 None None O
vs None None O
. None None O
1620 None None O
+ None None O
/ None None O
- None None O
494 None None O
and None None O
1019 None None O
+ None None O
/ None None O
- None None O
280 None None O
, None None O
respectively None None O
, None None O
p None None O
< None None O
= None None O
0 None None O
. None None O
001 None None O
] None None O
. None None O

The None None O
TG None None O
levels None None O
were None None O
increased None None O
significantly None None O
in None None O
MetS None None O
+ None None O
TG None None O
compared None None O
to None None O
MetS None None O
- None None O
TG None None O
subjects None None O
at None None O
4 None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
022 None None O
) None None O
, None None O
6 None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
8 None None O
hours None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

The None None O
TG None None O
were None None O
increased None None O
significantly None None O
in None None O
MetS None None O
- None None O
TG None None O
compared None None O
to None None O
healthy None None O
subjects None None O
at None None O
4 None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
011 None None O
) None None O
, None None O
6 None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
8 None None O
hours None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
015 None None O
) None None O
. None None O

In None None O
linear None None O
regression None None O
analysis None None O
only None None O
fasting None None O
TG None None O
levels None None O
were None None O
a None None O
significant None None O
predictor None None O
of None None O
the None None O
AUC None None O
( None None O
Coefficient None None O
B None None O
= None None O
8 None None O
. None None O
462 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

[ None None O
Tumor None None O
metastasis None None O
and None None O
the None None O
fibrinolytic None None O
system None None O
] None None O
. None None O

Metastatic None None O
spread None None O
of None None O
malignant None None O
tumor None None O
appears None None O
to None None O
correlate None None O
with None None O
activation None None O
of None None O
the None None O
fibrolytic None None O
system None None O
. None None O

The None None O
role None None O
of None None O
fibrinolysis None None O
in None None O
growth None None O
and None None O
metastasis None None O
was None None O
examined None None O
in None None O
Lewis None None O
lung None None O
carcinoma None None O
of None None O
mice None None O
. None None O

The None None O
inhibition None None O
of None None O
fibrinolysis None None O
or None None O
proteases None None O
decreased None None O
the None None O
primary None None O
tumor None None O
growth None None O
and None None O
pulmonary None None O
metastasis None None O
, None None O
whereas None None O
the None None O
activation None None O
of None None O
fibrinolysis None None O
or None None O
proteases None None O
increased None None O
the None None O
number None None O
of None None O
metastatic None None O
foci None None O
in None None O
the None None O
lung None None O
. None None O

Electronmicroscopically None None O
, None None O
thrombus None None O
formation None None O
in None None O
the None None O
primary None None O
site None None O
prevented None None O
tumor None None O
invasion None None O
and None None O
metastasis None None O
formation None None O
. None None O

Plasminogen None None O
activator None None O
( None None O
PA None None O
) None None O
content None None O
of None None O
excised None None O
tumors None None O
was None None O
determined None None O
by None None O
SDS None None O
- None None O
PAGE None None O
, None None O
and None None O
major None None O
PA None None O
was None None O
found None None O
to None None O
be None None O
urokinase None None O
( None None O
UK None None O
) None None O
type None None O
. None None O

Immunohistochemical None None O
study None None O
with None None O
specific None None O
antisera None None O
was None None O
done None None O
. None None O

When None None O
tumor None None O
cells None None O
possessed None None O
a None None O
high None None O
level None None O
of None None O
UK None None O
, None None O
laminin None None O
and None None O
type None None O
IV None None O
collagen None None O
, None None O
components None None O
of None None O
the None None O
basement None None O
membrane None None O
, None None O
disappeared None None O
from None None O
tumor None None O
tissues None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
PA None None O
through None None O
protease None None O
cascade None None O
plays None None O
a None None O
role None None O
in None None O
tumor None None O
invasion None None O
and None None O
metastasis None None O
. None None O

Clinically None None O
, None None O
patients None None O
with None None O
advanced None None O
cancer None None O
are None None O
usually None None O
in None None O
a None None O
hypercoagulable None None O
state None None O
with None None O
elevated None None O
fibrinogen None None O
, None None O
and None None O
fibrin None None O
deposition None None O
around None None O
tumor None None O
mass None None O
is None None O
a None None O
serious None None O
problem None None O
in None None O
cancer None None O
chemotherapy None None O
. None None O

UK None None O
infusion None None O
prior None None O
to None None O
5 None None O
- None None O
fluorouracil None None O
increased None None O
tissue None None O
concentration None None O
of None None O
antitumor None None O
agent None None O
. None None O

However None None O
, None None O
development None None O
of None None O
consumption None None O
coagulopathy None None O
characterized None None O
by None None O
progression None None O
from None None O
hypercoagulable None None O
state None None O
to None None O
disseminated None None O
intravascular None None O
coagulation None None O
has None None O
also None None O
been None None O
found None None O
in None None O
several None None O
cases None None O
. None None O

[ None None O
Organization None None O
of None None O
pectoral None None O
muscle None None O
motor None None O
neurons None None O
in None None O
the None None O
rat None None O
. None None O
Contribution None None O
to None None O
the None None O
study None None O
of None None O
the None None O
axillary None None O
arch None None O
( None None O
Achselbogen None None O
) None None O
] None None O
. None None O

In None None O
spite None None O
of None None O
their None None O
role None None O
of None None O
the None None O
forelimb None None O
activity None None O
, None None O
the None None O
organization None None O
of None None O
the None None O
mammalian None None O
pectoral None None O
muscles None None O
remains None None O
unclear None None O
. None None O

In None None O
order None None O
to None None O
get None None O
more None None O
information None None O
, None None O
we None None O
have None None O
studied None None O
, None None O
qualitatively None None O
and None None O
quantitatively None None O
, None None O
the None None O
motor None None O
pools None None O
of None None O
the None None O
various None None O
pectoral None None O
muscles None None O
in None None O
the None None O
rat None None O
( None None O
musculus None None O
pectoralis None None O
major None None O
, None None O
musculus None None O
pectoralis None None O
minor None None O
and None None O
musculus None None O
panniculus None None O
carnosus None None O
) None None O
. None None O

The None None O
method None None O
applied None None O
was None None O
the None None O
retrograde None None O
transport None None O
of None None O
horseradish None None O
peroxidase None None O
by None None O
the None None O
peripheral None None O
nerves None None O
supplying None None O
the None None O
various None None O
muscles None None O
. None None O

The None None O
results None None O
provided None None O
the None None O
precise None None O
localization None None O
within None None O
the None None O
ventral None None O
horn None None O
of None None O
the None None O
motor None None O
neurons None None O
from None None O
the None None O
pectoral None None O
muscles None None O
which None None O
were None None O
all None None O
in None None O
the None None O
most None None O
ventral None None O
part None None O
of None None O
the None None O
gray None None O
matter None None O
. None None O

Three None None O
distinct None None O
motor None None O
pools None None O
were None None O
observed None None O
, None None O
which None None O
confirms None None O
the None None O
functional None None O
identity None None O
of None None O
each None None O
muscle None None O
. None None O

The None None O
motor None None O
neurons None None O
of None None O
m None None O
. None None O
panniculus None None O
carnosus None None O
exhibited None None O
some None None O
particularities None None O
. None None O

They None None O
were None None O
4 None None O
times None None O
more None None O
numerous None None O
than None None O
those None None O
from None None O
m None None O
. None None O
pectoralis None None O
major None None O
, None None O
they None None O
occupied None None O
the None None O
whole None None O
ventral None None O
edge None None O
of None None O
the None None O
ventral None None O
horn None None O
, None None O
from None None O
its None None O
medial None None O
part None None O
to None None O
its None None O
lateral None None O
tip None None O
. None None O

The None None O
cell None None O
size None None O
was None None O
different None None O
from None None O
that None None O
of None None O
the None None O
other None None O
muscles None None O
. None None O

These None None O
results None None O
were None None O
discussed None None O
, None None O
according None None O
to None None O
the None None O
role None None O
of None None O
this None None O
muscle None None O
, None None O
which None None O
links None None O
the None None O
forelimb None None O
to None None O
the None None O
whole None None O
trunk None None O
. None None O

In None None O
mammals None None O
, None None O
m None None O
. None None O
panniculus None None O
carnosus None None O
constitutes None None O
, None None O
with None None O
musculus None None O
latissimus None None O
dorsi None None O
, None None O
the None None O
axillary None None O
arch None None O
( None None O
Achselbogen None None O
) None None O
. None None O

A None None O
small None None O
area None None O
of None None O
overlapping None None O
between None None O
the None None O
motor None None O
pools None None O
of None None O
these None None O
two None None O
muscles None None O
was None None O
observed None None O
. None None O

It None None O
was None None O
suggested None None O
that None None O
the None None O
muscular None None O
fibers None None O
from None None O
the None None O
axillary None None O
arch None None O
were None None O
innervated None None O
by None None O
the None None O
same None None O
, None None O
well None None O
- None None O
defined None None O
spinal None None O
area None None O
, None None O
independent None None O
of None None O
the None None O
muscle None None O
from None None O
which None None O
they None None O
originate None None O
. None None O

Novel None None O
method None None O
for None None O
multiturn None None O
extraction None None O
: None None O
trapping None None O
charged None None O
particles None None O
in None None O
islands None None O
of None None O
phase None None O
space None None O
. None None O

A None None O
novel None None O
method None None O
for None None O
multiturn None None O
extraction None None O
from None None O
a None None O
circular None None O
particle None None O
accelerator None None O
is None None O
presented None None O
, None None O
based None None O
on None None O
trapping None None O
particles None None O
into None None O
islands None None O
of None None O
phase None None O
space None None O
generated None None O
by None None O
nonlinear None None O
resonances None None O
. None None O

By None None O
appropriate None None O
use None None O
of None None O
sextupoles None None O
and None None O
octupoles None None O
, None None O
stable None None O
islands None None O
can None None O
be None None O
created None None O
at None None O
small None None O
amplitude None None O
in None None O
phase None None O
space None None O
. None None O

By None None O
varying None None O
the None None O
linear None None O
tune None None O
, None None O
particles None None O
can None None O
be None None O
trapped None None O
inside None None O
these None None O
islands None None O
and None None O
then None None O
transported None None O
towards None None O
higher None None O
amplitudes None None O
for None None O
extraction None None O
. None None O

Results None None O
of None None O
numerical None None O
simulations None None O
are None None O
discussed None None O
. None None O

Relationship None None O
of None None O
cellular None None O
immunity None None O
, None None O
cytokines None None O
and None None O
CRP None None O
with None None O
clinical None None O
course None None O
in None None O
breast None None O
cancer None None O
patients None None O
with None None O
endocrine None None O
- None None O
dependent None None O
distant None None O
metastases None None O
treated None None O
with None None O
immunotherapy None None O
. None None O

We None None O
have None None O
reported None None O
important None None O
benefits None None O
and None None O
survival None None O
with None None O
an None None O
immunotherapy None None O
schedule None None O
in None None O
patients None None O
with None None O
endocrine None None O
- None None O
dependent None None O
breast None None O
cancer None None O
and None None O
distant None None O
metastases None None O
. None None O

Here None None O
clinical None None O
outcome None None O
is None None O
updated None None O
and None None O
its None None O
correlation None None O
with None None O
new None None O
immunological None None O
data None None O
is None None O
shown None None O
. None None O

In None None O
32 None None O
evaluated None None O
breast None None O
cancer None None O
patients None None O
with None None O
endocrine None None O
- None None O
dependent None None O
distant None None O
metastases None None O
treated None None O
with None None O
a None None O
new None None O
immunotherapy None None O
schedule None None O
( None None O
cyclic None None O
administration None None O
of None None O
beta None None O
- None None O
interferon None None O
and None None O
interleukin None None O
- None None O
2 None None O
) None None O
, None None O
cellular None None O
immunity None None O
, None None O
cytokines None None O
and None None O
CRP None None O
were None None O
related None None O
to None None O
the None None O
clinical None None O
course None None O
. None None O

Estimated None None O
and None None O
true None None O
5 None None O
- None None O
10 None None O
year None None O
overall None None O
survival None None O
rates None None O
from None None O
first None None O
line None None O
antiestrogen None None O
and None None O
distant None None O
metastases None None O
were None None O
higher None None O
than None None O
previously None None O
reported None None O
in None None O
a None None O
similar None None O
population None None O
. None None O

Interleukin None None O
- None None O
2 None None O
administration None None O
was None None O
followed None None O
by None None O
a None None O
significant None None O
increase None None O
in None None O
total None None O
lymphocytes None None O
, None None O
CD4 None None O
+ None None O
, None None O
CD8 None None O
+ None None O
, None None O
CD16 None None O
+ None None O
56 None None O
+ None None O
( None None O
NK None None O
) None None O
cells None None O
, None None O
IL None None O
- None None O
6 None None O
, None None O
IL None None O
- None None O
12 None None O
, None None O
and None None O
CRP None None O
( None None O
from None None O
P None None O
< None None O
0 None None O
. None None O
04 None None O
to None None O
P None None O
< None None O
0 None None O
. None None O
000 None None O
) None None O
but None None O
no None None O
change None None O
in None None O
IL None None O
- None None O
10 None None O
and None None O
TGFbeta1 None None O
during None None O
clinical None None O
benefit None None O
. None None O

During None None O
progressive None None O
disease None None O
no None None O
change None None O
was None None O
observed None None O
in None None O
the None None O
former None None O
parameters None None O
, None None O
concomitant None None O
with None None O
a None None O
significant None None O
increase None None O
in None None O
IL None None O
- None None O
10 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
020 None None O
) None None O
and None None O
a None None O
significant None None O
decrease None None O
in None None O
TGFbeta1 None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
023 None None O
) None None O
. None None O

These None None O
findings None None O
confirm None None O
that None None O
cellular None None O
immunity None None O
is None None O
significantly None None O
stimulated None None O
by None None O
IL None None O
- None None O
2 None None O
only None None O
during None None O
clinical None None O
benefit None None O
. None None O

Furthermore None None O
, None None O
these None None O
results None None O
demonstrate None None O
that None None O
different None None O
changes None None O
of None None O
proinflammatory None None O
cytokines None None O
, None None O
CRP None None O
and None None O
inhibiting None None O
factors None None O
are None None O
consistent None None O
with None None O
associated None None O
clinical None None O
benefit None None O
or None None O
with None None O
disease None None O
progression None None O
, None None O
respectively None None O
. None None O

Transporters None None O
, None None O
enzymes None None O
, None None O
and None None O
enalapril None None O
removal None None O
in None None O
a None None O
rat None None O
( None None O
CC531 None None I-Cell-line-name
- None None O
induced None None O
) None None O
liver None None O
metastatic None None O
model None None O
. None None O

Temporal None None O
changes None None O
in None None O
physiological None None O
spaces None None O
, None None O
protein None None O
expression None None O
of None None O
transporters None None O
and None None O
enzymes None None O
, None None O
and None None O
enalapril None None O
removal None None O
were None None O
appraised None None O
in None None O
the None None O
metastatic None None O
liver None None O
tumor None None O
model None None O
developed None None O
from None None O
male None None O
Wag None None O
/ None None O
Rij None None O
rats None None O
after None None O
the None None O
intraportal None None O
injection None None O
of None None O
CC531 None None I-Cell-line-name
colon None None O
adenocarcinoma None None O
cells None None O
; None None O
sham None None O
- None None O
operated None None O
preparations None None O
received None None O
PBS None None O
. None None O

Liver None None O
tissue None None O
spaces None None O
, None None O
investigated None None O
with None None O
multiple None None O
indicator None None O
dilution None None O
technique None None O
in None None O
liver None None O
perfusion None None O
studies None None O
, None None O
were None None O
unchanged None None O
at None None O
week None None O
3 None None O
after None None O
tumor None None O
induction None None O
. None None O

At None None O
week None None O
4 None None O
, None None O
however None None O
, None None O
the None None O
sinusoidal None None O
blood None None O
volume None None O
and None None O
albumin None None O
Disse None None O
space None None O
in None None O
tumor None None O
- None None O
bearing None None O
livers None None O
were None None O
slightly None None O
lower None None O
compared None None O
with None None O
those None None O
of None None O
shams None None O
. None None O

Increased None None O
levels None None O
of None None O
the None None O
canalicular None None O
ATP None None O
transporters None None O
, None None O
P None None O
- None None O
glycoprotein None None O
, None None O
multidrug None None O
resistance None None O
- None None O
associated None None O
protein None None O
2 None None O
( None None O
Mrp2 None None O
) None None O
, None None O
and None None O
bile None None O
salt None None O
export None None O
pump None None O
( None None O
Bsep None None O
) None None O
at None None O
week None None O
2 None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
unchanged None None O
levels None None O
of None None O
Ntcp None None O
, None None O
Oatp1a1 None None O
, None None O
Oatp1a4 None None O
, None None O
and None None O
Mct2 None None O
, None None O
but None None O
decreased None None O
levels None None O
of None None O
cytochrome None None O
P450 None None O
3a2 None None O
( None None O
Cyp3a2 None None O
) None None O
and None None O
glutathione None None O
S None None O
- None None O
transferase None None O
( None None O
Gst4 None None O
- None None O
4 None None O
) None None O
at None None O
week None None O
4 None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
were None None O
observed None None O
in None None O
peritumor None None O
vs None None O
. None None O
sham None None O
- None None O
operated None None O
liver None None O
tissues None None O
with None None O
Western None None O
blotting None None O
. None None O

The None None O
steady None None O
- None None O
state None None O
extraction None None O
ratio None None O
of None None O
enalapril None None O
, None None O
a None None O
substrate None None O
that None None O
enters None None O
the None None O
liver None None O
rapidly None None O
via None None O
Oatp1a1 None None O
and None None O
primarily None None O
undergoes None None O
metabolism None None O
by None None O
the None None O
carboxylesterases None None O
, None None O
was None None O
unaffected None None O
by None None O
liver None None O
metastasis None None O
at None None O
week None None O
4 None None O
regardless None None O
of None None O
its None None O
delivery None None O
via None None O
the None None O
portal None None O
vein None None O
or None None O
hepatic None None O
artery None None O
into None None O
the None None O
perfused None None O
liver None None O
preparations None None O
. None None O

A None None O
transcript None None O
from None None O
the None None O
long None None O
terminal None None O
repeats None None O
of None None O
a None None O
murine None None O
retrovirus None None O
associated None None O
with None None O
trans None None O
activation None None O
of None None O
cellular None None O
genes None None O
. None None O

Infection None None O
of None None O
human None None O
or None None O
murine None None O
cells None None O
with None None O
murine None None O
leukemia None None O
viruses None None O
rapidly None None O
increases None None O
the None None O
expression None None O
of None None O
a None None O
number None None O
of None None O
genes None None O
that None None O
belong None None O
to None None O
the None None O
immunoglobulin None None O
superfamily None None O
and None None O
are None None O
involved None None O
in None None O
T None None O
- None None O
lymphocyte None None O
activation None None O
, None None O
including None None O
the None None O
class None None O
I None None O
major None None O
histocompatibility None None O
complex None None O
antigens None None O
. None None O

We None None O
have None None O
reported None None O
recently None None O
that None None O
the None None O
long None None O
terminal None None O
repeat None None O
( None None O
LTR None None O
) None None O
of None None O
Moloney None None O
murine None None O
leukemia None None O
virus None None O
encodes None None O
a None None O
trans None None O
activator None None O
which None None O
induces None None O
transcription None None O
and None None O
expression None None O
of None None O
class None None O
I None None O
major None None O
histocompatibility None None O
complex None None O
genes None None O
and None None O
certain None None O
cytokine None None O
genes None None O
. None None O

The None None O
portion None None O
of None None O
the None None O
LTR None None O
responsible None None O
for None None O
trans None None O
activation None None O
was None None O
mapped None None O
by None None O
deletions None None O
to None None O
lie None None O
within None None O
the None None O
U3 None None O
region None None O
. None None O

We None None O
demonstrate None None O
here None None O
that None None O
a None None O
transcript None None O
is None None O
initiated None None O
within None None O
the None None O
U3 None None O
region None None O
and None None O
that None None O
its None None O
presence None None O
correlates None None O
with None None O
the None None O
trans None None O
- None None O
activating None None O
activity None None O
. None None O

Analysis None None O
of None None O
the None None O
LTR None None O
region None None O
reveals None None O
a None None O
potential None None O
internal None None O
promoter None None O
element None None O
for None None O
RNA None None O
polymerase None None O
III None None O
transcription None None O
within None None O
the None None O
U3 None None O
region None None O
. None None O

Studies None None O
with None None O
polymerase None None O
inhibitors None None O
suggest None None O
that None None O
this None None O
LTR None None O
transcript None None O
, None None O
designated None None O
let None None O
( None None O
LTR None None O
- None None O
encoded None None O
trans None None O
activator None None O
) None None O
, None None O
is None None O
a None None O
product None None O
of None None O
RNA None None O
polymerase None None O
III None None O
. None None O

The None None O
mechanisms None None O
whereby None None O
RNA None None O
leukemia None None O
viruses None None O
cause None None O
lymphoid None None O
neoplasia None None O
after None None O
a None None O
long None None O
latent None None O
period None None O
have None None O
been None None O
extensively None None O
studied None None O
but None None O
are None None O
only None None O
partially None None O
understood None None O
. None None O

The None None O
region None None O
of None None O
the None None O
LTR None None O
identified None None O
here None None O
as None None O
being None None O
important None None O
in None None O
trans None None O
activation None None O
has None None O
recently None None O
been None None O
shown None None O
to None None O
be None None O
a None None O
critical None None O
determinant None None O
of None None O
the None None O
leukemogenicity None None O
and None None O
latency None None O
of None None O
Moloney None None O
murine None None O
leukemia None None O
virus None None O
. None None O

These None None O
findings None None O
suggest None None O
a None None O
novel None None O
mechanism None None O
of None None O
retrovirus None None O
- None None O
induced None None O
activation None None O
of None None O
cellular None None O
gene None None O
expression None None O
, None None O
potentially None None O
contributing None None O
to None None O
leukemogenesis None None O
. None None O

Glucagon None None O
induces None None O
suppression None None O
of None None O
ATP None None O
- None None O
sensitive None None O
K None None O
+ None None O
channel None None O
activity None None O
through None None O
a None None O
Ca2 None None O
+ None None O
/ None None O
calmodulin None None O
- None None O
dependent None None O
pathway None None O
in None None O
mouse None None O
pancreatic None None O
beta None None O
- None None O
cells None None O
. None None O

Glucagon None None O
is None None O
known None None O
to None None O
increase None None O
intracellular None None O
cAMP None None O
levels None None O
and None None O
enhance None None O
glucose None None O
- None None O
induced None None O
electrical None None O
activity None None O
and None None O
insulin None None O
secretion None None O
in None None O
pancreatic None None O
beta None None O
- None None O
cell None None O
perfused None None O
with None None O
Krebs None None O
- None None O
Ringer None None O
bicarbonate None None O
solution None None O
. None None O

The None None O
present None None O
experiments None None O
were None None O
aimed None None O
at None None O
evaluation None None O
of None None O
the None None O
hypothesis None None O
that None None O
changes None None O
in None None O
beta None None O
- None None O
cells None None O
ATP None None O
- None None O
sensitive None None O
K None None O
+ None None O
( None None O
K None None O
( None None O
ATP None None O
) None None O
) None None O
channel None None O
activity None None O
are None None O
involved None None O
in None None O
the None None O
glucagon None None O
- None None O
induced None None O
enhancement None None O
of None None O
electrical None None O
activity None None O
. None None O

Channel None None O
activity None None O
was None None O
recorded None None O
using None None O
the None None O
cell None None O
- None None O
attached None None O
configuration None None O
of None None O
the None None O
patch None None O
- None None O
clamp None None O
technique None None O
. None None O

Addition None None O
of None None O
glucagon None None O
( None None O
2 None None O
. None None O
9 None None O
x None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
m None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
11 None None O
. None None O
1 None None O
mm None None O
glucose None None O
caused None None O
closure None None O
of None None O
K None None O
( None None O
ATP None None O
) None None O
channels None None O
followed None None O
by None None O
an None None O
increase None None O
in None None O
the None None O
frequency None None O
of None None O
biphasic None None O
current None None O
transients None None O
( None None O
action None None O
currents None None O
) None None O
due None None O
to None None O
action None None O
potential None None O
generation None None O
in None None O
the None None O
cell None None O
. None None O

Three None None O
calmodulin None None O
- None None O
antagonists None None O
( None None O
W None None O
- None None O
7 None None O
, None None O
chlorpromazine None None O
, None None O
and None None O
trifluoperazine None None O
) None None O
restored None None O
with None None O
similar None None O
efficacy None None O
K None None O
( None None O
ATP None None O
) None None O
channel None None O
activity None None O
in None None O
cells None None O
being None None O
exposed None None O
to None None O
glucagon None None O
. None None O

At None None O
2 None None O
. None None O
8 None None O
mm None None O
glucose None None O
, None None O
glucagon None None O
did None None O
not None None O
affect None None O
K None None O
( None None O
ATP None None O
) None None O
channel None None O
activity None None O
until None None O
Ca2 None None O
+ None None O
was None None O
released None None O
from None None O
Nitr None None O
- None None O
5 None None O
by None None O
flash None None O
photolysis None None O
, None None O
at None None O
which None None O
point None None O
channel None None O
activity None None O
was None None O
transiently None None O
suppressed None None O
. None None O

Similar None None O
effects None None O
were None None O
seen None None O
when None None O
db None None O
- None None O
cAMP None None O
was None None O
used None None O
instead None None O
of None None O
glucagon None None O
. None None O

These None None O
results None None O
support None None O
the None None O
view None None O
that None None O
glucagon None None O
and None None O
other None None O
cAMP None None O
- None None O
generating None None O
agonists None None O
enhance None None O
glucose None None O
- None None O
induced None None O
beta None None O
- None None O
cell None None O
electrical None None O
activity None None O
through None None O
a None None O
Ca2 None None O
+ None None O
/ None None O
calmodulin None None O
dependent None None O
- None None O
closure None None O
of None None O
K None None O
( None None O
ATP None None O
) None None O
channels None None O
. None None O

Comparison None None O
of None None O
the None None O
Predicted None None O
Irr None None O
Regulon None None O
and None None O
ICE None None O
Motifs None None O
with None None O
the None None O
Published None None O
Expression None None O
Microarray None None O
Data None None O
for None None O
Iron None None O
- None None O
and None None O
Irr None None O
- None None O
Affected None None O
Genes None None O
in None None O
Bradyrhizobium None None O
japonicum None None O

Relationship None None O
of None None O
self None None O
- None None O
concept None None O
during None None O
late None None O
pregnancy None None O
to None None O
neonatal None None O
perception None None O
and None None O
parenting None None O
profile None None O
. None None O

Thirty None None O
- None None O
one None None O
gravidas None None O
were None None O
studied None None O
to None None O
examine None None O
the None None O
relationship None None O
between None None O
a None None O
woman None None O
' None None O
s None None O
feelings None None O
about None None O
herself None None O
during None None O
late None None O
pregnancy None None O
, None None O
her None None O
perception None None O
of None None O
her None None O
newborn None None O
, None None O
and None None O
her None None O
profile None None O
of None None O
parenting None None O
. None None O

The None None O
Tennessee None None O
Self None None O
- None None O
Concept None None O
Scale None None O
was None None O
completed None None O
during None None O
the None None O
third None None O
trimester None None O
of None None O
pregnancy None None O
, None None O
the None None O
Neonatal None None O
Perception None None O
Inventory None None O
I None None O
at None None O
one None None O
- None None O
to None None O
- None None O
two None None O
days None None O
postpartum None None O
, None None O
and None None O
the None None O
Neonatal None None O
Perception None None O
Inventory None None O
II None None O
and None None O
the None None O
Michigan None None O
Screening None None O
Profile None None O
of None None O
Parenting None None O
at None None O
four None None O
- None None O
to None None O
- None None O
six None None O
weeks None None O
postpartum None None O
. None None O

When None None O
considered None None O
separately None None O
, None None O
no None None O
positive None None O
significant None None O
relationships None None O
were None None O
found None None O
between None None O
scores None None O
on None None O
these None None O
variables None None O
. None None O

However None None O
, None None O
all None None O
subjects None None O
with None None O
negative None None O
scores None None O
on None None O
both None None O
self None None O
- None None O
concept None None O
and None None O
neonatal None None O
perception None None O
had None None O
negative None None O
scores None None O
on None None O
at None None O
least None None O
two None None O
subscales None None O
of None None O
the None None O
parenting None None O
profile None None O
. None None O

Stimulation None None O
/ None None O
Inhibition None None O
of None None O
iDC None None O
Functions None None O
by None None O
Activated None None O
NK None None O
Cells None None O
. None None O

Two None None O
previous None None O
studies None None O
have None None O
shown None None O
that None None O
both None None O
resting None None O
and None None O
activated None None O
NK None None O
cells None None O
partially None None O
kill None None O
autologous None None O
DCs None None O
, None None O
as None None O
measured None None O
by None None O
3 None None O
- None None O
4 None None O
- None None O
h None None O
chromium None None O
release None None O
assays None None O
using None None O
high None None O
NK None None O
/ None None O
DC None None O
ratios None None O
( None None O
11 None None O
, None None O
12 None None O
) None None O
. None None O

However None None O
, None None O
in None None O
our None None O
long None None O
- None None O
term None None O
cultures None None O
( None None O
24 None None O
- None None O
48 None None O
h None None O
) None None O
the None None O
NK None None O
cells None None O
stimulated None None O
the None None O
iDCs None None O
rather None None O
than None None O
lysing None None O
them None None O
. None None O

Based None None O
on None None O
these None None O
conflicting None None O
results None None O
, None None O
we None None O
examined None None O
in None None O
more None None O
detail None None O
the None None O
apparent None None O
stimulation None None O
of None None O
iDCs None None O
after None None O
contact None None O
with None None O
NK None None O
cells None None O
. None None O

We None None O
reasoned None None O
that None None O
activated None None O
NK None None O
cells None None O
would None None O
be None None O
more None None O
useful None None O
for None None O
these None None O
experiments None None O
because None None O
( None None O
i None None O
) None None O
an None None O
encounter None None O
in None None O
vivo None None O
between None None O
NK None None O
cells None None O
that None None O
normally None None O
traffic None None O
in None None O
the None None O
blood None None O
( None None O
4 None None O
) None None O
and None None O
iDCs None None O
which None None O
reside None None O
in None None O
the None None O
tissues None None O
( None None O
1 None None O
, None None O
3 None None O
) None None O
, None None O
should None None O
only None None O
occur None None O
when None None O
both None None O
cells None None O
are None None O
activated None None O
; None None O
( None None O
ii None None O
) None None O
activated None None O
NK None None O
cells None None O
mediate None None O
more None None O
potent None None O
lysis None None O
of None None O
iDCs None None O
( None None O
11 None None O
- None None O
13 None None O
) None None O
, None None O
thereby None None O
allowing None None O
for None None O
a None None O
more None None O
rigorous None None O
examination None None O
of None None O
a None None O
potential None None O
cytotoxic None None O
effect None None O
; None None O
and None None O
( None None O
iii None None O
) None None O
the None None O
number None None O
of None None O
NK None None O
cells None None O
obtained None None O
after None None O
short None None O
- None None O
term None None O
in None None O
vitro None None O
culture None None O
would None None O
be None None O
far None None O
greater None None O
providing None None O
more None None O
cells None None O
for None None O
analysis None None O
( None None O
9 None None O
) None None O
. None None O

The None None O
DC None None O
maturation None None O
induced None None O
by None None O
resting None None O
NK None None O
cells None None O
we None None O
observed None None O
was None None O
dependent None None O
on None None O
endogenous None None O
TNF None None O
- None None O
alpha None None O
production None None O
. None None O

Furthermore None None O
, None None O
TNF None None O
- None None O
alpha None None O
and None None O
other None None O
proinflammatory None None O
cytokines None None O
are None None O
important None None O
amplifiers None None O
of None None O
immune None None O
responses None None O
( None None O
14 None None O
) None None O
. None None O

Therefore None None O
, None None O
we None None O
used None None O
TNF None None O
- None None O
alpha None None O
production None None O
as None None O
a None None O
readout None None O
for None None O
DC None None O
stimulation None None O
in None None O
our None None O
culture None None O
system None None O
. None None O

Culturing None None O
activated None None O
NK None None O
cells None None O
with None None O
DCs None None O
at None None O
low None None O
NK None None O
/ None None O
DC None None O
ratios None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
led None None O
to None None O
increases None None O
in None None O
TNF None None O
- None None O
alpha None None O
production None None O
, None None O
which None None O
were None None O
augmented None None O
dramatically None None O
by None None O
the None None O
addition None None O
of None None O
suboptimal None None O
doses None None O
( None None O
10 None None O
ng None None O
/ None None O
ml None None O
) None None O
of None None O
LPS None None O
( None None O
Fig None None O
. None None O
2 None None O
A None None O
) None None O
. None None O

The None None O
increased None None O
TNF None None O
- None None O
alpha None None O
production None None O
was None None O
dependent None None O
on None None O
cell None None O
- None None O
to None None O
- None None O
cell None None O
contact None None O
because None None O
when None None O
the None None O
two None None O
cell None None O
types None None O
were None None O
separated None None O
in None None O
trans None None O
- None None O
wells None None O
, None None O
no None None O
stimulation None None O
was None None O
observed None None O
( None None O
Fig None None O
. None None O
2 None None O
B None None O
) None None O
. None None O

In None None O
separate None None O
experiments None None O
we None None O
observed None None O
this None None O
NK None None O
- None None O
stimulatory None None O
effect None None O
on None None O
TNF None None O
- None None O
alpha None None O
production None None O
at None None O
NK None None O
/ None None O
DC None None O
ratios None None O
as None None O
low None None O
as None None O
1 None None O
: None None O
20 None None O
and None None O
1 None None O
: None None O
40 None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Raising None None O
the None None O
NK None None O
/ None None O
DC None None O
ratio None None O
to None None O
5 None None O
: None None O
1 None None O
changes None None O
the None None O
interaction None None O
from None None O
one None None O
of None None O
potent None None O
DC None None O
stimulation None None O
to None None O
that None None O
of None None O
complete None None O
inhibition None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
LPS None None O
( None None O
Fig None None O
. None None O
2 None None O
C None None O
) None None O
. None None O

An None None O
identical None None O
pattern None None O
is None None O
seen None None O
for None None O
IL None None O
- None None O
12 None None O
p40 None None O
production None None O
( None None O
Fig None None O
. None None O
2 None None O
D None None O
) None None O
. None None O

No None None O
IL None None O
- None None O
10 None None O
production None None O
in None None O
the None None O
cultures None None O
was None None O
detected None None O
under None None O
any None None O
of None None O
the None None O
conditions None None O
tested None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

The None None O
massive None None O
production None None O
of None None O
TNF None None O
- None None O
alpha None None O
in None None O
the None None O
cultures None None O
at None None O
the None None O
lowest None None O
ratios None None O
was None None O
mediated None None O
primarily None None O
by None None O
DCs None None O
in None None O
the None None O
culture None None O
due None None O
to None None O
the None None O
low None None O
number None None O
of None None O
NK None None O
cells None None O
( None None O
2 None None O
x None None O
104 None None O
cells None None O
per None None O
well None None O
) None None O
used None None O
in None None O
these None None O
experiments None None O
. None None O

In None None O
addition None None O
, None None O
efforts None None O
to None None O
stimulate None None O
NK None None O
cells None None O
directly None None O
with None None O
optimal None None O
doses None None O
of None None O
anti None None O
- None None O
CD16 None None O
, None None O
rIL None None O
- None None O
2 None None O
, None None O
rIL None None O
- None None O
12 None None O
, None None O
and None None O
PMA None None O
/ None None O
ionomycin None None O
alone None None O
or None None O
in None None O
combination None None O
induced None None O
only None None O
moderate None None O
( None None O
< None None O
500 None None O
pg None None O
/ None None O
ml None None O
) None None O
TNF None None O
- None None O
alpha None None O
production None None O
by None None O
the None None O
NK None None O
cells None None O
alone None None O
which None None O
were None None O
present None None O
at None None O
2 None None O
x None None O
105 None None O
cells None None O
per None None O
well None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Figure None None O
2 None None O
. None None O

Activated None None O
/ None None O
cultured None None O
NK None None O
cell None None O
- None None O
mediated None None O
amplification None None O
/ None None O
inhibition None None O
of None None O
DC None None O
cytokine None None O
production None None O
. None None O

Results None None O
are None None O
presented None None O
on None None O
log None None O
scales None None O
. None None O

Cultured None None O
iDCs None None O
were None None O
incubated None None O
alone None None O
or None None O
with None None O
cultured None None O
/ None None O
purified None None O
NK None None O
cells None None O
for None None O
24 None None O
h None None O
( None None O
A None None O
and None None O
B None None O
) None None O
or None None O
48 None None O
h None None O
( None None O
C None None O
- None None O
E None None O
) None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
the None None O
indicated None None O
concentrations None None O
of None None O
LPS None None O
. None None O

After None None O
culture None None O
the None None O
supernatants None None O
were None None O
removed None None O
and None None O
analyzed None None O
by None None O
ELISA None None O
for None None O
TNF None None O
- None None O
alpha None None O
or None None O
IL None None O
- None None O
12 None None O
p40 None None O
. None None O

( None None O
A None None O
) None None O
TNF None None O
- None None O
alpha None None O
production None None O
was None None O
measured None None O
in None None O
the None None O
supernatants None None O
from None None O
cultures None None O
of None None O
: None None O
DCs None None O
alone None None O
( None None O
gray None None O
bars None None O
) None None O
; None None O
NK None None O
+ None None O
DC None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
( None None O
black None None O
bars None None O
) None None O
. None None O

LPS None None O
concentrations None None O
used None None O
were None None O
: None None O
0 None None O
, None None O
10 None None O
, None None O
and None None O
1 None None O
, None None O
000 None None O
ng None None O
/ None None O
ml None None O
( None None O
DCs None None O
alone None None O
only None None O
) None None O
. None None O

( None None O
B None None O
) None None O
Contact None None O
- None None O
dependent None None O
stimulation None None O
of None None O
iDC None None O
TNF None None O
- None None O
alpha None None O
production None None O
by None None O
NK None None O
cells None None O
was None None O
tested None None O
under None None O
the None None O
following None None O
conditions None None O
: None None O
DCs None None O
alone None None O
( None None O
gray None None O
bars None None O
) None None O
; None None O
NK None None O
+ None None O
DC None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
( None None O
black None None O
bars None None O
) None None O
; None None O
NK None None O
/ None None O
DC None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
trans None None O
- None None O
wells None None O
( None None O
striped None None O
bars None None O
) None None O
. None None O

LPS None None O
concentrations None None O
used None None O
were None None O
: None None O
10 None None O
ng None None O
/ None None O
ml None None O
( None None O
donor None None O
1 None None O
) None None O
and None None O
20 None None O
ng None None O
/ None None O
ml None None O
( None None O
donor None None O
2 None None O
) None None O
. None None O

( None None O
C None None O
and None None O
D None None O
) None None O
Effect None None O
of None None O
increasing None None O
the None None O
NK None None O
/ None None O
DC None None O
ratio None None O
( None None O
DCs None None O
alone None None O
; None None O
NK None None O
: None None O
DC None None O
- None None O
1 None None O
: None None O
5 None None O
; None None O
1 None None O
: None None O
1 None None O
; None None O
5 None None O
: None None O
1 None None O
) None None O
on None None O
( None None O
C None None O
) None None O
TNF None None O
- None None O
alpha None None O
and None None O
( None None O
D None None O
) None None O
IL None None O
- None None O
12 None None O
p40 None None O
production None None O
. None None O

LPS None None O
concentrations None None O
used None None O
were None None O
: None None O
0 None None O
ng None None O
/ None None O
ml None None O
( None None O
* None None O
) None None O
; None None O
20 None None O
ng None None O
/ None None O
ml None None O
( None None O
* None None O
) None None O
; None None O
50 None None O
ng None None O
/ None None O
ml None None O
( None None O
^ None None O
) None None O
; None None O
and None None O
1 None None O
, None None O
000 None None O
ng None None O
/ None None O
ml None None O
- None None O
LPS None None O
( None None O
* None None O
) None None O
( None None O
DCs None None O
alone None None O
only None None O
) None None O
. None None O

( None None O
E None None O
) None None O
The None None O
effect None None O
of None None O
neutralizing None None O
IFN None None O
- None None O
gamma None None O
production None None O
was None None O
tested None None O
under None None O
the None None O
following None None O
conditions None None O
: None None O
DCs None None O
alone None None O
( None None O
gray None None O
bars None None O
) None None O
; None None O
NK None None O
+ None None O
DC None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
( None None O
black None None O
bars None None O
) None None O
; None None O
NK None None O
+ None None O
DC None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
and None None O
10 None None O
mug None None O
/ None None O
ml None None O
of None None O
blocking None None O
anti None None O
- None None O
IFN None None O
- None None O
gamma None None O
mAb None None O
( None None O
stippled None None O
bars None None O
) None None O
. None None O

LPS None None O
concentrations None None O
used None None O
were None None O
: None None O
0 None None O
ng None None O
/ None None O
ml None None O
( None None O
NO None None O
LPS None None O
) None None O
and None None O
20 None None O
ng None None O
/ None None O
ml None None O
( None None O
LPS None None O
20 None None O
) None None O
. None None O

Blocking None None O
reagents None None O
for None None O
CD80 None None O
, None None O
CD86 None None O
, None None O
CD154 None None O
, None None O
CD95 None None O
, None None O
CD11a None None O
, None None O
CD50 None None O
, None None O
or None None O
IL None None O
- None None O
12 None None O
, None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
NK None None O
cell None None O
- None None O
induced None None O
TNF None None O
- None None O
alpha None None O
or None None O
IL None None O
- None None O
12 None None O
p40 None None O
production None None O
, None None O
whereas None None O
a None None O
neutralizing None None O
antibody None None O
for None None O
IFN None None O
- None None O
gamma None None O
while None None O
not None None O
affecting None None O
TNF None None O
- None None O
alpha None None O
production None None O
partially None None O
blocked None None O
( None None O
< None None O
20 None None O
% None None O
) None None O
IL None None O
- None None O
12 None None O
p40 None None O
production None None O
induced None None O
by None None O
the None None O
NK None None O
cells None None O
( None None O
Fig None None O
. None None O
2 None None O
E None None O
) None None O
. None None O

This None None O
partial None None O
inhibition None None O
is None None O
consistent None None O
with None None O
numerous None None O
previous None None O
reports None None O
demonstrating None None O
a None None O
central None None O
role None None O
for None None O
an None None O
IL None None O
- None None O
12 None None O
/ None None O
IFN None None O
- None None O
gamma None None O
positive None None O
feedback None None O
loop None None O
active None None O
between None None O
NK None None O
cells None None O
and None None O
IL None None O
- None None O
12 None None O
- None None O
producing None None O
cells None None O
( None None O
15 None None O
- None None O
17 None None O
) None None O
. None None O

Clearly None None O
, None None O
however None None O
, None None O
this None None O
well None None O
- None None O
described None None O
cytokine None None O
cross None None O
- None None O
talk None None O
mechanism None None O
is None None O
secondary None None O
to None None O
the None None O
contact None None O
- None None O
dependent None None O
activation None None O
of None None O
DCs None None O
by None None O
NK None None O
cells None None O
described None None O
here None None O
. None None O

Taken None None O
together None None O
these None None O
results None None O
indicate None None O
that None None O
novel None None O
mechanisms None None O
control None None O
cognate None None O
interactions None None O
between None None O
NK None None O
cells None None O
and None None O
DCs None None O
and None None O
that None None O
NK None None O
- None None O
DC None None O
contact None None O
has None None O
the None None O
potential None None O
to None None O
serve None None O
as None None O
an None None O
important None None O
control None None O
switch None None O
for None None O
both None None O
amplifying None None O
and None None O
attenuating None None O
innate None None O
immune None None O
responses None None O
in None None O
vivo None None O
. None None O

We None None O
next None None O
tested None None O
directly None None O
whether None None O
NK None None O
cell None None O
killing None None O
was None None O
active None None O
in None None O
our None None O
system None None O
using None None O
both None None O
short None None O
- None None O
term None None O
( None None O
4 None None O
- None None O
h None None O
) None None O
chromium None None O
release None None O
assays None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
and None None O
a None None O
flow None None O
cytometric None None O
assay None None O
which None None O
allowed None None O
us None None O
to None None O
follow None None O
the None None O
survival None None O
of None None O
the None None O
autologous None None O
iDCs None None O
in None None O
the None None O
presence None None O
of None None O
NK None None O
cells None None O
over None None O
longer None None O
periods None None O
( None None O
Fig None None O
. None None O
3 None None O
) None None O
. None None O

The None None O
results None None O
demonstrate None None O
that None None O
NK None None O
cells None None O
kill None None O
autologous None None O
iDCs None None O
( None None O
Fig None None O
. None None O
3 None None O
A None None O
) None None O
at None None O
all None None O
NK None None O
/ None None O
DC None None O
ratios None None O
tested None None O
after None None O
4 None None O
h None None O
and None None O
the None None O
level None None O
of None None O
killing None None O
is None None O
similar None None O
to None None O
the None None O
lysis None None O
of None None O
K562 None None I-Cell-line-name
cells None None O
over None None O
the None None O
same None None O
time None None O
( None None O
Fig None None O
. None None O
3 None None O
B None None O
) None None O
. None None O

After None None O
24 None None O
h None None O
, None None O
however None None O
, None None O
the None None O
presence None None O
of None None O
NK None None O
cells None None O
led None None O
to None None O
completely None None O
divergent None None O
effects None None O
on None None O
the None None O
DCs None None O
. None None O

At None None O
the None None O
5 None None O
: None None O
1 None None O
( None None O
NK None None O
/ None None O
DC None None O
) None None O
ratio None None O
, None None O
NK None None O
cell None None O
- None None O
mediated None None O
destruction None None O
of None None O
the None None O
iDCs None None O
was None None O
the None None O
dominant None None O
feature None None O
, None None O
whereas None None O
at None None O
the None None O
low None None O
ratio None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
the None None O
same None None O
NK None None O
cells None None O
promoted None None O
iDCs None None O
survival None None O
compared None None O
with None None O
iDCs None None O
alone None None O
over None None O
the None None O
same None None O
period None None O
( None None O
Fig None None O
. None None O
3 None None O
A None None O
) None None O
. None None O

The None None O
equal None None O
ratio None None O
of None None O
NK None None O
/ None None O
DC None None O
( None None O
1 None None O
: None None O
1 None None O
) None None O
fell None None O
between None None O
these None None O
two None None O
extremes None None O
. None None O

The None None O
NK None None O
cell None None O
- None None O
mediated None None O
lysis None None O
of None None O
the None None O
K562 None None I-Cell-line-name
targets None None O
increased None None O
at None None O
all None None O
ratios None None O
tested None None O
after None None O
the None None O
24 None None O
- None None O
h None None O
incubation None None O
. None None O

These None None O
striking None None O
differences None None O
between None None O
death None None O
and None None O
survival None None O
of None None O
DCs None None O
upon None None O
encountering None None O
NK None None O
cells None None O
correlate None None O
precisely None None O
with None None O
our None None O
previous None None O
results None None O
on None None O
TNF None None O
- None None O
alpha None None O
and None None O
IL None None O
- None None O
12 None None O
p40 None None O
production None None O
where None None O
increasing None None O
numbers None None O
of None None O
NK None None O
cells None None O
in None None O
the None None O
culture None None O
shifts None None O
the None None O
NK None None O
effect None None O
from None None O
potent None None O
stimulation None None O
to None None O
complete None None O
inhibition None None O
( None None O
Fig None None O
. None None O
2 None None O
) None None O
. None None O

Figure None None O
3 None None O
. None None O

Activated None None O
/ None None O
cultured None None O
NK None None O
cell None None O
- None None O
mediated None None O
death None None O
/ None None O
survival None None O
of None None O
DCs None None O
and None None O
NK None None O
- None None O
DC None None O
conjugate None None O
formation None None O
. None None O

NK None None O
cell None None O
mediated None None O
killing None None O
/ None None O
survival None None O
of None None O
CFDA None None O
. None None O
SE None None O
- None None O
loaded None None O
iDCs None None O
( None None O
A None None O
) None None O
and None None O
K562 None None I-Cell-line-name
cells None None O
( None None O
B None None O
) None None O
was None None O
measured None None O
by None None O
flow None None O
cytometry None None O
over None None O
4 None None O
h None None O
( None None O
* None None O
) None None O
or None None O
24 None None O
h None None O
( None None O
* None None O
) None None O
at None None O
the None None O
indicated None None O
NK None None O
/ None None O
DC None None O
ratios None None O
as None None O
described None None O
in None None O
Materials None None O
and None None O
Methods None None O
. None None O

Results None None O
are None None O
presented None None O
as None None O
percentage None None O
of None None O
specific None None O
lysis None None O
+ None None O
/ None None O
- None None O
SEM None None O
( None None O
n None None O
= None None O
3 None None O
independent None None O
experiments None None O
) None None O
. None None O

NK None None O
- None None O
DC None None O
( None None O
C None None O
- None None O
E None None O
) None None O
or None None O
NK None None O
- None None O
K562 None None I-Cell-line-name
( None None O
F None None O
- None None O
H None None O
) None None O
conjugate None None O
formation None None O
was None None O
measured None None O
by None None O
flow None None O
cytometry None None O
, None None O
at None None O
the None None O
following None None O
ratios None None O
( None None O
NK None None O
/ None None O
DC None None O
or None None O
NK None None O
/ None None O
K562 None None I-Cell-line-name
) None None O
: None None O
1 None None O
: None None O
5 None None O
( None None O
C None None O
and None None O
F None None O
) None None O
; None None O
1 None None O
: None None O
1 None None O
( None None O
D None None O
and None None O
G None None O
) None None O
; None None O
and None None O
5 None None O
: None None O
1 None None O
( None None O
E None None O
and None None O
H None None O
) None None O
. None None O

Snarf None None O
- None None O
1 None None O
( None None O
FL3 None None O
) None None O
- None None O
labeled None None O
iDCs None None O
or None None O
K562 None None I-Cell-line-name
cells None None O
were None None O
incubated None None O
( None None O
30 None None O
min None None O
) None None O
with None None O
CFDA None None O
. None None O
SE None None O
( None None O
FL1 None None O
) None None O
- None None O
labeled None None O
NK None None O
cells None None O
at None None O
the None None O
different None None O
ratios None None O
. None None O

The None None O
percentage None None O
of None None O
conjugates None None O
formed None None O
( None None O
top None None O
right None None O
quadrant None None O
) None None O
was None None O
calculated None None O
by None None O
determining None None O
the None None O
percentage None None O
of None None O
FL3 None None O
+ None None O
( None None O
Snarf None None O
- None None O
1 None None O
) None None O
events None None O
which None None O
were None None O
also None None O
positive None None O
for None None O
FL1 None None O
( None None O
CFDA None None O
. None None O
SE None None O
) None None O
. None None O

The None None O
results None None O
are None None O
representative None None O
of None None O
four None None O
experiments None None O
performed None None O
with None None O
activated None None O
NK None None O
cells None None O
. None None O

Resting None None O
NK None None O
cells None None O
also None None O
readily None None O
formed None None O
conjugates None None O
with None None O
autologous None None O
iDCs None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

NK None None O
cells None None O
can None None O
both None None O
efficiently None None O
kill None None O
and None None O
potently None None O
stimulate None None O
DCs None None O
in None None O
our None None O
model None None O
system None None O
and None None O
each None None O
of None None O
these None None O
opposing None None O
effects None None O
appear None None O
dependent None None O
on None None O
cell None None O
- None None O
to None None O
- None None O
cell None None O
contact None None O
. None None O

To None None O
quantify None None O
these None None O
apparent None None O
cognate None None O
interactions None None O
we None None O
measured None None O
the None None O
formation None None O
of None None O
NK None None O
- None None O
DC None None O
conjugates None None O
and None None O
compared None None O
them None None O
to None None O
conjugates None None O
formed None None O
by None None O
NK None None O
cells None None O
and None None O
tumor None None O
targets None None O
. None None O

Our None None O
analysis None None O
revealed None None O
that None None O
NK None None O
cells None None O
bound None None O
DC None None O
( None None O
Fig None None O
. None None O
3 None None O
C None None O
- None None O
E None None O
) None None O
with None None O
an None None O
efficiency None None O
almost None None O
equal None None O
to None None O
that None None O
of None None O
NK None None O
cell None None O
binding None None O
to None None O
the None None O
classical None None O
NK None None O
- None None O
target None None O
, None None O
K562 None None I-Cell-line-name
( None None O
Fig None None O
. None None O
3 None None O
F None None O
- None None O
H None None O
) None None O
. None None O

Binding None None O
was None None O
detectable None None O
even None None O
at None None O
the None None O
lowest None None O
NK None None O
/ None None O
DC None None O
ratio None None O
tested None None O
( None None O
1 None None O
: None None O
5 None None O
) None None O
indicating None None O
that None None O
NK None None O
- None None O
DC None None O
conjugates None None O
are None None O
formed None None O
in None None O
our None None O
other None None O
experiments None None O
measuring None None O
cytokine None None O
production None None O
and None None O
cell None None O
killing None None O
. None None O

Our None None O
initial None None O
experiments None None O
using None None O
resting None None O
NK None None O
cells None None O
( None None O
Fig None None O
. None None O
1 None None O
) None None O
demonstrated None None O
a None None O
contact None None O
- None None O
dependent None None O
NK None None O
effect None None O
driving None None O
iDCs None None O
to None None O
mature None None O
. None None O

Therefore None None O
, None None O
we None None O
tested None None O
what None None O
effects None None O
activated None None O
NK None None O
cells None None O
mediated None None O
on None None O
DC None None O
maturation None None O
( None None O
Fig None None O
. None None O
4 None None O
) None None O
. None None O

Similar None None O
to None None O
our None None O
previous None None O
results None None O
with None None O
activated None None O
NK None None O
cells None None O
( None None O
Figs None None O
. None None O
2 None None O
and None None O
3 None None O
) None None O
, None None O
addition None None O
of None None O
NK None None O
cells None None O
to None None O
the None None O
culture None None O
leads None None O
to None None O
opposing None None O
effects None None O
on None None O
the None None O
iDC None None O
population None None O
depending None None O
on None None O
the None None O
NK None None O
/ None None O
DC None None O
ratio None None O
. None None O

Compared None None O
with None None O
the None None O
untreated None None O
DCs None None O
( None None O
Fig None None O
. None None O
4 None None O
A None None O
- None None O
C None None O
) None None O
, None None O
low None None O
NK None None O
/ None None O
DC None None O
ratios None None O
( None None O
1 None None O
: None None O
5 None None O
or None None O
1 None None O
: None None O
1 None None O
) None None O
consistently None None O
augmented None None O
expression None None O
of None None O
the None None O
maturation None None O
markers None None O
: None None O
CD86 None None O
( None None O
Fig None None O
. None None O
4 None None O
D None None O
- None None O
I None None O
) None None O
, None None O
CD83 None None O
, None None O
and None None O
HLA None None O
- None None O
DR None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

At None None O
a None None O
5 None None O
: None None O
1 None None O
ratio None None O
( None None O
NK None None O
/ None None O
DC None None O
) None None O
most None None O
of None None O
the None None O
DCs None None O
are None None O
nonviable None None O
( None None O
Fig None None O
. None None O
4 None None O
J None None O
- None None O
L None None O
) None None O
. None None O

Addition None None O
of None None O
suboptimal None None O
doses None None O
of None None O
LPS None None O
( None None O
Fig None None O
. None None O
4 None None O
C None None O
, None None O
F None None O
, None None O
I None None O
, None None O
and None None O
L None None O
) None None O
augmented None None O
the None None O
NK None None O
- None None O
induced None None O
maturation None None O
at None None O
NK None None O
/ None None O
DC None None O
ratios None None O
of None None O
1 None None O
: None None O
5 None None O
and None None O
1 None None O
: None None O
1 None None O
, None None O
but None None O
had None None O
no None None O
effect None None O
at None None O
the None None O
5 None None O
: None None O
1 None None O
ratio None None O
. None None O

Again None None O
, None None O
DC None None O
maturation None None O
was None None O
dependent None None O
on None None O
NK None None O
cell None None O
contact None None O
and None None O
endogenously None None O
produced None None O
TNF None None O
- None None O
alpha None None O
, None None O
because None None O
it None None O
did None None O
not None None O
occur None None O
when None None O
the None None O
two None None O
cell None None O
types None None O
were None None O
separated None None O
in None None O
trans None None O
- None None O
wells None None O
or None None O
upon None None O
the None None O
addition None None O
of None None O
a None None O
neutralizing None None O
antibody None None O
for None None O
TNF None None O
- None None O
alpha None None O
( None None O
Fig None None O
. None None O
5 None None O
) None None O
. None None O

Moreover None None O
, None None O
addition None None O
of None None O
blocking None None O
reagents None None O
for None None O
CD80 None None O
, None None O
CD86 None None O
, None None O
CD154 None None O
, None None O
CD95 None None O
, None None O
CD11a None None O
, None None O
CD50 None None O
, None None O
IL None None O
- None None O
12 None None O
, None None O
IFN None None O
- None None O
gamma None None O
, None None O
IFN None None O
- None None O
alpha None None O
, None None O
or None None O
IFN None None O
- None None O
beta None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
NK None None O
- None None O
induced None None O
maturation None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Figure None None O
4 None None O
. None None O

Activated None None O
/ None None O
cultured None None O
NK None None O
cell None None O
- None None O
mediated None None O
maturation None None O
/ None None O
death None None O
of None None O
DCs None None O
. None None O

Cultured None None O
iDCs None None O
were None None O
incubated None None O
for None None O
48 None None O
h None None O
, None None O
alone None None O
( None None O
A None None O
- None None O
C None None O
) None None O
, None None O
or None None O
with None None O
NK None None O
cells None None O
at None None O
the None None O
following None None O
ratios None None O
( None None O
NK None None O
/ None None O
DC None None O
) None None O
, None None O
1 None None O
: None None O
5 None None O
( None None O
D None None O
- None None O
F None None O
) None None O
, None None O
1 None None O
: None None O
1 None None O
( None None O
G None None O
- None None O
I None None O
) None None O
, None None O
and None None O
5 None None O
: None None O
1 None None O
( None None O
J None None O
- None None O
L None None O
) None None O
. None None O

Forward None None O
versus None None O
side None None O
scatter None None O
plots None None O
( None None O
A None None O
, None None O
D None None O
, None None O
G None None O
, None None O
and None None O
J None None O
) None None O
show None None O
the None None O
gating None None O
on None None O
the None None O
DC None None O
subset None None O
and None None O
demonstrate None None O
its None None O
disappearance None None O
at None None O
the None None O
5 None None O
: None None O
1 None None O
( None None O
NK None None O
/ None None O
DC None None O
) None None O
ratio None None O
( None None O
J None None O
) None None O
. None None O

Propidium None None O
iodide None None O
staining None None O
of None None O
the None None O
NK None None O
/ None None O
DC None None O
( None None O
5 None None O
: None None O
1 None None O
) None None O
cultures None None O
confirmed None None O
the None None O
almost None None O
complete None None O
absence None None O
of None None O
viable None None O
DCs None None O
( None None O
data None None O
not None None O
shown None None O
) None None O
. None None O

Staining None None O
for None None O
CD86 None None O
expression None None O
was None None O
performed None None O
as None None O
described None None O
in None None O
Fig None None O
. None None O

1 None None O
and None None O
the None None O
histograms None None O
are None None O
shown None None O
for None None O
DCs None None O
cultured None None O
in None None O
the None None O
presence None None O
( None None O
C None None O
, None None O
F None None O
, None None O
I None None O
, None None O
and None None O
L None None O
) None None O
or None None O
absence None None O
( None None O
B None None O
, None None O
E None None O
, None None O
H None None O
, None None O
and None None O
K None None O
) None None O
of None None O
1 None None O
ng None None O
/ None None O
ml None None O
of None None O
LPS None None O
. None None O

Results None None O
are None None O
representative None None O
of None None O
six None None O
experiments None None O
performed None None O
. None None O

Figure None None O
5 None None O
. None None O

Activated None None O
/ None None O
cultured None None O
NK None None O
cell None None O
- None None O
induced None None O
DC None None O
maturation None None O
is None None O
dependent None None O
on None None O
cell None None O
- None None O
to None None O
- None None O
cell None None O
contact None None O
and None None O
endogenous None None O
TNF None None O
- None None O
alpha None None O
production None None O
. None None O

Cultured None None O
iDCs None None O
were None None O
incubated None None O
alone None None O
( None None O
A None None O
, None None O
D None None O
, None None O
and None None O
G None None O
) None None O
; None None O
with None None O
activated None None O
NK None None O
cells None None O
at None None O
an None None O
NK None None O
/ None None O
DC None None O
ratio None None O
of None None O
1 None None O
: None None O
5 None None O
( None None O
B None None O
, None None O
E None None O
, None None O
and None None O
H None None O
) None None O
; None None O
with None None O
activated None None O
NK None None O
cells None None O
( None None O
NK None None O
/ None None O
DC None None O
; None None O
1 None None O
: None None O
5 None None O
) None None O
separated None None O
in None None O
trans None None O
- None None O
wells None None O
( None None O
C None None O
and None None O
F None None O
) None None O
; None None O
or None None O
with None None O
activated None None O
NK None None O
cells None None O
and None None O
10 None None O
mug None None O
/ None None O
ml None None O
of None None O
a None None O
neutralizing None None O
antibody None None O
for None None O
TNF None None O
- None None O
alpha None None O
( None None O
I None None O
) None None O
. None None O

LPS None None O
concentrations None None O
used None None O
were None None O
: None None O
0 None None O
ng None None O
/ None None O
ml None None O
( None None O
A None None O
- None None O
C None None O
) None None O
; None None O
10 None None O
ng None None O
/ None None O
ml None None O
( None None O
D None None O
- None None O
F None None O
) None None O
and None None O
50 None None O
ng None None O
/ None None O
ml None None O
( None None O
G None None O
- None None O
I None None O
) None None O
. None None O

CD86 None None O
staining None None O
of None None O
the None None O
DC None None O
subset None None O
was None None O
performed None None O
as None None O
in None None O
Figs None None O
. None None O

1 None None O
and None None O
4 None None O
. None None O

Results None None O
are None None O
representative None None O
of None None O
four None None O
experiments None None O
performed None None O
. None None O

Loss None None O
of None None O
body None None O
weight None None O
after None None O
challenge None None O
- None None O
infection None None O
with None None O
WNV None None O
. None None O

Mice None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
were None None O
vaccinated None None O
intranasally None None O
with None None O
Flu None None O
- None None O
NA None None O
- None None O
DIII None None O
( None None O
* None None O
) None None O
or None None O
Flu None None O
- None None O
NA None None O
- None None O
GFP None None O
( None None O
o None None O
) None None O
or None None O
by None None O
the None None O
subcutaneous None None O
route None None O
( None None O
^ None None O
and None None O
^ None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
daily None None O
weights None None O
of None None O
each None None O
animal None None O
were None None O
calculated None None O
compared None None O
to None None O
their None None O
respective None None O
weight None None O
on None None O
the None None O
day None None O
of None None O
challenge None None O
, None None O
and None None O
data None None O
are None None O
shown None None O
as None None O
the None None O
average None None O
percentage None None O
of None None O
initial None None O
weight None None O
for None None O
each None None O
group None None O
. None None O

Error None None O
bars None None O
represent None None O
the None None O
standard None None O
error None None O
for None None O
all None None O
samples None None O
available None None O
at None None O
that None None O
time None None O
point None None O
. None None O

Subsequently None None O
, None None O
the None None O
mice None None O
were None None O
challenged None None O
subcutaneously None None O
with None None O
106 None None O
TCID50 None None O
WNV None None O
- None None O
NY99 None None O
and None None O
weighed None None O
daily None None O
. None None O

The None None O
mean None None O
body None None O
weight None None O
is None None O
expressed None None O
as None None O
the None None O
percentage None None O
of None None O
the None None O
body None None O
weight None None O
before None None O
challenge None None O
infection None None O
( None None O
A None None O
) None None O
. None None O

The None None O
survival None None O
rates None None O
of None None O
mice None None O
after None None O
challenge None None O
infection None None O
with None None O
WNV None None O
- None None O
NY99 None None O
are None None O
depicted None None O
as None None O
Kaplan None None O
- None None O
Meier None None O
survival None None O
curves None None O
( None None O
B None None O
) None None O
. None None O

The None None O
difference None None O
in None None O
survival None None O
rate None None O
between None None O
Flu None None O
- None None O
NA None None O
- None None O
DIII None None O
and None None O
Flu None None O
- None None O
NA None None O
- None None O
GFP None None O
vaccinated None None O
mice None None O
was None None O
statistically None None O
significant None None O
as None None O
determined None None O
by None None O
the None None O
logrank None None O
test None None O
. None None O

The None None O
symbols None None O
for None None O
the None None O
respective None None O
groups None None O
are None None O
the None None O
same None None O
as None None O
in None None O
panel None None O
A None None O
. None None O

Hypothetical None None O
distribution None None O
patterns None None O
of None None O
the None None O
meadow None None O
brown None None O
Maniola None None O
jurtina None None O
in None None O
Europe None None O
during None None O
the None None O
last None None O
glacial None None O
maximum None None O
( None None O
dark None None O
hatched None None O
areas None None O
) None None O
. None None O

Postglacial None None O
expansions None None O
are None None O
indicated None None O
by None None O
solid None None O
arrows None None O
. None None O

The None None O
postulated None None O
actual None None O
hybrid None None O
zone None None O
is None None O
shown None None O
by None None O
the None None O
hatched None None O
area None None O
. None None O

Question None None O
marks None None O
indicate None None O
lack None None O
of None None O
information None None O
concerning None None O
ancient None None O
distribution None None O
patterns None None O
in None None O
the None None O
South None None O
and None None O
present None None O
distribution None None O
of None None O
hybrid None None O
populations None None O
in None None O
the None None O
North None None O
. None None O

Redrawn None None O
from None None O
Schmitt None None O
et None None O
. None None O

al None None O
. None None O

[ None None O
36 None None O
] None None O
; None None O
based None None O
on None None O
Thomson None None O
[ None None O
37 None None O
] None None O
and None None O
Schmitt None None O
et None None O
al None None O
. None None O

[ None None O
36 None None O
] None None O
. None None O

Paederus None None O
dermatitis None None O
involving None None O
the None None O
neck None None O

Effectiveness None None O
of None None O
different None None O
approaches None None O
for None None O
establishing None None O
cisplatin None None O
- None None O
induced None None O
cochlear None None O
lesions None None O
in None None O
mice None None O
. None None O

CONCLUSIONS None None O
: None None O

Mouse None None O
cochleae None None O
are None None O
highly None None O
resistant None None O
to None None O
systemically None None O
administered None None O
cisplatin None None O
. None None O

However None None O
, None None O
cochlear None None O
lesions None None O
can None None O
be None None O
produced None None O
effectively None None O
in None None O
mice None None O
when None None O
cisplatin None None O
is None None O
applied None None O
locally None None O
through None None O
the None None O
round None None O
window None None O
niche None None O
or None None O
tympanum None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
explore None None O
the None None O
optimal None None O
approach None None O
for None None O
creating None None O
cisplatin None None O
- None None O
induced None None O
cochlear None None O
lesions None None O
in None None O
mice None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O

Cisplatin None None O
was None None O
administered None None O
to None None O
adult None None O
C57BL None None O
/ None None O
6J None None O
mice None None O
via None None O
four None None O
approaches None None O
: None None O
( None None O
1 None None O
) None None O
transtympanic None None O
injection None None O
, None None O
( None None O
2 None None O
) None None O
round None None O
window None None O
niche None None O
injection None None O
, None None O
( None None O
3 None None O
) None None O
intraperitoneal None None O
injection None None O
( None None O
i None None O
. None None O
p None None O
. None None O
) None None O
at None None O
4 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
for None None O
4 None None O
consecutive None None O
days None None O
, None None O
and None None O
( None None O
4 None None O
) None None O
one None None O
15 None None O
mg None None O
/ None None O
kg None None O
dose None None O
i None None O
. None None O
p None None O
. None None O

The None None O
hearing None None O
was None None O
monitored None None O
using None None O
frequency None None O
- None None O
specific None None O
auditory None None O
brainstem None None O
responses None None O
( None None O
ABRs None None O
) None None O
and None None O
distortion None None O
- None None O
product None None O
otoacoustic None None O
emissions None None O
( None None O
DPOAEs None None O
) None None O
. None None O

Cochlear None None O
pathology None None O
was None None O
observed None None O
in None None O
cochleograms None None O
with None None O
Harris None None O
' None None O
hematoxylin None None O
staining None None O
. None None O

RESULTS None None O
: None None O

Cisplatin None None O
applied None None O
systemically None None O
did None None O
not None None O
cause None None O
any None None O
significant None None O
ABR None None O
threshold None None O
elevation None None O
across None None O
the None None O
frequencies None None O
tested None None O
( None None O
2 None None O
- None None O
32 None None O
kHz None None O
) None None O
, None None O
whereas None None O
local None None O
application None None O
of None None O
cisplatin None None O
through None None O
the None None O
round None None O
window None None O
niche None None O
or None None O
tympanum None None O
resulted None None O
in None None O
significant None None O
ABR None None O
threshold None None O
elevations None None O
from None None O
high None None O
to None None O
medium None None O
frequencies None None O
. None None O

The None None O
functional None None O
changes None None O
were None None O
consistent None None O
with None None O
the None None O
cochlear None None O
pathology None None O
across None None O
groups None None O
. None None O

Enhancement None None O
of None None O
skin None None O
permeation None None O
of None None O
ketotifen None None O
by None None O
supersaturation None None O
generated None None O
by None None O
amorphous None None O
form None None O
of None None O
the None None O
drug None None O
. None None O

Pressure None None O
sensitive None None O
adhesive None None O
( None None O
PSA None None O
) None None O
matrices None None O
containing None None O
amorphous None None O
ketotifen None None O
were None None O
prepared None None O
and None None O
evaluated None None O
for None None O
enhanced None None O
skin None None O
permeability None None O
of None None O
the None None O
drug None None O
. None None O

A None None O
solvent None None O
casting None None O
method None None O
using None None O
silicone None None O
- None None O
typed None None O
PSA None None O
was None None O
employed None None O
, None None O
and None None O
n None None O
- None None O
hexane None None O
, None None O
an None None O
original None None O
solvent None None O
for None None O
the None None O
PSA None None O
and None None O
one None None O
more None None O
solvent None None O
, None None O
dichloromethane None None O
, None None O
tetrahydrofuran None None O
, None None O
acetone None None O
, None None O
ethyl None None O
acetate None None O
or None None O
toluene None None O
, None None O
were None None O
used None None O
for None None O
complete None None O
dissolution None None O
of None None O
ketotifen None None O
and None None O
high None None O
dispersion None None O
in None None O
an None None O
amorphous None None O
state None None O
of None None O
the None None O
drug None None O
. None None O

Presence None None O
of None None O
the None None O
amorphous None None O
form None None O
was None None O
judged None None O
based None None O
on None None O
the None None O
in None None O
vitro None None O
drug None None O
release None None O
rate None None O
from None None O
the None None O
matrix None None O
. None None O

As None None O
a None None O
result None None O
, None None O
dichloromethane None None O
and None None O
tetrahudrofuran None None O
were None None O
selected None None O
as None None O
appropriate None None O
dilution None None O
solvents None None O
. None None O

In None None O
vitro None None O
permeation None None O
experiments None None O
through None None O
excised None None O
hairless None None O
mouse None None O
skin None None O
revealed None None O
that None None O
the None None O
steady None None O
- None None O
state None None O
flux None None O
from None None O
the None None O
amorphous None None O
ketotifen None None O
- None None O
dispersed None None O
matrices None None O
was None None O
about None None O
five None None O
times None None O
greater None None O
than None None O
that None None O
of None None O
the None None O
crystalline None None O
ketotifen None None O
- None None O
dispersed None None O
matrices None None O
, None None O
and None None O
that None None O
the None None O
enhancement None None O
ratio None None O
was None None O
in None None O
good None None O
agreement None None O
with None None O
the None None O
solubility None None O
ratio None None O
of None None O
the None None O
amorphous None None O
to None None O
crystalline None None O
form None None O
of None None O
the None None O
drug None None O
. None None O

Comparison None None O
of None None O
the None None O
skin None None O
permeation None None O
profiles None None O
of None None O
amorphous None None O
ketotifen None None O
- None None O
dispersed None None O
matrices None None O
between None None O
two None None O
different None None O
drug None None O
contents None None O
suggested None None O
that None None O
the None None O
steady None None O
- None None O
state None None O
flux None None O
was None None O
not None None O
influenced None None O
by None None O
the None None O
drug None None O
content None None O
. None None O

In None None O
addition None None O
, None None O
at None None O
both None None O
drug None None O
contents None None O
, None None O
the None None O
period None None O
of None None O
the None None O
steady None None O
- None None O
state None None O
permeation None None O
coincided None None O
with None None O
the None None O
time None None O
until None None O
the None None O
amorphous None None O
drug None None O
was None None O
depleted None None O
from None None O
the None None O
matrix None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
increase None None O
in None None O
skin None None O
permeation None None O
of None None O
ketotifen None None O
from None None O
PSA None None O
matrix None None O
was None None O
due None None O
to None None O
the None None O
supersaturation None None O
generated None None O
by None None O
amorphous None None O
form None None O
, None None O
and None None O
that None None O
the None None O
amorphous None None O
form None None O
was None None O
stable None None O
during None None O
the None None O
application None None O
period None None O
. None None O

Characterization None None O
of None None O
the None None O
metabolic None None O
changes None None O
underlying None None O
growth None None O
factor None None O
angiogenic None None O
activation None None O
: None None O
identification None None O
of None None O
new None None O
potential None None O
therapeutic None None O
targets None None O
. None None O

Angiogenesis None None O
is None None O
a None None O
fundamental None None O
process None None O
to None None O
normal None None O
and None None O
abnormal None None O
tissue None None O
growth None None O
and None None O
repair None None O
, None None O
which None None O
consists None None O
of None None O
recruiting None None O
endothelial None None O
cells None None O
toward None None O
an None None O
angiogenic None None O
stimulus None None O
. None None O

The None None O
cells None None O
subsequently None None O
proliferate None None O
and None None O
differentiate None None O
to None None O
form None None O
endothelial None None O
tubes None None O
and None None O
capillary None None O
- None None O
like None None O
structures None None O
. None None O

Little None None O
is None None O
known None None O
about None None O
the None None O
metabolic None None O
adaptation None None O
of None None O
endothelial None None O
cells None None O
through None None O
such None None O
a None None O
transformation None None O
. None None O

We None None O
studied None None O
the None None O
metabolic None None O
changes None None O
of None None O
endothelial None None O
cell None None O
activation None None O
by None None O
growth None None O
factors None None O
using None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVECs None None O
) None None O
, None None O
[ None None O
1 None None O
, None None O
2 None None O
- None None O
( None None O
13 None None O
) None None O
C None None O
( None None O
2 None None O
) None None O
] None None O
- None None O
glucose None None O
and None None O
mass None None O
isotopomer None None O
distribution None None O
analysis None None O
. None None O

The None None O
metabolism None None O
of None None O
[ None None O
1 None None O
, None None O
2 None None O
- None None O
( None None O
13 None None O
) None None O
C None None O
( None None O
2 None None O
) None None O
] None None O
- None None O
glucose None None O
by None None O
HUVEC None None O
allows None None O
us None None O
to None None O
trace None None O
many None None O
of None None O
the None None O
main None None O
glucose None None O
metabolic None None O
pathways None None O
, None None O
including None None O
glycogen None None O
synthesis None None O
, None None O
the None None O
pentose None None O
cycle None None O
and None None O
the None None O
glycolytic None None O
pathways None None O
. None None O

So None None O
we None None O
established None None O
that None None O
these None None O
pathways None None O
were None None O
crucial None None O
to None None O
endothelial None None O
cell None None O
proliferation None None O
under None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
fibroblast None None O
growth None None O
factor None None O
( None None O
FGF None None O
) None None O
stimulation None None O
. None None O

A None None O
specific None None O
VEGF None None O
receptor None None O
- None None O
2 None None O
inhibitor None None O
demonstrated None None O
the None None O
importance None None O
of None None O
glycogen None None O
metabolism None None O
and None None O
pentose None None O
cycle None None O
pathway None None O
. None None O

Furthermore None None O
, None None O
we None None O
showed None None O
that None None O
glycogen None None O
was None None O
depleted None None O
in None None O
a None None O
low None None O
glucose None None O
medium None None O
, None None O
but None None O
conserved None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

Finally None None O
, None None O
we None None O
demonstrated None None O
that None None O
direct None None O
inhibition None None O
of None None O
key None None O
enzymes None None O
to None None O
glycogen None None O
metabolism None None O
and None None O
pentose None None O
phosphate None None O
pathways None None O
reduced None None O
HUVEC None None O
viability None None O
and None None O
migration None None O
. None None O

In None None O
this None None O
regard None None O
, None None O
inhibitors None None O
of None None O
these None None O
pathways None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
effective None None O
antitumoral None None O
agents None None O
. None None O

To None None O
sum None None O
up None None O
, None None O
our None None O
data None None O
suggest None None O
that None None O
the None None O
inhibition None None O
of None None O
metabolic None None O
pathways None None O
offers None None O
a None None O
novel None None O
and None None O
powerful None None O
therapeutic None None O
approach None None O
, None None O
which None None O
simultaneously None None O
inhibits None None O
tumor None None O
cell None None O
proliferation None None O
and None None O
tumor None None O
- None None O
induced None None O
angiogenesis None None O
. None None O

Fluoro None None O
- None None O
Jade None None O
B None None O
staining None None O
following None None O
zymosan None None O
microinjection None None O
into None None O
the None None O
spinal None None O
cord None None O
white None None O
matter None None O
. None None O

1 None None O
. None None O

The None None O
fluorescein None None O
derivate None None O
Fluoro None None O
- None None O
Jade None None O
B None None O
( None None O
FJB None None O
) None None O
, None None O
which None None O
primarily None None O
labels None None O
dead None None O
or None None O
dying None None O
neurons None None O
, None None O
was None None O
used None None O
to None None O
study None None O
the None None O
acute None None O
focal None None O
inflammation None None O
in None None O
the None None O
spinal None None O
cord None None O
white None None O
matter None None O
. None None O

Inflammation None None O
was None None O
induced None None O
by None None O
microinjection None None O
of None None O
the None None O
yeast None None O
particulate None None O
zymosan None None O
to None None O
evaluate None None O
the None None O
biological None None O
effects None None O
of None None O
intraspinal None None O
macrophages None None O
activation None None O
without None None O
the None None O
confounding None None O
effects None None O
of None None O
physical None None O
trauma None None O
. None None O

2 None None O
. None None O

A None None O
single None None O
bolus None None O
of None None O
zymosan None None O
( None None O
Sigma None None O
, None None O
75 None None O
nL None None O
) None None O
was None None O
stereotaxically None None O
injected None None O
at None None O
the None None O
thoracic None None O
level None None O
into None None O
the None None O
lateral None None O
white None None O
matter None None O
of None None O
rat None None O
spinal None None O
cord None None O
. None None O

A None None O
standard None None O
Fluoro None None O
- None None O
Jade None None O
B None None O
staining None None O
protocol None None O
was None None O
applied None None O
to None None O
spinal None None O
cord None None O
sections None None O
at None None O
6 None None O
, None None O
12 None None O
, None None O
24 None None O
h None None O
and None None O
2 None None O
, None None O
4 None None O
days None None O
postinjection None None O
. None None O

Neutral None None O
Red None None O
, None None O
NADPH None None O
- None None O
diaphorase None None O
, None None O
Iba1 None None O
- None None O
IR None None O
, None None O
and None None O
DAPI None None O
staining None None O
protocols None None O
accomplished None None O
examination None None O
of None None O
the None None O
cells None None O
participating None None O
in None None O
the None None O
acute None None O
inflammatory None None O
response None None O
. None None O

3 None None O
. None None O

Zymosan None None O
caused None None O
formation None None O
of None None O
clearly None None O
delineated None None O
inflammation None None O
lesions None None O
localized None None O
in None None O
the None None O
lateral None None O
white None None O
matter None None O
of None None O
the None None O
spinal None None O
cord None None O
. None None O

Fluoro None None O
- None None O
Jade None None O
B None None O
stained None None O
cells None None O
in None None O
the None None O
area None None O
of None None O
inflammation None None O
were None None O
not None None O
observed None None O
at None None O
12 None None O
h None None O
postinjection None None O
while None None O
mild None None O
FJB None None O
staining None None O
appeared None None O
at None None O
24 None None O
h None None O
and None None O
intense None None O
staining None None O
was None None O
observed None None O
at None None O
2 None None O
and None None O
4 None None O
days None None O
postinjection None None O
. None None O

4 None None O
. None None O

This None None O
study None None O
shows None None O
that None None O
the None None O
acute None None O
response None None O
to None None O
zymosan None None O
- None None O
induced None None O
inflammation None None O
in None None O
the None None O
rat None None O
spinal None None O
cord None None O
white None None O
matter None None O
causes None None O
a None None O
gradual None None O
appearance None None O
of None None O
phagocytic None None O
microglia None None O
/ None None O
macrophages None None O
and None None O
delayed None None O
FJB None None O
staining None None O
of None None O
the None None O
inflammatory None None O
cells None None O
. None None O

5 None None O
. None None O

FJB None None O
, None None O
a None None O
reliable None None O
marker None None O
of None None O
dying None None O
neurons None None O
, None None O
is None None O
a None None O
more None None O
universal None None O
agent None None O
than None None O
formerly None None O
believed None None O
. None None O

One None None O
possible None None O
explanation None None O
for None None O
the None None O
gradual None None O
appearance None None O
of None None O
FJB None None O
- None None O
stained None None O
cells None None O
in None None O
the None None O
area None None O
of None None O
inflammation None None O
is None None O
that None None O
specific None None O
time None None O
is None None O
required None None O
for None None O
sufficient None None O
levels None None O
of None None O
proteins None None O
and None None O
/ None None O
or None None O
myelin None None O
debris None None O
of None None O
axonal None None O
origin None None O
to None None O
appear None None O
in None None O
the None None O
cytoplasm None None O
of None None O
phagocytic None None O
microglia None None O
/ None None O
macrophages None None O
. None None O

Measured None None O
analytes None None O
in None None O
five None None O
biologic None None O
sample None None O
matrices None None O
. None None O
a None None O

Activated None None O
platelets None None O
enhance None None O
ovarian None None O
cancer None None O
cell None None O
invasion None None O
in None None O
a None None O
cellular None None O
model None None O
of None None O
metastasis None None O
. None None O

Increased None None O
platelet None None O
counts None None O
and None None O
systemic None None O
coagulation None None O
activation None None O
are None None O
associated None None O
with None None O
ovarian None None O
cancer None None O
progression None None O
. None None O

Platelet None None O
activation None None O
occurs None None O
in None None O
the None None O
tumor None None O
microenvironment None None O
and None None O
may None None O
influence None None O
local None None O
invasion None None O
and None None O
metastasis None None O
. None None O

We None None O
used None None O
a None None O
cellular None None O
model None None O
of None None O
tumor None None O
invasion None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
activated None None O
platelets None None O
on None None O
the None None O
human None None O
ovarian None None O
cancer None None O
cell None None O
line None None O
, None None O
SKOV3 None None I-Cell-line-name
. None None O

SKOV3 None None I-Cell-line-name
cells None None O
were None None O
exposed None None O
to None None O
washed None None O
, None None O
thrombin None None O
receptor None None O
activating None None O
peptide None None O
( None None O
TRAP None None O
) None None O
- None None O
activated None None O
or None None O
TRAP None None O
- None None O
naive None None O
platelets None None O
under None None O
various None None O
experimental None None O
conditions None None O
, None None O
and None None O
tumor None None O
cell None None O
invasion None None O
was None None O
assayed None None O
in None None O
Matrigel None None O
chambers None None O
. None None O

The None None O
effect None None O
of None None O
platelets None None O
on None None O
the None None O
content None None O
of None None O
urokinase None None O
plasminogen None None O
activator None None O
( None None O
uPA None None O
) None None O
and None None O
VEGF None None O
in None None O
SKOV3 None None I-Cell-line-name
cell None None O
conditioned None None O
medium None None O
was None None O
measured None None O
using None None O
an None None O
ELISA None None O
assay None None O
. None None O

TRAP None None O
- None None O
activated None None O
platelets None None O
stimulated None None O
a None None O
dose None None O
- None None O
dependent None None O
increase None None O
in None None O
SKOV3 None None I-Cell-line-name
cell None None O
invasion None None O
. None None O

Exposure None None O
to None None O
activated None None O
platelet None None O
membranes None None O
and None None O
to None None O
soluble None None O
proteins None None O
contained None None O
in None None O
activated None None O
platelet None None O
releasate None None O
both None None O
contributed None None O
to None None O
the None None O
observed None None O
increase None None O
in None None O
invasion None None O
. None None O

The None None O
inhibition None None O
of None None O
platelet None None O
activation None None O
with None None O
prostaglandin None None O
E1 None None O
( None None O
PGE None None O
( None None O
1 None None O
) None None O
) None None O
attenuated None None O
the None None O
invasive None None O
capacity None None O
of None None O
SKOV3 None None I-Cell-line-name
cells None None O
. None None O

Exposure None None O
to None None O
platelets None None O
resulted None None O
in None None O
significantly None None O
increased None None O
uPA None None O
and None None O
VEGF None None O
content None None O
of None None O
SKOV3 None None I-Cell-line-name
cell None None O
conditioned None None O
medium None None O
. None None O

Activated None None O
platelets None None O
enhance None None O
SKOV3 None None I-Cell-line-name
human None None O
ovarian None None O
cancer None None O
cell None None O
invasion None None O
through None None O
Matrigel None None O
and None None O
increase None None O
the None None O
amount None None O
of None None O
uPA None None O
and None None O
VEGF None None O
secreted None None O
into None None O
SKOV3 None None I-Cell-line-name
cell None None O
conditioned None None O
medium None None O
. None None O

If None None O
generalizable None None O
to None None O
additional None None O
cell None None O
lines None None O
and None None O
human None None O
disease None None O
, None None O
this None None O
observation None None O
may None None O
partially None None O
explain None None O
the None None O
adverse None None O
prognosis None None O
associated None None O
with None None O
thrombocytosis None None O
in None None O
ovarian None None O
cancer None None O
. None None O

Platelets None None O
, None None O
therefore None None O
, None None O
may None None O
represent None None O
a None None O
potential None None O
target None None O
for None None O
therapeutic None None O
intervention None None O
in None None O
human None None O
ovarian None None O
cancer None None O
. None None O

Some None None O
findings None None O
concerning None None O
beliefs None None O
about None None O
alcoholism None None O
. None None O

The None None O
beliefs None None O
that None None O
alcoholics None None O
hold None None O
about None None O
alcoholism None None O
and None None O
themselves None None O
, None None O
and None None O
the None None O
beliefs None None O
that None None O
hospital None None O
staff None None O
and None None O
other None None O
personnel None None O
hold None None O
about None None O
alcoholism None None O
, None None O
were None None O
investigated None None O
using None None O
methods None None O
derived None None O
from None None O
the None None O
repertory None None O
grid None None O
, None None O
with None None O
anonymous None None O
facial None None O
photographs None None O
as None None O
elements None None O
. None None O

Data None None O
are None None O
presented None None O
as None None O
to None None O
the None None O
degree None None O
of None None O
association None None O
of None None O
various None None O
characteristics None None O
with None None O
alcoholism None None O
for None None O
the None None O
various None None O
groups None None O
. None None O

Differences None None O
between None None O
groups None None O
, None None O
and None None O
overall None None O
changes None None O
during None None O
group None None O
psychotherapy None None O
for None None O
patients None None O
were None None O
small None None O
. None None O

The None None O
relative None None O
contribution None None O
of None None O
personal None None O
and None None O
shared None None O
aspects None None O
of None None O
belief None None O
was None None O
measured None None O
. None None O

It None None O
was None None O
found None None O
that None None O
the None None O
agreement None None O
between None None O
groups None None O
was None None O
high None None O
and None None O
closely None None O
similar None None O
to None None O
that None None O
predictable None None O
from None None O
consistencies None None O
within None None O
groups None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
there None None O
may None None O
be None None O
a None None O
very None None O
general None None O
stereotype None None O
of None None O
alcoholism None None O
, None None O
consistent None None O
with None None O
a None None O
personality None None O
disorder None None O
concept None None O
which None None O
is None None O
implicitly None None O
held None None O
even None None O
in None None O
the None None O
face None None O
of None None O
nominal None None O
acceptance None None O
of None None O
other None None O
concepts None None O
. None None O

The None None O
self None None O
constructs None None O
of None None O
alcoholics None None O
were None None O
found None None O
to None None O
be None None O
complex None None O
. None None O

In None None O
a None None O
small None None O
follow None None O
- None None O
up None None O
study None None O
of None None O
patients None None O
, None None O
there None None O
was None None O
found None None O
to None None O
be None None O
a None None O
relationship None None O
of None None O
poor None None O
outcome None None O
with None None O
tightness None None O
of None None O
construing None None O
for None None O
key None None O
constructs None None O
after None None O
psychotherapy None None O
. None None O

The None None O
implications None None O
of None None O
the None None O
findings None None O
are None None O
discussed None None O
briefly None None O
. None None O

Neuroblastoma None None O
and None None O
hepatocyte None None O
coculture None None O
conditioned None None O
media None None O
alter None None O
apoptosis None None O
. None None O

BACKGROUND None None O
: None None O
Neuroblastoma None None O
is None None O
a None None O
childhood None None O
tumor None None O
that None None O
often None None O
displays None None O
unusual None None O
biological None None O
behavior None None O
. None None O

The None None O
tumor None None O
may None None O
present None None O
with None None O
widespread None None O
metastases None None O
that None None O
are None None O
unresponsive None None O
to None None O
aggressive None None O
treatment None None O
. None None O

At None None O
other None None O
times None None O
, None None O
both None None O
the None None O
metastases None None O
and None None O
the None None O
primary None None O
tumor None None O
may None None O
spontaneously None None O
regress None None O
without None None O
treatment None None O
. None None O

Apoptosis None None O
, None None O
or None None O
programmed None None O
cell None None O
death None None O
, None None O
is None None O
thought None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
dichotomous None None O
behavior None None O
of None None O
neuroblastoma None None O
. None None O

We None None O
hypothesize None None O
that None None O
neuroblastoma None None O
cells None None O
will None None O
interact None None O
with None None O
host None None O
tissues None None O
to None None O
release None None O
mediators None None O
that None None O
affect None None O
apoptosis None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Human None None O
neuroblastoma None None O
cells None None O
and None None O
human None None O
Chang None None O
hepatocytes None None O
are None None O
grown None None O
in None None O
a None None O
noncontact None None O
, None None O
coculture None None O
system None None O
. None None O

After None None O
incubation None None O
for None None O
4 None None O
days None None O
, None None O
the None None O
medium None None O
from None None O
the None None O
coculture None None O
system None None O
is None None O
collected None None O
. None None O

Neuroblastoma None None O
cells None None O
and None None O
Chang None None O
hepatocytes None None O
are None None O
then None None O
plated None None O
separately None None O
with None None O
the None None O
conditioned None None O
medium None None O
and None None O
their None None O
own None None O
standard None None O
growth None None O
medium None None O
as None None O
controls None None O
. None None O

After None None O
4 None None O
days None None O
, None None O
these None None O
cells None None O
are None None O
harvested None None O
and None None O
cytospins None None O
made None None O
for None None O
immunostaining None None O
. None None O

Tumor None None O
necrosis None None O
factor None None O
alpha None None O
( None None O
TNF None None O
- None None O
alpha None None O
) None None O
, None None O
Fas None None O
ligand None None O
, None None O
and None None O
Bcl None None O
- None None O
2 None None O
, None None O
are None None O
measured None None O
with None None O
immunohistochemistry None None O
. None None O

Apoptosis None None O
is None None O
detected None None O
with None None O
the None None O
TUNEL None None O
method None None O
. None None O

Immunostaining None None O
data None None O
are None None O
interpreted None None O
with None None O
computer None None O
image None None O
analysis None None O
and None None O
reported None None O
as None None O
stain None None O
index None None O
. None None O

TUNEL None None O
data None None O
are None None O
reported None None O
as None None O
percentage None None O
apoptotic None None O
cells None None O
. None None O

All None None O
data None None O
are None None O
reported None None O
as None None O
means None None O
+ None None O
/ None None O
- None None O
SEM None None O
. None None O

Statistical None None O
analysis None None O
is None None O
performed None None O
and None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
considered None None O
significant None None O
. None None O

RESULTS None None O
: None None O
Chang None None O
hepatocytes None None O
grown None None O
in None None O
the None None O
coculture None None O
conditioned None None O
media None None O
have None None O
an None None O
increase None None O
in None None O
TNF None None O
- None None O
alpha None None O
and None None O
Fas None None O
ligand None None O
. None None O

The None None O
neuroblastoma None None O
cells None None O
have None None O
a None None O
significant None None O
decrease None None O
in None None O
Fas None None O
ligand None None O
. None None O

There None None O
is None None O
a None None O
significant None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
apoptotic None None O
hepatocytes None None O
when None None O
they None None O
are None None O
cultured None None O
in None None O
the None None O
conditioned None None O
media None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
neuroblastoma None None O
cells None None O
grown None None O
in None None O
the None None O
coculture None None O
conditioned None None O
media None None O
show None None O
no None None O
increase None None O
in None None O
apoptosis None None O
. None None O

Finally None None O
, None None O
Bcl None None O
- None None O
2 None None O
is None None O
significantly None None O
increased None None O
in None None O
the None None O
neuroblastoma None None O
cells None None O
cultured None None O
in None None O
the None None O
conditioned None None O
media None None O
. None None O

CONCLUSIONS None None O
: None None O
Neuroblastoma None None O
cells None None O
grown None None O
in None None O
coculture None None O
conditioned None None O
media None None O
show None None O
increased None None O
expression None None O
of None None O
Bcl None None O
- None None O
2 None None O
and None None O
decreased None None O
Fas None None O
ligand None None O
levels None None O
. None None O

These None None O
changes None None O
should None None O
diminish None None O
apoptosis None None O
activity None None O
in None None O
the None None O
tumor None None O
cells None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
conditioned None None O
media None None O
induce None None O
elevated None None O
levels None None O
of None None O
proapoptotic None None O
mediators None None O
in None None O
the None None O
Chang None None O
hepatocytes None None O
. None None O

A None None O
tumor None None O
' None None O
s None None O
ability None None O
to None None O
successfully None None O
metastasize None None O
may None None O
be None None O
dependent None None O
on None None O
mediators None None O
generated None None O
in None None O
the None None O
tumor None None O
- None None O
host None None O
interaction None None O
, None None O
and None None O
may None None O
not None None O
be None None O
just None None O
an None None O
independent None None O
characteristic None None O
of None None O
the None None O
tumor None None O
itself None None O
. None None O

Background None None O

[ None None O
Photodynamic None None O
therapy None None O
in None None O
severe None None O
chronic None None O
central None None O
serous None None O
chorioretinopaty None None O
] None None O

OBJECTIVE None None O
: None None O
To None None O
determine None None O
the None None O
efficacy None None O
of None None O
Photodynamic None None O
Therapy None None O
( None None O
PDT None None O
) None None O
in None None O
chronic None None O
Central None None O
Serous None None O
Chorioretinopathy None None O
( None None O
CSC None None O
) None None O
. None None O

METHODS None None O
: None None O
Patients None None O
diagnosed None None O
with None None O
chronic None None O
CSC None None O
, None None O
with None None O
clinical None None O
evidence None None O
of None None O
activity None None O
and None None O
treated None None O
with None None O
Photodynamic None None O
Therapy None None O
, None None O
are None None O
included None None O
in None None O
this None None O
report None None O
. None None O

All None None O
were None None O
assessed None None O
by None None O
a None None O
complete None None O
ophthalmological None None O
examination None None O
, None None O
including None None O
assessment None None O
of None None O
the None None O
best None None O
corrected None None O
visual None None O
acuity None None O
( None None O
BCVA None None O
) None None O
using None None O
an None None O
ETDRS None None O
chart None None O
, None None O
fluorescein None None O
and None None O
indocyanine None None O
angiography None None O
and None None O
optical None None O
coherence None None O
tomography None None O
( None None O
OCT None None O
) None None O
. None None O

The None None O
main None None O
objective None None O
of None None O
the None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
mean None None O
visual None None O
acuity None None O
change None None O
. None None O

RESULTS None None O
: None None O
11 None None O
eyes None None O
of None None O
11 None None O
patients None None O
were None None O
included None None O
in None None O
the None None O
study None None O
, None None O
which None None O
had None None O
a None None O
mean None None O
follow None None O
- None None O
up None None O
period None None O
of None None O
11 None None O
months None None O
. None None O

The None None O
mean None None O
BCVA None None O
increased None None O
from None None O
20 None None O
/ None None O
76 None None O
to None None O
20 None None O
/ None None O
64 None None O
. None None O

35 None None O
% None None O
of None None O
eyes None None O
improved None None O
their None None O
BCVA None None O
by None None O
2 None None O
lines None None O
or None None O
more None None O
, None None O
45 None None O
% None None O
remained None None O
stable None None O
and None None O
18 None None O
% None None O
lost None None O
2 None None O
lines None None O
or None None O
more None None O
. None None O

Choroidal None None O
hyperpermeability None None O
was None None O
reduced None None O
in None None O
every None None O
case None None O
. None None O

Neurosensorial None None O
retinal None None O
detachment None None O
decreased None None O
in None None O
80 None None O
% None None O
of None None O
cases None None O
. None None O

Only None None O
one None None O
eye None None O
received None None O
a None None O
second None None O
PDT None None O
treatment None None O
due None None O
to None None O
choroidal None None O
neovascularization None None O
. None None O

An None None O
increase None None O
of None None O
atrophy None None O
over None None O
the None None O
Retinal None None O
Pigment None None O
Epithelium None None O
( None None O
RPE None None O
) None None O
was None None O
observed None None O
in None None O
another None None O
patient None None O
. None None O

CONCLUSIONS None None O
: None None O
PDT None None O
can None None O
reduce None None O
the None None O
clinical None None O
signs None None O
of None None O
activity None None O
, None None O
such None None O
as None None O
choroidal None None O
hyperpermeability None None O
or None None O
neurosensorial None None O
retinal None None O
detachment None None O
, None None O
in None None O
patients None None O
affected None None O
by None None O
chronic None None O
CSC None None O
. None None O

However None None O
, None None O
the None None O
increase None None O
in None None O
visual None None O
acuity None None O
is None None O
variable None None O
, None None O
probably None None O
due None None O
to None None O
the None None O
extent None None O
of None None O
RPE None None O
damage None None O
. None None O

Sex None None O
and None None O
age None None O
distributions None None O
of None None O
confirmed None None O
cases None None O

Of None None O
480 None None O
confirmed None None O
cases None None O
, None None O
56 None None O
% None None O
( None None O
269 None None O
/ None None O
480 None None O
) None None O
were None None O
male None None O
patients None None O
and None None O
44 None None O
% None None O
( None None O
211 None None O
/ None None O
480 None None O
) None None O
were None None O
female None None O
, None None O
respectively None None O
. None None O

The None None O
percentage None None O
of None None O
male None None O
cases None None O
was None None O
higher None None O
than None None O
that None None O
of None None O
females None None O
in None None O
all None None O
groups None None O
except None None O
for None None O
the None None O
group None None O
aged None None O
31 None None O
- None None O
40 None None O
( None None O
chi2 None None O
= None None O
42 None None O
. None None O
4 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

278 None None O
( None None O
57 None None O
. None None O
9 None None O
% None None O
) None None O
cases None None O
were None None O
in None None O
the None None O
group None None O
aged None None O
21 None None O
- None None O
50 None None O
, None None O
followed None None O
by None None O
102 None None O
( None None O
21 None None O
. None None O
3 None None O
% None None O
) None None O
, None None O
79 None None O
( None None O
16 None None O
. None None O
5 None None O
% None None O
) None None O
and None None O
21 None None O
( None None O
4 None None O
. None None O
4 None None O
% None None O
) None None O
cases None None O
in None None O
the None None O
group None None O
aged None None O
51 None None O
- None None O
70 None None O
, None None O
0 None None O
- None None O
20 None None O
, None None O
and None None O
> None None O
= None None O
71 None None O
, None None O
respectively None None O
. None None O

The None None O
youngest None None O
and None None O
oldest None None O
cases None None O
were None None O
1 None None O
. None None O
5 None None O
and None None O
81 None None O
years None None O
old None None O
, None None O
respectively None None O
( None None O
Table None None O
2 None None O
) None None O
. None None O

Table None None O
2 None None O

Age None None O
and None None O
occupational None None O
distributions None None O
and None None O
activities None None O
( None None O
1 None None O
- None None O
3 None None O
weeks None None O
prior None None O
to None None O
symptom None None O
appearance None None O
) None None O
of None None O
confirmed None None O
cases None None O

Cases None None O
( None None O
% None None O
) None None O
( None None O
Male None None O
: None None O
Female None None O
, None None O
% None None O
) None None O

Age None None O
( None None O
Years None None O
) None None O

0 None None O
- None None O
10 None None O
46 None None O
( None None O
9 None None O
. None None O
6 None None O
) None None O
( None None O
76 None None O
: None None O
24 None None O
) None None O

11 None None O
- None None O
20 None None O
33 None None O
( None None O
6 None None O
. None None O
9 None None O
) None None O
( None None O
79 None None O
: None None O
21 None None O
) None None O

21 None None O
- None None O
30 None None O
78 None None O
( None None O
16 None None O
. None None O
3 None None O
) None None O
( None None O
51 None None O
: None None O
49 None None O
) None None O

31 None None O
- None None O
40 None None O
99 None None O
( None None O
20 None None O
. None None O
6 None None O
) None None O
( None None O
46 None None O
: None None O
54 None None O
) None None O

41 None None O
- None None O
50 None None O
101 None None O
( None None O
21 None None O
. None None O
0 None None O
) None None O
( None None O
56 None None O
: None None O
44 None None O
) None None O

51 None None O
- None None O
60 None None O
47 None None O
( None None O
9 None None O
. None None O
8 None None O
) None None O
( None None O
55 None None O
: None None O
45 None None O
) None None O

61 None None O
- None None O
70 None None O
55 None None O
( None None O
11 None None O
. None None O
5 None None O
) None None O
( None None O
53 None None O
: None None O
47 None None O
) None None O

> None None O
= None None O
71 None None O
21 None None O
( None None O
4 None None O
. None None O
4 None None O
) None None O
( None None O
52 None None O
: None None O
48 None None O
) None None O

Occupation None None O

Children None None O
at None None O
preschool None None O
age None None O
20 None None O
( None None O
4 None None O
. None None O
2 None None O
) None None O
( None None O
75 None None O
: None None O
25 None None O
) None None O

Pupils None None O
50 None None O
( None None O
10 None None O
. None None O
4 None None O
) None None O
( None None O
78 None None O
: None None O
22 None None O
) None None O

Farmers None None O
408 None None O
( None None O
85 None None O
. None None O
0 None None O
) None None O
( None None O
52 None None O
: None None O
48 None None O
) None None O

Others None None O
2 None None O
( None None O
0 None None O
. None None O
4 None None O
) None None O
( None None O
50 None None O
: None None O
50 None None O
) None None O

Activities None None O

Farm None None O
work None None O
325 None None O
( None None O
67 None None O
. None None O
7 None None O
) None None O
( None None O
53 None None O
: None None O
47 None None O
) None None O

Play None None O
on None None O
grassland None None O
65 None None O
( None None O
13 None None O
. None None O
5 None None O
) None None O
( None None O
75 None None O
: None None O
25 None None O
) None None O

Recreation None None O
20 None None O
( None None O
4 None None O
. None None O
2 None None O
) None None O
( None None O
65 None None O
: None None O
35 None None O
) None None O

Housework None None O
25 None None O
( None None O
5 None None O
. None None O
2 None None O
) None None O
( None None O
8 None None O
: None None O
92 None None O
) None None O

Unknown None None O
45 None None O
( None None O
9 None None O
. None None O
4 None None O
) None None O
( None None O
71 None None O
: None None O
29 None None O
) None None O

Stress None None O
and None None O
psychological None None O
distress None None O
among None None O
SARS None None O
survivors None None O
1 None None O
year None None O
after None None O
the None None O
outbreak None None O
. None None O

OBJECTIVE None None O
: None None O

Our None None O
study None None O
examined None None O
the None None O
stress None None O
level None None O
and None None O
psychological None None O
distress None None O
of None None O
severe None None O
acute None None O
respiratory None None O
syndrome None None O
( None None O
SARS None None O
) None None O
survivors None None O
1 None None O
year None None O
after None None O
the None None O
outbreak None None O
. None None O

METHOD None None O
: None None O

During None None O
the None None O
SARS None None O
outbreak None None O
in None None O
2003 None None O
, None None O
we None None O
used None None O
the None None O
10 None None O
- None None O
item None None O
Perceived None None O
Stress None None O
Scale None None O
( None None O
PSS None None O
- None None O
10 None None O
) None None O
to None None O
assess None None O
SARS None None O
survivors None None O
treated None None O
in None None O
2 None None O
major None None O
hospitals None None O
( None None O
non None None O
- None None O
health None None O
care None None O
workers None None O
, None None O
n None None O
= None None O
49 None None O
; None None O
health None None O
care None None O
workers None None O
, None None O
n None None O
= None None O
30 None None O
) None None O
. None None O

We None None O
invited None None O
SARS None None O
survivors None None O
from None None O
the None None O
same None None O
hospitals None None O
( None None O
non None None O
- None None O
health None None O
care None None O
workers None None O
, None None O
n None None O
= None None O
63 None None O
; None None O
health None None O
care None None O
workers None None O
, None None O
n None None O
= None None O
33 None None O
) None None O
to None None O
complete None None O
the None None O
PSS None None O
- None None O
10 None None O
again None None O
in None None O
2004 None None O
. None None O

At None None O
that None None O
time None None O
, None None O
they None None O
were None None O
also None None O
asked None None O
to None None O
complete None None O
the None None O
General None None O
Health None None O
Questionnaire None None O
( None None O
GHQ None None O
- None None O
12 None None O
) None None O
and None None O
measures None None O
of None None O
depression None None O
, None None O
anxiety None None O
, None None O
and None None O
posttraumatic None None O
symptoms None None O
. None None O

PSS None None O
- None None O
10 None None O
scores None None O
were None None O
also None None O
obtained None None O
from None None O
matched None None O
community None None O
control None None O
subjects None None O
during None None O
the None None O
outbreak None None O
( None None O
n None None O
= None None O
145 None None O
) None None O
and None None O
again None None O
in None None O
2004 None None O
( None None O
n None None O
= None None O
112 None None O
) None None O
. None None O

RESULTS None None O
: None None O

SARS None None O
survivors None None O
had None None O
higher None None O
stress None None O
levels None None O
during None None O
the None None O
outbreak None None O
, None None O
compared None None O
with None None O
control None None O
subjects None None O
( None None O
PSS None None O
- None None O
10 None None O
scores None None O
= None None O
19 None None O
. None None O
8 None None O
and None None O
17 None None O
. None None O
9 None None O
, None None O
respectively None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
, None None O
and None None O
this None None O
persisted None None O
1 None None O
year None None O
later None None O
( None None O
PSS None None O
- None None O
10 None None O
scores None None O
= None None O
19 None None O
. None None O
9 None None O
and None None O
17 None None O
. None None O
3 None None O
, None None O
respectively None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
without None None O
signs None None O
of None None O
decrease None None O
. None None O

In None None O
2004 None None O
, None None O
SARS None None O
survivors None None O
also None None O
showed None None O
worrying None None O
levels None None O
of None None O
depression None None O
, None None O
anxiety None None O
, None None O
and None None O
posttraumatic None None O
symptoms None None O
. None None O

An None None O
alarming None None O
proportion None None O
( None None O
64 None None O
% None None O
) None None O
scored None None O
above None None O
the None None O
GHQ None None O
- None None O
12 None None O
cut None None O
- None None O
off None None O
that None None O
suggests None None O
psychiatric None None O
morbidity None None O
. None None O

During None None O
the None None O
outbreak None None O
, None None O
health None None O
care None None O
worker None None O
SARS None None O
survivors None None O
had None None O
stress None None O
levels None None O
similar None None O
to None None O
those None None O
of None None O
non None None O
- None None O
health None None O
care None None O
workers None None O
, None None O
but None None O
health None None O
care None None O
workers None None O
showed None None O
significantly None None O
higher None None O
stress None None O
levels None None O
in None None O
2004 None None O
( None None O
PSS None None O
- None None O
10 None None O
score None None O
= None None O
22 None None O
. None None O
8 None None O
, None None O
compared None None O
with None None O
PSS None None O
- None None O
10 None None O
score None None O
= None None O
18 None None O
. None None O
4 None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
and None None O
had None None O
higher None None O
depression None None O
, None None O
anxiety None None O
, None None O
posttraumatic None None O
symptoms None None O
, None None O
and None None O
GHQ None None O
- None None O
12 None None O
scores None None O
. None None O

CONCLUSIONS None None O
: None None O

One None None O
year None None O
after None None O
the None None O
outbreak None None O
, None None O
SARS None None O
survivors None None O
still None None O
had None None O
elevated None None O
stress None None O
levels None None O
and None None O
worrying None None O
levels None None O
of None None O
psychological None None O
distress None None O
. None None O

The None None O
situation None None O
of None None O
health None None O
care None None O
worker None None O
SARS None None O
survivors None None O
is None None O
particularly None None O
worrying None None O
. None None O

The None None O
long None None O
- None None O
term None None O
psychological None None O
implications None None O
of None None O
infectious None None O
diseases None None O
should None None O
not None None O
be None None O
ignored None None O
. None None O

Mental None None O
health None None O
services None None O
could None None O
play None None O
an None None O
important None None O
role None None O
in None None O
rehabilitation None None O
. None None O

On None None O
the None None O
mechanism None None O
of None None O
glycolysis None None O
stimulation None None O
by None None O
neutral None None O
detergents None None O
in None None O
3T3 None None I-Cell-line-name
and None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
. None None O

Glycolysis None None O
of None None O
3T3 None None I-Cell-line-name
and None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
was None None O
greatly None None O
enhanced None None O
by None None O
Nonidet None None O
P None None O
- None None O
40 None None O
or None None O
Triton None None O
X None None O
- None None O
100 None None O
at None None O
about None None O
100 None None O
micrograms None None O
/ None None O
mg None None O
cell None None O
protein None None O
. None None O

This None None O
enhanced None None O
glycolysis None None O
was None None O
partly None None O
sensitive None None O
to None None O
rutamycin None None O
and None None O
partly None None O
sensitive None None O
to None None O
ouabain None None O
, None None O
suggesting None None O
that None None O
the None None O
detergent None None O
released None None O
the None None O
control None None O
of None None O
the None None O
ATPase None None O
of None None O
the None None O
mitochondria None None O
and None None O
of None None O
the None None O
plasma None None O
membrane None None O
Na None None O
+ None None O
K None None O
+ None None O
- None None O
ATPase None None O
. None None O

Nonidet None None O
P None None O
- None None O
40 None None O
had None None O
no None None O
effect None None O
on None None O
glycolysis None None O
in None None O
cell None None O
- None None O
free None None O
extracts None None O
from None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
to None None O
which None None O
soluble None None O
mitochondrial None None O
ATPase None None O
was None None O
added None None O
. None None O

Measuring None None O
ouabain None None O
- None None O
sensitive None None O
22Na None None O
efflux None None O
and None None O
using None None O
ouabain None None O
- None None O
sensitive None None O
lactate None None O
production None None O
as None None O
a None None O
measure None None O
of None None O
ATP None None O
hydrolysis None None O
by None None O
the None None O
Na None None O
+ None None O
K None None O
+ None None O
pump None None O
, None None O
it None None O
was None None O
shown None None O
that None None O
Nonidet None None O
P None None O
- None None O
40 None None O
greatly None None O
decreased None None O
the None None O
efficiency None None O
of None None O
the None None O
Na None None O
+ None None O
K None None O
+ None None O
pump None None O
. None None O

Quercetin None None O
increased None None O
the None None O
efficiency None None O
of None None O
pumping None None O
in None None O
EAT None None O
cells None None O
both None None O
in None None O
the None None O
absence None None O
and None None O
presence None None O
of None None O
the None None O
detergent None None O
. None None O

[ None None O
Considerations None None O
regarding None None O
two None None O
cases None None O
of None None O
macromastia None None O
( None None O
author None None O
' None None O
s None None O
transl None None O
) None None O
] None None O
. None None O

Two None None O
cases None None O
of None None O
macromastia None None O
have None None O
been None None O
shown None None O
; None None O
one None None O
which None None O
appeared None None O
during None None O
puberty None None O
, None None O
the None None O
other None None O
during None None O
menopause None None O
. None None O

Histopathological None None O
examination None None O
has None None O
demonstrated None None O
for None None O
the None None O
both None None O
cases None None O
a None None O
cystic None None O
degeneracy None None O
of None None O
the None None O
glandular None None O
tissue None None O
with None None O
a None None O
hyperplazia None None O
and None None O
hypertrophy None None O
of None None O
the None None O
conjunctive None None O
tissue None None O
. None None O

The None None O
pathogeny None None O
of None None O
macromastia None None O
is None None O
being None None O
discussed None None O
and None None O
it None None O
is None None O
demonstrated None None O
both None None O
the None None O
role None None O
of None None O
hypophysis None None O
hormones None None O
( None None O
prolactine None None O
and None None O
growth None None O
hormone None None O
) None None O
and None None O
of None None O
ovarian None None O
hormones None None O
( None None O
estrogens None None O
) None None O
. None None O

The None None O
treatment None None O
was None None O
surgical None None O
for None None O
the None None O
both None None O
cases None None O
. None None O

Mitochondrial None None O
apoptosis None None O
and None None O
FAK None None O
signaling None None O
disruption None None O
by None None O
a None None O
novel None None O
histone None None O
deacetylase None None O
inhibitor None None O
, None None O
HTPB None None O
, None None O
in None None O
antitumor None None O
and None None O
antimetastatic None None O
mouse None None O
models None None O
. None None O

BACKGROUND None None O
: None None O
Compound None None O
targeting None None O
histone None None O
deacetylase None None O
( None None O
HDAC None None O
) None None O
represents None None O
a None None O
new None None O
era None None O
in None None O
molecular None None O
cancer None None O
therapeutics None None O
. None None O

However None None O
, None None O
effective None None O
HDAC None None O
inhibitors None None O
for None None O
the None None O
treatment None None O
of None None O
solid None None O
tumors None None O
remain None None O
to None None O
be None None O
developed None None O
. None None O

METHODOLOGY None None O
/ None None O
PRINCIPAL None None O
FINDINGS None None O
: None None O
Here None None O
, None None O
we None None O
propose None None O
a None None O
novel None None O
HDAC None None O
inhibitor None None O
, None None O
N None None O
- None None O
Hydroxy None None O
- None None O
4 None None O
- None None O
( None None O
4 None None O
- None None O
phenylbutyryl None None O
- None None O
amino None None O
) None None O
benzamide None None O
( None None O
HTPB None None O
) None None O
, None None O
as None None O
a None None O
potential None None O
chemotherapeutic None None O
drug None None O
for None None O
solid None None O
tumors None None O
. None None O

The None None O
HDAC None None O
inhibition None None O
of None None O
HTPB None None O
was None None O
confirmed None None O
using None None O
HDAC None None O
activity None None O
assay None None O
. None None O

The None None O
antiproliferative None None O
and None None O
anti None None O
- None None O
migratory None None O
mechanisms None None O
of None None O
HTPB None None O
were None None O
investigated None None O
by None None O
cell None None O
proliferation None None O
, None None O
flow None None O
cytometry None None O
, None None O
DNA None None O
ladder None None O
, None None O
caspase None None O
activity None None O
, None None O
Rho None None O
activity None None O
, None None O
F None None O
- None None O
actin None None O
polymerization None None O
, None None O
and None None O
gelatin None None O
- None None O
zymography None None O
for None None O
matrix None None O
metalloproteinases None None O
( None None O
MMPs None None O
) None None O
. None None O

Mice None None O
with None None O
tumor None None O
xenograft None None O
and None None O
experimental None None O
metastasis None None O
model None None O
were None None O
used None None O
to None None O
evaluate None None O
effects None None O
on None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

Our None None O
results None None O
indicated None None O
that None None O
HTPB None None O
was None None O
a None None O
pan None None O
- None None O
HDAC None None O
inhibitor None None O
in None None O
suppressing None None O
cell None None O
viability None None O
specifically None None O
of None None O
lung None None O
cancer None None O
cells None None O
but None None O
not None None O
of None None O
the None None O
normal None None O
lung None None O
cells None None O
. None None O

Upon None None O
HTPB None None O
treatment None None O
, None None O
cell None None O
cycle None None O
arrest None None O
was None None O
induced None None O
and None None O
subsequently None None O
led None None O
to None None O
mitochondria None None O
- None None O
mediated None None O
apoptosis None None O
. None None O

HTPB None None O
disrupted None None O
F None None O
- None None O
actin None None O
dynamics None None O
via None None O
downregulating None None O
RhoA None None O
activity None None O
. None None O

Moreover None None O
, None None O
HTPB None None O
inhibited None None O
activity None None O
of None None O
MMP2 None None O
and None None O
MMP9 None None O
, None None O
reduced None None O
integrin None None O
- None None O
beta1 None None O
/ None None O
focal None None O
adhesion None None O
complex None None O
formation None None O
and None None O
decreased None None O
pericellular None None O
poly None None O
- None None O
fibronectin None None O
assemblies None None O
. None None O

Finally None None O
, None None O
intraperitoneal None None O
injection None None O
or None None O
oral None None O
administration None None O
of None None O
HTPB None None O
efficiently None None O
inhibited None None O
A549 None None I-Cell-line-name
xenograft None None O
tumor None None O
growth None None O
in None None O
vivo None None O
without None None O
side None None O
effects None None O
. None None O

HTPB None None O
delayed None None O
lung None None O
metastasis None None O
of None None O
4T1 None None I-Cell-line-name
mouse None None O
breast None None O
cancer None None O
cells None None O
. None None O

Acetylation None None O
of None None O
histone None None O
and None None O
non None None O
- None None O
histone None None O
proteins None None O
, None None O
induction None None O
of None None O
apoptotic None None O
- None None O
related None None O
proteins None None O
and None None O
de None None O
- None None O
phosphorylation None None O
of None None O
focal None None O
adhesion None None O
kinase None None O
were None None O
confirmed None None O
in None None O
treated None None O
mice None None O
. None None O

CONCLUSIONS None None O
/ None None O
SIGNIFICANCE None None O
: None None O
These None None O
results None None O
suggested None None O
that None None O
intrinsic None None O
apoptotic None None O
pathway None None O
may None None O
involve None None O
in None None O
anti None None O
- None None O
tumor None None O
growth None None O
effects None None O
of None None O
HTPB None None O
in None None O
lung None None O
cancer None None O
cells None None O
. None None O

HTPB None None O
significantly None None O
suppresses None None O
tumor None None O
metastasis None None O
partly None None O
through None None O
inhibition None None O
of None None O
integrin None None O
- None None O
beta1 None None O
/ None None O
FAK None None O
/ None None O
MMP None None O
/ None None O
RhoA None None O
/ None None O
F None None O
- None None O
actin None None O
pathways None None O
. None None O

We None None O
have None None O
provided None None O
convincing None None O
preclinical None None O
evidence None None O
that None None O
HTPB None None O
is None None O
a None None O
potent None None O
HDAC None None O
targeted None None O
inhibitor None None O
and None None O
is None None O
thus None None O
a None None O
promising None None O
candidate None None O
for None None O
lung None None O
cancer None None O
chemotherapy None None O
. None None O

Enhanced None None O
DNA None None O
- None None O
binding None None O
activity None None O
of None None O
a None None O
Stat3 None None O
- None None O
related None None O
protein None None O
in None None O
cells None None O
transformed None None O
by None None O
the None None O
Src None None O
oncoprotein None None O
. None None O

Cytokines None None O
and None None O
growth None None O
factors None None O
induce None None O
tyrosine None None O
phosphorylation None None O
of None None O
signal None None O
transducers None None O
and None None O
activators None None O
of None None O
transcription None None O
( None None O
STATs None None O
) None None O
that None None O
directly None None O
activate None None O
gene None None O
expression None None O
. None None O

Cells None None O
stably None None O
transformed None None O
by None None O
the None None O
Src None None O
oncogene None None O
tyrosine None None O
kinase None None O
were None None O
examined None None O
for None None O
STAT None None O
protein None None O
activation None None O
. None None O

Assays None None O
of None None O
electrophoretic None None O
mobility None None O
, None None O
DNA None None O
- None None O
binding None None O
specificity None None O
, None None O
and None None O
antigenicity None None O
indicated None None O
that None None O
Stat3 None None O
or None None O
a None None O
closely None None O
related None None O
STAT None None O
family None None O
member None None O
was None None O
constitutively None None O
activated None None O
by None None O
the None None O
Src None None O
oncoprotein None None O
. None None O

Induction None None O
of None None O
this None None O
DNA None None O
- None None O
binding None None O
activity None None O
was None None O
accompanied None None O
by None None O
tyrosine None None O
phosphorylation None None O
of None None O
Stat3 None None O
and None None O
correlated None None O
with None None O
Src None None O
transformation None None O
. None None O

These None None O
findings None None O
demonstrate None None O
that None None O
Src None None O
can None None O
activate None None O
STAT None None O
signaling None None O
pathways None None O
and None None O
raise None None O
the None None O
possibility None None O
that None None O
Stat3 None None O
contributes None None O
to None None O
oncogenesis None None O
by None None O
Src None None O
. None None O

Acetaminophen None None O
and None None O
hepatic None None O
dysfunction None None O
in None None O
infectious None None O
mononucleosis None None O
. None None O

Two None None O
family None None O
members None None O
developed None None O
severe None None O
hepatitic None None O
dysfunction None None O
in None None O
association None None O
with None None O
infectious None None O
mononucleosis None None O
and None None O
acetaminophen None None O
administration None None O
. None None O

Since None None O
severe None None O
hepatitis None None O
is None None O
an None None O
extremely None None O
rare None None O
complication None None O
of None None O
infectious None None O
mononucleosis None None O
, None None O
we None None O
postulate None None O
that None None O
the None None O
hepatic None None O
dysfunction None None O
was None None O
induced None None O
by None None O
acetaminophen None None O
. None None O

Study None None O
Population None None O

This None None O
prospective None None O
longitudinal None None O
study None None O
was None None O
conducted None None O
at None None O
the None None O
University None None O
of None None O
British None None O
Columbia None None O
and None None O
was None None O
approved None None O
by None None O
the None None O
human None None O
research None None O
ethics None None O
board None None O
at None None O
that None None O
institution None None O
. None None O

All None None O
subjects None None O
who None None O
received None None O
a None None O
renal None None O
transplant None None O
from None None O
January None None O
2005 None None O
to None None O
December None None O
2007 None None O
were None None O
invited None None O
to None None O
participate None None O
, None None O
and None None O
those None None O
who None None O
agreed None None O
and None None O
signed None None O
consent None None O
forms None None O
were None None O
enrolled None None O
in None None O
the None None O
study None None O
. None None O

Patients None None O
were None None O
followed None None O
routinely None None O
at None None O
the None None O
transplant None None O
center None None O
, None None O
and None None O
blood None None O
and None None O
urine None None O
samples None None O
were None None O
obtained None None O
prior None None O
to None None O
and None None O
serially None None O
post None None O
- None None O
transplant None None O
at None None O
0 None None O
. None None O
5 None None O
, None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
4 None None O
, None None O
8 None None O
, None None O
12 None None O
, None None O
and None None O
26 None None O
weeks None None O
; None None O
then None None O
every None None O
6 None None O
months None None O
through None None O
year None None O
3 None None O
; None None O
and None None O
also None None O
at None None O
the None None O
time None None O
of None None O
suspected None None O
rejection None None O
. None None O

Graft None None O
biopsy None None O
tissue None None O
was None None O
obtained None None O
pretransplant None None O
and None None O
at None None O
the None None O
time None None O
of None None O
all None None O
biopsies None None O
performed None None O
post None None O
- None None O
transplant None None O
. None None O

Blood None None O
samples None None O
from None None O
normal None None O
healthy None None O
controls None None O
served None None O
as None None O
reference None None O
samples None None O
. None None O

Samples None None O
from None None O
cases None None O
, None None O
controls None None O
, None None O
and None None O
comparators None None O
were None None O
treated None None O
identically None None O
. None None O

All None None O
rejection None None O
episodes None None O
were None None O
diagnosed None None O
by None None O
conventional None None O
clinical None None O
and None None O
laboratory None None O
parameters None None O
, None None O
confirmed None None O
by None None O
biopsy None None O
, None None O
and None None O
graded None None O
according None None O
to None None O
the None None O
Banff None None O
97 None None O
working None None O
classification None None O
of None None O
renal None None O
allograft None None O
pathology None None O
( None None O
28 None None O
) None None O
. None None O

Banff None None O
categories None None O
2 None None O
and None None O
4 None None O
( None None O
antibody None None O
- None None O
mediated None None O
or None None O
acute None None O
/ None None O
active None None O
cellular None None O
rejection None None O
) None None O
were None None O
considered None None O
significant None None O
. None None O

Category None None O
3 None None O
( None None O
borderline None None O
change None None O
) None None O
was None None O
only None None O
considered None None O
significant None None O
if None None O
associated None None O
with None None O
graft None None O
dysfunction None None O
and None None O
treated None None O
for None None O
rejection None None O
. None None O

All None None O
baseline None None O
demographic None None O
and None None O
follow None None O
- None None O
up None None O
data None None O
were None None O
recorded None None O
in None None O
the None None O
transplant None None O
program None None O
electronic None None O
database None None O
, None None O
and None None O
there None None O
was None None O
no None None O
loss None None O
to None None O
follow None None O
- None None O
up None None O
during None None O
the None None O
period None None O
of None None O
study None None O
. None None O

The None None O
Wilms None None O
tumor None None O
suppressor None None O
gene None None O
WT1 None None O
induces None None O
G1 None None O
arrest None None O
and None None O
apoptosis None None O
in None None O
myeloblastic None None O
leukemia None None O
M1 None None I-Cell-line-name
cells None None O
. None None O

WT1 None None O
was None None O
isolated None None O
as None None O
a None None O
tumor None None O
suppressor None None O
gene None None O
of None None O
Wilms None None O
tumor None None O
. None None O

However None None O
, None None O
high None None O
expression None None O
of None None O
WT1 None None O
correlates None None O
with None None O
poor None None O
prognosis None None O
in None None O
acute None None O
leukemia None None O
. None None O

In None None O
addition None None O
suppression None None O
of None None O
WT1 None None O
expression None None O
by None None O
WT1 None None O
anti None None O
- None None O
sense None None O
oligonucleotide None None O
inhibits None None O
proliferation None None O
of None None O
leukemia None None O
cells None None O
, None None O
suggesting None None O
that None None O
WT1 None None O
is None None O
important None None O
for None None O
their None None O
proliferation None None O
. None None O

To None None O
further None None O
elucidate None None O
the None None O
biological None None O
significance None None O
of None None O
WT1 None None O
in None None O
leukemic None None O
cell None None O
growth None None O
, None None O
we None None O
overexpressed None None O
exogenous None None O
WT1 None None O
in None None O
murine None None O
M1 None None I-Cell-line-name
myeloblastic None None O
leukemia None None O
cells None None O
using None None O
the None None O
isopropyl None None O
- None None O
beta None None O
- None None O
D None None O
- None None O
thiogalactoside None None O
( None None O
IPTG None None O
) None None O
- None None O
controlled None None O
expression None None O
system None None O
. None None O

We None None O
found None None O
that None None O
induction None None O
of None None O
one None None O
splicing None None O
variant None None O
of None None O
WT1 None None O
[ None None O
WT1 None None O
- None None O
17AA None None O
( None None O
+ None None O
) None None O
- None None O
KTS None None O
( None None O
- None None O
) None None O
] None None O
in None None O
M1 None None I-Cell-line-name
cells None None O
induces None None O
cell None None O
cycle None None O
arrest None None O
and None None O
apoptotic None None O
cell None None O
death None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
role None None O
of None None O
WT1 None None O
is None None O
different None None O
depending None None O
on None None O
the None None O
type None None O
of None None O
leukemia None None O
cell None None O
in None None O
which None None O
it None None O
is None None O
expressed None None O
. None None O

The None None O
ictal None None O
bradycardia None None O
syndrome None None O
: None None O
localization None None O
and None None O
lateralization None None O
. None None O

PURPOSE None None O
: None None O

Previous None None O
studies None None O
have None None O
established None None O
the None None O
importance None None O
of None None O
the None None O
insular None None O
cortex None None O
and None None O
temporal None None O
lobe None None O
in None None O
cardiovascular None None O
autonomic None None O
modulation None None O
. None None O

Some None None O
investigators None None O
, None None O
based None None O
on None None O
the None None O
results None None O
of None None O
cortical None None O
stimulation None None O
response None None O
, None None O
functional None None O
imaging None None O
, None None O
EEG None None O
recordings None None O
of None None O
seizures None None O
, None None O
and None None O
lesional None None O
studies None None O
, None None O
have None None O
suggested None None O
that None None O
cardiac None None O
sympathetic None None O
and None None O
parasympathetic None None O
function None None O
may None None O
be None None O
lateralized None None O
, None None O
with None None O
sympathetic None None O
representation None None O
lateralized None None O
to None None O
the None None O
right None None O
insula None None O
, None None O
and None None O
parasympathetic None None O
, None None O
to None None O
the None None O
left None None O
. None None O

These None None O
studies None None O
have None None O
suggested None None O
that None None O
ictal None None O
bradycardia None None O
is None None O
most None None O
commonly None None O
a None None O
manifestation None None O
of None None O
activation None None O
of None None O
the None None O
left None None O
temporal None None O
and None None O
insular None None O
cortex None None O
. None None O

However None None O
, None None O
the None None O
evidence None None O
for None None O
this None None O
is None None O
inconsistent None None O
. None None O

We None None O
sought None None O
to None None O
assess None None O
critically None None O
the None None O
predictable None None O
value None None O
of None None O
ictal None None O
bradycardia None None O
for None None O
seizure None None O
localization None None O
and None None O
lateralization None None O
. None None O

METHODS None None O
: None None O

In None None O
this None None O
study None None O
, None None O
we None None O
reviewed None None O
the None None O
localization None None O
of None None O
seizure None None O
activity None None O
in None None O
13 None None O
consecutive None None O
patients None None O
with None None O
ictal None None O
bradycardia None None O
diagnosed None None O
during None None O
prolonged None None O
video None None O
- None None O
EEG None None O
monitoring None None O
at None None O
Mayo None None O
Clinic None None O
Rochester None None O
. None None O

The None None O
localization None None O
of None None O
electrographic None None O
seizure None None O
activity None None O
at None None O
seizure None None O
onset None None O
and None None O
bradycardia None None O
onset None None O
was None None O
identified None None O
in None None O
all None None O
patients None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
performed None None O
a None None O
comprehensive None None O
review None None O
of None None O
the None None O
ictal None None O
bradycardia None None O
literature None None O
focusing None None O
on None None O
localization None None O
of None None O
seizure None None O
activity None None O
in None None O
ictal None None O
bradycardia None None O
cases None None O
. None None O

RESULTS None None O
: None None O

All None None O
occurrences None None O
of None None O
ictal None None O
bradycardia None None O
in None None O
the None None O
13 None None O
identified None None O
patients None None O
were None None O
associated None None O
with None None O
temporal None None O
lobe None None O
- None None O
onset None None O
seizures None None O
. None None O

However None None O
, None None O
no None None O
consistent None None O
lateralization None None O
of None None O
seizure None None O
activity None None O
was None None O
found None None O
at None None O
onset None None O
of None None O
seizure None None O
activity None None O
or None None O
at None None O
onset None None O
of None None O
bradycardia None None O
in None None O
this None None O
population None None O
. None None O

Seizure None None O
activity None None O
was None None O
bilateral None None O
at None None O
bradycardia None None O
onset None None O
in None None O
nine None None O
of None None O
13 None None O
patients None None O
. None None O

The None None O
results None None O
from None None O
the None None O
literature None None O
review None None O
also None None O
showed None None O
that None None O
a None None O
predominance None None O
of None None O
patients None None O
had None None O
bilateral None None O
activity None None O
at None None O
bradycardia None None O
onset None None O
; None None O
however None None O
, None None O
more None None O
of None None O
the None None O
ictal None None O
bradycardia None None O
cases None None O
from None None O
the None None O
literature None None O
had None None O
left None None O
hemispheric None None O
localization None None O
of None None O
seizure None None O
onset None None O
. None None O

CONCLUSIONS None None O
: None None O

Ictal None None O
bradycardia None None O
most None None O
often None None O
occurs None None O
in None None O
association None None O
with None None O
bilateral None None O
hemispheric None None O
seizure None None O
activity None None O
and None None O
is None None O
not None None O
a None None O
consistent None None O
lateralizing None None O
sign None None O
in None None O
localizing None None O
seizure None None O
onset None None O
. None None O

Our None None O
data None None O
do None None O
not None None O
support None None O
the None None O
existence None None O
of None None O
a None None O
strictly None None O
unilateral None None O
parasympathetic None None O
cardiomotor None None O
representation None None O
in None None O
the None None O
left None None O
hemisphere None None O
, None None O
as None None O
has None None O
been None None O
suggested None None O
. None None O

Impacts None None O
of None None O
water None None O
management None None O
options None None O
on None None O
flows None None O
in None None O
the None None O
Condamine None None O
River None None O
in None None O
Southern None None O
Queensland None None O
. None None O

This None None O
paper None None O
examines None None O
the None None O
implications None None O
for None None O
river None None O
flows None None O
of None None O
a None None O
number None None O
of None None O
water None None O
practices None None O
and None None O
potential None None O
management None None O
options None None O
in None None O
the None None O
alluvial None None O
plains None None O
of None None O
the None None O
Upper None None O
Condamine None None O
River None None O
. None None O

It None None O
is None None O
an None None O
intensively None None O
cultivated None None O
area None None O
where None None O
irrigation None None O
is None None O
limited None None O
by None None O
the None None O
availability None None O
of None None O
water None None O
resources None None O
. None None O

The None None O
practice None None O
of None None O
capturing None None O
overland None None O
flows None None O
was None None O
investigated None None O
by None None O
the None None O
development None None O
of None None O
a None None O
model None None O
that None None O
simulates None None O
the None None O
performance None None O
of None None O
clusters None None O
of None None O
offstream None None O
storages None None O
up None None O
to None None O
sub None None O
- None None O
catchment None None O
scale None None O
. None None O

Management None None O
options None None O
examined None None O
included None None O
improvement None None O
to None None O
on None None O
- None None O
farm None None O
water None None O
use None None O
efficiency None None O
, None None O
the None None O
suppression None None O
of None None O
evaporation None None O
from None None O
open None None O
water None None O
storages None None O
, None None O
increasing None None O
the None None O
depth None None O
of None None O
those None None O
storages None None O
, None None O
decreasing None None O
their None None O
number None None O
, None None O
and None None O
improved None None O
tailwater None None O
return None None O
from None None O
irrigated None None O
land None None O
. None None O

Impacts None None O
of None None O
management None None O
options None None O
were None None O
analysed None None O
using None None O
a None None O
catchment None None O
scale None None O
water None None O
allocation None None O
model None None O
. None None O

Hyperfibrinogenemia None None O
is None None O
associated None None O
with None None O
lymphatic None None O
as None None O
well None None O
as None None O
hematogenous None None O
metastasis None None O
and None None O
worse None None O
clinical None None O
outcome None None O
in None None O
T2 None None O
gastric None None O
cancer None None O
. None None O

BACKGROUND None None O
: None None O
Abnormal None None O
hemostasis None None O
in None None O
cancer None None O
patients None None O
has None None O
previously None None O
been None None O
described None None O
, None None O
however None None O
the None None O
correlation None None O
between None None O
the None None O
plasma None None O
fibrinogen None None O
level None None O
and None None O
cancer None None O
metastasis None None O
and None None O
prognosis None None O
has None None O
not None None O
been None None O
reported None None O
in None None O
a None None O
large None None O
- None None O
scale None None O
clinical None None O
study None None O
. None None O

METHODS None None O
: None None O
Preoperative None None O
plasma None None O
fibrinogen None None O
levels None None O
were None None O
retrospectively None None O
examined None None O
in None None O
405 None None O
patients None None O
who None None O
underwent None None O
surgery None None O
for None None O
advanced None None O
gastric None None O
cancer None None O
. None None O

The None None O
association None None O
of None None O
fibrinogen None None O
levels None None O
with None None O
clinical None None O
/ None None O
pathological None None O
findings None None O
and None None O
clinical None None O
outcome None None O
was None None O
evaluated None None O
. None None O

RESULTS None None O
: None None O
There None None O
was None None O
a None None O
positive None None O
correlation None None O
between None None O
plasma None None O
fibrinogen None None O
levels None None O
and None None O
the None None O
depth None None O
of None None O
invasion None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Hyperfibrinogenemia None None O
( None None O
> None None O
310 None None O
mg None None O
/ None None O
dl None None O
) None None O
was None None O
independently None None O
associated None None O
with None None O
lymph None None O
node None None O
( None None O
Odds None None O
Ratio None None O
; None None O
2 None None O
. None None O
342 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
0032 None None O
) None None O
and None None O
liver None None O
( None None O
Odds None None O
Ratio None None O
; None None O
2 None None O
. None None O
933 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
0147 None None O
) None None O
metastasis None None O
, None None O
not None None O
with None None O
peritoneal None None O
metastasis None None O
in None None O
this None None O
series None None O
. None None O

Patients None None O
with None None O
hyperfibrinogenemia None None O
showed None None O
worse None None O
clinical None None O
outcome None None O
in None None O
T2 None None O
gastric None None O
cancer None None O
, None None O
however None None O
, None None O
there None None O
was None None O
no None None O
correlation None None O
of None None O
plasma None None O
fibrinogen None None O
level None None O
with None None O
prognosis None None O
in None None O
T3 None None O
/ None None O
T4 None None O
gastric None None O
cancer None None O
. None None O

CONCLUSION None None O
: None None O
Our None None O
results None None O
might None None O
support None None O
the None None O
idea None None O
that None None O
hyperfibrinogenemia None None O
can None None O
augment None None O
lymphatic None None O
and None None O
hematogeneous None None O
metastasis None None O
of None None O
advanced None None O
gastric None None O
cancer None None O
, None None O
which None None O
is None None O
major None None O
determinant None None O
of None None O
the None None O
prognosis None None O
in None None O
T2 None None O
gastric None None O
cancer None None O
. None None O

Therefore None None O
, None None O
in None None O
the None None O
situation None None O
without None None O
peritoneal None None O
involvement None None O
, None None O
hyperfibrinogenemia None None O
is None None O
a None None O
useful None None O
biomarker None None O
to None None O
predict None None O
the None None O
possible None None O
metastasis None None O
and None None O
worse None None O
clinical None None O
outcome None None O
in None None O
T2 None None O
gastric None None O
cancer None None O
. None None O

Phosphorylation None None O
- None None O
induced None None O
mobility None None O
shift None None O
in None None O
phospholamban None None O
in None None O
sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gels None None O
. None None O

Evidence None None O
for None None O
a None None O
protein None None O
structure None None O
consisting None None O
of None None O
multiple None None O
identical None None O
phosphorylatable None None O
subunits None None O
. None None O

Phosphorylation None None O
of None None O
purified None None O
phospholamban None None O
isolated None None O
from None None O
canine None None O
cardiac None None O
sarcoplasmic None None O
reticulum None None O
vesicles None None O
decreased None None O
the None None O
electrophoretic None None O
mobility None None O
of None None O
the None None O
protein None None O
in None None O
sodium None None O
dodecyl None None O
sulfate None None O
( None None O
SDS None None O
) None None O
- None None O
polyacrylamide None None O
gels None None O
. None None O

Different None None O
mobility None None O
forms None None O
of None None O
phospholamban None None O
in None None O
SDS None None O
gels None None O
were None None O
visualized None None O
both None None O
by None None O
direct None None O
protein None None O
staining None None O
and None None O
by None None O
autoradiography None None O
. None None O

Unphosphorylated None None O
phospholamban None None O
migrated None None O
with None None O
an None None O
apparent None None O
Mr None None O
= None None O
25 None None O
, None None O
000 None None O
in None None O
SDS None None O
gels None None O
; None None O
maximal None None O
phosphorylation None None O
of None None O
phospholamban None None O
by None None O
cAMP None None O
- None None O
or None None O
Ca2 None None O
+ None None O
- None None O
calmodulin None None O
- None None O
dependent None None O
protein None None O
kinase None None O
increased None None O
the None None O
apparent None None O
Mr None None O
to None None O
27 None None O
, None None O
000 None None O
. None None O

Partial None None O
phosphorylation None None O
of None None O
phospholamban None None O
by None None O
either None None O
protein None None O
kinase None None O
gave None None O
intermediate None None O
mobility None None O
forms None None O
of None None O
molecular None None O
weights None None O
between None None O
25 None None O
, None None O
000 None None O
and None None O
27 None None O
, None None O
000 None None O
, None None O
suggesting None None O
that None None O
more None None O
than None None O
one None None O
phosphorylation None None O
site None None O
was None None O
present None None O
on None None O
the None None O
holoprotein None None O
for None None O
each None None O
activity None None O
. None None O

Boiling None None O
of None None O
phospholamban None None O
in None None O
SDS None None O
dissociated None None O
the None None O
holoprotein None None O
into None None O
an None None O
apparently None None O
homogeneous None None O
class None None O
of None None O
low None None O
molecular None None O
weight None None O
" None None O
monomers None None O
. None None O
" None None O
Only None None O
two None None O
mobility None None O
forms None None O
of None None O
monomeric None None O
phospholamban None None O
were None None O
observed None None O
in None None O
SDS None None O
gels None None O
after None None O
phosphorylation None None O
by None None O
cAMP None None O
- None None O
dependent None None O
protein None None O
kinase None None O
, None None O
corresponding None None O
to None None O
9 None None O
- None None O
kDa None None O
dephospho None None O
- None None O
and None None O
11 None None O
- None None O
kDa None None O
phosphoproteins None None O
. None None O

All None None O
of None None O
the None None O
9 None None O
- None None O
kDa None None O
protein None None O
could None None O
be None None O
phosphorylated None None O
and None None O
converted None None O
into None None O
the None None O
11 None None O
- None None O
kDa None None O
mobility None None O
form None None O
, None None O
suggesting None None O
the None None O
presence None None O
of None None O
only None None O
one None None O
site None None O
of None None O
phosphorylation None None O
on None None O
a None None O
single None None O
type None None O
of None None O
monomer None None O
for None None O
cAMP None None O
- None None O
dependent None None O
protein None None O
kinase None None O
. None None O

Simultaneous None None O
phosphorylation None None O
of None None O
monomeric None None O
phospholamban None None O
by None None O
cAMP None None O
- None None O
dependent None None O
protein None None O
kinase None None O
and None None O
Ca2 None None O
+ None None O
- None None O
calmodulin None None O
- None None O
dependent None None O
protein None None O
kinase None None O
gave None None O
an None None O
additional None None O
mobility None None O
form None None O
of None None O
the None None O
protein None None O
, None None O
suggesting None None O
that None None O
different None None O
sites None None O
of None None O
phosphorylation None None O
were None None O
present None None O
for None None O
each None None O
activity None None O
on None None O
each None None O
monomer None None O
. None None O

Incomplete None None O
dissociation None None O
of None None O
the None None O
holoprotein None None O
by None None O
boiling None None O
it None None O
in None None O
a None None O
relatively None None O
low None None O
concentration None None O
of None None O
SDS None None O
facilitated None None O
the None None O
detection None None O
of None None O
five None None O
major None None O
mobility None None O
forms None None O
of None None O
the None None O
protein None None O
in None None O
SDS None None O
gels None None O
, None None O
and None None O
the None None O
mobilities None None O
of None None O
all None None O
of None None O
these None None O
forms None None O
were None None O
decreased None None O
by None None O
phosphorylation None None O
. None None O

We None None O
propose None None O
that None None O
the None None O
high None None O
molecular None None O
weight None None O
form None None O
of None None O
phospholamban None None O
is None None O
a None None O
multimer None None O
of None None O
electrophoretically None None O
indistinguishable None None O
monomers None None O
, None None O
each None None O
of None None O
which None None O
contains None None O
a None None O
different None None O
phosphorylation None None O
site None None O
for None None O
cAMP None None O
- None None O
dependent None None O
protein None None O
kinase None None O
activity None None O
and None None O
Ca2 None None O
+ None None O
- None None O
calmodulin None None O
- None None O
dependent None None O
protein None None O
kinase None None O
activity None None O
. None None O

Phosphorylation None None O
of None None O
phospholamban None None O
at None None O
multiple None None O
sites None None O
is None None O
responsible None None O
for None None O
the None None O
various None None O
mobility None None O
forms None None O
of None None O
the None None O
holoprotein None None O
detected None None O
in None None O
SDS None None O
- None None O
polyacrylamide None None O
gels None None O
. None None O

Click None None O
here None None O
for None None O
file None None O

Thermostability None None O
and None None O
molecular None None O
encapsulation None None O
within None None O
an None None O
engineered None None O
caged None None O
protein None None O
scaffold None None O
. None None O

Self None None O
- None None O
assembling None None O
biological None None O
complexes None None O
such None None O
as None None O
viral None None O
capsids None None O
have None None O
been None None O
manipulated None None O
to None None O
function None None O
in None None O
innovative None None O
nanotechnology None None O
applications None None O
. None None O

The None None O
E2 None None O
component None None O
of None None O
pyruvate None None O
dehydrogenase None None O
from None None O
Bacillus None None O
stearothermophilus None None O
forms None None O
a None None O
dodecahedral None None O
complex None None O
and None None O
potentially None None O
provides None None O
another None None O
platform None None O
for None None O
these None None O
purposes None None O
. None None O

In None None O
this None None O
investigation None None O
, None None O
we None None O
show None None O
that None None O
this None None O
protein None None O
assembly None None O
exhibits None None O
unusual None None O
stability None None O
and None None O
can None None O
be None None O
modified None None O
to None None O
encapsulate None None O
model None None O
drug None None O
molecules None None O
. None None O

To None None O
distill None None O
the None None O
E2 None None O
protein None None O
down None None O
to None None O
its None None O
structural None None O
scaffold None None O
core None None O
, None None O
we None None O
synthesized None None O
a None None O
truncated None None O
gene None None O
optimized None None O
for None None O
expression None None O
in None None O
Escherichia None None O
coli None None O
. None None O

The None None O
correct None None O
assembly None None O
and None None O
dodecahedral None None O
structure None None O
of None None O
the None None O
resulting None None O
scaffold None None O
was None None O
confirmed None None O
with None None O
dynamic None None O
light None None O
scattering None None O
and None None O
transmission None None O
electron None None O
microscopy None None O
. None None O

Using None None O
circular None None O
dichroism None None O
and None None O
differential None None O
scanning None None O
calorimetry None None O
, None None O
we None None O
found None None O
the None None O
thermostability None None O
of None None O
the None None O
complex None None O
to None None O
be None None O
unusually None None O
high None None O
, None None O
with None None O
an None None O
onset None None O
temperature None None O
of None None O
unfolding None None O
at None None O
81 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
9 None None O
degrees None None O
C None None O
and None None O
an None None O
apparent None None O
midpoint None None O
unfolding None None O
temperature None None O
of None None O
91 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
4 None None O
degrees None None O
C None None O
. None None O

To None None O
evaluate None None O
the None None O
potential None None O
of None None O
this None None O
scaffold None None O
for None None O
encapsulation None None O
of None None O
guest None None O
molecules None None O
, None None O
we None None O
made None None O
variants None None O
at None None O
residues None None O
381 None None O
and None None O
239 None None O
which None None O
altered None None O
the None None O
physicochemical None None O
properties None None O
of None None O
the None None O
hollow None None O
internal None None O
cavity None None O
. None None O

These None None O
mutants None None O
, None None O
yielding None None O
60 None None O
and None None O
120 None None O
mutations None None O
within None None O
this None None O
cavity None None O
, None None O
assembled None None O
into None None O
the None None O
correct None None O
architecture None None O
and None None O
exhibited None None O
high None None O
thermostability None None O
that None None O
was None None O
comparable None None O
to None None O
the None None O
wild None None O
- None None O
type None None O
scaffold None None O
. None None O

To None None O
show None None O
the None None O
applicability None None O
of None None O
this None None O
scaffold None None O
, None None O
two None None O
different None None O
fluorescent None None O
dye None None O
molecules None None O
were None None O
covalently None None O
coupled None None O
to None None O
the None None O
cysteine None None O
mutant None None O
at None None O
site None None O
381 None None O
. None None O

We None None O
demonstrate None None O
that None None O
these None None O
mutations None None O
can None None O
introduce None None O
non None None O
- None None O
native None None O
functionality None None O
and None None O
enable None None O
molecular None None O
encapsulation None None O
within None None O
the None None O
cavity None None O
while None None O
still None None O
retaining None None O
the None None O
dodecahedral None None O
structure None None O
. None None O

The None None O
unusually None None O
robust None None O
nature None None O
of None None O
this None None O
scaffold None None O
and None None O
its None None O
amenability None None O
to None None O
internal None None O
changes None None O
reveal None None O
its None None O
potential None None O
for None None O
nanoscale None None O
applications None None O
. None None O

Stereoselective None None O
synthesis None None O
of None None O
1 None None O
- None None O
aminoalkanephosphonic None None O
acids None None O
with None None O
two None None O
chiral None None O
centers None None O
and None None O
their None None O
activity None None O
towards None None O
leucine None None O
aminopeptidase None None O
. None None O

The None None O
stereoselective None None O
synthesis None None O
of None None O
1 None None O
- None None O
amino None None O
- None None O
2 None None O
- None None O
alkylalkanephosphonic None None O
acids None None O
, None None O
namely None None O
, None None O
compounds None None O
bearing None None O
two None None O
chiral None None O
centers None None O
, None None O
was None None O
achieved None None O
by None None O
the None None O
condensation None None O
of None None O
hypophosphorous None None O
acid None None O
salts None None O
of None None O
( None None O
R None None O
) None None O
( None None O
+ None None O
) None None O
or None None O
( None None O
S None None O
) None None O
( None None O
- None None O
) None None O
- None None O
N None None O
- None None O
alpha None None O
- None None O
methylbenzylamine None None O
with None None O
the None None O
appropriate None None O
aldehydes None None O
in None None O
isopropanol None None O
. None None O

Simultaneous None None O
deprotection None None O
and None None O
oxidation None None O
by None None O
the None None O
action None None O
of None None O
bromine None None O
water None None O
provided None None O
equimolar None None O
mixtures None None O
of None None O
the None None O
RS None None O
: None None O
RR None None O
and None None O
SR None None O
: None None O
SS None None O
diastereomers None None O
of None None O
desired None None O
acids None None O
. None None O

They None None O
appeared None None O
to None None O
act None None O
as None None O
moderate None None O
inhibitors None None O
of None None O
kidney None None O
leucine None None O
aminopeptidase None None O
with None None O
potency None None O
dependent None None O
on None None O
the None None O
absolute None None O
configuration None None O
of None None O
both None None O
centers None None O
of None None O
chirality None None O
. None None O

[ None None O
Reconstruction None None O
of None None O
hepatic None None O
artery None None O
in None None O
adult None None O
to None None O
adult None None O
living None None O
donor None None O
liver None None O
transplantation None None O
in None None O
104 None None O
patients None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
report None None O
the None None O
experience None None O
of None None O
hepatic None None O
artery None None O
reconstruction None None O
with None None O
adult None None O
- None None O
to None None O
- None None O
adult None None O
living None None O
donor None None O
liver None None O
transplantation None None O
( None None O
ALDLT None None O
) None None O
using None None O
right None None O
lobe None None O
liver None None O
grafts None None O
. None None O

METHODS None None O
: None None O

From None None O
January None None O
2002 None None O
to None None O
August None None O
2007 None None O
, None None O
104 None None O
patients None None O
underwent None None O
ALDLT None None O
using None None O
right None None O
lobe None None O
grafts None None O
. None None O

Hepatic None None O
arteries None None O
of None None O
donors None None O
and None None O
recipients None None O
were None None O
assessed None None O
carefully None None O
with None None O
spiral None None O
CT None None O
angiography None None O
and None None O
DSA None None O
before None None O
ALDLT None None O
. None None O

All None None O
patients None None O
underwent None None O
reconstruction None None O
of None None O
hepatic None None O
artery None None O
between None None O
right None None O
lobe None None O
liver None None O
grafts None None O
of None None O
donor None None O
and None None O
recipient None None O
which None None O
included None None O
the None None O
anastomosis None None O
between None None O
right None None O
hepatic None None O
artery None None O
of None None O
donors None None O
and None None O
recipients None None O
; None None O
the None None O
reconstruction None None O
of None None O
right None None O
hepatic None None O
artery None None O
between None None O
donor None None O
grafts None None O
and None None O
left None None O
hepatic None None O
artery None None O
of None None O
recipients None None O
; None None O
interpositional None None O
bypass None None O
using None None O
autogenous None None O
saphenous None None O
vein None None O
and None None O
cryopreserved None None O
iliac None None O
artery None None O
between None None O
right None None O
hepatic None None O
artery None None O
of None None O
donors None None O
and None None O
hepatic None None O
artery None None O
, None None O
common None None O
hepatic None None O
artery None None O
and None None O
abdominal None None O
aorta None None O
of None None O
recipients None None O
. None None O

The None None O
microsurgical None None O
technique None None O
was None None O
employed None None O
under None None O
the None None O
magnification None None O
of None None O
3 None None O
. None None O
5 None None O
times None None O
and None None O
operative None None O
microscope None None O
of None None O
5 None None O
- None None O
10 None None O
times None None O
. None None O

RESULTS None None O
: None None O

In None None O
these None None O
series None None O
, None None O
HAT None None O
occurred None None O
in None None O
2 None None O
recipients None None O
at None None O
Days None None O
1 None None O
and None None O
7 None None O
post None None O
- None None O
ALDLT None None O
( None None O
1 None None O
. None None O
9 None None O
% None None O
) None None O
. None None O

Both None None O
were None None O
revascularized None None O
with None None O
autogenous None None O
saphenous None None O
vein None None O
between None None O
right None None O
hepatic None None O
artery None None O
of None None O
donor None None O
and None None O
abdominal None None O
aorta None None O
of None None O
recipient None None O
. None None O

HAT None None O
occurred None None O
in None None O
1 None None O
recipient None None O
at None None O
Days None None O
90 None None O
post None None O
- None None O
ALDLT None None O
, None None O
but None None O
no None None O
symptom None None O
was None None O
presented None None O
. None None O

There None None O
was None None O
no None None O
severe None None O
complication None None O
and None None O
mortality None None O
related None None O
to None None O
hepatic None None O
artery None None O
reconstruction None None O
in None None O
recipients None None O
. None None O

No None None O
HAT None None O
, None None O
hepatic None None O
artery None None O
stenosis None None O
and None None O
aneurysm None None O
occurred None None O
during None None O
the None None O
follow None None O
- None None O
up None None O
period None None O
of None None O
2 None None O
- None None O
60 None None O
months None None O
. None None O

The None None O
1 None None O
, None None O
2 None None O
and None None O
3 None None O
- None None O
year None None O
survival None None O
rates None None O
were None None O
89 None None O
. None None O
3 None None O
% None None O
, None None O
76 None None O
. None None O
0 None None O
% None None O
and None None O
69 None None O
. None None O
3 None None O
% None None O
respectively None None O
. None None O

CONCLUSION None None O
: None None O

Careful None None O
evaluation None None O
of None None O
hepatic None None O
artery None None O
condition None None O
and None None O
using None None O
microsurgical None None O
techniques None None O
are None None O
important None None O
for None None O
safer None None O
arterial None None O
reconstruction None None O
and None None O
a None None O
long None None O
- None None O
term None None O
patency None None O
of None None O
hepatic None None O
artery None None O
in None None O
living None None O
donor None None O
liver None None O
transplantation None None O
in None None O
adults None None O
using None None O
right None None O
lobe None None O
liver None None O
grafts None None O
. None None O

Increased None None O
serum None None O
levels None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
in None None O
patients None None O
with None None O
renal None None O
cell None None O
carcinoma None None O
. None None O

Neovascularization None None O
, None None O
an None None O
essential None None O
event None None O
for None None O
the None None O
growth None None O
of None None O
solid None None O
tumors None None O
, None None O
is None None O
regulated None None O
by None None O
a None None O
number None None O
of None None O
angiogenic None None O
factors None None O
. None None O

One None None O
such None None O
factor None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
is None None O
considered None None O
to None None O
exert None None O
a None None O
potent None None O
angiogenic None None O
activity None None O
, None None O
as None None O
indicated None None O
by None None O
immunohistochemical None None O
and None None O
molecular None None O
evidence None None O
. None None O

In None None O
this None None O
study None None O
we None None O
investigated None None O
the None None O
serum None None O
VEGF None None O
level None None O
( None None O
s None None O
- None None O
VEGF None None O
) None None O
in None None O
patients None None O
with None None O
renal None None O
cell None None O
carcinoma None None O
( None None O
RCC None None O
) None None O
. None None O

s None None O
- None None O
VEGF None None O
in None None O
peripheral None None O
blood None None O
samples None None O
was None None O
analyzed None None O
in None None O
40 None None O
RCC None None O
patients None None O
and None None O
40 None None O
patients None None O
without None None O
cancer None None O
( None None O
controls None None O
) None None O
using None None O
a None None O
sandwich None None O
enzyme None None O
- None None O
linked None None O
immunoassay None None O
. None None O

In None None O
20 None None O
RCC None None O
patients None None O
, None None O
serum None None O
samples None None O
were None None O
obtained None None O
separately None None O
from None None O
the None None O
bilateral None None O
renal None None O
veins None None O
. None None O

s None None O
- None None O
VEGF None None O
was None None O
also None None O
measured None None O
before None None O
, None None O
4 None None O
and None None O
8 None None O
weeks None None O
after None None O
nephrectomy None None O
in None None O
11 None None O
patients None None O
. None None O

There None None O
were None None O
significant None None O
differences None None O
in None None O
s None None O
- None None O
VEGF None None O
between None None O
the None None O
RCC None None O
patients None None O
and None None O
the None None O
controls None None O
( None None O
207 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
32 None None O
. None None O
9 None None O
vs None None O
. None None O
71 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
9 None None O
. None None O
1 None None O
pg None None O
/ None None O
ml None None O
, None None O
mean None None O
+ None None O
/ None None O
- None None O
SE None None O
) None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
005 None None O
) None None O
, None None O
between None None O
the None None O
tumor None None O
- None None O
bearing None None O
renal None None O
veins None None O
and None None O
the None None O
contralateral None None O
ones None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
, None None O
between None None O
the None None O
pre None None O
- None None O
and None None O
post None None O
- None None O
nephrectomy None None O
situations None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
among None None O
the None None O
various None None O
parameters None None O
of None None O
tumor None None O
status None None O
such None None O
as None None O
tumor None None O
extent None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
existence None None O
of None None O
metastasis None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

s None None O
- None None O
VEGF None None O
significantly None None O
correlated None None O
with None None O
the None None O
tumor None None O
volume None None O
obtained None None O
by None None O
a None None O
three None None O
- None None O
dimensional None None O
measurement None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
802 None None O
, None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

The None None O
sensitivity None None O
and None None O
specificity None None O
of None None O
s None None O
- None None O
VEGF None None O
at None None O
the None None O
cut None None O
- None None O
off None None O
level None None O
of None None O
100 None None O
pg None None O
/ None None O
ml None None O
, None None O
as None None O
determined None None O
by None None O
the None None O
receiver None None O
- None None O
operating None None O
- None None O
characteristics None None O
curve None None O
, None None O
were None None O
80 None None O
. None None O
0 None None O
% None None O
and None None O
72 None None O
. None None O
5 None None O
% None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
tumor None None O
tissue None None O
of None None O
RCC None None O
liberates None None O
VEGF None None O
into None None O
the None None O
systemic None None O
blood None None O
flow None None O
and None None O
that None None O
s None None O
- None None O
VEGF None None O
is None None O
a None None O
possible None None O
marker None None O
for None None O
RCC None None O
. None None O

Is None None O
the None None O
elimination None None O
of None None O
HIV None None O
infection None None O
within None None O
reach None None O
in None None O
the None None O
United None None O
States None None O
? None None O

Lessons None None O
from None None O
an None None O
epidemiologic None None O
transmission None None O
model None None O
. None None O

Recent None None O
estimates None None O
show None None O
that None None O
the None None O
transmission None None O
rate None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV None None O
) None None O
in None None O
the None None O
U None None O
. None None O
S None None O
. None None O
has None None O
substantially None None O
decreased None None O
. None None O

This None None O
raises None None O
the None None O
question None None O
, None None O
is None None O
elimination None None O
of None None O
HIV None None O
infection None None O
in None None O
the None None O
nation None None O
feasible None None O
in None None O
the None None O
foreseeable None None O
future None None O
? None None O

We None None O
demonstrate None None O
that None None O
if None None O
the None None O
HIV None None O
transmission None None O
rate None None O
were None None O
reduced None None O
by None None O
50 None None O
% None None O
, None None O
then None None O
the None None O
reproductive None None O
rate None None O
of None None O
HIV None None O
infection None None O
would None None O
drop None None O
below None None O
unity None None O
and None None O
lead None None O
to None None O
eventual None None O
elimination None None O
of None None O
infection None None O
. None None O

In None None O
recent None None O
congressional None None O
testimony None None O
, None None O
the None None O
director None None O
of None None O
the None None O
Centers None None O
for None None O
Disease None None O
Control None None O
and None None O
Prevention None None O
and None None O
others None None O
asserted None None O
that None None O
the None None O
HIV None None O
transmission None None O
rate None None O
can None None O
be None None O
halved None None O
by None None O
2020 None None O
, None None O
if None None O
not None None O
earlier None None O
, None None O
provided None None O
sufficient None None O
investment None None O
is None None O
made None None O
toward None None O
achieving None None O
this None None O
goal None None O
. None None O

We None None O
assert None None O
that None None O
if None None O
adequate None None O
investment None None O
is None None O
made None None O
and None None O
the None None O
transmission None None O
rate None None O
is None None O
in None None O
fact None None O
lowered None None O
by None None O
50 None None O
% None None O
, None None O
then None None O
the None None O
HIV None None O
reproductive None None O
rate None None O
would None None O
fall None None O
below None None O
unity None None O
, None None O
setting None None O
the None None O
stage None None O
for None None O
eventual None None O
elimination None None O
of None None O
HIV None None O
infection None None O
in None None O
the None None O
U None None O
. None None O
S None None O
. None None O

Historical None None O
Background None None O
of None None O
PTSD None None O

PTSD None None O
gained None None O
acceptance None None O
in None None O
the None None O
medical None None O
and None None O
psychiatric None None O
community None None O
after None None O
a None None O
number None None O
of None None O
studies None None O
appeared None None O
in None None O
prominent None None O
medical None None O
and None None O
psychiatric None None O
journals None None O
describing None None O
the None None O
psychiatric None None O
symptoms None None O
of None None O
soldiers None None O
who None None O
had None None O
served None None O
and None None O
fought None None O
in None None O
the None None O
Vietnam None None O
War None None O
( None None O
Fox None None O
1972 None None O
; None None O
Goldsmith None None O
and None None O
Cretekos None None O
1969 None None O
) None None O
. None None O

Subsequent None None O
publications None None O
described None None O
the None None O
profound None None O
psychological None None O
and None None O
emotional None None O
sequelae None None O
secondary None None O
to None None O
being None None O
exposed None None O
to None None O
extremely None None O
traumatic None None O
events None None O
such None None O
as None None O
fires None None O
, None None O
explosions None None O
, None None O
floods None None O
, None None O
torture None None O
, None None O
serious None None O
motor None None O
vehicle None None O
accidents None None O
( None None O
MVAs None None O
) None None O
, None None O
violent None None O
crimes None None O
, None None O
and None None O
sexual None None O
assault None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
Horowitz None None O
1976 None None O
) None None O
. None None O

These None None O
publications None None O
posited None None O
that None None O
individuals None None O
with None None O
PTSD None None O
no None None O
longer None None O
felt None None O
in None None O
control None None O
of None None O
their None None O
lives None None O
, None None O
viewed None None O
the None None O
world None None O
as None None O
an None None O
unpredictable None None O
and None None O
dangerous None None O
place None None O
, None None O
lived None None O
in None None O
fear None None O
, None None O
and None None O
reported None None O
a None None O
loss None None O
of None None O
trust None None O
in None None O
a None None O
" None None O
just None None O
world None None O
. None None O
" None None O
These None None O
studies None None O
also None None O
reported None None O
that None None O
individuals None None O
with None None O
PTSD None None O
avoided None None O
thoughts None None O
or None None O
situations None None O
that None None O
might None None O
trigger None None O
traumatic None None O
memories None None O
, None None O
complained None None O
of None None O
feelings None None O
of None None O
emotional None None O
numbness None None O
, None None O
and None None O
exhibited None None O
symptoms None None O
of None None O
blunted None None O
affect None None O
. None None O

The None None O
conceptual None None O
refinements None None O
coupled None None O
with None None O
the None None O
empirical None None O
information None None O
generated None None O
by None None O
these None None O
studies None None O
significantly None None O
advanced None None O
our None None O
understanding None None O
of None None O
individuals None None O
who None None O
have None None O
been None None O
exposed None None O
to None None O
a None None O
traumatic None None O
stressor None None O
. None None O

This None None O
led None None O
in None None O
1980 None None O
to None None O
the None None O
inclusion None None O
of None None O
the None None O
diagnostic None None O
criteria None None O
for None None O
PTSD None None O
in None None O
the None None O
Diagnostic None None O
and None None O
Statistical None None O
Manual None None O
of None None O
Mental None None O
Disorders None None O
III None None O
( None None O
DSM None None O
- None None O
III None None O
; None None O
American None None O
Psychiatric None None O
Association None None O
1980 None None O
) None None O
. None None O

At None None O
that None None O
time None None O
, None None O
PTSD None None O
was None None O
defined None None O
as None None O
a None None O
syndrome None None O
that None None O
developed None None O
in None None O
response None None O
to None None O
a None None O
" None None O
stressor None None O
that None None O
would None None O
evoke None None O
significant None None O
symptoms None None O
of None None O
distress None None O
in None None O
almost None None O
everyone None None O
" None None O
( None None O
p None None O
. None None O
238 None None O
) None None O
. None None O

The None None O
DSM None None O
- None None O
III None None O
criteria None None O
also None None O
required None None O
that None None O
the None None O
individual None None O
who None None O
developed None None O
PTSD None None O
had None None O
to None None O
have None None O
been None None O
directly None None O
exposed None None O
to None None O
a None None O
traumatic None None O
event None None O
. None None O

The None None O
DSM None None O
- None None O
IV None None O
criteria None None O
( None None O
APA None None O
1994 None None O
) None None O
significantly None None O
broadened None None O
the None None O
definition None None O
of None None O
PTSD None None O
to None None O
include None None O
( None None O
a None None O
) None None O
a None None O
" None None O
personal None None O
experience None None O
of None None O
an None None O
event None None O
that None None O
involves None None O
actual None None O
or None None O
threatened None None O
death None None O
or None None O
serious None None O
injury None None O
, None None O
or None None O
other None None O
threat None None O
to None None O
one None None O
' None None O
s None None O
physical None None O
integrity None None O
" None None O
( None None O
p None None O
. None None O
463 None None O
) None None O
or None None O
( None None O
b None None O
) None None O
witnessing None None O
a None None O
comparable None None O
traumatic None None O
event None None O
or None None O
even None None O
" None None O
learning None None O
about None None O
unexpected None None O
or None None O
violent None None O
death None None O
, None None O
serious None None O
harm None None O
, None None O
or None None O
threat None None O
of None None O
death None None O
or None None O
injury None None O
experienced None None O
by None None O
a None None O
family None None O
member None None O
or None None O
a None None O
close None None O
associate None None O
" None None O
( None None O
p None None O
. None None O
462 None None O
) None None O
. None None O

As None None O
a None None O
consequence None None O
of None None O
these None None O
modifications None None O
, None None O
the None None O
DSM None None O
- None None O
IV None None O
diagnostic None None O
criteria None None O
for None None O
PTSD None None O
have None None O
been None None O
criticized None None O
for None None O
failing None None O
to None None O
discriminate None None O
between None None O
symptoms None None O
of None None O
PTSD None None O
and None None O
normal None None O
stress None None O
reactions None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
learning None None O
about None None O
the None None O
9 None None O
/ None None O
11 None None O
disaster None None O
; None None O
Wakefield None None O
and None None O
Spitzer None None O
2002 None None O
) None None O
. None None O

Obstructive None None O
nephropathy None None O
: None None O
lessons None None O
from None None O
cystic None None O
kidney None None O
disease None None O
. None None O

Obstructive None None O
nephropathy None None O
is None None O
one None None O
of None None O
the None None O
most None None O
important None None O
causes None None O
of None None O
renal None None O
failure None None O
in None None O
infants None None O
and None None O
children None None O
, None None O
while None None O
polycystic None None O
kidney None None O
disease None None O
( None None O
PKD None None O
) None None O
is None None O
a None None O
major None None O
cause None None O
of None None O
renal None None O
failure None None O
in None None O
the None None O
adult None None O
population None None O
. None None O

This None None O
review None None O
summarizes None None O
the None None O
evidence None None O
that None None O
there None None O
may None None O
be None None O
a None None O
number None None O
of None None O
mechanisms None None O
common None None O
to None None O
the None None O
pathophysiology None None O
of None None O
both None None O
conditions None None O
. None None O

In None None O
animal None None O
models None None O
of None None O
obstructive None None O
nephropathy None None O
and None None O
PKD None None O
, None None O
the None None O
renal None None O
tubular None None O
expression None None O
of None None O
epidermal None None O
growth None None O
factor None None O
is None None O
suppressed None None O
, None None O
and None None O
expression None None O
of None None O
clusterin None None O
is None None O
increased None None O
, None None O
both None None O
of None None O
which None None O
suggest None None O
arrested None None O
maturation None None O
or None None O
dedifferentiation None None O
of None None O
the None None O
tubular None None O
cell None None O
. None None O

There None None O
is None None O
a None None O
marked None None O
increase None None O
in None None O
apoptosis None None O
of None None O
epithelial None None O
cells None None O
in None None O
dilated None None O
tubules None None O
, None None O
associated None None O
with None None O
an None None O
increase None None O
in None None O
apoptotic None None O
stimuli None None O
. None None O

The None None O
renin None None O
- None None O
angiotensin None None O
system None None O
is None None O
activated None None O
in None None O
both None None O
obstructive None None O
nephropathy None None O
and None None O
PKD None None O
, None None O
which None None O
may None None O
contribute None None O
to None None O
tubular None None O
atrophy None None O
and None None O
interstitial None None O
fibrosis None None O
, None None O
which None None O
characterize None None O
the None None O
progression None None O
of None None O
both None None O
conditions None None O
. None None O

Focal None None O
cystic None None O
dilatation None None O
of None None O
the None None O
tubule None None O
is None None O
found None None O
in None None O
obstructive None None O
nephropathy None None O
, None None O
while None None O
tubular None None O
obstruction None None O
is None None O
present None None O
in None None O
cystic None None O
kidney None None O
disease None None O
. None None O

It None None O
is None None O
therefore None None O
likely None None O
that None None O
elucidation None None O
of None None O
the None None O
effects None None O
of None None O
mechanical None None O
stretch None None O
on None None O
renal None None O
tubular None None O
epithelial None None O
cells None None O
will None None O
contribute None None O
to None None O
our None None O
understanding None None O
of None None O
both None None O
conditions None None O
. None None O

Handling None None O
within None None O
run None None O
retention None None O
time None None O
shifts None None O
in None None O
two None None O
- None None O
dimensional None None O
chromatography None None O
data None None O
using None None O
shift None None O
correction None None O
and None None O
modeling None None O
. None None O

The None None O
use None None O
of None None O
PARAFAC None None O
for None None O
modeling None None O
GC None None O
x None None O
GC None None O
- None None O
TOFMS None None O
peaks None None O
is None None O
well None None O
documented None None O
. None None O

This None None O
success None None O
is None None O
due None None O
to None None O
the None None O
trilinear None None O
structure None None O
of None None O
these None None O
data None None O
under None None O
ideal None None O
, None None O
or None None O
sufficiently None None O
close None None O
to None None O
ideal None None O
, None None O
chromatographic None None O
conditions None None O
. None None O

However None None O
, None None O
using None None O
temperature None None O
programming None None O
to None None O
cope None None O
with None None O
the None None O
general None None O
elution None None O
problem None None O
, None None O
deviations None None O
from None None O
trilinearity None None O
within None None O
a None None O
run None None O
are None None O
more None None O
likely None None O
to None None O
be None None O
seen None None O
for None None O
the None None O
following None None O
three None None O
cases None None O
: None None O
( None None O
1 None None O
) None None O
compounds None None O
( None None O
i None None O
. None None O
e None None O
. None None O
, None None O
analytes None None O
) None None O
severely None None O
broadened None None O
on None None O
the None None O
first None None O
column None None O
hence None None O
defined None None O
by None None O
many None None O
modulation None None O
periods None None O
, None None O
( None None O
2 None None O
) None None O
analytes None None O
with None None O
a None None O
very None None O
high None None O
retention None None O
factor None None O
on None None O
the None None O
second None None O
column None None O
and None None O
likely None None O
wrapped None None O
around None None O
in None None O
that None None O
dimension None None O
, None None O
or None None O
( None None O
3 None None O
) None None O
with None None O
fast None None O
temperature None None O
program None None O
rates None None O
. None None O

This None None O
deviation None None O
from None None O
trilinearity None None O
is None None O
seen None None O
as None None O
retention None None O
time None None O
- None None O
shifted None None O
peak None None O
profiles None None O
in None None O
subsequent None None O
modulation None None O
periods None None O
( None None O
first None None O
column None None O
fractions None None O
) None None O
. None None O

In None None O
this None None O
report None None O
, None None O
a None None O
relaxed None None O
yet None None O
powerful None None O
version None None O
of None None O
PARAFAC None None O
, None None O
known None None O
as None None O
PARAFAC2 None None O
has None None O
been None None O
applied None None O
to None None O
handle None None O
this None None O
shift None None O
within None None O
the None None O
model None None O
step None None O
by None None O
allowing None None O
generation None None O
of None None O
individual None None O
peak None None O
profiles None None O
in None None O
subsequent None None O
first None None O
column None None O
fractions None None O
. None None O

An None None O
alternative None None O
approach None None O
was None None O
also None None O
studied None None O
, None None O
utilizing None None O
a None None O
standard None None O
retention None None O
time None None O
shift None None O
correction None None O
to None None O
restore None None O
the None None O
data None None O
trilinearity None None O
structure None None O
followed None None O
by None None O
PARAFAC None None O
. None None O

These None None O
two None None O
approaches None None O
are None None O
compared None None O
when None None O
identifying None None O
and None None O
quantifying None None O
a None None O
known None None O
analyte None None O
over None None O
a None None O
large None None O
concentration None None O
series None None O
where None None O
a None None O
certain None None O
shift None None O
is None None O
simulated None None O
in None None O
the None None O
successive None None O
first None None O
column None None O
fractions None None O
. None None O

Finally None None O
, None None O
the None None O
methods None None O
are None None O
applied None None O
to None None O
real None None O
chromatographic None None O
data None None O
showing None None O
severely None None O
shifted None None O
peak None None O
profiles None None O
. None None O

The None None O
pros None None O
and None None O
cons None None O
of None None O
the None None O
presented None None O
approaches None None O
are None None O
discussed None None O
in None None O
relation None None O
to None None O
the None None O
model None None O
parameters None None O
, None None O
the None None O
signal None None O
- None None O
to None None O
- None None O
noise None None O
ratio None None O
and None None O
the None None O
degree None None O
of None None O
shift None None O
. None None O

Therapeutic None None O
Electromagnetic None None O
Field None None O
( None None O
TEMF None None O
) None None O
and None None O
gamma None None O
irradiation None None O
on None None O
human None None O
breast None None O
cancer None None O
xenograft None None O
growth None None O
, None None O
angiogenesis None None O
and None None O
metastasis None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
effects None None O
of None None O
a None None O
rectified None None O
semi None None O
- None None O
sinewave None None O
signal None None O
( None None O
15 None None O
mT None None O
amplitude None None O
, None None O
120 None None O
pulses None None O
per None None O
second None None O
, None None O
EMF None None O
Therapeutics None None O
, None None O
Inc None None O
. None None O
) None None O
( None None O
TEMF None None O
) None None O
alone None None O
and None None O
in None None O
combination None None O
with None None O
gamma None None O
irradiation None None O
( None None O
IR None None O
) None None O
therapy None None O
in None None O
nude None None O
mice None None O
bearing None None O
a None None O
human None None O
MDA None None I-Cell-line-name
MB231 None None I-Cell-line-name
breast None None O
cancer None None O
xenograft None None O
were None None O
tested None None O
. None None O

Green None None O
fluorescence None None O
protein None None O
transfected None None O
cancer None None O
cells None None O
were None None O
injected None None O
into None None O
the None None O
mammary None None O
fat None None O
pad None None O
of None None O
young None None O
female None None O
mice None None O
. None None O

Six None None O
weeks None None O
later None None O
, None None O
mice None None O
were None None O
randomly None None O
divided None None O
into None None O
four None None O
treatment None None O
groups None None O
: None None O
untreated None None O
controls None None O
; None None O
10 None None O
minute None None O
daily None None O
TEMF None None O
; None None O
200 None None O
cGy None None O
of None None O
IR None None O
every None None O
other None None O
day None None O
( None None O
total None None O
800 None None O
cGy None None O
) None None O
; None None O
IR None None O
plus None None O
daily None None O
TEMF None None O
. None None O

Some None None O
mice None None O
in None None O
each None None O
group None None O
were None None O
euthanized None None O
24 None None O
hours None None O
after None None O
the None None O
end None None O
of None None O
IR None None O
. None None O

TEMF None None O
treatment None None O
continued None None O
for None None O
3 None None O
additional None None O
weeks None None O
. None None O

Tumor None None O
sections None None O
were None None O
stained None None O
for None None O
: None None O
endothelial None None O
cells None None O
with None None O
CD31 None None O
and None None O
PAS None None O
or None None O
hypoxia None None O
inducible None None O
factor None None O
1alpha None None O
( None None O
HIF None None O
) None None O
. None None O

RESULTS None None O
: None None O
Most None None O
tumors None None O
less None None O
than None None O
35 None None O
mm3 None None O
were None None O
white None None O
but None None O
tumors None None O
greater None None O
than None None O
35 None None O
mm3 None None O
were None None O
pink None None O
and None None O
had None None O
a None None O
vascularized None None O
capsule None None O
. None None O

The None None O
cortex None None O
within None None O
100 None None O
microns None None O
of None None O
the None None O
capsule None None O
had None None O
little None None O
vascularization None None O
. None None O

Blood None None O
vessels None None O
, None None O
capillaries None None O
, None None O
and None None O
endothelial None None O
pseudopods None None O
were None None O
found None None O
at None None O
greater None None O
than None None O
100 None None O
microns None None O
from None None O
the None None O
capsule None None O
( None None O
subcortex None None O
) None None O
. None None O

Tumors None None O
greater None None O
than None None O
35 None None O
mm3 None None O
treated None None O
with None None O
IR None None O
24 None None O
hours None None O
previously None None O
or None None O
with None None O
TEMF None None O
had None None O
decreased None None O
blood None None O
vessels None None O
in None None O
the None None O
subcortex None None O
and None None O
more None None O
endothelial None None O
pseudopods None None O
projecting None None O
into None None O
hypoxic None None O
, None None O
HIF None None O
positive None None O
areas None None O
than None None O
tumors None None O
from None None O
the None None O
control None None O
group None None O
. None None O

Mice None None O
that None None O
received None None O
either None None O
IR None None O
or None None O
TEMF None None O
had None None O
significantly None None O
fewer None None O
lung None None O
metastatic None None O
sites None None O
and None None O
slower None None O
tumor None None O
growth None None O
than None None O
did None None O
untreated None None O
mice None None O
. None None O

No None None O
harmful None None O
side None None O
effects None None O
were None None O
attributed None None O
to None None O
TEMF None None O
. None None O

CONCLUSION None None O
: None None O
TEMF None None O
therapy None None O
provided None None O
a None None O
safe None None O
means None None O
for None None O
retarding None None O
tumor None None O
vascularization None None O
, None None O
growth None None O
and None None O
metastasis None None O
. None None O

Central None None O
nervous None None O
system None None O
infection None None O
with None None O
Eikenella None None O
corrodens None None O
: None None O
report None None O
of None None O
two None None O
cases None None O
. None None O

Two None None O
cases None None O
of None None O
central None None O
nervous None None O
system None None O
infections None None O
from None None O
which None None O
E None None O
. None None O
corrodens None None O
has None None O
been None None O
isolated None None O
are None None O
reported None None O
. None None O

The None None O
portals None None O
of None None O
entry None None O
, None None O
clinical None None O
course None None O
, None None O
and None None O
antimicrobial None None O
responses None None O
conform None None O
to None None O
other None None O
reports None None O
in None None O
the None None O
literature None None O
. None None O

The None None O
importance None None O
of None None O
obtaining None None O
careful None None O
anaerobic None None O
cultures None None O
is None None O
emphasized None None O
. None None O

CONCLUSIONS None None O

The None None O
lack None None O
of None None O
association None None O
between None None O
depression None None O
and None None O
glycemic None None O
control None None O
is None None O
not None None O
due None None O
to None None O
the None None O
use None None O
of None None O
a None None O
binary None None O
measure None None O
of None None O
depression None None O
. None None O

Findings None None O
further None None O
clarify None None O
the None None O
significant None None O
association None None O
between None None O
distress None None O
and None None O
A1C None None O
. None None O

Competing None None O
interests None None O

None None None O
declared None None O
. None None O

This None None O
article None None O
is None None O
the None None O
third None None O
in None None O
an None None O
ongoing None None O
, None None O
educational None None O
review None None O
series None None O
on None None O
medical None None O
statistics None None O
in None None O
critical None None O
care None None O
. None None O

Previous None None O
articles None None O
have None None O
covered None None O
' None None O
presenting None None O
and None None O
summarising None None O
data None None O
' None None O
[ None None O
3 None None O
] None None O
and None None O
' None None O
samples None None O
and None None O
populations None None O
' None None O
[ None None O
4 None None O
] None None O
. None None O

Future None None O
topics None None O
to None None O
be None None O
covered None None O
include None None O
power None None O
calculations None None O
, None None O
comparison None None O
of None None O
means None None O
, None None O
comparison None None O
of None None O
proportions None None O
, None None O
and None None O
analysis None None O
of None None O
survival None None O
data None None O
to None None O
name None None O
but None None O
a None None O
few None None O
. None None O

If None None O
there None None O
is None None O
a None None O
medical None None O
statistics None None O
topic None None O
you None None O
would None None O
like None None O
explained None None O
contact None None O
us None None O
on None None O
editorial None None O
@ None None O
ccforum None None O
. None None O
com None None O
. None None O

Selective None None O
activation None None O
of None None O
mast None None O
cells None None O
in None None O
rheumatoid None None O
synovial None None O
tissue None None O
results None None O
in None None O
production None None O
of None None O
TNF None None O
- None None O
alpha None None O
, None None O
IL None None O
- None None O
1beta None None O
and None None O
IL None None O
- None None O
1Ra None None O
. None None O

OBJECTIVES None None O
AND None None O
DESIGN None None O
: None None O

To None None O
study None None O
the None None O
consequences None None O
of None None O
mast None None O
cell None None O
activation None None O
in None None O
human None None O
synovial None None O
tissue None None O
. None None O

METHODS None None O
: None None O

Synovial None None O
tissue None None O
was None None O
obtained None None O
from None None O
18 None None O
RA None None O
patients None None O
and None None O
mast None None O
cells None None O
was None None O
selectively None None O
activated None None O
in None None O
synovial None None O
tissue None None O
explant None None O
cultures None None O
. None None O

Expression None None O
of None None O
TNF None None O
- None None O
alpha None None O
, None None O
IL None None O
- None None O
1beta None None O
and None None O
IL None None O
- None None O
1Ra None None O
were None None O
determined None None O
and None None O
tissue None None O
distribution None None O
of None None O
IL None None O
- None None O
1beta None None O
was None None O
studied None None O
. None None O

RESULTS None None O
: None None O

Compared None None O
to None None O
untreated None None O
synovia None None O
, None None O
selective None None O
activation None None O
of None None O
synovial None None O
mast None None O
cells None None O
increased None None O
significantly None None O
the None None O
production None None O
of None None O
TNF None None O
- None None O
alpha None None O
( None None O
0 None None O
. None None O
49 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
88 None None O
vs None None O
. None None O
4 None None O
. None None O
56 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
18 None None O
pg None None O
/ None None O
mg None None O
wet None None O
tissue None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
and None None O
IL None None O
- None None O
1beta None None O
( None None O
0 None None O
. None None O
058 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
032 None None O
vs None None O
. None None O
2 None None O
. None None O
55 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
98 None None O
pg None None O
/ None None O
mg None None O
wet None None O
tissue None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
013 None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
TNF None None O
- None None O
alpha None None O
and None None O
IL None None O
- None None O
1beta None None O
mRNA None None O
increased None None O
significantly None None O
( None None O
19 None None O
- None None O
fold None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
009 None None O
) None None O
and None None O
13 None None O
- None None O
fold None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
031 None None O
) None None O
, None None O
respectively None None O
) None None O
. None None O

Mast None None O
cell None None O
activation None None O
induced None None O
IL None None O
- None None O
1beta None None O
expression None None O
in None None O
particular None None O
in None None O
nearby None None O
CD68 None None O
positive None None O
synovial None None O
macrophages None None O
. None None O

Secretion None None O
of None None O
IL None None O
- None None O
1Ra None None O
was None None O
also None None O
increased None None O
but None None O
to None None O
a None None O
lesser None None O
degree None None O
than None None O
that None None O
of None None O
IL None None O
- None None O
1beta None None O
. None None O

CONCLUSIONS None None O
: None None O

Synovial None None O
mast None None O
cells None None O
produce None None O
proinflammmatory None None O
cytokines None None O
and None None O
may None None O
thus None None O
contribute None None O
to None None O
the None None O
inflammation None None O
in None None O
RA None None O
. None None O

Sealant None None O
application None None O
criteria None None O
for None None O
molar None None O
fissures None None O

Effects None None O
of None None O
dietary None None O
folate None None O
on None None O
ulcerative None None O
colitis None None O
- None None O
associated None None O
colorectal None None O
carcinogenesis None None O
in None None O
the None None O
interleukin None None O
2 None None O
- None None O
and None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
microglobulin None None O
- None None O
deficient None None O
mice None None O
. None None O

Folate None None O
supplementation None None O
may None None O
reduce None None O
the None None O
risk None None O
of None None O
colorectal None None O
dysplasia None None O
and None None O
cancer None None O
in None None O
subjects None None O
with None None O
chronic None None O
ulcerative None None O
colitis None None O
( None None O
UC None None O
) None None O
. None None O

The None None O
interleukin None None O
( None None O
IL None None O
) None None O
2 None None O
- None None O
and None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
microglobulin None None O
( None None O
beta None None O
( None None O
2 None None O
) None None O
m None None O
) None None O
- None None O
deficient None None O
( None None O
IL None None O
- None None O
2 None None O
( None None O
null None None O
) None None O
x None None O
beta None None O
( None None O
2 None None O
) None None O
m None None O
( None None O
null None None O
) None None O
) None None O
mice None None O
spontaneously None None O
develop None None O
colon None None O
cancer None None O
in None None O
the None None O
setting None None O
of None None O
chronic None None O
UC None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
effects None None O
of None None O
dietary None None O
folate None None O
on None None O
the None None O
development None None O
of None None O
UC None None O
- None None O
associated None None O
colon None None O
cancer None None O
in None None O
the None None O
IL None None O
- None None O
2 None None O
( None None O
null None None O
) None None O
x None None O
beta None None O
( None None O
2 None None O
) None None O
m None None O
( None None O
null None None O
) None None O
mice None None O
. None None O

Weaning None None O
IL None None O
- None None O
2 None None O
( None None O
null None None O
) None None O
x None None O
beta None None O
( None None O
2 None None O
) None None O
m None None O
( None None O
null None None O
) None None O
mice None None O
were None None O
randomized None None O
to None None O
receive None None O
0 None None O
( None None O
deficient None None O
; None None O
n None None O
= None None O
40 None None O
) None None O
, None None O
2 None None O
( None None O
basal None None O
requirement None None O
; None None O
control None None O
; None None O
n None None O
= None None O
46 None None O
) None None O
, None None O
or None None O
8 None None O
( None None O
supplemented None None O
; None None O
n None None O
= None None O
36 None None O
) None None O
mg None None O
folate None None O
/ None None O
kg None None O
diet None None O
for None None O
32 None None O
weeks None None O
. None None O

At None None O
necropsy None None O
, None None O
all None None O
macroscopic None None O
colonic None None O
tumors None None O
were None None O
identified None None O
and None None O
histologically None None O
classified None None O
as None None O
dysplasia None None O
or None None O
adenocarcinoma None None O
. None None O

The None None O
incidence None None O
of None None O
high None None O
- None None O
grade None None O
lesions None None O
( None None O
high None None O
- None None O
grade None None O
dysplasia None None O
/ None None O
carcinoma None None O
in None None O
situ None None O
and None None O
invasive None None O
adenocarcinoma None None O
) None None O
in None None O
the None None O
folate None None O
- None None O
supplemented None None O
group None None O
was None None O
46 None None O
% None None O
lower None None O
than None None O
that None None O
in None None O
the None None O
control None None O
group None None O
( None None O
35 None None O
. None None O
3 None None O
% None None O
versus None None O
65 None None O
. None None O
1 None None O
% None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
009 None None O
) None None O
. None None O

The None None O
incidence None None O
of None None O
high None None O
- None None O
grade None None O
lesions None None O
in None None O
the None None O
folate None None O
- None None O
deficient None None O
group None None O
was None None O
also None None O
49 None None O
% None None O
lower None None O
than None None O
that None None O
in None None O
the None None O
control None None O
group None None O
( None None O
33 None None O
. None None O
3 None None O
% None None O
versus None None O
65 None None O
. None None O
1 None None O
% None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
007 None None O
) None None O
. None None O

The None None O
higher None None O
mortality None None O
rate None None O
in None None O
the None None O
folate None None O
- None None O
deficient None None O
group None None O
compared None None O
with None None O
the None None O
other None None O
two None None O
groups None None O
( None None O
25 None None O
% None None O
versus None None O
6 None None O
. None None O
5 None None O
% None None O
and None None O
5 None None O
. None None O
6 None None O
% None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
02 None None O
) None None O
partially None None O
accounted None None O
for None None O
the None None O
low None None O
incidence None None O
of None None O
high None None O
- None None O
grade None None O
lesions None None O
in None None O
this None None O
group None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
dietary None None O
folate None None O
supplementation None None O
at None None O
4x None None O
the None None O
basal None None O
dietary None None O
requirement None None O
significantly None None O
suppresses None None O
UC None None O
- None None O
associated None None O
colorectal None None O
carcinogenesis None None O
in None None O
the None None O
IL None None O
- None None O
2 None None O
( None None O
null None None O
) None None O
x None None O
beta None None O
( None None O
2 None None O
) None None O
m None None O
( None None O
null None None O
) None None O
mice None None O
. None None O

These None None O
data None None O
also None None O
suggest None None O
that None None O
folate None None O
deficiency None None O
may None None O
inhibit None None O
colorectal None None O
carcinogenesis None None O
in None None O
chronic None None O
UC None None O
. None None O

However None None O
, None None O
the None None O
high None None O
mortality None None O
observed None None O
in None None O
the None None O
folate None None O
- None None O
deficient None None O
group None None O
precludes None None O
a None None O
definitive None None O
conclusion None None O
concerning None None O
the None None O
effect None None O
of None None O
folate None None O
deficiency None None O
on None None O
UC None None O
- None None O
associated None None O
colorectal None None O
carcinogenesis None None O
in None None O
this None None O
model None None O
. None None O

Isotype None None O
- None None O
specific None None O
inhibitors None None O
of None None O
the None None O
glycolytic None None O
key None None O
regulator None None O
pyruvate None None O
kinase None None O
subtype None None O
M2 None None O
moderately None None O
decelerate None None O
tumor None None O
cell None None O
proliferation None None O
. None None O

Tumor None None O
cells None None O
express None None O
the None None O
glycolytic None None O
regulator None None O
pyruvate None None O
kinase None None O
subtype None None O
M2 None None O
( None None O
M2 None None O
- None None O
PK None None O
) None None O
, None None O
which None None O
can None None O
occur None None O
in None None O
a None None O
tetrameric None None O
form None None O
with None None O
high None None O
affinity None None O
to None None O
its None None O
substrate None None O
phosphoenolpyruvate None None O
( None None O
PEP None None O
) None None O
and None None O
a None None O
dimeric None None O
form None None O
with None None O
a None None O
low None None O
PEP None None O
affinity None None O
. None None O

The None None O
transition None None O
between None None O
both None None O
conformations None None O
contributes None None O
to None None O
the None None O
control None None O
of None None O
glycolysis None None O
and None None O
is None None O
important None None O
for None None O
tumor None None O
cell None None O
proliferation None None O
and None None O
survival None None O
. None None O

Here None None O
we None None O
targeted None None O
M2 None None O
- None None O
PK None None O
by None None O
synthetic None None O
peptide None None O
aptamers None None O
, None None O
which None None O
specifically None None O
bind None None O
to None None O
M2 None None O
- None None O
PK None None O
and None None O
shift None None O
the None None O
isoenzyme None None O
into None None O
its None None O
low None None O
affinity None None O
dimeric None None O
conformation None None O
. None None O

The None None O
aptamer None None O
- None None O
induced None None O
dimerization None None O
and None None O
inactivation None None O
of None None O
M2 None None O
- None None O
PK None None O
led None None O
to None None O
a None None O
significant None None O
decrease None None O
in None None O
the None None O
PK None None O
mass None None O
- None None O
action None None O
ratio None None O
as None None O
well None None O
as None None O
ATP None None O
: None None O
ADP None None O
ratio None None O
in None None O
the None None O
target None None O
cells None None O
. None None O

Furthermore None None O
, None None O
the None None O
expression None None O
of None None O
M2 None None O
- None None O
PK None None O
- None None O
binding None None O
peptide None None O
aptamers None None O
moderately None None O
reduced None None O
the None None O
growth None None O
of None None O
immortalized None None O
NIH3T3 None None I-Cell-line-name
cell None None O
populations None None O
by None None O
decelerating None None O
cell None None O
proliferation None None O
, None None O
but None None O
without None None O
affecting None None O
apoptotic None None O
cell None None O
death None None O
. None None O

Moreover None None O
, None None O
the None None O
M2 None None O
- None None O
PK None None O
- None None O
binding None None O
peptide None None O
aptamers None None O
also None None O
reduced None None O
the None None O
proliferation None None O
rate None None O
of None None O
human None None O
U None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
OS None None O
osteosarcoma None None O
cells None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
developed None None O
the None None O
first None None O
specific None None O
inhibitors None None O
of None None O
the None None O
pyruvate None None O
kinase None None O
isoenzyme None None O
type None None O
M2 None None O
and None None O
present None None O
evidence None None O
that None None O
these None None O
inhibitors None None O
moderately None None O
decelerate None None O
tumor None None O
cell None None O
proliferation None None O
. None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Effect None None O
of None None O
the None None O
deletion None None O
of None None O
IRE1alpha None None O
on None None O
the None None O
liver None None O
. None None O

( None None O
A None None O
) None None O
HE None None O
- None None O
stained None None O
sections None None O
of None None O
the None None O
liver None None O
tissue None None O
( None None O
scale None None O
bar None None O
: None None O
50 None None O
mum None None O
) None None O
. None None O

( None None O
B None None O
) None None O
Comparison None None O
of None None O
the None None O
serum None None O
AST None None O
and None None O
ALT None None O
levels None None O
between None None O
the None None O
IRE1alpha None None O
CKO None None O
mice None None O
and None None O
the None None O
control None None O
mice None None O
. None None O

Data None None O
are None None O
expressed None None O
as None None O
mean None None O
+ None None O
/ None None O
- None None O
S None None O
. None None O
E None None O
. None None O
M None None O
( None None O
n None None O
= None None O
5 None None O
) None None O
. None None O

( None None O
C None None O
) None None O
Quantitative None None O
PCR None None O
analysis None None O
of None None O
lipid None None O
synthesis None None O
genes None None O
in None None O
the None None O
liver None None O
of None None O
mice None None O
fed None None O
normal None None O
or None None O
high None None O
- None None O
fructose None None O
feed None None O
. None None O

Columns None None O
indicate None None O
mean None None O
and None None O
error None None O
bars None None O
denote None None O
S None None O
. None None O
E None None O
. None None O
M None None O
( None None O
n None None O
= None None O
3 None None O
) None None O
. None None O

All None None O
the None None O
data None None O
were None None O
obtained None None O
from None None O
20 None None O
weeks None None O
old None None O
male None None O
mice None None O
. None None O

Nucleotide None None O
features None None O
of None None O
free None None O
- None None O
standing None None O
homing None None O
- None None O
endonucleases None None O

Gene None None O
control None None O
elements None None O
were None None O
identified None None O
for None None O
several None None O
members None None O
of None None O
each None None O
type None None O
of None None O
intervening None None O
homing None None O
endonuclease None None O
genes None None O
described None None O
in None None O
this None None O
study None None O
. None None O

In None None O
15 None None O
out None None O
of None None O
16 None None O
, None None O
5 None None O
' None None O
untranslated None None O
regions None None O
of None None O
the None None O
endonucleases None None O
we None None O
identified None None O
RNA None None O
hairpin None None O
structures None None O
upstream None None O
of None None O
initiation None None O
codons None None O
( None None O
Figures None None O
1 None None O
and None None O
4A None None O
) None None O
. None None O

This None None O
may None None O
be None None O
a None None O
translational None None O
regulatory None None O
hairpin None None O
structure None None O
known None None O
from None None O
various None None O
phage None None O
genes None None O
, None None O
including None None O
homing None None O
endonucleases None None O
( None None O
22 None None O
, None None O
47 None None O
- None None O
49 None None O
) None None O
. None None O

The None None O
hairpins None None O
we None None O
found None None O
are None None O
in None None O
fractured None None O
gene None None O
loci None None O
with None None O
different None None O
protein None None O
host None None O
types None None O
, None None O
including None None O
gp41 None None O
, None None O
IMPDH None None O
, None None O
DnaE None None O
, None None O
NrdJ None None O
and None None O
NrdA None None O
. None None O

Ten None None O
of None None O
these None None O
hairpins None None O
also None None O
include None None O
a None None O
conserved None None O
sequence None None O
of None None O
Aeh1 None None O
phage None None O
late None None O
promoter None None O
element None None O
( None None O
TATAAATA None None O
) None None O
, None None O
which None None O
was None None O
recently None None O
shown None None O
to None None O
inhibit None None O
the None None O
translation None None O
of None None O
a None None O
gene None None O
- None None O
fracturing None None O
endonuclease None None O
gene None None O
, None None O
by None None O
sequestering None None O
its None None O
ribosome None None O
binding None None O
site None None O
( None None O
22 None None O
, None None O
23 None None O
) None None O
. None None O

Analysis None None O
of None None O
the None None O
endonuclease None None O
5 None None O
' None None O
untranslated None None O
regions None None O
revealed None None O
two None None O
conserved None None O
motifs None None O
( None None O
Figures None None O
4A None None O
and None None O
Supplementary None None O
Figure None None O
S4 None None O
) None None O
, None None O
which None None O
usually None None O
complement None None O
each None None O
other None None O
on None None O
the None None O
stem None None O
of None None O
the None None O
conserved None None O
hairpin None None O
structures None None O
. None None O

Figure None None O
4 None None O
. None None O

Nucleotide None None O
features None None O
of None None O
endonuclease None None O
genes None None O
. None None O

( None None O
A None None O
) None None O
RNA None None O
hairpin None None O
structures None None O
at None None O
the None None O
5 None None O
' None None O
untranslated None None O
region None None O
of None None O
endonuclease None None O
ORFs None None O
in None None O
the None None O
gp41 None None O
- None None O
1 None None O
( None None O
representing None None O
the None None O
very None None O
similar None None O
sequences None None O
of None None O
gp41 None None O
- None None O
1 None None O
- None None O
7 None None O
) None None O
, None None O
nrdA None None O
- None None O
5 None None O
and None None O
DnaE None None O
- None None O
1 None None O
gene None None O
loci None None O
. None None O

Initiator None None O
codons None None O
are None None O
marked None None O
by None None O
arrows None None O
, None None O
conserved None None O
putative None None O
T4 None None O
late None None O
promoter None None O
elements None None O
are None None O
boxed None None O
, None None O
and None None O
conserved None None O
sequence None None O
motifs None None O
( None None O
Supplementary None None O
Figure None None O
S4 None None O
) None None O
are None None O
highlighted None None O
in None None O
grey None None O
. None None O

The None None O
expected None None O
values None None O
for None None O
motifs None None O
1 None None O
and None None O
2 None None O
are None None O
1 None None O
. None None O
7 None None O
- None None O
10 None None O
and None None O
9 None None O
. None None O
9 None None O
- None None O
3 None None O
, None None O
respectively None None O
. None None O

RNA None None O
structures None None O
were None None O
calculated None None O
using None None O
the None None O
Vienna None None O
package None None O
( None None O
http None None O
: None None O
/ None None O
/ None None O
rna None None O
. None None O
tbi None None O
. None None O
univie None None O
. None None O
ac None None O
. None None O
at None None O
/ None None O
cgi None None O
- None None O
bin None None O
/ None None O
RNAfold None None O
. None None O
cgi None None O
) None None O
, None None O
and None None O
sequence None None O
motifs None None O
were None None O
identified None None O
using None None O
the None None O
MEME None None O
program None None O
. None None O

( None None O
B None None O
) None None O
Overlapping None None O
# None None O
protein None None O
coding None None O
regions None None O
of None None O
endonuclease None None O
3 None None O
' None None O
termini None None O
and None None O
the None None O
5 None None O
' None None O
termini None None O
of None None O
their None None O
downstream None None O
genes None None O
. None None O

Additionally None None O
, None None O
15 None None O
loci None None O
included None None O
an None None O
overlapping None None O
region None None O
of None None O
6 None None O
- None None O
69 None None O
bp None None O
between None None O
the None None O
coding None None O
regions None None O
of None None O
the None None O
probable None None O
endonuclease None None O
C None None O
- None None O
termini None None O
and None None O
the None None O
downstream None None O
N None None O
- None None O
termini None None O
of None None O
the None None O
split None None O
- None None O
intein None None O
part None None O
( None None O
Figures None None O
1 None None O
and None None O
4B None None O
) None None O
. None None O

This None None O
overlap None None O
is None None O
present None None O
in None None O
both None None O
types None None O
of None None O
endonucleases None None O
, None None O
and None None O
is None None O
independent None None O
on None None O
the None None O
presence None None O
of None None O
a None None O
split None None O
- None None O
intein None None O
part None None O
in None None O
the None None O
fractured None None O
gene None None O
, None None O
also None None O
occurring None None O
in None None O
the None None O
putative None None O
sbcD None None O
DNA None None O
- None None O
repair None None O
gene None None O
that None None O
we None None O
found None None O
, None None O
as None None O
well None None O
as None None O
in None None O
the None None O
Aeh1 None None O
fractured None None O
nrdA None None O
found None None O
by None None O
Gibb None None O
and None None O
Edgell None None O
( None None O
22 None None O
) None None O
. None None O

Mechanical None None O
regulation None None O
of None None O
the None None O
proangiogenic None None O
factor None None O
CCN1 None None O
/ None None O
CYR61 None None O
gene None None O
requires None None O
the None None O
combined None None O
activities None None O
of None None O
MRTF None None O
- None None O
A None None O
and None None O
CREB None None O
- None None O
binding None None O
protein None None O
histone None None O
acetyltransferase None None O
. None None O

Smooth None None O
muscle None None O
- None None O
rich None None O
tissues None None O
respond None None O
to None None O
mechanical None None O
overload None None O
by None None O
an None None O
adaptive None None O
hypertrophic None None O
growth None None O
combined None None O
with None None O
activation None None O
of None None O
angiogenesis None None O
, None None O
which None None O
potentiates None None O
their None None O
mechanical None None O
overload None None O
- None None O
bearing None None O
capabilities None None O
. None None O

Neovascularization None None O
is None None O
associated None None O
with None None O
mechanical None None O
strain None None O
- None None O
dependent None None O
induction None None O
of None None O
angiogenic None None O
factors None None O
such None None O
as None None O
CCN1 None None O
, None None O
an None None O
immediate None None O
- None None O
early None None O
gene None None O
- None None O
encoded None None O
matricellular None None O
molecule None None O
critical None None O
for None None O
vascular None None O
development None None O
and None None O
repair None None O
. None None O

Here None None O
we None None O
have None None O
demonstrated None None O
that None None O
mechanical None None O
strain None None O
- None None O
dependent None None O
induction None None O
of None None O
the None None O
CCN1 None None O
gene None None O
involves None None O
signaling None None O
cascades None None O
through None None O
RhoA None None O
- None None O
mediated None None O
actin None None O
remodeling None None O
and None None O
the None None O
p38 None None O
stress None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
SAPK None None O
) None None O
. None None O

Actin None None O
signaling None None O
controls None None O
serum None None O
response None None O
factor None None O
( None None O
SRF None None O
) None None O
activity None None O
via None None O
SRF None None O
interaction None None O
with None None O
the None None O
myocardin None None O
- None None O
related None None O
transcriptional None None O
activator None None O
( None None O
MRTF None None O
) None None O
- None None O
A None None O
and None None O
tethering None None O
to None None O
a None None O
single None None O
CArG None None O
box None None O
sequence None None O
within None None O
the None None O
CCN1 None None O
promoter None None O
. None None O

Such None None O
activity None None O
was None None O
abolished None None O
in None None O
mechanically None None O
stimulated None None O
mouse None None O
MRTF None None O
- None None O
A None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
or None None O
upon None None O
inhibition None None O
of None None O
CREB None None O
- None None O
binding None None O
protein None None O
( None None O
CBP None None O
) None None O
histone None None O
acetyltransferase None None O
( None None O
HAT None None O
) None None O
either None None O
pharmacologically None None O
or None None O
by None None O
siRNAs None None O
. None None O

Mechanical None None O
strain None None O
induced None None O
CBP None None O
- None None O
mediated None None O
acetylation None None O
of None None O
histones None None O
3 None None O
and None None O
4 None None O
at None None O
the None None O
SRF None None O
- None None O
binding None None O
site None None O
and None None O
within None None O
the None None O
CCN1 None None O
gene None None O
coding None None O
region None None O
. None None O

Inhibition None None O
of None None O
p38 None None O
SAPK None None O
reduced None None O
CBP None None O
HAT None None O
activity None None O
and None None O
its None None O
recruitment None None O
to None None O
the None None O
SRF None None O
. None None O
MRTF None None O
- None None O
A None None O
complex None None O
, None None O
whereas None None O
enforced None None O
induction None None O
of None None O
p38 None None O
by None None O
upstream None None O
activators None None O
( None None O
e None None O
. None None O
g None None O
. None None O
MKK3 None None O
and None None O
MKK6 None None O
) None None O
enhanced None None O
both None None O
CBP None None O
HAT None None O
and None None O
CCN1 None None O
promoter None None O
activities None None O
. None None O

Similarly None None O
, None None O
mechanical None None O
overload None None O
- None None O
induced None None O
CCN1 None None O
gene None None O
expression None None O
in None None O
vivo None None O
was None None O
associated None None O
with None None O
nuclear None None O
localization None None O
of None None O
MRTF None None O
- None None O
A None None O
and None None O
enrichment None None O
of None None O
the None None O
CCN1 None None O
promoter None None O
with None None O
both None None O
MRTF None None O
- None None O
A None None O
and None None O
acetylated None None O
histone None None O
H3 None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
suggest None None O
that None None O
signal None None O
- None None O
controlled None None O
activation None None O
of None None O
SRF None None O
, None None O
MRTF None None O
- None None O
A None None O
, None None O
and None None O
CBP None None O
provides None None O
a None None O
novel None None O
connection None None O
between None None O
mechanical None None O
stimuli None None O
and None None O
angiogenic None None O
gene None None O
expression None None O
. None None O

Discussion None None O

In None None O
our None None O
previous None None O
work None None O
, None None O
we None None O
considered None None O
in None None O
CD None None O
families None None O
the None None O
risk None None O
to None None O
develop None None O
the None None O
disease None None O
according None None O
to None None O
a None None O
specific None None O
HLA None None O
haplotypes None None O
, None None O
obtaining None None O
a None None O
risk None None O
range None None O
from None None O
0 None None O
. None None O
01 None None O
to None None O
> None None O
= None None O
0 None None O
. None None O
20 None None O
[ None None O
1 None None O
] None None O
. None None O

In None None O
the None None O
present None None O
study None None O
we None None O
evaluated None None O
the None None O
role None None O
of None None O
3 None None O
non None None O
- None None O
HLA None None O
genetic None None O
markers None None O
to None None O
influence None None O
the None None O
CD None None O
risk None None O
in None None O
first None None O
relatives None None O
of None None O
CD None None O
affected None None O
children None None O
. None None O

We None None O
collected None None O
data None None O
on None None O
families None None O
with None None O
at None None O
least None None O
one None None O
CD None None O
- None None O
affected None None O
among None None O
offspring None None O
. None None O

This None None O
family None None O
set None None O
helped None None O
to None None O
evaluate None None O
the None None O
association None None O
between None None O
SNPs None None O
and None None O
CD None None O
( None None O
TDT None None O
on None None O
parents None None O
- None None O
offspring None None O
trios None None O
) None None O
and None None O
to None None O
estimate None None O
the None None O
risk None None O
of None None O
CD None None O
in None None O
the None None O
other None None O
sibs None None O
. None None O

The None None O
TDT None None O
design None None O
provides None None O
robustness None None O
to None None O
population None None O
stratification None None O
and None None O
mitigation None None O
of None None O
the None None O
possible None None O
confounding None None O
effect None None O
of None None O
environmental None None O
factors None None O
, None None O
because None None O
all None None O
family None None O
members None None O
share None None O
the None None O
same None None O
environment None None O
[ None None O
16 None None O
] None None O
. None None O

Ten None None O
SNPs None None O
, None None O
selected None None O
from None None O
those None None O
previously None None O
found None None O
to None None O
be None None O
associated None None O
with None None O
CD None None O
by None None O
GWAS None None O
[ None None O
13 None None O
] None None O
, None None O
were None None O
successfully None None O
genotyped None None O
. None None O

In None None O
our None None O
population None None O
three None None O
SNPs None None O
resulted None None O
significantly None None O
associated None None O
with None None O
CD None None O
( None None O
those None None O
in None None O
LPP None None O
, None None O
RGS1 None None O
and None None O
REL None None O
genes None None O
) None None O
and None None O
the None None O
other None None O
seven None None O
investigated None None O
SNPs None None O
, None None O
even None None O
if None None O
not None None O
statistically None None O
associated None None O
with None None O
CD None None O
, None None O
showed None None O
always None None O
an None None O
higher None None O
frequency None None O
of None None O
the None None O
previously None None O
reported None None O
risk None None O
alleles None None O
[ None None O
13 None None O
] None None O
in None None O
affected None None O
subjects None None O
than None None O
in None None O
controls None None O
. None None O

The None None O
three None None O
genes None None O
selected None None O
appear None None O
to None None O
be None None O
appealing None None O
for None None O
the None None O
pathogenesis None None O
of None None O
CD None None O
. None None O

LPP None None O
( None None O
OR None None O
= None None O
2 None None O
. None None O
36 None None O
; None None O
p None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
was None None O
reported None None O
to None None O
be None None O
highly None None O
expressed None None O
in None None O
small None None O
intestinal None None O
mucosa None None O
and None None O
may None None O
have None None O
a None None O
structural None None O
role None None O
at None None O
sites None None O
of None None O
cell None None O
adhesion None None O
in None None O
maintaining None None O
cell None None O
shape None None O
and None None O
motility None None O
[ None None O
7 None None O
] None None O
. None None O

RGS1 None None O
( None None O
OR None None O
= None None O
1 None None O
. None None O
75 None None O
; None None O
p None None O
= None None O
0 None None O
. None None O
025 None None O
) None None O
belongs None None O
to None None O
a None None O
family None None O
of None None O
RGS None None O
genes None None O
. None None O

It None None O
attenuates None None O
the None None O
signaling None None O
activity None None O
of None None O
G None None O
- None None O
proteins None None O
, None None O
blocking None None O
the None None O
homing None None O
of None None O
Intra None None O
Epithelial None None O
Lymphocytes None None O
( None None O
IELs None None O
) None None O
, None None O
and None None O
it None None O
is None None O
specifically None None O
expressed None None O
both None None O
in None None O
human None None O
small None None O
intestinal None None O
mucosa None None O
and None None O
in None None O
murine None None O
IELs None None O
, None None O
key None None O
players None None O
in None None O
the None None O
development None None O
of None None O
human None None O
CD None None O
villous None None O
atrophy None None O
[ None None O
7 None None O
] None None O
, None None O
[ None None O
17 None None O
] None None O
. None None O

REL None None O
( None None O
OR None None O
= None None O
1 None None O
. None None O
66 None None O
; None None O
p None None O
= None None O
0 None None O
. None None O
034 None None O
) None None O
is None None O
a None None O
subunit None None O
of None None O
NF None None O
- None None O
kB None None O
complex None None O
, None None O
implicated None None O
in None None O
T None None O
cell None None O
differentiation None None O
[ None None O
18 None None O
] None None O
and None None O
it None None O
appears None None O
to None None O
be None None O
a None None O
key None None O
molecule None None O
regulating None None O
inflammation None None O
and None None O
the None None O
switch None None O
from None None O
tolerance None None O
to None None O
autoimmunity None None O
[ None None O
19 None None O
] None None O
. None None O

It None None O
is None None O
interesting None None O
to None None O
note None None O
that None None O
our None None O
data None None O
confirm None None O
previous None None O
pathogenetic None None O
implications None None O
reported None None O
in None None O
literature None None O
of None None O
these None None O
SNPs None None O
with None None O
CD None None O
as None None O
well None None O
as None None O
with None None O
other None None O
autoimmune None None O
diseases None None O
[ None None O
20 None None O
] None None O
. None None O

By None None O
the None None O
Bayesian None None O
approach None None O
we None None O
calculated None None O
a None None O
ranking None None O
score None None O
( None None O
BS None None O
) None None O
among None None O
the None None O
sibs None None O
. None None O

However None None O
, None None O
it None None O
should None None O
be None None O
considered None None O
that None None O
BS None None O
is None None O
not None None O
a None None O
plain None None O
disease None None O
risk None None O
, None None O
rather None None O
a None None O
method None None O
to None None O
rank None None O
different None None O
genotypes None None O
according None None O
to None None O
their None None O
contribution None None O
to None None O
make None None O
an None None O
individual None None O
susceptible None None O
to None None O
CD None None O
. None None O

For None None O
instance None None O
, None None O
some None None O
of None None O
our None None O
BS None None O
are None None O
very None None O
near None None O
to None None O
1 None None O
, None None O
nevertheless None None O
none None None O
of None None O
the None None O
considered None None O
genotypes None None O
could None None O
give None None O
a None None O
100 None None O
% None None O
risk None None O
to None None O
develop None None O
the None None O
disease None None O
. None None O

In None None O
other None None O
terms None None O
, None None O
we None None O
considered None None O
the None None O
BS None None O
as None None O
a None None O
ranking None None O
measure None None O
, None None O
only None None O
stating None None O
that None None O
a None None O
given None None O
genotype None None O
could None None O
assign None None O
a None None O
higher None None O
risk None None O
than None None O
another None None O
genotype None None O
but None None O
does None None O
not None None O
allow None None O
a None None O
quantitative None None O
measure None None O
of None None O
the None None O
risk None None O
difference None None O
( None None O
2 None None O
- None None O
fold None None O
, None None O
3 None None O
- None None O
fold None None O
, None None O
etc None None O
) None None O
. None None O

However None None O
, None None O
even None None O
if None None O
the None None O
addition None None O
of None None O
only None None O
3 None None O
SNPs None None O
to None None O
HLA None None O
could None None O
be None None O
considered None None O
at None None O
" None None O
minor None None O
effect None None O
" None None O
[ None None O
13 None None O
] None None O
, None None O
we None None O
demonstrated None None O
that None None O
they None None O
could None None O
significantly None None O
improve None None O
the None None O
prediction None None O
of None None O
CD None None O
risk None None O
in None None O
sibs None None O
, None None O
in None None O
terms None None O
of None None O
diagnostic None None O
sensitivity None None O
and None None O
negative None None O
predictive None None O
value None None O
. None None O

So None None O
, None None O
in None None O
a None None O
cohort None None O
of None None O
CD None None O
families None None O
, None None O
our None None O
data None None O
confirm None None O
that None None O
non None None O
- None None O
HLA None None O
SNPs None None O
evaluation None None O
is None None O
an None None O
usefull None None O
diagnostic None None O
tool None None O
in None None O
CD None None O
risk None None O
evaluation None None O
as None None O
a None None O
previous None None O
study None None O
showed None None O
in None None O
CD None None O
unrelated None None O
subjects None None O
[ None None O
14 None None O
] None None O
. None None O

CD None None O
, None None O
on None None O
the None None O
basis None None O
of None None O
the None None O
actual None None O
knowledge None None O
, None None O
cannot None None O
be None None O
exactly None None O
predicted None None O
by None None O
genetic None None O
testing None None O
, None None O
but None None O
a None None O
reliable None None O
probabilistic None None O
method None None O
might None None O
be None None O
associated None None O
to None None O
careful None None O
surveillance None None O
of None None O
infants None None O
carrying None None O
the None None O
higher None None O
risk None None O
. None None O

This None None O
will None None O
help None None O
to None None O
significantly None None O
reduce None None O
the None None O
heavy None None O
load None None O
of None None O
anxiety None None O
and None None O
pain None None O
associated None None O
with None None O
the None None O
appearance None None O
of None None O
symptoms None None O
of None None O
CD None None O
, None None O
by None None O
anticipating None None O
, None None O
with None None O
simple None None O
serological None None O
tests None None O
, None None O
the None None O
clinical None None O
appearance None None O
of None None O
the None None O
disease None None O
. None None O

To None None O
improve None None O
the None None O
possibility None None O
to None None O
identify None None O
high None None O
risk None None O
patients None None O
in None None O
CD None None O
families None None O
we None None O
propose None None O
in None None O
alternative None None O
to None None O
the None None O
classical None None O
HLA None None O
classification None None O
( None None O
Fig None None O
. None None O
4 None None O
, None None O
panel None None O
A None None O
) None None O
a None None O
slight None None O
improved None None O
flow None None O
- None None O
chart None None O
( None None O
Fig None None O
. None None O
4 None None O
, None None O
panel None None O
B None None O
) None None O
: None None O
1 None None O
) None None O
HLA None None O
genotyping None None O
: None None O
subjects None None O
belonging None None O
to None None O
the None None O
HLA None None O
risk None None O
groups None None O
1 None None O
and None None O
2 None None O
will None None O
be None None O
classified None None O
as None None O
at None None O
high None None O
CD None None O
risk None None O
; None None O
2 None None O
) None None O
subjects None None O
belonging None None O
to None None O
the None None O
HLA None None O
risk None None O
groups None None O
3 None None O
and None None O
4 None None O
, None None O
will None None O
be None None O
further None None O
investigated None None O
for None None O
our None None O
SNPs None None O
combination None None O
( None None O
LPP None None O
, None None O
REL None None O
, None None O
RGS1 None None O
) None None O
in None None O
order None None O
to None None O
calculate None None O
their None None O
BS None None O
( None None O
Fig None None O
. None None O
4 None None O
, None None O
panel None None O
B None None O
) None None O
. None None O

Among None None O
these None None O
latter None None O
subjects None None O
those None None O
with None None O
a None None O
BS None None O
> None None O
= None None O
the None None O
median None None O
value None None O
will None None O
be None None O
classified None None O
at None None O
high None None O
risk None None O
; None None O
3 None None O
) None None O
subjects None None O
belonging None None O
to None None O
the None None O
HLA None None O
risk None None O
group None None O
5 None None O
will None None O
be None None O
considered None None O
at None None O
low None None O
CD None None O
risk None None O
. None None O

All None None O
CD None None O
familials None None O
belonging None None O
to None None O
the None None O
above None None O
high None None O
risk None None O
groups None None O
( None None O
HLA None None O
group None None O
1 None None O
- None None O
2 None None O
and None None O
HLA None None O
group None None O
3 None None O
- None None O
4 None None O
with None None O
BS None None O
> None None O
= None None O
median None None O
) None None O
will None None O
be None None O
undergo None None O
a None None O
strict None None O
surveillance None None O
. None None O

10 None None O
. None None O
1371 None None O
/ None None O
journal None None O
. None None O
pone None None O
. None None O
0026920 None None O
. None None O
g004 None None O
Figure None None O
4 None None O

Classification None None O
flow None None O
- None None O
chart None None O
. None None O

In None None O
panel None None O
A None None O
the None None O
classical None None O
HLA None None O
- None None O
based None None O
classification None None O
. None None O

In None None O
panel None None O
B None None O
the None None O
proposed None None O
BS None None O
- None None O
based None None O
classification None None O
considering None None O
the None None O
genotypes None None O
of None None O
HLA None None O
plus None None O
LPP None None O
, None None O
RGS1 None None O
and None None O
REL None None O
SNPs None None O
. None None O

One None None O
of None None O
the None None O
limitation None None O
of None None O
our None None O
cohort None None O
family None None O
study None None O
could None None O
be None None O
the None None O
sample None None O
size None None O
, None None O
which None None O
may None None O
have None None O
not None None O
allowed None None O
to None None O
explore None None O
genes None None O
at None None O
smaller None None O
effect None None O
, None None O
so None None O
explaining None None O
the None None O
lack None None O
of None None O
association None None O
between None None O
SNPs None None O
in None None O
TAGAP None None O
, None None O
IL2 None None O
/ None None O
IL21 None None O
, None None O
OLIG3 None None O
, None None O
CCR None None O
, None None O
SH2B3 None None O
, None None O
IL12A None None O
and None None O
IL12A None None O
/ None None O
SCHIP1 None None O
genes None None O
with None None O
CD None None O
although None None O
the None None O
trend None None O
observed None None O
in None None O
previous None None O
studies None None O
in None None O
unrelated None None O
CD None None O
patients None None O
was None None O
confirmed None None O
[ None None O
13 None None O
] None None O
. None None O

In None None O
the None None O
main None None O
time None None O
the None None O
homogeneity None None O
of None None O
the None None O
genetic None None O
and None None O
environmental None None O
domains None None O
in None None O
the None None O
tested None None O
families None None O
allows None None O
to None None O
explore None None O
risk None None O
factors None None O
within None None O
a None None O
controlled None None O
cohort None None O
. None None O

A None None O
second None None O
limit None None O
of None None O
the None None O
study None None O
is None None O
the None None O
relatively None None O
short None None O
( None None O
6 None None O
years None None O
) None None O
follow None None O
up None None O
of None None O
the None None O
sibship None None O
, None None O
which None None O
could None None O
cause None None O
an None None O
underestimation None None O
of None None O
the None None O
disease None None O
development None None O
at None None O
later None None O
ages None None O
. None None O

Our None None O
aim None None O
is None None O
to None None O
go None None O
on None None O
with None None O
the None None O
monitoring None None O
of None None O
these None None O
families None None O
in None None O
the None None O
next None None O
years None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
estimate None None O
of None None O
the None None O
CD None None O
risk None None O
by None None O
HLA None None O
+ None None O
SNPs None None O
approach None None O
, None None O
even None None O
if None None O
not None None O
applicable None None O
to None None O
prevention None None O
, None None O
could None None O
be None None O
a None None O
precious None None O
tool None None O
improving None None O
CD None None O
diagnosis None None O
respect None None O
to None None O
the None None O
only None None O
HLA None None O
( None None O
NPV None None O
: None None O
95 None None O
% None None O
vs None None O
91 None None O
% None None O
, None None O
and None None O
DS None None O
: None None O
79 None None O
% None None O
vs None None O
45 None None O
% None None O
) None None O
, None None O
in None None O
the None None O
cohort None None O
of None None O
first None None O
degree None None O
relatives None None O
. None None O

In None None O
fact None None O
in None None O
clinical None None O
practice None None O
the None None O
absence None None O
of None None O
HLA None None O
risk None None O
groups None None O
1 None None O
or None None O
2 None None O
, None None O
allows None None O
to None None O
exclude None None O
the None None O
disease None None O
with None None O
high None None O
probability None None O
, None None O
while None None O
testing None None O
the None None O
three None None O
SNPs None None O
in None None O
HLA None None O
groups None None O
3 None None O
or None None O
4 None None O
could None None O
represent None None O
a None None O
further None None O
tool None None O
to None None O
identify None None O
less None None O
frequent None None O
CD None None O
cases None None O
. None None O

So None None O
, None None O
an None None O
infant None None O
with None None O
high None None O
HLA None None O
+ None None O
SNPs None None O
score None None O
even None None O
if None None O
belonging None None O
to None None O
HLA None None O
low None None O
risk None None O
groups None None O
, None None O
shall None None O
undergo None None O
a None None O
simple None None O
surveillance None None O
system None None O
to None None O
allow None None O
proper None None O
diagnosis None None O
and None None O
treatment None None O
before None None O
the None None O
full None None O
blow None None O
disease None None O
appears None None O
. None None O

Novel None None O
insights None None O
into None None O
the None None O
pathogenesis None None O
of None None O
uric None None O
acid None None O
nephrolithiasis None None O
. None None O

PURPOSE None None O
OF None None O
REVIEW None None O
: None None O

The None None O
factors None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
uric None None O
acid None None O
nephrolithiasis None None O
are None None O
well None None O
known None None O
. None None O

A None None O
low None None O
urinary None None O
pH None None O
is None None O
the None None O
most None None O
significant None None O
element None None O
in None None O
the None None O
generation None None O
of None None O
stones None None O
, None None O
with None None O
hyperuricosuria None None O
being None None O
a None None O
less None None O
common None None O
finding None None O
. None None O

The None None O
underlying None None O
mechanism None None O
( None None O
s None None O
) None None O
responsible None None O
for None None O
these None None O
disturbances None None O
remain None None O
poorly None None O
characterized None None O
. None None O

This None None O
review None None O
summarizes None None O
previous None None O
knowledge None None O
and None None O
highlights None None O
some None None O
recent None None O
developments None None O
in None None O
the None None O
pathophysiology None None O
of None None O
low None None O
urine None None O
pH None None O
and None None O
hyperuricosuria None None O
. None None O

RECENT None None O
FINDINGS None None O
: None None O

Epidemiological None None O
and None None O
metabolic None None O
studies None None O
have None None O
indicated None None O
an None None O
association None None O
between None None O
uric None None O
acid None None O
nephrolithiasis None None O
and None None O
insulin None None O
resistance None None O
. None None O

Some None None O
potential None None O
mechanisms None None O
include None None O
impaired None None O
ammoniagenesis None None O
caused None None O
by None None O
resistance None None O
to None None O
insulin None None O
action None None O
in None None O
the None None O
renal None None O
proximal None None O
tubule None None O
, None None O
or None None O
substrate None None O
competition None None O
by None None O
free None None O
fatty None None O
acids None None O
. None None O

The None None O
evaluation None None O
of None None O
a None None O
large None None O
Sicilian None None O
kindred None None O
recently None None O
revealed None None O
a None None O
putative None None O
genetic None None O
locus None None O
linked None None O
to None None O
uric None None O
acid None None O
stone None None O
disease None None O
. None None O

The None None O
identification None None O
of None None O
novel None None O
complementary None None O
DNA None None O
has None None O
provided None None O
an None None O
interesting None None O
insight None None O
into None None O
the None None O
renal None None O
handling None None O
of None None O
uric None None O
acid None None O
, None None O
including None None O
one None None O
genetic None None O
cause None None O
of None None O
renal None None O
uric None None O
acid None None O
wasting None None O
. None None O

SUMMARY None None O
: None None O

The None None O
recognition None None O
of None None O
metabolic None None O
, None None O
molecular None None O
, None None O
and None None O
genetic None None O
factors None None O
that None None O
influence None None O
urinary None None O
pH None None O
, None None O
and None None O
uric None None O
acid None None O
metabolism None None O
and None None O
excretion None None O
, None None O
will None None O
provide None None O
novel None None O
insights None None O
into None None O
the None None O
pathogenesis None None O
of None None O
uric None None O
acid None None O
stones None None O
, None None O
and None None O
open None None O
the None None O
way None None O
for None None O
new None None O
therapeutic None None O
strategies None None O
. None None O

Quantitative None None O
reverse None None O
transcription None None O
PCR None None O

Reverse None None O
transcription None None O
was None None O
performed None None O
using None None O
0 None None O
. None None O
2 None None O
mug None None O
of None None O
total None None O
RNA None None O
from None None O
muscle None None O
of None None O
10 None None O
week None None O
- None None O
old None None O
and None None O
19 None None O
month None None O
- None None O
old None None O
C57Bl6 None None O
mice None None O
( None None O
five None None O
animals None None O
per None None O
group None None O
) None None O
, None None O
a None None O
Core None None O
kit None None O
( None None O
RT None None O
- None None O
RTCK None None O
- None None O
03 None None O
, None None O
Eurogentec None None O
) None None O
according None None O
to None None O
manufacturer None None O
' None None O
s None None O
instruction None None O
and None None O
a None None O
mix None None O
of None None O
random None None O
primers None None O
( None None O
9 None None O
mers None None O
) None None O
and None None O
oligodT None None O
. None None O

qPCR None None O
was None None O
performed None None O
on None None O
SDS7900HT None None O
( None None O
Applied None None O
Biosystem None None O
) None None O
using None None O
Mesagreen None None O
qPCR None None O
kit None None O
for None None O
SYBR None None O
( None None O
Eurogentec None None O
) None None O
and None None O
the None None O
following None None O
primers None None O
: None None O

PPARbeta None None O
: None None O
5 None None O
' None None O
- None None O
AGATGGTGGCAGAGCTATGACC None None O
- None None O
3 None None O
' None None O
; None None O
5 None None O
' None None O
- None None O
TCCTCCTGTGGCTGTTCC None None O
- None None O
3 None None O
' None None O
. None None O

Catalase None None O
: None None O
5 None None O
' None None O
- None None O
GGATCCTGACATGGTCTGGG None None O
- None None O
3 None None O
' None None O
; None None O
5 None None O
' None None O
- None None O
TGGAGAGACTCGGGACGAAG None None O
- None None O
3 None None O
' None None O
. None None O

PDK4 None None O
: None None O
5 None None O
' None None O
- None None O
GCATTTCTACTCGGATGCTCAATG None None O
- None None O
3 None None O
' None None O
; None None O
5 None None O
' None None O
- None None O
CCAATGTGGCTTGGGTTTCC None None O
- None None O
3 None None O
' None None O
. None None O

36B4 None None O
: None None O
5 None None O
' None None O
- None None O
TCCAGGCTTTGGGCATCA None None O
- None None O
3 None None O
' None None O
; None None O
5 None None O
' None None O
- None None O
CTTTATCAGCTGCACATCACTCAGA None None O
- None None O
3 None None O
' None None O
. None None O

Data None None O
were None None O
all None None O
normalised None None O
using None None O
36B4 None None O
as None None O
housekeeping None None O
gene None None O
. None None O

Yellow None None O
- None None O
green None None O
52 None None O
. None None O
3W None None O
laser None None O
at None None O
556nm None None O
based None None O
on None None O
frequency None None O
doubling None None O
of None None O
a None None O
diode None None O
side None None O
- None None O
pumped None None O
Q None None O
- None None O
switched None None O
Nd None None O
: None None O
YAG None None O
laser None None O
. None None O

We None None O
demonstrate None None O
a None None O
high None None O
- None None O
power None None O
556nm None None O
yellow None None O
- None None O
green None None O
laser None None O
generated None None O
by None None O
intracavity None None O
frequency None None O
doubling None None O
of None None O
a None None O
diode None None O
side None None O
- None None O
pumped None None O
Nd None None O
: None None O
YAG None None O
laser None None O
at None None O
1112nm None None O
. None None O

A None None O
symmetrical None None O
L None None O
- None None O
shaped None None O
flat None None O
- None None O
flat None None O
cavity None None O
was None None O
employed None None O
to None None O
implement None None O
efficient None None O
operation None None O
of None None O
the None None O
low None None O
- None None O
gain None None O
1112nm None None O
transition None None O
and None None O
to None None O
achieve None None O
good None None O
power None None O
scalability None None O
. None None O

The None None O
coatings None None O
of None None O
the None None O
cavity None None O
mirrors None None O
were None None O
carefully None None O
designed None None O
to None None O
optimize None None O
the None None O
performance None None O
of None None O
the None None O
laser None None O
, None None O
and None None O
a None None O
92W None None O
continuous None None O
wave None None O
laser None None O
output None None O
at None None O
1112nm None None O
was None None O
achieved None None O
when None None O
the None None O
pumping None None O
power None None O
of None None O
the None None O
laser None None O
diodes None None O
reached None None O
960W None None O
. None None O

By None None O
intracavity None None O
frequency None None O
doubling None None O
of None None O
the None None O
fundamental None None O
laser None None O
in None None O
a None None O
lithium None None O
triborate None None O
crystal None None O
, None None O
the None None O
maximum None None O
power None None O
of None None O
the None None O
frequency None None O
- None None O
doubled None None O
output None None O
at None None O
556nm None None O
was None None O
found None None O
to None None O
be None None O
as None None O
high None None O
as None None O
52 None None O
. None None O
3W None None O
with None None O
a None None O
pulse None None O
repetition None None O
frequency None None O
of None None O
10kHz None None O
. None None O

This None None O
corresponds None None O
to None None O
an None None O
optical None None O
- None None O
to None None O
- None None O
optical None None O
conversion None None O
efficiency None None O
of None None O
about None None O
5 None None O
. None None O
4 None None O
% None None O
. None None O

CXC None None O
chemokine None None O
receptors None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
: None None O
Role None None O
in None None O
cerebellar None None O
neuromodulation None None O
and None None O
development None None O
. None None O

Chemokines None None O
and None None O
their None None O
receptors None None O
are None None O
constitutively None None O
present None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
, None None O
expressed None None O
in None None O
neurons None None O
and None None O
glial None None O
cells None None O
. None None O

Much None None O
evidence None None O
suggests None None O
that None None O
, None None O
beyond None None O
their None None O
involvement None None O
in None None O
neuroinflammation None None O
, None None O
these None None O
proteins None None O
play None None O
a None None O
role None None O
in None None O
neurodevelopment None None O
and None None O
neurophysiological None None O
signaling None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
review None None O
is None None O
to None None O
summarize None None O
recent None None O
information None None O
concerning None None O
expression None None O
, None None O
signaling None None O
, None None O
and None None O
function None None O
of None None O
CXC None None O
chemokine None None O
receptor None None O
in None None O
the None None O
CNS None None O
, None None O
with None None O
the None None O
main None None O
focus None None O
on None None O
the None None O
developmental None None O
and None None O
neuromodulatory None None O
actions None None O
of None None O
chemokines None None O
in None None O
the None None O
cerebellum None None O
. None None O

Background None None O

Potato None None O
late None None O
blight None None O
, None None O
a None None O
disease None None O
caused None None O
by None None O
the None None O
oomycete None None O
pathogen None None O
Phytophthora None None O
infestans None None O
, None None O
is None None O
one None None O
of None None O
the None None O
world None None O
' None None O
s None None O
most None None O
devastating None None O
crop None None O
diseases None None O
. None None O

World None None O
- None None O
wide None None O
losses None None O
due None None O
to None None O
late None None O
blight None None O
exceed None None O
several None None O
billion None None O
dollars None None O
annually None None O
[ None None O
1 None None O
] None None O
. None None O

Most None None O
of None None O
the None None O
potato None None O
cultivars None None O
currently None None O
grown None None O
in None None O
the None None O
United None None O
States None None O
are None None O
highly None None O
susceptible None None O
to None None O
late None None O
blight None None O
and None None O
control None None O
of None None O
this None None O
disease None None O
relies None None O
almost None None O
exclusively None None O
on None None O
fungicide None None O
applications None None O
. None None O

The None None O
most None None O
effective None None O
and None None O
environmentally None None O
sound None None O
way None None O
for None None O
controlling None None O
late None None O
blight None None O
is None None O
to None None O
incorporate None None O
natural None None O
resistance None None O
into None None O
potato None None O
cultivars None None O
. None None O

The None None O
pedigrees None None O
of None None O
many None None O
potato None None O
cultivars None None O
currently None None O
used None None O
in None None O
different None None O
countries None None O
include None None O
late None None O
blight None None O
resistant None None O
germplasm None None O
derived None None O
from None None O
Solanum None None O
demissum None None O
, None None O
Solanum None None O
andigena None None O
, None None O
and None None O
other None None O
wild None None O
species None None O
. None None O

However None None O
, None None O
most None None O
of None None O
the None None O
resistance None None O
derived None None O
from None None O
these None None O
wild None None O
species None None O
is None None O
controlled None None O
by None None O
single None None O
dominant None None O
resistance None None O
genes None None O
( None None O
R None None O
genes None None O
) None None O
. None None O

These None None O
R None None O
genes None None O
are None None O
only None None O
effective None None O
in None None O
preventing None None O
the None None O
development None None O
of None None O
late None None O
blight None None O
if None None O
the None None O
invading None None O
P None None O
. None None O
infestans None None O
race None None O
contains None None O
the None None O
corresponding None None O
avirulence None None O
genes None None O
. None None O

This None None O
R None None O
gene None None O
- None None O
mediated None None O
resistance None None O
is None None O
often None None O
short None None O
- None None O
lived None None O
and None None O
is None None O
rapidly None None O
overcome None None O
by None None O
new None None O
races None None O
of None None O
the None None O
late None None O
blight None None O
pathogen None None O
. None None O

Solanum None None O
bulbocastanum None None O
( None None O
2n None None O
= None None O
2x None None O
= None None O
24 None None O
) None None O
is None None O
a None None O
diploid None None O
species None None O
that None None O
has None None O
adapted None None O
in None None O
the None None O
same None None O
environment None None O
as None None O
the None None O
late None None O
blight None None O
pathogen None None O
. None None O

This None None O
wild None None O
species None None O
was None None O
characterized None None O
as None None O
possessing None None O
durable None None O
resistance None None O
against None None O
P None None O
. None None O
infestans None None O
, None None O
even None None O
under None None O
high None None O
disease None None O
pressure None None O
[ None None O
2 None None O
, None None O
3 None None O
] None None O
. None None O

Two None None O
resistance None None O
genes None None O
, None None O
RB None None O
( None None O
Rpi None None O
- None None O
blb1 None None O
) None None O
and None None O
Rpi None None O
- None None O
blb2 None None O
, None None O
have None None O
been None None O
cloned None None O
from None None O
S None None O
. None None O
bulbocastanum None None O
[ None None O
4 None None O
- None None O
6 None None O
] None None O
. None None O

Both None None O
genes None None O
confer None None O
broad None None O
- None None O
spectrum None None O
resistance None None O
against None None O
a None None O
wide None None O
range None None O
of None None O
known None None O
P None None O
. None None O
infestans None None O
races None None O
. None None O

Transgenic None None O
potato None None O
lines None None O
containing None None O
a None None O
single None None O
RB None None O
gene None None O
showed None None O
a None None O
high None None O
- None None O
level None None O
resistance None None O
in None None O
the None None O
Toluca None None O
Valley None None O
, None None O
Mexico None None O
, None None O
where None None O
the None None O
potato None None O
fields None None O
are None None O
naturally None None O
intensively None None O
infested None None O
with None None O
the None None O
most None None O
diversified None None O
P None None O
. None None O
infestans None None O
populations None None O
[ None None O
7 None None O
] None None O
. None None O

Most None None O
interestingly None None O
, None None O
transgenic None None O
RB None None O
plants None None O
did None None O
not None None O
show None None O
total None None O
immunity None None O
to None None O
late None None O
blight None None O
, None None O
but None None O
instead None None O
showed None None O
a None None O
marked None None O
delay None None O
in None None O
both None None O
onset None None O
of None None O
symptoms None None O
and None None O
development None None O
of None None O
lesions None None O
. None None O

Such None None O
rate None None O
- None None O
limiting None None O
resistance None None O
may None None O
put None None O
less None None O
selection None None O
pressure None None O
on None None O
the None None O
P None None O
. None None O
infestans None None O
populations None None O
and None None O
protect None None O
the None None O
durability None None O
of None None O
this None None O
resistance None None O
gene None None O
. None None O

The None None O
RB None None O
gene None None O
therefore None None O
provides None None O
an None None O
excellent None None O
model None None O
to None None O
study None None O
the None None O
mechanism None None O
of None None O
broad None None O
- None None O
spectrum None None O
and None None O
rate None None O
- None None O
limiting None None O
disease None None O
resistances None None O
. None None O

An None None O
understanding None None O
of None None O
the None None O
underlying None None O
mechanism None None O
of None None O
this None None O
type None None O
of None None O
resistance None None O
is None None O
important None None O
for None None O
developing None None O
strategies None None O
to None None O
breed None None O
durable None None O
and None None O
sustainable None None O
disease None None O
resistance None None O
. None None O

Several None None O
genes None None O
have None None O
been None None O
implicated None None O
in None None O
the None None O
regulation None None O
of None None O
R None None O
gene None None O
function None None O
. None None O

Of None None O
these None None O
genes None None O
, None None O
Rar1 None None O
and None None O
Sgt1 None None O
are None None O
among None None O
the None None O
most None None O
extensively None None O
studied None None O
genes None None O
. None None O

The None None O
Rar1 None None O
( None None O
required None None O
for None None O
Mla12 None None O
resistance None None O
) None None O
gene None None O
was None None O
first None None O
identified None None O
for None None O
its None None O
essential None None O
role None None O
in None None O
the None None O
function None None O
of None None O
a None None O
subset None None O
of None None O
Mla None None O
genes None None O
that None None O
confer None None O
resistance None None O
to None None O
barley None None O
powdery None None O
mildew None None O
[ None None O
8 None None O
] None None O
. None None O

The None None O
RAR1 None None O
protein None None O
contains None None O
two None None O
highly None None O
similar None None O
but None None O
distinct None None O
cysteine None None O
- None None O
and None None O
histidine None None O
- None None O
rich None None O
( None None O
CHORD None None O
) None None O
Zn2 None None O
+ None None O
- None None O
binding None None O
domains None None O
and None None O
was None None O
proposed None None O
to None None O
play None None O
a None None O
role None None O
in None None O
stabilizing None None O
R None None O
proteins None None O
in None None O
a None None O
confirmation None None O
that None None O
is None None O
implicated None None O
in None None O
receiving None None O
pathogen None None O
signals None None O
[ None None O
9 None None O
] None None O
. None None O

The None None O
Sgt1 None None O
gene None None O
( None None O
suppressor None None O
of None None O
the None None O
G2 None None O
allele None None O
of None None O
skp1 None None O
) None None O
is None None O
an None None O
essential None None O
gene None None O
with None None O
multiple None None O
functions None None O
in None None O
yeast None None O
. None None O

SGT1 None None O
protein None None O
was None None O
initially None None O
identified None None O
as None None O
a None None O
RAR1 None None O
- None None O
interacting None None O
partner None None O
in None None O
a None None O
yeast None None O
two None None O
- None None O
hybrid None None O
screen None None O
[ None None O
10 None None O
] None None O
. None None O

SGT1 None None O
may None None O
play None None O
a None None O
role None None O
in None None O
R None None O
protein None None O
accumulation None None O
[ None None O
11 None None O
] None None O
. None None O

Rar1 None None O
and None None O
Sgt1 None None O
genes None None O
are None None O
required None None O
in None None O
various None None O
R None None O
- None None O
gene None None O
mediated None None O
resistance None None O
against None None O
viral None None O
, None None O
bacterial None None O
, None None O
oomycete None None O
or None None O
fungal None None O
pathogens None None O
[ None None O
12 None None O
] None None O
. None None O

However None None O
, None None O
none None None O
of None None O
the None None O
previously None None O
studied None None O
R None None O
genes None None O
showed None None O
a None None O
race None None O
- None None O
non None None O
- None None O
specific None None O
and None None O
rate None None O
- None None O
limiting None None O
resistance None None O
phenotype None None O
as None None O
the None None O
RB None None O
gene None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
role None None O
the None None O
Rar1 None None O
and None None O
Sgt1 None None O
genes None None O
are None None O
not None None O
universal None None O
and None None O
these None None O
genes None None O
are None None O
not None None O
essential None None O
for None None O
resistance None None O
involving None None O
some None None O
R None None O
genes None None O
[ None None O
12 None None O
, None None O
13 None None O
] None None O
. None None O

Besides None None O
the None None O
two None None O
broad None None O
- None None O
spectrum None None O
resistance None None O
genes None None O
RB None None O
and None None O
Rpi None None O
- None None O
blb2 None None O
, None None O
several None None O
race None None O
- None None O
specific None None O
late None None O
blight None None O
resistance None None O
genes None None O
have None None O
also None None O
been None None O
cloned None None O
[ None None O
14 None None O
- None None O
16 None None O
] None None O
. None None O

Numerous None None O
late None None O
blight None None O
resistance None None O
genes None None O
have None None O
recently None None O
been None None O
mapped None None O
in None None O
various None None O
potato None None O
species None None O
or None None O
populations None None O
[ None None O
17 None None O
- None None O
25 None None O
] None None O
. None None O

However None None O
, None None O
there None None O
is None None O
almost None None O
no None None O
information None None O
available None None O
about None None O
the None None O
resistance None None O
pathways None None O
mediated None None O
by None None O
any None None O
of None None O
these None None O
genes None None O
. None None O

As None None O
an None None O
initial None None O
effort None None O
to None None O
understand None None O
the None None O
RB None None O
- None None O
mediated None None O
late None None O
blight None None O
resistance None None O
pathway None None O
, None None O
we None None O
silenced None None O
the None None O
Rar1 None None O
and None None O
Sgt1 None None O
genes None None O
using None None O
an None None O
RNAi None None O
- None None O
based None None O
approach None None O
in None None O
a None None O
potato None None O
line None None O
containing None None O
the None None O
RB None None O
gene None None O
. None None O

We None None O
demonstrated None None O
that None None O
SGT1 None None O
, None None O
but None None O
not None None O
RAR1 None None O
, None None O
is None None O
essential None None O
for None None O
the None None O
RB None None O
- None None O
mediated None None O
broad None None O
- None None O
spectrum None None O
resistance None None O
to None None O
potato None None O
late None None O
blight None None O
. None None O

Transcripts None None O
Upregulated None None O
in None None O
ST None None O
- None None O
HSC None None O
Compared None None O
to None None O
LT None None O
- None None O
HSC None None O

( None None O
181 None None O
KB None None O
XLS None None O
) None None O

The None None O
candidate None None O
tumour None None O
suppressor None None O
protein None None O
ING4 None None O
regulates None None O
brain None None O
tumour None None O
growth None None O
and None None O
angiogenesis None None O
. None None O

Gliomas None None O
are None None O
the None None O
most None None O
common None None O
primary None None O
tumours None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
, None None O
with None None O
nearly None None O
15 None None O
, None None O
000 None None O
diagnosed None None O
annually None None O
in None None O
the None None O
United None None O
States None None O
and None None O
a None None O
lethality None None O
approaching None None O
80 None None O
% None None O
within None None O
the None None O
first None None O
year None None O
of None None O
glioblastoma None None O
diagnosis None None O
. None None O

The None None O
marked None None O
induction None None O
of None None O
angiogenesis None None O
in None None O
glioblastomas None None O
suggests None None O
that None None O
it None None O
is None None O
a None None O
necessary None None O
part None None O
of None None O
malignant None None O
progression None None O
; None None O
however None None O
, None None O
the None None O
precise None None O
molecular None None O
mechanisms None None O
underlying None None O
the None None O
regulation None None O
of None None O
brain None None O
tumour None None O
growth None None O
and None None O
angiogenesis None None O
remain None None O
unresolved None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
a None None O
candidate None None O
tumour None None O
suppressor None None O
gene None None O
, None None O
ING4 None None O
, None None O
is None None O
involved None None O
in None None O
regulating None None O
brain None None O
tumour None None O
growth None None O
and None None O
angiogenesis None None O
. None None O

Expression None None O
of None None O
ING4 None None O
is None None O
significantly None None O
reduced None None O
in None None O
gliomas None None O
as None None O
compared None None O
with None None O
normal None None O
human None None O
brain None None O
tissue None None O
, None None O
and None None O
the None None O
extent None None O
of None None O
reduction None None O
correlates None None O
with None None O
the None None O
progression None None O
from None None O
lower None None O
to None None O
higher None None O
grades None None O
of None None O
tumours None None O
. None None O

In None None O
mice None None O
, None None O
xenografts None None O
of None None O
human None None O
glioblastoma None None O
U87MG None None O
, None None O
which None None O
has None None O
decreased None None O
expression None None O
of None None O
ING4 None None O
, None None O
grow None None O
significantly None None O
faster None None O
and None None O
have None None O
higher None None O
vascular None None O
volume None None O
fractions None None O
than None None O
control None None O
tumours None None O
. None None O

We None None O
show None None O
that None None O
ING4 None None O
physically None None O
interacts None None O
with None None O
p65 None None O
( None None O
RelA None None O
) None None O
subunit None None O
of None None O
nuclear None None O
factor None None O
NF None None O
- None None O
kappaB None None O
, None None O
and None None O
that None None O
ING4 None None O
regulates None None O
brain None None O
tumour None None O
angiogenesis None None O
through None None O
transcriptional None None O
repression None None O
of None None O
NF None None O
- None None O
kappaB None None O
- None None O
responsive None None O
genes None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
ING4 None None O
has None None O
an None None O
important None None O
role None None O
in None None O
brain None None O
tumour None None O
pathogenesis None None O
. None None O

Statistical None None O
analysis None None O

All None None O
statistical None None O
analyses None None O
were None None O
performed None None O
using None None O
SPSS13 None None O
. None None O
0 None None O
software None None O
. None None O

The None None O
differences None None O
between None None O
groups None None O
were None None O
compared None None O
using None None O
Student None None O
' None None O
s None None O
t None None O
- None None O
test None None O
, None None O
and None None O
data None None O
were None None O
expressed None None O
as None None O
mean None None O
+ None None O
/ None None O
- None None O
SD None None O
. None None O

Statistical None None O
difference None None O
was None None O
accepted None None O
at None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
. None None O

Topoisomerase None None O
I None None O
protein None None O
expression None None O
in None None O
primary None None O
colorectal None None O
cancer None None O
and None None O
lymph None None O
node None None O
metastases None None O
. None None O

Topoisomerase None None O
I None None O
( None None O
topo None None O
I None None O
) None None O
is None None O
an None None O
important None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
malignant None None O
disease None None O
, None None O
especially None None O
colorectal None None O
cancer None None O
. None None O

Because None None O
there None None O
is None None O
little None None O
information None None O
on None None O
the None None O
expression None None O
of None None O
topo None None O
I None None O
in None None O
colorectal None None O
tumors None None O
, None None O
this None None O
study None None O
evaluated None None O
and None None O
characterized None None O
topo None None O
I None None O
protein None None O
expression None None O
in None None O
primary None None O
colorectal None None O
cancer None None O
and None None O
lymph None None O
node None None O
metastases None None O
and None None O
studied None None O
the None None O
association None None O
between None None O
topo None None O
I None None O
protein None None O
expression None None O
and None None O
clinicopathologic None None O
data None None O
, None None O
p53 None None O
status None None O
, None None O
and None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
( None None O
PCNA None None O
) None None O
status None None O
. None None O

Immunohistochemistry None None O
assay None None O
was None None O
performed None None O
for None None O
topo None None O
I None None O
protein None None O
expression None None O
in None None O
249 None None O
primary None None O
human None None O
colorectal None None O
cancer None None O
and None None O
42 None None O
paired None None O
lymph None None O
node None None O
metastasis None None O
samples None None O
. None None O

Topo None None O
I None None O
expression None None O
was None None O
described None None O
as None None O
the None None O
percentage None None O
of None None O
cells None None O
staining None None O
positive None None O
for None None O
topo None None O
I None None O
, None None O
along None None O
with None None O
the None None O
intensity None None O
and None None O
localization None None O
of None None O
the None None O
staining None None O
. None None O

Clinicopathologic None None O
data None None O
( None None O
sex None None O
, None None O
age None None O
, None None O
Dukes None None O
' None None O
stage None None O
, None None O
differentiation None None O
grade None None O
, None None O
survival None None O
status None None O
) None None O
, None None O
p53 None None O
status None None O
, None None O
and None None O
PCNA None None O
status None None O
were None None O
statistically None None O
analyzed None None O
for None None O
association None None O
with None None O
topo None None O
I None None O
protein None None O
expression None None O
. None None O

Topo None None O
I None None O
expression None None O
in None None O
paired None None O
primary None None O
lymph None None O
node None None O
metastases None None O
were None None O
studied None None O
for None None O
concordance None None O
. None None O

Topo None None O
I None None O
protein None None O
expression None None O
was None None O
detected None None O
in None None O
127 None None O
( None None O
51 None None O
% None None O
) None None O
samples None None O
, None None O
including None None O
24 None None O
. None None O
4 None None O
% None None O
with None None O
> None None O
50 None None O
% None None O
positive None None O
tumor None None O
cells None None O
. None None O

The None None O
majority None None O
had None None O
nuclear None None O
( None None O
70 None None O
. None None O
1 None None O
% None None O
) None None O
or None None O
nuclear None None O
and None None O
cytoplasmic None None O
staining None None O
( None None O
17 None None O
. None None O
3 None None O
% None None O
) None None O
. None None O

A None None O
higher None None O
percentage None None O
of None None O
cells None None O
expressing None None O
topo None None O
I None None O
in None None O
primary None None O
colorectal None None O
cancer None None O
was None None O
significantly None None O
associated None None O
with None None O
advanced None None O
age None None O
( None None O
P None None O
= None None O
. None None O
040 None None O
) None None O
. None None O

Patients None None O
with None None O
rectal None None O
cancer None None O
had None None O
greater None None O
topo None None O
I None None O
expression None None O
than None None O
those None None O
with None None O
colon None None O
tumors None None O
( None None O
P None None O
= None None O
. None None O
029 None None O
) None None O
. None None O

No None None O
significant None None O
correlation None None O
was None None O
found None None O
between None None O
topo None None O
I None None O
protein None None O
expression None None O
and None None O
sex None None O
, None None O
Dukes None None O
' None None O
stage None None O
, None None O
differentiation None None O
grade None None O
, None None O
survival None None O
status None None O
, None None O
p53 None None O
status None None O
, None None O
and None None O
PCNA None None O
status None None O
. None None O

Concordance None None O
in None None O
topo None None O
I None None O
staining None None O
between None None O
primary None None O
and None None O
lymph None None O
node None None O
metastases None None O
was None None O
observed None None O
in None None O
33 None None O
of None None O
42 None None O
cases None None O
( None None O
P None None O
= None None O
. None None O
029 None None O
) None None O
. None None O

This None None O
suggests None None O
that None None O
the None None O
activity None None O
of None None O
topo None None O
I None None O
inhibitors None None O
will None None O
not None None O
differ None None O
across None None O
various None None O
tumor None None O
stages None None O
, None None O
pathology None None O
, None None O
and None None O
patient None None O
gender None None O
. None None O

p53 None None O
and None None O
PCNA None None O
status None None O
do None None O
not None None O
appear None None O
to None None O
influence None None O
topo None None O
I None None O
expression None None O
, None None O
and None None O
topo None None O
I None None O
has None None O
no None None O
apparent None None O
association None None O
with None None O
the None None O
acquisition None None O
of None None O
a None None O
metastatic None None O
phenotype None None O
. None None O

Topo None None O
I None None O
expression None None O
now None None O
needs None None O
to None None O
be None None O
evaluated None None O
in None None O
patients None None O
undergoing None None O
topo None None O
I None None O
- None None O
inhibitor None None O
therapy None None O
, None None O
to None None O
better None None O
define None None O
the None None O
role None None O
of None None O
this None None O
protein None None O
as None None O
a None None O
predictive None None O
marker None None O
. None None O

Aim None None O

This None None O
study None None O
reports None None O
the None None O
results None None O
of None None O
a None None O
large None None O
prospective None None O
single None None O
- None None O
blinded None None O
clinical None None O
trial None None O
of None None O
3 None None O
SSRI None None O
( None None O
paroxetine None None O
, None None O
fluoxetine None None O
and None None O
escitalopram None None O
) None None O
in None None O
PE None None O
using None None O
a None None O
validated None None O
questionnaire None None O
. None None O

Results None None O

The None None O
observation None None O
that None None O
AP None None O
- None None O
3 None None O
is None None O
found None None O
in None None O
both None None O
cytosolic None None O
and None None O
membrane None None O
subcellular None None O
fractions None None O
, None None O
and None None O
that None None O
membrane None None O
- None None O
associated None None O
AP None None O
- None None O
3 None None O
can None None O
be None None O
extracted None None O
with None None O
salts None None O
( None None O
Dell None None O
' None None O
Angelica None None O
et None None O
al None None O
. None None O
, None None O
1997a None None O
) None None O
is None None O
consistent None None O
with None None O
its None None O
role None None O
as None None O
a None None O
membrane None None O
coat None None O
that None None O
can None None O
be None None O
recruited None None O
from None None O
a None None O
cytosolic None None O
pool None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
punctate None None O
staining None None O
of None None O
AP None None O
- None None O
3 None None O
by None None O
immunofluorescence None None O
microscopy None None O
, None None O
its None None O
redistribution None None O
to None None O
the None None O
cytosol None None O
by None None O
BFA None None O
, None None O
and None None O
the None None O
reversibility None None O
of None None O
the None None O
BFA None None O
effect None None O
( None None O
Dell None None O
' None None O
Angelica None None O
et None None O
al None None O
. None None O
, None None O
1997a None None O
; None None O
Simpson None None O
et None None O
al None None O
. None None O
, None None O
1997 None None O
) None None O
also None None O
indicate None None O
that None None O
AP None None O
- None None O
3 None None O
can None None O
cycle None None O
between None None O
the None None O
cytosol None None O
and None None O
membranes None None O
. None None O

The None None O
sensitivity None None O
of None None O
AP None None O
- None None O
3 None None O
to None None O
BFA None None O
in None None O
cells None None O
suggests None None O
that None None O
its None None O
membrane None None O
association None None O
may None None O
be None None O
regulated None None O
by None None O
ARF1 None None O
, None None O
since None None O
BFA None None O
inhibits None None O
ARF1 None None O
guanine None None O
nucleotide None None O
exchange None None O
, None None O
and None None O
has None None O
been None None O
shown None None O
to None None O
prevent None None O
ARF1 None None O
membrane None None O
binding None None O
in None None O
vitro None None O
( None None O
Donaldson None None O
et None None O
al None None O
. None None O
, None None O
1992 None None O
; None None O
Helms None None O
and None None O
Rothman None None O
, None None O
1992 None None O
; None None O
Randazzo None None O
et None None O
al None None O
. None None O
, None None O
1993 None None O
) None None O
. None None O

Etiology None None O

Anorectal None None O
malformations None None O
( None None O
ARM None None O
) None None O
represent None None O
a None None O
spectrum None None O
of None None O
abnormalities None None O
ranging None None O
from None None O
mild None None O
anal None None O
anomalies None None O
to None None O
complex None None O
cloacal None None O
malformations None None O
. None None O

The None None O
etiology None None O
of None None O
such None None O
malformations None None O
remains None None O
unclear None None O
and None None O
is None None O
likely None None O
multifactorial None None O
. None None O

There None None O
are None None O
however None None O
reasons None None O
to None None O
believe None None O
there None None O
is None None O
a None None O
genetic None None O
componenet None None O
. None None O

As None None O
early None None O
as None None O
the None None O
1950s None None O
, None None O
it None None O
was None None O
recognized None None O
that None None O
there None None O
was None None O
an None None O
increased None None O
risk None None O
for None None O
a None None O
sibling None None O
of None None O
a None None O
patient None None O
with None None O
ARM None None O
to None None O
be None None O
born None None O
with None None O
a None None O
malformation None None O
, None None O
as None None O
much None None O
as None None O
1 None None O
in None None O
100 None None O
, None None O
compared None None O
with None None O
the None None O
incidence None None O
of None None O
about None None O
1 None None O
in None None O
5000 None None O
in None None O
the None None O
general None None O
population None None O
. None None O

Since None None O
that None None O
time None None O
there None None O
have None None O
been None None O
reports None None O
of None None O
families None None O
with None None O
2 None None O
or None None O
more None None O
affected None None O
members None None O
and None None O
associations None None O
of None None O
ARMs None None O
with None None O
multisystem None None O
syndromes None None O
. None None O

In None None O
particular None None O
, None None O
mutations None None O
in None None O
specific None None O
genes None None O
encoding None None O
transcription None None O
factors None None O
have None None O
been None None O
described None None O
in None None O
patients None None O
having None None O
Townes None None O
- None None O
Broks None None O
syndrome None None O
, None None O
Currarino None None O
' None None O
s None None O
syndrome None None O
, None None O
and None None O
Pallister None None O
- None None O
Hall None None O
syndrome None None O
, None None O
each None None O
of None None O
which None None O
have None None O
autosomal None None O
dominant None None O
modes None None O
of None None O
inheritance None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
has None None O
been None None O
found None None O
that None None O
there None None O
is None None O
not None None O
only None None O
an None None O
increased None None O
incidence None None O
of None None O
ARM None None O
in None None O
patient None None O
with None None O
trisomy None None O
21 None None O
( None None O
Down None None O
' None None O
s None None O
syndrome None None O
) None None O
, None None O
but None None O
that None None O
95 None None O
% None None O
of None None O
patients None None O
with None None O
trisomy None None O
21 None None O
and None None O
ARM None None O
have None None O
imperforate None None O
anus None None O
without None None O
fistula None None O
, None None O
compared None None O
with None None O
only None None O
5 None None O
% None None O
of None None O
all None None O
patients None None O
with None None O
ARM None None O
. None None O

Based None None O
on None None O
this None None O
evidence None None O
, None None O
it None None O
is None None O
likely None None O
that None None O
the None None O
mutation None None O
of None None O
a None None O
variety None None O
of None None O
different None None O
genes None None O
can None None O
result None None O
in None None O
ARM None None O
, None None O
or None None O
that None None O
the None None O
etiology None None O
of None None O
ARM None None O
is None None O
multigenic None None O
[ None None O
13 None None O
] None None O
. None None O

Magnesium None None O
for None None O
treatment None None O
of None None O
asthma None None O
in None None O
children None None O
. None None O

QUESTION None None O
: None None O
Magnesium None None O
is None None O
considered None None O
adjuvant None None O
therapy None None O
for None None O
moderate None None O
to None None O
severe None None O
asthma None None O
exacerbations None None O
in None None O
adults None None O
, None None O
but None None O
can None None O
it None None O
be None None O
used None None O
to None None O
treat None None O
children None None O
? None None O

ANSWER None None O
: None None O
Magnesium None None O
seems None None O
to None None O
be None None O
beneficial None None O
in None None O
the None None O
treatment None None O
of None None O
moderate None None O
to None None O
severe None None O
asthma None None O
in None None O
children None None O
. None None O

It None None O
is None None O
a None None O
safe None None O
drug None None O
to None None O
administer None None O
, None None O
but None None O
there None None O
have None None O
been None None O
minor None None O
side None None O
effects None None O
reported None None O
, None None O
such None None O
as None None O
epigastric None None O
or None None O
facial None None O
warmth None None O
, None None O
flushing None None O
, None None O
pain None None O
and None None O
numbness None None O
at None None O
the None None O
infusion None None O
site None None O
, None None O
dry None None O
mouth None None O
, None None O
malaise None None O
, None None O
and None None O
hypotension None None O
. None None O

Owing None None O
to None None O
its None None O
bronchodilating None None O
and None None O
anti None None O
- None None O
inflammatory None None O
effects None None O
, None None O
magnesium None None O
is None None O
an None None O
encouraging None None O
adjuvant None None O
therapy None None O
for None None O
pediatric None None O
patients None None O
who None None O
do None None O
not None None O
respond None None O
to None None O
conventional None None O
treatment None None O
in None None O
acute None None O
severe None None O
exacerbations None None O
. None None O

Future None None O
studies None None O
should None None O
focus None None O
on None None O
establishing None None O
the None None O
optimal None None O
dosage None None O
for None None O
maximal None None O
benefits None None O
and None None O
the None None O
best None None O
route None None O
of None None O
administration None None O
. None None O

Magnesium None None O
should None None O
also None None O
be None None O
considered None None O
as None None O
a None None O
prophylactic None None O
treatment None None O
. None None O

Domain None None O
5 None None O
of None None O
cleaved None None O
high None None O
molecular None None O
weight None None O
kininogen None None O
inhibits None None O
endothelial None None O
cell None None O
migration None None O
through None None O
Akt None None O
. None None O

Domain None None O
5 None None O
( None None O
D5 None None O
) None None O
of None None O
cleaved None None O
high None None O
molecular None None O
weight None None O
kininogen None None O
( None None O
HKa None None O
) None None O
inhibits None None O
angiogenesis None None O
in None None O
vivo None None O
and None None O
endothelial None None O
cell None None O
migration None None O
in None None O
vitro None None O
, None None O
but None None O
the None None O
cell None None O
signaling None None O
pathways None None O
involved None None O
in None None O
HKa None None O
and None None O
D5 None None O
inhibition None None O
of None None O
endothelial None None O
cell None None O
migration None None O
are None None O
incompletely None None O
delineated None None O
. None None O

This None None O
study None None O
examines None None O
the None None O
mechanism None None O
of None None O
HKa None None O
and None None O
D5 None None O
inhibition None None O
of None None O
two None None O
potent None None O
stimulators None None O
of None None O
endothelial None None O
cell None None O
migration None None O
, None None O
sphingosine None None O
1 None None O
- None None O
phosphate None None O
( None None O
S1P None None O
) None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
that None None O
act None None O
through None None O
the None None O
P13 None None O
- None None O
kinase None None O
- None None O
Akt None None O
signaling None None O
pathway None None O
. None None O

HKa None None O
and None None O
D5 None None O
inhibit None None O
bovine None None O
pulmonary None None O
artery None None O
endothelial None None O
cell None None O
( None None O
BPAE None None O
) None None O
or None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
chemotaxis None None O
in None None O
the None None O
modified None None O
- None None O
Boyden None None O
chamber None None O
in None None O
response None None O
toVEGF None None O
or None None O
S1P None None O
. None None O

The None None O
inhibition None None O
of None None O
migration None None O
by None None O
HKa None None O
is None None O
reversed None None O
by None None O
antibodies None None O
to None None O
urokinase None None O
- None None O
type None None O
plasminogen None None O
activator None None O
receptor None None O
. None None O

Both None None O
HKa None None O
and None None O
D5 None None O
decrease None None O
the None None O
speed None None O
of None None O
BPAE None None O
cell None None O
migration None None O
and None None O
alter None None O
the None None O
morphology None None O
in None None O
live None None O
, None None O
time None None O
- None None O
lapse None None O
microscopy None None O
after None None O
stimulation None None O
with None None O
S1P None None O
or None None O
VEGF None None O
. None None O

HKa None None O
and None None O
D5 None None O
reduce None None O
the None None O
localization None None O
of None None O
paxillin None None O
to None None O
the None None O
focal None None O
adhesions None None O
after None None O
S1P None None O
and None None O
VEGF None None O
stimulation None None O
. None None O

To None None O
better None None O
understand None None O
the None None O
intracellular None None O
signaling None None O
pathways None None O
, None None O
we None None O
examined None None O
the None None O
effect None None O
of None None O
HKa None None O
on None None O
the None None O
phosphorylation None None O
of None None O
Akt None None O
and None None O
its None None O
downstream None None O
effector None None O
, None None O
GSK None None O
- None None O
3alpha None None O
HKa None None O
and None None O
D5 None None O
inhibit None None O
phosphorylation None None O
of None None O
Akt None None O
and None None O
GSK None None O
- None None O
3alpha None None O
after None None O
stimulation None None O
withVEGF None None O
and None None O
S1P None None O
. None None O

Inhibitors None None O
of None None O
Akt None None O
and None None O
P13 None None O
- None None O
kinase None None O
, None None O
the None None O
upstream None None O
activator None None O
of None None O
Akt None None O
, None None O
block None None O
endothelial None None O
cell None None O
migration None None O
and None None O
disrupt None None O
paxillin None None O
localization None None O
to None None O
the None None O
focal None None O
adhesions None None O
after None None O
stimulation None None O
with None None O
VEGF None None O
and None None O
S1P None None O
. None None O

Therefore None None O
we None None O
suggest None None O
that None None O
HKa None None O
through None None O
its None None O
D5 None None O
domain None None O
alters None None O
P13 None None O
- None None O
kinase None None O
- None None O
Akt None None O
signaling None None O
to None None O
inhibit None None O
endothelial None None O
cell None None O
migration None None O
through None None O
alterations None None O
in None None O
the None None O
focal None None O
adhesions None None O
. None None O

Hypoxia None None O
- None None O
inducible None None O
factor None None O
1 None None O
activation None None O
by None None O
aerobic None None O
glycolysis None None O
implicates None None O
the None None O
Warburg None None O
effect None None O
in None None O
carcinogenesis None None O
. None None O

Cancer None None O
cells None None O
display None None O
high None None O
rates None None O
of None None O
aerobic None None O
glycolysis None None O
, None None O
a None None O
phenomenon None None O
known None None O
historically None None O
as None None O
the None None O
Warburg None None O
effect None None O
. None None O

Lactate None None O
and None None O
pyruvate None None O
, None None O
the None None O
end None None O
products None None O
of None None O
glycolysis None None O
, None None O
are None None O
highly None None O
produced None None O
by None None O
cancer None None O
cells None None O
even None None O
in None None O
the None None O
presence None None O
of None None O
oxygen None None O
. None None O

Hypoxia None None O
- None None O
induced None None O
gene None None O
expression None None O
in None None O
cancer None None O
cells None None O
has None None O
been None None O
linked None None O
to None None O
malignant None None O
transformation None None O
. None None O

Here None None O
we None None O
provide None None O
evidence None None O
that None None O
lactate None None O
and None None O
pyruvate None None O
regulate None None O
hypoxia None None O
- None None O
inducible None None O
gene None None O
expression None None O
independently None None O
of None None O
hypoxia None None O
by None None O
stimulating None None O
the None None O
accumulation None None O
of None None O
hypoxia None None O
- None None O
inducible None None O
Factor None None O
1alpha None None O
( None None O
HIF None None O
- None None O
1alpha None None O
) None None O
. None None O

In None None O
human None None O
gliomas None None O
and None None O
other None None O
cancer None None O
cell None None O
lines None None O
, None None O
the None None O
accumulation None None O
of None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
under None None O
aerobic None None O
conditions None None O
requires None None O
the None None O
metabolism None None O
of None None O
glucose None None O
to None None O
pyruvate None None O
that None None O
prevents None None O
the None None O
aerobic None None O
degradation None None O
of None None O
HIF None None O
- None None O
1alpha None None O
protein None None O
, None None O
activates None None O
HIF None None O
- None None O
1 None None O
DNA None None O
binding None None O
activity None None O
, None None O
and None None O
enhances None None O
the None None O
expression None None O
of None None O
several None None O
HIF None None O
- None None O
1 None None O
- None None O
activated None None O
genes None None O
including None None O
erythropoietin None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
glucose None None O
transporter None None O
3 None None O
, None None O
and None None O
aldolase None None O
A None None O
. None None O

Our None None O
findings None None O
support None None O
a None None O
novel None None O
role None None O
for None None O
pyruvate None None O
in None None O
metabolic None None O
signaling None None O
and None None O
suggest None None O
a None None O
mechanism None None O
by None None O
which None None O
high None None O
rates None None O
of None None O
aerobic None None O
glycolysis None None O
can None None O
promote None None O
the None None O
malignant None None O
transformation None None O
and None None O
survival None None O
of None None O
cancer None None O
cells None None O
. None None O

Targeting None None O
angiogenesis None None O
: None None O
progress None None O
with None None O
anti None None O
- None None O
VEGF None None O
treatment None None O
with None None O
large None None O
molecules None None O
. None None O

Angiogenesis None None O
- None None O
- None None O
one None None O
of None None O
the None None O
hallmarks None None O
of None None O
cancer None None O
- None None O
- None None O
has None None O
emerged None None O
as None None O
a None None O
valid None None O
therapeutic None None O
target None None O
in None None O
oncology None None O
. None None O

The None None O
VEGF None None O
system None None O
represents None None O
a None None O
key None None O
mediator None None O
of None None O
tumor None None O
- None None O
initiated None None O
angiogenesis None None O
and None None O
the None None O
first None None O
target None None O
of None None O
antiangiogenesis None None O
agents None None O
introduced None None O
in None None O
clinical None None O
practice None None O
. None None O

Although None None O
anti None None O
- None None O
VEGF None None O
therapies None None O
have None None O
clearly None None O
demonstrated None None O
antitumor None None O
efficacy None None O
in None None O
various None None O
malignancies None None O
, None None O
especially None None O
when None None O
combined None None O
with None None O
conventional None None O
cytotoxic None None O
chemotherapy None None O
, None None O
their None None O
mechanism None None O
of None None O
action None None O
is None None O
not None None O
fully None None O
understood None None O
. None None O

This None None O
Review None None O
will None None O
discuss None None O
the None None O
rationale None None O
for None None O
using None None O
antiangiogenic None None O
compounds None None O
and None None O
will None None O
focus None None O
on None None O
large None None O
molecules None None O
, None None O
such None None O
as None None O
antibodies None None O
, None None O
that None None O
target None None O
the None None O
VEGF None None O
system None None O
. None None O

Clinical None None O
data None None O
on None None O
bevacizumab None None O
is None None O
discussed None None O
in None None O
detail None None O
. None None O

Predictive None None O
markers None None O
for None None O
anti None None O
- None None O
VEGF None None O
agents None None O
have None None O
not None None O
yet None None O
been None None O
identified None None O
and None None O
questions None None O
regarding None None O
the None None O
usefulness None None O
of None None O
bevacizumab None None O
in None None O
the None None O
adjuvant None None O
setting None None O
as None None O
well None None O
as None None O
its None None O
continued None None O
use None None O
beyond None None O
progression None None O
remain None None O
unanswered None None O
, None None O
in None None O
spite None None O
of None None O
negative None None O
data None None O
on None None O
bevacizumab None None O
in None None O
treating None None O
patients None None O
with None None O
adjuvant None None O
colon None None O
cancer None None O
. None None O

Nonetheless None None O
, None None O
anti None None O
- None None O
VEGF None None O
therapy None None O
has None None O
enhanced None None O
the None None O
arsenal None None O
of None None O
anticancer None None O
therapies None None O
and None None O
has None None O
provided None None O
new None None O
insights None None O
into None None O
the None None O
biology None None O
of None None O
malignancy None None O
. None None O

Intracerebral None None O
grafting None None O
of None None O
cultured None None O
autologous None None O
skin None None O
fibroblasts None None O
into None None O
the None None O
rat None None O
striatum None None O
: None None O
an None None O
assessment None None O
of None None O
graft None None O
size None None O
and None None O
ultrastructure None None O
. None None O

To None None O
identify None None O
a None None O
suitable None None O
donor None None O
cell None None O
population None None O
for None None O
gene None None O
therapy None None O
applications None None O
to None None O
the None None O
central None None O
nervous None None O
system None None O
, None None O
primary None None O
fibroblasts None None O
isolated None None O
from None None O
skin None None O
biopsies None None O
and None None O
maintained None None O
in None None O
culture None None O
are None None O
employed None None O
as None None O
autologous None None O
cells None None O
for None None O
intracerebral None None O
grafting None None O
within None None O
the None None O
adult None None O
rat None None O
striatum None None O
. None None O

Results None None O
from None None O
the None None O
present None None O
investigation None None O
reveal None None O
that None None O
cultured None None O
primary None None O
skin None None O
fibroblasts None None O
cease None None O
to None None O
proliferate None None O
once None None O
they None None O
reach None None O
confluence None None O
; None None O
these None None O
cells None None O
are None None O
thus None None O
contact None None O
inhibited None None O
in None None O
vitro None None O
. None None O

Following None None O
implantation None None O
within None None O
the None None O
striatum None None O
, None None O
the None None O
volume None None O
of None None O
the None None O
primary None None O
fibroblast None None O
grafts None None O
, None None O
stained None None O
immunohistochemically None None O
for None None O
fibronectin None None O
, None None O
does None None O
not None None O
differ None None O
significantly None None O
at None None O
3 None None O
and None None O
8 None None O
weeks None None O
. None None O

The None None O
graft None None O
size None None O
is None None O
dependent None None O
on None None O
the None None O
density None None O
of None None O
the None None O
cell None None O
suspension None None O
, None None O
but None None O
not None None O
dependent None None O
on None None O
either None None O
the None None O
number None None O
of None None O
passages None None O
the None None O
cells None None O
are None None O
taken None None O
through None None O
in None None O
culture None None O
prior None None O
to None None O
grafting None None O
or None None O
on None None O
the None None O
postoperative None None O
survival None None O
period None None O
. None None O

Ultrastructural None None O
evidence None None O
reveals None None O
that None None O
at None None O
8 None None O
weeks None None O
the None None O
grafts None None O
are None None O
composed None None O
primarily None None O
of None None O
collagen None None O
and None None O
fibroblasts None None O
with None None O
rough None None O
endoplasmic None None O
reticulum None None O
and None None O
vesicles None None O
. None None O

Reactive None None O
astrocytic None None O
processes None None O
and None None O
phagocytic None None O
cells None None O
are None None O
also None None O
present None None O
in None None O
the None None O
grafts None None O
. None None O

The None None O
grafts None None O
are None None O
extensively None None O
vascularized None None O
with None None O
capillaries None None O
composed None None O
of None None O
nonfenestrated None None O
endothelium None None O
; None None O
intercellular None None O
junctions None None O
are None None O
evident None None O
at None None O
sites None None O
of None None O
apposition None None O
between None None O
endothelial None None O
cells None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
primary None None O
skin None None O
fibroblasts None None O
are None None O
able None None O
to None None O
survive None None O
for None None O
at None None O
least None None O
8 None None O
weeks None None O
following None None O
intracerebral None None O
implantation None None O
and None None O
continue None None O
to None None O
synthesize None None O
collagen None None O
and None None O
fibronectin None None O
in None None O
vivo None None O
. None None O

Also None None O
, None None O
the None None O
grafts None None O
maintain None None O
a None None O
constant None None O
volume None None O
between None None O
3 None None O
and None None O
8 None None O
weeks None None O
, None None O
thereby None None O
indicating None None O
that None None O
primary None None O
skin None None O
fibroblasts None None O
do None None O
not None None O
produce None None O
tumors None None O
. None None O

Finally None None O
, None None O
dynamic None None O
host None None O
- None None O
to None None O
- None None O
graft None None O
interactions None None O
- None None O
- None None O
including None None O
phagocytic None None O
migration None None O
, None None O
astrocytic None None O
hypertrophy None None O
and None None O
infiltration None None O
within None None O
the None None O
grafts None None O
, None None O
and None None O
angiogenesis None None O
- None None O
- None None O
are None None O
features None None O
that None None O
constitute None None O
the None None O
structural None None O
integration None None O
of None None O
primary None None O
skin None None O
fibroblasts None None O
grafted None None O
within None None O
the None None O
adult None None O
rat None None O
central None None O
nervous None None O
system None None O
. None None O

Additional None None O
File None None O
2 None None O

Full None None O
Model None None O
Code None None O
. None None O

Full None None O
model None None O
code None None O
plus None None O
instructions None None O
for None None O
running None None O
in None None O
Berkeley None None O
Madonna None None O
( None None O
TM None None O
) None None O
. None None O

Involvement None None O
of None None O
PTEN None None O
promoter None None O
methylation None None O
in None None O
cerebral None None O
cavernous None None O
malformations None None O
. None None O

BACKGROUND None None O
AND None None O
PURPOSE None None O
: None None O
Cerebral None None O
cavernous None None O
malformations None None O
( None None O
CCMs None None O
) None None O
are None None O
prevalent None None O
cerebral None None O
vascular None None O
lesions None None O
involving None None O
aberrant None None O
angiogenesis None None O
. None None O

However None None O
, None None O
the None None O
underlying None None O
mechanism None None O
is None None O
poorly None None O
understood None None O
. None None O

Phosphatase None None O
and None None O
tension None None O
homolog None None O
deleted None None O
on None None O
chromosome None None O
10 None None O
( None None O
PTEN None None O
) None None O
, None None O
a None None O
tumor None None O
suppressor None None O
, None None O
is None None O
frequently None None O
deficient None None O
in None None O
various None None O
pathologies None None O
due None None O
to None None O
mutation None None O
or None None O
epigenetic None None O
alterations None None O
. None None O

PTEN None None O
promoter None None O
hypermethylation None None O
is None None O
a None None O
major None None O
epigenetic None None O
silencing None None O
mechanism None None O
leading None None O
to None None O
activation None None O
of None None O
angiogenesis None None O
in None None O
tumors None None O
. None None O

The None None O
present None None O
study None None O
aimed None None O
to None None O
investigate None None O
whether None None O
PTEN None None O
promoter None None O
methylation None None O
was None None O
involved None None O
in None None O
CCMs None None O
. None None O

METHODS None None O
: None None O
PTEN None None O
promoter None None O
methylation None None O
was None None O
detected None None O
in None None O
surgical None None O
specimens None None O
of None None O
CCMs None None O
( None None O
n None None O
= None None O
69 None None O
) None None O
by None None O
methylation None None O
- None None O
specific None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

The None None O
methylation None None O
status None None O
was None None O
correlated None None O
to None None O
the None None O
clinical None None O
manifestations None None O
and None None O
to None None O
PTEN None None O
expression None None O
, None None O
which None None O
was None None O
analyzed None None O
by None None O
both None None O
Western None None O
blot None None O
and None None O
immunohistochemistry None None O
. None None O

To None None O
investigate None None O
the None None O
endothelial None None O
proliferation None None O
and None None O
the None None O
potential None None O
signaling None None O
pathways None None O
affected None None O
by None None O
PTEN None None O
methylation None None O
, None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
as None None O
well None None O
as None None O
phosphor None None O
- None None O
Akt None None O
and None None O
phosphor None None O
- None None O
Erk1 None None O
, None None O
2 None None O
were None None O
detected None None O
by None None O
immunofluorescence None None O
and None None O
Western None None O
blot None None O
, None None O
respectively None None O
, None None O
in None None O
CCM None None O
specimens None None O
. None None O

RESULTS None None O
: None None O
Methylation None None O
- None None O
specific None None O
polymerase None None O
chain None None O
reaction None None O
revealed None None O
PTEN None None O
promoter None None O
methylation None None O
in None None O
15 None None O
. None None O
9 None None O
% None None O
CCMs None None O
. None None O

Strikingly None None O
, None None O
5 None None O
of None None O
6 None None O
familial None None O
CCMs None None O
showed None None O
PTEN None None O
promoter None None O
methylation None None O
( None None O
83 None None O
. None None O
3 None None O
% None None O
) None None O
, None None O
which None None O
was None None O
significantly None None O
higher None None O
than None None O
in None None O
sporadic None None O
cases None None O
( None None O
9 None None O
. None None O
4 None None O
% None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
PTEN None None O
promoter None None O
methylation None None O
appeared None None O
more None None O
frequently None None O
in None None O
multiple None None O
CCMs None None O
, None None O
including None None O
familial None None O
cases None None O
( None None O
46 None None O
. None None O
7 None None O
% None None O
) None None O
, None None O
than None None O
that None None O
in None None O
single None None O
- None None O
lesioned None None O
CCMs None None O
( None None O
11 None None O
. None None O
8 None None O
% None None O
; None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Immunostaining None None O
and None None O
Western None None O
blot None None O
revealed None None O
a None None O
more None None O
significant None None O
PTEN None None O
downregulation None None O
in None None O
PTEN None None O
- None None O
methylated None None O
CCMs None None O
in None None O
comparison None None O
to None None O
PTEN None None O
- None None O
unmethylated None None O
CCMs None None O
. None None O

Reduced None None O
PTEN None None O
expression None None O
was None None O
inversely None None O
correlated None None O
to None None O
the None None O
expression None None O
of None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
and None None O
to None None O
the None None O
activation None None O
of None None O
Erk1 None None O
, None None O
2 None None O
, None None O
but None None O
not None None O
of None None O
Akt None None O
. None None O

CONCLUSIONS None None O
: None None O
We None None O
reported None None O
here None None O
for None None O
the None None O
first None None O
time None None O
the None None O
involvement None None O
of None None O
PTEN None None O
promoter None None O
methylation None None O
in None None O
CCMs None None O
, None None O
particularly None None O
in None None O
familial None None O
CCMs None None O
, None None O
suggesting None None O
this None None O
epigenetic None None O
alteration None None O
as None None O
a None None O
potential None None O
pathomechanism None None O
of None None O
CCMs None None O
. None None O

The None None O
identification None None O
of None None O
Erk1 None None O
, None None O
2 None None O
as None None O
triggered None None O
signaling None None O
in None None O
the None None O
lesions None None O
may None None O
be None None O
valuable None None O
for None None O
the None None O
development None None O
of None None O
effective None None O
therapy None None O
for None None O
this None None O
disease None None O
. None None O

Authors None None O
' None None O
contributions None None O

All None None O
authors None None O
contributed None None O
to None None O
the None None O
development None None O
of None None O
the None None O
methodology None None O
. None None O

CY None None O
and None None O
NZ None None O
led None None O
method None None O
conceptualization None None O
and None None O
prepared None None O
the None None O
original None None O
draft None None O
, None None O
which None None O
was None None O
revised None None O
by None None O
JR None None O
. None None O

CY None None O
and None None O
VD None None O
performed None None O
most None None O
implementations None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O

Interleukin None None O
- None None O
1 None None O
receptor None None O
antagonist None None O
inhibits None None O
ischaemic None None O
and None None O
excitotoxic None None O
neuronal None None O
damage None None O
in None None O
the None None O
rat None None O
. None None O

Interleukin None None O
- None None O
1 None None O
( None None O
IL None None O
- None None O
1 None None O
) None None O
synthesis None None O
in None None O
the None None O
brain None None O
is None None O
stimulated None None O
by None None O
mechanical None None O
injury None None O
and None None O
IL None None O
- None None O
1 None None O
mimics None None O
some None None O
effects None None O
of None None O
injury None None O
, None None O
such None None O
as None None O
gliosis None None O
and None None O
neovascularization None None O
. None None O

We None None O
report None None O
that None None O
neuronal None None O
death None None O
resulting None None O
from None None O
focal None None O
cerebral None None O
ischaemia None None O
( None None O
middle None None O
cerebral None None O
artery None None O
occlusion None None O
, None None O
24 None None O
h None None O
) None None O
is None None O
significantly None None O
inhibited None None O
( None None O
by None None O
50 None None O
% None None O
) None None O
in None None O
rats None None O
injected None None O
with None None O
a None None O
recombinant None None O
IL None None O
- None None O
1 None None O
receptor None None O
antagonist None None O
( None None O
IL None None O
- None None O
1ra None None O
, None None O
10 None None O
micrograms None None O
, None None O
icv None None O
30 None None O
min None None O
before None None O
and None None O
10 None None O
min None None O
after None None O
ischaemia None None O
) None None O
. None None O

Excitotoxic None None O
damage None None O
due None None O
to None None O
striatal None None O
infusion None None O
of None None O
an None None O
NMDA None None O
- None None O
receptor None None O
agonist None None O
( None None O
cis None None O
- None None O
2 None None O
, None None O
4 None None O
- None None O
methanoglutamate None None O
) None None O
was None None O
also None None O
markedly None None O
inhibited None None O
( None None O
71 None None O
% None None O
) None None O
by None None O
injection None None O
of None None O
the None None O
IL None None O
- None None O
1ra None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
endogenous None None O
IL None None O
- None None O
1 None None O
is None None O
a None None O
mediator None None O
of None None O
ischaemic None None O
and None None O
excitotoxic None None O
brain None None O
damage None None O
, None None O
and None None O
that None None O
inhibitors None None O
of None None O
IL None None O
- None None O
1 None None O
action None None O
may None None O
be None None O
of None None O
therapeutic None None O
value None None O
in None None O
the None None O
treatment None None O
of None None O
acute None None O
or None None O
chronic None None O
neuronal None None O
death None None O
. None None O

An None None O
assay None None O
to None None O
measure None None O
angiogenesis None None O
in None None O
human None None O
fat None None O
tissue None None O
. None None O

BACKGROUND None None O
: None None O
Inhibition None None O
of None None O
angiogenesis None None O
reverses None None O
rodent None None O
obesity None None O
. None None O

A None None O
validated None None O
assay None None O
in None None O
human None None O
fat None None O
tissue None None O
is None None O
needed None None O
to None None O
study None None O
the None None O
role None None O
of None None O
angiogenesis None None O
in None None O
human None None O
obesity None None O
. None None O

METHODS None None O
: None None O
Human None None O
fat None None O
tissue None None O
fragments None None O
from None None O
surgery None None O
were None None O
placed None None O
in None None O
96 None None O
- None None O
well None None O
plates None None O
, None None O
embedded None None O
in None None O
fibrin None None O
thrombin None None O
clot None None O
and None None O
overlaid None None O
with None None O
cell None None O
culture None None O
media None None O
containing None None O
20 None None O
% None None O
fetal None None O
bovine None None O
serum None None O
. None None O

After None None O
15 None None O
days None None O
, None None O
the None None O
clots None None O
were None None O
examined None None O
by None None O
histology None None O
and None None O
electron None None O
microscopy None None O
. None None O

The None None O
effect None None O
of None None O
taxol None None O
, None None O
cobalt None None O
chloride None None O
and None None O
a None None O
heparin None None O
- None None O
steroid None None O
combination None None O
was None None O
tested None None O
in None None O
the None None O
fat None None O
tissue None None O
assay None None O
and None None O
compared None None O
to None None O
the None None O
validated None None O
human None None O
placental None None O
vein None None O
angiogenesis None None O
model None None O
( None None O
HPVAM None None O
) None None O
. None None O

RESULTS None None O
: None None O
Blood None None O
vessels None None O
initiated None None O
growth None None O
and None None O
elongated None None O
from None None O
the None None O
fat None None O
tissue None None O
fragments None None O
over None None O
15 None None O
days None None O
. None None O

Presence None None O
of None None O
blood None None O
vessels None None O
was None None O
confirmed None None O
with None None O
histology None None O
and None None O
electron None None O
microscopy None None O
. None None O

Taxol None None O
at None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
and None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
completely None None O
inhibited None None O
angiogenesis None None O
, None None O
while None None O
Taxol None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
and None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
and None None O
the None None O
heparin None None O
- None None O
steroid None None O
partially None None O
inhibited None None O
angiogenesis None None O
. None None O

The None None O
response None None O
to None None O
taxol None None O
and None None O
heparin None None O
- None None O
steroid None None O
was None None O
similar None None O
to None None O
that None None O
of None None O
the None None O
HPVAM None None O
, None None O
a None None O
validated None None O
angiogenesis None None O
assay None None O
. None None O

Cobalt None None O
chloride None None O
, None None O
a None None O
stimulator None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
stimulated None None O
angiogenesis None None O
initiation None None O
at None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
in None None O
fat None None O
tissue None None O
and None None O
the None None O
HPVAM None None O
, None None O
but None None O
at None None O
10 None None O
( None None O
- None None O
10 None None O
) None None O
M None None O
blood None None O
vessel None None O
growth None None O
was None None O
stimulated None None O
only None None O
in None None O
the None None O
fat None None O
assay None None O
. None None O

CONCLUSION None None O
: None None O
This None None O
angiogenesis None None O
assay None None O
based None None O
on None None O
human None None O
fat None None O
tissue None None O
uses None None O
three None None O
- None None O
dimensionally None None O
intact None None O
human None None O
tissue None None O
. None None O

The None None O
vessels None None O
are None None O
derived None None O
from None None O
quiescient None None O
vessels None None O
within None None O
the None None O
fat None None O
. None None O

These None None O
properties None None O
allow None None O
the None None O
angiogenic None None O
switch None None O
to None None O
be None None O
evaluated None None O
in None None O
an None None O
in None None O
vitro None None O
setting None None O
. None None O

The None None O
angiogenic None None O
response None None O
of None None O
fat None None O
tissue None None O
is None None O
not None None O
identical None None O
to None None O
placental None None O
tissue None None O
. None None O

This None None O
assay None None O
allows None None O
exploration None None O
of None None O
angiogenesis None None O
in None None O
fat None None O
tissue None None O
. None None O

[ None None O
Glaucoma None None O
and None None O
ocular None None O
ischemic None None O
syndrome None None O
- None None O
- None None O
case None None O
report None None O
] None None O

PURPOSE None None O
: None None O
Ocular None None O
ischemic None None O
syndrome None None O
( None None O
OIS None None O
) None None O
is None None O
often None None O
poorly None None O
diagnosed None None O
and None None O
treated None None O
as None None O
primary None None O
open None None O
angle None None O
glaucoma None None O
or None None O
later None None O
on None None O
, None None O
as None None O
neovascular None None O
glaucoma None None O
. None None O

We None None O
present None None O
a None None O
54 None None O
year None None O
old None None O
male None None O
, None None O
treated None None O
topical None None O
since None None O
23 None None O
years None None O
for None None O
glaucoma None None O
and None None O
sent None None O
to None None O
our None None O
clinic None None O
for None None O
trabeculectomy None None O
because None None O
of None None O
rapid None None O
worsening None None O
of None None O
vision None None O
on None None O
right None None O
eye None None O
with None None O
bilateral None None O
total None None O
excavation None None O
of None None O
optic None None O
disc None None O
. None None O

MATERIAL None None O
AND None None O
METHODS None None O
: None None O
Observational None None O
case None None O
report None None O
. None None O

RESULTS None None O
: None None O
Because None None O
of None None O
typical None None O
signs None None O
of None None O
IOS None None O
( None None O
iris None None O
neovascularization None None O
, None None O
mid None None O
- None None O
peripheral None None O
dot None None O
and None None O
blot None None O
hemorrhages None None O
in None None O
both None None O
eyes None None O
, None None O
narrowed None None O
arterioles None None O
in None None O
right None None O
eye None None O
, None None O
following None None O
examinations None None O
were None None O
performed None None O
: None None O
Doppler None None O
ultrasonography None None O
of None None O
carotid None None O
arteries None None O
, None None O
digital None None O
subtractional None None O
angiography None None O
of None None O
the None None O
carotid None None O
vessels None None O
and None None O
magnetic None None O
resonance None None O
angiography None None O
. None None O

The None None O
examinations None None O
showed None None O
occlusion None None O
of None None O
the None None O
right None None O
common None None O
carotid None None O
artery None None O
and None None O
with None None O
80 None None O
% None None O
stenosis None None O
of None None O
the None None O
left None None O
common None None O
carotid None None O
artery None None O
, None None O
occlusion None None O
of None None O
abdominal None None O
aorta None None O
. None None O

After None None O
phacoemulsification None None O
with None None O
implantation None None O
of None None O
intraocular None None O
lens None None O
because None None O
of None None O
rapid None None O
intumescence None None O
cataract None None O
in None None O
the None None O
right None None O
eye None None O
, None None O
and None None O
endarterectomy None None O
of None None O
left None None O
external None None O
carotid None None O
artery None None O
, None None O
the None None O
neovascularization None None O
of None None O
the None None O
iris None None O
regressed None None O
in None None O
both None None O
eyes None None O
. None None O

CONCLUSION None None O
: None None O
In None None O
case None None O
of None None O
iris None None O
neovascularization None None O
or None None O
mid None None O
- None None O
peripheral None None O
hemorrhages None None O
the None None O
Doppler None None O
sonography None None O
of None None O
carotid None None O
arteries None None O
should None None O
be None None O
performed None None O
. None None O

Quick None None O
cooperation None None O
between None None O
ophthalmologist None None O
, None None O
radiologist None None O
and None None O
vascular None None O
surgeon None None O
following None None O
endarterectomy None None O
seems None None O
to None None O
stop None None O
progressing None None O
changes None None O
of None None O
ocular None None O
ischemic None None O
syndrome None None O
. None None O

[ None None O
Expression None None O
and None None O
mutation None None O
of None None O
c None None O
- None None O
kit None None O
gene None None O
in None None O
gastrointestinal None None O
stromal None None O
tumor None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
effect None None O
of None None O
the None None O
expression None None O
and None None O
mutation None None O
of None None O
c None None O
- None None O
kit None None O
gene None None O
and None None O
its None None O
relationship None None O
with None None O
clinical None None O
pathology None None O
and None None O
prognosis None None O
of None None O
gastrointestinal None None O
stromal None None O
tumor None None O
( None None O
GIST None None O
) None None O
. None None O

METHODS None None O
: None None O
Immunohistochemical None None O
and None None O
PCR None None O
- None None O
SSCP None None O
techniques None None O
were None None O
used None None O
to None None O
detect None None O
c None None O
- None None O
kit None None O
protein None None O
expression None None O
and None None O
c None None O
- None None O
kit None None O
gene None None O
exon None None O
11 None None O
mutation None None O
in None None O
82 None None O
patients None None O
with None None O
GIST None None O
. None None O

RESULTS None None O
: None None O
The None None O
positive None None O
c None None O
- None None O
kit None None O
protein None None O
expression None None O
and None None O
c None None O
- None None O
kit None None O
gene None None O
mutation None None O
rates None None O
were None None O
97 None None O
. None None O
6 None None O
% None None O
( None None O
80 None None O
/ None None O
82 None None O
) None None O
and None None O
41 None None O
. None None O
5 None None O
% None None O
( None None O
34 None None O
/ None None O
82 None None O
) None None O
. None None O

Correlating None None O
the None None O
results None None O
of None None O
these None None O
two None None O
methods None None O
and None None O
clinicopathological None None O
factors None None O
, None None O
the None None O
c None None O
- None None O
kit None None O
expression None None O
and None None O
c None None O
- None None O
kit None None O
gene None None O
mutation None None O
rates None None O
were None None O
95 None None O
. None None O
0 None None O
% None None O
( None None O
19 None None O
/ None None O
20 None None O
) None None O
and None None O
0 None None O
in None None O
benign None None O
GIST None None O
, None None O
and None None O
were None None O
98 None None O
. None None O
4 None None O
% None None O
( None None O
61 None None O
/ None None O
62 None None O
) None None O
, None None O
54 None None O
. None None O
8 None None O
% None None O
( None None O
34 None None O
/ None None O
62 None None O
) None None O
in None None O
malignant None None O
GIST None None O
. None None O

Mutation None None O
positive None None O
GIST None None O
showed None None O
higher None None O
frequency None None O
of None None O
adjacent None None O
tissue None None O
invasion None None O
, None None O
metastasis None None O
and None None O
recurrence None None O
as None None O
compared None None O
with None None O
mutation None None O
negative None None O
ones None None O
. None None O

CONCLUSION None None O
: None None O
c None None O
- None None O
kit None None O
protein None None O
is None None O
an None None O
important None None O
diagnostic None None O
marker None None O
of None None O
gastrointestinal None None O
stromal None None O
tumor None None O
. None None O

c None None O
- None None O
kit None None O
gene None None O
mutation None None O
may None None O
play None None O
a None None O
significant None None O
role None None O
in None None O
the None None O
pathogenesis None None O
of None None O
GIST None None O
and None None O
also None None O
may None None O
be None None O
a None None O
prognostic None None O
marker None None O
. None None O

Runx2 None None O
and None None O
MYC None None O
collaborate None None O
in None None O
lymphoma None None O
development None None O
by None None O
suppressing None None O
apoptotic None None O
and None None O
growth None None O
arrest None None O
pathways None None O
in None None O
vivo None None O
. None None O

Members None None O
of None None O
the None None O
Runx None None O
and None None O
MYC None None O
families None None O
have None None O
been None None O
implicated None None O
as None None O
collaborating None None O
oncogenes None None O
. None None O

The None None O
mechanism None None O
of None None O
this None None O
potent None None O
collaboration None None O
is None None O
elucidated None None O
in None None O
this None None O
study None None O
of None None O
Runx2 None None O
/ None None O
MYC None None O
mice None None O
. None None O

As None None O
shown None None O
previously None None O
, None None O
ectopic None None O
expression None None O
of None None O
Runx2 None None O
in None None O
the None None O
thymus None None O
leads None None O
to None None O
a None None O
preneoplastic None None O
state None None O
defined None None O
by None None O
an None None O
accumulation None None O
of None None O
cells None None O
with None None O
an None None O
immature None None O
phenotype None None O
and None None O
a None None O
low None None O
proliferative None None O
rate None None O
. None None O

We None None O
now None None O
show None None O
that None None O
c None None O
- None None O
MYC None None O
overexpression None None O
is None None O
sufficient None None O
to None None O
rescue None None O
proliferation None None O
and None None O
to None None O
release None None O
the None None O
differentiation None None O
block None None O
imposed None None O
by None None O
Runx2 None None O
. None None O

Analysis None None O
of None None O
Runx2 None None O
- None None O
expressing None None O
lymphomas None None O
reveals None None O
a None None O
consistently None None O
low None None O
rate None None O
of None None O
apoptosis None None O
, None None O
in None None O
contrast None None O
to None None O
lymphomas None None O
of None None O
MYC None None O
mice None None O
which None None O
are None None O
often None None O
highly None None O
apoptotic None None O
. None None O

The None None O
low None None O
apoptosis None None O
phenotype None None O
is None None O
dominant None None O
in None None O
Runx2 None None O
/ None None O
MYC None None O
tumors None None O
, None None O
indicating None None O
that None None O
Runx2 None None O
confers None None O
a None None O
potent None None O
survival None None O
advantage None None O
to None None O
MYC None None O
- None None O
expressing None None O
tumor None None O
cells None None O
. None None O

The None None O
role None None O
of None None O
the None None O
p53 None None O
pathway None None O
in None None O
Runx2 None None O
/ None None O
MYC None None O
tumors None None O
was None None O
explored None None O
on None None O
a None None O
p53 None None O
heterozygote None None O
background None None O
. None None O

Surprisingly None None O
, None None O
functional None None O
p53 None None O
was None None O
retained None None O
in None None O
vivo None None O
, None None O
even None None O
after None None O
transplantation None None O
, None None O
whereas None None O
explanted None None O
tumor None None O
cells None None O
displayed None None O
rapid None None O
allele None None O
loss None None O
in None None O
vitro None None O
. None None O

Our None None O
results None None O
show None None O
that None None O
Runx2 None None O
and None None O
MYC None None O
overcome None None O
distinct None None O
" None None O
fail None None O
- None None O
safe None None O
" None None O
responses None None O
and None None O
that None None O
their None None O
selection None None O
as None None O
collaborating None None O
genes None None O
is None None O
due None None O
to None None O
their None None O
ability None None O
to None None O
neutralize None None O
each None None O
other None None O
' None None O
s None None O
negative None None O
growth None None O
effect None None O
. None None O

Furthermore None None O
, None None O
the None None O
Runx2 None None O
/ None None O
MYC None None O
combination None None O
overcomes None None O
the None None O
requirement None None O
for None None O
genetic None None O
inactivation None None O
of None None O
the None None O
p53 None None O
pathway None None O
in None None O
vivo None None O
. None None O

Blind None None O
separation None None O
of None None O
auditory None None O
event None None O
- None None O
related None None O
brain None None O
responses None None O
into None None O
independent None None O
components None None O
. None None O

Averaged None None O
event None None O
- None None O
related None None O
potential None None O
( None None O
ERP None None O
) None None O
data None None O
recorded None None O
from None None O
the None None O
human None None O
scalp None None O
reveal None None O
electroencephalographic None None O
( None None O
EEG None None O
) None None O
activity None None O
that None None O
is None None O
reliably None None O
time None None O
- None None O
locked None None O
and None None O
phase None None O
- None None O
locked None None O
to None None O
experimental None None O
events None None O
. None None O

We None None O
report None None O
here None None O
the None None O
application None None O
of None None O
a None None O
method None None O
based None None O
on None None O
information None None O
theory None None O
that None None O
decomposes None None O
one None None O
or None None O
more None None O
ERPs None None O
recorded None None O
at None None O
multiple None None O
scalp None None O
sensors None None O
into None None O
a None None O
sum None None O
of None None O
components None None O
with None None O
fixed None None O
scalp None None O
distributions None None O
and None None O
sparsely None None O
activated None None O
, None None O
maximally None None O
independent None None O
time None None O
courses None None O
. None None O

Independent None None O
component None None O
analysis None None O
( None None O
ICA None None O
) None None O
decomposes None None O
ERP None None O
data None None O
into None None O
a None None O
number None None O
of None None O
components None None O
equal None None O
to None None O
the None None O
number None None O
of None None O
sensors None None O
. None None O

The None None O
derived None None O
components None None O
have None None O
distinct None None O
but None None O
not None None O
necessarily None None O
orthogonal None None O
scalp None None O
projections None None O
. None None O

Unlike None None O
dipole None None O
- None None O
fitting None None O
methods None None O
, None None O
the None None O
algorithm None None O
does None None O
not None None O
model None None O
the None None O
locations None None O
of None None O
their None None O
generators None None O
in None None O
the None None O
head None None O
. None None O

Unlike None None O
methods None None O
that None None O
remove None None O
second None None O
- None None O
order None None O
correlations None None O
, None None O
such None None O
as None None O
principal None None O
component None None O
analysis None None O
( None None O
PCA None None O
) None None O
, None None O
ICA None None O
also None None O
minimizes None None O
higher None None O
- None None O
order None None O
dependencies None None O
. None None O

Applied None None O
to None None O
detected None None O
- None None O
and None None O
undetected None None O
- None None O
target None None O
ERPs None None O
from None None O
an None None O
auditory None None O
vigilance None None O
experiment None None O
, None None O
the None None O
algorithm None None O
derived None None O
ten None None O
components None None O
that None None O
decomposed None None O
each None None O
of None None O
the None None O
major None None O
response None None O
peaks None None O
into None None O
one None None O
or None None O
more None None O
ICA None None O
components None None O
with None None O
relatively None None O
simple None None O
scalp None None O
distributions None None O
. None None O

Three None None O
of None None O
these None None O
components None None O
were None None O
active None None O
only None None O
when None None O
the None None O
subject None None O
detected None None O
the None None O
targets None None O
, None None O
three None None O
other None None O
components None None O
only None None O
when None None O
the None None O
target None None O
went None None O
undetected None None O
, None None O
and None None O
one None None O
in None None O
both None None O
cases None None O
. None None O

Three None None O
additional None None O
components None None O
accounted None None O
for None None O
the None None O
steady None None O
- None None O
state None None O
brain None None O
response None None O
to None None O
a None None O
39 None None O
- None None O
Hz None None O
background None None O
click None None O
train None None O
. None None O

Major None None O
features None None O
of None None O
the None None O
decomposition None None O
proved None None O
robust None None O
across None None O
sessions None None O
and None None O
changes None None O
in None None O
sensor None None O
number None None O
and None None O
placement None None O
. None None O

This None None O
method None None O
of None None O
ERP None None O
analysis None None O
can None None O
be None None O
used None None O
to None None O
compare None None O
responses None None O
from None None O
multiple None None O
stimuli None None O
, None None O
task None None O
conditions None None O
, None None O
and None None O
subject None None O
states None None O
. None None O

Animals None None O

STOP None None O
null None None O
mice None None O
and None None O
their None None O
WT None None O
littermates None None O
were None None O
generated None None O
on None None O
a None None O
mixed None None O
BALBc None None O
/ None None O
129 None None O
SvPas None None O
and None None O
on None None O
a None None O
pure None None O
129 None None O
SvPas None None O
background None None O
as None None O
previously None None O
reported None None O
by None None O
Andrieux None None O
et None None O
al None None O
. None None O

[ None None O
4 None None O
] None None O
. None None O

All None None O
animals None None O
used None None O
in None None O
the None None O
study None None O
underwent None None O
immunohistochemistry None None O
for None None O
the None None O
detection None None O
of None None O
STOP None None O
protein None None O
, None None O
resulting None None O
in None None O
no None None O
staining None None O
in None None O
STOP None None O
null None None O
mice None None O
, None None O
and None None O
genotyping None None O
by None None O
PCR None None O
as None None O
described None None O
by None None O
Andrieux None None O
et None None O
al None None O
. None None O

[ None None O
4 None None O
] None None O
. None None O

All None None O
mice None None O
were None None O
kept None None O
under None None O
standard None None O
housing None None O
conditions None None O
with None None O
a None None O
12 None None O
- None None O
hour None None O
/ None None O
12 None None O
- None None O
hour None None O
dark None None O
- None None O
light None None O
cycle None None O
. None None O

The None None O
experiments None None O
were None None O
carried None None O
out None None O
in None None O
accordance None None O
with None None O
the None None O
European None None O
Communities None None O
Council None None O
Directive None None O
of None None O
24 None None O
November None None O
1986 None None O
( None None O
86 None None O
/ None None O
609 None None O
/ None None O
EEC None None O
) None None O
, None None O
and None None O
the None None O
French None None O
Department None None O
of None None O
Agriculture None None O
( None None O
License None None O
Ndegrees None None O
67 None None O
- None None O
95 None None O
) None None O
. None None O

The None None O
protocol None None O
was None None O
approved None None O
by None None O
the None None O
ethical None None O
Animal None None O
Research None None O
Committee None None O
of None None O
Louis None None O
Pasteur None None O
University None None O
( None None O
CREMEAS None None O
# None None O
AL None None O
/ None None O
01 None None O
/ None None O
19 None None O
/ None None O
10 None None O
/ None None O
07 None None O
) None None O
. None None O

In None None O
a None None O
first None None O
experiment None None O
, None None O
we None None O
searched None None O
for None None O
differences None None O
in None None O
glomerular None None O
ultrastructure None None O
and None None O
peripheral None None O
neurogenesis None None O
between None None O
WT None None O
and None None O
STOP None None O
null None None O
mice None None O
: None None O
a None None O
first None None O
group None None O
of None None O
24 None None O
mice None None O
, None None O
3 None None O
- None None O
to None None O
6 None None O
- None None O
month None None O
- None None O
old None None O
, None None O
was None None O
used None None O
for None None O
ultrastructural None None O
study None None O
of None None O
the None None O
OBs None None O
; None None O
a None None O
second None None O
group None None O
of None None O
13 None None O
animals None None O
was None None O
used None None O
to None None O
analyse None None O
proliferation None None O
and None None O
apoptosis None None O
in None None O
the None None O
OE None None O
and None None O
VNE None None O
on None None O
paraffin None None O
sections None None O
in None None O
3 None None O
- None None O
month None None O
- None None O
old None None O
mice None None O
. None None O

In None None O
a None None O
second None None O
experiment None None O
we None None O
analysed None None O
, None None O
in None None O
WT None None O
and None None O
STOP None None O
null None None O
mice None None O
, None None O
the None None O
effect None None O
of None None O
OE None None O
regeneration None None O
on None None O
glomeruli None None O
structure None None O
and None None O
ultrastructure None None O
and None None O
on None None O
peripheral None None O
neurogenesis None None O
at None None O
two None None O
age None None O
times None None O
( None None O
3 None None O
and None None O
10 None None O
months None None O
) None None O
. None None O

Figures None None O

Fig None None O
. None None O

1 None None O
. None None O

A None None O
view None None O
of None None O
( None None O
I None None O
) None None O
with None None O
displacement None None O
ellipsoids None None O
drawn None None O
at None None O
the None None O
30 None None O
% None None O
probability None None O
level None None O
. None None O

Fig None None O
. None None O

2 None None O
. None None O

Stereoview None None O
of None None O
the None None O
sheet None None O
formed None None O
by None None O
C None None O
- None None O
- None None O
H None None O
. None None O
. None None O
. None None O
pi None None O
interactions None None O
. None None O

Hydrogen None None O
atoms None None O
not None None O
involved None None O
in None None O
the None None O
motifs None None O
are None None O
not None None O
included None None O
. None None O

IL None None O
- None None O
12 None None O
inhibition None None O
of None None O
endothelial None None O
cell None None O
functions None None O
and None None O
angiogenesis None None O
depends None None O
on None None O
lymphocyte None None O
- None None O
endothelial None None O
cell None None O
cross None None O
- None None O
talk None None O
. None None O

In None None O
vivo None None O
IL None None O
- None None O
12 None None O
- None None O
dependent None None O
tumor None None O
inhibition None None O
rests None None O
on None None O
the None None O
ability None None O
of None None O
IL None None O
- None None O
12 None None O
to None None O
activate None None O
a None None O
CD8 None None O
- None None O
mediated None None O
cytotoxicity None None O
, None None O
inhibit None None O
angiogenesis None None O
, None None O
and None None O
cause None None O
vascular None None O
injury None None O
. None None O

Although None None O
in None None O
vivo None None O
studies None None O
have None None O
shown None None O
that None None O
such None None O
inhibition None None O
stems None None O
from None None O
complex None None O
interactions None None O
of None None O
immune None None O
cells None None O
and None None O
the None None O
production None None O
of None None O
IFN None None O
- None None O
gamma None None O
and None None O
other None None O
downstream None None O
angiostatic None None O
chemokines None None O
, None None O
the None None O
mechanisms None None O
involved None None O
are None None O
still None None O
poorly None None O
defined None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
IL None None O
- None None O
12 None None O
activates None None O
an None None O
anti None None O
- None None O
angiogenic None None O
program None None O
in None None O
Con None None O
A None None O
- None None O
activated None None O
mouse None None O
spleen None None O
cells None None O
( None None O
activated None None O
spc None None O
) None None O
or None None O
human None None O
PBMC None None O
( None None O
activated None None O
PBMC None None O
) None None O
. None None O

The None None O
soluble None None O
factors None None O
they None None O
release None None O
in None None O
its None None O
presence None None O
arrest None None O
the None None O
cycle None None O
of None None O
endothelial None None O
cells None None O
( None None O
EC None None O
) None None O
, None None O
inhibit None None O
in None None O
vitro None None O
angiogenesis None None O
, None None O
negatively None None O
modulate None None O
the None None O
production None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
, None None O
and None None O
the None None O
ability None None O
of None None O
EC None None O
to None None O
adhere None None O
to None None O
vitronectin None None O
and None None O
up None None O
- None None O
regulate None None O
ICAM None None O
- None None O
1 None None O
and None None O
VCAM None None O
- None None O
1 None None O
expression None None O
. None None O

These None None O
effects None None O
do None None O
not None None O
require None None O
direct None None O
cell None None O
- None None O
cell None None O
contact None None O
, None None O
yet None None O
result None None O
from None None O
continuous None None O
interaction None None O
between None None O
activated None None O
lymphoid None None O
cells None None O
and None None O
EC None None O
. None None O

We None None O
used None None O
neutralizing None None O
Abs None None O
to None None O
show None None O
that None None O
the None None O
IFN None None O
- None None O
inducible None None O
protein None None O
- None None O
10 None None O
and None None O
monokine None None O
- None None O
induced None None O
by None None O
IFN None None O
- None None O
gamma None None O
chemokines None None O
are None None O
pivotal None None O
in None None O
inducing None None O
these None None O
effects None None O
. None None O

Experiments None None O
with None None O
nu None None O
/ None None O
nu None None O
mice None None O
, None None O
nonobese None None O
diabetic None None O
- None None O
SCID None None O
mice None None O
, None None O
or None None O
activated None None O
spc None None O
enriched None None O
in None None O
specific None None O
cell None None O
subpopulations None None O
demonstrated None None O
that None None O
CD4 None None O
( None None O
+ None None O
) None None O
, None None O
CD8 None None O
( None None O
+ None None O
) None None O
, None None O
and None None O
NK None None O
cells None None O
are None None O
all None None O
needed None None O
to None None O
mediate None None O
the None None O
full None None O
anti None None O
- None None O
angiogenetic None None O
effect None None O
of None None O
IL None None O
- None None O
12 None None O
. None None O

Research None None O
advances None None O
of None None O
endostatin None None O
and None None O
its None None O
short None None O
internal None None O
fragments None None O
. None None O

Endostatin None None O
, None None O
the None None O
C None None O
- None None O
terminal None None O
fragment None None O
of None None O
collagen None None O
XVIII None None O
, None None O
is None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
. None None O

At None None O
present None None O
, None None O
there None None O
are None None O
a None None O
large None None O
number None None O
of None None O
research None None O
papers None None O
on None None O
endostatin None None O
. None None O

However None None O
, None None O
the None None O
action None None O
mechanism None None O
of None None O
endostatin None None O
is None None O
still None None O
a None None O
matter None None O
of None None O
ongoing None None O
discussion None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
review None None O
is None None O
to None None O
elucidate None None O
its None None O
origin None None O
and None None O
elementary None None O
structure None None O
, None None O
and None None O
to None None O
discuss None None O
its None None O
structure None None O
basis None None O
of None None O
activity None None O
and None None O
action None None O
mechanisms None None O
based None None O
on None None O
the None None O
latest None None O
research None None O
. None None O

Furthermore None None O
, None None O
some None None O
published None None O
studies None None O
reporting None None O
the None None O
antiangiogenic None None O
effects None None O
of None None O
endostatin None None O
- None None O
derived None None O
peptides None None O
were None None O
also None None O
reviewed None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
the None None O
amino None None O
acid None None O
sequence None None O
of None None O
endostatin None None O
contains None None O
both None None O
angiosuppressive None None O
and None None O
angiostimulatory None None O
domains None None O
. None None O

Short None None O
endostatin None None O
fragments None None O
may None None O
be None None O
exploited None None O
as None None O
a None None O
new None None O
angiogenesis None None O
inhibitor None None O
for None None O
therapeutic None None O
applications None None O
, None None O
in None None O
substitution None None O
of None None O
the None None O
full None None O
length None None O
endostatin None None O
. None None O

These None None O
studies None None O
on None None O
endostatin None None O
fragments None None O
also None None O
shed None None O
light None None O
on None None O
our None None O
understanding None None O
of None None O
the None None O
molecular None None O
action None None O
mechanisms None None O
of None None O
endostatin None None O
. None None O

Etymology None None O
. None None O

Professor None None O
Stephen None None O
Lane None None O
Wood None None O
worked None None O
extensively None None O
on None None O
collections None None O
of None None O
Scolytinae None None O
preserved None None O
in None None O
Indian None None O
museums None None O
, None None O
and None None O
described None None O
a None None O
number None None O
of None None O
new None None O
Scolytinae None None O
species None None O
from None None O
India None None O
. None None O

In None None O
this None None O
paper None None O
we None None O
describe None None O
one None None O
more None None O
new None None O
bark None None O
- None None O
beetle None None O
species None None O
from None None O
India None None O
kept None None O
in None None O
the None None O
Natural None None O
History None None O
Museum None None O
in None None O
Vienna None None O
( None None O
NHMW None None O
) None None O
and None None O
dedicate None None O
this None None O
species None None O
to None None O
the None None O
late None None O
Professor None None O
Stephen None None O
Lane None None O
Wood None None O
. None None O

MEK5 None None O
/ None None O
ERK5 None None O
signaling None None O
modulates None None O
endothelial None None O
cell None None O
migration None None O
and None None O
focal None None O
contact None None O
turnover None None O
. None None O

The None None O
formation None None O
of None None O
new None None O
blood None None O
vessels None None O
from None None O
pre None None O
- None None O
existing None None O
ones None None O
requires None None O
highly None None O
coordinated None None O
restructuring None None O
of None None O
endothelial None None O
cells None None O
( None None O
EC None None O
) None None O
and None None O
the None None O
surrounding None None O
extracellular None None O
matrix None None O
. None None O

Directed None None O
EC None None O
migration None None O
is None None O
a None None O
central None None O
step None None O
in None None O
this None None O
process None None O
and None None O
depends None None O
on None None O
cellular None None O
signaling None None O
cascades None None O
that None None O
initiate None None O
and None None O
control None None O
the None None O
structural None None O
rearrangements None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
earlier None None O
findings None None O
that None None O
ERK5 None None O
deficiency None None O
in None None O
mouse None None O
EC None None O
results None None O
in None None O
massive None None O
defects None None O
in None None O
vessel None None O
architecture None None O
, None None O
we None None O
focused None None O
on None None O
the None None O
impact None None O
of None None O
the None None O
MEK5 None None O
/ None None O
ERK5 None None O
signaling None None O
pathway None None O
on None None O
EC None None O
migration None None O
. None None O

Using None None O
a None None O
retroviral None None O
gene None None O
transfer None None O
approach None None O
, None None O
we None None O
found None None O
that None None O
constitutive None None O
activation None None O
of None None O
MEK5 None None O
/ None None O
ERK5 None None O
signaling None None O
strongly None None O
inhibits None None O
EC None None O
migration None None O
and None None O
results None None O
in None None O
massive None None O
morphological None None O
changes None None O
. None None O

The None None O
area None None O
covered None None O
by None None O
spread None None O
EC None None O
was None None O
dramatically None None O
enlarged None None O
, None None O
accompanied None None O
by None None O
an None None O
increase None None O
in None None O
focal None None O
contacts None None O
and None None O
altered None None O
organization None None O
of None None O
actin None None O
filaments None None O
. None None O

Consequently None None O
, None None O
cells None None O
were None None O
more None None O
rigid None None O
and None None O
show None None O
reduced None None O
motility None None O
. None None O

This None None O
phenotype None None O
was None None O
most None None O
likely None None O
based None None O
on None None O
decreased None None O
focal None None O
contact None None O
turnover None None O
caused None None O
by None None O
reduced None None O
expression None None O
of None None O
p130Cas None None O
, None None O
a None None O
key None None O
player None None O
in None None O
directed None None O
cell None None O
migration None None O
. None None O

We None None O
demonstrate None None O
for None None O
the None None O
first None None O
time None None O
that None None O
ERK5 None None O
signaling None None O
not None None O
only None None O
is None None O
involved None None O
in None None O
EC None None O
survival None None O
and None None O
stress None None O
response None None O
but None None O
also None None O
controls None None O
migration None None O
and None None O
morphology None None O
of None None O
EC None None O
. None None O

Mouse None None O
p10 None None O
, None None O
an None None O
alternative None None O
spliced None None O
form None None O
of None None O
p15INK4b None None O
, None None O
inhibits None None O
cell None None O
cycle None None O
progression None None O
and None None O
malignant None None O
transformation None None O
. None None O

The None None O
INK4 None None O
family None None O
of None None O
proteins None None O
negatively None None O
regulates None None O
cell None None O
cycle None None O
progression None None O
at None None O
the None None O
G None None O
( None None O
1 None None O
) None None O
- None None O
S None None O
transition None None O
by None None O
inhibiting None None O
cyclin None None O
- None None O
dependent None None O
kinases None None O
. None None O

Two None None O
of None None O
these None None O
cell None None O
cycle None None O
inhibitors None None O
, None None O
p16 None None O
( None None O
INK4A None None O
) None None O
and None None O
p15 None None O
( None None O
INK4B None None O
) None None O
, None None O
have None None O
tumor None None O
suppressor None None O
activities None None O
and None None O
are None None O
inactivated None None O
in None None O
human None None O
cancer None None O
. None None O

Interestingly None None O
, None None O
both None None O
INK4 None None O
genes None None O
express None None O
alternative None None O
splicing None None O
variants None None O
. None None O

In None None O
addition None None O
to None None O
p16 None None O
( None None O
INK4A None None O
) None None O
, None None O
the None None O
INK4A None None O
locus None None O
encodes None None O
a None None O
splice None None O
variant None None O
, None None O
termed None None O
p12 None None O
- None None O
- None None O
specifically None None O
expressed None None O
in None None O
human None None O
pancreas None None O
- None None O
- None None O
and None None O
ARF None None O
, None None O
a None None O
protein None None O
encoded None None O
by None None O
an None None O
alternative None None O
reading None None O
frame None None O
that None None O
acts None None O
as None None O
a None None O
tumor None None O
suppressor None None O
through None None O
the None None O
p53 None None O
pathway None None O
. None None O

Similarly None None O
, None None O
the None None O
human None None O
INK4B None None O
locus None None O
encodes None None O
the None None O
p15 None None O
( None None O
INK4B None None O
) None None O
tumor None None O
suppressor None None O
and None None O
one None None O
alternatively None None O
spliced None None O
form None None O
, None None O
termed None None O
as None None O
p10 None None O
. None None O

We None None O
show None None O
here None None O
that None None O
p10 None None O
, None None O
which None None O
arises None None O
from None None O
the None None O
use None None O
of None None O
an None None O
alternative None None O
splice None None O
donor None None O
site None None O
within None None O
intron None None O
1 None None O
, None None O
is None None O
conserved None None O
in None None O
the None None O
mouse None None O
genome None None O
and None None O
is None None O
widely None None O
expressed None None O
in None None O
mouse None None O
tissues None None O
. None None O

Similarly None None O
to None None O
mouse None None O
p15 None None O
( None None O
INK4B None None O
) None None O
, None None O
p10 None None O
expression None None O
is None None O
also None None O
induced None None O
by None None O
oncogenic None None O
insults None None O
and None None O
transforming None None O
growth None None O
factor None None O
- None None O
beta None None O
treatment None None O
and None None O
acts None None O
as None None O
a None None O
cell None None O
cycle None None O
inhibitor None None O
. None None O

Importantly None None O
, None None O
we None None O
show None None O
that None None O
mouse None None O
p10 None None O
is None None O
able None None O
to None None O
induce None None O
cell None None O
cycle None None O
arrest None None O
in None None O
a None None O
p53 None None O
- None None O
dependent None None O
manner None None O
. None None O

We None None O
also None None O
show None None O
that None None O
mouse None None O
p10 None None O
is None None O
able None None O
to None None O
inhibit None None O
foci None None O
formation None None O
and None None O
anchorage None None O
- None None O
independent None None O
growth None None O
in None None O
wild None None O
- None None O
type None None O
mouse None None O
embryonic None None O
fibroblasts None None O
, None None O
and None None O
that None None O
these None None O
antitransforming None None O
properties None None O
of None None O
mouse None None O
p10 None None O
are None None O
also None None O
p53 None None O
- None None O
dependent None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
the None None O
INK4B None None O
locus None None O
, None None O
similarly None None O
to None None O
INK4A None None O
- None None O
ARF None None O
, None None O
harbors None None O
two None None O
different None None O
splicing None None O
variants None None O
that None None O
can None None O
be None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
both None None O
the None None O
p53 None None O
and None None O
retinoblastoma None None O
pathways None None O
, None None O
the None None O
two None None O
major None None O
molecular None None O
pathways None None O
in None None O
tumor None None O
suppression None None O
. None None O

Summary None None O
of None None O
instrument None None O
characteristics None None O

Results None None O

Differential None None O
effects None None O
of None None O
carbachol None None O
on None None O
calcium None None O
entry None None O
and None None O
release None None O
in None None O
CHO None None I-Cell-line-name
cells None None O
expressing None None O
the None None O
m3 None None O
muscarinic None None O
receptor None None O
. None None O

Calcium None None O
signalling None None O
was None None O
examined None None O
in None None O
CHO None None I-Cell-line-name
- None None I-Cell-line-name
k1 None None I-Cell-line-name
cells None None O
that None None O
stably None None O
express None None O
the None None O
m3 None None O
subtype None None O
of None None O
the None None O
muscarinic None None O
receptor None None O
. None None O

The None None O
calcium None None O
indicator None None O
Fura None None O
- None None O
2 None None O
was None None O
retained None None O
in None None O
these None None O
cells None None O
only None None O
in None None O
the None None O
presence None None O
of None None O
probenecid None None O
( None None O
1 None None O
mM None None O
) None None O
, None None O
suggesting None None O
that None None O
Fura None None O
- None None O
2 None None O
efflux None None O
was None None O
mediated None None O
by None None O
an None None O
organic None None O
anion None None O
transporter None None O
. None None O

The None None O
addition None None O
of None None O
carbachol None None O
( None None O
CCh None None O
) None None O
to None None O
Fura None None O
- None None O
2 None None O
loaded None None O
cells None None O
in None None O
suspension None None O
caused None None O
a None None O
rapid None None O
transient None None O
increase None None O
in None None O
intracellular None None O
calcium None None O
[ None None O
Ca None None O
] None None O
i None None O
followed None None O
by None None O
a None None O
smaller None None O
sustained None None O
plateau None None O
phase None None O
. None None O

The None None O
transient None None O
rise None None O
in None None O
[ None None O
Ca None None O
] None None O
i None None O
was None None O
dose None None O
- None None O
dependent None None O
with None None O
a None None O
threshold None None O
response None None O
of None None O
89 None None O
+ None None O
/ None None O
- None None O
18 None None O
nM None None O
above None None O
baseline None None O
with None None O
10 None None O
nM None None O
CCh None None O
and None None O
a None None O
maximum None None O
stimulation None None O
of None None O
734 None None O
+ None None O
/ None None O
- None None O
46 None None O
nM None None O
with None None O
10 None None O
microM None None O
CCh None None O
. None None O

This None None O
phase None None O
was None None O
accompanied None None O
by None None O
a None None O
similar None None O
dose None None O
- None None O
dependent None None O
stimulation None None O
of None None O
total None None O
inositol None None O
phosphate None None O
production None None O
and None None O
was None None O
assumed None None O
to None None O
be None None O
generated None None O
by None None O
release None None O
from None None O
intracellular None None O
stores None None O
of None None O
the None None O
endoplasmic None None O
reticulum None None O
( None None O
ER None None O
) None None O
. None None O

The None None O
sustained None None O
increase None None O
in None None O
[ None None O
Ca None None O
] None None O
i None None O
was None None O
generated None None O
by None None O
entry None None O
from None None O
the None None O
extracellular None None O
bath None None O
since None None O
it None None O
was None None O
blocked None None O
by None None O
pretreatment None None O
with None None O
La3 None None O
+ None None O
( None None O
1 None None O
microM None None O
) None None O
and None None O
was None None O
absent None None O
when None None O
bath None None O
calcium None None O
was None None O
chelated None None O
with None None O
EGTA None None O
. None None O

This None None O
phase None None O
was None None O
not None None O
dependent None None O
on None None O
CCh None None O
dose None None O
, None None O
and None None O
a None None O
stimulation None None O
of None None O
[ None None O
Ca None None O
] None None O
i None None O
of None None O
approximately None None O
90 None None O
nM None None O
above None None O
baseline None None O
was None None O
observed None None O
with None None O
CCh None None O
concentrations None None O
between None None O
50 None None O
nM None None O
and None None O
10 None None O
microM None None O
. None None O

With None None O
this None None O
dose None None O
range None None O
, None None O
the None None O
rate None None O
of None None O
Mn2 None None O
+ None None O
quenching None None O
of None None O
Fura None None O
- None None O
2 None None O
at None None O
the None None O
Ca None None O
- None None O
insensitive None None O
excitation None None O
wavelength None None O
of None None O
360 None None O
nm None None O
was None None O
likewise None None O
maximally None None O
stimulated None None O
. None None O

At None None O
lower None None O
CCh None None O
concentrations None None O
( None None O
10 None None O
- None None O
50 None None O
nM None None O
) None None O
, None None O
it None None O
was None None O
clear None None O
that None None O
the None None O
activation None None O
of None None O
Ca None None O
entry None None O
could None None O
not None None O
be None None O
dissociated None None O
from None None O
a None None O
threshold None None O
release None None O
of None None O
Ca None None O
from None None O
intracellular None None O
stores None None O
. None None O

The None None O
phorbol None None O
ester None None O
PMA None None O
, None None O
which None None O
uncouples None None O
the None None O
muscarinic None None O
receptor None None O
from None None O
phospholipase None None O
C None None O
, None None O
reduced None None O
the None None O
transient None None O
rise None None O
in None None O
[ None None O
Ca None None O
] None None O
i None None O
by None None O
approximately None None O
50 None None O
% None None O
with None None O
little None None O
or None None O
no None None O
effect None None O
on None None O
Ca None None O
entry None None O
at None None O
higher None None O
CCh None None O
levels None None O
( None None O
> None None O
or None None O
= None None O
1 None None O
microM None None O
) None None O
. None None O

At None None O
lower None None O
CCh None None O
concentrations None None O
( None None O
< None None O
or None None O
= None None O
100 None None O
nM None None O
) None None O
however None None O
, None None O
pretreatment None None O
with None None O
PMA None None O
completely None None O
blocked None None O
all None None O
Ca None None O
mobilization None None O
and None None O
supports None None O
the None None O
contention None None O
that None None O
Ca None None O
entry None None O
is None None O
coupled None None O
to None None O
Ca None None O
release None None O
from None None O
stores None None O
or None None O
to None None O
store None None O
depletion None None O
. None None O

The None None O
emptying None None O
of None None O
inositol None None O
trisphosphate None None O
- None None O
sensitive None None O
stores None None O
with None None O
thapsigargin None None O
( None None O
10 None None O
nM None None O
) None None O
stimulated None None O
Ca None None O
entry None None O
and None None O
also None None O
the None None O
rate None None O
of None None O
Mn2 None None O
+ None None O
quenching None None O
. None None O

Store None None O
depletion None None O
by None None O
incubation None None O
in None None O
Ca None None O
- None None O
free None None O
media None None O
likewise None None O
stimulated None None O
Mn2 None None O
+ None None O
uptake None None O
without None None O
a None None O
rise None None O
in None None O
[ None None O
Ca None None O
] None None O
i None None O
. None None O

Our None None O
data None None O
are None None O
therefore None None O
consistent None None O
with None None O
a None None O
' None None O
capacitative None None O
' None None O
coupling None None O
model None None O
, None None O
whereby None None O
the None None O
activation None None O
of None None O
the None None O
plasma None None O
membrane None None O
receptor None None O
leads None None O
to None None O
an None None O
InsP3 None None O
- None None O
induced None None O
change None None O
in None None O
the None None O
degree None None O
of None None O
filling None None O
of None None O
the None None O
ER None None O
Ca None None O
pool None None O
. None None O
( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

[ None None O
Expression None None O
of None None O
metastasis None None O
suppressor None None O
gene None None O
nm23 None None O
in None None O
human None None O
hepatocellular None None O
carcinoma None None O
] None None O
. None None O

For None None O
the None None O
purpose None None O
of None None O
investigating None None O
the None None O
relationship None None O
between None None O
the None None O
metastatic None None O
potential None None O
of None None O
the None None O
tumor None None O
as None None O
well None None O
as None None O
the None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
, None None O
and None None O
for None None O
determing None None O
the None None O
location None None O
of None None O
the None None O
positive None None O
sites None None O
in None None O
the None None O
cells None None O
, None None O
tumor None None O
metastasis None None O
suppressor None None O
gene None None O
nm23 None None O
- None None O
H1 None None O
in None None O
human None None O
hepatocellular None None O
carcinoma None None O
( None None O
and None None O
the None None O
nonneoplastic None None O
area None None O
surrounding None None O
the None None O
tumor None None O
) None None O
was None None O
detected None None O
by None None O
in None None O
situ None None O
hybridization None None O
using None None O
digoxiginin None None O
- None None O
labeled None None O
nm23 None None O
- None None O
H1 None None O
antisense None None O
complementary None None O
RNA None None O
probe None None O
. None None O

The None None O
primary None None O
results None None O
indicated None None O
( None None O
i None None O
) None None O
positive None None O
results None None O
of None None O
in None None O
situ None None O
hybridization None None O
are None None O
presence None None O
of None None O
granules None None O
or None None O
masses None None O
in None None O
the None None O
cytoplasm None None O
; None None O
( None None O
ii None None O
) None None O
the None None O
less None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
, None None O
the None None O
higher None None O
metastatic None None O
rate None None O
of None None O
the None None O
human None None O
hepatocellular None None O
carcinoma None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
; None None O
( None None O
iii None None O
) None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
dose None None O
not None None O
correlate None None O
with None None O
some None None O
other None None O
factors None None O
such None None O
as None None O
tumor None None O
size None None O
and None None O
the None None O
background None None O
of None None O
other None None O
liver None None O
diseases None None O
. None None O

Emerging None None O
metabolic None None O
targets None None O
in None None O
cancer None None O
therapy None None O
. None None O

Cancer None None O
cells None None O
are None None O
different None None O
from None None O
normal None None O
cells None None O
in None None O
their None None O
metabolic None None O
properties None None O
. None None O

Normal None None O
cells None None O
mostly None None O
rely None None O
on None None O
mitochondrial None None O
oxidative None None O
phosphorylation None None O
to None None O
produce None None O
energy None None O
. None None O

In None None O
contrast None None O
, None None O
cancer None None O
cells None None O
depend None None O
mostly None None O
on None None O
glycolysis None None O
, None None O
the None None O
aerobic None None O
breakdown None None O
of None None O
glucose None None O
into None None O
ATP None None O
. None None O

This None None O
altered None None O
energy None None O
dependency None None O
is None None O
known None None O
as None None O
the None None O
" None None O
Warburg None None O
effect None None O
" None None O
and None None O
is None None O
a None None O
hallmark None None O
of None None O
cancer None None O
cells None None O
. None None O

In None None O
recent None None O
years None None O
, None None O
investigating None None O
the None None O
metabolic None None O
changes None None O
within None None O
cancer None None O
cells None None O
has None None O
been None None O
a None None O
rapidly None None O
growing None None O
area None None O
. None None O

Emerging None None O
evidence None None O
shows None None O
that None None O
oncogenes None None O
that None None O
drive None None O
the None None O
cancer None None O
- None None O
promoting None None O
signals None None O
also None None O
drive None None O
the None None O
altered None None O
metabolism None None O
. None None O

Although None None O
the None None O
exact None None O
mechanisms None None O
underlying None None O
the None None O
Warburg None None O
effect None None O
are None None O
unclear None None O
, None None O
the None None O
existing None None O
evidence None None O
suggests None None O
that None None O
increased None None O
glycolysis None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
support None None O
malignant None None O
behavior None None O
of None None O
cancer None None O
cells None None O
. None None O

A None None O
thorough None None O
understanding None None O
of None None O
the None None O
unique None None O
metabolism None None O
of None None O
cancer None None O
cells None None O
will None None O
help None None O
to None None O
design None None O
of None None O
more None None O
effective None None O
drugs None None O
targeting None None O
metabolic None None O
pathways None None O
, None None O
which None None O
will None None O
greatly None None O
impact None None O
the None None O
capacity None None O
to None None O
effectively None None O
treat None None O
cancer None None O
patients None None O
. None None O

Here None None O
we None None O
provide None None O
an None None O
overview None None O
of None None O
the None None O
current None None O
understanding None None O
of None None O
the None None O
Warburg None None O
effect None None O
upon None None O
tumor None None O
cell None None O
growth None None O
and None None O
survival None None O
, None None O
and None None O
discussion None None O
on None None O
the None None O
potential None None O
metabolic None None O
targets None None O
for None None O
cancer None None O
therapy None None O
. None None O

Duplicated None None O
HGT None None O
candidates None None O
in None None O
K None None O
. None None O
thermotolerans None None O
. None None O

( None None O
A None None O
) None None O
Part None None O
of None None O
the None None O
conserved None None O
synteny None None O
block None None O
surrounding None None O
KLTH0C07700g None None O
and None None O
KLTH0C07722g None None O
tandem None None O
genes None None O
. None None O

Same None None O
legend None None O
as None None O
Figure None None O
3A None None O
. None None O

( None None O
B None None O
) None None O
Part None None O
of None None O
the None None O
conserved None None O
synteny None None O
block None None O
surrounding None None O
KLTH0F12276g None None O
gene None None O
. None None O

Same None None O
legend None None O
as None None O
Figure None None O
3A None None O
. None None O

( None None O
C None None O
) None None O
Sequence None None O
alignment None None O
of None None O
proteins None None O
from None None O
K None None O
. None None O
thermotolerans None None O
and None None O
K None None O
. None None O
waltii None None O
. None None O

( None None O
D None None O
) None None O
Phylogenetic None None O
tree None None O
reconstructed None None O
from None None O
sequence None None O
alignment None None O
of None None O
100 None None O
sites None None O
of None None O
K None None O
. None None O
thermotolerans None None O
protein None None O
family None None O
members None None O
, None None O
K None None O
. None None O
waltii None None O
gene None None O
, None None O
bacterial None None O
( None None O
green None None O
) None None O
and None None O
amoebal None None O
( None None O
blue None None O
) None None O
proteins None None O
. None None O

Bootstrap None None O
values None None O
are None None O
indicated None None O
next None None O
to None None O
the None None O
nodes None None O
and None None O
branch None None O
length None None O
scale None None O
is None None O
shown None None O
at None None O
bottom None None O
left None None O
. None None O

Alpha None None O
- None None O
melanocyte None None O
- None None O
stimulating None None O
hormone None None O
modulates None None O
activation None None O
of None None O
NF None None O
- None None O
kappa None None O
B None None O
and None None O
AP None None O
- None None O
1 None None O
and None None O
secretion None None O
of None None O
interleukin None None O
- None None O
8 None None O
in None None O
human None None O
dermal None None O
fibroblasts None None O
. None None O

Alpha None None O
- None None O
melanocyte None None O
- None None O
stimulating None None O
hormone None None O
( None None O
alpha None None O
- None None O
MSH None None O
) None None O
has None None O
evolved None None O
as None None O
a None None O
mediator None None O
of None None O
diverse None None O
biological None None O
activities None None O
in None None O
an None None O
ever None None O
- None None O
growing None None O
number None None O
of None None O
non None None O
- None None O
melanocytic None None O
cell None None O
types None None O
. None None O

One None None O
mechanism None None O
by None None O
which None None O
alpha None None O
- None None O
MSH None None O
exerts None None O
its None None O
effects None None O
is None None O
modulation None None O
of None None O
AP None None O
- None None O
1 None None O
and None None O
NF None None O
- None None O
kappa None None O
B None None O
. None None O

These None None O
two None None O
transcription None None O
factors None None O
also None None O
play None None O
an None None O
important None None O
role None None O
in None None O
fibroblasts None None O
, None None O
in None None O
extracellular None None O
matrix None None O
composition None None O
, None None O
and None None O
in None None O
cytokine None None O
expression None None O
. None None O

By None None O
use None None O
of None None O
electric None None O
mobility None None O
shift None None O
assays None None O
, None None O
we None None O
demonstrate None None O
that None None O
alpha None None O
- None None O
MSH None None O
( None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
to None None O
10 None None O
( None None O
- None None O
14 None None O
) None None O
M None None O
) None None O
activates None None O
AP None None O
- None None O
1 None None O
in None None O
human None None O
dermal None None O
fibroblasts None None O
, None None O
whereas None None O
coincubation None None O
with None None O
interleukin None None O
- None None O
1 None None O
beta None None O
( None None O
IL None None O
- None None O
1 None None O
beta None None O
) None None O
results None None O
in None None O
suppression None None O
of None None O
its None None O
activation None None O
. None None O

alpha None None O
- None None O
MSH None None O
also None None O
induces None None O
activation None None O
of None None O
NF None None O
- None None O
kappa None None O
B None None O
but None None O
does None None O
not None None O
modulate None None O
DNA None None O
binding None None O
on None None O
costimulation None None O
with None None O
IL None None O
- None None O
1 None None O
beta None None O
. None None O

Since None None O
AP None None O
- None None O
1 None None O
and None None O
NF None None O
- None None O
kappa None None O
B None None O
are None None O
key None None O
elements None None O
in None None O
controlling None None O
interleukin None None O
- None None O
8 None None O
( None None O
IL None None O
- None None O
8 None None O
) None None O
transcription None None O
, None None O
human None None O
fibroblasts None None O
were None None O
treated None None O
with None None O
alpha None None O
- None None O
MSH None None O
and None None O
IL None None O
- None None O
1 None None O
beta None None O
for None None O
24 None None O
hours None None O
, None None O
and None None O
cytokine None None O
levels None None O
in None None O
the None None O
supernatants None None O
were None None O
measured None None O
by None None O
ELISA None None O
. None None O

alpha None None O
- None None O
MSH None None O
alone None None O
had None None O
little None None O
effect None None O
, None None O
whereas None None O
coincubation None None O
with None None O
IL None None O
- None None O
1 None None O
beta None None O
led None None O
to None None O
marked None None O
downregulation None None O
of None None O
IL None None O
- None None O
8 None None O
secretion None None O
( None None O
at None None O
most None None O
288 None None O
+ None None O
/ None None O
- None None O
152 None None O
ng None None O
/ None None O
mL None None O
) None None O
when None None O
compared None None O
to None None O
treatment None None O
with None None O
IL None None O
- None None O
1 None None O
beta None None O
alone None None O
( None None O
919 None None O
+ None None O
/ None None O
- None None O
157 None None O
ng None None O
/ None None O
mL None None O
) None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
alpha None None O
- None None O
MSH None None O
exerts None None O
modulatory None None O
effects None None O
on None None O
the None None O
activation None None O
of None None O
NF None None O
- None None O
kappa None None O
B None None O
and None None O
AP None None O
- None None O
1 None None O
, None None O
and None None O
that None None O
it None None O
can None None O
regulate None None O
chemokine None None O
secretion None None O
in None None O
human None None O
dermal None None O
fibroblasts None None O
. None None O

These None None O
effects None None O
of None None O
alpha None None O
- None None O
MSH None None O
may None None O
have None None O
important None None O
regulatory None None O
functions None None O
in None None O
extracellular None None O
matrix None None O
composition None None O
, None None O
wound None None O
healing None None O
, None None O
or None None O
angiogenesis None None O
. None None O

The None None O
relationship None None O
between None None O
brain None None O
activity None None O
and None None O
peak None None O
grip None None O
force None None O
is None None O
modulated None None O
by None None O
corticospinal None None O
system None None O
integrity None None O
after None None O
subcortical None None O
stroke None None O
. None None O

In None None O
healthy None None O
human None None O
subjects None None O
, None None O
the None None O
relative None None O
contribution None None O
of None None O
cortical None None O
regions None None O
to None None O
motor None None O
performance None None O
varies None None O
with None None O
the None None O
task None None O
parameters None None O
. None None O

Additionally None None O
, None None O
after None None O
stroke None None O
, None None O
recruitment None None O
of None None O
cortical None None O
areas None None O
during None None O
a None None O
simple None None O
motor None None O
task None None O
varies None None O
with None None O
corticospinal None None O
system None None O
integrity None None O
. None None O

We None None O
investigated None None O
whether None None O
the None None O
pattern None None O
of None None O
motor None None O
system None None O
recruitment None None O
in None None O
a None None O
task None None O
involving None None O
increasingly None None O
forceful None None O
hand None None O
grips None None O
is None None O
influenced None None O
by None None O
the None None O
degree None None O
of None None O
corticospinal None None O
system None None O
damage None None O
. None None O

Nine None None O
chronic None None O
subcortical None None O
stroke None None O
patients None None O
and None None O
nine None None O
age None None O
- None None O
matched None None O
controls None None O
underwent None None O
functional None None O
magnetic None None O
brain None None O
imaging None None O
whilst None None O
performing None None O
repetitive None None O
isometric None None O
hand None None O
grips None None O
. None None O

Target None None O
grip None None O
forces None None O
were None None O
varied None None O
between None None O
15 None None O
% None None O
and None None O
45 None None O
% None None O
of None None O
individual None None O
maximum None None O
grip None None O
force None None O
. None None O

Corticospinal None None O
system None None O
functional None None O
integrity None None O
was None None O
assessed None None O
with None None O
transcranial None None O
magnetic None None O
stimulation None None O
. None None O

Averaged None None O
across None None O
all None None O
forces None None O
, None None O
there None None O
was None None O
more None None O
task None None O
- None None O
related None None O
activation None None O
compared None None O
with None None O
rest None None O
in None None O
the None None O
secondary None None O
motor None None O
areas None None O
of None None O
patients None None O
with None None O
greater None None O
corticospinal None None O
system None None O
damage None None O
, None None O
confirming None None O
previous None None O
reports None None O
. None None O

However None None O
, None None O
here None None O
we None None O
were None None O
primarily None None O
interested None None O
in None None O
regional None None O
brain None None O
activation None None O
, None None O
which None None O
covaried None None O
with None None O
the None None O
amount None None O
of None None O
force None None O
generated None None O
, None None O
implying None None O
a None None O
prominent None None O
executive None None O
role None None O
in None None O
force None None O
production None None O
. None None O

We None None O
found None None O
that None None O
in None None O
control None None O
subjects None None O
and None None O
patients None None O
with None None O
lesser None None O
corticospinal None None O
system None None O
damage None None O
, None None O
signal None None O
change None None O
increased None None O
linearly None None O
with None None O
increasing None None O
force None None O
output None None O
in None None O
contralateral None None O
primary None None O
motor None None O
cortex None None O
, None None O
supplementary None None O
motor None None O
area None None O
and None None O
ipsilateral None None O
cerebellum None None O
. None None O

In None None O
contrast None None O
, None None O
in None None O
patients None None O
with None None O
greater None None O
corticospinal None None O
system None None O
damage None None O
, None None O
force None None O
- None None O
related None None O
signal None None O
changes None None O
were None None O
seen None None O
mainly None None O
in None None O
contralesional None None O
dorsolateral None None O
premotor None None O
cortex None None O
, None None O
bilateral None None O
ventrolateral None None O
premotor None None O
cortices None None O
and None None O
contralesional None None O
cerebellum None None O
, None None O
but None None O
not None None O
ipsilesional None None O
primary None None O
motor None None O
cortex None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
the None None O
premotor None None O
cortices None None O
might None None O
play None None O
a None None O
new None None O
and None None O
functionally None None O
relevant None None O
role None None O
in None None O
controlling None None O
force None None O
production None None O
in None None O
patients None None O
with None None O
more None None O
severe None None O
corticospinal None None O
system None None O
disruption None None O
. None None O

Regulation None None O
of None None O
tumor None None O
angiogenesis None None O
by None None O
thrombospondin None None O
- None None O
1 None None O
. None None O

Angiogenesis None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
growth None None O
and None None O
metastasis None None O
of None None O
tumors None None O
. None None O

Thrombospondin None None O
- None None O
1 None None O
( None None O
TSP None None O
- None None O
1 None None O
) None None O
is None None O
a None None O
potent None None O
angiogenesis None None O
inhibitor None None O
, None None O
and None None O
down None None O
- None None O
regulation None None O
of None None O
TSP None None O
- None None O
1 None None O
has None None O
been None None O
suggested None None O
to None None O
alter None None O
tumor None None O
growth None None O
by None None O
modulating None None O
angiogenesis None None O
in None None O
a None None O
variety None None O
of None None O
tumor None None O
types None None O
. None None O

Expression None None O
of None None O
TSP None None O
- None None O
1 None None O
is None None O
up None None O
- None None O
regulated None None O
by None None O
the None None O
tumor None None O
suppressor None None O
gene None None O
, None None O
p53 None None O
, None None O
and None None O
down None None O
- None None O
regulated None None O
by None None O
oncogenes None None O
such None None O
as None None O
Myc None None O
and None None O
Ras None None O
. None None O

TSP None None O
- None None O
1 None None O
inhibits None None O
angiogenesis None None O
by None None O
inhibiting None None O
endothelial None None O
cell None None O
migration None None O
and None None O
proliferation None None O
and None None O
by None None O
inducing None None O
apoptosis None None O
. None None O

In None None O
addition None None O
, None None O
activation None None O
of None None O
transforming None None O
growth None None O
factor None None O
beta None None O
( None None O
TGF None None O
- None None O
beta None None O
) None None O
by None None O
TSP None None O
- None None O
1 None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
tumor None None O
progression None None O
. None None O

An None None O
understanding None None O
of None None O
the None None O
molecular None None O
basis None None O
of None None O
TSP None None O
- None None O
1 None None O
- None None O
mediated None None O
inhibition None None O
of None None O
angiogenesis None None O
and None None O
tumor None None O
progression None None O
will None None O
aid None None O
in None None O
the None None O
development None None O
of None None O
novel None None O
therapeutics None None O
for None None O
the None None O
treatment None None O
of None None O
cancer None None O
. None None O

Antibodies None None O
to None None O
PAI None None O
- None None O
1 None None O
alter None None O
the None None O
invasive None None O
and None None O
migratory None None O
properties None None O
of None None O
human None None O
tumour None None O
cells None None O
in None None O
vitro None None O
. None None O

Recent None None O
reports None None O
suggest None None O
that None None O
elevated None None O
levels None None O
of None None O
plasminogen None None O
activator None None O
inhibitor None None O
- None None O
1 None None O
( None None O
PAI None None O
- None None O
1 None None O
) None None O
may None None O
contribute None None O
to None None O
tumour None None O
progression None None O
. None None O

The None None O
studies None None O
reported None None O
here None None O
were None None O
designed None None O
to None None O
help None None O
elucidate None None O
PAI None None O
- None None O
1 None None O
' None None O
s None None O
contribution None None O
to None None O
the None None O
invasive None None O
and None None O
migratory None None O
phenotype None None O
. None None O

Antibodies None None O
to None None O
PA None None O
- None None O
1 None None O
dose None None O
- None None O
dependently None None O
, None None O
and None None O
significantly None None O
, None None O
inhibited None None O
the None None O
invasive None None O
and None None O
migratory None None O
potential None None O
of None None O
human None None O
HT1080 None None I-Cell-line-name
fibrosarcoma None None O
cells None None O
, None None O
as None None O
did None None O
an None None O
antibody None None O
to None None O
uPA None None O
and None None O
the None None O
plasmin None None O
inhibitor None None O
aprotinin None None O
. None None O

Invasion None None O
of None None O
the None None O
human None None O
melanoma None None O
cell None None O
line None None O
, None None O
BLM None None I-Cell-line-name
, None None O
was None None O
also None None O
attenuated None None O
by None None O
the None None O
anti None None O
- None None O
PAI None None O
- None None O
1 None None O
monoclonal None None O
antibody None None O
MAI None None O
- None None O
12 None None O
. None None O

The None None O
non None None O
- None None O
invasive None None O
human None None O
melanoma None None O
cell None None O
line None None O
, None None O
IF6 None None I-Cell-line-name
, None None O
which None None O
does None None O
not None None O
express None None O
uPA None None O
, None None O
provided None None O
further None None O
confirmation None None O
of None None O
PAI None None O
- None None O
1 None None O
and None None O
uPA None None O
' None None O
s None None O
role None None O
as None None O
, None None O
upon None None O
transfection None None O
with None None O
uPA None None O
, None None O
this None None O
cell None None O
line None None O
attained None None O
an None None O
invasive None None O
phenotype None None O
, None None O
which None None O
was None None O
again None None O
attenuated None None O
by None None O
MAI None None O
- None None O
12 None None O
. None None O

Although None None O
antibodies None None O
to None None O
PAI None None O
- None None O
1 None None O
did None None O
not None None O
affect None None O
the None None O
adhesion None None O
of None None O
HT1080 None None I-Cell-line-name
cells None None O
to None None O
vitronectin None None O
, None None O
the None None O
antibody None None O
to None None O
uPA None None O
reduced None None O
their None None O
attachment None None O
. None None O

Addition None None O
of None None O
exogenous None None O
PAI None None O
- None None O
1 None None O
, None None O
however None None O
, None None O
prevented None None O
HT1080 None None I-Cell-line-name
cell None None O
adhesion None None O
( None None O
IC50 None None O
180 None None O
nM None None O
) None None O
and None None O
promoted None None O
cell None None O
detachment None None O
from None None O
vitronectin None None O
. None None O

Furthermore None None O
melanoma None None O
cells None None O
transfected None None O
with None None O
a None None O
uPA None None O
variant None None O
, None None O
which None None O
had None None O
an None None O
impaired None None O
interaction None None O
with None None O
PAI None None O
- None None O
1 None None O
, None None O
were None None O
not None None O
invasive None None O
and None None O
had None None O
impaired None None O
binding None None O
to None None O
vitronectin None None O
. None None O

These None None O
data None None O
highlight None None O
the None None O
importance None None O
of None None O
a None None O
balanced None None O
proteolysis None None O
and None None O
suggest None None O
an None None O
additional None None O
role None None O
for None None O
PAI None None O
- None None O
1 None None O
distinct None None O
from None None O
its None None O
role None None O
in None None O
proteolysis None None O
. None None O

These None None O
data None None O
also None None O
suggest None None O
that None None O
uPA None None O
and None None O
PAI None None O
- None None O
1 None None O
may None None O
co None None O
- None None O
operate None None O
in None None O
the None None O
migratory None None O
process None None O
by None None O
respectively None None O
facilitating None None O
the None None O
attachment None None O
to None None O
, None None O
and None None O
subsequent None None O
detachment None None O
from None None O
, None None O
vitronectin None None O
in None None O
the None None O
extracellular None None O
matrix None None O
. None None O

These None None O
results None None O
support None None O
the None None O
clinical None None O
findings None None O
and None None O
indicate None None O
that None None O
modulation None None O
of None None O
PAI None None O
- None None O
1 None None O
activity None None O
may None None O
be None None O
of None None O
therapeutic None None O
benefit None None O
for None None O
the None None O
treatment None None O
of None None O
cancer None None O
. None None O

Brick1 None None O
is None None O
an None None O
essential None None O
regulator None None O
of None None O
actin None None O
cytoskeleton None None O
required None None O
for None None O
embryonic None None O
development None None O
and None None O
cell None None O
transformation None None O
. None None O

Brick1 None None O
( None None O
Brk1 None None O
) None None O
is None None O
the None None O
less None None O
- None None O
studied None None O
component None None O
of None None O
the None None O
Wave None None O
/ None None O
Scar None None O
pathway None None O
involved None None O
in None None O
the None None O
branched None None O
nucleation None None O
of None None O
actin None None O
fibers None None O
. None None O

The None None O
clinical None None O
relevance None None O
of None None O
Brk1 None None O
is None None O
emphasized None None O
by None None O
correlative None None O
data None None O
showing None None O
that None None O
Von None None O
Hippel None None O
- None None O
Lindau None None O
( None None O
VHL None None O
) None None O
patients None None O
that None None O
also None None O
lose None None O
the None None O
BRK1 None None O
gene None None O
are None None O
protected None None O
against None None O
the None None O
development None None O
of None None O
tumors None None O
. None None O

This None None O
contrasts None None O
with None None O
recent None None O
evidence None None O
suggesting None None O
that None None O
the None None O
Wave None None O
complex None None O
may None None O
function None None O
as None None O
an None None O
invasion None None O
suppressor None None O
in None None O
epithelial None None O
cancers None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
the None None O
downregulation None None O
of None None O
Brk1 None None O
results None None O
in None None O
abnormal None None O
actin None None O
stress None None O
fiber None None O
formation None None O
and None None O
vinculin None None O
distribution None None O
and None None O
loss None None O
of None None O
Arp2 None None O
/ None None O
3 None None O
and None None O
Wave None None O
proteins None None O
at None None O
the None None O
cellular None None O
protrusions None None O
. None None O

Brk1 None None O
is None None O
required None None O
for None None O
cell None None O
proliferation None None O
and None None O
cell None None O
transformation None None O
by None None O
oncogenes None None O
. None None O

In None None O
addition None None O
, None None O
Brk1 None None O
downregulation None None O
results None None O
in None None O
defective None None O
directional None None O
migration None None O
and None None O
invasive None None O
growth None None O
in None None O
renal None None O
cell None None O
carcinoma None None O
cells None None O
as None None O
well None None O
as None None O
in None None O
other None None O
tumor None None O
cell None None O
types None None O
. None None O

Finally None None O
, None None O
genetic None None O
ablation None None O
of None None O
Brk1 None None O
results None None O
in None None O
dramatic None None O
defects None None O
in None None O
embryo None None O
compaction None None O
and None None O
development None None O
, None None O
suggesting None None O
an None None O
essential None None O
role None None O
for None None O
this None None O
protein None None O
in None None O
actin None None O
dynamics None None O
. None None O

Thus None None O
, None None O
genetic None None O
loss None None O
or None None O
inhibition None None O
of None None O
BRK1 None None O
is None None O
likely None None O
to None None O
be None None O
protective None None O
against None None O
tumor None None O
development None None O
due None None O
to None None O
proliferation None None O
and None None O
motility None None O
defects None None O
in None None O
affected None None O
cells None None O
. None None O

Effect None None O
of None None O
antitumor None None O
agents None None O
on None None O
cytotoxicity None None O
induction None None O
by None None O
sodium None None O
fluoride None None O
. None None O

We None None O
have None None O
recently None None O
found None None O
that None None O
sodium None None O
fluoride None None O
( None None O
NaF None None O
) None None O
induced None None O
apoptotic None None O
cell None None O
death None None O
in None None O
tumor None None O
cell None None O
lines None None O
. None None O

We None None O
investigated None None O
here None None O
whether None None O
6 None None O
popular None None O
antitumor None None O
compounds None None O
modify None None O
the None None O
cytotoxic None None O
activity None None O
of None None O
NaF None None O
against None None O
human None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
HSC None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
) None None O
and None None O
human None None O
promyelocytic None None O
leukemia None None O
( None None O
HL None None I-Cell-line-name
- None None I-Cell-line-name
60 None None I-Cell-line-name
) None None O
cell None None O
lines None None O
. None None O

Cytotoxic None None O
concentrations None None O
of None None O
cisplatin None None O
, None None O
etoposide None None O
, None None O
doxorubicin None None O
or None None O
peplomycin None None O
( None None O
tentatively None None O
termed None None O
as None None O
Group None None O
I None None O
compounds None None O
) None None O
, None None O
but None None O
not None None O
methotrexate None None O
and None None O
5 None None O
- None None O
FU None None O
( None None O
tentatively None None O
termed None None O
as None None O
Group None None O
II None None O
compounds None None O
) None None O
, None None O
enhanced None None O
the None None O
cytotoxic None None O
activity None None O
of None None O
NaF None None O
. None None O

NaF None None O
and None None O
Group None None O
I None None O
compounds None None O
induced None None O
internucleosomal None None O
DNA None None O
fragmentation None None O
in None None O
HL None None I-Cell-line-name
- None None I-Cell-line-name
60 None None I-Cell-line-name
cells None None O
, None None O
whereas None None O
Group None None O
II None None O
compounds None None O
were None None O
inactive None None O
even None None O
in None None O
the None None O
presence None None O
of None None O
NaF None None O
. None None O

Most None None O
Group None None O
I None None O
compounds None None O
except None None O
doxorubicin None None O
( None None O
which None None O
induced None None O
DNA None None O
fragmentation None None O
less None None O
effectively None None O
than None None O
others None None O
) None None O
activated None None O
caspase None None O
3 None None O
more None None O
efficiently None None O
than None None O
Group None None O
II None None O
compounds None None O
. None None O

Caspase None None O
8 None None O
( None None O
involved None None O
in None None O
non None None O
- None None O
mitochondrial None None O
extrinsic None None O
pathway None None O
) None None O
and None None O
caspase None None O
9 None None O
( None None O
involved None None O
in None None O
mitochondrial None None O
intrinsic None None O
pathway None None O
) None None O
were None None O
also None None O
activated None None O
, None None O
but None None O
to None None O
a None None O
much None None O
lesser None None O
extent None None O
. None None O

NaF None None O
reduced None None O
the None None O
glucose None None O
consumption None None O
at None None O
early None None O
stage None None O
, None None O
possibly None None O
by None None O
inhibition None None O
of None None O
glycolysis None None O
, None None O
whereas None None O
cisplatin None None O
and None None O
etoposide None None O
reduced None None O
the None None O
glucose None None O
consumption None None O
at None None O
later None None O
stage None None O
, None None O
suggesting None None O
that None None O
early None None O
decline None None O
of None None O
glucose None None O
consumption None None O
is None None O
rather None None O
specific None None O
to None None O
NaF None None O
. None None O

CD40 None None O
expression None None O
on None None O
human None None O
lung None None O
cancer None None O
correlates None None O
with None None O
metastatic None None O
spread None None O
. None None O

PURPOSE None None O
: None None O
The None None O
poor None None O
prognosis None None O
associated None None O
with None None O
lung None None O
cancer None None O
is None None O
related None None O
to None None O
the None None O
high None None O
incidence None None O
of None None O
regional None None O
and None None O
distant None None O
metastasis None None O
. None None O

There None None O
is None None O
a None None O
crucial None None O
need None None O
to None None O
identify None None O
parameters None None O
that None None O
can None None O
predict None None O
a None None O
tendancy None None O
to None None O
metastatic None None O
spread None None O
to None None O
allow None None O
better None None O
prognostic None None O
evaluation None None O
and None None O
therapeutic None None O
approach None None O
. None None O

METHODS None None O
: None None O
Using None None O
flow None None O
cytometry None None O
we None None O
evaluated None None O
18 None None O
human None None O
lung None None O
cancer None None O
cell None None O
lines None None O
for None None O
the None None O
expression None None O
of None None O
different None None O
surface None None O
markers None None O
on None None O
lung None None O
cancers None None O
suggested None None O
to None None O
be None None O
possible None None O
prognostic None None O
parameters None None O
, None None O
including None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
, None None O
intercellular None None O
adhesion None None O
molecule None None O
1 None None O
( None None O
ICAM None None O
- None None O
1 None None O
) None None O
, None None O
Fas None None O
and None None O
CD40 None None O
. None None O

RESULTS None None O
: None None O
No None None O
correlation None None O
was None None O
found None None O
between None None O
tumor None None O
prognosis None None O
and None None O
EGFR None None O
, None None O
ICAM None None O
- None None O
1 None None O
or None None O
Fas None None O
. None None O

However None None O
, None None O
a None None O
statistically None None O
significant None None O
correlation None None O
was None None O
found None None O
between None None O
the None None O
surface None None O
expression None None O
of None None O
CD40 None None O
and None None O
the None None O
metastatic None None O
spread None None O
of None None O
the None None O
tumor None None O
. None None O

In None None O
this None None O
study None None O
, None None O
14 None None O
of None None O
18 None None O
lung None None O
cancer None None O
cell None None O
lines None None O
( None None O
78 None None O
% None None O
) None None O
expressed None None O
CD40 None None O
on None None O
their None None O
surface None None O
. None None O

All None None O
of None None O
the None None O
4 None None O
tumors None None O
that None None O
were None None O
CD40 None None O
- None None O
negative None None O
, None None O
were None None O
stage None None O
I None None O
tumors None None O
, None None O
without None None O
any None None O
evidence None None O
of None None O
regional None None O
or None None O
distant None None O
metastasis None None O
. None None O

Of None None O
the None None O
14 None None O
tumors None None O
that None None O
expressed None None O
CD40 None None O
, None None O
all None None O
but None None O
1 None None O
( None None O
93 None None O
% None None O
) None None O
had None None O
either None None O
nodal None None O
or None None O
systemic None None O
metastasis None None O
at None None O
the None None O
time None None O
of None None O
diagnosis None None O
. None None O

Patients None None O
whose None None O
tumors None None O
were None None O
CD40 None None O
- None None O
negative None None O
showed None None O
a None None O
significantly None None O
better None None O
N None None O
stage None None O
, None None O
overall None None O
stage None None O
at None None O
presentation None None O
and None None O
survival None None O
than None None O
those None None O
patients None None O
with None None O
CD40 None None O
- None None O
positive None None O
patients None None O
. None None O

No None None O
significant None None O
differences None None O
between None None O
the None None O
two None None O
groups None None O
were None None O
observed None None O
in None None O
tumor None None O
size None None O
, None None O
gender None None O
, None None O
age None None O
, None None O
histology None None O
, None None O
differentiation None None O
or None None O
preoperative None None O
therapy None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
CD40 None None O
expression None None O
on None None O
lung None None O
cancer None None O
may None None O
play None None O
a None None O
role None None O
in None None O
metastatic None None O
spread None None O
, None None O
and None None O
also None None O
may None None O
serve None None O
as None None O
a None None O
prognostic None None O
marker None None O
and None None O
an None None O
indicator None None O
of None None O
advanced None None O
disease None None O
. None None O

[ None None O
Expression None None O
of None None O
Merlin None None O
protein None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
carcinoma None None O
and None None O
the None None O
clinical None None O
significance None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
determine None None O
the None None O
expression None None O
and None None O
clinical None None O
significance None None O
of None None O
Merlin None None O
protein None None O
in None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
cancer None None O
( None None O
NSCLC None None O
) None None O
. None None O

METHODS None None O
: None None O
The None None O
expression None None O
of None None O
Merlin None None O
protein None None O
in None None O
45 None None O
cases None None O
of None None O
NSCLC None None O
and None None O
adjacent None None O
tissue None None O
of None None O
NSCLC None None O
and None None O
normal None None O
lung None None O
tissue None None O
was None None O
checked None None O
by None None O
immunohistochemistry None None O
. None None O

The None None O
relation None None O
between None None O
the None None O
expression None None O
of None None O
Merlin None None O
protein None None O
and None None O
the None None O
multiple None None O
factors None None O
of None None O
pathological None None O
type None None O
, None None O
gender None None O
, None None O
P None None O
- None None O
TNM None None O
stage None None O
, None None O
differentiation None None O
and None None O
lymph None None O
node None None O
metastasis None None O
was None None O
analyzed None None O
. None None O

RESULTS None None O
: None None O
The None None O
expression None None O
rates None None O
of None None O
Merlin None None O
protein None None O
in None None O
NSCLC None None O
and None None O
normal None None O
lung None None O
tissue None None O
sections None None O
were None None O
73 None None O
. None None O
33 None None O
% None None O
and None None O
15 None None O
. None None O
56 None None O
% None None O
, None None O
respectively None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
Merlin None None O
protein None None O
was None None O
not None None O
associated None None O
with None None O
the None None O
pathological None None O
type None None O
, None None O
gender None None O
, None None O
P None None O
- None None O
TNM None None O
stage None None O
, None None O
differentiation None None O
and None None O
lymph None None O
node None None O
metastasis None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
Merlin None None O
protein None None O
might None None O
contribute None None O
to None None O
the None None O
initiation None None O
of None None O
metastasis None None O
of None None O
NSCLC None None O
. None None O

Current None None O
prospects None None O
for None None O
controlling None None O
cancer None None O
growth None None O
with None None O
non None None O
- None None O
cytotoxic None None O
agents None None O
- None None O
- None None O
nutrients None None O
, None None O
phytochemicals None None O
, None None O
herbal None None O
extracts None None O
, None None O
and None None O
available None None O
drugs None None O
. None None O

In None None O
animal None None O
or None None O
cell None None O
culture None None O
studies None None O
, None None O
the None None O
growth None None O
and None None O
spread None None O
of None None O
cancer None None O
can None None O
be None None O
slowed None None O
by None None O
many None None O
nutrients None None O
, None None O
food None None O
factors None None O
, None None O
herbal None None O
extracts None None O
, None None O
and None None O
well None None O
- None None O
tolerated None None O
, None None O
available None None O
drugs None None O
that None None O
are None None O
still None None O
rarely None None O
used None None O
in None None O
the None None O
clinical None None O
management None None O
of None None O
cancer None None O
, None None O
in None None O
part None None O
because None None O
they None None O
seem None None O
unlikely None None O
to None None O
constitute None None O
definitive None None O
therapies None None O
in None None O
themselves None None O
. None None O

However None None O
, None None O
it None None O
is None None O
reasonable None None O
to None None O
expect None None O
that None None O
mechanistically None None O
complementary None None O
combinations None None O
of None None O
these None None O
measures None None O
could None None O
have None None O
a None None O
worthwhile None None O
impact None None O
on None None O
survival None None O
times None None O
and None None O
, None None O
when None None O
used None None O
as None None O
adjuvants None None O
, None None O
could None None O
improve None None O
the None None O
cure None None O
rates None None O
achievable None None O
with None None O
standard None None O
therapies None None O
. None None O

The None None O
therapeutic None None O
options None None O
available None None O
in None None O
this None None O
regard None None O
include None None O
measures None None O
that None None O
: None None O
down None None O
- None None O
regulate None None O
serum None None O
free None None O
IGF None None O
- None None O
I None None O
; None None O
suppress None None O
the None None O
synthesis None None O
of None None O
mevalonic None None O
acid None None O
and None None O
/ None None O
or None None O
certain None None O
derivatives None None O
thereof None None O
; None None O
modulate None None O
arachidonate None None O
metabolism None None O
by None None O
inhibiting None None O
5 None None O
- None None O
lipoxygenase None None O
, None None O
12 None None O
- None None O
lipoxygenase None None O
, None None O
or None None O
COX None None O
- None None O
2 None None O
; None None O
antagonize None None O
the None None O
activation None None O
of None None O
AP None None O
- None None O
1 None None O
transcription None None O
factors None None O
; None None O
promote None None O
the None None O
activation None None O
of None None O
PPAR None None O
- None None O
gamma None None O
transcription None None O
factors None None O
; None None O
and None None O
that None None O
suppress None None O
angiogenesis None None O
by None None O
additional None None O
mechanisms None None O
. None None O

Many None None O
of None None O
these None None O
measures None None O
appear None None O
suitable None None O
for None None O
use None None O
in None None O
cancer None None O
prevention None None O
. None None O

Conclusions None None O

This None None O
is None None O
the None None O
first None None O
prospective None None O
evaluation None None O
of None None O
parents None None O
' None None O
preferences None None O
in None None O
newly None None O
diagnosed None None O
juvenile None None O
idiopathic None None O
arthritis None None O
patients None None O
participating None None O
in None None O
the None None O
BeSt None None O
for None None O
Kids None None O
trial None None O
. None None O

Within None None O
the None None O
limitations None None O
of None None O
the None None O
small None None O
amounts None None O
, None None O
patients None None O
clearly None None O
preferred None None O
initial None None O
combination None None O
therapy None None O
with None None O
etanercept None None O
and None None O
disliked None None O
taking None None O
prednisone None None O
. None None O

After None None O
actual None None O
exposure None None O
and None None O
follow None None O
up None None O
, None None O
this None None O
questionnaire None None O
will None None O
be None None O
repeated None None O
to None None O
see None None O
if None None O
preferences None None O
remain None None O
the None None O
same None None O
. None None O

Proteome None None O
analysis None None O
of None None O
NIH3T3 None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
activated None None O
Galpha12 None None O
: None None O
regulation None None O
of None None O
leukemia None None O
- None None O
associated None None O
protein None None O
SET None None O
. None None O

Galpha None None O
( None None O
12 None None O
) None None O
, None None O
the None None O
alpha None None O
- None None O
subunit None None O
of None None O
the None None O
G12 None None O
family None None O
of None None O
heterotrimeric None None O
G None None O
proteins None None O
is None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
cell None None O
proliferation None None O
and None None O
neoplastic None None O
transformation None None O
. None None O

GTPase None None O
- None None O
deficient None None O
, None None O
constitutively None None O
activated None None O
mutant None None O
of None None O
Galpha None None O
( None None O
12 None None O
) None None O
( None None O
Galpha None None O
( None None O
12 None None O
) None None O
Q229L None None O
or None None O
Galpha None None O
( None None O
12 None None O
) None None O
QL None None O
) None None O
has None None O
been None None O
previously None None O
shown None None O
to None None O
induce None None O
oncogenic None None O
transformation None None O
of None None O
NIH3T3 None None I-Cell-line-name
cells None None O
promoting None None O
serum None None O
- None None O
and None None O
anchorage None None O
- None None O
independent None None O
growth None None O
. None None O

Reduced None None O
growth None None O
- None None O
factor None None O
dependent None None O
, None None O
autonomous None None O
cell None None O
growth None None O
forms None None O
a None None O
critical None None O
defining None None O
point None None O
at None None O
which None None O
a None None O
normal None None O
cell None None O
turns None None O
into None None O
an None None O
oncogenic None None O
one None None O
. None None O

To None None O
identify None None O
the None None O
underlying None None O
mechanism None None O
involved None None O
in None None O
such None None O
growth None None O
- None None O
factor None None O
/ None None O
serum None None O
independent None None O
growth None None O
of None None O
Galpha None None O
( None None O
12 None None O
) None None O
QL None None O
- None None O
transformed None None O
NIH3T3 None None I-Cell-line-name
, None None O
we None None O
carried None None O
out None None O
a None None O
two None None O
- None None O
dimensional None None O
differential None None O
proteome None None O
analysis None None O
of None None O
Galpha None None O
( None None O
12 None None O
) None None O
QL None None O
- None None O
transformed None None O
NIH3T3 None None I-Cell-line-name
cells None None O
and None None O
cells None None O
expressing None None O
vector None None O
control None None O
. None None O

This None None O
analysis None None O
revealed None None O
a None None O
total None None O
of None None O
22 None None O
protein None None O
- None None O
spots None None O
whose None None O
expression None None O
was None None O
altered None None O
by None None O
more None None O
than None None O
3 None None O
- None None O
folds None None O
. None None O

Two None None O
of None None O
these None None O
spots None None O
were None None O
identified None None O
by None None O
MALDI None None O
- None None O
MS None None O
analysis None None O
as None None O
proliferating None None O
cell None None O
nuclear None None O
antigen None None O
( None None O
PCNA None None O
) None None O
and None None O
myeloid None None O
- None None O
leukemia None None O
- None None O
associated None None O
SET None None O
protein None None O
. None None O

The None None O
increased None None O
expressions None None O
of None None O
these None None O
proteins None None O
in None None O
Galpha None None O
( None None O
12 None None O
) None None O
QL None None O
cells None None O
were None None O
validated None None O
by None None O
immunoblot None None O
analysis None None O
. None None O

Furthermore None None O
, None None O
transient None None O
transfection None None O
studies None None O
with None None O
NIH3T3 None None I-Cell-line-name
cells None None O
indicated None None O
that None None O
the None None O
expression None None O
of None None O
activated None None O
Galpha None None O
( None None O
12 None None O
) None None O
readily None None O
increased None None O
the None None O
expression None None O
of None None O
SET None None O
protein None None O
by None None O
24 None None O
h None None O
. None None O

As None None O
SET None None O
has None None O
been None None O
previously None None O
reported None None O
to None None O
be None None O
an None None O
inhibitor None None O
of None None O
phosphatase None None O
PP2A None None O
, None None O
the None None O
nuclear None None O
phosphatase None None O
activity None None O
was None None O
monitored None None O
in None None O
cells None None O
expressing None None O
activated None None O
Galpha None None O
( None None O
12 None None O
) None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
the None None O
nuclear None None O
phosphatase None None O
activity None None O
is None None O
inhibited None None O
by None None O
greater None None O
than None None O
50 None None O
% None None O
in None None O
Galpha None None O
( None None O
12 None None O
) None None O
QL None None O
cells None None O
compared None None O
to None None O
vector None None O
control None None O
cells None None O
. None None O

Thus None None O
, None None O
our None None O
results None None O
from None None O
differential None None O
proteome None None O
analysis None None O
presented None None O
here None None O
report None None O
for None None O
the None None O
first None None O
time None None O
a None None O
role None None O
for None None O
SET None None O
in None None O
Galpha None None O
( None None O
12 None None O
) None None O
- None None O
mediated None None O
signaling None None O
pathways None None O
and None None O
a None None O
role None None O
for None None O
Galpha None None O
( None None O
12 None None O
) None None O
in None None O
the None None O
regulation None None O
of None None O
the None None O
leukemia None None O
- None None O
associated None None O
SET None None O
- None None O
protein None None O
expression None None O
. None None O

Molecular None None O
events None None O
leading None None O
to None None O
enhanced None None O
glucose None None O
transport None None O
in None None O
Rous None None O
sarcoma None None O
virus None None O
- None None O
transformed None None O
cells None None O
. None None O

Transformation None None O
by None None O
Rous None None O
sarcoma None None O
virus None None O
results None None O
in None None O
a None None O
dramatic None None O
increase None None O
in None None O
the None None O
rate None None O
at None None O
which None None O
the None None O
transformed None None O
cells None None O
transport None None O
glucose None None O
across None None O
the None None O
cell None None O
membrane None None O
. None None O

The None None O
increased None None O
transport None None O
rate None None O
is None None O
a None None O
consequence None None O
of None None O
an None None O
increased None None O
number None None O
of None None O
transporters None None O
in None None O
the None None O
transformed None None O
cells None None O
. None None O

Utilizing None None O
antibody None None O
raised None None O
against None None O
the None None O
purified None None O
human None None O
erythrocyte None None O
glucose None None O
transporter None None O
, None None O
we None None O
have None None O
identified None None O
the None None O
glucose None None O
transporter None None O
as None None O
a None None O
membrane None None O
glycoprotein None None O
with None None O
a None None O
monomer None None O
Mr None None O
of None None O
approximately None None O
41 None None O
, None None O
000 None None O
. None None O

The None None O
increased None None O
rate None None O
of None None O
glucose None None O
transport None None O
is None None O
dependent None None O
on None None O
the None None O
activity None None O
of None None O
pp60src None None O
, None None O
the None None O
transforming None None O
protein None None O
of None None O
Rous None None O
sarcoma None None O
virus None None O
. None None O

This None None O
protein None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
a None None O
protein None None O
kinase None None O
that None None O
phosphorylates None None O
on None None O
tyrosine None None O
residues None None O
. None None O

We None None O
have None None O
examined None None O
the None None O
tyrosine None None O
phosphorylation None None O
of None None O
a None None O
major None None O
cellular None None O
protein None None O
of None None O
Mr None None O
36 None None O
, None None O
000 None None O
in None None O
cells None None O
infected None None O
with None None O
a None None O
panel None None O
of None None O
partially None None O
transforming None None O
mutants None None O
of None None O
Rous None None O
sarcoma None None O
virus None None O
. None None O

One None None O
of None None O
these None None O
mutants None None O
( None None O
CU2 None None O
) None None O
increases None None O
the None None O
rate None None O
of None None O
glucose None None O
transport None None O
only None None O
slightly None None O
and None None O
does None None O
not None None O
render None None O
the None None O
infected None None O
cells None None O
fully None None O
anchorage None None O
independent None None O
or None None O
tumorigenic None None O
( None None O
although None None O
other None None O
transformation None None O
parameters None None O
are None None O
fully None None O
induced None None O
) None None O
. None None O

Cells None None O
infected None None O
with None None O
this None None O
mutant None None O
display None None O
a None None O
36 None None O
, None None O
000 None None O
- None None O
dalton None None O
protein None None O
that None None O
is None None O
phosphorylated None None O
to None None O
a None None O
considerably None None O
lesser None None O
extent None None O
than None None O
cells None None O
infected None None O
with None None O
wild None None O
- None None O
type None None O
virus None None O
. None None O

Analyses None None O
of None None O
this None None O
sort None None O
may None None O
help None None O
to None None O
identify None None O
the None None O
cellular None None O
targets None None O
of None None O
pp60src None None O
whose None None O
phosphorylation None None O
is None None O
necessary None None O
for None None O
the None None O
increased None None O
glucose None None O
transport None None O
rate None None O
. None None O

Enhanced None None O
IGF None None O
- None None O
1 None None O
expression None None O
improves None None O
smooth None None O
muscle None None O
cell None None O
engraftment None None O
after None None O
cell None None O
transplantation None None O
. None None O

The None None O
functional None None O
benefit None None O
of None None O
cell None None O
transplantation None None O
after None None O
a None None O
myocardial None None O
infarction None None O
is None None O
diminished None None O
by None None O
early None None O
cell None None O
losses None None O
. None None O

IGF None None O
- None None O
1 None None O
enhances None None O
cell None None O
proliferation None None O
and None None O
survival None None O
. None None O

We None None O
hypothesized None None O
that None None O
IGF None None O
- None None O
1 None None O
- None None O
transfected None None O
smooth None None O
muscle None None O
cells None None O
( None None O
SMCs None None O
) None None O
would None None O
enhance None None O
cell None None O
survival None None O
and None None O
improve None None O
engraftment None None O
after None None O
cell None None O
transplantation None None O
. None None O

The None None O
IGF None None O
- None None O
1 None None O
gene None None O
was None None O
transfected None None O
into None None O
male None None O
SMCs None None O
and None None O
compared None None O
with None None O
SMCs None None O
transfected None None O
with None None O
a None None O
plasmid None None O
vector None None O
( None None O
vector None None O
control None None O
) None None O
and None None O
nontransfected None None O
SMCs None None O
( None None O
cell None None O
control None None O
) None None O
. None None O

IGF None None O
- None None O
1 None None O
mRNA None None O
( None None O
n None None O
= None None O
10 None None O
/ None None O
group None None O
) None None O
and None None O
protein None None O
levels None None O
( None None O
n None None O
= None None O
6 None None O
/ None None O
group None None O
) None None O
were None None O
higher None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
for None None O
all None None O
groups None None O
) None None O
at None None O
3 None None O
, None None O
7 None None O
, None None O
and None None O
14 None None O
days None None O
compared None None O
with None None O
controls None None O
. None None O

VEGF None None O
was None None O
also None None O
increased None None O
in None None O
parallel None None O
to None None O
enhanced None None O
IGF None None O
- None None O
1 None None O
expression None None O
. None None O

IGF None None O
- None None O
1 None None O
- None None O
transfected None None O
cells None None O
demonstrated None None O
greater None None O
cell None None O
proliferation None None O
, None None O
stimulated None None O
angiogenesis None None O
, None None O
and None None O
decreased None None O
caspase None None O
- None None O
3 None None O
activity None None O
after None None O
simulated None None O
ischemia None None O
and None None O
reperfusion None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
for None None O
all None None O
groups None None O
compared None None O
with None None O
vector None None O
or None None O
cell None None O
controls None None O
) None None O
. None None O

A None None O
uniform None None O
left None None O
ventricular None None O
injury None None O
was None None O
produced None None O
in None None O
female None None O
rats None None O
using None None O
a None None O
cryoprobe None None O
. None None O

Three None None O
weeks None None O
later None None O
, None None O
2 None None O
x None None O
10 None None O
( None None O
6 None None O
) None None O
cells None None O
from None None O
three None None O
groups None None O
were None None O
implanted None None O
into None None O
the None None O
scar None None O
. None None O

One None None O
week None None O
later None None O
, None None O
IGF None None O
- None None O
1 None None O
- None None O
transfected None None O
SMCs None None O
had None None O
increased None None O
myocardial None None O
IGF None None O
- None None O
1 None None O
and None None O
VEGF None None O
levels None None O
, None None O
increased None None O
Bcl2 None None O
expression None None O
, None None O
limited None None O
cell None None O
apoptosis None None O
, None None O
and None None O
enhanced None None O
vessel None None O
formation None None O
in None None O
the None None O
myocardial None None O
scar None None O
compared None None O
with None None O
the None None O
two None None O
control None None O
groups None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
for None None O
all None None O
groups None None O
) None None O
. None None O

The None None O
proportion None None O
of None None O
SMCs None None O
surviving None None O
in None None O
the None None O
implanted None None O
region None None O
was None None O
greater None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
in None None O
the None None O
IGF None None O
- None None O
1 None None O
- None None O
transfected None None O
group None None O
than None None O
in None None O
the None None O
vector None None O
or None None O
cell None None O
controls None None O
. None None O

Gene None None O
enhancement None None O
with None None O
IGF None None O
- None None O
1 None None O
improved None None O
donor None None O
cell None None O
proliferation None None O
, None None O
survival None None O
, None None O
and None None O
engraftment None None O
after None None O
cell None None O
transplantation None None O
, None None O
perhaps None None O
mediated None None O
by None None O
enhanced None None O
angiogenesis None None O
and None None O
reduced None None O
apoptosis None None O
. None None O

Bee None None O
venom None None O
induces None None O
apoptosis None None O
and None None O
inhibits None None O
expression None None O
of None None O
cyclooxygenase None None O
- None None O
2 None None O
mRNA None None O
in None None O
human None None O
lung None None O
cancer None None O
cell None None O
line None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H1299 None None I-Cell-line-name
. None None O

To None None O
investigate None None O
whether None None O
bee None None O
venom None None O
( None None O
BV None None O
) None None O
induces None None O
apoptosis None None O
, None None O
the None None O
3 None None O
- None None O
( None None O
4 None None O
, None None O
5 None None O
- None None O
dimethylthiazol None None O
- None None O
2 None None O
- None None O
yl None None O
) None None O
- None None O
2 None None O
, None None O
5 None None O
- None None O
diphenyltetrazolium None None O
bromide None None O
assay None None O
, None None O
terminal None None O
deoxynucleotidyl None None O
transferase None None O
- None None O
mediated None None O
dUTP None None O
nick None None O
end None None O
- None None O
labeling None None O
assay None None O
, None None O
4 None None O
, None None O
6 None None O
- None None O
diamidino None None O
- None None O
2 None None O
- None None O
phenylindole None None O
staining None None O
, None None O
flow None None O
cytometric None None O
analysis None None O
, None None O
and None None O
DNA None None O
fragmentation None None O
assay None None O
were None None O
performed None None O
on None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H1299 None None I-Cell-line-name
lung None None O
cancer None None O
cells None None O
treated None None O
with None None O
BV None None O
. None None O

Through None None O
morphological None None O
and None None O
biochemical None None O
analyses None None O
, None None O
it None None O
was None None O
demonstrated None None O
that None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H1299 None None I-Cell-line-name
cells None None O
treated None None O
with None None O
BV None None O
exhibit None None O
several None None O
features None None O
of None None O
apoptosis None None O
. None None O

In None None O
addition None None O
, None None O
reverse None None O
transcription None None O
- None None O
polymerase None None O
chain None None O
reaction None None O
and None None O
prostaglandin None None O
E None None O
( None None O
2 None None O
) None None O
( None None O
PGE None None O
( None None O
2 None None O
) None None O
) None None O
immunoassay None None O
were None None O
performed None None O
to None None O
verify None None O
whether None None O
BV None None O
possesses None None O
an None None O
inhibitory None None O
effect None None O
on None None O
the None None O
expression None None O
of None None O
cyclooxygenase None None O
( None None O
COX None None O
) None None O
and None None O
PGE None None O
( None None O
2 None None O
) None None O
synthesis None None O
. None None O

Expression None None O
of None None O
COX None None O
- None None O
2 None None O
mRNA None None O
and None None O
synthesis None None O
of None None O
PGE None None O
( None None O
2 None None O
) None None O
were None None O
inhibited None None O
by None None O
BV None None O
. None None O

These None None O
results None None O
suggest None None O
the None None O
possibility None None O
that None None O
BV None None O
may None None O
exert None None O
an None None O
anti None None O
- None None O
tumor None None O
effect None None O
on None None O
human None None O
lung None None O
cancer None None O
. None None O

L None None O
- None None O
Carnitine None None O
ameliorates None None O
methotrexate None None O
- None None O
induced None None O
oxidative None None O
organ None None O
injury None None O
and None None O
inhibits None None O
leukocyte None None O
death None None O
. None None O

Methotrexate None None O
( None None O
MTX None None O
) None None O
, None None O
a None None O
folic None None O
acid None None O
antagonist None None O
widely None None O
used None None O
for None None O
the None None O
treatment None None O
of None None O
a None None O
variety None None O
of None None O
tumors None None O
and None None O
inflammatory None None O
diseases None None O
, None None O
affects None None O
normal None None O
tissues None None O
that None None O
have None None O
a None None O
high None None O
rate None None O
of None None O
proliferation None None O
, None None O
including None None O
the None None O
hematopoietic None None O
cells None None O
of None None O
the None None O
bone None None O
marrow None None O
and None None O
the None None O
gastrointestinal None None O
mucosal None None O
cells None None O
. None None O

To None None O
elucidate None None O
the None None O
role None None O
of None None O
free None None O
radicals None None O
and None None O
leukocytes None None O
in None None O
MTX None None O
- None None O
induced None None O
oxidative None None O
organ None None O
damage None None O
and None None O
the None None O
putative None None O
protective None None O
effect None None O
of None None O
L None None O
- None None O
carnitine None None O
( None None O
L None None O
- None None O
Car None None O
) None None O
, None None O
Wistar None None O
albino None None O
rats None None O
were None None O
administered None None O
a None None O
single None None O
dose None None O
of None None O
MTX None None O
( None None O
20 None None O
mg None None O
/ None None O
kg None None O
) None None O
followed None None O
by None None O
either None None O
saline None None O
or None None O
L None None O
- None None O
Car None None O
( None None O
500 None None O
mg None None O
/ None None O
kg None None O
) None None O
for None None O
5 None None O
days None None O
. None None O

After None None O
decapitation None None O
of None None O
the None None O
rats None None O
, None None O
trunk None None O
blood None None O
was None None O
obtained None None O
, None None O
and None None O
the None None O
ileum None None O
, None None O
liver None None O
, None None O
and None None O
kidney None None O
were None None O
removed None None O
for None None O
histological None None O
examination None None O
and None None O
for None None O
the None None O
measurement None None O
of None None O
malondialdehyde None None O
( None None O
MDA None None O
) None None O
and None None O
glutathione None None O
( None None O
GSH None None O
) None None O
levels None None O
, None None O
myeloperoxidase None None O
( None None O
MPO None None O
) None None O
activity None None O
, None None O
and None None O
collagen None None O
content None None O
. None None O

Our None None O
results None None O
showed None None O
that None None O
MTX None None O
administration None None O
increased None None O
the None None O
MDA None None O
and None None O
MPO None None O
activities None None O
and None None O
collagen None None O
content None None O
and None None O
decreased None None O
GSH None None O
levels None None O
in None None O
all None None O
tissues None None O
, None None O
while None None O
these None None O
alterations None None O
were None None O
reversed None None O
in None None O
L None None O
- None None O
Car None None O
- None None O
treated None None O
group None None O
. None None O

The None None O
elevated None None O
serum None None O
TNF None None O
- None None O
alpha None None O
level None None O
observed None None O
following None None O
MTX None None O
treatment None None O
was None None O
depressed None None O
with None None O
L None None O
- None None O
Car None None O
. None None O

The None None O
oxidative None None O
burst None None O
of None None O
neutrophils None None O
stimulated None None O
by None None O
Annexin None None O
V None None O
was None None O
reduced None None O
in None None O
the None None O
saline None None O
- None None O
treated None None O
MTX None None O
group None None O
, None None O
while None None O
L None None O
- None None O
Car None None O
abolished None None O
this None None O
inhibition None None O
. None None O

Similarly None None O
, None None O
flow None None O
cytometric None None O
measurements None None O
revealed None None O
that None None O
leukocyte None None O
apoptosis None None O
was None None O
increased None None O
in None None O
MTX None None O
- None None O
treated None None O
animals None None O
, None None O
while None None O
L None None O
- None None O
Car None None O
reversed None None O
these None None O
effects None None O
. None None O

Severe None None O
degeneration None None O
of None None O
the None None O
intestinal None None O
mucosa None None O
, None None O
liver None None O
parenchyma None None O
, None None O
and None None O
glomerular None None O
and None None O
tubular None None O
epithelium None None O
observed None None O
in None None O
the None None O
saline None None O
- None None O
treated None None O
MTX None None O
group None None O
was None None O
improved None None O
by None None O
L None None O
- None None O
Car None None O
treatment None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
L None None O
- None None O
Car None None O
, None None O
possibly None None O
via None None O
its None None O
free None None O
radical None None O
scavenging None None O
and None None O
antioxidant None None O
properties None None O
, None None O
ameliorates None None O
MTX None None O
- None None O
induced None None O
oxidative None None O
organ None None O
injury None None O
and None None O
inhibits None None O
leukocyte None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
supplementation None None O
with None None O
L None None O
- None None O
Carnitine None None O
as None None O
an None None O
adjuvant None None O
therapy None None O
may None None O
be None None O
promising None None O
in None None O
alleviating None None O
the None None O
systemic None None O
side None None O
- None None O
effects None None O
of None None O
chemotherapeutics None None O
. None None O

Serum None None O
soluble None None O
vascular None None O
adhesion None None O
protein None None O
- None None O
1 None None O
is None None O
a None None O
valuable None None O
prognostic None None O
marker None None O
in None None O
gastric None None O
cancer None None O
. None None O

BACKGROUND None None O
: None None O
Vascular None None O
adhesion None None O
protein None None O
- None None O
1 None None O
( None None O
VAP None None O
- None None O
1 None None O
) None None O
regulates None None O
leukocyte None None O
tissue None None O
infiltration None None O
. None None O

Elevated None None O
serum None None O
soluble None None O
VAP None None O
- None None O
1 None None O
( None None O
sVAP None None O
- None None O
1 None None O
) None None O
levels None None O
occur None None O
in None None O
certain None None O
diseases None None O
having None None O
an None None O
inflammatory None None O
component None None O
. None None O

We None None O
previously None None O
showed None None O
in None None O
colorectal None None O
cancer None None O
that None None O
sVAP None None O
- None None O
1 None None O
expression None None O
is None None O
significantly None None O
higher None None O
relative None None O
to None None O
controls None None O
, None None O
and None None O
this None None O
decreased None None O
expression None None O
is None None O
associated None None O
with None None O
poor None None O
prognosis None None O
and None None O
lymph None None O
node None None O
and None None O
liver None None O
metastasis None None O
. None None O

However None None O
, None None O
sVAP None None O
- None None O
1 None None O
expression None None O
has None None O
not None None O
been None None O
described None None O
for None None O
gastric None None O
cancer None None O
. None None O

This None None O
study None None O
determines None None O
the None None O
relationship None None O
between None None O
preoperative None None O
serum None None O
sVAP None None O
- None None O
1 None None O
levels None None O
and None None O
clinicopathological None None O
features None None O
and None None O
prognosis None None O
in None None O
gastric None None O
cancer None None O
. None None O

METHODS None None O
: None None O
Preoperative None None O
serum None None O
was None None O
collected None None O
from None None O
107 None None O
gastric None None O
cancer None None O
patients None None O
and None None O
33 None None O
normal None None O
controls None None O
. None None O

sVAP None None O
- None None O
1 None None O
levels None None O
were None None O
assayed None None O
by None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
. None None O

RESULTS None None O
: None None O
The None None O
mean None None O
sVAP None None O
- None None O
1 None None O
level None None O
for None None O
cancer None None O
patients None None O
was None None O
significantly None None O
higher None None O
relative None None O
to None None O
controls None None O
, None None O
and None None O
decreased None None O
with None None O
disease None None O
progression None None O
. None None O

Tumor None None O
size None None O
, None None O
serosal None None O
invasion None None O
, None None O
lymph None None O
node None None O
metastasis None None O
, None None O
peritoneal None None O
dissemination None None O
, None None O
and None None O
TNM None None O
classification None None O
was None None O
significantly None None O
correlated None None O
with None None O
sVAP None None O
- None None O
1 None None O
level None None O
. None None O

sVAP None None O
- None None O
1 None None O
is None None O
also None None O
an None None O
independent None None O
predictive None None O
marker None None O
for None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Patients None None O
having None None O
low None None O
sVAP None None O
- None None O
1 None None O
levels None None O
had None None O
significantly None None O
poorer None None O
prognosis None None O
relative None None O
to None None O
patients None None O
having None None O
elevated None None O
sVAP None None O
- None None O
1 None None O
in None None O
all None None O
or None None O
stages None None O
I None None O
- None None O
III None None O
gastric None None O
cancer None None O
patients None None O
, None None O
respectively None None O
. None None O

CONCLUSIONS None None O
: None None O
Low None None O
sVAP None None O
- None None O
1 None None O
levels None None O
are None None O
associated None None O
with None None O
poor None None O
prognosis None None O
in None None O
gastric None None O
cancer None None O
. None None O

Determining None None O
sVAP None None O
- None None O
1 None None O
levels None None O
may None None O
be None None O
valuable None None O
for None None O
predicting None None O
prognosis None None O
and None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Act None None O
No None None O
. None None O
16 None None O
. None None O
045 None None O
of None None O
2 None None O
June None None O
1989 None None O
prohibiting None None O
all None None O
discrimination None None O
that None None O
violates None None O
the None None O
principle None None O
of None None O
equality None None O
of None None O
treatment None None O
and None None O
opportunities None None O
for None None O
both None None O
sexes None None O
in None None O
all None None O
sectors None None O
of None None O
labor None None O
activity None None O
. None None O

This None None O
Uruguayan None None O
Act None None O
prohibits None None O
discrimination None None O
in None None O
employment None None O
with None None O
respect None None O
to None None O
the None None O
following None None O
areas None None O
, None None O
among None None O
others None None O
: None None O
1 None None O
) None None O
advertising None None O
for None None O
the None None O
provision None None O
of None None O
positions None None O
; None None O
2 None None O
) None None O
selection None None O
criteria None None O
; None None O
3 None None O
) None None O
recruitment None None O
and None None O
hiring None None O
; None None O
4 None None O
) None None O
evaluation None None O
of None None O
performance None None O
criteria None None O
; None None O
5 None None O
) None None O
the None None O
right None None O
to None None O
advancement None None O
and None None O
promotion None None O
; None None O
6 None None O
) None None O
labour None None O
stability None None O
; None None O
7 None None O
) None None O
social None None O
benefits None None O
; None None O
8 None None O
) None None O
suspension None None O
and None None O
dismissal None None O
, None None O
particularly None None O
in None None O
cases None None O
involving None None O
a None None O
change None None O
of None None O
civil None None O
status None None O
, None None O
pregnancy None None O
, None None O
or None None O
nursing None None O
; None None O
9 None None O
) None None O
possibilities None None O
for None None O
professional None None O
and None None O
technical None None O
education None None O
or None None O
retraining None None O
; None None O
and None None O
10 None None O
) None None O
remuneration None None O
criteria None None O
. None None O

Reserving None None O
places None None O
for None None O
one None None O
sex None None O
because None None O
of None None O
the None None O
presence None None O
of None None O
activities None None O
in None None O
which None None O
the None None O
sex None None O
of None None O
the None None O
employee None None O
is None None O
essential None None O
for None None O
performance None None O
or None None O
to None None O
comply None None O
with None None O
international None None O
labor None None O
treaties None None O
does None None O
not None None O
constitute None None O
discrimination None None O
. None None O

Nor None None O
do None None O
compensatory None None O
acts None None O
designed None None O
to None None O
promote None None O
equality None None O
of None None O
opportunities None None O
and None None O
treatment None None O
of None None O
both None None O
sexes None None O
in None None O
concrete None None O
situations None None O
. None None O

In None None O
cases None None O
where None None O
the None None O
provisions None None O
of None None O
this None None O
Act None None O
have None None O
been None None O
violated None None O
, None None O
specially None None O
designated None None O
judges None None O
will None None O
call None None O
the None None O
parties None None O
together None None O
and None None O
may None None O
adopt None None O
measures None None O
designed None None O
to None None O
end None None O
the None None O
situation None None O
complained None None O
of None None O
. None None O

If None None O
they None None O
deem None None O
it None None O
necessary None None O
, None None O
the None None O
judges None None O
may None None O
institute None None O
more None None O
formal None None O
proceedings None None O
. None None O

If None None O
the None None O
measures None None O
adopted None None O
are None None O
not None None O
carried None None O
out None None O
, None None O
the None None O
person None None O
violating None None O
the None None O
law None None O
is None None O
subject None None O
to None None O
a None None O
daily None None O
fine None None O
, None None O
as None None O
well None None O
as None None O
administrative None None O
penalties None None O
set None None O
out None None O
in None None O
Act None None O
15 None None O
. None None O
903 None None O
of None None O
10 None None O
November None None O
1987 None None O
. None None O

Adverse None None O
decisions None None O
may None None O
be None None O
appealed None None O
. None None O

The None None O
state None None O
is None None O
also None None O
to None None O
undertake None None O
educative None None O
campaigns None None O
to None None O
create None None O
interest None None O
in None None O
and None None O
understanding None None O
of None None O
the None None O
problems None None O
affecting None None O
women None None O
workers None None O
, None None O
thus None None O
promoting None None O
awareness None None O
in None None O
such None None O
workers None None O
and None None O
their None None O
employers None None O
of None None O
their None None O
situation None None O
. None None O

Dynein None None O
light None None O
chain None None O
1 None None O
, None None O
a None None O
p21 None None O
- None None O
activated None None O
kinase None None O
1 None None O
- None None O
interacting None None O
substrate None None O
, None None O
promotes None None O
cancerous None None O
phenotypes None None O
. None None O

We None None O
identified None None O
dynein None None O
light None None O
chain None None O
1 None None O
( None None O
DLC1 None None O
) None None O
as None None O
a None None O
physiologic None None O
substrate None None O
of None None O
p21 None None O
- None None O
activated None None O
kinase None None O
1 None None O
( None None O
Pak1 None None O
) None None O
. None None O

Pak1 None None O
- None None O
DLC1 None None O
interaction None None O
plays None None O
an None None O
essential None None O
role None None O
in None None O
cell None None O
survival None None O
, None None O
which None None O
depends None None O
on None None O
Pak1 None None O
' None None O
s None None O
phosphorylation None None O
of None None O
DLC1 None None O
on None None O
Ser88 None None O
. None None O

Pak1 None None O
associates None None O
with None None O
the None None O
complex None None O
of None None O
DLC1 None None O
and None None O
BimL None None O
, None None O
a None None O
proapoptotic None None O
BH3 None None O
- None None O
only None None O
protein None None O
, None None O
and None None O
phosphorylates None None O
both None None O
proteins None None O
. None None O

Phosphorylation None None O
of None None O
BimL None None O
by None None O
Pak1 None None O
prevents None None O
it None None O
from None None O
interacting None None O
with None None O
and None None O
inactivation None None O
of None None O
Bcl None None O
- None None O
2 None None O
, None None O
an None None O
antiapoptotic None None O
protein None None O
. None None O

Overexpression None None O
of None None O
DLC1 None None O
but None None O
not None None O
DLC1 None None O
- None None O
Ser88Ala None None O
mutant None None O
promotes None None O
cancerous None None O
properties None None O
of None None O
breast None None O
cancer None None O
cells None None O
. None None O

DLC1 None None O
protein None None O
level None None O
is None None O
elevated None None O
in None None O
more None None O
than None None O
90 None None O
% None None O
of None None O
human None None O
breast None None O
tumors None None O
. None None O

The None None O
regulation None None O
of None None O
cell None None O
survival None None O
functions None None O
by None None O
Pak1 None None O
- None None O
DLC1 None None O
interaction None None O
represents None None O
a None None O
novel None None O
mechanism None None O
by None None O
which None None O
a None None O
signaling None None O
kinase None None O
might None None O
regulate None None O
the None None O
cancerous None None O
phenotypes None None O
. None None O

Morphogenesis None None O
of None None O
embryonic None None O
CNS None None O
vessels None None O
. None None O

This None None O
chapter None None O
focuses None None O
on None None O
the None None O
morphology None None O
of None None O
blood None None O
vessel None None O
formation None None O
in None None O
and None None O
around None None O
the None None O
early None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
brain None None O
and None None O
spinal None None O
cord None None O
) None None O
of None None O
avian None None O
embryos None None O
. None None O

We None None O
discuss None None O
cell None None O
lineages None None O
, None None O
proliferation None None O
and None None O
interactions None None O
of None None O
endothelial None None O
cells None None O
, None None O
pericytes None None O
and None None O
smooth None None O
muscle None None O
cells None None O
, None None O
and None None O
macrophages None None O
. None None O

Due None None O
to None None O
space None None O
limitations None None O
, None None O
we None None O
can None None O
not None None O
review None None O
the None None O
molecular None None O
control None None O
of None None O
CNS None None O
angiogenesis None None O
, None None O
but None None O
refer None None O
the None None O
reader None None O
to None None O
other None None O
chapters None None O
in None None O
this None None O
book None None O
and None None O
to None None O
recent None None O
publications None None O
on None None O
the None None O
assembly None None O
of None None O
the None None O
vasculature None None O
( None None O
1 None None O
, None None O
2 None None O
) None None O
. None None O

Impact None None O
of None None O
technology None None O
on None None O
the None None O
utilisation None None O
of None None O
positron None None O
emission None None O
tomography None None O
in None None O
lymphoma None None O
: None None O
current None None O
and None None O
future None None O
perspectives None None O
. None None O

Positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
has None None O
now None None O
gained None None O
a None None O
place None None O
in None None O
the None None O
management None None O
of None None O
patients None None O
with None None O
cancer None None O
, None None O
including None None O
those None None O
with None None O
Hodgkin None None O
' None None O
s None None O
disease None None O
and None None O
non None None O
- None None O
Hodgkin None None O
' None None O
s None None O
lymphoma None None O
. None None O

Restaging None None O
studies None None O
and None None O
those None None O
addressing None None O
the None None O
monitoring None None O
of None None O
response None None O
to None None O
treatment None None O
are None None O
especially None None O
in None None O
focus None None O
. None None O

Most None None O
of None None O
the None None O
knowledge None None O
gained None None O
has None None O
been None None O
achieved None None O
with None None O
dedicated None None O
BGO None None O
- None None O
based None None O
PET None None O
technology None None O
, None None O
but None None O
there None None O
are None None O
a None None O
number None None O
of None None O
developments None None O
that None None O
will None None O
impact None None O
on None None O
the None None O
use None None O
of None None O
this None None O
metabolic None None O
imaging None None O
technique None None O
in None None O
the None None O
investigation None None O
of None None O
patients None None O
with None None O
lymphoma None None O
. None None O

The None None O
challenges None None O
ahead None None O
are None None O
determined None None O
by None None O
the None None O
need None None O
for None None O
high None None O
- None None O
quality None None O
whole None None O
- None None O
body None None O
imaging None None O
associated None None O
with None None O
increased None None O
patient None None O
throughput None None O
and None None O
the None None O
need None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
new None None O
labelled None None O
ligands None None O
. None None O

The None None O
latter None None O
are None None O
likely None None O
to None None O
yield None None O
new None None O
insights None None O
into None None O
tumour None None O
cell None None O
characterisation None None O
, None None O
tumour None None O
behaviour None None O
and None None O
tumour None None O
outcome None None O
assessment None None O
. None None O

The None None O
study None None O
of None None O
new None None O
radiolabelled None None O
ligands None None O
will None None O
impose None None O
further None None O
demands None None O
for None None O
rapid None None O
dynamic None None O
data None None O
acquisition None None O
and None None O
accurate None None O
tracer None None O
quantification None None O
. None None O

Current None None O
and None None O
future None None O
developments None None O
in None None O
PET None None O
technology None None O
range None None O
from None None O
the None None O
use None None O
of None None O
new None None O
detector None None O
materials None None O
to None None O
different None None O
detector None None O
geometries None None O
and None None O
data None None O
acquisition None None O
modes None None O
. None None O

The None None O
search None None O
for None None O
alternatives None None O
to None None O
BGO None None O
scintillation None None O
materials None None O
for None None O
PET None None O
has None None O
led None None O
to None None O
the None None O
development None None O
of None None O
PET None None O
instruments None None O
utilising None None O
new None None O
crystals None None O
such None None O
as None None O
LSO None None O
and None None O
GSO None None O
. None None O

The None None O
use None None O
of None None O
these None None O
new None None O
detectors None None O
and None None O
the None None O
increased None None O
sensitivity None None O
achieved None None O
with None None O
3D None None O
data None None O
acquisitions None None O
represent None None O
the None None O
most None None O
significant None None O
current None None O
developments None None O
in None None O
the None None O
field None None O
. None None O

With None None O
the None None O
increasing None None O
demands None None O
imposed None None O
on None None O
the None None O
clinical None None O
utilisation None None O
of None None O
PET None None O
, None None O
issues None None O
such None None O
as None None O
study None None O
cost None None O
and None None O
patient None None O
throughput None None O
will None None O
emerge None None O
as None None O
significant None None O
future None None O
factors None None O
. None None O

As None None O
a None None O
consequence None None O
, None None O
low None None O
- None None O
cost None None O
units None None O
are None None O
being None None O
offered None None O
by None None O
the None None O
manufacturers None None O
through None None O
the None None O
utilisation None None O
of None None O
gamma None None O
camera None None O
- None None O
based None None O
SPET None None O
systems None None O
for None None O
PET None None O
coincidence None None O
imaging None None O
. None None O

Unfortunately None None O
, None None O
clinical None None O
studies None None O
in None None O
lymphoma None None O
and None None O
other None None O
cancers None None O
have None None O
already None None O
demonstrated None None O
the None None O
limitations None None O
of None None O
this None None O
technology None None O
, None None O
with None None O
20 None None O
% None None O
of None None O
lesions None None O
< None None O
15 None None O
mm None None O
in None None O
size None None O
escaping None None O
detection None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
recent None None O
development None None O
of None None O
combined None None O
PET None None O
/ None None O
CT None None O
devices None None O
attempts None None O
to None None O
address None None O
the None None O
lack None None O
of None None O
anatomical None None O
information None None O
inherent None None O
with None None O
PET None None O
images None None O
, None None O
taking None None O
advantage None None O
of None None O
further None None O
improvement None None O
in None None O
patient None None O
throughput None None O
and None None O
hence None None O
cost None None O
- None None O
effectiveness None None O
. None None O

Preliminary None None O
studies None None O
using None None O
this None None O
multimodality None None O
imaging None None O
approach None None O
have None None O
already None None O
demonstrated None None O
the None None O
potential None None O
of None None O
the None None O
technique None None O
. None None O

Although None None O
the None None O
potential None None O
exists None None O
, None None O
certain None None O
technical None None O
issues None None O
with None None O
PET None None O
/ None None O
CT None None O
require None None O
refinement None None O
of None None O
the None None O
methodology None None O
. None None O

Such None None O
issues None None O
include None None O
organ None None O
movement None None O
( None None O
such None None O
as None None O
respiratory None None O
motion None None O
) None None O
, None None O
which None None O
strongly None None O
influences None None O
the None None O
image None None O
fusion None None O
of None None O
a None None O
rapidly None None O
acquired None None O
CT None None O
scan None None O
with None None O
the None None O
slower None None O
acquisition None None O
of None None O
a None None O
PET None None O
dataset None None O
, None None O
and None None O
the None None O
derivation None None O
of None None O
CT None None O
- None None O
based None None O
attenuation None None O
coefficients None None O
in None None O
the None None O
presence None None O
of None None O
contrast None None O
agents None None O
or None None O
metallic None None O
implants None None O
. None None O

The None None O
application None None O
of None None O
the None None O
technology None None O
for None None O
radiotherapy None None O
planning None None O
also None None O
poses None None O
a None None O
number None None O
of None None O
associated None None O
challenges None None O
. None None O

Finally None None O
, None None O
the None None O
development None None O
of None None O
dedicated None None O
PET None None O
systems None None O
based None None O
on None None O
planar None None O
detector None None O
arrangements None None O
with None None O
new None None O
detector None None O
components None None O
has None None O
the None None O
potential None None O
to None None O
improve None None O
clinical None None O
throughput None None O
by None None O
over None None O
100 None None O
% None None O
, None None O
but None None O
clinical None None O
trials None None O
using None None O
such None None O
systems None None O
have None None O
still None None O
to None None O
be None None O
carried None None O
out None None O
in None None O
order None None O
to None None O
establish None None O
the None None O
associated None None O
whole None None O
- None None O
body None None O
image None None O
quality None None O
. None None O

Pteris None None O
vittata None None O

Increased None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
messenger None None O
RNA None None O
expression None None O
and None None O
absence None None O
of None None O
mutations None None O
in None None O
colon None None O
carcinomas None None O
of None None O
low None None O
and None None O
high None None O
metastatic None None O
potential None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
murine None None O
nm23 None None O
gene None None O
suppresses None None O
the None None O
metastatic None None O
behavior None None O
of None None O
malignant None None O
rodent None None O
tumor None None O
lines None None O
, None None O
and None None O
reduced None None O
nm23 None None O
expression None None O
correlates None None O
with None None O
increased None None O
likelihood None None O
of None None O
lymph None None O
node None None O
metastases None None O
in None None O
human None None O
breast None None O
cancers None None O
. None None O

More None None O
recent None None O
data None None O
have None None O
demonstrated None None O
the None None O
existence None None O
of None None O
two None None O
human None None O
nm23 None None O
gene None None O
homologues None None O
, None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
, None None O
and None None O
have None None O
shown None None O
that None None O
deletion None None O
of None None O
nm23 None None O
- None None O
H1 None None O
alleles None None O
occurs None None O
in None None O
some None None O
colon None None O
carcinomas None None O
associated None None O
with None None O
poor None None O
prognosis None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
nm23 None None O
- None None O
H1 None None O
encodes None None O
for None None O
suppression None None O
of None None O
colon None None O
carcinoma None None O
metastasis None None O
. None None O

In None None O
contrast None None O
, None None O
we None None O
have None None O
previously None None O
reported None None O
that None None O
total None None O
nm23 None None O
messenger None None O
RNA None None O
( None None O
mRNA None None O
) None None O
expression None None O
is None None O
increased None None O
to None None O
similar None None O
levels None None O
in None None O
colon None None O
tumors None None O
of None None O
both None None O
high None None O
and None None O
low None None O
metastatic None None O
potential None None O
. None None O

PURPOSE None None O
: None None O
This None None O
study None None O
was None None O
designed None None O
to None None O
reconcile None None O
our None None O
previous None None O
findings None None O
with None None O
the None None O
recent None None O
report None None O
of None None O
nm23 None None O
- None None O
H1 None None O
allelic None None O
deletion None None O
in None None O
human None None O
colon None None O
cancers None None O
associated None None O
with None None O
poor None None O
prognosis None None O
. None None O

Our None None O
purpose None None O
was None None O
to None None O
examine None None O
human None None O
colon None None O
cancers None None O
for None None O
inactivation None None O
of None None O
two None None O
candidate None None O
metastasis None None O
suppressor None None O
genes None None O
, None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
, None None O
either None None O
by None None O
mutation None None O
or None None O
by None None O
loss None None O
of None None O
gene None None O
transcription None None O
. None None O

METHODS None None O
: None None O
We None None O
used None None O
ribonuclease None None O
protection None None O
assays None None O
to None None O
analyze None None O
human None None O
colon None None O
tumors None None O
for None None O
the None None O
level None None O
of None None O
nm23 None None O
- None None O
H1 None None O
( None None O
43 None None O
samples None None O
) None None O
and None None O
nm23 None None O
- None None O
H2 None None O
( None None O
41 None None O
samples None None O
) None None O
transcript None None O
( None None O
mRNA None None O
) None None O
expression None None O
and None None O
the None None O
presence None None O
of None None O
mutations None None O
that None None O
could None None O
inactivate None None O
potential None None O
suppressor None None O
function None None O
. None None O

RESULTS None None O
: None None O
We None None O
detected None None O
only None None O
wild None None O
- None None O
type None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
. None None O

Expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
mRNA None None O
increased None None O
in None None O
33 None None O
of None None O
41 None None O
colon None None O
tumors None None O
, None None O
and None None O
expression None None O
of None None O
nm23 None None O
- None None O
H2 None None O
mRNA None None O
was None None O
elevated None None O
in None None O
28 None None O
of None None O
41 None None O
colon None None O
tumors None None O
relative None None O
to None None O
that None None O
in None None O
matched None None O
normal None None O
mucosa None None O
. None None O

Increases None None O
in None None O
these None None O
mRNA None None O
levels None None O
were None None O
similar None None O
in None None O
tumors None None O
of None None O
both None None O
low None None O
and None None O
high None None O
metastatic None None O
potential None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
, None None O
despite None None O
correlation None None O
of None None O
nm23 None None O
- None None O
H1 None None O
allelic None None O
deletions None None O
with None None O
colon None None O
cancers None None O
associated None None O
with None None O
poor None None O
prognosis None None O
, None None O
nm23 None None O
- None None O
H1 None None O
and None None O
nm23 None None O
- None None O
H2 None None O
alleles None None O
do None None O
not None None O
directly None None O
mediate None None O
metastasis None None O
suppression None None O
in None None O
colon None None O
carcinoma None None O
. None None O

Our None None O
results None None O
leave None None O
unexplained None None O
the None None O
observation None None O
that None None O
nm23 None None O
- None None O
H1 None None O
allelic None None O
deletion None None O
correlates None None O
with None None O
metastatic None None O
potential None None O
of None None O
colon None None O
carcinomas None None O
. None None O

IMPLICATIONS None None O
: None None O
These None None O
findings None None O
also None None O
contrast None None O
with None None O
the None None O
demonstration None None O
of None None O
nm23 None None O
metastasis None None O
suppressor None None O
activity None None O
in None None O
murine None None O
melanoma None None O
and None None O
with None None O
the None None O
correlation None None O
of None None O
loss None None O
of None None O
nm23 None None O
expression None None O
in None None O
breast None None O
cancer None None O
with None None O
poor None None O
prognosis None None O
. None None O

It None None O
may None None O
be None None O
that None None O
metastasis None None O
suppression None None O
by None None O
the None None O
nm23 None None O
gene None None O
is None None O
a None None O
tissue None None O
- None None O
specific None None O
phenomenon None None O
. None None O

Immunohistochemical None None O
analysis None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
in None None O
node None None O
- None None O
positive None None O
lung None None O
cancer None None O
and None None O
lymph None None O
nodes None None O
. None None O

The None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
has None None O
been None None O
considered None None O
as None None O
an None None O
anti None None O
- None None O
metastatic None None O
protein None None O
and None None O
the None None O
level None None O
of None None O
its None None O
expression None None O
has None None O
been None None O
reported None None O
to None None O
correlate None None O
inversely None None O
with None None O
metastatic None None O
potential None None O
in None None O
some None None O
cancers None None O
. None None O

However None None O
, None None O
the None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
in None None O
the None None O
metastatic None None O
sites None None O
have None None O
not None None O
been None None O
studied None None O
in None None O
detail None None O
. None None O

We None None O
examined None None O
the None None O
expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
in None None O
surgically None None O
resected None None O
46 None None O
pairs None None O
of None None O
primary None None O
lung None None O
cancers None None O
and None None O
metastatic None None O
lymph None None O
nodes None None O
by None None O
immunohistochemistry None None O
. None None O

The None None O
positive None None O
staining None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
in None None O
primary None None O
cancers None None O
and None None O
metastatic None None O
lymph None None O
nodes None None O
were None None O
observed None None O
in None None O
56 None None O
. None None O
5 None None O
and None None O
67 None None O
. None None O
4 None None O
% None None O
, None None O
respectively None None O
. None None O

The None None O
heterogeneity None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
expression None None O
between None None O
primary None None O
cancers None None O
and None None O
metastatic None None O
lymph None None O
nodes None None O
was None None O
observed None None O
in None None O
41 None None O
. None None O
3 None None O
% None None O
. None None O

No None None O
correlations None None O
were None None O
found None None O
between None None O
the None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
expression None None O
in None None O
lung None None O
cancers None None O
and None None O
the None None O
patients None None O
survival None None O
. None None O

No None None O
significant None None O
association None None O
was None None O
also None None O
observed None None O
between None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
expression None None O
in None None O
lymph None None O
nodes None None O
and None None O
the None None O
patients None None O
survival None None O
. None None O

There None None O
was None None O
, None None O
furthermore None None O
, None None O
no None None O
correlation None None O
between None None O
the None None O
heterogeneity None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
expression None None O
and None None O
the None None O
patients None None O
survival None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
level None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
expression None None O
does None None O
not None None O
significantly None None O
reveal None None O
prognostic None None O
value None None O
in None None O
node None None O
- None None O
positive None None O
lung None None O
cancers None None O
. None None O

Expression None None O
of None None O
nm23 None None O
- None None O
H1 None None O
gene None None O
product None None O
in None None O
metastatic None None O
lymph None None O
nodes None None O
was None None O
also None None O
unrelated None None O
to None None O
patients None None O
survival None None O
. None None O

Matrix None None O
metalloproteinase None None O
/ None None O
tissue None None O
inhibitors None None O
of None None O
matrix None None O
metalloproteinase None None O
phenotype None None O
identifies None None O
poor None None O
prognosis None None O
colorectal None None O
cancers None None O
. None None O

PURPOSE None None O
: None None O
The None None O
matrix None None O
metalloproteinases None None O
( None None O
MMPs None None O
) None None O
are None None O
a None None O
family None None O
of None None O
proteolytic None None O
enzymes None None O
involved None None O
in None None O
tumor None None O
invasion None None O
; None None O
several None None O
individual None None O
members None None O
of None None O
which None None O
have None None O
been None None O
implicated None None O
in None None O
tumor None None O
prognosis None None O
. None None O

These None None O
enzymes None None O
and None None O
their None None O
physiologic None None O
inhibitors None None O
, None None O
the None None O
tissue None None O
inhibitors None None O
of None None O
matrix None None O
metalloproteinases None None O
( None None O
TIMPs None None O
) None None O
, None None O
act None None O
in None None O
a None None O
coordinated None None O
manner None None O
to None None O
form None None O
an None None O
integrated None None O
system None None O
. None None O

Therefore None None O
, None None O
to None None O
understand None None O
their None None O
role None None O
in None None O
tumor None None O
invasion None None O
, None None O
it None None O
is None None O
necessary None None O
to None None O
evaluate None None O
them None None O
collectively None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
In None None O
this None None O
study None None O
all None None O
of None None O
the None None O
major None None O
members None None O
of None None O
the None None O
matrix None None O
metalloproteinase None None O
( None None O
MMP None None O
- None None O
1 None None O
, None None O
MMP None None O
- None None O
2 None None O
, None None O
MMP None None O
- None None O
3 None None O
, None None O
MMP None None O
- None None O
7 None None O
, None None O
MMP None None O
- None None O
9 None None O
, None None O
MMP None None O
- None None O
13 None None O
, None None O
MT1 None None O
- None None O
MMP None None O
and None None O
MT2 None None O
- None None O
MMP None None O
) None None O
/ None None O
tissue None None O
inhibitor None None O
of None None O
matrix None None O
metalloproteinase None None O
( None None O
TIMP None None O
- None None O
1 None None O
, None None O
TIMP None None O
- None None O
2 None None O
, None None O
and None None O
TIMP None None O
- None None O
3 None None O
) None None O
system None None O
have None None O
been None None O
investigated None None O
by None None O
immunohistochemistry None None O
in None None O
a None None O
series None None O
( None None O
n None None O
= None None O
90 None None O
) None None O
of None None O
stage None None O
III None None O
( None None O
Dukes None None O
' None None O
C None None O
) None None O
colorectal None None O
cancers None None O
. None None O

An None None O
immunohistochemical None None O
score None None O
based None None O
on None None O
the None None O
intensity None None O
of None None O
immunoreactivity None None O
and None None O
proportion None None O
of None None O
immunoreactive None None O
cells None None O
was None None O
established None None O
for None None O
each None None O
MMP None None O
and None None O
TIMP None None O
. None None O

RESULTS None None O
: None None O
The None None O
MMP None None O
/ None None O
TIMP None None O
profile None None O
defined None None O
by None None O
hierarchical None None O
cluster None None O
analysis None None O
of None None O
the None None O
immunohistochemical None None O
score None None O
identifies None None O
a None None O
distinct None None O
group None None O
of None None O
colorectal None None O
cancers None None O
with None None O
poor None None O
prognosis None None O
( None None O
log None None O
- None None O
rank None None O
test None None O
, None None O
12 None None O
. None None O
22 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
0005 None None O
) None None O
. None None O

The None None O
median None None O
survival None None O
time None None O
of None None O
patients None None O
in None None O
this None None O
survival None None O
group None None O
was None None O
18 None None O
months None None O
compared None None O
with None None O
a None None O
median None None O
survival None None O
of None None O
49 None None O
months None None O
in None None O
the None None O
" None None O
good None None O
" None None O
survival None None O
group None None O
. None None O

Multivariate None None O
analysis None None O
showed None None O
that None None O
this None None O
profile None None O
was None None O
independently None None O
the None None O
most None None O
significant None None O
prognostic None None O
factor None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
This None None O
study None None O
has None None O
identified None None O
that None None O
the None None O
MMP None None O
/ None None O
TIMP None None O
profile None None O
is None None O
an None None O
independent None None O
indicator None None O
of None None O
poor None None O
prognosis None None O
in None None O
colorectal None None O
cancer None None O
. None None O

Vasodilator None None O
- None None O
stimulated None None O
phosphoprotein None None O
is None None O
involved None None O
in None None O
stress None None O
- None None O
fiber None None O
and None None O
membrane None None O
ruffle None None O
formation None None O
in None None O
endothelial None None O
cells None None O
. None None O

Vasodilator None None O
- None None O
stimulated None None O
phosphoprotein None None O
( None None O
VASP None None O
) None None O
is None None O
highly None None O
expressed None None O
in None None O
vascular None None O
endothelial None None O
cells None None O
, None None O
where None None O
it None None O
has None None O
been None None O
implicated None None O
in None None O
cellular None None O
reorganization None None O
during None None O
angiogenesis None None O
, None None O
as None None O
well None None O
as None None O
in None None O
endothelial None None O
retraction None None O
and None None O
changes None None O
in None None O
vessel None None O
permeability None None O
. None None O

However None None O
, None None O
the None None O
cellular None None O
functions None None O
of None None O
VASP None None O
are None None O
not None None O
known None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
expressed None None O
wild None None O
- None None O
type None None O
and None None O
mutant None None O
forms None None O
of None None O
VASP None None O
in None None O
endothelial None None O
cells None None O
to None None O
determine None None O
in None None O
what None None O
aspects None None O
of None None O
cytoskeletal None None O
behavior None None O
this None None O
protein None None O
participates None None O
. None None O

Expression None None O
of None None O
wild None None O
- None None O
type None None O
VASP None None O
induces None None O
marked None None O
membrane None None O
ruffling None None O
and None None O
formation None None O
of None None O
prominent None None O
stress None None O
fibers None None O
in None None O
bovine None None O
aortic None None O
endothelial None None O
cells None None O
. None None O

Deletion None None O
of None None O
the None None O
proline None None O
- None None O
rich None None O
domain None None O
of None None O
VASP None None O
abolishes None None O
its None None O
ability None None O
to None None O
bind None None O
profilin None None O
but None None O
does None None O
not None None O
affect None None O
ruffling None None O
or None None O
stress None None O
fiber None None O
formation None None O
. None None O

Further None None O
deletions None None O
reveal None None O
a None None O
sequence None None O
within None None O
the None None O
carboxy None None O
- None None O
terminal None None O
domain None None O
that None None O
is None None O
responsible None None O
for None None O
in None None O
vivo None None O
bundle None None O
formation None None O
. None None O

Ruffling None None O
occurs None None O
only None None O
on None None O
the None None O
expression None None O
of None None O
forms None None O
of None None O
VASP None None O
that None None O
possess None None O
bundling None None O
activity None None O
and None None O
the None None O
capacity None None O
to None None O
bind None None O
zyxin None None O
/ None None O
vinculin None None O
- None None O
derived None None O
peptide None None O
. None None O

The None None O
ability None None O
of None None O
distinct None None O
subdomains None None O
within None None O
VASP None None O
to None None O
bind None None O
adhesion None None O
proteins None None O
and None None O
induce None None O
F None None O
- None None O
actin None None O
bundling None None O
in None None O
vivo None None O
suggests None None O
that None None O
this None None O
protein None None O
could None None O
function None None O
in None None O
the None None O
aggregation None None O
and None None O
tethering None None O
of None None O
actin None None O
filaments None None O
during None None O
the None None O
formation None None O
of None None O
endothelial None None O
cell None None O
- None None O
substrate None None O
and None None O
cell None None O
- None None O
cell None None O
contacts None None O
. None None O

These None None O
data None None O
provide None None O
a None None O
mechanism None None O
whereby None None O
VASP None None O
can None None O
influence None None O
endothelial None None O
migration None None O
and None None O
organization None None O
during None None O
capillary None None O
formation None None O
and None None O
modulate None None O
vascular None None O
permeability None None O
via None None O
effects None None O
on None None O
endothelial None None O
cell None None O
contractility None None O
. None None O

Atypical None None O
mycobacteriosis None None O
of None None O
the None None O
larynx None None O
: None None O
an None None O
unusual None None O
clinical None None O
presentation None None O
secondary None None O
to None None O
steroids None None O
inhalation None None O
. None None O

Vocal None None O
cords None None O
stiffness None None O
can None None O
be None None O
associated None None O
with None None O
a None None O
variety None None O
of None None O
etiologic None None O
agents None None O
, None None O
but None None O
it None None O
is None None O
rarely None None O
seen None None O
with None None O
atypical None None O
mycobacteria None None O
, None None O
for None None O
example None None O
, None None O
Mycobacterium None None O
avium None None O
complex None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
a None None O
35 None None O
- None None O
year None None O
- None None O
old None None O
white None None O
woman None None O
who None None O
is None None O
and None None O
was None None O
maintained None None O
on None None O
inhaled None None O
steroids None None O
. None None O

She None None O
presented None None O
with None None O
hoarseness None None O
and None None O
low None None O
- None None O
grade None None O
fever None None O
, None None O
but None None O
her None None O
medical None None O
history None None O
was None None O
otherwise None None O
unremarkable None None O
. None None O

Laryngoscopy None None O
revealed None None O
bilateral None None O
scarring None None O
of None None O
the None None O
vocal None None O
cords None None O
. None None O

Vocal None None O
cord None None O
biopsies None None O
were None None O
performed None None O
. None None O

Histologic None None O
examination None None O
revealed None None O
unremarkable None None O
laryngeal None None O
mucosa None None O
, None None O
except None None O
for None None O
abundant None None O
subepithelial None None O
non None None O
- None None O
necrotizing None None O
granulomata None None O
. None None O

The None None O
differential None None O
diagnosis None None O
included None None O
sarcoid None None O
, None None O
Klebsiella None None O
scleroma None None O
, None None O
and None None O
tuberculosis None None O
. None None O

Special None None O
stains None None O
reviewed None None O
abundant None None O
acid None None O
- None None O
fast None None O
bacilli None None O
, None None O
later None None O
confirmed None None O
by None None O
a None None O
DNA None None O
assay None None O
on None None O
induced None None O
deep None None O
sputum None None O
, None None O
consistent None None O
with None None O
M None None O
avium None None O
complex None None O
. None None O

Subsequently None None O
, None None O
steroids None None O
were None None O
withdrawn None None O
, None None O
and None None O
the None None O
patient None None O
was None None O
treated None None O
with None None O
a None None O
multiple None None O
- None None O
drug None None O
antituberculous None None O
regimen None None O
and None None O
had None None O
a None None O
full None None O
recovery None None O
. None None O

This None None O
unusual None None O
clinical None None O
presentation None None O
of None None O
the None None O
atypical None None O
mycobacteriosis None None O
may None None O
be None None O
encountered None None O
by None None O
otolaryngologists None None O
and None None O
pathologists None None O
, None None O
and None None O
it None None O
is None None O
critical None None O
to None None O
recognize None None O
it None None O
in None None O
patients None None O
immunocompromised None None O
because None None O
of None None O
steroids None None O
. None None O

Calcium None None O
intake None None O
and None None O
effects None None O
on None None O
QUS None None O
T None None O
- None None O
score None None O

Figure None None O
5 None None O
shows None None O
the None None O
amounts None None O
of None None O
dietary None None O
calcium None None O
intake None None O
according None None O
to None None O
menopausal None None O
status None None O
. None None O

Calcium None None O
consumption None None O
in None None O
most None None O
groups None None O
, None None O
like None None O
that None None O
in None None O
the None None O
study None None O
population None None O
as None None O
a None None O
whole None None O
, None None O
was None None O
inadequate None None O
. None None O

Fewer None None O
than None None O
one None None O
third None None O
of None None O
premenopausal None None O
and None None O
postmenopausal None None O
women None None O
received None None O
more None None O
than None None O
800 None None O
mg None None O
calcium None None O
daily None None O
, None None O
and None None O
fewer None None O
than None None O
16 None None O
% None None O
of None None O
premenopausal None None O
women None None O
in None None O
the None None O
50 None None O
- None None O
59 None None O
age None None O
decade None None O
( None None O
n None None O
= None None O
38 None None O
) None None O
consumed None None O
more None None O
than None None O
800 None None O
mg None None O
calcium None None O
daily None None O
. None None O

Figure None None O
5 None None O

Daily None None O
calcium None None O
intake None None O
in None None O
premenopausal None None O
and None None O
postmenopausal None None O
women None None O
. None None O

This None None O
figure None None O
depicts None None O
the None None O
daily None None O
amounts None None O
of None None O
dietary None None O
calcium None None O
intake None None O
( None None O
and None None O
percent None None O
) None None O
according None None O
to None None O
menopausal None None O
status None None O
using None None O
800 None None O
mg None None O
daily None None O
as None None O
cut None None O
off None None O
point None None O
. None None O

QUS None None O
T None None O
- None None O
score None None O
were None None O
then None None O
calculated None None O
according None None O
to None None O
daily None None O
calcium None None O
intake None None O
in None None O
all None None O
premenopausal None None O
and None None O
postmenopausal None None O
activity None None O
groups None None O
using None None O
800 None None O
mg None None O
daily None None O
calcium None None O
as None None O
cutoff None None O
point None None O
. None None O

As None None O
shown None None O
in None None O
Tables None None O
3 None None O
and None None O
4 None None O
and None None O
Figure None None O
6 None None O
, None None O
premenopausal None None O
women None None O
who None None O
were None None O
systematically None None O
active None None O
and None None O
consumed None None O
more None None O
than None None O
800 None None O
mg None None O
calcium None None O
daily None None O
had None None O
significantly None None O
higher None None O
QUS None None O
T None None O
- None None O
scores None None O
compared None None O
with None None O
all None None O
other None None O
activity None None O
groups None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Among None None O
systematically None None O
active None None O
premenopausal None None O
women None None O
who None None O
received None None O
more None None O
than None None O
800 None None O
mg None None O
calcium None None O
per None None O
day None None O
, None None O
this None None O
difference None None O
was None None O
separately None None O
significant None None O
verses None None O
sedentary None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
028 None None O
) None None O
and None None O
moderately None None O
active None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
women None None O
. None None O

In None None O
contrast None None O
, None None O
postmenopausal None None O
women None None O
showed None None O
no None None O
difference None None O
in None None O
QUS None None O
T None None O
- None None O
scores None None O
regardless None None O
of None None O
the None None O
amount None None O
of None None O
daily None None O
calcium None None O
intake None None O
. None None O

Figure None None O
6 None None O

Synergy None None O
between None None O
physical None None O
activity None None O
and None None O
dietary None None O
calcium None None O
intake None None O
in None None O
women None None O
consuming None None O
calcium None None O
amounts None None O
greater None None O
than None None O
800 None None O
mg None None O
/ None None O
day None None O
. None None O

This None None O
graphic None None O
depicts None None O
mean None None O
QUS None None O
T None None O
- None None O
score None None O
values None None O
calculated None None O
according None None O
to None None O
daily None None O
calcium None None O
intake None None O
in None None O
all None None O
premenopausal None None O
and None None O
postmenopausal None None O
activity None None O
groups None None O
using None None O
800 None None O
mg None None O
daily None None O
as None None O
cut None None O
off None None O
point None None O
( None None O
for None None O
statistical None None O
significant None None O
values None None O
see None None O
text None None O
) None None O
. None None O

Downregulation None None O
of None None O
c None None O
- None None O
FLIP None None O
sensitizes None None O
DU145 None None I-Cell-line-name
prostate None None O
cancer None None O
cells None None O
to None None O
Fas None None O
- None None O
mediated None None O
apoptosis None None O
. None None O

Although None None O
DU145 None None I-Cell-line-name
prostate None None O
cancer None None O
cells None None O
are None None O
resistant None None O
to None None O
exogenously None None O
applied None None O
Fas None None O
agonist None None O
CH None None O
- None None O
11 None None O
( None None O
anti None None O
- None None O
Fas None None O
monoclonal None None O
antibody None None O
) None None O
, None None O
Fas None None O
- None None O
resistance None None O
can None None O
be None None O
overcome None None O
using None None O
a None None O
FasL None None O
expressing None None O
adenovirus None None O
( None None O
AdGFPFasL None None O
( None None O
TET None None O
) None None O
) None None O
[ None None O
Hyer None None O
et None None O
al None None O
. None None O
, None None O
Molecular None None O
Therapy None None O
, None None O
2000 None None O
; None None O
2 None None O
: None None O
348 None None O
- None None O
58 None None O
( None None O
ref None None O
. None None O
12 None None O
) None None O
] None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
try None None O
to None None O
understand None None O
why None None O
DU145 None None I-Cell-line-name
cells None None O
are None None O
resistant None None O
to None None O
CH None None O
- None None O
11 None None O
and None None O
determine None None O
the None None O
signaling None None O
pathway None None O
utilized None None O
by None None O
AdGFPFasL None None O
( None None O
TET None None O
) None None O
to None None O
induce None None O
apoptosis None None O
in None None O
these None None O
Fas None None O
- None None O
resistant None None O
cells None None O
. None None O

Using None None O
immunoblot None None O
analysis None None O
, None None O
we None None O
show None None O
that None None O
AdGFPFasL None None O
( None None O
TET None None O
) None None O
is None None O
capable None None O
of None None O
initiating None None O
the None None O
classic None None O
Fas None None O
- None None O
mediated None None O
apoptotic None None O
pathway None None O
in None None O
DU145 None None I-Cell-line-name
cells None None O
, None None O
which None None O
includes None None O
activation None None O
of None None O
caspases None None O
- None None O
8 None None O
, None None O
- None None O
3 None None O
, None None O
- None None O
7 None None O
, None None O
and None None O
- None None O
9 None None O
, None None O
BID None None O
cleavage None None O
, None None O
cytochrome None None O
c None None O
release None None O
from None None O
mitochondria None None O
, None None O
and None None O
PARP None None O
cleavage None None O
. None None O

In None None O
contrast None None O
, None None O
CH None None O
- None None O
11 None None O
binds None None O
to None None O
Fas None None O
, None None O
but None None O
is None None O
unable None None O
to None None O
transmit None None O
the None None O
death None None O
signal None None O
beyond None None O
the None None O
plasma None None O
membrane None None O
suggesting None None O
a None None O
block None None O
at None None O
the None None O
DISC None None O
( None None O
death None None O
inducing None None O
signaling None None O
complex None None O
) None None O
. None None O

The None None O
anti None None O
- None None O
apoptotic None None O
protein None None O
c None None O
- None None O
FLIP None None O
( None None O
cellular None None O
Flice None None O
- None None O
like None None O
inhibitory None None O
protein None None O
) None None O
, None None O
which None None O
has None None O
been None None O
shown None None O
to None None O
inhibit None None O
Fas None None O
- None None O
mediated None None O
apoptosis None None O
at None None O
the None None O
DISC None None O
, None None O
was None None O
down None None O
- None None O
regulated None None O
following None None O
AdGFPFasL None None O
( None None O
TET None None O
) None None O
treatment None None O
prompting None None O
us None None O
to None None O
investigate None None O
its None None O
role None None O
in None None O
inhibiting None None O
CH None None O
- None None O
11 None None O
- None None O
induced None None O
cell None None O
death None None O
. None None O

Using None None O
c None None O
- None None O
FLIP None None O
anti None None O
- None None O
sense None None O
oligonucleotides None None O
to None None O
down None None O
- None None O
regulate None None O
c None None O
- None None O
FLIP None None O
we None None O
sensitized None None O
DU145 None None I-Cell-line-name
cells None None O
to None None O
CH None None O
- None None O
11 None None O
- None None O
induced None None O
apoptosis None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
c None None O
- None None O
FLIP None None O
may None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
regulating None None O
Fas None None O
- None None O
mediated None None O
apoptosis None None O
in None None O
prostate None None O
cancer None None O
cells None None O
and None None O
that None None O
modulation None None O
of None None O
c None None O
- None None O
FLIP None None O
may None None O
enhance None None O
Fas None None O
signaling None None O
based None None O
therapies None None O
. None None O

Subjects None None O
and None None O
Methods None None O

ABPM None None O
was None None O
conducted None None O
for None None O
60 None None O
selected None None O
patients None None O
who None None O
had None None O
visited None None O
Sunlin None None O
Hospital None None O
between None None O
January None None O
2008 None None O
and None None O
August None None O
2008 None None O
. None None O

Patients None None O
were None None O
classified None None O
into None None O
3 None None O
groups None None O
; None None O
an None None O
obese None None O
group None None O
whose None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
was None None O
> None None O
the None None O
95th None None O
percentile None None O
, None None O
an None None O
overweight None None O
group None None O
whose None None O
BMI None None O
was None None O
> None None O
the None None O
85th None None O
percentile None None O
but None None O
less None None O
than None None O
the None None O
95th None None O
percentile None None O
, None None O
and None None O
a None None O
normal None None O
group None None O
whose None None O
BMI None None O
was None None O
below None None O
the None None O
85th None None O
percentile None None O
. None None O

Overall None None O
mean None None O
BP None None O
, None None O
day None None O
and None None O
night None None O
BP None None O
and None None O
BP None None O
load None None O
were None None O
measured None None O
by None None O
ABPM None None O
. None None O

p75 None None O
mediated None None O
apoptosis None None O
in None None O
neuroblastoma None None O
cells None None O
is None None O
inhibited None None O
by None None O
expression None None O
of None None O
TrkA None None O
. None None O

BACKGROUND None None O
: None None O
Neurotrophins None None O
mediate None None O
their None None O
effects None None O
by None None O
binding None None O
to None None O
members None None O
of None None O
the None None O
Trk None None O
family None None O
of None None O
receptor None None O
tyrosine None None O
kinases None None O
and None None O
to None None O
the None None O
low None None O
- None None O
affinity None None O
nerve None None O
growth None None O
factor None None O
receptor None None O
p75 None None O
. None None O

Nerve None None O
growth None None O
factor None None O
( None None O
NGF None None O
) None None O
has None None O
been None None O
demonstrated None None O
to None None O
support None None O
survival None None O
and None None O
differentiation None None O
of None None O
neuroblastoma None None O
( None None O
NB None None O
) None None O
cells None None O
by None None O
activation None None O
of None None O
the None None O
TrkA None None O
receptor None None O
. None None O

The None None O
p75 None None O
receptor None None O
belongs None None O
to None None O
the None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
family None None O
of None None O
death None None O
receptors None None O
and None None O
has None None O
been None None O
suggested None None O
as None None O
a None None O
receptor None None O
that None None O
mediates None None O
apoptosis None None O
in None None O
neuronal None None O
and None None O
NB None None O
cells None None O
. None None O

PROCEDURE None None O
: None None O
To None None O
investigate None None O
the None None O
effect None None O
of None None O
p75 None None O
expression None None O
in None None O
NB None None O
, None None O
we None None O
transfected None None O
the None None O
p75 None None O
cDNA None None O
into None None O
SH None None I-Cell-line-name
- None None I-Cell-line-name
SY5Y None None I-Cell-line-name
cells None None O
, None None O
an None None O
NB None None O
cell None None O
line None None O
lacking None None O
expression None None O
of None None O
both None None O
p75 None None O
and None None O
TrkA None None O
. None None O

RESULTS None None O
: None None O
Cell None None O
clones None None O
expressing None None O
elevated None None O
levels None None O
of None None O
p75 None None O
showed None None O
a None None O
high None None O
degree None None O
of None None O
apoptosis None None O
even None None O
in None None O
10 None None O
% None None O
serum None None O
- None None O
supplemented None None O
medium None None O
. None None O

Apoptotic None None O
signaling None None O
by None None O
p75 None None O
was None None O
ligand None None O
- None None O
independent None None O
and None None O
only None None O
partly None None O
caspase None None O
- None None O
dependent None None O
. None None O

The None None O
level None None O
of None None O
apoptosis None None O
correlated None None O
directly None None O
with None None O
the None None O
expression None None O
level None None O
of None None O
the None None O
receptor None None O
, None None O
indicating None None O
that None None O
p75 None None O
may None None O
activate None None O
the None None O
cell None None O
death None None O
program None None O
directly None None O
. None None O

However None None O
, None None O
additional None None O
transfection None None O
of None None O
TrkA None None O
into None None O
SY5Y None None I-Cell-line-name
- None None O
p75 None None O
cells None None O
resulted None None O
in None None O
a None None O
significantly None None O
reduced None None O
rate None None O
of None None O
apoptosis None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
NGF None None O
. None None O

CONCLUSIONS None None O
: None None O
Thus None None O
, None None O
expression None None O
of None None O
the None None O
TrkA None None O
receptor None None O
itself None None O
inhibits None None O
p75 None None O
mediated None None O
apoptosis None None O
in None None O
NB None None O
cells None None O
. None None O

[ None None O
Screening None None O
and None None O
identification None None O
of None None O
novel None None O
genes None None O
involved None None O
in None None O
biosynthesis None None O
of None None O
ginsenoside None None O
in None None O
Panax None None O
ginseng None None O
plant None None O
] None None O
. None None O

The None None O
root None None O
of None None O
Panax None None O
ginseng None None O
plant None None O
undergoes None None O
a None None O
specific None None O
developmental None None O
process None None O
to None None O
become None None O
a None None O
biosynthesis None None O
and None None O
accumulation None None O
organ None None O
for None None O
ginsenosides None None O
. None None O

To None None O
identify None None O
and None None O
analyze None None O
genes None None O
involved None None O
in None None O
the None None O
biosynthesis None None O
of None None O
ginsenoside None None O
, None None O
suppression None None O
subtractive None None O
hybridization None None O
( None None O
SSH None None O
) None None O
between None None O
mRNAs None None O
of None None O
4 None None O
- None None O
and None None O
1 None None O
- None None O
year None None O
- None None O
old None None O
root None None O
tissues None None O
was None None O
performed None None O
, None None O
and None None O
a None None O
subtracted None None O
cDNA None None O
library None None O
specific None None O
to None None O
4 None None O
- None None O
year None None O
- None None O
old None None O
roots None None O
was None None O
constructed None None O
. None None O

Forty None None O
cDNA None None O
clones None None O
selected None None O
randomly None None O
from None None O
the None None O
subtracted None None O
cDNA None None O
library None None O
were None None O
sequenced None None O
. None None O

Sequence None None O
information None None O
of None None O
all None None O
clones None None O
was None None O
evaluated None None O
by None None O
Nucleotide None None O
Blast None None O
analysis None None O
in None None O
GenBank None None O
/ None None O
DDBJ None None O
/ None None O
EMBL None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
six None None O
subtracted None None O
cDNA None None O
clones None None O
represented None None O
the None None O
novel None None O
genes None None O
( None None O
ESTs None None O
) None None O
, None None O
because None None O
no None None O
sequence None None O
homology None None O
with None None O
any None None O
known None None O
sequences None None O
was None None O
found None None O
in None None O
the None None O
database None None O
. None None O

Expression None None O
in None None O
4 None None O
- None None O
year None None O
- None None O
old None None O
P None None O
. None None O
ginseng None None O
root None None O
tissues None None O
was None None O
verified None None O
by None None O
reverse None None O
Northern None None O
dot None None O
hybridization None None O
for None None O
the None None O
six None None O
clones None None O
. None None O

These None None O
six None None O
novel None None O
genes None None O
were None None O
named None None O
GBR1 None None O
, None None O
GBR2 None None O
, None None O
GBR3 None None O
, None None O
GBR4 None None O
, None None O
GBR5 None None O
, None None O
and None None O
GBR6 None None O
, None None O
and None None O
their None None O
Accession None None O
numbers None None O
of None None O
GenBank None None O
are None None O
AF485334 None None O
, None None O
AF485335 None None O
, None None O
AF485336 None None O
, None None O
AF485337 None None O
, None None O
AF485332 None None O
, None None O
and None None O
AF485333 None None O
, None None O
respectively None None O
. None None O

Finally None None O
, None None O
Northern None None O
blot None None O
analysis None None O
and None None O
semi None None O
- None None O
quantitative None None O
reverse None None O
transcription None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT None None O
- None None O
PCR None None O
) None None O
confirmed None None O
that None None O
these None None O
six None None O
novel None None O
genes None None O
were None None O
differentially None None O
expressed None None O
in None None O
the None None O
defined None None O
development None None O
stage None None O
of None None O
P None None O
. None None O
ginseng None None O
plant None None O
roots None None O
. None None O

It None None O
is None None O
possible None None O
that None None O
their None None O
overexpression None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
ginsenoside None None O
biosynthesis None None O
. None None O

In None None O
addition None None O
, None None O
most None None O
of None None O
transcripts None None O
of None None O
all None None O
genes None None O
could None None O
also None None O
be None None O
detected None None O
in None None O
other None None O
P None None O
. None None O
ginseng None None O
plant None None O
tissues None None O
such None None O
as None None O
stem None None O
, None None O
leaf None None O
and None None O
seed None None O
. None None O

Our None None O
results None None O
provided None None O
a None None O
basis None None O
for None None O
obtaining None None O
the None None O
full None None O
- None None O
length None None O
cDNA None None O
sequences None None O
of None None O
such None None O
six None None O
novel None None O
genes None None O
, None None O
and None None O
for None None O
identifying None None O
their None None O
function None None O
involved None None O
in None None O
the None None O
biosynthesis None None O
of None None O
ginsenoside None None O
. None None O

Ventral None None O
and None None O
dorsal None None O
striatal None None O
dopamine None None O
efflux None None O
and None None O
behavior None None O
in None None O
rats None None O
with None None O
simple None None O
vs None None O
. None None O
co None None O
- None None O
morbid None None O
histories None None O
of None None O
cocaine None None O
sensitization None None O
and None None O
neonatal None None O
ventral None None O
hippocampal None None O
lesions None None O
. None None O

UNLABELLED None None O
: None None O

RATIONAL None None O
: None None O
Exposing None None O
animal None None O
models None None O
of None None O
mental None None O
illness None None O
to None None O
addictive None None O
drugs None None O
provides None None O
an None None O
approach None None O
to None None O
understanding None None O
the None None O
neural None None O
etiology None None O
of None None O
dual None None O
diagnosis None None O
disorders None None O
. None None O

Previous None None O
studies None None O
have None None O
shown None None O
that None None O
neonatal None None O
ventral None None O
hippocampal None None O
lesions None None O
( None None O
NVHL None None O
) None None O
in None None O
rats None None O
produce None None O
features None None O
of None None O
both None None O
schizophrenia None None O
and None None O
addiction None None O
vulnerability None None O
. None None O

OBJECTIVE None None O
: None None O

This None None O
study None None O
investigated None None O
ventral None None O
and None None O
dorsal None None O
striatal None None O
dopamine None None O
( None None O
DA None None O
) None None O
efflux None None O
in None None O
NVHL None None O
rats None None O
combined None None O
with None None O
behavioral None None O
sensitization None None O
to None None O
cocaine None None O
. None None O

METHODS None None O
: None None O

Adult None None O
NVHL None None O
vs None None O
. None None O
SHAM None None O
- None None O
operated None None O
rats None None O
underwent None None O
a None None O
5 None None O
- None None O
day None None O
injection None None O
series None None O
of None None O
cocaine None None O
( None None O
15 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
) None None O
vs None None O
. None None O
saline None None O
. None None O

One None None O
week None None O
later None None O
, None None O
rats None None O
were None None O
cannulated None None O
in None None O
nucleus None None O
accumbens None None O
SHELL None None O
, None None O
CORE None None O
, None None O
or None None O
caudate None None O
- None None O
putamen None None O
. None None O

Another None None O
week None None O
later None None O
, None None O
in None None O
vivo None None O
microdialysis None None O
sampled None None O
DA None None O
during None None O
locomotor None None O
testing None None O
in None None O
which None None O
a None None O
single None None O
cocaine None None O
injection None None O
( None None O
15 None None O
mg None None O
/ None None O
kg None None O
) None None O
was None None O
delivered None None O
. None None O

RESULTS None None O
: None None O

NVHLs None None O
and None None O
cocaine None None O
history None None O
significantly None None O
increased None None O
behavioral None None O
activation None None O
approximately None None O
2 None None O
- None None O
fold None None O
over None None O
SHAM None None O
- None None O
saline None None O
history None None O
rats None None O
. None None O

DA None None O
efflux None None O
curves None None O
corresponded None None O
time None None O
dependently None None O
with None None O
the None None O
cocaine None None O
injection None None O
and None None O
locomotor None None O
curves None None O
and None None O
varied None None O
significantly None None O
by None None O
striatal None None O
region None None O
: None None O
Baseline None None O
DA None None O
levels None None O
increased None None O
5 None None O
- None None O
fold None None O
while None None O
cocaine None None O
- None None O
stimulated None None O
DA None None O
efflux None None O
decreased None None O
by None None O
half None None O
across None None O
a None None O
ventral None None O
to None None O
dorsal None None O
striatal None None O
gradient None None O
. None None O

However None None O
, None None O
NVHLs None None O
, None None O
prior None None O
cocaine None None O
history None None O
, None None O
and None None O
individual None None O
differences None None O
in None None O
behavior None None O
were None None O
not None None O
underpinned None None O
by None None O
differential None None O
DA None None O
efflux None None O
overall None None O
or None None O
within None None O
any None None O
striatal None None O
region None None O
. None None O

CONCLUSION None None O
: None None O

Differences None None O
in None None O
ventral None None O
/ None None O
dorsal None None O
striatal None None O
DA None None O
efflux None None O
are None None O
not None None O
present None None O
in None None O
and None None O
are None None O
not None None O
required None None O
for None None O
producing None None O
differential None None O
levels None None O
of None None O
acute None None O
cocaine None None O
- None None O
induced None None O
behavioral None None O
activation None None O
in None None O
NVHLs None None O
with None None O
and None None O
without None None O
a None None O
behaviorally None None O
sensitizing None None O
cocaine None None O
history None None O
. None None O

These None None O
findings None None O
suggest None None O
other None None O
neurotransmitter None None O
systems None None O
, None None O
and None None O
alterations None None O
in None None O
striatal None None O
network None None O
function None None O
post None None O
- None None O
synaptic None None O
to None None O
DA None None O
transmission None None O
are None None O
more None None O
important None None O
to None None O
understanding None None O
the None None O
interactive None None O
effects None None O
of None None O
addictive None None O
drugs None None O
and None None O
mental None None O
illness None None O
. None None O

Torsade None None O
de None None O
pointes None None O
during None None O
loading None None O
with None None O
amiodarone None None O
. None None O

Torsade None None O
de None None O
pointes None None O
represents None None O
a None None O
potential None None O
complication None None O
of None None O
chronic None None O
amiodarone None None O
therapy None None O
. None None O

Several None None O
reports None None O
have None None O
emphasized None None O
the None None O
need None None O
for None None O
a None None O
loading None None O
dose None None O
in None None O
order None None O
to None None O
achieve None None O
therapeutic None None O
blood None None O
levels None None O
rapidly None None O
. None None O

We None None O
report None None O
a None None O
case None None O
of None None O
torsade None None O
de None None O
pointes None None O
following None None O
a None None O
single None None O
oral None None O
dose None None O
of None None O
amiodarone None None O
( None None O
1400 None None O
mg None None O
or None None O
30 None None O
mg None None O
kg None None O
- None None O
1 None None O
) None None O
administered None None O
after None None O
short None None O
intravenous None None O
loading None None O
for None None O
prevention None None O
of None None O
paroxysmal None None O
atrial None None O
flutter None None O
. None None O

Torsades None None O
de None None O
pointes None None O
were None None O
preceded None None O
and None None O
associated None None O
with None None O
marked None None O
QT None None O
prolongation None None O
and None None O
bradycardia None None O
. None None O

This None None O
report None None O
suggests None None O
that None None O
careful None None O
monitoring None None O
of None None O
patients None None O
undergoing None None O
oral None None O
amiodarone None None O
loading None None O
is None None O
necessary None None O
. None None O

TRADD None None O
domain None None O
of None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
transforming None None O
protein None None O
LMP1 None None O
is None None O
essential None None O
for None None O
inducing None None O
immortalization None None O
and None None O
suppressing None None O
senescence None None O
of None None O
primary None None O
rodent None None O
fibroblasts None None O
. None None O

Mutation None None O
analysis None None O
of None None O
latent None None O
membrane None None O
protein None None O
1 None None O
( None None O
LMP1 None None O
) None None O
in None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
- None None O
induced None None O
B None None O
- None None O
cell None None O
immortalization None None O
revealed None None O
two None None O
transformation None None O
effector None None O
sites None None O
, None None O
TES1 None None O
and None None O
TES2 None None O
. None None O

TES2 None None O
mediates None None O
the None None O
interaction None None O
with None None O
tumor None None O
necrosis None None O
factor None None O
receptor None None O
- None None O
associated None None O
death None None O
domain None None O
protein None None O
( None None O
TRADD None None O
) None None O
and None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
transactivating None None O
NF None None O
- None None O
kappa None None O
B None None O
and None None O
AP None None O
- None None O
1 None None O
. None None O

Recombinant None None O
EBV None None O
containing None None O
LMP1 None None O
with None None O
TES2 None None O
deleted None None O
induces None None O
a None None O
limited None None O
proliferation None None O
of None None O
B None None O
cells None None O
. None None O

The None None O
present None None O
study None None O
shows None None O
that None None O
a None None O
mutant None None O
with None None O
an None None O
LMP1 None None O
site None None O
- None None O
specific None None O
mutation None None O
at None None O
TES2 None None O
, None None O
LMP1 None None O
( None None O
TRADD None None O
) None None O
, None None O
initially None None O
stimulates None None O
cell None None O
growth None None O
and None None O
significantly None None O
extends None None O
the None None O
life None None O
span None None O
of None None O
MEF None None O
. None None O

However None None O
, None None O
it None None O
is None None O
not None None O
sufficient None None O
for None None O
the None None O
immortalization None None O
of None None O
MEF None None O
, None None O
and None None O
MEF None None O
- None None O
LMP1 None None O
( None None O
TRADD None None O
) None None O
cells None None O
eventually None None O
enter None None O
growth None None O
arrest None None O
. None None O

Further None None O
analysis None None O
reveals None None O
that None None O
although None None O
LMP1 None None O
( None None O
TRADD None None O
) None None O
promotes None None O
cell None None O
growth None None O
, None None O
it None None O
does None None O
not None None O
prevent None None O
the None None O
eventual None None O
onset None None O
of None None O
senescence None None O
and None None O
the None None O
expression None None O
of None None O
tumor None None O
suppressor None None O
p16 None None O
( None None O
Ink4a None None O
) None None O
. None None O

[ None None O
Uncommon None None O
etiology None None O
of None None O
gastrointestinal None None O
bleeding None None O
: None None O
duodenal None None O
metastases None None O
from None None O
renal None None O
cell None None O
carcinoma None None O
] None None O
. None None O

Because None None O
of None None O
its None None O
unpredictable None None O
behavior None None O
, None None O
renal None None O
cell None None O
carcinoma None None O
is None None O
one None None O
of None None O
the None None O
most None None O
controversial None None O
neoplasms None None O
. None None O

On None None O
the None None O
one None None O
hand None None O
, None None O
patients None None O
frequently None None O
show None None O
metastases None None O
at None None O
diagnosis None None O
because None None O
of None None O
its None None O
slight None None O
manifestations None None O
, None None O
while None None O
on None None O
the None None O
other None None O
, None None O
the None None O
neoplasm None None O
can None None O
remain None None O
stable None None O
after None None O
nephrectomy None None O
and None None O
can None None O
then None None O
metastasize None None O
many None None O
years None None O
later None None O
. None None O

When None None O
this None None O
happens None None O
, None None O
the None None O
metastases None None O
usually None None O
involve None None O
more None None O
than None None O
2 None None O
organs None None O
. None None O

The None None O
most None None O
frequent None None O
sites None None O
of None None O
metastases None None O
are None None O
the None None O
lung None None O
and None None O
lymph None None O
nodes None None O
, None None O
followed None None O
by None None O
the None None O
bones None None O
and None None O
liver None None O
, None None O
while None None O
duodenal None None O
involvement None None O
is None None O
rare None None O
. None None O

Indeed None None O
, None None O
intestinal None None O
metastases None None O
are None None O
found None None O
in None None O
only None None O
2 None None O
% None None O
of None None O
autopsies None None O
and None None O
of None None O
these None None O
, None None O
renal None None O
cell None None O
carcinoma None None O
metastases None None O
account None None O
for None None O
7 None None O
. None None O
1 None None O
% None None O
. None None O

We None None O
present None None O
a None None O
case None None O
of None None O
a None None O
solitary None None O
late None None O
recurrence None None O
presenting None None O
as None None O
upper None None O
gastrointestinal None None O
bleeding None None O
19 None None O
years None None O
after None None O
nephrectomy None None O
for None None O
clear None None O
cell None None O
renal None None O
carcinoma None None O
. None None O

Case None None O
Presentation None None O

The None None O
patient None None O
is None None O
an None None O
80 None None O
year None None O
old None None O
male None None O
with None None O
diabetes None None O
mellitus None None O
and None None O
hypertension None None O
, None None O
who None None O
at None None O
age None None O
74 None None O
( None None O
March None None O
2001 None None O
) None None O
had None None O
received None None O
a None None O
living None None O
non None None O
- None None O
related None None O
donor None None O
kidney None None O
transplant None None O
. None None O

At None None O
that None None O
time None None O
he None None O
was None None O
discharged None None O
with None None O
a None None O
double None None O
immunosuppressive None None O
therapy None None O
consisting None None O
of None None O
prednisone None None O
20 None None O
mg None None O
/ None None O
day None None O
and None None O
mophetil None None O
mycophenolate None None O
1 None None O
. None None O
5 None None O
gr None None O
/ None None O
day None None O
. None None O

No None None O
calcineurin None None O
inhibitor None None O
was None None O
administered None None O
. None None O

His None None O
prednisone None None O
dose None None O
was None None O
further None None O
decreased None None O
to None None O
5 None None O
mg None None O
/ None None O
day None None O
and None None O
mophetil None None O
mycophenolate None None O
doses None None O
sustained None None O
. None None O

In None None O
November None None O
2001 None None O
he None None O
developed None None O
cutaneous None None O
purple None None O
elevated None None O
lesions None None O
in None None O
his None None O
lower None None O
limbs None None O
that None None O
were None None O
diagnosed None None O
as None None O
KS None None O
by None None O
skin None None O
biopsy None None O
. None None O

He None None O
received None None O
19 None None O
administrations None None O
of None None O
vincristine None None O
( None None O
1 None None O
mg None None O
) None None O
and None None O
bleomycin None None O
( None None O
15 None None O
mg None None O
) None None O
weekly None None O
that None None O
resulted None None O
in None None O
flattening None None O
and None None O
fading None None O
of None None O
the None None O
lesions None None O
. None None O

Treatment None None O
was None None O
discontinued None None O
for None None O
two None None O
months None None O
, None None O
and None None O
KS None None O
recurred None None O
, None None O
with None None O
pain None None O
and None None O
edema None None O
in None None O
both None None O
legs None None O
. None None O

On None None O
July None None O
2002 None None O
, None None O
with None None O
an None None O
almost None None O
100 None None O
% None None O
involvement None None O
of None None O
his None None O
lower None None O
limbs None None O
skin None None O
with None None O
KS None None O
but None None O
no None None O
visceral None None O
involvement None None O
he None None O
received None None O
50 None None O
mg None None O
of None None O
liposomal None None O
- None None O
adriamycin None None O
. None None O

In None None O
addition None None O
, None None O
he None None O
was None None O
then None None O
prescribed None None O
valganciclovir None None O
450 None None O
mg None None O
BID None None O
( None None O
corrected None None O
for None None O
creatinine None None O
clearance None None O
) None None O
[ None None O
7 None None O
] None None O
and None None O
three None None O
additional None None O
administrations None None O
of None None O
liposomal None None O
- None None O
adriamycin None None O
, None None O
up None None O
to None None O
December None None O
2002 None None O
. None None O

He None None O
showed None None O
40 None None O
% None None O
response None None O
again None None O
with None None O
early None None O
relapse None None O
. None None O

On None None O
January None None O
2003 None None O
the None None O
patient None None O
developed None None O
disseminated None None O
herpes None None O
zoster None None O
, None None O
which None None O
was None None O
treated None None O
with None None O
IV None None O
acyclovir None None O
. None None O

In None None O
May None None O
2003 None None O
KS None None O
progression None None O
was None None O
observed None None O
and None None O
received None None O
radiotherapy None None O
with None None O
no None None O
benefit None None O
Figure None None O
1 None None O
. None None O

In None None O
August None None O
2003 None None O
he None None O
started None None O
oral None None O
etoposide None None O
at None None O
50 None None O
mg None None O
QD None None O
for None None O
two None None O
weeks None None O
followed None None O
by None None O
two None None O
weeks None None O
off None None O
until None None O
May None None O
2004 None None O
achieving None None O
a None None O
very None None O
slow None None O
50 None None O
% None None O
response None None O
. None None O

Tolerance None None O
was None None O
good None None O
and None None O
serum None None O
creatinine None None O
remain None None O
stable None None O
at None None O
around None None O
1 None None O
, None None O
4 None None O
mg None None O
/ None None O
dl None None O
. None None O

Mophetil None None O
mycophenolate None None O
dose None None O
was None None O
reduced None None O
to None None O
1 None None O
g None None O
/ None None O
day None None O
and None None O
prednisone None None O
to None None O
2 None None O
. None None O
5 None None O
mg None None O
/ None None O
day None None O
. None None O

Figure None None O
1 None None O

Kaposi None None O
' None None O
s None None O
sarcoma None None O
progressions None None O
after None None O
chemotherapy None None O
withdrawal None None O
, None None O
both None None O
lower None None O
limbs None None O
were None None O
completely None None O
covered None None O
with None None O
Kaposi None None O
' None None O
s None None O
Sarcoma None None O
( None None O
June None None O
2003 None None O
) None None O
. None None O

On None None O
May None None O
2004 None None O
the None None O
patient None None O
requested None None O
a None None O
second None None O
opinion None None O
and None None O
was None None O
prescribed None None O
Imatinib None None O
200 None None O
mg None None O
qd None None O
for None None O
two None None O
weeks None None O
followed None None O
by None None O
400 None None O
mg None None O
qd None None O
. None None O

After None None O
four None None O
weeks None None O
of None None O
Imatinib None None O
, None None O
his None None O
health None None O
deteriorated None None O
rapidly None None O
, None None O
he None None O
developed None None O
anasarca None None O
, None None O
worsening None None O
of None None O
KS None None O
, None None O
his None None O
serum None None O
creatinine None None O
increased None None O
from None None O
1 None None O
. None None O
4 None None O
mg None None O
/ None None O
dl None None O
to None None O
2 None None O
. None None O
3 None None O
mg None None O
/ None None O
dl None None O
and None None O
he None None O
developed None None O
grade None None O
4 None None O
granulocytopenia None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

The None None O
patient None None O
was None None O
hospitalized None None O
with None None O
fever None None O
and None None O
was None None O
started None None O
on None None O
IV None None O
antibiotics None None O
and None None O
daily None None O
G None None O
- None None O
CSF None None O
for None None O
four None None O
days None None O
after None None O
which None None O
his None None O
WBC None None O
count None None O
normalized None None O
. None None O

Two None None O
weeks None None O
later None None O
the None None O
creatinine None None O
level None None O
returned None None O
to None None O
1 None None O
. None None O
5 None None O
mg None None O
/ None None O
dl None None O
. None None O

On None None O
February None None O
2005 None None O
he None None O
was None None O
started None None O
on None None O
30 None None O
mg None None O
of None None O
paclitaxel None None O
IV None None O
every None None O
three None None O
weeks None None O
. None None O

After None None O
three None None O
courses None None O
with None None O
no None None O
clinical None None O
benefit None None O
he None None O
developed None None O
a None None O
skin None None O
rash None None O
that None None O
prompted None None O
discontinuation None None O
. None None O

Figure None None O
2 None None O

Patient None None O
developed None None O
anasarca None None O
with None None O
rapid None None O
progression None None O
of None None O
Kaposi None None O
' None None O
s None None O
Sarcoma None None O
after None None O
four None None O
weeks None None O
of None None O
taking None None O
Imatinib None None O
( None None O
June None None O
2004 None None O
) None None O
. None None O

On None None O
April None None O
2005 None None O
, None None O
he None None O
was None None O
started None None O
on None None O
Sirolimus None None O
2 None None O
mg None None O
a None None O
day None None O
, None None O
and None None O
after None None O
8 None None O
weeks None None O
escalated None None O
to None None O
4 None None O
mg None None O
a None None O
day None None O
. None None O

Three None None O
weeks None None O
later None None O
mophetil None None O
mycophenolate None None O
and None None O
prednisone None None O
were None None O
discontinued None None O
. None None O

Sustained None None O
and None None O
significant None None O
KS None None O
regression None None O
was None None O
evident None None O
after None None O
16 None None O
weeks None None O
, None None O
but None None O
he None None O
developed None None O
a None None O
basal None None O
cell None None O
carcinoma None None O
and None None O
pneumonia None None O
that None None O
required None None O
hospital None None O
admission None None O
; None None O
Sirolimus None None O
dose None None O
was None None O
lowered None None O
to None None O
2 None None O
mg None None O
a None None O
day None None O
. None None O

Thereafter None None O
his None None O
clinical None None O
course None None O
has None None O
been None None O
satisfactory None None O
with None None O
continuous None None O
and None None O
progressive None None O
regression None None O
of None None O
KS None None O
lesions None None O
( None None O
Figure None None O
3 None None O
) None None O
. None None O

His None None O
serum None None O
creatinine None None O
has None None O
remained None None O
under None None O
1 None None O
. None None O
6 None None O
mg None None O
/ None None O
dl None None O
and None None O
he None None O
has None None O
not None None O
developed None None O
new None None O
infectious None None O
episodes None None O
. None None O

Figure None None O
3 None None O

Extensive None None O
regression None None O
of None None O
Kaposi None None O
Sarcoma None None O
after None None O
immune None None O
- None None O
suppression None None O
was None None O
changed None None O
to None None O
Sirolimus None None O
, None None O
( None None O
14 None None O
months None None O
later None None O
) None None O
, None None O
he None None O
only None None O
has None None O
hyperpigmented None None O
areas None None O
at None None O
knee None None O
levels None None O
, None None O
skin None None O
looks None None O
thin None None O
and None None O
delicate None None O
and None None O
easily None None O
bruised None None O
( None None O
July None None O
2006 None None O
) None None O
. None None O

Results None None O

The None None O
set None None O
of None None O
E None None O
. None None O
coli None None O
expression None None O
vectors None None O
, None None O
encode None None O
for None None O
either None None O
a None None O
hexa None None O
- None None O
histidine None None O
tag None None O
or None None O
the None None O
three None None O
most None None O
commonly None None O
used None None O
solubility None None O
tags None None O
( None None O
GST None None O
, None None O
MBP None None O
, None None O
NusA None None O
) None None O
and None None O
all None None O
with None None O
an None None O
N None None O
- None None O
terminal None None O
hexa None None O
- None None O
histidine None None O
sequence None None O
. None None O

The None None O
result None None O
is None None O
two None None O
- None None O
fold None None O
: None None O
the None None O
His None None O
- None None O
tag None None O
facilitates None None O
purification None None O
by None None O
immobilised None None O
metal None None O
affinity None None O
chromatography None None O
, None None O
whilst None None O
the None None O
fusion None None O
domains None None O
act None None O
primarily None None O
as None None O
solubility None None O
aids None None O
during None None O
expression None None O
, None None O
in None None O
addition None None O
to None None O
providing None None O
an None None O
optional None None O
purification None None O
step None None O
. None None O

We None None O
have None None O
also None None O
incorporated None None O
a None None O
TEV None None O
recognition None None O
sequence None None O
following None None O
the None None O
solubility None None O
tag None None O
domain None None O
, None None O
which None None O
allows None None O
for None None O
highly None None O
specific None None O
cleavage None None O
( None None O
using None None O
TEV None None O
protease None None O
) None None O
of None None O
the None None O
fusion None None O
protein None None O
to None None O
yield None None O
native None None O
protein None None O
. None None O

These None None O
vectors None None O
are None None O
also None None O
designed None None O
for None None O
ligation None None O
- None None O
independent None None O
cloning None None O
and None None O
they None None O
possess None None O
a None None O
high None None O
- None None O
level None None O
expressing None None O
T7 None None O
promoter None None O
, None None O
which None None O
is None None O
suitable None None O
for None None O
auto None None O
- None None O
induction None None O
. None None O

To None None O
validate None None O
our None None O
vector None None O
system None None O
, None None O
we None None O
have None None O
cloned None None O
four None None O
different None None O
genes None None O
and None None O
also None None O
one None None O
gene None None O
into None None O
all None None O
four None None O
vectors None None O
and None None O
used None None O
small None None O
- None None O
scale None None O
expression None None O
and None None O
purification None None O
techniques None None O
. None None O

We None None O
demonstrate None None O
that None None O
the None None O
vectors None None O
are None None O
capable None None O
of None None O
high None None O
levels None None O
of None None O
expression None None O
and None None O
that None None O
efficient None None O
screening None None O
of None None O
new None None O
proteins None None O
can None None O
be None None O
readily None None O
achieved None None O
at None None O
the None None O
laboratory None None O
level None None O
. None None O

Met None None O
amplification None None O
and None None O
tumor None None O
progression None None O
in None None O
Cdkn2a None None O
- None None O
deficient None None O
melanocytes None None O
. None None O

While None None O
many None None O
genetic None None O
alterations None None O
have None None O
been None None O
identified None None O
in None None O
melanoma None None O
, None None O
the None None O
relevant None None O
molecular None None O
events None None O
that None None O
contribute None None O
to None None O
disease None None O
progression None None O
are None None O
poorly None None O
understood None None O
. None None O

Most None None O
primary None None O
human None None O
melanomas None None O
exhibit None None O
loss None None O
of None None O
expression None None O
of None None O
the None None O
CDKN2A None None O
locus None None O
in None None O
addition None None O
to None None O
activation None None O
of None None O
the None None O
canonical None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
signaling None None O
pathway None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
used None None O
a None None O
Cdkn2a None None O
- None None O
deficient None None O
mouse None None O
melanocyte None None O
cell None None O
line None None O
to None None O
screen None None O
for None None O
secondary None None O
genetic None None O
events None None O
in None None O
melanoma None None O
tumor None None O
progression None None O
. None None O

Upon None None O
investigation None None O
, None None O
intrachromosomal None None O
gene None None O
amplification None None O
of None None O
Met None None O
, None None O
a None None O
receptor None None O
tyrosine None None O
kinase None None O
implicated None None O
in None None O
melanoma None None O
progression None None O
, None None O
was None None O
identified None None O
in None None O
Cdkn2a None None O
- None None O
deficient None None O
tumors None None O
. None None O

RNA None None O
interference None None O
targeting None None O
Met None None O
in None None O
these None None O
tumor None None O
cells None None O
resulted None None O
in None None O
a None None O
significant None None O
delay None None O
in None None O
tumor None None O
growth None None O
in None None O
vivo None None O
compared None None O
with None None O
the None None O
control None None O
cells None None O
. None None O

MET None None O
expression None None O
is None None O
rarely None None O
detected None None O
in None None O
primary None None O
human None None O
melanoma None None O
but None None O
is None None O
frequently None None O
observed None None O
in None None O
metastatic None None O
disease None None O
. None None O

This None None O
study None None O
validates None None O
a None None O
role None None O
for None None O
Met None None O
activation None None O
in None None O
melanoma None None O
tumor None None O
progression None None O
in None None O
the None None O
context None None O
of None None O
Cdkn2a None None O
deficiency None None O
. None None O

AKT2 None None O
is None None O
a None None O
downstream None None O
target None None O
of None None O
metabotropic None None O
glutamate None None O
receptor None None O
1 None None O
( None None O
Grm1 None None O
) None None O
. None None O

We None None O
reported None None O
earlier None None O
on None None O
the None None O
oncogenic None None O
properties None None O
of None None O
Grm1 None None O
by None None O
demonstrating None None O
that None None O
stable None None O
Grm1 None None O
- None None O
mouse None None O
- None None O
melanocytic None None O
clones None None O
proliferate None None O
in None None O
the None None O
absence None None O
of None None O
growth None None O
supplement None None O
and None None O
anchorage None None O
in None None O
vitro None None O
. None None O

In None None O
addition None None O
, None None O
these None None O
clones None None O
also None None O
exhibit None None O
aggressive None None O
tumorigenic None None O
phenotypes None None O
in None None O
vivo None None O
with None None O
short None None O
latency None None O
in None None O
tumor None None O
formation None None O
in None None O
both None None O
immunodeficient None None O
and None None O
syngeneic None None O
mice None None O
. None None O

We None None O
also None None O
detected None None O
strong None None O
activation None None O
of None None O
AKT None None O
in None None O
allograft None None O
tumors None None O
specifically None None O
AKT2 None None O
as None None O
the None None O
predominant None None O
isoform None None O
involved None None O
. None None O

In None None O
parallel None None O
, None None O
we None None O
assessed None None O
several None None O
human None None O
melanoma None None O
biopsy None None O
samples None None O
and None None O
found None None O
again None None O
that None None O
AKT2 None None O
was None None O
the None None O
predominantly None None O
activated None None O
AKT None None O
in None None O
these None None O
human None None O
melanoma None None O
biopsies None None O
. None None O

In None None O
cultured None None O
stable None None O
Grm1 None None O
- None None O
mouse None None O
- None None O
melanocytic None None O
clones None None O
, None None O
as None None O
well None None O
as None None O
an None None O
metabotropic None None O
glutamate None None O
receptor None None O
1 None None O
( None None O
Grm1 None None O
) None None O
expressing None None O
human None None O
melanoma None None O
cell None None O
line None None O
, None None O
C8161 None None I-Cell-line-name
, None None O
stimulation None None O
of None None O
Grm1 None None O
by None None O
its None None O
agonist None None O
led None None O
to None None O
the None None O
activation None None O
of None None O
AKT None None O
, None None O
while None None O
preincubation None None O
with None None O
Grm1 None None O
- None None O
antagonist None None O
abolished None None O
Grm1 None None O
- None None O
agonist None None O
- None None O
induced None None O
AKT None None O
activation None None O
. None None O

In None None O
addition None None O
, None None O
a None None O
reduction None None O
in None None O
tumor None None O
volume None None O
of None None O
Grm1 None None O
- None None O
mouse None None O
- None None O
melanocytic None None O
- None None O
allografts None None O
was None None O
detected None None O
in None None O
the None None O
presence None None O
of None None O
small None None O
interfering None None O
AKT2 None None O
RNA None None O
( None None O
siAKT2 None None O
) None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
showed None None O
that None None O
, None None O
in None None O
addition None None O
to None None O
the None None O
MAPK None None O
pathway None None O
previously None None O
reported None None O
being None None O
a None None O
downstream None None O
target None None O
of None None O
stimulated None None O
Grm1 None None O
, None None O
AKT2 None None O
is None None O
another None None O
downstream None None O
target None None O
in None None O
Grm1 None None O
mediated None None O
melanocyte None None O
transformation None None O
. None None O

Potent None None O
antibacterial None None O
activity None None O
of None None O
Y None None O
- None None O
754 None None O
, None None O
a None None O
novel None None O
benzimidazole None None O
compound None None O
with None None O
selective None None O
action None None O
against None None O
Helicobacter None None O
pylori None None O
. None None O

Y None None O
- None None O
754 None None O
, None None O
a None None O
novel None None O
benzimidazole None None O
compound None None O
, None None O
was None None O
investigated None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
antibacterial None None O
activity None None O
. None None O

Unlike None None O
amoxicillin None None O
, None None O
clarithromycin None None O
, None None O
and None None O
metronidazole None None O
, None None O
the None None O
compound None None O
had None None O
no None None O
activity None None O
against None None O
common None None O
aerobic None None O
and None None O
anaerobic None None O
bacteria None None O
other None None O
than None None O
Helicobacter None None O
pylori None None O
. None None O

The None None O
minimum None None O
inhibitory None None O
concentration None None O
of None None O
Y None None O
- None None O
754 None None O
against None None O
H None None O
. None None O
pylori None None O
, None None O
at None None O
0 None None O
. None None O
025 None None O
microg None None O
/ None None O
ml None None O
, None None O
was None None O
nearly None None O
equal None None O
to None None O
that None None O
of None None O
amoxicillin None None O
and None None O
clarithromycin None None O
. None None O

The None None O
respective None None O
concentrations None None O
of None None O
Y None None O
- None None O
754 None None O
, None None O
amoxicillin None None O
, None None O
clarithromycin None None O
, None None O
and None None O
metronidazole None None O
required None None O
to None None O
inhibit None None O
90 None None O
% None None O
of None None O
39 None None O
isolates None None O
of None None O
H None None O
. None None O
pylori None None O
were None None O
0 None None O
. None None O
05 None None O
, None None O
0 None None O
. None None O
39 None None O
, None None O
6 None None O
. None None O
25 None None O
, None None O
and None None O
25 None None O
microg None None O
/ None None O
ml None None O
, None None O
indicating None None O
the None None O
potent None None O
activity None None O
of None None O
Y None None O
- None None O
754 None None O
, None None O
including None None O
activity None None O
against None None O
clarithromycin None None O
- None None O
and None None O
metronidazole None None O
- None None O
resistant None None O
strains None None O
. None None O

The None None O
anti None None O
- None None O
H None None O
. None None O
pylori None None O
activity None None O
of None None O
Y None None O
- None None O
754 None None O
was None None O
potent None None O
even None None O
at None None O
pH None None O
5 None None O
. None None O
5 None None O
and None None O
was None None O
bactericidal None None O
at None None O
concentrations None None O
of None None O
0 None None O
. None None O
1 None None O
microg None None O
/ None None O
ml None None O
and None None O
above None None O
. None None O

Exposure None None O
of None None O
H None None O
. None None O
pylori None None O
to None None O
Y None None O
- None None O
754 None None O
did None None O
not None None O
result None None O
in None None O
the None None O
induction None None O
of None None O
drug None None O
- None None O
resistant None None O
mutation None None O
. None None O

Oral None None O
administration None None O
( None None O
10 None None O
mg None None O
/ None None O
kg None None O
twice None None O
a None None O
day None None O
for None None O
7 None None O
days None None O
) None None O
to None None O
Mongolian None None O
gerbils None None O
infected None None O
with None None O
strain None None O
ATCC None None O
43504 None None O
demonstrated None None O
that None None O
Y None None O
- None None O
754 None None O
was None None O
effective None None O
in None None O
H None None O
. None None O
pylori None None O
eradication None None O
and None None O
that None None O
its None None O
eradication None None O
efficacy None None O
increased None None O
in None None O
line None None O
with None None O
the None None O
progress None None O
of None None O
damage None None O
to None None O
the None None O
gastric None None O
mucosa None None O
caused None None O
by None None O
H None None O
. None None O
pylori None None O
infection None None O
. None None O

Y None None O
- None None O
754 None None O
was None None O
also None None O
efficacious None None O
in None None O
the None None O
treatment None None O
of None None O
infection None None O
by None None O
the None None O
clarithromycin None None O
- None None O
resistant None None O
strain None None O
OIT None None O
- None None O
36 None None O
. None None O

The None None O
results None None O
obtained None None O
lead None None O
to None None O
the None None O
expectation None None O
that None None O
the None None O
new None None O
benzimidazole None None O
Y None None O
- None None O
754 None None O
will None None O
, None None O
in None None O
the None None O
near None None O
future None None O
, None None O
be None None O
used None None O
for None None O
H None None O
. None None O
pylori None None O
eradication None None O
therapy None None O
in None None O
peptic None None O
ulcer None None O
patients None None O
. None None O

Selective None None O
inhibition None None O
of None None O
nuclear None None O
factor None None O
- None None O
kappaB None None O
by None None O
nuclear None None O
factor None None O
- None None O
kappaB None None O
essential None None O
modulator None None O
- None None O
binding None None O
domain None None O
peptide None None O
suppresses None None O
the None None O
metastasis None None O
of None None O
highly None None O
metastatic None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Nuclear None None O
factor None None O
- None None O
kappaB None None O
( None None O
NF None None O
- None None O
kappaB None None O
) None None O
activation None None O
contributes None None O
to None None O
the None None O
development None None O
of None None O
metastasis None None O
, None None O
thus None None O
leading None None O
to None None O
a None None O
poor None None O
prognosis None None O
in None None O
many None None O
cancers None None O
, None None O
including None None O
OSCC None None O
. None None O

However None None O
, None None O
little None None O
in None None O
vivo None None O
experimental None None O
data None None O
are None None O
available None None O
about None None O
the None None O
effects None None O
of None None O
NF None None O
- None None O
kappaB None None O
inhibition None None O
on None None O
OSCC None None O
metastasis None None O
. None None O

OSCC None None I-Cell-line-name
sublines None None O
were None None O
established None None O
from None None O
a None None O
GFP None None O
- None None O
expressing None None O
parental None None O
cell None None O
line None None O
, None None O
GSAS None None I-Cell-line-name
, None None O
and None None O
designated None None O
GSAS None None I-Cell-line-name
/ None None O
N3 None None O
and None None O
N5 None None O
according None None O
to None None O
the None None O
in None None O
vivo None None O
passage None None O
number None None O
after None None O
cervical None None O
lymph None None O
node None None O
metastasis None None O
by None None O
a None None O
serial None None O
orthotopic None None O
transplantation None None O
model None None O
. None None O

In None None O
vitro None None O
migration None None O
and None None O
invasion None None O
were None None O
assessed None None O
in None None O
these None None O
cells None None O
, None None O
and None None O
the None None O
NF None None O
- None None O
kappaB None None O
activities None None O
and None None O
expression None None O
of None None O
NF None None O
- None None O
kappaB None None O
- None None O
regulated None None O
metastasis None None O
- None None O
related None None O
molecules None None O
were None None O
also None None O
examined None None O
. None None O

In None None O
in None None O
vivo None None O
experiments None None O
, None None O
the None None O
metastasis None None O
and None None O
survival None None O
of None None O
tumor None None O
- None None O
engrafted None None O
mice None None O
were None None O
monitored None None O
. None None O

Furthermore None None O
, None None O
the None None O
effects None None O
of None None O
a None None O
selective None None O
NF None None O
- None None O
kappaB None None O
inhibitor None None O
, None None O
NEMO None None O
- None None O
binding None None O
domain None None O
( None None O
NBD None None O
) None None O
peptide None None O
, None None O
on None None O
metastasis None None O
in None None O
GSAS None None I-Cell-line-name
/ None None O
N5 None None O
- None None O
engrafted None None O
mice None None O
were None None O
assessed None None O
, None None O
and None None O
engrafted None None O
tongue None None O
tumors None None O
were None None O
immunohistochemically None None O
examined None None O
. None None O

Highly None None O
metastatic None None O
GSAS None None I-Cell-line-name
/ None None O
N3 None None O
and None None O
N5 None None O
cells None None O
showed None None O
an None None O
enhanced None None O
NF None None O
- None None O
kappaB None None O
activity None None O
, None None O
thus None None O
contributing None None O
to None None O
increased None None O
migration None None O
, None None O
invasion None None O
, None None O
and None None O
a None None O
poor None None O
prognosis None None O
compared None None O
with None None O
the None None O
parent None None O
cells None None O
. None None O

Furthermore None None O
, None None O
the None None O
expression None None O
levels None None O
of None None O
NF None None O
- None None O
kappaB None None O
- None None O
regulated None None O
metastasis None None O
- None None O
related None None O
molecules None None O
, None None O
such None None O
as None None O
fibronectin None None O
, None None O
beta1 None None O
integrin None None O
, None None O
MMP None None O
- None None O
1 None None O
, None None O
- None None O
2 None None O
, None None O
- None None O
9 None None O
, None None O
and None None O
- None None O
14 None None O
, None None O
and None None O
VEGF None None O
- None None O
C None None O
, None None O
were None None O
upregulated None None O
in None None O
the None None O
highly None None O
metastatic None None O
cells None None O
. None None O

The None None O
NBD None None O
peptide None None O
suppressed None None O
metastasis None None O
and None None O
tongue None None O
tumor None None O
growth None None O
in None None O
GSAS None None I-Cell-line-name
/ None None O
N5 None None O
- None None O
inoculated None None O
mice None None O
, None None O
and None None O
was None None O
accompanied None None O
by None None O
the None None O
downregulation None None O
of None None O
the None None O
NF None None O
- None None O
kappaB None None O
- None None O
regulated None None O
metastasis None None O
- None None O
related None None O
molecules None None O
in None None O
engrafted None None O
tongue None None O
tumors None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
the None None O
selective None None O
inhibition None None O
of None None O
NF None None O
- None None O
kappaB None None O
activation None None O
by None None O
NBD None None O
peptide None None O
may None None O
provide None None O
an None None O
effective None None O
approach None None O
for None None O
the None None O
treatment None None O
of None None O
highly None None O
metastatic None None O
OSCC None None O
. None None O

Assembly None None O
strategies None None O
and None None O
GTPase None None O
regulation None None O
of None None O
the None None O
eukaryotic None None O
and None None O
Escherichia None None O
coil None None O
translocons None None O
. None None O

The None None O
translocation None None O
of None None O
most None None O
proteins None None O
across None None O
the None None O
endoplasmic None None O
reticulum None None O
or None None O
bacterial None None O
inner None None O
membrane None None O
occurs None None O
through None None O
an None None O
aqueous None None O
pore None None O
that None None O
spans None None O
the None None O
membrane None None O
. None None O

Substrates None None O
that None None O
are None None O
translocated None None O
co None None O
- None None O
translationally None None O
across None None O
the None None O
membrane None None O
are None None O
directed None None O
to None None O
the None None O
translocation None None O
pore None None O
via None None O
an None None O
interaction None None O
between None None O
the None None O
cytosolic None None O
signal None None O
recognition None None O
particle None None O
and None None O
its None None O
membrane None None O
- None None O
bound None None O
receptor None None O
. None None O

Together None None O
the None None O
translocation None None O
pore None None O
and None None O
the None None O
receptor None None O
are None None O
referred None None O
to None None O
as None None O
a None None O
translocon None None O
. None None O

By None None O
studying None None O
the None None O
biogenesis None None O
of None None O
the None None O
translocon None None O
a None None O
number None None O
of None None O
alternate None None O
targeting None None O
and None None O
membrane None None O
- None None O
integration None None O
pathways None None O
have None None O
been None None O
discovered None None O
that None None O
operate None None O
independently None None O
of None None O
the None None O
signal None None O
recognition None None O
particle None None O
( None None O
SRP None None O
) None None O
pathway None None O
. None None O

The None None O
novel None None O
assembly None None O
strategies None None O
of None None O
the None None O
translocon None None O
and None None O
the None None O
ways None None O
in None None O
which None None O
these None None O
components None None O
interact None None O
to None None O
ensure None None O
the None None O
fidelity None None O
and None None O
unidirectionality None None O
of None None O
the None None O
targeting None None O
and None None O
translocation None None O
process None None O
are None None O
reviewed None None O
here None None O
. None None O

Acknowledgements None None O

The None None O
authors None None O
gratefully None None O
acknowledge None None O
the None None O
support None None O
of None None O
DRUID None None O
study None None O
participants None None O
, None None O
study None None O
staff None None O
, None None O
members None None O
of None None O
the None None O
Indigenous None None O
Steering None None O
Group None None O
, None None O
and None None O
partner None None O
organisations None None O
. None None O

The None None O
DRUID None None O
Study None None O
was None None O
funded None None O
by None None O
the None None O
National None None O
Health None None O
and None None O
Medical None None O
Research None None O
Council None None O
( None None O
NHMRC None None O
Project None None O
Grant None None O
# None None O
236207 None None O
) None None O
, None None O
with None None O
additional None None O
support None None O
from None None O
the None None O
Australian None None O
Government None None O
Department None None O
of None None O
Employment None None O
and None None O
Workplace None None O
Relations None None O
, None None O
the None None O
Clive None None O
and None None O
Vera None None O
Ramaciotti None None O
Foundation None None O
, None None O
the None None O
Vincent None None O
Fairfax None None O
Family None None O
Foundation None None O
, None None O
the None None O
International None None O
Diabetes None None O
Institute None None O
( None None O
AusDiab None None O
Partnership None None O
) None None O
, None None O
and None None O
Bayer None None O
HealthCare None None O
. None None O

The None None O
DRUID None None O
Study None None O
is None None O
an None None O
in None None O
- None None O
kind None None O
project None None O
of None None O
the None None O
Cooperative None None O
Research None None O
Centre None None O
for None None O
Aboriginal None None O
Health None None O
. None None O

LMB None None O
had None None O
a None None O
NHMRC None None O
Scholarship None None O
2003 None None O
- None None O
5 None None O
and None None O
is None None O
supported None None O
by None None O
NHMRC None None O
Training None None O
Fellowship None None O
( None None O
# None None O
605837 None None O
) None None O
, None None O
NHMRC None None O
# None None O
320860 None None O
and None None O
the None None O
Centre None None O
of None None O
Clinical None None O
Research None None O
Excellence None None O
in None None O
Clinical None None O
Science None None O
in None None O
Diabetes None None O
, None None O
University None None O
of None None O
Melbourne None None O
. None None O

JC None None O
was None None O
supported None None O
by None None O
a None None O
NHMRC None None O
Career None None O
Development None None O
Award None None O
( None None O
# None None O
283310 None None O
) None None O
and None None O
a None None O
NHMRC None None O
Research None None O
Fellowship None None O
( None None O
# None None O
545200 None None O
) None None O
. None None O

AH None None O
is None None O
supported None None O
by None None O
NHMRC None None O
Fellowship None None O
( None None O
# None None O
520316 None None O
) None None O
. None None O

Thank None None O
you None None O
to None None O
Dr None None O
Jaquelyne None None O
Hughes None None O
for None None O
comments None None O
on None None O
the None None O
manuscript None None O
. None None O

Funding None None O
sources None None O
played None None O
no None None O
role None None O
in None None O
the None None O
study None None O
design None None O
, None None O
in None None O
the None None O
collection None None O
, None None O
analysis None None O
and None None O
interpretation None None O
of None None O
the None None O
data None None O
, None None O
in None None O
the None None O
writing None None O
of None None O
the None None O
manuscript None None O
, None None O
or None None O
in None None O
the None None O
decision None None O
to None None O
submit None None O
the None None O
manuscript None None O
for None None O
publication None None O
. None None O

Time None None O
course None None O
of None None O
transmitter None None O
action None None O
at None None O
the None None O
sympathetic None None O
neuroeffector None None O
junction None None O
in None None O
rodent None None O
vascular None None O
and None None O
non None None O
- None None O
vascular None None O
smooth None None O
muscle None None O
. None None O

1 None None O
. None None O

Transmitter None None O
release None None O
from None None O
sympathetic None None O
postganglionic None None O
nerve None None O
terminals None None O
innervating None None O
the None None O
guinea None None O
- None None O
pig None None O
and None None O
mouse None None O
vas None None O
deferens None None O
and None None O
the None None O
rat None None O
tail None None O
artery None None O
has None None O
been None None O
studied None None O
in None None O
vitro None None O
by None None O
focal None None O
extracellular None None O
recording None None O
with None None O
particular None None O
emphasis None None O
on None None O
the None None O
time None None O
course None None O
of None None O
transmitter None None O
action None None O
underlying None None O
the None None O
intracellular None None O
potential None None O
changes None None O
. None None O

2 None None O
. None None O

In None None O
the None None O
absence None None O
of None None O
stimulation None None O
, None None O
spontaneous None None O
excitatory None None O
junction None None O
currents None None O
( None None O
SEJCs None None O
) None None O
were None None O
recorded None None O
with None None O
amplitudes None None O
up None None O
to None None O
500 None None O
microV None None O
and None None O
durations None None O
between None None O
40 None None O
and None None O
100 None None O
ms None None O
. None None O

SEJCs None None O
were None None O
unaffected None None O
by None None O
the None None O
competitive None None O
alpha None None O
- None None O
adrenoceptor None None O
antagonist None None O
prazosin None None O
but None None O
blocked None None O
by None None O
alpha None None O
, None None O
beta None None O
- None None O
methylene None None O
ATP None None O
which None None O
desensitizes None None O
P2 None None O
- None None O
purinoceptors None None O
. None None O

3 None None O
. None None O

During None None O
trains None None O
of None None O
supramaximal None None O
stimuli None None O
at None None O
0 None None O
. None None O
1 None None O
- None None O
4 None None O
Hz None None O
stimulus None None O
locked None None O
excitatory None None O
junction None None O
currents None None O
( None None O
EJCs None None O
) None None O
were None None O
evoked None None O
intermittently None None O
from None None O
the None None O
population None None O
of None None O
varicosities None None O
located None None O
under None None O
the None None O
suction None None O
electrode None None O
. None None O

4 None None O
. None None O

SEJCs None None O
were None None O
similar None None O
in None None O
amplitude None None O
and None None O
time None None O
course None None O
to None None O
EJCs None None O
evoked None None O
by None None O
low None None O
- None None O
frequency None None O
stimulation None None O
in None None O
the None None O
same None None O
attachment None None O
in None None O
all None None O
three None None O
tissues None None O
. None None O

5 None None O
. None None O

SEJCs None None O
recorded None None O
using None None O
either None None O
a None None O
conventional None None O
AC None None O
amplifier None None O
or None None O
a None None O
patch None None O
clamp None None O
amplifier None None O
had None None O
the None None O
same None None O
time None None O
course None None O
. None None O

6 None None O
. None None O

These None None O
studies None None O
show None None O
that None None O
the None None O
time None None O
course None None O
of None None O
the None None O
current None None O
underlying None None O
the None None O
excitatory None None O
junction None None O
potential None None O
is None None O
brief None None O
and None None O
essentially None None O
the None None O
same None None O
in None None O
three None None O
different None None O
tissues None None O
. None None O

The None None O
prolonged None None O
time None None O
course None None O
of None None O
the None None O
excitatory None None O
junction None None O
potential None None O
in None None O
different None None O
tissues None None O
can None None O
be None None O
accounted None None O
for None None O
by None None O
the None None O
passive None None O
membrane None None O
properties None None O
. None None O

The None None O
semaphorin None None O
7A None None O
receptor None None O
Plexin None None O
C1 None None O
is None None O
lost None None O
during None None O
melanoma None None O
metastasis None None O
. None None O

The None None O
transformation None None O
of None None O
normal None None O
melanocytes None None O
, None None O
or None None O
melanocyte None None O
stem None None O
cells None None O
, None None O
to None None O
melanoma None None O
, None None O
is None None O
a None None O
complex None None O
process None None O
involving None None O
multiple None None O
mechanisms None None O
. None None O

Loss None None O
of None None O
tumor None None O
suppressor None None O
proteins None None O
, None None O
which None None O
function None None O
as None None O
brakes None None O
on None None O
cell None None O
growth None None O
, None None O
migration None None O
, None None O
or None None O
cell None None O
survival None None O
, None None O
was None None O
recognized None None O
early None None O
on None None O
as None None O
an None None O
important None None O
mechanism None None O
for None None O
initiation None None O
and None None O
progression None None O
of None None O
melanoma None None O
. None None O

Semaphorins None None O
and None None O
their None None O
cognate None None O
receptors None None O
, None None O
Plexins None None O
and None None O
neuropilins None None O
, None None O
are None None O
involved None None O
in None None O
neuronal None None O
pathfinding None None O
, None None O
immune None None O
function None None O
, None None O
and None None O
tumor None None O
progression None None O
through None None O
effects None None O
on None None O
blood None None O
vessel None None O
growth None None O
and None None O
cell None None O
migration None None O
. None None O

Semaphorin None None O
7A None None O
( None None O
Sema7A None None O
) None None O
is None None O
a None None O
membrane None None O
- None None O
linked None None O
semaphorin None None O
that None None O
is None None O
expressed None None O
by None None O
human None None O
keratinocytes None None O
, None None O
and None None O
we None None O
have None None O
shown None None O
that None None O
Sema7A None None O
binds None None O
to None None O
human None None O
melanocytes None None O
through None None O
beta1 None None O
- None None O
integrins None None O
and None None O
the None None O
Plexin None None O
C1 None None O
receptor None None O
. None None O

Functional None None O
studies None None O
showed None None O
that None None O
Sema7A None None O
stimulates None None O
cytoskeletal None None O
reorganization None None O
in None None O
human None None O
melanocytes None None O
, None None O
resulting None None O
in None None O
adhesion None None O
and None None O
dendrite None None O
formation None None O
. None None O

Downstream None None O
targets None None O
of None None O
Plexin None None O
C1 None None O
signaling None None O
in None None O
human None None O
melanocytes None None O
include None None O
cofilin None None O
and None None O
LIM None None O
kinase None None O
II None None O
, None None O
both None None O
of None None O
which None None O
are None None O
critical None None O
mediators None None O
of None None O
cell None None O
adhesion None None O
and None None O
migration None None O
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
analyzed None None O
the None None O
expression None None O
of None None O
Plexin None None O
C1 None None O
using None None O
immunohistochemistry None None O
on None None O
sections None None O
of None None O
primary None None O
and None None O
matched None None O
metastatic None None O
lesions None None O
from None None O
19 None None O
subjects None None O
and None None O
in None None O
a None None O
large None None O
melanoma None None O
tumor None None O
microarray None None O
. None None O

Our None None O
data None None O
show None None O
a None None O
significant None None O
loss None None O
of None None O
Plexin None None O
C1 None None O
in None None O
metastatic None None O
melanoma None None O
compared None None O
with None None O
primary None None O
melanoma None None O
, None None O
suggesting None None O
the None None O
possibility None None O
that None None O
the None None O
Plexin None None O
C1 None None O
receptor None None O
is None None O
a None None O
tumor None None O
suppressor None None O
protein None None O
for None None O
melanoma None None O
. None None O

Genuine None None O
monovalent None None O
ligands None None O
of None None O
TrkA None None O
nerve None None O
growth None None O
factor None None O
receptors None None O
reveal None None O
a None None O
novel None None O
pharmacological None None O
mechanism None None O
of None None O
action None None O
. None None O

Developing None None O
small None None O
molecule None None O
agonistic None None O
ligands None None O
for None None O
tyrosine None None O
kinase None None O
receptors None None O
has None None O
been None None O
difficult None None O
, None None O
and None None O
it None None O
is None None O
generally None None O
thought None None O
that None None O
such None None O
ligands None None O
require None None O
bivalency None None O
. None None O

Moreover None None O
, None None O
multisubunit None None O
receptors None None O
are None None O
difficult None None O
to None None O
target None None O
, None None O
because None None O
each None None O
subunit None None O
contributes None None O
to None None O
ligand None None O
affinity None None O
, None None O
and None None O
each None None O
subunit None None O
may None None O
have None None O
distinct None None O
and None None O
sometimes None None O
opposing None None O
functions None None O
. None None O

Here None None O
, None None O
the None None O
nerve None None O
growth None None O
factor None None O
receptor None None O
subunits None None O
p75 None None O
and None None O
the None None O
tyrosine None None O
kinase None None O
TrkA None None O
were None None O
studied None None O
using None None O
artificial None None O
ligands None None O
that None None O
bind None None O
specifically None None O
to None None O
their None None O
extracellular None None O
domain None None O
. None None O

Bivalent None None O
TrkA None None O
ligands None None O
afford None None O
robust None None O
signals None None O
. None None O

However None None O
, None None O
genuine None None O
monomeric None None O
and None None O
monovalent None None O
TrkA None None O
ligands None None O
afford None None O
partial None None O
agonism None None O
, None None O
activate None None O
the None None O
tyrosine None None O
kinase None None O
activity None None O
, None None O
cause None None O
receptor None None O
internalization None None O
, None None O
and None None O
induce None None O
survival None None O
and None None O
differentiation None None O
in None None O
cell None None O
lines None None O
and None None O
primary None None O
neurons None None O
. None None O

Monomeric None None O
and None None O
monovalent None None O
TrkA None None O
ligands None None O
can None None O
synergize None None O
with None None O
ligands None None O
that None None O
bind None None O
the None None O
p75 None None O
subunit None None O
. None None O

However None None O
, None None O
the None None O
p75 None None O
ligands None None O
used None None O
in None None O
this None None O
study None None O
must None None O
be None None O
bivalent None None O
, None None O
and None None O
monovalent None None O
p75 None None O
ligands None None O
have None None O
no None None O
effect None None O
. None None O

These None None O
findings None None O
will None None O
be None None O
useful None None O
in None None O
designing None None O
and None None O
developing None None O
screens None None O
of None None O
small None None O
molecules None None O
selective None None O
for None None O
tyrosine None None O
kinase None None O
receptors None None O
and None None O
indicate None None O
that None None O
strategies None None O
for None None O
designing None None O
agonists None None O
of None None O
multisubunit None None O
receptors None None O
require None None O
consideration None None O
of None None O
the None None O
role None None O
of None None O
each None None O
subunit None None O
. None None O

Last None None O
, None None O
the None None O
strategy None None O
of None None O
using None None O
anti None None O
- None None O
receptor None None O
mAbs None None O
and None None O
small None None O
molecule None None O
hormone None None O
mimics None None O
as None None O
receptor None None O
ligands None None O
could None None O
be None None O
applied None None O
to None None O
the None None O
study None None O
of None None O
many None None O
other None None O
heteromeric None None O
cell None None O
surface None None O
receptors None None O
. None None O

Treatment None None O
for None None O
patients None None O
with None None O
diabetes None None O

It None None O
is None None O
notable None None O
that None None O
treatment None None O
of None None O
diabetes None None O
has None None O
not None None O
been None None O
directly None None O
monitored None None O
by None None O
OECD None None O
indicators None None O
, None None O
largely None None O
due None None O
to None None O
complexity None None O
in None None O
data None None O
collection None None O
. None None O

Treatment None None O
is None None O
tailored None None O
for None None O
individuals None None O
depending None None O
on None None O
the None None O
patient None None O
' None None O
s None None O
disease None None O
status None None O
, None None O
and None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
diabetes None None O
management None None O
. None None O

Clinical None None O
trials None None O
have None None O
found None None O
that None None O
a None None O
one None None O
percentage None None O
point None None O
reduction None None O
in None None O
HbA1c None None O
levels None None O
would None None O
reduce None None O
micro None None O
- None None O
vascular None None O
complications None None O
by None None O
25 None None O
% None None O
to None None O
30 None None O
% None None O
[ None None O
49 None None O
, None None O
50 None None O
] None None O
and None None O
a None None O
10 None None O
mmHg None None O
reduction None None O
in None None O
blood None None O
pressure None None O
would None None O
decrease None None O
macro None None O
- None None O
and None None O
micro None None O
- None None O
vascular None None O
complications None None O
and None None O
death None None O
rates None None O
by None None O
32 None None O
% None None O
[ None None O
51 None None O
] None None O
. None None O

Improved None None O
control None None O
of None None O
blood None None O
lipids None None O
can None None O
reduce None None O
risk None None O
of None None O
coronary None None O
heart None None O
disease None None O
by None None O
39 None None O
% None None O
and None None O
risk None None O
of None None O
death None None O
by None None O
43 None None O
% None None O
[ None None O
52 None None O
] None None O
. None None O

RAND None None O
' None None O
s None None O
Quality None None O
Assessment None None O
Tools None None O
System None None O
offers None None O
indicators None None O
relating None None O
to None None O
diabetes None None O
treatment None None O
[ None None O
53 None None O
] None None O
, None None O
and None None O
application None None O
of None None O
these None None O
indicators None None O
in None None O
a None None O
national None None O
study None None O
in None None O
the None None O
US None None O
has None None O
provided None None O
insight None None O
into None None O
adherence None None O
to None None O
recommended None None O
treatment None None O
regimens None None O
. None None O

For None None O
people None None O
with None None O
newly None None O
diagnosed None None O
diabetes None None O
56 None None O
% None None O
received None None O
dietary None None O
and None None O
exercise None None O
counselling None None O
. None None O

In None None O
type None None O
2 None None O
diabetes None None O
patients None None O
, None None O
use None None O
of None None O
oral None None O
hypoglycaemic None None O
agents None None O
for None None O
those None None O
inadequately None None O
controlled None None O
on None None O
dietary None None O
therapy None None O
was None None O
38 None None O
% None None O
and None None O
use None None O
of None None O
insulin None None O
for None None O
those None None O
inadequately None None O
controlled None None O
on None None O
oral None None O
hypoglycaemics None None O
was None None O
39 None None O
% None None O
. None None O

Fifty None None O
- None None O
five None None O
percent None None O
of None None O
diabetics None None O
were None None O
offered None None O
an None None O
ACE None None O
inhibitor None None O
within None None O
3 None None O
months None None O
of None None O
the None None O
notation None None O
of None None O
proteinuria None None O
unless None None O
contraindicated None None O
. None None O

The None None O
AusDiab None None O
study None None O
reported None None O
the None None O
treatment None None O
pattern None None O
among None None O
Australian None None O
adults None None O
with None None O
type None None O
2 None None O
diabetes None None O
[ None None O
37 None None O
] None None O
. None None O

While None None O
32 None None O
% None None O
of None None O
diabetes None None O
patients None None O
were None None O
on None None O
diet None None O
regimen None None O
only None None O
, None None O
58 None None O
% None None O
used None None O
oral None None O
hypoglycaemic None None O
agents None None O
and None None O
diet None None O
only None None O
, None None O
and None None O
another None None O
10 None None O
% None None O
took None None O
insulin None None O
. None None O

Bailie None None O
and None None O
colleagues None None O
reported None None O
pharmaceutical None None O
interventions None None O
for None None O
diabetes None None O
patients None None O
in None None O
remote None None O
Aboriginal None None O
communities None None O
in None None O
the None None O
Northern None None O
Territory None None O
[ None None O
54 None None O
] None None O
. None None O

During None None O
the None None O
3 None None O
- None None O
years None None O
study None None O
period None None O
, None None O
75 None None O
- None None O
79 None None O
% None None O
of None None O
Aboriginal None None O
patients None None O
took None None O
oral None None O
hypoglycaemic None None O
agents None None O
, None None O
and None None O
4 None None O
- None None O
7 None None O
% None None O
used None None O
insulin None None O
. None None O

Appetite None None O
regulation None None O
by None None O
serotoninergic None None O
mechanisms None None O
and None None O
effects None None O
of None None O
d None None O
- None None O
fenfluramine None None O
. None None O

In None None O
this None None O
literature None None O
review None None O
, None None O
evidence None None O
is None None O
presented None None O
for None None O
the None None O
theory None None O
that None None O
the None None O
neurotransmitter None None O
, None None O
serotonin None None O
( None None O
5 None None O
- None None O
hydroxytryptamine None None O
, None None O
5HT None None O
) None None O
, None None O
in None None O
medial None None O
hypothalamic None None O
centres None None O
is None None O
an None None O
important None None O
regulator None None O
for None None O
appetite None None O
and None None O
for None None O
the None None O
selection None None O
of None None O
major None None O
food None None O
constituents None None O
. None None O

High None None O
local None None O
levels None None O
of None None O
5HT None None O
cause None None O
a None None O
reduction None None O
of None None O
appetite None None O
and None None O
a None None O
preference None None O
for None None O
protein None None O
, None None O
low None None O
levels None None O
the None None O
opposite None None O
. None None O

The None None O
main None None O
antagonistic None None O
system None None O
is None None O
noradrenergic None None O
. None None O

The None None O
drug None None O
d None None O
- None None O
fenfluramine None None O
mimics None None O
the None None O
effects None None O
of None None O
5HT None None O
by None None O
releasing None None O
5HT None None O
from None None O
serotoninergic None None O
nerve None None O
endings None None O
and None None O
inhibiting None None O
its None None O
neuronal None None O
re None None O
- None None O
uptake None None O
. None None O

Further None None O
experimental None None O
data None None O
prove None None O
that None None O
a None None O
high None None O
- None None O
carbohydrate None None O
, None None O
low None None O
- None None O
protein None None O
diet None None O
promotes None None O
uptake None None O
of None None O
serum None None O
tryptophan None None O
in None None O
the None None O
brain None None O
and None None O
its None None O
conversion None None O
into None None O
5HT None None O
. None None O

Hence None None O
, None None O
this None None O
serotoninergic None None O
system None None O
may None None O
function None None O
as None None O
a None None O
self None None O
- None None O
regulatory None None O
mechanism None None O
. None None O

In None None O
patients None None O
with None None O
decreased None None O
peripheral None None O
insulin None None O
sensitivity None None O
, None None O
the None None O
system None None O
may None None O
be None None O
disturbed None None O
, None None O
causing None None O
overconsumption None None O
of None None O
carbohydrates None None O
. None None O

This None None O
is None None O
sometimes None None O
compulsive None None O
( None None O
" None None O
carbohydrate None None O
craving None None O
" None None O
) None None O
. None None O

It None None O
may None None O
be None None O
presumed None None O
that None None O
in None None O
the None None O
treatment None None O
of None None O
obesity None None O
, None None O
in None None O
addition None None O
to None None O
the None None O
use None None O
of None None O
serotoninergic None None O
drugs None None O
, None None O
successes None None O
with None None O
reducing None None O
diets None None O
may None None O
be None None O
enhanced None None O
by None None O
including None None O
periods None None O
of None None O
high None None O
- None None O
carbohydrate None None O
, None None O
low None None O
- None None O
protein None None O
intake None None O
. None None O

It None None O
would None None O
be None None O
worthwhile None None O
to None None O
explore None None O
whether None None O
similar None None O
alimentary None None O
self None None O
- None None O
regulatory None None O
mechanisms None None O
of None None O
neurotransmitter None None O
function None None O
exist None None O
in None None O
other None None O
regulatory None None O
systems None None O
. None None O

Changes None None O
of None None O
lymphocyte None None O
subsets None None O
in None None O
leukemia None None O
patients None None O
who None None O
received None None O
allogenic None None O
bone None None O
marrow None None O
transplantation None None O
. None None O

Proportional None None O
changes None None O
of None None O
lymphocyte None None O
subsets None None O
in None None O
the None None O
peripheral None None O
blood None None O
were None None O
monitored None None O
by None None O
two None None O
- None None O
color None None O
flow None None O
- None None O
cytometry None None O
in None None O
seven None None O
leukemia None None O
patients None None O
who None None O
had None None O
received None None O
allogenic None None O
bone None None O
marrow None None O
transplantation None None O
( None None O
BMT None None O
) None None O
. None None O

Lymphocyte None None O
counts None None O
, None None O
and None None O
proportions None None O
of None None O
T None None O
and None None O
B None None O
- None None O
cells None None O
returned None None O
to None None O
normal None None O
ranges None None O
between None None O
the None None O
2nd None None O
and None None O
12th None None O
months None None O
after None None O
BMT None None O
. None None O

Activated None None O
T None None O
- None None O
cells None None O
prominently None None O
increased None None O
after None None O
BMT None None O
, None None O
and None None O
the None None O
values None None O
gradually None None O
returned None None O
toward None None O
normal None None O
. None None O

As None None O
to None None O
lymphocyte None None O
subsets None None O
, None None O
the None None O
proportions None None O
of None None O
CD None None O
4 None None O
+ None None O
cells None None O
had None None O
remained None None O
low None None O
, None None O
while None None O
those None None O
of None None O
CD None None O
8 None None O
+ None None O
cells None None O
high None None O
for None None O
a None None O
whole None None O
observation None None O
period None None O
after None None O
BMT None None O
. None None O

The None None O
changes None None O
of None None O
CD None None O
4 None None O
+ None None O
cells None None O
were None None O
caused None None O
by None None O
the None None O
decrease None None O
of None None O
suppressor None None O
- None None O
inducer None None O
T None None O
- None None O
cells None None O
( None None O
CD None None O
4 None None O
+ None None O
Leu None None O
8 None None O
+ None None O
) None None O
. None None O

High None None O
proportion None None O
of None None O
CD None None O
8 None None O
+ None None O
cells None None O
was None None O
mainly None None O
associated None None O
with None None O
increased None None O
suppressor None None O
T None None O
- None None O
cells None None O
( None None O
CD None None O
8 None None O
+ None None O
CD None None O
11 None None O
+ None None O
) None None O
. None None O

Among None None O
natural None None O
killer None None O
( None None O
NK None None O
) None None O
cells None None O
, None None O
highly None None O
active None None O
NK None None O
cells None None O
( None None O
CD None None O
16 None None O
+ None None O
CD None None O
57 None None O
- None None O
) None None O
markedly None None O
increased None None O
shortly None None O
after None None O
BMT None None O
, None None O
and None None O
gradually None None O
returned None None O
to None None O
normal None None O
. None None O

CD None None O
16 None None O
- None None O
CD None None O
57 None None O
+ None None O
NK None None O
cells None None O
increased None None O
beyond None None O
normal None None O
ranges None None O
after None None O
the None None O
2nd None None O
month None None O
. None None O

The None None O
incidence None None O
or None None O
degree None None O
of None None O
acute None None O
and None None O
chronic None None O
graft None None O
- None None O
versus None None O
- None None O
host None None O
diseases None None O
( None None O
GVHD None None O
) None None O
did None None O
not None None O
correlate None None O
with None None O
the None None O
changes None None O
of None None O
any None None O
lymphocyte None None O
subsets None None O
. None None O

The None None O
present None None O
results None None O
suggest None None O
that None None O
the None None O
increase None None O
of None None O
activated None None O
T None None O
- None None O
cells None None O
shortly None None O
after None None O
BMT None None O
reflects None None O
lymphocyte None None O
reconstitution None None O
. None None O

The None None O
prolonged None None O
immune None None O
deficiency None None O
after None None O
BMT None None O
might None None O
be None None O
related None None O
to None None O
either None None O
deficient None None O
expression None None O
of None None O
homing None None O
receptor None None O
( None None O
Leu None None O
8 None None O
antigen None None O
) None None O
on None None O
CD None None O
4 None None O
+ None None O
cells None None O
or None None O
increased None None O
suppressor None None O
T None None O
- None None O
cells None None O
( None None O
CD None None O
8 None None O
+ None None O
CD None None O
11 None None O
+ None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
early None None O
increase None None O
of None None O
NK None None O
cells None None O
after None None O
BMT None None O
may None None O
compensate None None O
for None None O
the None None O
immune None None O
deficiency None None O
in None None O
BMT None None O
patients None None O
. None None O

Mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
kinase None None O
signaling None None O
promotes None None O
growth None None O
and None None O
vascularization None None O
of None None O
fibrosarcoma None None O
. None None O

We None None O
hypothesized None None O
that None None O
signaling None None O
through None None O
multiple None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
kinase None None O
( None None O
MKK None None O
) None None O
pathways None None O
is None None O
essential None None O
for None None O
the None None O
growth None None O
and None None O
vascularization None None O
of None None O
soft None None O
- None None O
tissue None None O
sarcomas None None O
, None None O
which None None O
are None None O
malignant None None O
tumors None None O
derived None None O
from None None O
mesenchymal None None O
tissues None None O
. None None O

We None None O
tested None None O
this None None O
using None None O
HT None None I-Cell-line-name
- None None I-Cell-line-name
1080 None None I-Cell-line-name
, None None O
NCI None None I-Cell-line-name
, None None O
and None None O
Shac None None I-Cell-line-name
fibrosarcoma None None O
- None None O
derived None None O
cell None None O
lines None None O
and None None O
anthrax None None O
lethal None None O
toxin None None O
( None None O
LeTx None None O
) None None O
, None None O
a None None O
bacterial None None O
toxin None None O
that None None O
inactivates None None O
MKKs None None O
. None None O

Western None None O
blots None None O
confirmed None None O
that None None O
LeTx None None O
treatment None None O
reduced None None O
the None None O
levels None None O
of None None O
phosphorylated None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
and None None O
p38 None None O
MAPK None None O
in None None O
vitro None None O
. None None O

Although None None O
short None None O
treatments None None O
with None None O
LeTx None None O
only None None O
modestly None None O
affected None None O
cell None None O
proliferation None None O
, None None O
sustained None None O
treatment None None O
markedly None None O
reduced None None O
cell None None O
numbers None None O
. None None O

LeTx None None O
also None None O
substantially None None O
inhibited None None O
the None None O
extracellular None None O
release None None O
of None None O
angioproliferative None None O
factors None None O
including None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
interleukin None None O
- None None O
8 None None O
, None None O
and None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
. None None O

Similar None None O
results None None O
were None None O
obtained None None O
with None None O
cell None None O
lines None None O
derived None None O
from None None O
malignant None None O
fibrous None None O
histiocytomas None None O
, None None O
leiomyosarcomas None None O
, None None O
and None None O
liposarcomas None None O
. None None O

In None None O
vivo None None O
, None None O
LeTx None None O
decreased None None O
MAPK None None O
activity None None O
and None None O
blocked None None O
fibrosarcoma None None O
growth None None O
. None None O

Growth None None O
inhibition None None O
correlated None None O
with None None O
decreased None None O
cellular None None O
proliferation None None O
and None None O
extensive None None O
necrosis None None O
, None None O
and None None O
it None None O
was None None O
accompanied None None O
by None None O
a None None O
decrease None None O
in None None O
tumor None None O
mean None None O
vessel None None O
density None None O
as None None O
well None None O
as None None O
a None None O
reduction None None O
in None None O
serum None None O
expression None None O
of None None O
angioproliferative None None O
cytokines None None O
. None None O

Vital None None O
imaging None None O
using None None O
high None None O
- None None O
resolution None None O
ultrasound None None O
enhanced None None O
with None None O
contrast None None O
microbubbles None None O
revealed None None O
that None None O
the None None O
effects None None O
of None None O
LeTx None None O
on None None O
tumor None None O
perfusion None None O
were None None O
remarkably None None O
rapid None None O
( None None O
less None None O
than None None O
24 None None O
h None None O
) None None O
and None None O
resulted None None O
in None None O
a None None O
marked None None O
reduction None None O
of None None O
perfusion None None O
within None None O
the None None O
tumor None None O
but None None O
not None None O
in None None O
nontumor None None O
tissues None None O
. None None O

These None None O
results None None O
are None None O
consistent None None O
with None None O
our None None O
initial None None O
hypothesis None None O
and None None O
lead None None O
us None None O
to None None O
propose None None O
that None None O
MKK None None O
inhibition None None O
by None None O
LeTx None None O
is None None O
a None None O
broadly None None O
effective None None O
strategy None None O
for None None O
targeting None None O
neovascularization None None O
in None None O
fibrosarcomas None None O
and None None O
other None None O
similar None None O
proliferative None None O
lesions None None O
. None None O

Hippocampal None None O
afterdischarge None None O
interferes None None O
with None None O
storage None None O
of None None O
spatial None None O
information None None O
in None None O
a None None O
working None None O
memory None None O
test None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
impair None None O
spatial None None O
working None None O
memory None None O
by None None O
reversible None None O
functional None None O
blockade None None O
rather None None O
than None None O
by None None O
irreversible None None O
lesion None None O
of None None O
the None None O
hippocampus None None O
, None None O
eight None None O
male None None O
hooded None None O
rats None None O
were None None O
trained None None O
to None None O
asymptotic None None O
performance None None O
of None None O
1 None None O
. None None O
2 None None O
to None None O
1 None None O
. None None O
4 None None O
errors None None O
per None None O
trial None None O
in None None O
the None None O
spatial None None O
12 None None O
- None None O
choice None None O
apparatus None None O
( None None O
Bure None None O
s None None O
et None None O
al None None O
. None None O
1982 None None O
) None None O
, None None O
formally None None O
similar None None O
to None None O
the None None O
radial None None O
maze None None O
. None None O

The None None O
rats None None O
were None None O
implanted None None O
with None None O
hippocampal None None O
stimulating None None O
and None None O
recording None None O
electrodes None None O
, None None O
which None None O
were None None O
used None None O
for None None O
eliciting None None O
and None None O
monitoring None None O
hippocampal None None O
afterdischarge None None O
( None None O
HAD None None O
) None None O
lasting None None O
for None None O
at None None O
least None None O
20 None None O
s None None O
. None None O

In None None O
Experiment None None O
1 None None O
, None None O
HAD None None O
elicited None None O
1 None None O
or None None O
10 None None O
min None None O
before None None O
testing None None O
increased None None O
the None None O
incidence None None O
of None None O
errors None None O
to None None O
2 None None O
. None None O
75 None None O
or None None O
2 None None O
. None None O
50 None None O
per None None O
trial None None O
, None None O
respectively None None O
, None None O
but None None O
the None None O
performance None None O
still None None O
remained None None O
above None None O
chance None None O
level None None O
( None None O
4 None None O
. None None O
18 None None O
) None None O
. None None O

In None None O
Experiment None None O
2 None None O
, None None O
interruption None None O
of None None O
the None None O
trial None None O
by None None O
1 None None O
, None None O
10 None None O
, None None O
20 None None O
and None None O
30 None None O
min None None O
intervals None None O
inserted None None O
between None None O
choices None None O
6 None None O
and None None O
7 None None O
increased None None O
the None None O
incidence None None O
of None None O
errors None None O
in None None O
choices None None O
7 None None O
to None None O
12 None None O
to None None O
1 None None O
. None None O
0 None None O
, None None O
1 None None O
. None None O
5 None None O
, None None O
2 None None O
. None None O
1 None None O
and None None O
2 None None O
. None None O
5 None None O
, None None O
respectively None None O
. None None O

HAD None None O
elicited None None O
immediately None None O
after None None O
choice None None O
6 None None O
increased None None O
error None None O
incidence None None O
in None None O
the None None O
subsequent None None O
6 None None O
choices None None O
performed None None O
after None None O
1 None None O
- None None O
min None None O
or None None O
10 None None O
- None None O
min None None O
intervals None None O
to None None O
3 None None O
. None None O
1 None None O
or None None O
2 None None O
. None None O
75 None None O
, None None O
respectively None None O
, None None O
i None None O
. None None O
e None None O
. None None O
to None None O
the None None O
chance None None O
level None None O
of None None O
3 None None O
errors None None O
in None None O
6 None None O
choices None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
HAD None None O
elicits None None O
transient None None O
shortening None None O
of None None O
the None None O
memory None None O
span None None O
for None None O
newly None None O
acquired None None O
spatial None None O
information None None O
( None None O
anterograde None None O
effect None None O
) None None O
and None None O
erases None None O
the None None O
current None None O
spatial None None O
working None None O
memory None None O
record None None O
( None None O
retrograde None None O
effect None None O
) None None O
. None None O

Pro None None O
/ None None O
antioxidant None None O
status None None O
and None None O
AP None None O
- None None O
1 None None O
transcription None None O
factor None None O
in None None O
murine None None O
skin None None O
following None None O
topical None None O
exposure None None O
to None None O
cumene None None O
hydroperoxide None None O
. None None O

Organic None None O
peroxides None None O
, None None O
widely None None O
used None None O
in None None O
the None None O
chemical None None O
and None None O
pharmaceutical None None O
industries None None O
, None None O
can None None O
act None None O
as None None O
skin None None O
tumor None None O
promoters None None O
and None None O
cause None None O
epidermal None None O
hyperplasia None None O
. None None O

They None None O
are None None O
also None None O
known None None O
to None None O
trigger None None O
free None None O
radical None None O
generation None None O
. None None O

The None None O
present None None O
study None None O
evaluated None None O
the None None O
effect None None O
of None None O
cumene None None O
hydroperoxide None None O
( None None O
Cum None None O
- None None O
OOH None None O
) None None O
on None None O
the None None O
induction None None O
of None None O
activator None None O
protein None None O
- None None O
1 None None O
( None None O
AP None None O
- None None O
1 None None O
) None None O
, None None O
which None None O
is None None O
linked None None O
to None None O
the None None O
expression None None O
of None None O
genes None None O
regulating None None O
cell None None O
proliferation None None O
, None None O
growth None None O
and None None O
transformation None None O
. None None O

Previously None None O
, None None O
we None None O
reported None None O
that None None O
topical None None O
exposure None None O
to None None O
Cum None None O
- None None O
OOH None None O
caused None None O
formation None None O
of None None O
free None None O
radicals None None O
and None None O
oxidative None None O
stress None None O
in None None O
the None None O
skin None None O
of None None O
vitamin None None O
E None None O
- None None O
deficient None None O
mice None None O
. None None O

The None None O
present None None O
study None None O
used None None O
JB6 None None O
P None None O
+ None None O
mouse None None O
epidermal None None O
cells None None O
and None None O
AP None None O
- None None O
1 None None O
- None None O
luciferase None None O
reporter None None O
transgenic None None O
mice None None O
to None None O
identify None None O
whether None None O
exposure None None O
to None None O
Cum None None O
- None None O
OOH None None O
caused None None O
activation None None O
of None None O
AP None None O
- None None O
1 None None O
, None None O
oxidative None None O
stress None None O
, None None O
depletion None None O
of None None O
antioxidants None None O
and None None O
tumor None None O
formation None None O
during None None O
two None None O
- None None O
stage None None O
carcinogenesis None None O
. None None O

In None None O
vitro None None O
studies None None O
found None None O
that None None O
exposure None None O
to None None O
Cum None None O
- None None O
OOH None None O
reduced None None O
the None None O
level None None O
of None None O
glutathione None None O
( None None O
GSH None None O
) None None O
in None None O
mouse None None O
epidermal None None O
cells None None O
( None None O
JB6 None None O
P None None O
+ None None O
) None None O
and None None O
caused None None O
the None None O
induction None None O
of None None O
AP None None O
- None None O
1 None None O
. None None O

Mice None None O
primed None None O
with None None O
dimethyl None None O
- None None O
benz None None O
[ None None O
a None None O
] None None O
anthracene None None O
( None None O
DMBA None None O
) None None O
were None None O
topically None None O
exposed None None O
to None None O
Cum None None O
- None None O
OOH None None O
( None None O
82 None None O
. None None O
6 None None O
micromol None None O
) None None O
or None None O
the None None O
positive None None O
control None None O
, None None O
12 None None O
- None None O
O None None O
- None None O
tetradecanoylphorbol None None O
- None None O
13 None None O
- None None O
acetate None None O
( None None O
TPA None None O
, None None O
17 None None O
nmol None None O
) None None O
, None None O
twice None None O
weekly None None O
for None None O
29 None None O
weeks None None O
. None None O

Activation None None O
of None None O
AP None None O
- None None O
1 None None O
in None None O
skin None None O
was None None O
detected None None O
as None None O
early None None O
as None None O
2 None None O
weeks None None O
following None None O
Cum None None O
- None None O
OOH None None O
or None None O
TPA None None O
exposure None None O
. None None O

No None None O
AP None None O
- None None O
1 None None O
expression None None O
was None None O
found None None O
19 None None O
weeks None None O
after None None O
initiation None None O
. None None O

Papilloma None None O
formation None None O
was None None O
observed None None O
in None None O
both None None O
the None None O
DMBA None None O
- None None O
TPA None None O
- None None O
and None None O
DMBA None None O
- None None O
Cum None None O
- None None O
OOH None None O
- None None O
exposed None None O
animals None None O
, None None O
whereas None None O
skin None None O
carcinomas None None O
were None None O
found None None O
only None None O
in None None O
the None None O
DMBA None None O
- None None O
Cum None None O
- None None O
OOH None None O
- None None O
treated None None O
mice None None O
. None None O

A None None O
greater None None O
accumulation None None O
of None None O
peroxidative None None O
products None None O
( None None O
thiobarbituric None None O
acid None None O
- None None O
reactive None None O
substances None None O
) None None O
, None None O
inflammation None None O
and None None O
decreased None None O
levels None None O
of None None O
GSH None None O
and None None O
total None None O
antioxidant None None O
reserves None None O
were None None O
also None None O
observed None None O
in None None O
the None None O
skin None None O
of None None O
DMBA None None O
- None None O
Cum None None O
- None None O
OOH None None O
- None None O
exposed None None O
mice None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
Cum None None O
- None None O
OOH None None O
- None None O
induced None None O
carcinogenesis None None O
is None None O
accompanied None None O
by None None O
increased None None O
AP None None O
- None None O
1 None None O
activation None None O
and None None O
changes None None O
in None None O
antioxidant None None O
status None None O
. None None O

Tumor None None O
microenvironment None None O
, None None O
a None None O
dangerous None None O
society None None O
leading None None O
to None None O
cancer None None O
metastasis None None O
. None None O

From None None O
mechanisms None None O
to None None O
therapy None None O
and None None O
prevention None None O
. None None O

Cancer None None O
is None None O
no None None O
longer None None O
considered None None O
by None None O
scientists None None O
just None None O
a None None O
jumble None None O
of None None O
mutated None None O
cells None None O
. None None O

To None None O
grow None None O
, None None O
invade None None O
and None None O
metastasize None None O
, None None O
a None None O
treacherous None None O
society None None O
between None None O
cancer None None O
and None None O
host None None O
cells None None O
must None None O
be None None O
formed None None O
, None None O
and None None O
this None None O
association None None O
provides None None O
novel None None O
and None None O
effective None None O
clinical None None O
targets None None O
for None None O
cancer None None O
control None None O
and None None O
prevention None None O
. None None O

This None None O
collection None None O
of None None O
reviews None None O
at None None O
the None None O
front None None O
- None None O
edge None None O
of None None O
scientific None None O
knowledge None None O
focuses None None O
on None None O
host None None O
- None None O
tumor None None O
cell None None O
interactions None None O
, None None O
the None None O
disastrous None None O
consequences None None O
they None None O
can None None O
produce None None O
and None None O
approaches None None O
the None None O
ways None None O
to None None O
break None None O
up None None O
these None None O
cellular None None O
conspiracies None None O
, None None O
to None None O
leave None None O
the None None O
tumor None None O
cells None None O
unattended None None O
and None None O
vulnerable None None O
. None None O

Aquaporins None None O
in None None O
human None None O
breast None None O
cancer None None O
: None None O
identification None None O
and None None O
involvement None None O
in None None O
carcinogenesis None None O
of None None O
breast None None O
cancer None None O
. None None O

BACKGROUND None None O
AND None None O
OBJECTIVES None None O
: None None O
Aquaporins None None O
( None None O
AQPs None None O
) None None O
play None None O
important None None O
roles None None O
in None None O
water None None O
and None None O
glycerol None None O
transport None None O
. None None O

Recently None None O
, None None O
the None None O
role None None O
of None None O
AQPs None None O
in None None O
human None None O
carcinogenesis None None O
has None None O
become None None O
an None None O
area None None O
of None None O
great None None O
interest None None O
. None None O

However None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
function None None O
of None None O
AQPs None None O
in None None O
human None None O
breast None None O
cancer None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
expression None None O
profile None None O
of None None O
AQPs None None O
in None None O
human None None O
breast None None O
cancer None None O
and None None O
its None None O
significance None None O
. None None O

METHODS None None O
: None None O
In None None O
this None None O
study None None O
, None None O
we None None O
screened None None O
the None None O
expression None None O
profile None None O
of None None O
AQP0 None None O
- None None O
12 None None O
in None None O
breast None None O
cancer None None O
tissues None None O
and None None O
corresponding None None O
normal None None O
tissues None None O
by None None O
RT None None O
- None None O
PCR None None O
, None None O
Western None None O
blotting None None O
and None None O
immunohistochemistry None None O
. None None O

RESULTS None None O
: None None O
AQP1 None None O
, None None O
3 None None O
- None None O
5 None None O
, None None O
and None None O
10 None None O
- None None O
12 None None O
were None None O
expressed None None O
in None None O
human None None O
breast None None O
cancer None None O
and None None O
/ None None O
or None None O
normal None None O
breast None None O
tissues None None O
, None None O
and None None O
AQP1 None None O
and None None O
3 None None O
- None None O
5 None None O
exhibited None None O
differential None None O
expression None None O
. None None O

AQP1 None None O
was None None O
expressed None None O
in None None O
cell None None O
membranes None None O
and None None O
its None None O
expression None None O
was None None O
higher None None O
in None None O
cancer None None O
than None None O
that None None O
in None None O
normal None None O
tissues None None O
. None None O

AQP4 None None O
was None None O
expressed None None O
in None None O
the None None O
cell None None O
membrane None None O
and None None O
cytoplasm None None O
and None None O
was None None O
detected None None O
markedly None None O
stronger None None O
in None None O
normal None None O
than None None O
in None None O
cancer None None O
tissues None None O
. None None O

AQP5 None None O
was None None O
expressed None None O
mainly None None O
in None None O
cell None None O
membranes None None O
in None None O
carcinoma None None O
tissues None None O
, None None O
but None None O
was None None O
almost None None O
absent None None O
in None None O
normal None None O
breast None None O
tissues None None O
. None None O

Expression None None O
of None None O
AQP5 None None O
was None None O
associated None None O
with None None O
cellular None None O
differentiation None None O
, None None O
lymph None None O
node None None O
invasion None None O
, None None O
and None None O
clinicopathological None None O
staging None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
observations None None O
suggested None None O
that None None O
several None None O
subtypes None None O
of None None O
the None None O
AQP None None O
family None None O
play None None O
a None None O
role None None O
in None None O
human None None O
breast None None O
carcinogenesis None None O
. None None O

Neoplastic None None O
transformation None None O
by None None O
Notch None None O
requires None None O
nuclear None None O
localization None None O
. None None O

Notch None None O
proteins None None O
are None None O
plasma None None O
membrane None None O
- None None O
spanning None None O
receptors None None O
that None None O
mediate None None O
important None None O
cell None None O
fate None None O
decisions None None O
such None None O
as None None O
differentiation None None O
, None None O
proliferation None None O
, None None O
and None None O
apoptosis None None O
. None None O

The None None O
mechanism None None O
of None None O
Notch None None O
signaling None None O
remains None None O
poorly None None O
understood None None O
. None None O

However None None O
, None None O
it None None O
is None None O
clear None None O
that None None O
the None None O
Notch None None O
signaling None None O
pathway None None O
mediates None None O
its None None O
effects None None O
through None None O
intercellular None None O
contact None None O
between None None O
neighboring None None O
cells None None O
. None None O

The None None O
prevailing None None O
model None None O
for None None O
Notch None None O
signaling None None O
suggests None None O
that None None O
ligand None None O
, None None O
presented None None O
on None None O
a None None O
neighboring None None O
cell None None O
, None None O
triggers None None O
proteolytic None None O
processing None None O
of None None O
Notch None None O
. None None O

Following None None O
proteolysis None None O
, None None O
it None None O
is None None O
thought None None O
that None None O
the None None O
intracellular None None O
portion None None O
of None None O
Notch None None O
( None None O
N None None O
( None None O
ic None None O
) None None O
) None None O
translocates None None O
to None None O
the None None O
nucleus None None O
, None None O
where None None O
it None None O
is None None O
involved None None O
in None None O
regulating None None O
gene None None O
expression None None O
. None None O

There None None O
is None None O
considerable None None O
debate None None O
concerning None None O
where None None O
in None None O
the None None O
cell None None O
Notch None None O
functions None None O
and None None O
what None None O
proteins None None O
serve None None O
as None None O
effectors None None O
of None None O
the None None O
Notch None None O
signal None None O
. None None O

Several None None O
Notch None None O
genes None None O
have None None O
clearly None None O
been None None O
shown None None O
to None None O
be None None O
proto None None O
- None None O
oncogenes None None O
in None None O
mammalian None None O
cells None None O
. None None O

Activation None None O
of None None O
Notch None None O
proto None None O
- None None O
oncogenes None None O
has None None O
been None None O
associated None None O
with None None O
tumorigenesis None None O
in None None O
several None None O
human None None O
and None None O
other None None O
mammalian None None O
cancers None None O
. None None O

Transforming None None O
alleles None None O
of None None O
Notch None None O
direct None None O
the None None O
expression None None O
of None None O
truncated None None O
proteins None None O
that None None O
primarily None None O
consist None None O
of None None O
N None None O
( None None O
ic None None O
) None None O
and None None O
are None None O
not None None O
tethered None None O
to None None O
the None None O
plasma None None O
membrane None None O
. None None O

However None None O
, None None O
the None None O
mechanism None None O
by None None O
which None None O
Notch None None O
oncoproteins None None O
( None None O
generically None None O
termed None None O
here None None O
as None None O
N None None O
( None None O
ic None None O
) None None O
) None None O
induce None None O
neoplastic None None O
transformation None None O
is None None O
not None None O
known None None O
. None None O

Previously None None O
we None None O
demonstrated None None O
that None None O
N1 None None O
( None None O
ic None None O
) None None O
and None None O
N2 None None O
( None None O
ic None None O
) None None O
could None None O
transform None None O
E1A None None O
immortalized None None O
baby None None O
rat None None O
kidney None None O
cells None None O
( None None O
RKE None None O
) None None O
in None None O
vitro None None O
. None None O

We None None O
now None None O
report None None O
direct None None O
evidence None None O
that None None O
N1 None None O
( None None O
ic None None O
) None None O
must None None O
accumulate None None O
in None None O
the None None O
nucleus None None O
to None None O
induce None None O
transformation None None O
of None None O
RKE None None O
cells None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
define None None O
the None None O
minimal None None O
domain None None O
of None None O
N1 None None O
( None None O
ic None None O
) None None O
required None None O
to None None O
induce None None O
transformation None None O
and None None O
present None None O
evidence None None O
that None None O
transformation None None O
of None None O
RKE None None O
cells None None O
by None None O
N1 None None O
( None None O
ic None None O
) None None O
is None None O
likely None None O
to None None O
be None None O
through None None O
a None None O
CBF1 None None O
- None None O
independent None None O
pathway None None O
. None None O

TGFbeta1 None None O
, None None O
back None None O
to None None O
the None None O
future None None O
: None None O
revisiting None None O
its None None O
role None None O
as None None O
a None None O
transforming None None O
growth None None O
factor None None O
. None None O

TGFbeta1 None None O
was None None O
initially None None O
identified None None O
in None None O
culture None None O
media None None O
from None None O
transformed None None O
cells None None O
as None None O
part None None O
of None None O
a None None O
factor None None O
that None None O
could None None O
produce None None O
a None None O
transformed None None O
phenotype None None O
in None None O
a None None O
nontransformed None None O
cell None None O
line None None O
. None None O

Subsequently None None O
this None None O
activity None None O
was None None O
separated None None O
into None None O
TGFbeta None None O
and None None O
TGFalpha None None O
an None None O
EGF None None O
receptor None None O
ligand None None O
. None None O

With None None O
the None None O
discovery None None O
that None None O
TGFbeta1 None None O
was None None O
a None None O
potent None None O
growth None None O
inhibitor None None O
of None None O
epithelial None None O
cells None None O
, None None O
and None None O
the None None O
identification None None O
of None None O
inactivating None None O
mutations None None O
within None None O
the None None O
TGFbeta1 None None O
signaling None None O
pathway None None O
in None None O
cancers None None O
it None None O
became None None O
clear None None O
that None None O
TGFbeta1 None None O
signaling None None O
is None None O
a None None O
tumor None None O
suppressor None None O
pathway None None O
for None None O
early None None O
stages None None O
of None None O
cancer None None O
. None None O

However None None O
many None None O
human None None O
carcinomas None None O
overexpress None None O
TGFbeta1 None None O
and None None O
this None None O
is None None O
associated None None O
with None None O
poor None None O
patient None None O
prognosis None None O
and None None O
increased None None O
frequency None None O
of None None O
metastasis None None O
. None None O

Similar None None O
results None None O
have None None O
been None None O
obtained None None O
with None None O
tumor None None O
cell None None O
lines None None O
and None None O
experimental None None O
animal None None O
models None None O
. None None O

Thus None None O
stage None None O
specific None None O
duality None None O
of None None O
function None None O
is None None O
the None None O
emerging None None O
paradigm None None O
for None None O
the None None O
role None None O
of None None O
TGFbeta1 None None O
in None None O
cancer None None O
. None None O

This None None O
review None None O
will None None O
focus None None O
on None None O
the None None O
evidence None None O
for None None O
TGFbeta1 None None O
as None None O
a None None O
tumor None None O
promoting None None O
and None None O
metastasis None None O
factor None None O
and None None O
examine None None O
the None None O
biological None None O
and None None O
molecular None None O
basis None None O
for None None O
these None None O
effects None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
the None None O
switch None None O
from None None O
tumor None None O
suppressor None None O
to None None O
oncogene None None O
reflects None None O
genetic None None O
or None None O
epigenetic None None O
alterations None None O
in None None O
signaling None None O
pathways None None O
in None None O
tumor None None O
cells None None O
that None None O
alter None None O
the None None O
readout None None O
from None None O
the None None O
TGFbeta1 None None O
pathway None None O
. None None O

NIH3T3 None None I-Cell-line-name
transfectant None None O
containing None None O
human None None O
K None None O
- None None O
ras None None O
oncogene None None O
shows None None O
enhanced None None O
metastatic None None O
activity None None O
after None None O
in None None O
vivo None None O
tumor None None O
growth None None O
or None None O
co None None O
- None None O
culture None None O
with None None O
fibroblasts None None O
. None None O

A None None O
clone None None O
of None None O
NIH3T3 None None I-Cell-line-name
transformant None None O
( None None O
H None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
) None None O
, None None O
obtained None None O
by None None O
transfecting None None O
genomic None None O
DNA None None O
of None None O
a None None O
human None None O
colon None None O
carcinoma None None O
cell None None O
line None None O
, None None O
contains None None O
human None None O
K None None O
- None None O
ras None None O
oncogene None None O
and None None O
yields None None O
metastatic None None O
pulmonary None None O
nodules None None O
after None None O
intravenous None None O
injection None None O
of None None O
the None None O
cells None None O
into None None O
nude None None O
mice None None O
. None None O

This None None O
metastatic None None O
ability None None O
was None None O
enhanced None None O
remarkably None None O
after None None O
in None None O
vivo None None O
tumor None None O
growth None None O
( None None O
subcutaneous None None O
tumor None None O
formation None None O
in None None O
nude None None O
mice None None O
) None None O
accompanied None None O
by None None O
increased None None O
mRNA None None O
expression None None O
and None None O
gene None None O
amplification None None O
of None None O
the None None O
human None None O
- None None O
derived None None O
K None None O
- None None O
ras None None O
oncogene None None O
, None None O
while None None O
it None None O
declined None None O
gradually None None O
as None None O
the None None O
passage None None O
number None None O
increased None None O
in None None O
vitro None None O
, None None O
with None None O
corresponding None None O
decreases None None O
of None None O
gene None None O
amplification None None O
and None None O
mRNA None None O
expression None None O
. None None O

Six None None O
subclones None None O
were None None O
randomly None None O
selected None None O
from None None O
H None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
which None None O
had None None O
been None None O
subcultured None None O
to None None O
passage None None O
22 None None O
. None None O

All None None O
of None None O
the None None O
clones None None O
in None None O
culture None None O
showed None None O
almost None None O
the None None O
same None None O
low None None O
level None None O
of None None O
metastatic None None O
ability None None O
and None None O
exhibited None None O
little None None O
K None None O
- None None O
ras None None O
oncogene None None O
amplification None None O
with None None O
correspondingly None None O
low None None O
mRNA None None O
expression None None O
. None None O

However None None O
, None None O
after None None O
they None None O
formed None None O
tumors None None O
in None None O
nude None None O
mice None None O
, None None O
every None None O
clone None None O
acquired None None O
high None None O
metastatic None None O
ability None None O
and None None O
the None None O
gene None None O
amplification None None O
increased None None O
, None None O
with None None O
elevated None None O
mRNA None None O
expression None None O
. None None O

These None None O
experimental None None O
facts None None O
indicated None None O
that None None O
acquisition None None O
of None None O
metastatic None None O
ability None None O
coupled None None O
with None None O
the None None O
function None None O
of None None O
K None None O
- None None O
ras None None O
oncogene None None O
was None None O
conditional None None O
in None None O
nature None None O
, None None O
being None None O
strongly None None O
affected None None O
by None None O
in None None O
vivo None None O
tumor None None O
circumstances None None O
. None None O

The None None O
low None None O
metastatic None None O
and None None O
G None None O
- None None O
418 None None O
- None None O
resistant None None O
H None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
were None None O
co None None O
- None None O
cultured None None O
with None None O
BALB None None I-Cell-line-name
/ None None I-Cell-line-name
c3T3 None None I-Cell-line-name
fibroblasts None None O
for None None O
2 None None O
- None None O
4 None None O
weeks None None O
. None None O

After None None O
removal None None O
of None None O
fibroblasts None None O
by None None O
exposure None None O
to None None O
G None None O
- None None O
418 None None O
, None None O
the None None O
tumor None None O
cells None None O
exhibited None None O
increased None None O
metastatic None None O
ability None None O
and None None O
human None None O
K None None O
- None None O
ras None None O
oncogene None None O
mRNA None None O
, None None O
suggesting None None O
an None None O
intimate None None O
interaction None None O
between None None O
H None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
and None None O
fibroblasts None None O
influencing None None O
the None None O
function None None O
of None None O
transfected None None O
human None None O
K None None O
- None None O
ras None None O
oncogene None None O
. None None O

Fibroblasts None None O
of None None O
the None None O
host None None O
animal None None O
may None None O
thus None None O
have None None O
an None None O
important None None O
role None None O
in None None O
generating None None O
enhanced None None O
metastatic None None O
activity None None O
of None None O
H None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
. None None O

Method None None O

Background None None O

Hallucinations None None O
may None None O
occur None None O
in None None O
any None None O
sensory None None O
modalities None None O
. None None O

Formed None None O
musical None None O
hallucinations None None O
( None None O
i None None O
. None None O
e None None O
. None None O
Perception None None O
of None None O
either None None O
vocal None None O
or None None O
instrumental None None O
melodies None None O
) None None O
reported None None O
in None None O
English None None O
literature None None O
to None None O
date None None O
have None None O
typically None None O
been None None O
associated None None O
with None None O
marked None None O
hearing None None O
loss None None O
, None None O
advanced None None O
age None None O
, None None O
female None None O
sex None None O
( None None O
71 None None O
% None None O
) None None O
, None None O
lack None None O
of None None O
response None None O
to None None O
treatment None None O
and None None O
associated None None O
psychopathology None None O
[ None None O
1 None None O
] None None O
but None None O
has None None O
been None None O
concluded None None O
that None None O
hearing None None O
loss None None O
is None None O
neither None None O
a None None O
necessary None None O
nor None None O
sufficient None None O
condition None None O
for None None O
the None None O
occurrence None None O
of None None O
musical None None O
hallucinations None None O
[ None None O
1 None None O
] None None O
. None None O

Tumor None None O
like None None O
Astrocytoma None None O
, None None O
Temporal None None O
lobe None None O
epilepsy None None O
, None None O
raised None None O
intra None None O
cranial None None O
tension None None O
, None None O
drug None None O
induced None None O
( None None O
tricyclics None None O
, None None O
Propronolol None None O
etc None None O
; None None O
) None None O
, None None O
meningitis None None O
and None None O
psychotic None None O
illness None None O
were None None O
shown None None O
to None None O
cause None None O
palinacousis None None O
and None None O
musical None None O
hallucinations None None O
[ None None O
2 None None O
, None None O
3 None None O
] None None O
. None None O

Musical None None O
hallucinations None None O
are None None O
pseudo None None O
hallucinations None None O
that None None O
originate None None O
in None None O
memory None None O
representations None None O
and None None O
they None None O
may None None O
undergo None None O
a None None O
transition None None O
to None None O
true None None O
hallucination None None O
. None None O

In None None O
musical None None O
hallucination None None O
spatial None None O
projection None None O
is None None O
less None None O
definite None None O
. None None O

Sometimes None None O
they None None O
are None None O
perceived None None O
like None None O
the None None O
tinnitus None None O
in None None O
patient None None O
' None None O
s None None O
own None None O
head None None O
. None None O

The None None O
quality None None O
is None None O
usually None None O
very None None O
intense None None O
and None None O
distinct None None O
often None None O
very None None O
loud None None O
. None None O

They None None O
vary None None O
from None None O
elementary None None O
sounds None None O
to None None O
instrumental None None O
music None None O
, None None O
vocal None None O
music None None O
, None None O
bird None None O
songs None None O
, None None O
bells None None O
, None None O
pieces None None O
of None None O
melodies None None O
or None None O
sentences None None O
, None None O
religious None None O
music None None O
etc None None O
: None None O
- None None O
We None None O
report None None O
an None None O
unusual None None O
presentation None None O
of None None O
an None None O
elderly None None O
lady None None O
who None None O
had None None O
experienced None None O
musical None None O
hallucinations None None O
whilst None None O
being None None O
treated None None O
with None None O
Electro None None O
Convulsive None None O
Therapy None None O
. None None O

Though None None O
this None None O
has None None O
never None None O
been None None O
reported None None O
earlier None None O
, None None O
there None None O
seemed None None O
to None None O
have None None O
a None None O
good None None O
association None None O
between None None O
the None None O
initiation None None O
of None None O
Electro None None O
convulsive None None O
therapy None None O
and None None O
musical None None O
hallucination None None O
in None None O
our None None O
patient None None O
. None None O

Induction None None O
of None None O
Id None None O
- None None O
1 None None O
by None None O
FGF None None O
- None None O
2 None None O
involves None None O
activity None None O
of None None O
EGR None None O
- None None O
1 None None O
and None None O
sensitizes None None O
neuroblastoma None None O
cells None None O
to None None O
cell None None O
death None None O
. None None O

Inhibitor None None O
of None None O
differentiation None None O
- None None O
1 None None O
( None None O
Id None None O
- None None O
1 None None O
) None None O
is None None O
a None None O
member None None O
of None None O
helix None None O
- None None O
loop None None O
- None None O
helix None None O
( None None O
HLH None None O
) None None O
family None None O
of None None O
proteins None None O
that None None O
regulate None None O
gene None None O
transcription None None O
through None None O
their None None O
inhibitory None None O
binding None None O
to None None O
basic None None O
- None None O
HLH None None O
transcription None None O
factors None None O
. None None O

Similarly None None O
to None None O
other None None O
members None None O
of None None O
this None None O
family None None O
, None None O
Id None None O
- None None O
1 None None O
is None None O
involved None None O
in None None O
the None None O
repression None None O
of None None O
cell None None O
differentiation None None O
and None None O
activation None None O
of None None O
cell None None O
growth None None O
. None None O

The None None O
dual None None O
function None None O
of None None O
Id None None O
- None None O
1 None None O
, None None O
inhibition None None O
of None None O
differentiation None None O
, None None O
and None None O
stimulation None None O
of None None O
cell None None O
proliferation None None O
, None None O
might None None O
be None None O
interdependent None None O
, None None O
as None None O
cell None None O
differentiation None None O
is None None O
generally None None O
coupled None None O
with None None O
the None None O
exit None None O
from None None O
the None None O
cell None None O
cycle None None O
. None None O

Fibroblast None None O
growth None None O
factor None None O
- None None O
2 None None O
( None None O
FGF None None O
- None None O
2 None None O
) None None O
has None None O
been None None O
reported None None O
to None None O
play None None O
multiple None None O
roles None None O
in None None O
different None None O
biological None None O
processes None None O
during None None O
development None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
FGF None None O
- None None O
2 None None O
has None None O
been None None O
described None None O
to None None O
induce None None O
" None None O
neuronal None None O
- None None O
like None None O
" None None O
differentiation None None O
and None None O
trigger None None O
apoptosis None None O
in None None O
neuroblastoma None None O
SK None None I-Cell-line-name
- None None I-Cell-line-name
N None None I-Cell-line-name
- None None I-Cell-line-name
MC None None I-Cell-line-name
cells None None O
. None None O

Although None None O
regulation None None O
of None None O
Id None None O
- None None O
1 None None O
protein None None O
by None None O
several None None O
mitogenic None None O
factors None None O
is None None O
well None None O
- None None O
established None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
role None None O
of None None O
FGF None None O
- None None O
2 None None O
in None None O
the None None O
regulation None None O
of None None O
Id None None O
- None None O
1 None None O
. None None O

Using None None O
human None None O
neuroblastoma None None O
cell None None O
line None None O
, None None O
SK None None I-Cell-line-name
- None None I-Cell-line-name
N None None I-Cell-line-name
- None None I-Cell-line-name
MC None None I-Cell-line-name
, None None O
we None None O
found None None O
that None None O
treatment None None O
of None None O
these None None O
cells None None O
with None None O
FGF None None O
- None None O
2 None None O
resulted None None O
in None None O
early None None O
induction None None O
of None None O
both None None O
Id None None O
- None None O
1 None None O
mRNA None None O
and None None O
protein None None O
. None None O

The None None O
induction None None O
occurs None None O
within None None O
1 None None O
h None None O
from None None O
FGF None None O
- None None O
2 None None O
treatment None None O
and None None O
is None None O
mediated None None O
by None None O
ERK1 None None O
/ None None O
2 None None O
pathway None None O
, None None O
which None None O
in None None O
turn None None O
stimulates None None O
expression None None O
of None None O
the None None O
early None None O
growth None None O
response None None O
- None None O
1 None None O
( None None O
Egr None None O
- None None O
1 None None O
) None None O
transcription None None O
factor None None O
. None None O

We None None O
also None None O
demonstrate None None O
direct None None O
interaction None None O
of None None O
Egr None None O
- None None O
1 None None O
with None None O
Id None None O
- None None O
1 None None O
promoter None None O
in None None O
vitro None None O
and None None O
in None None O
cell None None O
culture None None O
. None None O

Finally None None O
, None None O
inhibition None None O
of None None O
Id None None O
- None None O
1 None None O
expression None None O
results None None O
in None None O
G None None O
( None None O
2 None None O
) None None O
/ None None O
M None None O
accumulation None None O
of None None O
FGF None None O
- None None O
2 None None O
- None None O
treated None None O
cells None None O
and None None O
delayed None None O
cell None None O
death None None O
. None None O

Follow None None O
- None None O
up None None O

Patients None None O
were None None O
followed None None O
up None None O
at None None O
the None None O
outpatient None None O
clinic None None O
at None None O
1 None None O
, None None O
4 None None O
, None None O
and None None O
7 None None O
months None None O
after None None O
the None None O
ablation None None O
procedure None None O
and None None O
every None None O
6 None None O
months None None O
thereafter None None O
. None None O

Routine None None O
24 None None O
or None None O
48 None None O
h None None O
Holter None None O
monitoring None None O
was None None O
performed None None O
before None None O
each None None O
appointment None None O
, None None O
and None None O
a None None O
12 None None O
- None None O
lead None None O
electrocardiogram None None O
was None None O
obtained None None O
at None None O
each None None O
visit None None O
. None None O

Patients None None O
were None None O
asked None None O
to None None O
report None None O
to None None O
the None None O
emergency None None O
room None None O
or None None O
our None None O
arrhythmia None None O
unit None None O
for None None O
an None None O
ECG None None O
if None None O
any None None O
symptom None None O
suggestive None None O
of None None O
recurrence None None O
occurred None None O
between None None O
scheduled None None O
visits None None O
. None None O

After None None O
the None None O
ablation None None O
procedure None None O
, None None O
all None None O
patients None None O
received None None O
anti None None O
- None None O
arrhythmic None None O
treatment None None O
for None None O
at None None O
least None None O
1 None None O
month None None O
to None None O
protect None None O
against None None O
early None None O
recurrences None None O
and None None O
continued None None O
oral None None O
anticoagulation None None O
for None None O
a None None O
minimum None None O
of None None O
2 None None O
months None None O
to None None O
maintain None None O
an None None O
international None None O
normalized None None O
ratio None None O
between None None O
2 None None O
. None None O
0 None None O
and None None O
3 None None O
. None None O
0 None None O
. None None O

Additionally None None O
, None None O
magnetic None None O
resonance None None O
angiography None None O
was None None O
repeated None None O
at None None O
3 None None O
- None None O
6 None None O
months None None O
after None None O
the None None O
procedure None None O
to None None O
evaluate None None O
the None None O
presence None None O
of None None O
PV None None O
stenosis None None O
. None None O

Arrhythmia None None O
recurrence None None O
was None None O
defined None None O
as None None O
a None None O
documented None None O
AF None None O
or None None O
atrial None None O
flutter None None O
episode None None O
of None None O
> None None O
30 None None O
s None None O
. None None O

Arrhythmic None None O
episodes None None O
within None None O
the None None O
first None None O
3 None None O
months None None O
after None None O
the None None O
CPVA None None O
( None None O
healing None None O
period None None O
) None None O
were None None O
not None None O
considered None None O
in None None O
the None None O
evaluation None None O
of None None O
final None None O
success None None O
rates None None O
because None None O
they None None O
are None None O
often None None O
described None None O
as None None O
transient None None O
recurrences None None O
related None None O
to None None O
atrial None None O
inflammatory None None O
processes None None O
following None None O
RF None None O
lesions None None O
. None None O
26 None None O

The None None O
endpoint None None O
of None None O
the None None O
study None None O
was None None O
freedom None None O
from None None O
arrhythmia None None O
recurrence None None O
after None None O
a None None O
single None None O
CPVA None None O
procedure None None O
, None None O
without None None O
anti None None O
- None None O
arrhythmic None None O
medication None None O
. None None O

A None None O
minimum None None O
follow None None O
- None None O
up None None O
of None None O
3 None None O
months None None O
was None None O
required None None O
. None None O

Simian None None O
virus None None O
40 None None O
large None None O
T None None O
antigen None None O
and None None O
two None None O
independent None None O
T None None O
- None None O
antigen None None O
segments None None O
sensitize None None O
cells None None O
to None None O
apoptosis None None O
following None None O
genotoxic None None O
damage None None O
. None None O

The None None O
simian None None O
virus None None O
40 None None O
( None None O
SV40 None None O
) None None O
large None None O
tumor None None O
( None None O
T None None O
) None None O
antigen None None O
is None None O
sufficient None None O
to None None O
transform None None O
cells None None O
in None None O
cultures None None O
and None None O
induce None None O
tumors None None O
in None None O
experimental None None O
animals None None O
. None None O

Transformation None None O
of None None O
primary None None O
cells None None O
in None None O
cultures None None O
requires None None O
both None None O
overcoming None None O
growth None None O
arrest None None O
by None None O
stimulating None None O
the None None O
cell None None O
cycle None None O
and None None O
blocking None None O
cell None None O
death None None O
activities None None O
presumably None None O
activated None None O
by None None O
oncogene None None O
- None None O
mediated None None O
hyperproliferation None None O
signals None None O
. None None O

The None None O
study None None O
presented None None O
here None None O
examined None None O
the None None O
ability None None O
of None None O
specific None None O
regions None None O
and None None O
activities None None O
of None None O
T None None O
antigen None None O
to None None O
modulate None None O
apoptosis None None O
in None None O
cells None None O
treated None None O
with None None O
the None None O
genotoxic None None O
agent None None O
5 None None O
- None None O
fluorouracil None None O
( None None O
5 None None O
- None None O
FU None None O
) None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
the None None O
expression None None O
of None None O
full None None O
- None None O
length None None O
T None None O
antigen None None O
rendered None None O
rat None None O
embryo None None O
fibroblasts None None O
( None None O
REF None None O
) None None O
sensitive None None O
to None None O
5 None None O
- None None O
FU None None O
- None None O
induced None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
neither None None O
the None None O
p53 None None O
- None None O
binding None None O
region None None O
nor None None O
the None None O
Bcl None None O
- None None O
2 None None O
homology None None O
region None None O
of None None O
T None None O
antigen None None O
was None None O
sufficient None None O
to None None O
prevent None None O
cell None None O
death None None O
induced None None O
by None None O
the None None O
DNA None None O
- None None O
damaging None None O
agent None None O
. None None O

T None None O
- None None O
antigen None None O
- None None O
mediated None None O
sensitization None None O
occurred None None O
independently None None O
of None None O
retinoblastoma None None O
protein None None O
or None None O
p53 None None O
and None None O
p300 None None O
binding None None O
. None None O

An None None O
N None None O
- None None O
terminal None None O
segment None None O
containing None None O
the None None O
first None None O
127 None None O
T None None O
- None None O
antigen None None O
amino None None O
acids None None O
( None None O
T1 None None O
- None None O
127 None None O
) None None O
was None None O
sufficient None None O
to None None O
sensitize None None O
cells None None O
. None None O

A None None O
C None None O
- None None O
terminal None None O
segment None None O
consisting None None O
of None None O
T None None O
- None None O
antigen None None O
amino None None O
acids None None O
251 None None O
to None None O
708 None None O
( None None O
T251 None None O
- None None O
708 None None O
) None None O
also None None O
sensitized None None O
cells None None O
to None None O
5 None None O
- None None O
FU None None O
- None None O
induced None None O
apoptosis None None O
. None None O

This None None O
sensitization None None O
did None None O
not None None O
occur None None O
when None None O
T251 None None O
- None None O
708 None None O
was None None O
targeted None None O
to None None O
the None None O
nucleus None None O
by None None O
inclusion None None O
of None None O
the None None O
SV40 None None O
nuclear None None O
localization None None O
signal None None O
. None None O

The None None O
introduction None None O
of None None O
mutations None None O
into None None O
the None None O
T None None O
- None None O
antigen None None O
J None None O
domain None None O
resulted None None O
in None None O
mutation None None O
- None None O
specific None None O
and None None O
variable None None O
inhibition None None O
of None None O
apoptosis None None O
. None None O

This None None O
result None None O
suggested None None O
that None None O
either None None O
the None None O
structural None None O
or None None O
the None None O
functional None None O
integrity None None O
of None None O
the None None O
J None None O
domain None None O
is None None O
required None None O
to None None O
sensitize None None O
cells None None O
to None None O
apoptosis None None O
. None None O

Treatment None None O
of None None O
REF None None O
or None None O
REF None None O
expressing None None O
full None None O
- None None O
length None None O
T None None O
antigen None None O
, None None O
an None None O
N None None O
- None None O
terminal None None O
segment None None O
, None None O
or None None O
T251 None None O
- None None O
708 None None O
resulted None None O
in None None O
increased None None O
expression None None O
of None None O
the None None O
p53 None None O
- None None O
responsive None None O
MDM2 None None O
gene None None O
; None None O
apoptosis None None O
occurred None None O
through None None O
a None None O
p53 None None O
- None None O
dependent None None O
pathway None None O
, None None O
as None None O
p53 None None O
- None None O
null None None O
cells None None O
expressing None None O
these None None O
T None None O
antigens None None O
were None None O
resistant None None O
to None None O
5 None None O
- None None O
FU None None O
- None None O
induced None None O
apoptosis None None O
. None None O

Possible None None O
mechanisms None None O
involved None None O
in None None O
sensitizing None None O
cells None None O
to None None O
a None None O
p53 None None O
- None None O
dependent None None O
apoptosis None None O
pathway None None O
in None None O
spite None None O
of None None O
the None None O
ability None None O
of None None O
T None None O
antigen None None O
to None None O
bind None None O
and None None O
inactivate None None O
the None None O
transcriptional None None O
transactivating None None O
activity None None O
of None None O
p53 None None O
are None None O
discussed None None O
. None None O

Ovarian None None O
cancers None None O
overexpress None None O
the None None O
antimicrobial None None O
protein None None O
hCAP None None O
- None None O
18 None None O
and None None O
its None None O
derivative None None O
LL None None O
- None None O
37 None None O
increases None None O
ovarian None None O
cancer None None O
cell None None O
proliferation None None O
and None None O
invasion None None O
. None None O

The None None O
role None None O
of None None O
the None None O
pro None None O
- None None O
inflammatory None None O
peptide None None O
, None None O
LL None None O
- None None O
37 None None O
, None None O
and None None O
its None None O
pro None None O
- None None O
form None None O
, None None O
human None None O
cationic None None O
antimicrobial None None O
protein None None O
18 None None O
( None None O
hCAP None None O
- None None O
18 None None O
) None None O
, None None O
in None None O
cancer None None O
development None None O
and None None O
progression None None O
is None None O
poorly None None O
understood None None O
. None None O

In None None O
damaged None None O
and None None O
inflamed None None O
tissue None None O
, None None O
LL None None O
- None None O
37 None None O
functions None None O
as None None O
a None None O
chemoattractant None None O
, None None O
mitogen None None O
and None None O
pro None None O
- None None O
angiogenic None None O
factor None None O
suggesting None None O
that None None O
the None None O
peptide None None O
may None None O
potentiate None None O
tumor None None O
progression None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
characterize None None O
the None None O
distribution None None O
of None None O
hCAP None None O
- None None O
18 None None O
/ None None O
LL None None O
- None None O
37 None None O
in None None O
normal None None O
and None None O
cancerous None None O
ovarian None None O
tissue None None O
and None None O
to None None O
examine None None O
the None None O
effects None None O
of None None O
LL None None O
- None None O
37 None None O
on None None O
ovarian None None O
cancer None None O
cells None None O
. None None O

Expression None None O
of None None O
hCAP None None O
- None None O
18 None None O
/ None None O
LL None None O
- None None O
37 None None O
was None None O
localized None None O
to None None O
immune None None O
and None None O
granulosa None None O
cells None None O
of None None O
normal None None O
ovarian None None O
tissue None None O
. None None O

By None None O
contrast None None O
, None None O
ovarian None None O
tumors None None O
displayed None None O
significantly None None O
higher None None O
levels None None O
of None None O
hCAP None None O
- None None O
18 None None O
/ None None O
LL None None O
- None None O
37 None None O
where None None O
expression None None O
was None None O
observed None None O
in None None O
tumor None None O
and None None O
stromal None None O
cells None None O
. None None O

Protein None None O
expression None None O
was None None O
statistically None None O
compared None None O
to None None O
the None None O
degree None None O
of None None O
immune None None O
cell None None O
infiltration None None O
and None None O
microvessel None None O
density None None O
in None None O
epithelial None None O
- None None O
derived None None O
ovarian None None O
tumors None None O
and None None O
a None None O
significant None None O
correlation None None O
was None None O
observed None None O
for None None O
both None None O
. None None O

It None None O
was None None O
demonstrated None None O
that None None O
ovarian None None O
tumor None None O
tissue None None O
lysates None None O
and None None O
ovarian None None O
cancer None None O
cell None None O
lines None None O
express None None O
hCAP None None O
- None None O
18 None None O
/ None None O
LL None None O
- None None O
37 None None O
. None None O

Treatment None None O
of None None O
ovarian None None O
cancer None None O
cell None None O
lines None None O
with None None O
recombinant None None O
LL None None O
- None None O
37 None None O
stimulated None None O
proliferation None None O
, None None O
chemotaxis None None O
, None None O
invasion None None O
and None None O
matrix None None O
metalloproteinase None None O
expression None None O
. None None O

These None None O
data None None O
demonstrate None None O
for None None O
the None None O
first None None O
time None None O
that None None O
hCAP None None O
- None None O
18 None None O
/ None None O
LL None None O
- None None O
37 None None O
is None None O
significantly None None O
overexpressed None None O
in None None O
ovarian None None O
tumors None None O
and None None O
suggest None None O
LL None None O
- None None O
37 None None O
may None None O
contribute None None O
to None None O
ovarian None None O
tumorigenesis None None O
through None None O
direct None None O
stimulation None None O
of None None O
tumor None None O
cells None None O
, None None O
initiation None None O
of None None O
angiogenesis None None O
and None None O
recruitment None None O
of None None O
immune None None O
cells None None O
. None None O

These None None O
data None None O
provide None None O
further None None O
evidence None None O
of None None O
the None None O
existing None None O
relationship None None O
between None None O
pro None None O
- None None O
inflammatory None None O
molecules None None O
and None None O
ovarian None None O
cancer None None O
progression None None O
. None None O

Conclusion None None O

The None None O
survey None None O
indicated None None O
that None None O
, None None O
the None None O
study None None O
area None None O
has None None O
plenty None None O
of None None O
medicinal None None O
plants None None O
to None None O
treat None None O
a None None O
wide None None O
spectrum None None O
of None None O
human None None O
ailments None None O
. None None O

Earlier None None O
studies None None O
on None None O
traditional None None O
medicinal None None O
plants None None O
also None None O
revealed None None O
that None None O
the None None O
economically None None O
backward None None O
local None None O
and None None O
tribal None None O
people None None O
of None None O
Tamil None None O
Nadu None None O
prefer None None O
folk None None O
medicine None None O
due None None O
to None None O
low None None O
cost None None O
and None None O
sometimes None None O
it None None O
is None None O
a None None O
part None None O
of None None O
their None None O
social None None O
life None None O
and None None O
culture None None O
[ None None O
40 None None O
- None None O
45 None None O
] None None O
. None None O

It None None O
is None None O
evident None None O
from None None O
the None None O
interviews None None O
conducted None None O
in None None O
different None None O
villages None None O
, None None O
knowledge None None O
of None None O
medicinal None None O
plants None None O
is None None O
limited None None O
to None None O
traditional None None O
healers None None O
, None None O
herbalists None None O
and None None O
elderly None None O
persons None None O
who None None O
are None None O
living None None O
in None None O
rural None None O
areas None None O
. None None O

This None None O
study None None O
also None None O
points None None O
out None None O
that None None O
certain None None O
species None None O
of None None O
medicinal None None O
plants None None O
are None None O
being None None O
exploited None None O
by None None O
the None None O
local None None O
residents None None O
who None None O
are None None O
unaware None None O
of None None O
the None None O
importance None None O
of None None O
medicinal None None O
plants None None O
in None None O
the None None O
ecosystem None None O
. None None O

This None None O
study None None O
concluded None None O
that None None O
even None None O
though None None O
the None None O
accessibility None None O
of None None O
Western None None O
medicine None None O
for None None O
simple None None O
and None None O
complicated None None O
diseases None None O
is None None O
available None None O
, None None O
many None None O
people None None O
in None None O
the None None O
studied None None O
parts None None O
of None None O
Kancheepuram None None O
district None None O
is None None O
still None None O
continue None None O
to None None O
depend None None O
on None None O
medicinal None None O
plants None None O
, None None O
at None None O
least None None O
for None None O
the None None O
treatment None None O
of None None O
some None None O
simple None None O
diseases None None O
such None None O
as None None O
, None None O
cold None None O
, None None O
cough None None O
, None None O
fever None None O
, None None O
headache None None O
, None None O
poison None None O
bites None None O
, None None O
skin None None O
diseases None None O
and None None O
tooth None None O
infections None None O
. None None O

Well None None O
- None None O
knowledged None None O
healers None None O
have None None O
good None None O
interactions None None O
with None None O
patients None None O
and None None O
this None None O
would None None O
improve None None O
the None None O
quality None None O
of None None O
healthcare None None O
delivery None None O
. None None O

The None None O
present None None O
- None None O
day None None O
traditional None None O
healers None None O
are None None O
very None None O
old None None O
. None None O

Due None None O
to None None O
lack None None O
of None None O
interest None None O
among None None O
the None None O
younger None None O
generation None None O
as None None O
well None None O
as None None O
their None None O
tendency None None O
to None None O
migrate None None O
to None None O
cities None None O
for None None O
lucrative None None O
jobs None None O
, None None O
there None None O
is None None O
a None None O
possibility None None O
of None None O
losing None None O
this None None O
wealth None None O
of None None O
knowledge None None O
in None None O
the None None O
near None None O
future None None O
. None None O

It None None O
thus None None O
becomes None None O
necessary None None O
to None None O
acquire None None O
and None None O
preserve None None O
this None None O
traditional None None O
system None None O
of None None O
medicine None None O
by None None O
proper None None O
documentation None None O
and None None O
identification None None O
of None None O
specimens None None O
. None None O

Are None None O
former None None O
female None None O
elite None None O
athletes None None O
more None None O
likely None None O
to None None O
experience None None O
urinary None None O
incontinence None None O
later None None O
in None None O
life None None O
than None None O
non None None O
- None None O
athletes None None O
? None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
whether None None O
former None None O
female None None O
elite None None O
athletes None None O
are None None O
more None None O
likely None None O
to None None O
experience None None O
urinary None None O
incontinence None None O
( None None O
UI None None O
) None None O
later None None O
in None None O
life None None O
than None None O
non None None O
- None None O
athletes None None O
and None None O
to None None O
assess None None O
possible None None O
risk None None O
factors None None O
for None None O
UI None None O
in None None O
athletes None None O
. None None O

Three None None O
hundred None None O
and None None O
thirty None None O
- None None O
one None None O
former None None O
elite None None O
athletes None None O
( None None O
response None None O
rate None None O
81 None None O
% None None O
) None None O
and None None O
640 None None O
controls None None O
replied None None O
to None None O
a None None O
postal None None O
questionnaire None None O
including None None O
validated None None O
questions None None O
on None None O
UI None None O
. None None O

While None None O
competing None None O
in None None O
sport None None O
, None None O
10 None None O
. None None O
9 None None O
% None None O
and None None O
2 None None O
. None None O
7 None None O
% None None O
of None None O
the None None O
former None None O
elite None None O
athletes None None O
reported None None O
stress None None O
urinary None None O
incontinence None None O
( None None O
SUI None None O
) None None O
and None None O
urge None None O
incontinence None None O
, None None O
respectively None None O
. None None O

Presently None None O
, None None O
36 None None O
. None None O
5 None None O
% None None O
of None None O
the None None O
former None None O
elite None None O
athletes None None O
and None None O
36 None None O
. None None O
9 None None O
% None None O
of None None O
the None None O
controls None None O
reported None None O
SUI None None O
. None None O

9 None None O
. None None O
1 None None O
% None None O
and None None O
9 None None O
. None None O
4 None None O
% None None O
reported None None O
urge None None O
incontinence None None O
. None None O

Among None None O
former None None O
elite None None O
athletes None None O
, None None O
those None None O
with None None O
two None None O
or None None O
three None None O
children None None O
were None None O
more None None O
likely None None O
than None None O
nulliparous None None O
women None None O
to None None O
have None None O
UI None None O
now None None O
. None None O

Also None None O
, None None O
among None None O
former None None O
athletes None None O
, None None O
UI None None O
was None None O
more None None O
common None None O
in None None O
women None None O
with None None O
vs None None O
those None None O
without None None O
UI None None O
while None None O
competing None None O
( None None O
odds None None O
ratio None None O
8 None None O
. None None O
57 None None O
, None None O
95 None None O
% None None O
confidence None None O
interval None None O
: None None O
3 None None O
. None None O
55 None None O
- None None O
20 None None O
. None None O
71 None None O
) None None O
. None None O

Age None None O
, None None O
menopause None None O
and None None O
being None None O
regularly None None O
physically None None O
active None None O
now None None O
were None None O
not None None O
associated None None O
with None None O
UI None None O
in None None O
either None None O
group None None O
. None None O

Based None None O
on None None O
this None None O
study None None O
, None None O
the None None O
prevalence None None O
of None None O
UI None None O
does None None O
not None None O
seem None None O
to None None O
be None None O
higher None None O
in None None O
former None None O
athletes None None O
than None None O
in None None O
controls None None O
. None None O

However None None O
, None None O
the None None O
results None None O
indicate None None O
that None None O
UI None None O
early None None O
in None None O
life None None O
, None None O
as None None O
reported None None O
during None None O
elite None None O
sport None None O
, None None O
is None None O
a None None O
strong None None O
predictor None None O
of None None O
UI None None O
later None None O
in None None O
life None None O
. None None O

Imaging None None O
tumor None None O
angiogenesis None None O
. None None O

Since None None O
the None None O
discovery None None O
of None None O
vascular None None O
- None None O
specific None None O
growth None None O
factors None None O
with None None O
angiogenic None None O
activity None None O
, None None O
there None None O
has None None O
been None None O
a None None O
significant None None O
effort None None O
to None None O
develop None None O
cancer None None O
drugs None None O
that None None O
restrict None None O
tumorigenesis None None O
by None None O
targeting None None O
the None None O
blood None None O
supply None None O
. None None O

In None None O
this None None O
issue None None O
of None None O
the None None O
JCI None None O
, None None O
Mancuso None None O
et None None O
al None None O
. None None O
use None None O
mouse None None O
models None None O
to None None O
better None None O
understand None None O
the None None O
plasticity None None O
of None None O
the None None O
tumor None None O
vasculature None None O
in None None O
the None None O
face None None O
of None None O
antiangiogenic None None O
therapy None None O
( None None O
see None None O
the None None O
related None None O
article None None O
beginning None None O
on None None O
page None None O
2610 None None O
) None None O
. None None O

They None None O
describe None None O
a None None O
rapid None None O
regrowth None None O
of None None O
the None None O
tumor None None O
vasculature None None O
following None None O
withdrawal None None O
of None None O
VEGFR None None O
inhibitors None None O
, None None O
emphasizing None None O
the None None O
importance None None O
of None None O
fully None None O
understanding None None O
the None None O
function None None O
of None None O
these None None O
and None None O
similar None None O
treatments None None O
used None None O
in None None O
the None None O
clinic None None O
at None None O
the None None O
cellular None None O
and None None O
molecular None None O
level None None O
. None None O

Early None None O
post None None O
- None None O
mortem None None O
metabolism None None O
and None None O
muscle None None O
shortening None None O
in None None O
the None None O
Pectoralis None None O
major None None O
muscle None None O
of None None O
broiler None None O
chickens None None O
. None None O

Three None None O
experiments None None O
were None None O
conducted None None O
to None None O
examine None None O
the None None O
effects None None O
of None None O
sodium None None O
pentobarbital None None O
( None None O
SP None None O
) None None O
, None None O
iodoacetate None None O
( None None O
IO None None O
) None None O
, None None O
tubocurarine None None O
( None None O
TC None None O
) None None O
, None None O
and None None O
surgical None None O
denervation None None O
( None None O
DN None None O
) None None O
on None None O
early None None O
rigor None None O
development None None O
in None None O
broiler None None O
breast None None O
muscle None None O
. None None O

In None None O
Experiment None None O
1 None None O
, None None O
birds None None O
were None None O
either None None O
anesthetized None None O
or None None O
not None None O
with None None O
SP None None O
before None None O
receiving None None O
an None None O
injection None None O
of None None O
IO None None O
or None None O
TC None None O
or None None O
maintained None None O
as None None O
noninjected None None O
controls None None O
. None None O

Experiment None None O
2 None None O
was None None O
identical None None O
except None None O
that None None O
a None None O
treatment None None O
of None None O
denervation None None O
of None None O
the None None O
breast None None O
muscle None None O
was None None O
added None None O
. None None O

Experiment None None O
3 None None O
was None None O
conducted None None O
to None None O
contrast None None O
birds None None O
at None None O
1 None None O
day None None O
( None None O
DN1 None None O
) None None O
and None None O
3 None None O
days None None O
( None None O
DN3 None None O
) None None O
denervation None None O
prior None None O
to None None O
slaughter None None O
to None None O
nonoperated None None O
controls None None O
. None None O

Measurements None None O
of None None O
muscle None None O
lactate None None O
, None None O
ATP None None O
, None None O
R None None O
value None None O
( None None O
ratio None None O
of None None O
inosine None None O
to None None O
adenine None None O
nucleotides None None O
) None None O
, None None O
pH None None O
, None None O
sarcomere None None O
lengths None None O
, None None O
and None None O
shear None None O
were None None O
used None None O
to None None O
evaluate None None O
treatment None None O
effects None None O
. None None O

Results None None O
for None None O
Experiment None None O
1 None None O
showed None None O
no None None O
significant None None O
differences None None O
among None None O
treatment None None O
and None None O
control None None O
groups None None O
for None None O
ATP None None O
and None None O
lactate None None O
contents None None O
, None None O
R None None O
values None None O
, None None O
or None None O
sarcomere None None O
lengths None None O
; None None O
however None None O
, None None O
significantly None None O
lower None None O
pH None None O
and None None O
higher None None O
shear None None O
values None None O
were None None O
observed None None O
for None None O
control None None O
birds None None O
. None None O

In None None O
Experiment None None O
2 None None O
, None None O
no None None O
significant None None O
differences None None O
were None None O
observed None None O
among None None O
the None None O
treatment None None O
groups None None O
for None None O
ATP None None O
, None None O
R None None O
values None None O
, None None O
or None None O
sarcomere None None O
lengths None None O
. None None O

However None None O
, None None O
lactate None None O
and None None O
shear None None O
values None None O
were None None O
significantly None None O
lower None None O
, None None O
and None None O
pH None None O
higher None None O
, None None O
for None None O
the None None O
DN None None O
and None None O
SP None None O
treated None None O
birds None None O
. None None O

Experiment None None O
3 None None O
resulted None None O
in None None O
lower None None O
lactate None None O
and None None O
higher None None O
pH None None O
values None None O
for None None O
the None None O
DN3 None None O
treatment None None O
in None None O
comparison None None O
with None None O
both None None O
DN1 None None O
and None None O
control None None O
groups None None O
. None None O

Results None None O
of None None O
these None None O
studies None None O
indicate None None O
that None None O
the None None O
use None None O
of None None O
SP None None O
and None None O
DN None None O
can None None O
be None None O
used None None O
to None None O
alter None None O
the None None O
early None None O
profiles None None O
of None None O
rigor None None O
development None None O
. None None O

Angiogenesis None None O
associated None None O
with None None O
visceral None None O
and None None O
subcutaneous None None O
adipose None None O
tissue None None O
in None None O
severe None None O
human None None O
obesity None None O
. None None O

OBJECTIVE None None O
: None None O
The None None O
expansion None None O
of None None O
adipose None None O
tissue None None O
is None None O
linked None None O
to None None O
the None None O
development None None O
of None None O
its None None O
vasculature None None O
. None None O

However None None O
, None None O
the None None O
regulation None None O
of None None O
adipose None None O
tissue None None O
angiogenesis None None O
in None None O
humans None None O
has None None O
not None None O
been None None O
extensively None None O
studied None None O
. None None O

Our None None O
aim None None O
was None None O
to None None O
compare None None O
the None None O
angiogenesis None None O
associated None None O
with None None O
subcutaneous None None O
adipose None None O
tissue None None O
( None None O
SAT None None O
) None None O
and None None O
visceral None None O
adipose None None O
tissue None None O
( None None O
VAT None None O
) None None O
from None None O
the None None O
same None None O
obese None None O
patients None None O
in None None O
an None None O
in None None O
vivo None None O
model None None O
. None None O

RESEARCH None None O
DESIGN None None O
AND None None O
METHODS None None O
: None None O
Adipose None None O
tissue None None O
samples None None O
from None None O
visceral None None O
( None None O
VAT None None O
) None None O
and None None O
subcutaneous None None O
( None None O
SAT None None O
) None None O
sites None None O
, None None O
obtained None None O
from None None O
36 None None O
obese None None O
patients None None O
( None None O
mean None None O
BMI None None O
46 None None O
. None None O
5 None None O
kg None None O
/ None None O
m None None O
( None None O
2 None None O
) None None O
) None None O
during None None O
bariatric None None O
surgery None None O
, None None O
were None None O
layered None None O
on None None O
chick None None O
chorioallantoic None None O
membrane None None O
( None None O
CAM None None O
) None None O
. None None O

RESULTS None None O
: None None O
Both None None O
SAT None None O
and None None O
VAT None None O
expressed None None O
angiogenic None None O
factors None None O
without None None O
significant None None O
difference None None O
for None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
expression None None O
. None None O

Adipose None None O
tissue None None O
layered None None O
on None None O
CAM None None O
stimulated None None O
angiogenesis None None O
. None None O

Angiogenic None None O
stimulation None None O
was None None O
macroscopically None None O
detectable None None O
, None None O
with None None O
engulfment None None O
of None None O
the None None O
samples None None O
, None None O
in None None O
39 None None O
% None None O
and None None O
was None None O
evidenced None None O
by None None O
angiography None None O
in None None O
59 None None O
% None None O
of None None O
the None None O
samples None None O
. None None O

A None None O
connection None None O
between None None O
CAM None None O
and None None O
adipose None None O
tissue None None O
vessels None None O
was None None O
evidenced None None O
by None None O
immunohistochemistry None None O
, None None O
with None None O
recruitment None None O
of None None O
both None None O
avian None None O
and None None O
human None None O
endothelial None None O
cells None None O
. None None O

The None None O
angiogenic None None O
potency None None O
of None None O
adipose None None O
tissue None None O
was None None O
not None None O
related None None O
to None None O
its None None O
localization None None O
( None None O
with None None O
an None None O
angiogenic None None O
stimulation None None O
in None None O
60 None None O
% None None O
of None None O
SAT None None O
samples None None O
and None None O
61 None None O
% None None O
of None None O
VAT None None O
samples None None O
) None None O
or None None O
to None None O
adipocyte None None O
size None None O
or None None O
inflammatory None None O
infiltrate None None O
assessed None None O
in None None O
adipose None None O
samples None None O
before None None O
the None None O
graft None None O
on None None O
CAM None None O
. None None O

Stimulation None None O
of None None O
angiogenesis None None O
by None None O
adipose None None O
tissue None None O
was None None O
nearly None None O
abolished None None O
by None None O
bevacizumab None None O
, None None O
which None None O
specifically None None O
targets None None O
human None None O
VEGF None None O
. None None O

CONCLUSIONS None None O
: None None O
We None None O
have None None O
established None None O
a None None O
model None None O
to None None O
study None None O
the None None O
regulation None None O
of None None O
angiogenesis None None O
by None None O
human None None O
adipose None None O
tissue None None O
. None None O

This None None O
model None None O
highlighted None None O
the None None O
role None None O
of None None O
VEGF None None O
in None None O
angiogenesis None None O
in None None O
both None None O
SAT None None O
and None None O
VAT None None O
. None None O

The None None O
eukaryotic None None O
parasite None None O
Trypanosoma None None O
brucei None None O
is None None O
able None None O
to None None O
import None None O
inositol None None O
from None None O
the None None O
environment None None O
or None None O
synthesize None None O
it None None O
de None None O
novo None None O
. None None O

However None None O
, None None O
according None None O
to None None O
the None None O
current None None O
model None None O
, None None O
inositol None None O
imported None None O
from None None O
the None None O
environment None None O
is None None O
utilized None None O
primarily None None O
in None None O
bulk None None O
phosphatidylinositol None None O
( None None O
red None None O
and None None O
yellow None None O
phospholipid None None O
) None None O
production None None O
via None None O
a None None O
phosphatidylinositol None None O
synthase None None O
( None None O
PIS None None O
) None None O
localized None None O
to None None O
the None None O
Golgi None None O
complex None None O
. None None O

Inositol None None O
synthesized None None O
de None None O
novo None None O
is None None O
primarily None None O
used None None O
to None None O
generate None None O
phosphatidylinositol None None O
that None None O
is None None O
used None None O
for None None O
production None None O
of None None O
glycosylphosphatidylinositols None None O
( None None O
GPIs None None O
) None None O
. None None O

The None None O
de None None O
novo None None O
- None None O
synthesized None None O
inositol None None O
is None None O
believed None None O
to None None O
be None None O
utilized None None O
mostly None None O
for None None O
GPI None None O
production None None O
because None None O
the None None O
IMPase None None O
that None None O
dephosphorylates None None O
inositol None None O
3 None None O
- None None O
phosphate None None O
to None None O
inositol None None O
is None None O
localized None None O
to None None O
the None None O
ER None None O
, None None O
where None None O
GPI None None O
synthesis None None O
occurs None None O
. None None O

Mutants None None O
lacking None None O
TbINO1 None None O
are None None O
inviable None None O
because None None O
of None None O
diminished None None O
GPI None None O
production None None O
. None None O

Further None None O
Characterization None None O
of None None O
Activin None None O
A None None O
- None None O
induced None None O
IgA None None O
Response None None O
in None None O
Murine None None O
B None None O
Lymphocytes None None O
. None None O

We None None O
have None None O
recently None None O
shown None None O
that None None O
activin None None O
A None None O
, None None O
a None None O
member None None O
of None None O
TGF None None O
- None None O
beta None None O
superfamily None None O
, None None O
stimulates None None O
mouse None None O
B None None O
cells None None O
to None None O
express None None O
IgA None None O
isotype None None O
but None None O
other None None O
isotypes None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
further None None O
characterized None None O
effects None None O
of None None O
activin None None O
A None None O
on None None O
B None None O
cell None None O
growth None None O
and None None O
IgA None None O
expression None None O
. None None O

We None None O
found None None O
that None None O
activin None None O
A None None O
did None None O
not None None O
have None None O
effect None None O
on None None O
LPS None None O
- None None O
stimulated None None O
cell None None O
viability None None O
. None None O

In None None O
parallel None None O
, None None O
CFSE None None O
staining None None O
analysis None None O
revealed None None O
that None None O
activin None None O
A None None O
did None None O
not None None O
alter None None O
cell None None O
division None None O
. None None O

An None None O
increase None None O
of None None O
IgA None None O
secretion None None O
by None None O
activin None None O
A None None O
was None None O
completely None None O
abrogated None None O
by None None O
anti None None O
- None None O
activin None None O
A None None O
Ab None None O
but None None O
not None None O
by None None O
anti None None O
- None None O
TGFbeta1 None None O
Ab None None O
. None None O

In None None O
the None None O
same None None O
conditions None None O
, None None O
no None None O
other None None O
isotypes None None O
are None None O
significantly None None O
affected None None O
by None None O
each None None O
antibody None None O
treatment None None O
. None None O

Finally None None O
, None None O
activin None None O
A None None O
, None None O
as None None O
similar None None O
to None None O
TGF None None O
- None None O
beta1 None None O
, None None O
increased None None O
IgA None None O
secretion None None O
by None None O
mesenteric None None O
lymph None None O
node None None O
cells None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
activin None None O
A None None O
can None None O
specifically None None O
stimulate None None O
IgA None None O
response None None O
, None None O
independent None None O
of None None O
TGF None None O
- None None O
beta None None O
in None None O
the None None O
gut None None O
. None None O

2 None None O
. None None O
1 None None O
. None None O
3 None None O

Pixel None None O
Classification None None O

The None None O
feature None None O
vector None None O
of None None O
a None None O
grid None None O
, None None O
which None None O
consists None None O
of None None O
nine None None O
features None None O
, None None O
is None None O
normalized None None O
to None None O
[ None None O
0 None None O
, None None O
1 None None O
] None None O
, None None O
and None None O
the None None O
position None None O
features None None O
are None None O
scaled None None O
by None None O
the None None O
weighting None None O
coefficient None None O
wpos None None O
. None None O

Then None None O
, None None O
taking None None O
the None None O
nine None None O
dimensional None None O
vector None None O
of None None O
each None None O
grid None None O
as None None O
the None None O
input None None O
of None None O
the None None O
classifier None None O
, None None O
the None None O
ROI None None O
and None None O
non None None O
- None None O
ROI None None O
background None None O
in None None O
ultrasonic None None O
breast None None O
tumor None None O
images None None O
can None None O
be None None O
distinguished None None O
. None None O

In None None O
this None None O
section None None O
, None None O
the None None O
self None None O
- None None O
organizing None None O
feature None None O
map None None O
neural None None O
network None None O
( None None O
SOMNN None None O
) None None O
[ None None O
25 None None O
] None None O
, None None O
proposed None None O
by None None O
Kohonen None None O
according None None O
to None None O
characteristics None None O
of None None O
the None None O
nervous None None O
system None None O
, None None O
is None None O
used None None O
for None None O
the None None O
classification None None O
of None None O
these None None O
grids None None O
to None None O
detect None None O
the None None O
ROI None None O
automatically None None O
. None None O

The None None O
SOM None None O
is None None O
trained None None O
by None None O
the None None O
unsupervised None None O
learning None None O
to None None O
produce None None O
a None None O
low None None O
- None None O
dimensional None None O
discretized None None O
representation None None O
of None None O
the None None O
input None None O
space None None O
of None None O
the None None O
training None None O
samples None None O
, None None O
and None None O
it None None O
uses None None O
a None None O
neighborhood None None O
function None None O
to None None O
preserve None None O
the None None O
topological None None O
properties None None O
of None None O
the None None O
input None None O
space None None O
, None None O
which None None O
makes None None O
it None None O
different None None O
from None None O
other None None O
artificial None None O
neural None None O
networks None None O
. None None O

In None None O
this None None O
way None None O
, None None O
the None None O
SOM None None O
is None None O
able None None O
to None None O
classify None None O
the None None O
sub None None O
- None None O
blocks None None O
into None None O
n None None O
clusters None None O
only None None O
by None None O
the None None O
unsupervised None None O
learning None None O
. None None O

In None None O
our None None O
study None None O
, None None O
the None None O
output None None O
layer None None O
number None None O
n None None O
is None None O
set None None O
to None None O
2 None None O
( None None O
ROI None None O
and None None O
non None None O
- None None O
ROI None None O
output None None O
) None None O
and None None O
the None None O
feature None None O
vector None None O
extracted None None O
from None None O
each None None O
grid None None O
is None None O
taken None None O
as None None O
the None None O
input None None O
. None None O

To None None O
map None None O
the None None O
sorted None None O
sub None None O
- None None O
blocks None None O
back None None O
to None None O
the None None O
size None None O
of None None O
the None None O
original None None O
ultrasonic None None O
images None None O
, None None O
the None None O
initial None None O
result None None O
of None None O
ROI None None O
detection None None O
can None None O
be None None O
represented None None O
by None None O
a None None O
binary None None O
image None None O
as None None O
shown None None O
in None None O
Fig None None O
. None None O

( None None O
2d None None O
) None None O
, None None O
where None None O
white None None O
areas None None O
indicate None None O
the None None O
ROI None None O
candidates None None O
while None None O
black None None O
areas None None O
the None None O
non None None O
- None None O
ROIs None None O
. None None O

Hemostasis None None O
and None None O
mechanism None None O
of None None O
action None None O
of None None O
selective None None O
antimetastatic None None O
drugs None None O
in None None O
mice None None O
bearing None None O
Lewis None None O
lung None None O
carcinoma None None O
. None None O

The None None O
selective None None O
antimetastatic None None O
agents None None O
p None None O
- None None O
( None None O
3 None None O
, None None O
3 None None O
- None None O
dimethyl None None O
- None None O
1 None None O
- None None O
triazeno None None O
) None None O
benzoic None None O
acid None None O
potassium None None O
salt None None O
( None None O
DM None None O
- None None O
COOK None None O
) None None O
, None None O
5 None None O
- None None O
( None None O
3 None None O
, None None O
3 None None O
- None None O
dimethyl None None O
- None None O
1 None None O
- None None O
triazeno None None O
) None None O
imidazole None None O
- None None O
4 None None O
- None None O
carboxamide None None O
( None None O
DTIC None None O
) None None O
and None None O
( None None O
+ None None O
/ None None O
- None None O
) None None O
1 None None O
, None None O
2 None None O
- None None O
di None None O
( None None O
3 None None O
, None None O
5 None None O
- None None O
dioxopiperazin None None O
- None None O
1 None None O
- None None O
yl None None O
) None None O
propane None None O
( None None O
ICRF None None O
- None None O
159 None None O
) None None O
have None None O
been None None O
shown None None O
to None None O
markedly None None O
depress None None O
the None None O
formation None None O
of None None O
spontaneous None None O
hematogenous None None O
metastases None None O
in None None O
mice None None O
bearing None None O
s None None O
. None None O
c None None O
. None None O

Lewis None None O
lung None None O
carcinoma None None O
, None None O
with None None O
a None None O
mechanism None None O
unrelated None None O
to None None O
cytotoxicity None None O
for None None O
tumor None None O
cells None None O
. None None O

The None None O
effects None None O
on None None O
hemostasis None None O
of None None O
DM None None O
- None None O
COOK None None O
, None None O
DTIC None None O
and None None O
ICRF None None O
- None None O
159 None None O
have None None O
thus None None O
been None None O
examined None None O
in None None O
comparison None None O
with None None O
those None None O
of None None O
a None None O
purely None None O
cytotoxic None None O
agent None None O
, None None O
cyclophosphamide None None O
, None None O
in None None O
mice None None O
bearing None None O
i None None O
. None None O
m None None O
. None None O

Lewis None None O
lung None None O
carcinoma None None O
. None None O

The None None O
parameters None None O
considered None None O
are None None O
the None None O
number None None O
of None None O
platelets None None O
and None None O
their None None O
aggregability None None O
, None None O
prothrombin None None O
and None None O
partial None None O
thromboplastin None None O
times None None O
, None None O
plasma None None O
fibrinogen None None O
concentration None None O
and None None O
tumor None None O
cell None None O
procoagulant None None O
activity None None O
. None None O

Slight None None O
variations None None O
are None None O
caused None None O
by None None O
drug None None O
treatment None None O
in None None O
tumor None None O
- None None O
bearing None None O
mice None None O
as None None O
compared None None O
with None None O
untreated None None O
tumor None None O
- None None O
bearing None None O
controls None None O
; None None O
the None None O
pattern None None O
of None None O
effects None None O
of None None O
the None None O
selective None None O
antimetastatic None None O
agents None None O
does None None O
not None None O
differ None None O
from None None O
that None None O
of None None O
the None None O
reference None None O
cytotoxic None None O
compound None None O
used None None O
, None None O
cyclophosphamide None None O
. None None O

These None None O
data None None O
thus None None O
indicate None None O
that None None O
the None None O
effects None None O
on None None O
hemostasis None None O
of None None O
the None None O
drugs None None O
examined None None O
can None None O
contribute None None O
only None None O
marginally None None O
to None None O
their None None O
antimetastatic None None O
action None None O
, None None O
since None None O
more None None O
pronounced None None O
effects None None O
on None None O
hemostasis None None O
have None None O
been None None O
shown None None O
to None None O
be None None O
required None None O
to None None O
significantly None None O
affect None None O
metastasis None None O
formation None None O
. None None O

Additional None None O
tests None None O
of None None O
interest None None O
to None None O
the None None O
dermatologist None None O
. None None O

The None None O
carcinoid None None O
syndrome None None O
and None None O
its None None O
clinical None None O
manifestations None None O
have None None O
been None None O
discussed None None O
. None None O

The None None O
standard None None O
laboratory None None O
test None None O
for None None O
making None None O
that None None O
diagnosis None None O
is None None O
urinary None None O
5 None None O
- None None O
HIAA None None O
levels None None O
but None None O
newer None None O
, None None O
more None None O
sensitive None None O
tests None None O
may None None O
also None None O
be None None O
available None None O
. None None O

Active None None O
hair None None O
growth None None O
( None None O
anagen None None O
) None None O
is None None O
associated None None O
with None None O
angiogenesis None None O
. None None O

After None None O
the None None O
completion None None O
of None None O
skin None None O
development None None O
, None None O
angiogenesis None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
the None None O
growth None None O
of None None O
new None None O
capillaries None None O
from None None O
pre None None O
- None None O
existing None None O
blood None None O
vessels None None O
, None None O
is None None O
held None None O
to None None O
occur None None O
in None None O
the None None O
skin None None O
only None None O
under None None O
pathologic None None O
conditions None None O
. None None O

It None None O
has None None O
long None None O
been None None O
noted None None O
, None None O
however None None O
, None None O
that None None O
hair None None O
follicle None None O
cycling None None O
is None None O
associated None None O
with None None O
prominent None None O
changes None None O
in None None O
skin None None O
perfusion None None O
, None None O
that None None O
the None None O
epithelial None None O
hair None None O
bulbs None None O
of None None O
anagen None None O
follicles None None O
display None None O
angiogenic None None O
properties None None O
, None None O
and None None O
that None None O
the None None O
follicular None None O
dermal None None O
papilla None None O
can None None O
produce None None O
angiogenic None None O
factors None None O
. None None O

Despite None None O
these None None O
suggestive None None O
observations None None O
, None None O
no None None O
formal None None O
proof None None O
is None None O
as None None O
yet None None O
available None None O
for None None O
the None None O
concept None None O
that None None O
angiogenesis None None O
is None None O
a None None O
physiologic None None O
event None None O
that None None O
occurs None None O
all None None O
over None None O
the None None O
mature None None O
mammalian None None O
integument None None O
whenever None None O
hair None None O
follicles None None O
switch None None O
from None None O
resting None None O
( None None O
telogen None None O
) None None O
to None None O
active None None O
growth None None O
( None None O
anagen None None O
) None None O
. None None O

This None None O
study None None O
uses None None O
quantitative None None O
histomorphometry None None O
and None None O
double None None O
- None None O
immunohistologic None None O
detection None None O
techniques None None O
for None None O
the None None O
demarcation None None O
of None None O
proliferating None None O
endothelial None None O
cells None None O
, None None O
to None None O
show None None O
that None None O
synchronized None None O
hair None None O
follicle None None O
cycling None None O
in None None O
adolescent None None O
C57BL None None O
/ None None O
6 None None O
mice None None O
is None None O
associated None None O
with None None O
substantial None None O
angiogenesis None None O
, None None O
and None None O
that None None O
inhibiting None None O
angiogenesis None None O
in None None O
vivo None None O
by None None O
the None None O
intraperitoneal None None O
application None None O
of None None O
a None None O
fumagillin None None O
derivative None None O
retards None None O
experimentally None None O
induced None None O
anagen None None O
development None None O
in None None O
these None None O
mice None None O
. None None O

Thus None None O
, None None O
angiogenesis None None O
is None None O
a None None O
physiologic None None O
event None None O
in None None O
normal None None O
postnatal None None O
murine None None O
skin None None O
, None None O
apparently None None O
is None None O
dictated None None O
by None None O
the None None O
hair None None O
follicle None None O
, None None O
and None None O
appears None None O
to None None O
be None None O
required None None O
for None None O
normal None None O
anagen None None O
development None None O
. None None O

Anagen None None O
- None None O
associated None None O
angiogenesis None None O
offers None None O
an None None O
attractive None None O
model None None O
for None None O
identifying None None O
the None None O
physiologic None None O
controls None None O
of None None O
cutaneous None None O
angiogenesis None None O
, None None O
and None None O
an None None O
interesting None None O
system None None O
for None None O
screening None None O
the None None O
effects None None O
of None None O
potential None None O
antiangiogenic None None O
drugs None None O
in None None O
vivo None None O
. None None O

Metabolic None None O
regulation None None O
by None None O
p53 None None O
. None None O

We None None O
are None None O
increasingly None None O
aware None None O
that None None O
cellular None None O
metabolism None None O
plays None None O
a None None O
vital None None O
role None None O
in None None O
diseases None None O
such None None O
as None None O
cancer None None O
, None None O
and None None O
that None None O
p53 None None O
is None None O
an None None O
important None None O
regulator None None O
of None None O
metabolic None None O
pathways None None O
. None None O

By None None O
transcriptional None None O
activation None None O
and None None O
other None None O
means None None O
, None None O
p53 None None O
is None None O
able None None O
to None None O
contribute None None O
to None None O
the None None O
regulation None None O
of None None O
glycolysis None None O
, None None O
oxidative None None O
phosphorylation None None O
, None None O
glutaminolysis None None O
, None None O
insulin None None O
sensitivity None None O
, None None O
nucleotide None None O
biosynthesis None None O
, None None O
mitochondrial None None O
integrity None None O
, None None O
fatty None None O
acid None None O
oxidation None None O
, None None O
antioxidant None None O
response None None O
, None None O
autophagy None None O
and None None O
mTOR None None O
signalling None None O
. None None O

The None None O
ability None None O
to None None O
positively None None O
and None None O
negatively None None O
regulate None None O
many None None O
of None None O
these None None O
pathways None None O
, None None O
combined None None O
with None None O
feedback None None O
signalling None None O
from None None O
these None None O
pathways None None O
to None None O
p53 None None O
, None None O
demonstrates None None O
the None None O
reciprocal None None O
and None None O
flexible None None O
nature None None O
of None None O
the None None O
regulation None None O
, None None O
facilitating None None O
a None None O
diverse None None O
range None None O
of None None O
responses None None O
to None None O
metabolic None None O
stress None None O
. None None O

Intriguingly None None O
, None None O
metabolic None None O
stress None None O
triggers None None O
primarily None None O
an None None O
adaptive None None O
( None None O
rather None None O
than None None O
pro None None O
- None None O
apoptotic None None O
) None None O
p53 None None O
response None None O
, None None O
and None None O
p53 None None O
is None None O
emerging None None O
as None None O
an None None O
important None None O
regulator None None O
of None None O
metabolic None None O
homeostasis None None O
. None None O

A None None O
better None None O
understanding None None O
of None None O
how None None O
p53 None None O
coordinates None None O
metabolic None None O
adaptation None None O
will None None O
facilitate None None O
the None None O
identification None None O
of None None O
novel None None O
therapeutic None None O
targets None None O
and None None O
will None None O
also None None O
illuminate None None O
the None None O
wider None None O
role None None O
of None None O
p53 None None O
in None None O
human None None O
biology None None O
. None None O

[ None None O
Activation None None O
of None None O
sterol None None O
regulatory None None O
element None None O
binding None None O
protein None None O
and None None O
its None None O
involvement None None O
in None None O
endothelial None None O
cell None None O
migration None None O
] None None O

OBJECTIVE None None O
: None None O
To None None O
study None None O
the None None O
activation None None O
of None None O
sterol None None O
regulatory None None O
element None None O
binding None None O
protein None None O
( None None O
SREBP None None O
) None None O
and None None O
its None None O
critical None None O
role None None O
in None None O
endothelial None None O
cell None None O
migration None None O
. None None O

METHODS None None O
: None None O
Bovine None None O
aortic None None O
endothelial None None O
cells None None O
( None None O
ECs None None O
) None None O
were None None O
cultured None None O
. None None O

The None None O
expression None None O
of None None O
SREBP None None O
and None None O
Cdc42 None None O
were None None O
determined None None O
by None None O
Western None None O
blot None None O
and None None O
quantitative None None O
real None None O
- None None O
time None None O
PCR None None O
. None None O

Moreover None None O
, None None O
outward None None O
growth None None O
migration None None O
model None None O
and None None O
transwell None None O
chamber None None O
assay None None O
were None None O
used None None O
to None None O
detect None None O
ECs None None O
migration None None O
. None None O

RESULTS None None O
: None None O
( None None O
1 None None O
) None None O
SREBP None None O
was None None O
activated None None O
during None None O
ECs None None O
migration None None O
. None None O

Western None None O
blot None None O
analysis None None O
demonstrated None None O
increased None None O
active None None O
form None None O
SREBP None None O
in None None O
migrating None None O
as None None O
compared None None O
to None None O
non None None O
- None None O
migrating None None O
ECs None None O
population None None O
. None None O

SREBP None None O
activation None None O
decreased None None O
as None None O
ECs None None O
migration None None O
slowed None None O
; None None O
( None None O
2 None None O
) None None O
Coincidental None None O
with None None O
SREBP None None O
activation None None O
, None None O
mRNA None None O
expression None None O
of None None O
its None None O
target None None O
genes None None O
such None None O
as None None O
low None None O
density None None O
lipoprotein None None O
receptor None None O
, None None O
HMG None None O
- None None O
CoA None None O
reductase None None O
, None None O
and None None O
fatty None None O
acid None None O
synthase None None O
also None None O
increased None None O
in None None O
migrating None None O
ECs None None O
population None None O
as None None O
detected None None O
by None None O
real None None O
- None None O
time None None O
PCR None None O
; None None O
( None None O
3 None None O
) None None O
Migration None None O
induced None None O
SREBP None None O
activation None None O
in None None O
ECs None None O
was None None O
inhibited None None O
by None None O
SREBP None None O
- None None O
acting None None O
protein None None O
RNAi None None O
and None None O
pharmacologically None None O
by None None O
25 None None O
- None None O
hydroxycholesterol None None O
; None None O
( None None O
4 None None O
) None None O
Inhibition None None O
of None None O
SREBP None None O
led None None O
to None None O
decreased None None O
ECs None None O
migration None None O
in None None O
various None None O
models None None O
; None None O
( None None O
5 None None O
) None None O
Cells None None O
genetically None None O
deficient None None O
in None None O
SREBP None None O
- None None O
acting None None O
protein None None O
, None None O
S1P None None O
, None None O
or None None O
S2P None None O
, None None O
phenotypically None None O
exhibited None None O
impaired None None O
migration None None O
; None None O
( None None O
6 None None O
) None None O
SREBP None None O
inhibition None None O
in None None O
ECs None None O
suppressed None None O
the None None O
activity None None O
of None None O
small None None O
GTPase None None O
Cdc42 None None O
, None None O
a None None O
key None None O
molecule None None O
for None None O
ECs None None O
motility None None O
. None None O

CONCLUSIONS None None O
: None None O
SREBP None None O
is None None O
activated None None O
during None None O
and None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
ECs None None O
migration None None O
. None None O

Targeting None None O
SREBP None None O
could None None O
become None None O
a None None O
novel None None O
approach None None O
in None None O
fighting None None O
diseases None None O
involving None None O
abnormal None None O
ECs None None O
migration None None O
. None None O

Structure None None O
of None None O
human None None O
hemoglobin None None O
messenger None None O
RNA None None O
and None None O
its None None O
relation None None O
to None None O
hemoglobinopathies None None O
. None None O

1 None None O
. None None O

One None None O
- None None O
fifth None None O
to None None O
1 None None O
/ None None O
4 None None O
of None None O
globin None None O
mRNA None None O
is None None O
untranslated None None O
sequence None None O
other None None O
than None None O
polyadenylic None None O
acid None None O
. None None O

2 None None O
. None None O

The None None O
untranslated None None O
sequences None None O
of None None O
mRNA None None O
vary None None O
markedly None None O
in None None O
their None None O
sequence None None O
and None None O
in None None O
their None None O
length None None O
. None None O

3 None None O
. None None O

Globin None None O
mRNAs None None O
demonstrate None None O
a None None O
marked None None O
bias None None O
in None None O
codon None None O
selection None None O
. None None O

4 None None O
. None None O

Viral None None O
mRNA None None O
shows None None O
a None None O
quite None None O
different None None O
pattern None None O
of None None O
codon None None O
selection None None O
; None None O
therefore None None O
, None None O
the None None O
selection None None O
of None None O
codons None None O
is None None O
not None None O
uniform None None O
for None None O
all None None O
mRNAs None None O
functioning None None O
in None None O
animal None None O
cells None None O
. None None O

5 None None O
. None None O

Elongated None None O
hemoglobin None None O
chains None None O
can None None O
be None None O
accounted None None O
for None None O
by None None O
frame None None O
- None None O
shift None None O
mutations None None O
, None None O
or None None O
point None None O
mutations None None O
within None None O
the None None O
normal None None O
termination None None O
codon None None O
. None None O

The None None O
additional None None O
amino None None O
acids None None O
are None None O
then None None O
coded None None O
for None None O
by None None O
sequences None None O
that None None O
are None None O
normally None None O
untranslated None None O
. None None O

6 None None O
. None None O

Certain None None O
hemoglobin None None O
deletion None None O
mutants None None O
occur None None O
at None None O
sites None None O
where None None O
there None None O
are None None O
partially None None O
reiterated None None O
sequences None None O
within None None O
the None None O
heomoglobin None None O
messenger None None O
RNA None None O
. None None O

Extrapyramidal None None O
symptoms None None O
based None None O
on None None O
Extrapyramidal None None O
Symptoms None None O
Rating None None O
Scale None None O

Contemporary None None O
perspectives None None O
on None None O
vital None None O
pulp None None O
therapy None None O
: None None O
views None None O
from None None O
the None None O
endodontists None None O
and None None O
pediatric None None O
dentists None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
level None None O
of None None O
agreement None None O
between None None O
pediatric None None O
dentists None None O
and None None O
endodontists None None O
at None None O
a None None O
pulp None None O
therapy None None O
symposium None None O
conjointly None None O
sponsored None None O
by None None O
the None None O
American None None O
Association None None O
of None None O
Endodontists None None O
( None None O
AAE None None O
) None None O
and None None O
the None None O
American None None O
Academy None None O
of None None O
Pediatric None None O
Dentistry None None O
( None None O
AAPD None None O
) None None O
on None None O
November None None O
2 None None O
- None None O
3 None None O
, None None O
2007 None None O
. None None O

Presymposium None None O
and None None O
postsymposium None None O
tests None None O
were None None O
administered None None O
, None None O
and None None O
respondent None None O
answers None None O
were None None O
compared None None O
between None None O
pediatric None None O
dentists None None O
and None None O
endodontists None None O
. None None O

Opinions None None O
on None None O
3 None None O
areas None None O
were None None O
sought None None O
: None None O
pulp None None O
therapy None None O
for None None O
cariously None None O
involved None None O
primary None None O
teeth None None O
; None None O
indirect None None O
pulp None None O
treatment None None O
( None None O
IPT None None O
) None None O
for None None O
cariously None None O
involved None None O
immature None None O
permanent None None O
teeth None None O
; None None O
and None None O
innovative None None O
treatment None None O
options None None O
including None None O
pulpal None None O
revascularization None None O
and None None O
regeneration None None O
. None None O

Results None None O
were None None O
analyzed None None O
with None None O
chi2 None None O
tests None None O
. None None O

Comparisons None None O
of None None O
presymposium None None O
and None None O
postsymposium None None O
responses None None O
and None None O
between None None O
the None None O
2 None None O
groups None None O
of None None O
attendees None None O
indicated None None O
that None None O
the None None O
pediatric None None O
dentistry None None O
and None None O
endodontic None None O
communities None None O
agree None None O
that None None O
formocresol None None O
will None None O
be None None O
replaced None None O
as None None O
a None None O
primary None None O
tooth None None O
pulpotomy None None O
agent None None O
, None None O
that None None O
mineral None None O
trioxide None None O
is None None O
the None None O
first None None O
choice None None O
to None None O
take None None O
its None None O
place None None O
, None None O
that None None O
IPT None None O
in None None O
primary None None O
teeth None None O
holds None None O
hope None None O
as None None O
a None None O
replacement None None O
for None None O
pulpotomy None None O
, None None O
and None None O
that None None O
IPT None None O
is None None O
an None None O
acceptable None None O
pulp None None O
therapy None None O
technique None None O
for None None O
cariously None None O
involved None None O
young None None O
permanent None None O
teeth None None O
. None None O

Both None None O
groups None None O
believe None None O
that None None O
pulp None None O
revascularization None None O
and None None O
regeneration None None O
will None None O
be None None O
viable None None O
treatment None None O
modalities None None O
in None None O
the None None O
future None None O
. None None O

The None None O
AAE None None O
and None None O
the None None O
AAPD None None O
are None None O
positioned None None O
to None None O
begin None None O
preparation None None O
of None None O
best None None O
practice None None O
guidelines None None O
that None None O
share None None O
common None None O
language None None O
and None None O
treatment None None O
recommendations None None O
for None None O
pulp None None O
therapies None None O
performed None None O
by None None O
both None None O
specialties None None O
. None None O

Regulation None None O
of None None O
p53 None None O
- None None O
dependent None None O
apoptosis None None O
, None None O
transcriptional None None O
repression None None O
, None None O
and None None O
cell None None O
transformation None None O
by None None O
phosphorylation None None O
of None None O
the None None O
55 None None O
- None None O
kilodalton None None O
E1B None None O
protein None None O
of None None O
human None None O
adenovirus None None O
type None None O
5 None None O
. None None O

The None None O
adenovirus None None O
type None None O
5 None None O
55 None None O
- None None O
kDa None None O
E1B None None O
protein None None O
( None None O
E1B None None O
- None None O
55kDa None None O
) None None O
cooperates None None O
with None None O
E1A None None O
gene None None O
products None None O
to None None O
induce None None O
cell None None O
transformation None None O
. None None O

E1A None None O
proteins None None O
stimulate None None O
DNA None None O
synthesis None None O
and None None O
cell None None O
proliferation None None O
; None None O
however None None O
, None None O
they None None O
also None None O
cause None None O
rapid None None O
cell None None O
death None None O
by None None O
p53 None None O
- None None O
dependent None None O
and None None O
p53 None None O
- None None O
independent None None O
apoptosis None None O
. None None O

It None None O
is None None O
believed None None O
that None None O
the None None O
role None None O
of None None O
the None None O
E1B None None O
- None None O
55kDa None None O
protein None None O
in None None O
transformation None None O
is None None O
to None None O
protect None None O
against None None O
p53 None None O
- None None O
dependent None None O
apoptosis None None O
by None None O
binding None None O
to None None O
and None None O
inactivating None None O
p53 None None O
. None None O

It None None O
has None None O
been None None O
shown None None O
previously None None O
that None None O
the None None O
55 None None O
- None None O
kDa None None O
polypeptide None None O
abrogates None None O
p53 None None O
- None None O
mediated None None O
transactivation None None O
and None None O
that None None O
mutants None None O
defective None None O
in None None O
p53 None None O
binding None None O
are None None O
unable None None O
to None None O
cooperate None None O
with None None O
E1A None None O
in None None O
transformation None None O
. None None O

We None None O
have None None O
previously None None O
mapped None None O
phosphorylation None None O
sites None None O
near None None O
the None None O
carboxy None None O
terminus None None O
of None None O
the None None O
E1B None None O
- None None O
55kDa None None O
protein None None O
at None None O
Ser None None O
- None None O
490 None None O
and None None O
Ser None None O
- None None O
491 None None O
, None None O
which None None O
lie None None O
within None None O
casein None None O
kinase None None O
II None None O
consensus None None O
sequences None None O
. None None O

Conversion None None O
of None None O
these None None O
sites None None O
to None None O
alanine None None O
residues None None O
greatly None None O
reduced None None O
transforming None None O
activity None None O
, None None O
and None None O
although None None O
the None None O
mutant None None O
55 None None O
- None None O
kDa None None O
protein None None O
was None None O
found None None O
to None None O
interact None None O
with None None O
p53 None None O
at None None O
normal None None O
levels None None O
, None None O
it None None O
was None None O
somewhat None None O
defective None None O
for None None O
suppression None None O
of None None O
p53 None None O
transactivation None None O
activity None None O
. None None O

We None None O
now None None O
report None None O
that None None O
a None None O
nearby None None O
residue None None O
, None None O
Thr None None O
- None None O
495 None None O
, None None O
also None None O
appears None None O
to None None O
be None None O
phosphorylated None None O
. None None O

We None None O
demonstrate None None O
directly None None O
that None None O
the None None O
wild None None O
- None None O
type None None O
55 None None O
- None None O
kDa None None O
protein None None O
is None None O
able None None O
to None None O
block None None O
E1A None None O
- None None O
induced None None O
p53 None None O
- None None O
dependent None None O
apoptosis None None O
, None None O
whereas None None O
cells None None O
infected None None O
by None None O
mutant None None O
pm490 None None O
/ None None O
1 None None O
/ None None O
5A None None O
, None None O
which None None O
contains None None O
alanine None None O
residues None None O
at None None O
all None None O
three None None O
phosphorylation None None O
sites None None O
, None None O
exhibited None None O
extensive None None O
DNA None None O
fragmentation None None O
and None None O
classic None None O
apoptotic None None O
cell None None O
death None None O
. None None O

The None None O
E1B None None O
- None None O
55kDa None None O
product None None O
has None None O
been None None O
shown None None O
to None None O
exhibit None None O
intrinsic None None O
transcriptional None None O
repression None None O
activity None None O
when None None O
localized None None O
to None None O
promoters None None O
, None None O
such None None O
as None None O
by None None O
fusion None None O
with None None O
the None None O
GAL4 None None O
DNA None None O
- None None O
binding None None O
domain None None O
, None None O
even None None O
in None None O
the None None O
absence None None O
of None None O
p53 None None O
. None None O

Such None None O
repression None None O
activity None None O
was None None O
totally None None O
absent None None O
with None None O
mutant None None O
pm490 None None O
/ None None O
1 None None O
/ None None O
5A None None O
. None None O

These None None O
data None None O
suggested None None O
that None None O
inhibition None None O
of None None O
p53 None None O
- None None O
dependent None None O
apoptosis None None O
may None None O
depend None None O
on None None O
the None None O
transcriptional None None O
repression None None O
function None None O
of None None O
the None None O
55 None None O
- None None O
kDa None None O
protein None None O
, None None O
which None None O
appears None None O
to None None O
be None None O
regulated None None O
be None None O
phosphorylation None None O
at None None O
the None None O
carboxy None None O
terminus None None O
. None None O

Inhibition None None O
of None None O
glucose None None O
metabolism None None O
sensitizes None None O
tumor None None O
cells None None O
to None None O
death None None O
receptor None None O
- None None O
triggered None None O
apoptosis None None O
through None None O
enhancement None None O
of None None O
death None None O
- None None O
inducing None None O
signaling None None O
complex None None O
formation None None O
and None None O
apical None None O
procaspase None None O
- None None O
8 None None O
processing None None O
. None None O

Tumors None None O
display None None O
a None None O
high None None O
rate None None O
of None None O
glucose None None O
uptake None None O
and None None O
glycolysis None None O
. None None O

We None None O
investigated None None O
how None None O
inhibition None None O
of None None O
glucose None None O
metabolism None None O
could None None O
affect None None O
death None None O
receptor None None O
- None None O
mediated None None O
apoptosis None None O
in None None O
human None None O
tumor None None O
cells None None O
of None None O
diverse None None O
origin None None O
. None None O

We None None O
show None None O
that None None O
both None None O
substitution None None O
of None None O
glucose None None O
for None None O
pyruvate None None O
and None None O
treatment None None O
with None None O
2 None None O
- None None O
deoxyglucose None None O
enhanced None None O
apoptosis None None O
induced None None O
by None None O
tumor None None O
necrosis None None O
factor None None O
( None None O
TNF None None O
) None None O
- None None O
alpha None None O
, None None O
CD95 None None O
agonistic None None O
antibody None None O
, None None O
and None None O
TNF None None O
- None None O
related None None O
apoptosis None None O
- None None O
inducing None None O
ligand None None O
( None None O
TRAIL None None O
) None None O
. None None O

Inhibition None None O
of None None O
glucose None None O
metabolism None None O
enhanced None None O
killing None None O
of None None O
myeloid None None O
leukemia None None O
U937 None None I-Cell-line-name
, None None O
cervical None None O
carcinoma None None O
HeLa None None I-Cell-line-name
, None None O
and None None O
breast None None O
carcinoma None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
upon None None O
death None None O
receptor None None O
ligation None None O
. None None O

Caspase None None O
activation None None O
, None None O
mitochondrial None None O
depolarization None None O
, None None O
and None None O
cytochrome None None O
c None None O
release None None O
were None None O
increased None None O
under None None O
these None None O
conditions None None O
. None None O

Glucose None None O
deprivation None None O
- None None O
mediated None None O
sensitization None None O
to None None O
apoptosis None None O
was None None O
prevented None None O
in None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
overexpressing None None O
BCL None None O
- None None O
2 None None O
. None None O

Interestingly None None O
, None None O
the None None O
human None None O
B None None O
- None None O
lymphoblastoid None None O
cell None None O
line None None I-Cell-line-name
SKW6 None None I-Cell-line-name
. None None I-Cell-line-name
4 None None I-Cell-line-name
, None None O
a None None O
prototype None None O
for None None O
mitochondria None None O
- None None O
independent None None O
death None None O
receptor None None O
- None None O
induced None None O
apoptosis None None O
, None None O
was None None O
also None None O
sensitized None None O
to None None O
anti None None O
- None None O
CD95 None None O
and None None O
TRAIL None None O
- None None O
induced None None O
apoptosis None None O
under None None O
glucose None None O
- None None O
free None None O
conditions None None O
. None None O

Changes None None O
in None None O
c None None O
- None None O
FLIP None None O
( None None O
L None None O
) None None O
and None None O
cFLIPs None None O
levels None None O
were None None O
observed None None O
in None None O
some None None O
but None None O
not None None O
all None None O
the None None O
cell None None O
lines None None O
studied None None O
following None None O
glucose None None O
deprivation None None O
. None None O

Glucose None None O
deprivation None None O
enhanced None None O
death None None O
receptor None None O
- None None O
triggered None None O
formation None None O
of None None O
death None None O
- None None O
inducing None None O
signaling None None O
complex None None O
and None None O
early None None O
processing None None O
of None None O
procaspase None None O
- None None O
8 None None O
. None None O

Altogether None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
the None None O
glycolytic None None O
pathway None None O
may None None O
be None None O
an None None O
important None None O
target None None O
for None None O
therapeutic None None O
intervention None None O
to None None O
sensitize None None O
tumor None None O
cells None None O
to None None O
selectively None None O
toxic None None O
soluble None None O
death None None O
ligands None None O
or None None O
death None None O
ligand None None O
- None None O
expressing None None O
cells None None O
of None None O
the None None O
immune None None O
system None None O
by None None O
facilitating None None O
the None None O
activation None None O
of None None O
initiator None None O
caspase None None O
- None None O
8 None None O
. None None O

Formation None None O
of None None O
new None None O
bone None None O
during None None O
vertical None None O
distraction None None O
osteogenesis None None O
of None None O
the None None O
human None None O
mandible None None O
is None None O
related None None O
to None None O
the None None O
presence None None O
of None None O
blood None None O
vessels None None O
. None None O

We None None O
examined None None O
the None None O
effect None None O
of None None O
distraction None None O
rate None None O
on None None O
blood None None O
vessel None None O
growth None None O
in None None O
intramembraneous None None O
ossification None None O
after None None O
vertical None None O
distraction None None O
osteogenesis None None O
in None None O
the None None O
human None None O
mandible None None O
. None None O

Six None None O
edentulous None None O
patients None None O
( None None O
aged None None O
60 None None O
+ None None O
/ None None O
- None None O
9 None None O
years None None O
) None None O
with None None O
a None None O
severely None None O
atrophic None None O
mandible None None O
underwent None None O
bone None None O
augmentation None None O
with None None O
distraction None None O
osteogenesis None None O
. None None O

Two None None O
distraction None None O
rates None None O
( None None O
0 None None O
. None None O
5 None None O
and None None O
1 None None O
mm None None O
/ None None O
day None None O
) None None O
were None None O
compared None None O
and None None O
for None None O
each None None O
group None None O
three None None O
patients None None O
were None None O
analyzed None None O
. None None O

Vascular None None O
histomorphometry None None O
was None None O
carried None None O
out None None O
in None None O
two None None O
different None None O
areas None None O
in None None O
the None None O
distraction None None O
gap None None O
: None None O
( None None O
1 None None O
) None None O
in None None O
the None None O
first None None O
and None None O
( None None O
2 None None O
) None None O
in None None O
the None None O
second None None O
1 None None O
mm None None O
area None None O
from None None O
the None None O
osteotomy None None O
line None None O
, None None O
representing None None O
the None None O
oldest None None O
and None None O
younger None None O
new None None O
- None None O
bone None None O
area None None O
, None None O
respectively None None O
. None None O

Correlation None None O
analysis None None O
was None None O
performed None None O
between None None O
blood None None O
vessel None None O
parameters None None O
and None None O
the None None O
amount None None O
of None None O
new None None O
bone None None O
formed None None O
during None None O
distraction None None O
. None None O

Histological None None O
analysis None None O
demonstrated None None O
the None None O
presence None None O
of None None O
blood None None O
vessels None None O
throughout None None O
the None None O
soft None None O
connective None None O
tissue None None O
in None None O
the None None O
distraction None None O
gap None None O
. None None O

The None None O
volume None None O
density None None O
of None None O
blood None None O
vessels None None O
between None None O
the None None O
two None None O
investigated None None O
areas None None O
was None None O
significantly None None O
lower None None O
in None None O
the None None O
1 None None O
mm None None O
/ None None O
day None None O
groups None None O
, None None O
suggesting None None O
a None None O
delay None None O
in None None O
angiogenesis None None O
in None None O
this None None O
group None None O
of None None O
patients None None O
. None None O

A None None O
positive None None O
correlation None None O
between None None O
blood None None O
vessel None None O
volume None None O
and None None O
bone None None O
volume None None O
density None None O
was None None O
found None None O
in None None O
the None None O
younger None None O
new None None O
- None None O
bone None None O
area None None O
but None None O
not None None O
in None None O
the None None O
oldest None None O
new None None O
- None None O
bone None None O
area None None O
. None None O

This None None O
correlation None None O
was None None O
due None None O
to None None O
a None None O
higher None None O
number None None O
of None None O
blood None None O
vessels None None O
rather None None O
than None None O
to None None O
a None None O
larger None None O
size None None O
of None None O
the None None O
blood None None O
vessels None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
the None None O
lower None None O
blood None None O
vessel None None O
density None None O
found None None O
in None None O
the None None O
patients None None O
with None None O
1 None None O
mm None None O
/ None None O
day None None O
distraction None None O
rate None None O
may None None O
be None None O
related None None O
to None None O
disruption None None O
of None None O
angiogenesis None None O
in None None O
the None None O
soft None None O
connective None None O
tissue None None O
of None None O
the None None O
gap None None O
or None None O
to None None O
a None None O
less None None O
optimal None None O
mechanical None None O
stimulation None None O
of None None O
cells None None O
involved None None O
in None None O
angiogenesis None None O
. None None O

This None None O
probably None None O
results None None O
in None None O
the None None O
slower None None O
rate None None O
of None None O
osteogenesis None None O
seen None None O
at None None O
the None None O
1 None None O
mm None None O
/ None None O
day None None O
distraction None None O
rate None None O
compared None None O
with None None O
the None None O
0 None None O
. None None O
5 None None O
mm None None O
/ None None O
day None None O
distraction None None O
rate None None O
. None None O

The None None O
data None None O
support None None O
the None None O
concept None None O
that None None O
a None None O
positive None None O
relationship None None O
exists None None O
between None None O
the None None O
density None None O
of None None O
blood None None O
vessels None None O
and None None O
the None None O
formation None None O
of None None O
bone None None O
. None None O

For None None O
distraction None None O
of None None O
the None None O
human None None O
mandible None None O
in None None O
elderly None None O
patients None None O
, None None O
a None None O
distraction None None O
rate None None O
of None None O
0 None None O
. None None O
5 None None O
mm None None O
/ None None O
day None None O
seems None None O
beneficial None None O
. None None O

Circulating None None O
endothelial None None O
cells None None O
in None None O
malignant None None O
disease None None O
. None None O

Cancer None None O
is None None O
a None None O
disease None None O
largely None None O
dependent None None O
on None None O
neoangiogenesis None None O
. None None O

Cancer None None O
neoangiogenesis None None O
is None None O
often None None O
disordered None None O
and None None O
abnormal None None O
, None None O
with None None O
evidence None None O
of None None O
coexisting None None O
vascular None None O
endothelial None None O
dysfunction None None O
. None None O

A None None O
novel None None O
method None None O
of None None O
assessing None None O
vascular None None O
endothelial None None O
function None None O
in None None O
cancer None None O
is None None O
via None None O
the None None O
quantification None None O
of None None O
circulating None None O
endothelial None None O
cells None None O
( None None O
CEC None None O
) None None O
. None None O

Unusual None None O
in None None O
healthy None None O
individuals None None O
, None None O
their None None O
presence None None O
in None None O
elevated None None O
numbers None None O
often None None O
indicates None None O
substantial None None O
vascular None None O
endothelial None None O
perturbation None None O
. None None O

Another None None O
interesting None None O
cell None None O
type None None O
is None None O
the None None O
endothelial None None O
progenitor None None O
cell None None O
( None None O
EPC None None O
) None None O
, None None O
whose None None O
numbers None None O
increase None None O
in None None O
the None None O
presence None None O
of None None O
vascular None None O
damage None None O
. None None O

Recent None None O
research None None O
suggests None None O
that None None O
EPCs None None O
have None None O
an None None O
important None None O
role None None O
in None None O
tumor None None O
vasculogenesis None None O
. None None O

Another None None O
marker None None O
being None None O
investigated None None O
in None None O
the None None O
context None None O
of None None O
vascular None None O
dysfunction None None O
and None None O
coagulopathy None None O
is None None O
the None None O
endothelial None None O
microparticle None None O
( None None O
EMP None None O
) None None O
. None None O

Thus None None O
, None None O
CECs None None O
, None None O
EPCs None None O
and None None O
EMPs None None O
may None None O
represent None None O
potentially None None O
novel None None O
methods None None O
for None None O
evaluating None None O
the None None O
vascular None None O
status None None O
of None None O
cancer None None O
patients None None O
. None None O

This None None O
review None None O
will None None O
summarize None None O
the None None O
current None None O
position None None O
of None None O
CECs None None O
, None None O
EPCs None None O
and None None O
EMPs None None O
in None None O
cell None None O
biology None None O
terms None None O
, None None O
with None None O
particular None None O
emphasis None None O
on None None O
their None None O
relationship None None O
to None None O
malignant None None O
disease None None O
. None None O

Insulin None None O
- None None O
induced None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
expression None None O
in None None O
retina None None O
. None None O

PURPOSE None None O
: None None O
Clinical None None O
studies None None O
have None None O
demonstrated None None O
that None None O
intensive None None O
insulin None None O
therapy None None O
causes None None O
a None None O
transient None None O
worsening None None O
of None None O
retinopathy None None O
. None None O

The None None O
mechanisms None None O
underlying None None O
the None None O
initial None None O
insulin None None O
- None None O
induced None None O
deterioration None None O
of None None O
retinal None None O
status None None O
in None None O
patients None None O
with None None O
diabetes None None O
remain None None O
unknown None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
known None None O
to None None O
be None None O
operative None None O
in None None O
the None None O
pathogenesis None None O
of None None O
diabetic None None O
retinopathy None None O
. None None O

The None None O
current None None O
study None None O
was None None O
conducted None None O
to None None O
characterize None None O
the None None O
effect None None O
of None None O
insulin None None O
on None None O
retinal None None O
VEGF None None O
gene None None O
expression None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

METHODS None None O
: None None O
The None None O
effect None None O
of None None O
insulin None None O
on None None O
VEGF None None O
expression None None O
in None None O
vivo None None O
was None None O
examined None None O
by None None O
in None None O
situ None None O
hybridization None None O
studies None None O
of None None O
rat None None O
retinal None None O
VEGF None None O
transcripts None None O
. None None O

To None None O
examine None None O
the None None O
mechanisms None None O
by None None O
which None None O
insulin None None O
regulates None None O
VEGF None None O
expression None None O
, None None O
human None None O
retinal None None O
pigment None None O
epithelial None None O
( None None O
RPE None None O
) None None O
cells None None O
were None None O
exposed None None O
to None None O
insulin None None O
, None None O
and None None O
VEGF None None O
mRNA None None O
levels None None O
were None None O
quantified None None O
with None None O
RNase None None O
protection None None O
assays None None O
( None None O
RPAs None None O
) None None O
. None None O

Conditioned None None O
media None None O
from None None O
insulin None None O
- None None O
treated None None O
RPE None None O
cells None None O
were None None O
assayed None None O
for None None O
VEGF None None O
protein None None O
and None None O
capillary None None O
endothelial None None O
cell None None O
proliferation None None O
. None None O

The None None O
capacity None None O
of None None O
insulin None None O
to None None O
stimulate None None O
the None None O
VEGF None None O
promoter None None O
linked None None O
to None None O
a None None O
luciferase None None O
reporter None None O
gene None None O
was None None O
characterized None None O
in None None O
transient None None O
transfection None None O
assays None None O
. None None O

RESULTS None None O
: None None O
Insulin None None O
increased None None O
VEGF None None O
mRNA None None O
levels None None O
in None None O
the None None O
ganglion None None O
, None None O
inner None None O
nuclear None None O
, None None O
and None None O
RPE None None O
cell None None O
layers None None O
. None None O

In None None O
vitro None None O
, None None O
insulin None None O
increased None None O
VEGF None None O
mRNA None None O
levels None None O
in None None O
human None None O
RPE None None O
cells None None O
and None None O
enhanced None None O
VEGF None None O
promoter None None O
activity None None O
without None None O
affecting None None O
transcript None None O
stability None None O
. None None O

Insulin None None O
treatment None None O
also None None O
increased None None O
VEGF None None O
protein None None O
levels None None O
in None None O
conditioned None None O
RPE None None O
cell None None O
media None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
with None None O
a None None O
median None None O
effective None None O
concentration None None O
of None None O
5 None None O
nM None None O
. None None O

The None None O
insulin None None O
- None None O
conditioned None None O
RPE None None O
cell None None O
media None None O
stimulated None None O
capillary None None O
endothelial None None O
cell None None O
proliferation None None O
, None None O
an None None O
effect None None O
that None None O
was None None O
completely None None O
blocked None None O
by None None O
anti None None O
- None None O
VEGF None None O
neutralizing None None O
antibody None None O
. None None O

CONCLUSIONS None None O
: None None O
Insulin None None O
increases None None O
VEGF None None O
mRNA None None O
and None None O
secreted None None O
protein None None O
levels None None O
in None None O
RPE None None O
cells None None O
through None None O
enhanced None None O
transcription None None O
of None None O
the None None O
VEGF None None O
gene None None O
. None None O

Intensive None None O
insulin None None O
therapy None None O
may None None O
cause None None O
a None None O
transient None None O
worsening None None O
of None None O
retinopathy None None O
in None None O
patients None None O
with None None O
diabetes None None O
through None None O
increased None None O
retinal None None O
VEGF None None O
gene None None O
expression None None O
. None None O

Procedural None None O
memory None None O
stimulation None None O
in None None O
Alzheimer None None O
' None None O
s None None O
disease None None O
: None None O
impact None None O
of None None O
a None None O
training None None O
programme None None O
. None None O

The None None O
study None None O
evaluates None None O
the None None O
efficacy None None O
of None None O
a None None O
procedural None None O
memory None None O
stimulation None None O
programme None None O
in None None O
mild None None O
and None None O
mild None None O
- None None O
moderate None None O
Alzheimer None None O
' None None O
s None None O
disease None None O
( None None O
AD None None O
) None None O
. None None O

Twenty None None O
basic None None O
and None None O
instrumental None None O
activities None None O
of None None O
daily None None O
living None None O
have None None O
been None None O
selected None None O
, None None O
and None None O
divided None None O
into None None O
two None None O
groups None None O
, None None O
comparable None None O
for None None O
difficulty None None O
. None None O

Ten None None O
normal None None O
elderly None None O
subjects None None O
( None None O
age None None O
68 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
8 None None O
years None None O
; None None O
MMSE None None O
score None None O
: None None O
28 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
9 None None O
; None None O
education None None O
: None None O
7 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
5 None None O
years None None O
) None None O
were None None O
asked None None O
to None None O
perform None None O
the None None O
two None None O
groups None None O
of None None O
daily None None O
activities None None O
and None None O
the None None O
time None None O
required None None O
to None None O
perform None None O
the None None O
tasks None None O
of None None O
each None None O
group None None O
was None None O
recorded None None O
and None None O
used None None O
as None None O
a None None O
reference None None O
. None None O

Ten None None O
mild None None O
and None None O
mild None None O
- None None O
moderate None None O
AD None None O
patients None None O
( None None O
age None None O
77 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
5 None None O
. None None O
3 None None O
years None None O
; None None O
MMSE None None O
score None None O
: None None O
19 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
5 None None O
; None None O
education None None O
: None None O
7 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
7 None None O
years None None O
) None None O
without None None O
major None None O
behavioural None None O
disturbances None None O
constituted None None O
the None None O
experimental None None O
group None None O
. None None O

Patients None None O
were None None O
evaluated None None O
in None None O
all None None O
20 None None O
daily None None O
activities None None O
and None None O
the None None O
time None None O
employed None None O
was None None O
recorded None None O
at None None O
baseline None None O
and None None O
after None None O
a None None O
3 None None O
- None None O
week None None O
training None None O
( None None O
1 None None O
h None None O
/ None None O
d None None O
, None None O
5 None None O
d None None O
/ None None O
week None None O
) None None O
period None None O
. None None O

Five None None O
patients None None O
were None None O
trained None None O
during None None O
the None None O
3 None None O
weeks None None O
on None None O
half None None O
of None None O
the None None O
20 None None O
daily None None O
activities None None O
and None None O
the None None O
other None None O
five None None O
patients None None O
were None None O
trained None None O
on None None O
the None None O
remainder None None O
. None None O

This None None O
procedure None None O
was None None O
adopted None None O
in None None O
order None None O
to None None O
detect None None O
separately None None O
the None None O
improvement None None O
in None None O
" None None O
trained None None O
" None None O
and None None O
" None None O
not None None O
trained None None O
" None None O
activities None None O
, None None O
allowing None None O
to None None O
control None None O
better None None O
the None None O
effects None None O
of None None O
the None None O
intervention None None O
. None None O

The None None O
assessment None None O
of None None O
the None None O
functional None None O
impact None None O
of None None O
the None None O
training None None O
was None None O
directly None None O
measured None None O
, None None O
through None None O
the None None O
variation None None O
of None None O
time None None O
employed None None O
to None None O
perform None None O
tasks None None O
before None None O
and None None O
after None None O
training None None O
. None None O

After None None O
3 None None O
weeks None None O
of None None O
training None None O
a None None O
significant None None O
improvement None None O
was None None O
observed None None O
for None None O
the None None O
trained None None O
activities None None O
, None None O
from None None O
3 None None O
. None None O
6 None None O
to None None O
1 None None O
. None None O
9 None None O
standard None None O
deviations None None O
below None None O
the None None O
performance None None O
of None None O
the None None O
normal None None O
elderly None None O
controls None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

AD None None O
patients None None O
improved None None O
also None None O
in None None O
not None None O
- None None O
trained None None O
activities None None O
from None None O
3 None None O
. None None O
5 None None O
to None None O
2 None None O
. None None O
7 None None O
standard None None O
deviations None None O
below None None O
the None None O
controls None None O
' None None O
performance None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
rehabilitation None None O
of None None O
activities None None O
of None None O
daily None None O
living None None O
through None None O
developing None None O
procedural None None O
memory None None O
strategies None None O
may None None O
be None None O
effective None None O
in None None O
mild None None O
and None None O
mild None None O
- None None O
moderate None None O
AD None None O
patients None None O
. None None O

Specific None None O
subgroup None None O
B None None O
adenovirus None None O
diagnosis None None O
by None None O
PCR None None O
of None None O
the None None O
fibre None None O
gene None None O
. None None O

OBJECTIVE None None O
: None None O

A None None O
highly None None O
sensitive None None O
and None None O
specific None None O
PCR None None O
assay None None O
targeting None None O
regions None None O
of None None O
the None None O
fibre None None O
gene None None O
was None None O
developed None None O
for None None O
the None None O
identification None None O
of None None O
subgroup None None O
B None None O
adenovirus None None O
strains None None O
. None None O

This None None O
is None None O
critical None None O
, None None O
since None None O
these None None O
adenovirus None None O
strains None None O
are None None O
frequently None None O
associated None None O
with None None O
severe None None O
respiratory None None O
infections None None O
in None None O
infants None None O
and None None O
new None None O
- None None O
borns None None O
. None None O

METHODS None None O
: None None O

Clinical None None O
samples None None O
from None None O
nasopharyngeal None None O
aspirates None None O
were None None O
analysed None None O
by None None O
PCR None None O
using None None O
several None None O
sets None None O
of None None O
primers None None O
corresponding None None O
to None None O
sequences None None O
of None None O
the None None O
gene None None O
coding None None O
for None None O
the None None O
fibre None None O
protein None None O
. None None O

RESULTS None None O
: None None O

The None None O
assay None None O
allowed None None O
the None None O
detection None None O
and None None O
identification None None O
of None None O
all None None O
the None None O
genotypes None None O
of None None O
adenovirus None None O
subgroup None None O
B None None O
, None None O
based None None O
on None None O
the None None O
size None None O
of None None O
the None None O
amplified None None O
product None None O
when None None O
analysed None None O
on None None O
polyacrilamide None None O
gel None None O
electrophoresis None None O
. None None O

Specifically None None O
, None None O
one None None O
set None None O
of None None O
primers None None O
was None None O
able None None O
to None None O
amplify None None O
DNA None None O
of None None O
subgroup None None O
B None None O
but None None O
not None None O
subgroup None None O
C None None O
and None None O
E None None O
viruses None None O
. None None O

CONCLUSION None None O
: None None O

The None None O
detection None None O
of None None O
adenovirus None None O
and None None O
the None None O
genotyping None None O
can None None O
be None None O
done None None O
on None None O
a None None O
routine None None O
basis None None O
by None None O
a None None O
PCR None None O
assay None None O
using None None O
the None None O
fibre None None O
gene None None O
as None None O
a None None O
target None None O
. None None O

The None None O
assay None None O
allows None None O
the None None O
identification None None O
of None None O
ADV None None O
subgroup None None O
B None None O
, None None O
including None None O
genotype None None O
7h None None O
, None None O
which None None O
is None None O
the None None O
single None None O
most None None O
important None None O
viral None None O
pathogen None None O
associated None None O
with None None O
respiratory None None O
diseases None None O
in None None O
infants None None O
and None None O
young None None O
children None None O
in None None O
the None None O
southern None None O
part None None O
of None None O
South None None O
America None None O
. None None O

Molecular None None O
characterization None None O
of None None O
angiogenic None None O
properties None None O
of None None O
human None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
cells None None O
. None None O

Little None None O
is None None O
known None None O
about None None O
the None None O
specificity None None O
of None None O
angiogenic None None O
properties None None O
of None None O
oral None None O
cancer None None O
cells None None O
and None None O
the None None O
possible None None O
mechanisms None None O
. None None O

Stimulatory None None O
effects None None O
on None None O
proliferation None None O
and None None O
migration None None O
of None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cells None None O
( None None O
HUVEC None None O
) None None O
characterized None None O
the None None O
angiogenic None None O
properties None None O
of None None O
oral None None O
cancer None None O
cells None None O
but None None O
not None None O
normal None None O
oral None None O
keratinocytes None None O
( None None O
NOK None None O
) None None O
. None None O

ELISA None None O
found None None O
the None None O
presence None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factors None None O
( None None O
VEGF None None O
) None None O
both None None O
in None None O
the None None O
tested None None O
oral None None O
cancer None None O
cells None None O
and None None O
NOK None None O
. None None O

Attenuation None None O
of None None O
the None None O
proangiogenic None None O
effects None None O
by None None O
neutralizing None None O
VEGF None None O
antibodies None None O
suggests None None O
VEGF None None O
play None None O
a None None O
key None None O
role None None O
in None None O
the None None O
acquisition None None O
of None None O
the None None O
angiogenic None None O
phenotype None None O
in None None O
oral None None O
cancer None None O
cells None None O
. None None O

Western None None O
blotting None None O
of None None O
p53 None None O
and None None O
murine None None O
double None None O
mutant None None O
2 None None O
( None None O
Mdm2 None None O
) None None O
together None None O
with None None O
p53 None None O
DNA None None O
sequencing None None O
analysis None None O
indicate None None O
that None None O
p53 None None O
function None None O
loss None None O
by None None O
mutation None None O
or None None O
overexpression None None O
of None None O
Mdm2 None None O
occurred None None O
in None None O
all None None O
tested None None O
oral None None O
cancer None None O
cells None None O
regardless None None O
of None None O
their None None O
etiology None None O
. None None O

In None None O
summary None None O
, None None O
the None None O
angiogenic None None O
property None None O
of None None O
oral None None O
cancer None None O
cells None None O
is None None O
mediated None None O
by None None O
many None None O
factors None None O
in None None O
addition None None O
to None None O
VEGF None None O
and None None O
the None None O
functional None None O
status None None O
of None None O
p53 None None O
. None None O

Urokinase None None O
receptor None None O
: None None O
a None None O
molecular None None O
organizer None None O
in None None O
cellular None None O
communication None None O
. None None O

In None None O
a None None O
variety None None O
of None None O
cell None None O
types None None O
, None None O
the None None O
glycolipid None None O
- None None O
anchored None None O
urokinase None None O
receptor None None O
( None None O
uPAR None None O
) None None O
is None None O
colocalized None None O
pericellularly None None O
with None None O
components None None O
of None None O
the None None O
plasminogen None None O
activation None None O
system None None O
and None None O
endocytosis None None O
receptors None None O
. None None O

uPAR None None O
is None None O
also None None O
coexpressed None None O
with None None O
caveolin None None O
and None None O
members None None O
of None None O
the None None O
integrin None None O
adhesion None None O
receptor None None O
superfamily None None O
. None None O

The None None O
formation None None O
of None None O
functional None None O
units None None O
with None None O
these None None O
various None None O
proteins None None O
allows None None O
the None None O
uPAR None None O
to None None O
mediate None None O
the None None O
focused None None O
proteolysis None None O
required None None O
for None None O
cell None None O
migration None None O
and None None O
invasion None None O
and None None O
to None None O
contribute None None O
both None None O
directly None None O
and None None O
indirectly None None O
to None None O
cell None None O
adhesive None None O
processes None None O
in None None O
a None None O
non None None O
- None None O
proteolytic None None O
fashion None None O
. None None O

This None None O
dual None None O
activity None None O
, None None O
together None None O
with None None O
the None None O
initiation None None O
of None None O
signal None None O
transduction None None O
pathways None None O
by None None O
uPAR None None O
, None None O
is None None O
believed None None O
to None None O
influence None None O
cellular None None O
behaviour None None O
in None None O
angiogenesis None None O
, None None O
inflammation None None O
, None None O
wound None None O
repair None None O
and None None O
tumor None None O
progression None None O
/ None None O
metastasis None None O
and None None O
open None None O
up None None O
the None None O
way None None O
for None None O
uPAR None None O
- None None O
based None None O
therapeutic None None O
approaches None None O
. None None O

Expression None None O
of None None O
osteoprotegerin None None O
and None None O
RANK None None O
ligand None None O
in None None O
breast None None O
cancer None None O
bone None None O
metastasis None None O
. None None O

Bone None None O
destruction None None O
is None None O
primarily None None O
mediated None None O
by None None O
osteoclastic None None O
bone None None O
resorption None None O
, None None O
and None None O
cancer None None O
cells None None O
stimulate None None O
the None None O
formation None None O
and None None O
activation None None O
of None None O
osteoclasts None None O
next None None O
to None None O
metastatic None None O
foci None None O
. None None O

Accumulating None None O
evidences None None O
indicate None None O
that None None O
receptor None None O
activator None None O
of None None O
NF None None O
- None None O
kB None None O
ligand None None O
( None None O
RANKL None None O
) None None O
is None None O
the None None O
ultimate None None O
extracellular None None O
mediator None None O
that None None O
stimulates None None O
osteoclast None None O
differentiation None None O
into None None O
mature None None O
osteoclasts None None O
. None None O

In None None O
contrast None None O
, None None O
osteoprotegerin None None O
( None None O
OPG None None O
) None None O
inhibits None None O
osteoclast None None O
development None None O
. None None O

In None None O
order None None O
to None None O
elucidate None None O
a None None O
mechanism None None O
for None None O
cancer None None O
- None None O
induced None None O
osteoclastogenesis None None O
, None None O
cells None None O
from None None O
a None None O
human None None O
breast None None O
cancer None None O
line None None O
, None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
, None None O
were None None O
directly None None O
co None None O
- None None O
cultured None None O
with None None O
ST2 None None I-Cell-line-name
, None None O
MC3T3 None None I-Cell-line-name
- None None I-Cell-line-name
E1 None None I-Cell-line-name
, None None O
or None None O
with None None O
primary None None O
mouse None None O
calvarial None None O
cells None None O
. None None O

Osteoclast None None O
- None None O
like None None O
cells None None O
and None None O
tartarate None None O
resistant None None O
acid None None O
phosphatase None None O
( None None O
TRAP None None O
) None None O
activities None None O
were None None O
then None None O
quantitated None None O
. None None O

We None None O
examined None None O
these None None O
cell None None O
lines None None O
and None None O
samples None None O
from None None O
breast None None O
cancer None None O
by None None O
RT None None O
- None None O
PCR None None O
for None None O
the None None O
expressions None None O
of None None O
OPG None None O
and None None O
RANKL None None O
mRNA None None O
. None None O

Compared None None O
to None None O
controls None None O
, None None O
co None None O
- None None O
culture None None O
of None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
cells None None O
with None None O
stromal None None O
or None None O
osteoblastic None None O
cells None None O
induced None None O
an None None O
increase None None O
in None None O
number None None O
of None None O
osteoclasts None None O
and None None O
TRAP None None O
activities None None O
. None None O

MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
cells None None O
alone None None O
or None None O
breast None None O
cancer None None O
samples None None O
did None None O
not None None O
express None None O
RANKL None None O
mRNA None None O
. None None O

However None None O
, None None O
co None None O
- None None O
culture None None O
of None None O
these None None O
cancer None None O
cells None None O
with None None O
stromal None None O
or None None O
osteoblastic None None O
cells None None O
induced None None O
RANKL None None O
mRNA None None O
expression None None O
and None None O
decreased None None O
OPG None None O
mRNA None None O
expression None None O
. None None O

These None None O
experiments None None O
demonstrate None None O
that None None O
direct None None O
interactions None None O
between None None O
breast None None O
cancer None None O
and None None O
stromal None None O
or None None O
osteoblastic None None O
cells None None O
induce None None O
osteoclastogenesis None None O
in None None O
vitro None None O
through None None O
modulating None None O
RANKL None None O
expression None None O
. None None O

Histology None None O
of None None O
the None None O
lung None None O

The None None O
left None None O
lung None None O
was None None O
fixed None None O
by None None O
gentle None None O
infusion None None O
of None None O
fixative None None O
( None None O
4 None None O
% None None O
paraformaldehyde None None O
) None None O
through None None O
the None None O
tracheal None None O
cannula None None O
[ None None O
24 None None O
] None None O
. None None O

After None None O
excision None None O
, None None O
the None None O
lung None None O
was None None O
immersed None None O
in None None O
a None None O
fresh None None O
fixative None None O
for None None O
2 None None O
h None None O
. None None O

The None None O
lung None None O
lobe None None O
was None None O
embedded None None O
in None None O
paraffin None None O
and None None O
cut None None O
into None None O
3 None None O
mum None None O
transverse None None O
sections None None O
, None None O
followed None None O
by None None O
immunohistochemical None None O
and None None O
chemical None None O
staining None None O
. None None O

Photomicrographs None None O
were None None O
captured None None O
using None None O
KS400 None None O
image None None O
analyze None None O
platform None None O
( None None O
Zeiss None None O
, None None O
Oberkochen None None O
, None None O
Germany None None O
) None None O
and None None O
analyzed None None O
quantitatively None None O
. None None O

Analysis None None O
of None None O
furAII None None O
- None None O
katGII None None O
region None None O

The None None O
cDNA None None O
from None None O
M None None O
. None None O
fortuitum None None O
under None None O
the None None O
different None None O
stresses None None O
was None None O
analysed None None O
by None None O
PCR None None O
using None None O
the None None O
primers None None O
furAII None None O
- None None O
Fo None None O
and None None O
P1 None None O
. None None O
1 None None O
( None None O
Table None None O
2 None None O
) None None O
to None None O
test None None O
the None None O
presence None None O
of None None O
furAII None None O
and None None O
katGII None None O
cotranscripts None None O
. None None O

PCR None None O
cycling None None O
was None None O
performed None None O
as None None O
follows None None O
: None None O
a None None O
denaturizing None None O
step None None O
at None None O
95degreesC None None O
for None None O
5 None None O
minutes None None O
; None None O
36 None None O
cycles None None O
of None None O
95degreesC None None O
for None None O
45 None None O
seconds None None O
, None None O
54degreesC None None O
for None None O
45 None None O
seconds None None O
and None None O
72degreesC None None O
for None None O
1 None None O
minute None None O
; None None O
and None None O
a None None O
final None None O
extension None None O
at None None O
72degreesC None None O
for None None O
10 None None O
minutes None None O
. None None O

Role None None O
of None None O
thrombogenic None None O
factors None None O
in None None O
the None None O
development None None O
of None None O
atherosclerosis None None O
. None None O

Hemostatic None None O
factors None None O
play None None O
a None None O
crucial None None O
role None None O
in None None O
generating None None O
thrombotic None None O
plugs None None O
at None None O
sites None None O
of None None O
vascular None None O
damage None None O
( None None O
atherothrombosis None None O
) None None O
. None None O

However None None O
, None None O
whether None None O
hemostatic None None O
factors None None O
contribute None None O
directly None None O
or None None O
indirectly None None O
to None None O
the None None O
pathogenesis None None O
of None None O
atherosclerosis None None O
remains None None O
uncertain None None O
. None None O

Autopsy None None O
studies None None O
have None None O
revealed None None O
that None None O
intimal None None O
thickening None None O
represents None None O
the None None O
first None None O
stage None None O
of None None O
atherosclerosis None None O
and None None O
that None None O
lipid None None O
- None None O
rich None None O
plaque None None O
arises None None O
from None None O
such None None O
lesions None None O
. None None O

Several None None O
factors None None O
contribute None None O
to None None O
the None None O
start None None O
of None None O
intimal None None O
thickening None None O
. None None O

Platelets None None O
release None None O
several None None O
growth None None O
factors None None O
and None None O
bioactive None None O
agents None None O
that None None O
play None None O
a None None O
central None None O
role None None O
in None None O
development None None O
of None None O
not None None O
only None None O
thrombus None None O
but None None O
also None None O
of None None O
intimal None None O
thickening None None O
. None None O

We None None O
have None None O
been None None O
investigating None None O
which None None O
coagulation None None O
factors None None O
simultaneously None None O
, None None O
or None None O
subsequently None None O
with None None O
platelet None None O
aggregation None None O
, None None O
participate None None O
in None None O
thrombus None None O
formation None None O
. None None O

Tissue None None O
factor None None O
( None None O
TF None None O
) None None O
is None None O
an None None O
essential None None O
initiator None None O
of None None O
blood None None O
coagulation None None O
that None None O
is None None O
expressed None None O
in None None O
various None None O
stages None None O
of None None O
atherosclerotic None None O
lesions None None O
in None None O
humans None None O
and None None O
other None None O
animals None None O
. None None O

Factors None None O
including None None O
thrombin None None O
and None None O
fibrin None None O
, None None O
which None None O
are None None O
downstream None None O
of None None O
the None None O
coagulation None None O
cascade None None O
activated None None O
by None None O
TF None None O
, None None O
also None None O
contribute None None O
to None None O
atherosclerosis None None O
. None None O

TF None None O
is None None O
involved None None O
in None None O
cell None None O
migration None None O
, None None O
embryogenesis None None O
and None None O
angiogenesis None None O
. None None O

Thus None None O
TF None None O
, None None O
in None None O
addition None None O
to None None O
factors None None O
downstream None None O
of None None O
the None None O
coagulation None None O
cascade None None O
and None None O
the None None O
protease None None O
- None None O
activated None None O
receptor None None O
2 None None O
activation None None O
system None None O
, None None O
would None None O
be None None O
a None None O
multifactorial None None O
regulator None None O
of None None O
atherogenesis None None O
. None None O

RNA None None O
damage None None O
and None None O
inhibition None None O
of None None O
neoplastic None None O
endothelial None None O
cell None None O
growth None None O
: None None O
effects None None O
of None None O
human None None O
and None None O
amphibian None None O
ribonucleases None None O
. None None O

Angiogenesis None None O
defines None None O
the None None O
many None None O
steps None None O
involved None None O
in None None O
the None None O
growth None None O
and None None O
migration None None O
of None None O
endothelial None None O
cell None None O
- None None O
derived None None O
blood None None O
vessels None None O
. None None O

This None None O
process None None O
is None None O
necessary None None O
for None None O
the None None O
growth None None O
and None None O
metastasis None None O
of None None O
tumors None None O
, None None O
and None None O
considerable None None O
effort None None O
is None None O
being None None O
expended None None O
to None None O
find None None O
inhibitors None None O
of None None O
tumor None None O
angiogenesis None None O
. None None O

This None None O
usually None None O
involves None None O
screening None None O
of None None O
potential None None O
anti None None O
- None None O
angiogenic None None O
compounds None None O
on None None O
endothelial None None O
cells None None O
. None None O

To None None O
this None None O
end None None O
, None None O
two None None O
candidate None None O
anti None None O
- None None O
angiogenic None None O
RNA None None O
- None None O
damaging None None O
agents None None O
, None None O
onconase None None O
and None None O
( None None O
- None None O
4 None None O
) None None O
rhEDN None None O
, None None O
were None None O
screened None None O
for None None O
their None None O
effects None None O
on None None O
endothelial None None O
cell None None O
proliferation None None O
using None None O
three None None O
distinct None None O
types None None O
of None None O
endothelial None None O
cells None None O
in None None O
culture None None O
: None None O
HPV None None O
- None None O
16 None None O
E6 None None O
/ None None O
E7 None None O
- None None O
immortalized None None O
human None None I-Cell-line-name
umbilical None None I-Cell-line-name
vein None None I-Cell-line-name
endothelial None None I-Cell-line-name
cells None None I-Cell-line-name
( None None O
HUVECs None None I-Cell-line-name
) None None O
, None None O
a None None O
Kras None None O
- None None O
transformed None None O
HPV None None O
- None None O
16 None None O
E6 None None O
/ None None O
E7 None None O
HUVEC None None I-Cell-line-name
( None None O
Rhim None None O
et None None O
al None None O
. None None O
, None None O
Carcinogenesis None None O
4 None None O
, None None O
673 None None O
- None None O
681 None None O
, None None O
1998 None None O
) None None O
, None None O
and None None O
primary None None O
HUVECs None None O
. None None O

Onconase None None O
similarly None None O
inhibited None None O
proliferation None None O
in None None O
all None None O
three None None O
cell None None O
lines None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0 None None O
. None None O
3 None None O
- None None O
1 None None O
. None None O
0 None None O
microM None None O
) None None O
while None None O
( None None O
- None None O
4 None None O
) None None O
rhEDN None None O
was None None O
more None None O
effective None None O
on None None O
immortalized None None O
HUVEC None None I-Cell-line-name
cell None None O
lines None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
0 None None O
. None None O
02 None None O
- None None O
0 None None O
. None None O
06 None None O
microM None None O
) None None O
than None None O
on None None O
primary None None O
HUVECs None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
> None None O
0 None None O
. None None O
1 None None O
microM None None O
) None None O
. None None O

Differential None None O
sensitivity None None O
to None None O
these None None O
agents None None O
implies None None O
that None None O
more None None O
than None None O
one None None O
endothelial None None O
cell None None O
type None None O
must None None O
be None None O
used None None O
in None None O
proliferation None None O
assays None None O
to None None O
screen None None O
for None None O
novel None None O
anti None None O
- None None O
angiogenic None None O
compounds None None O
. None None O

Tobacco None None O
smoke None None O
promotes None None O
lung None None O
tumorigenesis None None O
by None None O
triggering None None O
IKKbeta None None O
- None None O
and None None O
JNK1 None None O
- None None O
dependent None None O
inflammation None None O
. None None O

Chronic None None O
exposure None None O
to None None O
tobacco None None O
smoke None None O
, None None O
which None None O
contains None None O
over None None O
60 None None O
tumor None None O
- None None O
initiating None None O
carcinogens None None O
, None None O
is None None O
the None None O
major None None O
risk None None O
factor None None O
for None None O
development None None O
of None None O
lung None None O
cancer None None O
, None None O
accounting None None O
for None None O
a None None O
large None None O
portion None None O
of None None O
cancer None None O
- None None O
related None None O
deaths None None O
worldwide None None O
. None None O

It None None O
is None None O
well None None O
established None None O
that None None O
tobacco None None O
smoke None None O
is None None O
a None None O
tumor None None O
initiator None None O
, None None O
but None None O
we None None O
asked None None O
whether None None O
it None None O
also None None O
acts None None O
as None None O
a None None O
tumor None None O
promoter None None O
once None None O
malignant None None O
initiation None None O
, None None O
such None None O
as None None O
caused None None O
by None None O
K None None O
- None None O
ras None None O
activation None None O
, None None O
has None None O
taken None None O
place None None O
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
repetitive None None O
exposure None None O
to None None O
tobacco None None O
smoke None None O
promotes None None O
tumor None None O
development None None O
both None None O
in None None O
carcinogen None None O
- None None O
treated None None O
mice None None O
and None None O
in None None O
transgenic None None O
mice None None O
undergoing None None O
sporadic None None O
K None None O
- None None O
ras None None O
activation None None O
in None None O
lung None None O
epithelial None None O
cells None None O
. None None O

Tumor None None O
promotion None None O
is None None O
due None None O
to None None O
induction None None O
of None None O
inflammation None None O
that None None O
results None None O
in None None O
enhanced None None O
pneumocyte None None O
proliferation None None O
and None None O
is None None O
abrogated None None O
by None None O
IKKbeta None None O
ablation None None O
in None None O
myeloid None None O
cells None None O
or None None O
inactivation None None O
of None None O
JNK1 None None O
. None None O

Use None None O
of None None O
DNA None None O
microarray None None O
and None None O
small None None O
animal None None O
positron None None O
emission None None O
tomography None None O
in None None O
preclinical None None O
drug None None O
evaluation None None O
of None None O
RAF265 None None O
, None None O
a None None O
novel None None O
B None None O
- None None O
Raf None None O
/ None None O
VEGFR None None O
- None None O
2 None None O
inhibitor None None O
. None None O

Positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
imaging None None O
has None None O
become None None O
a None None O
useful None None O
tool None None O
for None None O
assessing None None O
early None None O
biologic None None O
response None None O
to None None O
cancer None None O
therapy None None O
and None None O
may None None O
be None None O
particularly None None O
useful None None O
in None None O
the None None O
development None None O
of None None O
new None None O
cancer None None O
therapeutics None None O
. None None O

RAF265 None None O
, None None O
a None None O
novel None None O
B None None O
- None None O
Raf None None O
/ None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
- None None O
2 None None O
inhibitor None None O
, None None O
was None None O
evaluated None None O
in None None O
the None None O
preclinical None None O
setting None None O
for None None O
its None None O
ability None None O
to None None O
inhibit None None O
the None None O
uptake None None O
of None None O
PET None None O
tracers None None O
in None None O
the None None O
A375M None None I-Cell-line-name
( None None O
B None None O
- None None O
Raf None None O
( None None O
V600E None None O
) None None O
) None None O
human None None O
melanoma None None O
cell None None O
line None None O
. None None O

RAF265 None None O
inhibited None None O
2 None None O
- None None O
deoxy None None O
- None None O
2 None None O
- None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
fluoro None None O
- None None O
d None None O
- None None O
glucose None None O
( None None O
FDG None None O
) None None O
accumulation None None O
in None None O
cell None None O
culture None None O
at None None O
28 None None O
hours None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
. None None O

RAF265 None None O
also None None O
inhibited None None O
FDG None None O
accumulation None None O
in None None O
tumor None None O
xenografts None None O
after None None O
1 None None O
day None None O
of None None O
drug None None O
treatment None None O
. None None O

This None None O
decrease None None O
persisted None None O
for None None O
the None None O
remaining None None O
2 None None O
weeks None None O
of None None O
treatment None None O
. None None O

DNA None None O
microarray None None O
analysis None None O
of None None O
treated None None O
tumor None None O
xenografts None None O
revealed None None O
significantly None None O
decreased None None O
expression None None O
of None None O
genes None None O
regulating None None O
glucose None None O
and None None O
thymidine None None O
metabolism None None O
and None None O
revealed None None O
changes None None O
in None None O
apoptotic None None O
genes None None O
, None None O
suggesting None None O
that None None O
the None None O
imaging None None O
tracers None None O
FDG None None O
, None None O
3 None None O
- None None O
deoxy None None O
- None None O
3 None None O
- None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
fluorothymidine None None O
, None None O
and None None O
annexin None None O
V None None O
could None None O
serve None None O
as None None O
potential None None O
imaging None None O
biomarkers None None O
for None None O
RAF265 None None O
therapy None None O
monitoring None None O
. None None O

We None None O
concluded None None O
that None None O
RAF265 None None O
is None None O
highly None None O
efficacious None None O
in None None O
this None None O
xenograft None None O
model None None O
of None None O
human None None O
melanoma None None O
and None None O
decreases None None O
glucose None None O
metabolism None None O
as None None O
measured None None O
by None None O
DNA None None O
microarray None None O
analysis None None O
, None None O
cell None None O
culture None None O
assays None None O
, None None O
and None None O
small None None O
animal None None O
FDG None None O
PET None None O
scans None None O
as None None O
early None None O
as None None O
1 None None O
day None None O
after None None O
treatment None None O
. None None O

Our None None O
results None None O
support None None O
the None None O
use None None O
of None None O
FDG None None O
PET None None O
in None None O
clinical None None O
trials None None O
with None None O
RAF265 None None O
to None None O
assess None None O
early None None O
tumor None None O
response None None O
. None None O

DNA None None O
microarray None None O
analysis None None O
and None None O
small None None O
animal None None O
PET None None O
studies None None O
may None None O
be None None O
used None None O
as None None O
complementary None None O
technologies None None O
in None None O
drug None None O
development None None O
. None None O

DNA None None O
microarray None None O
analysis None None O
allows None None O
for None None O
analysis None None O
of None None O
drug None None O
effects None None O
on None None O
multiple None None O
pathways None None O
linked None None O
to None None O
cancer None None O
and None None O
can None None O
suggest None None O
corresponding None None O
imaging None None O
tracers None None O
for None None O
further None None O
analysis None None O
as None None O
biomarkers None None O
of None None O
tumor None None O
response None None O
. None None O

Neoplastic None None O
transformation None None O
of None None O
ciliary None None O
body None None O
epithelium None None O
is None None O
associated None None O
with None None O
loss None None O
of None None O
opticin None None O
expression None None O
. None None O

BACKGROUND None None O
: None None O
Opticin None None O
is None None O
a None None O
recently None None O
discovered None None O
glycoprotein None None O
present None None O
predominantly None None O
in None None O
the None None O
vitreous None None O
humour None None O
. None None O

It None None O
is None None O
synthesised None None O
and None None O
secreted None None O
by None None O
the None None O
ciliary None None O
body None None O
epithelium None None O
( None None O
CBE None None O
) None None O
from None None O
the None None O
initiation None None O
of None None O
CBE None None O
development None None O
in None None O
the None None O
embryo None None O
, None None O
and None None O
production None None O
continues None None O
throughout None None O
life None None O
. None None O

AIM None None O
: None None O
To None None O
determine None None O
whether None None O
a None None O
variety None None O
of None None O
ciliary None None O
body None None O
tumours None None O
synthesise None None O
opticin None None O
to None None O
characterise None None O
further None None O
its None None O
role None None O
in None None O
ciliary None None O
body None None O
health None None O
and None None O
disease None None O
. None None O

METHODS None None O
: None None O
Immunohistochemistry None None O
was None None O
used None None O
to None None O
determine None None O
the None None O
distribution None None O
of None None O
opticin None None O
in None None O
normal None None O
human None None O
CBE None None O
, None None O
and None None O
in None None O
hyperplastic None None O
and None None O
neoplastic None None O
CBE None None O
lesions None None O
. None None O

RESULTS None None O
: None None O
Opticin None None O
was None None O
immunolocalised None None O
to None None O
the None None O
basal None None O
cell None None O
surface None None O
and None None O
basement None None O
membrane None None O
material None None O
of None None O
the None None O
non None None O
- None None O
pigmented None None O
CBE None None O
in None None O
nine None None O
donor None None O
eyes None None O
as None None O
well None None O
as None None O
four None None O
hyperplastic None None O
lesions None None O
of None None O
the None None O
CBE None None O
( None None O
Fuchs None None O
' None None O
s None None O
adenoma None None O
) None None O
. None None O

By None None O
contrast None None O
, None None O
none None None O
of None None O
eight None None O
neoplastic None None O
lesions None None O
( None None O
two None None O
adenoma None None O
and None None O
six None None O
adenocarcinoma None None O
) None None O
of None None O
CBE None None O
stained None None O
for None None O
opticin None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
present None None O
series None None O
supports None None O
the None None O
theory None None O
that None None O
opticin None None O
is None None O
produced None None O
by None None O
the None None O
non None None O
- None None O
pigmented None None O
CBE None None O
throughout None None O
adult None None O
life None None O
. None None O

Loss None None O
of None None O
opticin None None O
expression None None O
by None None O
this None None O
tissue None None O
is None None O
associated None None O
with None None O
and None None O
could None None O
contribute None None O
towards None None O
neoplastic None None O
transformation None None O
. None None O

SWAP None None O
- None None O
70 None None O
is None None O
required None None O
for None None O
oncogenic None None O
transformation None None O
by None None O
v None None O
- None None O
Src None None O
in None None O
mouse None None O
embryo None None O
fibroblasts None None O
. None None O

SWAP None None O
- None None O
70 None None O
is None None O
a None None O
phosphatidylinositol None None O
trisphosphate None None O
( None None O
PtdIns None None O
( None None O
3 None None O
, None None O
4 None None O
, None None O
5 None None O
) None None O
P None None O
( None None O
3 None None O
) None None O
) None None O
binding None None O
protein None None O
, None None O
which None None O
acts None None O
in None None O
F None None O
- None None O
actin None None O
rearrangement None None O
. None None O

The None None O
role None None O
of None None O
SWAP None None O
- None None O
70 None None O
in None None O
oncogenic None None O
transformation None None O
of None None O
mouse None None O
embryo None None O
fibroblasts None None O
( None None O
MEFs None None O
) None None O
by None None O
v None None O
- None None O
Src None None O
was None None O
examined None None O
by None None O
use None None O
of None None O
MEFs None None O
defective None None O
in None None O
SWAP None None O
- None None O
70 None None O
. None None O

v None None O
- None None O
Src None None O
morphologically None None O
transformed None None O
MEFs None None O
lacking None None O
SWAP None None O
- None None O
70 None None O
, None None O
but None None O
growth None None O
of None None O
the None None O
transformed None None O
cells None None O
in None None O
culture None None O
was None None O
slower None None O
than None None O
that None None O
of None None O
cells None None O
supplemented None None O
with None None O
exogenous None None O
SWAP None None O
- None None O
70 None None O
. None None O

The None None O
v None None O
- None None O
Src None None O
- None None O
transformed None None O
MEFs None None O
deficient None None O
in None None O
SWAP None None O
- None None O
70 None None O
were None None O
unable None None O
to None None O
grow None None O
in None None O
soft None None O
agar None None O
while None None O
those None None O
expressing None None O
SWAP70 None None O
readily None None O
formed None None O
colonies None None O
, None None O
suggesting None None O
that None None O
SWAP None None O
- None None O
70 None None O
is None None O
required None None O
for None None O
anchorage None None O
independent None None O
growth None None O
of None None O
v None None O
- None None O
Src None None O
transformed None None O
MEFs None None O
. None None O

When None None O
transplanted None None O
in None None O
nude None None O
mice None None O
, None None O
tumors None None O
formed None None O
by None None O
the None None O
v None None O
- None None O
Src None None O
transformed None None O
SWAP None None O
- None None O
70 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
MEFs None None O
were None None O
smaller None None O
than None None O
those None None O
formed None None O
by None None O
cells None None O
expressing None None O
exogenous None None O
SWAP None None O
- None None O
70 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
SWAP None None O
- None None O
70 None None O
may None None O
be None None O
required None None O
for None None O
oncogenic None None O
transformation None None O
and None None O
contributes None None O
to None None O
cell None None O
growth None None O
in None None O
MEFs None None O
transformed None None O
by None None O
v None None O
- None None O
Src None None O
. None None O

Autotaxin None None O
( None None O
ATX None None O
) None None O
, None None O
a None None O
potent None None O
tumor None None O
motogen None None O
, None None O
augments None None O
invasive None None O
and None None O
metastatic None None O
potential None None O
of None None O
ras None None O
- None None O
transformed None None O
cells None None O
. None None O

Autotaxin None None O
( None None O
ATX None None O
) None None O
, None None O
an None None O
exo None None O
- None None O
nucleotide None None O
pyrophosphatase None None O
and None None O
phosphodiesterase None None O
, None None O
was None None O
originally None None O
isolated None None O
as None None O
a None None O
potent None None O
stimulator None None O
of None None O
tumor None None O
cell None None O
motility None None O
. None None O

In None None O
order None None O
to None None O
study None None O
whether None None O
ATX None None O
expression None None O
affects None None O
motility None None O
- None None O
dependent None None O
processes None None O
such None None O
as None None O
invasion None None O
and None None O
metastasis None None O
, None None O
we None None O
stably None None O
transfected None None O
full None None O
- None None O
length None None O
ATX None None O
cDNA None None O
into None None O
two None None O
non None None O
- None None O
expressing None None O
cell None None O
lines None None O
, None None O
parental None None O
and None None O
ras None None O
- None None O
transformed None None O
NIH3T3 None None I-Cell-line-name
( None None O
clone7 None None O
) None None O
cells None None O
. None None O

The None None O
effect None None O
of None None O
ATX None None O
secretion None None O
on None None O
in None None O
vitro None None O
cell None None O
motility None None O
was None None O
variable None None O
. None None O

The None None O
ras None None O
- None None O
transformed None None O
, None None O
ATX None None O
- None None O
secreting None None O
subclones None None O
had None None O
enhanced None None O
motility None None O
to None None O
ATX None None O
as None None O
chemoattractant None None O
, None None O
but None None O
there None None O
was None None O
little None None O
difference None None O
in None None O
the None None O
motility None None O
responses None None O
of None None O
NIH3T3 None None I-Cell-line-name
cells None None O
transfected None None O
with None None O
atx None None O
, None None O
an None None O
inactive None None O
mutant None None O
gene None None O
, None None O
or None None O
empty None None O
vector None None O
. None None O

In None None O
MatrigelTM None None O
invasion None None O
assays None None O
, None None O
all None None O
subclones None None O
, None None O
which None None O
secreted None None O
enzymatically None None O
active None None O
ATX None None O
, None None O
demonstrated None None O
greater None None O
spontaneous None None O
and None None O
ATX None None O
- None None O
stimulated None None O
invasion None None O
than None None O
appropriate None None O
controls None None O
. None None O

This None None O
difference None None O
in None None O
invasiveness None None O
was None None O
not None None O
caused None None O
by None None O
differences None None O
in None None O
gelatinase None None O
production None None O
, None None O
which None None O
was None None O
constant None None O
within None None O
each None None O
group None None O
of None None O
transfectants None None O
. None None O

In None None O
vivo None None O
studies None None O
with None None O
athymic None None O
nude None None O
mice None None O
demonstrated None None O
that None None O
injection None None O
of None None O
atx None None O
- None None O
transfected None None O
NIH3T3 None None I-Cell-line-name
cells None None O
resulted None None O
in None None O
a None None O
weak None None O
tumorigenic None None O
capacity None None O
with None None O
few None None O
experimental None None O
metastases None None O
. None None O

Combination None None O
of None None O
ATX None None O
expression None None O
with None None O
ras None None O
transformation None None O
produced None None O
cells None None O
with None None O
greatly None None O
amplified None None O
tumorigenesis None None O
and None None O
metastatic None None O
potential None None O
compared None None O
to None None O
ras None None O
- None None O
transformed None None O
controls None None O
. None None O

Thus None None O
, None None O
ATX None None O
appears None None O
to None None O
augment None None O
cellular None None O
characteristics None None O
necessary None None O
for None None O
tumor None None O
aggressiveness None None O
. None None O

Fluoroscopically None None O
guided None None O
cervical None None O
prolotherapy None None O
for None None O
instability None None O
with None None O
blinded None None O
pre None None O
and None None O
post None None O
radiographic None None O
reading None None O
. None None O

BACKGROUND None None O
: None None O

Several None None O
authors None None O
have None None O
postulated None None O
that None None O
cervical None None O
instability None None O
is None None O
a None None O
major None None O
cause None None O
of None None O
traumatic None None O
spinal None None O
pain None None O
. None None O

OBJECTIVE None None O
: None None O

The None None O
purpose None None O
of None None O
this None None O
prospective None None O
case None None O
series None None O
study None None O
( None None O
n None None O
= None None O
6 None None O
) None None O
was None None O
to None None O
determine None None O
if None None O
proliferant None None O
injections None None O
have None None O
an None None O
effect None None O
on None None O
cervical None None O
translation None None O
as None None O
measured None None O
by None None O
a None None O
blinded None None O
reader None None O
. None None O

DESIGN None None O
: None None O

This None None O
study None None O
was None None O
a None None O
prospective None None O
case None None O
series None None O
. None None O

Study None None O
participants None None O
were None None O
selected None None O
from None None O
patients None None O
seen None None O
for None None O
the None None O
primary None None O
complaint None None O
of None None O
Motor None None O
Vehicle None None O
Collision None None O
related None None O
neck None None O
pain None None O
in None None O
a None None O
private None None O
sub None None O
- None None O
specialty None None O
pain None None O
clinic None None O
. None None O

METHODS None None O
: None None O

Flexion None None O
and None None O
extension None None O
views None None O
were None None O
obtained None None O
by None None O
standard None None O
radiographs None None O
taken None None O
with None None O
a None None O
C None None O
- None None O
Arm None None O
fluoroscope None None O
under None None O
Valium None None O
sedation None None O
. None None O

Patients None None O
with None None O
more None None O
than None None O
2 None None O
. None None O
7 None None O
mm None None O
of None None O
absolute None None O
cervical None None O
translation None None O
and None None O
at None None O
least None None O
50 None None O
% None None O
reduction None None O
of None None O
cervical None None O
and None None O
referred None None O
pain None None O
with None None O
a None None O
two None None O
day None None O
rigid None None O
cervical None None O
immobilization None None O
test None None O
were None None O
admitted None None O
into None None O
the None None O
study None None O
. None None O

Participants None None O
underwent None None O
3 None None O
prolotherapy None None O
injections None None O
at None None O
all None None O
sites None None O
that None None O
demonstrated None None O
translation None None O
. None None O

The None None O
difference None None O
in None None O
means None None O
between None None O
pre None None O
- None None O
test None None O
and None None O
post None None O
- None None O
test None None O
measurements None None O
( None None O
flexion None None O
translation None None O
, None None O
extension None None O
translation None None O
, None None O
and None None O
pain None None O
VAS None None O
scores None None O
) None None O
were None None O
assessed None None O
by None None O
a None None O
Wilcoxon None None O
signed None None O
ranks None None O
test None None O
( None None O
alpha None None O
= None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

RESULTS None None O
: None None O

The None None O
mean None None O
post None None O
- None None O
test None None O
VAS None None O
score None None O
( None None O
M None None O
= None None O
3 None None O
. None None O
83 None None O
, None None O
SD None None O
= None None O
2 None None O
. None None O
3 None None O
, None None O
t None None O
= None None O
2 None None O
. None None O
889 None None O
) None None O
was None None O
significantly None None O
less None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
04 None None O
) None None O
than None None O
the None None O
mean None None O
pre None None O
- None None O
test None None O
VAS None None O
score None None O
( None None O
M None None O
= None None O
5 None None O
. None None O
75 None None O
, None None O
SD None None O
= None None O
1 None None O
. None None O
94 None None O
) None None O
. None None O

The None None O
correlation None None O
between None None O
difference None None O
in None None O
mean None None O
extension None None O
at None None O
C2 None None O
- None None O
3 None None O
and None None O
C5 None None O
- None None O
6 None None O
and None None O
difference None None O
in None None O
mean None None O
extension None None O
was None None O
significant None None O
( None None O
rho None None O
= None None O
0 None None O
. None None O
89 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
02 None None O
and None None O
rho None None O
= None None O
0 None None O
. None None O
85 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
03 None None O
respectively None None O
) None None O
. None None O

Difference None None O
in None None O
mean None None O
flexion None None O
at None None O
C3 None None O
- None None O
4 None None O
and None None O
C4 None None O
- None None O
5 None None O
was None None O
significantly None None O
correlated None None O
with None None O
difference None None O
in None None O
mean None None O
flexion None None O
( None None O
rho None None O
= None None O
0 None None O
. None None O
88 None None O
, None None O
p None None O
= None None O
0 None None O
. None None O
02 None None O
and None None O
rho None None O
= None None O
0 None None O
. None None O
941 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
01 None None O
respectively None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

The None None O
results None None O
of None None O
this None None O
study None None O
demonstrate None None O
statistically None None O
significant None None O
correlations None None O
between None None O
proliferant None None O
injections None None O
, None None O
a None None O
reduction None None O
of None None O
both None None O
cervical None None O
flexion None None O
and None None O
extension None None O
translation None None O
, None None O
as None None O
well None None O
as None None O
a None None O
reduction None None O
in None None O
pain None None O
VAS None None O
score None None O
. None None O

Since None None O
patients None None O
with None None O
traumatic None None O
cervical None None O
instability None None O
have None None O
few None None O
viable None None O
treatment None None O
options None None O
other None None O
than None None O
surgical None None O
fusion None None O
, None None O
cervical None None O
proliferant None None O
injections None None O
under None None O
C None None O
- None None O
Arm None None O
fluoroscope None None O
may None None O
be None None O
a None None O
viable None None O
treatment None None O
option None None O
. None None O

Characterization None None O
of None None O
transferrin None None O
glycoforms None None O
in None None O
human None None O
serum None None O
by None None O
CE None None O
- None None O
UV None None O
and None None O
CE None None O
- None None O
ESI None None O
- None None O
MS None None O
. None None O

Human None None O
transferrin None None O
( None None O
Tf None None O
) None None O
is None None O
a None None O
model None None O
glycoprotein None None O
for None None O
congenital None None O
disorders None None O
of None None O
glycosylation None None O
( None None O
CDG None None O
) None None O
diagnosis None None O
. None None O

In None None O
the None None O
last None None O
few None None O
years None None O
, None None O
new None None O
CE None None O
- None None O
UV None None O
methods None None O
for None None O
intact None None O
Tf None None O
glycoforms None None O
analysis None None O
have None None O
been None None O
developed None None O
using None None O
nonvolatile None None O
BGEs None None O
and None None O
organic None None O
modifiers None None O
. None None O

However None None O
, None None O
the None None O
use None None O
of None None O
these None None O
BGEs None None O
does None None O
not None None O
allow None None O
the None None O
coupling None None O
of None None O
these None None O
procedures None None O
with None None O
electrospray None None O
MS None None O
( None None O
ESI None None O
- None None O
MS None None O
) None None O
. None None O

In None None O
this None None O
study None None O
, None None O
a None None O
new None None O
CE None None O
- None None O
UV None None O
separation None None O
method None None O
of None None O
Tf None None O
glycoforms None None O
is None None O
developed None None O
, None None O
using None None O
a None None O
double None None O
- None None O
layer None None O
stable None None O
coating None None O
and None None O
a None None O
volatile None None O
BGE None None O
based None None O
on None None O
ammonium None None O
acetate None None O
. None None O

The None None O
separation None None O
method None None O
is None None O
optimized None None O
using None None O
standard None None O
Tf None None O
and None None O
their None None O
potential None None O
is None None O
demonstrated None None O
applying None None O
the None None O
method None None O
to None None O
the None None O
analysis None None O
of None None O
sera None None O
Tf None None O
from None None O
healthy None None O
individuals None None O
and None None O
CDG None None O
patients None None O
. None None O

The None None O
CE None None O
- None None O
UV None None O
separation None None O
method None None O
has None None O
been None None O
coupled None None O
to None None O
ESI None None O
- None None O
MS None None O
detection None None O
. None None O

Main None None O
parameters None None O
such None None O
as None None O
sheath None None O
liquid None None O
composition None None O
are None None O
optimized None None O
in None None O
order None None O
to None None O
obtain None None O
a None None O
good None None O
sensitivity None None O
. None None O

The None None O
CE None None O
- None None O
ESI None None O
- None None O
MS None None O
method None None O
has None None O
also None None O
been None None O
used None None O
in None None O
serum None None O
samples None None O
obtaining None None O
the None None O
separation None None O
of None None O
the None None O
different None None O
proteins None None O
present None None O
in None None O
serum None None O
and None None O
partial None None O
separation None None O
of None None O
Tf None None O
glycoforms None None O
. None None O

Different None None O
mass None None O
spectra None None O
and None None O
deconvoluted None None O
molecular None None O
masses None None O
were None None O
obtained None None O
for None None O
each None None O
sialoform None None O
, None None O
allowing None None O
unequivocal None None O
glycoform None None O
identification None None O
. None None O

DNA None None O
methylation None None O
and None None O
expression None None O
of None None O
HLA None None O
- None None O
DR None None O
alpha None None O
. None None O

B None None O
- None None O
cell None None O
lines None None O
established None None O
from None None O
two None None O
individuals None None O
with None None O
T None None O
- None None O
cell None None O
acute None None O
lymphocytic None None O
leukemia None None O
( None None O
T None None O
- None None O
ALL None None O
) None None O
express None None O
HLA None None O
- None None O
DR None None O
antigens None None O
, None None O
whereas None None O
the None None O
isogenic None None O
T None None O
- None None O
cells None None O
do None None O
not None None O
. None None O

The None None O
lack None None O
of None None O
expression None None O
correlates None None O
with None None O
a None None O
lack None None O
of None None O
detectable None None O
HLA None None O
- None None O
DR None None O
mRNA None None O
. None None O

All None None O
of None None O
the None None O
DR None None O
alpha None None O
DNA None None O
sequences None None O
detected None None O
by None None O
a None None O
cloned None None O
DR None None O
alpha None None O
cDNA None None O
probe None None O
are None None O
contained None None O
in None None O
a None None O
BglII None None O
fragment None None O
which None None O
varies None None O
slightly None None O
in None None O
size None None O
( None None O
4 None None O
. None None O
0 None None O
to None None O
4 None None O
. None None O
8 None None O
kilobases None None O
) None None O
from None None O
one None None O
individual None None O
to None None O
another None None O
. None None O

In None None O
DNA None None O
from None None O
the None None O
T None None O
- None None O
cells None None O
not None None O
expressing None None O
DR None None O
alpha None None O
mRNA None None O
, None None O
all None None O
of None None O
the None None O
potential None None O
HpaII None None O
sites None None O
within None None O
the None None O
BglII None None O
fragment None None O
appeared None None O
to None None O
be None None O
methylated None None O
. None None O

In None None O
contrast None None O
, None None O
at None None O
least None None O
some None None O
of None None O
these None None O
sites None None O
were None None O
not None None O
methylated None None O
in None None O
DNA None None O
from None None O
the None None O
B None None O
- None None O
cells None None O
expressing None None O
high None None O
levels None None O
of None None O
DR None None O
alpha None None O
mRNA None None O
. None None O

Treatment None None O
of None None O
these None None O
T None None O
- None None O
cells None None O
with None None O
5 None None O
- None None O
azacytidine None None O
resulted None None O
in None None O
the None None O
induction None None O
of None None O
DR None None O
surface None None O
antigen None None O
expression None None O
, None None O
the None None O
appearance None None O
of None None O
DR None None O
alpha None None O
mRNA None None O
, None None O
and None None O
the None None O
partial None None O
demethylation None None O
of None None O
the None None O
DR None None O
alpha None None O
DNA None None O
sequences None None O
. None None O

T None None O
- None None O
cell None None O
lines None None O
established None None O
from None None O
human None None O
T None None O
- None None O
cell None None O
leukemia None None O
- None None O
lymphoma None None O
virus None None O
associated None None O
T None None O
- None None O
cell None None O
neoplasias None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
T None None O
- None None O
cell None None O
acute None None O
lymphocytic None None O
leukemia None None O
cell None None O
lines None None O
, None None O
expressed None None O
both None None O
DR None None O
antigens None None O
and None None O
DR None None O
alpha None None O
mRNA None None O
; None None O
the None None O
HpaII None None O
sites None None O
within None None O
the None None O
BglII None None O
fragment None None O
of None None O
DR None None O
alpha None None O
DNA None None O
of None None O
these None None O
human None None O
T None None O
- None None O
cell None None O
leukemia None None O
- None None O
lymphoma None None O
virus None None O
- None None O
positive None None O
T None None O
- None None O
cell None None O
lines None None O
were None None O
in None None O
all None None O
cases None None O
at None None O
least None None O
partially None None O
unmethylated None None O
. None None O

Uncultured None None O
peripheral None None O
blood None None O
T None None O
- None None O
cells None None O
from None None O
human None None O
T None None O
- None None O
cell None None O
leukemia None None O
- None None O
lymphoma None None O
virus None None O
- None None O
infected None None O
individuals None None O
expressed None None O
DR None None O
antigens None None O
at None None O
a None None O
low None None O
level None None O
, None None O
and None None O
the None None O
DR None None O
alpha None None O
locus None None O
was None None O
partially None None O
unmethylated None None O
. None None O

After None None O
48 None None O
h None None O
in None None O
culture None None O
, None None O
DR None None O
antigen None None O
expression None None O
was None None O
substantially None None O
increased None None O
, None None O
but None None O
no None None O
significant None None O
changes None None O
were None None O
observed None None O
in None None O
methylation None None O
of None None O
the None None O
DR None None O
alpha None None O
locus None None O
or None None O
in None None O
the None None O
amount None None O
of None None O
DR None None O
mRNA None None O
which None None O
was None None O
present None None O
. None None O

This None None O
suggests None None O
that None None O
expression None None O
of None None O
DR None None O
antigens None None O
also None None O
can None None O
be None None O
modulated None None O
post None None O
- None None O
transcriptionally None None O
. None None O

Preliminary None None O
evidence None None O
for None None O
a None None O
pyridine None None O
nucleotide None None O
cycle None None O
in None None O
Bordetella None None O
pertussis None None O
. None None O

Preliminary None None O
evidence None None O
that None None O
Bordetella None None O
pertussis None None O
has None None O
a None None O
functional None None O
pyridine None None O
nucleotide None None O
cycle None None O
was None None O
the None None O
observation None None O
that None None O
[ None None O
14C None None O
] None None O
- None None O
nicotinic None None O
acid None None O
was None None O
rapidly None None O
metabolized None None O
during None None O
its None None O
uptake None None O
by None None O
the None None O
bacteria None None O
to None None O
pyridine None None O
nucleotides None None O
and None None O
nicotinamide None None O
. None None O

Nicotinamide None None O
deamidase None None O
activity None None O
, None None O
necessary None None O
for None None O
the None None O
completion None None O
of None None O
the None None O
cycle None None O
by None None O
conversion None None O
of None None O
nicotinamide None None O
to None None O
nicotinic None None O
acid None None O
, None None O
was None None O
found None None O
in None None O
a None None O
soluble None None O
extract None None O
( None None O
20 None None O
000 None None O
X None None O
g None None O
supernatant None None O
) None None O
of None None O
B None None O
. None None O
pertussis None None O
cell None None O
lysates None None O
. None None O

The None None O
enlarging None None O
clinical None None O
spectrum None None O
of None None O
Lyme None None O
disease None None O
: None None O
Lyme None None O
cerebral None None O
vasculitis None None O
, None None O
a None None O
new None None O
disease None None O
entity None None O
. None None O

The None None O
case None None O
of None None O
a None None O
patient None None O
with None None O
cerebral None None O
vasculitis None None O
with None None O
a None None O
right None None O
thalamic None None O
infarct None None O
associated None None O
with None None O
cerebral None None O
spinal None None O
fluid None None O
Lyme None None O
disease None None O
is None None O
presented None None O
. None None O

This None None O
entity None None O
has None None O
not None None O
been None None O
described None None O
in None None O
the None None O
United None None O
States None None O
, None None O
and None None O
only None None O
one None None O
similar None None O
case None None O
in None None O
the None None O
world None None O
literature None None O
could None None O
be None None O
found None None O
. None None O

The None None O
patient None None O
presented None None O
with None None O
a None None O
progressive None None O
headache None None O
and None None O
subsequent None None O
development None None O
of None None O
grand None None O
mal None None O
seizure None None O
activity None None O
. None None O

Lyme None None O
disease None None O
has None None O
been None None O
associated None None O
with None None O
cranial None None O
nerve None None O
palsies None None O
, None None O
peripheral None None O
and None None O
cranial None None O
radiculopathies None None O
, None None O
aseptic None None O
meningitis None None O
, None None O
encephalitic None None O
symptoms None None O
, None None O
chorea None None O
, None None O
and None None O
demyelinating None None O
polyneuropathy None None O
presenting None None O
like None None O
Guillain None None O
- None None O
Barre None None O
syndrome None None O
. None None O

These None None O
syndromes None None O
can None None O
occur None None O
separately None None O
or None None O
in None None O
combination None None O
. None None O

Stroke None None O
and None None O
strokelike None None O
syndromes None None O
have None None O
been None None O
attributed None None O
to None None O
Lyme None None O
disease None None O
. None None O

The None None O
literature None None O
concerning None None O
the None None O
neurologic None None O
manifestations None None O
of None None O
Lyme None None O
disease None None O
is None None O
reviewed None None O
. None None O

PTHrP None None O
drives None None O
breast None None O
tumor None None O
initiation None None O
, None None O
progression None None O
, None None O
and None None O
metastasis None None O
in None None O
mice None None O
and None None O
is None None O
a None None O
potential None None O
therapy None None O
target None None O
. None None O

Parathyroid None None O
hormone None None O
- None None O
related None None O
protein None None O
( None None O
PTHrP None None O
) None None O
is None None O
a None None O
secreted None None O
factor None None O
expressed None None O
in None None O
almost None None O
all None None O
normal None None O
fetal None None O
and None None O
adult None None O
tissues None None O
. None None O

It None None O
is None None O
involved None None O
in None None O
a None None O
wide None None O
range None None O
of None None O
developmental None None O
and None None O
physiological None None O
processes None None O
, None None O
including None None O
serum None None O
calcium None None O
regulation None None O
. None None O

PTHrP None None O
is None None O
also None None O
associated None None O
with None None O
the None None O
progression None None O
of None None O
skeletal None None O
metastases None None O
, None None O
and None None O
its None None O
dysregulated None None O
expression None None O
in None None O
advanced None None O
cancers None None O
causes None None O
malignancy None None O
- None None O
associated None None O
hypercalcemia None None O
. None None O

Although None None O
PTHrP None None O
is None None O
frequently None None O
expressed None None O
by None None O
breast None None O
tumors None None O
and None None O
other None None O
solid None None O
cancers None None O
, None None O
its None None O
effects None None O
on None None O
tumor None None O
progression None None O
are None None O
unclear None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
in None None O
mice None None O
pleiotropic None None O
involvement None None O
of None None O
PTHrP None None O
in None None O
key None None O
steps None None O
of None None O
breast None None O
cancer None None O
- None None O
it None None O
influences None None O
the None None O
initiation None None O
and None None O
progression None None O
of None None O
primary None None O
tumors None None O
and None None O
metastases None None O
. None None O

Pthrp None None O
ablation None None O
in None None O
the None None O
mammary None None O
epithelium None None O
of None None O
the None None O
PyMT None None O
- None None O
MMTV None None O
breast None None O
cancer None None O
mouse None None O
model None None O
caused None None O
a None None O
delay None None O
in None None O
primary None None O
tumor None None O
initiation None None O
, None None O
inhibited None None O
tumor None None O
progression None None O
, None None O
and None None O
reduced None None O
metastasis None None O
to None None O
distal None None O
sites None None O
. None None O

Mechanistically None None O
, None None O
it None None O
reduced None None O
expression None None O
of None None O
molecular None None O
markers None None O
of None None O
cell None None O
proliferation None None O
( None None O
Ki67 None None O
) None None O
and None None O
angiogenesis None None O
( None None O
factor None None O
VIII None None O
) None None O
, None None O
antiapoptotic None None O
factor None None O
Bcl None None O
- None None O
2 None None O
, None None O
cell None None O
- None None O
cycle None None O
progression None None O
regulator None None O
cyclin None None O
D1 None None O
, None None O
and None None O
survival None None O
factor None None O
AKT1 None None O
. None None O

PTHrP None None O
also None None O
influenced None None O
expression None None O
of None None O
the None None O
adhesion None None O
factor None None O
CXCR4 None None O
, None None O
and None None O
coexpression None None O
of None None O
PTHrP None None O
and None None O
CXCR4 None None O
was None None O
crucial None None O
for None None O
metastatic None None O
spread None None O
. None None O

Importantly None None O
, None None O
PTHrP None None O
- None None O
specific None None O
neutralizing None None O
antibodies None None O
slowed None None O
the None None O
progression None None O
and None None O
metastasis None None O
of None None O
human None None O
breast None None O
cancer None None O
xenografts None None O
. None None O

Our None None O
data None None O
identify None None O
what None None O
we None None O
believe None None O
to None None O
be None None O
new None None O
functions None None O
for None None O
PTHrP None None O
in None None O
several None None O
key None None O
steps None None O
of None None O
breast None None O
cancer None None O
and None None O
suggest None None O
that None None O
PTHrP None None O
may None None O
constitute None None O
a None None O
novel None None O
target None None O
for None None O
therapeutic None None O
intervention None None O
. None None O

Hereditary None None O
paraganglioma None None O
/ None None O
pheochromocytoma None None O
and None None O
inherited None None O
succinate None None O
dehydrogenase None None O
deficiency None None O
. None None O

Mitochondrial None None O
complex None None O
II None None O
, None None O
or None None O
succinate None None O
dehydrogenase None None O
, None None O
is None None O
a None None O
key None None O
enzymatic None None O
complex None None O
involved None None O
in None None O
both None None O
the None None O
tricarboxylic None None O
acid None None O
( None None O
TCA None None O
) None None O
cycle None None O
and None None O
oxidative None None O
phosphorylation None None O
as None None O
part None None O
of None None O
the None None O
mitochondrial None None O
respiratory None None O
chain None None O
. None None O

Germline None None O
succinate None None O
dehydrogenase None None O
subunit None None O
A None None O
( None None O
SDHA None None O
) None None O
mutations None None O
have None None O
been None None O
reported None None O
in None None O
a None None O
few None None O
patients None None O
with None None O
a None None O
classical None None O
mitochondrial None None O
neurodegenerative None None O
disease None None O
. None None O

Mutations None None O
in None None O
the None None O
genes None None O
encoding None None O
the None None O
three None None O
other None None O
succinate None None O
dehydrogenase None None O
subunits None None O
( None None O
SDHB None None O
, None None O
SDHC None None O
and None None O
SDHD None None O
) None None O
have None None O
been None None O
identified None None O
in None None O
patients None None O
affected None None O
by None None O
familial None None O
or None None O
' None None O
apparently None None O
sporadic None None O
' None None O
paraganglioma None None O
and None None O
/ None None O
or None None O
pheochromocytoma None None O
, None None O
an None None O
autosomal None None O
inherited None None O
cancer None None O
- None None O
susceptibility None None O
syndrome None None O
. None None O

These None None O
discoveries None None O
have None None O
dramatically None None O
changed None None O
the None None O
work None None O
- None None O
up None None O
and None None O
genetic None None O
counseling None None O
of None None O
patients None None O
and None None O
families None None O
with None None O
paragangliomas None None O
and None None O
/ None None O
or None None O
pheochromocytomas None None O
. None None O

The None None O
subsequent None None O
identification None None O
of None None O
germline None None O
mutations None None O
in None None O
the None None O
gene None None O
encoding None None O
fumarase None None O
- None None O
- None None O
another None None O
TCA None None O
cycle None None O
enzyme None None O
- None None O
- None None O
in None None O
a None None O
new None None O
hereditary None None O
form None None O
of None None O
susceptibility None None O
to None None O
renal None None O
, None None O
uterine None None O
and None None O
cutaneous None None O
tumors None None O
has None None O
highlighted None None O
the None None O
potential None None O
role None None O
of None None O
the None None O
TCA None None O
cycle None None O
and None None O
, None None O
more None None O
generally None None O
, None None O
of None None O
the None None O
mitochondria None None O
in None None O
cancer None None O
. None None O

Fibroblast None None O
growth None None O
factor None None O
receptor None None O
2 None None O
- None None O
positive None None O
fibroblasts None None O
provide None None O
a None None O
suitable None None O
microenvironment None None O
for None None O
tumor None None O
development None None O
and None None O
progression None None O
in None None O
esophageal None None O
carcinoma None None O
. None None O

PURPOSE None None O
: None None O
Tumor None None O
fibroblasts None None O
( None None O
TF None None O
) None None O
have None None O
been None None O
suggested None None O
to None None O
play None None O
an None None O
essential None None O
role None None O
in None None O
the None None O
complex None None O
process None None O
of None None O
tumor None None O
- None None O
stroma None None O
interactions None None O
and None None O
tumorigenesis None None O
. None None O

The None None O
aim None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
specific None None O
role None None O
of None None O
TF None None O
in None None O
the None None O
esophageal None None O
cancer None None O
microenvironment None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
An None None O
Affymetrix None None O
expression None None O
microarray None None O
was None None O
used None None O
to None None O
compare None None O
gene None None O
expression None None O
profiles None None O
between None None O
six None None O
pairs None None O
of None None O
TFs None None O
and None None O
normal None None O
fibroblasts None None O
from None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
ESCC None None O
) None None O
. None None O

Differentially None None O
expressed None None O
genes None None O
were None None O
identified None None O
, None None O
and None None O
a None None O
subset None None O
was None None O
evaluated None None O
by None None O
quantitative None None O
real None None O
- None None O
time None None O
PCR None None O
and None None O
immunohistochemistry None None O
. None None O

RESULTS None None O
: None None O
About None None O
43 None None O
% None None O
( None None O
126 None None O
of None None O
292 None None O
) None None O
of None None O
known None None O
deregulated None None O
genes None None O
in None None O
TFs None None O
were None None O
associated None None O
with None None O
cell None None O
proliferation None None O
, None None O
extracellular None None O
matrix None None O
remodeling None None O
, None None O
and None None O
immune None None O
response None None O
. None None O

Up None None O
- None None O
regulation None None O
of None None O
fibroblast None None O
growth None None O
factor None None O
receptor None None O
2 None None O
( None None O
FGFR2 None None O
) None None O
, None None O
which None None O
showed None None O
the None None O
most None None O
significant None None O
change None None O
, None None O
was None None O
detected None None O
in None None O
all None None O
six None None O
tested None None O
TFs None None O
compared None None O
with None None O
their None None O
paired None None O
normal None None O
fibroblasts None None O
. None None O

A None None O
further None None O
study None None O
found None None O
that None None O
FGFR2 None None O
- None None O
positive None None O
fibroblasts None None O
were None None O
only None None O
observed None None O
inside None None O
the None None O
tumor None None O
tissues None None O
and None None O
not None None O
in None None O
tumor None None O
- None None O
surrounding None None O
stromal None None O
tissues None None O
, None None O
suggesting None None O
that None None O
FGFR2 None None O
could None None O
be None None O
used None None O
as None None O
a None None O
TF None None O
- None None O
specific None None O
marker None None O
in None None O
ESCC None None O
. None None O

Moreover None None O
, None None O
the None None O
conditioned None None O
medium None None O
from None None O
TFs None None O
was None None O
found None None O
to None None O
be None None O
able None None O
to None None O
promote None None O
ESCC None None O
tumor None None O
cell None None O
growth None None O
, None None O
migration None None O
, None None O
and None None O
invasion None None O
in None None O
vitro None None O
. None None O

CONCLUSIONS None None O
: None None O
Our None None O
study None None O
provides None None O
new None None O
candidate None None O
genes None None O
for None None O
the None None O
esophageal None None O
cancer None None O
microenvironment None None O
. None None O

Based None None O
on None None O
our None None O
results None None O
, None None O
we None None O
hypothesize None None O
that None None O
FGFR2 None None O
( None None O
+ None None O
) None None O
- None None O
TFs None None O
might None None O
provide None None O
cancer None None O
cells None None O
with None None O
a None None O
suitable None None O
microenvironment None None O
via None None O
secretion None None O
of None None O
proteins None None O
that None None O
could None None O
promote None None O
cancer None None O
development None None O
and None None O
progression None None O
through None None O
stimulation None None O
of None None O
cancer None None O
cell None None O
proliferation None None O
, None None O
induction None None O
of None None O
angiogenesis None None O
, None None O
inhibition None None O
of None None O
cell None None O
adhesion None None O
, None None O
enhancement None None O
of None None O
cell None None O
mobility None None O
, None None O
and None None O
promotion None None O
of None None O
the None None O
epithelial None None O
- None None O
mesenchymal None None O
transition None None O
. None None O

NF None None O
- None None O
kappaB None None O
and None None O
IKK None None O
as None None O
therapeutic None None O
targets None None O
in None None O
cancer None None O
. None None O

The None None O
transcription None None O
factor None None O
NF None None O
- None None O
kappaB None None O
and None None O
associated None None O
regulatory None None O
factors None None O
( None None O
including None None O
IkappaB None None O
kinase None None O
subunits None None O
and None None O
the None None O
IkappaB None None O
family None None O
member None None O
Bcl None None O
- None None O
3 None None O
) None None O
are None None O
strongly None None O
implicated None None O
in None None O
a None None O
variety None None O
of None None O
hematologic None None O
and None None O
solid None None O
tumor None None O
malignancies None None O
. None None O

A None None O
role None None O
for None None O
NF None None O
- None None O
kappaB None None O
in None None O
cancer None None O
cells None None O
appears None None O
to None None O
involve None None O
regulation None None O
of None None O
cell None None O
proliferation None None O
, None None O
control None None O
of None None O
apoptosis None None O
, None None O
promotion None None O
of None None O
angiogenesis None None O
, None None O
and None None O
stimulation None None O
of None None O
invasion None None O
/ None None O
metastasis None None O
. None None O

Consistent None None O
with None None O
a None None O
role None None O
for None None O
NF None None O
- None None O
kappaB None None O
in None None O
oncogenesis None None O
are None None O
observations None None O
that None None O
inhibition None None O
of None None O
NF None None O
- None None O
kappaB None None O
alone None None O
or None None O
in None None O
combination None None O
with None None O
cancer None None O
therapies None None O
leads None None O
to None None O
tumor None None O
cell None None O
death None None O
or None None O
growth None None O
inhibition None None O
. None None O

However None None O
, None None O
other None None O
experimental None None O
data None None O
indicate None None O
that None None O
NF None None O
- None None O
kappaB None None O
can None None O
play None None O
a None None O
tumor None None O
suppressor None None O
role None None O
in None None O
certain None None O
settings None None O
and None None O
that None None O
it None None O
can None None O
be None None O
important None None O
in None None O
promoting None None O
an None None O
apoptotic None None O
signal None None O
downstream None None O
of None None O
certain None None O
cancer None None O
therapy None None O
regimens None None O
. None None O

In None None O
order None None O
to None None O
appropriately None None O
move None None O
NF None None O
- None None O
kappaB None None O
inhibitors None None O
in None None O
the None None O
clinic None None O
, None None O
thorough None None O
approaches None None O
must None None O
be None None O
initiated None None O
to None None O
determine None None O
the None None O
molecular None None O
mechanisms None None O
that None None O
dictate None None O
the None None O
complexity None None O
of None None O
oncologic None None O
and None None O
therapeutic None None O
outcomes None None O
that None None O
are None None O
controlled None None O
by None None O
NF None None O
- None None O
kappaB None None O
. None None O

The None None O
disintegrin None None O
- None None O
like None None O
and None None O
cysteine None None O
- None None O
rich None None O
domains None None O
of None None O
ADAM None None O
- None None O
9 None None O
mediate None None O
interactions None None O
between None None O
melanoma None None O
cells None None O
and None None O
fibroblasts None None O
. None None O

A None None O
characteristic None None O
of None None O
malignant None None O
cells None None O
is None None O
their None None O
capacity None None O
to None None O
invade None None O
their None None O
surrounding None None O
and None None O
to None None O
metastasize None None O
to None None O
distant None None O
organs None None O
. None None O

During None None O
these None None O
processes None None O
, None None O
proteolytic None None O
activities None None O
of None None O
tumor None None O
and None None O
stromal None None O
cells None None O
modify None None O
the None None O
extracellular None None O
matrix None None O
to None None O
produce None None O
a None None O
microenvironment None None O
suitable None None O
for None None O
their None None O
growth None None O
and None None O
migration None None O
. None None O

In None None O
recent None None O
years None None O
the None None O
family None None O
of None None O
ADAM None None O
proteases None None O
has None None O
been None None O
ascribed None None O
important None None O
roles None None O
in None None O
these None None O
processes None None O
. None None O

ADAM None None O
- None None O
9 None None O
is None None O
expressed None None O
in None None O
human None None O
melanoma None None O
at None None O
the None None O
tumor None None O
- None None O
stroma None None O
border None None O
where None None O
direct None None O
or None None O
indirect None None O
interactions None None O
between None None O
tumor None None O
cells None None O
and None None O
fibroblasts None None O
occur None None O
. None None O

To None None O
analyze None None O
the None None O
role None None O
of None None O
ADAM None None O
- None None O
9 None None O
for None None O
the None None O
interaction None None O
between None None O
melanoma None None O
cells None None O
and None None O
stromal None None O
fibroblasts None None O
, None None O
we None None O
produced None None O
the None None O
recombinant None None O
disintegrin None None O
- None None O
like None None O
and None None O
cysteine None None O
- None None O
rich None None O
domain None None O
of None None O
ADAM None None O
- None None O
9 None None O
( None None O
DC None None O
- None None O
9 None None O
) None None O
. None None O

Melanoma None None O
cells None None O
and None None O
human None None O
fibroblasts None None O
adhered None None O
to None None O
immobilized None None O
DC None None O
- None None O
9 None None O
in None None O
a None None O
Mn None None O
( None None O
2 None None O
+ None None O
) None None O
- None None O
dependent None None O
fashion None None O
suggesting None None O
an None None O
integrin None None O
- None None O
mediated None None O
process None None O
. None None O

Inhibition None None O
studies None None O
showed None None O
that None None O
adhesion None None O
of None None O
fibroblasts None None O
was None None O
mediated None None O
by None None O
several None None O
beta1 None None O
integrin None None O
receptors None None O
independent None None O
of None None O
the None None O
RGD None None O
and None None O
ECD None None O
recognition None None O
motif None None O
. None None O

Furthermore None None O
, None None O
interaction None None O
of None None O
fibroblasts None None O
and None None O
high None None O
invasive None None O
melanoma None None O
cells None None O
with None None O
soluble None None O
recombinant None None O
DC None None O
- None None O
9 None None O
resulted None None O
in None None O
enhanced None None O
expression None None O
of None None O
MMP None None O
- None None O
1 None None O
and None None O
MMP None None O
- None None O
2 None None O
. None None O

Silencing None None O
of None None O
ADAM None None O
- None None O
9 None None O
in None None O
melanoma None None O
cells None None O
significantly None None O
reduced None None O
cell None None O
adhesion None None O
to None None O
fibroblasts None None O
. None None O

Ablation None None O
of None None O
ADAM None None O
- None None O
9 None None O
in None None O
fibroblasts None None O
almost None None O
completely None None O
abolished None None O
these None None O
cellular None None O
interactions None None O
and None None O
melanoma None None O
cell None None O
invasion None None O
in None None O
vitro None None O
. None None O

In None None O
summary None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
ADAM None None O
- None None O
9 None None O
expression None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
mediating None None O
cell None None O
- None None O
cell None None O
contacts None None O
between None None O
fibroblasts None None O
and None None O
melanoma None None O
cells None None O
and None None O
that None None O
these None None O
interactions None None O
contribute None None O
to None None O
proteolytic None None O
activities None None O
required None None O
during None None O
invasion None None O
of None None O
melanoma None None O
cells None None O
. None None O

Intraoperative None None O
handling None None O
and None None O
wound None None O
healing None None O
of None None O
arthroscopic None None O
portal None None O
wounds None None O
: None None O
a None None O
clinical None None O
study None None O
comparing None None O
nylon None None O
suture None None O
with None None O
wound None None O
closure None None O
strips None None O
. None None O

This None None O
prospective None None O
, None None O
single None None O
- None None O
centre None None O
study None None O
compared None None O
wound None None O
closure None None O
methods None None O
in None None O
patients None None O
undergoing None None O
arthroscopy None None O
. None None O

Closure None None O
of None None O
arthroscopic None None O
portal None None O
wounds None None O
with None None O
sterile None None O
adhesive None None O
strips None None O
is None None O
effective None None O
and None None O
convenient None None O
for None None O
wound None None O
management None None O
. None None O

The None None O
method None None O
was None None O
associated None None O
with None None O
a None None O
reduced None None O
potential None None O
for None None O
infection None None O
, None None O
faster None None O
renewal None None O
of None None O
tensile None None O
strength None None O
, None None O
greater None None O
cost None None O
effectiveness None None O
, None None O
and None None O
better None None O
cosmetic None None O
effects None None O
comparing None None O
with None None O
suture None None O
closure None None O
. None None O

This None None O
method None None O
of None None O
wound None None O
closure None None O
may None None O
also None None O
reduce None None O
the None None O
incidence None None O
of None None O
needle None None O
stick None None O
injury None None O
in None None O
the None None O
theatre None None O
environment None None O
. None None O

Thereby None None O
the None None O
incidence None None O
of None None O
percutaneous None None O
exposure None None O
following None None O
a None None O
surgical None None O
procedure None None O
may None None O
not None None O
facilitate None None O
transmission None None O
of None None O
blood None None O
borne None None O
pathogens None None O
such None None O
as None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV None None O
) None None O
, None None O
hepatitis None None O
C None None O
virus None None O
and None None O
hepatitis None None O
B None None O
virus None None O
. None None O

As None None O
a None None O
result None None O
it None None O
may None None O
reduce None None O
litigation None None O
in None None O
today None None O
' None None O
s None None O
changing None None O
healthcare None None O
climate None None O
. None None O

Different None None O
ROC None None O
analysis None None O

When None None O
the None None O
true None None O
positive None None O
peptides None None O
are None None O
not None None O
known None None O
a None None O
priori None None O
, None None O
there None None O
exist None None O
various None None O
strategies None None O
in None None O
classifying None None O
hits None None O
into None None O
true None None O
or None None O
false None None O
positives None None O
when None None O
making None None O
a None None O
ROC None None O
plot None None O
. None None O

These None None O
strategies None None O
, None None O
unfortunately None None O
, None None O
will None None O
make None None O
a None None O
notable None None O
difference None None O
in None None O
retrieval None None O
assessment None None O
. None None O

For None None O
example None None O
, None None O
in None None O
a None None O
cell None None O
lysate None None O
experiment None None O
of None None O
a None None O
certain None None O
organism None None O
, None None O
it None None O
is None None O
customary None None O
to None None O
estimate None None O
the None None O
number None None O
of None None O
false None None O
positive None None O
hits None None O
by None None O
introducing None None O
a None None O
decoy None None O
database None None O
during None None O
the None None O
data None None O
analysis None None O
. None None O

The None None O
main None None O
idea None None O
there None None O
is None None O
to None None O
first None None O
sort None None O
the None None O
peptide None None O
hits None None O
according None None O
to None None O
their None None O
scores None None O
. None None O

Then None None O
for None None O
each None None O
decoy None None O
hit None None O
, None None O
one None None O
assumes None None O
that None None O
there None None O
is None None O
just None None O
one None None O
corresponding None None O
false None None O
hit None None O
in None None O
the None None O
target None None O
database None None O
. None None O

This None None O
strategy None None O
has None None O
been None None O
used None None O
extensively None None O
[ None None O
24 None None O
] None None O
. None None O

ROC None None O
analyses None None O
done None None O
this None None O
way None None O
generally None None O
count None None O
false None None O
positives None None O
, None None O
which None None O
are None None O
highly None None O
homologous None None O
to None None O
the None None O
target None None O
peptides None None O
, None None O
towards None None O
true None None O
positives None None O
. None None O

This None None O
has None None O
two None None O
effects None None O
: None None O
an None None O
overcount None None O
of None None O
true None None O
positives None None O
and None None O
a None None O
undercount None None O
of None None O
false None None O
positives None None O
. None None O

As None None O
a None None O
consequence None None O
, None None O
the None None O
ROC None None O
curves None None O
will None None O
appear None None O
more None None O
impressive None None O
. None None O

To None None O
mimick None None O
this None None O
situation None None O
, None None O
we None None O
used None None O
BLAST None None O
to None None O
find None None O
in None None O
the None None O
NCBI None None O
' None None O
s None None O
nr None None O
database None None O
highly None None O
homologous None None O
proteins None None O
to None None O
the None None O
target None None O
proteins None None O
used None None O
in None None O
the None None O
experiment None None O
and None None O
include None None O
those None None O
proteins None None O
in None None O
our None None O
true None None O
positive None None O
set None None O
. None None O

This None None O
strategy None None O
produces None None O
ROC None None O
curves None None O
shown None None O
as None None O
the None None O
solid None None O
curves None None O
of None None O
Figure None None O
S8 None None O
. None None O

When None None O
compared None None O
to None None O
Figure None None O
6 None None O
and None None O
Figure None None O
S6 None None O
, None None O
the None None O
ROC None None O
curves None None O
produced None None O
by None None O
this None None O
strategy None None O
seem None None O
much None None O
more None None O
impressive None None O
. None None O

Not None None O
counting None None O
highly None None O
homologous None None O
proteins None None O
as None None O
false None None O
positives None None O
would None None O
probably None None O
be None None O
agreeable None None O
. None None O

However None None O
, None None O
counting None None O
those None None O
peptides None None O
/ None None O
proteins None None O
as None None O
true None None O
positives None None O
could None None O
be None None O
exaggerating None None O
. None None O

Therefore None None O
one None None O
may None None O
use None None O
a None None O
slightly None None O
different None None O
strategy None None O
: None None O
removing None None O
from None None O
consideration None None O
proteins None None O
homologous None None O
to None None O
the None None O
target None None O
proteins None None O
, None None O
which None None O
is None None O
called None None O
the None None O
cluster None None O
removal None None O
strategy None None O
[ None None O
11 None None O
] None None O
. None None O

The None None O
dashed None None O
curves None None O
of None None O
Figure None None O
S9 None None O
are None None O
ROC None None O
curves None None O
obtained None None O
this None None O
way None None O
. None None O

This None None O
strategy None None O
also None None O
produces None None O
slightly None None O
more None None O
impressive None None O
ROC None None O
curves None None O
than None None O
in None None O
Figure None None O
6 None None O
and None None O
Figure None None O
S6 None None O
. None None O

Apparently None None O
, None None O
this None None O
indicates None None O
the None None O
highly None None O
homologous None None O
false None None O
positive None None O
hits None None O
are None None O
the None None O
ones None None O
that None None O
degrade None None O
the None None O
retrieval None None O
performance None None O
. None None O

Thus None None O
, None None O
it None None O
can None None O
be None None O
useful None None O
to None None O
remove None None O
those None None O
false None None O
positives None None O
from None None O
consideration None None O
. None None O

Keeping None None O
only None None O
the None None O
best None None O
hit None None O
per None None O
spectrum None None O
turns None None O
out None None O
to None None O
be None None O
one None None O
way None None O
to None None O
achieve None None O
this None None O
goal None None O
. None None O

Predictive None None O
value None None O
of None None O
serum None None O
carbohydrate None None O
antigen None None O
19 None None O
- None None O
9 None None O
in None None O
malignant None None O
intraductal None None O
papillary None None O
mucinous None None O
neoplasms None None O
. None None O

BACKGROUND None None O
: None None O

The None None O
goal None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
predictive None None O
value None None O
of None None O
serum None None O
carbohydrate None None O
antigen None None O
19 None None O
- None None O
9 None None O
( None None O
CA None None O
19 None None O
- None None O
9 None None O
) None None O
in None None O
the None None O
diagnosis None None O
of None None O
malignant None None O
intraductal None None O
papillary None None O
mucinous None None O
neoplasms None None O
of None None O
pancreas None None O
( None None O
IPMNs None None O
) None None O
. None None O

METHODS None None O
: None None O

Eighty None None O
- None None O
six None None O
patients None None O
with None None O
pathological None None O
diagnosis None None O
of None None O
IPMNs None None O
in None None O
Zhongshan None None O
Hospital None None O
between None None O
March None None O
1999 None None O
and None None O
November None None O
2008 None None O
were None None O
retrospectively None None O
reviewed None None O
. None None O

Data None None O
reflecting None None O
clinical None None O
characteristics None None O
, None None O
tumor None None O
marker None None O
level None None O
, None None O
and None None O
prognosis None None O
were None None O
collected None None O
. None None O

The None None O
potential None None O
predictive None None O
value None None O
of None None O
CA None None O
19 None None O
- None None O
9 None None O
was None None O
analyzed None None O
by None None O
receiver None None O
operating None None O
characteristic None None O
( None None O
ROC None None O
) None None O
curve None None O
. None None O

RESULTS None None O
: None None O

Eighty None None O
- None None O
six None None O
consecutive None None O
patients None None O
with None None O
IPMNs None None O
all None None O
underwent None None O
surgical None None O
intervention None None O
. None None O

A None None O
high None None O
level None None O
of None None O
CA None None O
19 None None O
- None None O
9 None None O
or None None O
carcinoembryonic None None O
antigen None None O
( None None O
CEA None None O
) None None O
was None None O
associated None None O
with None None O
more None None O
advanced None None O
stage None None O
of None None O
malignant None None O
IPMNs None None O
. None None O

Carbohydrate None None O
antigen None None O
19 None None O
- None None O
9 None None O
was None None O
significant None None O
for None None O
judging None None O
malignant None None O
IPMNs None None O
in None None O
the None None O
binary None None O
logistic None None O
regression None None O
model None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
047 None None O
) None None O
. None None O

The None None O
hazard None None O
ratio None None O
was None None O
1 None None O
. None None O
014 None None O
, None None O
whose None None O
95 None None O
. None None O
0 None None O
% None None O
confidence None None O
interval None None O
was None None O
0 None None O
. None None O
91 None None O
- None None O
1 None None O
. None None O
028 None None O
. None None O

Receiver None None O
operating None None O
characteristic None None O
analysis None None O
showed None None O
that None None O
the None None O
serum None None O
CA None None O
19 None None O
- None None O
9 None None O
level None None O
had None None O
good None None O
predictive None None O
value None None O
for None None O
malignant None None O
or None None O
invasive None None O
IPMNs None None O
, None None O
postoperative None None O
survival None None O
, None None O
and None None O
disease None None O
- None None O
specific None None O
recurrence None None O
. None None O

The None None O
area None None O
under None None O
the None None O
curve None None O
( None None O
AUC None None O
) None None O
was None None O
0 None None O
. None None O
856 None None O
, None None O
0 None None O
. None None O
893 None None O
, None None O
0 None None O
. None None O
815 None None O
, None None O
and None None O
0 None None O
. None None O
857 None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
, None None O
respectively None None O
. None None O

According None None O
to None None O
the None None O
follow None None O
- None None O
up None None O
, None None O
mean None None O
survival None None O
time None None O
for None None O
groups None None O
with None None O
CA None None O
19 None None O
- None None O
9 None None O
> None None O
63 None None O
. None None O
60 None None O
U None None O
/ None None O
ml None None O
was None None O
dramatically None None O
shorter None None O
than None None O
that None None O
for None None O
groups None None O
with None None O
CA None None O
19 None None O
- None None O
9 None None O
< None None O
= None None O
63 None None O
. None None O
60 None None O
U None None O
/ None None O
ml None None O
( None None O
57 None None O
. None None O
38 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
85 None None O
versus None None O
29 None None O
. None None O
24 None None O
+ None None O
/ None None O
- None None O
5 None None O
. None None O
82 None None O
[ None None O
months None None O
] None None O
; None None O
p None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

Serum None None O
CA None None O
19 None None O
- None None O
9 None None O
level None None O
has None None O
good None None O
predictive None None O
value None None O
for None None O
malignant None None O
or None None O
invasive None None O
IPMNs None None O
. None None O

Patients None None O
with None None O
CA None None O
19 None None O
- None None O
9 None None O
> None None O
63 None None O
. None None O
60 None None O
U None None O
/ None None O
ml None None O
had None None O
poor None None O
postoperative None None O
prognosis None None O
in None None O
IPMNs None None O
. None None O

Preoperative None None O
abnormal None None O
serum None None O
CA None None O
19 None None O
- None None O
9 None None O
might None None O
be None None O
predictive None None O
for None None O
an None None O
aggressive None None O
surgical None None O
intervention None None O
in None None O
IPMNs None None O
. None None O

2 None None O
. None None O

CLINICAL None None O
PROTEOMICS None None O
AT None None O
THE None None O
BEDSIDE None None O

Clinically None None O
- None None O
based None None O
proteomics None None O
has None None O
a None None O
large None None O
potential None None O
for None None O
the None None O
development None None O
of None None O
strategies None None O
which None None O
aim None None O
to None None O
alleviate None None O
risk None None O
associated None None O
with None None O
cardiac None None O
disease None None O
. None None O

Biomarkers None None O
that None None O
are None None O
used None None O
in None None O
clinical None None O
practice None None O
are None None O
highly None None O
useful None None O
in None None O
that None None O
they None None O
support None None O
medical None None O
decision None None O
making None None O
, None None O
by None None O
complementing None None O
other None None O
diagnostic None None O
tests None None O
, None None O
such None None O
as None None O
the None None O
medical None None O
history None None O
, None None O
physical None None O
examination None None O
, None None O
and None None O
various None None O
other None None O
special None None O
tests None None O
. None None O

Theoretically None None O
, None None O
there None None O
are None None O
three None None O
criteria None None O
that None None O
, None None O
if None None O
satisfied None None O
, None None O
would None None O
provide None None O
an None None O
optimal None None O
biomarker None None O
of None None O
the None None O
disease None None O
state None None O
. None None O

First None None O
, None None O
the None None O
potential None None O
biomarkers None None O
must None None O
be None None O
easily None None O
measurable None None O
in None None O
a None None O
short None None O
time None None O
period None None O
at None None O
a None None O
cost None None O
that None None O
is None None O
practical None None O
. None None O

Second None None O
, None None O
elevation None None O
of None None O
this None None O
protein None None O
would None None O
offer None None O
diagnostic None None O
information None None O
that None None O
was None None O
not None None O
previously None None O
present None None O
in None None O
the None None O
absence None None O
of None None O
the None None O
protein None None O
. None None O

Third None None O
, None None O
the None None O
information None None O
obtained None None O
would None None O
aid None None O
in None None O
the None None O
medical None None O
decision None None O
making None None O
process None None O
performed None None O
by None None O
the None None O
clinician None None O
[ None None O
11 None None O
] None None O
. None None O

Fulfillment None None O
of None None O
such None None O
criteria None None O
encourages None None O
follow None None O
- None None O
up None None O
of None None O
such None None O
a None None O
biomarker None None O
in None None O
other None None O
model None None O
systems None None O
or None None O
patient None None O
cohort None None O
samples None None O
. None None O

For None None O
instance None None O
, None None O
cardiac None None O
troponin None None O
I None None O
has None None O
been None None O
previously None None O
shown None None O
to None None O
fulfill None None O
such None None O
criteria None None O
, None None O
and None None O
further None None O
follow None None O
- None None O
up None None O
in None None O
patient None None O
cohorts None None O
is None None O
underway None None O
. None None O

Recently None None O
, None None O
this None None O
approach None None O
was None None O
utilized None None O
to None None O
ascertain None None O
whether None None O
Cardiac None None O
Troponin None None O
I None None O
( None None O
CTN None None O
I None None O
) None None O
or None None O
Creatine None None O
Kinase None None O
- None None O
Myoglobin None None O
( None None O
CK None None O
- None None O
MB None None O
) None None O
could None None O
be None None O
used None None O
as None None O
short None None O
- None None O
term None None O
or None None O
long None None O
- None None O
term None None O
markers None None O
of None None O
risk None None O
associated None None O
with None None O
cardiac None None O
surgery None None O
[ None None O
12 None None O
] None None O
. None None O

In None None O
this None None O
study None None O
, None None O
a None None O
patient None None O
cohort None None O
of None None O
252 None None O
individuals None None O
who None None O
had None None O
undergone None None O
cardiac None None O
surgery None None O
was None None O
used None None O
to None None O
analyze None None O
levels None None O
of None None O
these None None O
two None None O
proteins None None O
in None None O
blood None None O
. None None O

Not None None O
only None None O
was None None O
CTN None None O
- None None O
I None None O
shown None None O
to None None O
be None None O
a None None O
strong None None O
predictor None None O
of None None O
mortality None None O
, None None O
but None None O
increases None None O
in None None O
the None None O
levels None None O
of None None O
this None None O
protein None None O
also None None O
correlated None None O
well None None O
with None None O
increases None None O
in None None O
mortality None None O
. None None O

Findings None None O
from None None O
this None None O
study None None O
support None None O
the None None O
utilization None None O
of None None O
patient None None O
cohorts None None O
as None None O
a None None O
means None None O
to None None O
ease None None O
the None None O
transition None None O
from None None O
bench None None O
to None None O
bedside None None O
. None None O

Measurement None None O
of None None O
IgA1 None None O
content None None O

IgA1 None None O
content None None O
in None None O
the None None O
supernatant None None O
from None None O
each None None O
culture None None O
well None None O
was None None O
measured None None O
in None None O
duplicate None None O
using None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
. None None O

All None None O
incubations None None O
were None None O
performed None None O
at None None O
room None None O
temperature None None O
except None None O
for None None O
capture None None O
antibody None None O
coating None None O
. None None O

Briefly None None O
, None None O
96 None None O
- None None O
well None None O
immunoplates None None O
( None None O
Thermo None None O
Fisher None None O
Scientific None None O
, None None O
Waltham None None O
, None None O
MA None None O
, None None O
USA None None O
) None None O
were None None O
coated None None O
with None None O
5 None None O
microg None None O
/ None None O
mL None None O
of None None O
F None None O
( None None O
ab None None O
' None None O
) None None O
2 None None O
fragment None None O
goat None None O
anti None None O
- None None O
human None None O
IgA None None O
antibody None None O
( None None O
Jackson None None O
ImmunoResearch None None O
Laboratories None None O
, None None O
West None None O
Grove None None O
, None None O
PA None None O
, None None O
USA None None O
) None None O
, None None O
in None None O
phosphate None None O
- None None O
buffered None None O
saline None None O
( None None O
PBS None None O
) None None O
at None None O
4degreesC None None O
overnight None None O
. None None O

After None None O
three None None O
washes None None O
with None None O
PBS None None O
containing None None O
0 None None O
. None None O
05 None None O
% None None O
Tween None None O
- None None O
20 None None O
( None None O
PBST None None O
) None None O
, None None O
plates None None O
were None None O
blocked None None O
by None None O
adding None None O
PBS None None O
containing None None O
1 None None O
% None None O
bovine None None O
serum None None O
albumin None None O
( None None O
BSA None None O
) None None O
to None None O
the None None O
wells None None O
for None None O
90 None None O
min None None O
. None None O

Next None None O
, None None O
50 None None O
microL None None O
of None None O
supernatant None None O
sample None None O
or None None O
standard None None O
human None None O
IgA1 None None O
( None None O
CALBIOCHEM None None O
, None None O
La None None O
Jolla None None O
, None None O
CA None None O
, None None O
USA None None O
) None None O
was None None O
added None None O
to None None O
the None None O
reaction None None O
wells None None O
and None None O
then None None O
incubated None None O
for None None O
90 None None O
min None None O
. None None O

After None None O
three None None O
washes None None O
, None None O
0 None None O
. None None O
75 None None O
microg None None O
/ None None O
mL None None O
alkaline None None O
phosphatase None None O
conjugated None None O
goat None None O
anti None None O
- None None O
human None None O
IgA None None O
( None None O
Southern None None O
Biotechnology None None O
Associates None None O
, None None O
Birmingham None None O
, None None O
AL None None O
, None None O
USA None None O
) None None O
in None None O
1 None None O
% None None O
BSA None None O
/ None None O
PBS None None O
was None None O
added None None O
to None None O
the None None O
reaction None None O
wells None None O
and None None O
then None None O
incubated None None O
for None None O
90 None None O
min None None O
. None None O

Plates None None O
were None None O
washed None None O
three None None O
times None None O
and None None O
developed None None O
with None None O
a None None O
substrate None None O
solution None None O
of None None O
1 None None O
mg None None O
/ None None O
mL None None O
p None None O
- None None O
nitrophenyl None None O
phosphate None None O
disodium None None O
salt None None O
( None None O
SIGMA None None O
, None None O
St None None O
. None None O
Louis None None O
, None None O
MO None None O
, None None O
USA None None O
) None None O
in None None O
0 None None O
. None None O
1 None None O
M None None O
glycine None None O
buffer None None O
containing None None O
1 None None O
mM None None O
MgCl2 None None O
, None None O
1 None None O
mM None None O
ZnCl2 None None O
, None None O
pH None None O
10 None None O
. None None O
4 None None O
. None None O

The None None O
optical None None O
density None None O
at None None O
405 None None O
nm None None O
was None None O
determined None None O
in None None O
a None None O
microplate None None O
reader None None O
( None None O
Benchmark None None O
PlusTM None None O
Bio None None O
- None None O
Rad None None O
Laboratories None None O
, None None O
Hercules None None O
, None None O
CA None None O
, None None O
USA None None O
) None None O
. None None O

IgA1 None None O
concentration None None O
in None None O
unknown None None O
duplicate None None O
samples None None O
was None None O
determined None None O
by None None O
interpolation None None O
of None None O
the None None O
respective None None O
optical None None O
density None None O
into None None O
the None None O
appropriate None None O
standard None None O
curve None None O
. None None O

IgG None None O
and None None O
IgM None None O
contents None None O
in None None O
the None None O
supernatant None None O
were None None O
measured None None O
using None None O
sandwich None None O
ELISA None None O
( None None O
IMMUNOtek None None O
( None None O
R None None O
) None None O
, None None O
ZeptoMetrix None None O
Corporation None None O
, None None O
Buffalo None None O
, None None O
NY None None O
, None None O
USA None None O
) None None O
according None None O
to None None O
the None None O
manufacturer None None O
' None None O
s None None O
instructions None None O
. None None O

Microvascular None None O
density None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
immunoreactivity None None O
as None None O
predictors None None O
of None None O
regional None None O
lymph None None O
node None None O
metastasis None None O
from None None O
betel None None O
- None None O
associated None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

PURPOSE None None O
: None None O
Neovascularization None None O
has None None O
profound None None O
effects None None O
on None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
a None None O
mitogen None None O
that None None O
acts None None O
exclusively None None O
on None None O
endothelial None None O
cells None None O
. None None O

The None None O
roles None None O
of None None O
miscrovascularity None None O
density None None O
( None None O
MVD None None O
) None None O
and None None O
VEGF None None O
expression None None O
in None None O
the None None O
progression None None O
of None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
OSCC None None O
) None None O
have None None O
been None None O
controversial None None O
. None None O

The None None O
purpose None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
measure None None O
the None None O
MVD None None O
and None None O
VEGF None None O
expression None None O
in None None O
a None None O
cohort None None O
of None None O
patients None None O
with None None O
betel None None O
- None None O
associated None None O
OSCC None None O
and None None O
to None None O
evaluate None None O
for None None O
possible None None O
clinicopathologic None None O
correlations None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
The None None O
paraffin None None O
sections None None O
from None None O
49 None None O
subjects None None O
with None None O
OSCC None None O
were None None O
subjected None None O
to None None O
immunohistochemical None None O
studies None None O
to None None O
measure None None O
the None None O
highest None None O
MVD None None O
( None None O
h None None O
- None None O
MVD None None O
) None None O
and None None O
cytoplasmic None None O
immunoreactivity None None O
of None None O
VEGF None None O
. None None O

The None None O
findings None None O
in None None O
the None None O
tissue None None O
samples None None O
were None None O
analyzed None None O
with None None O
regard None None O
to None None O
the None None O
patients None None O
' None None O
risk None None O
factors None None O
and None None O
clinical None None O
course None None O
. None None O

RESULTS None None O
: None None O
The None None O
OSCC None None O
samples None None O
had None None O
an None None O
average None None O
h None None O
- None None O
MVD None None O
score None None O
of None None O
27 None None O
. None None O
7 None None O
/ None None O
mm None None O
( None None O
2 None None O
) None None O
. None None O

VEGF None None O
immunoreactivity None None O
was None None O
positive None None O
in None None O
75 None None O
. None None O
5 None None O
% None None O
of None None O
samples None None O
. None None O

Both None None O
h None None O
- None None O
MVD None None O
and None None O
VEGF None None O
immunoreactivity None None O
were None None O
statistically None None O
associated None None O
with None None O
lymph None None O
node None None O
metastasis None None O
( None None O
P None None O
= None None O
. None None O
012 None None O
and None None O
. None None O
037 None None O
, None None O
respectively None None O
) None None O
. None None O

A None None O
marginally None None O
significant None None O
association None None O
was None None O
also None None O
noted None None O
between None None O
the None None O
h None None O
- None None O
MVD None None O
and None None O
patient None None O
survival None None O
( None None O
P None None O
= None None O
. None None O
056 None None O
) None None O
. None None O

The None None O
age None None O
and None None O
oral None None O
habits None None O
of None None O
patients None None O
, None None O
as None None O
well None None O
as None None O
the None None O
tumor None None O
site None None O
and None None O
size None None O
, None None O
did None None O
not None None O
appear None None O
to None None O
be None None O
correlated None None O
with None None O
h None None O
- None None O
MVD None None O
or None None O
VEGF None None O
immunoreactivity None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
data None None O
suggest None None O
that None None O
both None None O
h None None O
- None None O
MVD None None O
and None None O
VEGF None None O
immunoreactivity None None O
may None None O
be None None O
useful None None O
predictors None None O
for None None O
the None None O
progression None None O
of None None O
a None None O
subset None None O
of None None O
OSCC None None O
associated None None O
mostly None None O
with None None O
betel None None O
use None None O
. None None O

Antiangiogenesis None None O
therapy None None O
might None None O
have None None O
a None None O
role None None O
in None None O
reducing None None O
regional None None O
metastasis None None O
. None None O

Scheme None None O
of None None O
the None None O
activity None None O
of None None O
5 None None O
- None None O
HT None None O
( None None O
A None None O
) None None O
and None None O
norepinephrine None None O
( None None O
NE None None O
) None None O
( None None O
B None None O
) None None O
neurotransmission None None O
during None None O
treatment None None O
with None None O
milnacipran None None O
. None None O

A None None O
) None None O
5 None None O
- None None O
HT None None O
system None None O
. None None O

Acute None None O
treatment None None O
with None None O
milnacipran None None O
results None None O
in None None O
a None None O
decreased None None O
firing None None O
of None None O
5 None None O
- None None O
HT None None O
neurons None None O
from None None O
the None None O
raphe None None O
nucleus None None O
possibly None None O
due None None O
in None None O
part None None O
to None None O
increased None None O
stimulation None None O
of None None O
somatodendritic None None O
autoreceptors None None O
. None None O

Long None None O
- None None O
term None None O
treatment None None O
with None None O
milnacipran None None O
results None None O
in None None O
a None None O
full None None O
recovery None None O
in None None O
the None None O
firing None None O
rate None None O
of None None O
5 None None O
- None None O
HT None None O
neurons None None O
in None None O
the None None O
presence None None O
of None None O
milnacipran None None O
thereby None None O
leading None None O
to None None O
a None None O
net None None O
increase None None O
in None None O
5 None None O
- None None O
HT None None O
neurotransmission None None O
. None None O

Contributing None None O
to None None O
this None None O
enhancement None None O
are None None O
: None None O
1 None None O
) None None O
the None None O
normalized None None O
firing None None O
rate None None O
of None None O
5 None None O
- None None O
HT None None O
neurons None None O
in None None O
the None None O
presence None None O
of None None O
milnacipran None None O
2 None None O
) None None O
the None None O
desensitization None None O
of None None O
the None None O
terminal None None O
5 None None O
- None None O
HT1B None None O
autoreceptor None None O
, None None O
and None None O
3 None None O
) None None O
the None None O
desensitization None None O
of None None O
the None None O
alpha2 None None O
- None None O
adrenergic None None O
heteroreceptors None None O
on None None O
5 None None O
- None None O
HT None None O
terminals None None O
. None None O

B None None O
) None None O
NE None None O
system None None O
. None None O

Acute None None O
treatment None None O
with None None O
milnacipran None None O
results None None O
in None None O
increased None None O
synaptic None None O
concentrations None None O
of None None O
NE None None O
but None None O
decreased None None O
firing None None O
of None None O
the None None O
NE None None O
neurons None None O
of None None O
the None None O
locus None None O
coeruleus None None O
due None None O
to None None O
increased None None O
stimulation None None O
of None None O
the None None O
somatodendritic None None O
alpha2 None None O
- None None O
adrenergic None None O
autoreceptors None None O
. None None O

Long None None O
- None None O
term None None O
treatment None None O
with None None O
milnacipran None None O
results None None O
in None None O
a None None O
further None None O
increase None None O
in None None O
synaptic None None O
concentrations None None O
of None None O
NE None None O
due None None O
to None None O
desensitization None None O
of None None O
presynaptic None None O
autoreceptors None None O
. None None O

The None None O
somatodendritic None None O
alpha2 None None O
- None None O
adrenergic None None O
autoreceptors None None O
do None None O
not None None O
desensitize None None O
. None None O

Comparative None None O
immunohistochemical None None O
study None None O
of None None O
primary None None O
and None None O
metastatic None None O
carcinomas None None O
of None None O
the None None O
liver None None O
. None None O

Distinguishing None None O
primary None None O
hepatocellular None None O
carcinoma None None O
( None None O
HCC None None O
) None None O
from None None O
metastatic None None O
carcinomas None None O
to None None O
the None None O
liver None None O
is None None O
often None None O
difficult None None O
, None None O
if None None O
not None None O
impossible None None O
, None None O
particularly None None O
in None None O
needle None None O
biopsy None None O
and None None O
fine None None O
- None None O
needle None None O
aspiration None None O
specimens None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
identify None None O
a None None O
specific None None O
immunohistochemical None None O
profile None None O
that None None O
would None None O
distinguish None None O
HCC None None O
from None None O
metastatic None None O
carcinomas None None O
, None None O
we None None O
studied None None O
56 None None O
HCCs None None O
, None None O
8 None None O
cholangiocarcinomas None None O
, None None O
and None None O
24 None None O
metastatic None None O
adenocarcinomas None None O
with None None O
monoclonal None None O
antibodies None None O
to None None O
alpha None None O
- None None O
fetoprotein None None O
( None None O
AFP None None O
) None None O
, None None O
keratin None None O
( None None O
AE1 None None O
, None None O
AE3 None None O
, None None O
and None None O
CAM5 None None O
. None None O
2 None None O
) None None O
, None None O
Leu None None O
- None None O
M1 None None O
, None None O
human None None O
milk None None O
fat None None O
globule None None O
( None None O
HMFG None None O
- None None O
2 None None O
) None None O
, None None O
tumor None None O
- None None O
associated None None O
glycoprotein None None O
- None None O
72 None None O
( None None O
B72 None None O
. None None O
3 None None O
) None None O
, None None O
epithelial None None O
specific None None O
membrane None None O
antigen None None O
( None None O
Ber None None O
- None None O
EP4 None None O
) None None O
, None None O
and None None O
BCA None None O
- None None O
225 None None O
( None None O
CU None None O
- None None O
18 None None O
) None None O
. None None O

Both None None O
monoclonal None None O
and None None O
polyclonal None None O
( None None O
mCEA None None O
and None None O
pCEA None None O
) None None O
antibodies None None O
to None None O
carcinoembryonic None None O
antigen None None O
also None None O
were None None O
used None None O
. None None O

Metastatic None None O
adenocarcinomas None None O
were None None O
often None None O
positive None None O
for None None O
CU None None O
- None None O
18 None None O
( None None O
71 None None O
% None None O
) None None O
, None None O
Leu None None O
- None None O
M1 None None O
( None None O
75 None None O
% None None O
) None None O
, None None O
B72 None None O
. None None O
3 None None O
( None None O
50 None None O
% None None O
) None None O
, None None O
HMFG None None O
- None None O
2 None None O
( None None O
67 None None O
% None None O
) None None O
, None None O
Ber None None O
- None None O
EP4 None None O
( None None O
83 None None O
% None None O
) None None O
and None None O
mCEA None None O
( None None O
71 None None O
% None None O
) None None O
. None None O

Using None None O
these None None O
antibodies None None O
, None None O
the None None O
frequency None None O
of None None O
positivity None None O
for None None O
HCC None None O
was None None O
9 None None O
% None None O
, None None O
16 None None O
% None None O
, None None O
11 None None O
% None None O
, None None O
20 None None O
% None None O
, None None O
36 None None O
% None None O
, None None O
and None None O
11 None None O
% None None O
, None None O
respectively None None O
. None None O

CU None None O
- None None O
18 None None O
was None None O
the None None O
only None None O
monoclonal None None O
antibody None None O
in None None O
which None None O
there None None O
was None None O
a None None O
significant None None O
difference None None O
in None None O
positive None None O
rates None None O
between None None O
HCC None None O
and None None O
metastatic None None O
adenocarcinomas None None O
. None None O

Most None None O
HCCs None None O
( None None O
71 None None O
% None None O
) None None O
revealed None None O
a None None O
bile None None O
canalicular None None O
staining None None O
pattern None None O
with None None O
pCEA None None O
. None None O

Because None None O
this None None O
staining None None O
pattern None None O
was None None O
absent None None O
in None None O
metastatic None None O
carcinomas None None O
, None None O
pCEA None None O
appears None None O
to None None O
be None None O
useful None None O
in None None O
confirming None None O
a None None O
diagnosis None None O
of None None O
HCC None None O
. None None O

AE1 None None O
, None None O
AE3 None None O
and None None O
CAM5 None None O
. None None O
2 None None O
antibodies None None O
were None None O
not None None O
useful None None O
in None None O
distinguishing None None O
HCC None None O
from None None O
metastatic None None O
carcinomas None None O
. None None O

Each None None O
cholangiocarcinoma None None O
shared None None O
a None None O
staining None None O
profile None None O
similar None None O
to None None O
that None None O
of None None O
metastatic None None O
carcinomas None None O
. None None O

Cell None None O
surface None None O
binding None None O
characteristics None None O
correlate None None O
with None None O
consensus None None O
type None None O
I None None O
interferon None None O
enhanced None None O
activity None None O
. None None O

The None None O
binding None None O
characteristics None None O
of None None O
a None None O
genetically None None O
engineered None None O
consensus None None O
interferon None None O
with None None O
unusually None None O
high None None O
biologic None None O
activity None None O
were None None O
compared None None O
to None None O
the None None O
characteristics None None O
of None None O
recombinant None None O
interferon None None O
- None None O
alpha None None O
2 None None O
. None None O

Both None None O
interferon None None O
- None None O
alpha None None O
2 None None O
and None None O
the None None O
consensus None None O
interferon None None O
produced None None O
typical None None O
biphasic None None O
Scatchard None None O
plots None None O
, None None O
indicating None None O
multiple None None O
independent None None O
binding None None O
sites None None O
. None None O

The None None O
consensus None None O
interferon None None O
, None None O
which None None O
exhibited None None O
a None None O
biologic None None O
potency None None O
more None None O
than None None O
10 None None O
- None None O
fold None None O
greater None None O
than None None O
all None None O
other None None O
type None None O
I None None O
interferons None None O
, None None O
also None None O
exhibited None None O
binding None None O
site None None O
affinities None None O
greater None None O
than None None O
those None None O
for None None O
IFN None None O
- None None O
alpha None None O
2b None None O
. None None O

In None None O
addition None None O
, None None O
a None None O
larger None None O
number None None O
of None None O
high None None O
, None None O
and None None O
low None None O
- None None O
affinity None None O
cell None None O
surface None None O
sites None None O
were None None O
recognized None None O
by None None O
the None None O
consensus None None O
interferon None None O
, None None O
resulting None None O
in None None O
equivalent None None O
numbers None None O
of None None O
sites None None O
at None None O
reduced None None O
molar None None O
concentrations None None O
compared None None O
to None None O
IFN None None O
- None None O
a2b None None O
. None None O

Thus None None O
, None None O
at None None O
any None None O
given None None O
biologic None None O
activity None None O
, None None O
similar None None O
numbers None None O
of None None O
sites None None O
were None None O
bound None None O
by None None O
the None None O
consensus None None O
interferon None None O
and None None O
IFN None None O
- None None O
alpha None None O
2 None None O
, None None O
despite None None O
differences None None O
in None None O
their None None O
molar None None O
concentrations None None O
. None None O

No None None O
differences None None O
in None None O
internalization None None O
kinetics None None O
were None None O
identified None None O
between None None O
the None None O
two None None O
interferons None None O
, None None O
indicating None None O
that None None O
the None None O
differences None None O
in None None O
cell None None O
surface None None O
binding None None O
may None None O
be None None O
sufficient None None O
to None None O
produce None None O
the None None O
differences None None O
in None None O
biologic None None O
activity None None O
. None None O

Betulin None None O
induces None None O
mitochondrial None None O
cytochrome None None O
c None None O
release None None O
associated None None O
apoptosis None None O
in None None O
human None None O
cancer None None O
cells None None O
. None None O

We None None O
examined None None O
whether None None O
betulin None None O
, None None O
a None None O
naturally None None O
abundant None None O
compound None None O
, None None O
has None None O
anticancer None None O
functions None None O
in None None O
human None None O
cancer None None O
cells None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
betulin None None O
significantly None None O
inhibited None None O
cell None None O
viability None None O
in None None O
cervix None None O
carcinoma None None O
HeLa None None I-Cell-line-name
cells None None O
, None None O
hepatoma None None O
HepG2 None None I-Cell-line-name
cells None None O
, None None O
lung None None O
adenocarcinoma None None O
A549 None None I-Cell-line-name
cells None None O
, None None O
and None None O
breast None None O
cancer None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
with None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
ranging None None O
from None None O
10 None None O
to None None O
15 None None O
microg None None O
/ None None O
mL None None O
. None None O

While None None O
betulin None None O
exhibited None None O
only None None O
moderate None None O
anticancer None None O
activity None None O
in None None O
other None None O
human None None O
cancer None None O
cells None None O
such None None O
as None None O
hepatoma None None O
SK None None I-Cell-line-name
- None None I-Cell-line-name
HEP None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
cells None None O
, None None O
prostate None None O
carcinoma None None O
PC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
, None None O
and None None O
lung None None O
carcinoma None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H460 None None I-Cell-line-name
, None None O
with None None O
IC None None O
( None None O
50 None None O
) None None O
values None None O
ranging None None O
from None None O
20 None None O
to None None O
60 None None O
microg None None O
/ None None O
mL None None O
, None None O
it None None O
showed None None O
minor None None O
growth None None O
inhibition None None O
in None None O
human None None O
erythroleukemia None None O
K562 None None I-Cell-line-name
cells None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
> None None O
100 None None O
microg None None O
/ None None O
mL None None O
) None None O
. None None O

We None None O
further None None O
investigated None None O
the None None O
mechanism None None O
of None None O
anticancer None None O
activity None None O
by None None O
betulin None None O
, None None O
using None None O
HeLa None None I-Cell-line-name
cells None None O
as None None O
an None None O
experimental None None O
model None None O
. None None O

Betulin None None O
( None None O
10 None None O
microg None None O
/ None None O
mL None None O
) None None O
induces None None O
apoptotic None None O
cell None None O
death None None O
, None None O
as None None O
evidenced None None O
by None None O
morphological None None O
characteristics None None O
such None None O
as None None O
membrane None None O
phosphatidylserine None None O
translocation None None O
, None None O
nuclear None None O
condensation None None O
/ None None O
fragmentation None None O
, None None O
and None None O
apoptotic None None O
body None None O
formation None None O
. None None O

A None None O
kinetics None None O
analysis None None O
showed None None O
that None None O
the None None O
depolarization None None O
of None None O
mitochondrial None None O
membrane None None O
potential None None O
and None None O
the None None O
release None None O
of None None O
mitochondrial None None O
cytochrome None None O
c None None O
occurred None None O
as None None O
early None None O
as None None O
30 None None O
min None None O
after None None O
treatment None None O
with None None O
betulin None None O
. None None O

Betulin None None O
, None None O
unlike None None O
its None None O
chemical None None O
derivative None None O
betulinic None None O
acid None None O
, None None O
did None None O
not None None O
directly None None O
trigger None None O
mitochondrial None None O
cytochrome None None O
c None None O
release None None O
in None None O
isolated None None O
mitochondria None None O
. None None O

Importantly None None O
, None None O
Bax None None O
and None None O
Bak None None O
were None None O
rapidly None None O
translocated None None O
to None None O
the None None O
mitochondria None None O
30 None None O
min None None O
after None None O
betulin None None O
treatment None None O
. None None O

The None None O
sequential None None O
activation None None O
of None None O
caspase None None O
- None None O
9 None None O
and None None O
caspase None None O
- None None O
3 None None O
/ None None O
- None None O
7 None None O
and None None O
the None None O
cleavage None None O
of None None O
poly None None O
( None None O
ADP None None O
- None None O
ribose None None O
) None None O
polymerase None None O
( None None O
PARP None None O
) None None O
were None None O
observed None None O
behind None None O
those None None O
mitochondrial None None O
events None None O
. None None O

Furthermore None None O
, None None O
specific None None O
downregulation None None O
of None None O
either None None O
caspase None None O
- None None O
9 None None O
, None None O
Bax None None O
, None None O
or None None O
Bak None None O
by None None O
siRNA None None O
effectively None None O
reduced None None O
PARP None None O
cleavage None None O
and None None O
caspase None None O
- None None O
3 None None O
activation None None O
. None None O

Taken None None O
together None None O
, None None O
the None None O
lines None None O
of None None O
evidence None None O
demonstrate None None O
that None None O
betulin None None O
triggers None None O
apoptosis None None O
of None None O
human None None O
cancer None None O
cells None None O
through None None O
the None None O
intrinsic None None O
apoptotic None None O
pathway None None O
. None None O

Non None None O
- None None O
heart None None O
- None None O
beating None None O
organ None None O
donation None None O
in None None O
Italy None None O
. None None O

In None None O
2007 None None O
the None None O
non None None O
- None None O
heart None None O
- None None O
beating None None O
organ None None O
donation None None O
( None None O
NHBD None None O
) None None O
" None None O
Programma None None O
Alba None None O
" None None O
( None None O
Sunrise None None O
Programme None None O
) None None O
started None None O
in None None O
Pavia None None O
, None None O
Italy None None O
. None None O

The None None O
initial None None O
plan None None O
was None None O
to None None O
cut None None O
down None None O
waiting None None O
list None None O
for None None O
kidney None None O
transplantation None None O
, None None O
while None None O
its None None O
final None None O
aim None None O
is None None O
to None None O
shorten None None O
organ None None O
transplantation None None O
waiting None None O
lists None None O
. None None O

When None None O
compared None None O
to None None O
European None None O
countries None None O
and None None O
the None None O
USA None None O
, None None O
the None None O
Italian None None O
NHBD None None O
program None None O
has None None O
taken None None O
longer None None O
to None None O
get None None O
established None None O
. None None O

Initially None None O
Italian None None O
physicians None None O
were None None O
not None None O
entirely None None O
aware None None O
of None None O
the None None O
NHBD None None O
organ None None O
viability None None O
for None None O
transplantation None None O
, None None O
furthermore None None O
ethical None None O
issues None None O
and None None O
the None None O
need None None O
to None None O
regulate None None O
medical None None O
requirements None None O
to None None O
Italian None None O
law None None O
slowed None None O
down None None O
the None None O
NHBD None None O
program None None O
. None None O

In None None O
particular None None O
, None None O
Italian None None O
legislation None None O
provides None None O
for None None O
death None None O
ascertainment None None O
after None None O
irreversible None None O
cardiac None None O
arrest None None O
, None None O
20 None None O
- None None O
minute None None O
flat None None O
electrocardiogram None None O
. None None O

This None None O
no None None O
- None None O
touch None None O
period None None O
is None None O
longer None None O
when None None O
compared None None O
to None None O
worldwide None None O
legislation None None O
, None None O
and None None O
organ None None O
viability None None O
has None None O
been None None O
a None None O
main None None O
concern None None O
for None None O
Italian None None O
transplant None None O
doctors None None O
over None None O
the None None O
years None None O
. None None O

However None None O
, None None O
recent None None O
data None None O
let None None O
up None None O
to None None O
40 None None O
- None None O
minute None None O
warm None None O
ischemia None None O
time None None O
to None None O
preserve None None O
organ None None O
viability None None O
; None None O
this None None O
has None None O
encouraged None None O
Pavia None None O
' None None O
s None None O
group None None O
to None None O
establish None None O
the None None O
NHBD None None O
" None None O
Programma None None O
Alba None None O
" None None O
. None None O

It None None O
was None None O
designed None None O
according None None O
to None None O
Italian None None O
legislation None None O
from None None O
death None None O
diagnosis None None O
to None None O
graft None None O
placement None None O
, None None O
from None None O
this None None O
perspective None None O
must None None O
the None None O
significant None None O
role None None O
of None None O
the None None O
Transplant None None O
coordinator None None O
be None None O
recognized None None O
. None None O

Since None None O
2007 None None O
seven None None O
kidneys None None O
have None None O
been None None O
gathered None None O
from None None O
seven None None O
NHBD None None O
. None None O

Of None None O
these None None O
, None None O
six None None O
NHBD None None O
kidneys None None O
have None None O
been None None O
transplanted None None O
. None None O

Currently None None O
, None None O
four None None O
patients None None O
are None None O
out None None O
of None None O
dialysis None None O
. None None O

This None None O
report None None O
is None None O
a None None O
detailed None None O
description None None O
of None None O
NHBD None None O
" None None O
Programma None None O
Alba None None O
" None None O
and None None O
its None None O
preliminary None None O
results None None O
. None None O

Bmi None None O
- None None O
1 None None O
over None None O
- None None O
expression None None O
in None None O
neural None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
increases None None O
proliferation None None O
and None None O
neurogenesis None None O
in None None O
culture None None O
but None None O
has None None O
little None None O
effect None None O
on None None O
these None None O
functions None None O
in None None O
vivo None None O
. None None O

The None None O
polycomb None None O
gene None None O
Bmi None None O
- None None O
1 None None O
is None None O
required None None O
for None None O
the None None O
self None None O
- None None O
renewal None None O
of None None O
stem None None O
cells None None O
from None None O
diverse None None O
tissues None None O
, None None O
including None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
. None None O

Bmi None None O
- None None O
1 None None O
expression None None O
is None None O
elevated None None O
in None None O
most None None O
human None None O
gliomas None None O
, None None O
irrespective None None O
of None None O
grade None None O
, None None O
raising None None O
the None None O
question None None O
of None None O
whether None None O
Bmi None None O
- None None O
1 None None O
over None None O
- None None O
expression None None O
is None None O
sufficient None None O
to None None O
promote None None O
self None None O
- None None O
renewal None None O
or None None O
tumorigenesis None None O
by None None O
CNS None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
. None None O

To None None O
test None None O
this None None O
we None None O
generated None None O
Nestin None None O
- None None O
Bmi None None O
- None None O
1 None None O
- None None O
GFP None None O
transgenic None None O
mice None None O
. None None O

Analysis None None O
of None None O
two None None O
independent None None O
lines None None O
with None None O
expression None None O
in None None O
the None None O
fetal None None O
and None None O
adult None None O
CNS None None O
demonstrated None None O
that None None O
transgenic None None O
neural None None O
stem None None O
cells None None O
formed None None O
larger None None O
colonies None None O
, None None O
more None None O
self None None O
- None None O
renewing None None O
divisions None None O
, None None O
and None None O
more None None O
neurons None None O
in None None O
culture None None O
. None None O

However None None O
, None None O
in None None O
vivo None None O
, None None O
Bmi None None O
- None None O
1 None None O
over None None O
- None None O
expression None None O
had None None O
little None None O
effect None None O
on None None O
CNS None None O
stem None None O
cell None None O
frequency None None O
, None None O
subventricular None None O
zone None None O
proliferation None None O
, None None O
olfactory None None O
bulb None None O
neurogenesis None None O
, None None O
or None None O
neurogenesis None None O
/ None None O
gliogenesis None None O
during None None O
development None None O
. None None O

Bmi None None O
- None None O
1 None None O
transgenic None None O
mice None None O
were None None O
born None None O
with None None O
enlarged None None O
lateral None None O
ventricles None None O
and None None O
a None None O
minority None None O
developed None None O
idiopathic None None O
hydrocephalus None None O
as None None O
adults None None O
, None None O
but None None O
none None None O
of None None O
the None None O
transgenic None None O
mice None None O
formed None None O
detectable None None O
CNS None None O
tumors None None O
, None None O
even None None O
when None None O
aged None None O
. None None O

The None None O
more None None O
pronounced None None O
effects None None O
of None None O
Bmi None None O
- None None O
1 None None O
over None None O
- None None O
expression None None O
in None None O
culture None None O
were None None O
largely None None O
attributable None None O
to None None O
the None None O
attenuated None None O
induction None None O
of None None O
p16 None None O
( None None O
Ink4a None None O
) None None O
and None None O
p19 None None O
( None None O
Arf None None O
) None None O
in None None O
culture None None O
, None None O
proteins None None O
that None None O
are None None O
generally None None O
not None None O
expressed None None O
by None None O
neural None None O
stem None None O
/ None None O
progenitor None None O
cells None None O
in None None O
young None None O
mice None None O
in None None O
vivo None None O
. None None O

Bmi None None O
- None None O
1 None None O
over None None O
- None None O
expression None None O
therefore None None O
has None None O
more None None O
pronounced None None O
effects None None O
in None None O
culture None None O
and None None O
does None None O
not None None O
appear None None O
to None None O
be None None O
sufficient None None O
to None None O
induce None None O
tumorigenesis None None O
in None None O
vivo None None O
. None None O

RESEARCH None None O
DESIGN None None O
AND None None O
METHODS None None O

For None None O
this None None O
study None None O
, None None O
20 None None O
individuals None None O
( None None O
mean None None O
age None None O
39 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
11 None None O
. None None O
1 None None O
years None None O
) None None O
with None None O
long None None O
- None None O
standing None None O
type None None O
1 None None O
diabetes None None O
( None None O
21 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
10 None None O
. None None O
7 None None O
years None None O
) None None O
were None None O
enrolled None None O
in None None O
this None None O
prospective None None O
open None None O
- None None O
label None None O
crossover None None O
trial None None O
. None None O

After None None O
achieving None None O
optimal None None O
blood None None O
glucose None None O
control None None O
, None None O
16 None None O
subjects None None O
were None None O
randomized None None O
to None None O
exenatide None None O
with None None O
or None None O
without None None O
daclizumab None None O
. None None O

Endogenous None None O
insulin None None O
production None None O
was None None O
determined None None O
by None None O
repeatedly None None O
measuring None None O
serum None None O
C None None O
- None None O
peptide None None O
. None None O

[ None None O
The None None O
prediction None None O
of None None O
the None None O
level None None O
of None None O
depression None None O
by None None O
cognitive None None O
, None None O
behavioral None None O
, None None O
and None None O
temperamental None None O
variables None None O
in None None O
a None None O
six None None O
- None None O
month None None O
time None None O
interval None None O
] None None O
. None None O

Several None None O
models None None O
have None None O
been None None O
proposed None None O
to None None O
explain None None O
the None None O
depressive None None O
phenomenon None None O
, None None O
such None None O
as None None O
the None None O
theory None None O
of None None O
dysfunctional None None O
attitudes None None O
, None None O
the None None O
hopelessness None None O
theory None None O
, None None O
the None None O
behavioral None None O
model None None O
of None None O
activity None None O
level None None O
, None None O
or None None O
temperamental None None O
models None None O
. None None O

This None None O
article None None O
presents None None O
data None None O
about None None O
the None None O
role None None O
of None None O
those None None O
models None None O
in None None O
the None None O
prediction None None O
of None None O
the None None O
level None None O
of None None O
depression None None O
in None None O
a None None O
sample None None O
of None None O
414 None None O
college None None O
students None None O
, None None O
assessed None None O
over None None O
a None None O
temporal None None O
interval None None O
of None None O
six None None O
months None None O
. None None O

Dysfunctional None None O
attitudes None None O
, None None O
attributional None None O
styles None None O
, None None O
the None None O
level None None O
of None None O
activity None None O
, None None O
and None None O
the None None O
five None None O
- None None O
factors None None O
of None None O
personality None None O
were None None O
assessed None None O
. None None O

The None None O
BDI None None O
- None None O
II None None O
was None None O
the None None O
depression None None O
level None None O
measure None None O
. None None O

The None None O
results None None O
showed None None O
that None None O
these None None O
variables None None O
predict None None O
depression None None O
levels None None O
, None None O
but None None O
with None None O
low None None O
coefficients None None O
. None None O

The None None O
dimensions None None O
of None None O
Need None None O
of None None O
Achievement None None O
( None None O
a None None O
dysfunctional None None O
attitude None None O
) None None O
and None None O
Neuroticism None None O
had None None O
particularly None None O
greater None None O
weight None None O
in None None O
the None None O
prediction None None O
, None None O
but None None O
only None None O
Neuroticism None None O
seems None None O
to None None O
behave None None O
like None None O
a None None O
vulnerability None None O
element None None O
. None None O

Attributional None None O
styles None None O
did None None O
not None None O
contribute None None O
significantly None None O
to None None O
the None None O
prediction None None O
of None None O
depression None None O
. None None O

Activity None None O
level None None O
lost None None O
its None None O
predictive None None O
role None None O
during None None O
the None None O
6 None None O
- None None O
month None None O
interval None None O
. None None O

These None None O
results None None O
are None None O
discussed None None O
according None None O
to None None O
the None None O
role None None O
of None None O
the None None O
proposed None None O
models None None O
and None None O
the None None O
need None None O
for None None O
a None None O
deeper None None O
explanation None None O
of None None O
the None None O
variance None None O
of None None O
depression None None O
scores None None O
. None None O

E None None O
mu None None O
- None None O
bcl None None O
- None None O
2 None None O
transgene None None O
facilitates None None O
spontaneous None None O
transformation None None O
of None None O
early None None O
pre None None O
- None None O
B None None O
and None None O
immunoglobulin None None O
- None None O
secreting None None O
cells None None O
but None None O
not None None O
T None None O
cells None None O
. None None O

To None None O
assess None None O
the None None O
lymphoid None None O
tumorigenic None None O
potential None None O
of None None O
bcl None None O
- None None O
2 None None O
, None None O
mice None None O
of None None O
five None None O
independent None None O
strains None None O
expressing None None O
a None None O
bcl None None O
- None None O
2 None None O
transgene None None O
in None None O
B None None O
and None None O
/ None None O
or None None O
T None None O
cells None None O
were None None O
monitored None None O
for None None O
disease None None O
up None None O
to None None O
12 None None O
months None None O
of None None O
age None None O
. None None O

Lymphoma None None O
prevalence None None O
was None None O
minimal None None O
in None None O
the None None O
T None None O
lineage None None O
but None None O
significant None None O
, None None O
although None None O
low None None O
( None None O
3 None None O
- None None O
15 None None O
% None None O
) None None O
, None None O
in None None O
the None None O
B None None O
lineage None None O
. None None O

The None None O
principal None None O
types None None O
of None None O
tumors None None O
were None None O
plasmacytomas None None O
secreting None None O
immunoglobulin None None O
and None None O
novel None None O
lymphomas None None O
that None None O
expressed None None O
markers None None O
such None None O
as None None O
Sca None None O
- None None O
1 None None O
, None None O
CD4 None None O
, None None O
Thy None None O
- None None O
1 None None O
, None None O
CD34 None None O
and None None O
CD45 None None O
( None None O
B220 None None O
) None None O
, None None O
consistent None None O
with None None O
an None None O
origin None None O
very None None O
early None None O
in None None O
B None None O
- None None O
lymphoid None None O
development None None O
. None None O

Rearrangement None None O
of None None O
the None None O
c None None O
- None None O
myc None None O
gene None None O
was None None O
common None None O
in None None O
the None None O
plasmacytomas None None O
, None None O
implying None None O
a None None O
synergistic None None O
role None None O
for None None O
myc None None O
and None None O
bcl None None O
- None None O
2 None None O
in None None O
their None None O
etiology None None O
, None None O
but None None O
was None None O
not None None O
detected None None O
in None None O
the None None O
lymphomas None None O
. None None O

Parkin None None O
regulates None None O
the None None O
proteasomal None None O
degradation None None O
of None None O
PARIS None None O
and None None O
PGC None None O
- None None O
1alpha None None O
- None None O
dependent None None O
mitochondrial None None O
biogenesis None None O
. None None O

( None None O
A None None O
) None None O
Normal None None O
physiological None None O
conditions None None O
that None None O
maintain None None O
mitochondrial None None O
homeostasis None None O
: None None O
PINK1 None None O
recruits None None O
parkin None None O
to None None O
the None None O
mitochondria None None O
, None None O
where None None O
these None None O
two None None O
proteins None None O
interact None None O
to None None O
eliminate None None O
abnormal None None O
mitochondria None None O
through None None O
mitophagy None None O
. None None O

Alterations None None O
in None None O
mitochondrial None None O
membrane None None O
potential None None O
( None None O
DeltaPsim None None O
; None None O
a None None O
key None None O
indicator None None O
of None None O
mitochondrial None None O
physiology None None O
and None None O
cell None None O
viability None None O
) None None O
initiate None None O
the None None O
PINK1 None None O
- None None O
parkin None None O
cascade None None O
of None None O
events None None O
that None None O
lead None None O
to None None O
mitophagy None None O
. None None O

Furthermore None None O
, None None O
parkin None None O
ubiquitylates None None O
and None None O
thereby None None O
promotes None None O
proteasomal None None O
degradation None None O
of None None O
PARIS None None O
. None None O

Because None None O
PARIS None None O
represses None None O
the None None O
expression None None O
of None None O
PGC None None O
- None None O
1alpha None None O
, None None O
degradation None None O
of None None O
PARIS None None O
by None None O
parkin None None O
allows None None O
PGC None None O
- None None O
1alpha None None O
- None None O
dependent None None O
gene None None O
expression None None O
and None None O
enables None None O
mitochondrial None None O
biogenesis None None O
. None None O

Parkin None None O
seems None None O
to None None O
be None None O
an None None O
integral None None O
regulator None None O
of None None O
mitochondrial None None O
homeostasis None None O
, None None O
controlling None None O
both None None O
degradation None None O
and None None O
biogenesis None None O
. None None O

( None None O
B None None O
) None None O
Loss None None O
of None None O
parkin None None O
function None None O
as None None O
a None None O
result None None O
of None None O
familial None None O
mutations None None O
( None None O
in None None O
the None None O
case None None O
of None None O
AR None None O
- None None O
PD None None O
) None None O
or None None O
aging None None O
, None None O
environmental None None O
or None None O
cellular None None O
stress None None O
( None None O
in None None O
the None None O
case None None O
of None None O
sporadic None None O
PD None None O
) None None O
leads None None O
to None None O
the None None O
accumulation None None O
of None None O
abnormal None None O
mitochondria None None O
, None None O
owing None None O
to None None O
faulty None None O
mitophagy None None O
. None None O

In None None O
addition None None O
, None None O
PARIS None None O
accumulates None None O
and None None O
represses None None O
PGC None None O
- None None O
1alpha None None O
, None None O
preventing None None O
mitochondrial None None O
biogenesis None None O
. None None O

Loss None None O
of None None O
parkin None None O
function None None O
does None None O
not None None O
tip None None O
the None None O
balance None None O
between None None O
mitochondrial None None O
biogenesis None None O
and None None O
degradation None None O
to None None O
either None None O
side None None O
, None None O
but None None O
leads None None O
to None None O
a None None O
general None None O
breakdown None None O
of None None O
mitochondrial None None O
homeostasis None None O
that None None O
can None None O
ultimately None None O
lead None None O
to None None O
PD None None O
. None None O

Pathogenesis None None O
of None None O
thrombosis None None O
in None None O
essential None None O
thrombocythemia None None O
and None None O
polycythemia None None O
vera None None O
: None None O
the None None O
role None None O
of None None O
neutrophils None None O
. None None O

Thrombotic None None O
complications None None O
are None None O
frequently None None O
observed None None O
in None None O
patients None None O
with None None O
polycythemia None None O
vera None None O
( None None O
PV None None O
) None None O
and None None O
essential None None O
thrombocythemia None None O
( None None O
ET None None O
) None None O
. None None O

Abnormalities None None O
of None None O
red None None O
blood None None O
cells None None O
and None None O
platelets None None O
arising None None O
from None None O
the None None O
clonal None None O
rearrangement None None O
of None None O
hematopoietic None None O
cells None None O
have None None O
been None None O
considered None None O
, None None O
although None None O
causal None None O
relationships None None O
between None None O
any None None O
of None None O
these None None O
specific None None O
abnormalities None None O
and None None O
thrombosis None None O
have None None O
not None None O
been None None O
clearly None None O
established None None O
. None None O

The None None O
involvement None None O
of None None O
neutrophils None None O
and None None O
macrophages None None O
, None None O
which None None O
participate None None O
in None None O
thrombosis None None O
and None None O
hemostasis None None O
, None None O
has None None O
been None None O
insufficiently None None O
explored None None O
in None None O
PV None None O
and None None O
ET None None O
. None None O

Persistent None None O
activation None None O
of None None O
circulating None None O
neutrophils None None O
was None None O
recently None None O
demonstrated None None O
in None None O
ET None None O
and None None O
PV None None O
patients None None O
, None None O
in None None O
parallel None None O
with None None O
an None None O
increase None None O
in None None O
plasma None None O
concentrations None None O
of None None O
endothelial None None O
damage None None O
- None None O
derived None None O
and None None O
prothrombotic None None O
substances None None O
. None None O

Other None None O
studies None None O
have None None O
explored None None O
whether None None O
the None None O
augmentation None None O
of None None O
adhesion None None O
of None None O
neutrophils None None O
may None None O
affect None None O
neutrophil None None O
/ None None O
platelet None None O
interaction None None O
since None None O
a None None O
significant None None O
increase None None O
in None None O
circulating None None O
neutrophil None None O
/ None None O
platelet None None O
aggregates None None O
is None None O
found None None O
in None None O
ET None None O
and None None O
PV None None O
. None None O

This None None O
review None None O
summarizes None None O
the None None O
current None None O
knowledge None None O
of None None O
the None None O
pathogenesis None None O
of None None O
thrombosis None None O
in None None O
PV None None O
and None None O
ET None None O
, None None O
with None None O
emphasis None None O
on None None O
the None None O
role None None O
of None None O
neutrophils None None O
in None None O
hemostasis None None O
and None None O
their None None O
possible None None O
involvement None None O
in None None O
the None None O
mechanisms None None O
of None None O
the None None O
acquired None None O
thrombophilia None None O
of None None O
these None None O
patients None None O
. None None O

Available None None O
data None None O
suggest None None O
that None None O
these None None O
hemostatic None None O
markers None None O
deserve None None O
to None None O
be None None O
included None None O
in None None O
prospective None None O
clinical None None O
studies None None O
aimed None None O
at None None O
identifying None None O
their None None O
predictive None None O
role None None O
in None None O
the None None O
vascular None None O
complications None None O
of None None O
patients None None O
with None None O
ET None None O
and None None O
PV None None O
. None None O

Prognostic None None O
value None None O
of None None O
p53 None None O
protein None None O
expression None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
expression None None O
in None None O
resected None None O
squamous None None O
cell None None O
carcinoma None None O
of None None O
the None None O
esophagus None None O
. None None O

The None None O
most None None O
common None None O
genetic None None O
alterations None None O
found None None O
in None None O
a None None O
wide None None O
variety None None O
of None None O
cancers None None O
are None None O
p53 None None O
tumor None None O
suppressor None None O
gene None None O
mutations None None O
. None None O

p53 None None O
appears None None O
to None None O
be None None O
a None None O
nuclear None None O
transcription None None O
factor None None O
that None None O
plays None None O
a None None O
role None None O
in None None O
the None None O
control None None O
of None None O
cell None None O
proliferation None None O
, None None O
apoptosis None None O
, None None O
and None None O
the None None O
maintenance None None O
of None None O
genetic None None O
stability None None O
. None None O

Angiogenesis None None O
is None None O
a None None O
critical None None O
process None None O
in None None O
solid None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
a None None O
recently None None O
identified None None O
growth None None O
factor None None O
with None None O
significant None None O
angiogenic None None O
properties None None O
, None None O
may None None O
be None None O
a None None O
major None None O
tumor None None O
angiogenesis None None O
regulator None None O
. None None O

Few None None O
studies None None O
have None None O
investigated None None O
the None None O
association None None O
between None None O
p53 None None O
and None None O
VEGF None None O
expressions None None O
and None None O
prognosis None None O
in None None O
esophageal None None O
carcinoma None None O
. None None O

Forty None None O
- None None O
seven None None O
specimens None None O
resected None None O
from None None O
patients None None O
with None None O
stage None None O
II None None O
and None None O
III None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
SCC None None O
) None None O
of None None O
the None None O
esophagus None None O
were None None O
studied None None O
using None None O
immunohistochemical None None O
staining None None O
. None None O

VEGF None None O
and None None O
p53 None None O
expressions None None O
were None None O
observed None None O
in None None O
40 None None O
% None None O
and None None O
53 None None O
% None None O
of None None O
the None None O
tumors None None O
, None None O
respectively None None O
. None None O

The None None O
p53 None None O
and None None O
VEGF None None O
staining None None O
statuses None None O
were None None O
coincident None None O
in None None O
only None None O
21 None None O
% None None O
of None None O
the None None O
tumors None None O
, None None O
and None None O
no None None O
significant None None O
correlation None None O
was None None O
found None None O
between None None O
p53 None None O
and None None O
VEGF None None O
statuses None None O
. None None O

No None None O
clinicopathologic None None O
factors None None O
were None None O
significantly None None O
correlated None None O
with None None O
p53 None None O
or None None O
VEGF None None O
expression None None O
. None None O

No None None O
significant None None O
association None None O
between None None O
p53 None None O
and None None O
VEGF None None O
expressions None None O
and None None O
poor None None O
prognosis None None O
was None None O
found None None O
. None None O

In None None O
conclusion None None O
, None None O
p53 None None O
and None None O
VEGF None None O
were None None O
not None None O
correlated None None O
with None None O
prognosis None None O
in None None O
patients None None O
with None None O
stage None None O
II None None O
and None None O
III None None O
SCC None None O
of None None O
the None None O
esophagus None None O
. None None O

[ None None O
Altered None None O
expression None None O
of None None O
PTEN None None O
gene None None O
and None None O
LOH None None O
of None None O
its None None O
epigenetic None None O
microsatellite None None O
in None None O
gastric None None O
carcinoma None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
expression None None O
of None None O
PTEN None None O
and None None O
loss None None O
of None None O
heterozygosity None None O
( None None O
LOH None None O
) None None O
of None None O
its None None O
epigenetic None None O
microsatellite None None O
in None None O
gastric None None O
carcinoma None None O
and None None O
explore None None O
their None None O
roles None None O
in None None O
progression None None O
of None None O
gastric None None O
carcinoma None None O
. None None O

METHODS None None O
: None None O
LOH None None O
of None None O
epigenetic None None O
microsatellites None None O
of None None O
PTEN None None O
( None None O
D10S541 None None O
, None None O
D10S583 None None O
and None None O
D10S1687 None None O
) None None O
in None None O
advanced None None O
gastric None None O
cancer None None O
was None None O
detected None None O
by None None O
PCR None None O
- None None O
SSCP None None O
. None None O

Expression None None O
of None None O
PTEN None None O
mRNA None None O
and None None O
protein None None O
in None None O
normal None None O
gastric None None O
mucosa None None O
and None None O
gastric None None O
cancer None None O
was None None O
evaluated None None O
by None None O
RT None None O
- None None O
PCR None None O
and None None O
SABC None None O
immunohistochemistry None None O
, None None O
respectively None None O
. None None O

The None None O
relationship None None O
between None None O
expression None None O
of None None O
PTEN None None O
mRNA None None O
and None None O
protein None None O
and None None O
lymph None None O
node None None O
metastasis None None O
or None None O
LOH None None O
of None None O
microsatellites None None O
was None None O
discussed None None O
. None None O

RESULTS None None O
: None None O
LOH None None O
of None None O
D10S541 None None O
, None None O
D10S583 None None O
and None None O
D10S1687 None None O
was None None O
found None None O
in None None O
37 None None O
. None None O
5 None None O
% None None O
( None None O
21 None None O
/ None None O
56 None None O
) None None O
of None None O
advanced None None O
gastric None None O
cancers None None O
. None None O

The None None O
positive None None O
rates None None O
of None None O
PTEN None None O
mRNA None None O
expression None None O
were None None O
80 None None O
. None None O
4 None None O
% None None O
( None None O
45 None None O
/ None None O
56 None None O
) None None O
, None None O
45 None None O
. None None O
5 None None O
% None None O
( None None O
5 None None O
/ None None O
11 None None O
) None None O
and None None O
32 None None O
. None None O
1 None None O
% None None O
( None None O
18 None None O
/ None None O
56 None None O
) None None O
in None None O
normal None None O
mucosa None None O
, None None O
early None None O
and None None O
advanced None None O
gastric None None O
carcinomas None None O
, None None O
respectively None None O
, None None O
while None None O
78 None None O
. None None O
6 None None O
% None None O
( None None O
44 None None O
/ None None O
56 None None O
) None None O
, None None O
44 None None O
. None None O
5 None None O
% None None O
( None None O
5 None None O
/ None None O
11 None None O
) None None O
and None None O
28 None None O
. None None O
6 None None O
% None None O
( None None O
16 None None O
/ None None O
56 None None O
) None None O
at None None O
the None None O
protein None None O
level None None O
. None None O

PTEN None None O
mRNA None None O
and None None O
protein None None O
were None None O
less None None O
frequently None None O
expressed None None O
in None None O
early None None O
and None None O
advanced None None O
gastric None None O
carcinomas None None O
than None None O
that None None O
in None None O
normal None None O
gastric None None O
mucosa None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

There None None O
was None None O
positive None None O
correlation None None O
between None None O
PTEN None None O
mRNA None None O
expression None None O
and None None O
LOH None None O
of None None O
microsatellites None None O
in None None O
advanced None None O
gastric None None O
carcinomas None None O
. None None O

PTEN None None O
protein None None O
expression None None O
paralleled None None O
with None None O
its None None O
mRNA None None O
expression None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
PTEN None None O
mRNA None None O
and None None O
protein None None O
was None None O
negatively None None O
correlated None None O
with None None O
lymph None None O
node None None O
metastasis None None O
of None None O
advanced None None O
gastric None None O
carcinomas None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
Down None None O
- None None O
regulated None None O
expression None None O
of None None O
PTEN None None O
gene None None O
is None None O
found None None O
in None None O
different None None O
stages None None O
of None None O
gastric None None O
carcinoma None None O
, None None O
and None None O
is None None O
closely None None O
correlated None None O
with None None O
LOH None None O
of None None O
its None None O
epigenetic None None O
microsatellites None None O
, None None O
which None None O
probably None None O
is None None O
its None None O
underlying None None O
molecular None None O
mechanisms None None O
. None None O

It None None O
suggests None None O
that None None O
altered None None O
PTEN None None O
gene None None O
contributes None None O
to None None O
tumorigenesis None None O
and None None O
progression None None O
of None None O
gastric None None O
carcinomas None None O
. None None O

Trib1 None None O
and None None O
Evi1 None None O
cooperate None None O
with None None O
Hoxa None None O
and None None O
Meis1 None None O
in None None O
myeloid None None O
leukemogenesis None None O
. None None O

Cooperative None None O
activation None None O
of None None O
Meis1 None None O
and None None O
Hoxa9 None None O
perturbs None None O
myeloid None None O
differentiation None None O
and None None O
eventually None None O
leads None None O
myeloid None None O
progenitors None None O
to None None O
leukemia None None O
, None None O
yet None None O
it None None O
remains None None O
to None None O
be None None O
clarified None None O
what None None O
kinds None None O
of None None O
subsequent None None O
molecular None None O
processes None None O
are None None O
required None None O
for None None O
development None None O
of None None O
overt None None O
leukemia None None O
. None None O

To None None O
understand None None O
the None None O
molecular None None O
pathway None None O
in None None O
Hoxa9 None None O
/ None None O
Meis1 None None O
- None None O
induced None None O
leukemogenesis None None O
, None None O
retroviral None None O
insertional None None O
mutagenesis None None O
was None None O
applied None None O
using None None O
retrovirus None None O
- None None O
mediated None None O
gene None None O
transfer None None O
. None None O

The None None O
mice None None O
that None None O
received None None O
Hoxa9 None None O
/ None None O
Meis1 None None O
- None None O
transduced None None O
bone None None O
marrow None None O
cells None None O
developed None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
, None None O
and None None O
Trib1 None None O
, None None O
Evi1 None None O
, None None O
Ahi1 None None O
, None None O
Raralpha None None O
, None None O
Pitpnb None None O
, None None O
and None None O
AK039950 None None O
were None None O
identified None None O
as None None O
candidate None None O
cooperative None None O
genes None None O
located None None O
near None None O
common None None O
retroviral None None O
integration None None O
sites None None O
. None None O

Trib1 None None O
and None None O
Evi1 None None O
were None None O
up None None O
- None None O
regulated None None O
due None None O
to None None O
retroviral None None O
insertions None None O
, None None O
and None None O
coexpression None None O
of None None O
these None None O
genes None None O
significantly None None O
accelerated None None O
the None None O
onset None None O
of None None O
Hoxa9 None None O
/ None None O
Meis1 None None O
- None None O
induced None None O
AML None None O
, None None O
suggesting None None O
that None None O
Trib1 None None O
and None None O
Evi1 None None O
are None None O
the None None O
key None None O
collaborators None None O
. None None O

Furthermore None None O
, None None O
Trib1 None None O
by None None O
itself None None O
is None None O
a None None O
novel None None O
myeloid None None O
oncogene None None O
, None None O
enhancing None None O
phosphorylation None None O
of None None O
ERK None None O
, None None O
resulting None None O
in None None O
inhibition None None O
of None None O
apoptosis None None O
. None None O

These None None O
results None None O
demonstrate None None O
the None None O
importance None None O
of None None O
specific None None O
oncogene None None O
interaction None None O
in None None O
myeloid None None O
leukemogenesis None None O
. None None O

Modified None None O
radiology None None O
- None None O
guided None None O
percutaneous None None O
gastrostomy None None O
technique None None O
. None None O

A None None O
. None None O

21G None None O
fine None None O
needle None None O
punctured None None O
localized None None O
collection None None O
of None None O
air None None O
, None None O
which None None O
was None None O
visible None None O
in None None O
collapsed None None O
stomach None None O
under None None O
fluoroscopy None None O
- None None O
guided None None O
gastrostomy None None O
. None None O

Needle None None O
tip None None O
is None None O
then None None O
gradually None None O
withdrawn None None O
while None None O
injecting None None O
small None None O
amounts None None O
of None None O
water None None O
- None None O
soluble None None O
contrast None None O
medium None None O
. None None O

Location None None O
of None None O
stomach None None O
is None None O
confirmed None None O
by None None O
visualization None None O
of None None O
opacified None None O
gastric None None O
rugae None None O
. None None O

B None None O
. None None O

Stomach None None O
was None None O
inflated None None O
with None None O
approximately None None O
600 None None O
- None None O
800 None None O
mL None None O
of None None O
room None None O
air None None O
through None None O
21G None None O
fine None None O
needle None None O
. None None O

C None None O
. None None O

100 None None O
- None None O
cm None None O
stainless None None O
steel None None O
guide None None O
wire None None O
is None None O
inserted None None O
through None None O
needle None None O
, None None O
and None None O
gastro None None O
- None None O
percutaneous None None O
tract None None O
is None None O
gradually None None O
dilated None None O
. None None O

D None None O
. None None O

Insertion None None O
of None None O
14 None None O
- None None O
Fr None None O
pigtail None None O
gastrostomy None None O
catheter None None O
and None None O
injection None None O
of None None O
small None None O
amount None None O
of None None O
water None None O
- None None O
soluble None None O
contrast None None O
medium None None O
via None None O
pigtail None None O
catheter None None O
confirmed None None O
that None None O
gastrostomy None None O
catheter None None O
is None None O
correctly None None O
placed None None O
within None None O
stomach None None O
. None None O

Management None None O
of None None O
the None None O
tortuous None None O
internal None None O
carotid None None O
artery None None O
. None None O

The None None O
tortuous None None O
internal None None O
carotid None None O
artery None None O
as None None O
the None None O
basis None None O
of None None O
cerebral None None O
vascular None None O
insufficiency None None O
is None None O
a None None O
controversial None None O
entity None None O
, None None O
as None None O
such None None O
lesions None None O
frequently None None O
occur None None O
without None None O
neurologic None None O
symptoms None None O
. None None O

However None None O
, None None O
some None None O
tortuous None None O
vessels None None O
are None None O
associated None None O
with None None O
significant None None O
carotid None None O
atherosclerotic None None O
disease None None O
requiring None None O
a None None O
specific None None O
surgical None None O
approach None None O
. None None O

This None None O
formed None None O
the None None O
basis None None O
of None None O
our None None O
report None None O
. None None O

Symptoms None None O
of None None O
cerebrovascular None None O
insufficiency None None O
in None None O
association None None O
with None None O
a None None O
tortuous None None O
internal None None O
carotid None None O
artery None None O
was None None O
encountered None None O
in None None O
27 None None O
of None None O
853 None None O
carotid None None O
endarterectomies None None O
over None None O
a None None O
22 None None O
year None None O
period None None O
. None None O

Stenosis None None O
of None None O
hemodynamic None None O
significance None None O
was None None O
noted None None O
in None None O
nine None None O
patients None None O
and None None O
irregularities None None O
or None None O
ulceration None None O
were None None O
noted None None O
in None None O
the None None O
rest None None O
. None None O

With None None O
the None None O
standard None None O
technique None None O
of None None O
carotid None None O
endarterectomy None None O
, None None O
removal None None O
of None None O
plaque None None O
from None None O
a None None O
tortuous None None O
vessel None None O
leads None None O
to None None O
loss None None O
of None None O
the None None O
stenting None None O
effect None None O
provided None None O
by None None O
the None None O
plaque None None O
such None None O
that None None O
angulation None None O
occlusion None None O
is None None O
likely None None O
to None None O
occur None None O
. None None O

The None None O
optimal None None O
reconstruction None None O
in None None O
our None None O
experience None None O
is None None O
eversion None None O
endarterectomy None None O
by None None O
transection None None O
and None None O
lower None None O
reimplantation None None O
of None None O
the None None O
internal None None O
carotid None None O
artery None None O
on None None O
the None None O
common None None O
carotid None None O
artery None None O
. None None O

Our None None O
experience None None O
with None None O
17 None None O
such None None O
procedures None None O
in None None O
15 None None O
patients None None O
has None None O
been None None O
presented None None O
. None None O

Prophylactic None None O
thyroidectomy None None O
in None None O
MEN None None O
IIA None None O
: None None O
does None None O
the None None O
calcitonin None None O
level None None O
correlate None None O
with None None O
tumor None None O
spread None None O
? None None O

BACKGROUND None None O
: None None O
The None None O
fate None None O
of None None O
patients None None O
with None None O
multiple None None O
endocrine None None O
neoplasia None None O
of None None O
type None None O
II None None O
A None None O
( None None O
MEN None None O
II None None O
A None None O
) None None O
is None None O
determined None None O
by None None O
medullary None None O
thyroid None None O
carcinoma None None O
, None None O
which None None O
occurs None None O
in None None O
all None None O
cases None None O
. None None O

This None None O
has None None O
led None None O
to None None O
the None None O
therapeutic None None O
concept None None O
of None None O
prophylactic None None O
thyroidectomy None None O
in None None O
affected None None O
family None None O
members None None O
with None None O
the None None O
goal None None O
of None None O
removing None None O
the None None O
thyroid None None O
before None None O
the None None O
manifestation None None O
of None None O
carcinoma None None O
. None None O

We None None O
investigated None None O
a None None O
prophylactically None None O
thyroidectomized None None O
MEN None None O
II None None O
A None None O
population None None O
to None None O
determine None None O
whether None None O
the None None O
highly None None O
specific None None O
and None None O
sensitive None None O
tumor None None O
marker None None O
calcitonin None None O
correlates None None O
with None None O
tumor None None O
spread None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
Fifteen None None O
patients None None O
with None None O
MEN None None O
II None None O
A None None O
( None None O
aged None None O
4 None None O
- None None O
24 None None O
years None None O
) None None O
who None None O
had None None O
undergone None None O
prophylactic None None O
thyroidectomy None None O
since None None O
1990 None None O
were None None O
included None None O
in None None O
the None None O
study None None O
. None None O

Baseline None None O
and None None O
pentagastrin None None O
- None None O
stimulated None None O
calcitonin None None O
levels None None O
were None None O
preoperatively None None O
determined None None O
in None None O
all None None O
cases None None O
. None None O

The None None O
indication None None O
for None None O
surgery None None O
was None None O
established None None O
on None None O
the None None O
basis None None O
of None None O
pathologic None None O
calcitonin None None O
levels None None O
in None None O
the None None O
first None None O
seven None None O
patients None None O
and None None O
on None None O
the None None O
basis None None O
of None None O
detected None None O
RET None None O
proto None None O
- None None O
oncogene None None O
mutation None None O
in None None O
the None None O
other None None O
eight None None O
patients None None O
. None None O

Bilateral None None O
central None None O
lymphadenectomy None None O
was None None O
performed None None O
in None None O
all None None O
patients None None O
in None None O
addition None None O
to None None O
thyroidectomy None None O
. None None O

RESULTS None None O
: None None O
Histology None None O
demonstrated None None O
C None None O
- None None O
cell None None O
hyperplasia None None O
in None None O
five None None O
patients None None O
( None None O
aged None None O
4 None None O
- None None O
13 None None O
years None None O
) None None O
, None None O
unilateral None None O
medullary None None O
microcarcinoma None None O
in None None O
six None None O
( None None O
aged None None O
9 None None O
- None None O
17 None None O
years None None O
) None None O
and None None O
a None None O
bilateral None None O
medullary None None O
microcarcinoma None None O
in None None O
three None None O
cases None None O
( None None O
aged None None O
17 None None O
- None None O
24 None None O
years None None O
) None None O
. None None O

One None None O
9 None None O
- None None O
year None None O
- None None O
old None None O
boy None None O
with None None O
bilateral None None O
microcarcinoma None None O
already None None O
had None None O
a None None O
lymph None None O
node None None O
metastasis None None O
. None None O

The None None O
mean None None O
baseline None None O
calcitonin None None O
level None None O
correlated None None O
with None None O
the None None O
histologic None None O
findings None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
71 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
003 None None O
) None None O
but None None O
there None None O
was None None O
no None None O
correlation None None O
between None None O
pentagastrin None None O
- None None O
stimulated None None O
calcitonin None None O
levels None None O
and None None O
histology None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
21 None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
47 None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
In None None O
MEN None None O
II None None O
A None None O
patients None None O
undergoing None None O
prophylactic None None O
thyroidectomy None None O
, None None O
baseline None None O
but None None O
not None None O
stimulated None None O
calcitonin None None O
levels None None O
already None None O
correlate None None O
with None None O
the None None O
histologic None None O
tumor None None O
stage None None O
at None None O
the None None O
stage None None O
of None None O
clinically None None O
occult None None O
C None None O
- None None O
cell None None O
hyperplasia None None O
or None None O
medullary None None O
microcarcinoma None None O
. None None O

However None None O
, None None O
biochemical None None O
screening None None O
cannot None None O
reliably None None O
discriminate None None O
the None None O
transition None None O
from None None O
C None None O
- None None O
cell None None O
hyperplasia None None O
to None None O
invasive None None O
microcarcinoma None None O
. None None O

Individuals None None O
with None None O
MEN None None O
IIA None None O
should None None O
therefore None None O
undergo None None O
early None None O
prophylactic None None O
thyroidectomy None None O
once None None O
the None None O
diagnosis None None O
is None None O
confirmed None None O
by None None O
molecular None None O
genetic None None O
testing None None O
. None None O

Inhibition None None O
of None None O
Dll4 None None O
- None None O
mediated None None O
signaling None None O
induces None None O
proliferation None None O
of None None O
immature None None O
vessels None None O
and None None O
results None None O
in None None O
poor None None O
tissue None None O
perfusion None None O
. None None O

Vascular None None O
development None None O
is None None O
dependent None None O
on None None O
various None None O
growth None None O
factors None None O
and None None O
certain None None O
modifiers None None O
critical None None O
for None None O
providing None None O
arterial None None O
or None None O
venous None None O
identity None None O
, None None O
interaction None None O
with None None O
the None None O
surrounding None None O
stroma None None O
and None None O
tissues None None O
, None None O
hierarchic None None O
network None None O
formation None None O
, None None O
and None None O
recruitment None None O
of None None O
pericytes None None O
. None None O

Notch None None O
receptors None None O
and None None O
ligands None None O
( None None O
Jagged None None O
and None None O
Delta None None O
- None None O
like None None O
) None None O
play None None O
a None None O
critical None None O
role None None O
in None None O
this None None O
process None None O
in None None O
addition None None O
to None None O
VEGF None None O
. None None O

Dll4 None None O
is None None O
one None None O
of None None O
the None None O
Notch None None O
ligands None None O
that None None O
regulates None None O
arterial None None O
specification None None O
and None None O
maturation None None O
events None None O
. None None O

In None None O
the None None O
current None None O
study None None O
, None None O
we None None O
have None None O
shown None None O
that None None O
loss None None O
of None None O
function None None O
by None None O
either None None O
targeted None None O
allele None None O
deletion None None O
or None None O
use None None O
of None None O
a None None O
soluble None None O
form None None O
of None None O
Dll4 None None O
extracellular None None O
domain None None O
leads None None O
to None None O
inhibition None None O
of None None O
Notch None None O
signaling None None O
, None None O
resulting None None O
in None None O
increased None None O
vascular None None O
proliferation None None O
but None None O
defective None None O
maturation None None O
. None None O

Newly None None O
forming None None O
vessels None None O
have None None O
thin None None O
caliber None None O
, None None O
a None None O
markedly None None O
reduced None None O
vessel None None O
lumen None None O
, None None O
markedly None None O
reduced None None O
pericyte None None O
recruitment None None O
, None None O
and None None O
deficient None None O
vascular None None O
perfusion None None O
. None None O

sDll4 None None O
similarly None None O
induced None None O
defective None None O
vascular None None O
response None None O
in None None O
tumor None None O
implants None None O
leading None None O
to None None O
reduced None None O
tumor None None O
growth None None O
. None None O

Interference None None O
with None None O
Dll4 None None O
- None None O
Notch None None O
signaling None None O
may None None O
be None None O
particularly None None O
desirable None None O
in None None O
tumors None None O
that None None O
have None None O
highly None None O
induced None None O
Dll4 None None O
- None None O
Notch None None O
pathway None None O
. None None O

Real None None O
time None None O
RT None None O
- None None O
PCR None None O

RNA None None O
extraction None None O
and None None O
real None None O
- None None O
time None None O
RT None None O
- None None O
PCR None None O
were None None O
performed None None O
as None None O
we None None O
described None None O
previously None None O
[ None None O
22 None None O
] None None O
. None None O

The None None O
sequences None None O
of None None O
ABCG2 None None O
primers None None O
are None None O
5 None None O
' None None O
- None None O
GGCTTTCTACCTGCACGAAAACCAGTTGAG None None O
- None None O
3 None None O
' None None O
( None None O
forward None None O
) None None O
and None None O
5 None None O
' None None O
- None None O
ATGGCGTTGAGACCAG None None O
- None None O
3 None None O
' None None O
( None None O
reverse None None O
) None None O
. None None O

The None None O
sequences None None O
of None None O
GAPDH None None O
primers None None O
are None None O
5 None None O
' None None O
- None None O
AAGGACTCATGACCACAGTCCAT None None O
- None None O
3 None None O
' None None O
( None None O
forward None None O
) None None O
and None None O
5 None None O
' None None O
- None None O
CCATCACGCCACAGTTTCC None None O
- None None O
3 None None O
' None None O
( None None O
reverse None None O
) None None O
. None None O

The None None O
relative None None O
ABCG2 None None O
RNA None None O
level None None O
( None None O
2DeltaCT None None O
) None None O
treated None None O
with None None O
inhibitors None None O
was None None O
expressed None None O
as None None O
percentage None None O
of None None O
the None None O
control None None O
( None None O
in None None O
the None None O
presence None None O
of None None O
0 None None O
. None None O
1 None None O
% None None O
DMSO None None O
) None None O
where None None O
DeltaCT None None O
( None None O
threshold None None O
cycle None None O
) None None O
= None None O
( None None O
CTABCG2 None None O
- None None O
CTGAPDH None None O
) None None O
. None None O

Activation None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
through None None O
reactive None None O
oxygen None None O
species None None O
mediates None None O
20 None None O
- None None O
hydroxyeicosatetraenoic None None O
acid None None O
- None None O
induced None None O
endothelial None None O
cell None None O
proliferation None None O
. None None O

20 None None O
- None None O
Hydroxyeicosatetraenoic None None O
acid None None O
( None None O
20 None None O
- None None O
HETE None None O
) None None O
is None None O
formed None None O
by None None O
the None None O
omega None None O
- None None O
hydroxylation None None O
of None None O
arachidonic None None O
acid None None O
by None None O
cytochrome None None O
P450 None None O
4A None None O
and None None O
4F None None O
enzymes None None O
, None None O
and None None O
it None None O
induces None None O
angiogenic None None O
responses None None O
in None None O
vivo None None O
. None None O

To None None O
test None None O
the None None O
hypothesis None None O
that None None O
20 None None O
- None None O
HETE None None O
increases None None O
endothelial None None O
cell None None O
( None None O
EC None None O
) None None O
proliferation None None O
via None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
we None None O
studied None None O
the None None O
effects None None O
of None None O
WIT003 None None O
[ None None O
20 None None O
- None None O
hydroxyeicosa None None O
- None None O
5 None None O
( None None O
Z None None O
) None None O
, None None O
14 None None O
( None None O
Z None None O
) None None O
- None None O
dienoic None None O
acid None None O
] None None O
, None None O
a None None O
20 None None O
- None None O
HETE None None O
analog None None O
on None None O
human None None O
macrovascular None None O
or None None O
microvascular None None O
EC None None O
. None None O

WIT003 None None O
, None None O
as None None O
well None None O
as None None O
pure None None O
20 None None O
- None None O
HETE None None O
, None None O
stimulated None None O
EC None None O
proliferation None None O
by None None O
approximately None None O
40 None None O
% None None O
. None None O

These None None O
proliferative None None O
effects None None O
were None None O
accompanied None None O
by None None O
increased None None O
VEGF None None O
expression None None O
and None None O
release None None O
that None None O
were None None O
observed None None O
as None None O
early None None O
as None None O
4 None None O
h None None O
after None None O
20 None None O
- None None O
HETE None None O
agonist None None O
addition None None O
. None None O

This None None O
was None None O
accompanied None None O
by None None O
increased None None O
phosphorylation None None O
of None None O
the None None O
VEGF None None O
receptor None None O
2 None None O
. None None O

The None None O
proliferative None None O
effects None None O
of None None O
20 None None O
- None None O
HETE None None O
were None None O
markedly None None O
inhibited None None O
by None None O
a None None O
VEGF None None O
- None None O
neutralizing None None O
antibody None None O
. None None O

Polyethylene None None O
glycol None None O
- None None O
superoxide None None O
dismutase None None O
( None None O
PEG None None O
- None None O
SOD None None O
) None None O
markedly None None O
inhibited None None O
both None None O
the None None O
increases None None O
in None None O
VEGF None None O
expression None None O
and None None O
the None None O
proliferative None None O
effects None None O
of None None O
20 None None O
- None None O
HETE None None O
. None None O

In None None O
contrast None None O
, None None O
administration None None O
of None None O
the None None O
NAD None None O
( None None O
P None None O
) None None O
H None None O
oxidase None None O
inhibitor None None O
apocynin None None O
had None None O
no None None O
effect None None O
to None None O
the None None O
proliferative None None O
response None None O
to None None O
20 None None O
- None None O
HETE None None O
. None None O

The None None O
20 None None O
- None None O
HETE None None O
agonist None None O
markedly None None O
increased None None O
superoxide None None O
formation None None O
as None None O
reflected None None O
by None None O
an None None O
increase None None O
in None None O
dihydroethidium None None O
staining None None O
of None None O
EC None None O
, None None O
and None None O
this None None O
increase None None O
was None None O
inhibited None None O
by None None O
PEG None None O
- None None O
SOD None None O
but None None O
not None None O
by None None O
apocynin None None O
. None None O

20 None None O
- None None O
HETE None None O
also None None O
increased None None O
the None None O
phosphorylation None None O
of None None O
p42 None None O
/ None None O
p44 None None O
mitogen None None O
- None None O
activated None None O
protein None None O
kinase None None O
( None None O
MAPK None None O
) None None O
in None None O
EC None None O
, None None O
whereas None None O
an None None O
inhibitor None None O
of None None O
MAPK None None O
[ None None O
U0126 None None O
, None None O
1 None None O
, None None O
4 None None O
- None None O
diamino None None O
- None None O
2 None None O
, None None O
3 None None O
- None None O
dicyano None None O
- None None O
1 None None O
, None None O
4 None None O
- None None O
bis None None O
( None None O
2 None None O
- None None O
aminophenylthio None None O
) None None O
butadiene None None O
] None None O
suppressed None None O
the None None O
proliferative None None O
and None None O
the None None O
VEGF None None O
changes None None O
but None None O
not None None O
the None None O
pro None None O
- None None O
oxidant None None O
effects None None O
of None None O
20 None None O
- None None O
HETE None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
20 None None O
- None None O
HETE None None O
stimulates None None O
superoxide None None O
formation None None O
by None None O
pathways None None O
other None None O
than None None O
apocynin None None O
- None None O
sensitive None None O
NAD None None O
( None None O
P None None O
) None None O
H None None O
oxidase None None O
, None None O
thereby None None O
activating None None O
MAPK None None O
and None None O
then None None O
enhancing None None O
VEGF None None O
synthesis None None O
that None None O
drives None None O
EC None None O
proliferation None None O
. None None O

Thus None None O
, None None O
20 None None O
- None None O
HETE None None O
may None None O
be None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
EC None None O
functions None None O
, None None O
such None None O
as None None O
angiogenesis None None O
. None None O

Conclusions None None O
and None None O
policy None None O
implications None None O

Early None None O
postnatal None None O
home None None O
visit None None O
is None None O
one None None O
strategy None None O
for None None O
providing None None O
critical None None O
interventions None None O
to None None O
improve None None O
newborn None None O
survival None None O
. None None O

Given None None O
the None None O
compelling None None O
data None None O
in None None O
this None None O
study None None O
, None None O
we None None O
recommend None None O
that None None O
in None None O
developing None None O
countries None None O
, None None O
especially None None O
those None None O
where None None O
home None None O
delivery None None O
with None None O
unskilled None None O
attendants None None O
is None None O
the None None O
norm None None O
, None None O
all None None O
newborns None None O
should None None O
receive None None O
a None None O
home None None O
visit None None O
and None None O
undergo None None O
assessment None None O
by None None O
a None None O
trained None None O
worker None None O
as None None O
soon None None O
as None None O
possible None None O
, None None O
preferably None None O
on None None O
the None None O
day None None O
of None None O
birth None None O
but None None O
no None None O
later None None O
than None None O
48 None None O
hours None None O
after None None O
birth None None O
. None None O

The None None O
impact None None O
of None None O
this None None O
approach None None O
is None None O
likely None None O
to None None O
be None None O
dependent None None O
on None None O
the None None O
content None None O
, None None O
quality None None O
, None None O
and None None O
coverage None None O
of None None O
the None None O
technical None None O
interventions None None O
included None None O
. None None O

Reaching None None O
neonates None None O
within None None O
first None None O
day None None O
or None None O
first None None O
two None None O
days None None O
of None None O
life None None O
is None None O
a None None O
challenge None None O
. None None O

Given None None O
that None None O
the None None O
community None None O
health None None O
workers None None O
in None None O
this None None O
study None None O
were None None O
not None None O
skilled None None O
birth None None O
attendants None None O
and None None O
attended None None O
only None None O
about None None O
5 None None O
% None None O
of None None O
deliveries None None O
, None None O
a None None O
complementary None None O
strategy None None O
will None None O
be None None O
to None None O
ensure None None O
skilled None None O
attendance None None O
at None None O
delivery None None O
that None None O
is None None O
linked None None O
to None None O
essential None None O
obstetric None None O
care None None O
. None None O
31 None None O
32 None None O
Further None None O
operational None None O
research None None O
will None None O
be None None O
needed None None O
to None None O
develop None None O
context None None O
specific None None O
strategies None None O
to None None O
reach None None O
all None None O
newborns None None O
as None None O
soon None None O
as None None O
possible None None O
after None None O
birth None None O
. None None O

Supporting None None O
Information None None O

Alternate None None O
Language None None O
Article None None O
S1 None None O

Translation None None O
of None None O
the None None O
manuscript None None O
into None None O
French None None O
by None None O
EL None None O

( None None O
201 None None O
KB None None O
DOC None None O
) None None O
. None None O

Click None None O
here None None O
for None None O
additional None None O
data None None O
file None None O
. None None O

Prognostic None None O
significance None None O
of None None O
heat None None O
shock None None O
protein None None O
27 None None O
( None None O
HSP27 None None O
) None None O
in None None O
patients None None O
with None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Heat None None O
shock None None O
proteins None None O
( None None O
HSPs None None O
) None None O
have None None O
been None None O
defined None None O
as None None O
proteins None None O
induced None None O
by None None O
heat None None O
shock None None O
and None None O
other None None O
environmental None None O
and None None O
pathophysiologic None None O
stress None None O
. None None O

Heat None None O
shock None None O
protein None None O
27 None None O
( None None O
HSP27 None None O
) None None O
is None None O
one None None O
of None None O
the None None O
small None None O
heat None None O
shock None None O
proteins None None O
. None None O

HSP27 None None O
is None None O
implicated None None O
in None None O
protein None None O
- None None O
protein None None O
interactions None None O
such None None O
as None None O
folding None None O
, None None O
translocation None None O
, None None O
and None None O
prevention None None O
of None None O
inappropriate None None O
protein None None O
aggregation None None O
. None None O

Many None None O
of None None O
their None None O
functions None None O
suggest None None O
that None None O
they None None O
play None None O
important None None O
roles None None O
in None None O
cancers None None O
. None None O

Archival None None O
tissues None None O
from None None O
40 None None O
patients None None O
with None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
who None None O
received None None O
primary None None O
surgical None None O
resection None None O
were None None O
examined None None O
for None None O
HSP27 None None O
by None None O
immunohistochemistry None None O
and None None O
correlated None None O
with None None O
clinical None None O
stage None None O
, None None O
lymph None None O
node None None O
metastasis None None O
, None None O
histological None None O
grade None None O
and None None O
survival None None O
period None None O
. None None O

HSP27 None None O
expression None None O
was None None O
positive None None O
staining None None O
( None None O
+ None None O
) None None O
in None None O
20 None None O
( None None O
50 None None O
% None None O
) None None O
, None None O
weak None None O
or None None O
negative None None O
staining None None O
( None None O
- None None O
) None None O
in None None O
20 None None O
( None None O
50 None None O
% None None O
) None None O
of None None O
total None None O
40 None None O
cases None None O
. None None O

There None None O
was None None O
no None None O
correlation None None O
between None None O
HSP27 None None O
expression None None O
and None None O
clinical None None O
stage None None O
, None None O
lymph None None O
node None None O
metastasis None None O
and None None O
histological None None O
grade None None O
. None None O

However None None O
, None None O
when None None O
compared None None O
with None None O
clinicopathological None None O
features None None O
, None None O
the None None O
expression None None O
of None None O
HSP27 None None O
correlated None None O
inversely None None O
with None None O
survival None None O
period None None O
. None None O

This None None O
study None None O
suggests None None O
that None None O
the None None O
expression None None O
of None None O
HSP27 None None O
is None None O
frequently None None O
promoted None None O
in None None O
patients None None O
with None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
and None None O
should None None O
be None None O
considered None None O
an None None O
independent None None O
prognostic None None O
factor None None O
of None None O
oral None None O
squamous None None O
cell None None O
carcinoma None None O
patients None None O
. None None O

Background None None O

Refractive None None O
outcomes None None O
have None None O
become None None O
an None None O
increasingly None None O
important None None O
part None None O
of None None O
cataract None None O
surgery None None O
and None None O
the None None O
limbal None None O
relaxing None None O
incision None None O
( None None O
LRI None None O
) None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
a None None O
safe None None O
and None None O
effective None None O
procedure None None O
to None None O
reduce None None O
astigmatism None None O
[ None None O
1 None None O
- None None O
4 None None O
] None None O
. None None O

Currently None None O
, None None O
ophthalmic None None O
surgeons None None O
have None None O
only None None O
two None None O
material None None O
choices None None O
for None None O
knives None None O
to None None O
perform None None O
limbal None None O
relaxing None None O
incision None None O
, None None O
diamond None None O
and None None O
metal None None O
. None None O

BD None None O
( None None O
Becton None None O
, None None O
Dickinson None None O
and None None O
Company None None O
) None None O
, None None O
Franklin None None O
Lakes None None O
, None None O
NJ None None O
has None None O
developed None None O
a None None O
safety None None O
engineered None None O
, None None O
single None None O
use None None O
, None None O
uni None None O
- None None O
directional None None O
cutting None None O
silicon None None O
knife None None O
for None None O
these None None O
incisions None None O
. None None O

Previous None None O
research None None O
has None None O
suggested None None O
that None None O
the None None O
silicon None None O
BD None None O
Atomic None None O
Edge None None O
( None None O
TM None None O
) None None O
knife None None O
has None None O
superior None None O
performance None None O
characteristics None None O
when None None O
compared None None O
to None None O
a None None O
metal None None O
knife None None O
and None None O
performance None None O
similar None None O
to None None O
diamond None None O
knife None None O
when None None O
making None None O
various None None O
incisions None None O
[ None None O
5 None None O
, None None O
6 None None O
] None None O
. None None O

This None None O
study None None O
was None None O
designed None None O
to None None O
determine None None O
the None None O
performance None None O
characteristics None None O
of None None O
silicon None None O
accurate None None O
depth None None O
knives None None O
in None None O
comparison None None O
to None None O
diamond None None O
LRI None None O
knives None None O
and None None O
steel None None O
accurate None None O
depth None None O
knives None None O
in None None O
five None None O
performance None None O
characteristics None None O
. None None O

Proteomic None None O
comparison None None O
of None None O
nasopharyngeal None None O
cancer None None O
cell None None O
lines None None O
C666 None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
and None None O
NP69 None None I-Cell-line-name
identifies None None O
down None None O
- None None O
regulation None None O
of None None O
annexin None None O
II None None O
and None None O
beta2 None None O
- None None O
tubulin None None O
for None None O
nasopharyngeal None None O
carcinoma None None O
. None None O

CONTEXT None None O
: None None O
Nasopharyngeal None None O
carcinoma None None O
( None None O
NPC None None O
) None None O
, None None O
common None None O
in None None O
southern None None O
China None None O
and None None O
North None None O
Africa None None O
, None None O
has None None O
a None None O
complex None None O
etiology None None O
involving None None O
interplay None None O
between None None O
viral None None O
, None None O
environmental None None O
, None None O
and None None O
hereditary None None O
factors None None O
and None None O
is None None O
almost None None O
constantly None None O
associated None None O
with None None O
the None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
. None None O

Since None None O
the None None O
prognosis None None O
of None None O
locally None None O
advanced None None O
and None None O
metastatic None None O
diseases None None O
is None None O
poor None None O
, None None O
increased None None O
understanding None None O
of None None O
the None None O
pathogenesis None None O
of None None O
NPC None None O
would None None O
be None None O
important None None O
for None None O
discovering None None O
novel None None O
markers None None O
for None None O
patients None None O
' None None O
management None None O
. None None O

OBJECTIVES None None O
: None None O
To None None O
compare None None O
the None None O
proteomic None None O
expression None None O
profile None None O
between None None O
an None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
- None None O
associated None None O
NPC None None O
cell None None O
line None None O
( None None O
C666 None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
) None None O
and None None O
a None None O
normal None None O
NP None None O
cell None None O
line None None O
( None None O
NP69 None None I-Cell-line-name
) None None O
. None None O

The None None O
proteins None None O
with None None O
differential None None O
expression None None O
were None None O
analyzed None None O
in None None O
40 None None O
undifferentiated None None O
NPC None None O
paraffin None None O
- None None O
embedded None None O
specimens None None O
. None None O

DESIGN None None O
: None None O
Differentially None None O
expressed None None O
proteins None None O
discovered None None O
between None None O
the None None O
two None None O
cell None None O
lines None None O
were None None O
identified None None O
by None None O
mass None None O
spectrometry None None O
. None None O

After None None O
confirmation None None O
by None None O
immunocytochemical None None O
staining None None O
, None None O
their None None O
expression None None O
in None None O
patient None None O
samples None None O
was None None O
measured None None O
using None None O
40 None None O
pairs None None O
of None None O
undifferentiated None None O
NPCs None None O
together None None O
with None None O
their None None O
adjacent None None O
normal None None O
epithelia None None O
. None None O

RESULTS None None O
: None None O
Proteomic None None O
findings None None O
indicated None None O
that None None O
adenosine None None O
triphosphate None None O
synthase None None O
alpha None None O
chain None None O
was None None O
up None None O
- None None O
regulated None None O
, None None O
whereas None None O
annexin None None O
II None None O
, None None O
annexin None None O
V None None O
, None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
tubulin None None O
, None None O
and None None O
profilin None None O
1 None None O
were None None O
down None None O
- None None O
regulated None None O
. None None O

After None None O
confirming None None O
the None None O
results None None O
in None None O
agar None None O
- None None O
processed None None O
cell None None O
lines None None O
, None None O
annexin None None O
II None None O
and None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
tubulin None None O
expression None None O
were None None O
found None None O
to None None O
be None None O
lower None None O
in None None O
tumor None None O
cells None None O
than None None O
in None None O
adjacent None None O
normal None None O
epithelial None None O
cells None None O
in None None O
100 None None O
% None None O
and None None O
90 None None O
% None None O
of None None O
the None None O
patients None None O
' None None O
specimens None None O
, None None O
respectively None None O
. None None O

Finally None None O
, None None O
annexin None None O
II None None O
down None None O
- None None O
regulation None None O
was None None O
positively None None O
associated None None O
with None None O
lymph None None O
node None None O
metastasis None None O
, None None O
suggesting None None O
that None None O
it None None O
may None None O
be None None O
a None None O
prognostic None None O
factor None None O
in None None O
NPC None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
results None None O
suggest None None O
that None None O
annexin None None O
II None None O
and None None O
beta None None O
( None None O
2 None None O
) None None O
- None None O
tubulin None None O
down None None O
- None None O
regulation None None O
is None None O
important None None O
in None None O
NPC None None O
formation None None O
and None None O
may None None O
represent None None O
potential None None O
targets None None O
for None None O
further None None O
investigations None None O
. None None O

Thalidomide None None O
and None None O
angiostatin None None O
inhibit None None O
tumor None None O
growth None None O
in None None O
a None None O
murine None None O
xenograft None None O
model None None O
of None None O
human None None O
cervical None None O
cancer None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
determine None None O
the None None O
impact None None O
of None None O
thalidomide None None O
and None None O
angiostatin None None O
on None None O
tumor None None O
growth None None O
, None None O
angiogenesis None None O
, None None O
and None None O
apoptosis None None O
in None None O
a None None O
xenograft None None O
model None None O
of None None O
cervical None None O
cancer None None O
. None None O

METHODS None None O
: None None O
Human None None O
umbilical None None O
endothelial None None O
cells None None O
were None None O
treated None None O
with None None O
angiostatin None None O
or None None O
thalidomide None None O
and None None O
bFGF None None O
- None None O
induced None None O
proliferation None None O
was None None O
assessed None None O
with None None O
the None None O
MTT None None O
assay None None O
. None None O

Human None None O
cervical None None O
cancer None None O
cells None None O
( None None O
CaSki None None I-Cell-line-name
and None None O
SiHa None None I-Cell-line-name
) None None O
were None None O
injected None None O
into None None O
the None None O
flanks None None O
of None None O
nude None None O
mice None None O
. None None O

After None None O
tumors None None O
developed None None O
, None None O
mice None None O
were None None O
treated None None O
with None None O
angiostatin None None O
20 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
or None None O
thalidomide None None O
200 None None O
mg None None O
/ None None O
kg None None O
/ None None O
day None None O
for None None O
30 None None O
days None None O
. None None O

Fractional None None O
tumor None None O
growth None None O
was None None O
determined None None O
and None None O
immunohistochemical None None O
analysis None None O
of None None O
tumors None None O
was None None O
used None None O
to None None O
determine None None O
degree None None O
of None None O
angiogenesis None None O
. None None O

TUNEL None None O
assay None None O
was None None O
used None None O
to None None O
assess None None O
apoptosis None None O
. None None O

RESULTS None None O
: None None O
Angiostatin None None O
inhibited None None O
endothelial None None O
cell None None O
proliferation None None O
by None None O
50 None None O
- None None O
60 None None O
% None None O
. None None O

Thalidomide None None O
had None None O
no None None O
direct None None O
effect None None O
on None None O
endothelial None None O
cells None None O
. None None O

Angiostatin None None O
and None None O
thalidomide None None O
both None None O
inhibited None None O
tumor None None O
growth None None O
by None None O
about None None O
55 None None O
% None None O
. None None O

We None None O
found None None O
no None None O
additive None None O
or None None O
synergistic None None O
effect None None O
when None None O
the None None O
two None None O
agents None None O
were None None O
combined None None O
. None None O

Both None None O
agents None None O
inhibited None None O
angiogenesis None None O
and None None O
induced None None O
apoptosis None None O
when None None O
compared None None O
to None None O
tumors None None O
from None None O
control None None O
animals None None O
. None None O

CONCLUSIONS None None O
: None None O
Angiostatin None None O
and None None O
thalidomide None None O
inhibit None None O
tumor None None O
growth None None O
, None None O
angiogenesis None None O
, None None O
and None None O
induce None None O
apoptosis None None O
in None None O
this None None O
xenograft None None O
model None None O
of None None O
cervical None None O
cancer None None O
. None None O

[ None None O
Quantitative None None O
analysis None None O
of None None O
regional None None O
cerebral None None O
blood None None O
flow None None O
in None None O
elderly None None O
with None None O
white None None O
matter None None O
lesions None None O
] None None O
. None None O

OBJECTIVE None None O
: None None O

To None None O
observe None None O
whether None None O
the None None O
severity None None O
of None None O
white None None O
matter None None O
lesions None None O
( None None O
WML None None O
) None None O
is None None O
related None None O
to None None O
ischemia None None O
in None None O
elderly None None O
. None None O

METHODS None None O
: None None O

WML None None O
were None None O
divided None None O
into None None O
2 None None O
categories None None O
( None None O
centrum None None O
semiovale None None O
and None None O
periventricular None None O
regions None None O
) None None O
and None None O
four None None O
grades None None O
( None None O
grade None None O
0 None None O
, None None O
grade None None O
1 None None O
, None None O
grade None None O
2 None None O
and None None O
grade None None O
3 None None O
) None None O
according None None O
to None None O
the None None O
severity None None O
of None None O
WML None None O
showing None None O
on None None O
the None None O
FLAIR None None O
sequence None None O
of None None O
MRI None None O
using None None O
modified None None O
Fazekas None None O
scale None None O
. None None O

The None None O
values None None O
of None None O
regional None None O
cerebral None None O
blood None None O
flow None None O
( None None O
rCBF None None O
) None None O
within None None O
WML None None O
and None None O
other None None O
brain None None O
regions None None O
were None None O
measured None None O
using None None O
Xenon None None O
contrast None None O
CT None None O
. None None O

RESULTS None None O
: None None O

Mean None None O
rCBF None None O
( None None O
ml None None O
x None None O
100 None None O
g None None O
( None None O
- None None O
1 None None O
) None None O
x None None O
min None None O
( None None O
- None None O
1 None None O
) None None O
) None None O
within None None O
lesions None None O
around None None O
periventricular None None O
areas None None O
, None None O
in None None O
right None None O
and None None O
left None None O
centrum None None O
semiovale None None O
were None None O
20 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
8 None None O
, None None O
22 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
and None None O
22 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
1 None None O
in None None O
grade None None O
0 None None O
; None None O
20 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
5 None None O
, None None O
21 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
0 None None O
and None None O
21 None None O
. None None O
0 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
8 None None O
in None None O
grade1 None None O
; None None O
16 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
0 None None O
, None None O
15 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
7 None None O
and None None O
15 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
9 None None O
in None None O
grade None None O
2 None None O
; None None O
14 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
6 None None O
, None None O
14 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
2 None None O
. None None O
2 None None O
and None None O
14 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
in None None O
grade None None O
3 None None O
respectively None None O
. None None O

The None None O
severity None None O
of None None O
WML None None O
is None None O
associated None None O
significantly None None O
with None None O
reduction None None O
of None None O
rCBF None None O
within None None O
lesions None None O
both None None O
in None None O
centrum None None O
semiovale None None O
and None None O
periventricular None None O
regions None None O
( None None O
all None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

There None None O
was None None O
no None None O
significant None None O
difference None None O
in None None O
rCBF None None O
values None None O
between None None O
grade None None O
0 None None O
and None None O
1 None None O
, None None O
but None None O
significant None None O
differences None None O
existed None None O
between None None O
grade None None O
0 None None O
and None None O
grades None None O
2 None None O
and None None O
3 None None O
, None None O
between None None O
grade None None O
1 None None O
and None None O
grades None None O
2 None None O
and None None O
3 None None O
( None None O
all None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Statistical None None O
significance None None O
also None None O
existed None None O
between None None O
the None None O
severity None None O
of None None O
white None None O
matter None None O
lesions None None O
and None None O
rCBF None None O
in None None O
bilateral None None O
temporal None None O
lobes None None O
and None None O
lentiform None None O
nucleases None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O

The None None O
severity None None O
of None None O
WML None None O
both None None O
in None None O
centrum None None O
semiovale None None O
and None None O
periventricular None None O
regions None None O
is None None O
associated None None O
significantly None None O
with None None O
reduction None None O
of None None O
rCBF None None O
within None None O
lesions None None O
. None None O

The None None O
members None None O
of None None O
an None None O
Epstein None None O
- None None O
Barr None None O
virus None None O
microRNA None None O
cluster None None O
cooperate None None O
to None None O
transform None None O
B None None O
lymphocytes None None O
. None None O

Epstein None None O
- None None O
Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
transforms None None O
B None None O
lymphocytes None None O
through None None O
the None None O
expression None None O
of None None O
the None None O
latent None None O
viral None None O
proteins None None O
EBNA None None O
and None None O
latent None None O
membrane None None O
protein None None O
( None None O
LMP None None O
) None None O
. None None O

Recently None None O
, None None O
it None None O
has None None O
become None None O
apparent None None O
that None None O
microRNAs None None O
( None None O
miRNAs None None O
) None None O
also None None O
contribute None None O
to None None O
EBV None None O
' None None O
s None None O
oncogenic None None O
properties None None O
; None None O
recombinant None None O
EBVs None None O
that None None O
lack None None O
the None None O
BHRF1 None None O
miRNA None None O
cluster None None O
display None None O
a None None O
reduced None None O
ability None None O
to None None O
transform None None O
B None None O
lymphocytes None None O
in None None O
vitro None None O
. None None O

Furthermore None None O
, None None O
infected None None O
cells None None O
evince None None O
a None None O
marked None None O
upregulation None None O
of None None O
the None None O
EBNA None None O
genes None None O
. None None O

Using None None O
recombinant None None O
viruses None None O
that None None O
lack None None O
only None None O
one None None O
member None None O
of None None O
the None None O
cluster None None O
, None None O
we None None O
now None None O
show None None O
that None None O
all None None O
three None None O
BHRF1 None None O
miRNAs None None O
contribute None None O
to None None O
B None None O
- None None O
cell None None O
transformation None None O
. None None O

Recombinants None None O
that None None O
lacked None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
2 None None O
or None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
3 None None O
displayed None None O
enhanced None None O
EBNA None None O
expression None None O
initiated None None O
at None None O
the None None O
Cp None None O
and None None O
Wp None None O
promoters None None O
. None None O

Interestingly None None O
, None None O
we None None O
find None None O
that None None O
the None None O
deletion None None O
of None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
2 None None O
reduced None None O
the None None O
expression None None O
level None None O
of None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
3 None None O
and None None O
possibly None None O
that None None O
of None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
1 None None O
, None None O
demonstrating None None O
that None None O
the None None O
expression None None O
of None None O
one None None O
miRNA None None O
can None None O
potentiate None None O
the None None O
expression None None O
of None None O
other None None O
miRNAs None None O
located None None O
in None None O
the None None O
same None None O
cluster None None O
. None None O

Therefore None None O
, None None O
the None None O
phenotypic None None O
traits None None O
of None None O
the None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
2 None None O
null None None O
mutant None None O
could None None O
result None None O
partly None None O
from None None O
reduced None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
1 None None O
and None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
3 None None O
expression None None O
levels None None O
. None None O

Nevertheless None None O
, None None O
using None None O
an None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
1 None None O
and None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
3 None None O
double None None O
mutant None None O
, None None O
we None None O
could None None O
directly None None O
assess None None O
and None None O
confirm None None O
the None None O
contribution None None O
of None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
2 None None O
to None None O
B None None O
- None None O
cell None None O
transformation None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
the None None O
potentiating None None O
effect None None O
of None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
2 None None O
on None None O
miR None None O
- None None O
BHRF1 None None O
- None None O
3 None None O
synthesis None None O
can None None O
be None None O
reproduced None None O
with None None O
simple None None O
expression None None O
plasmids None None O
, None None O
provided None None O
that None None O
both None None O
miRNAs None None O
are None None O
processed None None O
from None None O
the None None O
same None None O
transcript None None O
. None None O

Therefore None None O
, None None O
this None None O
enhancing None None O
effect None None O
does None None O
not None None O
result None None O
from None None O
an None None O
idiosyncrasy None None O
of None None O
the None None O
EBV None None O
genome None None O
but None None O
rather None None O
reflects None None O
a None None O
general None None O
property None None O
of None None O
these None None O
miRNAs None None O
. None None O

This None None O
study None None O
highlights None None O
the None None O
advantages None None O
of None None O
arranging None None O
the None None O
BHRF1 None None O
miRNAs None None O
in None None O
clusters None None O
: None None O
it None None O
allows None None O
the None None O
synchronous None None O
and None None O
synergistic None None O
expression None None O
of None None O
genetic None None O
elements None None O
that None None O
cooperate None None O
to None None O
transform None None O
their None None O
target None None O
cells None None O
. None None O

Massive None None O
osteolysis None None O
in None None O
a None None O
dog None None O
resembling None None O
Gorham None None O
' None None O
s None None O
disease None None O
in None None O
humans None None O
. None None O

An None None O
eight None None O
- None None O
month None None O
- None None O
old None None O
mixed None None O
- None None O
breed None None O
dog None None O
was None None O
presented None None O
with None None O
a None None O
history None None O
of None None O
sudden None None O
onset None None O
pelvic None None O
limb None None O
lameness None None O
. None None O

Radiographic None None O
and None None O
computed None None O
tomographic None None O
examinations None None O
demonstrated None None O
an None None O
osteolytic None None O
process None None O
involving None None O
the None None O
lumbar None None O
spine None None O
and None None O
pelvis None None O
. None None O

A None None O
comprehensive None None O
work None None O
- None None O
up None None O
including None None O
serial None None O
radiographic None None O
skeletal None None O
survey None None O
, None None O
biopsy None None O
, None None O
routine None None O
laboratory None None O
investigation None None O
and None None O
evaluation None None O
of None None O
parathyroid None None O
hormone None None O
( None None O
PTH None None O
) None None O
and None None O
25 None None O
- None None O
hydroxy None None O
- None None O
vitamin None None O
D None None O
levels None None O
failed None None O
to None None O
reveal None None O
any None None O
underlying None None O
cause None None O
for None None O
the None None O
osteolysis None None O
. None None O

Conservative None None O
treatment None None O
using None None O
the None None O
bisphosphonate None None O
drug None None O
alendronate None None O
and None None O
oral None None O
analgesic None None O
medications None None O
resulted None None O
in None None O
a None None O
return None None O
to None None O
nearly None None O
normal None None O
long None None O
- None None O
term None None O
function None None O
, None None O
despite None None O
massive None None O
lumbar None None O
and None None O
pelvic None None O
osteolysis None None O
. None None O

The None None O
clinical None None O
, None None O
radiological None None O
and None None O
histopathological None None O
features None None O
in None None O
this None None O
dog None None O
are None None O
reported None None O
, None None O
and None None O
similarities None None O
with None None O
the None None O
human None None O
condition None None O
known None None O
as None None O
Gorham None None O
' None None O
s None None O
disease None None O
are None None O
discussed None None O
. None None O

Correlation None None O
between None None O
sperm None None O
morphology None None O
and None None O
seminal None None O
plasma None None O
NO None None O
( None None O
a None None O
) None None O
and None None O
TBARS None None O
( None None O
b None None O
) None None O
levels None None O
in None None O
both None None O
groups None None O
. None None O

Regulation None None O
of None None O
the None None O
Warburg None None O
effect None None O
in None None O
early None None O
- None None O
passage None None O
breast None None O
cancer None None O
cells None None O
. None None O

Malignancy None None O
in None None O
cancer None None O
is None None O
associated None None O
with None None O
aerobic None None O
glycolysis None None O
( None None O
Warburg None None O
effect None None O
) None None O
evidenced None None O
by None None O
increased None None O
trapping None None O
of None None O
[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
deoxyglucose None None O
( None None O
FdG None None O
) None None O
in None None O
patients None None O
imaged None None O
by None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
. None None O

[ None None O
( None None O
18 None None O
) None None O
F None None O
] None None O
deoxyglucose None None O
uptake None None O
correlates None None O
with None None O
glucose None None O
transporter None None O
( None None O
GLUT None None O
- None None O
1 None None O
) None None O
expression None None O
, None None O
which None None O
can None None O
be None None O
regulated None None O
by None None O
hypoxia None None O
- None None O
inducible None None O
factor None None O
1 None None O
alpha None None O
( None None O
HIF None None O
- None None O
1alpha None None O
) None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
in None None O
established None None O
breast None None O
lines None None O
that None None O
HIF None None O
- None None O
1alpha None None O
levels None None O
in None None O
the None None O
presence None None O
of None None O
oxygen None None O
leads None None O
to None None O
the None None O
Warburg None None O
effect None None O
. None None O

However None None O
, None None O
glycolysis None None O
and None None O
GLUT None None O
- None None O
1 None None O
can None None O
also None None O
be None None O
induced None None O
independent None None O
of None None O
HIF None None O
- None None O
1alpha None None O
by None None O
other None None O
factors None None O
, None None O
such None None O
as None None O
c None None O
- None None O
Myc None None O
and None None O
phosphorylated None None O
Akt None None O
( None None O
pAkt None None O
) None None O
. None None O

This None None O
study None None O
investigates None None O
HIF None None O
- None None O
1alpha None None O
, None None O
c None None O
- None None O
Myc None None O
, None None O
pAkt None None O
, None None O
and None None O
aerobic None None O
glycolysis None None O
in None None O
low None None O
- None None O
passage None None O
breast None None O
cancer None None O
cells None None O
under None None O
the None None O
assumption None None O
that None None O
these None None O
represent None None O
the None None O
in None None O
vivo None None O
condition None None O
better None None O
than None None O
established None None O
lines None None O
. None None O

Similar None None O
to None None O
in None None O
vivo None None O
FdG None None O
- None None O
PET None None O
or None None O
primary None None O
breast None None O
cancers None None O
, None None O
rates None None O
of None None O
glycolysis None None O
were None None O
diverse None None O
, None None O
being None None O
higher None None O
in None None O
cells None None O
expressing None None O
both None None O
c None None O
- None None O
Myc None None O
and None None O
HIF None None O
- None None O
1alpha None None O
and None None O
lower None None O
in None None O
cell None None O
lines None None O
low None None O
or None None O
negative None None O
in None None O
both None None O
transcription None None O
factors None None O
. None None O

No None None O
correlations None None O
were None None O
observed None None O
between None None O
glycolytic None None O
rates None None O
and None None O
pAkt None None O
levels None None O
. None None O

Two None None O
of None None O
12 None None O
cell None None O
lines None None O
formed None None O
xenografts None None O
in None None O
mice None None O
. None None O

Both None None O
were None None O
positive None None O
for None None O
HIF None None O
- None None O
1alpha None None O
and None None O
phosphorylated None None O
c None None O
- None None O
Myc None None O
, None None O
and None None O
only None None O
one None None O
was None None O
positive None None O
for None None O
pAkt None None O
. None None O

Glycolysis None None O
was None None O
affected None None O
by None None O
pharmacological None None O
regulation None None O
of None None O
c None None O
- None None O
Myc None None O
and None None O
HIF None None O
- None None O
1alpha None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
c None None O
- None None O
Myc None None O
and None None O
/ None None O
or None None O
HIF None None O
- None None O
1alpha None None O
activities None None O
are None None O
both None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
glycolysis None None O
in None None O
breast None None O
cancers None None O
. None None O

Secchi None None O
depth None None O
in None None O
the None None O
Baltic None None O
Proper None None O
, None None O
June None None O
- None None O
August None None O
, None None O
1957 None None O
- None None O
1998 None None O
. None None O

Number None None O
of None None O
data None None O
: None None O
3 None None O
, None None O
452 None None O
. None None O

New None None O
vectors None None O
and None None O
strategies None None O
for None None O
cardiovascular None None O
gene None None O
therapy None None O
. None None O

Cardiovascular None None O
diseases None None O
are None None O
the None None O
major None None O
cause None None O
of None None O
morbidity None None O
and None None O
mortality None None O
in None None O
both None None O
men None None O
and None None O
women None None O
in None None O
industrially None None O
developed None None O
countries None None O
. None None O

These None None O
disorders None None O
may None None O
result None None O
from None None O
impaired None None O
angiogenesis None None O
, None None O
particularly None None O
in None None O
response None None O
to None None O
hypoxia None None O
. None None O

Despite None None O
many None None O
limitations None None O
, None None O
gene None None O
therapy None None O
is None None O
still None None O
emerging None None O
as None None O
a None None O
potential None None O
alternative None None O
for None None O
patients None None O
who None None O
are None None O
not None None O
candidates None None O
for None None O
traditional None None O
revascularization None None O
procedures None None O
, None None O
like None None O
angioplasty None None O
or None None O
vein None None O
grafts None None O
. None None O

This None None O
review None None O
focuses None None O
on None None O
recent None None O
approaches None None O
in None None O
the None None O
development None None O
of None None O
new None None O
gene None None O
delivery None None O
vectors None None O
, None None O
with None None O
great None None O
respect None None O
to None None O
newly None None O
discovered None None O
AAV None None O
serotypes None None O
and None None O
their None None O
modified None None O
forms None None O
. None None O

Moreover None None O
, None None O
some None None O
new None None O
cardiovascular None None O
gene None None O
therapy None None O
strategies None None O
have None None O
been None None O
highlighted None None O
, None None O
such None None O
as None None O
combination None None O
of None None O
different None None O
angiogenic None None O
growth None None O
factors None None O
or None None O
simultaneous None None O
application None None O
of None None O
genes None None O
and None None O
progenitor None None O
cells None None O
in None None O
order None None O
to None None O
obtain None None O
stable None None O
and None None O
functional None None O
blood None None O
vessels None None O
in None None O
ischemic None None O
tissue None None O
. None None O

1 None None O
. None None O

Background None None O

The None None O
United None None O
Republic None None O
of None None O
Tanzania None None O
, None None O
is None None O
among None None O
the None None O
many None None O
countries None None O
in None None O
sub None None O
- None None O
Saharan None None O
Africa None None O
facing None None O
a None None O
human None None O
resources None None O
crisis None None O
in None None O
its None None O
health None None O
sector None None O
, None None O
with None None O
a None None O
small None None O
and None None O
inequitably None None O
distributed None None O
health None None O
workforce None None O
[ None None O
1 None None O
] None None O
that None None O
shoulders None None O
a None None O
disproportionately None None O
high None None O
burden None None O
of None None O
disease None None O
[ None None O
2 None None O
] None None O
. None None O

Although None None O
all None None O
poor None None O
countries None None O
in None None O
the None None O
world None None O
face None None O
a None None O
severe None None O
human None None O
resource None None O
crisis None None O
in None None O
their None None O
health None None O
sectors None None O
[ None None O
3 None None O
, None None O
4 None None O
] None None O
, None None O
the None None O
problem None None O
is None None O
most None None O
acute None None O
in None None O
Sub None None O
- None None O
Saharan None None O
Africa None None O
, None None O
in None None O
which None None O
an None None O
estimated None None O
workforce None None O
of None None O
750 None None O
000 None None O
health None None O
workers None None O
in None None O
the None None O
region None None O
serves None None O
682 None None O
million None None O
people None None O
[ None None O
2 None None O
] None None O
. None None O

By None None O
comparison None None O
, None None O
the None None O
ratio None None O
is None None O
10 None None O
to None None O
15 None None O
times None None O
higher None None O
in None None O
developed None None O
countries None None O
. None None O

Moreover None None O
, None None O
this None None O
estimated None None O
workforce None None O
of None None O
doctors None None O
, None None O
nurses None None O
and None None O
allied None None O
health None None O
workers None None O
in None None O
Sub None None O
- None None O
Saharan None None O
Africa None None O
constitutes None None O
1 None None O
. None None O
3 None None O
% None None O
of None None O
the None None O
world None None O
' None None O
s None None O
health None None O
workforce None None O
, None None O
while None None O
Africa None None O
suffers None None O
from None None O
25 None None O
% None None O
of None None O
the None None O
world None None O
' None None O
s None None O
burden None None O
of None None O
disease None None O
[ None None O
2 None None O
] None None O
. None None O

A None None O
minimum None None O
level None None O
of None None O
a None None O
health None None O
workforce None None O
of None None O
2 None None O
. None None O
5 None None O
health None None O
workers None None O
per None None O
1000 None None O
people None None O
is None None O
required None None O
to None None O
achieve None None O
the None None O
Millennium None None O
Development None None O
Goals None None O
[ None None O
5 None None O
] None None O
. None None O

Africa None None O
is None None O
far None None O
from None None O
this None None O
level None None O
with None None O
a None None O
health None None O
workforce None None O
density None None O
that None None O
only None None O
averages None None O
0 None None O
. None None O
8 None None O
worker None None O
per None None O
1000 None None O
people None None O
, None None O
while None None O
the None None O
world None None O
median None None O
density None None O
of None None O
health None None O
personnel None None O
is None None O
5 None None O
per None None O
1000 None None O
people None None O
[ None None O
5 None None O
] None None O
. None None O

There None None O
is None None O
a None None O
positive None None O
correlation None None O
between None None O
health None None O
worker None None O
density None None O
and None None O
various None None O
health None None O
indices None None O
, None None O
most None None O
notably None None O
infant None None O
mortality None None O
rate None None O
, None None O
maternal None None O
mortality None None O
rates None None O
, None None O
and None None O
various None None O
disease None None O
specific None None O
mortality None None O
and None None O
morbidity None None O
rates None None O
[ None None O
6 None None O
, None None O
7 None None O
] None None O
. None None O

An None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
health None None O
workers None None O
per None None O
capita None None O
is None None O
associated None None O
with None None O
a None None O
notable None None O
decline None None O
in None None O
the None None O
rates None None O
mentioned None None O
above None None O
. None None O

As None None O
a None None O
consequence None None O
, None None O
it None None O
has None None O
been None None O
argued None None O
that None None O
health None None O
worker None None O
shortages None None O
have None None O
impeded None None O
the None None O
implementation None None O
of None None O
development None None O
goals None None O
in None None O
many None None O
poor None None O
countries None None O
[ None None O
8 None None O
] None None O
. None None O

Homeobox None None O
genes None None O
in None None O
hematopoiesis None None O
and None None O
leukemogenesis None None O
. None None O

Homeobox None None O
genes None None O
have None None O
a None None O
strikingly None None O
conserved None None O
61 None None O
- None None O
amino None None O
acid None None O
sequence None None O
, None None O
encoding None None O
DNA None None O
- None None O
binding None None O
domain None None O
. None None O

Some None None O
homeobox None None O
genes None None O
, None None O
located None None O
in None None O
four None None O
clusters None None O
are None None O
designated None None O
HOX None None O
A None None O
through None None O
D None None O
, None None O
while None None O
others None None O
are None None O
known None None O
as None None O
divergent None None O
homeobox None None O
genes None None O
. None None O

Many None None O
researchers None None O
have None None O
demonstrated None None O
that None None O
hematopoietic None None O
cells None None O
express None None O
many None None O
homeobox None None O
genes None None O
. None None O

Induced None None O
over None None O
- None None O
and None None O
under None None O
- None None O
expression None None O
of None None O
these None None O
genes None None O
has None None O
been None None O
used None None O
to None None O
demonstrate None None O
their None None O
affect None None O
on None None O
some None None O
aspects None None O
of None None O
hematopoiesis None None O
and None None O
leukemogenesis None None O
. None None O

Recently None None O
, None None O
knock None None O
- None None O
out None None O
mice None None O
of None None O
homeobox None None O
genes None None O
by None None O
targeted None None O
disruption None None O
have None None O
also None None O
been None None O
used None None O
to None None O
examine None None O
their None None O
hematological None None O
effect None None O
. None None O

There None None O
are None None O
examples None None O
of None None O
the None None O
aberrant None None O
expression None None O
of None None O
a None None O
homeobox None None O
gene None None O
causing None None O
leukemias None None O
in None None O
humans None None O
. None None O

In None None O
pre None None O
- None None O
B None None O
acute None None O
lymphoblastic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
with None None O
t None None O
( None None O
1 None None O
; None None O
19 None None O
) None None O
translocation None None O
, None None O
a None None O
fusion None None O
protein None None O
is None None O
created None None O
between None None O
E2A None None O
and None None O
a None None O
homeobox None None O
gene None None O
PBX None None O
. None None O

In None None O
T None None O
- None None O
cell None None O
ALL None None O
with None None O
t None None O
( None None O
10 None None O
; None None O
14 None None O
) None None O
translocation None None O
, None None O
the None None O
HOX None None O
11 None None O
gene None None O
is None None O
deregulated None None O
. None None O

In None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
with None None O
t None None O
( None None O
7 None None O
; None None O
11 None None O
) None None O
translocation None None O
, None None O
the None None O
HOX None None O
A9 None None O
gene None None O
is None None O
rearranged None None O
. None None O

In None None O
this None None O
review None None O
article None None O
, None None O
many None None O
functions None None O
of None None O
homeobox None None O
genes None None O
both None None O
at None None O
the None None O
early None None O
stem None None O
cell None None O
level None None O
as None None O
well None None O
as None None O
at None None O
the None None O
later None None O
stages None None O
of None None O
hematopoietic None None O
differentiation None None O
, None None O
and None None O
the None None O
leukemogenic None None O
effect None None O
of None None O
altered None None O
homeobox None None O
genes None None O
are None None O
discussed None None O
. None None O

Discussion None None O

Because None None O
Netherton None None O
syndrome None None O
exhibits None None O
allergic None None O
phenotype None None O
, None None O
it None None O
is None None O
reasonable None None O
to None None O
speculate None None O
that None None O
SPINK5 None None O
, None None O
which None None O
is None None O
mutated None None O
in None None O
Netherton None None O
syndrome None None O
, None None O
may None None O
act None None O
as None None O
a None None O
candidate None None O
gene None None O
for None None O
asthma None None O
and None None O
other None None O
allergic None None O
diseases None None O
[ None None O
9 None None O
] None None O
. None None O

An None None O
extensive None None O
search None None O
for None None O
single None None O
nucleotide None None O
polymorphisms None None O
in None None O
the None None O
SPINK5 None None O
led None None O
to None None O
the None None O
identification None None O
of None None O
a None None O
number None None O
of None None O
SNPs None None O
, None None O
including None None O
six None None O
nonsynonymous None None O
SNPs None None O
in None None O
coding None None O
region None None O
that None None O
might None None O
perturb None None O
its None None O
immune None None O
function None None O
. None None O

Subsequent None None O
genotyping None None O
of None None O
three None None O
nonsynonymous None None O
SNPs None None O
, None None O
A1103G None None O
, None None O
G1156A None None O
and None None O
G1258A None None O
in None None O
two None None O
independent None None O
panels None None O
of None None O
British None None O
families None None O
showed None None O
a None None O
significant None None O
association None None O
between None None O
SNP None None O
G1258A None None O
( None None O
Glu420Lys None None O
) None None O
and None None O
atopy None None O
, None None O
atopic None None O
dermatitis None None O
, None None O
elevated None None O
serum None None O
IgE None None O
levels None None O
and None None O
asthma None None O
[ None None O
10 None None O
] None None O
. None None O

This None None O
association None None O
was None None O
confirmed None None O
in None None O
a None None O
large None None O
German None None O
population None None O
and None None O
two None None O
Japanese None None O
populations None None O
[ None None O
16 None None O
- None None O
18 None None O
] None None O
. None None O

Kato None None O
et None None O
al None None O
analyzed None None O
eight None None O
SNPs None None O
in None None O
exon None None O
13 None None O
and None None O
14 None None O
of None None O
the None None O
SPINK5 None None O
including None None O
G1258A None None O
( None None O
Glu420Lys None None O
) None None O
, None None O
and None None O
found None None O
a None None O
positive None None O
association None None O
of None None O
seven None None O
SNPs None None O
with None None O
atopic None None O
dermatitis None None O
in None None O
a None None O
Japanese None None O
study None None O
sample None None O
using None None O
a None None O
case None None O
- None None O
control None None O
study None None O
design None None O
[ None None O
16 None None O
] None None O
. None None O

Nishio None None O
et None None O
al None None O
surveyed None None O
five None None O
of None None O
six None None O
previously None None O
reported None None O
nonsynonymous None None O
SPINK5 None None O
SNPs None None O
in None None O
Japanese None None O
atopic None None O
families None None O
identified None None O
through None None O
asthmatic None None O
children None None O
or None None O
subjects None None O
with None None O
atopic None None O
dermatitis None None O
and None None O
found None None O
that None None O
SPINK5 None None O
was None None O
associated None None O
with None None O
development None None O
of None None O
atopic None None O
dermatitis None None O
but None None O
not None None O
asthma None None O
[ None None O
17 None None O
] None None O
. None None O

Kabesch None None O
M None None O
et None None O
al None None O
. None None O
analyzed None None O
G1258A None None O
( None None O
Glu420Lys None None O
) None None O
in None None O
a None None O
German None None O
population None None O
of None None O
school None None O
children None None O
, None None O
and None None O
found None None O
its None None O
association None None O
with None None O
asthma None None O
as None None O
well None None O
as None None O
a None None O
concomitant None None O
occurrence None None O
of None None O
asthma None None O
and None None O
atopic None None O
dermatitis None None O
[ None None O
18 None None O
] None None O
. None None O

However None None O
, None None O
two None None O
subsequent None None O
studies None None O
failed None None O
to None None O
replicate None None O
the None None O
original None None O
SPINK5 None None O
findings None None O
for None None O
allergic None None O
diseases None None O
[ None None O
19 None None O
, None None O
20 None None O
] None None O
. None None O

Folster None None O
- None None O
Holst None None O
et None None O
al None None O
genotyped None None O
four None None O
nonsynonymous None None O
SNPs None None O
( None None O
Asp106Asn None None O
, None None O
Asn368Ser None None O
, None None O
Asp386Asn None None O
, None None O
and None None O
Glu420Lys None None O
) None None O
, None None O
and None None O
detected None None O
no None None O
association None None O
between None None O
SPINK5 None None O
and None None O
atopic None None O
dermatitis None None O
in None None O
populations None None O
of None None O
Northern None None O
German None None O
origin None None O
[ None None O
20 None None O
] None None O
. None None O

Jongepier None None O
H None None O
et None None O
al None None O
. None None O
failed None None O
to None None O
detect None None O
any None None O
association None None O
between None None O
SPINK5 None None O
and None None O
asthma None None O
, None None O
atopic None None O
phenotypes None None O
and None None O
atopic None None O
dermatitis None None O
in None None O
a None None O
Dutch None None O
population None None O
[ None None O
19 None None O
] None None O
. None None O

These None None O
discordant None None O
findings None None O
probably None None O
reflect None None O
different None None O
genetic None None O
and None None O
environmental None None O
backgrounds None None O
in None None O
various None None O
populations None None O
. None None O

To None None O
determine None None O
whether None None O
nonsynonymous None None O
SNPs None None O
of None None O
the None None O
SPINK5 None None O
are None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
asthma None None O
in None None O
the None None O
Chinese None None O
Han None None O
population None None O
, None None O
we None None O
performed None None O
a None None O
case None None O
- None None O
control None None O
study None None O
by None None O
genotyping None None O
four None None O
nonsynonymous None None O
SNPs None None O
in None None O
the None None O
SPINK5 None None O
. None None O

We None None O
did None None O
not None None O
detect None None O
any None None O
significant None None O
association None None O
between None None O
these None None O
nonsynonymous None None O
SNPs None None O
and None None O
asthma None None O
in None None O
our None None O
Chinese None None O
samples None None O
. None None O

With None None O
our None None O
sample None None O
size None None O
, None None O
we None None O
expected None None O
a None None O
power None None O
of None None O
at None None O
least None None O
80 None None O
% None None O
in None None O
detecting None None O
an None None O
effect None None O
of None None O
OR None None O
> None None O
= None None O
1 None None O
. None None O
3 None None O
for None None O
each None None O
of None None O
these None None O
SNPs None None O
. None None O

Therefore None None O
, None None O
our None None O
failure None None O
to None None O
detect None None O
an None None O
association None None O
for None None O
these None None O
4 None None O
SNPs None None O
was None None O
not None None O
due None None O
to None None O
the None None O
sample None None O
size None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
polymorphisms None None O
in None None O
the None None O
coding None None O
region None None O
of None None O
the None None O
SPINK5 None None O
are None None O
unlikely None None O
to None None O
contribute None None O
to None None O
asthma None None O
risk None None O
in None None O
the None None O
Chinese None None O
Han None None O
population None None O
. None None O

However None None O
, None None O
because None None O
our None None O
patients None None O
were None None O
ascertained None None O
for None None O
asthma None None O
, None None O
we None None O
could None None O
not None None O
exclude None None O
a None None O
role None None O
of None None O
the None None O
coding None None O
SNPs None None O
of None None O
the None None O
SPINK5 None None O
in None None O
atopic None None O
dermatitis None None O
in None None O
our None None O
population None None O
. None None O

The None None O
variations None None O
in None None O
the None None O
regulatory None None O
sequences None None O
of None None O
genes None None O
may None None O
determine None None O
risks None None O
to None None O
common None None O
diseases None None O
by None None O
causing None None O
different None None O
levels None None O
of None None O
expression None None O
. None None O

Therefore None None O
, None None O
the None None O
identification None None O
and None None O
functional None None O
evaluation None None O
of None None O
polymorphisms None None O
in None None O
promoter None None O
region None None O
are None None O
of None None O
great None None O
value None None O
in None None O
understanding None None O
the None None O
genetic None None O
susceptibility None None O
to None None O
asthma None None O
. None None O

In None None O
order None None O
to None None O
determine None None O
the None None O
role None None O
of None None O
the None None O
SPINK5 None None O
promoter None None O
polymorphism None None O
in None None O
the None None O
pathogenesis None None O
of None None O
asthma None None O
, None None O
we None None O
genotyped None None O
a None None O
promoter None None O
polymorphism None None O
, None None O
- None None O
206G None None O
> None None O
A None None O
, None None O
in None None O
422 None None O
asthma None None O
patients None None O
and None None O
410 None None O
controls None None O
, None None O
and None None O
found None None O
a None None O
marginal None None O
association None None O
. None None O

The None None O
frequency None None O
of None None O
allele None None O
G None None O
was None None O
significantly None None O
higher None None O
in None None O
asthmatic None None O
patients None None O
than None None O
that None None O
in None None O
controls None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
022 None None O
) None None O
. None None O

To None None O
confirm None None O
the None None O
association None None O
, None None O
additional None None O
267 None None O
asthma None None O
patients None None O
and None None O
301 None None O
controls None None O
newly None None O
recruited None None O
from None None O
the None None O
same None None O
hospital None None O
were None None O
genotyped None None O
, None None O
and None None O
the None None O
- None None O
206G None None O
> None None O
A None None O
polymorphism None None O
remained None None O
significantly None None O
associated None None O
with None None O
asthma None None O
( None None O
P None None O
= None None O
0 None None O
. None None O
001 None None O
) None None O
, None None O
even None None O
after None None O
Bonferroni None None O
correction None None O
( None None O
adjusted None None O
P None None O
= None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

To None None O
our None None O
knowledge None None O
, None None O
this None None O
is None None O
the None None O
first None None O
report None None O
of None None O
an None None O
association None None O
of None None O
- None None O
206G None None O
> None None O
A None None O
polymorphism None None O
with None None O
asthma None None O
. None None O

We None None O
further None None O
examined None None O
the None None O
potential None None O
functional None None O
role None None O
of None None O
this None None O
promoter None None O
polymorphism None None O
, None None O
and None None O
found None None O
that None None O
the None None O
G None None O
to None None O
A None None O
substitution None None O
at None None O
- None None O
206 None None O
generated None None O
a None None O
GATA None None O
- None None O
3 None None O
transcription None None O
factor None None O
binding None None O
site None None O
. None None O

Major None None O
transcription None None O
factors None None O
controlling None None O
Th1 None None O
and None None O
Th2 None None O
development None None O
, None None O
such None None O
as None None O
T None None O
- None None O
box None None O
transcription None None O
factor None None O
and None None O
GATA3 None None O
, None None O
are None None O
possibly None None O
involved None None O
in None None O
asthma None None O
and None None O
atopic None None O
diseases None None O
. None None O

GATA None None O
- None None O
3 None None O
, None None O
a None None O
transcription None None O
factor None None O
specifically None None O
expressed None None O
in None None O
T None None O
helper None None O
2 None None O
( None None O
Th2 None None O
) None None O
cells None None O
, None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
differentiation None None O
of None None O
Th2 None None O
cells None None O
from None None O
uncommitted None None O
CD4 None None O
+ None None O
lymphocytes None None O
. None None O

In None None O
addition None None O
, None None O
GATA None None O
- None None O
3 None None O
is None None O
essential None None O
for None None O
the None None O
expression None None O
of None None O
the None None O
cytokines None None O
IL None None O
- None None O
4 None None O
, None None O
IL None None O
- None None O
5 None None O
and None None O
IL None None O
- None None O
13 None None O
that None None O
mediate None None O
allergic None None O
inflammation None None O
[ None None O
23 None None O
] None None O
. None None O

Our None None O
luciferase None None O
reporter None None O
assay None None O
confirmed None None O
that None None O
SNP None None O
- None None O
206G None None O
> None None O
A None None O
is None None O
associated None None O
with None None O
the None None O
transcriptional None None O
activity None None O
of None None O
SPINK5 None None O
. None None O

The None None O
G None None O
allele None None O
was None None O
associated None None O
with None None O
decreased None None O
transcriptional None None O
activity None None O
of None None O
the None None O
SPINK5 None None O
. None None O

The None None O
mechanism None None O
by None None O
which None None O
the None None O
- None None O
206G None None O
> None None O
A None None O
SNP None None O
affects None None O
SPINK5 None None O
expression None None O
may None None O
be None None O
explained None None O
by None None O
the None None O
potential None None O
differential None None O
transcription None None O
factor None None O
binding None None O
of None None O
GATA None None O
binding None None O
factor None None O
, None None O
since None None O
- None None O
206G None None O
> None None O
A None None O
is None None O
located None None O
at None None O
the None None O
core None None O
sequence None None O
of None None O
GATA None None O
binding None None O
factor None None O
binding None None O
site None None O
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assay None None O
confirmed None None O
that None None O
the None None O
A None None O
to None None O
G None None O
substitution None None O
at None None O
- None None O
206 None None O
significantly None None O
reduced None None O
the None None O
binding None None O
efficiency None None O
of None None O
nuclear None None O
proteins None None O
to None None O
this None None O
element None None O
. None None O

Our None None O
data None None O
suggest None None O
that None None O
loss None None O
of None None O
GATA None None O
transcription None None O
factor None None O
regulation None None O
with None None O
the None None O
- None None O
206G None None O
may None None O
decrease None None O
the None None O
SPINK5 None None O
expression None None O
and None None O
thereby None None O
potentially None None O
perturb None None O
the None None O
immunosuppressive None None O
function None None O
of None None O
LEKTI None None O
. None None O

Clozapine None None O
- None None O
induced None None O
agranulocytosis None None O
and None None O
thrombopenia None None O
in None None O
a None None O
patient None None O
with None None O
dopaminergic None None O
psychosis None None O
. None None O

In None None O
patients None None O
with None None O
Parkinson None None O
' None None O
disease None None O
and None None O
dopaminergic None None O
psychosis None None O
, None None O
clozapine None None O
treatment None None O
is None None O
recommended None None O
as None None O
the None None O
drug None None O
is None None O
free None None O
from None None O
extrapyramidal None None O
side None None O
effects None None O
and None None O
does None None O
not None None O
worsen None None O
motor None None O
symptoms None None O
of None None O
the None None O
underlying None None O
disease None None O
. None None O

The None None O
use None None O
of None None O
clozapine None None O
, None None O
however None None O
, None None O
is None None O
limited None None O
due None None O
to None None O
its None None O
hematotoxic None None O
side None None O
effects None None O
. None None O

For None None O
treatment None None O
of None None O
clozapine None None O
- None None O
induced None None O
agranulocytosis None None O
, None None O
granulocyte None None O
colony None None O
- None None O
stimulating None None O
factors None None O
( None None O
G None None O
- None None O
CSF None None O
) None None O
are None None O
recommended None None O
. None None O

We None None O
report None None O
the None None O
case None None O
of None None O
a None None O
72 None None O
- None None O
years None None O
- None None O
old None None O
male None None O
patient None None O
with None None O
clozapine None None O
- None None O
induced None None O
agranulocytosis None None O
and None None O
thrombopenia None None O
. None None O

Neutropenia None None O
was None None O
successfully None None O
treated None None O
with None None O
G None None O
- None None O
CSF None None O
, None None O
but None None O
thrombopenia None None O
persisted None None O
and None None O
resolved None None O
spontaneously None None O
after None None O
14 None None O
days None None O
. None None O

Bone None None O
marrow None None O
toxicity None None O
of None None O
clozapine None None O
is None None O
not None None O
restricted None None O
to None None O
white None None O
cell None None O
maturation None None O
, None None O
but None None O
may None None O
also None None O
impair None None O
thrombocytopoesis None None O
. None None O

Gastric None None O
microcirculatory None None O
change None None O
and None None O
development None None O
of None None O
acute None None O
gastric None None O
mucosal None None O
lesions None None O
( None None O
stress None None O
ulcer None None O
) None None O
. None None O

Concerning None None O
the None None O
pathogenesis None None O
of None None O
acute None None O
gastric None None O
mucosal None None O
lesions None None O
, None None O
gastric None None O
microcirculatory None None O
change None None O
has None None O
drawn None None O
attention None None O
as None None O
an None None O
important None None O
factor None None O
. None None O

In None None O
view None None O
of None None O
this None None O
fact None None O
, None None O
gastric None None O
mucosal None None O
blood None None O
flow None None O
and None None O
microvascular None None O
structure None None O
were None None O
investigated None None O
in None None O
normal None None O
and None None O
in None None O
burn None None O
stressed None None O
rats None None O
. None None O

Moreover None None O
, None None O
alterations None None O
in None None O
acid None None O
and None None O
pepsin None None O
activities None None O
in None None O
by None None O
morphological None None O
and None None O
biochemical None None O
procedures None None O
in None None O
order None None O
to None None O
evaluate None None O
the None None O
relationship None None O
between None None O
defensive None None O
and None None O
aggressive None None O
factors None None O
of None None O
the None None O
gastric None None O
mucosa None None O
. None None O

Gastric None None O
mucosal None None O
blood None None O
flow None None O
decreased None None O
significantly None None O
in None None O
early None None O
period None None O
after None None O
induction None None O
of None None O
stress None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

The None None O
incidence None None O
of None None O
ulceration None None O
showed None None O
a None None O
correlative None None O
relation None None O
with None None O
the None None O
decrease None None O
of None None O
mucosal None None O
blood None None O
flow None None O
. None None O

Reduction None None O
of None None O
blood None None O
flow None None O
in None None O
burn None None O
was None None O
due None None O
to None None O
opening None None O
of None None O
arteriovenular None None O
shunt None None O
and None None O
it None None O
appeared None None O
that None None O
this None None O
was None None O
responsible None None O
for None None O
mucosal None None O
ischemia None None O
and None None O
congestion None None O
. None None O

Following None None O
the None None O
decrease None None O
of None None O
blood None None O
flow None None O
, None None O
acid None None O
output None None O
was None None O
lower None None O
in None None O
stress None None O
than None None O
that None None O
in None None O
control None None O
. None None O

Finally None None O
, None None O
the None None O
results None None O
of None None O
these None None O
studies None None O
demonstrated None None O
the None None O
importance None None O
of None None O
defensive None None O
factors None None O
. None None O

The None None O
reduction None None O
of None None O
mucosal None None O
blood None None O
flow None None O
resulted None None O
in None None O
the None None O
sequence None None O
of None None O
events None None O
that None None O
led None None O
to None None O
formation None None O
of None None O
acute None None O
gastric None None O
mucosal None None O
lesion None None O
. None None O

The None None O
molecular None None O
structure None None O
of None None O
( None None O
I None None O
) None None O
, None None O
showing None None O
displacement None None O
ellipsoids None None O
at None None O
the None None O
30 None None O
% None None O
probability None None O
level None None O
for None None O
non None None O
- None None O
H None None O
atoms None None O
. None None O

Systematic None None O
proteomic None None O
analysis None None O
of None None O
human None None O
hepotacellular None None O
carcinoma None None O
cells None None O
reveals None None O
molecular None None O
pathways None None O
and None None O
networks None None O
involved None None O
in None None O
metastasis None None O
. None None O

Systematic None None O
proteomic None None O
studying None None O
of None None O
the None None O
mechanism None None O
of None None O
hepatocellular None None O
carcinoma None None O
( None None O
HCC None None O
) None None O
metastasis None None O
remains None None O
challenging None None O
. None None O

We None None O
performed None None O
comparative None None O
proteomic None None O
and None None O
pathway None None O
analysis None None O
of None None O
four None None O
human None None O
metastatic None None O
HCC None None O
cell None None O
lines None None O
to None None O
identify None None O
metastasis None None O
- None None O
associated None None O
proteins None None O
. None None O

These None None O
HCC None None O
cell None None O
lines None None O
had None None O
a None None O
similar None None O
genetic None None O
background None None O
but None None O
with None None O
an None None O
increasing None None O
potential None None O
of None None O
metastasis None None O
. None None O

Using None None O
a None None O
combination None None O
of None None O
two None None O
dimensional None None O
electrophoresis None None O
( None None O
2 None None O
- None None O
DE None None O
) None None O
and None None O
MALDI None None O
- None None O
TOF None None O
mass None None O
spectrometry None None O
, None None O
a None None O
total None None O
of None None O
125 None None O
proteins None None O
and None None O
their None None O
post None None O
- None None O
translational None None O
modification None None O
forms None None O
or None None O
isoforms None None O
were None None O
found None None O
to None None O
be None None O
differentially None None O
expressed None None O
in None None O
the None None O
cell None None O
lines None None O
. None None O

Among None None O
them None None O
, None None O
29 None None O
were None None O
gradually None None O
up None None O
- None None O
regulated None None O
whereas None None O
17 None None O
were None None O
down None None O
- None None O
regulated None None O
with None None O
increasing None None O
metastatic None None O
potential None None O
. None None O

Instead None None O
of None None O
a None None O
traditional None None O
single None None O
- None None O
gene None None O
readout None None O
, None None O
global None None O
bioinformatics None None O
analysis None None O
was None None O
carried None None O
out None None O
, None None O
which None None O
revealed None None O
that None None O
the None None O
glycolysis None None O
pathway None None O
was None None O
the None None O
most None None O
significantly None None O
enriched None None O
pathway None None O
. None None O

The None None O
heat None None O
shock None None O
proteins None None O
( None None O
HSPs None None O
) None None O
centered None None O
and None None O
NF None None O
- None None O
kappaB None None O
centered None None O
networks None None O
were None None O
also None None O
enriched None None O
in None None O
the None None O
result None None O
, None None O
which None None O
may None None O
imply None None O
the None None O
key None None O
function None None O
of None None O
inflaming None None O
on None None O
metastasis None None O
. None None O

Meanwhile None None O
, None None O
knockdown None None O
of None None O
HDGF None None O
, None None O
an None None O
up None None O
- None None O
regulated None None O
protein None None O
and None None O
a None None O
target None None O
of None None O
NF None None O
- None None O
kappaB None None O
, None None O
induced None None O
cell None None O
apoptosis None None O
in None None O
the None None O
metastatic None None O
HCC None None O
cells None None O
. None None O

This None None O
work None None O
provides None None O
a None None O
demonstration None None O
that None None O
a None None O
combination None None O
of None None O
bioinformatics None None O
and None None O
comparative None None O
proteomics None None O
can None None O
help None None O
in None None O
finding None None O
out None None O
potential None None O
biomarkers None None O
associated None None O
with None None O
HCC None None O
metastasis None None O
on None None O
the None None O
level None None O
of None None O
pathways None None O
. None None O

Adenovirus None None O
5 None None O
E1A None None O
enhances None None O
histone None None O
deacetylase None None O
inhibitors None None O
- None None O
induced None None O
apoptosis None None O
through None None O
Egr None None O
- None None O
1 None None O
- None None O
mediated None None O
Bim None None O
upregulation None None O
. None None O

Histone None None O
deacetylase None None O
inhibitors None None O
( None None O
HDACi None None O
) None None O
are None None O
potent None None O
anti None None O
- None None O
cancer None None O
agents None None O
for None None O
variety None None O
of None None O
cancer None None O
types None None O
. None None O

Suberoylanilide None None O
hydroxamic None None O
acid None None O
( None None O
SAHA None None O
) None None O
has None None O
been None None O
approved None None O
as None None O
a None None O
drug None None O
to None None O
treat None None O
cutaneous None None O
T None None O
cell None None O
lymphoma None None O
, None None O
and None None O
the None None O
combination None None O
of None None O
HDACi None None O
and None None O
other None None O
agents None None O
have None None O
been None None O
actively None None O
tested None None O
in None None O
many None None O
clinical None None O
trials None None O
. None None O

Adenovirus None None O
5 None None O
early None None O
region None None O
1A None None O
( None None O
E1A None None O
) None None O
has None None O
been None None O
shown None None O
to None None O
exhibit None None O
high None None O
tumor None None O
suppressor None None O
activity None None O
, None None O
and None None O
gene None None O
therapy None None O
using None None O
E1A None None O
has None None O
been None None O
tested None None O
in None None O
clinical None None O
trials None None O
. None None O

Here None None O
, None None O
we None None O
showed None None O
that None None O
proapoptotic None None O
activity None None O
of None None O
HDACi None None O
was None None O
robustly None None O
enhanced None None O
by None None O
E1A None None O
in None None O
multiple None None O
cancer None None O
cells None None O
, None None O
but None None O
not None None O
in None None O
normal None None O
cells None None O
. None None O

Moreover None None O
, None None O
we None None O
showed None None O
that None None O
combination None None O
of None None O
E1A None None O
gene None None O
therapy None None O
and None None O
SAHA None None O
showed None None O
high None None O
therapeutic None None O
efficacy None None O
with None None O
low None None O
toxicity None None O
in None None O
vivo None None O
ovarian None None O
and None None O
breast None None O
xenograft None None O
models None None O
. None None O

SAHA None None O
downregulated None None O
Bcl None None O
- None None O
XL None None O
and None None O
upregulated None None O
proapoptotic None None O
BH3 None None O
- None None O
only None None O
protein None None O
Bim None None O
, None None O
whose None None O
expression None None O
was None None O
further None None O
enhanced None None O
by None None O
E1A None None O
in None None O
cancer None None O
cells None None O
. None None O

These None None O
alterations None None O
of None None O
Bcl None None O
- None None O
2 None None O
family None None O
proteins None None O
were None None O
critical None None O
for None None O
apoptosis None None O
induced None None O
by None None O
the None None O
combination None None O
in None None O
cancer None None O
cells None None O
. None None O

SAHA None None O
enhanced None None O
acetylation None None O
of None None O
histone None None O
H3 None None O
in None None O
Bim None None O
promoter None None O
region None None O
, None None O
while None None O
E1A None None O
upregulated None None O
Egr None None O
- None None O
1 None None O
, None None O
which None None O
was None None O
directly None None O
involved None None O
in None None O
Bim None None O
transactivation None None O
. None None O

Together None None O
, None None O
our None None O
results None None O
provide None None O
not None None O
only None None O
a None None O
novel None None O
insight None None O
into None None O
the None None O
mechanisms None None O
underlying None None O
anti None None O
- None None O
tumor None None O
activity None None O
of None None O
E1A None None O
, None None O
but None None O
also None None O
a None None O
rationale None None O
for None None O
the None None O
combined None None O
HDACi None None O
and None None O
E1A None None O
gene None None O
therapy None None O
in None None O
future None None O
clinical None None O
trials None None O
. None None O

Whole None None O
- None None O
Body None None O
gamma None None O
- None None O
Irradiation None None O

To None None O
evaluate None None O
differential None None O
sensitivity None None O
to None None O
irradiation None None O
, None None O
mice None None O
were None None O
exposed None None O
to None None O
gamma None None O
- None None O
irradiation None None O
( None None O
4 None None O
- None None O
10 None None O
Gy None None O
, None None O
single None None O
dose None None O
) None None O
and None None O
closely None None O
monitored None None O
throughout None None O
the None None O
experimentation None None O
period None None O
. None None O

Animals None None O
were None None O
killed None None O
at None None O
the None None O
first None None O
appearance None None O
of None None O
signs None None O
of None None O
poor None None O
health None None O
. None None O

Recipients None None O
of None None O
bone None None O
marrow None None O
transplants None None O
were None None O
pre None None O
- None None O
irradiated None None O
with None None O
a None None O
total None None O
dose None None O
of None None O
10 None None O
. None None O
2 None None O
Gy None None O
( None None O
two None None O
doses None None O
of None None O
5 None None O
. None None O
1 None None O
Gy None None O
, None None O
3 None None O
h None None O
apart None None O
) None None O
. None None O

For None None O
in None None O
vivo None None O
DNA None None O
damage None None O
experiments None None O
, None None O
mice None None O
were None None O
irradiated None None O
with None None O
a None None O
single None None O
dose None None O
of None None O
5Gy None None O
and None None O
killed None None O
after None None O
1 None None O
, None None O
3 None None O
or None None O
6 None None O
hours None None O
. None None O

All None None O
irradiations None None O
were None None O
carried None None O
out None None O
in None None O
a None None O
Cesium None None O
Mark1 None None O
irradiator None None O
( None None O
Shepherd None None O
Associates None None O
) None None O
. None None O

Tumor None None O
angiogenesis None None O
modulates None None O
leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
in None None O
vivo None None O
by None None O
reducing None None O
endothelial None None O
adhesion None None O
molecule None None O
expression None None O
. None None O

The None None O
expression None None O
of None None O
endothelial None None O
cell None None O
( None None O
EC None None O
) None None O
adhesion None None O
molecules None None O
involved None None O
in None None O
leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
is None None O
suppressed None None O
in None None O
malignancies None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
in None None O
vivo None None O
the None None O
regulation None None O
of None None O
leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
by None None O
the None None O
presence None None O
of None None O
a None None O
tumor None None O
. None None O

By None None O
means None None O
of None None O
intravital None None O
microscopy None None O
, None None O
tumor None None O
necrosis None None O
factor None None O
alpha None None O
- None None O
stimulated None None O
leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
were None None O
studied None None O
in None None O
ear None None O
skin None None O
microvessels None None O
of None None O
nude None None O
mice None None O
bearing None None O
small None None O
human None None O
LS174T None None I-Cell-line-name
colon None None O
carcinomas None None O
and None None O
in None None O
C57Bl None None O
/ None None O
6 None None O
mice None None O
bearing None None O
murine None None O
B16F10 None None I-Cell-line-name
melanomas None None O
. None None O

Leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
were None None O
studied None None O
both None None O
within None None O
and None None O
outside None None O
small None None O
tumors None None O
growing None None O
in None None O
the None None O
ear None None O
, None None O
and None None O
in None None O
ear None None O
microvessels None None O
of None None O
mice None None O
with None None O
a None None O
large None None O
tumor None None O
growing None None O
on None None O
their None None O
flank None None O
. None None O

Tumor None None O
- None None O
free None None O
mice None None O
were None None O
used None None O
as None None O
controls None None O
. None None O

Compared None None O
with None None O
values None None O
measured None None O
at None None O
the None None O
edge None None O
of None None O
the None None O
ear None None O
and None None O
in None None O
the None None O
contralateral None None O
ear None None O
, None None O
leukocyte None None O
adhesion None None O
was None None O
found None None O
to None None O
be None None O
diminished None None O
significantly None None O
in None None O
vessels None None O
inside None None O
the None None O
ear None None O
tumor None None O
in None None O
both None None O
mouse None None O
models None None O
. None None O

This None None O
reduction None None O
disappeared None None O
with None None O
increasing None None O
distance None None O
from None None O
the None None O
tumor None None O
. None None O

Surprisingly None None O
, None None O
the None None O
level None None O
of None None O
leukocyte None None O
adhesion None None O
in None None O
ear None None O
venules None None O
of None None O
mice None None O
with None None O
a None None O
large None None O
flank None None O
tumor None None O
was None None O
also None None O
reduced None None O
significantly None None O
. None None O

Leukocyte None None O
rolling None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
the None None O
step None None O
preceding None None O
adhesion None None O
, None None O
was None None O
not None None O
influenced None None O
by None None O
the None None O
presence None None O
of None None O
a None None O
tumor None None O
in None None O
nude None None O
mice None None O
, None None O
but None None O
was None None O
down None None O
- None None O
regulated None None O
in None None O
immune None None O
- None None O
competent None None O
C57Bl None None O
/ None None O
6 None None O
mice None None O
. None None O

Treatment None None O
of None None O
mice None None O
bearing None None O
a None None O
small None None O
ear None None O
tumor None None O
with None None O
a None None O
humanized None None O
antivascular None None O
endothelial None None O
growth None None O
factor None None O
antibody None None O
prevented None None O
the None None O
down None None O
- None None O
regulation None None O
of None None O
leukocyte None None O
- None None O
vessel None None O
wall None None O
interactions None None O
inside None None O
the None None O
tumor None None O
vessels None None O
compared None None O
with None None O
the None None O
nontreated None None O
group None None O
. None None O

Fluorescence None None O
- None None O
activated None None O
cell None None O
sorter None None O
analysis None None O
showed None None O
that None None O
isolated None None O
tumor None None O
ECs None None O
have None None O
suppressed None None O
levels None None O
of None None O
intercellular None None O
adhesion None None O
molecule None None O
1 None None O
as None None O
compared None None O
with None None O
ECs None None O
from None None O
normal None None O
mouse None None O
tissues None None O
. None None O

In None None O
cultured None None O
b None None I-Cell-line-name
. None None I-Cell-line-name
END5 None None I-Cell-line-name
cells None None I-Cell-line-name
the None None O
tumor None None O
necrosis None None O
factor None None O
alpha None None O
- None None O
induced None None O
up None None O
- None None O
regulation None None O
of None None O
intercellular None None O
adhesion None None O
molecule None None O
1 None None O
and None None O
vascular None None O
cell None None O
adhesion None None O
molecule None None O
1 None None O
was None None O
reduced None None O
in None None O
ECs None None O
that None None O
were None None O
preincubated None None O
with None None O
basic None None O
fibroblast None None O
growth None None O
factor None None O
or None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
. None None O

The None None O
current None None O
results None None O
may None None O
have None None O
an None None O
impact None None O
on None None O
the None None O
effectiveness None None O
of None None O
clinical None None O
immunotherapeutic None None O
treatment None None O
protocols None None O
, None None O
because None None O
immune None None O
effector None None O
cells None None O
may None None O
not None None O
be None None O
able None None O
to None None O
enter None None O
tumor None None O
tissue None None O
. None None O

[ None None O
Study None None O
of None None O
fungus None None O
polysaccharides None None O
compounds None None O
( None None O
FPC None None O
) None None O
in None None O
inducing None None O
the None None O
apoptosis None None O
of None None O
liver None None O
cancer None None O
cell None None O
Bel None None I-Cell-line-name
- None None I-Cell-line-name
7402 None None I-Cell-line-name
] None None O
. None None O

To None None O
observe None None O
the None None O
influence None None O
of None None O
fungus None None O
polysaccharides None None O
compounds None None O
( None None O
FPC None None O
) None None O
in None None O
inducing None None O
human None None O
liver None None O
cancer None None O
cell None None O
Bel None None I-Cell-line-name
- None None I-Cell-line-name
7402 None None I-Cell-line-name
apoptosis None None O
in None None O
cell None None O
cultivating None None O
in None None O
vitro None None O
, None None O
the None None O
authors None None O
analyzed None None O
tumor None None O
inhibitive None None O
gene None None O
P53 None None O
expression None None O
in None None O
Bel None None I-Cell-line-name
- None None I-Cell-line-name
7402 None None I-Cell-line-name
apoptosis None None O
by None None O
applying None None O
double None None O
immuno None None O
- None None O
marker None None O
. None None O

The None None O
result None None O
showed None None O
that None None O
the None None O
multilevel None None O
of None None O
FPC None None O
could None None O
all None None O
apparently None None O
induce None None O
Bel None None I-Cell-line-name
- None None I-Cell-line-name
7402 None None I-Cell-line-name
apoptosis None None O
. None None O

With None None O
the None None O
enhancement None None O
of None None O
FPC None None O
concentration None None O
, None None O
the None None O
authors None None O
observed None None O
chromatin None None O
condensation None None O
in None None O
some None None O
phases None None O
companying None None O
with None None O
the None None O
characteristic None None O
apoptosis None None O
. None None O

In None None O
the None None O
meantime None None O
, None None O
it None None O
could None None O
also None None O
greatly None None O
reduce None None O
the None None O
G1 None None O
and None None O
S None None O
, None None O
with None None O
obviously None None O
dose None None O
- None None O
response None None O
relationship None None O
. None None O

The None None O
percentage None None O
of None None O
cell None None O
apoptosis None None O
increased None None O
with None None O
the None None O
enhancing None None O
of None None O
concentration None None O
. None None O

In None None O
the None None O
high None None O
- None None O
level None None O
group None None O
the None None O
authors None None O
found None None O
typical None None O
DNA None None O
ladder None None O
eletrophoresis None None O
stripe None None O
. None None O

The None None O
result None None O
showed None None O
that None None O
the None None O
mechanism None None O
of None None O
the None None O
FPC None None O
antineoplastic None None O
effect None None O
had None None O
an None None O
intimate None None O
relation None None O
with None None O
its None None O
induction None None O
to None None O
apoptosis None None O
and None None O
that None None O
the None None O
result None None O
of None None O
FPC None None O
inducing None None O
tumor None None O
cell None None O
apoptosis None None O
had None None O
the None None O
character None None O
of None None O
P53 None None O
independence None None O
. None None O

Dendrimer None None O
- None None O
templated None None O
Fe None None O
nanoparticles None None O
for None None O
the None None O
growth None None O
of None None O
single None None O
- None None O
wall None None O
carbon None None O
nanotubes None None O
by None None O
plasma None None O
- None None O
enhanced None None O
CVD None None O
. None None O

A None None O
fourth None None O
- None None O
generation None None O
( None None O
G4 None None O
) None None O
poly None None O
( None None O
amidoamine None None O
) None None O
( None None O
PAMAM None None O
) None None O
dendrimer None None O
( None None O
G4 None None O
- None None O
NH2 None None O
) None None O
has None None O
been None None O
used None None O
as None None O
a None None O
template None None O
to None None O
deliver None None O
nearly None None O
monodispersed None None O
catalyst None None O
nanoparticles None None O
to None None O
SiO2 None None O
/ None None O
Si None None O
, None None O
Ti None None O
/ None None O
Si None None O
, None None O
sapphire None None O
, None None O
and None None O
porous None None O
anodic None None O
alumina None None O
( None None O
PAA None None O
) None None O
substrates None None O
. None None O

Fe2O3 None None O
nanoparticles None None O
obtained None None O
after None None O
calcination None None O
of None None O
the None None O
immobilized None None O
Fe3 None None O
+ None None O
/ None None O
G4 None None O
- None None O
NH2 None None O
composite None None O
served None None O
as None None O
catalytic None None O
" None None O
seeds None None O
" None None O
for None None O
the None None O
growth None None O
of None None O
single None None O
- None None O
wall None None O
carbon None None O
nanotubes None None O
( None None O
SWNTs None None O
) None None O
by None None O
microwave None None O
plasma None None O
- None None O
enhanced None None O
CVD None None O
( None None O
PECVD None None O
) None None O
. None None O

To None None O
surmount None None O
the None None O
difficulty None None O
associated None None O
with None None O
SWNT None None O
growth None None O
via None None O
PECVD None None O
, None None O
reaction None None O
conditions None None O
that None None O
promote None None O
the None None O
stabilization None None O
of None None O
Fe None None O
nanoparticles None None O
, None None O
resulting None None O
in None None O
enhanced None None O
SWNT None None O
selectivity None None O
and None None O
quality None None O
, None None O
have None None O
been None None O
identified None None O
. None None O

In None None O
particular None None O
, None None O
in None None O
situ None None O
annealing None None O
of None None O
Fe None None O
catalyst None None O
in None None O
an None None O
N2 None None O
atmosphere None None O
was None None O
found None None O
to None None O
improve None None O
SWNT None None O
selectivity None None O
and None None O
quality None None O
. None None O

H2 None None O
prereduction None None O
at None None O
900 None None O
degrees None None O
C None None O
for None None O
5 None None O
min None None O
was None None O
also None None O
found None None O
to None None O
enhance None None O
SWNT None None O
selectivity None None O
and None None O
quality None None O
for None None O
SiO2 None None O
/ None None O
Si None None O
supported None None O
catalyst None None O
, None None O
albeit None None O
of None None O
lower None None O
quality None None O
for None None O
sapphire None None O
supported None None O
catalyst None None O
. None None O

The None None O
application None None O
of None None O
positive None None O
dc None None O
bias None None O
voltage None None O
( None None O
+ None None O
200 None None O
V None None O
) None None O
during None None O
SWNT None None O
growth None None O
was None None O
shown None None O
to None None O
be None None O
very None None O
effective None None O
in None None O
removing None None O
amorphous None None O
carbon None None O
impurities None None O
while None None O
enhancing None None O
graphitization None None O
, None None O
SWNT None None O
selectivity None None O
, None None O
and None None O
vertical None None O
alignment None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
should None None O
promote None None O
the None None O
use None None O
of None None O
exposed None None O
Fe None None O
nanoparticles None None O
supported None None O
on None None O
different None None O
substrates None None O
for None None O
the None None O
growth None None O
of None None O
high None None O
- None None O
quality None None O
SWNTs None None O
by None None O
PECVD None None O
. None None O

Clinical None None O
evaluation None None O
of None None O
radiotherapy None None O
for None None O
Graves None None O
' None None O
ophthalmopathy None None O
. None None O

Seventeen None None O
patients None None O
with None None O
moderately None None O
severe None None O
ophthalmopathy None None O
due None None O
to None None O
Graves None None O
' None None O
disease None None O
were None None O
treated None None O
by None None O
cobalt None None O
or None None O
supervoltage None None O
radiotherapy None None O
. None None O

All None None O
patients None None O
complained None None O
of None None O
diplopia None None O
. None None O

The None None O
mean None None O
proptosis None None O
value None None O
was None None O
21 None None O
. None None O
4 None None O
mm None None O
. None None O

Three None None O
patients None None O
( None None O
18 None None O
% None None O
) None None O
showed None None O
good None None O
response None None O
, None None O
7 None None O
( None None O
41 None None O
% None None O
) None None O
moderate None None O
and None None O
7 None None O
minimal None None O
or None None O
no None None O
response None None O
. None None O

Improvement None None O
was None None O
noted None None O
mainly None None O
in None None O
soft None None O
tissue None None O
changes None None O
and None None O
diplopia None None O
, None None O
while None None O
proptosis None None O
decreased None None O
in None None O
only None None O
5 None None O
patients None None O
. None None O

All None None O
except None None O
one None None O
patient None None O
who None None O
had None None O
marked None None O
extraocular None None O
muscle None None O
involvement None None O
revealed None None O
by None None O
computed None None O
tomography None None O
responded None None O
to None None O
treatment None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
radiotherapy None None O
may None None O
be None None O
indicated None None O
in None None O
patients None None O
with None None O
progressive None None O
ophthalmopathy None None O
, None None O
especially None None O
in None None O
those None None O
who None None O
are None None O
associated None None O
with None None O
extraocular None None O
muscle None None O
enlargement None None O
. None None O

Target None None O
volumes None None O
' None None O
coverage None None O

The None None O
mean None None O
PTV1 None None O
and None None O
PTV2 None None O
volumes None None O
were None None O
452 None None O
cm3 None None O
( None None O
range None None O
276 None None O
- None None O
1074 None None O
cm3 None None O
) None None O
and None None O
300 None None O
cm3 None None O
( None None O
range None None O
137 None None O
- None None O
567 None None O
cm3 None None O
) None None O
respectively None None O
. None None O

A None None O
mean None None O
of None None O
> None None O
98 None None O
% None None O
( None None O
range None None O
92 None None O
- None None O
100 None None O
% None None O
) None None O
of None None O
the None None O
PTV1 None None O
received None None O
100 None None O
% None None O
of None None O
the None None O
prescribed None None O
dose None None O
in None None O
all None None O
planning None None O
methods None None O
. None None O

A None None O
mean None None O
of None None O
95 None None O
. None None O
5 None None O
% None None O
and None None O
95 None None O
. None None O
7 None None O
% None None O
of None None O
the None None O
PTV2 None None O
received None None O
100 None None O
% None None O
of None None O
the None None O
prescribed None None O
dose None None O
with None None O
TOMO None None O
and None None O
IMRT None None O
plans None None O
respectively None None O
. None None O

A None None O
mean None None O
of None None O
94 None None O
% None None O
and None None O
92 None None O
% None None O
of None None O
the None None O
PTV2 None None O
received None None O
100 None None O
% None None O
of None None O
the None None O
prescribed None None O
dose None None O
with None None O
IB None None O
and None None O
3D None None O
treatment None None O
plans None None O
, None None O
respectively None None O
. None None O

The None None O
mean None None O
IB None None O
and None None O
3D None None O
plans None None O
PTV2 None None O
coverage None None O
was None None O
significantly None None O
inferior None None O
then None None O
the None None O
IMRT None None O
and None None O
TOMO None None O
plans None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
02 None None O
, None None O
for None None O
all None None O
comparisons None None O
) None None O
. None None O

The None None O
mean None None O
Inhomogeneity None None O
Coefficient None None O
( None None O
IC None None O
) None None O
was None None O
significantly None None O
lower None None O
( None None O
better None None O
) None None O
with None None O
the None None O
TOMO None None O
plans None None O
, None None O
compared None None O
to None None O
all None None O
other None None O
plans None None O
for None None O
both None None O
PTV1 None None O
and None None O
PTV2 None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
0003 None None O
for None None O
all None None O
comparisons None None O
) None None O
( None None O
figure None None O
3 None None O
) None None O
. None None O

The None None O
mean None None O
IC None None O
of None None O
the None None O
IMRT None None O
plans None None O
was None None O
significantly None None O
higher None None O
( None None O
worse None None O
) None None O
than None None O
the None None O
mean None None O
IC None None O
of None None O
the None None O
3D None None O
plans None None O
regarding None None O
PTV None None O
1 None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
02 None None O
) None None O
and None None O
higher None None O
( None None O
worse None None O
) None None O
then None None O
the None None O
mean None None O
IC None None O
of None None O
the None None O
IB None None O
plans None None O
regarding None None O
PTV2 None None O
( None None O
p None None O
< None None O
0 None None O
. None None O
03 None None O
) None None O
( None None O
figure None None O
3 None None O
) None None O
. None None O

No None None O
significant None None O
difference None None O
was None None O
found None None O
between None None O
the None None O
means None None O
of None None O
the None None O
IC None None O
of None None O
the None None O
3D None None O
and None None O
IB None None O
plans None None O
. None None O

Figure None None O
3 None None O

The None None O
mean None None O
Inhomogeneity None None O
Coefficient None None O
( None None O
IC None None O
) None None O
achieved None None O
by None None O
the None None O
different None None O
planning None None O
methods None None O
. None None O

The None None O
mean None None O
of None None O
the None None O
Inhomogeneity None None O
Coefficient None None O
is None None O
a None None O
measure None None O
of None None O
dose None None O
inhomogeneity None None O
in None None O
the None None O
target None None O
volumes None None O
. None None O

The None None O
closer None None O
the None None O
IC None None O
to None None O
zero None None O
, None None O
the None None O
more None None O
homogenous None None O
the None None O
dose None None O
is None None O
. None None O

Comparison None None O
of None None O
the None None O
molecular None None O
organisation None None O
of None None O
the None None O
tra None None O
- None None O
2 None None O
of None None O
A None None O
. None None O
obliqua None None O
( None None O
A None None O
) None None O
, None None O
C None None O
. None None O
capitata None None O
( None None O
B None None O
) None None O
and None None O
D None None O
. None None O
melanogaster None None O
( None None O
C None None O
) None None O
and None None O
their None None O
proteins None None O
. None None O

Exons None None O
( None None O
boxes None None O
) None None O
and None None O
introns None None O
( None None O
dashed None None O
lines None None O
) None None O
are None None O
not None None O
drawn None None O
to None None O
scale None None O
. None None O

The None None O
numbers None None O
inside None None O
the None None O
boxes None None O
indicate None None O
the None None O
number None None O
of None None O
the None None O
exon None None O
. None None O

The None None O
beginning None None O
and None None O
the None None O
end None None O
of None None O
the None None O
ORF None None O
are None None O
indicated None None O
by None None O
ATG None None O
and None None O
TAA None None O
respectively None None O
. None None O

AAA None None O
stands None None O
for None None O
poly None None O
- None None O
A None None O
( None None O
+ None None O
) None None O
. None None O

( None None O
D None None O
) None None O
Expression None None O
of None None O
gene None None O
tra None None O
- None None O
2 None None O
of None None O
A None None O
. None None O
obliqua None None O
. None None O

RT None None O
- None None O
PCR None None O
analyses None None O
of None None O
total None None O
RNA None None O
from None None O
ovaries None None O
( None None O
O None None O
) None None O
, None None O
embryos None None O
( None None O
E None None O
) None None O
, None None O
from None None O
male None None O
and None None O
female None None O
larvae None None O
( None None O
L None None O
) None None O
, None None O
male None None O
soma None None O
( None None O
head None None O
plus None None O
thorax None None O
, None None O
MS None None O
) None None O
and None None O
female None None O
soma None None O
( None None O
head None None O
plus None None O
thorax None None O
, None None O
FS None None O
) None None O
. None None O

( None None O
E None None O
) None None O
Expression None None O
of None None O
gene None None O
tra None None O
- None None O
2 None None O
of None None O
A None None O
. None None O
obliqua None None O
. None None O

RT None None O
- None None O
PCR None None O
analysis None None O
of None None O
total None None O
RNA None None O
from None None O
A None None O
. None None O
obliqua None None O
testis None None O
. None None O

Lane None None O
1 None None O
corresponds None None O
to None None O
PCR None None O
with None None O
primers None None O
PM1 None None O
and None None O
P2 None None O
; None None O
lane None None O
2 None None O
corresponds None None O
to None None O
PCR None None O
with None None O
primers None None O
P1 None None O
and None None O
P2 None None O
( None None O
see None None O
location None None O
of None None O
primers None None O
in None None O
Figure None None O
1A None None O
) None None O
. None None O

( None None O
F None None O
) None None O
Southern None None O
- None None O
blot None None O
corresponding None None O
to None None O
the None None O
gel None None O
shown None None O
in None None O
( None None O
E None None O
) None None O
and None None O
hybridisation None None O
with None None O
a None None O
probe None None O
specific None None O
for None None O
intron None None O
3 None None O
of None None O
A None None O
. None None O
obliqua None None O
. None None O

The None None O
arrow None None O
marks None None O
the None None O
hybridisation None None O
to None None O
the None None O
higher None None O
band None None O
in None None O
lane None None O
1 None None O
of None None O
Figure None None O
1E None None O
. None None O

The None None O
size None None O
of None None O
the None None O
mRNAs None None O
encoding None None O
the None None O
proteins None None O
shown None None O
in None None O
this None None O
figure None None O
are None None O
: None None O
1923 None None O
bp None None O
for None None O
A None None O
. None None O
obliqua None None O
mRNA None None O
, None None O
1113 None None O
bp None None O
for None None O
C None None O
. None None O
capitata None None O
mRNA None None O
, None None O
and None None O
960 None None O
, None None O
1583 None None O
and None None O
1391 None None O
bp None None O
for None None O
D None None O
. None None O
melanogaster None None O
mRNAs None None O
tra2 None None O
- None None O
179 None None O
, None None O
tra2 None None O
- None None O
226 None None O
and None None O
tra2 None None O
- None None O
264 None None O
, None None O
respectively None None O
. None None O

Male None None O
role None None O
in None None O
fertility None None O
decisions None None O
in None None O
Robertsport None None O
, None None O
Liberia None None O
: None None O
an None None O
experimental None None O
exercise None None O
for None None O
policy None None O
formulation None None O
. None None O

There None None O
is None None O
a None None O
tendency None None O
to None None O
believe None None O
that None None O
in None None O
African None None O
societies None None O
men None None O
are None None O
the None None O
dominant None None O
decision None None O
makers None None O
in None None O
the None None O
family None None O
. None None O

In None None O
Robertsport None None O
, None None O
Liberia None None O
, None None O
there None None O
are None None O
indications None None O
that None None O
, None None O
with None None O
respect None None O
to None None O
fertility None None O
regulation None None O
, None None O
the None None O
dominance None None O
of None None O
the None None O
husband None None O
in None None O
fertility None None O
decisions None None O
exists None None O
, None None O
but None None O
it None None O
is None None O
also None None O
apparent None None O
that None None O
many None None O
of None None O
these None None O
decisions None None O
are None None O
made None None O
jointly None None O
by None None O
both None None O
husband None None O
and None None O
wife None None O
. None None O

Education None None O
is None None O
particularly None None O
influential None None O
in None None O
the None None O
joint None None O
fertility None None O
decision None None O
- None None O
making None None O
process None None O
. None None O

The None None O
100 None None O
husbands None None O
sampled None None O
in None None O
1982 None None O
desired None None O
a None None O
large None None O
number None None O
of None None O
children None None O
and None None O
had None None O
experience None None O
with None None O
infant None None O
and None None O
child None None O
mortality None None O
. None None O

If None None O
family None None O
planning None None O
programs None None O
should None None O
attain None None O
their None None O
goals None None O
, None None O
men None None O
should None None O
be None None O
more None None O
involved None None O
, None None O
than None None O
at None None O
present None None O
, None None O
in None None O
every None None O
aspect None None O
of None None O
the None None O
programs None None O
. None None O

Equally None None O
important None None O
is None None O
the None None O
urgency None None O
for None None O
studies None None O
related None None O
to None None O
the None None O
role None None O
of None None O
men None None O
in None None O
fertility None None O
regulation None None O
, None None O
using None None O
adequately None None O
large None None O
samples None None O
. None None O

3 None None O
. None None O
2 None None O
. None None O

Cell None None O
line None None O
and None None O
culture None None O

DU145 None None I-Cell-line-name
( None None O
prostate None None O
cancer None None O
) None None O
cell None None O
line None None O
was None None O
used None None O
in None None O
this None None O
assay None None O
. None None O

DU145 None None I-Cell-line-name
was None None O
grown None None O
in None None O
DMEM None None O
/ None None O
F None None O
- None None O
12 None None O
medium None None O
( None None O
Gibco None None O
BRL None None O
Life None None O
Technologies None None O
, None None O
San None None O
Diego None None O
, None None O
CA None None O
. None None O
, None None O
USA None None O
) None None O
supplemented None None O
with None None O
10 None None O
% None None O
fetal None None O
calf None None O
serum None None O
and None None O
kept None None O
in None None O
a None None O
humidified None None O
37 None None O
degreesC None None O
, None None O
5 None None O
% None None O
CO2 None None O
incubator None None O
. None None O

Inflammation None None O
- None None O
modulating None None O
effect None None O
of None None O
antithrombin None None O
on None None O
the None None O
endothelium None None O
. None None O

Ligation None None O
of None None O
heparan None None O
sulfate None None O
proteoglycans None None O
( None None O
HSPGs None None O
) None None O
of None None O
endothelium None None O
with None None O
antithrombin None None O
( None None O
AT None None O
) None None O
induces None None O
cellular None None O
signalling None None O
events None None O
that None None O
alter None None O
the None None O
cell None None O
' None None O
s None None O
biochemical None None O
and None None O
functional None None O
responses None None O
to None None O
inflammatory None None O
stimuli None None O
( None None O
e None None O
. None None O
g None None O
. None None O
bacterial None None O
lipopolysaccharide None None O
[ None None O
LPS None None O
] None None O
) None None O
. None None O

Changes None None O
include None None O
reduced None None O
release None None O
of None None O
inflammatory None None O
and None None O
procoagulatory None None O
mediators None None O
( None None O
e None None O
. None None O
g None None O
. None None O
interleukin None None O
[ None None O
IL None None O
] None None O
- None None O
1 None None O
, None None O
IL None None O
- None None O
6 None None O
, None None O
tumour None None O
necrosis None None O
factor None None O
- None None O
alpha None None O
[ None None O
TNF None None O
] None None O
) None None O
, None None O
tissue None None O
factor None None O
( None None O
TF None None O
) None None O
, None None O
adenosine None None O
diphosphate None None O
( None None O
ADP None None O
) None None O
and None None O
cellular None None O
adhesion None None O
molecules None None O
( None None O
not None None O
shown None None O
) None None O
, None None O
as None None O
well None None O
as None None O
increased None None O
release None None O
of None None O
anticoagulatory None None O
prostacyclin None None O
( None None O
prostaglandin None None O
[ None None O
PG None None O
] None None O
I None None O
) None None O
or None None O
CD39 None None O
/ None None O
ATPDase None None O
. None None O

In None None O
neuronal None None O
tissue None None O
, None None O
protective None None O
mechanisms None None O
may None None O
by None None O
mediated None None O
via None None O
the None None O
release None None O
of None None O
calcitonin None None O
gene None None O
- None None O
related None None O
peptide None None O
and None None O
nitric None None O
oxide None None O
with None None O
the None None O
potential None None O
to None None O
affect None None O
prostacyclin None None O
release None None O
[ None None O
55 None None O
] None None O
. None None O

Experimental None None O

Authors None None O
' None None O
contributions None None O

EEKN None None O
was None None O
responsible None None O
for None None O
data None None O
collection None None O
, None None O
statistical None None O
analysis None None O
and None None O
drafting None None O
the None None O
manuscript None None O
. None None O

SAGN None None O
and None None O
YW None None O
involved None None O
in None None O
data None None O
collection None None O
and None None O
helped None None O
with None None O
the None None O
data None None O
analysis None None O
. None None O

AS None None O
helped None None O
in None None O
data None None O
analysis None None O
. None None O

EST None None O
and None None O
JL None None O
directed None None O
the None None O
study None None O
and None None O
helped None None O
in None None O
revising None None O
the None None O
manuscript None None O
. None None O

RMVD None None O
helped None None O
in None None O
data None None O
analysis None None O
, None None O
interpretation None None O
of None None O
the None None O
results None None O
and None None O
led None None O
writing None None O
of None None O
the None None O
manuscript None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O

Human None None O
cytomegalovirus None None O
5 None None O
- None None O
kilobase None None O
immediate None None O
- None None O
early None None O
RNA None None O
is None None O
a None None O
stable None None O
intron None None O
. None None O

Immediate None None O
- None None O
early None None O
viral None None O
gene None None O
products None None O
of None None O
human None None O
cytomegalovirus None None O
( None None O
HCMV None None O
) None None O
are None None O
derived None None O
from None None O
several None None O
genomic None None O
loci None None O
and None None O
largely None None O
serve None None O
to None None O
establish None None O
a None None O
cellular None None O
environment None None O
conducive None None O
to None None O
viral None None O
replication None None O
. None None O

We None None O
have None None O
further None None O
examined None None O
an None None O
unusual None None O
immediate None None O
- None None O
early None None O
transcript None None O
known None None O
as None None O
the None None O
5 None None O
- None None O
kb None None O
RNA None None O
, None None O
concluding None None O
that None None O
it None None O
is None None O
a None None O
stable None None O
intron None None O
encoded None None O
by None None O
HCMV None None O
. None None O

The None None O
5 None None O
- None None O
kb None None O
RNA None None O
is None None O
highly None None O
AT None None O
rich None None O
in None None O
sequence None None O
and None None O
lacks None None O
open None None O
reading None None O
frames None None O
likely None None O
to None None O
be None None O
translated None None O
into None None O
protein None None O
. None None O

We None None O
confirmed None None O
the None None O
absence None None O
of None None O
polyadenylation None None O
of None None O
the None None O
transcript None None O
and None None O
showed None None O
that None None O
it None None O
is None None O
primarily None None O
nuclear None None O
localized None None O
during None None O
viral None None O
infection None None O
. None None O

We None None O
mapped None None O
the None None O
5 None None O
' None None O
end None None O
of None None O
the None None O
5 None None O
- None None O
kb None None O
RNA None None O
to None None O
a None None O
consensus None None O
splice None None O
donor None None O
site None None O
and None None O
localized None None O
the None None O
3 None None O
' None None O
end None None O
in None None O
the None None O
vicinity None None O
of None None O
a None None O
splice None None O
acceptor None None O
site None None O
. None None O

In None None O
transfection None None O
studies None None O
, None None O
we None None O
showed None None O
that None None O
the None None O
5 None None O
- None None O
kb None None O
RNA None None O
can None None O
be None None O
spliced None None O
from None None O
a None None O
heterologous None None O
primary None None O
transcript None None O
. None None O

Using None None O
bacterial None None O
artificial None None O
chromosome None None O
technology None None O
, None None O
we None None O
constructed None None O
a None None O
viral None None O
recombinant None None O
containing None None O
a None None O
mutation None None O
in None None O
the None None O
5 None None O
' None None O
splice None None O
donor None None O
site None None O
that None None O
defines None None O
the None None O
5 None None O
' None None O
end None None O
of None None O
the None None O
RNA None None O
and None None O
found None None O
that None None O
this None None O
mutation None None O
eliminates None None O
expression None None O
of None None O
the None None O
5 None None O
- None None O
kb None None O
RNA None None O
during None None O
viral None None O
infection None None O
. None None O

This None None O
mutant None None O
grows None None O
in None None O
human None None O
fibroblasts None None O
without None None O
complementation None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
support None None O
the None None O
conclusion None None O
that None None O
the None None O
5 None None O
- None None O
kb None None O
RNA None None O
is None None O
a None None O
stable None None O
intron None None O
expressed None None O
by None None O
HCMV None None O
. None None O

Evaluation None None O
of None None O
electrical None None O
stimulation None None O
for None None O
ischemic None None O
wound None None O
therapy None None O
: None None O
a None None O
feasibility None None O
study None None O
using None None O
the None None O
lapine None None O
wound None None O
model None None O
. None None O

Chronic None None O
wounds None None O
are None None O
a None None O
major None None O
secondary None None O
complication None None O
for None None O
many None None O
people None None O
with None None O
impaired None None O
mobility None None O
. None None O

Electrical None None O
stimulation None None O
( None None O
ES None None O
) None None O
has None None O
been None None O
recommended None None O
as None None O
a None None O
adjunctive None None O
therapy None None O
, None None O
however None None O
optimal None None O
treatment None None O
paradigms None None O
have None None O
not None None O
been None None O
established None None O
. None None O

Our None None O
group None None O
seeks None None O
to None None O
determine None None O
the None None O
basic None None O
mechanisms None None O
underlying None None O
ES None None O
wound None None O
therapy None None O
, None None O
an None None O
area None None O
where None None O
understanding None None O
is None None O
currently None None O
limited None None O
. None None O

A None None O
feasibility None None O
study None None O
was None None O
carried None None O
out None None O
to None None O
develop None None O
the None None O
Ahn None None O
/ None None O
Mustoe None None O
lapine None None O
wound None None O
model None None O
for None None O
systematic None None O
investigation None None O
of None None O
the None None O
effects None None O
of None None O
electrical None None O
stimulation None None O
on None None O
ischemic None None O
wound None None O
therapy None None O
. None None O

A None None O
standardized None None O
surgical None None O
procedure None None O
incorporated None None O
a None None O
hybrid None None O
stimulation None None O
system None None O
comprising None None O
an None None O
implantable None None O
mini None None O
- None None O
stimulator None None O
and None None O
surface None None O
electrodes None None O
, None None O
with None None O
creation None None O
of None None O
repeatable None None O
ischemic None None O
wounds None None O
. None None O

Twenty None None O
mature None None O
male None None O
New None None O
Zealand None None O
white None None O
rabbits None None O
( None None O
3 None None O
kg None None O
weight None None O
) None None O
were None None O
employed None None O
to None None O
evaluate None None O
the None None O
effects None None O
of None None O
two None None O
empirically None None O
selected None None O
stimulation None None O
paradigms None None O
applied None None O
continuously None None O
for None None O
7 None None O
- None None O
21 None None O
days None None O
, None None O
using None None O
each None None O
animal None None O
as None None O
its None None O
own None None O
control None None O
. None None O

Outcomes None None O
measures None None O
included None None O
transcutaneous None None O
blood None None O
gas None None O
levels None None O
, None None O
histology None None O
, None None O
total None None O
RNA None None O
content None None O
and None None O
analysis None None O
of None None O
alpha2 None None O
( None None O
I None None O
) None None O
collagen None None O
( None None O
COL None None O
- None None O
I None None O
) None None O
, None None O
type None None O
IV None None O
collagen None None O
( None None O
COL None None O
- None None O
IV None None O
) None None O
, None None O
alpha1 None None O
( None None O
V None None O
) None None O
collagen None None O
( None None O
COL None None O
- None None O
V None None O
) None None O
, None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
expression None None O
using None None O
real None None O
- None None O
time None None O
quantitative None None O
PCR None None O
. None None O

All None None O
markers None None O
for None None O
stimulated None None O
wounds None None O
showed None None O
increased None None O
activity None None O
relative None None O
to None None O
non None None O
- None None O
stimulated None None O
control None None O
wounds None None O
between None None O
7 None None O
and None None O
14 None None O
days None None O
following None None O
injury None None O
, None None O
with None None O
peak None None O
activity None None O
at None None O
14 None None O
days None None O
. None None O

By None None O
21 None None O
days None None O
post None None O
- None None O
injury None None O
, None None O
all None None O
activity None None O
had None None O
returned None None O
to None None O
near None None O
baseline None None O
level None None O
. None None O

VEGF None None O
and None None O
COL None None O
- None None O
IV None None O
levels None None O
were None None O
found None None O
to None None O
be None None O
significantly None None O
higher None None O
for None None O
pattern None None O
A None None O
( None None O
110 None None O
mus None None O
pulse None None O
width None None O
) None None O
compared None None O
to None None O
pattern None None O
B None None O
( None None O
5 None None O
mus None None O
pulse None None O
width None None O
) None None O
at None None O
14 None None O
days None None O
, None None O
implying None None O
that None None O
pattern None None O
A None None O
may None None O
be None None O
more None None O
effective None None O
at None None O
promoting None None O
angiogenesis None None O
. None None O

All None None O
wounds None None O
were None None O
fully None None O
re None None O
- None None O
epithelialized None None O
by None None O
10 None None O
days None None O
post None None O
- None None O
injury None None O
. None None O

Both None None O
COL None None O
- None None O
I None None O
and None None O
COL None None O
- None None O
V None None O
showed None None O
statistically None None O
significant None None O
( None None O
P None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
) None None O
increased None None O
activity None None O
between None None O
day None None O
7 None None O
and None None O
day None None O
14 None None O
for None None O
pattern None None O
A None None O
, None None O
potentially None None O
indicating None None O
a None None O
continued None None O
effect None None O
on None None O
matrix None None O
remodeling None None O
. None None O

The None None O
early None None O
closure None None O
of None None O
all None None O
wounds None None O
implies None None O
that None None O
the None None O
rabbit None None O
ear None None O
model None None O
may None None O
not None None O
be None None O
valid None None O
for None None O
chronic None None O
wound None None O
studies None None O
. None None O

Stimulation None None O
of None None O
beta None None O
- None None O
adrenergic None None O
receptors None None O
in None None O
the None None O
pineal None None O
gland None None O
increases None None O
the None None O
noradrenaline None None O
stores None None O
of None None O
its None None O
sympathetic None None O
nerves None None O
. None None O

The None None O
administration None None O
of None None O
isoproterenol None None O
decreases None None O
the None None O
level None None O
of None None O
serotonin None None O
in None None O
the None None O
rat None None O
pineal None None O
gland None None O
and None None O
at None None O
the None None O
same None None O
time None None O
it None None O
increases None None O
pineal None None O
noradrenaline None None O
. None None O

These None None O
effects None None O
depend None None O
on None None O
the None None O
stimulation None None O
of None None O
a None None O
beta None None O
- None None O
adrenergic None None O
receptor None None O
because None None O
they None None O
are None None O
blocked None None O
by None None O
pretreatment None None O
of None None O
the None None O
animals None None O
with None None O
propranolol None None O
; None None O
this None None O
drug None None O
by None None O
itself None None O
does None None O
not None None O
modify None None O
either None None O
serotonin None None O
or None None O
noradrenaline None None O
levels None None O
in None None O
the None None O
pineal None None O
. None None O

The None None O
elevation None None O
of None None O
noradrenaline None None O
produced None None O
by None None O
isoproterenol None None O
is None None O
selective None None O
for None None O
the None None O
pineal None None O
because None None O
it None None O
is None None O
not None None O
observed None None O
in None None O
the None None O
salivary None None O
gland None None O
innervated None None O
by None None O
postganglionic None None O
adrenergic None None O
fibers None None O
from None None O
the None None O
same None None O
origin None None O
as None None O
pineal None None O
nerves None None O
. None None O

Pineal None None O
serotonin None None O
is None None O
stored None None O
in None None O
equilibrium None None O
in None None O
two None None O
compartments None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
the None None O
parenchymal None None O
cells None None O
and None None O
the None None O
adrenergic None None O
nerves None None O
and None None O
thus None None O
is None None O
most None None O
probably None None O
reduced None None O
in None None O
both None None O
sites None None O
. None None O

Since None None O
noradrenaline None None O
and None None O
serotonin None None O
are None None O
detected None None O
in None None O
pineal None None O
nerve None None O
vesicles None None O
and None None O
may None None O
coexist None None O
in None None O
them None None O
, None None O
the None None O
diminution None None O
of None None O
intravesicular None None O
serotonin None None O
, None None O
by None None O
making None None O
more None None O
storage None None O
sites None None O
available None None O
, None None O
probably None None O
determines None None O
the None None O
selective None None O
increase None None O
of None None O
pineal None None O
noradrenaline None None O
. None None O

A None None O
similar None None O
modification None None O
in None None O
the None None O
ratio None None O
of None None O
intravesicular None None O
amines None None O
as None None O
a None None O
result None None O
of None None O
the None None O
physiological None None O
stimulation None None O
of None None O
pineal None None O
beta None None O
- None None O
adrenergic None None O
receptors None None O
by None None O
the None None O
adrenergic None None O
neurotransmitter None None O
may None None O
explain None None O
some None None O
of None None O
the None None O
changes None None O
observed None None O
in None None O
the None None O
content None None O
of None None O
pineal None None O
amines None None O
. None None O

Kinins None None O
contribute None None O
to None None O
the None None O
improvement None None O
of None None O
insulin None None O
sensitivity None None O
during None None O
treatment None None O
with None None O
angiotensin None None O
converting None None O
enzyme None None O
inhibitor None None O
. None None O

Although None None O
angiotensin None None O
converting None None O
enzyme None None O
inhibitors None None O
and None None O
alpha None None O
1 None None O
- None None O
blockers None None O
have None None O
been None None O
reported None None O
to None None O
improve None None O
insulin None None O
sensitivity None None O
, None None O
their None None O
mechanisms None None O
of None None O
action None None O
have None None O
not None None O
been None None O
elucidated None None O
. None None O

To None None O
investigate None None O
the None None O
role None None O
of None None O
kinins None None O
in None None O
insulin None None O
sensitivity None None O
, None None O
we None None O
treated None None O
4 None None O
- None None O
week None None O
- None None O
old None None O
spontaneously None None O
hypertensive None None O
rats None None O
with None None O
either None None O
an None None O
angiotensin None None O
converting None None O
enzyme None None O
inhibitor None None O
( None None O
enalapril None None O
) None None O
, None None O
an None None O
alpha None None O
1 None None O
- None None O
blocker None None O
( None None O
doxazosin None None O
) None None O
, None None O
or None None O
an None None O
angiotensin None None O
II None None O
antagonist None None O
( None None O
losartan None None O
) None None O
for None None O
3 None None O
weeks None None O
. None None O

A None None O
control None None O
group None None O
received None None O
no None None O
drugs None None O
. None None O

In None None O
addition None None O
, None None O
18 None None O
rats None None O
treated None None O
with None None O
enalapril None None O
or None None O
doxazosin None None O
received None None O
a None None O
simultaneous None None O
administration None None O
of None None O
a None None O
kinin None None O
antagonist None None O
( None None O
Hoe None None O
140 None None O
) None None O
. None None O

Glucose None None O
clamp None None O
testing None None O
was None None O
performed None None O
in None None O
each None None O
group None None O
. None None O

Enalapril None None O
( None None O
128 None None O
+ None None O
/ None None O
- None None O
1 None None O
mmHg None None O
) None None O
and None None O
doxazosin None None O
( None None O
132 None None O
+ None None O
/ None None O
- None None O
2 None None O
mmHg None None O
) None None O
decreased None None O
mean None None O
blood None None O
pressure None None O
compared None None O
with None None O
control None None O
levels None None O
( None None O
148 None None O
+ None None O
/ None None O
- None None O
1 None None O
mmHg None None O
) None None O
( None None O
P None None O
< None None O
. None None O
01 None None O
) None None O
. None None O

The None None O
glucose None None O
requirement None None O
for None None O
the None None O
clamp None None O
test None None O
during None None O
the None None O
administration None None O
of None None O
enalapril None None O
( None None O
25 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
mg None None O
/ None None O
kg None None O
per None None O
minute None None O
) None None O
or None None O
doxazosin None None O
( None None O
28 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
7 None None O
mg None None O
/ None None O
kg None None O
per None None O
minute None None O
) None None O
was None None O
higher None None O
than None None O
that None None O
of None None O
the None None O
control None None O
group None None O
( None None O
19 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
mg None None O
/ None None O
kg None None O
per None None O
minute None None O
) None None O
( None None O
P None None O
< None None O
. None None O
05 None None O
) None None O
. None None O

Although None None O
Hoe None None O
140 None None O
did None None O
not None None O
alter None None O
the None None O
glucose None None O
requirement None None O
of None None O
doxazosin None None O
( None None O
27 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
mg None None O
/ None None O
kg None None O
per None None O
minute None None O
) None None O
, None None O
it None None O
decreased None None O
that None None O
of None None O
enalapril None None O
( None None O
22 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
9 None None O
mg None None O
/ None None O
kg None None O
per None None O
minute None None O
) None None O
( None None O
P None None O
< None None O
. None None O
05 None None O
) None None O
without None None O
affecting None None O
the None None O
changes None None O
in None None O
mean None None O
blood None None O
pressure None None O
induced None None O
by None None O
enalapril None None O
. None None O

In None None O
addition None None O
, None None O
losartan None None O
decreased None None O
mean None None O
blood None None O
pressure None None O
but None None O
did None None O
not None None O
affect None None O
the None None O
glucose None None O
requirement None None O
. None None O

Thus None None O
, None None O
the None None O
improvement None None O
in None None O
insulin None None O
sensitivity None None O
produced None None O
by None None O
an None None O
angiotensin None None O
converting None None O
enzyme None None O
inhibitor None None O
is None None O
mostly None None O
dependent None None O
on None None O
kinins None None O
but None None O
not None None O
on None None O
angiotensin None None O
II None None O
antagonism None None O
, None None O
and None None O
an None None O
alpha None None O
1 None None O
- None None O
blocker None None O
improves None None O
insulin None None O
sensitivity None None O
irrespective None None O
of None None O
kinins None None O
. None None O

Ras None None O
p21 None None O
onco None None O
- None None O
protein None None O
in None None O
the None None O
sera None None O
of None None O
mice None None O
carrying None None O
an None None O
experimentally None None O
induced None None O
tumor None None O
and None None O
in None None O
human None None O
cancer None None O
patients None None O
. None None O

We None None O
have None None O
established None None O
a None None O
model None None O
system None None O
to None None O
detect None None O
the None None O
presence None None O
of None None O
ras None None O
p21 None None O
in None None O
the None None O
sera None None O
of None None O
Balb None None O
/ None None O
c None None O
mice None None O
carrying None None O
tumors None None O
induced None None O
by None None O
a None None O
mouse None None O
cell None None O
line None None O
transformed None None O
with None None O
the None None O
Harvey None None O
murine None None O
sarcoma None None O
virus None None O
in None None O
the None None O
presence None None O
of None None O
a None None O
helper None None O
Friend None None O
murine None None O
leukemia None None O
virus None None O
. None None O

As None None O
determined None None O
by None None O
ELISA None None O
and None None O
immunoblot None None O
assays None None O
, None None O
ras None None O
p21 None None O
in None None O
the None None O
serum None None O
increased None None O
with None None O
increased None None O
tumor None None O
growth None None O
. None None O

Since None None O
ras None None O
genes None None O
have None None O
been None None O
found None None O
to None None O
be None None O
frequently None None O
activated None None O
in None None O
human None None O
tumours None None O
, None None O
we None None O
examined None None O
the None None O
levels None None O
of None None O
ras None None O
p21 None None O
in None None O
the None None O
sera None None O
of None None O
a None None O
variety None None O
of None None O
human None None O
cancer None None O
patients None None O
. None None O

In None None O
only None None O
3 None None O
out None None O
of None None O
13 None None O
cases None None O
, None None O
representing None None O
patients None None O
with None None O
adenocarcinomas None None O
of None None O
the None None O
stomach None None O
receiving None None O
chemotherapy None None O
, None None O
was None None O
ras None None O
p21 None None O
detected None None O
at None None O
elevated None None O
levels None None O
, None None O
whereas None None O
in None None O
patients None None O
with None None O
the None None O
following None None O
types None None O
of None None O
cancer None None O
no None None O
substantial None None O
change None None O
in None None O
serum None None O
ras None None O
p21 None None O
was None None O
observed None None O
; None None O
nine None None O
with None None O
breast None None O
, None None O
5 None None O
colon None None O
, None None O
5 None None O
lung None None O
, None None O
5 None None O
ovarian None None O
and None None O
5 None None O
hepatocellular None None O
carcinomas None None O
. None None O

Optimizing None None O
treatment None None O
of None None O
choroidal None None O
neovascularization None None O
feeder None None O
vessels None None O
associated None None O
with None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
. None None O

PURPOSE None None O
: None None O
To None None O
optimize None None O
the None None O
method None None O
of None None O
treating None None O
choroidal None None O
neovascularization None None O
( None None O
CNV None None O
) None None O
associated None None O
with None None O
age None None O
- None None O
related None None O
macular None None O
degeneration None None O
( None None O
AMD None None O
) None None O
. None None O

DESIGN None None O
: None None O
Experimental None None O
study None None O
and None None O
interventional None None O
case None None O
series None None O
. None None O

METHODS None None O
: None None O
The None None O
parameters None None O
associated None None O
with None None O
locating None None O
and None None O
then None None O
photocoagulating None None O
CNV None None O
feeder None None O
vessels None None O
were None None O
identified None None O
and None None O
optimized None None O
using None None O
published None None O
data None None O
and None None O
data None None O
derived None None O
from None None O
modeling None None O
the None None O
choroidal None None O
vasculature None None O
. None None O

Based None None O
on None None O
these None None O
optimized None None O
parameters None None O
, None None O
a None None O
prototype None None O
diagnostic None None O
/ None None O
treatment None None O
system None None O
was None None O
designed None None O
that None None O
captures None None O
high None None O
- None None O
speed None None O
indocyanine None None O
green None None O
( None None O
ICG None None O
) None None O
angiogram None None O
images None None O
and None None O
facilitates None None O
analysis None None O
of None None O
the None None O
images None None O
by None None O
enhancing None None O
visualization None None O
of None None O
dye None None O
movement None None O
through None None O
CNV None None O
feeder None None O
vessels None None O
( None None O
FVs None None O
) None None O
. None None O

The None None O
system None None O
also None None O
permits None None O
precise None None O
aiming None None O
and None None O
delivery None None O
of None None O
810 None None O
- None None O
nm None None O
wavelength None None O
photocoagulation None None O
laser None None O
energy None None O
to None None O
target None None O
FVs None None O
on None None O
a None None O
real None None O
- None None O
time None None O
ICG None None O
angiogram None None O
image None None O
of None None O
the None None O
choroidal None None O
vasculature None None O
. None None O

Target None None O
FVs None None O
are None None O
tracked None None O
by None None O
a None None O
joy None None O
- None None O
stick None None O
controlled None None O
laser None None O
aiming None None O
beam None None O
until None None O
an None None O
intravenously None None O
- None None O
injected None None O
high None None O
- None None O
concentration None None O
ICG None None O
dye None None O
bolus None None O
is None None O
observed None None O
to None None O
enter None None O
the None None O
target None None O
vessel None None O
, None None O
at None None O
which None None O
time None None O
the None None O
laser None None O
is None None O
fired None None O
. None None O

Proof None None O
of None None O
principle None None O
of None None O
the None None O
combined None None O
diagnosis None None O
/ None None O
treatment None None O
system None None O
design None None O
for None None O
performing None None O
dye None None O
- None None O
enhanced None None O
photocoagulation None None O
( None None O
DEP None None O
) None None O
in None None O
the None None O
clinical None None O
setting None None O
and None None O
determination None None O
of None None O
the None None O
minimum None None O
DEP None None O
laser None None O
energy None None O
needed None None O
to None None O
close None None O
CNV None None O
FVs None None O
was None None O
made None None O
in None None O
11 None None O
AMD None None O
patients None None O
requiring None None O
treatment None None O
of None None O
CNV None None O
, None None O
but None None O
for None None O
whom None None O
other None None O
treatment None None O
was None None O
not None None O
appropriate None None O
. None None O

RESULTS None None O
: None None O
Using None None O
ICG None None O
- None None O
DEP None None O
, None None O
CNV None None O
feeder None None O
vessels None None O
were None None O
closed None None O
with None None O
single None None O
pulse None None O
laser None None O
energy None None O
, None None O
delivering None None O
as None None O
little None None O
as None None O
0 None None O
. None None O
6 None None O
to None None O
1 None None O
. None None O
8 None None O
J None None O
of None None O
energy None None O
to None None O
the None None O
fundus None None O
, None None O
producing None None O
no None None O
visible None None O
change None None O
in None None O
the None None O
fundus None None O
. None None O

Successful None None O
FV None None O
closure None None O
was None None O
usually None None O
indicated None None O
immediately None None O
by None None O
presence None None O
of None None O
incarcerated None None O
ICG None None O
dye None None O
in None None O
the None None O
vessel None None O
adjacent None None O
to None None O
the None None O
burn None None O
site None None O
. None None O

The None None O
prototype None None O
system None None O
proved None None O
relatively None None O
easy None None O
to None None O
operate None None O
. None None O

After None None O
acquiring None None O
and None None O
interpreting None None O
diagnostic None None O
angiograms None None O
and None None O
repositioning None None O
a None None O
patient None None O
in None None O
front None None O
of None None O
the None None O
device None None O
, None None O
feeder None None O
vessel None None O
DEP None None O
and None None O
treatment None None O
evaluation None None O
required None None O
15 None None O
to None None O
20 None None O
minutes None None O
. None None O

CONCLUSIONS None None O
: None None O
Indocyanine None None O
green None None O
dye None None O
- None None O
enhanced None None O
photocoagulation None None O
of None None O
CNV None None O
feeder None None O
vessels None None O
, None None O
facilitated None None O
by None None O
use None None O
of None None O
a None None O
device None None O
that None None O
permits None None O
real None None O
- None None O
time None None O
visualization None None O
of None None O
the None None O
choroidal None None O
circulation None None O
while None None O
aiming None None O
the None None O
treatment None None O
laser None None O
beam None None O
, None None O
appears None None O
to None None O
minimize None None O
the None None O
amount None None O
of None None O
energy None None O
applied None None O
to None None O
the None None O
fundus None None O
and None None O
the None None O
volume None None O
of None None O
fundus None None O
tissue None None O
affected None None O
by None None O
treatment None None O
, None None O
compared None None O
with None None O
other None None O
treatment None None O
modalities None None O
. None None O

The None None O
combination None None O
diagnosis None None O
/ None None O
treatment None None O
device None None O
should None None O
be None None O
useful None None O
in None None O
optimizing None None O
FV None None O
treatment None None O
and None None O
in None None O
refining None None O
and None None O
evaluating None None O
the None None O
efficacy None None O
of None None O
DEP None None O
in None None O
future None None O
clinical None None O
trials None None O
. None None O

Histological None None O
analysis None None O

A None None O
cross None None O
- None None O
section None None O
of None None O
the None None O
distal None None O
colon None None O
( None None O
2 None None O
cm None None O
) None None O
was None None O
fixed None None O
in None None O
10 None None O
% None None O
paraformaldehyde None None O
solution None None O
. None None O

Afterwards None None O
, None None O
it None None O
was None None O
cut None None O
into None None O
small None None O
fragments None None O
, None None O
dehydrated None None O
through None None O
an None None O
ethanol None None O
series None None O
( None None O
70 None None O
% None None O
- None None O
100 None None O
% None None O
) None None O
, None None O
cleared None None O
in None None O
xylol None None O
and None None O
embedded None None O
in None None O
paraffin None None O
. None None O

The None None O
fragments None None O
were None None O
sliced None None O
into None None O
5 None None O
mum None None O
thick None None O
sections None None O
and None None O
stained None None O
with None None O
hematoxylin None None O
- None None O
eosin None None O
. None None O

Histological None None O
evaluation None None O
was None None O
done None None O
by None None O
a None None O
pathologist None None O
who None None O
was None None O
blinded None None O
to None None O
the None None O
experimental None None O
groups None None O
, None None O
and None None O
it None None O
was None None O
based None None O
on None None O
the None None O
intensity None None O
of None None O
mononuclear None None O
and None None O
polymorphonuclear None None O
infiltrates None None O
in None None O
the None None O
lamina None None O
propria None None O
, None None O
crypt None None O
dilation None None O
, None None O
cellular None None O
destruction None None O
and None None O
mucosal None None O
ulceration None None O
. None None O

Histopathological None None O
changes None None O
were None None O
graded None None O
according None None O
to None None O
the None None O
degree None None O
of None None O
inflammation None None O
using None None O
the None None O
following None None O
scale None None O
: None None O
absent None None O
( None None O
0 None None O
) None None O
, None None O
light None None O
( None None O
1 None None O
) None None O
, None None O
moderate None None O
( None None O
2 None None O
) None None O
and None None O
intense None None O
( None None O
3 None None O
) None None O
, None None O
and None None O
the None None O
numbers None None O
represented None None O
the None None O
inflammation None None O
score None None O
( None None O
IS None None O
) None None O
. None None O

Results None None O
were None None O
expressed None None O
as None None O
mean None None O
values None None O
of None None O
IS None None O
+ None None O
/ None None O
- None None O
standard None None O
error None None O
of None None O
the None None O
mean None None O
( None None O
SEM None None O
) None None O
for None None O
each None None O
experimental None None O
group None None O
. None None O

Effects None None O
of None None O
doxycycline None None O
on None None O
in None None O
vitro None None O
growth None None O
, None None O
migration None None O
, None None O
and None None O
gelatinase None None O
activity None None O
of None None O
breast None None O
carcinoma None None O
cells None None O
. None None O

Metastatic None None O
disease None None O
is None None O
one None None O
of None None O
the None None O
major None None O
causes None None O
of None None O
death None None O
from None None O
cancer None None O
in None None O
human None None O
beings None None O
. None None O

Several None None O
enzyme None None O
systems None None O
have None None O
been None None O
implicated None None O
in None None O
the None None O
metastatic None None O
process None None O
, None None O
but None None O
the None None O
metalloproteinases None None O
( None None O
MPs None None O
) None None O
appear None None O
to None None O
be None None O
the None None O
major None None O
group None None O
involved None None O
in None None O
most None None O
instances None None O
of None None O
neoplastic None None O
invasion None None O
. None None O

Increased None None O
MP None None O
activity None None O
has None None O
been None None O
correlated None None O
with None None O
the None None O
metastatic None None O
potential None None O
of None None O
many None None O
cancers None None O
, None None O
including None None O
breast None None O
cancer None None O
. None None O

MPs None None O
also None None O
play None None O
a None None O
role None None O
in None None O
tumor None None O
angiogenesis None None O
. None None O

Tetracyclines None None O
are None None O
antimicrobial None None O
agents None None O
that None None O
can None None O
suppress None None O
MP None None O
activity None None O
in None None O
a None None O
variety None None O
of None None O
tissues None None O
, None None O
including None None O
gingiva None None O
, None None O
bone None None O
, None None O
and None None O
cartilage None None O
. None None O

Several None None O
reports None None O
have None None O
indicated None None O
that None None O
tetracyclines None None O
can None None O
suppress None None O
tumor None None O
MPs None None O
as None None O
well None None O
. None None O

A None None O
synthetic None None O
tetracycline None None O
, None None O
doxycycline None None O
, None None O
inhibits None None O
migration None None O
of None None O
human None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
435 None None I-Cell-line-name
breast None None O
adenocarcinoma None None O
cells None None O
through None None O
a None None O
reconstituted None None O
basement None None O
membrane None None O
( None None O
Matrigel None None O
) None None O
, None None O
an None None O
assay None None O
used None None O
as None None O
an None None O
in None None O
vitro None None O
surrogate None None O
for None None O
the None None O
in None None O
vivo None None O
process None None O
of None None O
tumor None None O
invasion None None O
through None None O
basement None None O
membranes None None O
. None None O

Additionally None None O
, None None O
doxycycline None None O
diminishes None None O
the None None O
proliferation None None O
of None None O
this None None O
breast None None O
cancer None None O
cell None None O
line None None O
and None None O
also None None O
decreases None None O
its None None O
gelatinolytic None None O
activity None None O
, None None O
as None None O
determined None None O
by None None O
gel None None O
zymography None None O
. None None O

The None None O
thickness None None O
of None None O
the None None O
inner None None O
retina None None O
was None None O
established None None O
as None None O
the None None O
distance None None O
between None None O
retinal None None O
nerve None None O
fiber None None O
layer None None O
and None None O
inner None None O
nuclear None None O
layer None None O
and None None O
was None None O
measured None None O
using None None O
the None None O
1 None None O
, None None O
000 None None O
mum None None O
caliper None None O
available None None O
in None None O
the None None O
OCT None None O
- None None O
SLO None None O
Spectralis None None O
. None None O

Ten None None O
age None None O
- None None O
matched None None O
normal None None O
eyes None None O
were None None O
used None None O
as None None O
controls None None O
. None None O

Observe None None O
the None None O
decrease None None O
in None None O
the None None O
nasal None None O
and None None O
temporal None None O
inner None None O
retinal None None O
thickness None None O
in None None O
the None None O
right None None O
eye None None O
in None None O
comparison None None O
to None None O
the None None O
left None None O
and None None O
normal None None O
control None None O
eyes None None O
. None None O

Introduction None None O

Adipose None None O
tissue None None O
, None None O
once None None O
viewed None None O
as None None O
simply None None O
a None None O
storage None None O
and None None O
release None None O
depot None None O
for None None O
lipids None None O
, None None O
is None None O
now None None O
considered None None O
an None None O
endocrine None None O
tissue None None O
[ None None O
1 None None O
, None None O
2 None None O
] None None O
that None None O
secretes None None O
various None None O
substances None None O
( None None O
adipokines None None O
) None None O
, None None O
including None None O
tumor None None O
necrosis None None O
factor None None O
- None None O
alpha None None O
( None None O
TNF None None O
- None None O
alpha None None O
) None None O
, None None O
interleukin None None O
( None None O
IL None None O
) None None O
- None None O
6 None None O
, None None O
leptin None None O
, None None O
adiponectin None None O
, None None O
resistin None None O
, None None O
visfatin None None O
, None None O
and None None O
omenetin None None O
[ None None O
3 None None O
, None None O
4 None None O
] None None O
. None None O

Among None None O
these None None O
adipokines None None O
, None None O
much None None O
attention None None O
has None None O
been None None O
paid None None O
to None None O
adiponectin None None O
' None None O
s None None O
relationship None None O
with None None O
insulin None None O
sensitivity None None O
and None None O
glucose None None O
and None None O
lipid None None O
metabolism None None O
in None None O
the None None O
past None None O
10 None None O
years None None O
. None None O

In None None O
addition None None O
, None None O
adiponectin None None O
is None None O
known None None O
to None None O
exhibit None None O
potent None None O
anti None None O
- None None O
inflammatory None None O
[ None None O
5 None None O
] None None O
, None None O
atheroprotective None None O
[ None None O
6 None None O
] None None O
, None None O
and None None O
antidiabetic None None O
[ None None O
7 None None O
] None None O
effects None None O
. None None O

Recent None None O
findings None None O
suggest None None O
that None None O
adiponectin None None O
may None None O
be None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
rheumatoid None None O
arthritis None None O
( None None O
RA None None O
) None None O
. None None O

Levels None None O
of None None O
adiponectin None None O
in None None O
synovial None None O
fluid None None O
and None None O
sera None None O
were None None O
elevated None None O
in None None O
patients None None O
with None None O
RA None None O
[ None None O
8 None None O
, None None O
9 None None O
] None None O
. None None O

Adiponectin None None O
also None None O
induces None None O
the None None O
production None None O
of None None O
proinflammatory None None O
cytokines None None O
, None None O
IL None None O
- None None O
6 None None O
, None None O
matrix None None O
metalloproteinase None None O
( None None O
MMP None None O
) None None O
- None None O
1 None None O
, None None O
and None None O
IL None None O
- None None O
8 None None O
from None None O
RA None None O
synovial None None O
fibroblasts None None O
in None None O
vitro None None O
[ None None O
10 None None O
, None None O
11 None None O
] None None O
. None None O

Thus None None O
, None None O
it None None O
was None None O
suggested None None O
that None None O
adiponectin None None O
can None None O
also None None O
exert None None O
significant None None O
proinflammatory None None O
and None None O
matrix None None O
- None None O
degrading None None O
effects None None O
. None None O

However None None O
, None None O
the None None O
role None None O
of None None O
adiponectin None None O
in None None O
the None None O
pathogenesis None None O
of None None O
RA None None O
is None None O
still None None O
controversial None None O
because None None O
of None None O
conflicting None None O
reports None None O
about None None O
its None None O
function None None O
[ None None O
10 None None O
, None None O
12 None None O
- None None O
15 None None O
] None None O
. None None O

In None None O
particular None None O
, None None O
adiponectin None None O
seems None None O
to None None O
play None None O
an None None O
anti None None O
- None None O
inflammatory None None O
role None None O
because None None O
it None None O
significantly None None O
inhibited None None O
IL None None O
- None None O
1beta None None O
- None None O
stimulated None None O
synovial None None O
cell None None O
proliferation None None O
in None None O
collagen None None O
- None None O
induced None None O
arthritic None None O
mice None None O
, None None O
despite None None O
increased None None O
IL None None O
- None None O
6 None None O
expression None None O
[ None None O
16 None None O
] None None O
. None None O

In None None O
contrast None None O
, None None O
high None None O
- None None O
grade None None O
inflammation None None O
in None None O
RA None None O
patients None None O
was None None O
negatively None None O
correlated None None O
with None None O
circulating None None O
adiponectin None None O
concentrations None None O
[ None None O
17 None None O
] None None O
. None None O

Rather None None O
, None None O
it None None O
was None None O
suggested None None O
that None None O
circulating None None O
adiponectin None None O
may None None O
be None None O
involved None None O
in None None O
cardiovascular None None O
disease None None O
in None None O
RA None None O
patients None None O
. None None O

Although None None O
this None None O
contradiction None None O
was None None O
partly None None O
explained None None O
by None None O
the None None O
induction None None O
of None None O
tolerance None None O
to None None O
inflammatory None None O
stimuli None None O
by None None O
adiponectin None None O
[ None None O
18 None None O
] None None O
, None None O
the None None O
pro None None O
- None None O
or None None O
anti None None O
- None None O
inflammatory None None O
effects None None O
of None None O
adiponectin None None O
on None None O
the None None O
pathogenesis None None O
of None None O
RA None None O
remain None None O
unknown None None O
. None None O

With None None O
regard None None O
to None None O
adiponectin None None O
' None None O
s None None O
proinflammatory None None O
effects None None O
, None None O
we None None O
wondered None None O
whether None None O
adiponectin None None O
might None None O
stimulate None None O
the None None O
production None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
MMPs None None O
as None None O
well None None O
as None None O
proinflammatory None None O
mediators None None O
like None None O
IL None None O
- None None O
1beta None None O
and None None O
TNF None None O
- None None O
alpha None None O
do None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
stimulatory None None O
effect None None O
of None None O
adiponectin None None O
on None None O
the None None O
production None None O
of None None O
IL None None O
- None None O
6 None None O
, None None O
IL None None O
- None None O
8 None None O
, None None O
prostaglandin None None O
E2 None None O
( None None O
PGE2 None None O
) None None O
, None None O
VEGF None None O
, None None O
and None None O
MMPs None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
correlation None None O
between None None O
adiponectin None None O
and None None O
VEGF None None O
or None None O
MMPs None None O
was None None O
investigated None None O
by None None O
measuring None None O
the None None O
levels None None O
of None None O
these None None O
three None None O
proteins None None O
in None None O
the None None O
joint None None O
fluid None None O
of None None O
patients None None O
with None None O
RA None None O
or None None O
osteoarthritis None None O
( None None O
OA None None O
) None None O
. None None O

Functional None None O
model None None O
of None None O
benign None None O
paroxysmal None None O
positional None None O
vertigo None None O
using None None O
an None None O
isolated None None O
frog None None O
semicircular None None O
canal None None O
. None None O

Bull None None O
frogs None None O
posterior None None O
semicircular None None O
canals None None O
( None None O
psc None None O
) None None O
wee None None O
used None None O
to None None O
simulate None None O
the None None O
condition None None O
of None None O
benign None None O
paroxysmal None None O
positional None None O
vertigo None None O
( None None O
BPPV None None O
) None None O
. None None O

The None None O
psc None None O
was None None O
isolated None None O
in None None O
frog None None O
Ringer None None O
' None None O
s None None O
solution None None O
, None None O
and None None O
the None None O
saccular None None O
otoconia None None O
were None None O
used None None O
as None None O
a None None O
responsible None None O
material None None O
to None None O
stimulate None None O
the None None O
cupula None None O
. None None O

When None None O
the None None O
otoconia None None O
were None None O
placed None None O
on None None O
the None None O
cupular None None O
surface None None O
to None None O
mimic None None O
the None None O
condition None None O
of None None O
cupulolithiasis None None O
, None None O
the None None O
psc None None O
ampullary None None O
nerve None None O
action None None O
potentials None None O
instantaneously None None O
changed None None O
according None None O
to None None O
the None None O
direction None None O
of None None O
the None None O
gravity None None O
produced None None O
by None None O
otoconia None None O
. None None O

When None None O
the None None O
otoconia None None O
were None None O
dropped None None O
into None None O
the None None O
canal None None O
to None None O
mimic None None O
the None None O
condition None None O
of None None O
moving None None O
otoconia None None O
in None None O
the None None O
canal None None O
, None None O
the None None O
action None None O
potentials None None O
changed None None O
together None None O
with None None O
the None None O
otoconial None None O
flow None None O
after None None O
a None None O
latent None None O
period None None O
. None None O

Both None None O
cupulolithiasis None None O
and None None O
moving None None O
otoconia None None O
are None None O
possibly None None O
valid None None O
mechanisms None None O
of None None O
BPPV None None O
, None None O
since None None O
they None None O
effectively None None O
stimulate None None O
the None None O
cupula None None O
. None None O

However None None O
, None None O
moving None None O
otoconia None None O
with None None O
a None None O
latent None None O
period None None O
would None None O
better None None O
explain None None O
clinical None None O
features None None O
of None None O
BPPV None None O
. None None O

Adenomatoid None None O
tumour None None O
of None None O
the None None O
liver None None O
. None None O

An None None O
unusual None None O
primary None None O
adenomatoid None None O
tumour None None O
arising None None O
in None None O
the None None O
normal None None O
liver None None O
is None None O
described None None O
. None None O

Hepatectomy None None O
was None None O
performed None None O
, None None O
and None None O
the None None O
patient None None O
is None None O
alive None None O
and None None O
free None None O
of None None O
disease None None O
1 None None O
year None None O
postsurgery None None O
. None None O

Grossly None None O
, None None O
the None None O
tumour None None O
showed None None O
a None None O
haemorrhagic None None O
cut None None O
surface None None O
with None None O
numerous None None O
microcystic None None O
structures None None O
. None None O

Histological None None O
examination None None O
revealed None None O
cystic None None O
or None None O
angiomatoid None None O
spaces None None O
of None None O
various None None O
sizes None None O
lined None None O
by None None O
cuboidal None None O
, None None O
low None None O
- None None O
columnar None None O
, None None O
or None None O
flattened None None O
epithelioid None None O
cells None None O
with None None O
vacuolated None None O
cytoplasm None None O
and None None O
round None None O
to None None O
oval None None O
nuclei None None O
. None None O

The None None O
epithelioid None None O
cells None None O
were None None O
entirely None None O
supported None None O
by None None O
proliferated None None O
capillaries None None O
and None None O
arteries None None O
together None None O
with None None O
collagenous None None O
stroma None None O
. None None O

Immunohistochemical None None O
studies None None O
showed None None O
that None None O
the None None O
epithelioid None None O
cells None None O
were None None O
strongly None None O
positive None None O
for None None O
a None None O
broad None None O
spectrum None None O
of None None O
cytokeratins None None O
( None None O
AE1 None None O
/ None None O
AE3 None None O
, None None O
CAM5 None None O
. None None O
2 None None O
, None None O
epithelial None None O
membrane None None O
antigen None None O
and None None O
cytokeratin None None O
7 None None O
) None None O
and None None O
mesothelial None None O
markers None None O
( None None O
calretinin None None O
, None None O
Wilms None None O
' None None O
tumour None None O
1 None None O
and None None O
D2 None None O
- None None O
40 None None O
) None None O
. None None O

These None None O
cells None None O
were None None O
negative None None O
for None None O
Hep None None O
par None None O
- None None O
1 None None O
, None None O
carcinoembryonic None None O
antigen None None O
, None None O
neural None None O
cell None None O
adhesion None None O
molecule None None O
, None None O
CD34 None None O
, None None O
CD31 None None O
and None None O
HMB45 None None O
. None None O

Atypically None None O
, None None O
abundant None None O
capillaries None None O
were None None O
observed None None O
; None None O
however None None O
, None None O
the None None O
cystic None None O
proliferation None None O
of None None O
epithelioid None None O
cells None None O
with None None O
vacuoles None None O
and None None O
immunohistochemical None None O
profile None None O
of None None O
the None None O
epithelioid None None O
element None None O
were None None O
consistent None None O
with None None O
hepatic None None O
adenomatoid None None O
tumour None None O
. None None O

[ None None O
Preliminary None None O
results None None O
of None None O
observing None None O
18 None None O
cases None None O
of None None O
retinoblastoma None None O
carried None None O
within None None O
the None None O
international None None O
research None None O
program None None O
RICS None None O
] None None O
. None None O

In None None O
the None None O
years None None O
1988 None None O
- None None O
1989 None None O
, None None O
the None None O
Ophthalmological None None O
Clinic None None O
in None None O
Cracow None None O
took None None O
part None None O
in None None O
the None None O
International None None O
Research None None O
Programme None None O
on None None O
Retinoblastoma None None O
as None None O
one None None O
of None None O
28 None None O
clinical None None O
centres None None O
in None None O
14 None None O
countries None None O
. None None O

The None None O
study None None O
included None None O
18 None None O
children None None O
with None None O
retinoblastoma None None O
, None None O
in None None O
most None None O
cases None None O
in None None O
the None None O
advanced None None O
stadium None None O
of None None O
the None None O
disease None None O
. None None O

As None None O
a None None O
rule None None O
, None None O
the None None O
eyes None None O
filled None None O
with None None O
tumours None None O
were None None O
enucleated None None O
, None None O
and None None O
the None None O
less None None O
advanced None None O
cases None None O
were None None O
treated None None O
with None None O
combined None None O
methods None None O
applying None None O
radiation None None O
with None None O
60Co None None O
plaques None None O
with None None O
xenon None None O
arc None None O
photocoagulation None None O
, None None O
cryopexy None None O
, None None O
and None None O
chemotherapy None None O
. None None O

In None None O
18 None None O
treated None None O
children None None O
23 None None O
eyes None None O
were None None O
enucleated None None O
( None None O
in None None O
5 None None O
children None None O
both None None O
eyes None None O
, None None O
in None None O
6 None None O
children None None O
with None None O
bilateral None None O
retinoblastoma None None O
1 None None O
eye None None O
, None None O
and None None O
7 None None O
eyes None None O
in None None O
all None None O
unilateral None None O
cases None None O
) None None O
. None None O

Six None None O
eyes None None O
with None None O
less None None O
advanced None None O
lesions None None O
were None None O
treated None None O
with None None O
combined None None O
methods None None O
. None None O

One None None O
child None None O
died None None O
because None None O
of None None O
metastases None None O
to None None O
the None None O
brain None None O
. None None O

The None None O
obtained None None O
data None None O
reveal None None O
that None None O
retinoblastoma None None O
is None None O
diagnosed None None O
too None None O
late None None O
, None None O
which None None O
decreases None None O
the None None O
chance None None O
of None None O
cure None None O
and None None O
causes None None O
great None None O
danger None None O
for None None O
the None None O
life None None O
of None None O
the None None O
child None None O
. None None O

Brn None None O
- None None O
3a None None O
, None None O
a None None O
neuronal None None O
transcription None None O
factor None None O
of None None O
the None None O
POU None None O
gene None None O
family None None O
: None None O
indications None None O
for None None O
its None None O
involvement None None O
in None None O
cancer None None O
and None None O
angiogenesis None None O
. None None O

Brn None None O
- None None O
3a None None O
, None None O
a None None O
member None None O
of None None O
the None None O
POU None None O
gene None None O
family None None O
( None None O
so None None O
- None None O
called None None O
because None None O
of None None O
the None None O
similarity None None O
with None None O
the None None O
group None None O
of None None O
transcription None None O
factors None None O
Pit None None O
, None None O
Oct None None O
, None None O
and None None O
Unc None None O
) None None O
, None None O
was None None O
found None None O
in None None O
neuronal None None O
cells None None O
engaged None None O
in None None O
the None None O
transcription None None O
activity None None O
of None None O
the None None O
p1 None None O
and None None O
p2 None None O
promoters None None O
of None None O
the None None O
most None None O
powerful None None O
antiapoptotic None None O
gene None None O
, None None O
namely None None O
, None None O
Bcl None None O
- None None O
2 None None O
. None None O

The None None O
alternative None None O
splicing None None O
of None None O
Brn None None O
- None None O
3a None None O
mRNA None None O
produces None None O
two None None O
molecular None None O
forms None None O
: None None O
a None None O
longer None None O
, None None O
Bcl None None O
- None None O
2 None None O
transactivating None None O
form None None O
, None None O
and None None O
a None None O
shorter None None O
inactive None None O
form None None O
, None None O
lacking None None O
84 None None O
AA None None O
in None None O
the None None O
aminoterminus None None O
. None None O

In None None O
neuronal None None O
cells None None O
, None None O
following None None O
Brn None None O
- None None O
3a None None O
gene None None O
transfection None None O
and None None O
superexpression None None O
, None None O
an None None O
increase None None O
of None None O
30 None None O
fold None None O
of None None O
the None None O
Bcl None None O
- None None O
2 None None O
protein None None O
occurs None None O
, None None O
leading None None O
to None None O
apoptosis None None O
protection None None O
. None None O

However None None O
, None None O
recent None None O
works None None O
demonstrate None None O
that None None O
Brn None None O
- None None O
3a None None O
expression None None O
is None None O
not None None O
restricted None None O
to None None O
neuronal None None O
cells None None O
, None None O
as None None O
its None None O
activity None None O
was None None O
detected None None O
also None None O
in None None O
cancer None None O
cells None None O
of None None O
non None None O
- None None O
neuronal None None O
nature None None O
. None None O

Looking None None O
for None None O
mechanisms None None O
linking None None O
Brn None None O
- None None O
3a None None O
to None None O
carcinogenesis None None O
, None None O
we None None O
discuss None None O
the None None O
role None None O
of None None O
this None None O
transcription None None O
factor None None O
in None None O
influencing None None O
Bcl None None O
- None None O
2 None None O
/ None None O
p53 None None O
antagonism None None O
and None None O
Bcl None None O
- None None O
2 None None O
/ None None O
VEGF None None O
induction None None O
of None None O
tumor None None O
angiogenesis None None O
, None None O
concluding None None O
this None None O
review None None O
with None None O
a None None O
proposal None None O
for None None O
the None None O
oncogenic None None O
nature None None O
of None None O
Brn None None O
- None None O
3a None None O
. None None O

The None None O
pedigree None None O
of None None O
a None None O
Korean None None O
family None None O
with None None O
macular None None O
dystrophy None None O
demonstrating None None O
the None None O
characteristics None None O
of None None O
an None None O
autosomal None None O
dominant None None O
inheritance None None O
trait None None O
. None None O

Silencing None None O
of None None O
monocarboxylate None None O
transporters None None O
via None None O
small None None O
interfering None None O
ribonucleic None None O
acid None None O
inhibits None None O
glycolysis None None O
and None None O
induces None None O
cell None None O
death None None O
in None None O
malignant None None O
glioma None None O
: None None O
an None None O
in None None O
vitro None None O
study None None O
. None None O

OBJECTIVE None None O
: None None O
Dependence None None O
on None None O
glycolysis None None O
is None None O
a None None O
hallmark None None O
of None None O
malignant None None O
tumors None None O
. None None O

As None None O
a None None O
consequence None None O
, None None O
these None None O
tumors None None O
generate None None O
more None None O
lactate None None O
, None None O
which None None O
is None None O
effluxed None None O
from None None O
cells None None O
by None None O
monocarboxylate None None O
transporters None None O
( None None O
MCTs None None O
) None None O
. None None O

We None None O
hypothesized None None O
that None None O
1 None None O
) None None O
MCT None None O
expression None None O
in None None O
malignant None None O
tumors None None O
may None None O
differ None None O
from None None O
normal None None O
tissue None None O
in None None O
quantity None None O
, None None O
isoform None None O
, None None O
or None None O
both None None O
; None None O
and None None O
2 None None O
) None None O
silencing None None O
MCT None None O
expression None None O
would None None O
induce None None O
intracellular None None O
acidification None None O
, None None O
resulting None None O
in None None O
decreased None None O
proliferation None None O
and None None O
/ None None O
or None None O
increased None None O
cell None None O
death None None O
. None None O

METHODS None None O
: None None O
We None None O
quantified None None O
expression None None O
of None None O
MCT None None O
isoforms None None O
in None None O
human None None O
glioblastoma None None O
multiforme None None O
and None None O
glioma None None O
- None None O
derived None None O
cells None None O
lines None None O
by None None O
Western None None O
blot None None O
analysis None None O
. None None O

MCTs None None O
that None None O
were None None O
abundant None None O
or None None O
specific None None O
to None None O
glioma None None O
then None None O
were None None O
targeted None None O
in None None O
the None None O
model None None O
U None None I-Cell-line-name
- None None I-Cell-line-name
87 None None I-Cell-line-name
MG None None O
glioma None None O
cell None None O
line None None O
via None None O
small None None O
interfering None None O
ribonucleic None None O
acid None None O
- None None O
mediated None None O
gene None None O
silencing None None O
and None None O
tested None None O
for None None O
inhibition None None O
of None None O
lactate None None O
efflux None None O
, None None O
intracellular None None O
pH None None O
changes None None O
, None None O
reduced None None O
proliferation None None O
, None None O
and None None O
/ None None O
or None None O
induction None None O
of None None O
cell None None O
death None None O
. None None O

RESULTS None None O
: None None O
MCT None None O
1 None None O
and None None O
2 None None O
were None None O
the None None O
primary None None O
isoforms None None O
expressed None None O
in None None O
human None None O
glioblastoma None None O
multiforme None None O
and None None O
glioma None None O
- None None O
derived None None O
cell None None O
lines None None O
. None None O

In None None O
contrast None None O
, None None O
MCT None None O
3 None None O
was None None O
the None None O
predominantly None None O
expressed None None O
isoform None None O
in None None O
normal None None O
brain None None O
. None None O

Small None None O
interfering None None O
ribonucleic None None O
acid None None O
specific None None O
for None None O
MCT None None O
1 None None O
and None None O
2 None None O
reduced None None O
expression None None O
of None None O
these None None O
isoforms None None O
in None None O
U None None I-Cell-line-name
- None None I-Cell-line-name
87 None None I-Cell-line-name
MG None None I-Cell-line-name
cells None None O
to None None O
barely None None O
detectable None None O
levels None None O
and None None O
reduced None None O
lactate None None O
efflux None None O
by None None O
30 None None O
% None None O
individually None None O
and None None O
85 None None O
% None None O
in None None O
combination None None O
, None None O
with None None O
a None None O
concomitant None None O
decrease None None O
of None None O
intracellular None None O
pH None None O
by None None O
0 None None O
. None None O
6 None None O
units None None O
( None None O
a None None O
fourfold None None O
increase None None O
in None None O
intracellular None None O
H None None O
( None None O
+ None None O
) None None O
) None None O
. None None O

Prolonged None None O
silencing None None O
of None None O
both None None O
MCTs None None O
reduced None None O
viability None None O
by None None O
75 None None O
% None None O
individually None None O
and None None O
92 None None O
% None None O
in None None O
combination None None O
, None None O
as None None O
measured None None O
by None None O
both None None O
phenotypic None None O
and None None O
flow None None O
cytometric None None O
analyses None None O
. None None O

CONCLUSION None None O
: None None O
MCT None None O
targeting None None O
significantly None None O
reduced None None O
the None None O
viability None None O
of None None O
U None None I-Cell-line-name
- None None I-Cell-line-name
87 None None I-Cell-line-name
MG None None I-Cell-line-name
cells None None O
mediated None None O
by None None O
both None None O
apoptosis None None O
and None None O
necrosis None None O
. None None O

This None None O
indicates None None O
that None None O
the None None O
strategy None None O
may None None O
be None None O
a None None O
useful None None O
therapeutic None None O
avenue None None O
for None None O
treatment None None O
of None None O
patients None None O
with None None O
malignant None None O
glioma None None O
. None None O

Summary None None O
of None None O
studies None None O
reporting None None O
comorbidities None None O
with None None O
diabetes None None O
. None None O

SV40 None None O
Tag None None O
transformation None None O
of None None O
the None None O
normal None None O
invasive None None O
trophoblast None None O
results None None O
in None None O
a None None O
premalignant None None O
phenotype None None O
. None None O

I None None O
. None None O

Mechanisms None None O
responsible None None O
for None None O
hyperinvasiveness None None O
and None None O
resistance None None O
to None None O
anti None None O
- None None O
invasive None None O
action None None O
of None None O
TGFbeta None None O
. None None O

Invasion None None O
of None None O
the None None O
uterus None None O
by None None O
first None None O
trimester None None O
human None None O
placental None None O
extravillous None None O
trophoblast None None O
( None None O
EVT None None O
) None None O
cells None None O
depends None None O
on None None O
mechanisms None None O
shared None None O
by None None O
malignant None None O
cells None None O
. None None O

However None None O
, None None O
unlike None None O
tumor None None O
invasion None None O
, None None O
trophoblast None None O
invasion None None O
of None None O
the None None O
uterus None None O
is None None O
stringently None None O
controlled None None O
in None None O
situ None None O
by None None O
local None None O
molecules None None O
such None None O
as None None O
transforming None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
beta None None O
. None None O

Since None None O
EVT None None O
cells None None O
possess None None O
active None None O
invasion None None O
- None None O
associated None None O
genes None None O
but None None O
are None None O
nontumorigenic None None O
, None None O
our None None O
objective None None O
was None None O
to None None O
induce None None O
premalignant None None O
and None None O
then None None O
malignant None None O
phenotype None None O
into None None O
a None None O
normal None None O
EVT None None I-Cell-line-name
cell None None O
line None None O
in None None O
order None None O
to None None O
identify None None O
the None None O
molecular None None O
basis None None O
of None None O
tumor None None O
progression None None O
. None None O

Simian None None O
virus None None O
40 None None O
large None None O
T None None O
antigen None None O
( None None O
SV40 None None O
Tag None None O
) None None O
was None None O
introduced None None O
into None None O
a None None O
normal None None O
human None None O
first None None O
trimester None None O
invasive None None O
EVT None None I-Cell-line-name
cell None None O
line None None O
, None None O
HTR8 None None I-Cell-line-name
, None None O
established None None O
in None None O
our None None O
laboratory None None O
. None None O

Since None None O
the None None O
HTR8 None None I-Cell-line-name
line None None O
has None None O
a None None O
limited None None O
in None None O
vitro None None O
lifespan None None O
of None None O
12 None None O
- None None O
15 None None O
passages None None O
, None None O
SV40 None None O
Tag None None O
- None None O
transformed None None O
cells None None O
were None None O
selected None None O
on None None O
the None None O
basis None None O
of None None O
extended None None O
lifespan None None O
. None None O

A None None O
long None None O
- None None O
lived None None O
line None None O
, None None O
RSVT None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
, None None O
was None None O
produced None None O
and None None O
an None None O
immortalized None None O
subclone None None O
, None None O
RSVT2 None None I-Cell-line-name
/ None None I-Cell-line-name
C None None I-Cell-line-name
, None None O
was None None O
further None None O
derived None None O
under None None O
a None None O
forced None None O
crisis None None O
regimen None None O
. None None O

We None None O
examined None None O
transformation None None O
- None None O
induced None None O
alterations None None O
in None None O
proliferative None None O
and None None O
invasive None None O
abilities None None O
, None None O
responses None None O
to None None O
the None None O
invasion None None O
and None None O
proliferation None None O
- None None O
regulating None None O
growth None None O
factor None None O
TGFbeta None None O
and None None O
changes None None O
in None None O
gene None None O
expression None None O
for None None O
invasion None None O
- None None O
associated None None O
enzymes None None O
or None None O
enzyme None None O
inhibitors None None O
. None None O

RSVT None None I-Cell-line-name
- None None I-Cell-line-name
2 None None I-Cell-line-name
and None None O
RSVT2 None None I-Cell-line-name
/ None None I-Cell-line-name
C None None I-Cell-line-name
cell None None O
lines None None O
were None None O
hyperproliferative None None O
and None None O
hyperinvasive None None O
when None None O
compared None None O
with None None O
the None None O
parental None None O
HTR8 None None I-Cell-line-name
cell None None O
line None None O
. None None O

They None None O
were None None O
also None None O
variably None None O
resistant None None O
to None None O
the None None O
anti None None O
- None None O
proliferative None None O
and None None O
anti None None O
- None None O
invasive None None O
signals None None O
from None None O
TGFbeta None None O
. None None O

Since None None O
both None None O
cell None None O
lines None None O
remained None None O
non None None O
- None None O
tumorigenic None None O
in None None O
nude None None O
mice None None O
, None None O
these None None O
properties None None O
indicate None None O
that None None O
they None None O
attained None None O
a None None O
premalignant None None O
phenotype None None O
. None None O

Both None None O
cell None None O
lines None None O
showed None None O
reduced None None O
expression None None O
of None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteases None None O
( None None O
TIMP None None O
) None None O
- None None O
1 None None O
, None None O
while None None O
TIMP None None O
- None None O
2 None None O
and None None O
plasminogen None None O
activator None None O
inhibitor None None O
( None None O
PAI None None O
) None None O
- None None O
I None None O
expression None None O
was None None O
was None None O
also None None O
reduced None None O
in None None O
RSVT2 None None I-Cell-line-name
/ None None I-Cell-line-name
C None None I-Cell-line-name
cells None None O
, None None O
thus None None O
contributing None None O
to None None O
their None None O
hyperinvasiveness None None O
. None None O

Their None None O
resistance None None O
to None None O
the None None O
anti None None O
- None None O
invasive None None O
action None None O
of None None O
TGFbeta None None O
was None None O
explained None None O
by None None O
the None None O
failure None None O
of None None O
TGFbeta None None O
to None None O
upregulate None None O
TIMPs None None O
and None None O
PAI None None O
- None None O
I None None O
, None None O
in None None O
contrast None None O
to None None O
the None None O
TGFbeta None None O
- None None O
induced None None O
upregulation None None O
noted None None O
in None None O
parental None None O
HTR8 None None I-Cell-line-name
cells None None O
. None None O

Immunocytochemistry None None O

C2C12 None None I-Cell-line-name
cells None None O
grown None None O
in None None O
8 None None O
- None None O
chamber None None O
slides None None O
( None None O
Nunc None None O
) None None O
were None None O
fixed None None O
in None None O
4 None None O
% None None O
PFA None None O
/ None None O
PBS None None O
for None None O
10 None None O
min None None O
and None None O
permeabilized None None O
in None None O
0 None None O
. None None O
1 None None O
% None None O
Triton None None O
X None None O
- None None O
100 None None O
for None None O
20 None None O
min None None O
. None None O

In None None O
some None None O
cases None None O
, None None O
they None None O
were None None O
fixed None None O
and None None O
permeabilized None None O
in None None O
methanol None None O
at None None O
- None None O
20degreesC None None O
for None None O
2 None None O
min None None O
. None None O

The None None O
fixed None None O
and None None O
permeabilized None None O
cells None None O
were None None O
blocked None None O
in None None O
PBS None None O
containing None None O
3 None None O
% None None O
BSA None None O
( None None O
Jackson None None O
ImmunoResearch None None O
Laboratories None None O
) None None O
and None None O
incubated None None O
overnight None None O
at None None O
4degreesC None None O
with None None O
primary None None O
antibodies None None O
in None None O
blocking None None O
solution None None O
. None None O

Immunoreactivity None None O
was None None O
detected None None O
with None None O
either None None O
Alexa None None O
- None None O
conjugated None None O
secondary None None O
antibody None None O
( None None O
Molecular None None O
Probes None None O
) None None O
or None None O
a None None O
combination None None O
of None None O
biotin None None O
- None None O
conjugated None None O
secondary None None O
antibody None None O
( None None O
Vector None None O
Laboratories None None O
) None None O
and None None O
Alexa None None O
- None None O
conjugated None None O
streptavidin None None O
( None None O
Molecular None None O
Probes None None O
) None None O
. None None O

M None None O
. None None O
leprae None None O
- None None O
and None None O
BCG None None O
- None None O
induced None None O
chemiluminescence None None O
response None None O
of None None O
monocytes None None O
from None None O
leprosy None None O
patients None None O
and None None O
healthy None None O
subjects None None O
: None None O
effects None None O
of None None O
gamma None None O
- None None O
interferon None None O
and None None O
GM None None O
- None None O
CSF None None O
. None None O

Mycobacterium None None O
leprae None None O
, None None O
in None None O
contrast None None O
to None None O
BCG None None O
, None None O
failed None None O
to None None O
trigger None None O
any None None O
chemiluminescence None None O
( None None O
CL None None O
) None None O
response None None O
in None None O
mononuclear None None O
cells None None O
from None None O
either None None O
leprosy None None O
patients None None O
or None None O
healthy None None O
subjects None None O
, None None O
a None None O
deficit None None O
not None None O
reversed None None O
by None None O
either None None O
interferon None None O
- None None O
gamma None None O
or None None O
GM None None O
- None None O
CSF None None O
. None None O

Chemiluminescence None None O
responses None None O
induced None None O
without None None O
mycobacteria None None O
or None None O
with None None O
BCG None None O
were None None O
found None None O
to None None O
be None None O
lower None None O
in None None O
leprosy None None O
patients None None O
than None None O
in None None O
controls None None O
. None None O

M None None O
. None None O
leprae None None O
were None None O
also None None O
less None None O
well None None O
phagocytosed None None O
than None None O
BCG None None O
. None None O

However None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
difference None None O
in None None O
phagocytosis None None O
between None None O
healthy None None O
and None None O
tuberculoid None None O
leprosy None None O
subjects None None O
. None None O

Phagocytosis None None O
was None None O
not None None O
altered None None O
by None None O
the None None O
addition None None O
of None None O
either None None O
lymphokine None None O
, None None O
and None None O
no None None O
major None None O
differences None None O
between None None O
healthy None None O
subjects None None O
and None None O
patients None None O
were None None O
observed None None O
. None None O

Preincubating None None O
mononuclear None None O
cells None None O
with None None O
anti None None O
- None None O
mycobacteria None None O
antibodies None None O
( None None O
lepromatous None None O
patients None None O
' None None O
sera None None O
) None None O
did None None O
not None None O
increase None None O
the None None O
CL None None O
response None None O
nor None None O
the None None O
phagocytosis None None O
of None None O
M None None O
. None None O
leprae None None O
or None None O
BCG None None O
. None None O

Arteriogenesis None None O
: None None O
the None None O
development None None O
and None None O
growth None None O
of None None O
collateral None None O
arteries None None O
. None None O

In None None O
patients None None O
with None None O
atherosclerotic None None O
vascular None None O
diseases None None O
, None None O
collateral None None O
vessels None None O
bypassing None None O
major None None O
arterial None None O
obstructions None None O
have None None O
frequently None None O
been None None O
observed None None O
. None None O

This None None O
may None None O
explain None None O
why None None O
some None None O
patients None None O
remain None None O
without None None O
symptoms None None O
or None None O
signs None None O
of None None O
ischemia None None O
. None None O

The None None O
term None None O
" None None O
arteriogenesis None None O
" None None O
was None None O
introduced None None O
to None None O
differentiate None None O
the None None O
formation None None O
of None None O
collateral None None O
arteries None None O
from None None O
angiogenesis None None O
, None None O
which None None O
mainly None None O
occurs None None O
in None None O
the None None O
ischemic None None O
, None None O
collateral None None O
flow None None O
- None None O
dependent None None O
tissue None None O
. None None O

Many None None O
observations None None O
in None None O
various None None O
animal None None O
models None None O
and None None O
humans None None O
support None None O
that None None O
the None None O
remodeling None None O
of None None O
preexisting None None O
collateral None None O
vessels None None O
is None None O
the None None O
mechanism None None O
of None None O
collateral None None O
artery None None O
formation None None O
. None None O

This None None O
remodeling None None O
process None None O
seems None None O
to None None O
be None None O
mainly None None O
flow None None O
- None None O
mediated None None O
. None None O

It None None O
involves None None O
endothelial None None O
cell None None O
activation None None O
, None None O
basal None None O
membrane None None O
degradation None None O
, None None O
leukocyte None None O
invasion None None O
, None None O
proliferation None None O
of None None O
vascular None None O
cells None None O
, None None O
neointima None None O
formation None None O
( None None O
in None None O
most None None O
species None None O
studied None None O
) None None O
, None None O
and None None O
changes None None O
of None None O
the None None O
extracellular None None O
matrix None None O
. None None O

The None None O
contribution None None O
of None None O
ischemia None None O
to None None O
arteriogenesis None None O
is None None O
still None None O
unclear None None O
, None None O
but None None O
arteriogenesis None None O
clearly None None O
can None None O
occur None None O
in None None O
the None None O
absence None None O
of None None O
any None None O
significant None None O
ischemia None None O
. None None O

It None None O
is None None O
questionable None None O
, None None O
whether None None O
collateral None None O
arteries None None O
also None None O
form None None O
de None None O
novo None None O
in None None O
ischemic None None O
vascular None None O
diseases None None O
. None None O

A None None O
better None None O
understanding None None O
of None None O
the None None O
mechanisms None None O
of None None O
arteriogenesis None None O
will None None O
be None None O
important None None O
for None None O
the None None O
design None None O
of None None O
more None None O
effective None None O
strategies None None O
for None None O
the None None O
treatment None None O
of None None O
patients None None O
with None None O
ischemic None None O
vascular None None O
diseases None None O
. None None O

Monitoring None None O
the None None O
efficiency None None O
of None None O
interferon None None O
- None None O
alpha None None O
therapy None None O
in None None O
chronic None None O
myelogenous None None O
leukemia None None O
( None None O
CML None None O
) None None O
patients None None O
by None None O
competitive None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

Interferon None None O
alpha None None O
( None None O
IFN None None O
- None None O
alpha None None O
) None None O
induces None None O
cytogenetic None None O
responses None None O
of None None O
variable None None O
degree None None O
in None None O
patients None None O
with None None O
CML None None O
. None None O

We None None O
sought None None O
to None None O
establish None None O
the None None O
relationship None None O
between None None O
BCR None None O
- None None O
ABL None None O
transcript None None O
numbers None None O
measured None None O
by None None O
competitive None None O
two None None O
- None None O
step None None O
reverse None None O
transcription None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT None None O
- None None O
PCR None None O
) None None O
and None None O
cytogenetic None None O
status None None O
in None None O
CML None None O
patients None None O
treated None None O
with None None O
IFN None None O
- None None O
alpha None None O
. None None O

All None None O
398 None None O
samples None None O
from None None O
163 None None O
patients None None O
investigated None None O
by None None O
RT None None O
- None None O
PCR None None O
were None None O
positive None None O
for None None O
BCR None None O
- None None O
ABL None None O
transcripts None None O
. None None O

In None None O
order None None O
to None None O
standardize None None O
results None None O
for None None O
variability None None O
in None None O
RNA None None O
and None None O
cDNA None None O
quality None None O
, None None O
we None None O
quantified None None O
total None None O
ABL None None O
transcripts None None O
in None None O
each None None O
sample None None O
as None None O
internal None None O
control None None O
. None None O

The None None O
BCR None None O
- None None O
ABL None None O
/ None None O
ABL None None O
ratios None None O
correlated None None O
with None None O
the None None O
cytogenetic None None O
results None None O
. None None O

Quantitative None None O
nested None None O
PCR None None O
allowed None None O
the None None O
detection None None O
of None None O
residual None None O
BCR None None O
- None None O
ABL None None O
transcripts None None O
in None None O
all None None O
complete None None O
cytogenetic None None O
responders None None O
on None None O
IFN None None O
- None None O
alpha None None O
. None None O

We None None O
conclude None None O
that None None O
competitive None None O
PCR None None O
with None None O
internal None None O
controls None None O
is None None O
a None None O
reliable None None O
method None None O
for None None O
monitoring None None O
patients None None O
on None None O
IFN None None O
- None None O
alpha None None O
and None None O
reduces None None O
the None None O
need None None O
for None None O
repeated None None O
marrow None None O
investigations None None O
. None None O

Constitutively None None O
nuclear None None O
FOXO3a None None O
localization None None O
predicts None None O
poor None None O
survival None None O
and None None O
promotes None None O
Akt None None O
phosphorylation None None O
in None None O
breast None None O
cancer None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
PI3K None None O
- None None O
Akt None None O
signal None None O
pathway None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
tumorigenesis None None O
and None None O
the None None O
development None None O
of None None O
drug None None O
- None None O
resistance None None O
. None None O

Cytotoxic None None O
chemotherapy None None O
resistance None None O
is None None O
linked None None O
to None None O
limited None None O
therapeutic None None O
options None None O
and None None O
poor None None O
prognosis None None O
. None None O

METHODOLOGY None None O
/ None None O
PRINCIPAL None None O
FINDINGS None None O
: None None O
Examination None None O
of None None O
FOXO3a None None O
and None None O
phosphorylated None None O
- None None O
Akt None None O
( None None O
P None None O
- None None O
Akt None None O
) None None O
expression None None O
in None None O
breast None None O
cancer None None O
tissue None None O
microarrays None None O
showed None None O
nuclear None None O
FOXO3a None None O
was None None O
associated None None O
with None None O
lymph None None O
node None None O
positivity None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
052 None None O
) None None O
, None None O
poor None None O
prognosis None None O
( None None O
p None None O
= None None O
0 None None O
. None None O
014 None None O
) None None O
, None None O
and None None O
P None None O
- None None O
Akt None None O
expression None None O
in None None O
invasive None None O
ductal None None O
carcinoma None None O
. None None O

Using None None O
tamoxifen None None O
and None None O
doxorubicin None None O
- None None O
sensitive None None O
and None None O
- None None O
resistant None None O
breast None None O
cancer None None O
cell None None O
lines None None O
as None None O
models None None O
, None None O
we None None O
found None None O
that None None O
doxorubicin None None O
- None None O
but None None O
not None None O
tamoxifen None None O
- None None O
resistance None None O
is None None O
associated None None O
with None None O
nuclear None None O
accumulation None None O
of None None O
FOXO3a None None O
, None None O
consistent None None O
with None None O
the None None O
finding None None O
that None None O
sustained None None O
nuclear None None O
FOXO3a None None O
is None None O
associated None None O
with None None O
poor None None O
prognosis None None O
. None None O

We None None O
also None None O
established None None O
that None None O
doxorubicin None None O
treatment None None O
induces None None O
proliferation None None O
arrest None None O
and None None O
FOXO3a None None O
nuclear None None O
relocation None None O
in None None O
sensitive None None O
breast None None O
cancer None None O
cells None None O
. None None O

Induction None None O
of None None O
FOXO3a None None O
activity None None O
in None None O
doxorubicin None None O
- None None O
sensitive None None O
MCF None None I-Cell-line-name
- None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
was None None O
sufficient None None O
to None None O
promote None None O
Akt None None O
phosphorylation None None O
and None None O
arrest None None O
cell None None O
proliferation None None O
. None None O

Conversely None None O
, None None O
knockdown None None O
of None None O
endogenous None None O
FOXO3a None None O
expression None None O
reduced None None O
PI3K None None O
/ None None O
Akt None None O
activity None None O
. None None O

Using None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
231 None None I-Cell-line-name
cells None None O
, None None O
in None None O
which None None O
FOXO3a None None O
activity None None O
can None None O
be None None O
induced None None O
by None None O
4 None None O
- None None O
hydroxytamoxifen None None O
, None None O
we None None O
showed None None O
that None None O
FOXO3a None None O
induction None None O
up None None O
- None None O
regulates None None O
PI3K None None O
- None None O
Akt None None O
activity None None O
and None None O
enhanced None None O
doxorubicin None None O
resistance None None O
. None None O

However None None O
FOXO3a None None O
induction None None O
has None None O
little None None O
effect None None O
on None None O
cell None None O
proliferation None None O
, None None O
indicating None None O
that None None O
FOXO3a None None O
or None None O
its None None O
downstream None None O
activity None None O
is None None O
deregulated None None O
in None None O
the None None O
cytotoxic None None O
drug None None O
resistant None None O
breast None None O
cancer None None O
cells None None O
. None None O

Thus None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
sustained None None O
FOXO3a None None O
activation None None O
can None None O
enhance None None O
hyperactivation None None O
of None None O
the None None O
PI3K None None O
/ None None O
Akt None None O
pathway None None O
. None None O

CONCLUSIONS None None O
/ None None O
SIGNIFICANCE None None O
: None None O
Together None None O
these None None O
data None None O
suggest None None O
that None None O
lymph None None O
node None None O
metastasis None None O
and None None O
poor None None O
survival None None O
in None None O
invasive None None O
ductal None None O
breast None None O
carcinoma None None O
are None None O
linked None None O
to None None O
an None None O
uncoupling None None O
of None None O
the None None O
Akt None None O
- None None O
FOXO3a None None O
signaling None None O
axis None None O
. None None O

In None None O
these None None O
breast None None O
cancers None None O
activated None None O
Akt None None O
fails None None O
to None None O
inactivate None None O
and None None O
re None None O
- None None O
localize None None O
FOXO3a None None O
to None None O
the None None O
cytoplasm None None O
, None None O
and None None O
nuclear None None O
- None None O
targeted None None O
FOXO3a None None O
does None None O
not None None O
induce None None O
cell None None O
death None None O
or None None O
cell None None O
cycle None None O
arrest None None O
. None None O

As None None O
such None None O
, None None O
sustained None None O
nuclear None None O
FOXO3a None None O
expression None None O
in None None O
breast None None O
cancer None None O
may None None O
culminate None None O
in None None O
cancer None None O
progression None None O
and None None O
the None None O
development None None O
of None None O
an None None O
aggressive None None O
phenotype None None O
similar None None O
to None None O
that None None O
observed None None O
in None None O
cytotoxic None None O
chemotherapy None None O
resistant None None O
breast None None O
cancer None None O
cell None None O
models None None O
. None None O

Assessment None None O
of None None O
various None None O
forms None None O
of None None O
bevavioural None None O
addictions None None O

A None None O
first None None O
approach None None O
for None None O
the None None O
comprehensive None None O
and None None O
standardized None None O
assessment None None O
of None None O
different None None O
forms None None O
of None None O
behavioural None None O
addictions None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
pathological None None O
gambling None None O
, None None O
workaholism None None O
, None None O
compulsive None None O
buying None None O
) None None O
is None None O
the None None O
German None None O
self None None O
- None None O
assessment None None O
questionnaire None None O
" None None O
Fragebogen None None O
zur None None O
Differenzierten None None O
Anamnese None None O
exzessiver None None O
Verhaltensweisen None None O
" None None O
( None None O
FDAV None None O
, None None O
Questionnaire None None O
on None None O
Differentiated None None O
Assessment None None O
of None None O
Excessive None None O
Behaviours None None O
) None None O
[ None None O
96 None None O
] None None O
. None None O

The None None O
FDAV None None O
is None None O
based None None O
on None None O
the None None O
criteria None None O
of None None O
substance None None O
- None None O
related None None O
addictions None None O
, None None O
pathological None None O
gambling None None O
and None None O
impulse None None O
control None None O
disorders None None O
of None None O
the None None O
ICD None None O
- None None O
10 None None O
[ None None O
3 None None O
] None None O
and None None O
the None None O
DSM None None O
- None None O
IV None None O
- None None O
TR None None O
[ None None O
2 None None O
] None None O
. None None O

The None None O
FDAV None None O
is None None O
a None None O
modified None None O
version None None O
of None None O
the None None O
" None None O
Fragebogen None None O
zur None None O
Differenzierten None None O
Drogenanamnese None None O
" None None O
( None None O
FDDA None None O
; None None O
Questionnaire None None O
on None None O
Differentiated None None O
Assessment None None O
of None None O
Addiction None None O
, None None O
QDAA None None O
) None None O
[ None None O
97 None None O
] None None O
. None None O

Its None None O
seven None None O
modules None None O
obtain None None O
" None None O
sociodemographic None None O
information None None O
" None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
age None None O
, None None O
profession None None O
, None None O
marital None None O
status None None O
) None None O
, None None O
" None None O
history None None O
of None None O
excessive None None O
behaviour None None O
" None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
diagnostic None None O
criteria None None O
for None None O
addictions None None O
and None None O
impulse None None O
control None None O
disorder None None O
, None None O
individual None None O
patterns None None O
of None None O
behaviour None None O
, None None O
craving None None O
symptoms None None O
) None None O
, None None O
" None None O
critical None None O
life None None O
events None None O
" None None O
( None None O
stress None None O
caused None None O
by None None O
traumatic None None O
events None None O
) None None O
, None None O
" None None O
legal None None O
situation None None O
" None None O
, None None O
" None None O
medical None None O
history None None O
" None None O
, None None O
" None None O
physical None None O
and None None O
psychological None None O
complaints None None O
" None None O
, None None O
and None None O
" None None O
emotional None None O
state None None O
" None None O
( None None O
triggering None None O
psychological None None O
conditions None None O
, None None O
or None None O
consequences None None O
of None None O
the None None O
addictive None None O
behaviour None None O
, None None O
respectively None None O
) None None O
. None None O

Every None None O
module None None O
can None None O
be None None O
administered None None O
separately None None O
according None None O
to None None O
the None None O
suspected None None O
behavioural None None O
addiction None None O
, None None O
thereby None None O
making None None O
the None None O
FDAV None None O
an None None O
economical None None O
tool None None O
in None None O
assessing None None O
behavioural None None O
addictions None None O
. None None O

The None None O
FDAV None None O
is None None O
suitable None None O
for None None O
diagnostics None None O
, None None O
evaluation None None O
of None None O
therapy None None O
and None None O
follow None None O
- None None O
up None None O
in None None O
clinical None None O
practice None None O
and None None O
research None None O
. None None O

Currently None None O
, None None O
the None None O
FDAV None None O
is None None O
being None None O
validated None None O
in None None O
clinical None None O
and None None O
non None None O
- None None O
clinical None None O
samples None None O
. None None O

Angiogenesis None None O
- None None O
- None None O
biomedical None None O
technology None None O
. None None O

All None None O
of None None O
these None None O
studies None None O
show None None O
that None None O
angiogenesis None None O
research None None O
can None None O
benefit None None O
from None None O
new None None O
biomedical None None O
technology None None O
tools None None O
currently None None O
being None None O
developed None None O
, None None O
as None None O
well None None O
as None None O
contribute None None O
by None None O
providing None None O
new None None O
technologies None None O
that None None O
can None None O
be None None O
used None None O
in None None O
other None None O
areas None None O
of None None O
medicine None None O
. None None O

It None None O
is None None O
hoped None None O
that None None O
the None None O
chapters None None O
in None None O
this None None O
book None None O
in None None O
this None None O
area None None O
will None None O
provide None None O
the None None O
reader None None O
with None None O
an None None O
up None None O
- None None O
to None None O
- None None O
date None None O
appreciation None None O
of None None O
some None None O
of None None O
the None None O
exciting None None O
research None None O
that None None O
is None None O
currently None None O
being None None O
pursued None None O
. None None O

mirAct None None O
: None None O
a None None O
web None None O
tool None None O
for None None O
evaluating None None O
microRNA None None O
activity None None O
based None None O
on None None O
gene None None O
expression None None O
data None None O
. None None O

MicroRNAs None None O
( None None O
miRNAs None None O
) None None O
are None None O
critical None None O
regulators None None O
in None None O
the None None O
complex None None O
cellular None None O
networks None None O
. None None O

The None None O
mirAct None None O
web None None O
server None None O
( None None O
http None None O
: None None O
/ None None O
/ None None O
sysbio None None O
. None None O
ustc None None O
. None None O
edu None None O
. None None O
cn None None O
/ None None O
software None None O
/ None None O
mirAct None None O
) None None O
is None None O
a None None O
tool None None O
designed None None O
to None None O
investigate None None O
miRNA None None O
activity None None O
based None None O
on None None O
gene None None O
- None None O
expression None None O
data None None O
by None None O
using None None O
the None None O
negative None None O
regulation None None O
relationship None None O
between None None O
miRNAs None None O
and None None O
their None None O
target None None O
genes None None O
. None None O

mirAct None None O
supports None None O
multiple None None O
- None None O
class None None O
data None None O
and None None O
enables None None O
clustering None None O
analysis None None O
based None None O
on None None O
computationally None None O
determined None None O
miRNA None None O
activity None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
the None None O
framework None None O
of None None O
mirAct None None O
, None None O
demonstrate None None O
its None None O
performance None None O
by None None O
comparing None None O
with None None O
other None None O
similar None None O
programs None None O
and None None O
exemplify None None O
its None None O
applications None None O
using None None O
case None None O
studies None None O
. None None O

The None None O
threshold None None O
level None None O
of None None O
adenomatous None None O
polyposis None None O
coli None None O
protein None None O
for None None O
mouse None None O
intestinal None None O
tumorigenesis None None O
. None None O

The None None O
adenomatous None None O
polyposis None None O
coli None None O
( None None O
APC None None O
) None None O
gene None None O
, None None O
whose None None O
mutations None None O
are None None O
responsible None None O
for None None O
familial None None O
adenomatous None None O
polyposis None None O
, None None O
is None None O
a None None O
major None None O
negative None None O
controller None None O
of None None O
the None None O
Wnt None None O
/ None None O
beta None None O
- None None O
catenin None None O
pathway None None O
. None None O

To None None O
investigate None None O
the None None O
dose None None O
- None None O
dependent None None O
effects None None O
of None None O
APC None None O
protein None None O
in None None O
suppressing None None O
intestinal None None O
tumorigenesis None None O
, None None O
we None None O
constructed None None O
mutant None None O
mice None None O
carrying None None O
hypomorphic None None O
Apc None None O
alleles None None O
Apc None None O
( None None O
neoR None None O
) None None O
and None None O
Apc None None O
( None None O
neoF None None O
) None None O
whose None None O
expression None None O
levels None None O
were None None O
reduced None None O
to None None O
20 None None O
% None None O
and None None O
10 None None O
% None None O
of None None O
the None None O
wild None None O
type None None O
, None None O
respectively None None O
. None None O

Although None None O
both None None O
hypomorphic None None O
heterozygotes None None O
developed None None O
intestinal None None O
polyps None None O
, None None O
tumor None None O
multiplicities None None O
were None None O
much None None O
lower None None O
than None None O
that None None O
in None None O
Apc None None O
( None None O
Delta716 None None O
) None None O
mice None None O
, None None O
heterozygotes None None O
of None None O
an None None O
Apc None None O
null None None O
allele None None O
. None None O

Like None None O
in None None O
Apc None None O
( None None O
Delta716 None None O
) None None O
mice None None O
, None None O
loss None None O
of None None O
the None None O
wild None None O
- None None O
type None None O
Apc None None O
allele None None O
was None None O
confirmed None None O
for None None O
all None None O
polyps None None O
examined None None O
in None None O
the None None O
Apc None None O
( None None O
neoR None None O
) None None O
and None None O
Apc None None O
( None None O
neoF None None O
) None None O
mice None None O
. None None O

In None None O
the None None O
embryonic None None O
stem None None O
cells None None O
homozygous None None O
for None None O
these None None O
hypomorphic None None O
Apc None None O
alleles None None O
, None None O
the None None O
level None None O
of None None O
the None None O
APC None None O
protein None None O
was None None O
inversely None None O
correlated None None O
with None None O
both None None O
the None None O
beta None None O
- None None O
catenin None None O
accumulation None None O
and None None O
beta None None O
- None None O
catenin None None O
/ None None O
T None None O
- None None O
cell None None O
factor None None O
transcriptional None None O
activity None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
reduced None None O
APC None None O
protein None None O
level None None O
increases None None O
intestinal None None O
polyp None None O
multiplicity None None O
through None None O
quantitative None None O
stimulation None None O
of None None O
the None None O
beta None None O
- None None O
catenin None None O
/ None None O
T None None O
- None None O
cell None None O
factor None None O
transcription None None O
. None None O

We None None O
further None None O
estimated None None O
the None None O
threshold None None O
of None None O
APC None None O
protein None None O
level None None O
that None None O
forms None None O
one None None O
polyp None None O
per None None O
mouse None None O
as None None O
approximately None None O
15 None None O
% None None O
of None None O
the None None O
wild None None O
type None None O
. None None O

These None None O
results None None O
also None None O
suggest None None O
therapeutic None None O
implications None None O
concerning None None O
Wnt None None O
signaling None None O
inhibitors None None O
. None None O

Using None None O
a None None O
web None None O
- None None O
based None None O
orthopaedic None None O
clinic None None O
in None None O
the None None O
curricular None None O
teaching None None O
of None None O
a None None O
German None None O
university None None O
hospital None None O
: None None O
analysis None None O
of None None O
learning None None O
effect None None O
, None None O
student None None O
usage None None O
and None None O
reception None None O
. None None O

PURPOSE None None O
: None None O

Modern None None O
teaching None None O
concepts None None O
for None None O
undergraduate None None O
medical None None O
students None None O
in None None O
Germany None None O
include None None O
problem None None O
based None None O
learning None None O
as None None O
a None None O
major None None O
component None None O
of None None O
the None None O
new None None O
licensing None None O
regulations None None O
for None None O
physicians None None O
. None None O

Here None None O
we None None O
describe None None O
the None None O
usage None None O
of None None O
a None None O
web None None O
- None None O
based None None O
virtual None None O
outpatient None None O
clinic None None O
in None None O
the None None O
teaching None None O
curriculum None None O
of None None O
undergraduate None None O
medical None None O
students None None O
, None None O
its None None O
effect None None O
on None None O
learning None None O
success None None O
, None None O
and None None O
student None None O
reception None None O
. None None O

METHODS None None O
: None None O

Fifth None None O
year None None O
medial None None O
students None None O
were None None O
requested None None O
to None None O
examine None None O
7 None None O
virtual None None O
orthopaedic None None O
patients None None O
which None None O
had None None O
been None None O
created None None O
by None None O
the None None O
authors None None O
using None None O
the None None O
Inmedea None None O
- None None O
Simulator None None O
. None None O

They None None O
also None None O
had None None O
to None None O
take None None O
a None None O
multiple None None O
- None None O
choice None None O
examination None None O
on None None O
two None None O
different None None O
occasions None None O
and None None O
their None None O
utilisation None None O
of None None O
the None None O
simulator None None O
was None None O
analysed None None O
subjectively None None O
and None None O
objectively None None O
. None None O

RESULTS None None O
: None None O

One None None O
hundred None None O
and None None O
sixty None None O
students None None O
took None None O
part None None O
in None None O
the None None O
study None None O
. None None O

The None None O
average None None O
age None None O
was None None O
24 None None O
. None None O
9 None None O
years None None O
, None None O
60 None None O
% None None O
were None None O
female None None O
. None None O

Most None None O
of None None O
the None None O
participants None None O
studied None None O
on None None O
their None None O
own None None O
using None None O
their None None O
private None None O
computer None None O
with None None O
a None None O
fast None None O
internet None None O
- None None O
connection None None O
at None None O
home None None O
. None None O

The None None O
average None None O
usage None None O
time None None O
was None None O
263 None None O
min None None O
, None None O
most None None O
of None None O
the None None O
students None None O
worked None None O
with None None O
the None None O
system None None O
in None None O
the None None O
afternoon None None O
, None None O
although None None O
a None None O
considerable None None O
number None None O
used None None O
it None None O
late None None O
in None None O
the None None O
night None None O
. None None O

Regarding None None O
learning None None O
success None None O
, None None O
we None None O
found None None O
that None None O
the None None O
examination None None O
results None None O
were None None O
significantly None None O
better None None O
after None None O
using None None O
the None None O
system None None O
( None None O
7 None None O
. None None O
66 None None O
versus None None O
8 None None O
. None None O
37 None None O
, None None O
p None None O
< None None O
0 None None O
. None None O
0001 None None O
) None None O
. None None O

Eighty None None O
percent None None O
of None None O
the None None O
students None None O
enjoyed None None O
dealing None None O
with None None O
the None None O
virtual None None O
patients None None O
emphasizing None None O
the None None O
completeness None None O
of None None O
patient None None O
cases None None O
, None None O
the None None O
artistic None None O
graphic None None O
design None None O
and None None O
the None None O
expert None None O
comments None None O
available None None O
, None None O
as None None O
well None None O
as None None O
the None None O
good None None O
applicability None None O
to None None O
real None None O
cases None None O
. None None O

Eighty None None O
- None None O
seven None None O
percent None None O
of None None O
the None None O
students None None O
graded None None O
the None None O
virtual None None O
orthopaedic None None O
clinic None None O
as None None O
appropriate None None O
to None None O
teach None None O
orthopaedic None None O
content None None O
. None None O

CONCLUSION None None O
: None None O

Using None None O
the None None O
Inmedea None None O
- None None O
Simulator None None O
is None None O
an None None O
effective None None O
method None None O
to None None O
enhance None None O
students None None O
' None None O
learning None None O
efficacy None None O
. None None O

The None None O
way None None O
the None None O
system None None O
was None None O
used None None O
by None None O
the None None O
students None None O
emphasises None None O
the None None O
advantages None None O
of None None O
the None None O
internet None None O
- None None O
like None None O
free None None O
time None None O
management None None O
and None None O
the None None O
implementation None None O
of None None O
multimedia None None O
- None None O
based None None O
content None None O
. None None O

Expression None None O
, None None O
regulation None None O
, None None O
and None None O
function None None O
of None None O
IGF None None O
- None None O
1 None None O
, None None O
IGF None None O
- None None O
1R None None O
, None None O
and None None O
IGF None None O
- None None O
1 None None O
binding None None O
proteins None None O
in None None O
blood None None O
vessels None None O
. None None O

The None None O
vascular None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
( None None O
IGF None None O
) None None O
- None None O
1 None None O
system None None O
includes None None O
the None None O
IGFs None None O
, None None O
the None None O
IGF None None O
- None None O
1 None None O
receptor None None O
( None None O
IGF None None O
- None None O
1R None None O
) None None O
, None None O
and None None O
multiple None None O
binding None None O
proteins None None O
. None None O

This None None O
growth None None O
factor None None O
system None None O
exerts None None O
multiple None None O
physiologic None None O
effects None None O
on None None O
the None None O
vasculature None None O
through None None O
both None None O
endocrine None None O
and None None O
autocrine None None O
/ None None O
paracrine None None O
mechanisms None None O
. None None O

The None None O
effects None None O
of None None O
IGF None None O
- None None O
1 None None O
are None None O
mediated None None O
principally None None O
through None None O
the None None O
IGF None None O
- None None O
1R None None O
but None None O
are None None O
modulated None None O
by None None O
complex None None O
interactions None None O
with None None O
multiple None None O
IGF None None O
binding None None O
proteins None None O
that None None O
themselves None None O
are None None O
regulated None None O
by None None O
phosphorylation None None O
, None None O
proteolysis None None O
, None None O
polymerization None None O
, None None O
and None None O
cell None None O
or None None O
matrix None None O
association None None O
. None None O

During None None O
the None None O
last None None O
decade None None O
, None None O
a None None O
significant None None O
body None None O
of None None O
evidence None None O
has None None O
accumulated None None O
, None None O
indicating None None O
that None None O
expression None None O
of None None O
the None None O
components None None O
of None None O
the None None O
IGF None None O
system None None O
are None None O
regulated None None O
by None None O
multiple None None O
factors None None O
, None None O
including None None O
growth None None O
factors None None O
, None None O
cytokines None None O
, None None O
lipoproteins None None O
, None None O
reactive None None O
oxygen None None O
species None None O
, None None O
and None None O
hemodynamic None None O
forces None None O
. None None O

In None None O
addition None None O
, None None O
cross None None O
- None None O
talk None None O
between None None O
the None None O
IGF None None O
system None None O
and None None O
other None None O
growth None None O
factors None None O
and None None O
integrin None None O
receptors None None O
has None None O
been None None O
demonstrated None None O
. None None O

There None None O
is None None O
accumulating None None O
evidence None None O
of None None O
a None None O
role None None O
for None None O
IGF None None O
- None None O
1 None None O
in None None O
multiple None None O
vascular None None O
pathologies None None O
, None None O
including None None O
atherosclerosis None None O
, None None O
hypertension None None O
, None None O
restenosis None None O
, None None O
angiogenesis None None O
, None None O
and None None O
diabetic None None O
vascular None None O
disease None None O
. None None O

This None None O
review None None O
will None None O
discuss None None O
the None None O
regulation None None O
of None None O
expression None None O
of None None O
IGF None None O
- None None O
1 None None O
, None None O
IGF None None O
- None None O
1R None None O
, None None O
and None None O
IGF None None O
binding None None O
proteins None None O
in None None O
the None None O
vasculature None None O
and None None O
summarize None None O
evidence None None O
implicating None None O
involvement None None O
of None None O
this None None O
system None None O
in None None O
vascular None None O
diseases None None O
. None None O

TEL None None O
, None None O
a None None O
putative None None O
tumor None None O
suppressor None None O
, None None O
modulates None None O
cell None None O
growth None None O
and None None O
cell None None O
morphology None None O
of None None O
ras None None O
- None None O
transformed None None O
cells None None O
while None None O
repressing None None O
the None None O
transcription None None O
of None None O
stromelysin None None O
- None None O
1 None None O
. None None O

TEL None None O
is None None O
a None None O
member None None O
of None None O
the None None O
ETS None None O
family None None O
of None None O
transcription None None O
factors None None O
that None None O
interacts None None O
with None None O
the None None O
mSin3 None None O
and None None O
SMRT None None O
corepressors None None O
to None None O
regulate None None O
transcription None None O
. None None O

TEL None None O
is None None O
biallelically None None O
disrupted None None O
in None None O
acute None None O
leukemia None None O
, None None O
and None None O
loss None None O
of None None O
heterozygosity None None O
at None None O
the None None O
TEL None None O
locus None None O
has None None O
been None None O
observed None None O
in None None O
various None None O
cancers None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
expression None None O
of None None O
TEL None None O
in None None O
Ras None None O
- None None O
transformed None None O
NIH None None I-Cell-line-name
3T3 None None I-Cell-line-name
cells None None O
inhibits None None O
cell None None O
growth None None O
in None None O
soft None None O
agar None None O
and None None O
in None None O
normal None None O
cultures None None O
. None None O

Unexpectedly None None O
, None None O
cells None None O
expressing None None O
both None None O
Ras None None O
and None None O
TEL None None O
grew None None O
as None None O
aggregates None None O
. None None O

To None None O
begin None None O
to None None O
explain None None O
the None None O
morphology None None O
of None None O
Ras None None O
- None None O
plus None None O
TEL None None O
- None None O
expressing None None O
cells None None O
, None None O
we None None O
demonstrated None None O
that None None O
the None None O
endogenous None None O
matrix None None O
metalloproteinase None None O
stromelysin None None O
- None None O
1 None None O
was None None O
repressed None None O
by None None O
TEL None None O
. None None O

TEL None None O
bound None None O
sequences None None O
in None None O
the None None O
stromelysin None None O
- None None O
1 None None O
promoter None None O
and None None O
repressed None None O
the None None O
promoter None None O
in None None O
transient None None O
- None None O
expression None None O
assays None None O
, None None O
suggesting None None O
that None None O
it None None O
is None None O
a None None O
direct None None O
target None None O
for None None O
TEL None None O
- None None O
mediated None None O
regulation None None O
. None None O

Mutants None None O
of None None O
TEL None None O
that None None O
removed None None O
a None None O
binding None None O
site None None O
for None None O
the None None O
mSin3A None None O
corepressor None None O
but None None O
retained None None O
the None None O
ETS None None O
domain None None O
failed None None O
to None None O
repress None None O
stromelysin None None O
- None None O
1 None None O
. None None O

When None None O
BB None None O
- None None O
94 None None O
, None None O
a None None O
matrix None None O
metalloproteinase None None O
inhibitor None None O
, None None O
was None None O
added None None O
to None None O
the None None O
culture None None O
medium None None O
of None None O
Ras None None O
- None None O
expressing None None O
cells None None O
, None None O
it None None O
caused None None O
a None None O
cell None None O
aggregation None None O
phenotype None None O
similar None None O
to None None O
that None None O
caused None None O
by None None O
TEL None None O
expression None None O
. None None O

In None None O
addition None None O
, None None O
TEL None None O
inhibited None None O
the None None O
invasiveness None None O
of None None O
Ras None None O
- None None O
transformed None None O
cells None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
TEL None None O
acts None None O
as None None O
a None None O
tumor None None O
suppressor None None O
, None None O
in None None O
part None None O
, None None O
by None None O
transcriptional None None O
repression None None O
of None None O
stromelysin None None O
- None None O
1 None None O
. None None O

Verrucous None None O
carcinoma None None O
of None None O
the None None O
endometrium None None O
- None None O
- None None O
a None None O
unique None None O
neoplasm None None O
with None None O
long None None O
survival None None O
. None None O

A None None O
case None None O
of None None O
verrucous None None O
carcinoma None None O
of None None O
the None None O
endometrium None None O
with None None O
long None None O
survival None None O
is None None O
described None None O
. None None O

It None None O
represents None None O
the None None O
first None None O
of None None O
its None None O
type None None O
to None None O
be None None O
recorded None None O
in None None O
this None None O
site None None O
. None None O

The None None O
literature None None O
on None None O
verrucous None None O
carcinoma None None O
and None None O
on None None O
other None None O
cases None None O
of None None O
squamous None None O
carcinoma None None O
of None None O
the None None O
endometrium None None O
is None None O
briefly None None O
reviewed None None O
. None None O

The None None O
differential None None O
regulation None None O
of None None O
human None None O
telomerase None None O
reverse None None O
transcriptase None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
may None None O
contribute None None O
to None None O
the None None O
clinically None None O
more None None O
aggressive None None O
behavior None None O
of None None O
p63 None None O
- None None O
positive None None O
breast None None O
carcinomas None None O
. None None O

p63 None None O
, None None O
a None None O
p53 None None O
homologue None None O
, None None O
is None None O
a None None O
myoepithelial None None O
cell None None O
marker None None O
in None None O
the None None O
normal None None O
mammary None None O
gland None None O
but None None O
p63 None None O
- None None O
positive None None O
neoplastic None None O
cells None None O
may None None O
be None None O
found None None O
in None None O
up None None O
to None None O
11 None None O
% None None O
of None None O
invasive None None O
breast None None O
carcinomas None None O
. None None O

This None None O
study None None O
aims None None O
to None None O
verify None None O
the None None O
relationship None None O
between None None O
p63 None None O
expression None None O
and None None O
several None None O
clinicopathological None None O
features None None O
and None None O
tumor None None O
markers None None O
of None None O
clinical None None O
significance None None O
in None None O
breast None None O
pathology None None O
including None None O
key None None O
regulators None None O
of None None O
the None None O
cell None None O
cycle None None O
, None None O
oncogenes None None O
, None None O
apoptosis None None O
- None None O
related None None O
proteins None None O
, None None O
metalloproteinases None None O
and None None O
their None None O
inhibitors None None O
. None None O

Immunohistochemistry None None O
with None None O
27 None None O
primary None None O
antibodies None None O
was None None O
performed None None O
in None None O
100 None None O
formalin None None O
- None None O
fixed None None O
paraffin None None O
- None None O
embedded None None O
samples None None O
of None None O
invasive None None O
ductal None None O
carcinomas None None O
. None None O

p63 None None O
- None None O
positive None None O
cells None None O
were None None O
found None None O
in None None O
16 None None O
% None None O
of None None O
carcinomas None None O
. None None O

p63 None None O
- None None O
positive None None O
carcinomas None None O
were None None O
poorly None None O
differentiated None None O
, None None O
hormone None None O
receptor None None O
- None None O
negative None None O
neoplasms None None O
with None None O
a None None O
high None None O
proliferation None None O
rate None None O
. None None O

p63 None None O
also None None O
correlated None None O
with None None O
advanced None None O
pathological None None O
stage None None O
, None None O
tumor None None O
size None None O
, None None O
and None None O
the None None O
expression None None O
of None None O
human None None O
telomerase None None O
reverse None None O
transcriptase None None O
( None None O
hTERT None None O
) None None O
, None None O
tissue None None O
inhibitor None None O
of None None O
matrix None None O
metalloproteinase None None O
1 None None O
( None None O
TIMP1 None None O
) None None O
and None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
. None None O

The None None O
expression None None O
of None None O
TIMP1 None None O
suggests None None O
that None None O
the None None O
anti None None O
- None None O
proteolytic None None O
stimuli None None O
may None None O
be None None O
preponderant None None O
in None None O
p63 None None O
- None None O
positive None None O
carcinomas None None O
. None None O

hTERT None None O
activity None None O
is None None O
associated None None O
with None None O
nodal None None O
metastases None None O
and None None O
cellular None None O
proliferation None None O
. None None O

VEGF None None O
regulates None None O
angiogenesis None None O
, None None O
which None None O
is None None O
also None None O
a None None O
fundamental None None O
event None None O
in None None O
the None None O
process None None O
of None None O
tumor None None O
growth None None O
and None None O
metastatic None None O
dissemination None None O
. None None O

Thus None None O
, None None O
the None None O
differential None None O
regulation None None O
of None None O
hTERT None None O
and None None O
VEGF None None O
in None None O
p63 None None O
- None None O
positive None None O
breast None None O
carcinomas None None O
may None None O
contribute None None O
to None None O
the None None O
clinically None None O
more None None O
aggressive None None O
behavior None None O
of None None O
these None None O
neoplasms None None O
. None None O

Transforming None None O
growth None None O
factor None None O
beta None None O
1 None None O
promotes None None O
spontaneous None None O
transformation None None O
of None None O
cultured None None O
rat None None O
liver None None O
epithelial None None O
cells None None O
. None None O

The None None O
neoplastic None None O
transformation None None O
of None None O
cultured None None O
rat None None O
liver None None O
epithelial None None O
cells None None O
by None None O
various None None O
means None None O
has None None O
consistently None None O
been None None O
associated None None O
with None None O
the None None O
development None None O
of None None O
resistance None None O
to None None O
the None None O
mito None None O
- None None O
inhibitory None None O
effect None None O
of None None O
transforming None None O
growth None None O
factor None None O
beta None None O
( None None O
TGF None None O
- None None O
beta None None O
) None None O
, None None O
suggesting None None O
that None None O
such None None O
phenotype None None O
plays None None O
a None None O
mechanistic None None O
role None None O
during None None O
the None None O
transformation None None O
of None None O
these None None O
cells None None O
. None None O

We None None O
have None None O
studied None None O
the None None O
induction None None O
of None None O
the None None O
" None None O
TGF None None O
- None None O
beta None None O
- None None O
resistant None None O
" None None O
phenotype None None O
in None None O
a None None O
clonal None None O
strain None None O
of None None O
early None None O
passage None None O
WB None None I-Cell-line-name
- None None I-Cell-line-name
F344 None None I-Cell-line-name
normal None None O
cultured None None O
rat None None O
liver None None O
epithelial None None O
cells None None O
, None None O
the None None O
proliferation None None O
of None None O
which None None O
was None None O
markedly None None O
inhibited None None O
by None None O
TGF None None O
- None None O
beta None None O
. None None O

The None None O
control None None O
WB None None O
cells None None O
in None None O
continuous None None O
culture None None O
slowly None None O
developed None None O
TGF None None O
- None None O
beta None None O
resistance None None O
. None None O

However None None O
, None None O
when None None O
the None None O
same None None O
cells None None O
were None None O
exposed None None O
to None None O
step None None O
- None None O
wise None None O
increases None None O
of None None O
TGF None None O
- None None O
beta None None O
concentration None None O
in None None O
their None None O
culture None None O
medium None None O
, None None O
the None None O
development None None O
of None None O
TGF None None O
- None None O
beta None None O
resistance None None O
was None None O
accelerated None None O
. None None O

Cells None None O
which None None O
had None None O
been None None O
grown None None O
in None None O
medium None None O
containing None None O
1 None None O
ng None None O
/ None None O
ml None None O
TGF None None O
- None None O
beta None None O
developed None None O
colony None None O
- None None O
forming None None O
capacity None None O
in None None O
soft None None O
agar None None O
containing None None O
epidermal None None O
growth None None O
factor None None O
. None None O

Cells None None O
which None None O
were None None O
grown None None O
in None None O
media None None O
containing None None O
5 None None O
and None None O
10 None None O
ng None None O
/ None None O
ml None None O
TGF None None O
- None None O
beta None None O
demonstrated None None O
a None None O
low None None O
level None None O
of None None O
colony None None O
- None None O
forming None None O
efficiency None None O
in None None O
soft None None O
agar None None O
medium None None O
without None None O
added None None O
epidermal None None O
growth None None O
factor None None O
and None None O
tumorigenicity None None O
in None None O
isogeneic None None O
rats None None O
. None None O

These None None O
TGF None None O
- None None O
beta None None O
- None None O
resistant None None O
cells None None O
also None None O
exhibited None None O
progressively None None O
increasing None None O
levels None None O
of None None O
expression None None O
of None None O
the None None O
c None None O
- None None O
fos None None O
and None None O
and None None O
myc None None O
mRNA None None O
, None None O
and None None O
increased None None O
resistance None None O
to None None O
the None None O
cytotoxicity None None O
of None None O
Adriamycin None None O
and None None O
melphalan None None O
. None None O

The None None O
latter None None O
phenomenon None None O
was None None O
accompanied None None O
by None None O
an None None O
increase None None O
in None None O
the None None O
mdr None None O
- None None O
1 None None O
mRNA None None O
expression None None O
, None None O
cellular None None O
glutathione None None O
level None None O
, None None O
and None None O
glutathione None None O
S None None O
- None None O
transferase None None O
activity None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
chronic None None O
exposure None None O
to None None O
high None None O
concentration None None O
of None None O
TGF None None O
- None None O
beta None None O
promotes None None O
the None None O
spontaneous None None O
neoplastic None None O
transformation None None O
of None None O
cultured None None O
rat None None O
liver None None O
epithelial None None O
cells None None O
, None None O
and None None O
that None None O
this None None O
process None None O
may None None O
represent None None O
one None None O
of None None O
the None None O
mechanisms None None O
of None None O
cellular None None O
adaptation None None O
for None None O
induction None None O
of None None O
the None None O
multidrug None None O
- None None O
resistant None None O
phenotype None None O
during None None O
the None None O
carcinogenesis None None O
of None None O
epithelial None None O
cells None None O
. None None O

Bradycardia None None O
- None None O
induced None None O
coronary None None O
angiogenesis None None O
is None None O
dependent None None O
on None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
. None None O

A None None O
marked None None O
coronary None None O
angiogenesis None None O
is None None O
known None None O
to None None O
occur None None O
with None None O
chronic None None O
bradycardia None None O
. None None O

We None None O
tested None None O
the None None O
hypothesis None None O
that None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
an None None O
endothelial None None O
cell None None O
mitogen None None O
and None None O
a None None O
major None None O
regulator None None O
of None None O
angiogenesis None None O
, None None O
is None None O
upregulated None None O
in None None O
response None None O
to None None O
low None None O
heart None None O
rate None None O
and None None O
consequential None None O
increased None None O
stroke None None O
volume None None O
. None None O

Bradycardia None None O
was None None O
induced None None O
in None None O
rats None None O
by None None O
administering None None O
the None None O
bradycardic None None O
drug None None O
alinidine None None O
( None None O
3 None None O
mg None None O
/ None None O
kg None None O
body None None O
weight None None O
) None None O
twice None None O
daily None None O
. None None O

Heart None None O
rate None None O
decreased None None O
by None None O
32 None None O
% None None O
for None None O
20 None None O
to None None O
40 None None O
minutes None None O
after None None O
injection None None O
and None None O
was None None O
chronically None None O
reduced None None O
by None None O
10 None None O
% None None O
, None None O
14 None None O
% None None O
, None None O
and None None O
18 None None O
. None None O
5 None None O
% None None O
after None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
3 None None O
weeks None None O
of None None O
treatment None None O
, None None O
respectively None None O
. None None O

Arterial None None O
pressure None None O
and None None O
cardiac None None O
output None None O
were None None O
unchanged None None O
. None None O

Left None None O
ventricular None None O
capillary None None O
length None None O
density None None O
( None None O
mm None None O
/ None None O
mm None None O
( None None O
3 None None O
) None None O
) None None O
increased None None O
gradually None None O
with None None O
alinidine None None O
administration None None O
; None None O
a None None O
15 None None O
% None None O
increase None None O
after None None O
2 None None O
weeks None None O
and None None O
a None None O
40 None None O
% None None O
increase None None O
after None None O
3 None None O
weeks None None O
of None None O
alinidine None None O
treatment None None O
were None None O
documented None None O
. None None O

Left None None O
ventricular None None O
weight None None O
, None None O
body None None O
weight None None O
, None None O
and None None O
their None None O
ratio None None O
were None None O
not None None O
significantly None None O
altered None None O
by None None O
alinidine None None O
treatment None None O
. None None O

After None None O
1 None None O
week None None O
of None None O
treatment None None O
, None None O
before None None O
an None None O
increase None None O
in None None O
capillary None None O
length None None O
density None None O
, None None O
VEGF None None O
mRNA None None O
increased None None O
greater None None O
than None None O
2 None None O
- None None O
fold None None O
and None None O
then None None O
declined None None O
to None None O
control None None O
levels None None O
after None None O
3 None None O
weeks None None O
of None None O
treatment None None O
. None None O

VEGF None None O
protein None None O
was None None O
higher None None O
in None None O
alinidine None None O
- None None O
treated None None O
rats None None O
than None None O
in None None O
controls None None O
after None None O
2 None None O
weeks None None O
and None None O
increased None None O
further None None O
after None None O
3 None None O
weeks None None O
of None None O
treatment None None O
. None None O

Injection None None O
of None None O
VEGF None None O
- None None O
neutralizing None None O
antibodies None None O
over None None O
a None None O
2 None None O
- None None O
week None None O
period None None O
completely None None O
blocked None None O
alinidine None None O
- None None O
stimulated None None O
angiogenesis None None O
. None None O

In None None O
contrast None None O
, None None O
bFGF None None O
mRNA None None O
was None None O
not None None O
altered None None O
by None None O
alinidine None None O
treatment None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
VEGF None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
the None None O
angiogenic None None O
response None None O
that None None O
occurs None None O
with None None O
chronic None None O
bradycardia None None O
. None None O

The None None O
mechanism None None O
underlying None None O
this None None O
VEGF None None O
- None None O
associated None None O
angiogenesis None None O
may None None O
be None None O
an None None O
increase None None O
in None None O
stretch None None O
due None None O
to None None O
enhanced None None O
diastolic None None O
filling None None O
. None None O

Human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
viral None None O
background None None O
plays None None O
a None None O
major None None O
role None None O
in None None O
development None None O
of None None O
resistance None None O
to None None O
protease None None O
inhibitors None None O
. None None O

The None None O
observed None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
benefit None None O
of None None O
combination None None O
treatment None None O
with None None O
anti None None O
- None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV None None O
) None None O
agents None None O
prompted None None O
us None None O
to None None O
examine None None O
the None None O
potential None None O
of None None O
resistance None None O
development None None O
when None None O
two None None O
protease None None O
inhibitors None None O
are None None O
used None None O
concurrently None None O
. None None O

Recombinant None None O
HIV None None O
- None None O
1 None None O
( None None O
NL4 None None O
- None None O
3 None None O
) None None O
proteases None None O
containing None None O
combined None None O
resistance None None O
mutations None None O
associated None None O
with None None O
BMS None None O
- None None O
186318 None None O
and None None O
A None None O
- None None O
77003 None None O
( None None O
or None None O
saquinavir None None O
) None None O
were None None O
either None None O
inactive None None O
or None None O
had None None O
impaired None None O
enzyme None None O
activity None None O
. None None O

Subsequent None None O
construction None None O
of None None O
HIV None None O
- None None O
1 None None O
( None None O
NL4 None None O
- None None O
3 None None O
) None None O
proviral None None O
clones None None O
containing None None O
the None None O
same None None O
mutations None None O
yielded None None O
viruses None None O
that None None O
were None None O
severely None None O
impaired None None O
in None None O
growth None None O
or None None O
nonviable None None O
, None None O
confirming None None O
that None None O
combination None None O
therapy None None O
may None None O
be None None O
advantageous None None O
. None None O

However None None O
, None None O
passage None None O
of None None O
BMS None None O
- None None O
186318 None None O
- None None O
resistant None None O
HIV None None O
- None None O
1 None None O
( None None O
RF None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
either None None O
saquinavir None None O
or None None O
SC52151 None None O
, None None O
which None None O
represented None None O
sequential None None O
drug None None O
treatment None None O
, None None O
produced None None O
viable None None O
viruses None None O
resistant None None O
to None None O
both None None O
BMS None None O
- None None O
186318 None None O
and None None O
the None None O
second None None O
compound None None O
. None None O

The None None O
predominant None None O
breakthrough None None O
virus None None O
contained None None O
the None None O
G48V None None O
/ None None O
A71T None None O
/ None None O
V82A None None O
protease None None O
mutations None None O
. None None O

The None None O
clone None None O
- None None O
purified None None O
RF None None O
( None None O
G48V None None O
/ None None O
A71T None None O
/ None None O
V82A None None O
) None None O
virus None None O
, None None O
unlike None None O
the None None O
corresponding None None O
defective None None O
NL4 None None O
- None None O
3 None None O
triple None None O
mutant None None O
, None None O
grew None None O
well None None O
and None None O
displayed None None O
cross None None O
- None None O
resistance None None O
to None None O
four None None O
distinct None None O
protease None None O
inhibitors None None O
. None None O

Chimeric None None O
virus None None O
and None None O
in None None O
vitro None None O
mutagenesis None None O
studies None None O
indicated None None O
that None None O
the None None O
RF None None O
- None None O
specific None None O
protease None None O
sequence None None O
, None None O
specifically None None O
the None None O
Ile None None O
at None None O
residue None None O
10 None None O
, None None O
enabled None None O
the None None O
NL4 None None O
- None None O
3 None None O
strain None None O
with None None O
the None None O
triple None None O
mutant None None O
to None None O
grow None None O
. None None O

Our None None O
results None None O
clearly None None O
indicate None None O
that None None O
viral None None O
genetic None None O
background None None O
will None None O
play None None O
a None None O
key None None O
role None None O
in None None O
determining None None O
whether None None O
cross None None O
- None None O
resistance None None O
variants None None O
will None None O
arise None None O
. None None O

Large None None O
nodular None None O
hepatic None None O
flexure None None O
lesions None None O
as None None O
seen None None O
on None None O
Colonoscopy None None O
. None None O

Truncated None None O
galectin None None O
- None None O
3 None None O
inhibits None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
in None None O
orthotopic None None O
nude None None O
mouse None None O
model None None O
of None None O
human None None O
breast None None O
cancer None None O
. None None O

PURPOSE None None O
: None None O
The None None O
goal None None O
of None None O
this None None O
research None None O
was None None O
to None None O
evaluate None None O
a None None O
potential None None O
therapeutic None None O
agent None None O
for None None O
breast None None O
cancer None None O
based None None O
on None None O
galectin None None O
- None None O
3 None None O
that None None O
has None None O
been None None O
implicated None None O
in None None O
tumorigenicity None None O
and None None O
metastasis None None O
of None None O
breast None None O
cancer None None O
. None None O

The None None O
hypothesis None None O
was None None O
that None None O
therapy None None O
with None None O
NH None None O
( None None O
2 None None O
) None None O
- None None O
terminally None None O
truncated None None O
form None None O
of None None O
galectin None None O
- None None O
3 None None O
( None None O
galectin None None O
- None None O
3C None None O
) None None O
will None None O
be None None O
efficacious None None O
for None None O
reduction None None O
in None None O
tumor None None O
growth None None O
and None None O
for None None O
inhibition None None O
of None None O
metastases None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
Recombinant None None O
human None None O
galectin None None O
- None None O
3 None None O
was None None O
produced None None O
in None None O
Escherichia None None O
coli None None O
from None None O
which None None O
galectin None None O
- None None O
3C None None O
was None None O
derived None None O
by None None O
collagenase None None O
enzyme None None O
digestion None None O
. None None O

Toxicity None None O
, None None O
pharmacokinetic None None O
, None None O
and None None O
organ None None O
biodistribution None None O
studies None None O
were None None O
performed None None O
in None None O
nude None None O
mice None None O
. None None O

For None None O
efficacy None None O
studies None None O
, None None O
nude None None O
mice None None O
bearing None None O
orthotopically None None O
implanted None None O
tumors None None O
derived None None O
from None None O
breast None None O
cancer None None O
cell None None O
line None None O
MDA None None I-Cell-line-name
- None None I-Cell-line-name
MB None None I-Cell-line-name
- None None I-Cell-line-name
435 None None I-Cell-line-name
were None None O
treated None None O
with None None O
galectin None None O
- None None O
3C None None O
or None None O
a None None O
vehicle None None O
control None None O
i None None O
. None None O
m None None O
. None None O
twice None None O
daily None None O
for None None O
90 None None O
days None None O
. None None O

RESULTS None None O
: None None O
The None None O
maximum None None O
tolerated None None O
dose None None O
of None None O
galectin None None O
- None None O
3C None None O
in None None O
nude None None O
mice None None O
was None None O
determined None None O
to None None O
be None None O
> None None O
125 None None O
mg None None O
/ None None O
kg None None O
without None None O
overt None None O
adverse None None O
effects None None O
. None None O

The None None O
elimination None None O
half None None O
- None None O
life None None O
when None None O
administered None None O
i None None O
. None None O
m None None O
. None None O
was None None O
found None None O
to None None O
be None None O
3 None None O
. None None O
0 None None O
h None None O
in None None O
the None None O
serum None None O
and None None O
4 None None O
. None None O
3 None None O
h None None O
in None None O
the None None O
cellular None None O
fraction None None O
of None None O
the None None O
blood None None O
. None None O

Organ None None O
biodistribution None None O
studies None None O
revealed None None O
that None None O
galectin None None O
- None None O
3C None None O
localized None None O
in None None O
the None None O
liver None None O
, None None O
kidneys None None O
, None None O
and None None O
spleen None None O
but None None O
not None None O
in None None O
the None None O
heart None None O
or None None O
lungs None None O
. None None O

We None None O
found None None O
that None None O
the None None O
mean None None O
tumor None None O
volumes None None O
and None None O
weights None None O
were None None O
statistically None None O
significantly None None O
less None None O
in None None O
mice None None O
treated None None O
with None None O
galectin None None O
- None None O
3C None None O
compared None None O
with None None O
control None None O
mice None None O
, None None O
and None None O
that None None O
fewer None None O
numbers None None O
of None None O
mice None None O
exhibited None None O
lymph None None O
node None None O
metastases None None O
in None None O
the None None O
treated None None O
group None None O
compared None None O
with None None O
the None None O
control None None O
group None None O
. None None O

CONCLUSIONS None None O
: None None O
Galectin None None O
- None None O
3C None None O
is None None O
not None None O
overtly None None O
toxic None None O
, None None O
and None None O
is None None O
efficacious None None O
in None None O
reducing None None O
metastases None None O
and None None O
tumor None None O
volumes None None O
and None None O
weights None None O
in None None O
primary None None O
tumors None None O
in None None O
an None None O
orthotopic None None O
nude None None O
mouse None None O
model None None O
of None None O
human None None O
breast None None O
cancer None None O
. None None O

Tumors None None O
of None None O
the None None O
retinal None None O
pigment None None O
epithelium None None O
metastasize None None O
to None None O
inguinal None None O
lymph None None O
nodes None None O
and None None O
spleen None None O
in None None O
tyrosinase None None O
- None None O
related None None O
protein None None O
1 None None O
/ None None O
SV40 None None O
T None None O
antigen None None O
transgenic None None O
mice None None O
. None None O

The None None O
pigment None None O
epithelium None None O
of None None O
the None None O
retina None None O
( None None O
RPE None None O
) None None O
is None None O
derived None None O
from None None O
the None None O
optic None None O
cup None None O
and None None O
is None None O
essential None None O
for None None O
function None None O
and None None O
development None None O
of None None O
the None None O
eye None None O
. None None O

We None None O
produced None None O
a None None O
transgenic None None O
mouse None None O
line None None O
that None None O
expresses None None O
simian None None O
virus None None O
( None None O
SV40 None None O
) None None O
transforming None None O
sequences None None O
under None None O
control None None O
of None None O
the None None O
1 None None O
. None None O
4 None None O
kb None None O
tyrosinase None None O
- None None O
related None None O
protein None None O
1 None None O
( None None O
TRP None None O
- None None O
1 None None O
) None None O
promoter None None O
, None None O
targeting None None O
expression None None O
of None None O
T None None O
antigen None None O
( None None O
Tag None None O
) None None O
to None None O
the None None O
RPE None None O
. None None O

In None None O
transgenic None None O
embryos None None O
, None None O
RPE None None O
cells None None O
proliferated None None O
in None None O
the None None O
anterior None None O
part None None O
of None None O
the None None O
eye None None O
and None None O
near None None O
the None None O
optic None None O
nerve None None O
. None None O

This None None O
resulted None None O
in None None O
formation None None O
of None None O
tumors None None O
, None None O
which None None O
were None None O
pigmented None None O
and None None O
of None None O
epithelial None None O
origin None None O
. None None O

In None None O
3 None None O
months None None O
- None None O
old None None O
mice None None O
, None None O
pigmented None None O
cells None None O
were None None O
detected None None O
in None None O
spleen None None O
and None None O
inguinal None None O
lymph None None O
nodes None None O
. None None O

In None None O
spleen None None O
, None None O
tyrosinase None None O
, None None O
TRP None None O
- None None O
1 None None O
and None None O
SV40 None None O
Tag None None O
were None None O
expressed None None O
and None None O
tyrosinase None None O
was None None O
enzymatically None None O
active None None O
. None None O

Pigmented None None O
regions None None O
were None None O
positive None None O
for None None O
an None None O
epithelial None None O
marker None None O
, None None O
cytokeratin None None O
. None None O

Cell None None O
lines None None O
were None None O
established None None O
from None None O
tumor None None O
and None None O
metastases None None O
and None None O
kept None None O
in None None O
culture None None O
for None None O
more None None O
than None None O
2 None None O
months None None O
. None None O

These None None O
were None None O
pigmented None None O
, None None O
and None None O
maintained None None O
expression None None O
of None None O
tyrosinase None None O
, None None O
TRP None None O
- None None O
1 None None O
, None None O
cytokeratin None None O
and None None O
SV40 None None O
Tag None None O
. None None O

This None None O
demonstrates None None O
that None None O
RPE None None O
tumor None None O
cells None None O
metastasize None None O
to None None O
lymph None None O
node None None O
and None None O
spleen None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
metastasis None None O
from None None O
TRP None None O
- None None O
1 None None O
/ None None O
Tag None None O
RPE None None O
tumors None None O
towards None None O
spleen None None O
and None None O
lymph None None O
nodes None None O
serves None None O
as None None O
potential None None O
tool None None O
to None None O
investigate None None O
biology None None O
and None None O
metastasis None None O
of None None O
tumors None None O
derived None None O
from None None O
the None None O
pigment None None O
epithelium None None O
. None None O

Characteristics None None O
of None None O
cases None None O
with None None O
childhood None None O
leukaemia None None O
( None None O
n None None O
= None None O
162 None None O
) None None O
and None None O
matched None None O
controls None None O
( None None O
n None None O
= None None O
2125 None None O
) None None O
, None None O
all None None O
registered None None O
within None None O
3 None None O
months None None O
of None None O
birth None None O

The None None O
TGF None None O
- None None O
beta None None O
type None None O
II None None O
receptor None None O
in None None O
chronic None None O
myeloid None None O
leukemia None None O
: None None O
analysis None None O
of None None O
microsatellite None None O
regions None None O
and None None O
gene None None O
expression None None O
. None None O

Genomic None None O
instability None None O
is None None O
one None None O
mechanism None None O
proposed None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
disease None None O
progression None None O
of None None O
chronic None None O
myeloid None None O
leukemia None None O
( None None O
CML None None O
) None None O
. None None O

Microsatellite None None O
regions None None O
in None None O
the None None O
type None None O
II None None O
transforming None None O
growth None None O
factor None None O
- None None O
beta None None O
receptor None None O
( None None O
TGF None None O
- None None O
beta None None O
RII None None O
) None None O
gene None None O
appear None None O
to None None O
be None None O
targets None None O
for None None O
mutation None None O
in None None O
some None None O
cancers None None O
displaying None None O
microsatellite None None O
instability None None O
( None None O
replication None None O
error None None O
phenotype None None O
, None None O
RER None None O
+ None None O
) None None O
. None None O

Furthermore None None O
, None None O
TGF None None O
- None None O
beta None None O
RII None None O
mutations None None O
in None None O
RER None None O
+ None None O
tumors None None O
have None None O
been None None O
associated None None O
with None None O
decreased None None O
TGF None None O
- None None O
beta None None O
RII None None O
mRNA None None O
levels None None O
. None None O

As None None O
TGF None None O
- None None O
beta None None O
is None None O
a None None O
potent None None O
negative None None O
growth None None O
regulator None None O
of None None O
hematopoietic None None O
cells None None O
, None None O
investigations None None O
were None None O
undertaken None None O
to None None O
determine None None O
whether None None O
inactivation None None O
of None None O
the None None O
receptor None None O
by None None O
microsatellite None None O
alteration None None O
might None None O
be None None O
involved None None O
in None None O
the None None O
progression None None O
of None None O
CML None None O
. None None O

Analysis None None O
of None None O
TGF None None O
- None None O
beta None None O
RII None None O
mRNA None None O
expression None None O
by None None O
RNase None None O
protection None None O
, None None O
with None None O
comparison None None O
of None None O
cells None None O
from None None O
the None None O
chronic None None O
, None None O
accelerated None None O
and None None O
blast None None O
phases None None O
of None None O
CML None None O
, None None O
showed None None O
no None None O
change None None O
in None None O
TGF None None O
- None None O
beta None None O
RII None None O
transcript None None O
levels None None O
during None None O
disease None None O
progression None None O
. None None O

However None None O
, None None O
during None None O
each None None O
phase None None O
of None None O
the None None O
disease None None O
, None None O
low None None O
levels None None O
of None None O
TGF None None O
- None None O
beta None None O
RII None None O
were None None O
detected None None O
when None None O
compared None None O
with None None O
the None None O
hematopoietic None None O
cells None None O
of None None O
normal None None O
donors None None O
. None None O

Furthermore None None O
, None None O
this None None O
decreased None None O
expression None None O
was None None O
also None None O
observed None None O
in None None O
the None None O
other None None O
myeloproliferative None None O
disorders None None O
, None None O
polycythemia None None O
rubra None None O
vera None None O
( None None O
PRV None None O
) None None O
and None None O
essential None None O
thrombocythemia None None O
( None None O
ET None None O
) None None O
. None None O

The None None O
leukemia None None O
cell None None O
lines None None O
K562 None None I-Cell-line-name
and None None O
HL None None I-Cell-line-name
- None None I-Cell-line-name
60 None None I-Cell-line-name
had None None O
no None None O
detectable None None O
TGF None None O
- None None O
beta None None O
RII None None O
mRNA None None O
. None None O

Two None None O
microsatellite None None O
regions None None O
found None None O
altered None None O
in None None O
RER None None O
+ None None O
colon None None O
cancers None None O
were None None O
analyzed None None O
to None None O
establish None None O
if None None O
these None None O
sequences None None O
were None None O
aberrant None None O
in None None O
CML None None O
. None None O

No None None O
alteration None None O
was None None O
detected None None O
in None None O
either None None O
of None None O
these None None O
regions None None O
in None None O
any None None O
phase None None O
of None None O
the None None O
disease None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
alterations None None O
of None None O
the None None O
microsatellite None None O
regions None None O
in None None O
the None None O
TGF None None O
- None None O
beta None None O
RII None None O
gene None None O
are None None O
not None None O
involved None None O
in None None O
the None None O
progression None None O
of None None O
CML None None O
. None None O

Decreased None None O
expression None None O
of None None O
TGF None None O
- None None O
beta None None O
RII None None O
in None None O
CML None None O
cells None None O
and None None O
leukemia None None O
cell None None O
lines None None O
raises None None O
the None None O
possibility None None O
that None None O
altered None None O
expression None None O
of None None O
the None None O
receptor None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
initiation None None O
and None None O
/ None None O
or None None O
maintenance None None O
of None None O
the None None O
disease None None O
state None None O
. None None O

Cells None None O
transformed None None O
by None None O
Rous None None O
sarcoma None None O
virus None None O
release None None O
transforming None None O
growth None None O
factors None None O
. None None O

Chicken None None O
embryo None None O
fibroblasts None None O
and None None O
hamster None None O
BHK None None I-Cell-line-name
cells None None O
transformed None None O
by None None O
Rous None None O
sarcoma None None O
virus None None O
( None None O
RSV None None O
) None None O
release None None O
in None None O
their None None O
culture None None O
media None None O
growth None None O
factors None None O
which None None O
enhance None None O
markedly None None O
anchorage None None O
- None None O
independent None None O
colony None None O
formation None None O
in None None O
gelified None None O
medium None None O
, None None O
at None None O
the None None O
restrictive None None O
temperature None None O
( None None O
41 None None O
degrees None None O
5 None None O
C None None O
) None None O
, None None O
of None None O
chicken None None O
embryo None None O
fibroblasts None None O
( None None O
CEF None None O
) None None O
infected None None O
by None None O
RSV None None O
mutants None None O
with None None O
a None None O
ts None None O
mutation None None O
of None None O
the None None O
src None None O
gene None None O
. None None O

This None None O
action None None O
is None None O
not None None O
observed None None O
with None None O
uninfected None None O
CEF None None O
, None None O
and None None O
, None None O
therefore None None O
, None None O
appears None None O
to None None O
require None None O
some None None O
expression None None O
of None None O
the None None O
viral None None O
src None None O
gene None None O
in None None O
the None None O
target None None O
cells None None O
. None None O

The None None O
enhancing None None O
factors None None O
are None None O
proteins None None O
related None None O
to None None O
the None None O
family None None O
of None None O
the None None O
transforming None None O
growth None None O
factors None None O
( None None O
TGFs None None O
) None None O
by None None O
their None None O
molecular None None O
weight None None O
( None None O
about None None O
20 None None O
kd None None O
) None None O
, None None O
their None None O
heat None None O
and None None O
acid None None O
resistance None None O
, None None O
and None None O
their None None O
sensitivity None None O
to None None O
dithiothreitol None None O
. None None O

They None None O
do None None O
not None None O
compete None None O
with None None O
125I None None O
EGF None None O
for None None O
binding None None O
on None None O
the None None O
EGF None None O
receptors None None O
of None None O
the None None O
membrane None None O
of None None O
A431 None None I-Cell-line-name
cells None None O
. None None O

As None None O
chicken None None O
embryo None None O
fibroblasts None None O
are None None O
devoid None None O
of None None O
EGF None None O
receptors None None O
, None None O
their None None O
activity None None O
is None None O
not None None O
potentiated None None O
by None None O
EGF None None O
. None None O

Anion None None O
to None None O
cation None None O
selectivity None None O
ratio None None O
determined None None O
from None None O
the None None O
relative None None O
rates None None O
of None None O
reaction None None O
of None None O
MTSES None None O
- None None O
and None None O
MTSET None None O
+ None None O
with None None O
the None None O
water None None O
exposed None None O
residues None None O
in None None O
the None None O
M6 None None O
segment None None O
. None None O

The None None O
anion None None O
selectivity None None O
ratio None None O
is None None O
calculated None None O
as None None O
described None None O
in None None O
Table None None O
II None None O
, None None O
column None None O
5 None None O
. None None O

Note None None O
the None None O
marked None None O
increase None None O
in None None O
anion None None O
selectivity None None O
at None None O
the None None O
residues None None O
T351C None None O
and None None O
Q353C None None O
. None None O

A None None O
ratio None None O
of None None O
1 None None O
indicates None None O
no None None O
selectivity None None O
between None None O
anions None None O
and None None O
cations None None O
. None None O

The None None O
larger None None O
the None None O
ratio None None O
the None None O
greater None None O
the None None O
anion None None O
selectivity None None O
. None None O

Sunitinib None None O
induces None None O
apoptosis None None O
in None None O
pheochromocytoma None None O
tumor None None O
cells None None O
by None None O
inhibiting None None O
VEGFR2 None None O
/ None None O
Akt None None O
/ None None O
mTOR None None O
/ None None O
S6K1 None None O
pathways None None O
through None None O
modulation None None O
of None None O
Bcl None None O
- None None O
2 None None O
and None None O
BAD None None O
. None None O

Sunitinib None None O
is None None O
an None None O
oral None None O
multitargeted None None O
receptor None None O
tyrosine None None O
kinase None None O
inhibitor None None O
with None None O
antiangiogenic None None O
and None None O
antitumor None None O
activity None None O
that None None O
mainly None None O
targets None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptors None None O
( None None O
VEGFRs None None O
) None None O
. None None O

Very None None O
recently None None O
, None None O
sunitinib None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
an None None O
active None None O
agent None None O
for None None O
the None None O
treatment None None O
of None None O
malignant None None O
pheochromocytomas None None O
. None None O

However None None O
, None None O
it None None O
is None None O
unclear None None O
whether None None O
sunitinib None None O
acts None None O
only None None O
through None None O
an None None O
antiangiogenic None None O
mechanism None None O
or None None O
whether None None O
it None None O
may None None O
also None None O
directly None None O
target None None O
tumor None None O
cells None None O
. None None O

Sunitinib None None O
markedly None None O
induced None None O
apoptosis None None O
of None None O
PC12 None None I-Cell-line-name
cells None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
and None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

Furthermore None None O
, None None O
in None None O
support None None O
of None None O
these None None O
findings None None O
, None None O
we None None O
found None None O
that None None O
sunitinib None None O
induced None None O
a None None O
reduction None None O
in None None O
the None None O
expression None None O
of None None O
the None None O
antiapoptotic None None O
molecule None None O
Bcl None None O
- None None O
2 None None O
as None None O
well None None O
as None None O
dephosphorylation None None O
of None None O
the None None O
proapoptotic None None O
molecule None None O
BAD None None O
, None None O
which None None O
results None None O
in None None O
the None None O
activation None None O
of None None O
BAD None None O
in None None O
these None None O
cells None None O
. None None O

Consistent None None O
with None None O
these None None O
apoptotic None None O
effects None None O
, None None O
our None None O
results None None O
showed None None O
that None None O
sunitinib None None O
inhibited None None O
phosphorylation None None O
of None None O
Akt None None O
and None None O
mTOR None None O
and None None O
was None None O
followed None None O
by None None O
a None None O
reduction None None O
of None None O
S6K1 None None O
, None None O
which None None O
is None None O
a None None O
well None None O
- None None O
known None None O
target None None O
of None None O
mTOR None None O
. None None O

Knockdown None None O
of None None O
VEGFR None None O
- None None O
2 None None O
attenuated None None O
the None None O
sunitinib None None O
- None None O
induced None None O
effects None None O
, None None O
including None None O
apoptosis None None O
and None None O
inhibition None None O
of None None O
signaling None None O
pathways None None O
such None None O
as None None O
the None None O
phosphorylation None None O
of None None O
Akt None None O
as None None O
well None None O
as None None O
mTOR None None O
, None None O
and None None O
Bcl None None O
- None None O
2 None None O
, None None O
which None None O
confirmed None None O
that None None O
these None None O
effects None None O
could None None O
be None None O
mediated None None O
by None None O
VEGFR None None O
- None None O
2 None None O
. None None O

In None None O
addition None None O
, None None O
silencing None None O
of None None O
S6K1 None None O
induced None None O
apoptosis None None O
accompanied None None O
by None None O
a None None O
decrease None None O
in None None O
the None None O
phosphorylation None None O
of None None O
BAD None None O
and None None O
Bcl None None O
- None None O
2 None None O
, None None O
similar None None O
to None None O
that None None O
observed None None O
with None None O
sunitinib None None O
treatment None None O
. None None O

Thus None None O
, None None O
these None None O
results None None O
together None None O
suggest None None O
that None None O
sunitinib None None O
initially None None O
exerts None None O
its None None O
apoptotic None None O
effect None None O
through None None O
the None None O
inhibition None None O
of None None O
VEGFR None None O
- None None O
2 None None O
, None None O
which None None O
, None None O
when None None O
followed None None O
by None None O
reduction None None O
of None None O
its None None O
downstream None None O
effectors None None O
, None None O
including None None O
Akt None None O
/ None None O
mTOR None None O
/ None None O
S6K1 None None O
, None None O
may None None O
lead None None O
to None None O
inhibition None None O
of None None O
the None None O
antiapoptotic None None O
molecule None None O
Bcl None None O
- None None O
2 None None O
and None None O
activation None None O
of None None O
the None None O
proapoptotic None None O
molecule None None O
BAD None None O
in None None O
PC12 None None I-Cell-line-name
cells None None O
. None None O

However None None O
, None None O
PC12 None None I-Cell-line-name
cells None None O
do None None O
not None None O
precisely None None O
reflect None None O
the None None O
pathogenesis None None O
of None None O
malignant None None O
cells None None O
. None None O

Therefore None None O
, None None O
we None None O
confirmed None None O
the None None O
key None None O
findings None None O
by None None O
replicating None None O
these None None O
experiments None None O
in None None O
human None None O
neuroblastoma None None O
SK None None I-Cell-line-name
- None None I-Cell-line-name
N None None I-Cell-line-name
- None None I-Cell-line-name
SH None None I-Cell-line-name
cells None None O
. None None O

Statistical None None O
Analysis None None O

Mitochondrial None None O
DNA None None O
haplogroup None None O
frequencies None None O
were None None O
calculated None None O
by None None O
counting None None O
from None None O
the None None O
observed None None O
genotypes None None O
. None None O

The None None O
Pearson None None O
chi None None O
- None None O
square None None O
test None None O
and None None O
the None None O
chi None None O
- None None O
square None None O
test None None O
for None None O
linear None None O
- None None O
by None None O
- None None O
linear None None O
association None None O
were None None O
used None None O
to None None O
analyze None None O
the None None O
significances None None O
between None None O
the None None O
prevalence None None O
of None None O
haplogroups None None O
and None None O
different None None O
age None None O
groups None None O
. None None O

SPSS None None O
software None None O
( None None O
version None None O
10 None None O
. None None O
0 None None O
) None None O
was None None O
used None None O
. None None O

Identification None None O
of None None O
Dss1 None None O
as None None O
a None None O
12 None None O
- None None O
O None None O
- None None O
tetradecanoylphorbol None None O
- None None O
13 None None O
- None None O
acetate None None O
- None None O
responsive None None O
gene None None O
expressed None None O
in None None O
keratinocyte None None O
progenitor None None O
cells None None O
, None None O
with None None O
possible None None O
involvement None None O
in None None O
early None None O
skin None None O
tumorigenesis None None O
. None None O

This None None O
study None None O
identifies None None O
genes None None O
expressed None None O
early None None O
in None None O
12 None None O
- None None O
O None None O
- None None O
tetradecanoylphorbol None None O
- None None O
13 None None O
- None None O
acetate None None O
( None None O
TPA None None O
) None None O
- None None O
induced None None O
skin None None O
carcinogenesis None None O
in None None O
genetically None None O
initiated None None O
Tg None None O
. None None O
AC None None O
v None None O
- None None O
Ha None None O
- None None O
ras None None O
transgenic None None O
mice None None O
. None None O

Keratinocyte None None O
progenitor None None O
cells None None O
from None None O
TPA None None O
- None None O
treated None None O
Tg None None O
. None None O
AC None None O
mice None None O
were None None O
isolated None None O
with None None O
fluorescence None None O
- None None O
activated None None O
cell None None O
sorting None None O
and None None O
expression None None O
was None None O
analyzed None None O
using None None O
cDNA None None O
microarray None None O
technology None None O
. None None O

Eleven None None O
genes None None O
were None None O
identified None None O
whose None None O
expression None None O
changed None None O
significantly None None O
in None None O
response None None O
to None None O
carcinogen None None O
treatment None None O
. None None O

Deleted None None O
in None None O
split None None O
hand None None O
/ None None O
split None None O
foot None None O
1 None None O
( None None O
Dss1 None None O
) None None O
is None None O
a None None O
gene None None O
associated None None O
with None None O
a None None O
heterogeneous None None O
limb None None O
developmental None None O
disorder None None O
called None None O
split None None O
hand None None O
/ None None O
split None None O
foot None None O
malformation None None O
. None None O

cDNA None None O
microarray None None O
expression None None O
analysis None None O
showed None None O
that None None O
the None None O
mouse None None O
homologue None None O
of None None O
Dss1 None None O
is None None O
induced None None O
by None None O
TPA None None O
. None None O

Dss1 None None O
overexpression None None O
was None None O
detected None None O
by None None O
Northern None None O
blot None None O
analysis None None O
in None None O
early None None O
TPA None None O
- None None O
treated None None O
hyperplastic None None O
skins None None O
and None None O
in None None O
JB6 None None O
Cl None None O
41 None None O
- None None O
5a None None O
epidermal None None O
cells None None O
. None None O

Interestingly None None O
, None None O
Dss1 None None O
expression None None O
was None None O
also None None O
shown None None O
to None None O
be None None O
elevated None None O
in None None O
skin None None O
papillomas None None O
relative None None O
to None None O
normal None None O
skins None None O
, None None O
and None None O
further None None O
increased None None O
in None None O
squamous None None O
cell None None O
malignancies None None O
. None None O

Functional None None O
studies None None O
by None None O
ectopically None None O
constitutive None None O
expression None None O
of None None O
Dss1 None None O
in None None O
JB6 None None O
Cl None None O
41 None None O
- None None O
5a None None O
preneoplastic None None O
cells None None O
strongly None None O
increased None None O
focus None None O
formation None None O
and None None O
proliferation None None O
of None None O
these None None O
cells None None O
and None None O
enhanced None None O
efficiency None None O
of None None O
neoplastic None None O
transformation None None O
of None None O
the None None O
cells None None O
in None None O
soft None None O
agar None None O
. None None O

These None None O
results None None O
strongly None None O
suggest None None O
that None None O
Dss1 None None O
is None None O
a None None O
TPA None None O
- None None O
inducible None None O
gene None None O
that None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
early None None O
stages None None O
of None None O
skin None None O
carcinogenesis None None O
. None None O

Differential None None O
mechanisms None None O
of None None O
radiosensitization None None O
by None None O
2 None None O
- None None O
deoxy None None O
- None None O
D None None O
- None None O
glucose None None O
in None None O
the None None O
monolayers None None O
and None None O
multicellular None None O
spheroids None None O
of None None O
a None None O
human None None O
glioma None None O
cell None None O
line None None O
. None None O

In None None O
vitro None None O
studies None None O
using None None O
monolayer None None O
cultures None None O
of None None O
human None None O
tumor None None O
cell None None O
lines None None O
have None None O
shown None None O
that None None O
2 None None O
- None None O
DG None None O
selectively None None O
inhibits None None O
energy None None O
- None None O
dependent None None O
DNA None None O
repair None None O
and None None O
cellular None None O
recovery None None O
processes None None O
in None None O
cancer None None O
cells None None O
. None None O

However None None O
, None None O
monolayer None None O
cultures None None O
differ None None O
greatly None None O
from None None O
the None None O
complex None None O
environmental None None O
conditions None None O
generated None None O
in None None O
solid None None O
tumors None None O
that None None O
develop None None O
inhomogeneous None None O
hypoxic None None O
and None None O
necrotic None None O
regions None None O
. None None O

In None None O
contrast None None O
, None None O
multicellular None None O
spheroids None None O
mimic None None O
heterogeneous None None O
cellular None None O
behavior None None O
and None None O
the None None O
consequent None None O
functional None None O
characteristics None None O
of None None O
in None None O
vivo None None O
solid None None O
tumors None None O
, None None O
and None None O
serve None None O
as None None O
important None None O
in None None O
vitro None None O
model None None O
to None None O
investigate None None O
tumor None None O
biology None None O
and None None O
responses None None O
to None None O
potential None None O
therapeutic None None O
agents None None O
. None None O

The None None O
present None None O
study None None O
compares None None O
the None None O
radiomodification None None O
by None None O
2 None None O
- None None O
DG None None O
in None None O
monolayer None None O
cultures None None O
and None None O
spheroids None None O
of None None O
a None None O
human None None O
glioma None None O
cell None None O
line None None O
( None None O
BMG None None I-Cell-line-name
- None None I-Cell-line-name
1 None None I-Cell-line-name
) None None O
to None None O
gain None None O
insight None None O
into None None O
the None None O
effects None None O
in None None O
solid None None O
tumors None None O
. None None O

In None None O
spheroids None None O
, None None O
the None None O
glucose None None O
consumption None None O
( None None O
2 None None O
. None None O
1 None None O
p None None O
mole None None O
/ None None O
cell None None O
/ None None O
h None None O
) None None O
and None None O
lactate None None O
production None None O
( None None O
3 None None O
. None None O
67 None None O
p None None O
mole None None O
/ None None O
cell None None O
/ None None O
h None None O
) None None O
was None None O
nearly None None O
2 None None O
- None None O
3 None None O
fold None None O
higher None None O
than None None O
in None None O
monolayer None None O
cells None None O
( None None O
0 None None O
. None None O
83 None None O
and None None O
1 None None O
. None None O
43 None None O
p None None O
mole None None O
/ None None O
cell None None O
/ None None O
h None None O
respectively None None O
) None None O
. None None O

Presence None None O
of None None O
2 None None O
- None None O
DG None None O
( None None O
5 None None O
mM None None O
) None None O
for None None O
2 None None O
- None None O
4 None None O
h None None O
inhibited None None O
the None None O
glucose None None O
usage None None O
and None None O
lactate None None O
production None None O
by None None O
70 None None O
% None None O
in None None O
spheroids None None O
, None None O
while None None O
a None None O
35 None None O
% None None O
reduction None None O
was None None O
observed None None O
in None None O
monolayer None None O
cells None None O
. None None O

Under None None O
these None None O
conditions None None O
, None None O
2 None None O
- None None O
DG None None O
drastically None None O
enhanced None None O
the None None O
radiation None None O
- None None O
induced None None O
cell None None O
death None None O
of None None O
spheroids None None O
( None None O
by None None O
2 None None O
- None None O
3 None None O
folds None None O
) None None O
; None None O
while None None O
a None None O
40 None None O
% None None O
increase None None O
was None None O
observed None None O
in None None O
monolayer None None O
cells None None O
. None None O

Radiosensitization None None O
by None None O
2 None None O
- None None O
DG None None O
in None None O
monolayer None None O
cells None None O
was None None O
primarily None None O
due None None O
to None None O
an None None O
increase None None O
in None None O
mitotic None None O
death None None O
( None None O
23 None None O
% None None O
) None None O
linked None None O
to None None O
cytogenetic None None O
damage None None O
( None None O
micronuclei None None O
) None None O
, None None O
whereas None None O
a None None O
profound None None O
induction None None O
of None None O
apoptosis None None O
( None None O
40 None None O
% None None O
) None None O
accounted None None O
for None None O
the None None O
sensitization None None O
in None None O
spheroids None None O
. None None O

Although None None O
the None None O
Bcl None None O
- None None O
2 None None O
and None None O
Bax None None O
levels None None O
were None None O
significantly None None O
higher None None O
in None None O
spheroids None None O
, None None O
Bcl None None O
- None None O
2 None None O
/ None None O
Bax None None O
ratio None None O
was None None O
similar None None O
in None None O
monolayers None None O
and None None O
spheroids None None O
. None None O

Comet None None O
assay None None O
revealed None None O
a None None O
late None None O
onset None None O
of None None O
DNA None None O
breaks None None O
in None None O
the None None O
presence None None O
of None None O
2 None None O
- None None O
DG None None O
following None None O
irradiation None None O
only None None O
in None None O
spheroids None None O
, None None O
which None None O
corroborated None None O
well None None O
with None None O
the None None O
late None None O
onset None None O
of None None O
oxidative None None O
stress None None O
. None None O

2 None None O
- None None O
DG None None O
did None None O
not None None O
induce None None O
a None None O
significant None None O
cell None None O
cycle None None O
delay None None O
in None None O
monolayers None None O
, None None O
while None None O
a None None O
transient None None O
G None None O
( None None O
2 None None O
) None None O
delay None None O
was None None O
apparent None None O
in None None O
spheroids None None O
. None None O

Acylase None None O
I None None O
- None None O
catalyzed None None O
deacetylation None None O
of None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteine None None O
and None None O
S None None O
- None None O
alkyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteines None None O
. None None O

The None None O
aminoacylase None None O
that None None O
catalyzes None None O
the None None O
hydrolysis None None O
of None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteine None None O
( None None O
NAC None None O
) None None O
was None None O
identified None None O
as None None O
acylase None None O
I None None O
after None None O
purification None None O
by None None O
column None None O
chromatography None None O
and None None O
electrophoretic None None O
analysis None None O
. None None O

Rat None None O
kidney None None O
cytosol None None O
was None None O
fractionated None None O
by None None O
ammonium None None O
sulfate None None O
precipitation None None O
, None None O
and None None O
the None None O
proteins None None O
were None None O
separated None None O
by None None O
ion None None O
- None None O
exchange None None O
column None None O
chromatography None None O
, None None O
gel None None O
- None None O
filtration None None O
column None None O
chromatography None None O
, None None O
and None None O
hydrophobic None None O
interaction None None O
column None None O
chromatography None None O
. None None O

Acylase None None O
activity None None O
with None None O
NAC None None O
and None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
methionine None None O
( None None O
NAM None None O
) None None O
, None None O
a None None O
known None None O
substrate None None O
for None None O
acylase None None O
I None None O
, None None O
as None None O
substrates None None O
coeluted None None O
during None None O
all None None O
chromatographic None None O
steps None None O
. None None O

Sodium None None O
dodecyl None None O
sulfate None None O
- None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
showed None None O
that None None O
the None None O
protein None None O
was None None O
purified None None O
to None None O
near None None O
homogeneity None None O
and None None O
had None None O
a None None O
subunit None None O
Mr None None O
of None None O
43 None None O
000 None None O
, None None O
which None None O
is None None O
identical None None O
with None None O
the None None O
Mr None None O
of None None O
acylase None None O
I None None O
from None None O
porcine None None O
kidney None None O
and None None O
bovine None None O
liver None None O
. None None O

n None None O
- None None O
Butylmalonic None None O
acid None None O
was None None O
a None None O
slow None None O
- None None O
binding None None O
inhibitor None None O
of None None O
acylase None None O
I None None O
and None None O
inhibited None None O
the None None O
deacetylation None None O
of None None O
NAC None None O
with None None O
a None None O
Ki None None O
of None None O
192 None None O
+ None None O
/ None None O
- None None O
27 None None O
microM None None O
. None None O

These None None O
results None None O
show None None O
that None None O
acylase None None O
I None None O
catalyzes None None O
the None None O
deacetylation None None O
of None None O
NAC None None O
. None None O

The None None O
acylase None None O
I None None O
- None None O
catalyzed None None O
deacetylation None None O
of None None O
a None None O
range None None O
of None None O
S None None O
- None None O
alkyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteines None None O
, None None O
their None None O
carbon None None O
and None None O
oxygen None None O
analogues None None O
, None None O
and None None O
the None None O
selenium None None O
analogue None None O
of None None O
NAM None None O
was None None O
also None None O
studied None None O
with None None O
porcine None None O
kidney None None O
acylase None None O
I None None O
. None None O

The None None O
specific None None O
activity None None O
of None None O
the None None O
acylase None None O
I None None O
- None None O
catalyzed None None O
deacetylation None None O
of None None O
these None None O
substrates None None O
was None None O
related None None O
to None None O
their None None O
calculated None None O
molar None None O
volumes None None O
and None None O
log None None O
P None None O
values None None O
. None None O

The None None O
S None None O
- None None O
alkyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteines None None O
with None None O
short None None O
( None None O
C0 None None O
- None None O
C3 None None O
) None None O
and None None O
unbranched None None O
S None None O
- None None O
alkyl None None O
substituents None None O
were None None O
good None None O
acylase None None O
I None None O
substrates None None O
, None None O
whereas None None O
the None None O
S None None O
- None None O
alkyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteines None None O
with None None O
long None None O
( None None O
> None None O
C3 None None O
) None None O
and None None O
branched None None O
S None None O
- None None O
alkyl None None O
substituents None None O
were None None O
poLr None None O
acylase None None O
I None None O
substrates None None O
. None None O

The None None O
carbon None None O
and None None O
oxygen None None O
analogues None None O
of None None O
S None None O
- None None O
methyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteine None None O
and None None O
the None None O
carbon None None O
analogue None None O
of None None O
S None None O
- None None O
ethyl None None O
- None None O
N None None O
- None None O
acetyl None None O
- None None O
L None None O
- None None O
cysteine None None O
were None None O
poor None None O
acylase None None O
I None None O
substrates None None O
, None None O
whereas None None O
the None None O
selenium None None O
analogue None None O
of None None O
NAM None None O
was None None O
a None None O
good None None O
acylase None None O
I None None O
substrate None None O
. None None O

PTTG None None O
overexpression None None O
promotes None None O
lymph None None O
node None None O
metastasis None None O
in None None O
human None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
. None None O

Human None None O
pituitary None None O
tumor None None O
transforming None None O
gene None None O
( None None O
PTTG None None O
) None None O
overexpression None None O
correlates None None O
with None None O
metastasis None None O
in None None O
multiple None None O
tumors None None O
, None None O
and None None O
yet None None O
its None None O
molecular None None O
mechanisms None None O
of None None O
action None None O
remain None None O
elusive None None O
. None None O

We None None O
detected None None O
PTTG None None O
overexpression None None O
in None None O
66 None None O
% None None O
( None None O
111 None None O
of None None O
169 None None O
) None None O
of None None O
primary None None O
esophageal None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
ESCC None None O
) None None O
tumor None None O
tissues None None O
by None None O
in None None O
situ None None O
hybridization None None O
. None None O

PTTG None None O
overexpression None None O
correlated None None O
with None None O
lymph None None O
node None None O
metastasis None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

Ectopic None None O
PTTG None None O
overexpression None None O
in None None O
a None None O
representative None None O
ESCC None None O
cell None None O
line None None O
, None None O
EC9706 None None I-Cell-line-name
, None None O
increased None None O
in None None O
vitro None None O
cell None None O
migration None None O
and None None O
invasion None None O
and None None O
promoted None None O
in None None O
vivo None None O
lymph None None O
node None None O
metastasis None None O
. None None O

Suppressing None None O
PTTG None None O
expression None None O
by None None O
siRNA None None O
decreased None None O
cell None None O
motility None None O
in None None O
both None None O
PTTG None None O
- None None O
HA None None O
/ None None O
EC9706 None None I-Cell-line-name
and None None O
KYSE150 None None I-Cell-line-name
cells None None O
. None None O

By None None O
using None None O
mass None None O
spectrometric None None O
analysis None None O
, None None O
we None None O
identified None None O
that None None O
PTTG None None O
up None None O
- None None O
regulated None None O
S100A4 None None O
and None None O
galectin None None O
- None None O
1 None None O
secretion None None O
and None None O
down None None O
- None None O
regulated None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinase None None O
- None None O
2 None None O
secretion None None O
to None None O
the None None O
culture None None O
media None None O
. None None O

PTTG None None O
induced None None O
S100A4 None None O
and None None O
galectin None None O
- None None O
1 None None O
mRNA None None O
and None None O
protein None None O
expression None None O
as None None O
assessed None None O
by None None O
Western None None O
blot None None O
and None None O
reverse None None O
transcription None None O
- None None O
PCR None None O
. None None O

Attenuating None None O
galectin None None O
- None None O
1 None None O
expression None None O
by None None O
siRNA None None O
constrained None None O
PTTG None None O
- None None O
HA None None O
/ None None O
EC9706 None None I-Cell-line-name
cell None None O
motility None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

PTTG None None O
activated None None O
E None None O
- None None O
box None None O
transcription None None O
and None None O
induced None None O
c None None O
- None None O
Myc None None O
protein None None O
expression None None O
in None None O
EC9706 None None I-Cell-line-name
cells None None O
, None None O
which None None O
in None None O
turn None None O
may None None O
act None None O
on None None O
an None None O
E None None O
- None None O
box None None O
motif None None O
within None None O
the None None O
galectin None None O
- None None O
1 None None O
promoter None None O
. None None O

Chromatin None None O
immunoprecipitation None None O
assays None None O
further None None O
confirmed None None O
specific None None O
c None None O
- None None O
Myc None None O
binding None None O
to None None O
galectin None None O
- None None O
1 None None O
promoter None None O
. None None O

PTTG None None O
- None None O
induced None None O
galectin None None O
- None None O
1 None None O
transactivation None None O
and None None O
expression None None O
were None None O
mediated None None O
by None None O
c None None O
- None None O
Myc None None O
, None None O
and None None O
both None None O
inductions None None O
were None None O
suppressed None None O
by None None O
c None None O
- None None O
Myc None None O
RNAi None None O
cotranfection None None O
. None None O

These None None O
findings None None O
elucidate None None O
the None None O
molecular None None O
mechanisms None None O
of None None O
PTTG None None O
overexpression None None O
in None None O
promoting None None O
tumor None None O
metastasis None None O
, None None O
whereby None None O
up None None O
- None None O
regulated None None O
PTTG None None O
modulates None None O
expression None None O
and None None O
secretion None None O
of None None O
metastasis None None O
- None None O
related None None O
factors None None O
to None None O
facilitate None None O
cell None None O
motility None None O
. None None O

3 None None O
. None None O

Results None None O
and None None O
discussion None None O

AbsC None None O
was None None O
overexpressed None None O
and None None O
purified None None O
with None None O
a None None O
final None None O
yield None None O
of None None O
approximately None None O
10 None None O
mg None None O
of None None O
protein None None O
from None None O
1 None None O
l None None O
culture None None O
and None None O
was None None O
judged None None O
to None None O
be None None O
greater None None O
than None None O
98 None None O
% None None O
pure None None O
by None None O
SDS None None O
- None None O
PAGE None None O
analysis None None O
. None None O

The None None O
DLS None None O
analysis None None O
after None None O
gel None None O
filtration None None O
showed None None O
a None None O
monomodal None None O
distribution None None O
, None None O
with None None O
a None None O
polydispersity None None O
value None None O
of None None O
18 None None O
. None None O
9 None None O
% None None O
and None None O
a None None O
molecular None None O
- None None O
size None None O
estimate None None O
of None None O
39 None None O
. None None O
6 None None O
kDa None None O
. None None O

This None None O
was None None O
comparable None None O
to None None O
the None None O
value None None O
of None None O
36 None None O
kDa None None O
estimated None None O
from None None O
the None None O
calibrated None None O
gel None None O
- None None O
filtration None None O
column None None O
, None None O
strongly None None O
suggesting None None O
that None None O
AbsC None None O
exists None None O
as None None O
a None None O
homodimer None None O
in None None O
solution None None O
( None None O
calculated None None O
molecular None None O
weight None None O
of None None O
41 None None O
. None None O
0 None None O
kDa None None O
for None None O
the None None O
His None None O
- None None O
tagged None None O
dimer None None O
) None None O
, None None O
in None None O
agreement None None O
with None None O
other None None O
characterized None None O
MarR None None O
homologues None None O
. None None O

Preliminary None None O
crystals None None O
grew None None O
within None None O
24 None None O
h None None O
at None None O
293 None None O
K None None O
from None None O
several None None O
different None None O
crystallization None None O
conditions None None O
. None None O

Improved None None O
crystals None None O
were None None O
subsequently None None O
obtained None None O
with None None O
a None None O
precipitant None None O
solution None None O
consisting None None O
of None None O
1 None None O
M None None O
ammonium None None O
sulfate None None O
, None None O
0 None None O
. None None O
55 None None O
M None None O
potassium None None O
sodium None None O
tartrate None None O
in None None O
100 None None O
mM None None O
citrate None None O
pH None None O
5 None None O
. None None O
6 None None O
, None None O
giving None None O
crystals None None O
with None None O
approximate None None O
dimensions None None O
of None None O
700 None None O
x None None O
50 None None O
x None None O
50 None None O
microm None None O
( None None O
Fig None None O
. None None O
1 None None O
> None None O
) None None O
. None None O

Native None None O
X None None O
- None None O
ray None None O
data None None O
were None None O
collected None None O
from None None O
a None None O
single None None O
AbsC None None O
crystal None None O
: None None O
a None None O
total None None O
of None None O
214 None None O
x None None O
0 None None O
. None None O
4degrees None None O
oscillation None None O
images None None O
were None None O
recorded None None O
in None None O
a None None O
continuous None None O
sweep None None O
to None None O
a None None O
maximum None None O
resolution None None O
of None None O
2 None None O
. None None O
25 None None O
A None None O
. None None O

Indexing None None O
was None None O
consistent None None O
with None None O
a None None O
primitive None None O
orthorhombic None None O
lattice None None O
, None None O
with None None O
unit None None O
- None None O
cell None None O
parameters None None O
a None None O
= None None O
43 None None O
. None None O
53 None None O
, None None O
b None None O
= None None O
121 None None O
. None None O
30 None None O
, None None O
c None None O
= None None O
143 None None O
. None None O
75 None None O
A None None O
. None None O

After None None O
processing None None O
the None None O
data None None O
in None None O
space None None O
group None None O
P222 None None O
, None None O
pseudo None None O
- None None O
precession None None O
plots None None O
were None None O
analysed None None O
using None None O
HKLVIEW None None O
( None None O
Collaborative None None O
Computational None None O
Project None None O
, None None O
Number None None O
4 None None O
, None None O
1994 None None O
> None None O
) None None O
and None None O
the None None O
systematic None None O
absences None None O
were None None O
indicative None None O
of None None O
space None None O
group None None O
P212121 None None O
. None None O

Reprocessing None None O
in None None O
this None None O
space None None O
group None None O
yielded None None O
a None None O
data None None O
set None None O
that None None O
was None None O
95 None None O
. None None O
6 None None O
% None None O
complete None None O
to None None O
2 None None O
. None None O
25 None None O
A None None O
resolution None None O
. None None O

Data None None O
- None None O
collection None None O
statistics None None O
are None None O
summarized None None O
in None None O
Table None None O
1 None None O
> None None O
. None None O

Estimation None None O
of None None O
the None None O
content None None O
of None None O
the None None O
asymmetric None None O
unit None None O
( None None O
ASU None None O
) None None O
suggested None None O
that None None O
three None None O
or None None O
four None None O
His None None O
- None None O
tagged None None O
AbsC None None O
subunits None None O
were None None O
most None None O
likely None None O
, None None O
giving None None O
solvent None None O
contents None None O
of None None O
60 None None O
. None None O
3 None None O
% None None O
or None None O
47 None None O
. None None O
0 None None O
% None None O
and None None O
crystal None None O
- None None O
packing None None O
parameters None None O
( None None O
V None None O
M None None O
) None None O
of None None O
3 None None O
. None None O
09 None None O
or None None O
2 None None O
. None None O
32 None None O
A3 None None O
Da None None O
- None None O
1 None None O
, None None O
respectively None None O
. None None O

Given None None O
that None None O
both None None O
DLS None None O
and None None O
gel None None O
filtration None None O
suggest None None O
that None None O
AbsC None None O
is None None O
dimeric None None O
and None None O
that None None O
MarR None None O
homologues None None O
exist None None O
as None None O
homodimers None None O
( None None O
Wilkinson None None O
& None None O
Grove None None O
, None None O
2006 None None O
> None None O
) None None O
, None None O
an None None O
even None None O
number None None O
of None None O
subunits None None O
per None None O
ASU None None O
, None None O
i None None O
. None None O
e None None O
. None None O
four None None O
, None None O
would None None O
seem None None O
to None None O
be None None O
the None None O
most None None O
probable None None O
( None None O
Matthews None None O
, None None O
1968 None None O
> None None O
) None None O
. None None O

A None None O
Patterson None None O
function None None O
calculated None None O
on None None O
data None None O
in None None O
the None None O
resolution None None O
range None None O
10 None None O
. None None O
0 None None O
- None None O
3 None None O
. None None O
0 None None O
A None None O
revealed None None O
a None None O
significant None None O
peak None None O
( None None O
at None None O
24 None None O
% None None O
of None None O
the None None O
origin None None O
peak None None O
) None None O
with None None O
a None None O
vector None None O
of None None O
u None None O
= None None O
0 None None O
. None None O
0 None None O
, None None O
v None None O
= None None O
0 None None O
. None None O
5 None None O
, None None O
w None None O
= None None O
0 None None O
. None None O
014 None None O
, None None O
indicating None None O
that None None O
one None None O
or None None O
more None None O
molecules None None O
in None None O
the None None O
ASU None None O
were None None O
similarly None None O
orientated None None O
. None None O

A None None O
self None None O
- None None O
rotation None None O
function None None O
calculated None None O
on None None O
data None None O
in None None O
the None None O
resolution None None O
range None None O
10 None None O
. None None O
0 None None O
- None None O
5 None None O
. None None O
0 None None O
A None None O
using None None O
MOLREP None None O
( None None O
Vagin None None O
& None None O
Teplyakov None None O
, None None O
2000 None None O
> None None O
) None None O
did None None O
not None None O
show None None O
any None None O
clear None None O
noncrystallographic None None O
symmetry None None O
( None None O
NCS None None O
) None None O
, None None O
perhaps None None O
suggesting None None O
that None None O
if None None O
NCS None None O
axes None None O
were None None O
present None None O
they None None O
were None None O
parallel None None O
( None None O
or None None O
almost None None O
parallel None None O
) None None O
to None None O
crystallographic None None O
axes None None O
. None None O

Fold None None O
prediction None None O
, None None O
based None None O
on None None O
the None None O
amino None None O
- None None O
acid None None O
sequence None None O
of None None O
AbsC None None O
, None None O
was None None O
performed None None O
using None None O
the None None O
FUGUE None None O
server None None O
( None None O
http None None O
: None None O
/ None None O
/ None None O
www None None O
- None None O
cryst None None O
. None None O
bioc None None O
. None None O
cam None None O
. None None O
ac None None O
. None None O
uk None None O
/ None None O
~ None None O
fugue None None O
/ None None O
prfsearch None None O
. None None O
html None None O
; None None O
Shi None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
> None None O
) None None O
. None None O

This None None O
found None None O
eight None None O
' None None O
certain None None O
' None None O
hits None None O
, None None O
with None None O
the None None O
top None None O
three None None O
being None None O
MarR None None O
( None None O
PDB None None O
code None None O
1jgs None None O
; None None O
Z None None O
score None None O
21 None None O
. None None O
4 None None O
; None None O
18 None None O
% None None O
sequence None None O
identity None None O
) None None O
, None None O
SlyA None None O
( None None O
PDB None None O
code None None O
1lj9 None None O
; None None O
Z None None O
score None None O
18 None None O
. None None O
4 None None O
; None None O
16 None None O
% None None O
sequence None None O
identity None None O
) None None O
and None None O
YusO None None O
( None None O
PDB None None O
code None None O
1s3j None None O
; None None O
Z None None O
score None None O
15 None None O
. None None O
7 None None O
; None None O
16 None None O
% None None O
sequence None None O
identity None None O
) None None O
. None None O

All None None O
three None None O
hits None None O
were None None O
used None None O
as None None O
search None None O
models None None O
for None None O
molecular None None O
replacement None None O
in None None O
the None None O
program None None O
AMoRe None None O
( None None O
Navaza None None O
, None None O
1994 None None O
> None None O
) None None O
, None None O
but None None O
none None None O
yielded None None O
plausible None None O
solutions None None O
against None None O
the None None O
2 None None O
. None None O
25 None None O
A None None O
resolution None None O
native None None O
data None None O
set None None O
, None None O
although None None O
this None None O
is None None O
not None None O
too None None O
surprising None None O
given None None O
their None None O
very None None O
low None None O
sequence None None O
identities None None O
. None None O

Thus None None O
, None None O
we None None O
will None None O
need None None O
to None None O
solve None None O
the None None O
AbsC None None O
structure None None O
by None None O
isomorphous None None O
replacement None None O
methods None None O
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
are None None O
preparing None None O
selenomethionine None None O
- None None O
labelled None None O
protein None None O
; None None O
there None None O
are None None O
a None None O
total None None O
of None None O
seven None None O
methionine None None O
residues None None O
present None None O
in None None O
the None None O
158 None None O
- None None O
amino None None O
- None None O
acid None None O
sequence None None O
of None None O
AbsC None None O
. None None O

Purification None None O
and None None O
characterization None None O
of None None O
various None None O
esterases None None O
from None None O
rat None None O
liver None None O
. None None O

The None None O
major None None O
rat None None O
liver None None O
microsomal None None O
esterases None None O
acting None None O
on None None O
o None None O
- None None O
nitrophenylacetate None None O
with None None O
isoelectric None None O
points None None O
5 None None O
. None None O
0 None None O
, None None O
5 None None O
. None None O
5 None None O
, None None O
6 None None O
. None None O
1 None None O
and None None O
6 None None O
. None None O
4 None None O
were None None O
resolved None None O
by None None O
isoelectric None None O
focusing None None O
. None None O

Molecular None None O
weights None None O
were None None O
determined None None O
by None None O
sedimentation None None O
analysis None None O
in None None O
isokinetic None None O
gradients None None O
of None None O
sucrose None None O
and None None O
, None None O
after None None O
purification None None O
, None None O
in None None O
sodium None None O
dodecyl None None O
sulphate None None O
/ None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
. None None O

Their None None O
subunit None None O
molecular None None O
weights None None O
were None None O
between None None O
57 None None O
000 None None O
and None None O
60 None None O
000 None None O
. None None O

They None None O
behaved None None O
as None None O
monomers None None O
except None None O
the None None O
pI None None O
- None None O
6 None None O
. None None O
1 None None O
enzyme None None O
which None None O
behaved None None O
as None None O
a None None O
trimer None None O
. None None O

Esterases None None O
of None None O
pI None None O
5 None None O
. None None O
0 None None O
, None None O
pI None None O
6 None None O
. None None O
1 None None O
and None None O
pI None None O
6 None None O
. None None O
4 None None O
behaved None None O
like None None O
glycoproteins None None O
of None None O
the None None O
polymannose None None O
type None None O
in None None O
the None None O
presence None None O
of None None O
125I None None O
- None None O
labelled None None O
concanavalin None None O
A None None O
. None None O

Preparations None None O
of None None O
the None None O
pI None None O
- None None O
5 None None O
. None None O
0 None None O
enzyme None None O
contained None None O
two None None O
esterases None None O
of None None O
highly None None O
homologous None None O
structure None None O
. None None O

Antibodies None None O
directed None None O
against None None O
this None None O
preparation None None O
did None None O
not None None O
inhibit None None O
but None None O
precipitated None None O
pI None None O
- None None O
5 None None O
. None None O
0 None None O
esterase None None O
activity None None O
quantitatively None None O
. None None O

They None None O
did None None O
not None None O
react None None O
with None None O
the None None O
pI None None O
- None None O
6 None None O
. None None O
1 None None O
and None None O
pI None None O
- None None O
6 None None O
. None None O
4 None None O
esterases None None O
but None None O
precipitated None None O
several None None O
nonimmunologically None None O
related None None O
esterases None None O
. None None O

Two None None O
of None None O
these None None O
enzymes None None O
were None None O
inducible None None O
by None None O
phenobarbital None None O
. None None O

Total None None O
activity None None O
was None None O
very None None O
low None None O
in None None O
3 None None O
- None None O
day None None O
- None None O
old None None O
animals None None O
. None None O

Individual None None O
esterase None None O
activities None None O
rose None None O
at None None O
different None None O
rates None None O
during None None O
development None None O
; None None O
the None None O
enzyme None None O
focusing None None O
near None None O
pI None None O
5 None None O
. None None O
0 None None O
was None None O
about None None O
three None None O
times None None O
more None None O
active None None O
in None None O
adult None None O
females None None O
than None None O
in None None O
males None None O
. None None O

All None None O
microsomal None None O
esterases None None O
are None None O
located None None O
on None None O
the None None O
luminal None None O
side None None O
of None None O
the None None O
endoplasmic None None O
reticulum None None O
. None None O

Promoting None None O
angiogenesis None None O
via None None O
manipulation None None O
of None None O
VEGF None None O
responsiveness None None O
with None None O
notch None None O
signaling None None O
. None None O

Promoting None None O
angiogenesis None None O
via None None O
delivery None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
other None None O
angiogenic None None O
factors None None O
is None None O
both None None O
a None None O
potential None None O
therapy None None O
for None None O
cardiovascular None None O
diseases None None O
and None None O
a None None O
critical None None O
aspect None None O
for None None O
tissue None None O
regeneration None None O
. None None O

The None None O
recent None None O
demonstration None None O
that None None O
VEGF None None O
signaling None None O
is None None O
modulated None None O
by None None O
the None None O
Notch None None O
signaling None None O
pathway None None O
, None None O
however None None O
, None None O
suggests None None O
that None None O
inhibiting None None O
Notch None None O
signaling None None O
may None None O
enhance None None O
regional None None O
neovascularization None None O
, None None O
by None None O
altering None None O
the None None O
responsiveness None None O
of None None O
local None None O
endothelial None None O
cells None None O
to None None O
angiogenic None None O
stimuli None None O
. None None O

We None None O
tested None None O
this None None O
possibility None None O
with None None O
in None None O
vitro None None O
assays None None O
using None None O
human None None O
endothelial None None O
cells None None O
, None None O
as None None O
well None None O
as None None O
in None None O
a None None O
rodent None None O
hindlimb None None O
ischemia None None O
model None None O
. None None O

Treatment None None O
of None None O
cultured None None O
human None None O
endothelial None None O
cells None None O
with None None O
DAPT None None O
, None None O
a None None O
gamma None None O
secretase None None O
inhibitor None None O
, None None O
increased None None O
cell None None O
migration None None O
and None None O
sprout None None O
formation None None O
in None None O
response None None O
to None None O
VEGF None None O
stimulation None None O
with None None O
a None None O
biphasic None None O
dependence None None O
on None None O
DAPT None None O
concentration None None O
. None None O

Further None None O
, None None O
delivery None None O
of None None O
an None None O
appropriate None None O
combination None None O
of None None O
DAPT None None O
and None None O
VEGF None None O
from None None O
an None None O
injectable None None O
alginate None None O
hydrogel None None O
system None None O
into None None O
ischemic None None O
hindlimbs None None O
led None None O
to None None O
a None None O
faster None None O
recovery None None O
of None None O
blood None None O
flow None None O
than None None O
VEGF None None O
or None None O
DAPT None None O
alone None None O
; None None O
perfusion None None O
levels None None O
reached None None O
80 None None O
% None None O
of None None O
the None None O
normal None None O
level None None O
by None None O
week None None O
4 None None O
with None None O
combined None None O
DAPT None None O
and None None O
VEGF None None O
delivery None None O
. None None O

Direct None None O
intramuscular None None O
or None None O
intraperitoneal None None O
injection None None O
of None None O
DAPT None None O
did None None O
not None None O
result None None O
in None None O
the None None O
same None None O
level None None O
of None None O
improvement None None O
, None None O
suggesting None None O
that None None O
appropriate None None O
presentation None None O
of None None O
DAPT None None O
( None None O
gel None None O
delivery None None O
) None None O
is None None O
important None None O
for None None O
its None None O
activity None None O
. None None O

DAPT None None O
delivery None None O
from None None O
the None None O
hydrogels None None O
also None None O
did None None O
not None None O
lead None None O
to None None O
any None None O
adverse None None O
side None None O
effects None None O
, None None O
in None None O
contrast None None O
to None None O
systemic None None O
introduction None None O
of None None O
DAPT None None O
. None None O

Altogether None None O
, None None O
these None None O
results None None O
suggest None None O
a None None O
new None None O
approach None None O
to None None O
promote None None O
angiogenesis None None O
by None None O
controlling None None O
Notch None None O
signaling None None O
, None None O
and None None O
may None None O
provide None None O
new None None O
options None None O
to None None O
treat None None O
patients None None O
with None None O
diseases None None O
that None None O
diminish None None O
angiogenic None None O
responsiveness None None O
. None None O

Multicriteria None None O
evaluation None None O
of None None O
simulated None None O
logging None None O
scenarios None None O
in None None O
a None None O
tropical None None O
rain None None O
forest None None O
. None None O

Forest None None O
growth None None O
models None None O
are None None O
useful None None O
tools None None O
for None None O
investigating None None O
the None None O
long None None O
- None None O
term None None O
impacts None None O
of None None O
logging None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
the None None O
results None None O
of None None O
the None None O
rain None None O
forest None None O
growth None None O
model None None O
FORMIND None None O
were None None O
assessed None None O
by None None O
a None None O
multicriteria None None O
decision None None O
analysis None None O
. None None O

The None None O
main None None O
processes None None O
covered None None O
by None None O
FORMIND None None O
include None None O
tree None None O
growth None None O
, None None O
mortality None None O
, None None O
regeneration None None O
and None None O
competition None None O
. None None O

Tree None None O
growth None None O
is None None O
calculated None None O
based None None O
on None None O
a None None O
carbon None None O
balance None None O
approach None None O
. None None O

Trees None None O
compete None None O
for None None O
light None None O
and None None O
space None None O
; None None O
dying None None O
large None None O
trees None None O
fall None None O
down None None O
and None None O
create None None O
gaps None None O
in None None O
the None None O
forest None None O
. None None O

Sixty None None O
- None None O
four None None O
different None None O
logging None None O
scenarios None None O
for None None O
an None None O
initially None None O
undisturbed None None O
forest None None O
stand None None O
at None None O
Deramakot None None O
( None None O
Malaysia None None O
) None None O
were None None O
simulated None None O
. None None O

The None None O
scenarios None None O
differ None None O
regarding None None O
the None None O
logging None None O
cycle None None O
, None None O
logging None None O
method None None O
, None None O
cutting None None O
limit None None O
and None None O
logging None None O
intensity None None O
. None None O

We None None O
characterise None None O
the None None O
impacts None None O
with None None O
four None None O
criteria None None O
describing None None O
the None None O
yield None None O
, None None O
canopy None None O
opening None None O
and None None O
changes None None O
in None None O
species None None O
composition None None O
. None None O

Multicriteria None None O
decision None None O
analysis None None O
was None None O
used None None O
for None None O
the None None O
first None None O
time None None O
to None None O
evaluate None None O
the None None O
scenarios None None O
and None None O
identify None None O
the None None O
efficient None None O
ones None None O
. None None O

Our None None O
results None None O
plainly None None O
show None None O
that None None O
reduced None None O
- None None O
impact None None O
logging None None O
scenarios None None O
are None None O
more None None O
' None None O
efficient None None O
' None None O
than None None O
the None None O
others None None O
, None None O
since None None O
in None None O
these None None O
scenarios None None O
forest None None O
damage None None O
is None None O
minimised None None O
without None None O
significantly None None O
reducing None None O
yield None None O
. None None O

Nevertheless None None O
, None None O
there None None O
is None None O
a None None O
trade None None O
- None None O
off None None O
between None None O
yield None None O
and None None O
achieving None None O
a None None O
desired None None O
ecological None None O
state None None O
of None None O
logged None None O
forest None None O
; None None O
the None None O
ecological None None O
state None None O
of None None O
the None None O
logged None None O
forests None None O
can None None O
only None None O
be None None O
improved None None O
by None None O
reducing None None O
yields None None O
and None None O
enlarging None None O
the None None O
logging None None O
cycles None None O
. None None O

Our None None O
study None None O
also None None O
demonstrates None None O
that None None O
high None None O
cutting None None O
limits None None O
or None None O
low None None O
logging None None O
intensities None None O
cannot None None O
compensate None None O
for None None O
the None None O
high None None O
level None None O
of None None O
damage None None O
caused None None O
by None None O
conventional None None O
logging None None O
techniques None None O
. None None O

Refinement None None O

The None None O
H None None O
- None None O
atoms None None O
were None None O
positioned None None O
geometrically None None O
( None None O
O None None O
- None None O
H None None O
= None None O
0 None None O
. None None O
82 None None O
, None None O
C None None O
- None None O
H None None O
= None None O
0 None None O
. None None O
93 None None O
A None None O
) None None O
and None None O
were None None O
included None None O
in None None O
the None None O
refinement None None O
in None None O
the None None O
riding None None O
model None None O
approximation None None O
, None None O
with None None O
Uiso None None O
( None None O
H None None O
) None None O
= None None O
xUeq None None O
( None None O
C None None O
, None None O
O None None O
) None None O
, None None O
where None None O
x None None O
= None None O
1 None None O
. None None O
2 None None O
for None None O
all None None O
H None None O
- None None O
atoms None None O
. None None O

Results None None O
: None None O

All None None O
fractures None None O
united None None O
. None None O

Individual None None O
movement None None O
of None None O
dorsiflexion None None O
, None None O
palmar None None O
flexion None None O
, None None O
supination None None O
, None None O
pronation None None O
and None None O
radial None None O
- None None O
ulnar None None O
deviation None None O
were None None O
all None None O
significantly None None O
better None None O
in None None O
the None None O
dorsiflexed None None O
- None None O
immobilized None None O
group None None O
as None None O
compared None None O
with None None O
the None None O
palmar None None O
flexed None None O
immobilized None None O
group None None O
. None None O

Grip None None O
strength None None O
recovery None None O
with None None O
subjective None None O
assessment None None O
was None None O
better None None O
in None None O
the None None O
dorsiflexed None None O
group None None O
( None None O
77 None None O
% None None O
) None None O
as None None O
compared None None O
to None None O
the None None O
palmar None None O
flexed None None O
group None None O
( None None O
23 None None O
% None None O
) None None O
. None None O

Radiological None None O
parameters None None O
were None None O
markedly None None O
better None None O
in None None O
the None None O
dorsiflexed None None O
group None None O
. None None O

Ninety None None O
- None None O
one None None O
per None None O
cent None None O
of None None O
patients None None O
in None None O
the None None O
dorsiflexed None None O
group None None O
had None None O
excellent None None O
to None None O
good None None O
results None None O
as None None O
compared None None O
to None None O
66 None None O
% None None O
in None None O
the None None O
palmar None None O
flexed None None O
group None None O
. None None O

The None None O
posterior None None O
tether None None O
in None None O
scoliosis None None O
. None None O

The None None O
hypothesis None None O
that None None O
a None None O
localized None None O
lordosis None None O
, None None O
or None None O
tethering None None O
of None None O
the None None O
posterior None None O
elements None None O
of None None O
the None None O
spine None None O
, None None O
is None None O
the None None O
primary None None O
cause None None O
of None None O
the None None O
vertebral None None O
rotation None None O
in None None O
idiopathic None None O
scoliosis None None O
was None None O
investigated None None O
in None None O
anatomic None None O
specimens None None O
of None None O
human None None O
and None None O
calf None None O
spinal None None O
columns None None O
. None None O

The None None O
specimens None None O
were None None O
axially None None O
loaded None None O
with None None O
and None None O
without None None O
a None None O
posterior None None O
tether None None O
created None None O
using None None O
Zielke None None O
instrumentation None None O
. None None O

Lateral None None O
deflection None None O
and None None O
axial None None O
rotation None None O
were None None O
monitored None None O
roentgenographically None None O
. None None O

The None None O
vertebrae None None O
of None None O
tethered None None O
spines None None O
showed None None O
increased None None O
rotation None None O
in None None O
the None None O
direction None None O
associated None None O
with None None O
idiopathic None None O
scoliosis None None O
. None None O

The None None O
spinous None None O
processes None None O
moved None None O
toward None None O
the None None O
concavity None None O
at None None O
the None None O
apex None None O
of None None O
the None None O
induced None None O
lateral None None O
curve None None O
. None None O

Conversely None None O
, None None O
untethered None None O
spines None None O
either None None O
exhibited None None O
little None None O
rotation None None O
or None None O
rotated None None O
in None None O
the None None O
opposite None None O
direction None None O
; None None O
the None None O
spinous None None O
processes None None O
moved None None O
toward None None O
the None None O
convexity None None O
of None None O
the None None O
curve None None O
. None None O

Rotations None None O
toward None None O
the None None O
convexity None None O
occur None None O
in None None O
rotational None None O
kyphosis None None O
. None None O

Thus None None O
the None None O
hypothesis None None O
that None None O
idiopathic None None O
scoliosis None None O
is None None O
a None None O
rotational None None O
lordosis None None O
is None None O
substantiated None None O
; None None O
the None None O
characteristic None None O
rotation None None O
can None None O
be None None O
explained None None O
with None None O
the None None O
aid None None O
of None None O
a None None O
geometric None None O
model None None O
. None None O

EPOX None None O
inhibits None None O
angiogenesis None None O
by None None O
degradation None None O
of None None O
Mcl None None O
- None None O
1 None None O
through None None O
ERK None None O
inactivation None None O
. None None O

PURPOSE None None O
: None None O
Antiangiogenic None None O
therapy None None O
is None None O
considered None None O
as None None O
an None None O
effective None None O
strategy None None O
for None None O
controlling None None O
the None None O
growth None None O
and None None O
metastasis None None O
of None None O
tumors None None O
. None None O

Among None None O
a None None O
myriad None None O
of None None O
biological None None O
activities None None O
described None None O
for None None O
xanthone None None O
derivatives None None O
, None None O
the None None O
anticancer None None O
activity None None O
is None None O
quite None None O
remarkable None None O
, None None O
but None None O
the None None O
molecular None None O
mechanism None None O
is None None O
not None None O
clearly None None O
resolved None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
antiangiogenic None None O
mechanism None None O
of None None O
3 None None O
, None None O
6 None None O
- None None O
di None None O
( None None O
2 None None O
, None None O
3 None None O
- None None O
epoxypropoxy None None O
) None None O
xanthone None None O
( None None O
EPOX None None O
) None None O
, None None O
a None None O
novel None None O
Mcl None None O
- None None O
1 None None O
targeting None None O
drug None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
To None None O
evaluate None None O
the None None O
antiangiogenic None None O
activity None None O
of None None O
EPOX None None O
, None None O
we None None O
did None None O
cell None None O
viability None None O
, None None O
cell None None O
cycle None None O
, None None O
tube None None O
formation None None O
assay None None O
in None None O
vitro None None O
, None None O
and None None O
Matrigel None None O
plug None None O
assay None None O
in None None O
vivo None None O
. None None O

To None None O
evaluate None None O
the None None O
effect None None O
of None None O
EPOX None None O
on None None O
the None None O
endothelial None None O
signaling None None O
pathway None None O
, None None O
we None None O
did None None O
immunoblotting None None O
, None None O
immunoprecipitation None None O
, None None O
and None None O
immunofluorescence None None O
analysis None None O
. None None O

Intracellular None None O
glutathione None None O
levels None None O
were None None O
determined None None O
with None None O
the None None O
use None None O
of None None O
monochlorobimane None None O
, None None O
a None None O
glutathione None None O
- None None O
specific None None O
probe None None O
. None None O

RESULTS None None O
: None None O
EPOX None None O
induced None None O
endothelial None None O
cell None None O
apoptosis None None O
in None None O
association None None O
with None None O
proteasome None None O
- None None O
dependent None None O
Mcl None None O
- None None O
1 None None O
degradation None None O
. None None O

Down None None O
- None None O
regulation None None O
of None None O
Mcl None None O
- None None O
1 None None O
resulted None None O
in None None O
an None None O
increase None None O
in None None O
Mcl None None O
- None None O
1 None None O
- None None O
free None None O
Bim None None O
, None None O
activation None None O
of None None O
Bax None None O
, None None O
and None None O
then None None O
signaling None None O
of None None O
mitochondria None None O
- None None O
mediated None None O
apoptosis None None O
. None None O

Additionally None None O
, None None O
glutathione None None O
depletion None None O
and None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
( None None O
ERK None None O
) None None O
inactivation None None O
was None None O
observed None None O
in None None O
EPOX None None O
- None None O
treated None None O
cells None None O
. None None O

Glutathione None None O
supplementation None None O
reversed None None O
the None None O
inhibitory None None O
effects None None O
of None None O
EPOX None None O
on None None O
ERK None None O
, None None O
which None None O
increases None None O
the None None O
phosphorylation None None O
of None None O
Mcl None None O
- None None O
1 None None O
at None None O
T None None O
( None None O
163 None None O
. None None O
) None None O
Overexpression None None O
of None None O
mitogen None None O
- None None O
activated None None O
protein None None O
/ None None O
ERK None None O
kinase None None O
( None None O
MEK None None O
) None None O
partially None None O
reversed None None O
the None None O
effect None None O
of None None O
EPOX None None O
on None None O
Mcl None None O
- None None O
1 None None O
dephosphorylation None None O
, None None O
ubiquitination None None O
, None None O
and None None O
degradation None None O
, None None O
further None None O
implicating None None O
ERK None None O
in None None O
the None None O
regulation None None O
of None None O
Mcl None None O
- None None O
1 None None O
stability None None O
. None None O

CONCLUSIONS None None O
: None None O
This None None O
study None None O
provides None None O
evidence None None O
that None None O
EPOX None None O
induces None None O
glutathione None None O
depletion None None O
, None None O
ERK None None O
inactivation None None O
, None None O
and None None O
Mcl None None O
- None None O
1 None None O
degradation None None O
on None None O
endothelial None None O
cells None None O
, None None O
which None None O
leads None None O
to None None O
inhibition None None O
of None None O
angiogenesis None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
EPOX None None O
is None None O
a None None O
novel None None O
antiangiogenic None None O
agent None None O
, None None O
making None None O
it None None O
a None None O
promising None None O
lead None None O
compound None None O
for None None O
further None None O
development None None O
in None None O
the None None O
treatment None None O
of None None O
angiogenesis None None O
- None None O
related None None O
pathologies None None O
. None None O

CD56 None None O
+ None None O
putative None None O
natural None None O
killer None None O
cell None None O
lymphomas None None O
: None None O
production None None O
of None None O
cytolytic None None O
effectors None None O
and None None O
related None None O
proteins None None O
mediating None None O
tumor None None O
cell None None O
apoptosis None None O
? None None O

Apoptosis None None O
is None None O
a None None O
regulated None None O
form None None O
of None None O
cell None None O
death None None O
that None None O
may None None O
be None None O
triggered None None O
by None None O
natural None None O
killer None None O
( None None O
NK None None O
) None None O
or None None O
cytotoxic None None O
T None None O
cells None None O
, None None O
which None None O
effect None None O
target None None O
cell None None O
lysis None None O
by None None O
cytolytic None None O
effector None None O
and None None O
related None None O
proteins None None O
through None None O
complex None None O
intracellular None None O
signals None None O
. None None O

This None None O
study None None O
was None None O
aimed None None O
to None None O
investigate None None O
whether None None O
there None None O
is None None O
selective None None O
expression None None O
of None None O
these None None O
cytolytic None None O
markers None None O
in None None O
the None None O
putative None None O
NK None None O
- None None O
cell None None O
lymphomas None None O
and None None O
whether None None O
there None None O
is None None O
correlation None None O
with None None O
zonal None None O
tumor None None O
cell None None O
death None None O
in None None O
these None None O
tumors None None O
. None None O

Expression None None O
of None None O
the None None O
cytolytic None None O
effectors None None O
perforin None None O
, None None O
granzyme None None O
B9 None None O
, None None O
and None None O
the None None O
granule None None O
membrane None None O
protein None None O
TIA1 None None O
were None None O
examined None None O
in None None O
24 None None O
putative None None O
NK None None O
- None None O
cell None None O
lymphomas None None O
, None None O
18 None None O
postthymic None None O
T None None O
- None None O
cell None None O
lymphomas None None O
( None None O
one None None O
case None None O
CD8 None None O
+ None None O
CD56 None None O
+ None None O
and None None O
three None None O
anaplastic None None O
large None None O
cell None None O
lymphomas None None O
( None None O
ALCL None None O
) None None O
, None None O
three None None O
T None None O
- None None O
lymphoblastic None None O
lymphomas None None O
, None None O
and None None O
20 None None O
B None None O
- None None O
cell None None O
lymphomas None None O
. None None O

Nineteen None None O
( None None O
79 None None O
% None None O
) None None O
putative None None O
NK None None O
- None None O
cell None None O
lymphomas None None O
expressed None None O
perforin None None O
, None None O
and None None O
all None None O
24 None None O
cases None None O
expressed None None O
granzyme None None O
B9 None None O
and None None O
TIA1 None None O
. None None O

The None None O
only None None O
CD8 None None O
+ None None O
CD56 None None O
+ None None O
postthymic None None O
T None None O
- None None O
cell None None O
lymphoma None None O
also None None O
expressed None None O
all None None O
three None None O
cytolytic None None O
markers None None O
, None None O
two None None O
CD8 None None O
- None None O
ALCL None None O
expressed None None O
TIA1 None None O
; None None O
other None None O
postthymic None None O
T None None O
- None None O
cell None None O
, None None O
T None None O
- None None O
lymphoblastic None None O
, None None O
and None None O
B None None O
- None None O
cell None None O
lymphomas None None O
were None None O
consistently None None O
negative None None O
. None None O

There None None O
was None None O
strong None None O
correlation None None O
between None None O
percentage None None O
perforin None None O
- None None O
positive None None O
cells None None O
and None None O
zonal None None O
tumor None None O
cell None None O
death None None O
. None None O

Angioinvasion None None O
, None None O
in None None O
contrast None None O
, None None O
was None None O
present None None O
only None None O
in None None O
a None None O
proportion None None O
( None None O
37 None None O
% None None O
) None None O
of None None O
these None None O
lymphomas None None O
despite None None O
the None None O
frequent None None O
presence None None O
of None None O
zonal None None O
tumor None None O
cell None None O
death None None O
( None None O
71 None None O
% None None O
) None None O
. None None O

We None None O
propose None None O
that None None O
cytolytic None None O
effector None None O
and None None O
related None None O
proteins None None O
produced None None O
by None None O
putative None None O
NK None None O
and None None O
some None None O
CD8 None None O
+ None None O
CD56 None None O
+ None None O
postthymic None None O
T None None O
- None None O
cell None None O
lymphomas None None O
, None None O
probably None None O
in None None O
conjunction None None O
with None None O
other None None O
mechanisms None None O
, None None O
may None None O
effect None None O
massive None None O
tumor None None O
cell None None O
apoptosis None None O
. None None O

The None None O
frequent None None O
expression None None O
of None None O
cytolytic None None O
effector None None O
markers None None O
in None None O
the None None O
CD2 None None O
+ None None O
surface None None O
CD3 None None O
- None None O
CD56 None None O
+ None None O
putative None None O
NK None None O
- None None O
cell None None O
lymphomas None None O
lends None None O
further None None O
support None None O
to None None O
their None None O
probable None None O
NK None None O
cell None None O
origin None None O
. None None O

Intervention None None O

Patients None None O
' None None O
initial None None O
introduction None None O
to None None O
the None None O
Wrist None None O
Extension None None O
Dynasplint None None O
( None None O
WED None None O
) None None O
system None None O
, None None O
[ None None O
Dynasplint None None O
Systems None None O
, None None O
Inc None None O
. None None O
, None None O
Severna None None O
Park None None O
, None None O
MD None None O
, None None O
USA None None O
] None None O
included None None O
customized None None O
fitting None None O
( None None O
wrist None None O
length None None O
, None None O
width None None O
, None None O
and None None O
girth None None O
so None None O
that None None O
the None None O
force None None O
and None None O
counter None None O
force None None O
straps None None O
could None None O
be None None O
properly None None O
aligned None None O
) None None O
and None None O
training None None O
on None None O
donning None None O
and None None O
doffing None None O
of None None O
the None None O
device None None O
. None None O

( None None O
See None None O
figure None None O
1 None None O
. None None O
) None None O
Verbal None None O
and None None O
written None None O
instructions None None O
were None None O
provided None None O
throughout None None O
the None None O
duration None None O
of None None O
treatment None None O
for None None O
safety None None O
, None None O
general None None O
wear None None O
and None None O
care None None O
, None None O
and None None O
tension None None O
setting None None O
goals None None O
based None None O
on None None O
patient None None O
tolerance None None O
. None None O

Figure None None O
1 None None O

Wrist None None O
Extension None None O
Dynasplint None None O
. None None O

Each None None O
patient None None O
initially None None O
wore None None O
the None None O
WED None None O
for None None O
4 None None O
- None None O
6 None None O
continuous None None O
hours None None O
at None None O
an None None O
initial None None O
tension None None O
setting None None O
of None None O
# None None O
2 None None O
( None None O
0 None None O
. None None O
1 None None O
foot None None O
pounds None None O
of None None O
torque None None O
) None None O
. None None O

This None None O
duration None None O
was None None O
for None None O
acclimatization None None O
to None None O
the None None O
system None None O
; None None O
then None None O
patients None None O
were None None O
instructed None None O
to None None O
wear None None O
the None None O
WED None None O
system None None O
at None None O
night None None O
while None None O
sleeping None None O
for None None O
6 None None O
- None None O
8 None None O
hours None None O
of None None O
continuous None None O
wear None None O
. None None O

After None None O
each None None O
patient None None O
was None None O
comfortable None None O
wearing None None O
the None None O
unit None None O
for None None O
one None None O
week None None O
at None None O
tension None None O
level None None O
# None None O
2 None None O
, None None O
they None None O
were None None O
instructed None None O
to None None O
increase None None O
the None None O
tension None None O
level None None O
to None None O
# None None O
3 None None O
( None None O
0 None None O
. None None O
3 None None O
ft None None O
lbs None None O
. None None O
) None None O
and None None O
make None None O
continual None None O
increases None None O
every None None O
two None None O
weeks None None O
. None None O

If None None O
prolonged None None O
soreness None None O
followed None None O
a None None O
session None None O
( None None O
soreness None None O
for None None O
more None None O
than None None O
15 None None O
minutes None None O
) None None O
the None None O
patient None None O
was None None O
instructed None None O
to None None O
decrease None None O
the None None O
tension None None O
one None None O
half None None O
a None None O
setting None None O
for None None O
two None None O
days None None O
until None None O
they None None O
were None None O
comfortable None None O
wearing None None O
it None None O
for None None O
6 None None O
- None None O
8 None None O
hours None None O
at None None O
the None None O
new None None O
tension None None O
setting None None O
. None None O

The None None O
majority None None O
of None None O
all None None O
patients None None O
reached None None O
level None None O
# None None O
5 None None O
( None None O
0 None None O
. None None O
8 None None O
foot None None O
pounds None None O
of None None O
torque None None O
) None None O
by None None O
the None None O
end None None O
of None None O
two None None O
months None None O
. None None O

All None None O
range None None O
of None None O
motion None None O
measurements None None O
were None None O
recorded None None O
by None None O
the None None O
prescribing None None O
clinician None None O
. None None O

Matrix None None O
metalloproteinase None None O
activity None None O
and None None O
immunohistochemical None None O
profile None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
2 None None O
and None None O
- None None O
9 None None O
and None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinase None None O
- None None O
1 None None O
during None None O
human None None O
dermal None None O
wound None None O
healing None None O
. None None O

Proteolytic None None O
activity None None O
is None None O
required None None O
for None None O
the None None O
turnover None None O
of None None O
the None None O
extracellular None None O
matrix None None O
during None None O
wound None None O
healing None None O
. None None O

Matrix None None O
metalloproteinases None None O
can None None O
collectively None None O
cleave None None O
all None None O
components None None O
of None None O
the None None O
extracellular None None O
matrix None None O
, None None O
with None None O
the None None O
endogenous None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinase None None O
- None None O
1 None None O
regulating None None O
their None None O
activity None None O
. None None O

Breast None None O
tissue None None O
taken None None O
at None None O
varying None None O
postoperative None None O
times None None O
( None None O
n None None O
= None None O
92 None None O
) None None O
or None None O
during None None O
surgery None None O
( None None O
controls None None O
, None None O
n None None O
= None None O
17 None None O
) None None O
, None None O
was None None O
used None None O
to None None O
investigate None None O
the None None O
temporal None None O
and None None O
spatial None None O
activity None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
2 None None O
and None None O
- None None O
9 None None O
and None None O
tissue None None O
inhibitor None None O
of None None O
metalloproteinase None None O
- None None O
1 None None O
during None None O
human None None O
wound None None O
healing None None O
. None None O

Matrix None None O
metalloproteinase None None O
activity None None O
, None None O
determined None None O
using None None O
a None None O
quenched None None O
fluorescence None None O
substrate None None O
assay None None O
, None None O
increased None None O
during None None O
early None None O
healing None None O
( None None O
3 None None O
- None None O
8 None None O
weeks None None O
) None None O
compared None None O
to None None O
controls None None O
, None None O
and None None O
then None None O
decreased None None O
between None None O
24 None None O
and None None O
36 None None O
weeks None None O
after None None O
surgery None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
05 None None O
until None None O
24 None None O
weeks None None O
, None None O
Mann None None O
- None None O
Whitney None None O
U None None O
- None None O
test None None O
) None None O
. None None O

Immunohistochemistry None None O
scores None None O
for None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
expression None None O
were None None O
significantly None None O
elevated None None O
compared None None O
to None None O
controls None None O
in None None O
scar None None O
endothelial None None O
cells None None O
and None None O
fibroblasts None None O
from None None O
2 None None O
until None None O
12 None None O
and None None O
20 None None O
weeks None None O
, None None O
respectively None None O
. None None O

Matrix None None O
metalloproteinase None None O
- None None O
2 None None O
staining None None O
was None None O
observed None None O
exclusively None None O
in None None O
fibroblasts None None O
, None None O
reaching None None O
maximum None None O
levels None None O
8 None None O
- None None O
12 None None O
weeks None None O
after None None O
surgery None None O
, None None O
decreasing None None O
by None None O
1 None None O
. None None O
5 None None O
years None None O
but None None O
remaining None None O
significantly None None O
increased None None O
. None None O

Tissue None None O
inhibitor None None O
of None None O
metalloproteinase None None O
- None None O
1 None None O
staining None None O
was None None O
relatively None None O
sparse None None O
but None None O
was None None O
significantly None None O
increased None None O
until None None O
8 None None O
weeks None None O
after None None O
surgery None None O
. None None O

These None None O
results None None O
show None None O
that None None O
matrix None None O
metalloproteinases None None O
are None None O
present None None O
at None None O
elevated None None O
levels None None O
during None None O
early None None O
wound None None O
healing None None O
, None None O
when None None O
angiogenesis None None O
occurs None None O
, None None O
and None None O
suggest None None O
that None None O
matrix None None O
metalloproteinase None None O
- None None O
9 None None O
may None None O
play None None O
a None None O
significant None None O
role None None O
. None None O

The None None O
later None None O
expression None None O
of None None O
matrix None None O
metalloproteinase None None O
- None None O
2 None None O
and None None O
- None None O
9 None None O
in None None O
fibroblasts None None O
suggests None None O
a None None O
role None None O
in None None O
extracellular None None O
matrix None None O
remodeling None None O
. None None O

The None None O
merits None None O
of None None O
vascular None None O
targeting None None O
for None None O
gynecologic None None O
malignancies None None O
. None None O

Neovascularization None None O
is None None O
an None None O
early None None O
and None None O
critical None None O
step None None O
in None None O
tumor None None O
development None None O
and None None O
progression None None O
. None None O

Tumor None None O
vessels None None O
are None None O
distinct None None O
from None None O
their None None O
normal None None O
counterparts None None O
morphologically None None O
as None None O
well None None O
as None None O
at None None O
a None None O
molecular None None O
level None None O
. None None O

Recent None None O
studies None None O
on None None O
factors None None O
involved None None O
in None None O
tumor None None O
vascular None None O
development None None O
have None None O
identified None None O
new None None O
therapeutic None None O
targets None None O
for None None O
inhibiting None None O
tumor None None O
neovascularization None None O
and None None O
thus None None O
tumor None None O
progression None None O
. None None O

However None None O
, None None O
the None None O
process None None O
of None None O
tumor None None O
blood None None O
vessel None None O
formation None None O
is None None O
complex None None O
, None None O
and None None O
each None None O
tumor None None O
exhibits None None O
unique None None O
features None None O
in None None O
its None None O
vasculature None None O
. None None O

An None None O
understanding None None O
of None None O
the None None O
relative None None O
contribution None None O
of None None O
various None None O
pathways None None O
in None None O
the None None O
development None None O
of None None O
tumor None None O
vasculature None None O
is None None O
critical None None O
for None None O
developing None None O
effective None None O
and None None O
selective None None O
therapeutic None None O
approaches None None O
. None None O

Several None None O
such None None O
agents None None O
are None None O
currently None None O
in None None O
clinical None None O
trials None None O
, None None O
and None None O
many None None O
others None None O
are None None O
under None None O
development None None O
. None None O

In None None O
this None None O
review None None O
, None None O
the None None O
mechanisms None None O
and None None O
factors None None O
involved None None O
in None None O
tumor None None O
blood None None O
vessel None None O
formation None None O
are None None O
discussed None None O
. None None O

In None None O
addition None None O
, None None O
selected None None O
novel None None O
classes None None O
of None None O
antivascular None None O
therapies None None O
, None None O
including None None O
those None None O
targeting None None O
tumor None None O
endothelial None None O
cells None None O
and None None O
other None None O
components None None O
of None None O
the None None O
tumor None None O
vasculature None None O
, None None O
are None None O
summarized None None O
. None None O

Impaired None None O
apoptosis None None O
of None None O
pulmonary None None O
endothelial None None O
cells None None O
is None None O
associated None None O
with None None O
intimal None None O
proliferation None None O
and None None O
irreversibility None None O
of None None O
pulmonary None None O
hypertension None None O
in None None O
congenital None None O
heart None None O
disease None None O
. None None O

OBJECTIVES None None O
: None None O
This None None O
study None None O
sought None None O
to None None O
assess None None O
the None None O
cellular None None O
and None None O
histologic None None O
basis None None O
of None None O
irreversible None None O
pulmonary None None O
hypertension None None O
( None None O
PHT None None O
) None None O
in None None O
the None None O
clinical None None O
setting None None O
of None None O
congenital None None O
heart None None O
disease None None O
( None None O
CHD None None O
) None None O
. None None O

BACKGROUND None None O
: None None O
Although None None O
many None None O
children None None O
with None None O
CHD None None O
develop None None O
pulmonary None None O
vascular None None O
disease None None O
, None None O
it None None O
is None None O
unclear None None O
why None None O
this None None O
complication None None O
is None None O
reversible None None O
after None None O
complete None None O
repair None None O
in None None O
some None None O
cases None None O
but None None O
irreversible None None O
in None None O
others None None O
. None None O

Because None None O
failure None None O
of None None O
endothelial None None O
cell None None O
apoptosis None None O
might None None O
lead None None O
to None None O
intimal None None O
proliferation None None O
and None None O
lack None None O
of None None O
reversibility None None O
of None None O
PHT None None O
, None None O
we None None O
investigated None None O
this None None O
and None None O
other None None O
key None None O
markers None None O
of None None O
vasoactivity None None O
and None None O
angiogenesis None None O
in None None O
subjects None None O
with None None O
PHT None None O
and None None O
CHD None None O
. None None O

METHODS None None O
: None None O
We None None O
assessed None None O
antiapoptotic None None O
and None None O
proapoptotic None None O
markers None None O
in None None O
vascular None None O
and None None O
perivascular None None O
cells None None O
in None None O
lung None None O
biopsy None None O
samples None None O
from None None O
18 None None O
patients None None O
with None None O
CHD None None O
, None None O
7 None None O
with None None O
reversible None None O
and None None O
11 None None O
with None None O
irreversible None None O
PHT None None O
, None None O
and None None O
6 None None O
control None None O
patients None None O
. None None O

Immunostaining None None O
for None None O
endothelial None None O
nitric None None O
oxide None None O
synthase None None O
, None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
, None None O
and None None O
CD34 None None O
( None None O
markers None None O
of None None O
vasoactivity None None O
and None None O
neoangiogenesis None None O
) None None O
was None None O
also None None O
performed None None O
. None None O

RESULTS None None O
: None None O
The None None O
antiapoptotic None None O
protein None None O
Bcl None None O
- None None O
2 None None O
was None None O
highly None None O
expressed None None O
by None None O
pulmonary None None O
endothelial None None O
cells None None O
in None None O
all None None O
cases None None O
of None None O
irreversible None None O
PHT None None O
but None None O
in None None O
no None None O
cases None None O
of None None O
reversible None None O
PHT None None O
, None None O
nor None None O
in None None O
control None None O
patients None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Intimal None None O
proliferation None None O
was None None O
present None None O
in None None O
10 None None O
of None None O
11 None None O
irreversible None None O
PHT None None O
cases None None O
, None None O
but None None O
never None None O
observed None None O
in None None O
reversible None None O
PHT None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Similarly None None O
, None None O
perivascular None None O
inflammatory None None O
T None None O
- None None O
cells None None O
expressed None None O
more None None O
antiapoptotic None None O
proteins None None O
in None None O
irreversible None None O
PHT None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Irreversible None None O
PHT None None O
cases None None O
were None None O
also None None O
more None None O
likely None None O
to None None O
show None None O
compensatory None None O
upregulation None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
and None None O
new None None O
small None None O
vessel None None O
formation None None O
at None None O
the None None O
sites None None O
of None None O
native None None O
vessel None None O
stenosis None None O
or None None O
occlusion None None O
( None None O
p None None O
less None None O
than None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
Irreversible None None O
PHT None None O
is None None O
strongly None None O
associated None None O
with None None O
impaired None None O
endothelial None None O
cell None None O
apoptosis None None O
and None None O
antiapoptotic None None O
signaling None None O
from None None O
perivascular None None O
inflammatory None None O
cells None None O
. None None O

These None None O
changes None None O
are None None O
associated None None O
with None None O
intimal None None O
proliferation None None O
and None None O
vessel None None O
narrowing None None O
, None None O
and None None O
thereby None None O
may None None O
contribute None None O
to None None O
clinical None None O
outcomes None None O
associated None None O
with None None O
pulmonary None None O
hypertension None None O
. None None O

Magnitude None None O
of None None O
malate None None O
- None None O
aspartate None None O
reduced None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
shuttle None None O
activity None None O
in None None O
intact None None O
respiring None None O
tumor None None O
cells None None O
. None None O

Measurements None None O
of None None O
respiration None None O
, None None O
CO2 None None O
and None None O
lactate None None O
production None None O
, None None O
and None None O
changes None None O
in None None O
the None None O
levels None None O
of None None O
various None None O
key None None O
metabolites None None O
of None None O
the None None O
glycolytic None None O
sequence None None O
and None None O
tricarboxylic None None O
acid None None O
cycle None None O
were None None O
made None None O
on None None O
five None None O
lines None None O
of None None O
rodent None None O
ascites None None O
tumor None None O
cells None None O
( None None O
two None None O
strains None None O
of None None O
Ehrlich None None O
ascites None None O
tumor None None O
cells None None O
, None None O
Krebs None None I-Cell-line-name
II None None I-Cell-line-name
carcinoma None None O
, None None O
AS None None I-Cell-line-name
- None None I-Cell-line-name
30D None None I-Cell-line-name
carcinoma None None O
, None None O
and None None O
L1210 None None I-Cell-line-name
cells None None O
) None None O
incubated None None O
aerobically None None O
in None None O
the None None O
presence None None O
of None None O
uniformly None None O
labeled None None O
D None None O
- None None O
[ None None O
14C None None O
] None None O
glucose None None O
. None None O

From None None O
these None None O
data None None O
, None None O
as None None O
well None None O
as None None O
earlier None None O
evidence None None O
demonstrating None None O
that None None O
the None None O
reduced None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
( None None O
NADH None None O
) None None O
shuttle None None O
in None None O
these None None O
cells None None O
requires None None O
a None None O
transaminase None None O
step None None O
and None None O
is None None O
thus None None O
identified None None O
as None None O
the None None O
malate None None O
- None None O
aspartate None None O
shuttle None None O
( None None O
W None None O
. None None O
V None None O
. None None O
V None None O
. None None O
Greenhouse None None O
and None None O
A None None O
. None None O
L None None O
. None None O
Lehninger None None O
, None None O
Cancer None None O
Res None None O
. None None O
, None None O
36 None None O
: None None O
1392 None None O
- None None O
1396 None None O
, None None O
1976 None None O
) None None O
, None None O
metabolic None None O
flux None None O
diagrams None None O
were None None O
constructed None None O
for None None O
the None None O
five None None O
cell None None O
lines None None O
. None None O

These None None O
diagrams None None O
show None None O
the None None O
relative None None O
rates None None O
of None None O
glycolysis None None O
, None None O
the None None O
tricarboxylic None None O
acid None None O
cycle None None O
, None None O
electron None None O
transport None None O
, None None O
and None None O
the None None O
malate None None O
- None None O
aspartate None None O
shuttle None None O
in None None O
these None None O
tumors None None O
. None None O

Large None None O
amounts None None O
of None None O
cytosolic None None O
NADH None None O
were None None O
oxidized None None O
by None None O
the None None O
mitochondrial None None O
respiratory None None O
chain None None O
via None None O
the None None O
NADH None None O
shuttle None None O
, None None O
comprising None None O
anywhere None None O
from None None O
about None None O
20 None None O
to None None O
80 None None O
% None None O
of None None O
the None None O
total None None O
flow None None O
of None None O
reducing None None O
equivalents None None O
to None None O
oxygen None None O
in None None O
these None None O
tumors None None O
. None None O

Calculations None None O
of None None O
the None None O
sources None None O
of None None O
energy None None O
for None None O
adenosine None None O
triphosphate None None O
synthesis None None O
indicated None None O
that None None O
on None None O
the None None O
average None None O
about None None O
one None None O
- None None O
third None None O
of None None O
the None None O
respiratory None None O
adenosine None None O
triphosphate None None O
is None None O
generated None None O
by None None O
electron None None O
flow None None O
originating None None O
from None None O
cytosolic None None O
NADH None None O
via None None O
the None None O
malate None None O
- None None O
aspartate None None O
shuttle None None O
. None None O

Investigation None None O
of None None O
the None None O
effect None None O
of None None O
kaolin None None O
and None None O
tissue None None O
- None None O
factor None None O
- None None O
activated None None O
citrated None None O
whole None None O
blood None None O
, None None O
on None None O
clot None None O
- None None O
forming None None O
variables None None O
, None None O
as None None O
evaluated None None O
by None None O
thromboelastography None None O
. None None O

BACKGROUND None None O
: None None O

The None None O
Thrombelastograph None None O
( None None O
TEG None None O
; None None O
Haemoscope None None O
Corp None None O
. None None O
) None None O
analyzes None None O
clot None None O
formation None None O
in None None O
whole None None O
blood None None O
( None None O
WB None None O
) None None O
and None None O
treatment None None O
based None None O
on None None O
this None None O
analysis None None O
has None None O
been None None O
shown None None O
to None None O
reduce None None O
transfusion None None O
requirements None None O
in None None O
liver None None O
and None None O
cardiac None None O
surgery None None O
when None None O
compared None None O
to None None O
conventional None None O
coagulation None None O
analysis None None O
. None None O

Implementing None None O
TEG None None O
as None None O
a None None O
routine None None O
laboratory None None O
- None None O
based None None O
analysis None None O
, None None O
however None None O
, None None O
requires None None O
validation None None O
of None None O
the None None O
activators None None O
employed None None O
and None None O
the None None O
effect None None O
of None None O
storage None None O
of None None O
the None None O
WB None None O
sample None None O
in None None O
citrate None None O
before None None O
analysis None None O
. None None O

STUDY None None O
DESIGN None None O
AND None None O
METHODS None None O
: None None O

The None None O
effect None None O
of None None O
kaolin None None O
, None None O
tissue None None O
factor None None O
( None None O
TF None None O
) None None O
1 None None O
: None None O
17 None None O
, None None O
000 None None O
, None None O
or None None O
TF None None O
1 None None O
: None None O
42 None None O
, None None O
500 None None O
on None None O
TEG None None O
clotting None None O
time None None O
( None None O
R None None O
) None None O
, None None O
Angle None None O
( None None O
velocity None None O
of None None O
clot None None O
formation None None O
) None None O
, None None O
and None None O
maximum None None O
clot None None O
strength None None O
( None None O
amplitude None None O
[ None None O
MA None None O
] None None O
) None None O
were None None O
evaluated None None O
, None None O
together None None O
with None None O
day None None O
- None None O
to None None O
- None None O
day None None O
variation None None O
, None None O
the None None O
coefficient None None O
of None None O
variance None None O
( None None O
CV None None O
% None None O
) None None O
, None None O
and None None O
the None None O
effect None None O
of None None O
citrate None None O
storage None None O
time None None O
. None None O

RESULTS None None O
: None None O

Clot None None O
formation None None O
variables None None O
were None None O
equally None None O
affected None None O
by None None O
TF None None O
1 None None O
: None None O
17 None None O
, None None O
000 None None O
and None None O
kaolin None None O
activation None None O
, None None O
whereas None None O
R None None O
was None None O
significantly None None O
longer None None O
when None None O
TF None None O
1 None None O
: None None O
42 None None O
, None None O
500 None None O
was None None O
used None None O
. None None O

The None None O
CV None None O
for None None O
the None None O
different None None O
variables None None O
varied None None O
from None None O
3 None None O
to None None O
13 None None O
percent None None O
with None None O
no None None O
significant None None O
differences None None O
between None None O
assays None None O
. None None O

Storage None None O
of None None O
citrated None None O
WB None None O
significantly None None O
affected None None O
the None None O
TEG None None O
variables None None O
in None None O
a None None O
hypercoagulable None None O
direction None None O
. None None O

Only None None O
the None None O
R None None O
, None None O
however None None O
, None None O
was None None O
significantly None None O
affected None None O
( None None O
12 None None O
% None None O
) None None O
when None None O
samples None None O
rested None None O
for None None O
0 None None O
and None None O
30 None None O
minutes None None O
were None None O
evaluated None None O
with None None O
kaolin None None O
as None None O
the None None O
activator None None O
. None None O

CONCLUSION None None O
: None None O

The None None O
TEG None None O
assays None None O
evaluated None None O
were None None O
reproducible None None O
and None None O
present None None O
with None None O
an None None O
acceptable None None O
CV None None O
% None None O
for None None O
routine None None O
clinical None None O
practice None None O
. None None O

Kaolin None None O
and None None O
TF None None O
1 None None O
: None None O
17 None None O
, None None O
000 None None O
equally None None O
affected None None O
the None None O
clot None None O
formation None None O
variables None None O
. None None O

Storage None None O
of None None O
WB None None O
for None None O
up None None O
to None None O
30 None None O
minutes None None O
in None None O
citrate None None O
did None None O
not None None O
, None None O
except None None O
for None None O
R None None O
, None None O
affect None None O
clot None None O
formation None None O
variables None None O
when None None O
kaolin None None O
was None None O
used None None O
as None None O
activator None None O
allowing None None O
for None None O
immediate None None O
analysis None None O
when None None O
the None None O
sample None None O
arrives None None O
in None None O
the None None O
laboratory None None O
. None None O

Medical None None O
adherence None None O
and None None O
childhood None None O
chronic None None O
illness None None O
: None None O
family None None O
daily None None O
management None None O
skills None None O
and None None O
emotional None None O
climate None None O
as None None O
emerging None None O
contributors None None O
. None None O

PURPOSE None None O
OF None None O
REVIEW None None O
: None None O

To None None O
describe None None O
recent None None O
research None None O
that None None O
examines None None O
family None None O
factors None None O
that None None O
promote None None O
or None None O
derail None None O
adherence None None O
to None None O
medical None None O
regimens None None O
for None None O
children None None O
with None None O
chronic None None O
health None None O
conditions None None O
, None None O
primarily None None O
asthma None None O
, None None O
diabetes None None O
, None None O
and None None O
cystic None None O
fibrosis None None O
. None None O

From None None O
the None None O
past None None O
2 None None O
years None None O
, None None O
eight None None O
correlational None None O
studies None None O
were None None O
identified None None O
which None None O
specifically None None O
examined None None O
the None None O
links None None O
between None None O
family None None O
management None None O
strategies None None O
, None None O
family None None O
climate None None O
and None None O
medical None None O
adherence None None O
. None None O

RECENT None None O
FINDINGS None None O
: None None O

Findings None None O
from None None O
the None None O
studies None None O
suggest None None O
that None None O
team None None O
- None None O
based None None O
management None None O
strategies None None O
and None None O
cohesive None None O
family None None O
climate None None O
promote None None O
adherence None None O
to None None O
medical None None O
treatments None None O
over None None O
time None None O
. None None O

Family None None O
interactions None None O
that None None O
are None None O
characterized None None O
by None None O
conflict None None O
and None None O
disengagement None None O
tend None None O
to None None O
disrupt None None O
adherence None None O
and None None O
inevitably None None O
cause None None O
a None None O
decline None None O
in None None O
child None None O
health None None O
. None None O

Moreover None None O
, None None O
these None None O
findings None None O
seem None None O
to None None O
be None None O
moderated None None O
by None None O
child None None O
age None None O
in None None O
that None None O
poorer None None O
adherence None None O
often None None O
occurs None None O
when None None O
a None None O
child None None O
reaches None None O
adolescence None None O
and None None O
is None None O
searching None None O
for None None O
greater None None O
autonomy None None O
. None None O

SUMMARY None None O
: None None O

Future None None O
research None None O
should None None O
consider None None O
the None None O
challenges None None O
in None None O
measuring None None O
medical None None O
adherence None None O
in None None O
the None None O
family None None O
context None None O
as None None O
well None None O
as None None O
incorporating None None O
more None None O
naturalistic None None O
studies None None O
of None None O
family None None O
interactions None None O
. None None O

Randomized None None O
controlled None None O
trials None None O
using None None O
family None None O
- None None O
based None None O
interventions None None O
may None None O
consider None None O
focusing None None O
on None None O
medical None None O
adherence None None O
as None None O
an None None O
important None None O
mediator None None O
between None None O
family None None O
process None None O
and None None O
child None None O
health None None O
outcomes None None O
. None None O

Angiopoietin None None O
- None None O
1 None None O
prevents None None O
VEGF None None O
- None None O
induced None None O
endothelial None None O
permeability None None O
by None None O
sequestering None None O
Src None None O
through None None O
mDia None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
and None None O
Angiopoietin None None O
1 None None O
( None None O
Ang1 None None O
) None None O
are None None O
both None None O
potent None None O
proangiogenic None None O
factors None None O
, None None O
but None None O
, None None O
whereas None None O
VEGF None None O
causes None None O
vascular None None O
permeability None None O
, None None O
Ang1 None None O
stabilizes None None O
blood None None O
vessels None None O
and None None O
protects None None O
them None None O
from None None O
VEGF None None O
- None None O
induced None None O
plasma None None O
leakage None None O
. None None O

The None None O
antivascular None None O
permeability None None O
mechanisms None None O
deployed None None O
by None None O
Ang1 None None O
are None None O
still None None O
undefined None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
Ang1 None None O
halts None None O
the None None O
ability None None O
of None None O
VEGF None None O
to None None O
induce None None O
the None None O
phosphorylation None None O
- None None O
dependent None None O
redistribution None None O
of None None O
the None None O
adhesion None None O
molecule None None O
VE None None O
- None None O
cadherin None None O
, None None O
thereby None None O
rescuing None None O
the None None O
endothelial None None O
barrier None None O
function None None O
. None None O

Ang1 None None O
inhibits None None O
the None None O
activation None None O
of None None O
Src None None O
by None None O
VEGF None None O
, None None O
the None None O
most None None O
upstream None None O
component None None O
of None None O
the None None O
pathway None None O
linking None None O
VEGF None None O
receptors None None O
to None None O
VE None None O
- None None O
cadherin None None O
internalization None None O
. None None O

Indeed None None O
, None None O
Ang1 None None O
promotes None None O
the None None O
activation None None O
of None None O
mDia None None O
through None None O
RhoA None None O
, None None O
resulting None None O
in None None O
the None None O
association None None O
of None None O
mDia None None O
with None None O
Src None None O
. None None O

This None None O
ultimately None None O
deprives None None O
VEGF None None O
receptors None None O
of None None O
an None None O
essential None None O
molecule None None O
required None None O
for None None O
promoting None None O
the None None O
disruption None None O
of None None O
endothelial None None O
cell None None O
- None None O
cell None None O
contacts None None O
and None None O
paracellular None None O
permeability None None O
. None None O

AVE8062 None None O
: None None O
a None None O
new None None O
combretastatin None None O
derivative None None O
vascular None None O
disrupting None None O
agent None None O
. None None O

Angiogenesis None None O
has None None O
an None None O
essential None None O
role None None O
in None None O
promoting None None O
and None None O
supporting None None O
tumor None None O
growth None None O
and None None O
it None None O
is None None O
an None None O
important None None O
therapeutic None None O
target None None O
. None None O

The None None O
tumor None None O
vascular None None O
network None None O
is None None O
the None None O
result None None O
of None None O
pro None None O
- None None O
angiogenic None None O
and None None O
inhibitory None None O
factors None None O
as None None O
well None None O
as None None O
of None None O
the None None O
interaction None None O
between None None O
endothelial None None O
cells None None O
and None None O
extracellular None None O
matrix None None O
. None None O

Different None None O
antiangiogenic None None O
therapeutics None None O
have None None O
been None None O
developed None None O
to None None O
improve None None O
tumor None None O
control None None O
through None None O
vascular None None O
- None None O
targeting None None O
agents None None O
( None None O
VTA None None O
) None None O
. None None O

VTAs None None O
can None None O
be None None O
divided None None O
into None None O
two None None O
groups None None O
: None None O
antiangiogenic None None O
agents None None O
and None None O
vascular None None O
- None None O
disrupting None None O
agents None None O
( None None O
VDAs None None O
) None None O
. None None O

VTAs None None O
inhibit None None O
specific None None O
factors None None O
required None None O
to None None O
induce None None O
and None None O
direct None None O
the None None O
angiogenic None None O
process None None O
, None None O
with None None O
major None None O
activity None None O
against None None O
small None None O
tumor None None O
masses None None O
and None None O
at None None O
the None None O
tumor None None O
periphery None None O
, None None O
encompassing None None O
monoclonal None None O
antibodies None None O
and None None O
small None None O
molecules None None O
inhibitors None None O
of None None O
the None None O
tyrosine None None O
kinase None None O
domain None None O
of None None O
the None None O
VEGF None None O
receptor None None O
. None None O

VDAs None None O
specifically None None O
target None None O
and None None O
destroy None None O
well None None O
- None None O
established None None O
tumor None None O
vessels None None O
with None None O
ischemia None None O
and None None O
destruction None None O
of None None O
large None None O
masses None None O
with None None O
central None None O
hemorrhagic None None O
necrosis None None O
and None None O
survival None None O
of None None O
a None None O
thin None None O
peripheral None None O
tumor None None O
layer None None O
. None None O

VDAs None None O
can None None O
be None None O
divided None None O
into None None O
biologics None None O
, None None O
such None None O
as None None O
ligand None None O
- None None O
based None None O
, None None O
and None None O
small None None O
- None None O
molecule None None O
agents None None O
; None None O
this None None O
second None None O
group None None O
includes None None O
small None None O
- None None O
molecule None None O
VDAs None None O
like None None O
flavonoids None None O
, None None O
such None None O
as None None O
5 None None O
, None None O
6 None None O
- None None O
dimethylxanthenone None None O
- None None O
4 None None O
- None None O
acetic None None O
acid None None O
( None None O
DMXAA None None O
) None None O
, None None O
and None None O
microtubule None None O
- None None O
destabilizing None None O
agents None None O
. None None O

In None None O
this None None O
review None None O
we None None O
will None None O
discuss None None O
the None None O
mechanism None None O
of None None O
action None None O
, None None O
as None None O
well None None O
as None None O
the None None O
preclinical None None O
and None None O
clinical None None O
results None None O
, None None O
of None None O
one None None O
of None None O
the None None O
most None None O
promising None None O
antitubulin None None O
agents None None O
: None None O
the None None O
combretastatin None None O
A4 None None O
- None None O
phosphate None None O
derivative None None O
, None None O
AVE8062A None None O
. None None O

Pain None None O
assessment None None O
by None None O
continuous None None O
EEG None None O
: None None O
association None None O
between None None O
subjective None None O
perception None None O
of None None O
tonic None None O
pain None None O
and None None O
peak None None O
frequency None None O
of None None O
alpha None None O
oscillations None None O
during None None O
stimulation None None O
and None None O
at None None O
rest None None O
. None None O

Recordings None None O
of None None O
neurophysiological None None O
brain None None O
responses None None O
to None None O
noxious None None O
stimuli None None O
have None None O
been None None O
traditionally None None O
based None None O
on None None O
short None None O
stimuli None None O
, None None O
in None None O
the None None O
order None None O
of None None O
milliseconds None None O
, None None O
which None None O
induce None None O
distinct None None O
event None None O
- None None O
related None None O
potentials None None O
( None None O
ERPs None None O
) None None O
. None None O

However None None O
, None None O
using None None O
such None None O
stimuli None None O
in None None O
the None None O
experimental None None O
setting None None O
is None None O
disadvantageous None None O
as None None O
they None None O
are None None O
too None None O
brief None None O
to None None O
faithfully None None O
simulate None None O
clinical None None O
pain None None O
. None None O

We None None O
aimed None None O
at None None O
utilizing None None O
continuous None None O
EEG None None O
to None None O
investigate None None O
the None None O
properties None None O
of None None O
peak None None O
alpha None None O
frequency None None O
( None None O
PAF None None O
) None None O
as None None O
an None None O
objective None None O
cortical None None O
measure None None O
associated None None O
with None None O
subjective None None O
perception None None O
of None None O
tonic None None O
pain None None O
. None None O

Five None None O
minute None None O
long None None O
continuous None None O
EEG None None O
was None None O
recorded None None O
in None None O
18 None None O
healthy None None O
volunteers None None O
under None None O
: None None O
( None None O
i None None O
) None None O
resting None None O
- None None O
state None None O
; None None O
( None None O
ii None None O
) None None O
innocuous None None O
temperature None None O
; None None O
and None None O
( None None O
iii None None O
) None None O
psychophysically None None O
- None None O
anchored None None O
noxious None None O
temperature None None O
. None None O

Numerical None None O
pain None None O
scores None None O
( None None O
NPSs None None O
) None None O
collected None None O
during None None O
the None None O
application None None O
of None None O
tonic None None O
noxious None None O
stimuli None None O
were None None O
tested None None O
for None None O
correlation None None O
with None None O
peak None None O
frequencies None None O
of None None O
alpha None None O
power None None O
- None None O
curves None None O
derived None None O
from None None O
central None None O
, None None O
temporal None None O
and None None O
frontal None None O
electrodes None None O
. None None O

NPSs None None O
and None None O
PAFs None None O
remained None None O
stable None None O
throughout None None O
the None None O
recording None None O
conditions None None O
( None None O
RM None None O
- None None O
ANOVAs None None O
; None None O
Ps None None O
> None None O
0 None None O
. None None O
51 None None O
) None None O
. None None O

In None None O
the None None O
noxious None None O
condition None None O
, None None O
PAFs None None O
obtained None None O
at None None O
the None None O
bilateral None None O
temporal None None O
scalp None None O
were None None O
correlated None None O
with None None O
NPSs None None O
( None None O
Ps None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Moreover None None O
, None None O
resting None None O
- None None O
state None None O
PAFs None None O
recorded None None O
at None None O
the None None O
bilateral None None O
temporal None None O
scalp None None O
were None None O
correlated None None O
with None None O
NPSs None None O
reported None None O
during None None O
the None None O
noxious None None O
condition None None O
( None None O
Ps None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

These None None O
psychophysical None None O
- None None O
neurophysiological None None O
relations None None O
attest None None O
to None None O
the None None O
properties None None O
of None None O
PAF None None O
as None None O
a None None O
novel None None O
cortical None None O
objective None None O
measure None None O
of None None O
subjective None None O
perception None None O
of None None O
tonic None None O
pain None None O
. None None O

Moreover None None O
, None None O
resting None None O
- None None O
state None None O
PAFs None None O
might None None O
hold None None O
inherent None None O
pain None None O
modulation None None O
attributes None None O
, None None O
possibly None None O
enabling None None O
the None None O
prediction None None O
of None None O
individual None None O
responsiveness None None O
to None None O
prolonged None None O
pain None None O
. None None O

The None None O
relevance None None O
of None None O
PAF None None O
to None None O
the None None O
neural None None O
processing None None O
of None None O
tonic None None O
pain None None O
may None None O
indicate None None O
its None None O
potential None None O
to None None O
advance None None O
pain None None O
research None None O
as None None O
well None None O
as None None O
clinical None None O
pain None None O
characterization None None O
. None None O

Rural None None O
/ None None O
urban None None O
differences None None O
in None None O
access None None O
to None None O
and None None O
utilization None None O
of None None O
services None None O
among None None O
people None None O
in None None O
Alabama None None O
with None None O
sickle None None O
cell None None O
disease None None O
. None None O

OBJECTIVE None None O
: None None O

This None None O
study None None O
examined None None O
relationships None None O
between None None O
socioeconomic None None O
factors None None O
and None None O
the None None O
geographic None None O
distribution None None O
of None None O
662 None None O
cases None None O
of None None O
sickle None None O
cell None None O
disease None None O
in None None O
Alabama None None O
in None None O
1999 None None O
- None None O
2001 None None O
. None None O

METHODS None None O
: None None O

Measures None None O
of None None O
community None None O
distress None None O
, None None O
physical None None O
functioning None None O
, None None O
and None None O
medical None None O
problems None None O
were None None O
used None None O
in None None O
analyzing None None O
utilization None None O
differences None None O
between None None O
individuals None None O
with None None O
sickle None None O
cell None None O
disease None None O
living None None O
in None None O
urban None None O
and None None O
rural None None O
areas None None O
. None None O

RESULTS None None O
: None None O

Utilization None None O
of None None O
comprehensive None None O
sickle None None O
cells None None O
disease None None O
services None None O
was None None O
lower None None O
for None None O
individuals None None O
with None None O
sickle None None O
cell None None O
disease None None O
living None None O
in None None O
rural None None O
areas None None O
than None None O
for None None O
those None None O
living None None O
in None None O
urban None None O
areas None None O
. None None O

Rural None None O
clients None None O
reported None None O
significantly None None O
more None None O
limitations None None O
than None None O
urban None None O
clients None None O
on None None O
several None None O
measures None None O
of None None O
physical None None O
functioning None None O
. None None O

The None None O
results None None O
also None None O
suggest None None O
that None None O
utilization None None O
of None None O
services None None O
was None None O
higher None None O
for None None O
those None None O
with None None O
more None None O
medical None None O
problems None None O
and None None O
those None None O
who None None O
lived None None O
in None None O
high None None O
distress None None O
areas None None O
, None None O
although None None O
these None None O
findings None None O
did None None O
not None None O
meet None None O
the None None O
criterion None None O
for None None O
statistical None None O
significance None None O
. None None O

CONCLUSIONS None None O
: None None O

Conclusions None None O
based None None O
on None None O
statistical None None O
evidence None None O
that None None O
geographic None None O
location None None O
and None None O
socioeconomic None None O
factors None None O
relate None None O
to None None O
significantly None None O
different None None O
health None None O
care None None O
service None None O
experience None None O
bear None None O
important None None O
implications None None O
for None None O
medical None None O
and None None O
health None None O
care None None O
support None None O
systems None None O
, None None O
especially None None O
on None None O
the None None O
community None None O
level None None O
. None None O

Antibiotic None None O
- None None O
induced None None O
persistence None None O
of None None O
cytotoxic None None O
Staphylococcus None None O
aureus None None O
in None None O
non None None O
- None None O
phagocytic None None O
cells None None O
. None None O

OBJECTIVES None None O
: None None O

After None None O
infection None None O
of None None O
non None None O
- None None O
phagocytic None None O
cells None None O
, None None O
some None None O
Staphylococcus None None O
aureus None None O
strains None None O
are None None O
able None None O
to None None O
survive None None O
and None None O
kill None None O
their None None O
host None None O
cells None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
action None None O
of None None O
various None None O
antibiotics None None O
on None None O
the None None O
survival None None O
of None None O
host None None O
cells None None O
and None None O
/ None None O
or None None O
intracellular None None O
S None None O
. None None O
aureus None None O
. None None O

METHODS None None O
: None None O

Murine None None O
keratinocyte None None O
( None None O
PAM212 None None I-Cell-line-name
) None None O
and None None O
fibroblast None None O
( None None O
mKSA None None I-Cell-line-name
) None None O
cell None None O
lines None None O
were None None O
infected None None O
with None None O
cytotoxic None None O
S None None O
. None None O
aureus None None O
and None None O
cultured None None O
in None None O
the None None O
presence None None O
of None None O
various None None O
antibiotics None None O
at None None O
graded None None O
concentrations None None O
. None None O

The None None O
viability None None O
of None None O
host None None O
cells None None O
was None None O
measured None None O
24 None None O
h None None O
after None None O
infection None None O
. None None O

To None None O
determine None None O
the None None O
bacterial None None O
viability None None O
within None None O
host None None O
cells None None O
, None None O
cellular None None O
lysates None None O
were None None O
prepared None None O
and None None O
colony None None O
forming None None O
units None None O
were None None O
quantified None None O
using None None O
a None None O
spiral None None O
plater None None O
. None None O

Host None None O
cells None None O
infected None None O
with None None O
fluorescein None None O
isothiocyanate None None O
( None None O
FITC None None O
) None None O
- None None O
labelled None None O
S None None O
. None None O
aureus None None O
were None None O
analysed None None O
by None None O
flow None None O
cytometry None None O
and None None O
microscopy None None O
to None None O
determine None None O
the None None O
subcellular None None O
localization None None O
S None None O
. None None O
aureus None None O
. None None O

RESULTS None None O
: None None O

Oxacillin None None O
, None None O
vancomycin None None O
, None None O
gentamicin None None O
, None None O
ciprofloxacin None None O
and None None O
trimethoprim None None O
/ None None O
sulfamethoxazole None None O
did None None O
not None None O
rescue None None O
host None None O
cells None None O
from None None O
cell None None O
death None None O
induced None None O
by None None O
intracellular None None O
S None None O
. None None O
aureus None None O
. None None O

In None None O
contrast None None O
, None None O
linezolid None None O
, None None O
rifampicin None None O
, None None O
azithromycin None None O
, None None O
clindamycin None None O
, None None O
erythromycin None None O
and None None O
quinupristin None None O
/ None None O
dalfopristin None None O
suppressed None None O
the None None O
cytotoxic None None O
action None None O
of None None O
S None None O
. None None O
aureus None None O
. None None O

After None None O
withdrawal None None O
of None None O
antibiotics None None O
, None None O
intracellular None None O
S None None O
. None None O
aureus None None O
regained None None O
cytotoxic None None O
activity None None O
and None None O
killed None None O
their None None O
host None None O
cells None None O
. None None O

Only None None O
rifampicin None None O
was None None O
able None None O
to None None O
eliminate None None O
intracellular None None O
S None None O
. None None O
aureus None None O
completely None None O
within None None O
72 None None O
h None None O
. None None O

In None None O
contrast None None O
, None None O
clindamycin None None O
, None None O
azithromycin None None O
and None None O
linezolid None None O
induced None None O
a None None O
state None None O
of None None O
intracellular None None O
persistence None None O
of None None O
viable None None O
S None None O
. None None O
aureus None None O
. None None O

CONCLUSIONS None None O
: None None O

Antibiotics None None O
commonly None None O
used None None O
for None None O
the None None O
management None None O
of None None O
S None None O
. None None O
aureus None None O
infections None None O
appear None None O
to None None O
create None None O
a None None O
niche None None O
for None None O
invasive None None O
intracellular None None O
S None None O
. None None O
aureus None None O
, None None O
which None None O
may None None O
play None None O
an None None O
important None None O
role None None O
for None None O
persistence None None O
and None None O
recurrence None None O
of None None O
infection None None O
. None None O

Because None None O
of None None O
its None None O
unique None None O
ability None None O
to None None O
eliminate None None O
intracellular None None O
S None None O
. None None O
aureus None None O
, None None O
rifampicin None None O
appears None None O
to None None O
be None None O
valuable None None O
for None None O
the None None O
treatment None None O
of None None O
invasive None None O
S None None O
. None None O
aureus None None O
infections None None O
. None None O

GDP None None O
and None None O
AGE None None O
receptors None None O
: None None O
mechanisms None None O
of None None O
peritoneal None None O
damage None None O
. None None O

Long None None O
- None None O
term None None O
peritoneal None None O
dialysis None None O
( None None O
PD None None O
) None None O
is None None O
limited None None O
by None None O
morphological None None O
changes None None O
of None None O
the None None O
peritoneal None None O
membrane None None O
. None None O

Structural None None O
changes None None O
were None None O
promoted None None O
by None None O
toxicity None None O
of None None O
glucose None None O
degradation None None O
products None None O
( None None O
GDPs None None O
) None None O
which None None O
are None None O
generated None None O
during None None O
heat None None O
sterilization None None O
in None None O
peritoneal None None O
dialysis None None O
fluids None None O
( None None O
PDFs None None O
) None None O
. None None O

Besides None None O
their None None O
direct None None O
toxicity None None O
GDPs None None O
promote None None O
formation None None O
of None None O
advanced None None O
glycation None None O
endproducts None None O
( None None O
AGEs None None O
) None None O
. None None O

RAGE None None O
( None None O
receptor None None O
for None None O
AGE None None O
) None None O
is None None O
the None None O
best None None O
characterized None None O
signal None None O
transduction None None O
receptor None None O
for None None O
AGEs None None O
and None None O
is None None O
expressed None None O
on None None O
mesothelial None None O
cells None None O
. None None O

The None None O
effects None None O
of None None O
PDFs None None O
with None None O
different None None O
amounts None None O
of None None O
GDPs None None O
were None None O
compared None None O
on None None O
morphological None None O
changes None None O
in None None O
the None None O
peritoneal None None O
membrane None None O
in None None O
a None None O
RAGE None None O
- None None O
/ None None O
- None None O
mouse None None O
model None None O
. None None O

It None None O
could None None O
be None None O
demonstrated None None O
that None None O
RAGE None None O
plays None None O
a None None O
pivotal None None O
role None None O
in None None O
structural None None O
damage None None O
( None None O
e None None O
. None None O
g None None O
. None None O
inflammation None None O
, None None O
neoangiogenesis None None O
and None None O
fibrosis None None O
) None None O
of None None O
the None None O
peritoneal None None O
membrane None None O
. None None O

Further None None O
investigations None None O
of None None O
this None None O
pathway None None O
with None None O
regard None None O
to None None O
preventing None None O
peritoneal None None O
fibrosis None None O
should None None O
be None None O
performed None None O
to None None O
maintain None None O
the None None O
integrity None None O
of None None O
the None None O
peritoneal None None O
membrane None None O
in None None O
peritoneal None None O
dialysis None None O
patients None None O
. None None O

Acoustic None None O
trauma None None O
evokes None None O
hyperactivity None None O
and None None O
changes None None O
in None None O
gene None None O
expression None None O
in None None O
guinea None None O
- None None O
pig None None O
auditory None None O
brainstem None None O
. None None O

Hearing None None O
loss None None O
from None None O
acoustic None None O
trauma None None O
is None None O
a None None O
risk None None O
factor None None O
for None None O
tinnitus None None O
. None None O

Animal None None O
models None None O
using None None O
acoustic None None O
trauma None None O
have None None O
demonstrated None None O
hyperactivity None None O
in None None O
central None None O
auditory None None O
pathways None None O
, None None O
which None None O
has None None O
been None None O
suggested None None O
as None None O
a None None O
substrate None None O
for None None O
tinnitus None None O
. None None O

We None None O
used None None O
a None None O
guinea None None O
- None None O
pig None None O
model None None O
of None None O
unilateral None None O
acoustic None None O
trauma None None O
. None None O

Within None None O
the None None O
same None None O
animals None None O
, None None O
measurements None None O
of None None O
peripheral None None O
hearing None None O
loss None None O
, None None O
spontaneous None None O
activity None None O
of None None O
single None None O
neurons None None O
in None None O
the None None O
inferior None None O
colliculus None None O
and None None O
gene None None O
expression None None O
in None None O
cochlear None None O
nucleus None None O
and None None O
inferior None None O
colliculus None None O
were None None O
combined None None O
, None None O
acutely None None O
and None None O
after None None O
recovery None None O
from None None O
acoustic None None O
trauma None None O
. None None O

Genes None None O
investigated None None O
related None None O
to None None O
inhibitory None None O
( None None O
GABA None None O
- None None O
A None None O
receptor None None O
subunit None None O
alpha None None O
1 None None O
; None None O
glycine None None O
receptor None None O
subunit None None O
alpha None None O
1 None None O
) None None O
and None None O
excitatory None None O
neurotransmission None None O
( None None O
glutamate None None O
decarboxylase None None O
1 None None O
; None None O
glutamate None None O
receptor None None O
AMPA None None O
subunit None None O
alpha None None O
2 None None O
; None None O
glutamate None None O
receptor None None O
NMDA None None O
subunit None None O
1 None None O
) None None O
, None None O
regulation None None O
of None None O
transmitter None None O
release None None O
( None None O
member None None O
of None None O
RAB None None O
family None None O
of None None O
small None None O
GTPase None None O
; None None O
RAB3 None None O
GTPase None None O
activating None None O
protein None None O
subunit None None O
1 None None O
) None None O
and None None O
neuronal None None O
excitability None None O
( None None O
potassium None None O
channel None None O
subfamily None None O
K None None O
member None None O
15 None None O
) None None O
. None None O

Acoustic None None O
trauma None None O
resulted None None O
in None None O
unilateral None None O
hearing None None O
loss None None O
and None None O
hyperactivity None None O
bilaterally None None O
in None None O
inferior None None O
colliculus None None O
. None None O

Changes None None O
in None None O
expression None None O
of None None O
different None None O
mRNAs None None O
were None None O
observed None None O
in None None O
ipsilateral None None O
cochlear None None O
nucleus None None O
and None None O
in None None O
ipsi None None O
- None None O
and None None O
contralateral None None O
inferior None None O
colliculus None None O
, None None O
immediately None None O
after None None O
acoustic None None O
trauma None None O
, None None O
and None None O
after None None O
2 None None O
and None None O
4 None None O
weeks None None O
' None None O
recovery None None O
. None None O

Gene None None O
expression None None O
was None None O
generally None None O
reduced None None O
immediately None None O
after None None O
trauma None None O
, None None O
followed None None O
by None None O
a None None O
return None None O
to None None O
near None None O
normal None None O
levels None None O
or None None O
over None None O
- None None O
expression None None O
as None None O
recovery None None O
time None None O
increased None None O
. None None O

Different None None O
mechanisms None None O
appear None None O
to None None O
underlie None None O
the None None O
spontaneous None None O
hyperactivity None None O
observed None None O
. None None O

There None None O
is None None O
evidence None None O
of None None O
down None None O
- None None O
regulation None None O
of None None O
genes None None O
associated None None O
with None None O
neuronal None None O
inhibition None None O
in None None O
the None None O
contralateral None None O
inferior None None O
colliculus None None O
, None None O
whereas None None O
in None None O
ipsilateral None None O
cochlear None None O
nucleus None None O
, None None O
competing None None O
actions None None O
of None None O
inhibitory None None O
and None None O
excitatory None None O
systems None None O
seem None None O
to None None O
play None None O
a None None O
major None None O
role None None O
in None None O
determining None None O
overall None None O
excitability None None O
. None None O

Regulation None None O
of None None O
the None None O
composition None None O
of None None O
the None None O
extracellular None None O
matrix None None O
by None None O
low None None O
density None None O
lipoprotein None None O
receptor None None O
- None None O
related None None O
protein None None O
- None None O
1 None None O
: None None O
activities None None O
based None None O
on None None O
regulation None None O
of None None O
mRNA None None O
expression None None O
. None None O

Low None None O
density None None O
lipoprotein None None O
receptor None None O
- None None O
related None None O
protein None None O
- None None O
1 None None O
( None None O
LRP None None O
- None None O
1 None None O
) None None O
is None None O
a None None O
catabolic None None O
receptor None None O
for None None O
extracellular None None O
matrix None None O
( None None O
ECM None None O
) None None O
structural None None O
proteins None None O
and None None O
for None None O
proteins None None O
that None None O
bind None None O
to None None O
ECM None None O
. None None O

LRP None None O
- None None O
1 None None O
also None None O
is None None O
implicated None None O
in None None O
integrin None None O
maturation None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
applied None None O
a None None O
proteomics None None O
strategy None None O
to None None O
identify None None O
novel None None O
proteins None None O
involved None None O
in None None O
ECM None None O
modeling None None O
that None None O
are None None O
regulated None None O
by None None O
LRP None None O
- None None O
1 None None O
. None None O

We None None O
show None None O
that None None O
LRP None None O
- None None O
1 None None O
deficiency None None O
in None None O
murine None None O
embryonic None None O
fibroblasts None None O
( None None O
MEFs None None O
) None None O
is None None O
associated None None O
with None None O
increased None None O
levels None None O
of None None O
type None None O
III None None O
collagen None None O
and None None O
pigment None None O
epithelium None None O
- None None O
derived None None O
factor None None O
, None None O
which None None O
accumulate None None O
in None None O
the None None O
substratum None None O
surrounding None None O
cells None None O
. None None O

The None None O
collagen None None O
receptor None None O
, None None O
uPAR None None O
- None None O
AP None None O
/ None None O
Endo None None O
- None None O
180 None None O
, None None O
is None None O
also None None O
increased None None O
in None None O
LRP None None O
- None None O
1 None None O
- None None O
deficient None None O
MEFs None None O
. None None O

Human None None O
LRP None None O
- None None O
1 None None O
reversed None None O
the None None O
changes None None O
in None None O
protein None None O
expression None None O
associated None None O
with None None O
LRP None None O
- None None O
1 None None O
deficiency None None O
; None None O
however None None O
, None None O
the None None O
endocytic None None O
activity None None O
of None None O
LRP None None O
- None None O
1 None None O
was None None O
not None None O
involved None None O
. None None O

Instead None None O
, None None O
regulation None None O
occurred None None O
at None None O
the None None O
mRNA None None O
level None None O
. None None O

Inhibition None None O
of None None O
c None None O
- None None O
Jun None None O
amino None None O
- None None O
terminal None None O
kinase None None O
( None None O
JNK None None O
) None None O
blocked None None O
type None None O
III None None O
collagen None None O
expression None None O
in None None O
LRP None None O
- None None O
1 None None O
- None None O
deficient None None O
MEFs None None O
, None None O
suggesting None None O
regulation None None O
of None None O
JNK None None O
activity None None O
as None None O
a None None O
mechanism None None O
by None None O
which None None O
LRP None None O
- None None O
1 None None O
controls None None O
mRNA None None O
expression None None O
. None None O

The None None O
ability None None O
of None None O
LRP None None O
- None None O
1 None None O
to None None O
regulate None None O
expression None None O
of None None O
the None None O
factors None None O
identified None None O
here None None O
suggests None None O
a None None O
role None None O
for None None O
LRP None None O
- None None O
1 None None O
in None None O
determining None None O
blood None None O
vessel None None O
structure None None O
and None None O
in None None O
angiogenesis None None O
. None None O

4 None None O
. None None O
2 None None O
. None None O

Histological None None O
Findings None None O

Microscopy None None O
revealed None None O
features None None O
of None None O
a None None O
diffusely None None O
growing None None O
discohesive None None O
carcinoma None None O
, None None O
exclusively None None O
growing None None O
in None None O
the None None O
alveolar None None O
interstitium None None O
, None None O
thus None None O
expanding None None O
it None None O
, None None O
while None None O
leaving None None O
the None None O
original None None O
alveolar None None O
architecture None None O
intact None None O
( None None O
Figure None None O
2 None None O
) None None O
. None None O

There None None O
was None None O
local None None O
ulceration None None O
of None None O
the None None O
pleura None None O
, None None O
while None None O
, None None O
beyond None None O
this None None O
ulcer None None O
, None None O
the None None O
tumor None None O
formed None None O
a None None O
thick None None O
cake None None O
of None None O
discohesive None None O
tumor None None O
cells None None O
lining None None O
the None None O
pleural None None O
membrane None None O
( None None O
Figure None None O
2 None None O
( None None O
c None None O
) None None O
) None None O
, None None O
with None None O
only None None O
focal None None O
, None None O
microscopic None None O
invasion None None O
into None None O
the None None O
fatty None None O
tissue None None O
of None None O
the None None O
parietal None None O
pleura None None O
. None None O

The None None O
tumor None None O
consisted None None O
of None None O
atypical None None O
, None None O
moderately None None O
polymorphous None None O
, None None O
and None None O
irregularly None None O
shaped None None O
tumor None None O
cells None None O
with None None O
marked None None O
discohesiveness None None O
. None None O

They None None O
featured None None O
scant None None O
eosinophilic None None O
cytoplasm None None O
and None None O
irregularly None None O
contoured None None O
and None None O
hyperchromatic None None O
nuclei None None O
, None None O
often None None O
containing None None O
one None None O
or None None O
more None None O
prominent None None O
nucleoli None None O
( None None O
Figure None None O
2 None None O
( None None O
b None None O
) None None O
) None None O
. None None O

There None None O
were None None O
many None None O
mitoses None None O
and None None O
apoptoses None None O
present None None O
, None None O
but None None O
necrosis None None O
was None None O
not None None O
observed None None O
. None None O

No None None O
squamous None None O
or None None O
glandular None None O
differentiation None None O
was None None O
observed None None O
, None None O
and None None O
mucin None None O
stains None None O
( None None O
PAS None None O
- None None O
D None None O
and None None O
alcian None None O
blue None None O
) None None O
were None None O
negative None None O
. None None O

Within None None O
the None None O
tumor None None O
, None None O
there None None O
were None None O
multiple None None O
small None None O
blood None None O
- None None O
filled None None O
clefts None None O
and None None O
blood None None O
lakes None None O
. None None O

Angioinvasion None None O
in None None O
medium None None O
- None None O
sized None None O
vessels None None O
, None None O
including None None O
an None None O
artery None None O
, None None O
was None None O
demonstrated None None O
( None None O
Figure None None O
2 None None O
( None None O
d None None O
) None None O
) None None O
. None None O

Of None None O
note None None O
, None None O
the None None O
broadened None None O
alveolar None None O
septa None None O
were None None O
lined None None O
by None None O
markedly None None O
atypical None None O
epithelial None None O
cells None None O
, None None O
yet None None O
less None None O
atypical None None O
than None None O
the None None O
interstitial None None O
carcinoma None None O
( None None O
Figures None None O
2 None None O
( None None O
a None None O
) None None O
and None None O
2 None None O
( None None O
b None None O
) None None O
) None None O
. None None O

The None None O
atypia None None O
of None None O
the None None O
lining None None O
cells None None O
extended None None O
beyond None None O
the None None O
tumor None None O
front None None O
, None None O
showing None None O
a None None O
sharp None None O
demarcation None None O
with None None O
normal None None O
type None None O
I None None O
pneumocytes None None O
( None None O
Figure None None O
2 None None O
( None None O
a None None O
) None None O
) None None O
, None None O
a None None O
feature None None O
characteristic None None O
to None None O
nonmucinous None None O
adenocarcinoma None None O
in None None O
situ None None O
with None None O
lepidic None None O
growth None None O
pattern None None O
( None None O
former None None O
bronchioloalveolar None None O
carcinoma None None O
, None None O
BAC None None O
) None None O
[ None None O
3 None None O
] None None O
. None None O

Peptide None None O
- None None O
BSA None None O
conjugates None None O
as None None O
diagnostic None None O
antigens None None O

To None None O
analyse None None O
the None None O
potential None None O
of None None O
the None None O
peptides None None O
to None None O
behave None None O
as None None O
antigen None None O
mimics None None O
, None None O
their None None O
ability None None O
to None None O
react None None O
with None None O
IgM None None O
antibodies None None O
from None None O
individuals None None O
infected None None O
with None None O
EBV None None O
was None None O
assessed None None O
. None None O

In None None O
our None None O
previous None None O
study None None O
, None None O
we None None O
demonstrated None None O
that None None O
the None None O
sensitivity None None O
of None None O
detection None None O
was None None O
greatly None None O
improved None None O
when None None O
the None None O
peptides None None O
were None None O
coupled None None O
to None None O
a None None O
carrier None None O
molecule None None O
such None None O
as None None O
BSA None None O
prior None None O
to None None O
immobilisation None None O
onto None None O
a None None O
solid None None O
surface None None O
( None None O
Casey None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
) None None O
. None None O

This None None O
strategy None None O
was None None O
adopted None None O
to None None O
test None None O
peptides None None O
Eb1 None None O
- None None O
4 None None O
and None None O
H1 None None O
. None None O

A None None O
set None None O
of None None O
40 None None O
clinical None None O
samples None None O
that None None O
were None None O
classified None None O
as None None O
EBV None None O
seropositive None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
, None None O
seronegative None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
or None None O
potentially None None O
cross None None O
- None None O
reactive None None O
sera None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
were None None O
assessed None None O
for None None O
reactivity None None O
with None None O
Eb1 None None O
- None None O
4 None None O
and None None O
H1 None None O
peptides None None O
individually None None O
. None None O

The None None O
cut None None O
- None None O
off None None O
level None None O
was None None O
defined None None O
as None None O
the None None O
mean None None O
optical None None O
density None None O
of None None O
the None None O
seronegative None None O
samples None None O
plus None None O
3 None None O
standard None None O
deviations None None O
shown None None O
as None None O
a None None O
line None None O
on None None O
the None None O
graphs None None O
in None None O
Fig None None O
. None None O

5 None None O
. None None O

Readings None None O
above None None O
this None None O
level None None O
were None None O
defined None None O
as None None O
positive None None O
and None None O
below None None O
this None None O
level None None O
negative None None O
. None None O

The None None O
same None None O
set None None O
of None None O
samples None None O
were None None O
analysed None None O
on None None O
BSA None None O
alone None None O
and None None O
these None None O
values None None O
were None None O
subtracted None None O
from None None O
the None None O
peptide None None O
- None None O
BSA None None O
conjugate None None O
readings None None O
and None None O
the None None O
corrected None None O
absorbance None None O
readings None None O
were None None O
plotted None None O
individually None None O
for None None O
our None None O
new None None O
peptides None None O
Eb1 None None O
- None None O
4 None None O
and None None O
H1 None None O
in None None O
Fig None None O
. None None O

5 None None O
. None None O

There None None O
was None None O
a None None O
clear None None O
difference None None O
in None None O
the None None O
detection None None O
of None None O
seropositive None None O
antibodies None None O
by None None O
all None None O
the None None O
peptides None None O
( None None O
Fig None None O
. None None O
5A None None O
- None None O
E None None O
) None None O
compared None None O
with None None O
the None None O
analysis None None O
of None None O
BSA None None O
alone None None O
( None None O
Fig None None O
. None None O
5F None None O
) None None O
, None None O
with None None O
the None None O
majority None None O
of None None O
absorbance None None O
readings None None O
above None None O
the None None O
cut None None O
- None None O
off None None O
level None None O
. None None O

We None None O
compared None None O
the None None O
ability None None O
of None None O
our None None O
panel None None O
of None None O
peptide None None O
mimotopes None None O
to None None O
be None None O
recognised None None O
by None None O
antibodies None None O
in None None O
the None None O
same None None O
set None None O
of None None O
seropositive None None O
samples None None O
in None None O
Fig None None O
. None None O

6A None None O
and None None O
the None None O
sensitivity None None O
of None None O
detection None None O
is None None O
shown None None O
in None None O
Fig None None O
. None None O

6B None None O
. None None O

We None None O
also None None O
included None None O
F1 None None O
and None None O
Gp125 None None O
mimotopes None None O
specific None None O
for None None O
two None None O
mAbs None None O
in None None O
our None None O
previous None None O
study None None O
( None None O
Casey None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
) None None O
. None None O

Of None None O
the None None O
peptides None None O
identified None None O
from None None O
polyclonal None None O
sera None None O
Eb1 None None O
, None None O
Gp125 None None O
and None None O
F1 None None O
had None None O
the None None O
highest None None O
sensitivity None None O
( None None O
94 None None O
% None None O
) None None O
. None None O

Slightly None None O
lower None None O
sensitivity None None O
was None None O
observed None None O
for None None O
Eb2 None None O
, None None O
3 None None O
and None None O
4 None None O
( None None O
88 None None O
% None None O
) None None O
and None None O
H1 None None O
peptide None None O
had None None O
the None None O
lowest None None O
sensitivity None None O
( None None O
81 None None O
% None None O
) None None O
as None None O
summarised None None O
in None None O
Fig None None O
. None None O

6B None None O
. None None O

The None None O
sensitivity None None O
of None None O
F1 None None O
and None None O
Gp125 None None O
was None None O
similar None None O
to None None O
that None None O
produced None None O
by None None O
the None None O
mimotopes None None O
selected None None O
in None None O
our None None O
previous None None O
study None None O
, None None O
95 None None O
% None None O
for None None O
F1 None None O
and None None O
92 None None O
% None None O
for None None O
Gp125 None None O
. None None O

Fig None None O
. None None O

5 None None O

Evaluation None None O
of None None O
peptides None None O
Eb1 None None O
- None None O
4 None None O
and None None O
H1 None None O
coupled None None O
to None None O
BSA None None O
as None None O
EBV None None O
diagnostic None None O
reagents None None O
. None None O

Human None None O
serum None None O
( None None O
n None None O
= None None O
40 None None O
) None None O
previously None None O
analysed None None O
using None None O
a None None O
diagnostic None None O
test None None O
for None None O
VCA None None O
IgM None None O
was None None O
allowed None None O
to None None O
react None None O
with None None O
the None None O
peptides None None O
and None None O
the None None O
bound None None O
IgM None None O
antibodies None None O
were None None O
detected None None O
using None None O
anti None None O
- None None O
human None None O
IgM None None O
HRP None None O
. None None O

The None None O
absorbance None None O
readings None None O
for None None O
1 None None O
( None None O
positive None None O
) None None O
, None None O
2 None None O
( None None O
negative None None O
) None None O
and None None O
putative None None O
cross None None O
- None None O
reactive None None O
sera None None O
for None None O
3 None None O
( None None O
Parvo None None O
) None None O
, None None O
4 None None O
( None None O
HSV None None O
) None None O
, None None O
5 None None O
( None None O
CMV None None O
) None None O
and None None O
6 None None O
( None None O
RF None None O
) None None O
are None None O
plotted None None O
for None None O
( None None O
A None None O
) None None O
Eb1 None None O
, None None O
( None None O
B None None O
) None None O
Eb2 None None O
, None None O
( None None O
C None None O
) None None O
Eb3 None None O
, None None O
( None None O
D None None O
) None None O
Eb4 None None O
, None None O
( None None O
E None None O
) None None O
H1 None None O
and None None O
( None None O
F None None O
) None None O
BSA None None O
, None None O
respectively None None O
. None None O

The None None O
cut None None O
- None None O
off None None O
value None None O
is None None O
defined None None O
as None None O
the None None O
mean None None O
of None None O
the None None O
negative None None O
population None None O
+ None None O
3SD None None O
indicated None None O
by None None O
a None None O
solid None None O
horizontal None None O
line None None O
; None None O
since None None O
there None None O
were None None O
no None None O
false None None O
positives None None O
, None None O
the None None O
specificity None None O
for None None O
each None None O
mimotope None None O
was None None O
100 None None O
% None None O
. None None O

Fig None None O
. None None O

6 None None O

Comparison None None O
of None None O
the None None O
reactivities None None O
of None None O
our None None O
panel None None O
of None None O
mimotopes None None O
Eb1 None None O
- None None O
4 None None O
, None None O
H1 None None O
, None None O
F1 None None O
and None None O
Gp125 None None O
conjugated None None O
to None None O
BSA None None O
with None None O
EBV None None O
IgM None None O
- None None O
positive None None O
sera None None O
( None None O
n None None O
= None None O
16 None None O
) None None O
absorbance None None O
values None None O
are None None O
plotted None None O
and None None O
the None None O
cut None None O
- None None O
off None None O
levels None None O
are None None O
depicted None None O
by None None O
a None None O
horizontal None None O
line None None O
in None None O
( None None O
A None None O
) None None O
. None None O

( None None O
B None None O
) None None O
Summary None None O
of None None O
the None None O
false None None O
- None None O
negative None None O
results None None O
from None None O
the None None O
5 None None O
/ None None O
16 None None O
serum None None O
samples None None O
seropositive None None O
for None None O
IgM None None O
EBV None None O
and None None O
the None None O
overall None None O
sensitivity None None O
for None None O
each None None O
mimotope None None O
for None None O
diagnosis None None O
of None None O
EBV None None O
IgM None None O
antibodies None None O
. None None O

We None None O
also None None O
considered None None O
which None None O
seropositive None None O
EBV None None O
samples None None O
contained None None O
antibodies None None O
that None None O
did None None O
not None None O
recognise None None O
the None None O
panel None None O
of None None O
peptides None None O
, None None O
i None None O
. None None O
e None None O
. None None O
false None None O
- None None O
negative None None O
readings None None O
, None None O
listed None None O
in None None O
Fig None None O
. None None O

6B None None O
. None None O

The None None O
antibodies None None O
in None None O
serum None None O
1 None None O
( None None O
s1 None None O
) None None O
were None None O
unreactive None None O
with None None O
all None None O
of None None O
the None None O
peptides None None O
identified None None O
in None None O
this None None O
study None None O
, None None O
s2 None None O
was None None O
not None None O
reactive None None O
with None None O
Eb3 None None O
, None None O
Eb4 None None O
and None None O
H1 None None O
and None None O
s3 None None O
was None None O
unreactive None None O
with None None O
H1 None None O
. None None O

Gp125 None None O
and None None O
F1 None None O
that None None O
were None None O
selected None None O
in None None O
our None None O
previous None None O
study None None O
were None None O
recognised None None O
by None None O
s1 None None O
, None None O
2 None None O
and None None O
3 None None O
; None None O
however None None O
, None None O
two None None O
different None None O
serum None None O
samples None None O
( None None O
s4 None None O
and None None O
5 None None O
) None None O
did None None O
not None None O
recognise None None O
F1 None None O
or None None O
Gp125 None None O
, None None O
respectively None None O
. None None O

This None None O
demonstrates None None O
that None None O
individual None None O
peptides None None O
are None None O
not None None O
recognised None None O
by None None O
all None None O
EBV None None O
antibodies None None O
and None None O
confirms None None O
that None None O
different None None O
peptides None None O
are None None O
required None None O
to None None O
represent None None O
different None None O
epitopes None None O
. None None O

Therefore None None O
, None None O
a None None O
combination None None O
of None None O
Eb1 None None O
peptide None None O
F1 None None O
and None None O
Gp125 None None O
peptides None None O
could None None O
be None None O
recognised None None O
by None None O
antibodies None None O
present None None O
in None None O
all None None O
this None None O
set None None O
of None None O
EBV None None O
clinical None None O
samples None None O
resulting None None O
in None None O
100 None None O
% None None O
sensitivity None None O
. None None O

For None None O
the None None O
samples None None O
defined None None O
as None None O
EBV None None O
- None None O
seronegative None None O
, None None O
there None None O
were None None O
no None None O
readings None None O
above None None O
the None None O
cut None None O
- None None O
off None None O
level None None O
and None None O
therefore None None O
no None None O
false None None O
positives None None O
, None None O
resulting None None O
in None None O
100 None None O
% None None O
specificity None None O
. None None O

In None None O
addition None None O
, None None O
there None None O
were None None O
no None None O
absorbance None None O
readings None None O
above None None O
the None None O
cut None None O
- None None O
off None None O
levels None None O
for None None O
the None None O
potentially None None O
cross None None O
- None None O
reactive None None O
serum None None O
samples None None O
, None None O
inferring None None O
that None None O
the None None O
peptides None None O
identified None None O
in None None O
this None None O
study None None O
have None None O
high None None O
specificity None None O
for None None O
EBV None None O
antibodies None None O
. None None O

Click None None O
here None None O
for None None O
file None None O

Materials None None O
and None None O
Methods None None O
: None None O

A None None O
total None None O
of None None O
75 None None O
brain None None O
abscess None None O
pus None None O
specimens None None O
were None None O
collected None None O
during None None O
neurosurgery None None O
, None None O
either None None O
by None None O
burr None None O
hole None None O
or None None O
by None None O
craniotomy None None O
. None None O

These None None O
specimens None None O
were None None O
further None None O
subjected None None O
to None None O
Gram None None O
stain None None O
, None None O
Ziehl None None O
- None None O
Neelsen None None O
( None None O
ZN None None O
) None None O
stain None None O
, None None O
and None None O
conventional None None O
microbiological None None O
culture None None O
. None None O

Only None None O
those None None O
cases None None O
which None None O
showed None None O
presence None None O
of None None O
AFB None None O
on None None O
ZN None None O
stain None None O
along None None O
with None None O
the None None O
growth None None O
of None None O
Mycobacterium None None O
tuberculosis None None O
were None None O
considered None None O
as None None O
TBAs None None O
. None None O

Such None None O
TBA None None O
cases None None O
were None None O
further None None O
presented None None O
along None None O
with None None O
their None None O
In None None O
vitro None None O
Proton None None O
Magnetic None None O
Resonance None None O
( None None O
MR None None O
) None None O
Spectroscopic None None O
findings None None O
. None None O

In None None O
vivo None None O
effects None None O
of None None O
insulin None None O
on None None O
tumor None None O
and None None O
skeletal None None O
muscle None None O
glucose None None O
metabolism None None O
in None None O
patients None None O
with None None O
lymphoma None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
anabolic None None O
properties None None O
of None None O
insulin None None O
have None None O
been None None O
suggested None None O
for None None O
use None None O
to None None O
reverse None None O
malnutrition None None O
associated None None O
with None None O
cancer None None O
. None None O

The None None O
host None None O
and None None O
tumor None None O
sensitivities None None O
to None None O
insulin None None O
are None None O
critical None None O
for None None O
such None None O
treatments None None O
, None None O
which None None O
aim None None O
to None None O
improve None None O
patient None None O
nutrition None None O
. None None O

The None None O
authors None None O
studied None None O
insulin None None O
effects None None O
on None None O
tumor None None O
and None None O
skeletal None None O
muscle None None O
metabolism None None O
with None None O
2 None None O
- None None O
[ None None O
18F None None O
] None None O
- None None O
fluoro None None O
- None None O
2 None None O
- None None O
deoxy None None O
- None None O
D None None O
- None None O
glucose None None O
( None None O
[ None None O
18F None None O
] None None O
FDG None None O
) None None O
and None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
. None None O

METHODS None None O
: None None O
Six None None O
patients None None O
with None None O
lymphoma None None O
twice None None O
underwent None None O
[ None None O
18F None None O
] None None O
FDG None None O
- None None O
PET None None O
imaging None None O
: None None O
once None None O
after None None O
fasting None None O
overnight None None O
and None None O
once None None O
during None None O
euglycemic None None O
hyperinsulinemic None None O
clamp None None O
. None None O

The None None O
dynamic None None O
uptake None None O
of None None O
the None None O
glucose None None O
analogue None None O
[ None None O
18F None None O
] None None O
FDG None None O
was None None O
measured None None O
in None None O
diseased None None O
nodes None None O
and None None O
upper None None O
arm None None O
skeletal None None O
muscle None None O
in None None O
both None None O
metabolic None None O
states None None O
. None None O

The None None O
[ None None O
18F None None O
] None None O
FDG None None O
uptake None None O
in None None O
muscle None None O
and None None O
the None None O
whole None None O
body None None O
glucose None None O
use None None O
during None None O
euglycemic None None O
hyperinsulinemic None None O
clamp None None O
were None None O
compared None None O
with None None O
those None None O
of None None O
weight None None O
- None None O
matched None None O
healthy None None O
subjects None None O
studied None None O
under None None O
similar None None O
circumstances None None O
. None None O

RESULTS None None O
: None None O
In None None O
lymphomatous None None O
tissue None None O
, None None O
[ None None O
18F None None O
] None None O
FDG None None O
uptake None None O
rates None None O
were None None O
similar None None O
in None None O
overnight None None O
fasting None None O
and None None O
euglycemic None None O
hyperinsulinemic None None O
clamp None None O
( None None O
38 None None O
+ None None O
/ None None O
- None None O
10 None None O
versus None None O
41 None None O
+ None None O
/ None None O
- None None O
9 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
minute None None O
, None None O
not None None O
significant None None O
) None None O
, None None O
whereas None None O
glucose None None O
uptake None None O
in None None O
skeletal None None O
muscle None None O
was None None O
increased None None O
by None None O
insulin None None O
( None None O
1 None None O
. None None O
7 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
2 None None O
versus None None O
3 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
minute None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
012 None None O
) None None O
. None None O

Both None None O
basal None None O
( None None O
2 None None O
. None None O
3 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
2 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
minute None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
061 None None O
) None None O
and None None O
insulin None None O
- None None O
stimulated None None O
( None None O
8 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
9 None None O
mumol None None O
/ None None O
100 None None O
g None None O
/ None None O
minute None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
055 None None O
) None None O
skeletal None None O
arm None None O
muscle None None O
glucose None None O
uptake None None O
rates None None O
were None None O
higher None None O
in None None O
control None None O
subjects None None O
than None None O
in None None O
patients None None O
. None None O

Whole None None O
body None None O
glucose None None O
use None None O
was None None O
55 None None O
% None None O
lower None None O
in None None O
patients None None O
than None None O
in None None O
control None None O
subjects None None O
( None None O
17 None None O
+ None None O
/ None None O
- None None O
3 None None O
mumol None None O
/ None None O
kg None None O
/ None None O
minute None None O
versus None None O
38 None None O
+ None None O
/ None None O
- None None O
3 None None O
mumol None None O
/ None None O
kg None None O
/ None None O
minute None None O
, None None O
P None None O
= None None O
0 None None O
. None None O
002 None None O
) None None O
, None None O
consistent None None O
with None None O
insulin None None O
resistance None None O
in None None O
cancer None None O
. None None O

CONCLUSIONS None None O
: None None O
We None None O
found None None O
that None None O
insulin None None O
does None None O
not None None O
induce None None O
major None None O
changes None None O
in None None O
glucose None None O
uptake None None O
of None None O
lymphomatous None None O
tissue None None O
. None None O

Although None None O
insulin None None O
sensitivity None None O
of None None O
skeletal None None O
muscle None None O
was None None O
also None None O
reduced None None O
in None None O
patients None None O
with None None O
lymphoma None None O
, None None O
the None None O
net None None O
insulin None None O
effect None None O
may None None O
counteract None None O
imbalance None None O
between None None O
glucose None None O
uptake None None O
of None None O
tumor None None O
and None None O
muscle None None O
, None None O
offering None None O
a None None O
potential None None O
means None None O
to None None O
circumvent None None O
at None None O
least None None O
some None None O
metabolic None None O
abnormalities None None O
found None None O
in None None O
cancer None None O
. None None O

Selective None None O
inhibition None None O
of None None O
the None None O
renal None None O
dopamine None None O
subtype None None O
D1A None None O
receptor None None O
induces None None O
antinatriuresis None None O
in None None O
conscious None None O
rats None None O
. None None O

Both None None O
dopamine None None O
D1 None None O
- None None O
like None None O
( None None O
D1A None None O
and None None O
D1B None None O
) None None O
and None None O
D2 None None O
- None None O
like None None O
( None None O
D2 None None O
, None None O
D3 None None O
, None None O
and None None O
D4 None None O
) None None O
receptor None None O
subfamilies None None O
are None None O
present None None O
in None None O
the None None O
kidney None None O
. None None O

Blockade None None O
of None None O
the None None O
intrarenal None None O
D1 None None O
- None None O
like None None O
receptor None None O
family None None O
is None None O
associated None None O
with None None O
natriuresis None None O
and None None O
diuresis None None O
. None None O

Because None None O
the None None O
D1A None None O
and None None O
D1B None None O
receptor None None O
subtypes None None O
are None None O
not None None O
distinguishable None None O
by None None O
currently None None O
available None None O
dopaminergic None None O
agents None None O
, None None O
their None None O
functional None None O
role None None O
remains None None O
undefined None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
the None None O
effect None None O
of None None O
selective None None O
inhibition None None O
of None None O
the None None O
renal None None O
D1A None None O
receptor None None O
with None None O
phosphorothioated None None O
antisense None None O
oligodeoxynucleotide None None O
( None None O
AS None None O
- None None O
ODN None None O
) None None O
was None None O
investigated None None O
in None None O
conscious None None O
uninephrectomized None None O
rats None None O
. None None O

After None None O
renal None None O
interstitial None None O
administration None None O
of None None O
Texas None None O
red None None O
- None None O
labeled None None O
D1A None None O
receptor None None O
AS None None O
- None None O
ODN None None O
, None None O
intense None None O
fluorescent None None O
signal None None O
was None None O
localized None None O
in None None O
the None None O
renal None None O
tubular None None O
epithelium None None O
and None None O
vasculature None None O
. None None O

In None None O
rats None None O
on None None O
normal None None O
salt None None O
intake None None O
, None None O
AS None None O
- None None O
ODN None None O
injected None None O
interstitially None None O
into None None O
the None None O
kidney None None O
reduced None None O
daily None None O
urinary None None O
sodium None None O
excretion None None O
( None None O
1 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
04 None None O
versus None None O
0 None None O
. None None O
8 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
2 None None O
mEq None None O
/ None None O
d None None O
, None None O
n None None O
= None None O
5 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
and None None O
urine None None O
output None None O
( None None O
16 None None O
. None None O
9 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
8 None None O
versus None None O
12 None None O
. None None O
5 None None O
+ None None O
/ None None O
- None None O
3 None None O
. None None O
6 None None O
mL None None O
/ None None O
d None None O
, None None O
n None None O
= None None O
5 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
) None None O
. None None O

In None None O
rats None None O
on None None O
high None None O
sodium None None O
intake None None O
, None None O
continuous None None O
renal None None O
interstitial None None O
administration None None O
of None None O
D1A None None O
receptor None None O
AS None None O
- None None O
ODN None None O
transiently None None O
decreased None None O
daily None None O
urinary None None O
sodium None None O
excretion None None O
( None None O
5 None None O
. None None O
4 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
5 None None O
versus None None O
4 None None O
. None None O
2 None None O
+ None None O
/ None None O
- None None O
0 None None O
. None None O
3 None None O
mEq None None O
/ None None O
d None None O
, None None O
n None None O
= None None O
7 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
and None None O
urine None None O
output None None O
( None None O
27 None None O
. None None O
6 None None O
+ None None O
/ None None O
- None None O
4 None None O
. None None O
5 None None O
versus None None O
18 None None O
. None None O
1 None None O
+ None None O
/ None None O
- None None O
1 None None O
. None None O
8 None None O
mL None None O
/ None None O
d None None O
, None None O
n None None O
= None None O
7 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Neither None None O
vehicle None None O
nor None None O
sense None None O
oligodeoxynucleotide None None O
had None None O
significant None None O
effects None None O
. None None O

Systolic None None O
blood None None O
pressure None None O
remained None None O
unchanged None None O
. None None O

The None None O
renal None None O
D1A None None O
receptor None None O
protein None None O
was None None O
significantly None None O
decreased None None O
by None None O
35 None None O
% None None O
and None None O
46 None None O
% None None O
at None None O
the None None O
end None None O
of None None O
the None None O
study None None O
in None None O
AS None None O
- None None O
ODN None None O
- None None O
treated None None O
rats None None O
on None None O
normal None None O
and None None O
high None None O
salt None None O
intake None None O
, None None O
respectively None None O
, None None O
whereas None None O
the None None O
D1B None None O
receptor None None O
and None None O
beta None None O
- None None O
actin None None O
were None None O
not None None O
affected None None O
. None None O

These None None O
results None None O
provide None None O
the None None O
first None None O
direct None None O
evidence None None O
that None None O
the None None O
renal None None O
D1A None None O
receptor None None O
subtype None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
control None None O
of None None O
sodium None None O
excretion None None O
. None None O

Introduction None None O

During None None O
the None None O
weaning None None O
period None None O
and None None O
transition None None O
to None None O
solid None None O
foods None None O
in None None O
the None None O
first None None O
year None None O
of None None O
life None None O
, None None O
infants None None O
take None None O
a None None O
critical None None O
step None None O
in None None O
their None None O
eating None None O
behavior None None O
and None None O
need None None O
to None None O
meet None None O
high None None O
nutrient None None O
requirements None None O
[ None None O
1 None None O
, None None O
2 None None O
] None None O
. None None O

They None None O
are None None O
exposed None None O
to None None O
new None None O
foods None None O
and None None O
food None None O
combinations None None O
, None None O
which None None O
should None None O
ensure None None O
a None None O
smooth None None O
transition None None O
to None None O
the None None O
family None None O
diet None None O
later None None O
in None None O
life None None O
. None None O

At None None O
this None None O
stage None None O
, None None O
either None None O
homemade None None O
or None None O
commercially None None O
prepared None None O
foods None None O
may None None O
be None None O
fed None None O
. None None O

It None None O
is None None O
worth None None O
noting None None O
that None None O
in None None O
prosperous None None O
countries None None O
the None None O
modern None None O
diet None None O
differs None None O
considerably None None O
from None None O
that None None O
of None None O
previous None None O
generations None None O
, None None O
now None None O
dominated None None O
by None None O
products None None O
that None None O
have None None O
been None None O
processed None None O
, None None O
stored None None O
, None None O
and None None O
transported None None O
over None None O
great None None O
distances None None O
. None None O

Traditional None None O
, None None O
cold None None O
- None None O
pressed None None O
vegetable None None O
oils None None O
of None None O
the None None O
highest None None O
nutritional None None O
quality None None O
, None None O
e None None O
. None None O
g None None O
. None None O
extra None None O
virgin None None O
olive None None O
oil None None O
, None None O
may None None O
therefore None None O
constitute None None O
an None None O
important None None O
part None None O
of None None O
the None None O
modern None None O
diet None None O
[ None None O
3 None None O
, None None O
4 None None O
] None None O
. None None O

In None None O
Poland None None O
, None None O
many None None O
infants None None O
do None None O
not None None O
receive None None O
any None None O
traditional None None O
homemade None None O
foods None None O
and None None O
even None None O
fruits None None O
come None None O
from None None O
purchased None None O
jars None None O
. None None O

Commercial None None O
baby None None O
foods None None O
are None None O
regarded None None O
by None None O
some None None O
parents None None O
and None None O
medical None None O
professionals None None O
to None None O
be None None O
more None None O
appropriate None None O
for None None O
several None None O
reasons None None O
: None None O
they None None O
undergo None None O
intense None None O
screening None None O
for None None O
contaminants None None O
in None None O
comparison None None O
to None None O
foods None None O
sold None None O
for None None O
the None None O
general None None O
population None None O
, None None O
contain None None O
no None None O
additives None None O
of None None O
certain None None O
types None None O
, None None O
and None None O
are None None O
thought None None O
to None None O
be None None O
designed None None O
to None None O
help None None O
infants None None O
meet None None O
nutrient None None O
requirements None None O
[ None None O
5 None None O
] None None O
. None None O

The None None O
process None None O
of None None O
peeling None None O
, None None O
however None None O
, None None O
was None None O
identified None None O
as None None O
the None None O
most None None O
effective None None O
, None None O
and None None O
simple None None O
, None None O
procedure None None O
in None None O
reducing None None O
residues None None O
, None None O
e None None O
. None None O
g None None O
. None None O
pesticides None None O
, None None O
in None None O
fruits None None O
and None None O
vegetables None None O
[ None None O
6 None None O
] None None O
. None None O

Moreover None None O
, None None O
contrary None None O
to None None O
homemade None None O
food None None O
, None None O
which None None O
does None None O
not None None O
contain None None O
furan None None O
, None None O
the None None O
highest None None O
average None None O
content None None O
of None None O
this None None O
chemical None None O
was None None O
found None None O
in None None O
ready None None O
- None None O
to None None O
- None None O
eat None None O
baby None None O
foods None None O
with None None O
pasta None None O
meals None None O
, None None O
followed None None O
by None None O
vegetable None None O
meals None None O
and None None O
meals None None O
with None None O
meat None None O
[ None None O
7 None None O
] None None O
. None None O

Furan None None O
is None None O
considered None None O
to None None O
be None None O
potentially None None O
hazardous None None O
chemical None None O
and None None O
is None None O
classified None None O
as None None O
a None None O
possible None None O
carcinogen None None O
. None None O

The None None O
problem None None O
of None None O
this None None O
chemical None None O
in None None O
homemade None None O
food None None O
may None None O
only None None O
arise None None O
if None None O
meals None None O
with None None O
potatoes None None O
are None None O
stored None None O
and None None O
then None None O
hardly None None O
re None None O
- None None O
heated None None O
[ None None O
7 None None O
] None None O
. None None O

There None None O
is None None O
a None None O
growing None None O
body None None O
of None None O
evidence None None O
that None None O
flavor None None O
experiences None None O
and None None O
dietary None None O
patterns None None O
in None None O
childhood None None O
influence None None O
these None None O
patterns None None O
later None None O
in None None O
life None None O
[ None None O
1 None None O
, None None O
8 None None O
, None None O
9 None None O
] None None O
. None None O

It None None O
is None None O
most None None O
likely None None O
early None None O
in None None O
life None None O
that None None O
culture None None O
- None None O
specific None None O
flavor None None O
preferences None None O
are None None O
initiated None None O
[ None None O
10 None None O
, None None O
11 None None O
] None None O
. None None O

Consequently None None O
, None None O
exposure None None O
to None None O
flavors None None O
and None None O
smells None None O
of None None O
transitory None None O
foods None None O
may None None O
serve None None O
to None None O
heighten None None O
preferences None None O
for None None O
" None None O
known None None O
tastes None None O
" None None O
in None None O
the None None O
family None None O
diet None None O
later None None O
in None None O
adulthood None None O
. None None O

Moreover None None O
, None None O
adopting None None O
elements None None O
of None None O
childhood None None O
dinner None None O
patterns None None O
was None None O
recognized None None O
to None None O
be None None O
an None None O
important None None O
part None None O
of None None O
the None None O
social None None O
reproduction None None O
of None None O
family None None O
identities None None O
across None None O
generations None None O
[ None None O
12 None None O
] None None O
. None None O

Processing None None O
industries None None O
have None None O
been None None O
successful None None O
in None None O
manufacturing None None O
and None None O
marketing None None O
jarred None None O
baby None None O
foods None None O
on None None O
a None None O
commercial None None O
scale None None O
. None None O

Available None None O
products None None O
contain None None O
different None None O
ingredients None None O
and None None O
depend None None O
on None None O
the None None O
manufacturer None None O
, None None O
country None None O
, None None O
traditional None None O
cuisine None None O
, None None O
income None None O
rate None None O
, None None O
and None None O
lastly None None O
, None None O
personal None None O
beliefs None None O
and None None O
values None None O
of None None O
parents None None O
[ None None O
9 None None O
, None None O
11 None None O
] None None O
. None None O

Jarred None None O
foods None None O
with None None O
vegetables None None O
, None None O
meats None None O
, None None O
and None None O
desserts None None O
may None None O
contain None None O
added None None O
fat None None O
from None None O
a None None O
variety None None O
of None None O
sources None None O
: None None O
vegetable None None O
oils None None O
, None None O
cow None None O
milk None None O
butter None None O
, None None O
or None None O
cream None None O
. None None O

Manufacturer None None O
advertising None None O
makes None None O
the None None O
majority None None O
of None None O
consumers None None O
feel None None O
safe None None O
, None None O
causing None None O
them None None O
to None None O
believe None None O
that None None O
they None None O
are None None O
doing None None O
the None None O
best None None O
possible None None O
in None None O
buying None None O
given None None O
products None None O
[ None None O
11 None None O
] None None O
. None None O

A None None O
noteworthy None None O
fact None None O
is None None O
that None None O
many None None O
types None None O
of None None O
baby None None O
foods None None O
produced None None O
by None None O
international None None O
manufacturers None None O
are None None O
, None None O
in None None O
essence None None O
, None None O
the None None O
same None None O
mixtures None None O
with None None O
different None None O
names None None O
; None None O
this None None O
procedure None None O
aims None None O
to None None O
exploit None None O
the None None O
specifics None None O
of None None O
local None None O
markets None None O
without None None O
delivering None None O
any None None O
new None None O
, None None O
real None None O
value None None O
[ None None O
11 None None O
] None None O
. None None O

In None None O
the None None O
book None None O
, None None O
How None None O
to None None O
Eat None None O
Well None None O
and None None O
Stay None None O
Well None None O
the None None O
Mediterranean None None O
Way None None O
by None None O
Keys None None O
[ None None O
13 None None O
] None None O
first None None O
used None None O
the None None O
term None None O
" None None O
good None None O
Mediterranean None None O
diet None None O
" None None O
to None None O
describe None None O
the None None O
eating None None O
patterns None None O
of None None O
populations None None O
dwelling None None O
in None None O
southern None None O
Europe None None O
, None None O
where None None O
the None None O
olive None None O
tree None None O
( None None O
Olea None None O
europaea None None O
) None None O
is None None O
an None None O
emblematic None None O
species None None O
[ None None O
4 None None O
, None None O
14 None None O
] None None O
. None None O

There None None O
is None None O
variation None None O
between None None O
the None None O
exact None None O
diet None None O
in None None O
different None None O
parts None None O
of None None O
the None None O
Mediterranean None None O
region None None O
. None None O

However None None O
, None None O
generalized None None O
and None None O
distinctive None None O
dietary None None O
patterns None None O
do None None O
exist None None O
, None None O
including None None O
olive None None O
oil None None O
as None None O
the None None O
main None None O
source None None O
of None None O
visible None None O
fat None None O
, None None O
employed None None O
both None None O
in None None O
cooking None None O
and None None O
as None None O
a None None O
dressing None None O
, None None O
moderate None None O
fish None None O
and None None O
poultry None None O
but None None O
low None None O
red None None O
meat None None O
consumption None None O
, None None O
high None None O
intake None None O
of None None O
vegetables None None O
, None None O
fruits None None O
, None None O
legumes None None O
, None None O
nuts None None O
, None None O
and None None O
whole None None O
- None None O
grain None None O
cereals None None O
[ None None O
4 None None O
, None None O
14 None None O
- None None O
16 None None O
] None None O
. None None O

When None None O
dietary None None O
fats None None O
are None None O
added None None O
, None None O
in None None O
accordance None None O
with None None O
the None None O
traditional None None O
Mediterranean None None O
diet None None O
, None None O
olive None None O
oil None None O
is None None O
the None None O
choice None None O
for None None O
children None None O
[ None None O
17 None None O
] None None O
. None None O

It None None O
has None None O
been None None O
repeatedly None None O
observed None None O
that None None O
individuals None None O
applying None None O
the None None O
Mediterranean None None O
diet None None O
have None None O
reduced None None O
risks None None O
of None None O
type None None O
2 None None O
diabetes None None O
and None None O
other None None O
diseases None None O
associated None None O
with None None O
the None None O
metabolic None None O
syndrome None None O
, None None O
autoimmunological None None O
diseases None None O
, None None O
and None None O
certain None None O
forms None None O
of None None O
cancer None None O
[ None None O
18 None None O
] None None O
. None None O

Moreover None None O
, None None O
considerable None None O
evidence None None O
exists None None O
that None None O
the None None O
Mediterranean None None O
diet None None O
increases None None O
quality None None O
of None None O
life None None O
in None None O
the None None O
course None None O
of None None O
ageing None None O
, None None O
as None None O
well None None O
as None None O
longevity None None O
[ None None O
13 None None O
, None None O
19 None None O
] None None O
. None None O

The None None O
health None None O
benefits None None O
of None None O
olive None None O
oil None None O
have None None O
been None None O
attributed None None O
to None None O
two None None O
main None None O
constituents None None O
: None None O
a None None O
high None None O
oleic None None O
acid None None O
( None None O
monounsaturated None None O
fatty None None O
acid None None O
, None None O
18 None None O
: None None O
1n None None O
- None None O
9 None None O
) None None O
content None None O
( None None O
70 None None O
- None None O
85 None None O
% None None O
) None None O
and None None O
a None None O
large None None O
amount None None O
of None None O
antioxidant None None O
compounds None None O
, None None O
which None None O
also None None O
possess None None O
antiviral None None O
, None None O
antibacterial None None O
, None None O
and None None O
immunomodulating None None O
effects None None O
[ None None O
3 None None O
, None None O
4 None None O
, None None O
14 None None O
, None None O
16 None None O
] None None O
. None None O

Polyphenols None None O
found None None O
in None None O
virgin None None O
olive None None O
oil None None O
are None None O
linked None None O
to None None O
both None None O
its None None O
flavor None None O
and None None O
its None None O
remarkable None None O
stability None None O
[ None None O
3 None None O
] None None O
. None None O

The None None O
introduction None None O
of None None O
solid None None O
foods None None O
in None None O
infancy None None O
is None None O
one None None O
of None None O
the None None O
primary None None O
matters None None O
often None None O
discussed None None O
by None None O
parents None None O
with None None O
their None None O
child None None O
' None None O
s None None O
pediatrician None None O
. None None O

However None None O
, None None O
many None None O
parents None None O
do None None O
not None None O
feel None None O
that None None O
the None None O
diet None None O
of None None O
their None None O
child None None O
may None None O
be None None O
linked None None O
to None None O
poor None None O
health None None O
outcomes None None O
in None None O
the None None O
future None None O
. None None O

Parents None None O
should None None O
be None None O
educated None None O
about None None O
the None None O
interplay None None O
of None None O
environmental None None O
and None None O
genetic None None O
influences None None O
on None None O
children None None O
, None None O
specifically None None O
during None None O
the None None O
early None None O
years None None O
of None None O
development None None O
when None None O
the None None O
child None None O
is None None O
maturing None None O
and None None O
taking None None O
control None None O
of None None O
its None None O
own None None O
diet None None O
[ None None O
11 None None O
] None None O
. None None O

Nutrition None None O
educators None None O
should None None O
increase None None O
the None None O
critical None None O
awareness None None O
of None None O
parents None None O
in None None O
relation None None O
to None None O
their None None O
child None None O
' None None O
s None None O
solid None None O
food None None O
choices None None O
. None None O

It None None O
is None None O
important None None O
to None None O
emphasize None None O
to None None O
parents None None O
the None None O
fundamental None None O
role None None O
that None None O
the None None O
Mediterranean None None O
diet None None O
and None None O
consumption None None O
of None None O
foods None None O
with None None O
olive None None O
oil None None O
play None None O
in None None O
a None None O
healthy None None O
life None None O
style None None O
[ None None O
14 None None O
, None None O
20 None None O
] None None O
. None None O

Parental None None O
management None None O
of None None O
the None None O
family None None O
food None None O
environment None None O
may None None O
be None None O
complicated None None O
by None None O
numerous None None O
mitigating None None O
factors None None O
, None None O
e None None O
. None None O
g None None O
. None None O
health None None O
literacy None None O
, None None O
time None None O
availability None None O
, None None O
and None None O
financial None None O
resources None None O
. None None O

Considering None None O
the None None O
role None None O
baby None None O
food None None O
manufacturers None None O
play None None O
in None None O
the None None O
infant None None O
' None None O
s None None O
contextual None None O
environment None None O
, None None O
their None None O
products None None O
, None None O
as None None O
well None None O
as None None O
the None None O
manufacturers None None O
themselves None None O
, None None O
should None None O
also None None O
be None None O
viewed None None O
as None None O
key None None O
players None None O
and None None O
central None None O
agents None None O
in None None O
establishing None None O
dietary None None O
habits None None O
. None None O

Consequently None None O
, None None O
we None None O
attempted None None O
to None None O
survey None None O
manufacturer None None O
claims None None O
concerning None None O
added None None O
fat None None O
in None None O
jarred None None O
infant None None O
foods None None O
supplied None None O
to None None O
the None None O
Polish None None O
market None None O
. None None O

Discussion None None O

Our None None O
results None None O
indicate None None O
beneficial None None O
effects None None O
of None None O
motivational None None O
incentives None None O
on None None O
cognitive None None O
performance None None O
and None None O
alleviating None None O
effects None None O
on None None O
cognitive None None O
decline None None O
. None None O

These None None O
beneficial None None O
effects None None O
were None None O
evident None None O
in None None O
healthy None None O
young None None O
and None None O
older None None O
adults None None O
and None None O
in None None O
patients None None O
with None None O
Parkinson None None O
' None None O
s None None O
disease None None O
. None None O

Young None None O
adults None None O
showed None None O
improved None None O
antisaccade None None O
preparation None None O
when None None O
a None None O
reward None None O
was None None O
at None None O
stake None None O
; None None O
older None None O
adults None None O
and None None O
PD None None O
patients None None O
could None None O
utilize None None O
reward None None O
prospect None None O
to None None O
improve None None O
their None None O
impaired None None O
antisaccade None None O
preparation None None O
. None None O

Elderly None None O
participants None None O
and None None O
PD None None O
patients None None O
were None None O
not None None O
only None None O
better None None O
prepared None None O
by None None O
means None None O
of None None O
commonly None None O
used None None O
preparatory None None O
aids None None O
( None None O
i None None O
. None None O
e None None O
. None None O
, None None O
more None None O
preparation None None O
time None None O
and None None O
advance None None O
information None None O
on None None O
the None None O
upcoming None None O
response None None O
) None None O
but None None O
also None None O
by None None O
means None None O
of None None O
motivational None None O
incentives None None O
. None None O

These None None O
beneficial None None O
effects None None O
of None None O
motivational None None O
incentives None None O
on None None O
cognitive None None O
action None None O
preparation None None O
in None None O
healthy None None O
and None None O
pathological None None O
aging None None O
further None None O
support None None O
views None None O
that None None O
question None None O
the None None O
notion None None O
of None None O
monotonic None None O
deterioration None None O
of None None O
cognitive None None O
function None None O
with None None O
age None None O
( None None O
Allen None None O
et None None O
al None None O
. None None O
, None None O
2001 None None O
) None None O
. None None O

They None None O
indicate None None O
that None None O
age None None O
- None None O
related None None O
declines None None O
can None None O
be None None O
modulated None None O
by None None O
emotion None None O
- None None O
cognition None None O
interactions None None O
. None None O

In None None O
line None None O
with None None O
the None None O
predominant None None O
view None None O
that None None O
cognitive None None O
control None None O
deteriorates None None O
in None None O
aging None None O
and None None O
Parkinson None None O
' None None O
s None None O
disease None None O
, None None O
and None None O
in None None O
line None None O
with None None O
previous None None O
findings None None O
on None None O
age None None O
- None None O
related None None O
changes None None O
in None None O
antisaccade None None O
control None None O
specifically None None O
( None None O
Eenshuistra None None O
et None None O
al None None O
. None None O
, None None O
2004 None None O
; None None O
Chan None None O
et None None O
al None None O
. None None O
, None None O
2005 None None O
; None None O
Amador None None O
et None None O
al None None O
. None None O
, None None O
2006 None None O
; None None O
Abel None None O
and None None O
Douglas None None O
, None None O
2007 None None O
) None None O
, None None O
the None None O
current None None O
results None None O
showed None None O
decline None None O
in None None O
antisaccade None None O
preparation None None O
in None None O
PD None None O
patients None None O
with None None O
severe None None O
motor None None O
symptoms None None O
as None None O
compared None None O
to None None O
healthy None None O
seniors None None O
. None None O

Mild None None O
- None None O
symptom None None O
patients None None O
and None None O
healthy None None O
elderly None None O
did None None O
not None None O
differ None None O
in None None O
antisaccade None None O
preparation None None O
. None None O

Healthy None None O
seniors None None O
showed None None O
declining None None O
antisaccade None None O
preparation None None O
as None None O
compared None None O
to None None O
young None None O
adults None None O
. None None O

Decline None None O
was None None O
evident None None O
on None None O
several None None O
oculomotor None None O
parameters None None O
and None None O
most None None O
pronounced None None O
on None None O
antisaccade None None O
onset None None O
latencies None None O
. None None O

In None None O
line None None O
with None None O
the None None O
notion None None O
that None None O
in None None O
general None None O
, None None O
elderly None None O
tend None None O
to None None O
prefer None None O
accuracy None None O
over None None O
speed None None O
, None None O
elderly None None O
showed None None O
no None None O
decreased None None O
antisaccade None None O
accuracy None None O
as None None O
compared None None O
to None None O
young None None O
adults None None O
. None None O

As None None O
compared None None O
to None None O
the None None O
young None None O
group None None O
, None None O
elderly None None O
and None None O
PD None None O
patients None None O
exhibited None None O
slightly None None O
, None None O
but None None O
not None None O
significantly None None O
more None None O
premature None None O
eye None None O
movements None None O
. None None O

Premature None None O
eye None None O
movements None None O
, None None O
however None None O
significantly None None O
increased None None O
in None None O
elderly None None O
and None None O
PD None None O
patients None None O
but None None O
only None None O
slightly None None O
in None None O
the None None O
young None None O
, None None O
when None None O
more None None O
specific None None O
information None None O
on None None O
the None None O
upcoming None None O
movement None None O
was None None O
available None None O
in None None O
advance None None O
. None None O

Presumably None None O
, None None O
this None None O
increase None None O
in None None O
premature None None O
eye None None O
movements None None O
reflects None None O
difficulties None None O
with None None O
the None None O
inhibition None None O
of None None O
externally None None O
guided None None O
movement None None O
and None None O
/ None None O
or None None O
the None None O
suppression None None O
of None None O
strongly None None O
activated None None O
prepotent None None O
action None None O
plans None None O
. None None O

On None None O
the None None O
one None None O
hand None None O
, None None O
the None None O
choice None None O
for None None O
medicated None None O
PD None None O
patients None None O
represents None None O
a None None O
limitation None None O
of None None O
the None None O
current None None O
study None None O
as None None O
we None None O
cannot None None O
exclude None None O
differential None None O
effects None None O
of None None O
medication None None O
on None None O
behavior None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
PD None None O
patients None None O
generally None None O
take None None O
medication None None O
in None None O
their None None O
daily None None O
routine None None O
, None None O
such None None O
that None None O
the None None O
results None None O
can None None O
be None None O
generalized None None O
to None None O
clinical None None O
practice None None O
. None None O

Exploratory None None O
analysis None None O
within None None O
the None None O
PD None None O
patient None None O
group None None O
revealed None None O
that None None O
patients None None O
with None None O
more None None O
severe None None O
motoric None None O
symptoms None None O
( None None O
as None None O
indexed None None O
by None None O
their None None O
motoric None None O
subscore None None O
on None None O
the None None O
UPDRS None None O
) None None O
displayed None None O
more None None O
signs None None O
of None None O
antisaccade None None O
decline None None O
, None None O
such None None O
as None None O
longer None None O
antisaccade None None O
latencies None None O
and None None O
lower None None O
accuracy None None O
compared None None O
to None None O
mildly None None O
affected None None O
patients None None O
, None None O
who None None O
initiated None None O
saccades None None O
equally None None O
fast None None O
as None None O
healthy None None O
adults None None O
. None None O

This None None O
suggests None None O
that None None O
dopaminergic None None O
medication None None O
was None None O
not None None O
sufficient None None O
to None None O
raise None None O
the None None O
patient None None O
' None None O
s None None O
antisaccadic None None O
preparation None None O
up None None O
to None None O
the None None O
level None None O
of None None O
the None None O
healthy None None O
older None None O
adults None None O
. None None O

One None None O
intriguing None None O
observation None None O
was None None O
that None None O
despite None None O
the None None O
different None None O
extents None None O
of None None O
observed None None O
antisaccade None None O
performance None None O
decline None None O
in None None O
elderly None None O
and None None O
PD None None O
patients None None O
, None None O
reward None None O
prospect None None O
led None None O
to None None O
beneficial None None O
effects None None O
on None None O
antisaccade None None O
latency None None O
and None None O
accuracy None None O
in None None O
young None None O
, None None O
elderly None None O
, None None O
and None None O
PD None None O
patients None None O
alike None None O
. None None O

Young None None O
, None None O
elderly None None O
and None None O
PD None None O
patients None None O
benefited None None O
from None None O
reward None None O
prospect None None O
to None None O
the None None O
same None None O
extent None None O
, None None O
confirming None None O
that None None O
the None None O
expectancy None None O
of None None O
reward None None O
is None None O
a None None O
powerful None None O
mediator None None O
of None None O
cognitive None None O
control None None O
, None None O
even None None O
if None None O
cognitive None None O
control None None O
suffers None None O
from None None O
decline None None O
. None None O

The None None O
expectation None None O
of None None O
rewarding None None O
incentives None None O
thus None None O
seems None None O
to None None O
support None None O
older None None O
adults None None O
' None None O
and None None O
PD None None O
patients None None O
' None None O
ability None None O
to None None O
anticipate None None O
, None None O
prepare None None O
and None None O
initiate None None O
goal None None O
- None None O
directed None None O
behavior None None O
. None None O

These None None O
findings None None O
imply None None O
that None None O
despite None None O
a None None O
general None None O
decline None None O
in None None O
the None None O
action None None O
preparation None None O
system None None O
as None None O
indexed None None O
by None None O
increased None None O
antisaccade None None O
latency None None O
, None None O
action None None O
preparation None None O
processes None None O
remain None None O
susceptible None None O
to None None O
the None None O
prospect None None O
of None None O
future None None O
reward None None O
. None None O

It None None O
could None None O
thus None None O
be None None O
argued None None O
that None None O
the None None O
neural None None O
representations None None O
of None None O
upcoming None None O
rewards None None O
influence None None O
neural None None O
systems None None O
concerned None None O
with None None O
action None None O
preparation None None O
and None None O
oculomotor None None O
control None None O
. None None O

Although None None O
the None None O
current None None O
behavioral None None O
results None None O
cannot None None O
exclude None None O
or None None O
confirm None None O
neural None None O
links None None O
between None None O
reward None None O
anticipation None None O
and None None O
action None None O
preparation None None O
systems None None O
in None None O
the None None O
brain None None O
, None None O
they None None O
suggest None None O
intact None None O
cross None None O
- None None O
talk None None O
among None None O
subcortical None None O
circuits None None O
that None None O
allow None None O
goal None None O
- None None O
directed None None O
action None None O
to None None O
be None None O
modified None None O
by None None O
motivational None None O
factors None None O
. None None O

The None None O
motivational None None O
neural None None O
reward None None O
anticipation None None O
signal None None O
presumably None None O
activates None None O
the None None O
reward None None O
network None None O
including None None O
the None None O
amygdala None None O
, None None O
orbitofrontal None None O
cortex None None O
, None None O
the None None O
more None None O
ventral None None O
and None None O
dorsal None None O
striatum None None O
( None None O
nucleus None None O
accumbens None None O
, None None O
putamen None None O
, None None O
and None None O
caudate None None O
) None None O
, None None O
leading None None O
to None None O
an None None O
release None None O
of None None O
caudate None None O
/ None None O
SNr None None O
inhibition None None O
on None None O
the None None O
executive None None O
oculomotor None None O
structure None None O
superior None None O
colliculus None None O
. None None O

This None None O
transiently None None O
decreased None None O
inhibitory None None O
force None None O
on None None O
superior None None O
colliculus None None O
may None None O
improve None None O
goal None None O
- None None O
directed None None O
oculomotor None None O
control None None O
. None None O

Thus None None O
reward None None O
anticipation None None O
might None None O
compensate None None O
for None None O
the None None O
age None None O
- None None O
and None None O
disease None None O
- None None O
related None None O
dopaminergic None None O
loss None None O
in None None O
the None None O
SNc None None O
projections None None O
to None None O
the None None O
caudate None None O
/ None None O
SNr None None O
and None None O
may None None O
thus None None O
play None None O
a None None O
compensatory None None O
role None None O
in None None O
" None None O
boosting None None O
" None None O
the None None O
efficiency None None O
of None None O
interactions None None O
between None None O
motivational None None O
and None None O
impaired None None O
cognitive None None O
control None None O
processes None None O
. None None O

However None None O
the None None O
reward None None O
- None None O
related None None O
modulation None None O
of None None O
the None None O
oculomotor None None O
control None None O
system None None O
may None None O
not None None O
only None None O
apply None None O
to None None O
the None None O
basal None None O
ganglia None None O
part None None O
of None None O
the None None O
oculomotor None None O
network None None O
. None None O

Although None None O
speculative None None O
, None None O
it None None O
could None None O
extend None None O
to None None O
the None None O
cortical None None O
eyefields None None O
( None None O
frontal None None O
, None None O
supplementary None None O
, None None O
and None None O
parietal None None O
eyefields None None O
) None None O
and None None O
to None None O
parts None None O
of None None O
the None None O
visual None None O
cortex None None O
. None None O

Human None None O
research None None O
shows None None O
that None None O
more None None O
preparatory None None O
activation None None O
in None None O
the None None O
frontal None None O
eyefields None None O
leads None None O
to None None O
a None None O
faster None None O
antisaccade None None O
latency None None O
( None None O
Connolly None None O
et None None O
al None None O
. None None O
, None None O
2002 None None O
, None None O
2005 None None O
) None None O
. None None O

The None None O
compensatory None None O
effect None None O
on None None O
the None None O
antisaccade None None O
latency None None O
, None None O
therefore None None O
, None None O
could None None O
theoretically None None O
stem None None O
from None None O
a None None O
propagation None None O
of None None O
reward None None O
anticipation None None O
signal None None O
in None None O
the None None O
caudate None None O
to None None O
the None None O
frontal None None O
eyefields None None O
. None None O

Complex None None O
structural None None O
connections None None O
enable None None O
the None None O
striatum None None O
to None None O
exert None None O
a None None O
controlling None None O
influence None None O
over None None O
the None None O
cerebral None None O
cortex None None O
via None None O
a None None O
series None None O
of None None O
reentrant None None O
corticobasal None None O
ganglia None None O
circuits None None O
. None None O

Thus None None O
reward None None O
anticipation None None O
may None None O
increase None None O
the None None O
level None None O
of None None O
preparation None None O
in None None O
the None None O
intact None None O
cortical None None O
eyefields None None O
and None None O
thereby None None O
compensate None None O
for None None O
age None None O
- None None O
and None None O
disease None None O
- None None O
related None None O
subcortical None None O
decrements None None O
in None None O
the None None O
oculomotor None None O
network None None O
. None None O

Taken None None O
together None None O
, None None O
it None None O
seems None None O
plausible None None O
that None None O
motivational None None O
reward None None O
processes None None O
in None None O
the None None O
caudate None None O
enhance None None O
preparatory None None O
activation None None O
in None None O
subcortical None None O
as None None O
well None None O
as None None O
in None None O
cortical None None O
nodes None None O
of None None O
the None None O
oculomotor None None O
network None None O
. None None O

Several None None O
neurotransmission None None O
mechanisms None None O
may None None O
underlie None None O
the None None O
remedial None None O
effect None None O
of None None O
positive None None O
incentives None None O
on None None O
declining None None O
antisaccadic None None O
control None None O
. None None O

Given None None O
the None None O
convergence None None O
of None None O
dopamine None None O
and None None O
glutamate None None O
inputs None None O
at None None O
the None None O
spiny None None O
projection None None O
neurons None None O
in None None O
the None None O
striatum None None O
( None None O
Burns None None O
et None None O
al None None O
. None None O
, None None O
1994 None None O
) None None O
, None None O
an None None O
interaction None None O
between None None O
dopamine None None O
and None None O
glutamate None None O
might None None O
underlie None None O
striatal None None O
processes None None O
of None None O
reward None None O
anticipation None None O
and None None O
action None None O
preparation None None O
. None None O

However None None O
, None None O
it None None O
cannot None None O
be None None O
fully None None O
excluded None None O
that None None O
alterations None None O
in None None O
other None None O
neurotransmitter None None O
systems None None O
may None None O
also None None O
have None None O
an None None O
effect None None O
on None None O
declining None None O
oculomotor None None O
control None None O
and None None O
on None None O
remediating None None O
incentive None None O
effects None None O
. None None O

Non None None O
- None None O
dopaminergic None None O
changes None None O
such None None O
as None None O
noradrenergic None None O
, None None O
serotonergic None None O
, None None O
and None None O
cholinergic None None O
deafferentation None None O
of None None O
the None None O
cortex None None O
also None None O
occur None None O
in None None O
PD None None O
and None None O
can None None O
inflict None None O
cognitive None None O
deficits None None O
( None None O
Agid None None O
et None None O
al None None O
. None None O
, None None O
1987 None None O
) None None O
. None None O

Evidence None None O
from None None O
non None None O
- None None O
human None None O
primates None None O
suggests None None O
that None None O
basal None None O
ganglia None None O
dopamine None None O
acts None None O
to None None O
speed None None O
motor None None O
responding None None O
in None None O
response None None O
to None None O
rewarding None None O
cues None None O
( None None O
Niv None None O
, None None O
2007 None None O
; None None O
Niv None None O
et None None O
al None None O
. None None O
, None None O
2007 None None O
) None None O
. None None O

Among None None O
at None None O
least None None O
five None None O
types None None O
of None None O
DA None None O
receptors None None O
, None None O
mainly None None O
D1 None None O
and None None O
D2 None None O
receptors None None O
are None None O
expressed None None O
in None None O
caudate None None O
projection None None O
neurons None None O
( None None O
Nakamura None None O
and None None O
Hikosaka None None O
, None None O
2006 None None O
) None None O
. None None O

Tendencies None None O
to None None O
speed None None O
responses None None O
to None None O
obtain None None O
large None None O
rewards None None O
have None None O
been None None O
found None None O
to None None O
be None None O
dependent None None O
on None None O
striatal None None O
D1 None None O
receptors None None O
( None None O
Dalley None None O
et None None O
al None None O
. None None O
, None None O
2005 None None O
; None None O
Berridge None None O
, None None O
2007 None None O
) None None O
. None None O

In None None O
contrast None None O
to None None O
this None None O
D1 None None O
modulated None None O
speeding None None O
in None None O
reward None None O
- None None O
motor None None O
tasks None None O
, None None O
evidence None None O
from None None O
saccade None None O
tasks None None O
in None None O
non None None O
- None None O
human None None O
primates None None O
suggests None None O
D2 None None O
receptor None None O
modulation None None O
of None None O
reward None None O
dependent None None O
improvements None None O
of None None O
performance None None O
( None None O
Nakamura None None O
and None None O
Hikosaka None None O
, None None O
2006 None None O
) None None O
. None None O

Injections None None O
of None None O
a None None O
D1 None None O
antagonist None None O
and None None O
a None None O
D2 None None O
antagonist None None O
into None None O
the None None O
region None None O
of None None O
the None None O
caudate None None O
where None None O
saccade None None O
- None None O
related None None O
neurons None None O
are None None O
clustered None None O
while None None O
the None None O
monkey None None O
performed None None O
a None None O
reward None None O
- None None O
biased None None O
saccade None None O
task None None O
showed None None O
that None None O
D1 None None O
antagonists None None O
attenuate None None O
the None None O
reward None None O
modulation None None O
of None None O
saccade None None O
behavior None None O
whereas None None O
D2 None None O
antagonists None None O
into None None O
the None None O
same None None O
region None None O
enhanced None None O
the None None O
reward None None O
- None None O
dependent None None O
changes None None O
. None None O

Future None None O
studies None None O
of None None O
Parkinson None None O
patients None None O
on None None O
versus None None O
off None None O
medication None None O
, None None O
could None None O
provide None None O
some None None O
information None None O
on None None O
the None None O
role None None O
of None None O
dopaminergic None None O
mechanisms None None O
in None None O
the None None O
remedial None None O
effects None None O
on None None O
antisaccadic None None O
performance None None O
. None None O

A None None O
recent None None O
study None None O
of None None O
reward None None O
learning None None O
in None None O
Parkinson None None O
patients None None O
on None None O
/ None None O
off None None O
dopaminergic None None O
medication None None O
showed None None O
that None None O
patients None None O
adapted None None O
their None None O
behavior None None O
to None None O
maximize None None O
expected None None O
reward None None O
value None None O
dependent None None O
on None None O
their None None O
medication None None O
status None None O
( None None O
Moustafa None None O
et None None O
al None None O
. None None O
, None None O
2008 None None O
) None None O
. None None O

Whilst None None O
off None None O
dopaminergic None None O
medication None None O
, None None O
patients None None O
slowed None None O
their None None O
responses None None O
to None None O
avoid None None O
low None None O
expected None None O
values None None O
, None None O
but None None O
succeeded None None O
less None None O
well None None O
in None None O
speeding None None O
responses None None O
when None None O
a None None O
reward None None O
was None None O
at None None O
stake None None O
. None None O

The None None O
opposite None None O
pattern None None O
emerged None None O
when None None O
the None None O
same None None O
patients None None O
were None None O
on None None O
medication None None O
; None None O
patients None None O
showed None None O
better None None O
response None None O
speeding None None O
, None None O
and None None O
worse None None O
response None None O
slowing None None O
, None None O
to None None O
maximize None None O
expected None None O
value None None O
. None None O

The None None O
current None None O
behavioral None None O
findings None None O
are None None O
in None None O
line None None O
with None None O
neuroimaging None None O
research None None O
showing None None O
intact None None O
neural None None O
representations None None O
of None None O
future None None O
reward None None O
in None None O
the None None O
aging None None O
striatum None None O
( None None O
Samanez None None O
- None None O
Larkin None None O
et None None O
al None None O
. None None O
, None None O
2007 None None O
) None None O
. None None O

The None None O
observation None None O
however None None O
that None None O
older None None O
adults None None O
and None None O
PD None None O
patients None None O
can None None O
use None None O
this None None O
intact None None O
neural None None O
representation None None O
of None None O
reward None None O
anticipation None None O
( None None O
a None None O
positive None None O
motivational None None O
incentive None None O
) None None O
to None None O
optimize None None O
their None None O
preparatory None None O
processes None None O
, None None O
cannot None None O
necessarily None None O
be None None O
generalized None None O
to None None O
cognitive None None O
contexts None None O
with None None O
negative None None O
motivational None None O
incentives None None O
. None None O

Samanez None None O
- None None O
Larkin None None O
et None None O
al None None O
. None None O
( None None O
2010 None None O
) None None O
recently None None O
showed None None O
that None None O
older None None O
adults None None O
were None None O
not None None O
able None None O
to None None O
optimally None None O
use None None O
their None None O
intact None None O
neural None None O
reward None None O
anticipation None None O
system None None O
in None None O
risky None None O
financial None None O
decision None None O
making None None O
. None None O

Elderly None None O
made None None O
more None None O
suboptimal None None O
choices None None O
when None None O
they None None O
were None None O
to None None O
choose None None O
risky None None O
assets None None O
. None None O

The None None O
authors None None O
deemed None None O
it None None O
likely None None O
that None None O
these None None O
decrements None None O
in None None O
value None None O
- None None O
based None None O
decision None None O
making None None O
are None None O
explained None None O
by None None O
the None None O
fact None None O
that None None O
value None None O
- None None O
based None None O
decision None None O
making None None O
requires None None O
the None None O
weighting None None O
of None None O
behavioral None None O
alternatives None None O
, None None O
that None None O
may None None O
lead None None O
to None None O
either None None O
gain None None O
or None None O
loss None None O
. None None O

During None None O
anticipation None None O
of None None O
rewards None None O
older None None O
adults None None O
show None None O
similar None None O
neural None None O
responses None None O
as None None O
young None None O
adults None None O
but None None O
they None None O
show None None O
reduced None None O
neural None None O
activation None None O
during None None O
the None None O
anticipation None None O
of None None O
losses None None O
( None None O
Samanez None None O
- None None O
Larkin None None O
et None None O
al None None O
. None None O
, None None O
2007 None None O
) None None O
. None None O

The None None O
latter None None O
, None None O
together None None O
with None None O
the None None O
observation None None O
that None None O
older None None O
adults None None O
tend None None O
to None None O
shift None None O
their None None O
attention None None O
away None None O
from None None O
negative None None O
stimuli None None O
and None None O
attend None None O
to None None O
positive None None O
information None None O
instead None None O
( None None O
Mather None None O
and None None O
Carstensen None None O
, None None O
2003 None None O
, None None O
2005 None None O
) None None O
, None None O
may None None O
have None None O
led None None O
to None None O
the None None O
underestimation None None O
of None None O
loss None None O
and None None O
therefore None None O
to None None O
more None None O
risky None None O
and None None O
suboptimal None None O
decisions None None O
. None None O

In None None O
this None None O
respect None None O
, None None O
one None None O
limitation None None O
of None None O
the None None O
current None None O
task None None O
is None None O
that None None O
it None None O
built None None O
solely None None O
on None None O
reward None None O
prospect None None O
and None None O
not None None O
on None None O
the None None O
prospect None None O
of None None O
loss None None O
, None None O
such None None O
that None None O
the None None O
question None None O
of None None O
how None None O
the None None O
anticipation None None O
of None None O
loss None None O
influences None None O
action None None O
preparation None None O
was None None O
not None None O
tested None None O
. None None O

The None None O
impact None None O
of None None O
negative None None O
incentives None None O
might None None O
be None None O
an None None O
intriguing None None O
question None None O
for None None O
future None None O
research None None O
, None None O
as None None O
due None None O
to None None O
the None None O
decreased None None O
activation None None O
of None None O
the None None O
neural None None O
loss None None O
anticipation None None O
system None None O
( None None O
Samanez None None O
- None None O
Larkin None None O
et None None O
al None None O
. None None O
, None None O
2007 None None O
) None None O
together None None O
with None None O
the None None O
observed None None O
differential None None O
attentional None None O
bias None None O
for None None O
negative None None O
and None None O
positive None None O
information None None O
( None None O
Mather None None O
and None None O
Carstensen None None O
, None None O
2003 None None O
) None None O
, None None O
it None None O
seems None None O
likely None None O
that None None O
negative None None O
motivational None None O
incentives None None O
, None None O
i None None O
. None None O
e None None O
. None None O
, None None O
the None None O
prospect None None O
of None None O
loss None None O
, None None O
might None None O
have None None O
a None None O
different None None O
impact None None O
on None None O
action None None O
preparation None None O
in None None O
older None None O
adults None None O
than None None O
in None None O
the None None O
young None None O
. None None O

Future None None O
approaches None None O
to None None O
the None None O
effect None None O
of None None O
loss None None O
anticipation None None O
on None None O
declining None None O
antisaccade None None O
control None None O
may None None O
ideally None None O
contain None None O
a None None O
sequence None None O
of None None O
experiments None None O
, None None O
starting None None O
with None None O
a None None O
separate None None O
( None None O
punishment None None O
only None None O
) None None O
approach None None O
before None None O
moving None None O
to None None O
combined None None O
reward None None O
- None None O
punishment None None O
designs None None O
. None None O

This None None O
might None None O
be None None O
necessary None None O
as None None O
previous None None O
evidence None None O
( None None O
from None None O
healthy None None O
young None None O
adults None None O
) None None O
suggests None None O
that None None O
the None None O
reward None None O
effect None None O
on None None O
oculomotor None None O
control None None O
disappears None None O
in None None O
the None None O
presence None None O
of None None O
punishment None None O
trials None None O
. None None O

The None None O
authors None None O
deemed None None O
it None None O
likely None None O
that None None O
the None None O
participants None None O
increased None None O
caution None None O
to None None O
all None None O
incentive None None O
( None None O
reward None None O
and None None O
punishment None None O
) None None O
trials None None O
( None None O
Blaukopf None None O
and None None O
DiGirolamo None None O
, None None O
2006 None None O
) None None O
. None None O

As None None O
of None None O
yet None None O
, None None O
age None None O
- None None O
related None None O
changes None None O
in None None O
neural None None O
reward None None O
anticipation None None O
have None None O
mainly None None O
been None None O
studied None None O
in None None O
isolation None None O
. None None O

Recently None None O
however None None O
, None None O
the None None O
interaction None None O
of None None O
neural None None O
reward None None O
processing None None O
with None None O
other None None O
cognitive None None O
functions None None O
and None None O
their None None O
underlying None None O
neural None None O
systems None None O
, None None O
such None None O
as None None O
the None None O
action None None O
control None None O
system None None O
, None None O
has None None O
gained None None O
increasing None None O
interest None None O
( None None O
Haber None None O
and None None O
Knutson None None O
, None None O
2010 None None O
) None None O
. None None O

Initial None None O
evidence None None O
suggests None None O
coordinated None None O
activity None None O
between None None O
distant None None O
brain None None O
regions None None O
responsible None None O
for None None O
reward None None O
processing None None O
( None None O
Cohen None None O
et None None O
al None None O
. None None O
, None None O
2009 None None O
) None None O
. None None O

The None None O
current None None O
results None None O
encourage None None O
further None None O
neural None None O
network None None O
investigations None None O
on None None O
the None None O
role None None O
of None None O
coordinated None None O
brain None None O
network None None O
activity None None O
in None None O
motivated None None O
behavior None None O
. None None O

Behavioral None None O
benefits None None O
from None None O
motivation None None O
might None None O
be None None O
associated None None O
with None None O
changes None None O
in None None O
functional None None O
brain None None O
connectivity None None O
on None None O
a None None O
larger None None O
scale None None O
, None None O
e None None O
. None None O
g None None O
. None None O
, None None O
between None None O
frontostriatal None None O
reward None None O
and None None O
action None None O
preparation None None O
structures None None O
. None None O

Another None None O
important None None O
factor None None O
that None None O
emerges None None O
from None None O
the None None O
present None None O
and None None O
previous None None O
results None None O
, None None O
is None None O
the None None O
importance None None O
of None None O
the None None O
training None None O
of None None O
the None None O
motivational None None O
aspects None None O
of None None O
the None None O
instructions None None O
that None None O
need None None O
to None None O
be None None O
kept None None O
in None None O
working None None O
memory None None O
when None None O
performing None None O
a None None O
cognitive None None O
task None None O
. None None O

Samanez None None O
- None None O
Larkin None None O
et None None O
al None None O
. None None O

( None None O
2007 None None O
) None None O
found None None O
intact None None O
neural None None O
reward None None O
anticipation None None O
processes None None O
specifically None None O
in None None O
the None None O
absence None None O
of None None O
learning None None O
( None None O
after None None O
the None None O
learning None None O
process None None O
of None None O
reward None None O
cue None None O
- None None O
reward None None O
associations None None O
was None None O
completed None None O
) None None O
. None None O

Therefore None None O
it None None O
might None None O
be None None O
important None None O
for None None O
researchers None None O
doing None None O
experiments None None O
with None None O
motivation None None O
based None None O
instructions None None O
to None None O
keep None None O
in None None O
mind None None O
that None None O
, None None O
compared None None O
to None None O
young None None O
adults None None O
, None None O
elderly None None O
and None None O
PD None None O
patients None None O
are None None O
generally None None O
hampered None None O
on None None O
stimulus None None O
- None None O
response None None O
learning None None O
( None None O
Shohamy None None O
et None None O
al None None O
. None None O
, None None O
2004 None None O
; None None O
Marschner None None O
et None None O
al None None O
. None None O
, None None O
2005 None None O
) None None O
. None None O

Reward None None O
instruction None None O
cues None None O
, None None O
as None None O
they None None O
were None None O
used None None O
in None None O
the None None O
current None None O
study None None O
require None None O
participants None None O
to None None O
form None None O
reward None None O
cue None None O
- None None O
reward None None O
associations None None O
. None None O

Impairments None None O
in None None O
the None None O
learning None None O
of None None O
associations None None O
between None None O
the None None O
cue None None O
signaling None None O
reward None None O
and None None O
the None None O
actual None None O
reward None None O
might None None O
conceal None None O
intact None None O
reward None None O
anticipation None None O
processes None None O
. None None O

When None None O
the None None O
formation None None O
of None None O
associations None None O
is None None O
weakened None None O
, None None O
it None None O
could None None O
appear None None O
as None None O
a None None O
failure None None O
to None None O
capitalize None None O
on None None O
the None None O
neural None None O
reward None None O
anticipation None None O
system None None O
, None None O
whereas None None O
it None None O
represents None None O
an None None O
indirect None None O
effect None None O
of None None O
non None None O
- None None O
available None None O
reward None None O
associations None None O
in None None O
working None None O
memory None None O
when None None O
preparing None None O
the None None O
response None None O
. None None O

Hence None None O
, None None O
one None None O
might None None O
circumvent None None O
the None None O
effect None None O
of None None O
potential None None O
learning None None O
impairments None None O
on None None O
reward None None O
anticipation None None O
processes None None O
by None None O
the None None O
training None None O
of None None O
abstract None None O
reward None None O
cues None None O
( None None O
as None None O
in None None O
the None None O
current None None O
and None None O
in None None O
Samanez None None O
- None None O
Larkin None None O
' None None O
s None None O
study None None O
) None None O
or None None O
by None None O
using None None O
explicit None None O
and None None O
concrete None None O
rewards None None O
. None None O

Once None None O
the None None O
learning None None O
of None None O
reward None None O
cues None None O
is None None O
accomplished None None O
the None None O
intact None None O
reward None None O
anticipation None None O
processes None None O
might None None O
become None None O
evident None None O
. None None O

In None None O
sum None None O
, None None O
the None None O
results None None O
confirmed None None O
that None None O
the None None O
preparation None None O
of None None O
goal None None O
- None None O
directed None None O
actions None None O
declined None None O
in None None O
PD None None O
patients None None O
compared None None O
to None None O
healthy None None O
seniors None None O
, None None O
and None None O
in None None O
healthy None None O
seniors None None O
compared None None O
to None None O
young None None O
adults None None O
. None None O

Due None None O
perhaps None None O
to None None O
deterioration None None O
in None None O
dopaminergic None None O
striatal None None O
circuitry None None O
, None None O
antisaccade None None O
performance None None O
is None None O
subject None None O
to None None O
decline None None O
in None None O
healthy None None O
seniors None None O
, None None O
and None None O
even None None O
more None None O
in None None O
individuals None None O
with None None O
Parkinson None None O
' None None O
s None None O
disease None None O
. None None O

The None None O
prospect None None O
of None None O
future None None O
reward None None O
however None None O
provided None None O
a None None O
motivational None None O
incentive None None O
for None None O
optimizing None None O
oculomotor None None O
preparation None None O
in None None O
all None None O
groups None None O
alike None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
reward None None O
- None None O
processing None None O
networks None None O
and None None O
oculomotor None None O
- None None O
control None None O
networks None None O
in None None O
the None None O
brain None None O
are None None O
connected None None O
in None None O
such None None O
a None None O
way None None O
( None None O
presumably None None O
with None None O
the None None O
dorsal None None O
striatum None None O
as None None O
a None None O
common None None O
nexus None None O
) None None O
that None None O
reward None None O
anticipation None None O
can None None O
facilitate None None O
oculomotor None None O
control None None O
and None None O
alleviate None None O
the None None O
deficiencies None None O
experienced None None O
by None None O
healthy None None O
seniors None None O
and None None O
PD None None O
patients None None O
. None None O

Future None None O
investigations None None O
should None None O
examine None None O
whether None None O
the None None O
observed None None O
effects None None O
are None None O
specific None None O
for None None O
the None None O
current None None O
task None None O
or None None O
generalize None None O
to None None O
other None None O
tasks None None O
that None None O
show None None O
age None None O
- None None O
and None None O
PD None None O
- None None O
related None None O
cognitive None None O
decrements None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
in None None O
task None None O
switching None None O
) None None O
and None None O
have None None O
been None None O
related None None O
to None None O
dopaminergic None None O
denervation None None O
in None None O
the None None O
caudate None None O
( None None O
e None None O
. None None O
g None None O
. None None O
, None None O
impaired None None O
verbal None None O
episodic None None O
memory None None O
, None None O
attention None None O
, None None O
and None None O
response None None O
inhibition None None O
; None None O
Rinne None None O
et None None O
al None None O
. None None O
, None None O
2000 None None O
; None None O
Bruck None None O
et None None O
al None None O
. None None O
, None None O
2005 None None O
) None None O
. None None O

Future None None O
studies None None O
on None None O
network None None O
processes None None O
may None None O
help None None O
to None None O
localize None None O
the None None O
neural None None O
link None None O
between None None O
reward None None O
prospect None None O
and None None O
action None None O
preparation None None O
that None None O
enables None None O
alleviating None None O
effects None None O
of None None O
motivational None None O
incentives None None O
on None None O
cognitive None None O
decline None None O
. None None O

Origins None None O
of None None O
Acquired None None O
Antibiotic None None O
Resistance None None O
Mechanisms None None O

Recently None None O
, None None O
D None None O
' None None O
Costa None None O
et None None O
al None None O
. None None O

( None None O
2011 None None O
) None None O
have None None O
reported None None O
a None None O
metagenomic None None O
analysis None None O
of None None O
the None None O
Beringian None None O
permafrost None None O
, None None O
which None None O
is None None O
30 None None O
, None None O
000 None None O
years None None O
old None None O
. None None O

They None None O
showed None None O
molecular None None O
evidences None None O
of None None O
the None None O
ancient None None O
origins None None O
of None None O
antibiotic None None O
resistances None None O
, None None O
detecting None None O
beta None None O
- None None O
lactamases None None O
genes None None O
, None None O
vanX None None O
- None None O
like None None O
, None None O
component None None O
of None None O
the None None O
vancomycin None None O
resistance None None O
operon None None O
, None None O
and None None O
tetM None None O
, None None O
coding None None O
for None None O
a None None O
protein None None O
protecting None None O
the None None O
ribosomal None None O
target None None O
from None None O
tetracycline None None O
. None None O

Sequence None None O
analysis None None O
revealed None None O
that None None O
the None None O
beta None None O
- None None O
lactamases None None O
genes None None O
recovered None None O
from None None O
the None None O
permafrost None None O
demonstrated None None O
an None None O
amino None None O
- None None O
acid None None O
homology None None O
( None None O
53 None None O
- None None O
84 None None O
% None None O
) None None O
to None None O
known None None O
beta None None O
- None None O
lactamases None None O
from None None O
beta None None O
- None None O
lactams None None O
producing None None O
Streptomyces None None O
. None None O

The None None O
tetM None None O
sequences None None O
revealed None None O
a None None O
high None None O
similarity None None O
to None None O
the None None O
genes None None O
coding None None O
for None None O
the None None O
ribosomal None None O
protection None None O
protein None None O
of None None O
actinomycetes None None O
. None None O

The None None O
vanX None None O
sequence None None O
showed None None O
a None None O
similarity None None O
to None None O
the None None O
vanX None None O
gene None None O
recovered None None O
in None None O
pathogenic None None O
vancomycin None None O
resistant None None O
enterococci None None O
( None None O
VRE None None O
) None None O
and None None O
to None None O
the None None O
vanX None None O
gene None None O
from None None O
Amycolatopsis None None O
orientalis None None O
. None None O

This None None O
environmental None None O
species None None O
, None None O
belonging None None O
to None None O
the None None O
actinobacteria None None O
phylum None None O
, None None O
is None None O
a None None O
natural None None O
producer None None O
of None None O
vancomycin None None O
, None None O
and None None O
very None None O
likely None None O
the None None O
progenitor None None O
of None None O
the None None O
van None None O
genes None None O
operons None None O
, None None O
responsible None None O
for None None O
resistance None None O
to None None O
vancomycin None None O
. None None O

The None None O
integration None None O
of None None O
the None None O
van None None O
operons None None O
on None None O
transposons None None O
and None None O
on None None O
conjugative None None O
plasmids None None O
has None None O
enhanced None None O
their None None O
spread None None O
( None None O
Courvalin None None O
, None None O
2006 None None O
) None None O
. None None O

Reports None None O
of None None O
VRE None None O
in None None O
freshwater None None O
have None None O
been None None O
provided None None O
by None None O
several None None O
authors None None O
( None None O
Talebi None None O
et None None O
al None None O
. None None O
, None None O
2008 None None O
; None None O
Lata None None O
et None None O
al None None O
. None None O
, None None O
2009 None None O
; None None O
Luczkiewicz None None O
et None None O
al None None O
. None None O
, None None O
2010 None None O
) None None O
. None None O

Interestingly None None O
, None None O
Schwartz None None O
et None None O
al None None O
. None None O

( None None O
2003 None None O
) None None O
detected None None O
vanA None None O
genes None None O
in None None O
the None None O
biofilm None None O
of None None O
drinking None None O
water None None O
supplies None None O
, None None O
in None None O
the None None O
absence None None O
of None None O
enterococci None None O
, None None O
demonstrating None None O
the None None O
lateral None None O
transfer None None O
of None None O
this None None O
gene None None O
. None None O

Notably None None O
, None None O
the None None O
progenitors None None O
of None None O
these None None O
resistance None None O
genes None None O
are None None O
soil None None O
bacteria None None O
thus None None O
most None None O
likely None None O
, None None O
a None None O
shuttle None None O
has None None O
been None None O
responsible None None O
for None None O
the None None O
introduction None None O
of None None O
these None None O
genes None None O
into None None O
the None None O
commensal None None O
bacterial None None O
community None None O
and None None O
afterward None None O
into None None O
the None None O
pathogenic None None O
species None None O
. None None O

Challenges None None O
to None None O
creating None None O
and None None O
implementing None None O
a None None O
perioperative None None O
glycemic None None O
control None None O
protocol None None O
. None None O

Power None None O
( None None O
Y None None O
- None None O
axis None None O
) None None O
as None None O
a None None O
function None None O
of None None O
main None None O
effects None None O
( None None O
x None None O
- None None O
axis None None O
) None None O
. None None O

For None None O
a None None O
pure None None O
main None None O
- None None O
effects None None O
model None None O
( None None O
x None None O
- None None O
axis None None O
= None None O
a1 None None O
> None None O
0 None None O
; None None O
interaction None None O
effects None None O
a2 None None O
= None None O
a3 None None O
= None None O
0 None None O
are None None O
all None None O
zero None None O
) None None O
, None None O
Figure None None O
1 None None O
shows None None O
that None None O
pattern None None O
( None None O
solid None None O
red None None O
line None None O
) None None O
and None None O
single None None O
- None None O
locus None None O
( None None O
broken None None O
blue None None O
line None None O
) None None O
approaches None None O
have None None O
virtually None None O
the None None O
same None None O
power None None O
. None None O

[ None None O
Ambiguity None None O
role None None O
of None None O
neutrophils None None O
in None None O
oncogenesis None None O
] None None O

The None None O
review None None O
is None None O
focused None None O
on None None O
the None None O
participation None None O
of None None O
polymorphonuclear None None O
granulocytes None None O
( None None O
neutrophils None None O
) None None O
in None None O
development None None O
and None None O
spreading None None O
of None None O
a None None O
tumor None None O
. None None O

We None None O
consider None None O
both None None O
the None None O
well None None O
known None None O
functions None None O
of None None O
neutrophils None None O
( None None O
degranulation None None O
, None None O
production None None O
of None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
) None None O
and None None O
the None None O
recently None None O
shown None None O
one None None O
( None None O
presentation None None O
of None None O
an None None O
antigene None None O
) None None O
. None None O

The None None O
special None None O
attention None None O
is None None O
focused None None O
on None None O
the None None O
ambiguity None None O
of None None O
the None None O
neutrophil None None O
role None None O
in None None O
oncogenesis None None O
. None None O

The None None O
dominant None None O
view None None O
is None None O
that None None O
neutrophils None None O
display None None O
exclusively None None O
antitumor None None O
properties None None O
. None None O

The None None O
update None None O
information None None O
testifies None None O
about None None O
protumoral None None O
activity None None O
of None None O
neutrophils None None O
: None None O
they None None O
migrate None None O
to None None O
a None None O
tumor None None O
and None None O
promote None None O
angiogenesis None None O
and None None O
metastasis None None O
at None None O
late None None O
stages None None O
of None None O
the None None O
tumor None None O
. None None O

It None None O
is None None O
interesting None None O
that None None O
certain None None O
components None None O
of None None O
neutrophil None None O
cytotoxic None None O
arsenal None None O
( None None O
ROS None None O
, None None O
cytokines None None O
, None None O
specific None None O
enzymes None None O
) None None O
participate None None O
both None None O
in None None O
antitumoral None None O
defenses None None O
of None None O
an None None O
organism None None O
and None None O
protumoral None None O
activity None None O
. None None O

Upregulation None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptors None None O
is None None O
associated None None O
with None None O
advanced None None O
neuroblastoma None None O
. None None O

BACKGROUND None None O
: None None O
Angiogenesis None None O
is None None O
essential None None O
for None None O
tumor None None O
growth None None O
and None None O
relies None None O
on None None O
the None None O
production None None O
of None None O
angiogenic None None O
factors None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
is None None O
a None None O
major None None O
regulator None None O
of None None O
angiogenesis None None O
that None None O
binds None None O
to None None O
tyrosine None None O
kinase None None O
receptors None None O
Flt None None O
- None None O
1 None None O
and None None O
KDR None None O
. None None O

The None None O
interaction None None O
of None None O
VEGF None None O
and None None O
its None None O
receptors None None O
at None None O
gene None None O
and None None O
protein None None O
levels None None O
in None None O
neuroblastoma None None O
remains None None O
widely None None O
unknown None None O
. None None O

METHODS None None O
: None None O
Tumor None None O
biopsy None None O
specimens None None O
and None None O
serum None None O
were None None O
obtained None None O
from None None O
37 None None O
neuroblastoma None None O
patients None None O
; None None O
adrenal None None O
biopsy None None O
sections None None O
and None None O
sera None None O
of None None O
7 None None O
normal None None O
children None None O
served None None O
as None None O
controls None None O
. None None O

Biopsy None None O
specimens None None O
were None None O
examined None None O
by None None O
real None None O
- None None O
time None None O
reverse None None O
transcription None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT None None O
- None None O
PCR None None O
) None None O
and None None O
Western None None O
blotting None None O
; None None O
serum None None O
was None None O
analyzed None None O
by None None O
enzyme None None O
- None None O
linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
. None None O

VEGF None None O
- None None O
A None None O
( None None O
165 None None O
) None None O
, None None O
B None None O
, None None O
C None None O
, None None O
Flt None None O
- None None O
1 None None O
, None None O
and None None O
KDR None None O
were None None O
analyzed None None O
. None None O

RESULTS None None O
: None None O
VEGF None None O
isoforms None None O
and None None O
its None None O
receptors None None O
' None None O
mRNA None None O
were None None O
expressed None None O
in None None O
neuroblastoma None None O
and None None O
control None None O
tissues None None O
. None None O

Whereas None None O
the None None O
ligands None None O
were None None O
increased None None O
in None None O
stages None None O
III None None O
and None None O
IV None None O
, None None O
the None None O
receptors None None O
were None None O
upregulated None None O
in None None O
stage None None O
III None None O
only None None O
. None None O

At None None O
protein None None O
level None None O
, None None O
VEGF None None O
- None None O
B None None O
and None None O
C None None O
, None None O
Flt None None O
- None None O
1 None None O
, None None O
and None None O
KDR None None O
were None None O
not None None O
detectable None None O
in None None O
tissue None None O
lysates None None O
, None None O
whereas None None O
VEGF None None O
- None None O
A None None O
was None None O
increased None None O
in None None O
stages None None O
III None None O
and None None O
IV None None O
. None None O

Serum None None O
VEGF None None O
protein None None O
levels None None O
were None None O
upregulated None None O
in None None O
stage None None O
III None None O
. None None O

CONCLUSIONS None None O
: None None O
VEGF None None O
- None None O
A None None O
( None None O
165 None None O
) None None O
is None None O
one None None O
of None None O
the None None O
major None None O
angiogenesis None None O
regulators None None O
among None None O
the None None O
ligands None None O
' None None O
family None None O
of None None O
VEGF None None O
, None None O
whereas None None O
its None None O
receptors None None O
KDR None None O
, None None O
and None None O
most None None O
probably None None O
Flt None None O
- None None O
1 None None O
, None None O
may None None O
contribute None None O
to None None O
a None None O
poor None None O
prognosis None None O
( None None O
angiogenic None None O
) None None O
phenotype None None O
, None None O
as None None O
indicated None None O
by None None O
their None None O
upregulated None None O
MRNA None None O
levels None None O
in None None O
stage None None O
III None None O
neuroblastoma None None O
. None None O

VEGF None None O
- None None O
A None None O
( None None O
165 None None O
) None None O
mainly None None O
contributes None None O
to None None O
increased None None O
serum None None O
VEGF None None O
levels None None O
and None None O
may None None O
serve None None O
as None None O
a None None O
diagnostic None None O
tool None None O
in None None O
advanced None None O
- None None O
stage None None O
neuroblastoma None None O
. None None O

Subcellular None None O
localisation None None O
of None None O
BAG None None O
- None None O
1 None None O
and None None O
its None None O
regulation None None O
of None None O
vitamin None None O
D None None O
receptor None None O
- None None O
mediated None None O
transactivation None None O
and None None O
involucrin None None O
expression None None O
in None None O
oral None None O
keratinocytes None None O
: None None O
implications None None O
for None None O
oral None None O
carcinogenesis None None O
. None None O

In None None O
oral None None O
cancers None None O
, None None O
cytoplasmic None None O
BAG None None O
- None None O
1 None None O
overexpression None None O
is None None O
a None None O
marker None None O
of None None O
poor None None O
prognosis None None O
. None None O

BAG None None O
- None None O
1 None None O
regulates None None O
cellular None None O
growth None None O
, None None O
differentiation None None O
and None None O
survival None None O
through None None O
interactions None None O
with None None O
diverse None None O
proteins None None O
, None None O
including None None O
the None None O
vitamin None None O
D None None O
receptor None None O
( None None O
VDR None None O
) None None O
, None None O
a None None O
key None None O
regulator None None O
of None None O
keratinocyte None None O
growth None None O
and None None O
differentiation None None O
. None None O

BAG None None O
- None None O
1 None None O
is None None O
expressed None None O
ubiquitously None None O
in None None O
human None None O
cells None None O
as None None O
three None None O
major None None O
isoforms None None O
of None None O
50 None None O
kDa None None O
( None None O
BAG None None O
- None None O
1L None None O
) None None O
, None None O
46 None None O
kDa None None O
( None None O
BAG None None O
- None None O
1M None None O
) None None O
and None None O
36 None None O
kDa None None O
( None None O
BAG None None O
- None None O
1S None None O
) None None O
from None None O
a None None O
single None None O
mRNA None None O
. None None O

In None None O
oral None None O
keratinocytes None None O
BAG None None O
- None None O
1L None None O
, None None O
but None None O
not None None O
BAG None None O
- None None O
1M None None O
and None None O
BAG None None O
- None None O
1S None None O
, None None O
enhanced None None O
VDR None None O
transactivation None None O
in None None O
response None None O
to None None O
1alpha None None O
, None None O
25 None None O
- None None O
dihydroxyvitamin None None O
D3 None None O
. None None O

BAG None None O
- None None O
1L None None O
was None None O
nucleoplasmic None None O
and None None O
nucleolar None None O
, None None O
whereas None None O
BAG None None O
- None None O
1S None None O
and None None O
BAG None None O
- None None O
1M None None O
were None None O
cytoplasmic None None O
and None None O
nucleoplasmic None None O
in None None O
localisation None None O
. None None O

Having None None O
identified None None O
the None None O
nucleolar None None O
localisation None None O
sequence None None O
in None None O
BAG None None O
- None None O
1L None None O
, None None O
we None None O
showed None None O
that None None O
mutation None None O
of None None O
this None None O
sequence None None O
did None None O
not None None O
prevent None None O
BAG None None O
- None None O
1L None None O
from None None O
potentiating None None O
VDR None None O
activity None None O
. None None O

BAG None None O
- None None O
1L None None O
also None None O
potentiated None None O
transactivation None None O
of None None O
known None None O
vitamin None None O
- None None O
D None None O
- None None O
responsive None None O
gene None None O
promoters None None O
, None None O
osteocalcin None None O
and None None O
24 None None O
- None None O
hydroxylase None None O
, None None O
and None None O
enhanced None None O
VDR None None O
- None None O
dependent None None O
transcription None None O
and None None O
protein None None O
expression None None O
of None None O
the None None O
keratinocyte None None O
differentiation None None O
marker None None O
, None None O
involucrin None None O
. None None O

These None None O
results None None O
demonstrate None None O
endogenous None None O
gene None None O
regulation None None O
by None None O
BAG None None O
- None None O
1L None None O
by None None O
potentiating None None O
nuclear None None O
hormone None None O
receptor None None O
function None None O
and None None O
suggest None None O
a None None O
role None None O
for None None O
BAG None None O
- None None O
1L None None O
in None None O
24 None None O
- None None O
hydroxylase None None O
regulation None None O
of None None O
vitamin None None O
D None None O
metabolism None None O
and None None O
the None None O
cellular None None O
response None None O
of None None O
oral None None O
keratinocytes None None O
to None None O
1alpha None None O
, None None O
25 None None O
- None None O
dihydroxyvitamin None None O
D3 None None O
. None None O

By None None O
contrast None None O
to None None O
the None None O
cytoplasmic None None O
BAG None None O
- None None O
1 None None O
isoforms None None O
, None None O
BAG None None O
- None None O
1L None None O
may None None O
act None None O
to None None O
suppress None None O
tumorigenesis None None O
. None None O

Retinal None None O
revascularisation None None O
in None None O
diabetic None None O
retinopathy None None O
. None None O

The None None O
case None None O
history None None O
of None None O
a None None O
33 None None O
- None None O
year None None O
- None None O
old None None O
diabetic None None O
patient None None O
who None None O
has None None O
had None None O
diabetes None None O
for None None O
24 None None O
years None None O
is None None O
presented None None O
. None None O

When None None O
first None None O
seen None None O
in None None O
1975 None None O
he None None O
had None None O
bilateral None None O
proliferative None None O
retinopathy None None O
with None None O
new None None O
vessels None None O
in None None O
the None None O
retinal None None O
periphery None None O
. None None O

He None None O
had None None O
large None None O
areas None None O
of None None O
capillary None None O
non None None O
- None None O
perfusion None None O
lateral None None O
to None None O
the None None O
macula None None O
in None None O
the None None O
right None None O
eye None None O
associated None None O
with None None O
the None None O
new None None O
vessels None None O
. None None O

Nine None None O
years None None O
later None None O
, None None O
after None None O
extensive None None O
repeated None None O
photocoagulation None None O
, None None O
revascularisation None None O
of None None O
large None None O
areas None None O
previously None None O
not None None O
perfused None None O
were None None O
seen None None O
. None None O

The None None O
vessels None None O
are None None O
in None None O
the None None O
plane None None O
of None None O
the None None O
retina None None O
and None None O
do None None O
not None None O
have None None O
the None None O
appearance None None O
of None None O
new None None O
vessels None None O
. None None O

The None None O
inhibition None None O
of None None O
cultured None None O
myoblast None None O
differentiation None None O
by None None O
the None None O
simian None None O
virus None None O
40 None None O
large None None O
T None None O
antigen None None O
occurs None None O
after None None O
myogenin None None O
expression None None O
and None None O
Rb None None O
up None None O
- None None O
regulation None None O
and None None O
is None None O
not None None O
exerted None None O
by None None O
transformation None None O
- None None O
competent None None O
cytoplasmic None None O
mutants None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
mechanism None None O
by None None O
which None None O
the None None O
simian None None O
virus None None O
40 None None O
large None None O
T None None O
antigen None None O
( None None O
SVLT None None O
) None None O
interferes None None O
with None None O
the None None O
differentiation None None O
of None None O
C2 None None I-Cell-line-name
myoblasts None None O
. None None O

SVLT None None O
mutants None None O
, None None O
defective None None O
either None None O
in None None O
the None None O
Rb None None O
binding None None O
site None None O
, None None O
near None None O
the None None O
N None None O
- None None O
terminal None None O
end None None O
, None None O
in None None O
a None None O
region None None O
that None None O
affects None None O
binding None None O
to None None O
p53 None None O
, None None O
or None None O
in None None O
the None None O
nuclear None None O
transport None None O
signal None None O
, None None O
were None None O
also None None O
employed None None O
to None None O
determine None None O
whether None None O
the None None O
interference None None O
was None None O
especially None None O
dependent None None O
on None None O
these None None O
functional None None O
domains None None O
. None None O

It None None O
was None None O
found None None O
that None None O
wild None None O
- None None O
type None None O
( None None O
wt None None O
) None None O
SVLT None None O
strongly None None O
inhibited None None O
the None None O
terminal None None O
differentiation None None O
of None None O
mouse None None O
C2 None None I-Cell-line-name
myoblasts None None O
, None None O
but None None O
this None None O
arrest None None O
occurred None None O
only None None O
after None None O
the None None O
synthesis None None O
of None None O
myogenin None None O
, None None O
an None None O
initial None None O
step None None O
in None None O
biochemical None None O
differentiation None None O
. None None O

Neither None None O
the None None O
synthesis None None O
nor None None O
some None None O
basic None None O
activities None None O
of None None O
MyoD None None O
appeared None None O
to None None O
be None None O
affected None None O
by None None O
wt None None O
SVLT None None O
. None None O

In None None O
these None None O
transformants None None O
, None None O
mitogen None None O
depletion None None O
elicited None None O
an None None O
increase None None O
in None None O
the None None O
Rb None None O
level None None O
comparable None None O
to None None O
that None None O
in None None O
normal None None O
C2 None None I-Cell-line-name
cells None None O
; None None O
wt None None O
SVLT None None O
, None None O
however None None O
, None None O
promoted None None O
the None None O
phosphorylation None None O
of None None O
a None None O
large None None O
part None None O
of None None O
the None None O
induced None None O
Rb None None O
. None None O

Mutations None None O
affecting None None O
nuclear None None O
transport None None O
were None None O
far None None O
more None None O
critical None None O
for None None O
the None None O
ability None None O
to None None O
interfere None None O
with None None O
myogenic None None O
differentiation None None O
than None None O
were None None O
those None None O
affecting None None O
the None None O
transforming None None O
potential None None O
; None None O
cytoplasmic None None O
SVLT None None O
expression None None O
was None None O
fully None None O
compatible None None O
with None None O
the None None O
terminal None None O
differentiation None None O
of None None O
C2 None None I-Cell-line-name
cells None None O
, None None O
despite None None O
enabling None None O
them None None O
to None None O
grow None None O
in None None O
semisolid None None O
medium None None O
, None None O
thus None None O
showing None None O
that None None O
the None None O
myogenesis None None O
- None None O
inhibiting None None O
property None None O
can None None O
be None None O
dissociated None None O
from None None O
transforming None None O
competence None None O
. None None O

The None None O
remaining None None O
SVLT None None O
mutants None None O
presented None None O
different None None O
degrees None None O
of None None O
ability None None O
to None None O
inhibit None None O
differentiation None None O
( None None O
as None None O
shown None None O
by None None O
the None None O
expression None None O
of None None O
tissue None None O
- None None O
specific None None O
markers None None O
in None None O
transformants None None O
) None None O
. None None O

The None None O
inhibiting None None O
mutants None None O
, None None O
including None None O
the None None O
Rb None None O
binding None None O
site None None O
mutant None None O
, None None O
were None None O
able None None O
to None None O
promote None None O
a None None O
higher None None O
state None None O
of None None O
Rb None None O
phosphorylation None None O
than None None O
that None None O
observed None None O
in None None O
either None None O
normal None None O
cells None None O
or None None O
cytoplasmic None None O
- None None O
SVLT None None O
transformants None None O
. None None O

Images None None O

Figure None None O
1 None None O

Figure None None O
5 None None O

Figure None None O
6 None None O

The None None O
EGFR None None O
- None None O
GEP100 None None O
- None None O
Arf6 None None O
- None None O
AMAP1 None None O
signaling None None O
pathway None None O
specific None None O
to None None O
breast None None O
cancer None None O
invasion None None O
and None None O
metastasis None None O
. None None O

Tumors None None O
are None None O
tissue None None O
- None None O
specific None None O
diseases None None O
, None None O
and None None O
their None None O
mechanisms None None O
of None None O
invasion None None O
and None None O
metastasis None None O
are None None O
highly None None O
diverse None None O
. None None O

In None None O
breast None None O
cancer None None O
, None None O
biomarkers None None O
that None None O
specifically None None O
correlate None None O
with None None O
the None None O
invasive None None O
phenotypes None None O
have None None O
not None None O
been None None O
clearly None None O
identified None None O
. None None O

A None None O
small None None O
GTPase None None O
Arf6 None None O
primarily None None O
regulates None None O
recycling None None O
of None None O
plasma None None O
membrane None None O
components None None O
. None None O

We None None O
have None None O
shown None None O
that None None O
Arf6 None None O
and None None O
its None None O
effector None None O
AMAP1 None None O
( None None O
DDEF1 None None O
, None None O
DEF1 None None O
, None None O
ASAP1 None None O
and None None O
centaurin None None O
beta4 None None O
) None None O
are None None O
abnormally None None O
overexpressed None None O
in None None O
some None None O
breast None None O
cancers None None O
and None None O
used None None O
for None None O
their None None O
invasion None None O
and None None O
metastasis None None O
. None None O

Overexpression None None O
of None None O
these None None O
proteins None None O
is None None O
independent None None O
of None None O
the None None O
transcriptional None None O
upregulation None None O
of None None O
their None None O
genes None None O
, None None O
and None None O
occurs None None O
only None None O
in None None O
highly None None O
malignant None None O
breast None None O
cancer None None O
cells None None O
. None None O

We None None O
recently None None O
identified None None O
GEP100 None None O
( None None O
BRAG2 None None O
) None None O
to None None O
be None None O
responsible None None O
for None None O
the None None O
Arf6 None None O
activation None None O
to None None O
induce None None O
invasion None None O
and None None O
metastasis None None O
, None None O
by None None O
directly None None O
binding None None O
to None None O
ligand None None O
- None None O
activated None None O
epidermal None None O
growth None None O
factor None None O
receptor None None O
( None None O
EGFR None None O
) None None O
. None None O

A None None O
series None None O
of None None O
our None None O
studies None None O
revealed None None O
that None None O
for None None O
activation None None O
of None None O
the None None O
invasion None None O
pathway None None O
of None None O
EGFR None None O
, None None O
it None None O
is None None O
prerequisite None None O
that None None O
Arf6 None None O
and None None O
AMAP1 None None O
both None None O
are None None O
highly None None O
overexpressed None None O
, None None O
and None None O
that None None O
EGFR None None O
is None None O
activated None None O
by None None O
ligands None None O
. None None O

Pathological None None O
analyses None None O
indicate None None O
that None None O
a None None O
significant None None O
large None None O
population None None O
of None None O
human None None O
ductal None None O
cancers None None O
may None None O
utilize None None O
the None None O
EGFR None None O
- None None O
GEP100 None None O
- None None O
Arf6 None None O
- None None O
AMAP1 None None O
pathway None None O
for None None O
their None None O
malignancy None None O
. None None O

Microenvironments None None O
have None None O
been None None O
highly None None O
implicated None None O
in None None O
the None None O
malignancy None None O
of None None O
mammary None None O
tumors None None O
. None None O

Our None None O
results None None O
reveal None None O
an None None O
aspect None None O
of None None O
the None None O
precise None None O
molecular None None O
mechanisms None None O
of None None O
some None None O
breast None None O
cancers None None O
, None None O
in None None O
which None None O
full None None O
invasiveness None None O
is None None O
not None None O
acquired None None O
just None None O
by None None O
intracellular None None O
alterations None None O
of None None O
cancer None None O
cells None None O
, None None O
but None None O
extracellular None None O
factors None None O
from None None O
microenvironments None None O
may None None O
also None None O
be None None O
necessary None None O
. None None O

Possible None None O
translation None None O
of None None O
our None None O
knowledge None None O
to None None O
cancer None None O
therapeutics None None O
will None None O
also None None O
be None None O
discussed None None O
. None None O

Desipramine None None O
inhibits None None O
the None None O
growth None None O
of None None O
a None None O
mouse None None O
skin None None O
squamous None None O
cell None None O
carcinoma None None O
cell None None O
line None None O
and None None O
affects None None O
glucocorticoid None None O
receptor None None O
- None None O
mediated None None O
transcription None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
examine None None O
the None None O
effect None None O
of None None O
tricyclic None None O
antidepressant None None O
desipramine None None O
( None None O
DMI None None O
) None None O
on None None O
the None None O
growth None None O
inhibition None None O
and None None O
translocation None None O
of None None O
the None None O
glucocorticoid None None O
receptor None None O
( None None O
GR None None O
) None None O
from None None O
the None None O
cytoplasm None None O
to None None O
the None None O
nucleus None None O
in None None O
cancerous None None O
and None None O
noncancerous None None O
cell None None O
lines None None O
and None None O
the None None O
effect None None O
of None None O
DMI None None O
on None None O
GR None None O
- None None O
mediated None None O
transcription None None O
. None None O

Nontumorigenic None None O
, None None O
immortalized None None O
keratinocytes None None O
cell None None O
line None None O
( None None O
3PC None None I-Cell-line-name
) None None O
, None None O
papilloma None None O
( None None O
MT1 None None I-Cell-line-name
/ None None I-Cell-line-name
2 None None I-Cell-line-name
) None None O
, None None O
and None None O
squamous None None O
cell None None O
carcinoma None None O
( None None O
Ca3 None None I-Cell-line-name
/ None None I-Cell-line-name
7 None None I-Cell-line-name
) None None O
cell None None O
lines None None O
were None None O
initially None None O
used None None O
to None None O
study None None O
the None None O
cell None None O
growth None None O
inhibition None None O
by None None O
DMI None None O
. None None O

Although None None O
, None None O
the None None O
growth None None O
of None None O
all None None O
three None None O
cell None None O
lines None None O
was None None O
suppressed None None O
by None None O
DMI None None O
, None None O
it None None O
was None None O
more None None O
effective None None O
in None None O
Ca3 None None I-Cell-line-name
/ None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
. None None O

Therefore None None O
, None None O
we None None O
next None None O
examined None None O
the None None O
effect None None O
of None None O
DMI None None O
on None None O
Ca3 None None I-Cell-line-name
/ None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
, None None O
resistant None None O
to None None O
growth None None O
inhibition None None O
by None None O
the None None O
synthetic None None O
glucocorticoid None None O
fluocinolone None None O
acetonide None None O
( None None O
FA None None O
) None None O
. None None O

DMI None None O
inhibited None None O
cell None None O
proliferation None None O
in None None O
a None None O
time None None O
- None None O
dependent None None O
manner None None O
. None None O

The None None O
translocation None None O
of None None O
GR None None O
was None None O
induced None None O
by None None O
FA None None O
alone None None O
, None None O
DMI None None O
alone None None O
, None None O
and None None O
combination None None O
of None None O
both None None O
agents None None O
. None None O

FA None None O
induced None None O
GR None None O
- None None O
mediated None None O
transcription None None O
in None None O
Ca3 None None I-Cell-line-name
/ None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
transfected None None O
with None None O
a None None O
luciferase None None O
reporter None None O
gene None None O
under None None O
the None None O
control None None O
of None None O
glucocorticoid None None O
response None None O
element None None O
( None None O
GRE None None O
) None None O
, None None O
but None None O
DMI None None O
alone None None O
did None None O
not None None O
affect None None O
GR None None O
- None None O
mediated None None O
transcription None None O
. None None O

However None None O
, None None O
DMI None None O
inhibited None None O
FA None None O
- None None O
induced None None O
, None None O
GR None None O
- None None O
mediated None None O
transcription None None O
when None None O
both None None O
agents None None O
were None None O
given None None O
together None None O
. None None O

Pretreatment None None O
with None None O
DMI None None O
followed None None O
by None None O
combination None None O
of None None O
DMI None None O
and None None O
FA None None O
decreased None None O
GR None None O
- None None O
mediated None None O
transcription None None O
more None None O
than None None O
pretreatment None None O
with None None O
FA None None O
. None None O

The None None O
expression None None O
of None None O
metallothionein None None O
- None None O
1 None None O
( None None O
Mt None None O
- None None O
1 None None O
) None None O
gene None None O
, None None O
which None None O
is None None O
regulated None None O
by None None O
GR None None O
, None None O
was None None O
induced None None O
significantly None None O
by None None O
the None None O
combination None None O
of None None O
DMI None None O
and None None O
FA None None O
, None None O
and None None O
enhanced None None O
significantly None None O
by None None O
pretreatment None None O
with None None O
FA None None O
but None None O
not None None O
DMI None None O
. None None O

DMI None None O
is None None O
suggested None None O
to None None O
inhibit None None O
the None None O
growth None None O
of None None O
Ca3 None None I-Cell-line-name
/ None None I-Cell-line-name
7 None None I-Cell-line-name
cells None None O
and None None O
to None None O
affect None None O
GR None None O
- None None O
mediated None None O
transcription None None O
. None None O

Expression None None O
and None None O
purification None None O
of None None O
the None None O
catalytic None None O
domain None None O
of None None O
human None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
for None None O
inhibitor None None O
screening None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
an None None O
endothelial None None O
cell None None O
- None None O
specific None None O
mitogen None None O
, None None O
can None None O
act None None O
in None None O
tumor None None O
- None None O
induced None None O
angiogenesis None None O
by None None O
binding None None O
to None None O
specific None None O
receptors None None O
on None None O
the None None O
surface None None O
of None None O
endothelial None None O
cells None None O
. None None O

One None None O
such None None O
receptor None None O
, None None O
VEGFR None None O
- None None O
2 None None O
/ None None O
KDR None None O
, None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
VEGF None None O
- None None O
induced None None O
angiogenesis None None O
. None None O

Here None None O
, None None O
we None None O
expressed None None O
the None None O
catalytic None None O
domain None None O
of None None O
VEGFR None None O
- None None O
2 None None O
as None None O
a None None O
soluble None None O
active None None O
kinase None None O
using None None O
Bac None None O
- None None O
to None None O
- None None O
Bac None None O
expression None None O
system None None O
, None None O
and None None O
investigated None None O
correlations None None O
between None None O
VEGFR None None O
- None None O
2 None None O
activity None None O
and None None O
enzyme None None O
concentration None None O
, None None O
ATP None None O
concentration None None O
, None None O
substrate None None O
concentration None None O
and None None O
divalent None None O
cation None None O
type None None O
. None None O

We None None O
used None None O
these None None O
data None None O
to None None O
establish None None O
a None None O
convenient None None O
, None None O
effective None None O
and None None O
non None None O
- None None O
radioactive None None O
ELISA None None O
screening None None O
technique None None O
for None None O
the None None O
identification None None O
and None None O
evaluation None None O
of None None O
potential None None O
inhibitors None None O
for None None O
VEGFR None None O
- None None O
2 None None O
kinase None None O
. None None O

We None None O
screened None None O
200 None None O
RTK None None O
target None None O
- None None O
based None None O
compounds None None O
and None None O
identified None None O
one None None O
( None None O
TKI None None O
- None None O
31 None None O
) None None O
that None None O
potently None None O
inhibited None None O
VEGFR None None O
- None None O
2 None None O
kinase None None O
activity None None O
( None None O
IC50 None None O
= None None O
0 None None O
. None None O
596 None None O
microM None None O
) None None O
. None None O

Treatment None None O
of None None O
NIH3T3 None None I-Cell-line-name
/ None None O
KDR None None O
cells None None O
with None None O
TKI None None O
- None None O
31 None None O
blocked None None O
VEGF None None O
- None None O
induced None None O
phosphorylation None None O
of None None O
KDR None None O
in None None O
a None None O
dose None None O
- None None O
dependent None None O
manner None None O
. None None O

Moreover None None O
, None None O
TKI None None O
- None None O
31 None None O
dose None None O
- None None O
dependently None None O
suppressed None None O
HUVEC None None O
tube None None O
formation None None O
. None None O

Thus None None O
, None None O
we None None O
herein None None O
report None None O
a None None O
novel None None O
, None None O
efficient None None O
method None None O
for None None O
identifying None None O
VEGFR None None O
- None None O
2 None None O
kinase None None O
inhibitors None None O
and None None O
introduce None None O
one None None O
, None None O
TKI None None O
- None None O
31 None None O
, None None O
that None None O
may None None O
prove None None O
to None None O
be None None O
a None None O
useful None None O
new None None O
angiogenesis None None O
inhibitor None None O
. None None O

Sensitivity None None O
variation None None O
in None None O
two None None O
- None None O
center None None O
holographic None None O
recording None None O
. None None O

An None None O
experimental None None O
study None None O
of None None O
variation None None O
of None None O
sensitivity None None O
with None None O
recording None None O
and None None O
sensitizing None None O
intensities None None O
in None None O
two None None O
- None None O
center None None O
recording None None O
is None None O
presented None None O
. None None O

The None None O
experimental None None O
results None None O
are None None O
in None None O
good None None O
agreement None None O
with None None O
the None None O
theoretical None None O
predictions None None O
. None None O

It None None O
is None None O
shown None None O
experimentally None None O
, None None O
for None None O
what None None O
is None None O
to None None O
our None None O
knowledge None None O
the None None O
first None None O
time None None O
, None None O
that None None O
the None None O
sensitivity None None O
is None None O
a None None O
function None None O
of None None O
the None None O
ratio None None O
of None None O
recording None None O
to None None O
sensitizing None None O
intensities None None O
and None None O
not None None O
the None None O
absolute None None O
intensities None None O
. None None O

Also None None O
, None None O
the None None O
ratio None None O
of None None O
recording None None O
to None None O
sensitizing None None O
intensities None None O
should None None O
be None None O
small None None O
to None None O
obtain None None O
high None None O
sensitivity None None O
values None None O
. None None O

We None None O
also None None O
report None None O
the None None O
highest None None O
sensitivity None None O
( None None O
S None None O
= None None O
0 None None O
. None None O
15 None None O
cm None None O
/ None None O
J None None O
) None None O
that None None O
has None None O
been None None O
achieved None None O
to None None O
date None None O
for None None O
a None None O
LiNbO3 None None O
: None None O
Fe None None O
: None None O
Mn None None O
crystal None None O
. None None O

A None None O
novel None None O
putative None None O
tyrosine None None O
kinase None None O
receptor None None O
with None None O
oncogenic None None O
potential None None O
. None None O

We None None O
have None None O
detected None None O
transforming None None O
activity None None O
by None None O
a None None O
tumorigenicity None None O
assay None None O
using None None O
NIH3T3 None None I-Cell-line-name
cells None None O
transfected None None O
with None None O
DNA None None O
from None None O
a None None O
chronic None None O
myeloproliferative None None O
disorder None None O
patient None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
cDNA None None O
cloning None None O
of None None O
the None None O
corresponding None None O
oncogene None None O
, None None O
designated None None O
UFO None None O
, None None O
in None None O
allusion None None O
to None None O
the None None O
as None None O
yet None None O
unidentified None None O
function None None O
of None None O
its None None O
protein None None O
. None None O

Nucleotide None None O
sequence None None O
analysis None None O
of None None O
a None None O
3116bp None None O
cDNA None None O
clone None None O
revealed None None O
a None None O
2682 None None O
- None None O
bp None None O
- None None O
long None None O
open None None O
reading None None O
frame None None O
capable None None O
of None None O
directing None None O
the None None O
synthesis None None O
of None None O
a None None O
894 None None O
amino None None O
acid None None O
polypeptide None None O
. None None O

The None None O
predicted None None O
UFO None None O
protein None None O
exhibits None None O
characteristic None None O
features None None O
of None None O
a None None O
transmembrane None None O
receptor None None O
with None None O
associated None None O
tyrosine None None O
kinase None None O
activity None None O
. None None O

The None None O
UFO None None O
proto None None O
- None None O
oncogene None None O
maps None None O
to None None O
human None None O
chromosome None None O
19q13 None None O
. None None O
1 None None O
and None None O
is None None O
transcribed None None O
into None None O
two None None O
5 None None O
. None None O
0 None None O
kb None None O
and None None O
3 None None O
. None None O
2 None None O
kb None None O
mRNAs None None O
in None None O
human None None O
bone None None O
marrow None None O
and None None O
human None None O
tumor None None O
cell None None O
lines None None O
. None None O

The None None O
UFO None None O
locus None None O
is None None O
evolutionarily None None O
conserved None None O
between None None O
vertebrate None None O
species None None O
. None None O

A None None O
4 None None O
. None None O
0 None None O
kb None None O
mRNA None None O
of None None O
the None None O
murine None None O
UFO None None O
homolog None None O
is None None O
expressed None None O
in None None O
a None None O
variety None None O
of None None O
different None None O
mouse None None O
tissues None None O
. None None O

We None None O
thus None None O
have None None O
identified None None O
a None None O
novel None None O
element None None O
of None None O
the None None O
complex None None O
signaling None None O
network None None O
involved None None O
in None None O
the None None O
control None None O
of None None O
cell None None O
proliferation None None O
and None None O
differentiation None None O
. None None O

Risk None None O
of None None O
myelodysplastic None None O
syndrome None None O
and None None O
acute None None O
myeloid None None O
leukemia None None O
in None None O
congenital None None O
neutropenias None None O
. None None O

Granulocyte None None O
colony None None O
- None None O
stimulating None None O
factor None None O
( None None O
G None None O
- None None O
CSF None None O
) None None O
has None None O
had None None O
a None None O
major None None O
impact None None O
on None None O
the None None O
management None None O
of None None O
" None None O
severe None None O
chronic None None O
neutropenia None None O
" None None O
( None None O
SCN None None O
) None None O
, None None O
a None None O
collective None None O
term None None O
referring None None O
to None None O
congenital None None O
, None None O
idiopathic None None O
, None None O
or None None O
cyclic None None O
neutropenia None None O
. None None O

Almost None None O
all None None O
patients None None O
respond None None O
to None None O
G None None O
- None None O
CSF None None O
with None None O
increased None None O
neutrophils None None O
, None None O
reduced None None O
infections None None O
, None None O
and None None O
improved None None O
survival None None O
. None None O

Some None None O
responders None None O
with None None O
congenital None None O
neutropenia None None O
and None None O
Shwachman None None O
- None None O
Diamond None None O
syndrome None None O
( None None O
SDS None None O
) None None O
have None None O
developed None None O
myelodysplastic None None O
syndrome None None O
and None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
MDS None None O
/ None None O
AML None None O
) None None O
, None None O
which None None O
raises None None O
the None None O
question None None O
of None None O
the None None O
role None None O
of None None O
G None None O
- None None O
CSF None None O
in None None O
pathogenesis None None O
. None None O

The None None O
issue None None O
is None None O
complicated None None O
because None None O
both None None O
disorders None None O
have None None O
a None None O
propensity None None O
for None None O
MDS None None O
or None None O
AML None None O
as None None O
part None None O
of None None O
their None None O
natural None None O
history None None O
. None None O

To None None O
address None None O
this None None O
, None None O
the None None O
Severe None None O
Chronic None None O
Neutropenia None None O
International None None O
Registry None None O
( None None O
SCNIR None None O
) None None O
used None None O
its None None O
large None None O
database None None O
of None None O
chronic None None O
neutropenia None None O
patients None None O
treated None None O
with None None O
G None None O
- None None O
CSF None None O
to None None O
determine None None O
the None None O
incidence None None O
of None None O
malignant None None O
myeloid None None O
transformation None None O
in None None O
the None None O
two None None O
disorders None None O
, None None O
and None None O
its None None O
relationship None None O
to None None O
treatment None None O
and None None O
to None None O
other None None O
patient None None O
characteristics None None O
. None None O

No None None O
statistically None None O
significant None None O
relationships None None O
were None None O
found None None O
between None None O
age None None O
at None None O
onset None None O
of None None O
MDS None None O
or None None O
AML None None O
and None None O
patient None None O
gender None None O
, None None O
G None None O
- None None O
CSF None None O
dose None None O
, None None O
or None None O
duration None None O
of None None O
G None None O
- None None O
CSF None None O
therapy None None O
. None None O

What None None O
was None None O
observed None None O
, None None O
however None None O
, None None O
was None None O
the None None O
multistep None None O
acquisition None None O
of None None O
aberrant None None O
cellular None None O
genetic None None O
changes None None O
in None None O
marrow None None O
cells None None O
from None None O
patients None None O
who None None O
transformed None None O
, None None O
including None None O
activating None None O
ras None None O
oncogene None None O
mutations None None O
, None None O
clonal None None O
cytogenetic None None O
abnormalities None None O
, None None O
and None None O
G None None O
- None None O
CSF None None O
receptor None None O
mutations None None O
. None None O

In None None O
murine None None O
models None None O
, None None O
the None None O
latter None None O
produces None None O
a None None O
hyperproliferative None None O
response None None O
to None None O
G None None O
- None None O
CSF None None O
, None None O
confers None None O
resistance None None O
to None None O
apoptosis None None O
, None None O
and None None O
enhances None None O
cell None None O
survival None None O
. None None O

Since None None O
congenital None None O
neutropenia None None O
and None None O
SDS None None O
are None None O
inherited None None O
forms None None O
of None None O
bone None None O
marrow None None O
failure None None O
, None None O
G None None O
- None None O
CSF None None O
may None None O
accelerate None None O
the None None O
propensity None None O
for None None O
MDS None None O
/ None None O
AML None None O
in None None O
the None None O
genetically None None O
altered None None O
stem None None O
and None None O
progenitor None None O
cells None None O
, None None O
especially None None O
in None None O
those None None O
with None None O
G None None O
- None None O
CSF None None O
receptor None None O
and None None O
ras None None O
mutations None None O
( None None O
82 None None O
% None None O
and None None O
50 None None O
% None None O
of None None O
patients None None O
who None None O
transform None None O
, None None O
respectively None None O
) None None O
. None None O

Alternatively None None O
, None None O
and None None O
equally None None O
plausible None None O
, None None O
G None None O
- None None O
CSF None None O
may None None O
simply None None O
be None None O
an None None O
" None None O
innocent None None O
bystander None None O
" None None O
that None None O
corrects None None O
neutropenia None None O
, None None O
prolongs None None O
patient None None O
survival None None O
, None None O
and None None O
allows None None O
time None None O
for None None O
the None None O
malignant None None O
predisposition None None O
to None None O
declare None None O
itself None None O
. None None O

In None None O
patients None None O
who None None O
transform None None O
to None None O
overt None None O
MDS None None O
or None None O
AML None None O
, None None O
hematopoietic None None O
stem None None O
cell None None O
transplantation None None O
is None None O
the None None O
only None None O
chance None None O
for None None O
cure None None O
. None None O

In None None O
those None None O
with None None O
" None None O
soft None None O
" None None O
signs None None O
of None None O
MDS None None O
, None None O
such None None O
as None None O
an None None O
isolated None None O
clonal None None O
cytogenetic None None O
change None None O
but None None O
without None None O
other None None O
evidence None None O
of None None O
MDS None None O
, None None O
or None None O
with None None O
an None None O
isolated None None O
G None None O
- None None O
CSF None None O
receptor None None O
mutation None None O
, None None O
there None None O
is None None O
room None None O
for None None O
conservative None None O
management None None O
. None None O

One None None O
option None None O
is None None O
to None None O
reduce None None O
the None None O
G None None O
- None None O
CSF None None O
dosage None None O
as None None O
much None None O
as None None O
possible None None O
, None None O
and None None O
observe None None O
the None None O
tempo None None O
of None None O
progression None None O
, None None O
if None None O
any None None O
, None None O
to None None O
more None None O
overt None None O
signs None None O
of None None O
malignancy None None O
. None None O

Modulation None None O
of None None O
apoptosis None None O
in None None O
human None None O
myeloid None None O
leukemic None None O
cells None None O
by None None O
GM None None O
- None None O
CSF None None O
. None None O

Apoptosis None None O
( None None O
programmed None None O
cell None None O
death None None O
) None None O
regulates None None O
cell None None O
population None None O
size None None O
. None None O

To None None O
determine None None O
the None None O
mechanisms None None O
whereby None None O
hematopoietic None None O
growth None None O
factors None None O
( None None O
HGFs None None O
) None None O
modulate None None O
apoptosis None None O
in None None O
human None None O
myeloid None None O
leukemic None None O
cells None None O
, None None O
we None None O
evaluated None None O
the None None O
roles None None O
of None None O
protein None None O
and None None O
mRNA None None O
synthesis None None O
for None None O
altering None None O
apoptosis None None O
in None None O
growth None None O
factor None None O
- None None O
stimulated None None O
vs None None O
. None None O
quiescent None None O
leukemic None None O
TF1 None None I-Cell-line-name
cells None None O
. None None O

Lysates None None O
of None None O
cells None None O
from None None O
the None None O
granulocyte None None O
- None None O
macrophage None None O
colony None None O
- None None O
stimulating None None O
factor None None O
( None None O
GM None None O
- None None O
CSF None None O
) None None O
- None None O
dependent None None O
myeloid None None O
leukemic None None O
cell None None O
line None None O
TF1 None None I-Cell-line-name
were None None O
separated None None O
into None None O
high None None O
molecular None None O
weight None None O
( None None O
HMW None None O
) None None O
pellets None None O
of None None O
intact None None O
DNA None None O
and None None O
supernatants None None O
of None None O
fragmented None None O
low None None O
MW None None O
( None None O
LMW None None O
) None None O
DNA None None O
, None None O
and None None O
the None None O
DNA None None O
purified None None O
from None None O
these None None O
fractions None None O
was None None O
quantified None None O
. None None O

In None None O
the None None O
absence None None O
of None None O
both None None O
GM None None O
- None None O
CSF None None O
and None None O
fetal None None O
bovine None None O
serum None None O
( None None O
FBS None None O
) None None O
, None None O
70 None None O
% None None O
of None None O
the None None O
DNA None None O
was None None O
fragmented None None O
after None None O
3 None None O
days None None O
in None None O
culture None None O
, None None O
with None None O
a None None O
characteristic None None O
apoptotic None None O
ladder None None O
- None None O
like None None O
pattern None None O
on None None O
agarose None None O
gel None None O
electrophoresis None None O
, None None O
whereas None None O
this None None O
proportion None None O
had None None O
initially None None O
been None None O
< None None O
5 None None O
% None None O
. None None O

In None None O
contrast None None O
, None None O
less None None O
than None None O
5 None None O
% None None O
of None None O
the None None O
DNA None None O
was None None O
fragmented None None O
in None None O
cells None None O
incubated None None O
with None None O
GM None None O
- None None O
CSF None None O
plus None None O
FBS None None O
or None None O
GM None None O
- None None O
CSF None None O
alone None None O
. None None O

Delayed None None O
addition None None O
of None None O
GM None None O
- None None O
CSF None None O
, None None O
but None None O
not None None O
FBS None None O
, None None O
permitted None None O
partial None None O
rescue None None O
of None None O
the None None O
cells None None O
, None None O
inhibiting None None O
increasing None None O
rates None None O
of None None O
accumulation None None O
of None None O
fragmented None None O
DNA None None O
. None None O

When None None O
the None None O
macro None None O
- None None O
molecular None None O
synthesis None None O
inhibitor None None O
cycloheximide None None O
( None None O
CHX None None O
) None None O
or None None O
actinomycin None None O
D None None O
( None None O
Act None None O
D None None O
) None None O
was None None O
present None None O
for None None O
26 None None O
hours None None O
in None None O
the None None O
absence None None O
of None None O
GM None None O
- None None O
CSF None None O
and None None O
FBS None None O
, None None O
apoptosis None None O
was None None O
inhibited None None O
. None None O

In None None O
contrast None None O
, None None O
in None None O
the None None O
presence None None O
of None None O
GM None None O
- None None O
CSF None None O
or None None O
FBS None None O
, None None O
apoptosis None None O
was None None O
enhanced None None O
upon None None O
addition None None O
of None None O
CHX None None O
or None None O
Act None None O
D None None O
. None None O

The None None O
latter None None O
effect None None O
persisted None None O
even None None O
with None None O
the None None O
late None None O
addition None None O
of None None O
CHX None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
disparate None None O
mechanisms None None O
of None None O
enhancing None None O
or None None O
inhibiting None None O
apoptosis None None O
exist None None O
in None None O
myeloid None None O
leukemic None None O
cells None None O
related None None O
to None None O
environmental None None O
conditions None None O
, None None O
including None None O
HGF None None O
- None None O
regulated None None O
cellular None None O
synthesis None None O
of None None O
distinct None None O
proteins None None O
and None None O
mRNA None None O
. None None O

Ovariectomy None None O

Based None None O
on None None O
the None None O
uterine None None O
weight None None O
, None None O
we None None O
determined None None O
seven None None O
unsuccessful None None O
OVXs None None O
. None None O

The None None O
rats None None O
concerned None None O
were None None O
removed None None O
from None None O
further None None O
analyses None None O
, None None O
which None None O
left None None O
nine None None O
rats None None O
in None None O
the None None O
control None None O
group None None O
, None None O
five None None O
in None None O
the None None O
OVX None None O
group None None O
, None None O
seven None None O
in None None O
the None None O
OVX None None O
and None None O
late None None O
ZOL None None O
group None None O
, None None O
and None None O
eight None None O
in None None O
the None None O
OVX None None O
and None None O
early None None O
ZOL None None O
group None None O
. None None O

For None None O
each None None O
animal None None O
, None None O
we None None O
determined None None O
the None None O
percentage None None O
change None None O
in None None O
structural None None O
parameters None None O
compared None None O
to None None O
the None None O
values None None O
at None None O
week None None O
0 None None O
. None None O

Figure None None O
1 None None O
shows None None O
the None None O
average None None O
percentage None None O
change None None O
and None None O
upper None None O
standard None None O
deviation None None O
for None None O
all None None O
groups None None O
for None None O
BV None None O
/ None None O
TV None None O
, None None O
Conn None None O
. None None O
D None None O
, None None O
SMI None None O
, None None O
Tb None None O
. None None O
N None None O
, None None O
Tb None None O
. None None O
Th None None O
, None None O
and None None O
Tb None None O
. None None O
Sp None None O
. None None O

The None None O
OVX None None O
group None None O
without None None O
treatment None None O
showed None None O
large None None O
changes None None O
in None None O
structural None None O
parameters None None O
, None None O
indicating None None O
the None None O
development None None O
of None None O
OVX None None O
- None None O
induced None None O
bone None None O
loss None None O
( None None O
Figs None None O
. None None O
1 None None O
and None None O
2 None None O
) None None O
. None None O

Paired None None O
Student None None O
' None None O
s None None O
t None None O
- None None O
test None None O
indicated None None O
significant None None O
changes None None O
within None None O
2 None None O
weeks None None O
after None None O
OVX None None O
for None None O
all None None O
structural None None O
parameters None None O
. None None O

BV None None O
/ None None O
TV None None O
, None None O
Conn None None O
. None None O
D None None O
, None None O
and None None O
Tb None None O
. None None O
N None None O
decreased None None O
during None None O
the None None O
experiment None None O
and None None O
SMI None None O
and None None O
Tb None None O
. None None O
Sp None None O
increased None None O
. None None O

Both None None O
Tb None None O
. None None O
Th None None O
and None None O
Tb None None O
. None None O
N None None O
decreased None None O
within None None O
2 None None O
weeks None None O
, None None O
indicating None None O
that None None O
both None None O
thinning None None O
and None None O
complete None None O
resorption None None O
of None None O
trabeculae None None O
started None None O
directly None None O
after None None O
OVX None None O
. None None O

The None None O
initial None None O
rapid None None O
loss None None O
of None None O
bone None None O
and None None O
connectivity None None O
was None None O
largely None None O
accompanied None None O
by None None O
trabecular None None O
thinning None None O
, None None O
while None None O
secondary None None O
, None None O
slower None None O
loss None None O
of None None O
bone None None O
was None None O
concomitant None None O
with None None O
a None None O
decrease None None O
in None None O
Tb None None O
. None None O
N None None O
. None None O

While None None O
BV None None O
/ None None O
TV None None O
, None None O
Conn None None O
. None None O
D None None O
, None None O
SMI None None O
, None None O
Tb None None O
. None None O
N None None O
, None None O
and None None O
Tb None None O
. None None O
Sp None None O
showed None None O
continuous None None O
changes None None O
in None None O
the None None O
same None None O
direction None None O
throughout None None O
the None None O
experiment None None O
, None None O
Tb None None O
. None None O
Th None None O
initially None None O
decreased None None O
significantly None None O
until None None O
4 None None O
weeks None None O
after None None O
OVX None None O
and None None O
then None None O
increased None None O
again None None O
until None None O
after None None O
16 None None O
weeks None None O
Tb None None O
. None None O
Th None None O
was None None O
significantly None None O
higher None None O
than None None O
in None None O
the None None O
control None None O
group None None O
. None None O

Fig None None O
. None None O

1 None None O

Average None None O
percentage None None O
change None None O
in None None O
structural None None O
parameters None None O
in None None O
the None None O
metaphyseal None None O
proximal None None O
tibia None None O
and None None O
upper None None O
standard None None O
deviation None None O
for None None O
all None None O
groups None None O
at None None O
all None None O
time None None O
points None None O
. None None O

Brackets None None O
indicate None None O
P None None O
< None None O
0 None None O
. None None O
05 None None O
at None None O
week None None O
16 None None O

Fig None None O
. None None O

2 None None O

Same None None O
slice None None O
of None None O
an None None O
unprocessed None None O
CT None None O
scan None None O
of None None O
the None None O
same None None O
rat None None O
in None None O
the None None O
OVX None None O
group None None O
taken None None O
at None None O
weeks None None O
0 None None O
( None None O
a None None O
) None None O
, None None O
2 None None O
( None None O
b None None O
) None None O
, None None O
4 None None O
( None None O
c None None O
) None None O
, None None O
8 None None O
( None None O
d None None O
) None None O
, None None O
12 None None O
( None None O
e None None O
) None None O
, None None O
and None None O
16 None None O
( None None O
f None None O
) None None O
. None None O

Images None None O
show None None O
typical None None O
trabecular None None O
bone None None O
loss None None O
due None None O
to None None O
OVX None None O
in None None O
the None None O
metaphysis None None O
. None None O

Green None None O
line None None O
shows None None O
the None None O
analyzed None None O
metaphyseal None None O
bone None None O

The None None O
absolute None None O
average None None O
values None None O
and None None O
standard None None O
deviations None None O
for None None O
all None None O
structural None None O
parameters None None O
of None None O
all None None O
measurements None None O
are None None O
shown None None O
in None None O
Table None None O
1 None None O
. None None O

At None None O
the None None O
starting None None O
point None None O
, None None O
some None None O
differences None None O
in None None O
the None None O
values None None O
between None None O
the None None O
groups None None O
were None None O
present None None O
. None None O

This None None O
was None None O
due None None O
to None None O
the None None O
fact None None O
that None None O
some None None O
animals None None O
, None None O
which None None O
mostly None None O
had None None O
a None None O
relatively None None O
low None None O
BV None None O
/ None None O
TV None None O
, None None O
were None None O
removed None None O
from None None O
the None None O
study None None O
because None None O
they None None O
did None None O
not None None O
respond None None O
to None None O
the None None O
OVX None None O
. None None O

However None None O
, None None O
since None None O
we None None O
compared None None O
the None None O
relative None None O
changes None None O
in None None O
each None None O
animal None None O
, None None O
the None None O
results None None O
were None None O
most None None O
likely None None O
not None None O
affected None None O
by None None O
the None None O
difference None None O
in None None O
absolute None None O
values None None O
. None None O

Table None None O
1 None None O

Mean None None O
values None None O
and None None O
standard None None O
deviation None None O
of None None O
all None None O
structural None None O
parameters None None O
of None None O
all None None O
groups None None O
at None None O
the None None O
start None None O
of None None O
the None None O
experiment None None O

Group None None O
BV None None O
/ None None O
TV None None O
( None None O
1 None None O
) None None O
Conn None None O
. None None O
D None None O
( None None O
1 None None O
/ None None O
mm None None O
) None None O
SMI None None O
( None None O
1 None None O
) None None O
Tb None None O
. None None O
N None None O
( None None O
1 None None O
/ None None O
mm None None O
) None None O
Tb None None O
. None None O
Th None None O
( None None O
mum None None O
) None None O
Tb None None O
. None None O
Sp None None O
( None None O
mum None None O
) None None O

Control None None O
0 None None O
. None None O
17 None None O
( None None O
0 None None O
. None None O
056 None None O
) None None O
41 None None O
( None None O
47 None None O
) None None O
1 None None O
. None None O
52 None None O
( None None O
0 None None O
. None None O
53 None None O
) None None O
1 None None O
. None None O
89 None None O
( None None O
1 None None O
. None None O
38 None None O
) None None O
105 None None O
( None None O
49 None None O
) None None O
613 None None O
( None None O
368 None None O
) None None O

OVX None None O
0 None None O
. None None O
26 None None O
( None None O
0 None None O
. None None O
055 None None O
) None None O
141 None None O
( None None O
76 None None O
) None None O
1 None None O
. None None O
22 None None O
( None None O
0 None None O
. None None O
39 None None O
) None None O
3 None None O
. None None O
77 None None O
( None None O
1 None None O
. None None O
66 None None O
) None None O
84 None None O
( None None O
10 None None O
) None None O
335 None None O
( None None O
174 None None O
) None None O

OVX None None O
+ None None O
late None None O
ZOL None None O
0 None None O
. None None O
23 None None O
( None None O
0 None None O
. None None O
062 None None O
) None None O
86 None None O
( None None O
66 None None O
) None None O
1 None None O
. None None O
23 None None O
( None None O
0 None None O
. None None O
34 None None O
) None None O
2 None None O
. None None O
77 None None O
( None None O
1 None None O
. None None O
55 None None O
) None None O
89 None None O
( None None O
13 None None O
) None None O
482 None None O
( None None O
227 None None O
) None None O

OVX None None O
+ None None O
early None None O
ZOL None None O
0 None None O
. None None O
17 None None O
( None None O
0 None None O
. None None O
056 None None O
) None None O
38 None None O
( None None O
21 None None O
) None None O
1 None None O
. None None O
70 None None O
( None None O
0 None None O
. None None O
39 None None O
) None None O
1 None None O
. None None O
86 None None O
( None None O
0 None None O
. None None O
80 None None O
) None None O
95 None None O
( None None O
7 None None O
) None None O
647 None None O
( None None O
207 None None O
) None None O

Radiation None None O
retinopathy None None O
is None None O
treatable None None O
with None None O
anti None None O
- None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
bevacizumab None None O
( None None O
Avastin None None O
) None None O
. None None O

PURPOSE None None O
: None None O
To None None O
report None None O
on None None O
bevacizumab None None O
treatment None None O
for None None O
radiation None None O
retinopathy None None O
affecting None None O
the None None O
macula None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
Twenty None None O
- None None O
one None None O
patients None None O
with None None O
radiation None None O
retinopathy None None O
( None None O
edema None None O
, None None O
hemorrhages None None O
, None None O
capillary None None O
dropout None None O
, None None O
and None None O
neovascularization None None O
) None None O
and None None O
a None None O
subjective None None O
or None None O
objective None None O
loss None None O
of None None O
vision None None O
were None None O
treated None None O
. None None O

Treatment None None O
involved None None O
intravitreal None None O
injection None None O
of None None O
bevacizumab None None O
( None None O
1 None None O
. None None O
25 None None O
mg None None O
in None None O
0 None None O
. None None O
05 None None O
mL None None O
) None None O
every None None O
6 None None O
- None None O
12 None None O
weeks None None O
. None None O

Treatment None None O
was None None O
discontinued None None O
at None None O
patient None None O
request None None O
or None None O
if None None O
there None None O
was None None O
no None None O
measurable None None O
response None None O
to None None O
therapy None None O
. None None O

Main None None O
outcome None None O
measures None None O
included None None O
best None None O
corrected None None O
visual None None O
acuity None None O
, None None O
ophthalmic None None O
examination None None O
, None None O
retinal None None O
photography None None O
, None None O
and None None O
angiography None None O
. None None O

RESULTS None None O
: None None O
Bevacizumab None None O
treatment None None O
was None None O
followed None None O
by None None O
reductions None None O
in None None O
retinal None None O
hemorrhage None None O
, None None O
exudation None None O
, None None O
and None None O
edema None None O
. None None O

Visual None None O
acuities None None O
were None None O
stable None None O
or None None O
improved None None O
in None None O
86 None None O
% None None O
( None None O
n None None O
= None None O
18 None None O
) None None O
. None None O

Three None None O
patients None None O
discontinued None None O
therapy None None O
. None None O

Each None None O
was None None O
legally None None O
blind None None O
before None None O
treatment None None O
( None None O
n None None O
= None None O
1 None None O
) None None O
, None None O
experienced None None O
little None None O
to None None O
no None None O
subjective None None O
improvement None None O
( None None O
n None None O
= None None O
2 None None O
) None None O
, None None O
or None None O
was None None O
poorly None None O
compliant None None O
( None None O
n None None O
= None None O
2 None None O
) None None O
. None None O

Three None None O
patients None None O
( None None O
14 None None O
% None None O
) None None O
regained None None O
2 None None O
or None None O
more None None O
lines None None O
of None None O
visual None None O
acuity None None O
. None None O

No None None O
ocular None None O
or None None O
systemic None None O
bevacizumab None None O
- None None O
related None None O
side None None O
effects None None O
were None None O
observed None None O
. None None O

CONCLUSIONS None None O
: None None O
Intravitreal None None O
bevacizumab None None O
can None None O
be None None O
used None None O
to None None O
treat None None O
radiation None None O
retinopathy None None O
. None None O

In None None O
most None None O
cases None None O
treatment None None O
was None None O
associated None None O
with None None O
decreased None None O
vascular None None O
leakage None None O
, None None O
stabilization None None O
, None None O
or None None O
improved None None O
vision None None O
. None None O

An None None O
anti None None O
- None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
strategy None None O
may None None O
reduce None None O
tissue None None O
damage None None O
associated None None O
with None None O
radiation None None O
vasculopathy None None O
and None None O
neuropathy None None O
. None None O

[ None None O
Role None None O
of None None O
the None None O
tumor None None O
suppressor None None O
ARF None None O
in None None O
oncogenesis None None O
] None None O

The None None O
paper None None O
reviews None None O
the None None O
data None None O
available None None O
in None None O
the None None O
literature None None O
on None None O
a None None O
role None None O
of None None O
the None None O
tumor None None O
suppressor None None O
ARF None None O
in None None O
oncogenesis None None O
and None None O
considers None None O
the None None O
structure None None O
of None None O
a None None O
gene None None O
encoding None None O
ARF None None O
protein None None O
. None None O

The None None O
p53 None None O
- None None O
dependent None None O
and None None O
p None None O
- None None O
53 None None O
- None None O
independent None None O
functions None None O
of None None O
this None None O
protein None None O
are None None O
under None None O
many None None O
studies None None O
. None None O

There None None O
is None None O
evidence None None O
for None None O
the None None O
implication None None O
of None None O
ARF None None O
in None None O
angiogenesis None None O
. None None O

There None None O
is None None O
more None None O
and None None O
more None None O
information None None O
on None None O
the None None O
role None None O
of None None O
ARF None None O
in None None O
the None None O
regulation None None O
of None None O
a None None O
cell None None O
cycle None None O
, None None O
apoptosis None None O
, None None O
and None None O
autophagy None None O
. None None O

The None None O
importance None None O
of None None O
this None None O
tumor None None O
suppressor None None O
in None None O
the None None O
mechanisms None None O
of None None O
carcinogenesis None None O
is None None O
beyond None None O
question None None O
as None None O
the None None O
inactivation None None O
of None None O
ARF None None O
suppressor None None O
activity None None O
leads None None O
to None None O
the None None O
rapid None None O
growth None None O
of None None O
neoplasia None None O
. None None O

However None None O
, None None O
the None None O
exact None None O
mechanisms None None O
of None None O
ARF None None O
action None None O
yet None None O
remain None None O
unclear None None O
and None None O
require None None O
further None None O
studies None None O
by None None O
different None None O
specialists None None O
at None None O
both None None O
the None None O
molecular None None O
genetic None None O
and None None O
other None None O
levels None None O
of None None O
investigation None None O
. None None O

MMTV None None O
- None None O
cre None None O
- None None O
mediated None None O
fur None None O
inactivation None None O
concomitant None None O
with None None O
PLAG1 None None O
proto None None O
- None None O
oncogene None None O
activation None None O
delays None None O
salivary None None O
gland None None O
tumorigenesis None None O
in None None O
mice None None O
. None None O

Proprotein None None O
convertases None None O
are None None O
serine None None O
endoproteases None None O
implicated None None O
in None None O
the None None O
proteolytic None None O
processing None None O
of None None O
a None None O
large None None O
variety None None O
of None None O
regulatory None None O
proteins None None O
. None None O

An None None O
important None None O
role None None O
of None None O
proprotein None None O
convertases None None O
in None None O
tumorigenic None None O
processes None None O
has None None O
been None None O
suggested None None O
by None None O
various None None O
studies None None O
. None None O

In None None O
this None None O
study None None O
, None None O
the None None O
role None None O
of None None O
the None None O
proprotein None None O
convertase None None O
furin None None O
in None None O
PLAG1 None None O
proto None None O
- None None O
oncogene None None O
- None None O
induced None None O
salivary None None O
gland None None O
tumorigenesis None None O
was None None O
investigated None None O
. None None O

PLAG1 None None O
overexpression None None O
in None None O
salivary None None O
glands None None O
has None None O
previously None None O
been None None O
shown None None O
to None None O
result None None O
in None None O
salivary None None O
gland None None O
tumors None None O
in None None O
100 None None O
% None None O
of None None O
mice None None O
within None None O
5 None None O
weeks None None O
after None None O
birth None None O
. None None O

MMTV None None O
- None None O
cre None None O
- None None O
mediated None None O
inactivation None None O
of None None O
fur None None O
without None None O
over None None O
- None None O
expression None None O
of None None O
PLAG1 None None O
caused None None O
smaller None None O
but None None O
histologically None None O
normal None None O
salivary None None O
glands None None O
. None None O

Moreover None None O
, None None O
the None None O
lymph None None O
nodes None None O
close None None O
to None None O
the None None O
salivary None None O
glands None None O
were None None O
enlarged None None O
, None None O
and None None O
histology None None O
showed None None O
that None None O
they None None O
had None None O
activated None None O
follicles None None O
. None None O

When None None O
genetic None None O
ablation None None O
of None None O
1 None None O
or None None O
2 None None O
alleles None None O
of None None O
fur None None O
and None None O
overexpression None None O
of None None O
the None None O
PLAG1 None None O
transgene None None O
were None None O
simultaneously None None O
achieved None None O
, None None O
a None None O
significant None None O
delay None None O
in None None O
tumorigenesis None None O
was None None O
observed None None O
. None None O

Collectively None None O
, None None O
these None None O
results None None O
suggest None None O
an None None O
important None None O
role None None O
for None None O
furin None None O
in None None O
PLAG1 None None O
- None None O
induced None None O
salivary None None O
gland None None O
tumorigenesis None None O
in None None O
mice None None O
. None None O

Enterococci None None O
at None None O
the None None O
crossroads None None O
of None None O
food None None O
safety None None O
? None None O

Enterococci None None O
are None None O
gram None None O
- None None O
positive None None O
bacteria None None O
and None None O
fit None None O
within None None O
the None None O
general None None O
definition None None O
of None None O
lactic None None O
acid None None O
bacteria None None O
. None None O

Modern None None O
classification None None O
techniques None None O
resulted None None O
in None None O
the None None O
transfer None None O
of None None O
some None None O
members None None O
of None None O
the None None O
genus None None O
Streptococcus None None O
, None None O
notably None None O
some None None O
of None None O
the None None O
Lancefield None None O
' None None O
s None None O
group None None O
D None None O
streptococci None None O
, None None O
to None None O
the None None O
new None None O
genus None None O
Enterococcus None None O
. None None O

Enterococci None None O
can None None O
be None None O
used None None O
as None None O
indicators None None O
of None None O
faecal None None O
contamination None None O
. None None O

They None None O
have None None O
been None None O
implicated None None O
in None None O
outbreaks None None O
of None None O
foodborne None None O
illness None None O
, None None O
and None None O
they None None O
have None None O
been None None O
ascribed None None O
a None None O
beneficial None None O
or None None O
detrimental None None O
role None None O
in None None O
foods None None O
. None None O

In None None O
processed None None O
meats None None O
, None None O
enterococci None None O
may None None O
survive None None O
heat None None O
processing None None O
and None None O
cause None None O
spoilage None None O
, None None O
though None None O
in None None O
certain None None O
cheeses None None O
the None None O
growth None None O
of None None O
enterococci None None O
contributes None None O
to None None O
ripening None None O
and None None O
development None None O
of None None O
product None None O
flavour None None O
. None None O

Some None None O
enterococci None None O
of None None O
food None None O
origin None None O
produce None None O
bacteriocins None None O
that None None O
exert None None O
anti None None O
- None None O
Listeria None None O
activity None None O
. None None O

Enterococci None None O
are None None O
used None None O
as None None O
probiotics None None O
to None None O
improve None None O
the None None O
microbial None None O
balance None None O
of None None O
the None None O
intestine None None O
, None None O
or None None O
as None None O
a None None O
treatment None None O
for None None O
gastroenteritis None None O
in None None O
humans None None O
and None None O
animals None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
enterococci None None O
have None None O
become None None O
recognised None None O
as None None O
serious None None O
nosocomial None None O
pathogens None None O
causing None None O
bacteraemia None None O
, None None O
endocarditis None None O
, None None O
urinary None None O
tract None None O
and None None O
other None None O
infections None None O
. None None O

This None None O
is None None O
in None None O
part None None O
explained None None O
by None None O
the None None O
resistance None None O
of None None O
some None None O
of None None O
these None None O
bacteria None None O
to None None O
most None None O
antibiotics None None O
that None None O
are None None O
currently None None O
in None None O
use None None O
. None None O

Resistance None None O
is None None O
acquired None None O
by None None O
gene None None O
transfer None None O
systems None None O
, None None O
such None None O
as None None O
conjugative None None O
or None None O
nonconjugative None None O
plasmids None None O
or None None O
transposons None None O
. None None O

Virulence None None O
of None None O
enterococci None None O
is None None O
not None None O
well None None O
understood None None O
but None None O
adhesins None None O
, None None O
haemolysin None None O
, None None O
hyaluronidase None None O
, None None O
aggregation None None O
substance None None O
and None None O
gelatinase None None O
are None None O
putative None None O
virulence None None O
factors None None O
. None None O

It None None O
appears None None O
that None None O
foods None None O
could None None O
be None None O
a None None O
source None None O
of None None O
vancomycin None None O
- None None O
resistant None None O
enterococci None None O
. None None O

This None None O
review None None O
addresses None None O
the None None O
issue None None O
of None None O
the None None O
health None None O
risk None None O
of None None O
foods None None O
containing None None O
enterococci None None O
. None None O

Crystal None None O
data None None O

C24H21ClN4O2S None None O

M None None O
r None None O
= None None O
464 None None O
. None None O
96 None None O

Triclinic None None O
, None None O

a None None O
= None None O
8 None None O
. None None O
6798 None None O
( None None O
18 None None O
) None None O
A None None O

b None None O
= None None O
11 None None O
. None None O
078 None None O
( None None O
2 None None O
) None None O
A None None O

c None None O
= None None O
11 None None O
. None None O
372 None None O
( None None O
2 None None O
) None None O
A None None O

alpha None None O
= None None O
78 None None O
. None None O
984 None None O
( None None O
7 None None O
) None None O
degrees None None O

beta None None O
= None None O
81 None None O
. None None O
867 None None O
( None None O
10 None None O
) None None O
degrees None None O

gamma None None O
= None None O
81 None None O
. None None O
718 None None O
( None None O
11 None None O
) None None O
degrees None None O

V None None O
= None None O
1054 None None O
. None None O
8 None None O
( None None O
4 None None O
) None None O
A3 None None O

Z None None O
= None None O
2 None None O

Cu None None O
Kalpha None None O
radiation None None O

mu None None O
= None None O
2 None None O
. None None O
78 None None O
mm None None O
- None None O
1 None None O

T None None O
= None None O
113 None None O
K None None O

0 None None O
. None None O
28 None None O
x None None O
0 None None O
. None None O
24 None None O
x None None O
0 None None O
. None None O
20 None None O
mm None None O

Reagents None None O
and None None O
antibodies None None O

Maxisorp None None O
strips None None O
( None None O
NunC None None O
, None None O
Roskilde None None O
, None None O
Denmark None None O
) None None O
, None None O
GST None None O
- None None O
PNMA2 None None O
recombinant None None O
protein None None O
( None None O
Abnova None None O
, None None O
Taipei None None O
, None None O
Taiwan None None O
) None None O
; None None O
3 None None O
, None None O
3 None None O
' None None O
, None None O
5 None None O
, None None O
5 None None O
- None None O
tetramethylbenzidine None None O
( None None O
TMB None None O
) None None O
+ None None O
substrate None None O
( None None O
Dako None None O
, None None O
Glostrup None None O
, None None O
Denmark None None O
) None None O
, None None O
Peroxidase None None O
with None None O
dakocytomation None None O
peroxidase None None O
block None None O
( None None O
Dako None None O
) None None O
, None None O
Dakocytomation None None O
envision None None O
( None None O
R None None O
) None None O
system None None O
labeled None None O
polymer None None O
- None None O
HRP None None O
anti None None O
- None None O
rabbit None None O
kit None None O
and None None O
3 None None O
- None None O
3 None None O
' None None O
- None None O
diaminobenzidine None None O
( None None O
Dako None None O
) None None O
, None None O
Mayer None None O
' None None O
s None None O
hematoxylin None None O
( None None O
Histolab None None O
Product None None O
AB None None O
, None None O
Gothenburg None None O
, None None O
Sweden None None O
) None None O
, None None O
Graded None None O
alcohol None None O
( None None O
Kemetyl None None O
, None None O
Vestby None None O
, None None O
Norway None None O
) None None O
, None None O
Xylen None None O
( None None O
Solveco None None O
, None None O
Rosersberg None None O
, None None O
Sweden None None O
) None None O
, None None O
Pertex None None O
( None None O
R None None O
) None None O
( None None O
Histolab None None O
, None None O
Gothenburg None None O
, None None O
Sweden None None O
) None None O
, None None O
Tris None None O
- None None O
Glycine None None O
blotting None None O
buffer None None O
( None None O
Amresco None None O
, None None O
Solon None None O
, None None O
OH None None O
) None None O
, None None O
Western None None O
blotting None None O
( None None O
WB None None O
) None None O
reagent None None O
and None None O
Lumi None None O
- None None O
Light None None O
WB None None O
substrate None None O
( None None O
Roche None None O
, None None O
Basel None None O
, None None O
Switzerland None None O
) None None O
, None None O
EasyTag None None O
Methionine None None O
- None None O
L None None O
- None None O
35S None None O
, None None O
NEG709A005MC None None O
( None None O
PerkinElmer None None O
, None None O
Waltham None None O
, None None O
MA None None O
) None None O
, None None O
Full None None O
- None None O
length None None O
cDNA None None O
clone None None O
for None None O
human None None O
PNMA2 None None O
, None None O
ID6580976 None None O
( None None O
BioScience None None O
Geneservice None None O
, None None O
Cambridge None None O
, None None O
UK None None O
) None None O
, None None O
TnT None None O
( None None O
R None None O
) None None O
SP6 None None O
Quick None None O
Coupled None None O
Transcription None None O
/ None None O
Translation None None O
System None None O
( None None O
Promega None None O
, None None O
Madison None None O
, None None O
WI None None O
) None None O
, None None O
Protein None None O
G None None O
- None None O
Sepharose None None O
beads None None O
( None None O
GE None None O
Healthcare None None O
, None None O
Little None None O
Chalfont None None O
, None None O
Buckinghamshire None None O
, None None O
UK None None O
) None None O
, None None O
Peroxidase None None O
( None None O
HRP None None O
) None None O
- None None O
conjugated None None O
rabbit None None O
anti None None O
human None None O
IgG None None O
( None None O
anti None None O
- None None O
IgG None None O
) None None O
( None None O
Dako None None O
) None None O
, None None O
rabbit None None O
polyclonal None None O
antibody None None O
anti None None O
- None None O
PNMA2 None None O
( None None O
Atlas None None O
Antibodies None None O
, None None O
Stockholm None None O
, None None O
Sweden None None O
) None None O
, None None O
monoclonal None None O
mouse None None O
anti None None O
- None None O
GST None None O
, None None O
sc None None O
- None None O
138 None None O
, None None O
polyclonal None None O
goat None None O
anti None None O
- None None O
human None None O
Ma2 None None O
, None None O
sc None None O
- None None O
68099 None None O
, None None O
HRP None None O
- None None O
donkey None None O
anti None None O
- None None O
goat None None O
, None None O
sc None None O
- None None O
2020 None None O
, None None O
( None None O
Santa None None O
Cruz None None O
Biotechnology None None O
, None None O
Santa None None O
Cruz None None O
, None None O
CA None None O
) None None O
, None None O
HRP None None O
- None None O
goat None None O
anti None None O
- None None O
rabbit None None O
, None None O
P0448 None None O
, None None O
( None None O
Dako None None O
) None None O
and None None O
Ravo None None O
PNS None None O
- None None O
Blot None None O
, None None O
( None None O
Ravo None None O
Diagnostika None None O
GmbH None None O
, None None O
Freiburg None None O
, None None O
Germany None None O
) None None O
. None None O

Hematogenous None None O
metastasis None None O
in None None O
gastric None None O
cancer None None O
requires None None O
isolated None None O
tumor None None O
cells None None O
and None None O
expression None None O
of None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
- None None O
1 None None O
. None None O

PURPOSE None None O
: None None O
Recent None None O
studies None None O
of None None O
cancer None None O
metastasis None None O
have None None O
focused None None O
on None None O
the None None O
role None None O
of None None O
premetastatic None None O
gene None None O
expression None None O
and None None O
circulating None None O
tumor None None O
cells None None O
. None None O

We None None O
did None None O
a None None O
blind None None O
prospective None None O
study None None O
in None None O
gastric None None O
cancer None None O
to None None O
assess None None O
the None None O
significance None None O
of None None O
isolated None None O
tumor None None O
cells None None O
( None None O
ITC None None O
) None None O
and None None O
to None None O
test None None O
the None None O
hypothesis None None O
that None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
- None None O
1 None None O
( None None O
VEGFR None None O
- None None O
1 None None O
) None None O
is None None O
expressed None None O
within None None O
the None None O
bone None None O
marrow None None O
at None None O
tumor None None O
- None None O
specific None None O
, None None O
premetastatic None None O
sites None None O
. None None O

EXPERIMENTAL None None O
DESIGN None None O
: None None O
Both None None O
bone None None O
marrow None None O
and None None O
peripheral None None O
blood None None O
samples None None O
from None None O
810 None None O
gastric None None O
cancer None None O
patients None None O
were None None O
collected None None O
at None None O
the None None O
Central None None O
Hospital None None O
, None None O
National None None O
Cancer None None O
Center None None O
( None None O
Tokyo None None O
, None None O
Japan None None O
) None None O
. None None O

The None None O
samples None None O
were None None O
transferred None None O
to None None O
Kyushu None None O
University None None O
Hospital None None O
( None None O
Beppu None None O
, None None O
Japan None None O
) None None O
where None None O
they None None O
were None None O
analyzed None None O
by None None O
quantitative None None O
real None None O
- None None O
time None None O
reverse None None O
transcription None None O
- None None O
PCR None None O
for None None O
three None None O
epithelial None None O
cell None None O
markers None None O
, None None O
carcinoembryonic None None O
antigen None None O
, None None O
cytokeratin None None O
- None None O
19 None None O
, None None O
and None None O
cytokeratin None None O
- None None O
7 None None O
, None None O
as None None O
well None None O
as None None O
VEGFR None None O
- None None O
1 None None O
. None None O

RESULTS None None O
: None None O
ITCs None None O
were None None O
observed None None O
in None None O
peripheral None None O
blood None None O
and None None O
bone None None O
marrow None None O
even None None O
in None None O
early None None O
stages None None O
of None None O
gastric None None O
cancer None None O
. None None O

The None None O
frequency None None O
of None None O
ITC None None O
in None None O
bone None None O
marrow None None O
was None None O
significantly None None O
associated None None O
with None None O
the None None O
stage None None O
of None None O
disease None None O
by None None O
ANOVA None None O
( None None O
P None None O
< None None O
0 None None O
. None None O
01 None None O
) None None O
. None None O

Gastric None None O
cancer None None O
metastasized None None O
when None None O
ITCs None None O
were None None O
observed None None O
in None None O
the None None O
presence None None O
of None None O
VEGFR None None O
- None None O
1 None None O
. None None O

In None None O
the None None O
380 None None O
patients None None O
who None None O
were None None O
ITC None None O
negative None None O
and None None O
showed None None O
low None None O
VEGFR None None O
- None None O
1 None None O
expression None None O
, None None O
synchronous None None O
( None None O
at None None O
the None None O
time None None O
of None None O
surgery None None O
) None None O
and None None O
heterochronous None None O
( None None O
recurrent None None O
) None None O
metastases None None O
were None None O
not None None O
observed None None O
. None None O

CONCLUSIONS None None O
: None None O
ITCs None None O
circulate None None O
even None None O
in None None O
early None None O
stages None None O
of None None O
disease None None O
. None None O

Furthermore None None O
, None None O
elevated None None O
expression None None O
of None None O
VEGFR None None O
- None None O
1 None None O
facilitates None None O
the None None O
establishment None None O
of None None O
hematogenous None None O
metastases None None O
in None None O
gastric None None O
cancer None None O
. None None O

This None None O
study None None O
indicates None None O
that None None O
the None None O
simultaneous None None O
presence None None O
of None None O
ITC None None O
and None None O
VEGFR None None O
- None None O
1 None None O
expression None None O
at None None O
premetastatic None None O
sites None None O
is None None O
clinically None None O
significant None None O
for None None O
disease None None O
progression None None O
. None None O

VEGF None None O
, None None O
angiopoietin None None O
- None None O
1 None None O
and None None O
- None None O
2 None None O
in None None O
bronchial None None O
asthma None None O
: None None O
new None None O
molecular None None O
targets None None O
in None None O
airway None None O
angiogenesis None None O
and None None O
microvascular None None O
remodeling None None O
. None None O

Airway None None O
angiogenesis None None O
and None None O
microvascular None None O
remodeling None None O
are None None O
known None None O
features None None O
of None None O
bronchial None None O
asthma None None O
, None None O
but None None O
the None None O
mechanisms None None O
of None None O
these None None O
structural None None O
alterations None None O
are None None O
just None None O
beginning None None O
to None None O
be None None O
elucidated None None O
. None None O

Vascular None None O
endothelial None None O
growth None None O
factor None None O
( None None O
VEGF None None O
) None None O
, None None O
one None None O
of None None O
the None None O
most None None O
potent None None O
angiogenic None None O
factors None None O
, None None O
stimulates None None O
endothelial None None O
cell None None O
proliferation None None O
and None None O
induces None None O
the None None O
angiogenesis None None O
. None None O

Recently None None O
, None None O
considerable None None O
attentions None None O
have None None O
been None None O
devoted None None O
to None None O
the None None O
physiological None None O
roles None None O
of None None O
angiopoietin None None O
( None None O
Ang None None O
) None None O
- None None O
1 None None O
and None None O
- None None O
2 None None O
as None None O
regulatory None None O
factors None None O
of None None O
VEGF None None O
. None None O

Ang None None O
- None None O
1 None None O
has None None O
been None None O
shown None None O
to None None O
induce None None O
the None None O
migration None None O
and None None O
sprouting None None O
of None None O
endothelial None None O
cells None None O
, None None O
and None None O
coexpression None None O
of None None O
Ang None None O
- None None O
1 None None O
and None None O
VEGF None None O
enhanced None None O
angiogenesis None None O
. None None O

In None None O
the None None O
presence None None O
of None None O
high None None O
levels None None O
of None None O
VEGF None None O
, None None O
Ang None None O
- None None O
2 None None O
also None None O
promotes None None O
rapid None None O
increase None None O
in None None O
capillary None None O
diameter None None O
, None None O
remodeling None None O
of None None O
the None None O
basal None None O
lamina None None O
, None None O
proliferation None None O
and None None O
migration None None O
of None None O
endothelial None None O
cells None None O
, None None O
and None None O
stimulates None None O
sprouting None None O
of None None O
new None None O
blood None None O
vessels None None O
. None None O

Thus None None O
, None None O
VEGF None None O
, None None O
Ang None None O
- None None O
1 None None O
and None None O
- None None O
2 None None O
may None None O
play None None O
complementary None None O
and None None O
coordinated None None O
roles None None O
in None None O
airway None None O
angiogenesis None None O
and None None O
microvascular None None O
remodeling None None O
, None None O
and None None O
these None None O
structural None None O
changes None None O
are None None O
potentially None None O
reversible None None O
by None None O
therapeutic None None O
intervention None None O
. None None O

The None None O
scope None None O
of None None O
the None None O
present None None O
review None None O
is None None O
to None None O
discuss None None O
from None None O
a None None O
clinical None None O
point None None O
of None None O
view None None O
the None None O
potential None None O
interactions None None O
between None None O
VEGF None None O
and None None O
angiopoietins None None O
in None None O
the None None O
asthmatic None None O
airways None None O
, None None O
and None None O
focus None None O
on None None O
the None None O
therapeutic None None O
implications None None O
targeting None None O
for None None O
these None None O
angiogenic None None O
factors None None O
. None None O

Recently None None O
, None None O
there None None O
is None None O
an None None O
increasing None None O
number None None O
of None None O
patents None None O
which None None O
have None None O
been None None O
focused None None O
on None None O
the None None O
inhibitors None None O
of None None O
VEGF None None O
action None None O
. None None O

These None None O
inhibitors None None O
are None None O
directed None None O
towards None None O
the None None O
receptors None None O
of None None O
VEGF None None O
or None None O
intracellular None None O
substrates None None O
for None None O
the None None O
receptors None None O
. None None O

We None None O
will None None O
also None None O
discuss None None O
several None None O
patents None None O
regarding None None O
inhibitors None None O
of None None O
VEGF None None O
action None None O
in None None O
the None None O
present None None O
review None None O
. None None O

Non None None O
- None None O
invasive None None O
grading None None O
of None None O
primary None None O
brain None None O
tumours None None O
: None None O
results None None O
of None None O
a None None O
comparative None None O
study None None O
between None None O
SPET None None O
with None None O
123I None None O
- None None O
alpha None None O
- None None O
methyl None None O
tyrosine None None O
and None None O
PET None None O
with None None O
18F None None O
- None None O
deoxyglucose None None O
. None None O

Use None None O
of None None O
iodine None None O
- None None O
123 None None O
- None None O
alpha None None O
- None None O
methyl None None O
tyrosine None None O
( None None O
123I None None O
- None None O
IMT None None O
) None None O
allows None None O
investigation None None O
of None None O
the None None O
amino None None O
acid None None O
transport None None O
rate None None O
in None None O
gliomas None None O
. None None O

It None None O
was None None O
the None None O
aim None None O
of None None O
this None None O
study None None O
to None None O
compare None None O
the None None O
value None None O
of None None O
measurement None None O
of None None O
glucose None None O
metabolism None None O
with None None O
that None None O
of None None O
measurement None None O
of None None O
123I None None O
- None None O
IMT None None O
uptake None None O
for None None O
the None None O
non None None O
- None None O
invasive None None O
grading None None O
of None None O
brain None None O
tumours None None O
. None None O

The None None O
study None None O
population None None O
comprised None None O
23 None None O
patients None None O
with None None O
histopathologically None None O
proven None None O
primary None None O
brain None None O
tumours None None O
; None None O
14 None None O
had None None O
high None None O
- None None O
grade None None O
gliomas None None O
, None None O
and None None O
nine None None O
low None None O
- None None O
grade None None O
brain None None O
neoplasms None None O
. None None O

Glucose None None O
metabolism None None O
was None None O
studied None None O
using None None O
an None None O
ECAT None None O
EXACT None None O
47 None None O
positron None None O
emission None None O
tomography None None O
( None None O
PET None None O
) None None O
camera None None O
and None None O
fluorine None None O
- None None O
18 None None O
fluorodeoxyglucose None None O
( None None O
18F None None O
- None None O
FDG None None O
) None None O
; None None O
123I None None O
- None None O
IMT None None O
uptake None None O
was None None O
measured None None O
with None None O
the None None O
triple None None O
- None None O
headed None None O
single None None O
- None None O
photon None None O
emission None None O
tomography None None O
( None None O
SPET None None O
) None None O
camera None None O
, None None O
MULTISPECT None None O
3 None None O
. None None O

18F None None O
- None None O
FDG None None O
and None None O
123I None None O
- None None O
IMT None None O
uptake None None O
was None None O
quantified None None O
as None None O
ratios None None O
between None None O
the None None O
uptake None None O
by None None O
the None None O
tumour None None O
and None None O
contralateral None None O
regions None None O
of None None O
reference None None O
. None None O

Glucose None None O
metabolism None None O
and None None O
amino None None O
acid None None O
uptake None None O
of None None O
the None None O
brain None None O
tumours None None O
correlated None None O
significantly None None O
( None None O
r None None O
= None None O
0 None None O
. None None O
71 None None O
, None None O
P None None O
< None None O
0 None None O
. None None O
001 None None O
) None None O
. None None O

Assuming None None O
discrimination None None O
thresholds None None O
between None None O
high None None O
- None None O
grade None None O
and None None O
low None None O
- None None O
grade None None O
tumours None None O
of None None O
0 None None O
. None None O
8 None None O
for None None O
18F None None O
- None None O
FDG None None O
uptake None None O
and None None O
1 None None O
. None None O
8 None None O
for None None O
123I None None O
- None None O
IMT None None O
uptake None None O
, None None O
the None None O
accuracy None None O
values None None O
of None None O
18F None None O
- None None O
FDG None None O
PET None None O
and None None O
123I None None O
- None None O
IMT None None O
SPET None None O
for None None O
differentiating None None O
between None None O
high None None O
- None None O
grade None None O
and None None O
low None None O
- None None O
grade None None O
tumours None None O
were None None O
21 None None O
/ None None O
23 None None O
( None None O
91 None None O
% None None O
) None None O
and None None O
19 None None O
/ None None O
23 None None O
( None None O
83 None None O
% None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
difference None None O
in None None O
diagnostic None None O
performance None None O
was None None O
not None None O
significant None None O
on None None O
receiver None None O
operating None None O
characteristic None None O
analysis None None O
( None None O
P None None O
> None None O
0 None None O
. None None O
4 None None O
) None None O
. None None O

It None None O
is None None O
concluded None None O
that None None O
there None None O
is None None O
no None None O
major None None O
difference None None O
between None None O
the None None O
PET None None O
investigation None None O
of None None O
glucose None None O
metabolism None None O
and None None O
the None None O
less None None O
expensive None None O
SPET None None O
measurement None None O
of None None O
amino None None O
acid None None O
uptake None None O
in None None O
terms None None O
of None None O
their None None O
accuracy None None O
in None None O
evaluating None None O
the None None O
malignancy None None O
grade None None O
of None None O
primary None None O
brain None None O
tumours None None O
. None None O

This None None O
encourages None None O
the None None O
performance None None O
of None None O
further None None O
studies None None O
to None None O
analyse None None O
the None None O
potential None None O
impact None None O
of None None O
123I None None O
- None None O
IMT None None O
SPET None None O
on None None O
the None None O
therapeutic None None O
management None None O
of None None O
patients None None O
with None None O
brain None None O
tumours None None O
. None None O

Role None None O
of None None O
thrombin None None O
in None None O
angiogenesis None None O
and None None O
tumor None None O
progression None None O
. None None O

Clinical None None O
, None None O
laboratory None None O
, None None O
histopathological None None O
, None None O
and None None O
pharmacological None None O
evidence None None O
support None None O
the None None O
notion None None O
that None None O
the None None O
coagulation None None O
system None None O
, None None O
which None None O
is None None O
activated None None O
in None None O
most None None O
cancer None None O
patients None None O
, None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
tumor None None O
biology None None O
. None None O

Our None None O
laboratory None None O
has None None O
provided None None O
evidence None None O
that None None O
thrombin None None O
activates None None O
angiogenesis None None O
, None None O
a None None O
process None None O
which None None O
is None None O
essential None None O
in None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
. None None O

This None None O
event None None O
is None None O
independent None None O
of None None O
fibrin None None O
formation None None O
. None None O

At None None O
the None None O
cellular None None O
level None None O
many None None O
actions None None O
of None None O
thrombin None None O
can None None O
contribute None None O
to None None O
activation None None O
of None None O
angiogenesis None None O
: None None O
( None None O
1 None None O
) None None O
. None None O

Thrombin None None O
decreases None None O
the None None O
ability None None O
of None None O
endothelial None None O
cells None None O
to None None O
attach None None O
to None None O
basement None None O
membrane None None O
proteins None None O
. None None O

( None None O
2 None None O
) None None O
. None None O

Thrombin None None O
greatly None None O
potentiates None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
- None None O
( None None O
VEGF None None O
- None None O
) None None O
induced None None O
endothelial None None O
cell None None O
proliferation None None O
. None None O

This None None O
potentiation None None O
is None None O
accompanied None None O
by None None O
up None None O
- None None O
regulation None None O
of None None O
the None None O
expression None None O
of None None O
VEGF None None O
receptors None None O
( None None O
kinase None None O
insert None None O
domain None None O
- None None O
containing None None O
receptor None None O
[ None None O
KDR None None O
] None None O
and None None O
fms None None O
- None None O
like None None O
tyrosine None None O
kinase None None O
[ None None O
Flt None None O
- None None O
1 None None O
] None None O
) None None O
. None None O

( None None O
3 None None O
) None None O
. None None O

Thrombin None None O
increases None None O
the None None O
mRNA None None O
and None None O
protein None None O
levels None None O
of None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
integrin None None O
and None None O
serves None None O
as None None O
a None None O
ligand None None O
to None None O
this None None O
receptor None None O
. None None O

Furthermore None None O
, None None O
thrombin None None O
increases None None O
the None None O
secretion None None O
of None None O
VEGF None None O
and None None O
enhances None None O
the None None O
expression None None O
and None None O
protein None None O
synthesis None None O
of None None O
matrix None None O
metalloprotease None None O
- None None O
9 None None O
and None None O
alpha None None O
( None None O
v None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
integrin None None O
in None None O
human None None O
prostate None None O
cancer None None O
PC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
cells None None O
. None None O

These None None O
results None None O
could None None O
explain None None O
the None None O
angiogenic None None O
and None None O
tumor None None O
- None None O
promoting None None O
effect None None O
of None None O
thrombin None None O
and None None O
provide None None O
the None None O
basis None None O
for None None O
development None None O
of None None O
thrombin None None O
receptor None None O
mimetics None None O
or None None O
antagonists None None O
for None None O
therapeutic None None O
application None None O
. None None O

Rapid None None O
mixing None None O
between None None O
old None None O
and None None O
new None None O
C None None O
pools None None O
in None None O
the None None O
canopy None None O
of None None O
mature None None O
forest None None O
trees None None O
. None None O

Stable None None O
C None None O
isotope None None O
signals None None O
in None None O
plant None None O
tissues None None O
became None None O
a None None O
key None None O
tool None None O
in None None O
explaining None None O
growth None None O
responses None None O
to None None O
the None None O
environment None None O
. None None O

The None None O
technique None None O
is None None O
based None None O
on None None O
the None None O
fundamental None None O
assumption None None O
that None None O
the None None O
isotopic None None O
composition None None O
of None None O
a None None O
given None None O
unit None None O
of None None O
tissue None None O
( None None O
e None None O
. None None O
g None None O
. None None O
a None None O
tree None None O
ring None None O
) None None O
reflects None None O
the None None O
specific None None O
C None None O
uptake None None O
conditions None None O
in None None O
the None None O
leaf None None O
at None None O
a None None O
given None None O
time None None O
. None None O

Beyond None None O
the None None O
methodological None None O
implications None None O
of None None O
any None None O
deviation None None O
from None None O
this None None O
assumption None None O
, None None O
it None None O
is None None O
of None None O
physiological None None O
interest None None O
whether None None O
new None None O
C None None O
is None None O
transferred None None O
directly None None O
from None None O
sources None None O
( None None O
a None None O
photosynthesizing None None O
leaf None None O
) None None O
to None None O
structural None None O
sinks None None O
( None None O
e None None O
. None None O
g None None O
. None None O
adjacent None None O
stem None None O
tissue None None O
) None None O
, None None O
or None None O
inherently None None O
passes None None O
through None None O
existing None None O
( None None O
mobile None None O
) None None O
C None None O
pools None None O
, None None O
which None None O
may None None O
be None None O
of None None O
variable None None O
( None None O
older None None O
) None None O
age None None O
. None None O

Here None None O
, None None O
we None None O
explore None None O
the None None O
fate None None O
of None None O
( None None O
13 None None O
) None None O
C None None O
- None None O
labelled None None O
photosynthates None None O
in None None O
the None None O
crowns None None O
of None None O
a None None O
30 None None O
- None None O
35 None None O
m None None O
tall None None O
, None None O
mixed None None O
forest None None O
using None None O
a None None O
canopy None None O
crane None None O
. None None O

In None None O
all None None O
nine None None O
study None None O
species None None O
labelled None None O
C None None O
reached None None O
woody None None O
tissue None None O
within None None O
2 None None O
- None None O
9 None None O
h None None O
after None None O
labelling None None O
. None None O

Four None None O
months None None O
later None None O
, None None O
very None None O
small None None O
signals None None O
were None None O
left None None O
in None None O
branch None None O
wood None None O
of None None O
Tilia None None O
suggesting None None O
that None None O
low None None O
mixing None None O
of None None O
new None None O
, None None O
labelled None None O
C None None O
with None None O
old None None O
C None None O
had None None O
taken None None O
place None None O
. None None O

In None None O
contrast None None O
, None None O
signals None None O
in None None O
Fagus None None O
and None None O
Quercus None None O
had None None O
increased None None O
, None None O
indicating None None O
more None None O
intense None None O
mixing None None O
. None None O

This None None O
species None None O
- None None O
specific None None O
mixing None None O
of None None O
new None None O
with None None O
old None None O
C None None O
pools None None O
is None None O
likely None None O
to None None O
mask None None O
year None None O
- None None O
or None None O
season None None O
- None None O
specific None None O
linkages None None O
between None None O
tree None None O
ring None None O
formation None None O
and None None O
climate None None O
and None None O
has None None O
considerable None None O
implications None None O
for None None O
climate None None O
reconstruction None None O
using None None O
stable None None O
isotopes None None O
as None None O
proxies None None O
for None None O
past None None O
climatic None None O
conditions None None O
. None None O

An None None O
antibody None None O
directed None None O
against None None O
PDGF None None O
receptor None None O
beta None None O
enhances None None O
the None None O
antitumor None None O
and None None O
the None None O
anti None None O
- None None O
angiogenic None None O
activities None None O
of None None O
an None None O
anti None None O
- None None O
VEGF None None O
receptor None None O
2 None None O
antibody None None O
. None None O

Platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
( None None O
PDGF None None O
) None None O
and None None O
its None None O
receptors None None O
( None None O
PDGFR None None O
) None None O
play None None O
important None None O
roles None None O
in None None O
tumorigenesis None None O
through None None O
stimulating None None O
tumor None None O
growth None None O
and None None O
promoting None None O
angiogenesis None None O
via None None O
enhancing None None O
pericyte None None O
recruitment None None O
and None None O
vessel None None O
maturation None None O
. None None O

Here None None O
we None None O
produced None None O
a None None O
neutralizing None None O
antibody None None O
, None None O
1B3 None None O
, None None O
directed None None O
against None None O
mouse None None O
PDGFRbeta None None O
. None None O

1B3 None None O
binds None None O
to None None O
PDGFRbeta None None O
with None None O
high None None O
affinity None None O
( None None O
9x10 None None O
( None None O
- None None O
11 None None O
) None None O
M None None O
) None None O
and None None O
blocks None None O
PDGF None None O
- None None O
BB None None O
from None None O
binding None None O
to None None O
the None None O
receptor None None O
with None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
approximately None None O
1 None None O
. None None O
2 None None O
nM None None O
. None None O

The None None O
antibody None None O
also None None O
blocks None None O
ligand None None O
- None None O
stimulated None None O
activation None None O
of None None O
PDGFRbeta None None O
and None None O
downstream None None O
signaling None None O
molecules None None O
, None None O
including None None O
Akt None None O
and None None O
MAPK None None O
p42 None None O
/ None None O
44 None None O
, None None O
in None None O
tumor None None O
cells None None O
. None None O

In None None O
animal None None O
studies None None O
, None None O
1B3 None None O
significantly None None O
enhanced None None O
the None None O
antitumor None None O
and None None O
the None None O
anti None None O
- None None O
angiogenic None None O
activities None None O
of None None O
DC101 None None O
, None None O
an None None O
antibody None None O
directed None None O
against None None O
mouse None None O
vascular None None O
endothelial None None O
growth None None O
factor None None O
receptor None None O
2 None None O
, None None O
in None None O
a None None O
pancreatic None None O
( None None O
BxPC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
) None None O
and None None O
a None None O
non None None O
- None None O
small None None O
cell None None O
lung None None O
( None None O
NCI None None I-Cell-line-name
- None None I-Cell-line-name
H460 None None I-Cell-line-name
) None None O
tumor None None O
xenograft None None O
models None None O
. None None O

Treatment None None O
with None None O
the None None O
combination None None O
of None None O
1B3 None None O
and None None O
DC101 None None O
in None None O
BxPC None None I-Cell-line-name
- None None I-Cell-line-name
3 None None I-Cell-line-name
xenograft None None O
- None None O
bearing None None O
mice None None O
resulted None None O
in None None O
tumor None None O
regression None None O
in None None O
58 None None O
% None None O
of None None O
mice None None O
compared None None O
to None None O
that None None O
in None None O
18 None None O
% None None O
of None None O
mice None None O
treated None None O
with None None O
DC101 None None O
alone None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
lend None None O
great None None O
support None None O
to None None O
use None None O
PDGFRbeta None None O
antagonists None None O
in None None O
combinations None None O
with None None O
other None None O
antitumor None None O
and None None O
/ None None O
or None None O
anti None None O
- None None O
angiogenic None None O
agents None None O
in None None O
the None None O
treatment None None O
of None None O
a None None O
variety None None O
of None None O
cancers None None O
. None None O

Discussion None None O

This None None O
is None None O
the None None O
first None None O
study None None O
to None None O
employ None None O
such None None O
a None None O
large None None O
number None None O
of None None O
replicated None None O
samples None None O
in None None O
order None None O
to None None O
assess None None O
the None None O
bacterial None None O
communities None None O
of None None O
healthy None None O
and None None O
diseased None None O
corals None None O
, None None O
and None None O
the None None O
first None None O
culture None None O
- None None O
independent None None O
assessment None None O
of None None O
bacterial None None O
communities None None O
on None None O
Acroporid None None O
WS None None O
corals None None O
on None None O
the None None O
GBR None None O
. None None O

Despite None None O
the None None O
potential None None O
of None None O
not None None O
capturing None None O
rare None None O
or None None O
very None None O
low None None O
abundance None None O
bacterial None None O
ribotypes None None O
, None None O
the None None O
DGGE None None O
analysis None None O
used None None O
in None None O
this None None O
study None None O
indicated None None O
similar None None O
results None None O
of None None O
captured None None O
bacterial None None O
ribotypes None None O
and None None O
tentative None None O
bacterial None None O
species None None O
replacement None None O
in None None O
unhealthy None None O
corals None None O
to None None O
that None None O
of None None O
less None None O
replicated None None O
studies None None O
using None None O
other None None O
non None None O
- None None O
culture None None O
based None None O
techniques None None O
( None None O
e None None O
. None None O
g None None O
. None None O
[ None None O
3 None None O
] None None O
, None None O
[ None None O
54 None None O
] None None O
, None None O
[ None None O
69 None None O
] None None O
; None None O
Figure None None O
4 None None O
) None None O
. None None O

The None None O
results None None O
from None None O
this None None O
research None None O
reinforce None None O
, None None O
with None None O
statistically None None O
relevant None None O
data None None O
, None None O
that None None O
corals None None O
harbour None None O
bacterial None None O
communities None None O
different None None O
to None None O
the None None O
water None None O
column None None O
[ None None O
7 None None O
] None None O
, None None O
[ None None O
9 None None O
] None None O
, None None O
[ None None O
42 None None O
] None None O
, None None O
corroborate None None O
findings None None O
that None None O
corals None None O
associate None None O
only None None O
with None None O
certain None None O
specific None None O
bacterial None None O
groups None None O
, None None O
and None None O
that None None O
these None None O
coral None None O
- None None O
associated None None O
bacterial None None O
communities None None O
are None None O
' None None O
host None None O
' None None O
species None None O
- None None O
specific None None O
[ None None O
2 None None O
] None None O
. None None O

The None None O
data None None O
presented None None O
here None None O
highlight None None O
a None None O
cluster None None O
of None None O
bacterial None None O
ribotypes None None O
frequently None None O
associated None None O
with None None O
corals None None O
, None None O
and None None O
the None None O
distribution None None O
of None None O
these None None O
bacterial None None O
ribotypes None None O
on None None O
healthy None None O
and None None O
diseased None None O
corals None None O
, None None O
which None None O
allows None None O
for None None O
further None None O
targeted None None O
research None None O
into None None O
a None None O
tentative None None O
link None None O
between None None O
these None None O
common None None O
coral None None O
associates None None O
and None None O
coral None None O
health None None O
. None None O

This None None O
study None None O
indicates None None O
that None None O
coral None None O
bacterial None None O
community None None O
assessments None None O
require None None O
a None None O
number None None O
of None None O
replicates None None O
per None None O
coral None None O
species None None O
and None None O
site None None O
to None None O
accurately None None O
describe None None O
the None None O
diversity None None O
present None None O
across None None O
the None None O
population None None O
and None None O
in None None O
order None None O
to None None O
draw None None O
inferences None None O
on None None O
health None None O
- None None O
related None None O
changes None None O
in None None O
the None None O
community None None O
composition None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
comparisons None None O
of None None O
healthy None None O
and None None O
diseased None None O
Acropora None None O
hyacinthus None None O
samples None None O
showed None None O
that None None O
bacterial None None O
communities None None O
can None None O
change None None O
dramatically None None O
in None None O
diseased None None O
individuals None None O
. None None O

The None None O
DGGE None None O
profiles None None O
observed None None O
for None None O
corals None None O
displaying None None O
signs None None O
of None None O
White None None O
Syndrome None None O
comprised None None O
a None None O
range None None O
of None None O
bacterial None None O
ribotypes None None O
not None None O
generally None None O
found None None O
on None None O
healthy None None O
corals None None O
, None None O
including None None O
close None None O
relatives None None O
of None None O
bacteria None None O
previously None None O
found None None O
on None None O
Black None None O
Band None None O
Diseased None None O
corals None None O
. None None O

However None None O
the None None O
community None None O
profiles None None O
across None None O
the None None O
samples None None O
taken None None O
from None None O
diseased None None O
coral None None O
colonies None None O
were None None O
inconsistent None None O
and None None O
not None None O
indicative None None O
of None None O
a None None O
single None None O
bacterial None None O
causative None None O
agent None None O
. None None O

Inhibition None None O
of None None O
PDGF None None O
- None None O
stimulated None None O
and None None O
matrix None None O
- None None O
mediated None None O
proliferation None None O
of None None O
human None None O
vascular None None O
smooth None None O
muscle None None O
cells None None O
by None None O
SPARC None None O
is None None O
independent None None O
of None None O
changes None None O
in None None O
cell None None O
shape None None O
or None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
inhibitors None None O
. None None O

Interactions None None O
among None None O
growth None None O
factors None None O
, None None O
cells None None O
, None None O
and None None O
extracellular None None O
matrix None None O
regulate None None O
proliferation None None O
during None None O
normal None None O
development None None O
and None None O
in None None O
pathologies None None O
such None None O
as None None O
atherosclerosis None None O
. None None O

SPARC None None O
( None None O
secreted None None O
protein None None O
, None None O
acidic None None O
, None None O
and None None O
rich None None O
in None None O
cysteine None None O
) None None O
is None None O
a None None O
matrix None None O
- None None O
associated None None O
glycoprotein None None O
that None None O
modulates None None O
the None None O
adhesion None None O
and None None O
proliferation None None O
of None None O
vascular None None O
cells None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
SPARC None None O
inhibits None None O
human None None O
arterial None None O
smooth None None O
muscle None None O
cell None None O
proliferation None None O
stimulated None None O
by None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
or None None O
by None None O
adhesion None None O
to None None O
monomeric None None O
type None None O
I None None O
collagen None None O
. None None O

Binding None None O
studies None None O
with None None O
SPARC None None O
and None None O
SPARC None None O
peptides None None O
indicate None None O
specific None None O
and None None O
saturable None None O
interaction None None O
with None None O
smooth None None O
muscle None None O
cells None None O
that None None O
involves None None O
the None None O
C None None O
- None None O
terminal None None O
Ca2 None None O
+ None None O
- None None O
binding None None O
region None None O
of None None O
the None None O
protein None None O
. None None O

We None None O
also None None O
report None None O
that None None O
SPARC None None O
arrests None None O
monomeric None None O
collagen None None O
- None None O
supported None None O
smooth None None O
muscle None None O
cell None None O
proliferation None None O
in None None O
the None None O
late None None O
G1 None None O
- None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
in None None O
the None None O
absence None None O
of None None O
an None None O
effect None None O
on None None O
cell None None O
shape None None O
or None None O
on None None O
levels None None O
of None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
inhibitors None None O
. None None O

Cyclin None None O
- None None O
dependent None None O
kinase None None O
- None None O
2 None None O
activity None None O
, None None O
p107 None None O
and None None O
cyclin None None O
A None None O
levels None None O
, None None O
and None None O
retinoblastoma None None O
protein None None O
phosphorylation None None O
are None None O
markedly None None O
reduced None None O
in None None O
response None None O
to None None O
the None None O
addition None None O
of None None O
exogenous None None O
SPARC None None O
and None None O
/ None None O
or None None O
peptides None None O
derived None None O
from None None O
specific None None O
domains None None O
of None None O
SPARC None None O
. None None O

Thus None None O
, None None O
SPARC None None O
, None None O
previously None None O
characterized None None O
as None None O
an None None O
inhibitor None None O
of None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
binding None None O
to None None O
its None None O
receptor None None O
, None None O
also None None O
antagonizes None None O
smooth None None O
muscle None None O
cell None None O
proliferation None None O
mediated None None O
by None None O
monomeric None None O
collagen None None O
at None None O
the None None O
level None None O
of None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
- None None O
2 None None O
activity None None O
. None None O

Authors None None O
' None None O
contributions None None O

PM None None O
carried None None O
out None None O
and None None O
analyzed None None O
molecular None None O
assay None None O
and None None O
sequencing None None O
data None None O
and None None O
drafted None None O
the None None O
manuscript None None O
. None None O

NS None None O
participated None None O
in None None O
study None None O
design None None O
and None None O
in None None O
the None None O
local None None O
coordination None None O
during None None O
the None None O
study None None O
. None None O

She None None O
helped None None O
to None None O
draft None None O
the None None O
manuscript None None O
. None None O

MD None None O
has None None O
made None None O
substantial None None O
contributions None None O
to None None O
the None None O
acquisition None None O
and None None O
analysis None None O
of None None O
data None None O
. None None O

He None None O
participated None None O
in None None O
design None None O
of None None O
the None None O
study None None O
and None None O
helped None None O
to None None O
draft None None O
the None None O
manuscript None None O
. None None O

MO None None O
has None None O
made None None O
substantial None None O
contributions None None O
to None None O
acquisition None None O
and None None O
analysis None None O
of None None O
data None None O
. None None O

GB None None O
has None None O
made None None O
substantial None None O
contributions None None O
to None None O
acquisition None None O
and None None O
analysis None None O
of None None O
data None None O
. None None O

GP None None O
carried None None O
out None None O
microscopy None None O
and None None O
microbiology None None O
analyses None None O
in None None O
Italy None None O
and None None O
contributed None None O
in None None O
drafting None None O
the None None O
manuscript None None O
. None None O

GBM None None O
has None None O
made None None O
substantial None None O
contributions None None O
in None None O
conceiving None None O
, None None O
analysing None None O
and None None O
writing None None O
the None None O
manuscript None None O
. None None O

AM None None O
participated None None O
in None None O
the None None O
design None None O
of None None O
the None None O
study None None O
and None None O
helped None None O
to None None O
draft None None O
the None None O
manuscript None None O
. None None O

DMC None None O
participated None None O
in None None O
the None None O
design None None O
of None None O
the None None O
study None None O
and None None O
conceived None None O
, None None O
and None None O
analysed None None O
the None None O
manuscript None None O
. None None O

All None None O
authors None None O
read None None O
and None None O
approved None None O
the None None O
final None None O
manuscript None None O
. None None O
